PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Hsi, AC; Rosman, IS				Hsi, Andy C.; Rosman, Ilana S.			Histopathology of Cutaneous Inflammatory Disorders in Children	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						cutaneous; dermatopathology; inflammatory; infectious; pediatric; vasculitis	TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; HENOCH-SCHONLEIN PURPURA; PLASMACYTOID DENDRITIC CELLS; LINKED-IMMUNOSORBENT-ASSAY; PITYRIASIS-RUBRA-PILARIS; LINEAR IGA DISEASE; DISSEMINATED INTRAVASCULAR COAGULATION; GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALLERGIC CONTACT-DERMATITIS	Inflammatory dermatoses encompass a variety of histologic patterns that affect different portions of the skin. In spongiotic, psoriasiform, lichenoid, pityriasiform, and blistering disorders, there are predominately epidermal and junctional activities with variable superficial dermal inflammation. Hypersensitivity reactions can show either epidermal or mostly dermal changes depending on whether the exposure of the exogenous allergen occurs through an external or internal route, respectively. Exceptions include erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis, where the etiology is often due to infection or ingested medications, but the histologic features are almost exclusively confined to the epidermis and dermoepidermal junction. Autoimmune disorders are unique in that lesions typically incorporate a mixture of epidermal and dermal inflammatory patterns with periadnexal inflammation, while the vast majority of vasculitis/vasculopathy and alopecia have changes limited to only the vessels and hair follicles, respectively. It is critical to recognize that a relatively limited number of histologic patterns are seen in a large array of clinical entities. Therefore, clinicopathologic correlation and careful examination of histologic details are of the utmost importance when evaluating skin biopsies for inflammatory disorders.	[Hsi, Andy C.; Rosman, Ilana S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Rosman, Ilana S.] Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA	Rosman, IS (reprint author), Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	irosman@wustl.edu		Rosman, Ilana/0000-0001-5842-5691			Abagge KT, 2004, PEDIATR DERMATOL, V21, P440, DOI 10.1111/j.0736-8046.2004.21403.x; ABEL EA, 1986, J AM ACAD DERMATOL, V15, P1007, DOI 10.1016/S0190-9622(86)70265-X; Adame J, 1996, J AM ACAD DERMATOL, V34, P229, DOI 10.1016/S0190-9622(96)80117-4; Admani S, 2015, CLIN DERMATOL, V33, P657, DOI 10.1016/j.clindermatol.2015.09.008; Admani S, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0421-0; AHMED AR, 1982, AM J DIS CHILD, V136, P214, DOI 10.1001/archpedi.1982.03970390028009; Al-Johani KA, 2007, ORAL SURG ORAL MED O, V103, P642, DOI 10.1016/j.tripleo.2006.12.008; AlKharafi NNAH, 2016, PEDIATR DERMATOL, V33, P200, DOI 10.1111/pde.12788; Allen J, 2003, BRIT J DERMATOL, V149, P1055, DOI 10.1111/j.1365-2133.2003.05647.x; Allison DS, 2002, J AM ACAD DERMATOL, V47, P386, DOI 10.1067/mjd.2002.124619; Alomari A, 2014, J CUTAN PATHOL, V41, P347, DOI 10.1111/cup.12275; Amagai M, 1999, BRIT J DERMATOL, V140, P351; Amagai M, 2002, J INVEST DERMATOL, V118, P845, DOI 10.1046/j.1523-1747.2002.01751.x; AMANO S, 1979, JPN CIRC J, V43, P741, DOI 10.1253/jcj.43.741; [Anonymous], 1985, Am J Dermatopathol, V7, P181; Ardigo M, 2011, ARCH DERMATOL, V147, P61, DOI 10.1001/archdermatol.2010.288; Arenas R, 2006, INT J DERMATOL, V45, P215, DOI 10.1111/j.1365-4632.2004.02449.x; Arkin LM, 2015, J AM ACAD DERMATOL, V72, P628, DOI 10.1016/j.jaad.2014.12.028; Arora A, 2014, MAYO CLIN PROC, V89, P1515, DOI 10.1016/j.mayocp.2014.04.015; Atanaskovic-Markovic M, 2013, PEDIAT ALLERG IMM-UK, V24, P645, DOI 10.1111/pai.12121; Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019; Avalos-Diaz E, 2000, J AM ACAD DERMATOL, V43, P1130, DOI 10.1067/mjd.2000.110400; Balma-Mena A, 2011, INT J DERMATOL, V50, P682, DOI 10.1111/j.1365-4632.2010.04751.x; Barba A, 1999, BRIT J DERMATOL, V140, P365; BARKSDALE SK, 1995, AM J SURG PATHOL, V19, P161, DOI 10.1097/00000478-199502000-00005; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Batya BD, 2006, J AM ACAD DERMATOL, V55, P525, DOI 10.1016/j.jaad.2006.05.010; Bauza A, 2002, BRIT J DERMATOL, V146, P694, DOI 10.1046/j.1365-2133.2002.04624.x; Beckum KM, 2014, PEDIATR DERMATOL, V31, pE6, DOI 10.1111/pde.12207; BEDI TR, 1976, BRIT J DERMATOL, V95, P243, DOI 10.1111/j.1365-2133.1976.tb07010.x; Bellet JS, 2009, J AM ACAD DERMATOL, V60, P679, DOI 10.1016/j.jaad.2008.12.019; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Besli GE, 2017, PEDIATR EMERG CARE, V33, P494, DOI 10.1097/PEC.0000000000000489; Bhattacharjee P, 2007, J CUTAN PATHOL, V34, P716, DOI 10.1111/j.1600-0560.2006.00723.x; BHOGAL B, 1986, CLIN EXP DERMATOL, V11, P49, DOI 10.1111/j.1365-2230.1986.tb00423.x; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; Bigby M, 2001, ARCH DERMATOL, V137, P765; Bohm M, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-18; Bowers S, 2006, J AM ACAD DERMATOL, V55, P557, DOI 10.1016/j.jaad.2005.07.058; Bowyer S, 1996, J RHEUMATOL, V23, P1968; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Brod BA, 2015, CLIN DERMATOL, V33, P605, DOI 10.1016/j.clindermatol.2015.09.003; Browning JC, 2009, CURR OPIN PEDIATR, V21, P481, DOI 10.1097/MOP.0b013e32832db96e; Bunagan MJK, 2015, J CUTAN MED SURG, V19, P45, DOI 10.2310/7750.2014.13218; Buyon JP, 1998, J AM COLL CARDIOL, V31, P1658, DOI 10.1016/S0735-1097(98)00161-2; Cabral DA, 2009, ARTHRITIS RHEUM-US, V60, P3413, DOI 10.1002/art.24876; CALABRESE LH, 1990, ARTHRITIS RHEUM, V33, P1108; Canpolat Kirac B, 2009, J EUR ACAD DERMATOL, V23, P16, DOI 10.1111/j.1468-3083.2008.02939.x; Castano E, 2013, J CUTAN PATHOL, V40, P924, DOI 10.1111/cup.12217; Castelo-Soccio L, 2014, PEDIATR CLIN N AM, V61, P427, DOI 10.1016/j.pcl.2013.12.002; Cepeda LT, 2003, AM J SURG PATHOL, V27, P912, DOI 10.1097/00000478-200307000-00006; Chamblin SL, 2002, J PEDIATR-US, V141, P572, DOI 10.1067/mpd.2002.127503; Chao PH, 2009, PEDIATR DERMATOL, V26, P352, DOI 10.1111/j.1525-1470.2009.00918.x; Chiu YE, 2012, PEDIATR DERMATOL, V29, P738, DOI 10.1111/pde.12001; Christen-Zaech S, 2008, J AM ACAD DERMATOL, V59, P385, DOI 10.1016/j.jaad.2008.05.005; Christensen KN, 2015, PEDIATR DERMATOL, V32, P621, DOI 10.1111/pde.12624; Churg A, 2001, MODERN PATHOL, V14, P1284, DOI 10.1038/modpathol.3880475; Ciliberto H, 2013, JAMA DERMATOL, V149, P1425, DOI 10.1001/jamadermatol.2013.4457; Cimaz R, 2003, J PEDIATR-US, V142, P678, DOI 10.1067/mpd.2003.233; Clavenna A, 2009, ARCH DIS CHILD, V94, P724, DOI 10.1136/adc.2008.154377; COLMAN RW, 1977, INT J DERMATOL, V16, P47, DOI 10.1111/j.1365-4362.1977.tb00740.x; CROTTY C, 1983, J AM ACAD DERMATOL, V8, P337, DOI 10.1016/S0190-9622(83)70036-8; Daneshpazhooh M, 2007, J EUR ACAD DERMATOL, V21, P1319, DOI 10.1111/j.1468-3083.2007.02254.x; DARMSTADT GL, 1994, PEDIATR DERMATOL, V11, P293, DOI 10.1111/j.1525-1470.1994.tb00092.x; Davis MDP, 1998, J AM ACAD DERMATOL, V38, P899; Davis MDP, 1997, J AM ACAD DERMATOL, V37, P199, DOI 10.1016/S0190-9622(97)80125-9; de Diego J, 1998, AM J DERMATOPATH, V20, P518, DOI 10.1097/00000372-199810000-00019; Dereure O, 2000, ARCH DERMATOL, V136, P1483, DOI 10.1001/archderm.136.12.1483; DIAZPERE.JL, 1974, ARCH DERMATOL, V110, P407, DOI 10.1001/archderm.110.3.407; Dickey BZ, 2013, BRIT J DERMATOL, V169, P428, DOI 10.1111/bjd.12383; Drago F, 2002, J CUTAN PATHOL, V29, P359, DOI 10.1034/j.1600-0560.2002.290606.x; EDWARDS BL, 1989, J RHEUMATOL, V16, P387; Eginli AN, 2017, PEDIATR DERMATOL, V34, P133, DOI 10.1111/pde.13046; El-Gamal Y, 2008, WORLD ALLERGY ORGAN, V1, P34, DOI 10.1097/WOX.0b013e3181626fde; ELIAS PM, 1976, ARCH DERMATOL, V112, P856, DOI 10.1001/archderm.112.6.856; Elston DM, 2000, AM J DERMATOPATH, V22, P242, DOI 10.1097/00000372-200006000-00006; Elston DM, 1997, J AM ACAD DERMATOL, V37, P101, DOI 10.1016/S0190-9622(97)70219-6; Ersoy S, 2004, ARCH DERMATOL, V140, P1172, DOI 10.1001/archderm.140.9.1172; Faloyin M, 2004, PEDIATRICS, V114, P270, DOI 10.1542/peds.114.2.e270; Fan X, 2007, J EUR ACAD DERMATOL, V21, P762, DOI 10.1111/j.1468-3083.2007.02014.x; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Ferneiny M, 2016, J EUR ACAD DERMATOL, V30, P1401, DOI 10.1111/jdv.13245; Ferrandiz-Pulido C, 2011, J EUR ACAD DERMATOL, V25, P1153, DOI 10.1111/j.1468-3083.2010.03935.x; Ferrandiz-Pulido C, 2013, ARCH DIS CHILD, V98, P998, DOI 10.1136/archdischild-2013-303718; Ferri C, 2002, J CLIN PATHOL, V55, P4, DOI 10.1136/jcp.55.1.4; Fiore E, 2008, J AM ACAD DERMATOL, V59, P684, DOI 10.1016/j.jaad.2008.06.005; Fischer G, 2000, PEDIATR DERMATOL, V17, P1, DOI 10.1046/j.1525-1470.2000.01701.x; Foeldvari I, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-014-0491-y; Fonacier LS, 2012, CURR ALLERGY ASTHM R, V12, P599, DOI 10.1007/s11882-012-0305-0; Fortna RR, 2010, J CUTAN PATHOL, V37, P932, DOI 10.1111/j.1600-0560.2010.01570.x; Fraitag S, 2009, J CUTAN PATHOL, V36, P966, DOI 10.1111/j.1600-0560.2009.01206.x; Fry L, 2007, CLIN DERMATOL, V25, P606, DOI 10.1016/j.clindermatol.2007.08.015; Fung MA, 1998, AM J SURG PATHOL, V22, P473, DOI 10.1097/00000478-199804000-00013; Gabbi TVB, 2004, J AM ACAD DERMATOL, V51, P1012, DOI 10.1016/j.jaad.2004.07.038; Gajic-Veljic M, 2010, J EUR ACAD DERMATOL, V24, P69, DOI 10.1111/j.1468-3083.2009.03264.x; Gardner-Medwin JMM, 2002, LANCET, V360, P1197, DOI 10.1016/S0140-6736(02)11279-7; Geller L, 2015, PEDIATR DERMATOL, V32, P579, DOI 10.1111/pde.12581; Gelmetti C, 1986, Pediatr Dermatol, V3, P446, DOI 10.1111/j.1525-1470.1986.tb00648.x; George PM, 1996, PEDIATR DERMATOL, V13, P269, DOI 10.1111/j.1442-200X.1996.tb02863.x; Gluth MB, 2004, INT J PEDIATR OTORHI, V68, P965, DOI 10.1016/j.ijporl.2004.02.014; Goldberg LJ, 2015, CLIN DERMATOL, V33, P622, DOI 10.1016/j.clindermatol.2015.09.005; Guitart J, 1999, AM J DERMATOPATH, V21, P178, DOI 10.1097/00000372-199904000-00013; Gupta R, 2012, CLIN DERMATOL, V30, P60, DOI 10.1016/j.clindermatol.2011.03.011; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Hadj-Rabia S, 2003, ARCH DERMATOL, V139, P1163, DOI 10.1001/archderm.139.9.1163; Hadj-Rabia S, 2011, J AM ACAD DERMATOL, V64, P508, DOI 10.1016/j.jaad.2010.01.045; Halevy S, 2010, BRIT J DERMATOL, V163, P1245, DOI 10.1111/j.1365-2133.2010.09967.x; Haliasos EC, 2007, CUTIS, V79, P425; Hamad A, 2017, ANN ALLERG ASTHMA IM, V118, P394, DOI 10.1016/j.anai.2017.01.017; Handa S, 2002, INT J DERMATOL, V41, P423, DOI 10.1046/j.1365-4362.2002.01522.x; Hantash BM, 2003, CUTIS, V71, P18; Harr T, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-39; HARRIST TJ, 1980, ARTHRITIS RHEUM-US, V23, P479, DOI 10.1002/art.1780230411; Hashimoto T, 1997, J INVEST DERMATOL, V109, P127, DOI 10.1111/1523-1747.ep12319025; HEADINGTON JT, 1984, ARCH DERMATOL, V120, P449, DOI 10.1001/archderm.120.4.449; HEADINGTON JT, 1989, ARCH DERMATOL, V125, P639, DOI 10.1001/archderm.125.5.639; HELANDER SD, 1995, ACTA DERM-VENEREOL, V75, P125; Hengge UR, 2006, LANCET INFECT DIS, V6, P769, DOI 10.1016/S1473-3099(06)70654-5; Hernandez-Machin B, 2007, J AM ACAD DERMATOL, V56, pS49, DOI 10.1016/j.jaad.2006.02.016; Hernandez-Martin A, 2013, J AM ACAD DERMATOL, V68, P150, DOI 10.1016/j.jaad.2012.05.025; Hoang MP, 2004, J CUTAN PATHOL, V31, P595, DOI 10.1111/j.0303-6987.2004.00236.x; Holman Robert C, 2010, Hawaii Med J, V69, P194; Holman RC, 2010, PEDIATR INFECT DIS J, V29, P483, DOI 10.1097/INF.0b013e3181cf8705; Hoss DM, 1996, ARCH DERMATOL, V132, P315, DOI 10.1001/archderm.132.3.315; Howe K, 1996, J CUTAN PATHOL, V23, P270, DOI 10.1111/j.1600-0560.1996.tb01478.x; HOWLAND WW, 1984, J AM ACAD DERMATOL, V10, P438, DOI 10.1016/S0190-9622(84)80090-0; HRUZA LL, 1993, PEDIATR DERMATOL, V10, P171; Hull CM, 2008, BRIT J DERMATOL, V159, P120, DOI 10.1111/j.1365-2133.2008.08629.x; Impicciatore P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/j.0306-5251.2001.01407.x; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; Jen M, 2010, PEDIATR ANN, V39, P658, DOI 10.3928/00904481-20100922-05; Jo JH, 2007, J AM ACAD DERMATOL, V57, P904, DOI 10.1016/j.jaad.2005.09.048; Jordaan HF, 1997, AM J DERMATOPATH, V19, P119, DOI 10.1097/00000372-199704000-00004; Kanwar AJ, 2010, CLIN EXP DERMATOL, V35, P257, DOI 10.1111/j.1365-2230.2009.03613.x; Kanwar AJ, 2010, INDIAN J DERMATOL VE, V76, P366, DOI 10.4103/0378-6323.66581; Kaplan AP, 2008, WORLD ALLERGY ORGAN, V1, P103, DOI 10.1097/WOX.0b013e31817aecbe; Karpati S, 2000, EXP DERMATOL, V9, P224, DOI 10.1034/j.1600-0625.2000.009003224.x; Keegan BR, 2007, PEDIATR DERMATOL, V24, P621, DOI 10.1111/j.1525-1470.2007.00550.x; Kempf W, 2012, AM J SURG PATHOL, V36, P1021, DOI 10.1097/PAS.0b013e31824f4f66; Khachemoune A, 2007, AM J CLIN DERMATOL, V8, P29, DOI 10.2165/00128071-200708010-00004; Khachemoune A, 2006, J AM ACAD DERMATOL, V54, P1046, DOI 10.1016/j.jaad.2006.02.029; Kilcline C, 2005, ARCH DERMATOL, V141, P248, DOI 10.1001/archderm.141.2.248; Kim MS, 2013, PEDIATR DERMATOL, V30, P141, DOI 10.1111/j.1525-1470.2011.01560.x; Kindt TJ, 2007, KUBY IMMUNOLOGY, pxxii; Kluger N, 2008, BRIT J DERMATOL, V159, P615, DOI 10.1111/j.1365-2133.2008.08725.x; Ko CJ, 2011, INT J DERMATOL, V50, P1480, DOI 10.1111/j.1365-4632.2011.04990.x; Kobayashi R, 2009, AUTOIMMUN REV, V8, P462, DOI 10.1016/j.autrev.2008.12.013; KOEHN GG, 1990, J AM ACAD DERMATOL, V23, P526, DOI 10.1016/S0190-9622(08)81117-6; Koh MJA, 2010, J AM ACAD DERMATOL, V62, P54, DOI 10.1016/j.jaad.2009.06.085; Koh MJA, 2009, CURR OPIN PEDIATR, V21, P505, DOI 10.1097/MOP.0b013e32832d1fef; Kriseman YL, 2007, J AM ACAD DERMATOL, V57, P112, DOI 10.1016/j.jaad.2006.11.033; KUECHLE MK, 1994, J AM ACAD DERMATOL, V30, P187, DOI 10.1016/S0190-9622(94)70015-X; KUMAR L, 1995, ANN RHEUM DIS, V54, P134, DOI 10.1136/ard.54.2.134; Kyriakis KP, 2006, J EUR ACAD DERMATOL, V20, P625, DOI 10.1111/j.1468-3083.2006.01513.x; Lamoreux MR, 2006, AM FAM PHYSICIAN, V74, P1883; Larson AR, 2015, AM J CLIN PATHOL, V144, P945, DOI 10.1309/AJCPZE77UAPSMDCD; LeBoit PE, 2000, AM J DERMATOPATH, V22, P457, DOI 10.1097/00000372-200010000-00014; Lee JYY, 2005, J AM ACAD DERMATOL, V52, P1003, DOI 10.1016/j.jaad.2005.02.032; Lee PW, 2009, CURR OPIN PEDIATR, V21, P491, DOI 10.1097/MOP.0b013e32832d2008; Letko E, 2005, ANN ALLERG ASTHMA IM, V94, P419, DOI 10.1016/S1081-1206(10)61112-X; Letko E, 2005, ANN ALLERG ASTHMA IM, V94, P56, DOI DOI 10.1016/S1081-1206(10)61112-X; Lis-Swiety A, 2017, J EUR ACAD DERMATOL; Lourenco DMR, 2014, LUPUS, V23, P1422, DOI 10.1177/0961203314544187; LOWNEY ED, 1967, ARCH DERMATOL, V95, P359, DOI 10.1001/archderm.95.4.359; Luis-Montoya P, 2005, PEDIATR DERMATOL, V22, P295, DOI 10.1111/j.1525-1470.2005.22402.x; Magro C, 2002, HUM PATHOL, V33, P788, DOI 10.1053/hupa.2002.125381; Magro CM, 2001, J CUTAN PATHOL, V28, P235, DOI 10.1034/j.1600-0560.2001.028005235.x; Magro CM, 1997, J CUTAN PATHOL, V24, P416, DOI 10.1111/j.1600-0560.1997.tb00816.x; Magro CM, 2007, HUM PATHOL, V38, P479, DOI 10.1016/j.humpath.2006.09.013; Mancini A. J., 2011, HURWITZ CLIN PEDIAT; Marathe K, 2015, CLIN DERMATOL, V33, P644, DOI 10.1016/j.clindermatol.2015.09.007; Maronn ML, 2005, PEDIATRICS, V115, pE230, DOI 10.1542/peds.2004-1544; Martin N, 2012, ARTHRIT CARE RES, V64, P1665, DOI 10.1002/acr.21753; MASCARO JM, 1985, J AM ACAD DERMATOL, V13, P913, DOI 10.1016/S0190-9622(85)70241-1; Matsuo K, 2001, BRIT J DERMATOL, V145, P132, DOI 10.1046/j.1365-2133.2001.04297.x; McCalmont TH, 2000, AM J DERMATOPATH, V22, P188, DOI 10.1097/00000372-200004000-00019; McNiff JM, 2008, J CUTAN PATHOL, V35, P452, DOI 10.1111/j.1600-0560.2007.00848.x; Meadows KP, 2000, PEDIATR DERMATOL, V17, P399, DOI 10.1046/j.1525-1470.2000.017005399.x; MEHREGAN DR, 1992, J AM ACAD DERMATOL, V26, P441, DOI 10.1016/0190-9622(92)70069-R; Mercy K, 2013, PEDIATR DERMATOL, V30, P424, DOI 10.1111/pde.12072; MOBACKEN H, 1983, ACTA DERM-VENEREOL, V63, P123; Moretti D, 2014, INT J DERMATOL, V53, P1508, DOI 10.1111/j.1365-4632.2012.05809.x; Morgan AJ, 2010, INT J DERMATOL, V49, P750, DOI 10.1111/j.1365-4632.2010.04522.x; Morris A, 2001, PEDIATR DERMATOL, V18, P188, DOI 10.1046/j.1525-1470.2001.018003188.x; Morris P, 2010, J PEDIAT HEMATOL ONC, V32, P189, DOI 10.1097/MPH.0b013e3181bf29a2; Muller CSL, 2011, J CUTAN PATHOL, V38, P185, DOI 10.1111/j.1600-0560.2010.01640.x; Muller BA, 2004, AM FAM PHYSICIAN, V69, P1123; MULLER SA, 1990, J AM ACAD DERMATOL, V23, P56, DOI 10.1016/0190-9622(90)70186-L; Nanda A, 2013, AM J DERMATOPATH, V35, P503, DOI 10.1097/DAD.0b013e3182770626; Narchi H, 2005, ARCH DIS CHILD, V90, P916, DOI 10.1136/adc.2005.074641; Neill SM, 2010, BRIT J DERMATOL, V163, P672, DOI 10.1111/j.1365-2133.2010.09997.x; Neri I, 2004, MYCOSES, V47, P475, DOI 10.1111/j.1439-0507.2004.01027.x; Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182; Ng Patricia P L, 2005, Australas J Dermatol, V46, P239, DOI 10.1111/j.1440-0960.2005.00191.x; Nguyen JV, 2011, J CUTAN PATHOL, V38, P401, DOI 10.1111/j.1600-0560.2010.01669.x; OSTLERE LS, 1992, CLIN EXP DERMATOL, V17, P36, DOI 10.1111/j.1365-2230.1992.tb02531.x; Pandhi D, 2014, PEDIATR DERMATOL, V31, P59, DOI 10.1111/pde.12155; Panko J, 2009, J AM ACAD DERMATOL, V60, P1057, DOI 10.1016/j.jaad.2008.10.025; Patrizi A, 2004, PEDIATR DERMATOL, V21, P197, DOI 10.1111/j.0736-8046.2004.21302.x; Patterson J. W., 2016, WEEDONS SKIN PATHOLO; Peckham SJ, 2011, J AM ACAD DERMATOL, V65, P615, DOI 10.1016/j.jaad.2011.02.017; de Silva NP, 2011, EUR J CLIN PHARMACOL, V67, P463, DOI 10.1007/s00228-011-1005-8; PIETTE WW, 1989, ARCH DERMATOL, V125, P53, DOI 10.1001/archderm.125.1.53; Pinal-Fernandez I, 2014, AUTOIMMUN REV, V13, P379, DOI 10.1016/j.autrev.2014.01.019; Pincus LB, 2010, J CUTAN PATHOL, V37, P416, DOI 10.1111/j.1600-0560.2010.01516.x; Pincus LB, 2009, AM J DERMATOPATH, V31, P520, DOI 10.1097/DAD.0b013e3181a84f32; Plaza JA, 2008, J CUTAN PATHOL, V35, P358, DOI 10.1111/j.1600-0560.2007.00813.x; Poindexter G, 2007, PEDIATR ANN, V36, P785, DOI 10.3928/0090-4481-20071201-07; Posso-De Los Rios CJ, 2014, J AM ACAD DERMATOL, V70, P767, DOI 10.1016/j.jaad.2013.11.005; Ragaz A, 1979, Am J Dermatopathol, V1, P199, DOI 10.1097/00000372-197900130-00002; Requena L, 2001, J AM ACAD DERMATOL, V45, P163, DOI 10.1067/mjd.2001.114736; Requena L, 2001, J AM ACAD DERMATOL, V45, P84; Rider LG, 2016, J INTERN MED, V280, P24, DOI 10.1111/joim.12444; Rider LG, 2009, ARTHRITIS RHEUM-US, V60, P3425, DOI 10.1002/art.24904; Riedl MA, 2003, AM FAM PHYSICIAN, V68, P1781; ROBBOY SJ, 1973, BRIT J DERMATOL, V88, P221, DOI 10.1111/j.1365-2133.1973.tb07538.x; ROBBOY SJ, 1972, HUM PATHOL, V3, P327, DOI 10.1016/S0046-8177(72)80034-0; RONGIOLETTI F, 1987, DERMATOLOGICA, V175, P41, DOI 10.1159/000248780; Rose C, 2009, J AM ACAD DERMATOL, V61, P39, DOI 10.1016/j.jaad.2008.12.037; Rositto AE, 2008, PEDIATR DERMATOL, V25, P339, DOI 10.1111/j.1525-1470.2008.00677.x; Rosman IS, 2013, PEDIATR DERMATOL, V30, P90, DOI 10.1111/j.1525-1470.2011.01669.x; Saadeh D, 2016, EXP DERMATOL, V25, P415, DOI 10.1111/exd.12957; Sackesen C, 2004, PEDIATR DERMATOL, V21, P102, DOI 10.1111/j.0736-8046.2004.21202.x; Sakuma-Oyama Y, 2004, BRIT J DERMATOL, V151, P126, DOI 10.1111/j.1365-2133.2004.06082.x; Saulsbury FT, 1999, MEDICINE, V78, P395, DOI 10.1097/00005792-199911000-00005; SAYAMA K, 1991, INT J DERMATOL, V30, P873, DOI 10.1111/j.1365-4362.1991.tb04356.x; Schmidt E, 2000, ARCH DERMATOL, V136, P174, DOI 10.1001/archderm.136.2.174; Shani-Adir A, 2004, J AM ACAD DERMATOL, V50, pS18, DOI 10.1016/S0190-9622(03)00746-1; Sharma VK, 2006, INT J DERMATOL, V45, P518, DOI 10.1111/j.1365-4632.2006.02593.x; Shinkai K, 2008, CLIN EXP DERMATOL, V33, P1, DOI 10.1111/j.1365-2230.2007.02540.x; Shinkai K, 2005, ARCH DERMATOL, V141, P242, DOI 10.1001/archderm.141.2.242; Shockman S, 2013, CUTIS, V92, P28897; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Silverberg NB, 2002, PEDIATR DERMATOL, V19, P110, DOI 10.1046/j.1525-1470.2002.00057.x; Sirois DA, 2000, ARCH DERMATOL, V136, P1569, DOI 10.1001/archderm.136.12.1569; SMITH SB, 1984, ARCH DERMATOL, V120, P324, DOI 10.1001/archderm.120.3.324; SOEPRONO FF, 1986, AM J DERMATOPATH, V8, P277, DOI 10.1097/00000372-198608000-00001; Sperling LC, 2012, ATLAS OF HAIR PATHOLOGY WITH CLINICAL CORRELATIONS, 2ND EDITION, P1; SPERLING LC, 1995, J CUTAN PATHOL, V22, P97, DOI 10.1111/j.1600-0560.1995.tb01391.x; Stefanaki C, 2011, J EUR ACAD DERMATOL, V25, P417, DOI 10.1111/j.1468-3083.2010.03801.x; Stefanato CM, 2010, HISTOPATHOLOGY, V56, P24, DOI 10.1111/j.1365-2559.2009.03439.x; Stitt WZD, 1998, PEDIATR DERMATOL, V15, P112, DOI 10.1046/j.1525-1470.1998.1998015112.x; Stulberg DL, 2004, AM FAM PHYSICIAN, V69, P87; SU WPD, 1981, AM J DERMATOPATH, V3, P251; Templet JT, 2007, CUTIS, V80, P473; Thong BYH, 2011, BRIT J CLIN PHARMACO, V71, P684, DOI 10.1111/j.1365-2125.2010.03774.x; Tilly JJ, 2004, J AM ACAD DERMATOL, V51, P606, DOI 10.1016/j.jaad.2003.12.012; Timpane S, 2016, CLIN DERMATOL, V34, P678, DOI 10.1016/j.clindermatol.2016.07.002; Tollefson MM, 2010, J AM ACAD DERMATOL, V62, P979, DOI 10.1016/j.jaad.2009.07.029; Tomasini D, 2004, J CUTAN PATHOL, V31, P531, DOI 10.1111/j.0303-6987.2004.00186.x; Tomasini D, 2010, J CUTAN PATHOL, V37, P1132, DOI 10.1111/j.1600-0560.2010.01587.x; Toppe E, 1998, BRIT J DERMATOL, V138, P248; Tosti A, 2005, BRIT J DERMATOL, V152, P556, DOI 10.1111/J.1365-2133.2004.06279.X; Tosti A, 2001, ARCH DERMATOL, V137, P1027; Tosti A, 2006, J AM ACAD DERMATOL, V55, P438, DOI 10.1016/j.jaad.2006.05.008; Trapani S, 2005, SEMIN ARTHRITIS RHEU, V35, P143, DOI 10.1016/j.semarthrit.2005.08.007; Triplett DA, 2002, ARCH PATHOL LAB MED, V126, P1424; Tsai KS, 2001, INT J DERMATOL, V40, P694, DOI 10.1046/j.1365-4362.2001.01301.x; UITTO J, 1980, J AM ACAD DERMATOL, V3, P271, DOI 10.1016/S0190-9622(80)80190-3; Vicente J, 1996, BRIT J DERMATOL, V135, P807; Viglizzo G, 2007, INT J DERMATOL, V46, P1302, DOI 10.1111/j.1365-4632.2007.03317.x; VIGNONPENNAMEN MD, 1986, ARCH DERMATOL, V122, P1155, DOI 10.1001/archderm.122.10.1155; Vodegel RM, 2002, J AM ACAD DERMATOL, V47, P919, DOI 10.1067/mjd.2002.125079; Volcheck GW, 2004, IMMUNOL ALLERGY CLIN, V24, P357, DOI 10.1016/j.iac.2004.03.003; Waisbourd-Zinman O, 2008, J AM ACAD DERMATOL, V58, P41, DOI 10.1016/j.jaad.2007.08.010; Wananukul S, 1998, PEDIATR DERMATOL, V15, P342, DOI 10.1046/j.1525-1470.1998.1998015342.x; Watanabe T, 2002, J INVEST DERMATOL, V119, P793, DOI 10.1046/j.1523-1747.2002.00200.x; Watts PJ, 2016, AM J CLIN DERMATOL, V17, P653, DOI 10.1007/s40257-016-0202-8; Weedon D, 2010, WEEDONS SKIN PATHOLO; Weinberg JM, 2002, ARCH DERMATOL, V138, P1063, DOI 10.1001/archderm.138.8.1063; Weinstein S, 2008, HEMATOL ONCOL CLIN N, V22, P67, DOI 10.1016/j.hoc.2007.10.011; Weiss PF, 2012, PEDIATR CLIN N AM, V59, P407, DOI 10.1016/j.pcl.2012.03.013; Weiss PF, 2010, J RHEUMATOL, V37, P2587, DOI 10.3899/jrheum.100364; Werner B, 2008, J CUTAN PATHOL, V35, P1100, DOI 10.1111/j.1600-0560.2007.00979.x; Wetter DA, 2010, MAYO CLIN PROC, V85, P131, DOI 10.4065/mcp.2009.0379; Weyers Wolfgang, 2011, Dermatol Pract Concept, V1, P33, DOI 10.5826/dpc.0101a09; Wildemore JK, 2003, J AM ACAD DERMATOL, V49, P243, DOI 10.1067/S0190-9622(03)00865-X; Wojnarowska F, 2000, J EUR ACAD DERMATOL, V14, P441, DOI 10.1046/j.1468-3083.2000.00157.x; WOJNAROWSKA F, 1988, J AM ACAD DERMATOL, V19, P792, DOI 10.1016/S0190-9622(88)70236-4; Yanagawa H, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e65; Yang YS, 2015, ANN DERMATOL, V27, P349, DOI 10.5021/ad.2015.27.3.349; Yoon TY, 2014, JAMA DERMATOL, V150, P952, DOI 10.1001/jamadermatol.2014.62; Yu C, 2014, J AUTOIMMUN, V48-49, P10, DOI 10.1016/j.jaut.2014.01.004; Zhang YQ, 2001, J CUTAN PATHOL, V28, P65, DOI 10.1034/j.1600-0560.2001.280202.x; Ziemer M, 2005, AM J DERMATOPATH, V27, P443, DOI 10.1097/01.dad.0000178003.96465.63; Zulian F, 2006, RHEUMATOLOGY, V45, P614, DOI 10.1093/rheumatology/kei251; Zwerina J, 2009, SEMIN ARTHRITIS RHEU, V39, P108, DOI 10.1016/j.semarthrit.2008.05.004	287	1	1	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAR-APR	2018	21	2			SI		115	149		10.1177/1093526617748781			35	Pathology; Pediatrics	Pathology; Pediatrics	GI7NF	WOS:000434688500002	29607753				2019-10-28	
J	Meuten, D; Munday, JS; Hauck, M				Meuten, Don; Munday, John S.; Hauck, Marlene			Time to Standardize? Time to Validate?	VETERINARY PATHOLOGY			English	Editorial Material							CANINE OSTEOSARCOMA; GRADING SYSTEM; APPENDICULAR OSTEOSARCOMA; DOGS; TUMORS; LYMPHOMA; CARBOPLATIN; GUIDELINES; AMPUTATION; ADJUVANT		[Meuten, Don] North Carolina State Univ, 1060 William Moore Dr, Raleigh, NC 27606 USA; [Munday, John S.] Massey Sch Vet Sci, Palmerston North, New Zealand; [Hauck, Marlene] Coll Vet Med, Raleigh, NC USA	Meuten, D (reprint author), North Carolina State Univ, 1060 William Moore Dr, Raleigh, NC 27606 USA.	don_meuten@ncsu.edu					Avallone G, 2014, VET PATHOL, V51, P713, DOI 10.1177/0300985813503565; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; COINDRE JM, 1986, CANCER, V58, P306, DOI 10.1002/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO;2-7; Frantz AM, 2013, VET PATHOL, V50, P693, DOI 10.1177/0300985812465325; Giuffrida MA, 2017, JAVMA-J AM VET MED A, V251, P1405, DOI 10.2460/javma.251.12.1405; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Karr A., 2011, SIGNIFICANCE, V8, P116, DOI [10.1111/j.1740-9713.2011.00506.x, DOI 10.1111/J.1740-9713.2011.00506.X]; Keller SM, 2016, VET PATHOL, V53, P711, DOI 10.1177/0300985815626576; Kirpensteijn J, 2002, VET PATHOL, V39, P240, DOI 10.1354/vp.39-2-240; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Kruse MA, 2013, VET PATHOL, V50, P704, DOI 10.1177/0300985812471542; Loukopoulos P, 2007, J COMP PATHOL, V136, P65, DOI 10.1016/j.jcpa.2006.11.005; Meuten DJ, 2016, VET PATHOL, V53, P7, DOI 10.1177/0300985815593349; Min SJ, 2016, ONCOTARGET, V7, P27848, DOI 10.18632/oncotarget.8425; Philips B, 2009, J AM ANIM HOSP ASSOC, V45, P33, DOI 10.5326/0450033; Richards KL, 2013, CANCER RES, V73, P5029, DOI 10.1158/0008-5472.CAN-12-3546; Saam DE, 2011, JAVMA-J AM VET MED A, V238, P195, DOI 10.2460/javma.238.2.195; Schott CR, 2018, VET PATHOL, V55, P202, DOI 10.1177/0300985817747329; Stefanello D, 2015, JAVMA-J AM VET MED A, V246, P765, DOI 10.2460/javma.246.7.765; Stokol T, 2015, VET CLIN PATH, V44, P79, DOI 10.1111/vcp.12227; Straw RC, 1996, J AM ANIM HOSP ASSOC, V32, P257, DOI 10.5326/15473317-32-3-257; Tasca S, 2009, VET CLIN PATH, V38, P2, DOI 10.1111/j.1939-165X.2008.00099.x; Thalheim L, 2013, J VET INTERN MED, V27, P1509, DOI 10.1111/jvim.12185; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; Turner H, 2017, JAVMA-J AM VET MED A, V251, P1293, DOI 10.2460/javma.251.11.1293; Veta M, 2015, MED IMAGE ANAL, V20, P237, DOI 10.1016/j.media.2014.11.010; Webster JD, 2011, VET PATHOL, V48, P7, DOI 10.1177/0300985810377187	28	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					195	199		10.1177/0300985817753869			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300002	29457567				2019-10-28	
J	Konradt, G; Cruz, RAS; Bassuino, DM; Bianchi, MV; de Andrade, CP; da Silva, FS; Driemeier, D; Pavarini, SP				Konradt, Guilherme; Cruz, Raquel A. S.; Bassuino, Daniele M.; Bianchi, Matheus V.; de Andrade, Caroline P.; da Silva, Fernando S.; Driemeier, David; Pavarini, Saulo P.			Granulomatous Necrotizing Myositis in Swine Affected by Porcine Circovirus Disease	VETERINARY PATHOLOGY			English	Article						myopathy; pigs; porcine circovirus; swine diseases	MULTISYSTEMIC WASTING SYNDROME; VASCULAR-LESIONS; TYPE-2; PIGS; GENOTYPES; VACCINATION; DIAGNOSIS	Porcine circovirus type 2 (PCV2) is associated with multiple clinical syndromes in pigs, known as porcine circovirus diseases. This work describes an outbreak of porcine circovirus diseases with severe lesions affecting the skeletal muscle. Ninety-two pigs had apathy, weight loss, and diarrhea over a clinical course of 7 to 10 days. Approximately 30 of the pigs had stiff gait, muscle weakness, hind limb paresis, and recumbency. Twelve of the 92 pigs were necropsied, and 4 had pale discoloration of skeletal muscles with microscopic lesions of granulomatous necrotizing myositis. Immunohistochemistry of skeletal muscle showed that PCV2 antigen was located primarily in the cytoplasm and nuclei of macrophages, lymphocytes, and multinucleated giant cells, with a lower amount in the cytoplasm of endothelial cells, necrotic fibers, and satellite cells. Affected muscle samples were polymerase chain reaction-positive for PCV2 and the amplicon exhibited 99% identity with sequences belonging to the PCV2b genotype. Locomotor clinical signs and granulomatous necrotizing myositis should be considered as another expression of PCV2 infection in pigs.	[Konradt, Guilherme; Cruz, Raquel A. S.; Bassuino, Daniele M.; Bianchi, Matheus V.; de Andrade, Caroline P.; da Silva, Fernando S.; Driemeier, David; Pavarini, Saulo P.] Univ Fed Rio Grande do Sul, Fac Vet, Setor Patol Vet, Ave Bento Goncalves 9090, BR-91540000 Porto Alegre, RS, Brazil	Konradt, G (reprint author), Univ Fed Rio Grande do Sul, Fac Vet, Setor Patol Vet, Ave Bento Goncalves 9090, BR-91540000 Porto Alegre, RS, Brazil.	guikonradt@yahoo.com.br	Matheus Viezzer Bianchi, DVM Ms/I-1456-2017; Driemeier, David/H-3461-2012	Matheus Viezzer Bianchi, DVM Ms/0000-0002-3951-0038; Driemeier, David/0000-0003-3766-0654			Cooper B. J., 2016, JUBB KENNEDY PALMERS, V1, P164; Dupont K, 2008, VET MICROBIOL, V128, P56, DOI 10.1016/j.vetmic.2007.09.016; Ellis J, 1999, J VET DIAGN INVEST, V11, P3, DOI 10.1177/104063879901100101; Fort M, 2008, VACCINE, V26, P1063, DOI 10.1016/j.vaccine.2007.12.019; Franzo G, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0361-x; Kim J, 2005, VET REC, V156, P177, DOI 10.1136/vr.156.6.177; Langohr IM, 2010, VET PATHOL, V47, P140, DOI 10.1177/0300985809352793; Olvera A, 2007, VIROLOGY, V357, P175, DOI 10.1016/j.virol.2006.07.047; Opriessnig T, 2006, J COMP PATHOL, V134, P105, DOI 10.1016/j.jcpa.2005.06.007; Opriessnig T, 2013, VET PATHOL, V50, P23, DOI 10.1177/0300985812450726; Opriessnig T, 2007, J VET DIAGN INVEST, V19, P591, DOI 10.1177/104063870701900601; Resendes AR, 2015, VET PATHOL, V52, P497, DOI 10.1177/0300985814540542; Correa AMR, 2007, J VET DIAGN INVEST, V19, P109, DOI 10.1177/104063870701900120; Segales J, 2008, VET REC, V162, P867, DOI 10.1136/vr.162.26.867; Segales J., 2006, DIS SWINE, P299; Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007; Shen HG, 2012, J GEN VIROL, V93, P1345, DOI 10.1099/vir.0.039552-0; Shen HG, 2010, PREV VET MED, V97, P228, DOI 10.1016/j.prevetmed.2010.09.020; Shimshoni JA, 2014, FOOD CHEM TOXICOL, V68, P283, DOI 10.1016/j.fct.2014.03.034; TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0; Xiao CT, 2012, J VIROL, V86, P12469, DOI 10.1128/JVI.02345-12; Zlotowski P, 2013, VET REC, V172, P637, DOI 10.1136/vr.101409	22	1	1	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					268	272		10.1177/0300985817736114			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300011	29050543	Bronze			2019-10-28	
J	Magstadt, DR; Fales-Williams, AJ; Palerme, JS; Flaherty, H; Lindquist, T; Miles, KG				Magstadt, Drew R.; Fales-Williams, Amanda J.; Palerme, Jean-Sebastien; Flaherty, Heather; Lindquist, Tracy; Miles, Kristina G.			Severe Disseminated Necrotizing and Granulomatous Lymphadenitis and Encephalitis in a Dog Due to Sporotrichum pruinosum (Teleomorph: Phanerochaete chrysosporium)	VETERINARY PATHOLOGY			English	Article						dogs; lymphadenitis; encephalitis; fungus; basidiomycete; Sporotrichum; Phanerochaete; white rot fungus	TROPICALIS PHYLUM-BASIDIOMYCOTA; OXYPORUS-CORTICOLA; INFECTION	A 9-year-old female mixed breed dog presented for an acute onset of anorexia, vomiting, and cough. Initial examination and diagnostics revealed a large multilobular cranial mediastinal mass with unidentified fungal organisms on cytology. The disease progressed in spite of therapy until the dog was euthanized 8 months later. Gross necropsy findings were a large multilobular intrathoracic mass, mild pleuritis, and generalized lymphadenopathy. Histologic evaluation showed granulomatous inflammation and necrosis with numerous 20- to 70-micron, periodic acid-Schiff-and Gomori methenamine silver-positive spherules effacing lymph node parenchyma, as well as severe inflammation within the midbrain. Endosporulation was a common finding, and large numbers of fungal hyphae were also present in affected areas. Ribosomal RNA gene sequencing found 100% identity to published sequences of Phanerochaete chrysosporium, the teleomorph form of Sporotrichum pruinosum. This is the first published report of disease caused by natural infection with this basidiomycete organism in animals.	[Magstadt, Drew R.] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, 1800 Christensen Dr, Ames, IA 50011 USA; [Fales-Williams, Amanda J.; Flaherty, Heather; Lindquist, Tracy] Iowa State Univ, Dept Vet Pathol, Coll Vet Med, Ames, IA 50011 USA; [Palerme, Jean-Sebastien; Miles, Kristina G.] Iowa State Univ, Dept Vet Clin Sci, Coll Vet Med, Ames, IA 50011 USA	Magstadt, DR (reprint author), Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, 1800 Christensen Dr, Ames, IA 50011 USA.	magstadt@iastate.edu		Palerme, Jean-Sebastien/0000-0001-7459-708X	Iowa State University Department of Veterinary Pathology	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Iowa State University Department of Veterinary Pathology provided funding for fungal sequencing at the Washington Animal Disease Diagnostic Laboratory.	Brockus CW, 2009, MED MYCOL, V47, P862, DOI 10.3109/13693780902962267; Bryan LK, 2014, J COMP PATHOL, V151, P157, DOI 10.1016/j.jcpa.2014.04.015; Connolly SL, 2012, VET CLIN PATH, V41, P419, DOI 10.1111/j.1939-165X.2012.00447.x; Kano R, 2002, J CLIN MICROBIOL, V40, P3535, DOI 10.1128/JCM.40.9.3535-3537.2002; KHAN ZU, 1988, J MED VET MYCOL, V26, P145; Lanspa MJ, 2014, RESPIROL CASE REP, V2, P7, DOI 10.1002/rcr2.31; Miller SA, 2012, J VET DIAGN INVEST, V24, P178, DOI 10.1177/1040638711425944; Ribas T, 2015, J VET CARDIOL, V17, P142, DOI 10.1016/j.jvc.2015.01.004; Roy Partha, 2015, Med J Armed Forces India, V71, pS456, DOI 10.1016/j.mjafi.2014.11.011; Sheppard BJ, 2013, J VET DIAGN INVEST, V25, P566, DOI 10.1177/1040638713499341; Singh D, 2008, APPL MICROBIOL BIOT, V81, P399, DOI 10.1007/s00253-008-1706-9	11	3	3	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					298	302		10.1177/0300985817741731			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300016	29191132	Bronze			2019-10-28	
J	Speight, PM; Takata, T				Speight, Paul M.; Takata, Takashi			New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours: odontogenic and maxillofacial bone tumours	VIRCHOWS ARCHIV			English	Review						Odontogenic tumours; Odontogenic cysts; Fibro-osseous lesions; WHO classification; Maxillofacial pathology	PTCH GENE; CARCINOMA; CYSTS; KERATOCYST; FIBROMA; MARSUPIALIZATION; REARRANGEMENTS; ODONTOMAS; NEOPLASM; VARIANT	The latest (4th) edition of the World Health Organization Classification of Head and Neck tumours has recently been published with a number of significant changes across all tumour sites. In particular, there has been a major attempt to simplify classifications and to use defining criteria which can be used globally in all situations, avoiding wherever possible the use of complex molecular techniques which may not be affordable or widely available. This review summarises the changes in Chapter 8: Odontogenic and maxillofacial bone lesions. The most significant change is the re-introduction of the classification of the odontogenic cysts, restoring this books status as the only text which classifies and defines the full range of lesions of the odontogenic tissues. The consensus group considered carefully the terminology of lesions and were concerned to ensure that the names used properly reflected the best evidence regarding the true nature of specific entities. For this reason, this new edition restores the odontogenic keratocyst and calcifying odontogenic cyst to the classification of odontogenic cysts and rejects the previous terminology (keratocystic odontogenic tumour and calcifying cystic odontogenic tumour) which were intended to suggest that they are true neoplasms. New entities which have been introduced include the sclerosing odontogenic carcinoma and primordial odontogenic tumour. In addition, some previously poorly defined lesions have been removed, including the ameloblastic fibrodentinoma, ameloblastic fibro-odontoma, which are probably developing odontomas, and the odontoameloblastoma, which is not regarded as an entity. Finally, the terminology "cemento" has been restored to cemento-ossifying fibroma and cemento-osseous dysplasias, to properly reflect that they are of odontogenic origin and are found in the tooth-bearing areas of the jaws.	[Speight, Paul M.] Univ Sheffield, Sch Clin Dent, Unit Oral & Maxillofacial Pathol, Claremont Cresent S10 2TA, England; [Takata, Takashi] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan	Speight, PM (reprint author), Univ Sheffield, Sch Clin Dent, Unit Oral & Maxillofacial Pathol, Claremont Cresent S10 2TA, England.	p.speight@sheffield.ac.uk; ttakata@hiroshima-u.ac.jpI					Barnes L, 2005, ODONTOGENIC TUMOURS; Barnes LEJW, 2005, WHO CLASSIFICATION T, P296; Bell D, 2017, WHO CLASSIFICATION H, P185; Bilodeau EA, 2013, AM J SURG PATHOL, V37, P1001, DOI 10.1097/PAS.0b013e31828a6727; Bologna-Molina R, 2017, MED ORAL PATOL ORAL, V22, pE314, DOI 10.4317/medoral.21859; Cheng YSL, 2015, HEAD NECK PATHOL, V9, P153, DOI 10.1007/s12105-014-0545-5; Chikosi R, 2011, J ORAL MAXIL SURG, V69, P1501, DOI 10.1016/j.joms.2010.05.071; Chrcanovic BR, 2017, J ORAL MAXIL SURG, V75, P1425, DOI 10.1016/j.joms.2016.12.038; El-Mofty SK, 2014, HEAD NECK PATHOL, V8, P432, DOI 10.1007/s12105-014-0590-0; El- Mofty SK, 2017, WHO CLASSIFICATION H, P251; El-Mofty SK, 2017, WHO CLASSIFICATION H, P254; El-Naggar AK, 2017, WHO CLASSIFICATION H, V9, P213; El-Naggar AK, 2017, WHO CLASSIFICATION H, P204; HONG SP, 1991, ORAL SURG ORAL MED O, V72, P56, DOI 10.1016/0030-4220(91)90190-N; Hussain O, 2013, OR SURG OR MED OR PA, V116, pE283, DOI 10.1016/j.oooo.2013.01.018; Ide F, 2011, PATHOL INT, V61, P259, DOI 10.1111/j.1440-1827.2011.02648.x; Irie T, 2010, PATHOL INT, V60, P694, DOI 10.1111/j.1440-1827.2010.02583.x; Kim IK, 2015, J KOR ASSOC ORAL MAX, V41, P139, DOI 10.5125/jkaoms.2015.41.3.139; Koutlas IG, 2008, AM J SURG PATHOL, V32, P1613, DOI 10.1097/PAS.0b013e31817a8a58; Kramer IRH, 1992, HISTOLOGICAL TYPING; Kunkel M, 2004, ORAL ONCOL, V40, P444, DOI 10.1016/j.oraloncology.2003.09.010; LANGDON JD, 1976, BRIT J ORAL SURG, V14, P1, DOI 10.1016/0007-117X(76)90087-1; Ledesma-Montes C, 2008, J ORAL PATHOL MED, V37, P302, DOI 10.1111/j.1600-0714.2007.00623.x; Levanat S, 2000, J MOL MED, V78, P140, DOI 10.1007/s001090000090; Li TJ, 2011, J DENT RES, V90, P133, DOI 10.1177/0022034510379016; Li TJ, 2000, AM J SURG PATHOL, V24, P1385, DOI 10.1097/00000478-200010000-00008; Li TJ, 2003, AM J SURG PATHOL, V27, P372, DOI 10.1097/00000478-200303000-00011; Li TJ, 1998, HISTOPATHOLOGY, V32, P242; MacDonald-Jankowski DS, 2010, DENTOMAXILLOFAC RAD, V39, P455, DOI 10.1259/dmfr/19728573; Mosqueda-Taylor A, 2014, HISTOPATHOLOGY, V65, P606, DOI 10.1111/his.12451; Muller S, 2017, WHO CLASSIFICATION H, P222; Pavelic B, 2001, J ORAL PATHOL MED, V30, P569, DOI 10.1034/j.1600-0714.2001.300911.x; Philipsen HP, 1997, ORAL ONCOL, V33, P86, DOI 10.1016/S0964-1955(96)00067-X; Philipsen HP, 2005, WHO CLASSIFICATION T, P306; Pindborg J, 1971, WHO INT HISTOLOGICAL; Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029; Qu JF, 2015, ORAL ONCOL, V51, P40, DOI 10.1016/j.oraloncology.2014.09.016; Shear M, 2007, CYSTS ORAL MAXILLOFA; Shear M, 2007, CYSTS ORAL MAXILLOFA, P100; Slama A, 2002, Rev Stomatol Chir Maxillofac, V103, P124; Slater LJ, 2016, J ORAL MAXIL SURG, V74, P547, DOI 10.1016/j.joms.2015.08.019; SLOOTWEG PJ, 1981, ORAL SURG ORAL MED O, V51, P266, DOI 10.1016/0030-4220(81)90056-6; Speight P, WHO CLASSIFICATION H, P239; Tan SH, 2014, OR SURG OR MED OR PA, V118, pE119, DOI 10.1016/j.oooo.2014.02.010; Vered M, 2017, WHO CLASSIFICATION H, P217; Wood A, 2016, OR SURG OR MED OR PA, V122, pE204, DOI 10.1016/j.oooo.2016.07.009; WRIGHT JM, 1981, ORAL SURG ORAL MED O, V51, P609, DOI 10.1016/S0030-4220(81)80011-4; Wright JM, 2014, HEAD NECK PATHOL, V8, P373, DOI 10.1007/s12105-014-0585-x; Wushou A, 2014, J CRANIO MAXILL SURG, V42, P1540, DOI 10.1016/j.jcms.2014.04.027; Yancoskie AE, 2014, OR SURG OR MED OR PA, V118, pE115, DOI 10.1016/j.oooo.2014.02.004; Zegalie N, 2015, DIAGN HISTOPATHOL, V2015, P370	51	31	33	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					331	339		10.1007/s00428-017-2182-3			9	Pathology	Pathology	GB8UF	WOS:000429350100003	28674741	Other Gold, Green Accepted, Green Published			2019-10-28	
J	Visser, NCM; van der Wurff, AAM; Pijnenborg, JMA; Massuger, LFAG; Bulten, J; Nagtegaal, ID				Visser, Nicole C. M.; van der Wurff, Anneke A. M.; Pijnenborg, Johanna M. A.; Massuger, Leon F. A. G.; Bulten, Johan; Nagtegaal, Iris D.			Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer	VIRCHOWS ARCHIV			English	Article						Endometrial cancer; Endometrial sampling; Tissue microarray; Biomarkers; Immunohistochemistry	MISMATCH REPAIR; EXPRESSION; CARCINOMA; VALIDATION; SPECIMENS; TUMORS; P53; TECHNOLOGY; MANAGEMENT; PREDICTOR	The aim of this study was to define the concordance between tissue microarrays (TMAs) of different sizes and whole slide for 15 different antibodies in endometrial cancer and study the use of TMAs in preoperative endometrial samples. Cores of preoperative and hysterectomy specimens of 14 endometrial cancer and three atypical hyperplasia cases were collected in TMA blocks. Two 0.6-mm and two 2.0-mm cores were used from each sample. Different antibodies were tested in TMAs and compared with results of whole slides of hysterectomy. Tested antibodies were as follows: ER, PR, p53, Ki-67, MLH1, PMS2, MSH2, MSH6, ARID1A, stathmin, IMP3, L1CAM, PTEN, beta-catenin, and p16. Seventeen cases with four cores per paraffin block (both 0.6 and 2.0 mm in duplicate) and 15 different antibodies resulted in a total of 1020 cores for both preoperative and hysterectomy specimen. Overall, 2.0-mm cores were more assessable for evaluation than 0.6-mm cores (96.0 versus 79.5%, p < 0.01). For most antibodies, a substantial to good agreement between hysterectomy TMA and whole slide was present, with lowest agreement for p16 and stathmin and perfect agreement for mismatch repair proteins. Preoperative TMAs showed for most antibodies moderate to perfect agreement with hysterectomy TMAs. In conclusion, 2.0-mm cores are the preferred size for immunohistochemical studies in endometrial cancer. For all tested antibodies, TMAs are a good alternative for whole slide analysis in scientific studies with large patient cohorts, even in preoperative endometrial samples. However, caution is required for interpretation of TMA results of p16 and stathmin.	[Visser, Nicole C. M.; Bulten, Johan; Nagtegaal, Iris D.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands; [van der Wurff, Anneke A. M.] Elisabeth TweeSteden Hosp, Dept Pathol, Tilburg, Netherlands; [Pijnenborg, Johanna M. A.; Massuger, Leon F. A. G.] Radboud Univ Nijmegen, Dept Obstet & Gynecol, Med Ctr, Nijmegen, Netherlands	Visser, NCM (reprint author), Radboud Univ Nijmegen, Dept Pathol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	nicole.visser@radboudumc.nl	Pijnenborg, Johanna MA/G-4455-2016; Nagtegaal, Iris D/A-2448-2014; Bulten, J./L-4237-2015	Pijnenborg, Johanna MA/0000-0002-6138-1236; Nagtegaal, Iris D/0000-0003-0887-4127; 			Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Anagnostou VK, 2010, ARCH PATHOL LAB MED, V134, P613, DOI 10.1043/1543-2165-134.4.613; Boone J, 2008, VIRCHOWS ARCH, V452, P507, DOI 10.1007/s00428-008-0602-0; Bosse T, 2014, EUR J CANCER, V50, P2602, DOI 10.1016/j.ejca.2014.07.014; Clark TJ, 2002, BJOG-INT J OBSTET GY, V109, P313, DOI 10.1111/j.1471-0528.2002.01088.x; Engelsen IB, 2006, AM J OBSTET GYNECOL, V195, P979, DOI 10.1016/j.ajog.2006.02.045; Fons G, 2007, J CLIN PATHOL, V60, P500, DOI 10.1136/jcp.2006.040170; Fonseca FP, 2014, OR SURG OR MED OR PA, V117, P81, DOI 10.1016/j.oooo.2013.08.029; Frumovitz M, 2004, GYNECOL ONCOL, V95, P463, DOI 10.1016/j.ygyno.2004.07.016; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; Helpman L, 2014, BRIT J CANCER, V110, P609, DOI 10.1038/bjc.2013.766; Hendriks Y, 2003, AM J PATHOL, V162, P469, DOI 10.1016/S0002-9440(10)63841-2; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Ilyas M, 2013, HISTOPATHOLOGY, V62, P827, DOI 10.1111/his.12118; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kyndi M, 2008, ACTA ONCOL, V47, P591, DOI 10.1080/02841860701851871; Leversha MA, 2003, J PATHOL, V200, P610, DOI 10.1002/path.1374; Mhawech-Fauceglia P, 2013, HISTOPATHOLOGY, V62, P976, DOI 10.1111/his.12096; Neubauer NL, 2009, GYNECOL ONCOL, V112, P511, DOI 10.1016/j.ygyno.2008.11.012; Neves-Silva R, 2016, J ORAL PATHOL MED, V45, P704, DOI 10.1111/jop.12428; Petersen RW, 2000, AUST NZ J OBSTET GYN, V40, P191, DOI 10.1111/j.1479-828X.2000.tb01145.x; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Shaco-Levy R, 2008, ACTA OBSTET GYN SCAN, V87, P868, DOI 10.1080/00016340802253775; Trovik J, 2013, EUR J CANCER, V49, P3431, DOI 10.1016/j.ejca.2013.06.016; Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412; van der Putten LJM, 2016, BRIT J CANCER, V115, P716, DOI 10.1038/bjc.2016.235; Williams ARW, 2008, BJOG-INT J OBSTET GY, V115, P1028, DOI 10.1111/j.1471-0528.2008.01773.x; Zeimet AG, 2013, JNCI-J NATL CANCER I, V105, P1142, DOI 10.1093/jnci/djt144	28	5	5	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					407	413		10.1007/s00428-017-2289-6			7	Pathology	Pathology	GB8UF	WOS:000429350100010	29426961	Green Published, Other Gold			2019-10-28	
J	Dantonello, TM; Vokuhl, C; Scheer, M; Sparber-Sauer, M; Stegmaier, S; Seitz, G; Scheithauer, H; Faber, J; Veit-Friedrich, I; Kaatsch, P; Bielack, SS; Klingebiel, T; Koscielniak, E				Dantonello, Tobias M.; Vokuhl, Christian; Scheer, Monika; Sparber-Sauer, Monika; Stegmaier, Sabine; Seitz, Guido; Scheithauer, Heike; Faber, Joerg; Veit-Friedrich, Iris; Kaatsch, Peter; Bielack, Stefan S.; Klingebiel, Thomas; Koscielniak, Ewa		CWS	Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?	VIRCHOWS ARCHIV			English	Article						Rhabdomyosarcoma; Paratesticular; Alveolar subtype; Pediatric oncology	SOFT-TISSUE SARCOMA; FUSION GENE STATUS; INTERGROUP RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; RISK STRATIFICATION; COOPERATIVE GROUP; MOLECULAR MARKER; CHILDHOOD; ADOLESCENCE; CHILDREN	The alveolar subtype of rhabdomyosarcoma (RMA) is a strong risk factor. Cases of RMA located in paratesticular sites have however been reported to have similar outcomes to those of embryonal rhabdomyosarcoma (RME). We wanted to re-evaluate the impact of subtype in paratesticular rhabdomyosarcoma (PT-RMS). Patients from a population-based cohort diagnosed with paratesticular RMA in 1990-2013 were analyzed. All tumor samples were re-reviewed using conventional morphology, immunohistochemistry, and molecular testing. Seven patients were eligible. Four tumors showed focal areas morphologically compatible with RMA (mixed RMA/RME). One case was undifferentiated, with a solid round-cell morphology which had to be reclassified as poorly differentiated RME. Two cases had a "microalveolar" morphology which is today regarded as sclerosing RME. No tumor showed the characteristic gene fusion of RMA. Five children had localized disease, one bone metastases, and another lymph-node involvement. All primaries were grossly resected. One locoregional relapse occurred. At a median follow-up of 7 years, all patients were alive disease-free. PT-RMS can show a focal alveolar histology combined with typical features of RME. In current morphological classifications, all rhabdomyosarcomas qualify for the alveolar subtype if typical features of RMA are realized at least focally. Rhabdomyosarcomas consisting of pure RMA morphology were however not found in our patients with PT-RMS. The mixed RMA/RMEs identified in our population-based study did not show a translocation typical for RMA and had a good prognosis. Further prospective studies need to evaluate if mixed RMA/RMEs have a similar favorable outcome in non-paratesticular sites as well.	[Dantonello, Tobias M.; Scheer, Monika; Sparber-Sauer, Monika; Stegmaier, Sabine; Veit-Friedrich, Iris; Bielack, Stefan S.; Koscielniak, Ewa] Klinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany; [Dantonello, Tobias M.] Klinikum Stuttgart, Olgahosp, Pediat Cardiol Pulmonol Intens Care 3, Kriegsbergstr 62, D-70174 Stuttgart, Germany; [Vokuhl, Christian] Univ Kiel, Dept Pediat Pathol, Kiel Pediat Tumor Registry, Kiel, Germany; [Seitz, Guido] Univ Marburg, Dept Pediat Surg, Marburg, Germany; [Scheithauer, Heike] Ludwig Maximilians Univ Munchen, Dept Radiotherapy, Munich, Germany; [Faber, Joerg] Johannes Gutenberg Univ Mainz, Dept Pediat Oncol, Mainz, Germany; [Kaatsch, Peter] German Childhood Canc Registry, Mainz, Germany; [Bielack, Stefan S.] Univ Childrens Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany; [Klingebiel, Thomas] Univ Frankfurt Main, Dept Pediat Oncol, Frankfurt, Germany; [Koscielniak, Ewa] Univ Tubingen, Dept Pediat Oncol, Tubingen, Germany	Dantonello, TM (reprint author), Klinikum Stuttgart Olgahosp, Stuttgart Canc Ctr, Pediat Oncol Hematol Immunol 5, Stuttgart, Germany.; Dantonello, TM (reprint author), Klinikum Stuttgart, Olgahosp, Pediat Cardiol Pulmonol Intens Care 3, Kriegsbergstr 62, D-70174 Stuttgart, Germany.	t.dantonello@klinikum-stuttgart.de	Vokuhl, Christian/M-1511-2017	Seitz, Prof. Dr. Guido/0000-0001-9280-1451	Deutsche Kinderkrebsstiftung, Bonn; Deutsche Krebshilfe e.V., Bonn; Forderkreis Krebskranke kinder e.V. Stuttgart, Germany	This article is dedicated to Ivo Leuschner, who did most of the pathologic review. We are indebted to the personnel of all participating institutions and thank all patients, parents, and guardians for their willingness to participate in the CWS trials. We thank Erika Hallmen and Simone Feuchtgruber for their excellent data management. This research was supported by the Deutsche Kinderkrebsstiftung, Bonn; Deutsche Krebshilfe e.V., Bonn; and the Forderkreis Krebskranke kinder e.V. Stuttgart, Germany.	Anderson JR, 2010, J CLIN ONCOL, V28, pE587, DOI 10.1200/JCO.2010.30.5466; Arndt CAS, 2009, J CLIN ONCOL, V27, P5182, DOI 10.1200/JCO.2009.22.3768; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; Bisogno G, 2014, PEDIAT BLOOD CANC, V61; Bisogno G, 2005, SARCOMA, V9; CAVAZZANA AO, 1992, AM J SURG PATHOL, V16, P229, DOI 10.1097/00000478-199203000-00002; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; Dantonello TM, 2008, J CLIN ONCOL, V26, P406, DOI 10.1200/JCO.2007.12.2382; Dantonello TM, 2015, PEDIATR BLOOD CANCER, V62, P16, DOI 10.1002/pbc.25207; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Deyrup AT, 2006, HISTOPATHOLOGY, V48, P42, DOI 10.1111/j.1365-2559.2005.02288.x; Ferrari A, 2004, PEDIATR BLOOD CANCER, V42, P134, DOI 10.1002/pbc.10460; Ferrari A, 2002, J CLIN ONCOL, V20, P449, DOI 10.1200/JCO.20.2.449; Fletcher C, 2013, WHO CLASSIFICATION T; Hachitanda Y, 1998, MODERN PATHOL, V11, P1222; Kaatsch P, 2015, GERMAN CHILDHOOD CAN; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klingebiel T, 2008, PEDIATR BLOOD CANCER, V50, P739, DOI 10.1002/pbc.21494; Koscielniak E, 1999, J CLIN ONCOL, V17, P3706, DOI 10.1200/JCO.1999.17.12.3706; Koscielniak E, 2013, PEDIATR BLOOD CANCER, V60, P32; LEUSCHNER I, 1993, AM J SURG PATHOL, V17, P221, DOI 10.1097/00000478-199303000-00002; Mentzel T, 2000, VIRCHOWS ARCH, V436, P305, DOI 10.1007/s004280050451; Meyer WH, 2012, J CLIN ONCOL, V30, P2431, DOI 10.1200/JCO.2012.42.4275; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Modritz D, 2005, WIEN KLIN WOCHENSCHR, V117, P196, DOI 10.1007/s00508-004-5-0285-8; NEWTON WA, 1995, CANCER-AM CANCER SOC, V76, P1073, DOI 10.1002/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L; Nishio J, 2006, LAB INVEST, V86, P547, DOI 10.1038/labinvest.3700416; Parham DM, 2013, ADV ANAT PATHOL, V20, P387, DOI 10.1097/PAP.0b013e3182a92d0d; RANEY RB, 1987, CANCER, V60, P2337, DOI 10.1002/1097-0142(19871101)60:9<2337::AID-CNCR2820600937>3.0.CO;2-3; Rosenberg AR, 2012, CANCER EPIDEM BIOMAR, V21, P1012, DOI 10.1158/1055-9965.EPI-12-0207; Rossig C, 2013, PEDIATR BLOOD CANCER, V60, P1574, DOI 10.1002/pbc.24598; Rudzinski ER, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26645; Rudzinski ER, 2013, AM J CLIN PATHOL, V140, P82, DOI 10.1309/AJCPA1WN7ARPCMKQ; Seitz G, 2016, ANN SURG, V264, P1148, DOI 10.1097/SLA.0000000000001550; Seitz G, 2014, J UROLOGY, V192, P902, DOI 10.1016/j.juro.2014.03.005; Selfe J, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26386; Stegmaier S, 2012, J CLIN ONCOL, V30, P4039, DOI 10.1200/JCO.2012.43.5628; Stegmaier S, 2011, PEDIATR BLOOD CANCER, V57, P406, DOI 10.1002/pbc.22958; Stewart RJ, 2003, J CLIN ONCOL, V21, P793, DOI 10.1200/JCO.2003.06.040; Treetipsatit J, 2009, PEDIATR DEVEL PATHOL, V12, P383, DOI 10.2350/08-08-0518.1; Weihkopf T, 2008, EUR J CANCER, V44, P432, DOI 10.1016/j.ejca.2007.11.013; Wexler LH, 2010, J CLIN ONCOL, V28, P2126, DOI 10.1200/JCO.2009.27.5339; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814	43	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					441	449		10.1007/s00428-018-2311-7			9	Pathology	Pathology	GB8UF	WOS:000429350100014	29468306				2019-10-28	
J	Chlopik, A; Selim, MA; Peng, Y; Wu, CL; Tell-Marti, G; Paral, KM; Shalin, SC; Kraft, S; Hsu, CK; Shea, CR; Puig, S; Fernandez-Figueras, MT; Biernat, W; Rys, J; Marszalek, A; Hoang, MP				Chlopik, Agata; Selim, M. Angelica; Peng, Yan; Wu, Cheng-Lin; Tell-Marti, Gemma; Paral, Kristen M.; Shalin, Sara C.; Kraft, Stefan; Hsu, Chao-Kai; Shea, Christopher R.; Puig, Susana; Fernandez-Figueras, Maria-Teresa; Biernat, Wojciech; Rys, Janusz; Marszalek, Andrzej; Hoang, Mai P.			Prognostic rote of tumoral PDL1 expression and peritumoral FoxP3+lymphocytes in vulvar melanomas	HUMAN PATHOLOGY			English	Article						Vulvar melanoma; Survival; PDL1; CD8; FoxP3; Immunohistochemistry	REGULATORY T-CELLS; INFILTRATING IMMUNE CELLS; MALIGNANT-MELANOMA; METASTATIC MELANOMA; MUCOSAL MELANOMA; CANCER; LYMPHOCYTES; RESISTANCE; BLOCKADE; SURVIVAL	The prognostic role of PDL1 expression, CD8+ and FoxP3+ lymphocytes in vulvar melanomas has not been studied. We correlated PDL1 expression and CD8+ and FoxP3+ immune infiltrates with dinicopathologic variables and patient outcomes in a series of 75 vulvar melanomas. Tumoral PDL1 expression (>5%) was seen in 23% of cases. By Fisher exact test, PDL1 expression and peritumoral FoxP3+ lymphocytes significantly correlated with less disease-specific death. By linear regression analysis, correlations between tumoral PDL1 expression with the density of tumoral CD8+ and peritumoral CD8+ lymphocytes, tumoral FoxP3+ with tumoral CD8+ lymphocytes, and peritumoral FoxP3+ with peritumoral CD8+ lymphocytes were observed. By univariate analyses, tumor thickness >4 mm predicted poorer progression-free survival, melanoma-specific survival, and overall survival. PDL1 expression >5% and peritumoral CD8+, peritumoral FoxP3+, and tumoral FoxP3+ lymphocytes correlated with better overall survival. By multivariate analyses, high peritumoral FoxP3+ lymphocytes independently predicted better melanoma-specific survival (P = .023), and tumor thickness independently predicted poorer progression-free survival (P = .05) and overall survival (P = .039). In conclusion, our study shows that, independent from tumor thickness, an increased density of peritumoral FoxP3+ lymphocytes may positively impact survival in a subset of vulvar melanomas. Tumoral PDL1 expression correlated with tumoral as well as peritumoral CD8+ and FoxP3+ lymphocytes, supportive of an adaptive immune response. Although the frequency of PDLI expression is low in vulvar melanoma, its expression may identify a subset of vulvar melanoma that might respond to immunotherapy. (C) 2018 Elsevier Inc. All rights reserved.	[Chlopik, Agata; Marszalek, Andrzej] Poznan Univ Med Sci, Dept Pathol, PL-60206 Poznan, Poland; [Chlopik, Agata; Marszalek, Andrzej] Greater Poland Canc Ctr, PL-60206 Poznan, Poland; [Selim, M. Angelica; Paral, Kristen M.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Peng, Yan] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Wu, Cheng-Lin] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan 70403, Taiwan; [Tell-Marti, Gemma; Puig, Susana] Hosp Clin Barcelona, IDIBAPS, Melanoma Unit, Dept Dermatol, Barcelona 08193, Spain; [Tell-Marti, Gemma; Puig, Susana] ISCIII, Ctr Biomed Res Rare Dis CIBERER, Barcelona 08193, Spain; [Shalin, Sara C.] Univ Arkansas, Dept Pathol, Little Rock, AR 72204 USA; [Kraft, Stefan] Ctr Dermatopathol, Dept Pathol, D-79016 Freiburg, Germany; [Hsu, Chao-Kai] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Dermatol, Tainan 70403, Taiwan; [Shea, Christopher R.] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA; [Fernandez-Figueras, Maria-Teresa] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Pathol, E-08193 Barcelona, Spain; [Biernat, Wojciech] Med Univ Gdansk, Dept Pathol, PL-80309 Gdansk, Poland; [Rys, Janusz] M Sklodowska Curie Mem Inst, Ctr Oncol, Dept Pathol, PL-31115 Krakow, Poland; [Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA; [Hoang, Mai P.] Harvard Med Sch, Boston, MA 02114 USA	Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.	mhoang@mgh.harvard.edu	Hsu, Chao-Kai/L-4408-2019	Hsu, Chao-Kai/0000-0003-4365-4533; Chlopik-Olkiewicz, Agata/0000-0001-7147-5634; Tell-Marti, Gemma/0000-0003-2728-6961			Badoual C, 2006, CLIN CANCER RES, V12, P465, DOI 10.1158/1078-0432.CCR-05-1886; Blank C, 2006, INT J CANCER, V119, P317, DOI 10.1002/ijc.21775; D'Angelo SP, 2017, J CLIN ONCOL, V35, P226, DOI 10.1200/JCO.2016.67.9258; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Erdag G, 2012, CANCER RES, V72, P1070, DOI 10.1158/0008-5472.CAN-11-3218; Erdman SE, 2005, CANCER RES, V65, P3998, DOI 10.1158/0008-5472.CAN-04-3104; Gerber AL, 2014, BRIT J DERMATOL, V170, P103, DOI 10.1111/bjd.12641; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kakavand H, 2015, MODERN PATHOL, V28, P1535, DOI 10.1038/modpathol.2015.110; Klages K, 2010, CANCER RES, V70, P7788, DOI 10.1158/0008-5472.CAN-10-1736; Kraft S, 2017, J AM ACAD DERMATOL, V77, P534, DOI 10.1016/j.jaad.2017.05.007; Ladanyi A, 2010, PATHOL ONCOL RES, V16, P303, DOI 10.1007/s12253-010-9254-x; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Massi D, 2015, ANN ONCOL, V26, P1980, DOI 10.1093/annonc/mdv255; Miracco C, 2007, ONCOL REP, V18, P1115; Nagarajan P, 2017, CLIN CANCER RES, V23, P2093, DOI 10.1158/1078-0432.CCR-16-2126; Panizzon RG, 1996, SEMIN DERMATOL, V15, P67, DOI 10.1016/S1085-5629(96)80021-6; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; R Core Team, 2016, R LANG ENV STAT COMP; Ragnarsson-Olding BK, 1999, CANCER, V86, P1273, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179; Shimizu J, 1999, J IMMUNOL, V163, P5211; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Thierauf J, 2017, EUR J DERMATOL, V27, P160, DOI 10.1684/ejd.2016.2949; Thierauf J, 2015, MELANOMA RES, V25, P503, DOI 10.1097/CMR.0000000000000197; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Tzankov A, 2008, HAEMATOL-HEMATOL J, V93, P193, DOI 10.3324/haematol.11702; Venet F, 2006, J IMMUNOL, V177, P6540, DOI 10.4049/jimmunol.177.9.6540; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444	35	0	0	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						176	183		10.1016/j.humpath.2017.12.022			8	Pathology	Pathology	GB3PJ	WOS:000428969600022	29307625				2019-10-28	
J	Duggan, MA				Duggan, Maire A.			Glandular Lesions of the Uterine Cervix: Cytology and Histology Updates	AJSP-REVIEWS AND REPORTS			English	Editorial Material							INVASIVE ENDOCERVICAL ADENOCARCINOMA; CLASSIFICATION-SYSTEM; PATTERN; CRITERIA		[Duggan, Maire A.] Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med, Calgary, AB, Canada	Duggan, MA (reprint author), Foothills Med Ctr, Dept Pathol & Lab Med, Room 7543 McCaig Tower,1403 29th St NW, Calgary, AB T2N 2Y9, Canada.	duggan@ucalgary.ca					De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; Djordjevic B, 2016, INT J GYNECOL PATHOL, V35, P456, DOI 10.1097/PGP.0000000000000264; Lee S, 2017, INT J GYNECOL PATHOL; Lee S, 2017, INT J GYNECOL PATHOL, V36, P310, DOI 10.1097/PGP.0000000000000345; Nayar R, 2013, AJSP-REV REP, V18, P149, DOI 10.1097/PCR.0b013e3182990d8a; Rutgers JKL, 2016, MODERN PATHOL, V29, P1083, DOI 10.1038/modpathol.2016.94; Sar A, 2018, J LOW GENITAL TRACT; Simard EP, 2012, GYNECOL ONCOL, V127, P611, DOI 10.1016/j.ygyno.2012.08.021; Stoler M, 2014, WHO CLASSIFICATION T, P170; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Wells M, 2003, WHO CLASSIFICATION T, P260	11	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					51	53		10.1097/PCR.0000000000000238			3	Pathology	Pathology	GL9WS	WOS:000437694400001					2019-10-28	
J	McCluggage, WG				McCluggage, W. Glenn			Adenocarcinoma of the Uterine Cervix: Measuring, Staging, and Synoptic Reporting	AJSP-REVIEWS AND REPORTS			English	Review						adenocarcinoma; cervix; International Collaboration on Cancer Reporting (ICCR); measuring; multifocal tumors; staging; synoptic reporting	SQUAMOUS-CELL CARCINOMA; ENDOCERVICAL GLANDULAR LESIONS; OVARIAN METASTASES; UNITED-STATES; CANCER; TRENDS; EQUIVALENT; PROGNOSIS; INVASION; CRITERIA	Adenocarcinoma of the cervix is increasing in incidence in relative and real terms given the reduction in cervical squamous carcinomas in many developed countries. In this review, various aspects relating to the pathological staging of cervical carcinomas are discussed with emphasis on adenocarcinomas. These include the distinction between adenocarcinoma in situ and invasive lesions and the measurement of invasive adenocarcinomas; both of these issues are often more difficult than with the corresponding squamous lesions. The measurement of multifocal cervical carcinomas is covered with discussion of the International Collaboration on Cancer Reporting recommendations, although these were chiefly proposed for multifocal squamous carcinomas. The issue of adnexal involvement in cervical adenocarcinoma is discussed. A checklist of parameters that should be included on the pathology report of resection specimens of cervical carcinomas is presented, again with particular reference to the International Collaboration on Cancer Reporting recommendations. The advantages of synoptic reporting, in comparison to free text reporting, are discussed.	[McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland	McCluggage, WG (reprint author), Belfast Hlth & Social Care Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.	glenn.mccluggage@belfasttrust.hscni.net					Al-Kalbani M, 2012, INT J GYNECOL CANCER, V22, P291, DOI 10.1097/IGC.0b013e3182339fff; Baalbergen A, 2011, INT J GYNECOL CANCER, V21, P1640, DOI 10.1097/IGC.0b013e3182262059; Bulk S, 2005, INT J CANCER, V113, P1005, DOI 10.1002/ijc.20678; Chang MC, 2010, INT J GYNECOL PATHOL, V29, P88, DOI 10.1097/PGP.0b013e3181acefbf; Day E, 2016, INT J GYNECOL PATHOL, V35, P467, DOI 10.1097/PGP.0000000000000269; GIRARDI F, 1994, GYNECOL ONCOL, V55, P427, DOI 10.1006/gyno.1994.1317; Hemminki K, 2002, EUR J OBSTET GYN R B, V101, P64, DOI 10.1016/S0301-2115(01)00508-5; Holl K, 2015, INT J CANCER, V137, P2858, DOI 10.1002/ijc.29651; Hu T, 2013, ANN SURG ONCOL, V20, P881, DOI 10.1245/s10434-012-2632-8; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Landoni F, 2007, INT J GYNECOL CANCER, V17, P623, DOI 10.1111/j.1525-1438.2006.00854.x; Lankshear S, 2013, ARCH PATHOL LAB MED, V137, P1599, DOI 10.5858/arpa.2012-0656-OA; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; McCluggage WG, 2013, HISTOPATHOLOGY, V62, P138, DOI 10.1111/his.12012; McCluggage WG, 2010, J CLIN PATHOL, V63, P768, DOI 10.1136/jcp.2010.080978; McCluggage WG, 2003, J CLIN PATHOL, V56, P164, DOI 10.1136/jcp.56.3.164; McCluggage WG, 2017, INT J GYNECOL PATHOL; McIlwaine P, 2014, INT J GYNECOL PATHOL, V33, P213, DOI 10.1097/PGP.0b013e31829040ce; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Ostor AG, 2000, INT J GYNECOL PATHOL, V19, P29; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; ROLLASON TP, 1989, INT J GYNECOL PATHOL, V8, P230, DOI 10.1097/00004347-198909000-00006; Ronnett BM, 2008, AM J SURG PATHOL, V32, P1835, DOI 10.1097/PAS.0b013e3181758831; Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Srigley JR, 2009, J SURG ONCOL, V99, P517, DOI 10.1002/jso.21282; Talia K, 2017, PATHOLOGY; Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064; Wheeler DT, 2005, INT J GYNECOL PATHOL, V24, P125, DOI 10.1097/01.PGP.0000152025.45106.6D; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P914, DOI 10.1097/PAS.0b013e3181971fdd; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x	32	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					54	61		10.1097/PCR.0000000000000236			8	Pathology	Pathology	GL9WS	WOS:000437694400002					2019-10-28	
J	Pirog, EC				Pirog, Edyta Catalina			Primary Adenocarcinoma of the Uterine Cervix: Classification and Grading	AJSP-REVIEWS AND REPORTS			English	Review						adenocarcinoma of the cervix; cervical adenocarcinoma; clear cell adenocarcinoma of the cervix; endocervical adenocarcinoma usual type; endometrioid adenocarcinoma of the cervix; gastric adenocarcinoma of the cervix; HPV; intestinal adenocarcinoma of the cervix; mesonephric adenocarcinoma of the cervix; minimal deviation adenocarcinoma of the cervix; serous adenocarcinoma of the cervix; signet ring cell carcinoma of the cervix; villoglandular adenocarcinoma of the cervix	EARLY INVASIVE ADENOCARCINOMA; DIFFERENTIATED VILLOGLANDULAR ADENOCARCINOMA; MINIMAL DEVIATION ADENOCARCINOMA; PAPILLARY SEROUS CARCINOMA; CLEAR-CELL CARCINOMA; HPV DNA DETECTION; HUMAN-PAPILLOMAVIRUS; IN-SITU; ENDOCERVICAL ADENOCARCINOMA; MESONEPHRIC ADENOCARCINOMAS	Cervical adenocarcinomas are a group of malignancies with several distinct histologic tumor types, which include endocervical usual type, endometrioid, intestinal, villoglandular, gastric, signet ring, serous, clear cell, and mesonephric. Diagnosis of cervical adenocarcinoma, in particular early diagnosis, and classification of the tumor type may pose a significant challenge. The goal of this article is to review the current classification, diagnostic criteria, adjunct markers, and differential diagnosis of various subtypes of cervical adenocarcinomas. The article presents up-to-date summary of such problematic issues as differentiating glandular tumors from benign mimics, differentiating early invasive lesions from adenocarcinoma in situ, determining the tumor type, and, finally, differentiating primary cervical adenocarcinoma from uterine endometrioid adenocarcinoma. Discussion of human papillomavirus detection in different tumor types is provided.	[Pirog, Edyta Catalina] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Pirog, EC (reprint author), Cornell Univ, Weill Med Coll, Dept Pathol, New York Presbyterian Hosp, 525 E 68th St,ST-1041, New York, NY 10065 USA.	ecpirog@med.cornell.edu					Ansari-Lari MA, 2004, AM J SURG PATHOL, V28, P160, DOI 10.1097/00000478-200402000-00002; Arora A, 2017, BMJ CASE REP, V16; CLEMENT PB, 1995, AM J SURG PATHOL, V19, P1158, DOI 10.1097/00000478-199510000-00006; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; GOODMAN HM, 1989, GYNECOL ONCOL, V33, P241, DOI 10.1016/0090-8258(89)90560-X; Goyal A, 2014, INT J GYNECOL PATHOL, V33, P613, DOI 10.1097/PGP.0000000000000102; Hanselaar A, 1997, CANCER, V79, P2229, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2229::AID-CNCR22>3.0.CO;2-X; Hiromura T, 2009, Br J Radiol, V82, pe20, DOI 10.1259/bjr/75304693; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; IMACHI M, 1993, CANCER, V71, P3472, DOI 10.1002/1097-0142(19930601)71:11<3472::AID-CNCR2820711103>3.0.CO;2-V; Jones MW, 2013, INT J GYNECOL CANCER, V23, P380, DOI 10.1097/IGC.0b013e31825cc8ee; JONES MW, 1993, INT J GYNECOL PATHOL, V12, P1, DOI 10.1097/00004347-199301000-00001; Jones MW, 2000, INT J GYNECOL PATHOL, V19, P110, DOI 10.1097/00004347-200004000-00003; Ju B, 2017, INT J GYNECOL PATHOL; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Lee KR, 2000, CANCER, V89, P1048, DOI 10.1002/1097-0142(20000901)89:5<1048::AID-CNCR14>3.3.CO;2-J; Li CZ, 2007, MODERN PATHOL, V20, P242, DOI 10.1038/modpathol.3800735; Liang L, 2016, ARCH PATHOL LAB MED, V140, P148, DOI 10.5858/arpa.2015-0081-OA; Liebrich C, 2009, EUR J GYNAECOL ONCOL, V30, P45; Lu X, 1999, INT J GYNECOL PATHOL, V18, P109; McCluggage WG, 2008, INT J GYNECOL PATHOL, V27, P92, DOI 10.1097/pgp.0b013e31815698e7; Mirkovic J, 2015, MOD PATHOL, V28; Molijn A, 2016, INT J CANCER, V138, P409, DOI 10.1002/ijc.29722; NANBU K, 1995, GYNECOL ONCOL, V58, P136, DOI 10.1006/gyno.1995.1198; Nofech-Mozes S, 2006, INT J GYNECOL CANCER, V16, P286, DOI 10.1111/j.1525-1438.2006.00514.x; Onishi J, 2016, HUM PATHOL, V55, P174, DOI 10.1016/j.humpath.2016.05.007; Ostor AG, 2000, INT J GYNECOL PATHOL, V19, P29; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Park KJ, 2009, APPL IMMUNOHISTO M M, V17, P8, DOI 10.1097/PAI.0b013e318174f012; Pirog EC, 2002, INT J GYNECOL PATHOL, V21, P22, DOI 10.1097/00004347-200201000-00005; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Quint KD, 2009, GYNECOL ONCOL, V114, P390, DOI 10.1016/j.ygyno.2009.05.013; Rabban JT, 2010, AM J SURG PATHOL, V34, P137, DOI 10.1097/PAS.0b013e3181c89c98; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Saad RS, 2009, AM J CLIN PATHOL, V132, P531, DOI 10.1309/AJCP7E5ASGOENPFP; Sal V, 2016, INT J SURG CASE REP, V21, P1, DOI 10.1016/j.ijscr.2016.02.007; Shukla A, 2013, INT J GYNECOL PATHOL, V32, P116, DOI 10.1097/PGP.0b013e318257df46; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Thomas MB, 2008, GYNECOL ONCOL, V109, P335, DOI 10.1016/j.ygyno.2008.02.007; Tringler B, 2004, HUM PATHOL, V35, P689, DOI 10.1016/j.humpath.2004.02.012; Ueno S, 2013, INT J GYNECOL CANCER, V23, P1084, DOI 10.1097/IGC.0b013e3182981bdc; Washimi K, 2015, PATHOL INT, V65, P393, DOI 10.1111/pin.12275; YOUNG RH, 1989, CANCER, V63, P1773; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x; Young RH, 1993, AM J SURG PATHOL, V17; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P314, DOI 10.1097/01.PGP.0000035801.90350.90; Zhou C, 1998, AM J SURG PATHOL, V22, P113, DOI 10.1097/00000478-199801000-00015	50	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					62	72		10.1097/PCR.0000000000000232			11	Pathology	Pathology	GL9WS	WOS:000437694400003					2019-10-28	
J	Harrison, BT; Nucci, MR				Harrison, Beth T.; Nucci, Marisa R.			Glandular Pseudoneoplasms of the Uterine Cervix	AJSP-REVIEWS AND REPORTS			English	Review						Arias-Stella reaction; endocervical glandular hyperplasia; mesonephric hyperplasia; microglandular hyperplasia; pseudoneoplastic lesions; uterine cervix	ARIAS-STELLA REACTION; ECTOPIC PROSTATIC TISSUE; FEMALE GENITAL-TRACT; MINIMAL DEVIATION ADENOCARCINOMA; PEUTZ-JEGHERS SYNDROME; SIMULATING MICROGLANDULAR HYPERPLASIA; DETAILED IMMUNOHISTOCHEMICAL ANALYSIS; TUBO-ENDOMETRIOID METAPLASIA; ENDOCERVICAL TUNNEL CLUSTERS; CLEAR-CELL CARCINOMA	Several benign glandular lesions of the uterine cervix can mimic malignancy. These glandular pseudoneoplasms include microglandular hyperplasia, lobular and diffuse laminar types of endocervical glandular hyperplasia, tunnel clusters, adenomyoma of endocervical type, mesonephric hyperplasia, ectopic prostate, endometriosis and tuboendometrioid metaplasia, and the Arias-Stella reaction, among others. Each of these entities may show a variety of unusual morphologic features that complicate the diagnosis. This review covers the clinical and pathologic features of this selected group of glandular pseudoneoplasms, as well as the immunohistochemical and molecular markers that distinguish them from premalignant and malignant lesions in the differential diagnosis. New developments in the molecular characterization of the latter are briefly discussed in regard to their potential utility in the diagnosis of selected challenging cases. For example, recurrent KRAS mutations distinguish microglandular-like endometrial adenocarcinoma from microglandular hyperplasia, as well as mesonephric and mesonephric-like carcinomas from mesonephric hyperplasia; a p53 mutant phenotype favors minimal deviation or gastric-type adenocarcinoma over lobular endocervical glandular hyperplasia (typical), tunnel clusters, endocervical adenomyomas, and other lesions, and p16 positivity has emerged as a very useful marker of human papillomavirus-related neoplasia in the appropriate clinicopathologic setting.	[Harrison, Beth T.; Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA	Harrison, BT (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA.	bharrison3@bwh.harvard.edu					Abi-Raad R, 2014, INT J GYNECOL PATHOL, V33, P524, DOI 10.1097/PGP.0000000000000086; ANDERSON W R, 1968, Journal of the Iowa State Medical Society, V58, P585; ARIAS STELLA J, 1956, An Fac Med Lima, V39, P1377; ARIASSTELLA J, 1954, AMA ARCH PATHOL, V58, P112; Baker PM, 1999, INT J GYNECOL PATHOL, V18, P198, DOI 10.1097/00004347-199907000-00002; Cameron RI, 2002, HISTOPATHOLOGY, V41, P313, DOI 10.1046/j.1365-2559.2002.01465.x; CANDY J, 1968, J AMER MED ASSOC, V203, P323; CARBIA E, 1970, OBSTET GYNECOL, V35, P381; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Casey S, 2015, HISTOPATHOLOGY, V66, P420, DOI 10.1111/his.12546; Chekmareva M, 2008, INT J GYNECOL PATHOL, V27, P547, DOI 10.1097/PGP.0b013e318177eadc; CLEMENT PB, 1990, AM J SURG PATHOL, V14, P449, DOI 10.1097/00000478-199005000-00004; COVE H, 1979, AM J SURG PATHOL, V3, P567, DOI 10.1097/00000478-197912000-00011; Dainty LA, 2009, INT J GYNECOL CANCER, V19, P1091, DOI 10.1111/IGC.0b013e3181a839d3; DUCATMAN BS, 1993, DIAGN CYTOPATHOL, V9, P98, DOI 10.1002/dc.2840090121; Fadare O, 2016, HUM PATHOL, V54, P202, DOI 10.1016/j.humpath.2016.02.028; Farlie R, 1998, ACTA OBSTET GYN SCAN, V77, P131, DOI 10.1080/00016349808565830; FARRAR HK, 1961, AM J OBSTET GYNECOL, V81, P124, DOI 10.1016/S0002-9378(16)36314-1; FERRY JA, 1990, AM J SURG PATHOL, V14, P1100, DOI 10.1097/00000478-199012000-00002; FERRY JA, 1988, AM J SURG PATHOL, V12, P134, DOI 10.1097/00000478-198802000-00007; FLUHMANN CF, 1961, OBSTET GYNECOL, V17, P206; Fukunaga M, 2000, PATHOL INT, V50, P541, DOI 10.1046/j.1440-1827.2000.01074.x; Fukunaga M, 2001, VIRCHOWS ARCH, V438, P302, DOI 10.1007/s004280000299; Fukunaga M, 2013, INT J GYNECOL PATHOL, V32, P426, DOI 10.1097/PGP.0b013e3182630d69; Gardner H L, 1966, Clin Obstet Gynecol, V9, P358, DOI 10.1097/00003081-196606000-00006; Gilks CB, 1996, MODERN PATHOL, V9, P220; GILTMAN LI, 1986, ARCH GYNECOL OBSTET, V237, P243, DOI 10.1007/BF02133787; GOULD PR, 1979, AM J PATHOL, V95, P1; GOVAN ADT, 1969, J CLIN PATHOL, V22, P84, DOI 10.1136/jcp.22.1.84; Goyal A, 2016, INT J GYNECOL PATHOL, V35, P82, DOI 10.1097/PGP.0000000000000221; Goyal A, 2014, INT J GYNECOL PATHOL, V33, P613, DOI 10.1097/PGP.0000000000000102; GRAHAM J, 1968, OBSTET GYNECOL, V31, P190; GREELEY C, 1995, INT J GYNECOL PATHOL, V14, P50, DOI 10.1097/00004347-199501000-00009; Hashi A, 2008, DIAGN CYTOPATHOL, V36, P535, DOI 10.1002/dc.20859; Hirasawa A, 2012, ANN ONCOL, V23, P2990, DOI 10.1093/annonc/mds492; Hiromura T, 2009, Br J Radiol, V82, pe20, DOI 10.1259/bjr/75304693; Hoang LN, 2014, HISTOPATHOLOGY, V64, P585, DOI 10.1111/his.12286; Hong W, 2015, HUM PATHOL, V46, P1000, DOI 10.1016/j.humpath.2015.03.010; Hoogduin KJ, 2013, INT J GYNECOL PATHOL, V32, P122, DOI 10.1097/PGP.0b013e318253c6f6; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; HUFFMAN JW, 1948, AM J OBSTET GYNECOL, V56, P23, DOI 10.1016/0002-9378(48)90188-4; Ikeda Y, 2015, GYNECOL ONCOL REP, V12, P27, DOI 10.1016/j.gore.2015.02.001; ISMAIL SM, 1991, HISTOPATHOLOGY, V18, P107, DOI 10.1111/j.1365-2559.1991.tb01452.x; JACQUES SM, 1995, INT J GYNECOL PATHOL, V14, P191, DOI 10.1097/00004347-199507000-00001; Jaiman S, 2014, ARCH GYNECOL OBSTET, V289, P915, DOI 10.1007/s00404-013-3112-5; JONES MA, 1993, GYNECOL ONCOL, V49, P41, DOI 10.1006/gyno.1993.1083; Jones MA, 1996, AM J SURG PATHOL, V20, P1312, DOI 10.1097/00000478-199611000-00002; JONES MA, 1991, AM J SURG PATHOL, V15, P1123, DOI 10.1097/00000478-199112000-00002; Kano H, 2003, J Obstet Gynaecol, V23, P84; Kaspar HG, 2015, ARCH PATHOL LAB MED, V139, P39, DOI 10.5858/arpa.2014-0057-RA; Kato N, 2011, PATHOL INT, V61, P369, DOI 10.1111/j.1440-1827.2011.02670.x; Kawauchi S, 2008, AM J SURG PATHOL, V32, P1807, DOI 10.1097/PAS.0b013e3181883722; Kelly P, 2011, INT J GYNECOL PATHOL, V30, P605, DOI 10.1097/PGP.0b013e31821713b6; Kim KR, 2004, INT J GYNECOL PATHOL, V23, P182, DOI 10.1097/01.pgp.0000116619.70699.7d; Kondi-Pafitis A, 2003, EUR J GYNAECOL ONCOL, V24, P154; Kondo T, 2007, HISTOPATHOLOGY, V50, P843, DOI 10.1111/j.1365-2559.2007.02705.x; Kondo T, 2005, MODERN PATHOL, V18, P1199, DOI 10.1038/modpathol.3800403; Kwek JW, 2010, ULTRASOUND OBST GYN, V36, P252, DOI 10.1002/uog.7635; KYRIAKOS M, 1968, CANCER, V22, P99, DOI 10.1002/1097-0142(196807)22:1<99::AID-CNCR2820220113>3.0.CO;2-4; LANG G, 1990, INT J GYNECOL PATHOL, V9, P145, DOI 10.1097/00004347-199004000-00006; LarrazaHernandez O, 1997, INT J GYNECOL PATHOL, V16, P291, DOI 10.1097/00004347-199707000-00018; Liao SY, 2011, BRIT J CANCER, V104, P353, DOI 10.1038/sj.bjc.6606049; Luks S, 2012, AM J CASE REP, V13, P271, DOI 10.12659/AJCR.883584; MARUYAMA R, 1995, PATHOL INT, V45, P283, DOI 10.1111/j.1440-1827.1995.tb03457.x; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; McCluggage G, 1997, INT J GYNECOL PATHOL, V16, P22, DOI 10.1097/00004347-199701000-00004; McCluggage WG, 2003, HISTOPATHOLOGY, V43, P144, DOI 10.1046/j.1365-2559.2003.01684.x; McCluggage WG, 2006, AM J SURG PATHOL, V30, P209, DOI 10.1097/01.pas.0000180446.17517.b8; McCluggage WG, 2002, HISTOPATHOLOGY, V40, P107, DOI 10.1046/j.1365-2559.2002.1340d.x; McCluggage WG, 2000, HISTOPATHOLOGY, V37, P285, DOI 10.1046/j.1365-2559.2000.01020-4.x; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; Mikami Y, 2001, HISTOPATHOLOGY, V39, P364, DOI 10.1046/j.1365-2559.2001.01239.x; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mikami Y, 2013, PATHOL RES PRACT, V209, P173, DOI 10.1016/j.prp.2012.12.003; Mikami Y, 2009, HISTOPATHOLOGY, V55, P362, DOI 10.1111/j.1365-2559.2009.03346.x; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x; MILCHGRUB S, 1991, AM J CLIN PATHOL, V95, P892, DOI 10.1093/ajcp/95.6.892; Mirkovic J, 2017, AM J SURG PATHOL; Mirkovic J, 2017, HISTOPATHOLOGY, V71, P1003, DOI 10.1111/his.13307; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Mockler D, 2017, AM J CLIN PATHOL, V148, P264, DOI [10.1093/AJCP/AQX077, 10.1093/ajcp/aqx077]; MOLLER N E, 1959, Acta Obstet Gynecol Scand, V38, P271; Moritani S, 2002, INT J GYNECOL PATHOL, V21, P125, DOI 10.1097/00004347-200204000-00004; Nagahama Kiyotaka, 2013, Gynecol Oncol Case Rep, V5, P4, DOI 10.1016/j.gynor.2013.02.005; Nucci MR, 2000, AM J SURG PATHOL, V24, P1224, DOI 10.1097/00000478-200009000-00005; Nucci MR, 2004, AM J SURG PATHOL, V28, P608, DOI 10.1097/00000478-200405000-00007; Nucci MR, 2002, INT J GYNECOL PATHOL, V21, P347, DOI 10.1097/01.PGP.0000035803.90350.02; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; Oliva E, 2004, ADV ANAT PATHOL, V11, P310, DOI 10.1097/01.pap.0000138140.81139.46; OLIVA E, 1995, AM J CLIN PATHOL, V103, P618; Ordi J, 2003, AM J SURG PATHOL, V27, P178, DOI 10.1097/00000478-200302000-00005; Ordi J, 2001, AM J SURG PATHOL, V25, P1540, DOI 10.1097/00000478-200112000-00011; Ota H, 2011, AM J CLIN PATHOL, V135, P253, DOI 10.1309/AJCPQMAO3PW4OGOF; Park HM, 2009, J KOREAN MED SCI, V24, P767, DOI 10.3346/jkms.2009.24.4.767; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Pavlakis K, 2010, GYNECOL ONCOL, V116, P468, DOI 10.1016/j.ygyno.2009.10.055; PRAHALADA S, 1988, BIOL REPROD, V38, P935, DOI 10.1095/biolreprod38.4.935; Qiu WS, 2003, INT J GYNECOL PATHOL, V22, P261, DOI 10.1097/01.PGP.0000071043.12278.8D; Rabban JT, 2010, AM J SURG PATHOL, V34, P137, DOI 10.1097/PAS.0b013e3181c89c98; ROBBOY SJ, 1984, CANCER, V54, P869, DOI 10.1002/1097-0142(19840901)54:5<869::AID-CNCR2820540519>3.0.CO;2-I; Roh MH, 2009, INT J GYNECOL PATHOL, V28, P107, DOI 10.1097/PGP.0b013e3181877a73; Roma AA, 2016, ANN DIAGN PATHOL, V22, P63, DOI 10.1016/j.anndiagpath.2016.04.005; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Samarawardana P, 2011, APPL IMMUNOHISTO M M, V19, P1514, DOI 10.1097/PAI.0b013e3182167c66; Schlesinger C, 1999, INT J GYNECOL PATHOL, V18, P1, DOI 10.1097/00004347-199901000-00001; SCHNEIDER V, 1981, ACTA CYTOL, V25, P224; SEGAL GH, 1990, AM J SURG PATHOL, V14, P895, DOI 10.1097/00000478-199010000-00001; SEIDMAN JD, 1995, INT J GYNECOL PATHOL, V14, P293, DOI 10.1097/00004347-199510000-00002; SHERRER CW, 1977, OBSTET GYNECOL, V49, P65; SPAUN E, 1986, ACTA OBSTET GYN SCAN, V65, P505, DOI 10.3109/00016348609157395; Stewart CJR, 2015, INT J GYNECOL PATHOL, V34, P90, DOI 10.1097/PGP.0000000000000107; SUH KS, 1990, INT J GYNECOL PATHOL, V9, P122, DOI 10.1097/00004347-199004000-00003; Sumathi VP, 2002, J CLIN PATHOL, V55, P391, DOI 10.1136/jcp.55.5.391; Takatsu A, 2013, VIRCHOWS ARCH, V462, P645, DOI 10.1007/s00428-013-1417-1; Takei Y, 2015, J OBSTET GYNAECOL RE, V41, P468, DOI 10.1111/jog.12541; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Tambouret R, 2000, AM J SURG PATHOL, V24, P369, DOI 10.1097/00000478-200003000-00005; TAYLOR HB, 1967, J AMER MED ASSOC, V202, P637, DOI 10.1001/jama.202.7.637; Tsuji T, 2011, HISTOPATHOLOGY, V59, P55, DOI 10.1111/j.1365-2559.2011.03886.x; Vang R, 2004, INT J GYNECOL PATHOL, V23, P223, DOI 10.1097/01.pgp.0000130106.13533.38; Vang R, 2005, INT J GYNECOL PATHOL, V24, P391, DOI 10.1097/01.pgp.0000170064.95465.5c; VEIGAFERREIRA MM, 1987, AM J OBSTET GYNECOL, V157, P849, DOI 10.1016/S0002-9378(87)80070-4; Wallace C, 2001, AM J SURG PATHOL, V25, P1215, DOI 10.1097/00000478-200109000-00016; WILKINSON E, 1976, OBSTET GYNECOL, V47, P189; WILLIAMS GA, 1955, OBSTET GYNECOL, V6, P309; Witkiewicz AK, 2005, HUM PATHOL, V36, P154, DOI 10.1016/j.humpath.2004.10.017; WOLFE SA, 1961, AM J OBSTET GYNECOL, V81, P111, DOI 10.1016/S0002-9378(16)36313-X; Wolfe SA, 1940, AM J OBSTET GYNECOL, V39, P312, DOI 10.1016/S0002-9378(40)90828-6; Yamamoto S, 2007, HUM PATHOL, V38, P1074, DOI 10.1016/j.humpath.2006.12.018; YOUNG RH, 1991, SEMIN DIAGN PATHOL, V8, P234; YOUNG RH, 1989, AM J SURG PATHOL, V13, P50, DOI 10.1097/00000478-198901000-00007; YOUNG RH, 1992, AM J SURG PATHOL, V16, P1092, DOI 10.1097/00000478-199211000-00008; Zaloudek C, 1997, INT J GYNECOL PATHOL, V16, P52, DOI 10.1097/00004347-199701000-00009; Zamecnik M, 2002, INT J GYNECOL PATHOL, V21, P424, DOI 10.1097/00004347-200210000-00017	135	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					73	83		10.1097/PCR.0000000000000237			11	Pathology	Pathology	GL9WS	WOS:000437694400004					2019-10-28	
J	Park, KJ				Park, Kay J.			Case Review: Gastric-Type Adenocarcinoma of the Uterine Cervix and Precursor Lesions	AJSP-REVIEWS AND REPORTS			English	Review						gastric-type adenocarcinoma; lobular endocervical glandular hyperplasia; pyloric metaplasia; uterine cervix; adenocarcinoma in-situ	ENDOCERVICAL-GLANDULAR-HYPERPLASIA; MINIMAL DEVIATION ADENOCARCINOMA; PEUTZ-JEGHERS-SYNDROME; SQUAMOUS-CELL CARCINOMA; ADENOMA-MALIGNUM; IMMUNOHISTOCHEMICAL-ANALYSES; HUMAN-PAPILLOMAVIRUS; EXPRESSION; BENIGN; METAPLASIA	A case of gastric-type endocervical adenocarcinoma that was originally diagnosed as possibly of endometrial or pancreatobiliary/upper gastrointestinal tract origin is reported. This report reviews the pertinent medical literature, differential diagnoses, etiology, and pitfalls of this disease, as well as use of immunohistochemistry and human papillomavirus (HPV) testing in establishing the diagnosis. The morphology of these tumors can range from extremely well differentiated (minimal deviation adenocarcinoma) to poorly differentiated, and therefore, the differential diagnosis can be quite varied. On one end of the spectrum, the tumor can be difficult to differentiate from benign endocervical glands, whereas at the other end, it can be difficult to determine the origin of the tumor. Because these tumors are not associated with HPV infection, the use of ancillary studies such as p16 can be misleading, and these may not be detected on standard Papanicolaou cytology with HPV screening. Molecular testing was also performed in this case with a TP53 hotpot mutation detected, along with mutations in ELF3 and PTPRS.	[Park, Kay J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Park, KJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	ParkK@MSKCC.ORG			NIH/NCI Cancer CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]	This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.	[Anonymous], 2017, CANC CELL, V32; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; FLUHMANN CF, 1961, OBSTET GYNECOL, V17, P206; Gusserow U., 1870, ARCH GYNAKOL, V1, P240; Hemminki A, 1998, NATURE, V391, P184; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Ito S, 2014, PATHOL INT, V64, P283, DOI 10.1111/pin.12173; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JONES MA, 1991, AM J SURG PATHOL, V15, P1123, DOI 10.1097/00000478-199112000-00002; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kawauchi S, 2008, AM J SURG PATHOL, V32, P1807, DOI 10.1097/PAS.0b013e3181883722; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kondo T, 2005, MODERN PATHOL, V18, P1199, DOI 10.1038/modpathol.3800403; Kurman RJ, 2014, WHO CLASSIFICATION T; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; McAlpine JN, 2017, HISTOPATHOLOGY, V71, P238, DOI 10.1111/his.13205; McCluggage WG, 2010, J CLIN PATHOL, V63, P935, DOI 10.1136/jcp.2010.080150; MCKELVEY JL, 1963, CANCER, V16, P549, DOI 10.1002/1097-0142(196305)16:5<549::AID-CNCR2820160502>3.0.CO;2-M; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; Mikami Y, 2000, AM J SURG PATHOL, V24, P323, DOI 10.1097/00000478-200002000-00042; Mikami Y, 2001, HISTOPATHOLOGY, V39, P364, DOI 10.1046/j.1365-2559.2001.01239.x; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mikami Y, 2013, PATHOL RES PRACT, V209, P173, DOI 10.1016/j.prp.2012.12.003; Mikami Y, 2009, HISTOPATHOLOGY, V55, P362, DOI 10.1111/j.1365-2559.2009.03346.x; Murali R, 2016, MODERN PATHOLOGY, p298A; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Rabban JT, 2010, AM J SURG PATHOL, V34, P137, DOI 10.1097/PAS.0b013e3181c89c98; Rajendran S, 2018, AM J SURG PATHOL; Sedghizadeh PP, 2016, ORAL ONCOL, V54, P15, DOI 10.1016/j.oraloncology.2016.01.002; SILVERBERG SG, 1975, AM J OBSTET GYNECOL, V121, P971, DOI 10.1016/0002-9378(75)90920-5; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Tacha D, 2013, APPL IMMUNOHISTO M M, V21, P59, DOI 10.1097/PAI.0b013e318257cc1c; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Tsuji T, 2011, HISTOPATHOLOGY, V59, P55, DOI 10.1111/j.1365-2559.2011.03886.x; Wada T, 2017, AM J SURG PATHOL, V41, P696, DOI 10.1097/PAS.0000000000000833; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; Yuan CT, 2016, VIRCHOWS ARCH, V469, P351, DOI 10.1007/s00428-016-1978-x	43	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					84	90		10.1097/PCR.0000000000000233			7	Pathology	Pathology	GL9WS	WOS:000437694400005					2019-10-28	
J	Djordjevic, B; Busca, A; Parra-Herran, C				Djordjevic, Bojana; Busca, Aurelia; Parra-Herran, Carlos			Metastatic Adenocarcinoma to the Uterine Cervix Versus Primary Cervical Adenocarcinoma	AJSP-REVIEWS AND REPORTS			English	Review						cervix; endocervix; metastases	FEMALE GENITAL-TRACT; OF-THE-LITERATURE; DEVIATION ENDOMETRIOID ADENOCARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; ENDOCERVICAL ADENOCARCINOMAS; SEROUS CARCINOMA; BREAST-CANCER; UROTHELIAL CARCINOMA; LOBULAR CARCINOMA; TAMOXIFEN THERAPY	Adenocarcinoma metastases to the cervix can originate from the endometrium, the upper mullerian tract, or from extramullerian sites such as the gastrointestinal and pancreatobiliary tract, bladder, breast, lung, or even the salivary gland. In some cases, the metastatic lesions have signetring morphology, infiltrative pattern, and/or extensive lymphovascular spread. In others, however, the distinction between a primary cervical lesion and a metastasis to the cervix is more challenging because metastases may mimic endocervical adenocarcinoma in situ by colonizing the native endocervical mucosa through intraepithelial spread. Careful morphologic interpretation, combined with immunohistochemistry, human papillomavirus molecular testing, and clinical correlation, is required in order to arrive at the correct diagnosis.	[Djordjevic, Bojana; Parra-Herran, Carlos] Sunnybrook Hlth Sci Ctr, Div Anat Pathol, 2075 Bayview Ave,Room E4 27b, Toronto, ON M4N 3M5, Canada; [Djordjevic, Bojana; Parra-Herran, Carlos] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Busca, Aurelia] Ottawa Hosp, Div Anat Pathol, Ottawa, ON, Canada; [Busca, Aurelia] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada	Djordjevic, B (reprint author), Sunnybrook Hlth Sci Ctr, Div Anat Pathol, 2075 Bayview Ave,Room E4 27b, Toronto, ON M4N 3M5, Canada.	bojana.djordjevic@sunnybrook.ca					Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x; Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Ansari-Lari MA, 2004, AM J SURG PATHOL, V28, P160, DOI 10.1097/00000478-200402000-00002; Behzatoglu K, 2011, ANN DIAGN PATHOL, V15, P422, DOI 10.1016/j.anndiagpath.2011.06.003; Bogliolo S, 2010, ARCH GYNECOL OBSTET, V281, P769, DOI 10.1007/s00404-009-1264-0; BOYSEN TH, 1951, AM J OBSTET GYNECOL, V61, P923, DOI 10.1016/0002-9378(51)90357-2; BROWN BL, 1980, CANCER, V46, P543, DOI 10.1002/1097-0142(19800801)46:3<543::AID-CNCR2820460320>3.0.CO;2-6; Castadot P, 2005, Cancer Radiother, V9, P183, DOI 10.1016/j.canrad.2005.03.001; Castrillon DH, 2002, INT J GYNECOL PATHOL, V21, P4, DOI 10.1097/00004347-200201000-00002; Dabbs DJ, 1996, HUM PATHOL, V27, P172, DOI 10.1016/S0046-8177(96)90371-8; Dessole S, 1999, EUR J GYNAECOL ONCOL, V20, P416; ESPOSITO J M, 1965, American Journal of Obstetrics and Gynecology, V92, P792; Euscher ED, 2005, AM J SURG PATHOL, V29, P1074; Ferlicot S, 2004, EUR J CANCER, V40, P336, DOI 10.1016/j.ejca.2003.08.007; Frippiat C, 2000, EXP GERONTOL, V35, P733, DOI 10.1016/S0531-5565(00)00167-4; Fujiwara H, 1997, CANCER, V79, P505, DOI 10.1002/(SICI)1097-0142(19970201)79:3<505::AID-CNCR12>3.3.CO;2-X; Goldstein NS, 2002, AM J CLIN PATHOL, V117, P541; Grayson W, 1997, INT J GYNECOL PATHOL, V16, P307, DOI 10.1097/00004347-199710000-00003; Green AE, 2004, GYNECOL ONCOL, V95, P267, DOI 10.1016/j.ygyno.2004.07.006; Haji BE, 2005, CYTOPATHOLOGY, V16, P42, DOI 10.1111/j.1365-2303.2004.00211.x; Han CP, 2009, INT J GYNECOL PATHOL, V28, P489, DOI 10.1097/PGP.0b013e31819e8ab4; Hashi A, 2003, INT J GYNECOL PATHOL, V22, P374, DOI 10.1097/01.pgp.0000092130.10100.88; Herawi M, 2006, UROLOGY, V67, P746, DOI 10.1016/j.urology.2005.10.023; Hirschowitz L, 2009, HISTOPATHOLOGY, V55, P478, DOI 10.1111/j.1365-2559.2009.03390.x; Hodges KB, 2010, APPL IMMUNOHISTO M M, V18, P401, DOI 10.1097/PAI.0b013e3181e04816; Horn LC, 2006, INT J GYNECOL PATHOL, V25, P182, DOI 10.1097/01.pgp.0000185406.85685.df; Hornick JL, 2005, AM J SURG PATHOL, V29, P381, DOI 10.1097/01.pas.0000149710.01559.fe; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; Howitt BE, 2013, AM J SURG PATHOL, V37, P625, DOI 10.1097/PAS.0b013e318285be00; Huang CY, 2015, J PULM RESP MED, V5, P282; IMACHI M, 1993, CANCER, V71, P3472, DOI 10.1002/1097-0142(19930601)71:11<3472::AID-CNCR2820711103>3.0.CO;2-V; Kamoi S, 2002, INT J GYNECOL PATHOL, V21, P217, DOI 10.1097/00004347-200207000-00003; Kapoor Rakesh, 2013, J Gastrointest Cancer, V44, P231, DOI 10.1007/s12029-012-9437-7; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kong CS, 2010, AM J SURG PATHOL, V34, P915, DOI 10.1097/PAS.0b013e3181e3291e; Kos Z, 2014, INT J GYNECOL PATHOL, V33, P443, DOI 10.1097/PGP.0b013e31829c728b; Landry D, 2003, HISTOPATHOLOGY, V42, P77, DOI 10.1046/j.1365-2559.2003.01399.x; Le Bouedec G., 1993, Archives d'Anatomie et de Cytologie Pathologiques, V41, P140; Lee YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107027; Lokadasan R, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.571; Mallow DW, 1997, ACTA CYTOL, V41, P549, DOI 10.1159/000332555; Matsushita H, 2011, EUR J GYNAECOL ONCOL, V32, P199; MAZUR MT, 1984, CANCER, V53, P1978, DOI 10.1002/1097-0142(19840501)53:9<1978::AID-CNCR2820530929>3.0.CO;2-1; McCluggage WG, 2008, INT J GYNECOL PATHOL, V27, P92, DOI 10.1097/pgp.0b013e31815698e7; McCluggage WG, 2016, ADV ANAT PATHOL, V23, P58, DOI 10.1097/PAP.0000000000000095; McCluggage WG, 2010, AM J SURG PATHOL, V34, P735, DOI 10.1097/PAS.0b013e3181d6b8fd; McCluggage WG, 2002, INT J GYNECOL PATHOL, V21, P11, DOI 10.1097/00004347-200201000-00003; McCluggage WG, 2003, INT J GYNECOL PATHOL, V22, P231, DOI 10.1097/01.PGP.0000055172.04957.2F; Nakagami K, 1999, JPN J CLIN ONCOL, V29, P640, DOI 10.1093/jjco/29.12.640; Nofech-Mozes S, 2008, MODERN PATHOL, V21, P1147, DOI 10.1038/modpathol.2008.108; Nofech-Mozes S, 2010, APPL IMMUNOHISTO M M, V18, P80, DOI 10.1097/PAI.0b013e3181ae7240; O'Neill CJ, 2006, ADV ANAT PATHOL, V13, P8, DOI 10.1097/01.pap.0000201828.92719.f3; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Parini CL, 2007, INT J GYNECOL CANCER, V17, p731A, DOI 10.1111/j.1525-1438.2007.00837.x; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Perez-Montiel D, 2012, J OBSTET GYNAECOL RE, V38, P541, DOI 10.1111/j.1447-0756.2011.01747.x; Perisic D, 2007, J OBSTET GYNAECOL RE, V33, P578, DOI 10.1111/j.1447-0756.2007.00554.x; Piaton E, 2014, CANCER CYTOPATHOL, V122, P760, DOI 10.1002/cncy.21462; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Piura B, 1999, EUR J OBSTET GYN R B, V83, P57, DOI 10.1016/S0301-2115(98)00268-1; RAHILLY MA, 1992, HISTOPATHOLOGY, V20, P351, DOI 10.1111/j.1365-2559.1992.tb00993.x; Raspollini MR, 2003, ARCH PATHOL LAB MED, V127, P1586; Rau AR, 2003, DIAGN CYTOPATHOL, V29, P300, DOI 10.1002/dc.10385; Reyes MC, 2012, AM J SURG PATHOL, V36, P1058, DOI 10.1097/PAS.0b013e318251eade; Salem H, 2011, INT J GYNECOL OBSTET, V115, P188, DOI 10.1016/j.ijgo.2011.05.026; Scopa CD, 2005, GYNECOL ONCOL, V96, P543, DOI 10.1016/j.ygyno.2004.09.064; Staebler A, 2002, AM J SURG PATHOL, V26, P998, DOI 10.1097/01.PAS.0000018103.32686.98; Suarez-Penaranda JM, 2007, INT J GYNECOL PATHOL, V26, P254, DOI 10.1097/01.pgp.0000236949.49161.31; Suzuki Y, 2000, INT J RADIAT ONCOL, V47, P1229, DOI 10.1016/S0360-3016(00)00495-8; Togami S, 2015, PATHOL ONCOL RES, V21, P487, DOI 10.1007/s12253-014-9854-y; Tot T, 2002, EUR J CANCER, V38, P758, DOI 10.1016/S0959-8049(02)00008-4; Ueno S, 2013, INT J GYNECOL CANCER, V23, P1084, DOI 10.1097/IGC.0b013e3182981bdc; Varkarakis IM, 2007, INT UROL NEPHROL, V39, P1015, DOI 10.1007/s11255-006-9158-6; Verduin L, 2016, APPL IMMUNOHISTO M M, V24, P509, DOI 10.1097/PAI.0000000000000221; Vinette-Leduc D, 1999, DIAGN CYTOPATHOL, V21, P271, DOI 10.1002/(SICI)1097-0339(199910)21:4<271::AID-DC8>3.0.CO;2-A; Watrowski R, 2012, ANTICANCER RES, V32, P5075; Westin SN, 2008, J CLIN ONCOL, V26, P5965, DOI 10.1200/JCO.2008.18.6296; Yamamoto Takuro, 2014, Gynecol Oncol Case Rep, V8, P17, DOI 10.1016/j.gynor.2014.01.002; Yantiss RK, 2005, AM J SURG PATHOL, V29, P188, DOI 10.1097/01.pas.0000149688.98333.54; Yeh KY, 2003, JPN J CLIN ONCOL, V33, P404, DOI 10.1093/jjco/hyg078; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5; YOUNG RH, 1993, AM J SURG PATHOL, V17, P660, DOI 10.1097/00000478-199307000-00002; YOUNG RH, 1985, GYNECOL ONCOL, V21, P337, DOI 10.1016/0090-8258(85)90272-0	84	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					91	98		10.1097/PCR.0000000000000234			8	Pathology	Pathology	GL9WS	WOS:000437694400006					2019-10-28	
J	Li, ZB; Zhao, CQ				Li, Zaibo; Zhao, Chengquan			The "Atypical Glandular Cells" Papanicolaou Test: Recent Updates	AJSP-REVIEWS AND REPORTS			English	Review						atypical glandular cells; cervical adenocarcinoma; endometrial carcinoma; HPV test; Pap test	UNDETERMINED SIGNIFICANCE AGUS; HUMAN-PAPILLOMAVIRUS; CERVICAL CYTOLOGY; CYTOHISTOLOGIC CORRELATION; FOLLOW-UP; MICROGLANDULAR HYPERPLASIA; CLINICALLY SIGNIFICANT; TUBAL METAPLASIA; UTERINE CERVIX; HPV DETECTION	Atypical glandular cells are gynecologic cytology abnormalities representing glandular cells with morphologic changes that exceed obvious reactive/reparative changes, but fall short of an interpretation of adenocarcinoma either quantitatively or qualitatively. This cytological diagnosis occurs in less than 1% of the results of gynecologic cytology tests (0.2%-0.8%) but potentially reflects a wide range of conditions, from benign changes and cervical squamous/glandular precursor lesions, to invasive cervical or other gynecologic cancers. In this article, we aim at reviewing different subcategories, potential ancillary studies, histological follow-up results, and clinical management of atypical glandular cells.	[Li, Zaibo] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Zhao, Chengquan] Magee Womens Hosp, Pittsburgh, PA USA; [Zhao, Chengquan] Univ Pittsburgh, Pittsburgh, PA USA	Li, ZB (reprint author), Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave, Columbus, OH 43210 USA.	Zaibo.Li@osumc.edu					Badr RE, 2008, AM J SURG PATHOL, V32A, P899, DOI 10.1097/PAS.0b013e31815bbb69; BOSE S, 1994, AM J CLIN PATHOL, V101, P708, DOI 10.1093/ajcp/101.6.708; Burja IT, 1999, ACTA CYTOL, V43, P351, DOI 10.1159/000331080; Chhieng DC, 2000, ACTA CYTOL, V44, P557, DOI 10.1159/000328530; Clifford G, 2008, INT J CANCER, V122, P1684, DOI 10.1002/ijc.23282; Crothers JW, 2015, J LOW GENIT TRACT DI, V19, P22, DOI 10.1097/LGT.0000000000000044; DUCATMAN BS, 1993, DIAGN CYTOPATHOL, V9, P98, DOI 10.1002/dc.2840090121; Duska LR, 1998, OBSTET GYNECOL, V91, P278, DOI 10.1016/S0029-7844(97)00659-5; Eversole GM, 2010, ARCH PATHOL LAB MED, V134, P331, DOI 10.1043/1543-2165-134.3.331; Fletcher AH, 2011, J LOW GENIT TRACT DI, V15, P6, DOI 10.1097/LGT.0b013e3181f0b4b7; George NB, 2017, DIAGN CYTOPATHOL, V45, P520, DOI 10.1002/dc.23707; GUPTA PK, 1982, ACTA CYTOL, V26, P571; Jones BA, 1996, ARCH PATHOL LAB MED, V120, P523; Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0; Kawakami F, 2015, DIAGN CYTOPATHOL, V43, P791, DOI 10.1002/dc.23304; Kennedy AW, 1996, GYNECOL ONCOL, V63, P14, DOI 10.1006/gyno.1996.0270; Kim MK, 2017, DIAGN CYTOPATHOL, V45, P867, DOI 10.1002/dc.23777; Koss LG, 2005, DIAGNOSTIC CYTOLOGY, V1, P663; Krane JF, 2001, CANCER CYTOPATHOL, V93, P8, DOI 10.1002/1097-0142(20010225)93:1<8::AID-CNCR9001>3.0.CO;2-K; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Lastra RR, 2014, DIAGN CYTOPATHOL, V42, P375, DOI 10.1002/dc.23029; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Moriarty AT, 2003, DIAGN CYTOPATHOL, V28, P171, DOI 10.1002/dc.00000; Mulhem E, 2012, ACTA CYTOL, V56, P155, DOI 10.1159/000334199; Nasuti JF, 2002, DIAGN CYTOPATHOL, V26, P186, DOI 10.1002/dc.10070; NOVOTNY DB, 1992, ACTA CYTOL, V36, P1; Patadji S, 2017, CANCER CYTOPATHOL, V125, P205, DOI 10.1002/cncy.21791; Pinto AP, 2008, MODERN PATHOL, V21, P1067, DOI 10.1038/modpathol.2008.101; RAAB SS, 1995, AM J CLIN PATHOL, V104, P574; Rabelo-Santos SH, 2009, INT J GYNECOL PATHOL, V28, P272, DOI 10.1097/PGP.0b013e318190ed27; Risse EKJ, 2011, ACTA CYTOL, V55, P327, DOI 10.1159/000327525; Ronnett BM, 1999, HUM PATHOL, V30, P816, DOI 10.1016/S0046-8177(99)90143-0; Schindler S, 1998, Ann Diagn Pathol, V2, P312, DOI 10.1016/S1092-9134(98)80024-5; SCHNEIDER V, 1981, ACTA CYTOL, V25, P616; Selvaggi SM, 1997, DIAGN CYTOPATHOL, V16, P168, DOI 10.1002/(SICI)1097-0339(199702)16:2<168::AID-DC15>3.0.CO;2-K; Selvaggi SM, 2016, DIAGN CYTOPATHOL, V44, P389, DOI 10.1002/dc.23452; Sharpless KE, 2009, J LOW GENIT TRACT DI, V13, P72, DOI 10.1097/LGT.0b013e318183bb0e; Shi J, 2007, HUM PATHOL, V38, P1335, DOI 10.1016/j.humpath.2007.01.025; Soofer SB, 2000, CANCER CYTOPATHOL, V90, P207, DOI 10.1002/1097-0142(20000825)90:4<207::AID-CNCR2>3.0.CO;2-H; VALENTE PT, 1994, DIAGN CYTOPATHOL, V10, P326, DOI 10.1002/dc.2840100407; Walts AE, 2009, HUM PATHOL, V40, P957, DOI 10.1016/j.humpath.2008.12.005; Wang JR, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i276; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Wilbur DC, 2016, MODERN PATHOL, V29, pS1, DOI 10.1038/modpathol.2015.138; Wilbur DC, 1995, DIAGN CYTOPATHOL, V13, P463, DOI 10.1002/dc.2840130515; Xing W, 2014, CANCER CYTOPATHOL, V122, P8, DOI 10.1002/cncy.21343; YAHR LJ, 1991, DIAGN CYTOPATHOL, V7, P248, DOI 10.1002/dc.2840070308; Zeferino LC, 2011, EUR J OBSTET GYN R B, V159, P160, DOI 10.1016/j.ejogrb.2011.05.023; Zhao CQ, 2010, ARCH PATHOL LAB MED, V134, P103, DOI 10.1043/2008-0755-OAR1.1; Zhao CQ, 2009, GYNECOL ONCOL, V114, P383, DOI 10.1016/j.ygyno.2009.05.019	50	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	MAR-APR	2018	23	2					99	104		10.1097/PCR.0000000000000235			6	Pathology	Pathology	GL9WS	WOS:000437694400007					2019-10-28	
J	Reyes-Mugica, M; Chou, PM				Reyes-Mugica, Miguel; Chou, Pauline M.			Founders of Pediatric Pathology: Francisco Gonzalez-Crussi	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Biographical-Item									[Reyes-Mugica, Miguel] UPMC, Childrens Hosp Pittsburgh, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA; [Chou, Pauline M.] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA	Reyes-Mugica, M (reprint author), UPMC, Childrens Hosp Pittsburgh, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.	miguel.reyes@chp.edu					RETESMUGICA M, PUBLICATION LIST	1	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAR-APR	2018	21	2			SI		111	114		10.1177/1093526618754671			4	Pathology; Pediatrics	Pathology; Pediatrics	GI7NF	WOS:000434688500001	29607754				2019-10-28	
J	Dehner, LP; Gru, AA				Dehner, Louis P.; Gru, Alejandro A.			Nonepithelial Tumors and Tumor-like Lesions of the Skin and Subcutis in Children	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						sarcoma; myofibroma; infantile hemangioma; neurofibroma; giant cell fibroblastoma	NERVE SHEATH TUMORS; PLEXIFORM FIBROHISTIOCYTIC TUMOR; DERMAL DENDROCYTE HAMARTOMA; PALISADED ENCAPSULATED NEUROMA; NEUROFIBROMATOSIS TYPE-2 NF2; GRANULAR-CELL TUMORS; SOFT-TISSUE TUMORS; ENDOVASCULAR PAPILLARY ANGIOENDOTHELIOMA; VIRUS-ASSOCIATED LEIOMYOSARCOMA; SOLITARY CIRCUMSCRIBED NEUROMA	This overview of mesenchymal tumors presenting in the skin and/or subcutis in children brings together the range of neoplasms and hamartomas which are seen in this age-group. It is not surprising from the perspective of the pediatric or general surgical pathologist that vascular anomalies, including true neoplasms and vascular malformations, are the common phenotypic category. Since there is considerable morphologic overlap among these lesions, clinicopathologic correlation may be more important than for many of the other mesenchymal tumors. The skin and subcutis are the most common sites of clinical presentation for the infantile myofibroma which is the most common of fibrous mesenchymal tumors in children. Several of the other mesenchymal tumors are more common adults-like dermatofibrosarcoma protuberans, but nonetheless have an important presence in children, even as a congenital neoplasm. A lipomatous tumor in a young child should be considered as a possible manifestation of an overgrowth syndrome.	[Dehner, Louis P.] Washington Univ, Med Ctr, St Louis Childrens Hosp, Lauren V Ackerman Lab Surg Pathol, St Louis, MO USA; [Dehner, Louis P.] Washington Univ, Med Ctr, Dermatopathol Ctr, St Louis, MO USA; [Dehner, Louis P.] Washington Univ, Med Ctr, Div Dermatol, St Louis, MO USA; [Gru, Alejandro A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Gru, Alejandro A.] Univ Virginia, Dept Dermatol, Charlottesville, VA USA	Gru, AA (reprint author), Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.	aag4b@virginia.edu					Aboutalebi A, 2012, FACIAL PLAST SURG, V28, P545, DOI 10.1055/s-0032-1329929; AbuHilal M, 2016, J CUTAN MED SURG, V20, P216, DOI 10.1177/1203475415612421; Adler BL, 2016, J AM ACAD DERMATOL, V74, P506, DOI 10.1016/j.jaad.2015.10.011; Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Agarwal S, 2013, J HAND SURG-AM, V38A, P392, DOI 10.1016/j.jhsa.2012.10.042; Ahrens WA, 2008, HUM PATHOL, V39, P1519, DOI 10.1016/j.humpath.2008.03.002; Akdur NC, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-167; Al Dhaybi R, 2012, J AM ACAD DERMATOL, V66, P116, DOI 10.1016/j.jaad.2011.05.025; Al Dhaybi R, 2010, J AM ACAD DERMATOL, V63, P1052, DOI 10.1016/j.jaad.2009.12.017; Al-Adnani M, 2006, J CLIN PATHOL, V59, P1278, DOI 10.1136/jcp.2006.038240; Al-Ibraheemi A, 2017, MODERN PATHOL, V30, P474, DOI 10.1038/modpathol.2016.215; Alberola Fernando Toledo, 2010, Dermatol Online J, V16, P2; Albertini AF, 2011, AM J DERMATOPATH, V33, pE84, DOI 10.1097/DAD.0b013e31821b0a9f; Aldrich SL, 2010, J AM ACAD DERMATOL, V63, P244, DOI 10.1016/j.jaad.2009.08.042; Aldrink JH, 2013, J PEDIATR SURG, V48, P56, DOI 10.1016/j.jpedsurg.2012.10.018; Alemayehu H, 2015, J PEDIATR SURG, V50, P775, DOI 10.1016/j.jpedsurg.2015.02.032; Allen P W, 2000, Ann Diagn Pathol, V4, P99, DOI 10.1016/S1092-9134(00)90019-4; ALLEN PW, 1988, AM J SURG PATHOL, V12, P519, DOI 10.1097/00000478-198807000-00003; Amary MF, 2013, SKELETAL RADIOL, V42, P947, DOI 10.1007/s00256-013-1577-8; Aneiros-Fernandez J, 2017, HISTOL HISTOPATHOL, V32, P153, DOI 10.14670/HH-11-782; Aneiros-Fernandez J, 2016, EUR J DERMATOL, V26, P9, DOI 10.1684/ejd.2015.2681; Antonescu CR, 2016, WHO CLASSIFICATION T, P214; Antonescu CR, 2017, AM J SURG PATHOL, V41, P677, DOI 10.1097/PAS.0000000000000811; ARGENYI ZB, 1993, J CUTAN PATHOL, V20, P294, DOI 10.1111/j.1600-0560.1993.tb01265.x; ARGENYI ZB, 1990, J CUTAN PATHOL, V17, P329, DOI 10.1111/j.1600-0560.1990.tb00108.x; Asano N, 2015, ANN SURG ONCOL, V22, P2624, DOI 10.1245/s10434-014-4294-1; Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Baheti AD, 2015, AM J ROENTGENOL, V204, P374, DOI 10.2214/AJR.14.12888; Bain EE, 2013, J CUTAN PATHOL, V40, P321, DOI 10.1111/cup.12027; Barak S, 2012, AM J SURG PATHOL, V36, P1404, DOI 10.1097/PAS.0b013e3182556def; Barasoain-Millan A, 2015, J PEDIATR ENDOCR MET, V28, P443, DOI 10.1515/jpem-2014-0029; Barr KL, 2010, CUTIS, V86, P130; Barrick B, 2014, JAMA DERMATOL, V150, P781, DOI 10.1001/jamadermatol.2013.7530; Barthelmess S, 2014, AM J PATHOL, V184, P1209, DOI 10.1016/j.ajpath.2013.12.016; Baykal C, 2007, CUTIS, V79, P129; Beachkofsky TM, 2010, J AM ACAD DERMATOL, V63, P799, DOI 10.1016/j.jaad.2009.12.012; BEHAM A, 1993, HISTOPATHOLOGY, V22, P335, DOI 10.1111/j.1365-2559.1993.tb00132.x; Bennett JT, 2016, AM J HUM GENET, V98, P579, DOI 10.1016/j.ajhg.2016.02.006; Berenguer B, 2003, PEDIATR DEVEL PATHOL, V6, P495, DOI 10.1017/s10024-003-2134-6; Berg JC, 2008, HUM PATHOL, V39, P633, DOI 10.1016/j.humpath.2007.10.029; Bieser S, 2015, AM J MED GENET A, V167, P878, DOI 10.1002/ajmg.a.37017; Bisceglia M, 2007, ADV ANAT PATHOL, V14, P46, DOI 10.1097/PAP.0b013e31802f04b7; Blackwell MG, 2016, J CUTAN PATHOL, V43, P1096, DOI 10.1111/cup.12786; Blei F, 2015, CURR PROB PEDIATR AD, V45, P118, DOI 10.1016/j.cppeds.2015.03.002; Boland JM, 2013, ADV ANAT PATHOL, V20, P75, DOI 10.1097/PAP.0b013e31828625bf; Boon LM, 2004, ARCH DERMATOL, V140, P971, DOI 10.1001/archderm.140.8.971; Boos MD, 2014, PEDIATR DERMATOL, V31, P298, DOI 10.1111/pde.12335; Boppudi S, 2016, CLIN GENET, V90, P334, DOI 10.1111/cge.12775; Boybeyi O, 2010, J PEDIATR SURG, V45, pE19, DOI 10.1016/j.jpedsurg.2009.10.059; Brenn T, 2014, ADV ANAT PATHOL, V21, P108, DOI 10.1097/PAP.0000000000000009; Brouillard P, 2013, MOL SYNDROMOL, V4, P157, DOI 10.1159/000348675; Brown A, 2008, CUTIS, V81, P390; Byun M, 2013, J EXP MED, V210, P1743, DOI 10.1084/jem.20130592; Calonje E, 1999, AM J SURG PATHOL, V23, P910, DOI 10.1097/00000478-199908000-00008; CALONJE E, 1995, HISTOPATHOLOGY, V26, P159, DOI 10.1111/j.1365-2559.1995.tb00646.x; Canelas MMCA, 2010, AN BRAS DERMATOL, V85, P211, DOI 10.1590/S0365-05962010000200011; CANGIARELLA J, 1993, PEDIATR PATHOL, V13, P281, DOI 10.3109/15513819309048214; Carney JA, 1996, AM J SURG PATHOL, V20, P259, DOI 10.1097/00000478-199603000-00001; CARNEY JA, 1990, AM J SURG PATHOL, V14, P206, DOI 10.1097/00000478-199003000-00002; Castren E, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1623; Castren E, 2016, ACTA PAEDIATR, V105, P940, DOI 10.1111/apa.13460; Chamberlain BK, 2014, HUM PATHOL, V45, P1039, DOI 10.1016/j.humpath.2013.12.021; CHANG Y, 1990, AM J SURG PATHOL, V14, P977, DOI 10.1097/00000478-199010000-00012; Chappell AG, 2016, PEDIATR DERMATOL, V33, pE228, DOI 10.1111/pde.12852; Chauhan SP, 2014, SEMIN PERINATOL, V38, P210, DOI 10.1053/j.semperi.2014.04.007; Chen D, 2011, AM J DERMATOPATH, V33, P144, DOI 10.1097/DAD.0b013e3181e169f5; Cheon M, 2013, ANN DERMATOL, V25, P382, DOI 10.5021/ad.2013.25.3.382; Chernoff KA, 2016, CLIN DERMATOL, V34, P183, DOI 10.1016/j.clindermatol.2015.11.003; Cheung YH, 2013, AM J HUM GENET, V92, P996, DOI 10.1016/j.ajhg.2013.04.026; Childers ELB, 2011, ANN DIAGN PATHOL, V15, P157, DOI 10.1016/j.anndiagpath.2010.10.003; Chu CY, 2003, DERMATOLOGY, V206, P334, DOI 10.1159/000069947; Chung Joon, 1994, Journal of Dermatology (Tokyo), V21, P54; Clarke LE, 2012, DERMATOL CLIN, V30, P643, DOI 10.1016/j.det.2012.06.005; Clemens RK, 2015, VASA, V44, P92, DOI 10.1024/0301-1526/a000414; Cobb ARM, 2012, J CRANIO MAXILL SURG, V40, pE258, DOI 10.1016/j.jcms.2011.10.031; Coffin CM, 2012, PEDIATR DEVEL PATHOL, V15, P239, DOI 10.2350/10-05-0836-PB.1; Coffin CM, 2012, PEDIATR DEVEL PATHOL, V15, P127, DOI 10.2350/10-12-0944-PB.1; Coffin CM, 2012, PEDIATR DEVEL PATHOL, V15, P11, DOI 10.2350/11-08-1081-PB.1; Coffin CM, 2009, AM J SURG PATHOL, V33, P1705, DOI 10.1097/PAS.0b013e3181b76462; Conrad R, 2014, ARCH PATHOL LAB MED, V138, P128, DOI 10.5858/arpa.2012-0306-RS; Couto Javier A, 2015, Plast Reconstr Surg, V136, P72, DOI 10.1097/01.prs.0000472371.96995.e5; Couto JA, 2015, AM J HUM GENET, V96, P480, DOI 10.1016/j.ajhg.2015.01.007; Craiglow BG, 2014, PEDIATR DERMATOL, V31, P507, DOI 10.1111/pde.12071; Croteau SE, 2016, SEMIN CUTAN MED SURG, V35, P147, DOI 10.12788/j.sder.2016.048; Croteau SE, 2013, J PEDIATR-US, V162, P142, DOI 10.1016/j.jpeds.2012.06.044; Dadone B, 2015, CANCER GENET-NY, V208, P469, DOI 10.1016/j.cancergen.2015.06.005; DAKIN MC, 1992, HISTOPATHOLOGY, V20, P405, DOI 10.1111/j.1365-2559.1992.tb01010.x; Dastgheib L, 2016, AN BRAS DERMATOL, V91, P212, DOI 10.1590/abd1806-4841.20164060; de Feraudy S, 2012, AM J SURG PATHOL, V36, P1509, DOI 10.1097/PAS.0b013e31825e63bf; de Feraudy S, 2010, AM J SURG PATHOL, V34, P1377, DOI 10.1097/PAS.0b013e3181ed7374; de Lima LL, 2011, AN BRAS DERMATOL, V86, P363, DOI 10.1590/S0365-05962011000200025; Dehner LP, 2003, AM J SURG PATHOL, V27, P579, DOI 10.1097/00000478-200305000-00003; Gomez-Mateo MD, 2013, SEMIN DIAGN PATHOL, V30, P58, DOI 10.1053/j.semdp.2012.01.004; Deveza E, 2015, ARCH PEDIATRIE, V22, P685, DOI 10.1016/j.arcped.2015.04.003; Deyrup AT, 2011, AM J SURG PATHOL, V35, P70, DOI 10.1097/PAS.0b013e3181ffd9d5; Deyrup AT, 2006, AM J SURG PATHOL, V30, P75, DOI 10.1097/01.pas.0000178088.69394.7b; Deyrup AT, 2008, AM J SURG PATHOL, V32, P472; Di Giannatale A, 2015, PEDIATR BLOOD CANCER, V62, P1555, DOI 10.1002/pbc.25535; Diaz-Flores L, 2016, HISTOL HISTOPATHOL, V31, P1271, DOI 10.14670/HH-11-795; Dompmartin A, 2010, PHLEBOLOGY, V25, P224, DOI 10.1258/phleb.2009.009041; Dossett LA, 2015, CURR PROB CANCER, V39, P258, DOI 10.1016/j.currproblcancer.2015.07.007; Doyle LA, 2015, MODERN PATHOL, V28, P904, DOI 10.1038/modpathol.2015.49; Doyle LA, 2013, AM J SURG PATHOL, V37, P484, DOI 10.1097/PAS.0b013e31827070d4; Dray MS, 2006, J CLIN PATHOL, V59, P67, DOI 10.1136/jcp.2005.028704; Drut R, 2005, INT J SURG PATHOL, V13, P181, DOI 10.1177/106689690501300209; Edmondson AC, 2015, J PEDIATR GENET, V4, P136, DOI 10.1055/s-0035-1564440; Egberts F, 2008, J CUTAN PATHOL, V35, P80, DOI 10.1111/j.1600-0560.2008.00996.x; Elwood Hillary, 2011, Surg Pathol Clin, V4, P819, DOI 10.1016/j.path.2011.08.006; Emberger M, 2009, J CUTAN PATHOL, V36, P987, DOI 10.1111/j.1600-0560.2009.01161.x; Eng C, 2001, GENEREVIEW; Enos T, 2017, J CUTAN PATHOL, V44, P193, DOI 10.1111/cup.12854; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16; Fanburg-Smith JC, 1999, AM J SURG PATHOL, V23, P1004, DOI 10.1097/00000478-199909000-00002; Fauth CT, 2010, J CUTAN PATHOL, V37, P269, DOI 10.1111/j.1600-0560.2009.01405.x; Feasel PC, 2014, J CUTAN PATHOL, V41, P588, DOI 10.1111/cup.12340; Fernandez Y, 2009, EUR J INTERN MED, V20, P106, DOI 10.1016/j.ejim.2008.06.008; Fetsch JF, 2000, AM J SURG PATHOL, V24, P331, DOI 10.1097/00000478-200003000-00001; FETSCH JF, 1991, MODERN PATHOL, V4, P449; Fetsch JF, 2000, AM J SURG PATHOL, V24, P1491, DOI 10.1097/00000478-200011000-00004; Filippi L, 2015, MED RES REV, V35, P619, DOI 10.1002/med.21336; FLETCHER CDM, 1989, AM J SURG PATHOL, V13, P574, DOI 10.1097/00000478-198907000-00005; Foad SL, 2008, J BONE JOINT SURG AM, V90A, P1258, DOI 10.2106/JBJS.G.00853; Folpe AL, 2014, MODERN PATHOL, V27, pS64, DOI 10.1038/modpathol.2013.175; Fontana SC, 2016, ANN OTO RHINOL LARYN, V125, P775, DOI 10.1177/0003489416646796; Forcucci JA, 2016, SEMIN DIAGN PATHOL, V33, P50, DOI 10.1053/j.semdp.2015.09.007; Forschner A, 2003, J AM ACAD DERMATOL, V49, P113, DOI 10.1067/mjd.2003.416; Fox MD, 2012, AM J DERMATOPATH, V34, P157, DOI 10.1097/DAD.0b013e3182286a03; Frank-Raue K, 2015, RECENT RESULTS CANC, V204, P139, DOI 10.1007/978-3-319-22542-5_6; Franke FE, 2004, J CUTAN PATHOL, V31, P362, DOI 10.1111/j.0303-6987.2004.00192.x; Frater JL, 2006, J CUTAN MED SURG, V10, P281, DOI 10.2310/7750.2006.00067; Frigerio A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133158; Fukunaga M, 2007, AM J SURG PATHOL, V31, P1567, DOI 10.1097/PAS.0b013e318038f6b5; Garzon MC, 2016, J PEDIATR-US, V178, P24, DOI 10.1016/j.jpeds.2016.07.054; Gleason BC, 2008, AM J SURG PATHOL, V32, P354, DOI 10.1097/PAS.0b013e31813c6b85; Gnarra Maria, 2016, World J Clin Pediatr, V5, P273, DOI 10.5409/wjcp.v5.i3.273; Goelz R, 2015, ARCH DIS CHILD-FETAL, V100, pF85, DOI 10.1136/archdischild-2014-306197; Greenberger S, 2013, BRIT J DERMATOL, V169, P12, DOI 10.1111/bjd.12435; Greenberger S, 2010, NEW ENGL J MED, V362, P1005, DOI 10.1056/NEJMoa0903036; Groesser L, 2016, J INVEST DERMATOL, V136, P481, DOI 10.1038/JID.2015.376; Grynspan D, 2007, J CUTAN PATHOL, V34, P39, DOI 10.1111/j.1600-0560.2006.00575.x; Gucev ZS, 2008, AM J MED GENET A, V146A, P2688, DOI 10.1002/ajmg.a.32515; Guillou L, 1999, AM J SURG PATHOL, V23, P97, DOI 10.1097/00000478-199901000-00011; Guo B, 2013, BULL HOSP JT DIS, V71, P17; Guo R, ARCH PATHOL LAB MED, V139, P683; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Han HH, 2015, ANN DERMATOL, V27, P597, DOI 10.5021/ad.2015.27.5.597; Harder A, 2012, AM J SURG PATHOL, V36, P702, DOI 10.1097/PAS.0b013e31824d3155; Hardisson D, 2002, J AM ACAD DERMATOL, V46, pS37, DOI 10.1067/mjd.2002.106359; Harris MN, 2000, J AM ACAD DERMATOL, V42, P1012, DOI 10.1016/S0190-9622(00)90295-0; Hart J, 2016, AM J SURG PATHOL, V40, P704, DOI 10.1097/PAS.0000000000000589; He JF, 2014, ANN PLAS SURG, V72, P725, DOI 10.1097/SAP.0b013e31826c42c2; Herron MD, 2002, PEDIATR DERMATOL, V19, P394, DOI 10.1046/j.1525-1470.2002.00113.x; Hoang MP, 2002, AM J DERMATOPATH, V24, P26, DOI 10.1097/00000372-200202000-00005; Hoeger PH, 2014, BRIT J DERMATOL, V171, P466, DOI 10.1111/bjd.12650; Holcomb M, 2013, INT J DERMATOL, V52, P25, DOI 10.1111/j.1365-4632.2012.05690.x; Hollmann TJ, 2012, AM J SURG PATHOL, V36, P789, DOI 10.1097/PAS.0b013e31824a0b83; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Honda M, 2016, J DERMATOL, V43, P346, DOI 10.1111/1346-8138.13189; Horenstein MG, 2000, AM J SURG PATHOL, V24, P996, DOI 10.1097/00000478-200007000-00011; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Hornick JL, 2009, AM J SURG PATHOL, V33, P1554, DOI 10.1097/PAS.0b013e3181accc6c; Hornick JL, 2005, AM J SURG PATHOL, V29, P845, DOI 10.1097/01.pas.0000155166.86409.d2; Hsueh C, 1998, ARCH PATHOL LAB MED, V122, P1099; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Hwang S, 2017, INDIAN J DERMATOL VE, V83, P337, DOI 10.4103/0378-6323.193611; Iacobas I, 2010, J PEDIATR-US, V157, P795, DOI 10.1016/j.jpeds.2010.05.027; Isaacs H, 2011, PEDIATR DERMATOL, V28, P85, DOI 10.1111/j.1525-1470.2011.01372.x; Ishikawa K, 2005, DERMATOLOGY, V210, P346, DOI 10.1159/000084764; Itinteang T, 2014, FRONT SURG, V1, DOI 10.3389/fsurg.2014.00038; Itinteang T, 2012, J CLIN PATHOL, V65, P394, DOI 10.1136/jclinpath-2011-200462; Itinteang T, 2011, J CLIN PATHOL, V64, P870, DOI 10.1136/jclinpath-2011-200191; Izadpanah A, 2007, J AM ACAD DERMATOL, V56, pS6, DOI 10.1016/j.jaad.2006.04.013; Jackson CC, 2016, PEDIATR BLOOD CANCER, V63, P392, DOI 10.1002/pbc.25779; Jacobson-Dunlop E, 2011, AM J DERMATOPATH, V33, P551, DOI 10.1097/DAD.0b013e318206a648; Jaffer S, 2009, AM J SURG PATHOL, V33, P905, DOI 10.1097/PAS.0b013e31819c79f7; Janicke EC, 2014, PEDIATR DERMATOL, V31, P731, DOI 10.1111/pde.12280; Janmohamed SR, 2015, EUR J PEDIATR, V174, P97, DOI 10.1007/s00431-014-2403-6; Jawad MU, 2009, CLIN ORTHOP RELAT R, V467, P2939, DOI 10.1007/s11999-009-0749-2; Jha P, 2007, ANN DIAGN PATHOL, V11, P81, DOI 10.1016/j.anndiagpath.2006.12.010; Jinnin M, 2008, NAT MED, V14, P1236, DOI 10.1038/nm.1877; Jo Vickie Y, 2015, Surg Pathol Clin, V8, P445, DOI 10.1016/j.path.2015.05.005; Jo VY, 2015, HEAD NECK PATHOL, V9, P32, DOI 10.1007/s12105-015-0618-0; Jokinen CH, 2010, J CUTAN PATHOL, V37, P35, DOI 10.1111/j.1600-0560.2009.01293.x; Jokinen CH, 2010, J CUTAN PATHOL, V37, P43, DOI 10.1111/j.1600-0560.2009.01380.x; Jozwiak S, 1998, INT J DERMATOL, V37, P911; Kaddu S, 2002, AM J SURG PATHOL, V26, P35, DOI 10.1097/00000478-200201000-00004; Kehrer-Sawatzki H, 2017, HUM GENET, V136, P129, DOI 10.1007/s00439-016-1753-8; Keppler-Noreuil KM, 2015, AM J MED GENET A, V167, P287, DOI 10.1002/ajmg.a.36836; Kesserwan C, 2012, J ALLERGY CLIN IMMUN, V129, P762, DOI 10.1016/j.jaci.2011.10.028; Khoo M, 2016, SKELETAL RADIOL, V45, P29, DOI 10.1007/s00256-015-2256-8; Kilcline C, 2008, PEDIATR DERMATOL, V25, P168, DOI 10.1111/j.1525-1470.2008.00626.x; Kim HJ, 2010, PEDIATR RADIOL, V40, P30, DOI 10.1007/s00247-010-1766-8; Kirkorian AY, 2016, SEMIN CUTAN MED SURG, V35, P128, DOI 10.12788/j.sder.2016.051; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Ko Jennifer S, 2015, Surg Pathol Clin, V8, P331, DOI 10.1016/j.path.2015.05.001; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Kossard S, 1999, J CUTAN PATHOL, V26, P31, DOI 10.1111/j.1600-0560.1999.tb01787.x; Kraemer KH, GENEREVIEW; Krol A, 2005, ARCH FACIAL PLAST S, V7, P307, DOI 10.1001/archfaci.7.5.307; Kumar E, 2016, J CUTAN PATHOL, V43, P1143, DOI 10.1111/cup.12828; Kurek KC, 2013, AM J PATHOL, V182, P1494, DOI 10.1016/j.ajpath.2013.01.012; Kurek KC, 2012, AM J SURG PATHOL, V36, P671, DOI 10.1097/PAS.0b013e31824dd86c; Kurtkaya-Yapicier O, 2003, HISTOL HISTOPATHOL, V18, P925, DOI 10.14670/HH-18.925; Kutzner H, 2010, AM J SURG PATHOL, V34, P190, DOI 10.1097/PAS.0b013e3181c7cf11; Kuzel P, 2012, DERMATOL SURG, V38, P1461, DOI 10.1111/j.1524-4725.2012.02482.x; Laing EL, 2013, J CUTAN PATHOL, V40, P391, DOI 10.1111/cup.12078; Laskin WB, 2005, AM J SURG PATHOL, V29, P39, DOI 10.1097/01.pas.0000146044.90901.4c; Laskin WB, 2000, HUM PATHOL, V31, P1230, DOI 10.1053/hupa.2000.18474; Laskin WB, 2009, AM J SURG PATHOL, V33, P1, DOI 10.1097/PAS.0b013e3181788533; Law RM, 2008, J CUTAN PATHOL, V35, P779, DOI 10.1111/j.1600-0560.2007.00901.x; Leber GE, 2003, PEDIATR DERMATOL, V20, P108, DOI 10.1046/j.1525-1470.2003.20202.x; LeBlanc Robert E, 2011, Surg Pathol Clin, V4, P745, DOI 10.1016/j.path.2011.08.003; Lee PW, 2014, J AM ACAD DERMATOL, V70, P899, DOI 10.1016/j.jaad.2014.01.860; Li B, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-160; Lian CG, 2014, JAMA DERMATOL, V150, P1336, DOI 10.1001/jamadermatol.2014.1244; Liang MG, 2014, SEMIN PEDIATR SURG, V23, P162, DOI 10.1053/j.sempedsurg.2014.06.017; Lim YH, 2016, AM J HUM GENET, V99, P443, DOI 10.1016/j.ajhg.2016.06.010; Lim YH, 2015, J INVEST DERMATOL, V135, P1698, DOI 10.1038/jid.2015.55; Line A, 2017, ANN CHIR PLAST ESTH, V62, P232, DOI 10.1016/j.anplas.2016.05.010; Linos K, 2013, AM J DERMATOPATH, V35, P98, DOI 10.1097/DAD.0b013e318259944a; Liu GY, 2016, J DERMATOL, V43, P560, DOI 10.1111/1346-8138.13154; Llombart B, 2013, SEMIN DIAGN PATHOL, V30, P13, DOI 10.1053/j.semdp.2012.01.002; Lloyd SKW, 2013, HAND CLINIC, V115, P957, DOI 10.1016/B978-0-444-52902-2.00054-0; Lopez L, 2016, ARCH PATHOL LAB MED, V140, P376, DOI 10.5858/arpa.2014-0495-RS; Lopez V, 2010, ACTAS DERMO-SIFILOGR, V101, P771, DOI 10.1016/j.ad.2010.02.016; Rodriguez-Peralto JL, 2013, SEMIN DIAGN PATHOL, V30, P45, DOI 10.1053/j.semdp.2012.01.008; Luks VL, 2015, J PEDIATR-US, V166, P1048, DOI 10.1016/j.jpeds.2014.12.069; Luu M, 2016, SEMIN CUTAN MED SURG, V35, P117, DOI 10.12788/j.sder.2016.047; Luzar Bostjan, 2017, Surg Pathol Clin, V10, P337, DOI 10.1016/j.path.2017.01.008; Luzar B, 2010, HISTOPATHOLOGY, V56, P148, DOI 10.1111/j.1365-2559.2009.03447.x; Ma EH, 2017, PEDIATR DERMATOL, V34, P64, DOI 10.1111/pde.13022; Ma XR, 2014, INT J CLIN EXP PATHO, V7, P3809; Macarenco RS, 2007, ARCH PATHOL LAB MED, V131, P625; Magro G, 2011, J CUTAN PATHOL, V38, P59, DOI 10.1111/j.1600-0560.2009.01460.x; Magro G, 2010, VIRCHOWS ARCH, V456, P71, DOI 10.1007/s00428-009-0859-y; Makino T, 2002, INT J ORAL MAX SURG, V31, P451, DOI 10.1054/ijom.2001.0202; Malik S, 2014, CLIN GENET, V85, P203, DOI 10.1111/cge.12276; MANIVEL JC, 1986, HUM PATHOL, V17, P1240, DOI 10.1016/S0046-8177(86)80567-6; Marburger TB, 2012, J CUTAN PATHOL, V39, P987, DOI 10.1111/cup.12007; Marcon I, 2004, PEDIATR HEMAT ONCOL, V21, P23, DOI 10.1080/08880010490263380; Marino-Sanchez F, 2016, RESPIR MED CASE REP, V18, P31, DOI 10.1016/j.rmcr.2016.03.009; Marks E, 2016, ARCH PATHOL LAB MED, V140, P1153, DOI 10.5858/arpa.2015-0492-RS; Marti N, 2011, PEDIATR DERMATOL, V28, P462, DOI 10.1111/j.1525-1470.2010.01291.x; Martignetti JA, 2013, AM J HUM GENET, V92, P1001, DOI 10.1016/j.ajhg.2013.04.024; Martinez-Mata G, 2011, HEAD NECK PATHOL, V5, P184, DOI 10.1007/s12105-011-0241-7; Matsuo M, 2014, BRAIN DEV-JPN, V36, P148, DOI 10.1016/j.braindev.2013.01.007; McDonald J, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00001; McElroy AK, 2013, J PEDIATR INFECT DIS, V2, P175, DOI 10.1093/jpids/pis085; McGee JS, 2014, PEDIATR DERMATOL, V31, P105, DOI [10.1111/j.1525-1470.2012.01801.x, 10.1111/j.1525-1470.2011.01681.x]; MEGAHED M, 1994, AM J DERMATOPATH, V16, P120, DOI 10.1097/00000372-199404000-00002; MEISKINDBLOM JM, 1994, AM J SURG PATHOL, V18, P479, DOI 10.1097/00000478-199405000-00007; Melnick L, 2015, PEDIATR DERMATOL, V32, P533, DOI 10.1111/pde.12459; Mentzel T, 2006, AM J SURG PATHOL, V30, P104, DOI 10.1097/01.pas.0000178091.54147.b1; Mentzel T, 1998, AM J SURG PATHOL, V22, P576, DOI 10.1097/00000478-199805000-00009; Mentzel T, 2014, PATHOLOGY, V46, P149, DOI 10.1097/PAT.0000000000000046; Mentzel T, 2009, AM J DERMATOPATH, V31, P44, DOI 10.1097/DAD.0b013e3181914e6f; Merker VL, 2012, ONCOLOGIST, V17, P1317, DOI 10.1634/theoncologist.2012-0162; Miettinen M, 2006, AM J SURG PATHOL, V30, P521, DOI 10.1097/00000478-200604000-00014; Miettinen M, 1999, HUM PATHOL, V30, P934, DOI 10.1016/S0046-8177(99)90247-2; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Miller K, 2012, AM J SURG PATHOL, V36, P1317, DOI 10.1097/PAS.0b013e31825359e1; Misago N, 2007, AM J DERMATOPATH, V29, P160, DOI 10.1097/01.dad.0000256688.91974.09; Miyakawa T, 2007, J DERMATOL, V34, P60, DOI 10.1111/j.1346-8138.2007.00218.x; Montgomery BK, 2016, CLIN NEUROPATHOL, V35, P78, DOI 10.5414/NP300895; Moosavi C, 2007, ANN DIAGN PATHOL, V11, P313, DOI 10.1016/j.anndiagpath.2007.01.003; Morimitsu Y, 1998, HISTOPATHOLOGY, V32, P547, DOI 10.1046/j.1365-2559.1998.t01-1-00428.x; Morota N, 2017, J NEUROSURG-PEDIATR, V19, P428, DOI 10.3171/2016.10.PEDS16247; Mota Amanda, 2013, Dermatol Pract Concept, V3, P11, DOI 10.5826/dpc.0304a03; Motoi T, 2005, HUM PATHOL, V36, P871, DOI 10.1016/j.humpath.2005.05.018; Muller CSL, 2015, J DTSCH DERMATOL GES, V13, P1282, DOI 10.1111/ddg.12817; Mulliken JB, 2004, J AM ACAD DERMATOL, V50, P875, DOI 10.1016/j.jaad.2003.10.670; Mulliken JB, 2013, MULLIKEN YOUNGS VAS, V4, P68; Mulliken JB, 2013, MULLIKEN YOUNGS VASC, P22; Munden A, 2014, BRIT J DERMATOL, V170, P907, DOI 10.1111/bjd.12804; Murphy CM, 1995, J CUTAN PATHOL, V22, P556, DOI 10.1111/j.1600-0560.1995.tb01151.x; Mutgi KAJ, 2016, PEDIATR DERMATOL, V33, pE16, DOI 10.1111/pde.12726; Nakashima K, 2008, AM J DERMATOPATH, V30, P278, DOI 10.1097/DAD.0b013e3181684525; Napekoski KM, 2014, J CUTAN PATHOL, V41, P816, DOI 10.1111/cup.12386; Nascimento AF, 2007, AM J SURG PATHOL, V31, P1363, DOI 10.1097/PAS.0b013e318031bc0c; Nasseri E, 2014, J AM ACAD DERMATOL, V70, P75, DOI 10.1016/j.jaad.2013.09.018; Neves RI, 2011, J PEDIATR SURG, V46, pE25, DOI 10.1016/j.jpedsurg.2010.09.046; Niamba P, 2007, PEDIATR DERMATOL, V24, P280, DOI 10.1111/j.1525-1470.2007.00403.x; North PE, 2000, HUM PATHOL, V31, P11, DOI 10.1016/S0046-8177(00)80192-6; OROZCOCOVARRUBIAS MD, 1994, J AM ACAD DERMATOL, V30, P243, DOI 10.1016/S0190-9622(94)70024-9; Osio A, 2010, ARCH DERMATOL, V146, P758, DOI 10.1001/archdermatol.2010.135; Oudijk L, 2012, HISTOPATHOLOGY, V60, pE1, DOI 10.1111/j.1365-2559.2012.04221.x; Pagliai KA, 2004, PEDIATR DERMATOL, V21, P10, DOI 10.1111/j.0736-8046.2004.21102.x; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Pantanowitz L, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-24; Park JY, 2016, AM J SURG PATHOL, V40, P1713, DOI 10.1097/PAS.0000000000000729; Parsons A, 2008, AM J DERMATOPATH, V30, P31, DOI 10.1097/DAD.0b013e31815ea7c5; Patt JC, 2016, SEMIN ONCOL, V43, P413, DOI 10.1053/j.seminoncol.2016.02.026; Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109; Perez-Gonzalez YC, 2015, AM J DERMATOPATH, V37, P334, DOI 10.1097/DAD.0000000000000106; Perkins P, 1996, AM J SURG PATHOL, V20, P1196, DOI 10.1097/00000478-199610000-00004; PierreKahn A, 1997, CHILD NERV SYST, V13, P298, DOI 10.1007/s003810050090; Alves JVP, 2014, AN BRAS DERMATOL, V89, P472, DOI 10.1590/abd1806-4841.20142629; Pina-Oviedo S, 2008, ADV ANAT PATHOL, V15, P147, DOI 10.1097/PAP.0b013e31816f8519; Pinto-Almeida T, 2013, AN BRAS DERMATOL, V88, P63, DOI 10.1590/abd1806-4841.20132647; Pouryazdanparast P, 2009, J CUTAN PATHOL, V36, P859, DOI 10.1111/j.1600-0560.2008.01179.x; Prokopchuk Olga, 2016, BMC Res Notes, V9, P126, DOI 10.1186/s13104-016-1913-x; Putra J, 2017, PATHOLOGY, V49, P356, DOI 10.1016/j.pathol.2017.03.001; Putra J, 2017, J CUTAN PATHOL, V44, P516, DOI 10.1111/cup.12923; Qiu MK, 2015, FRONT BIOSCI-LANDMRK, V20, P1004, DOI 10.2741/4353; Quante M, 1998, AM J DERMATOPATH, V20, P541, DOI 10.1097/00000372-199812000-00001; Ramdial PK, 2011, AM J DERMATOPATH, V33, P392, DOI 10.1097/DAD.0b013e3181e5d16a; Ranga SM, 2014, INDIAN J DERMATOL, V59, DOI 10.4103/0019-5154.143583; Rawal YB, 2017, HEAD NECK PATHOL, V11, P404, DOI 10.1007/s12105-016-0760-3; Pontes HAR, 2011, J CRANIO MAXILL SURG, V39, P102, DOI 10.1016/j.jcms.2010.10.006; Rees CA, 2016, PEDIATR BLOOD CANCER, V63, P1325, DOI 10.1002/pbc.26021; Reimer A, 2016, PEDIATR DERMATOL, V33, P621, DOI 10.1111/pde.12956; Reimer A, 2016, J AM ACAD DERMATOL, V75, P556, DOI 10.1016/j.jaad.2016.03.029; Reis JS, 2002, PATHOL RES PRACT, V198, P621, DOI 10.1078/0344-0338-00311; Reis JS, 2002, J CUTAN PATHOL, V29, P226, DOI 10.1034/j.1600-0560.2002.290405.x; Reith JD, 1996, ARCH PATHOL LAB MED, V120, P399; Rekhi B, 2017, APMIS, V125, P679, DOI 10.1111/apm.12702; Rekhi B, 2010, ANN DIAGN PATHOL, V14, P162, DOI 10.1016/j.anndiagpath.2010.01.005; Requena L, 2013, JAMA DERMATOL, V149, P459, DOI 10.1001/jamadermatol.2013.3190; Requena L, 2013, SEMIN DIAGN PATHOL, V30, P29, DOI 10.1053/j.semdp.2012.01.003; Rezanko T, 2012, ANN DIAGN PATHOL, V16, P521, DOI 10.1016/j.anndiagpath.2011.05.003; Rios JJ, 2013, HUM MOL GENET, V22, P444, DOI 10.1093/hmg/dds440; Rizk T, 2013, J NEUROSURG-PEDIATR, V11, P79, DOI 10.3171/2012.10.PEDS11250; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z; Rouhani P, 2008, CANCER-AM CANCER SOC, V113, P616, DOI 10.1002/cncr.23571; Rubio GA, 2017, J CRANIOFAC SURG, V28, P182, DOI 10.1097/SCS.0000000000003203; Ruggieri M, 2005, NEUROPEDIATRICS, V36, P21, DOI 10.1055/s-2005-837581; Ruggieri M, 2015, SEMIN PEDIATR NEUROL, V22, P240, DOI 10.1016/j.spen.2015.10.008; Ruggieri M, 2015, SEMIN PEDIATR NEUROL, V22, P207, DOI 10.1016/j.spen.2015.11.001; Saab ST, 2014, AM J SURG PATHOL, V38, P394, DOI 10.1097/PAS.0000000000000104; Safadi RA, 2010, HEAD NECK PATHOL, V4, P242, DOI 10.1007/s12105-010-0183-5; Samborska M, 2016, WSPOLCZESNA ONKOL, V20, P444, DOI 10.5114/wo.2016.65602; Sandell RF, 2015, HUM PATHOL, V46, P1390, DOI 10.1016/j.humpath.2015.05.025; Schmidt CS, 2005, J CRANIOFAC SURG, V16, P926, DOI 10.1097/01.scs.0000181049.99071.23; Schoolmeester JK, 2015, HUM PATHOL, V46, P1242, DOI 10.1016/j.humpath.2015.04.004; Selmin A, 2014, PATHOL RES PRACT, V210, P548, DOI 10.1016/j.prp.2014.04.007; Senerchia AA, 2014, PEDIATR BLOOD CANCER, V61, P211, DOI 10.1002/pbc.24639; Senser M, 1997, ARCH PEDIATRIE, V4, P653, DOI 10.1016/S0929-693X(97)83367-2; Serpa MS, 2017, OR SURG OR MED OR PA, V123, pE99, DOI 10.1016/j.oooo.2016.10.009; Shahgholi E, 2011, J PEDIATR ENDOCR MET, V24, P1063, DOI 10.1515/JPEM.2011.378; Shaikh R, 2014, SKELETAL RADIOL, V43, P895, DOI 10.1007/s00256-014-1836-3; Shao L, 2007, PEDIATR DEVEL PATHOL, V10, P149, DOI 10.2350/06-06-0103.1; Sheth S, 2011, MODERN PATHOL, V24, P343, DOI 10.1038/modpathol.2010.203; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; SILVERMAN TA, 1985, AM J SURG PATHOL, V9, P7, DOI 10.1097/00000478-198501000-00004; Soblet J, 2013, MOL SYNDROMOL, V4, P179, DOI 10.1159/000348327; SOULE EH, 1977, CANCER-AM CANCER SOC, V40, P1711, DOI 10.1002/1097-0142(197710)40:4<1711::AID-CNCR2820400447>3.0.CO;2-9; Spock CL, 2015, ANN PLAS SURG, V74, P230, DOI 10.1097/SAP.0000000000000080; Stratakis CA, 2003, GENEREVIEW; Stratton J, 2014, MODERN PATHOL, V27, P701, DOI 10.1038/modpathol.2013.190; Stuart LN, 2014, J CUTAN PATHOL, V41, P625, DOI 10.1111/cup.12375; Sundaram SK, 2017, NEUROPEDIATRICS, V48, P385, DOI 10.1055/s-0037-1603515; Tahiri Y, 2013, J HAND SURG-AM, V38A, P2055, DOI 10.1016/j.jhsa.2013.03.022; Talamanca LF, 2012, NEUROPEDIATRICS, V43, P349, DOI 10.1055/s-0032-1324401; Tannous Z, 2010, J CUTAN PATHOL, V37, P88, DOI 10.1111/j.1600-0560.2010.01519.x; Tardio JC, 2009, J CUTAN PATHOL, V36, P89, DOI 10.1111/j.1600-0560.2008.01212.x; Tari AS, 2006, ORBIT-ABINGDON, V25, P235, DOI 10.1080/01676830600575535; Tennant LB, 2006, PEDIATR DERMATOL, V23, P208, DOI 10.1111/j.1525-1470.2006.00219.x; Terrier-Lacombe MJ, 2009, MODERN PATHOL, V22, P87, DOI 10.1038/modpathol.2008.156; Tetzlaff MT, 2011, J CUTAN PATHOL, V38, P731, DOI 10.1111/j.1600-0560.2011.01721.x; Thomas AK, 2016, PEDIATR RADIOL, V46, P430, DOI 10.1007/s00247-015-3482-x; Thway K, 2016, ANN DIAGN PATHOL, V25, P64, DOI 10.1016/j.anndiagpath.2016.09.013; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Thway K, 2016, ADV ANAT PATHOL, V23, P41, DOI 10.1097/PAP.0000000000000102; Thway K, 2009, PEDIATR DEVEL PATHOL, V12, P292, DOI 10.2350/08-07-0506.1; Tolkachjov SN, 2017, DERMATOL SURG, V43, P116, DOI 10.1097/DSS.0000000000000936; Tomita S, 2009, J PEDIATR SURG, V44, pE17, DOI 10.1016/j.jpedsurg.2009.01.047; Torres-Mora J, 2014, AM J SURG PATHOL, V38, P94, DOI 10.1097/PAS.0b013e3182a0a150; Trindade F, 2013, J CUTAN PATHOL, V40, P472, DOI 10.1111/cup.12123; Trindade F, 2012, AM J DERMATOPATH, V34, P810, DOI 10.1097/DAD.0b013e31824d2c27; Tukenmez Demirci Gulsen, 2015, J Clin Med Res, V7, P770, DOI 10.14740/jocmr2190w; Val-Bernal JF, 2005, J CUTAN PATHOL, V32, P274, DOI 10.1111/j.0303-6987.2005.00311.x; van Steensel MAM, 2016, J INVEST DERMATOL, V136, P359, DOI 10.1016/j.jid.2015.10.059; Vargas SO, 2001, AM J SURG PATHOL, V25, P185, DOI 10.1097/00000478-200102000-00006; Volpicelli ER, 2012, J CUTAN PATHOL, V39, P747, DOI 10.1111/j.1600-0560.2012.01944.x; Wachter DL, 2012, J CUTAN PATHOL, V39, P454, DOI 10.1111/j.1600-0560.2011.01823.x; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Wang GY, 2017, PATHOLOGY, V49, P44, DOI 10.1016/j.pathol.2016.09.061; Wang HQ, 2016, PATHOL RES PRACT, V212, P817, DOI 10.1016/j.prp.2016.06.014; Wang L, 2014, J CUTAN PATHOL, V41, P823, DOI 10.1111/cup.12385; Wang L, 2014, J CUTAN PATHOL, V41, P447, DOI 10.1111/cup.12309; Ward Katherine A, 2010, Dermatol Online J, V16, P4; Warren M, 2016, CANCER GENET-NY, V209, P21, DOI 10.1016/j.cancergen.2015.11.004; WEISS SW, 1982, CANCER, V50, P970, DOI 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z; Weitz NA, 2014, J AM ACAD DERMATOL, V71, P542, DOI 10.1016/j.jaad.2014.04.062; Wesche WA, 2000, J CUTAN PATHOL, V27, P485, DOI 10.1034/j.1600-0560.2000.027010485.x; Wetzel-Strong SE, 2017, J PATHOL, V241, P281, DOI 10.1002/path.4844; Winchester DS, 2014, J AM ACAD DERMATOL, V71, P919, DOI 10.1016/j.jaad.2014.07.020; Wood L, 2010, AM J DERMATOPATH, V32, P764, DOI 10.1097/DAD.0b013e3181d0c587; Woodhoo A, 2008, GLIA, V56, P1481, DOI 10.1002/glia.20723; Woodruff JM, 2003, AM J SURG PATHOL, V27, P1321, DOI 10.1097/00000478-200310000-00004; Wouters V, 2010, EUR J HUM GENET, V18, P414, DOI 10.1038/ejhg.2009.193; Xu Y, 2016, PEDIATR DERMATOL, V33, pE27, DOI 10.1111/pde.12706; Yamada S, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0604-9; Yoshida H, 2014, GENE CHROMOSOME CANC, V53, P606, DOI 10.1002/gcc.22170; Yuste V, 2015, FETAL PEDIATR PATHOL, V34, P315, DOI 10.3109/15513815.2015.1068411; Zarraga M, 2011, AM J DERMATOPATH, V33, P513, DOI 10.1097/DAD.0b013e3181ec846a; Zelger BG, 2000, HISTOPATHOLOGY, V36, P529, DOI 10.1046/j.1365-2559.2000.00901.x	400	1	1	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAR-APR	2018	21	2			SI		150	207		10.1177/1093526617751529			58	Pathology; Pediatrics	Pathology; Pediatrics	GI7NF	WOS:000434688500003	29607758				2019-10-28	
J	Gru, AA; Dehner, LP				Gru, Alejandro A.; Dehner, Louis P.			Cutaneous Hematolymphoid and Histiocytic Proliferations in Children	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						lymphomas; histiocytosis; Langerhans cell; lymphoproliferative disorders; leukemia; lymphoblastic	T-CELL LYMPHOMA; EPSTEIN-BARR-VIRUS; ROSAI-DORFMAN-DISEASE; ALEUKEMIC LEUKEMIA-CUTIS; OF-THE-LITERATURE; ERDHEIM-CHESTER DISEASE; HYPOPIGMENTED MYCOSIS-FUNGOIDES; BENIGN CEPHALIC HISTIOCYTOSIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLASMACYTOID DENDRITIC CELLS	This article focuses on cutaneous hematopoietic neoplasms that are more likely to be encountered in the pediatric age-group and includes both lymphoproliferative and histiocytic disorders. The cutaneous hematologic disorders in children have a different epidemiologic profile to what is seen during adulthood. Although mycosis fungoides is the most frequent form of cutaneous lymphoma in adults, it is very rare in children. Because lymphoblastic leukemias and lymphomas are more frequent in the pediatric setting, cutaneous leukemic infiltrates are relatively common in this age-group. Similarly, histiocytic disorders are more common in children, particularly Langerhans cell histiocytosis and juvenile xanthogranuloma. Notably, the histiocytic disorders have undergone significant modifications on their nomenclature in the basis of the molecular characteristics that are present in them. A summary of the most frequent cutaneous hematopoietic disorders in children will be discussed further in this review.	[Gru, Alejandro A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Dehner, Louis P.] Washington Univ, Med Ctr, St Louis Childrens Hosp, Lauren V Ackerman Lab Surg Pathol, St Louis, MO USA; [Dehner, Louis P.] Washington Univ, Med Ctr, Dermatopathol, St Louis, MO USA	Gru, AA (reprint author), Univ Virginia, POB 800904, Charlottesville, VA 22908 USA.	AAG4B@hscmail.mcc.virginia.edu					Abdul-Wahab A, 2014, J AM ACAD DERMATOL, V70, P1010, DOI 10.1016/j.jaad.2014.01.862; Aboutalebi A, 2013, J CUTAN PATHOL, V40, P996, DOI 10.1111/cup.12231; Acree SC, 2013, FETAL PEDIATR PATHOL, V32, P175, DOI 10.3109/15513815.2012.701264; Agrawal AK, 2011, PEDIATR BLOOD CANCER, V57, P338, DOI 10.1002/pbc.23053; Ai WYZ, 2014, JAMA DERMATOL, V150, P709, DOI 10.1001/jamadermatol.2013.7747; Alberti-Violetti S, 2016, J CUTAN PATHOL, V43, P1121, DOI 10.1111/cup.12806; Ali SK, 2000, SAUDI MED J, V21, P1074; Alikhan A, 2013, PEDIATR DERMATOL, V30, P192, DOI 10.1111/pde.12019; Amador-Ortiz C, 2011, J CUTAN PATHOL, V38, P945, DOI 10.1111/j.1600-0560.2011.01809.x; Amin A, 2009, PEDIATR DERMATOL, V26, P112, DOI 10.1111/j.1525-1470.2008.00844.x; Amitay-Laish I, 2017, BRIT J DERMATOL, V176, P1010, DOI 10.1111/bjd.14932; Amitay-Laish I, 2009, BRIT J DERMATOL, V161, P140, DOI 10.1111/j.1365-2133.2009.09121.x; Ansell LH, 2013, J CLIN ONCOL, V31, pE353, DOI 10.1200/JCO.2012.46.1939; Arachchillage DRJ, 2010, J PEDIAT HEMATOL ONC, V32, P152, DOI 10.1097/MPH.0b013e3181cf4575; Asada H, 2005, J INVEST DERMATOL, V125, P956, DOI 10.1111/j.0022-202X.2005.23915.x; Attia AM, 2014, J POSTGRAD MED, V60, P69, DOI 10.4103/0022-3859.128817; Attygalle AD, 2004, BLOOD, V104, P3343, DOI 10.1182/blood-2004-01-0385; Au WY, 2009, BLOOD, V113, P3931, DOI 10.1182/blood-2008-10-185256; Bachmeyer C, 2003, ANN DERMATOL VENER, V130, P773; Badalian-Very G, 2013, ANNU REV PATHOL-MECH, V8, P1, DOI 10.1146/annurev-pathol-020712-163959; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Bader-Meunier B, 2013, PEDIATRICS, V132, pE545, DOI 10.1542/peds.2012-3256; Barrionuevo C, 2002, APPL IMMUNOHISTO M M, V10, P7, DOI 10.1097/00022744-200203000-00002; Barrionuevo C, 2007, APPL IMMUNOHISTO M M, V15, P38, DOI 10.1097/01.pai.0000205062.27174.56; Barzilai A, 2002, CUTIS, V69, P301; Baum CL, 2011, J AM ACAD DERMATOL, V65, P739, DOI 10.1016/j.jaad.2010.07.028; Bekkenk MW, 2000, BLOOD, V95, P3653; BELJAARDS RC, 1993, CANCER, V71, P2097, DOI 10.1002/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO;2-7; Beltraminelli H, 2009, AM J DERMATOPATH, V31, P317, DOI 10.1097/DAD.0b013e31819f19bb; Beltran BE, 2014, AM J HEMATOL, V89, P1160, DOI 10.1002/ajh.23843; Ben-Amitai D, 2003, ACTA DERM-VENEREOL, V83, P451, DOI 10.1080/00015550310020530; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076.2076_2076_2084; Bergman R, 2001, ARCH DERMATOL, V137, P432; Berres ML, 2014, J EXP MED, V211, P669, DOI 10.1084/jem.20130977; BERTI E, 1991, SEMIN DIAGN PATHOL, V8, P82; Berti E, 1999, AM J PATHOL, V155, P483, DOI 10.1016/S0002-9440(10)65144-9; BERTI E, 1988, J AM ACAD DERMATOL, V19, P259, DOI 10.1016/S0190-9622(88)70169-3; Beylot-Barry M, 1998, BLOOD, V91, P4668, DOI 10.1182/blood.V91.12.4668.412k20_4668_4676; Bidet Audrey, 2015, Br J Haematol, V168, P2, DOI 10.1111/bjh.13166; Bittencourt AL, 2011, CASE REP ONCOL MED, DOI 10.1155/2011/639240; Boccara O, 2012, PEDIATR BLOOD CANCER, V58, P226, DOI 10.1002/pbc.23103; Boccara O, 2012, J AM ACAD DERMATOL, V66, P51, DOI 10.1016/j.jaad.2010.10.040; Boddu D, 2015, J PEDIAT HEMATOL ONC, V37, pE223, DOI 10.1097/MPH.0000000000000221; BOGGS DR, 1962, MEDICINE, V41, P163, DOI 10.1097/00005792-196209000-00001; Borowitz M, 2008, LYMPHOBLASTIC LEUKAE; Boudova L, 2005, AM J DERMATOPATH, V27, P375, DOI 10.1097/01.dad.0000179463.55129.8a; Brenner I, 2013, MODERN PATHOL, V26, P1568, DOI 10.1038/modpathol.2013.106; Burg G, 2005, J CUTAN PATHOL, V32, P647, DOI 10.1111/j.0303-6987.2005.00495.x; Burgdorf WHC, 2004, PEDIATR DERMATOL, V21, P174, DOI 10.1111/j.0736-8046.2004.21219.x; BYRD JC, 1995, J CLIN ONCOL, V13, P1800, DOI 10.1200/JCO.1995.13.7.1800; Camacho FM, 1997, PEDIATR DERMATOL, V14, P204, DOI 10.1111/j.1525-1470.1997.tb00238.x; CAMISA C, 1993, J AM ACAD DERMATOL, V29, P696, DOI 10.1016/0190-9622(93)70233-J; Cao QH, 2014, J CLIN PATHOL, V67, P90, DOI 10.1136/jclinpath-2013-201792; CAPUTO R, 1987, J AM ACAD DERMATOL, V17, P449, DOI 10.1016/S0190-9622(87)70228-X; Carrie E, 2007, ANN DERMATOL VENER, V134, P471, DOI 10.1016/S0151-9638(07)89217-9; Cartin-Ceba R, 2010, RESP MED, V104, P1344, DOI 10.1016/j.rmed.2010.03.024; Castano E, 2013, J CUTAN PATHOL, V40, P924, DOI 10.1111/cup.12217; Cerroni L, 2000, BLOOD, V95, P3922; Cerroni L, 2001, LEUKEMIA LYMPHOMA, V42, P891, DOI 10.3109/10428190109097708; Cerroni L, 2001, AM J DERMATOPATH, V23, P370, DOI 10.1097/00000372-200108000-00015; Cervini AB, 2017, ACTAS DERMO-SIFILOGR, V108, P564, DOI 10.1016/j.ad.2017.01.008; Chakraborty R, 2017, ONCOTARGET, V8, P46065, DOI 10.18632/oncotarget.17521; Chan DV, 2011, J AM ACAD DERMATOL, V65, P671, DOI 10.1016/j.jaad.2010.06.016; Chan J K, 1998, Anat Pathol, V3, P77; Chan JK, 2008, EXTRANODAL NK T CELL; Chan JKC, 1997, BLOOD, V89, P4501, DOI 10.1182/blood.V89.12.4501; Chan JKC, 2008, BLOOD, V112, P2965, DOI 10.1182/blood-2008-03-147017; Chang SE, 2002, AM J DERMATOPATH, V24, P72, DOI 10.1097/00000372-200202000-00015; Chaperot L, 2001, BLOOD, V97, P3210, DOI 10.1182/blood.V97.10.3210; Chaperot L, 2004, EUR J IMMUNOL, V34, P418, DOI 10.1002/eji.200324531; Chappell JA, 2009, AM J DERMATOPATH, V31, P487, DOI 10.1097/DAD.0b013e318196f883; Chen HH, 2002, BRIT J DERMATOL, V147, P587, DOI 10.1046/j.1365-2133.2002.04862.x; Chikwava K, 2004, PEDIATR DEVEL PATHOL, V7, P607, DOI 10.1007/s10024-004-3027-z; Chim CS, 2004, BLOOD, V103, P216, DOI 10.1182/blood-2003-05-1401; Cho EY, 2008, J KOREAN MED SCI, V23, P185, DOI 10.3346/jkms.2008.23.2.185; Cho Jae Hoon, 2006, J Infect, V52, pe173, DOI 10.1016/j.jinf.2005.08.035; Cho KH, 2004, BRIT J DERMATOL, V151, P372, DOI 10.1111/j.1365-2133.2004.06038.x; Cho-Vega JH, 2008, AM J CLIN PATHOL, V129, P130, DOI 10.1309/WYACYWF6NGM3WBRT; CHU P, 1992, J CUTAN PATHOL, V19, P201, DOI 10.1111/j.1600-0560.1992.tb01659.x; CHU T, 1987, LANCET, V2, P41; Chung Joo Seop, 2003, Korean Journal of Internal Medicine, V18, P50; Cibull TL, 2008, J CUTAN PATHOL, V35, P180, DOI 10.1111/j.1600-0560.2007.00784.x; Cohen JI, 2009, ANN ONCOL, V20, P1472, DOI 10.1093/annonc/mdp064; Collin M, 2015, HEMATOL ONCOL CLIN N, V29, P825, DOI 10.1016/j.hoc.2015.06.003; Condarco T, 2008, FETAL PEDIATR PATHOL, V27, P206, DOI 10.1080/15513810802319442; CONVIT J, 1973, ARCH DERMATOL, V107, P271, DOI 10.1001/archderm.107.2.271; Cortelazzo S, 2011, CRIT REV ONCOL HEMAT, V79, P330, DOI 10.1016/j.critrevonc.2010.12.003; Criscione VD, 2007, ARCH DERMATOL, V143, P854, DOI 10.1001/archderm.143.7.854; Cronin DMP, 2009, AM J CLIN PATHOL, V132, P101, DOI 10.1309/AJCP6GR8BDEXPKHR; Crowley JJ, 1998, J AM ACAD DERMATOL, V38, P696, DOI 10.1016/S0190-9622(98)70198-7; Cuadra-Garcia I, 1999, AM J SURG PATHOL, V23, P1356, DOI 10.1097/00000478-199911000-00006; Daoud MS, 1996, MAYO CLIN PROC, V71, P166, DOI 10.4065/71.2.166; De Souza A, 2018, APPL IMMUNOHISTO M M, V26, P462, DOI 10.1097/PAI.0000000000000462; de Souza A, 2009, J AM ACAD DERMATOL, V61, P993, DOI 10.1016/j.jaad.2009.05.014; DEBRUIN PC, 1993, HISTOPATHOLOGY, V23, P127, DOI 10.1111/j.1365-2559.1993.tb00470.x; Dehner LP, 2005, AM J SURG PATHOL, V29, P119, DOI 10.1097/01.pas.0000147412.33950.9c; Dehner LP, 2003, AM J SURG PATHOL, V27, P579, DOI 10.1097/00000478-200305000-00003; Delsol G, 2008, ANAPLASTIC LARGE CEL; Demachi A, 2003, MICROBIOL IMMUNOL, V47, P543, DOI 10.1111/j.1348-0421.2003.tb03416.x; DESCH JK, 1993, J CUTAN PATHOL, V20, P407, DOI 10.1111/j.1600-0560.1993.tb00662.x; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; DICKSON R J, 1960, J Chronic Dis, V12, P417, DOI 10.1016/0021-9681(60)90067-9; Dijkman R, 2007, BLOOD, V109, P1720, DOI 10.1182/blood-2006-04-018143; Durham BH, 2017, BLOOD, V130, P176, DOI 10.1182/blood-2016-12-757377; Eguaras AVC, 2007, J PEDIAT HEMATOL ONC, V29, P766, DOI 10.1097/MPH.0b013e318159a4e6; El Shabrawi-Caelen L, 2002, AM J SURG PATHOL, V26, P450; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Emile JF, 2014, BLOOD, V124, P3016, DOI 10.1182/blood-2014-04-570937; Estrada-Veras JI, 2017, BLOOD ADV, V1, P357, DOI 10.1182/bloodadvances.2016001784; Facchetti F, 2008, BLASTIC PLASMACYTOID; Falini B, 1999, BLOOD, V93, P2697; Fan Ping-Chin, 1995, Kaohsiung Journal of Medical Sciences, V11, P420; Fenot M, 2014, J AM ACAD DERMATOL, V71, P389, DOI 10.1016/j.jaad.2014.02.049; Ferrandiz-Pulido C, 2012, J AM ACAD DERMATOL, V66, pE238, DOI 10.1016/j.jaad.2011.07.016; Ferrari F, 2014, JAMA DERMATOL, V150, P42, DOI 10.1001/jamadermatol.2013.6434; Ferreri AJM, 2012, CRIT REV ONCOL HEMAT, V83, P293, DOI 10.1016/j.critrevonc.2012.02.005; Feuillard J, 2002, BLOOD, V99, P1556, DOI 10.1182/blood.V99.5.1556; Fink-Puches R, 2004, PEDIATR DERMATOL, V21, P525, DOI 10.1111/j.0736-8046.2004.21500.x; Frater JL, 2006, J CUTAN MED SURG, V10, P281, DOI 10.2310/7750.2006.00067; Freyer DR, 1996, J PEDIATR-US, V129, P227, DOI 10.1016/S0022-3476(96)70247-0; Frontanes Abymael, 2012, Bol Asoc Med P R, V104, P52; Gambichler T, 2009, AM J CLIN DERMATOL, V10, P169, DOI 10.2165/00128071-200910030-00003; Garcia-Herrera A, 2008, J CLIN ONCOL, V26, P3364, DOI 10.1200/JCO.2008.16.1307; Garcia-Herrera A, 2011, AM J SURG PATHOL, V35, P1214, DOI 10.1097/PAS.0b013e31822067d1; Gau JP, 2009, INT J HEMATOL, V89, P63, DOI 10.1007/s12185-008-0202-4; Gerami P, 2007, AM J SURG PATHOL, V31, P1430, DOI 10.1097/PAS.0b013e3180439bdc; Ghatalia P, 2013, J CUTAN PATHOL, V40, P477, DOI 10.1111/cup.12102; Ghislanzoni M, 2005, J AM ACAD DERMATOL, V52, pS73, DOI 10.1016/j.jaad.2004.05.025; GIANOTTI F, 1986, ARCH DERMATOL, V122, P1038, DOI 10.1001/archderm.122.9.1038; GIANOTTI R, 1993, AM J DERMATOPATH, V15, P315, DOI 10.1097/00000372-199308000-00004; GilMateo MP, 1997, J AM ACAD DERMATOL, V36, P837, DOI 10.1016/S0190-9622(97)70035-5; Goodman WT, 2013, DERMATOLOGY, V2, P1542; Grabczynska SA, 2001, BRIT J DERMATOL, V145, P323, DOI 10.1046/j.1365-2133.2001.04325.x; Grassi S, 2013, GIORN ITAL DERMAT V, V148, P371; Greer John P, 2009, Curr Hematol Malig Rep, V4, P245, DOI 10.1007/s11899-009-0032-3; Grogg KL, 2008, MODERN PATHOL, V21, P708, DOI 10.1038/modpathol.2008.40; Gru AA, 2017, SEMIN DIAGN PATHOL, V34, P60, DOI 10.1053/j.semdp.2016.11.003; Gru AA, 2016, SEMIN DIAGN PATHOL, V33, P441, DOI 10.1053/j.semdp.2016.08.004; Gru AA, 2015, AM J DERMATOPATH, V37, P477, DOI 10.1097/DAD.0000000000000190; Guitart J, 2008, AM J DERMATOPATH, V30, P494, DOI 10.1097/DAD.0b013e31817d1391; Guitart J, 2017, MODERN PATHOL, V30, P761, DOI 10.1038/modpathol.2016.240; Guitart J, 2012, AM J SURG PATHOL, V36, P1656, DOI 10.1097/PAS.0b013e31826a5038; Gupta G, 2000, J AM ACAD DERMATOL, V42, P208, DOI 10.1016/S0190-9622(00)90127-0; Gupta V, 2016, PEDIATR DERMATOL, V33, pE72, DOI 10.1111/pde.12776; Hanna S, 2006, PEDIATR DERMATOL, V23, P350, DOI 10.1111/j.1525-1470.2006.00259.x; Haroche J, 2017, LANCET ONCOL, V18, pE113, DOI 10.1016/S1470-2045(17)30031-1; Haroche J, 2015, HEMATOL-AM SOC HEMAT, P571, DOI 10.1182/asheducation-2015.1.571; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; HARRIS N, 1991, AM J SURG PATHOL, V15, P87, DOI 10.1097/00000478-199101000-00011; Hasserjian RP, 2007, AM J CLIN PATHOL, V127, P860, DOI 10.1309/2F39NX1AL3L54WU8; Hejmadi RK, 2008, J CUTAN PATHOL, V35, P46, DOI 10.1111/j.1600-0560.2008.00982.x; HELM KF, 1992, BRIT J DERMATOL, V126, P142, DOI 10.1111/j.1365-2133.1992.tb07811.x; Heng YK, 2014, PEDIATR DERMATOL, V31, P477, DOI 10.1111/pde.12352; Heritier S, 2016, J CLIN ONCOL, V34, P3023, DOI 10.1200/JCO.2015.65.9508; Hervier B, 2014, BLOOD, V124, P1119, DOI 10.1182/blood-2013-12-543793; HESKEL NS, 1983, J AM ACAD DERMATOL, V9, P423, DOI 10.1016/S0190-9622(83)70153-2; HIDANO A, 1982, JPN J EXP MED, V52, P303; Hilker O, 2013, J DTSCH DERMATOL GES, V11, P301, DOI 10.1111/j.1610-0387.2012.08069.x; Hodak E, 2006, J AM ACAD DERMATOL, V55, P276, DOI 10.1016/j.jaad.2006.01.020; Hodak E, 2014, J AM ACAD DERMATOL, V70, P993, DOI 10.1016/j.jaad.2013.12.029; Hong M, 2013, KOREAN J PATHOL, V47, P137, DOI 10.4132/KoreanJPathol.2013.47.2.137; Howarth DM, 1999, CANCER-AM CANCER SOC, V85, P2278, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U; Hsiao CH, 2003, J FORMOS MED ASSOC, V102, P193; Huang WT, 2005, HAEMATOL-HEMATOL J, V90, P1063; Huang YH, 2016, AM J CLIN PATHOL, V145, P46, DOI [10.1093/ajcp/aqv010, 10.1093/AJCP/AQV010]; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Huppmann AR, 2013, PEDIATR BLOOD CANCER, V60, P1165, DOI 10.1002/pbc.24462; Iliadis A, 2016, AM J DERMATOPATH, V38, P312, DOI 10.1097/DAD.0000000000000531; Imanaka K, 1988, Radiat Med, V6, P229; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; Isaacs H, 2011, PEDIATR DERMATOL, V28, P85, DOI 10.1111/j.1525-1470.2011.01372.x; Isaacson PG, 2008, EXTRANODAL MARGINAL; Ishihara S, 2000, INT J HEMATOL, V72, P223; Ishihara S, 1997, JPN J CANCER RES, V88, P82, DOI 10.1111/j.1349-7006.1997.tb00305.x; ISHIHARA S, 1995, ACTA PAEDIATR, V84, P1271, DOI 10.1111/j.1651-2227.1995.tb13547.x; Ishihara S, 1997, AM J HEMATOL, V54, P276, DOI 10.1002/(SICI)1096-8652(199704)54:4<276::AID-AJH3>3.0.CO;2-S; Iwatsuki K, 1999, J AM ACAD DERMATOL, V40, P283, DOI 10.1016/S0190-9622(99)70210-0; Iwatsuki K, 2006, ARCH DERMATOL, V142, P587, DOI 10.1001/archderm.142.5.587; Iwatsuki Keiji, 2006, Nihon Rinsho, V64 Suppl 3, P657; Jaffe ES, 2013, MODERN PATHOL, V26, pS71, DOI 10.1038/modpathol.2012.181; Jans SRR, 2015, PEDIATR DERMATOL, V32, pE29, DOI 10.1111/pde.12478; Janssen D, 2005, AM J SURG PATHOL, V29, P21, DOI 10.1097/01.pas.0000147395.01229.06; Jegalian AG, 2010, HAEMATOL-HEMATOL J, V95, P1873, DOI 10.3324/haematol.2010.026179; Jegalian AG, 2009, ADV ANAT PATHOL, V16, P392, DOI 10.1097/PAP.0b013e3181bb6bc2; Jhala DN, 2000, AM J CLIN PATHOL, V114, P478, DOI 10.1093/ajcp/114.3.478; Jhuang JY, 2015, HUM PATHOL, V46, P313, DOI 10.1016/j.humpath.2014.11.008; Johnson RC, 2016, AM J SURG PATHOL, V40, P502, DOI 10.1097/PAS.0000000000000595; Johnson WT, 2016, J CUTAN PATHOL, V43, P270, DOI 10.1111/cup.12636; Johnston EE, 2015, PEDIATR BLOOD CANCER, V62, P2025, DOI 10.1002/pbc.25626; Jones D, 1997, AM J CLIN PATHOL, V107, P637; Julia F, 2014, AM J SURG PATHOL, V38, P673, DOI 10.1097/PAS.0000000000000156; Jung HD, 2011, ANN DERMATOL, V23, pS270, DOI 10.5021/ad.2011.23.S2.S270; Kadin ME, 2008, AM J SURG PATHOL, V32, P1421, DOI 10.1097/PAS.0b013e3181648d6d; KADIN ME, 1985, LANCET, V2, P864; Kahwash SB, 2002, PEDIATR DEVEL PATHOL, V5, P45, DOI 10.1007/s10024-001-0104-4; KAISERLING E, 1994, MODERN PATHOL, V7, P771; Kala C, 2011, J CYTOL, V28, P131, DOI 10.4103/0970-9371.83473; KANAVAROS P, 1993, BLOOD, V81, P2688; Kanegane H, 2009, INT J HEMATOL, V89, P86, DOI 10.1007/s12185-008-0216-y; Karai LJ, 2013, AM J SURG PATHOL, V37, P1173, DOI 10.1097/PAS.0b013e318282d01e; KAUDEWITZ P, 1985, DERMATOL CLIN, V3, P749, DOI 10.1016/S0733-8635(18)30870-2; Kawa K, 2001, BLOOD, V98, P3173, DOI 10.1182/blood.V98.10.3173; Kawachi Y, 2012, PEDIATR DERMATOL, V29, P374, DOI 10.1111/j.1525-1470.2011.01658.x; Kempf W, 2006, J CUTAN PATHOL, V33, P58, DOI 10.1111/j.0303-6987.2006.00548.x; Kempf W, 2015, J EUR ACAD DERMATOL, V29, P1696, DOI 10.1111/jdv.13044; Kempf W, 2014, AM J DERMATOPATH, V36, P661, DOI 10.1097/DAD.0000000000000062; Kempf W, 2014, AM J DERMATOPATH, V36, P598, DOI 10.1097/DAD.0000000000000011; Kempf W, 2013, J AM ACAD DERMATOL, V68, P809, DOI 10.1016/j.jaad.2012.12.952; Kempf W, 2013, AM J SURG PATHOL, V37, P1, DOI 10.1097/PAS.0b013e3182648596; Kerbout M, 2014, ANN BIOL CLIN-PARIS, V72, P483, DOI 10.1684/abc.2014.0970; Khoo B. P., 1999, SMJ, V40, P697; Kikuchi Y, 2011, PEDIATR INT, V53, P393, DOI 10.1111/j.1442-200X.2011.03369.x; Kim S, 2016, CHILD NERV SYST, V32, P893, DOI 10.1007/s00381-015-2929-6; Kimura H, 2001, BLOOD, V98, P280, DOI 10.1182/blood.V98.2.280; Kimura H, 2005, J INFECT DIS, V191, P531, DOI 10.1086/427239; Kimura H, 2003, J INFECT DIS, V187, P527, DOI 10.1086/367988; Kinney MC, 2011, ARCH PATHOL LAB MED, V135, P19, DOI 10.1043/2010-0507-RAR.1; Kishimoto H, 2001, EUR J DERMATOL, V11, P151; Ko YH, 2016, HEMATOPATHOLOGY; Kobayashi R, 2010, PEDIATR BLOOD CANCER, V54, P212, DOI 10.1002/pbc.22329; KOCH SE, 1987, J AM ACAD DERMATOL, V17, P563, DOI 10.1016/S0190-9622(87)70238-2; Koh MJA, 2009, J AM ACAD DERMATOL, V61, P875, DOI 10.1016/j.jaad.2009.01.045; Koksal Y, 2009, J PEDIAT HEMATOL ONC, V31, P359, DOI 10.1097/MPH.0b013e3181984f6b; Kong YY, 2009, HISTOPATHOLOGY, V55, P189, DOI 10.1111/j.1365-2559.2009.03359.x; Kong Yun-yi, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P133; Krawczyk Janusz, 2012, Br J Haematol, V157, P280, DOI 10.1111/j.1365-2141.2012.09079.x; Krishna VVR, 2014, J RADIOL CASE REP, V8, P7, DOI 10.3941/jrcr.v8i8.1899; Kumar S, 2005, PEDIATR DEVEL PATHOL, V8, P52, DOI 10.1007/s10024-004-8087-6; Kummer JA, 1997, J INVEST DERMATOL, V109, P636, DOI 10.1111/1523-1747.ep12337633; Kunishige JH, 2009, CLIN EXP DERMATOL, V34, P576, DOI 10.1111/j.1365-2230.2008.03024.x; Kuo TT, 2004, INT J SURG PATHOL, V12, P375, DOI 10.1177/106689690401200410; Lamant L, 2010, HAEMATOL-HEMATOL J, V95, P449, DOI 10.3324/haematol.2009.015024; Landers MC, 2005, PEDIATR DERMATOL, V22, P26, DOI 10.1111/j.1525-1470.2005.22106.x; LEBOIT PE, 1988, BLOOD, V71, P1329; LEBOIT PE, 1987, J INVEST DERMATOL, V89, P183, DOI 10.1111/1523-1747.ep12470557; Lee WJ, 2014, J AM ACAD DERMATOL, V70, P318, DOI 10.1016/j.jaad.2013.10.020; Liang XY, 2008, CANCER-AM CANCER SOC, V112, P1425, DOI 10.1002/cncr.23316; Lieberman PH, 1996, AM J SURG PATHOL, V20, P519, DOI 10.1097/00000478-199605000-00001; Lim GY, 2009, PEDIATR RADIOL, V39, P57, DOI 10.1007/s00247-008-1002-y; Lima M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-95; Liu LP, 2013, AM J CLIN PATHOL, V140, P395, DOI 10.1309/AJCPFH0SJ6YILXJU; Liy-Wong C, 2017, J AM ACAD DERMATOL, V76, P1084, DOI 10.1016/j.jaad.2016.12.012; LONGAKER MA, 1994, J AM ACAD DERMATOL, V31, P910, DOI 10.1016/S0190-9622(94)70258-6; Lu CI, 2004, J AM ACAD DERMATOL, V51, P931, DOI 10.1016/j.jaad.2004.04.030; Lu D, 2002, J CUTAN PATHOL, V29, P465, DOI 10.1034/j.1600-0560.2002.290804.x; Luftl Matthias, 2006, J Dtsch Dermatol Ges, V4, P236, DOI 10.1111/j.1610-0387.2006.05907.x; Lysell J, 2009, ACTA DERM-VENEREOL, V89, P393, DOI 10.2340/00015555-0670; MACAULAY WL, 1968, ARCH DERMATOL, V97, P23, DOI 10.1001/archderm.97.1.23; Magana M, 1998, J AM ACAD DERMATOL, V38, P574, DOI 10.1016/S0190-9622(98)70120-3; Magro CM, 2016, INDIAN J DERMATOL VE, V82, P395, DOI 10.4103/0378-6323.181502; Magro CM, 2012, AM J CLIN PATHOL, V138, P50, DOI 10.1309/AJCPQGVLTZQ77VFF; Magro G, 2015, ACTA HISTOCHEM, V117, P397, DOI 10.1016/j.acthis.2015.03.011; Mahajan VK, 2016, INDIAN J DERMATOL VE, V82, P98, DOI 10.4103/0378-6323.171643; Mandel VD, 2014, J DERMATOL, V41, P1098, DOI 10.1111/1346-8138.12670; Marafioti T, 2008, BLOOD, V111, P3778, DOI 10.1182/blood-2007-10-117531; Rodriguez-Pinilla SM, 2010, AM J SURG PATHOL, V34, P1773, DOI 10.1097/PAS.0b013e3181fbb4fd; MARROGI AJ, 1992, AM J DERMATOPATH, V14, P8, DOI 10.1097/00000372-199202000-00002; Martinez-Escaname M, 2013, AM J DERMATOPATH, V35, P419, DOI 10.1097/DAD.0b013e31826ffe6f; Martorell-Calatayud A, 2010, ACTAS DERMO-SIFILOGR, V101, P693, DOI 10.1016/j.ad.2010.03.022; Marzano AV, 2000, ARCH DERMATOL, V136, P889, DOI 10.1001/archderm.136.7.889; Marzban Saeed, 2011, Rare Tumors, V3, pe34, DOI 10.4081/rt.2011.e34; Matsuzaki Y, 2009, J AM ACAD DERMATOL, V61, P120, DOI 10.1016/j.jaad.2008.10.045; MEISTER L, 1993, J AM ACAD DERMATOL, V28, P93, DOI 10.1016/0190-9622(93)70017-N; Mellgren K, 2016, ANN HEMATOL, V95, P1295, DOI 10.1007/s00277-016-2722-y; Mendese GW, 2012, CLIN EXP DERMATOL, V37, P759, DOI 10.1111/j.1365-2230.2012.04352.x; Menezes J, 2014, LEUKEMIA, V28, P823, DOI 10.1038/leu.2013.283; Menon MP, 2014, HISTOPATHOLOGY, V64, P455, DOI 10.1111/his.12274; Merrill ED, 2017, AM J SURG PATHOL, V41, P204, DOI 10.1097/PAS.0000000000000768; Merritt BY, 2013, PEDIATR BLOOD CANCER, V60, P1916, DOI 10.1002/pbc.24638; Meyer N, 2005, J INVEST DERMATOL, V124, P668, DOI 10.1111/j.0022-202X.2005.23617.x; Miedler JD, 2008, J AM ACAD DERMATOL, V58, P679, DOI 10.1016/j.jaad.2007.07.030; Milne P, 2017, BLOOD, V130, P167, DOI 10.1182/blood-2016-12-757823; Miquel J, 2014, BRIT J DERMATOL, V171, P1138, DOI 10.1111/bjd.13061; Mixon B, 2010, FETAL PEDIATR PATHOL, V29, P380, DOI 10.3109/15513815.2010.494703; Molho-Pessach V, 2014, J AM ACAD DERMATOL, V70, P80, DOI 10.1016/j.jaad.2013.09.019; MONPOUX F, 1992, PEDIATRIE, V47, P691; Monpoux F, 1996, PEDIATR DERMATOL, V13, P472, DOI 10.1111/j.1525-1470.1996.tb00727.x; Moon HR, 2014, J EUR ACAD DERMATOL, V28, P1798, DOI 10.1111/jdv.12440; Moraes AJP, 2006, PEDIATR INT, V48, P48, DOI 10.1111/j.1442-200X.2006.02169.x; Morgan NV, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000833; Morizane S, 2005, BRIT J DERMATOL, V153, P981, DOI 10.1111/j.1365-2133.2005.06849.x; Morren MA, 2016, PEDIATR BLOOD CANCER, V63, P486, DOI 10.1002/pbc.25834; MOTOI M, 1980, HISTOPATHOLOGY, V4, P585, DOI 10.1111/j.1365-2559.1980.tb02955.x; Moulonguet I, 2012, DERMATOLOGY, V225, P27, DOI 10.1159/000341519; Muljono A, 2009, PATHOLOGY, V41, P223, DOI 10.1080/00313020902756246; Nagai K, 2014, PEDIATR HEMAT ONCOL, V31, P528, DOI 10.3109/08880018.2014.896062; Nagata H, 2001, BLOOD, V97, P708, DOI 10.1182/blood.V97.3.708; Najem N, 2011, PEDIATR DERMATOL, V28, P535, DOI 10.1111/j.1525-1470.2011.01578.x; Nakayashiki N, 2014, J PLAST SURG HAND SU, V48, P80, DOI 10.3109/2000656X.2012.748323; Neuhaus IM, 2000, PEDIATR DERMATOL, V17, P403, DOI 10.1046/j.1525-1470.2000.017005403.x; Ng SSY, 2013, ACTA PAEDIATR, V102, pE514, DOI 10.1111/apa.12376; Ngo JT, 2009, J CUTAN MED SURG, V13, P230, DOI 10.2310/7750.2008.08050; Nicolae A, 2017, AM J SURG PATHOL, V41, P67, DOI 10.1097/PAS.0000000000000735; Nijsten T, 2004, ARCH DERMATOL, V140, P306, DOI 10.1001/archderm.140.3.306; NOTO G, 1994, BRIT J DERMATOL, V131, P275; O'Suoji C, 2016, PEDIATR BLOOD CANCER, V63, P794, DOI 10.1002/pbc.25881; Ohsawa T, 2001, ACTA DERM-VENEREOL, V81, P360, DOI 10.1080/000155501317140106; Ohshima K, 1997, HISTOPATHOLOGY, V31, P444, DOI 10.1046/j.1365-2559.1997.2880887.x; Ohshima K, 2008, PATHOL INT, V58, P209, DOI 10.1111/j.1440-1827.2008.02213.x; OKANO M, 1991, CLIN MICROBIOL REV, V4, P129; Omar A, 2012, J PAEDIATR CHILD H, V48, P184, DOI 10.1111/j.1440-1754.2011.02407.x; Onaindia A, 2015, HISTOPATHOLOGY, V66, P846, DOI 10.1111/his.12529; OONO T, 1986, ARCH DERMATOL, V122, P1306, DOI 10.1001/archderm.122.11.1306; ORANJE AP, 1988, EUR J PEDIATR, V148, P29, DOI 10.1007/BF00441808; Oschlies I, 2013, HAEMATOL-HEMATOL J, V98, P50, DOI 10.3324/haematol.2012.065664; Otsubo K, 2012, PEDIATR BLOOD CANCER, V59, P959, DOI 10.1002/pbc.24199; Papalas JA, 2010, AM J DERMATOPATH, V32, P821, DOI 10.1097/DAD.0b013e3181d81dc3; Park MY, 2010, EUR J DERMATOL, V20, P533, DOI 10.1684/ejd.2010.0987; Parveen Z, 2009, ARCH PATHOL LAB MED, V133, P303, DOI 10.1043/1543-2165-133.2.303; PETERS MS, 1990, J AM ACAD DERMATOL, V22, P1011, DOI 10.1016/0190-9622(90)70143-6; Petrella T, 2005, AM J CLIN PATHOL, V123, P662, DOI 10.1309/GJWNPD8HU5MAJ837; Petrella T, 2002, AM J SURG PATHOL, V26, P852, DOI 10.1097/00000478-200207000-00003; Picarsic J, 2015, HEMATOL ONCOL CLIN N, V29, P799, DOI 10.1016/j.hoc.2015.06.001; PIERARD GE, 1981, AM J DERMATOPATH, V3, P179, DOI 10.1097/00000372-198100320-00009; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Pimpinelli N, 2005, J AM ACAD DERMATOL, V53, P1053, DOI 10.1016/j.jaad.2005.08.057; Plaza JA, 2015, AM J DERMATOPATH, V37, P20, DOI 10.1097/DAD.0000000000000158; Plaza JA, 2013, J CUTAN PATHOL, V40, P236, DOI 10.1111/cup.12047; Pope E, 2010, J CUTAN MED SURG, V14, P1, DOI 10.2310/7750.2009.08091; Poppe H, 2015, J CUTAN PATHOL, V42, P258, DOI 10.1111/cup.12452; Postini AM, 2012, J PEDIAT HEMATOL ONC, V34, P353, DOI 10.1097/MPH.0b013e318257a6ea; Quaglino P, 1999, DERMATOLOGY, V199, P8, DOI 10.1159/000018196; Quintanilla-Martinez L, 2008, EBV T CELL LYMPHOPRO; Quintanilla-Martinez L, 2013, BLOOD, V122, P3101, DOI 10.1182/blood-2013-05-502203; Rajic L, 2010, COLLEGIUM ANTROPOL, V34, P679; Ralfkiaer E, 2008, CD30 POSITIVE T CELL; RAMSAY B, 1990, ARCH DERMATOL, V126, P1524, DOI 10.1001/archderm.126.11.1524; REPISO T, 1995, BRIT J DERMATOL, V132, P978; RISDALL RJ, 1983, ARCH PATHOL LAB MED, V107, P59; Rodriguez-Jurado R, 2000, AM J DERMATOPATH, V22, P70, DOI 10.1097/00000372-200002000-00014; Rollins BJ, 2015, HEMATOL ONCOL CLIN N, V29, P839, DOI 10.1016/j.hoc.2015.06.004; Romero M, 2008, PEDIATR DERMATOL, V25, P565, DOI 10.1111/j.1525-1470.2008.00763.x; Ross NA, 2016, AM J DERMATOPATH, V38, pe1, DOI 10.1097/DAD.0000000000000395; Rossi JG, 2006, LEUKEMIA LYMPHOMA, V47, P715, DOI 10.1080/10428190500353216; Saggini A, 2010, AM J SURG PATHOL, V34, P1168, DOI 10.1097/PAS.0b013e3181e75356; Salama S, 2005, AM J DERMATOPATH, V27, P217, DOI 10.1097/01.dad.0000154414.46851.18; Salama S, 2000, Am J Clin Pathol, V114 Suppl, pS104; Salotti JA, 2009, ARCH DIS CHILD, V94, P376, DOI 10.1136/adc.2008.144527; SANDER CA, 1991, J AM ACAD DERMATOL, V25, P1023, DOI 10.1016/0190-9622(91)70302-I; Sangueza M, 2013, J AM ACAD DERMATOL, V69, P112, DOI 10.1016/j.jaad.2013.01.037; Santos-Briz A, 2013, PEDIATR DERMATOL, V30, pE218, DOI 10.1111/pde.12061; Sapienza MR, 2014, LEUKEMIA, V28, P1606, DOI 10.1038/leu.2014.64; Satter EK, 2008, PEDIATR DERMATOL, V25, P291, DOI 10.1111/j.1525-1470.2008.00669.x; Savage NM, 2013, HUM PATHOL, V44, P451, DOI 10.1016/j.humpath.2012.02.007; Scarisbrick JJ, 1999, BRIT J DERMATOL, V141, P1125, DOI 10.1046/j.1365-2133.1999.03218.x; Schmid MH, 1999, DERMATOLOGY, V198, P284, DOI 10.1159/000018131; Sciallis AP, 2012, MODERN PATHOL, V25, P983, DOI 10.1038/modpathol.2012.38; Seckin D, 2009, J AM ACAD DERMATOL, V61, P519, DOI 10.1016/j.jaad.2008.11.888; Senff NJ, 2008, BLOOD, V112, P1600, DOI 10.1182/blood-2008-04-152850; Senff NJ, 2007, J CLIN ONCOL, V25, P1581, DOI 10.1200/JCO.2006.09.6396; Sharon V, 2009, PEDIATR DERMATOL, V26, P34, DOI 10.1111/j.1525-1470.2008.00843.x; Shin HT, 2004, J PEDIAT HEMATOL ONC, V26, P591, DOI 10.1097/01.mph.0000135282.39550.99; Singh ZN, 2006, MODERN PATHOL, V19, P1255, DOI 10.1038/modpathol.3800644; Smoller BR, 2003, HEMATOL ONCOL CLIN N, V17, P1277, DOI 10.1016/S0889-8588(03)00115-1; Sroa N, 2006, J CUTAN PATHOL, V33, P1, DOI 10.1111/j.1600-0560.2006.00506.x; Stenzinger A, 2014, ONCOTARGET, V5, P6404, DOI 10.18632/oncotarget.2223; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; Streubel B, 2006, AM J SURG PATHOL, V30, P529, DOI 10.1097/00000478-200604000-00015; Streubel B, 2005, LEUKEMIA, V19, P652, DOI 10.1038/sj.leu.2403644; Streubel B, 2004, LEUKEMIA, V18, P1722, DOI 10.1038/sj.leu.2403501; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Su HH, 2018, BRIT J DERMATOL, V178, P261, DOI 10.1111/bjd.15306; SU WPD, 1984, J AM ACAD DERMATOL, V11, P121; Suson K, 2010, PEDIATR DEVEL PATHOL, V13, P39, DOI 10.2350/09-06-0665-OA.1; Swerdlow SH, 2017, SEMIN DIAGN PATHOL, V34, P76, DOI 10.1053/j.semdp.2016.11.007; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, AM J SURG PATHOL, V38, pE60, DOI 10.1097/PAS.0000000000000295; Swerdlow SH, 2013, AM J CLIN PATHOL, V139, P515, DOI 10.1309/AJCPNLC9NC9WTQYY; Taddesse-Heath L, 2003, AM J SURG PATHOL, V27, P522, DOI 10.1097/00000478-200304000-00014; Tan E, 2000, PEDIATR DERMATOL, V17, P352, DOI 10.1046/j.1525-1470.2000.017005352.x; Tang X, 2007, INT J DERMATOL, V46, P1073, DOI 10.1111/j.1365-4632.2006.03045.x; Taniguchi S, 1996, J AM ACAD DERMATOL, V35, P849, DOI 10.1016/S0190-9622(96)90101-2; TAUNTON OD, 1978, ARCH DERMATOL, V114, P1505, DOI 10.1001/archderm.114.10.1505; Techavichit P, 2017, HUM PATHOL, V69, P118, DOI 10.1016/j.humpath.2017.04.026; Tekin B, 2015, ACTA DERM-VENEREOL, V95, P1021, DOI 10.2340/00015555-2145; Termuhlen AM, 2017, CLIN ADV HEMATOL ONC, V15, P200; THAWERANI H, 1978, ARCH DERMATOL, V114, P191, DOI 10.1001/archderm.114.2.191; Thomas GJ, 1998, PEDIATR DERMATOL, V15, P146, DOI 10.1046/j.1525-1470.1998.1998015146.x; Tokura Y, 2005, CANCER SCI, V96, P519, DOI 10.1111/j.1349-7006.2005.00076.x; TOKURA Y, 1990, ARCH DERMATOL, V126, P362, DOI 10.1001/archderm.126.3.362; Tokura Y, 2001, J AM ACAD DERMATOL, V45, P569, DOI 10.1067/mjd.2001.114751; Tomasini C, 1998, AM J DERMATOPATH, V20, P417, DOI 10.1097/00000372-199808000-00018; Tomaszewski MM, 1999, J AM ACAD DERMATOL, V40, P857, DOI 10.1053/jd.1999.v40.a95960; Torrelo A, 2004, PEDIATR DERMATOL, V21, P458, DOI 10.1111/j.0736-8046.2004.21408.x; Tripodo C, 2009, NAT REV CLIN ONCOL, V6, P707, DOI 10.1038/nrclinonc.2009.169; Tsai W C, 1989, Taiwan Yi Xue Hui Za Zhi, V88, P639; Vaid R, 2009, PEDIATR DERMATOL, V26, P721, DOI 10.1111/j.1525-1470.2009.01021.x; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Valladeau J, 2003, IMMUNOL RES, V28, P93, DOI 10.1385/IR:28:2:93; Valladeau J, 2002, J IMMUNOL, V168, P782, DOI 10.4049/jimmunol.168.2.782; Valladeau J, 2001, PATHOL BIOL, V49, P454, DOI 10.1016/S0369-8114(01)00163-8; Vallonthaiel AG, 2016, WORLD J RADIOL, V8, P757, DOI 10.4329/wjr.v8.i8.757; van Doorn R, 2002, ARCH DERMATOL, V138, P191, DOI 10.1001/archderm.138.2.191; Vanchinathan V, 2009, AM J DERMATOPATH, V31, P193, DOI 10.1097/DAD.0b013e31819114c4; Vassallo J, 2006, AM J SURG PATHOL, V30, P223, DOI 10.1097/01.pas.0000179123.66748.c2; Verma SB, 2012, INT J DERMATOL, V51, P445, DOI 10.1111/j.1365-4632.2011.05288.x; Volks N, 2013, PEDIATR DERMATOL, V30, P595, DOI 10.1111/pde.12168; Vural S, 2017, CYTOGENET GENOME RES, V151, P186, DOI 10.1159/000475908; Wain EM, 2005, J AM ACAD DERMATOL, V53, P158, DOI 10.1016/j.jaad.2005.01.133; Wain EM, 2003, CANCER, V98, P2282, DOI 10.1002/cncr.11780; Wang KH, 2006, BRIT J DERMATOL, V154, P277, DOI 10.1111/j.1365-2133.2005.06917.x; Wang Tao, 2010, Zhonghua Yi Xue Za Zhi, V90, P3287; Wang Xue-mei, 2013, Zhonghua Xue Ye Xue Za Zhi, V34, P36; Wang XJ, 2017, HUM PATHOL, V64, P19, DOI 10.1016/j.humpath.2017.01.003; Wang ZY, 2012, BLOOD, V120, P2003, DOI 10.1182/blood-2012-06-435024; Watabe H, 2002, CLIN EXP DERMATOL, V27, P341, DOI 10.1046/j.1365-2230.2002.01042.x; Weedon D., 2010, CUTANEOUS INFILTRATE, P959; Weingartner JS, 2012, PEDIATR DERMATOL, V29, P169, DOI 10.1111/j.1525-1470.2011.01544.x; Weitzman S, 2005, PEDIATR BLOOD CANCER, V45, P256, DOI 10.1002/pbc.20246; Werner B, 2005, AM J DERMATOPATH, V27, P56, DOI 10.1097/01.dad.0000144161.49294.5a; Weston WL, 2000, PEDIATR DERMATOL, V17, P296, DOI 10.1046/j.1525-1470.2000.01779.x; Whittam LR, 2000, BRIT J DERMATOL, V143, P1199, DOI 10.1046/j.1365-2133.2000.03888.x; Wieser I, 2016, PEDIATR DERMATOL, V33, pE296, DOI 10.1111/pde.12959; Wieser I, 2016, AM J CLIN DERMATOL, V17, P319, DOI 10.1007/s40257-016-0192-6; WILLEMZE R, 1993, J AM ACAD DERMATOL, V28, P973, DOI 10.1016/0190-9622(93)70140-O; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Willemze R, 2008, BLOOD, V111, P838, DOI 10.1182/blood-2007-04-087288; Willis B, 1996, J CLIN ONCOL, V14, P2073, DOI 10.1200/JCO.1996.14.7.2073; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Wimmer DB, 2013, ARCH PATHOL LAB MED, V137, P999, DOI 10.5858/arpa.2011-0547-CR; Wu YH, 2007, INT J DERMATOL, V46, P1081, DOI 10.1111/j.1365-4632.2007.03102.x; Xu B, 2016, AM J DERMATOPATH, V38, P672, DOI 10.1097/DAD.0000000000000491; Yamaguchi M, 2008, CANCER SCI, V99, P1016, DOI 10.1111/j.1349-7006.2008.00768.x; Yang CC, 2014, EUR J DERMATOL, V24, P70, DOI 10.1684/ejd.2013.2216; Yim JH, 2006, PEDIATR DERMATOL, V23, P537, DOI 10.1111/j.1525-1470.2006.00305.x; Yoshii Y, 2016, J EUR ACAD DERMATOL, V30, P529, DOI 10.1111/jdv.12927; Yurkovich Marko, 2013, Dermatol Online J, V19, P3; Zackheim HS, 1997, J AM ACAD DERMATOL, V36, P557, DOI 10.1016/S0190-9622(97)70243-3; Zackheim HS, 2003, J AM ACAD DERMATOL, V49, P620, DOI 10.1067/S0190-9622(03)01577-9; Zackheim HS, 2002, J AM ACAD DERMATOL, V47, P914, DOI 10.1067/mjd.2002.124696; Zambrano E, 2006, INT J SURG PATHOL, V14, P163, DOI 10.1177/106689690601400213; Zebisch A, 2003, ANN HEMATOL, V82, P705, DOI 10.1007/s00277-003-0717-y; Zelger B, 2001, Adv Dermatol, V17, P77; Zelger BWH, 1996, AM J DERMATOPATH, V18, P490, DOI 10.1097/00000372-199610000-00008; Zelger BWH, 2001, BRIT J DERMATOL, V145, P369, DOI 10.1046/j.1365-2133.2001.04367.x; Zengin N, 1998, J AM ACAD DERMATOL, V38, P620, DOI 10.1016/S0190-9622(98)70127-6; Zhang Y, 2003, BRIT J HAEMATOL, V121, P805, DOI 10.1046/j.1365-2141.2003.04359.x; Zheng M, 2013, DISCOV MED, V16, P193	439	1	1	1	3	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAR-APR	2018	21	2			SI		208	251		10.1177/1093526617750947			44	Pathology; Pediatrics	Pathology; Pediatrics	GI7NF	WOS:000434688500004	29607757				2019-10-28	
J	Yang, C; Gru, AA; Dehner, LP				Yang, Chen; Gru, Alejandro A.; Dehner, Louis P.			Common and not so Common Melanocytic Lesions in Children and Adolescents	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						melanocytic nevus; congenital melanocytic nevus; Spitz nevus; atypical Spitz tumor; spitzoid melanoma; BRAF; NRAS	ATYPICAL SPITZ TUMORS; COMPONENTS CLONAL NEVUS; EPITHELIOID BLUE NEVUS; CENTRAL-NERVOUS-SYSTEM; MALIGNANT-MELANOMA; PEDIATRIC MELANOMA; PROLIFERATIVE NODULES; HISTOLOGIC FEATURES; ERUPTIVE NEVI; NEUROCUTANEOUS MELANOSIS	The acquired melanocytic nevus is the most common lesion encountered by pediatric pathologists and dermatopathologists in their daily practice. In most cases, there are few difficulties in histopathologic diagnosis. However, it is the acquired melanocytic lesion known as the Spitz nevus, with its intrinsic atypical features which becomes the challenge since it exists along a histopathologic and biologic continuum from the atypical Spitz tumor to spitzoid melanoma. The frustration with some of these spitzoid lesions is that even the "experts" cannot agree as to the differentiation of one from the other even at the level of molecular genetics. Other melanocytic lesions are discussed including the congenital melanocytic nevus with its proliferative nodule(s) and melanoma as the ultimate complication. Although uncommon, cutaneous melanoma in the first 2 decades is emerging as a clinical problem especially in young women in the second decade of life. These are ultraviolet-associated neoplasms whose histopathologic and prognostic features are identical to the adult experience. Considerable progress has been made over the past 15 to 20 years in our understanding of cutaneous melanocytic lesions, but gaps still exist in the important group of spitzoid lesions. It can also be anticipated that more cutaneous melanomas in children will be seen in the future based upon epidemiologic studies.	[Yang, Chen; Dehner, Louis P.] Washington Univ, Med Ctr, St Louis Childrens Hosp, Lauren V Ackerman Lab Surg Pathol, St Louis, MO 63110 USA; [Gru, Alejandro A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA	Dehner, LP (reprint author), Washington Univ, Med Ctr, Sch Med, Campus Box 8116,660 S Euclid Ave, St Louis, MO 63110 USA.	Dehner@path.wustl.edu		Yang, Chen/0000-0002-6371-5930			Aguilera P, 2009, DERMATOLOGY, V218, P203, DOI 10.1159/000183179; Ahn CS, 2016, AM J DERMATOPATH, V38, P867, DOI 10.1097/DAD.0000000000000568; Al Dhaybi R, 2011, J AM ACAD DERMATOL, V65, P357, DOI 10.1016/j.jaad.2010.07.031; Aldrink JH, 2009, J PEDIATR SURG, V44, P1514, DOI 10.1016/j.jpedsurg.2008.12.003; Alikhan A, 2012, J AM ACAD DERMATOL, V67, P512; ALLEN AC, 1954, AMA ARCH DERM SYPH, V69, P150, DOI 10.1001/archderm.1954.01540140018002; Alomari AK, 2015, J CUTAN PATHOL, V42, P757, DOI 10.1111/cup.12523; Aung PP, 2015, J CLIN PATHOL, V68, P963, DOI 10.1136/jclinpath-2015-202887; Austin MT, 2013, J PEDIATR SURG, V48, P2207, DOI 10.1016/j.jpedsurg.2013.06.002; Averbook BJ, 2013, CANCER-AM CANCER SOC, V119, P4012, DOI 10.1002/cncr.28289; Bar Michael, 2012, Dermatol Pract Concept, V2, P13, DOI 10.5826/dpc.0201a03.; Baran JL, 2011, AM J SURG PATHOL, V35, P1540, DOI 10.1097/PAS.0b013e31822e9f5e; Barnhill RL, 2010, ADV ANAT PATHOL, V17, P73, DOI 10.1097/PAP.0b013e3181cfe758; Barnhill RL, 2006, MODERN PATHOL, V19, pS21, DOI 10.1038/modpathol.3800519; Barnhill RL, 1999, HUM PATHOL, V30, P513, DOI 10.1016/S0046-8177(99)90193-4; BARNHILL RL, 1995, J AM ACAD DERMATOL, V33, P780, DOI 10.1016/0190-9622(95)91816-7; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bax MJ, 2017, J AM ACAD DERMATOL, V77, P328, DOI 10.1016/j.jaad.2017.01.029; Berk DR, 2010, PEDIATR DERMATOL, V27, P244, DOI 10.1111/j.1525-1470.2009.01078.x; Bishop J, 2011, HARPERS TXB PEDIAT D, P1; Bolande RP, 1997, PEDIATR PATHOL LAB M, V17, P1, DOI 10.1080/107710497174994; BOLANDE RP, 1974, LANCET, V2, P1497; Botella-Estrada R, 2015, AM J DERMATOPATH, V37, P376, DOI 10.1097/DAD.0000000000000205; Bowen AR, 2015, J CUTAN PATHOL, V42, P832, DOI 10.1111/cup.12580; Brecht IB, 2015, EUR J CANCER, V51, P861, DOI 10.1016/j.ejca.2015.02.014; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Carney JA, 1998, SEMIN DIAGN PATHOL, V15, P216; Carney JA, 1996, AM J SURG PATHOL, V20, P259, DOI 10.1097/00000478-199603000-00001; CASSO EM, 1992, J AM ACAD DERMATOL, V27, P901, DOI 10.1016/0190-9622(92)70286-O; Charbel C, 2014, J INVEST DERMATOL, V134, P1067, DOI 10.1038/jid.2013.429; Christman MP, 2014, PEDIATR DERMATOL, V31, P584, DOI 10.1111/pde.12359; CLEMMENSEN OJ, 1988, J AM ACAD DERMATOL, V19, P742, DOI 10.1016/S0190-9622(88)70231-5; Cooper C, 2012, ADV ANAT PATHOL, V19, P410, DOI 10.1097/PAP.0b013e318271a5cb; Cramer SF, 2016, PEDIATR DEVEL PATHOL, V19, P409, DOI 10.2350/15-06-1662-OA.1; Cribier BJ, 1999, BRIT J DERMATOL, V141, P1004, DOI 10.1046/j.1365-2133.1999.03197.x; Crowson AN, 2014, MELANOCYTIC PROLIFERATIONS: A COMPREHENSIVE TEXTBOOK OF PIGMENTED LESIONS, 2ND EDITION, P107; Crowson AN, 2014, MELANOCYTIC PROLIFERATIONS: A COMPREHENSIVE TEXTBOOK OF PIGMENTED LESIONS, 2ND EDITION, P1, DOI 10.1002/9781118488935; Da Forno PD, 2009, BRIT J DERMATOL, V161, P364, DOI 10.1111/j.1365-2133.2009.09181.x; Daltro LR, 2017, AN BRAS DERMATOL, V92, P110, DOI 10.1590/abd1806-4841.20174502; Davar D, 2015, J INVEST DERMATOL, V135, P659, DOI 10.1038/jid.2014.467; De Giorgi V, 2010, BRIT J DERMATOL, V162, P345, DOI 10.1111/j.1365-2133.2009.09486.x; Dean PH, 2017, PRS-GLOB OPEN, V5, DOI 10.1097/GOX.0000000000001252; DeDavid M, 1996, J AM ACAD DERMATOL, V35, P529, DOI 10.1016/S0190-9622(96)90674-X; Diaz A, 2011, AM J SURG PATHOL, V35, P1733, DOI 10.1097/PAS.0b013e318229cf66; Dika E, 2017, PEDIATR DERMATOL, V34, P25, DOI 10.1111/pde.13025; Dodd AT, 2007, CANCER EPIDEM BIOMAR, V16, P2136, DOI 10.1158/1055-9965.EPI-07-0453; Dua R, 2012, J NEUROL SURG PART A, V73, P337, DOI 10.1055/s-0032-1313593; Duffy K, 2012, J AM ACAD DERMATOL, V67, P17; Duffy K, 2012, J AM ACAD DERMATOL, V67, P1, DOI DOI 10.1016/J.JAAD.2012.03.013; Emley A, 2011, HUM PATHOL, V42, P136, DOI 10.1016/j.humpath.2010.05.027; Evans MJ, 1998, PEDIATR DEVEL PATHOL, V1, P388, DOI 10.1007/s100249900053; Fabrizi G, 2007, J CUTAN PATHOL, V34, P365, DOI 10.1111/j.1600-0560.2006.00622.x; Fernandez AP, 2016, J CUTAN PATHOL, V43, P932, DOI 10.1111/cup.12774; Ferrara G, 2007, J CUTAN PATHOL, V34, P543, DOI 10.1111/j.1600-0560.2006.00650.x; Ferrara G, 2016, AM J DERMATOPATH, V38, P253, DOI 10.1097/DAD.0000000000000380; Ferrari A, 2014, J PEDIAT, V164; Fisher KR, 2013, J AM ACAD DERMATOL, V68, P466, DOI 10.1016/j.jaad.2012.10.046; Friedman RJ, 2009, CLIN DERMATOL, V27, P103, DOI 10.1016/j.clindermatol.2008.09.008; Garrido-Ruiz MC, 2010, MODERN PATHOL, V23, P1215, DOI 10.1038/modpathol.2010.102; Gerami P, 2014, AM J SURG PATHOL, V38, P934, DOI 10.1097/PAS.0000000000000198; Gerami P, 2013, AM J SURG PATHOL, V37, P676, DOI 10.1097/PAS.0b013e3182753de6; Gleason BC, 2008, AM J SURG PATHOL, V32, P51, DOI 10.1097/PAS.0b013e318068420c; Guegan S, 2016, EXP DERMATOL, V25, P789, DOI 10.1111/exd.13073; Gupta M, 2010, ARCH DERMATOL, V146, P506, DOI 10.1001/archdermatol.2010.88; Harms KL, 2015, ARCH PATHOL LAB MED, V139, P1263, DOI 10.5858/arpa.2015-0207-RA; Harms PW, 2016, HUM PATHOL, V58, P152, DOI 10.1016/j.humpath.2016.07.029; Harvell JD, 1997, J CUTAN PATHOL, V24, P611, DOI 10.1111/j.1600-0560.1997.tb01092.x; Hawkes JE, 2016, SEMIN ONCOL, V43, P591, DOI 10.1053/j.seminoncol.2016.08.003; Held L, 2013, AM J PATHOL, V182, P640, DOI 10.1016/j.ajpath.2012.11.010; HENDRICKSON MR, 1981, AM J SURG PATHOL, V5, P109, DOI 10.1097/00000478-198103000-00004; Heng YK, 2013, AM J DERMATOPATH, V35, P486, DOI 10.1097/DAD.0b013e318261ea3a; Herron MD, 2004, AM J SURG PATHOL, V28, P1017, DOI 10.1097/01.pas.0000126785.61609.6e; High WA, 2006, J AM ACAD DERMATOL, V55, P460, DOI 10.1016/j.jaad.2006.04.054; Holt JB, 2004, AM J CLIN PATHOL, V121, P58, DOI 10.1309/Y5QAD623MYA21PUY; Hung T, 2016, AM J DERMATOPATH, V38, P499, DOI 10.1097/DAD.0000000000000483; Hung T, 2014, HUM PATHOL, V45, P2369, DOI 10.1016/j.humpath.2014.08.009; Hunt RD, 2014, J AM ACAD DERMATOL, V70, P429, DOI 10.1016/j.jaad.2013.10.022; ISHII N, 1991, BRIT J DERMATOL, V124, P492, DOI 10.1111/j.1365-2133.1991.tb00633.x; Islam Monica P, 2015, Handb Clin Neurol, V132, P111, DOI 10.1016/B978-0-444-62702-5.00007-X; Jain P, 2014, J CHILD NEUROL, V29, P846, DOI 10.1177/0883073813485432; Jaramillo-Averbe F, 2004, PEDIATR DERMATOL, V21, P218, DOI 10.1111/j.0736-8046.2004.21305.x; Jen M, 2009, CLIN DERMATOL, V27, P529, DOI 10.1016/j.clindermatol.2008.09.011; Kamino H, 2009, CLIN DERMATOL, V27, P545, DOI 10.1016/j.clindermatol.2008.09.013; Kinsler VA, 2017, BRIT J DERMATOL, V176, P1131, DOI 10.1111/bjd.15301; Kinsler VA, 2009, BRIT J DERMATOL, V160, P143, DOI 10.1111/j.1365-2133.2008.08849.x; Kinsler VA, 2014, J INVEST DERMATOL, V134, P2658, DOI 10.1038/jid.2014.195; Kinsler VA, 2013, J INVEST DERMATOL, V133, P2229, DOI 10.1038/jid.2013.70; Krengel S, 2006, BRIT J DERMATOL, V155, P1, DOI 10.1111/j.1365-2133.2006.07218.x; Krengel S, 2013, J AM ACAD DERMATOL, V68, P441, DOI 10.1016/j.jaad.2012.05.043; Kusters-Vandevelde HVN, 2015, BRAIN PATHOL, V25, P209, DOI 10.1111/bpa.12241; Kunisada T, 2014, BIRTH DEFECTS RES C, V102, P251, DOI 10.1002/bdrc.21079; Lallas A, 2014, LANCET ONCOL, V15, pE178, DOI 10.1016/S1470-2045(13)70608-9; Lange JR, 2007, J CLIN ONCOL, V25, P1363, DOI 10.1200/JCO.2006.08.8310; Latchana N, 2017, ANN SURG ONCOL, V24, P347, DOI 10.1245/s10434-016-5476-9; Lee CY, 2017, AM J DERMATOPATH, V39, P181, DOI 10.1097/DAD.0000000000000629; Lee NR, 2015, AM J DERMATOPATH, V37, pE137, DOI 10.1097/DAD.0000000000000311; Levy R, 2016, PEDIATR ANN, V45, pE293, DOI 10.3928/19382359-20160720-07; Lomas A, 2012, BRIT J DERMATOL, V166, P1069, DOI 10.1111/j.1365-2133.2012.10830.x; Lopez V, 2010, ACTAS DERMO-SIFILOGR, V101, P771, DOI 10.1016/j.ad.2010.02.016; Lorimer PD, 2016, ANN SURG ONCOL, V23, P4058, DOI 10.1245/s10434-016-5349-2; Lott JP, 2014, J AM ACAD DERMATOL, V71, P1077, DOI 10.1016/j.jaad.2014.08.026; Lovett A, 2009, J AM ACAD DERMATOL, V61, P766, DOI 10.1016/j.jaad.2008.11.022; Lu C, 2015, J INVEST DERMATOL, V135, P816, DOI 10.1038/jid.2014.425; Lu DS, 2015, J CUTAN PATHOL, V42, P959, DOI 10.1111/cup.12598; Ludgate MW, 2009, CANCER-AM CANCER SOC, V115, P631, DOI 10.1002/cncr.24047; Luo S, 2014, J INVEST DERMATOL, V134, P2493, DOI 10.1038/jid.2014.244; Magana M, 2015, AM J DERMATOPATH, V37, P31, DOI 10.1097/DAD.0000000000000183; MARK GJ, 1973, HUM PATHOL, V4, P395, DOI 10.1016/S0046-8177(73)80101-7; Martin Hernandez J M, 2006, An Pediatr (Barc), V65, P260; da Silva VPM, 2017, J AM ACAD DERMATOL, V76, P689, DOI 10.1016/j.jaad.2016.05.042; Marusic Z, 2015, J CUTAN PATHOL, V42, P406, DOI 10.1111/cup.12493; Marzuka-Alcala A, 2014, METHODS MOL BIOL, V1102, P381, DOI 10.1007/978-1-62703-727-3_20; Mason A, 2012, J CUTAN PATHOL, V39, P1062, DOI 10.1111/cup.12014; Massi D, 2016, PATHOLOGY, V48, P132, DOI 10.1016/j.pathol.2015.12.003; Massi D, 2015, J AM ACAD DERMATOL, V72, P37, DOI 10.1016/j.jaad.2014.09.049; Mazaud C, 2015, ARCH PEDIATRIE, V22, P409, DOI 10.1016/j.arcped.2015.01.010; MOONEY MA, 1995, J CUTAN PATHOL, V22, P342, DOI 10.1111/j.1600-0560.1995.tb01417.x; Moscarella E, 2012, BRIT J DERMATOL, V167, P368, DOI 10.1111/j.1365-2133.2012.10952.x; Murali R, 2007, J AM ACAD DERMATOL, V56, P889, DOI 10.1016/j.jaad.2006.11.029; Murali R, 2009, ADV ANAT PATHOL, V16, P365, DOI 10.1097/PAP.0b013e3181bb6b53; Neuhold JC, 2015, PEDIATR DERMATOL, V32, P13, DOI 10.1111/pde.12400; Nguyen TLT, 2013, AM J DERMATOPATH, V35, pE16, DOI 10.1097/DAD.0b013e318265fe12; O'Rourke EA, 2013, AM J DERMATOPATH, V35, P30, DOI 10.1097/DAD.0b013e3182587ef8; O'Shea SJ, 2017, HUM MOL GENET, V26, P717, DOI 10.1093/hmg/ddw403; Osio A, 2013, AM J DERMATOPATH, V35, P284, DOI 10.1097/DAD.0b013e3182631622; Pappo AS, 2003, EUR J CANCER, V39, P2651, DOI 10.1016/j.ejca.2003.06.001; Phadke PA, 2011, CLIN LAB MED, V31, P345, DOI 10.1016/j.cll.2011.03.011; Piepkorn M, 2005, AM J DERMATOPATH, V27, P367, DOI 10.1097/01.dad.0000154417.67447.b0; Pins A, 2015, HUM PATHOL, V46, P239, DOI 10.1016/j.humpath.2014.10.015; Pinto A, 2012, AM J DERMATOPATH, V34, P838, DOI 10.1097/DAD.0b013e31825d79b3; Plaza JA, 2014, AM J DERMATOPATH, V36, P283, DOI 10.1097/DAD.0b013e3182a64bb9; Pozo L, 2001, AM J CLIN PATHOL, V115, P194; Price HN, 2015, PEDIATR DERMATOL, V32, P23, DOI 10.1111/pde.12428; Prieto-Granada CN, 2016, PATHOLOGY, V48, P705, DOI 10.1016/j.pathol.2016.08.008; PULITZER DR, 1991, AM J SURG PATHOL, V15, P1111, DOI 10.1097/00000478-199112000-00001; Puri PK, 2011, J CUTAN PATHOL, V38, P14, DOI 10.1111/j.1600-0560.2010.01624.x; Ramesh R, 2017, CLIN EXP DERMATOL, V42, P75, DOI 10.1111/ced.12969; Redon S, 2018, APPL IMMUNOHISTO M M, V26, P714, DOI 10.1097/PAI.0000000000000511; Requena C, 2017, PIGM CELL MELANOMA R, V30, P265, DOI 10.1111/pcmr.12565; Requena C, 2009, AM J DERMATOPATH, V31, P107, DOI 10.1097/DAD.0b013e3181934218; RHODES AR, 1985, ARCH DERMATOL, V121, P1266, DOI 10.1001/archderm.121.10.1266; Ribe A, 2003, MODERN PATHOL, V16, P505, DOI 10.1097/01.MP.0000071128.67149.FD; Richards MK, 2017, JAMA OTOLARYNGOL, V143, P34, DOI 10.1001/jamaoto.2016.2630; Robson A, 2003, HISTOPATHOLOGY, V43, P529, DOI 10.1111/j.1365-2559.2003.01730.x; Roh MR, 2015, PIGM CELL MELANOMA R, V28, P661, DOI 10.1111/pcmr.12412; Rongioletti F, 2004, J CUTAN PATHOL, V31, P137, DOI 10.1111/j.0303-6987.2004.00159.x; ROSE DSC, 1995, J CLIN PATHOL, V48, P676, DOI 10.1136/jcp.48.7.676; Rosendahl CO, 2015, J AM ACAD DERMATOL, V73, P507, DOI 10.1016/j.jaad.2015.04.029; Ruhoy SM, 2011, AM J DERMATOPATH, V33, P167, DOI 10.1097/DAD.0b013e3181f3dba3; Salgado CM, 2015, MELANOMA RES, V25, P453, DOI 10.1097/CMR.0000000000000188; Salgado CM, 2015, PEDIATR DEVEL PATHOL, V18, P1, DOI 10.2350/14-10-1566-OA.1; Sargen MR, 2015, J AM ACAD DERMATOL, V72, P496, DOI 10.1016/j.jaad.2014.11.014; Schaffer JV, 2015, CLIN DERMATOL, V33, P368, DOI 10.1016/j.clindermatol.2014.12.015; Shang ZW, 2015, INT J CLIN EXP MED, V8, P11048; Sherrill AM, 2011, AM J DERMATOPATH, V33, P35, DOI 10.1097/DAD.0b013e3181e5dfa0; Sibbald C, 2015, BRIT J DERMATOL, V173, P1522, DOI 10.1111/bjd.13949; Simons EA, 2017, J AM ACAD DERMATOL, V76, P941, DOI 10.1016/j.jaad.2016.12.026; Soura E, 2016, J AM ACAD DERMATOL, V74, P21; Soura E, 2016, J AM ACAD DERMATOL, V74, P411, DOI 10.1016/j.jaad.2015.08.037; Spatz A, 1999, J AM ACAD DERMATOL, V40, P223, DOI 10.1016/S0190-9622(99)70192-1; Stanelle EJ, 2015, J PEDIATR SURG, V50, P1019, DOI 10.1016/j.jpedsurg.2015.03.030; Strazzula L, 2014, J AM ACAD DERMATOL, V71, P1234, DOI 10.1016/j.jaad.2014.07.026; Su A, 2014, AM J DERMATOPATH, V36, P915, DOI 10.1097/DAD.0000000000000128; Tannous ZS, 2005, J AM ACAD DERMATOL, V52, P197, DOI 10.1016/j.jaad.2004.07.020; Tariq S, 2017, ANN MED SURG, V21, P93, DOI 10.1016/j.amsu.2017.07.042; Tcheung WJ, 2013, PEDIATR DERMATOL, V30, P568, DOI 10.1111/pde.12153; Turkeltaub AE, 2016, J AM ACAD DERMATOL, V74, P1128, DOI 10.1016/j.jaad.2016.01.024; Tzu J, 2013, J CUTAN PATHOL, V40, P879, DOI 10.1111/cup.12200; Uguen A, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0431-9; Urso Carmelo, 2016, Dermatol Pract Concept, V6, P43, DOI 10.5826/dpc.0602a08; Valdebran M, 2016, J AM ACAD DERMATOL, V75, P1032, DOI 10.1016/j.jaad.2016.06.051; van Engen-van Grunsven ACH, 2010, AM J SURG PATHOL, V34, P1436, DOI 10.1097/PAS.0b013e3181f0a749; van Engen-van Grunsven Adriana C H, 2014, Front Med (Lausanne), V1, P39, DOI 10.3389/fmed.2014.00039; Vergier B, 2016, JAMA DERMATOL, V152, P1147, DOI 10.1001/jamadermatol.2016.2667; Vourc'h-Jourdain M, 2013, J AM ACAD DERMATOL, V68, P493, DOI 10.1016/j.jaad.2012.09.039; Vyas R, 2015, J AM ACAD DERMATOL, V73, P1031, DOI 10.1016/j.jaad.2015.08.016; Waelchli R, 2015, BRIT J DERMATOL, V173, P739, DOI 10.1111/bjd.13898; Wang EKW, 2016, PEDIATR DERMATOL, V33, pE368, DOI 10.1111/pde.12953; Wenk C, 2003, PEDIATR DERMATOL, V20, P482, DOI 10.1111/j.1525-1470.2003.20605.x; Weyant GW, 2015, INT J DERMATOL, V54, pE433, DOI 10.1111/ijd.12843; Wiesner T, 2016, PATHOLOGY, V48, P113, DOI 10.1016/j.pathol.2015.12.007; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wiesner T, 2012, AM J SURG PATHOL, V36, P818, DOI 10.1097/PAS.0b013e3182498be5; Wong JR, 2013, PEDIATRICS, V131, P846, DOI 10.1542/peds.2012-2520; Wood BA, 2016, PATHOLOGY, V48, P155, DOI 10.1016/j.pathol.2015.12.001; Woodhouse J, 2005, J AM ACAD DERMATOL, V52, pS96, DOI 10.1016/j.jaad.2004.08.009; Wu D, 2011, AM J DERMATOPATH, V33, P341, DOI 10.1097/DAD.0b013e3181fb5bc7; Wu G, 2016, MODERN PATHOL, V29, P359, DOI 10.1038/modpathol.2016.37; Yazdan P, 2014, AM J SURG PATHOL, V38, P638, DOI 10.1097/PAS.0000000000000160; Yelamos O, 2015, AM J SURG PATHOL, V39, P405, DOI 10.1097/PAS.0000000000000351; Zaal LH, 2004, BRIT J PLAST SURG, V57, P707, DOI 10.1016/j.bjps.2004.04.022; Zhang DC, 2014, BIRTH DEFECTS RES C, V102, P275, DOI 10.1002/bdrc.21081; Zhao G, 2017, J CUTAN PATHOL, V44, P5, DOI 10.1111/cup.12826	193	1	1	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	MAR-APR	2018	21	2			SI		252	270		10.1177/1093526617751720			19	Pathology; Pediatrics	Pathology; Pediatrics	GI7NF	WOS:000434688500005	29607755				2019-10-28	
J	Ouk, D; Delcourt, S; Tessonnier, L; Casalta, JP; Habib, G; Mundler, O; Guedj, E; Cammilleri, S				Ouk, D.; Delcourt, S.; Tessonnier, L.; Casalta, J-P; Habib, G.; Mundler, O.; Guedj, E.; Cammilleri, S.			Contribution of F-18-FDG PET/CT on non-operated prosthetic valve infective endocarditis follow-up	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Infective endocarditis; Prosthetic valve; F-18-FDG PET/CT; Recurrence; Inflammation	EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; REPLACEMENT SURGERY; DIAGNOSIS; MORTALITY; MULTICENTER; RECURRENCE; THERAPY; IMPACT; COHORT	Introduction. - Prosthetic valve endocarditis is a diagnostic and therapeutic challenge; F-18-FDG PET/CT has seen increasing use and has been incorporated in the latest ESC endocarditis guidelines. Follow-up by PET/CT has never been studied. The aim was to study the use of PET/CT to help predicting recurrences after full antibiotic treatment. Methods. - From January 2011 to April 2016, all patients presenting with definite or possible prosthetic valve endocarditis were included and had a PET/CT after admission. After discharge, non-operated patients had a second PET/CT from 6 to 10 weeks after the end of intravenous antibiotic treatment, in addition to clinical and echocardiographic follow-up. Results. - Among 276 patients with prosthetic valve admitted for suspicion of infective endocarditis, 43 of them with an abnormal prosthetic uptake on the first PET/CT had a second PET/CT within a mean period of 67.3 days after the end of intravenous antibiotic treatment. The mean follow-up was 414 days. Five recurrences occurred among the 34 patients with persistent abnormal prosthetic uptake on second PET/CT, there was no recurrence among the nine patients who had no more abnormal prosthetic uptake. Conclusion. - This is the first study to evaluate the potential benefits of PET/CT for medically treated PVE follow-up. All recurrences occurred among patients with persistent abnormal prosthetic uptake on second PET/CT. An unexpected finding was the potential of bone-marrow and splenic uptake evolution, which is underused in IE and showed an interesting potential in the prognosis of these patients. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Ouk, D.; Delcourt, S.; Tessonnier, L.; Mundler, O.; Guedj, E.; Cammilleri, S.] Aix Marseille Univ, Inst Fresnel, Cent Marseille, CNRS, Marseille, France; [Habib, G.] CHU Marseille, Hop la Timone, AP HM, Serv Cardiol, 264 Rue St Pierre, F-13005 Marseille, France; [Casalta, J-P] CHU Marseille, IHU Hop la Timone, AP HM, 264 Rue St Pierre, F-13005 Marseille, France	Guedj, E (reprint author), Aix Marseille Univ, Inst Fresnel, Cent Marseille, CNRS, Marseille, France.	eric.guedj@univ-amu.fr					Alagna L, 2014, CLIN MICROBIOL INFEC, V20, P566, DOI 10.1111/1469-0691.12395; Asabella AN, 2015, HELL J NUCL MED, V18, P17; Bartoletti Michele, 2014, BMC Res Notes, V7, P32, DOI 10.1186/1756-0500-7-32; Challapalli A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00044; Chang FY, 2003, MEDICINE, V82, P333, DOI 10.1097/01.md.0000091184.93122.09; Chu VH, 2005, CLIN INFECT DIS, V41, P406, DOI 10.1086/431590; Fedoruk LM, 2009, J THORAC CARDIOV SUR, V137, P326, DOI 10.1016/j.jtcvs.2008.08.024; Fernandez-Hidalgo N, 2012, CLIN MICROBIOL INFEC, V18, pE522, DOI 10.1111/1469-0691.12033; Habib G, 2005, HEART, V91, P954, DOI 10.1136/hrt.2004.046177; Habib G, 2015, EUR HEART J, V36, P3075, DOI [10.1093/eurheartj/ehv319, 10.1093/eurheartj/ehv488]; Habib G, 2010, EUR J ECHOCARDIOGR, V11, P202, DOI 10.1093/ejechocard/jeq004; Heiro M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-49; Husmann L, 2015, J NUCL MED, V56, P1024, DOI 10.2967/jnumed.115.156265; Inoue K, 2009, ANN NUCL MED, V23, P643, DOI 10.1007/s12149-009-0286-9; Kaiser SP, 2007, ANN THORAC SURG, V83, P30, DOI 10.1016/j.athoracsur.2006.07.037; Kestler M, 2014, J NUCL MED, V55, P1093, DOI 10.2967/jnumed.113.134981; Lalani T, 2010, CIRCULATION, V121, P1005, DOI 10.1161/CIRCULATIONAHA.109.864488; Liu YY, 2009, NUCL MED COMMUN, V30, P763, DOI 10.1097/MNM.0b013e32832fa254; Mansur AJ, 2001, AM HEART J, V141, P78, DOI 10.1067/mhj.2001.111952; Martinez-Selles M, 2008, MAYO CLIN PROC, V83, P1213, DOI 10.4065/83.11.1213; Millar BC, 2013, INT J CARDIOL, V167, P1724, DOI 10.1016/j.ijcard.2012.12.005; Mokhles MM, 2011, ANN THORAC SURG, V91, P1407, DOI 10.1016/j.athoracsur.2011.02.007; Netzer ROM, 2002, HEART, V88, P61, DOI 10.1136/heart.88.1.61; Orvin K, 2015, CLIN MICROBIOL INFEC, V21, P69, DOI 10.1016/j.cmi.2014.08.012; Pizzi MN, 2016, JACC-CARDIOVASC IMAG, V9, P1224, DOI 10.1016/j.jcmg.2016.05.013; Pizzi MN, 2015, CIRCULATION, V132, P1113, DOI 10.1161/CIRCULATIONAHA.115.015316; Rouzet F, 2014, J NUCL MED, V55, P1980, DOI 10.2967/jnumed.114.141895; Saby L, 2013, J AM COLL CARDIOL, V61, P2374, DOI 10.1016/j.jacc.2013.01.092; Salaun PY, 2009, EUR J NUCL MED MOL I, V36, P1813, DOI 10.1007/s00259-009-1183-0; Terasawa T, 2009, J CLIN ONCOL, V27, P1906, DOI 10.1200/JCO.2008.16.0861; Ternhag A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067519; Thuny F, 2012, AM HEART J, V164, P94, DOI 10.1016/j.ahj.2012.04.003; Tornos P, 2011, CURR PROB CARDIOLOGY, V36, P175, DOI 10.1016/j.cpcardiol.2011.03.004; Van Riet J, 2010, EUR J NUCL MED MOL I, V37, P1189, DOI 10.1007/s00259-010-1380-x; Wang A, 2007, JAMA-J AM MED ASSOC, V297, P1354, DOI 10.1001/jama.297.12.1354	35	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					59	69		10.1016/j.mednuc.2018.02.005			11	Pathology	Pathology	GI1AP	WOS:000434101900001					2019-10-28	
J	Sinigaglia, M; Zerdoud, S; Bastie, D; Dierickx, L; Racaru, LV; Courbon, F				Sinigaglia, M.; Zerdoud, S.; Bastie, D.; Dierickx, L.; Racaru, L. Vija; Courbon, F.			Fluorocholine PET/CT parameters predictive for hematological toxicity to (223)Radium therapy in castrate-resistant prostate cancer patients with bone metastases	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						(223)Radium; Target radiotherapy; Choline PET; Prostate cancer; Bone metastases	F-18-FLUOROCHOLINE PET/CT; TRIAL; CONSENSUS; ACCESS	Background. - (223)RadiumCl(2) (Ra-223) demonstrated in the study ASLYMPCA an improved median overall survival in patients with bone metastases and castration resistant prostate cancer. This treatment is expensive and carries a risk for hematologic toxicity. The main objective of our work was to study a biomarker on F-18-FCH PET/CT to predict the risk of hematological complications of Ra-223. The impact of F-18-FCH PET/CT on the initial management of Ra-223 therapy was also investigated. Materials and Methods. - Eighteen patients were included in this retrospective study between January 2015 and June 2016. F-18-FCH PET/CT was performed before Ra-223 therapy to evaluate contraindications. A new biomarker was developed: RVV (bone tumor volume/total bone volume). Results. - The initial PET confirmed the possibility of treatment for 67 % of included patients. For the other 33 %, the cause of the exclusion was the presence of visceral metastasis or lymph node(s) (50 %), extensive bone disease (17 %) or both (33 %). Five patients had hematological toxicity, one grade 3, five grade 1-2. RVV was correlated with the decrease in hemoglobin (r = 0.88; P = 0.004) and to thrombocyte decrease (r = 0.68; P = 0.06). The best cut-off to prevent hematologic toxicities was RVV = 7.1 which means 7.1 % of tumoral bone. Conclusion. - Baseline F-18-FCH PET/CT allow patient selection for Ra-223. RVV could be an efficient biomarker of hematological toxicity of Ra-223. (C) 2018 Published by Elsevier Masson SAS.	[Sinigaglia, M.; Zerdoud, S.; Bastie, D.; Dierickx, L.; Racaru, L. Vija; Courbon, F.] Inst Univ Canc Oncopole Toulouse, Serv Med Nucl, F-31100 Toulouse, France; [Sinigaglia, M.; Bastie, D.] CHU Toulouse, Serv Med Nucl, F-31400 Toulouse, France	Courbon, F (reprint author), Inst Univ Canc Oncopole Toulouse, Serv Med Nucl, F-31100 Toulouse, France.	sinigaglia.mathieu@gmail.com; Frederic.courbon@iuct-toulouse.fr					Basely M, 2015, RADIOTHERAPIE INTERN; COLLINS C, 1993, J NUCL MED, V34, P1839; D'Amico AV, 2014, J CLIN ONCOL, V32, P362, DOI 10.1200/JCO.2013.53.9528; Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257; Kwee SA, 2014, J NUCL MED, V55, P905, DOI 10.2967/jnumed.113.135194; Lee J, 2016, J NUCL MED, V57, P1058, DOI 10.2967/jnumed.115.169177; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; Omlin A, 2013, EUR UROL, V64, P300, DOI 10.1016/j.eururo.2012.12.029; Oudard S, 2017, ANN ONCOL, V28, P421, DOI 10.1093/annonc/mdw546; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Parker C, 2016, EUR UROL; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Picchio M, 2015, EUR J NUCL MED MOL I, V42, P644, DOI 10.1007/s00259-014-2982-5; PORTER AT, 1994, EUR UROL, V26, P20; Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470-2045(16)30173-5; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Terrier M, 2017, DIAGNOSTIC PRONOSTIC; Vogelzang NJ, 2017, CLIN GENITOURIN CANC, V15, P42, DOI [10.1016/j.clgc.2016.07.027, 10.1016/clgc.2016.07.027]	18	0	0	1	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					70	77		10.1016/j.mednuc.2018.01.002			8	Pathology	Pathology	GI1AP	WOS:000434101900002					2019-10-28	
J	Jardak, I; Hamza, F; Hentati, Y; Amouri, W; Kallel, F; Maaloul, M; Charfeddine, S; Chtourou, K; Mnif, Z; Guermazi, F				Jardak, I; Hamza, F.; Hentati, Y.; Amouri, W.; Kallel, F.; Maaloul, M.; Charfeddine, S.; Chtourou, K.; Mnif, Z.; Guermazi, F.			Place of SPECT/CT of the axial skeleton in the diagnosis of bone metastases: Prospective study about 150 cases	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						SPECT-CT; Bone scintigraphy; Bone metastases; Hybrid imaging	CANCER-PATIENTS; CONVENTIONAL RADIOGRAPHY; CT; SCINTIGRAPHY; BODY; INDETERMINATE	Aim of the study. - Show the added value of SPECT-CT of the trunk in the diagnosis of bone metastases, compare its results to those of whole body scintigraphy (WBS) and specify the diagnostic impact while taking into account the cost of additional irradiation attributable to the scanner. Patients and methods. - Prospective study including 150 patients presenting neoplasic pathology between June 2013 and December 2014. All patients have had WBS followed by a SPECT-CT of the axial skeleton. Results. - A total of 1375 lesions were noted, of which 15.7 % were not seen in the WBS. The rate of indeterminate lesions increased from 18.7 % in the WBS to 1.9 % in the SPECT-CT. The concordance and discordance rates between WBS and SPECT-CT in the characterization of lesions according to their nature were 63.9 % and 1.5 %, respectively. The rib cage and the thoracic spine were the first localizations of the suspicious lesions of malignancy in SPECT-CT. Patient analysis showed a reduction in the number of scintigraphies classified as indeterminate to the WBS of 69 %. It also made it possible to better specify the metastatic extension without modification of the status in 32 patients and to change the status of the patient in 6 cases. SPECT-CT did not provide additional information to the WBS in 47 patients. The effective dose of 4 mSv was due to emission imaging while the scanner delivered an average effective dose estimated at 10.4 mSv. Conclusion. - The SPECT-CT of the trunk has an indisputable contribution since it improves the quality of the report, reduces the number of undecided exams and increases the confidence level in favor of a non-significant irradiation. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Jardak, I; Hamza, F.; Amouri, W.; Kallel, F.; Maaloul, M.; Charfeddine, S.; Chtourou, K.; Guermazi, F.] CHU Habib Bourguiba, Serv Med Nucl, Sfax, Tunisia; [Hentati, Y.; Mnif, Z.] CHU Hedi Chaker, Serv Radiol, Sfax, Tunisia	Jardak, I (reprint author), CHU Habib Bourguiba, Serv Med Nucl, Sfax, Tunisia.	issam.jardak@hotmail.fr					ALGRA PR, 1991, RADIOGRAPHICS, V11, P219, DOI 10.1148/radiographics.11.2.2028061; ALGRA PR, 1992, AM J ROENTGENOL, V158, P1275, DOI 10.2214/ajr.158.6.1590123; Brix G, 2005, J NUCL MED, V46, P608; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Chassang M, 2007, CLIN IMAG, V31, P225, DOI 10.1016/j.clinimag.2007.04.005; Cordoliani YS, 2007, J RADIOL, V88, P329, DOI 10.1016/S0221-0363(07)89828-3; CRP, ICRP PUBL, V80; de Beaulieu MA, 2015, MED NUCL, V39, P486, DOI 10.1016/j.mednuc.2015.09.003; De Ddel a R, 2010, HEAL; Erradi M, 2014, MED NUCL, V38, P155; Erradi M, 2015, MED NUCL; Ferretti G, 2010, REV MAL RESPIR, V27, P644, DOI 10.1016/j.rmr.2010.03.024; Franson T, 2008, MED NUCL, V32, P273, DOI 10.1016/j.mednuc.2008.01.009; Ghezaiel MJ, 2012, MED NUCL, V36, P545, DOI 10.1016/j.mednuc.2012.08.006; Granier P, 2008, MED NUCL, V32, P265, DOI 10.1016/j.mednuc.2007.12.003; Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181; Hapdey S, 2009, MED NUCL, V33, P285, DOI 10.1016/j.mednuc.2009.02.009; Horger M, 2005, EUR J RADIOL, V54, P289, DOI 10.1016/j.ejrad.2004.04.015; Horger M, 2006, SEMIN NUCL MED, V36, P286, DOI 10.1053/j.semnuclmed.2006.05.001; Larkin Ann M, 2011, Int J Mol Imaging, V2011, P897202, DOI 10.1155/2011/897202; Netter F, 2008, MED NUCL, V32, P76, DOI 10.1016/j.mednuc.2007.11.008; Ouvrier MJ, 2012, MED NUCL, V36, P205; Palmedo H, 2014, EUR J NUCL MED MOL I, V41, P59, DOI 10.1007/s00259-013-2532-6; Romer W, 2006, J NUCL MED, V47, P1102; Utsunomiya D, 2006, RADIOLOGY, V238, P264, DOI 10.1148/radiol.2373041358; Zhao Z, 2010, SKELETAL RADIOL, V39, P147, DOI 10.1007/s00256-009-0764-0	26	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					78	87		10.1016/j.mednuc.2018.02.001			10	Pathology	Pathology	GI1AP	WOS:000434101900003					2019-10-28	
J	Dechmi-Khiar, A; Amegassi, F; Kotbi, O; Clerc, J; Daou, D				Dechmi-Khiar, A.; Amegassi, F.; Kotbi, O.; Clerc, J.; Daou, D.			Apical left ventricular radiotracer uptake on attenuation correction with SPECT/TDM myocardial perfusion scintigraphy in non-ischemic patients	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Attenuation correction; Apical thinning; SPECT/CT; Myocardial perfusion scintigraphy	CORONARY-ARTERY-DISEASE; COMPUTED-TOMOGRAPHY; CARDIAC SPECT; TRANSMISSION; RESOLUTION; ACCURACY; IMAGES; CT	Introduction. - Attenuation correction (AC) has been shown to improve the accuracy of myocardial perfusion single photon emission computed scintigraphy (SPECT). It often reveals a decrease in apical uptake in the AC of the left ventricular (LV) in non-ischemic patients. We aimed to identify the parameters that could affect the apical radiotracer uptake in non-ischemic patients. Materials and methods. - Prospectively, we included 340 consecutive non-ischemic patients. They underwent sequential CT and myocardial SPECT imaging. We studied the apical uptake with the AC (combined to scatter correction, resolution recovery and noise regularization) and its correlation with various parameters related to patient and the technique. Results. - The apical uptake with AC was lower than with filtered back projection (FBP). On univariate analysis, several parameters correlated to apical uptake with AC, of which only 4 remained significant on step-by-step regression analysis: uptake with FBP, angle of the LV in the frontal plane, type of stress, arm's position at acquisition. These four parameters explain 51% of the variation of apical uptake with CA. Conclusions. - Apical uptake in myocardial perfusion scintigraphy is lower with AC compared with RPF in non-ischemic patients. The apical uptake with AC is correlated to that of FBP, angle of the LV in the frontal plane, type of stress and arm's position at acquisition. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Dechmi-Khiar, A.; Amegassi, F.; Kotbi, O.; Clerc, J.; Daou, D.] CHU Cochin, AP HP, Dept Med Nucl, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France; [Daou, D.] Univ Paris Diderot, Sorbonne Paris Cite, EA REMES 7334, Paris, France	Dechmi-Khiar, A (reprint author), CHU Cochin, AP HP, Dept Med Nucl, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.	amina.dechmi@aphp.fr					Apostolopoulos DJ, 2016, HELL J NUCL MED, V19, P89, DOI 10.1967/s0024499100360; Beekman FJ, 2001, COMPUT MED IMAG GRAP, V25, P135, DOI 10.1016/S0895-6111(00)00064-1; BRADFIELD JWB, 1977, BRIT HEART J, V39, P806; FICARO EP, 1995, J NUCL MED, V36, P921; Galt JR, 1999, SEMIN NUCL MED, V29, P204, DOI 10.1016/S0001-2998(99)80011-7; Goetze S, 2007, J NUCL CARDIOL, V14, P200, DOI 10.1016/j.nuclcard.2006.12.325; Hansen CL, 2000, AM J CARDIOL, V85, P749, DOI 10.1016/S0002-9149(99)00853-X; Hendel RC, 2002, J NUCL CARDIOL, V9, P135, DOI 10.1067/mnc.2002.120680; Hesse B, 2008, EUR J NUCL MED MOL I, V35, P851, DOI 10.1007/s00259-007-0694-9; Huang JY, 2016, J NUCL MED, V57, P1893, DOI 10.2967/jnumed.115.171462; JOHNSTONE DE, 1979, J NUCL MED, V20, P183; Links JM, 2004, J NUCL CARDIOL, V11, P26, DOI 10.1016/j.nuclcard.2003.10.004; MANGLOS SH, 1993, J NUCL MED, V34, P992; Matsunari I, 1998, J NUCL MED, V39, P411; Nishina H, 2006, J NUCL MED, V47, P51; Okuda K, 2011, NUCL MED COMMUN, V32, P1033, DOI 10.1097/MNM.0b013e32834b69e1; Singh B, 2007, J NUCL CARDIOL, V14, P153, DOI 10.1016/j.nuclcard.2007.01.037; Tonge CM, 2006, NUCL MED COMMUN, V27, P843, DOI 10.1097/01.mnm.0000239483.69027.23; WACKERS F J T, 1992, American Journal of Cardiac Imaging, V6, P42	19	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					88	96		10.1016/j.mednuc.2018.02.003			9	Pathology	Pathology	GI1AP	WOS:000434101900004					2019-10-28	
J	Spasic, E; Bernardini, M				Spasic, E.; Bernardini, M.			Dispensing system for radiopharmaceuticals: Quality control in two hospitals and comparison with actual French regulation	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Unidose; Dose calibrator performances; Internal quality control in nuclear medicine; French regulation		An increasing number of nuclear medicine departments are equipped with automated measurement systems for the preparation of radiopharmaceuticals, with the main aim of minimising technician's irradiation. However, the automatic measurement of the patient activity differs from the manual measurement in material and method. In this context, the objective of the present study was to test the performances of one of these systems, the Unidose by TRASIS (R), in two newly equipped hospitals. The particularity of these systems is they are made up of two dose calibrators: the entrance calibrator (well chamber) and the exit calibrator (probe). Controls were performed on both of these dose calibrators. The results obtained, as well as the methodology employed, were then compared with the regulatory requirements in France. The results found are coherent between the two sites and have highlighted several non-conformities compared to the current regulations, part of which concerning the carpule dose calibrator, which is actually a probe. These results raise the question of a suitable regulation for the new automated measurement systems in nuclear medicine. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Spasic, E.] Inst Curie, Nucl Med Dept, 26 Rue Ulm, F-75005 Paris, France; [Bernardini, M.] Hop Europeen Georges Pompidou, Nucl Med Dept, 20 Rue Leblanc, F-75015 Paris, France	Spasic, E (reprint author), Inst Curie, Nucl Med Dept, 26 Rue Ulm, F-75005 Paris, France.	Estelle.spasic@gmail.com					CEA-LNHB SFPM, 2006, SFMN GUID UT CONTR Q; Celier D, 2012, MED NUCL, V36, P193, DOI [10.1016/j.mednuc.2012.02.123, DOI 10.1016/J.MEDNUC.2012.02.123]; Ranger NT, 1999, RAD DETECTORS NUCL M	3	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					97	103		10.1016/j.mednuc.2018.02.002			7	Pathology	Pathology	GI1AP	WOS:000434101900005					2019-10-28	
J	Denis, A; Mirallie, E; Dru, D; Renaudin, KA; Kraeber-Bodere, F; Ansquer, C				Denis, A.; Mirallie, E.; Dru, D.; Renaudin, K. Autain; Kraeber-Bodere, F.; Ansquer, C.			Contribution of 18F-FDG PET/CT in preoperative evaluation of pheochromocytoma: Comparison with MIBG scintigraphy	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Pheochromocytoma; FDG; PET/CT; MIBG; Scintigraphy; Adrenal gland	POSITRON-EMISSION-TOMOGRAPHY; F-18-FDG PET/CT; I-123-MIBG SPECT; PARAGANGLIOMA; DIAGNOSIS; METAIODOBENZYLGUANIDINE; LOCALIZATION; MANAGEMENT; GENETICS; TUMORS	Pheochromocytomas (PHEO) are tumors arisen from the adrenal medulla, with a high secretory risk. Malignancy is rare and difficult to establish before metastastic spread. The risk of multifocality becomes greater whether genetic predisposition exists. MIBG scintigraphy is the reference functional imaging of PHEO. The place of 18FDG PET/CT is not well-established in literature. Our study retrospectively analyzes patients operated for a PHEO and who underwent both MIBG and 18FDG PET/CT before surgery, between 2007 and 2015. On the 49 patients included (52 lesions), among them 13 had genetic mutation, MIBG detected 39 lesions (75%) and 18FDG PET/CT forty-eight (92%), enabling a combined sensitivity of 98%. Sensitivity was not affected by the predominant secretion (metanephrine or normetanephrine), whereas MIBGnegative lesions showed a higher proliferation index (Ki67) than MIBG-positive lesions (6.6 vs. 2.8; P = 0.0044). FDG PET/CT semi-quantitative indices vary with the germline mutation status and were significantly higher for Cluster 1 lesions (SDHx, VHL or FH mutations) than for any other lesions (SUVmax = 27.73 vs. 5.92 for the others mutations (Cluster 2), 9.53 for lesions without mutation and 3.78 for undetermined lesions; P = 0.002). In conclusion, because of their capacity to take up FDG, 18FDG PET/CT could be useful in the preoperative imaging of PHEO, especially when MIBG is not contributive or when F-DOPA PET/CT is not available. An intense FDG uptake may orient to a Cluster I mutation. (C) 2018 Published by Elsevier Masson SAS.	[Denis, A.; Kraeber-Bodere, F.; Ansquer, C.] CHU Hotel Dieu, Serv Med Nucl, 1 Pl Alexis Ricordeau, F-44000 Nantes, France; [Mirallie, E.] CHU Hotel Dieu, Serv Chirurg Viscerale & Endocrinienne, 1 Pl Alexis Ricordeau, F-44000 Nantes, France; [Dru, D.] CHU Nord, Serv Endocrinol, Blvd Prof Jacques Monod, F-44800 St Herblain, France; [Renaudin, K. Autain] CHU Nantes, CHU Hotel Dieu, Serv Pathol, 1 Pl Alexis Ricordeau, F-44000 Nantes, France	Ansquer, C (reprint author), CHU Hotel Dieu, Serv Med Nucl, 1 Pl Alexis Ricordeau, F-44000 Nantes, France.	antoine.denis2@etu.univ-nantes.fr; catherine.ansquer@free.fr					Ansquer C, 2010, EUR J NUCL MED MOL I, V37, P1669, DOI 10.1007/s00259-010-1471-8; APELDOORN L, 1995, NETH J MED, V46, P239, DOI 10.1016/0300-2977(94)00098-0; Benn DE, 2006, J CLIN ENDOCR METAB, V91, P827, DOI 10.1210/jc.2005-1862; Bhatia KSS, 2008, CLIN ENDOCRINOL, V69, P181, DOI 10.1111/j.1365-2265.2008.03256.x; Blake MA, 2006, RADIOLOGY, V238, P970, DOI 10.1148/radiol.2383042164; Favier J, 2012, M S-MED SCI, V28, P625, DOI 10.1051/medsci/2012286016; Fikri ASF, 2014, ACTA RADIOL, V55, P631, DOI 10.1177/0284185113504330; Fonte JS, 2012, ENDOCR-RELAT CANCER, V19, P83, DOI 10.1530/ERC-11-0243; Gilsanz V, 2012, J PEDIATR-US, V160, P604, DOI 10.1016/j.jpeds.2011.09.035; Groussin L, 2009, J CLIN ENDOCR METAB, V94, P1713, DOI 10.1210/jc.2008-2302; Guerin C, 2017, J CLIN ENDOCR METAB, V102, P2465, DOI 10.1210/jc.2017-00254; GUILLOTEAU D, 1988, EUR J NUCL MED, V14, P341; Hadi M, 2007, J NUCL MED, V48, P1077, DOI 10.2967/jnumed.106.035915; Havekes B, 2008, Q J NUCL MED MOL IM, V52, P419; Khorram-Manesh A, 2004, EJSO, V30, P556, DOI 10.1016/j.ejso.2004.03.006; Kolby L, 2003, BRIT J CANCER, V89, P1383, DOI 10.1038/sj.bjc.6601276; Lenders JWM, 2014, J CLIN ENDOCR METAB, V99, P1915, DOI 10.1210/jc.2014-1498; Lepoutre-Lussey C, 2015, EUR J NUCL MED MOL I, V42, P868, DOI 10.1007/s00259-015-3003-z; McNeil AR, 2000, AUST NZ J MED, V30, P648, DOI 10.1111/j.1445-5994.2000.tb04358.x; Nakajo M, 2015, ABDOM IMAGING, V40, P1655, DOI 10.1007/s00261-014-0291-x; Naswa N, 2012, EUR RADIOL, V22, P710, DOI 10.1007/s00330-011-2289-x; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Pacak K, 2001, ANN INTERN MED, V134, P315, DOI 10.7326/0003-4819-134-4-200102200-00016; Puar T, 2016, J CLIN ENDOCR METAB, V101, P223, DOI 10.1210/jc.2015-3205; R Development Core Team, 2017, R LANG ENV STAT COMP; Taieb D, 2008, CLIN ENDOCRINOL, V69, P580, DOI 10.1111/j.1365-2265.2008.03257.x; Taieb D, 2004, CLIN ENDOCRINOL, V61, P102, DOI 10.1111/j.1365-2265.2004.02077.x; Taieb D, 2012, EUR J NUCL MED MOL I, V39, P1977, DOI 10.1007/s00259-012-2215-8; Taieb D, 2009, J NUCL MED, V50, P711, DOI 10.2967/jnumed.108.060731; Thompson LDR, 2002, AM J SURG PATHOL, V26, P551, DOI 10.1097/00000478-200205000-00002; Timmers HJLM, 2012, J NATL CANCER I, V104, P700, DOI 10.1093/jnci/djs188; Timmers HJLM, 2009, J CLIN ENDOCR METAB, V94, P4757, DOI 10.1210/jc.2009-1248; Tiwari A, 2017, J MED IMAGING RAD ON; van Berkel A, 2014, CLIN ENDOCRINOL, V81, P329, DOI 10.1111/cen.12482	34	0	0	1	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					104	113		10.1016/j.mednuc.2018.01.003			10	Pathology	Pathology	GI1AP	WOS:000434101900006					2019-10-28	
J	Besson, A; Baillet, C; Herbaux, C; Foucher, C; Lambilliotte, A; Morschhauser, F; Huglo, D				Besson, A.; Baillet, C.; Herbaux, C.; Foucher, C.; Lambilliotte, A.; Morschhauser, F.; Huglo, D.			Variability of hepatic SUVs and SULs in response assessment of avid FDG lymphoma during chemotherapy	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						Lymphoma; 18-FDG; Response assessment	POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUES; INTERIM F-18-FDG PET; HODGKIN-LYMPHOMA; PROGNOSTIC VALUE; METABOLIC-ACTIVITY; TREATMENT FAILURE; ADAPTED TREATMENT; PROGRESSION-FREE; PREDICTIVE-VALUE	Purpose. - The aim of our study was to assess the variability of 18-FDG uptake in the liver and the relationship between hepatic SUVs and SULs and several clinical and technical factors among patients with 18-FDG avid lymphoma. Methods. - Two hundred and thirty eight patients who underwent 18-FDG PET/CT for a Hodgkin lymphoma (HL), Diffuse Large B Cell Lymphoma (DLBCL) or mantle Cell Lymphoma (MCL) at baseline (PET1), interim (PET2), and end-of-treatment (PET3) were retrospectively included. Linear regression models were used to assess the variability of hepatic SUVmax, SUVmean, SULmax and SULmean. Correlation between SUVs and SULs and several factors including Body Mass Index (BMI), age, histological type, Ann Arbor classification, LDH levels, AST and ALT levels, chemotherapy, corticosteroid therapy, fasting blood glucose, uptake time, and injected activity. Univariate and multivariate regression models were established. Finally, we compared residual lymphoma and hepatic SUVs at PET 2 and PET 3 for the patients categorized Deauville 3 and 4. Results. - Liver SUVs were all significantly increased at PET2 and PET3 in comparison with PET1. SULmean was the less variable index. BMI, age, histological type and injected dose were significantly associated with SUVs. In multivariate analysis, only BMI and injected dose remained significantly associated with hepatic SUVs. Residual tumoral uptake at PET2 were lower than hepatic SUVmax in 32/47 patients classified Deauville 3 and higher than hepatic SUVmean and SULmax in almost all Deauville 3 patients. Conclusion. - While the hepatic SUVmax was the most prone to variability, especially sensitive to BMI, it appears to be more appropriate than SUVmean or SULmax in assessing tumor response to treatment. Factors affecting SUVs must be considered in the evaluation of therapeutic response in lymphoma. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Besson, A.; Herbaux, C.; Foucher, C.; Morschhauser, F.; Huglo, D.] Univ Lille, F-59000 Lille, France; [Besson, A.; Baillet, C.; Huglo, D.] CHU Lille, Hop Huriez, Med Nucl, Rue Michel Polonowski, F-59000 Lille, France; [Herbaux, C.; Morschhauser, F.] CHU Lille, Hop Huriez, Serv Malad Sang, F-59000 Lille, France; [Foucher, C.] CHU Lille, Hop Salengro, Med Nucl, F-59000 Lille, France; [Lambilliotte, A.] CHU Lille, Hop Jeanne de Flandre, Serv Hematol Pediat, F-59000 Lille, France	Huglo, D (reprint author), Univ Lille, F-59000 Lille, France.; Huglo, D (reprint author), CHU Lille, Hop Huriez, Med Nucl, Rue Michel Polonowski, F-59000 Lille, France.	Alix.besson1@gmail.com; damien.huglo@chru-lille.fr					Abele JT, 2010, RADIOLOGY, V254, P917, DOI 10.1148/radiol.09090768; Abikhzer G, 2011, AM J ROENTGENOL, V196, P176, DOI 10.2214/AJR.10.4679; Adams HJA, 2016, CRIT REV ONCOL HEMAT, V106, P55, DOI 10.1016/j.critrevonc.2016.07.003; Andre MPE, 2017, J CLIN ONCOL, V35, P1786, DOI 10.1200/JCO.2016.68.6394; Barrington SF, 2016, MED NUCL, V40, P55, DOI 10.1016/j.mednuc.2015.12.004; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Batalles SM, 2013, REV ESP MED NUCL IMA, V32, P26, DOI 10.1016/j.remn.2012.02.003; Biggi A, 2013, J NUCL MED, V54, P683, DOI 10.2967/jnumed.112.110890; Carr R, 2014, J NUCL MED, V55, P1936, DOI 10.2967/jnumed.114.145326; Casasnovas O, 2015, BLOOD, V126, P577; Ceriani L, 2012, CLIN NUCL MED, V37, P949, DOI 10.1097/RLU.0b013e318263831d; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chiaravalloti A, 2014, EUR J NUCL MED MOL I, V41, P1123, DOI 10.1007/s00259-014-2703-0; Dostbil Z, 2013, REV ESP MED NUCL IMA, V32, P156, DOI 10.1016/j.remn.2012.04.006; Erselcan T, 2002, EUR J NUCL MED MOL I, V29, P1630, DOI 10.1007/s00259-002-0974-3; Ferrari C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005973; Gallamini A, 2006, HAEMATOL-HEMATOL J, V91, P475; Gallamini A, 2018, J CLIN ONCOL, V23; Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525; Gordien P, 2014, MED NUCL, V38, P83, DOI 10.1016/j.mednuc.2014.01.004; Gordien P, 2015, MED NUCL, V39, P252; Groheux D, 2013, CLIN NUCL MED, V38, P422, DOI 10.1097/RLU.0b013e3182872f0e; Haioun C, 2005, BLOOD, V106, P1376, DOI 10.1182/blood-2005-01-0272; Huntington SF, 2015, LEUKEMIA LYMPHOMA, V56, P2579, DOI 10.3109/10428194.2015.1007506; Hutchings M, 2005, ANN ONCOL, V16, P1160, DOI 10.1093/annonc/mdi200; Hutchings M, 2006, BLOOD, V107, P52, DOI 10.1182/blood-2005-06-2252; Itti E, 2013, EUR J NUCL MED MOL I, V40, P1312, DOI 10.1007/s00259-013-2435-6; Itti E, 2009, J NUCL MED, V50, P527, DOI 10.2967/jnumed.108.057703; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Kaya B, 2015, CLIN IMAG, V39, P632, DOI 10.1016/j.clinimag.2015.02.006; Kim S, 2016, J PATHOL TRANSL MED, V50, P300, DOI 10.4132/jptm.2015.12.01; Kubota K, 2011, NUCL MED BIOL, V38, P347, DOI 10.1016/j.nucmedbio.2010.09.004; Lin CY, 2010, CLIN IMAG, V34, P109, DOI 10.1016/j.clinimag.2009.05.007; Lin CY, 2010, CLIN IMAG, V34, P348, DOI 10.1016/j.clinimag.2009.11.003; Malladi A, 2013, J MED IMAG RADIAT ON, V57, P169, DOI 10.1111/1754-9485.12015; Mikhaeel NG, 2005, ANN ONCOL, V16, P1514, DOI 10.1093/annonc/mdi272; Press OW, 2016, J CLIN ONCOL, V34, P2020, DOI 10.1200/JCO.2015.63.1119; Radford J, 2015, NEW ENGL J MED, V372, P1598, DOI 10.1056/NEJMoa1408648; Rossi C, 2014, J NUCL MED, V55, P569, DOI 10.2967/jnumed.113.130609; Rubello D, 2015, CLIN NUCL MED, V40, pE405, DOI 10.1097/RLU.0000000000000828; Straus DJ, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.578.578; Swinnen LJ, 2015, BRIT J HAEMATOL, V170, P56, DOI 10.1111/bjh.13389; Wu XC, 2017, MOL IMAGING BIOL, V19, P787, DOI 10.1007/s11307-017-1044-3; Yang DH, 2011, EUR J CANCER, V47, P1312, DOI 10.1016/j.ejca.2010.12.027; ZASADNY KR, 1993, RADIOLOGY, V189, P847, DOI 10.1148/radiology.189.3.8234714; Zinzani PL, 2011, CANCER-AM CANCER SOC, V117, P1010, DOI 10.1002/cncr.25579	47	0	0	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	MAR-APR	2018	42	2					114	124		10.1016/j.mednuc.2018.02.004			11	Pathology	Pathology	GI1AP	WOS:000434101900007					2019-10-28	
J	Pal, P; Khan, Z				Pal, P.; Khan, Z.			ROS1-1 (vol 70, pg 1001, 2017)	JOURNAL OF CLINICAL PATHOLOGY			English	Correction																Pal P, 2017, J CLIN PATHOL, V70, P1001, DOI 10.1136/jclinpath-2016-204244	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					283	283		10.1136/jclinpath-2016-204244			1	Pathology	Pathology	GB5HD	WOS:000429094200015					2019-10-28	
J	Slootweg, PJ; El-Naggar, AK				Slootweg, P. J.; El-Naggar, A. K.			World Health Organization 4th edition of head and neck tumor classification: insight into the consequential modifications	VIRCHOWS ARCHIV			English	Editorial Material							ANALOG SECRETORY CARCINOMA; LOW-GRADE ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ACINIC CELL-CARCINOMA; SALIVARY-GLANDS		[Slootweg, P. J.] Radboud Univ Nijmegen, Dept Pathol, Nijmegen Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands; [El-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 0085, Houston, TX 77030 USA	Slootweg, PJ (reprint author), Radboud Univ Nijmegen, Dept Pathol, Nijmegen Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	piet.slootweg@radboudumc.nl; anaggar@mdanderson.org	Slootweg, P.J./H-8089-2014				[Anonymous], HISTOPATHOLOGY, V59, P741; Barnes L, 2005, WHO CLASSIFICATION T; Bell D, 2009, HUM PATHOL, V40, P1798, DOI 10.1016/j.humpath.2009.01.028; Brannon RB, 2001, ORAL SURG ORAL MED O, V92, P68, DOI 10.1067/moe.2001.115978; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; El-Naggar A, 2017, WHO CLASSIFICATION H; Gillenwater AM, 2013, HEAD NECK-J SCI SPEC, V35, pE234, DOI 10.1002/hed.23059; Kimple AJ, 2014, LARYNGOSCOPE, V124, P2714, DOI 10.1002/lary.24788; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Marques RC, 2014, VIRCHOWS ARCH, V464, P621, DOI 10.1007/s00428-014-1551-4; McHugh CH, 2012, CANCER-AM CANCER SOC, V118, P3928, DOI 10.1002/cncr.26697; Noseri H, 2007, EUR ARCH OTO-RHINO-L, V264, P1385, DOI 10.1007/s00405-007-0371-4; Patel NR, 2014, LARYNGOSCOPE, V124, P172, DOI 10.1002/lary.24231; Patel TD, 2015, LARYNGOSCOPE, V125, P1644, DOI 10.1002/lary.25266; Seethala RR, 2007, AM J SURG PATHOL, V31, P1683, DOI 10.1097/PAS.0b013e3180dc928c; Seethala RR, 2010, ARCH OTOLARYNGOL, V136, P385, DOI 10.1001/archoto.2010.39; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Speight PM, 2018, VIRCHOWS ARCH; Thompson LDR, 2018, VIRCHOWS ARCH; van Weert S, 2015, ORAL ONCOL, V51, P71, DOI 10.1016/j.oraloncology.2014.10.007; Vazquez A, 2015, HEAD NECK-J SCI SPEC, V37, P18, DOI 10.1002/hed.23543; Weiler C, 2011, HISTOPATHOLOGY, V59, P741, DOI 10.1111/j.1365-2559.2011.03937.x; Weinreb I, 2009, AM J SURG PATHOL, V33, P1322, DOI 10.1097/PAS.0b013e3181a55c15	25	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					311	313		10.1007/s00428-018-2320-6			3	Pathology	Pathology	GB8UF	WOS:000429350100001	29450648	Bronze			2019-10-28	
J	Thompson, LDR; Franchi, A				Thompson, Lester D. R.; Franchi, Alessandro			New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base	VIRCHOWS ARCHIV			English	Review						Nasal cavity; Paranasal sinuses; Skull base; Tumor; WHO; Carcinoma, squamous cell; SMARCB1-deficient carcinoma; HPV-related adenoid cystic carcinoma; Sinonasal papilloma; Biphenotypic sinonasal sarcoma; Neuroectodermal tumors; Adenocarcinoma, sinonasal type; Immunohistochemistry	NK/T-CELL LYMPHOMA; SINONASAL NEUROENDOCRINE CARCINOMA; POPULATION-BASED ANALYSIS; SOLITARY FIBROUS TUMOR; RISK HUMAN-PAPILLOMAVIRUS; EWING FAMILY TUMORS; OF-THE-LITERATURE; BETA-CATENIN EXPRESSION; PERIPHERAL T-CELL; OLFACTORY NEUROBLASTOMA	The World Health Organization recently published the 4th edition of the Classification of Head and Neck Tumors, including several new entities, emerging entities, and significant updates to the classification and characterization of tumor and tumor-like lesions, specifically as it relates to nasal cavity, paranasal sinuses, and skull base in this overview. Of note, three new entities (NUT carcinoma, seromucinous hamartoma, biphenotypic sinonasal sarcoma,) were added to this section, while emerging entities (SMARCB1-deficient carcinoma and HPV-related carcinoma with adenoid cystic-like features) and several tumor-like entities (respiratory epithelial adenomatoid hamartoma, chondromesenchymal hamartoma) were included as provisional diagnoses or discussed in the setting of the differential diagnosis. The sinonasal tract houses a significant diversity of entities, but interestingly, the total number of entities has been significantly reduced by excluding tumor types if they did not occur exclusively or predominantly at this site or if they are discussed in detail elsewhere in the book. Refinements to nomenclature and criteria were provided to sinonasal papilloma, borderline soft tissue tumors, and neuroendocrine neoplasms. Overall, the new WHO classification reflects the state of current understanding for many relatively rare neoplasms, with this article highlighting the most significant changes.	[Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91367 USA; [Franchi, Alessandro] Univ Florence, Sect Pathol Anat, Dept Surg & Translat Med, Largo Brambilla 3, I-50134 Florence, Italy	Thompson, LDR (reprint author), Southern Calif Permanente Med Grp, Woodland Hills Med Ctr, Dept Pathol, 5601 De Soto Ave, Woodland Hills, CA 91367 USA.	Lester.D.Thompson@kp.org	Franchi, Alessandro/B-9951-2018; Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432			Agaimy A, 2014, HISTOPATHOLOGY, V65, P667, DOI 10.1111/his.12452; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Akaike K, 2015, HUM PATHOL, V46, P347, DOI 10.1016/j.humpath.2014.11.018; Alos L, 2009, CANCER-AM CANCER SOC, V115, P2701, DOI 10.1002/cncr.24309; Anari S, 2010, J LARYNGOL OTOL, V124, P705, DOI 10.1017/S0022215110000599; Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Aoki R, 2008, PATHOL INT, V58, P174, DOI 10.1111/j.1440-1827.2007.02207.x; Au WY, 2009, BLOOD, V113, P3931, DOI 10.1182/blood-2008-10-185256; Barnes L, 2002, MODERN PATHOL, V15, P279, DOI 10.1038/modpathol.3880524; Bates T, 2012, HEAD NECK PATHOL, V6, P150, DOI 10.1007/s12105-011-0293-8; Bell D, 2015, VIRCHOWS ARCH, V467, P649, DOI 10.1007/s00428-015-1853-1; Bettio D, 2004, CANCER GENET CYTOGEN, V155, P79, DOI 10.1016/j.cancergencyto.2004.03.010; Bhattacharya B, 2005, AM J SURG PATHOL, V29, P653, DOI 10.1097/01.pas.0000157938.95785.da; Bishop JA, 2017, WHO CLASSIFICATION H, P14; Bishop JA, 2017, WHO CLASSIFICATION H, P15; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2013, AM J SURG PATHOL, V37, P836, DOI 10.1097/PAS.0b013e31827b1cd6; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Broich G, 1997, ANTICANCER RES, V17, P2683; Bruder E, 2012, PEDIATR DEVEL PATHOL, V15, P26, DOI 10.2350/11-11-1119-PB.1; Bullerdiek J, 2017, WHO CLASSIFICATION H, P41; Carlson JW, 2007, HISTOPATHOLOGY, V51, P509, DOI 10.1111/j.1365-2559.2007.02794.x; Chai L, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-199; Chapman-Fredricks J, 2009, APPL IMMUNOHISTO M M, V17, P207, DOI 10.1097/PAI.0b013e31818fc85c; Chen YW, 2015, BLOOD, V125, P1589, DOI 10.1182/blood-2014-07-588970; Chuang SS, 2014, PATHOLOGY, V46, P581, DOI 10.1097/PAT.0000000000000161; Chuang SS, 2014, J AM ACAD DERMATOL, V70, P724, DOI 10.1016/j.jaad.2013.11.047; Chuang SS, 2017, WHO CLASSIFICATION H, P52; Chung CH, 2015, ANN ONCOL, V26, P1216, DOI 10.1093/annonc/mdv109; Coffin CM, 2007, AM J SURG PATHOL, V31, P410, DOI 10.1097/01.pas.0000213348.65014.0a; Colombo C, 2012, HISTOL HISTOPATHOL, V27, P641, DOI 10.14670/HH-27.641; Cooper JS, 2009, HEAD NECK-J SCI SPEC, V31, P748, DOI 10.1002/hed.21022; Coppo P, 2009, LEUKEMIA, V23, P1667, DOI 10.1038/leu.2009.91; Cordes B, 2009, HUM PATHOL, V40, P283, DOI 10.1016/j.humpath.2008.07.019; Crane GM, 2016, SEMIN DIAGN PATHOL, V33, P71, DOI 10.1053/j.semdp.2015.09.008; Demicco EG, 2015, HUM PATHOL, V46, P1015, DOI 10.1016/j.humpath.2015.03.014; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Dubal PM, 2015, LARYNGOSCOPE, V125, P1077, DOI 10.1002/lary.25111; El-Mofty SK, 2005, AM J SURG PATHOL, V29, P1367, DOI 10.1097/01.pas.0000173240.63073.fe; El-Naggar AK, 2017, WHO CLASSIFICATION O; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Faragalla H, 2009, ADV ANAT PATHOL, V16, P322, DOI 10.1097/PAP.0b013e3181b544cf; Flucke U, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-131; Flucke U, 2014, HISTOPATHOLOGY, V64, P769, DOI 10.1111/his.12323; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Franchi A, 2017, WHO CLASSIFICATION H, P26; Franchi A, 2014, PATHOL ONCOL RES, V20, P571, DOI 10.1007/s12253-013-9730-1; Franchi A, 2009, ORAL ONCOL, V45, P835, DOI 10.1016/j.oraloncology.2008.12.005; French CA, 2017, WHO CLASSIFICATION H, P20; Gallagher KK, 2014, ANN OTO RHINOL LARYN, V123, P353, DOI 10.1177/0003489414526368; Garcia-Inclan C, 2012, CELL ONCOL, V35, P443, DOI 10.1007/s13402-012-0103-7; Gil Z, 2008, HEAD NECK-J SCI SPEC, V30, P567, DOI 10.1002/hed.20741; Gu M, 2000, AM J SURG PATHOL, V24, P410, DOI 10.1097/00000478-200003000-00010; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hafezi S, 2011, HEAD NECK PATHOL, V5, P8, DOI 10.1007/s12105-010-0227-x; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; HEFFNER DK, 1992, CANCER, V70, P1089, DOI 10.1002/1097-0142(19920901)70:5<1089::AID-CNCR2820700513>3.0.CO;2-J; HELLQUIST HB, 1991, J LARYNGOL OTOL, V105, P186, DOI 10.1017/S0022215100115312; Hoffman HT, 1998, ARCH OTOLARYNGOL, V124, P951, DOI 10.1001/archotol.124.9.951; Holbrook EH, 2011, LARYNGOSCOPE, V121, P1687, DOI 10.1002/lary.21856; Holmila R, 2010, INT J CANCER, V127, P578, DOI 10.1002/ijc.25064; Howarth KL, 2004, INT J PEDIATR OTORHI, V68, P221, DOI 10.1016/j.ijporl.2003.09.011; Huang Shi, 2013, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V27, P751; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Hunt JL, 2017, WHO CLASSIFICATION H, P28; Hunt JL, 2017, WHO CLASSIFICATION H, P29; Hunt JL, 2017, WHO CLASSIFICATION H, P30; Huss S, 2013, HISTOPATHOLOGY, V62, P294, DOI 10.1111/j.1365-2559.2012.04355.x; Igwe OJ, 2006, NEUROSCIENCE, V138, P313, DOI 10.1016/j.neuroscience.2005.10.061; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Jaffe ES, 2013, MODERN PATHOL, V26, pS71, DOI 10.1038/modpathol.2012.181; Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276; Jhuang JY, 2015, HUM PATHOL, V46, P313, DOI 10.1016/j.humpath.2014.11.008; Jo VY, 2017, MODERN PATHOL, V30, P650, DOI 10.1038/modpathol.2016.239; KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L; Kaur G, 2013, J CLIN NEUROSCI, V20, P275, DOI 10.1016/j.jocn.2012.05.029; Koo GC, 2012, CANCER DISCOV, V2, P591, DOI 10.1158/2159-8290.CD-12-0028; Kreisel FH, 2016, HEAD NECK PATHOL, V10, P109, DOI 10.1007/s12105-016-0698-5; Krouse JH, 2001, AM J OTOLARYNG, V22, P87, DOI 10.1053/ajot.2001.22563; Laco J, 2015, VIRCHOWS ARCH, V467, P405, DOI 10.1007/s00428-015-1812-x; Larque AB, 2014, MODERN PATHOL, V27, P343, DOI 10.1038/modpathol.2013.155; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Laurini JA, 2012, BLOOD, V120, P4795, DOI 10.1182/blood-2012-07-440073; Le Guellec S, 2012, MODERN PATHOL, V25, P1551, DOI 10.1038/modpathol.2012.115; Lee S, 2015, ONCOTARGET, V6, P17764, DOI 10.18632/oncotarget.3776; Lewis J, 2017, WHO CLASSIFICATION H, P40; Lewis JS, 2016, HEAD NECK PATHOL, V10, P60, DOI 10.1007/s12105-016-0692-y; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Lewis JS, 2017, WHO CLASSIFICATION H, P18; Li SY, 2013, AM J SURG PATHOL, V37, P14, DOI 10.1097/PAS.0b013e31826731b5; Likhacheva A, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-32; LLOMBARTBOSCH A, 1989, VIRCHOWS ARCH A, V414, P199, DOI 10.1007/BF00822023; Lopez F, 2012, ORAL ONCOL, V48, P692, DOI 10.1016/j.oraloncology.2012.02.018; Machado I, 2014, PATHOL RES PRACT, V210, P508, DOI 10.1016/j.prp.2014.04.005; Mao L, 2009, ONCOLOGY-BASEL, V77, P231, DOI 10.1159/000236047; McDermott MB, 1998, AM J SURG PATHOL, V22, P425, DOI 10.1097/00000478-199804000-00006; Menon S, 2010, INDIAN J PATHOL MICR, V53, P28, DOI 10.4103/0377-4929.59179; Mentzel T, 1997, AM J SURG PATHOL, V21, P363, DOI 10.1097/00000478-199704000-00001; Mitchell EH, 2012, HEAD NECK-J SCI SPEC, V34, P1372, DOI 10.1002/hed.21940; Miyagami Mitsusuke, 2002, Medical Electron Microscopy, V35, P160, DOI 10.1007/s007950200020; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002; Nudell J, 2014, HEAD NECK PATHOL, V8, P269, DOI 10.1007/s12105-014-0527-7; Ozolek JA, 2005, ARCH PATHOL LAB MED, V129, P1444; Ozolek JA, 2006, AM J SURG PATHOL, V30, P1576, DOI 10.1097/01.pas.0000213344.55605.77; Patel TD, 2016, INT FORUM ALLERGY RH, V6, P201, DOI 10.1002/alr.21639; Patel TD, 2015, INT FORUM ALLERGY RH, V5, P448, DOI 10.1002/alr.21497; Perez-Escuredo J, 2012, HUM PATHOL, V43, P1894, DOI 10.1016/j.humpath.2012.01.016; Perrone F, 2003, INT J CANCER, V105, P196, DOI 10.1002/ijc.11062; Platek ME, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-41; Pongpruttipan T, 2012, AM J SURG PATHOL, V36, P481, DOI 10.1097/PAS.0b013e31824433d8; Powers KA, 2015, OR SURG OR MED OR PA, V119, pE265, DOI 10.1016/j.oooo.2014.10.007; Qian Guo-hong, 2011, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V46, P1033; Ro JY, 2017, WHO CLASSIFICATION H, P32; Rodic N, 2012, DIAGN CYTOPATHOL, V40, P1100, DOI 10.1002/dc.21711; Saade RE, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-014-0423-z; Sarioglu S, 2007, HEAD NECK PATHOL, V1, P44, DOI 10.1007/s12105-007-0009-2; Schiessling S, 2013, BRIT J SURG, V100, P694, DOI 10.1002/bjs.9053; Shen TS, 2015, HUM PATHOL, V46, P1598, DOI 10.1016/j.humpath.2015.06.017; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stelow EB, 2017, WHO CLASSIFICATION H, P23; Stelow EB, 2017, WHO CLASSIFICATION H, P24; Stelow EB, 2011, AM J SURG PATHOL, V35, P971, DOI 10.1097/PAS.0b013e31821cbd72; Stewart DR, 2014, HUM GENET, V133, P1443, DOI 10.1007/s00439-014-1474-9; Storck K, 2008, HEAD NECK PATHOL, V2, P75, DOI 10.1007/s12105-008-0047-4; Su SY, 2014, INT ARCH OTORHINOLAR, V18, pS149, DOI 10.1055/s-0034-1390014; Sugita Y, 2006, NEUROPATHOLOGY, V26, P400, DOI 10.1111/j.1440-1789.2006.00703.x; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Swerdlow SH, 2014, AM J SURG PATHOL, V38, pE60, DOI 10.1097/PAS.0000000000000295; Tajudeen BA, 2014, JAMA OTOLARYNGOL, V140, P1124, DOI 10.1001/jamaoto.2014.2541; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; Thompson LDR, 2003, AM J SURG PATHOL, V27, P737, DOI 10.1097/00000478-200306000-00004; Thompson LDR, 2017, WHO CLASSIFICATION H, P21; Thompson LDR, 2017, MODERN PATHOL, V30, pS1, DOI 10.1038/modpathol.2016.119; Thompson LDR, 2009, HEAD NECK PATHOL, V3, P252, DOI 10.1007/s12105-009-0125-2; Thway K, 2009, PEDIATR DEVEL PATHOL, V12, P292, DOI 10.2350/08-07-0506.1; Tomlins SA, 2013, AM J CLIN PATHOL, V139, P771, DOI 10.1309/AJCPN4L1BMRQPEIT; Toner M, 2017, WHO CLASSIFICATION H, P51; Udager AM, 2016, J PATHOL, V239, P394, DOI 10.1002/path.4750; Udager AM, 2015, CANCER RES, V75, P2600, DOI 10.1158/0008-5472.CAN-15-0340; van der Laan TP, 2013, EUR ARCH OTO-RHINO-L, V270, P2565, DOI 10.1007/s00405-013-2554-5; Wang WL, 2012, MODERN PATHOL, V25, P1378, DOI 10.1038/modpathol.2012.97; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Weinreb I, 2007, HEAD NECK PATHOL, V1, P21, DOI 10.1007/s12105-007-0004-7; Weinreb I, 2009, HISTOPATHOLOGY, V54, P205, DOI 10.1111/j.1365-2559.2008.03198.x; WEISS SW, 1982, CANCER, V50, P970, DOI 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z; Wenig BM, 2017, WHO CLASSIFICATION H, P56; Wenig BM, 2017, WHO CLASSIFICATION H, P43; Wenig BM, 2017, WHO CLASSIFICATION H, P31; Windfuhr JP, 2004, ANN OTO RHINOL LARYN, V113, P533, DOI 10.1177/000348940411300705; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295; Wooff JC, 2011, AM J SURG PATHOL, V35, P1786, DOI 10.1097/PAS.0b013e3182363b78; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137; Zur KB, 2002, ARCH OTOLARYNGOL, V128, P441, DOI 10.1001/archotol.128.4.441	161	12	12	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					315	330		10.1007/s00428-017-2116-0			16	Pathology	Pathology	GB8UF	WOS:000429350100002	28444451				2019-10-28	
J	Kloppel, G; La Rosa, S				Kloeppel, Guenter; La Rosa, Stefano			Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms	VIRCHOWS ARCHIV			English	Review						Ki67; History; Assessment; Prognostic marker; Neuroendocrine neoplasms; Pancreas; Stomach; Intestine	PANCREATIC ENDOCRINE TUMORS; ENETS CONSENSUS GUIDELINES; NUCLEAR ANTIGEN; DISEASE PROGRESSION; GRADING SYSTEM; CLASSIFICATION; CELL; PROLIFERATION; CARCINOMA; MIDGUT	In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where the antibody was produced in the university department of pathology and refers to the number of the original clone (67). Systematic assessment of the proliferative activity of tumors using Ki67 started in the 1990s, when Ki67, which only worked on frozen tissue, was complemented by the antibody MIB-1 that also worked in formalin-fixed tissues. Pancreatic neuroendocrine neoplasms (PanNENs) were the first endocrine tumors whose proliferative activity was assessed with Ki67. This approach was so successful that Ki67 was included as prognostic marker in the 2000 and 2004 WHO classifications of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In 2010, the WHO classification of GEP-NENs introduced a three-tiered grading, originally proposed by ENETS in 2006 that was mainly based on the Ki67 index. As it has subsequently been shown that the Ki67 index is the most reliable factor in the prognostic evaluation of GEP-NENs, especially of PanNENs, the 2017 WHO classification of PanNENs requires its use and strongly recommends exact assessment of the proportion Ki67-labeled cells as basis for the calculation of the Ki67 index. Problems in assessing the Ki67 index include intertumoral and intratumoral staining heterogeneity and counting methods. Despite such problems, the Ki67 index has emerged as indispensable for the prognostic and therapeutic stratification of the majority of GEP-NENs and can barely be replaced by counting mitoses. In future, however, it can be anticipated that the Ki67 cut-offs experience refinement in relation to the type of tumor, its location, and its response to therapy. It is also possible that the prognostic risk of an individual tumor is calculated for each Ki67 unit and not for an "a priori" fixed Ki67 class.	[Kloeppel, Guenter] Tech Univ Munich, Inst Pathol, Consultat Ctr Pancreat & Endocrine Tumors, Trogerstr 18, D-81675 Munich, Germany; [La Rosa, Stefano] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, Lausanne, Switzerland	Kloppel, G (reprint author), Tech Univ Munich, Inst Pathol, Consultat Ctr Pancreat & Endocrine Tumors, Trogerstr 18, D-81675 Munich, Germany.	guenter.kloeppel@tum.de; stefano.larosa@chuv.ch					Adsay V, 2012, AM J SURG PATHOL, V36, P1743, DOI 10.1097/PAS.0b013e318272ff77; Ahmed A, 2009, ENDOCR-RELAT CANCER, V16, P885, DOI 10.1677/ERC-09-0042; Araujo PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061538; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Blank A, 2015, VIRCHOWS ARCH, V467, P543, DOI 10.1007/s00428-015-1843-3; CAPELLA C, 1995, VIRCHOWS ARCH, V425, P547; Clift AK, 2017, ENDOCR CONNECT, V6, P71, DOI 10.1530/EC-16-0114; Clift AK, 2016, J GASTROINTEST SURG, V20, P180, DOI 10.1007/s11605-015-2953-6; Combs SE, 2016, LAB INVEST, V96, P264, DOI 10.1038/labinvest.2015.138; Cunningham JL, 2007, ACTA ONCOL, V46, P747, DOI 10.1080/0284160701218659; Cuylen S, 2016, NATURE, V535, P308, DOI 10.1038/nature18610; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Gonzalez RS, 2014, MODERN PATHOL, V27, P1288, DOI 10.1038/modpathol.2013.232; Grozinsky-Glasberg S, 2013, WORLD J GASTROENTERO, V19, P8687, DOI 10.3748/wjg.v19.i46.8687; Hong Su Min, 2013, Korean J Gastroenterol, V61, P82; Jernman J, 2012, NEUROENDOCRINOLOGY, V95, P317, DOI 10.1159/000333035; Kim GU, 2013, ENDOSCOPY, V45, P1018, DOI 10.1055/s-0033-1344860; Kloppel G, 2011, ENDOCR-RELAT CANCER, V18, pS1, DOI 10.1530/ERC-11-0013; Kloppel G, 2004, ANN NY ACAD SCI, V1014, P13, DOI 10.1196/annals.1294.002; Konukiewitz B, 2017, MOD PATHOL; KREIPE H, 1993, AM J PATHOL, V142, P3; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa S, 2014, J CLIN PATHOL, V67, P938, DOI 10.1136/jclinpath-2014-202515; La Rosa S, 2011, HUM PATHOL, V42, P1373, DOI 10.1016/j.humpath.2011.01.018; Lardiere-Deguelte S, 2016, NEUROENDOCRINOLOGY, V103, P552, DOI 10.1159/000441423; LaRosa S, 1996, VIRCHOWS ARCH, V429, P323, DOI 10.1007/BF00198436; Li P, 2015, INT J CLIN EXP PATHO, V8, P13331; Lloyd RV, 2017, WHO CLASSIFICATION T; Milione M, 2017, NEUROENDOCRINOLOGY, V104, P85, DOI 10.1159/000445165; Modlin IM, 2010, NEUROENDOCRINOLOGY, V92, P143, DOI 10.1159/000319784; Nakamura K, 2016, SCAND J GASTROENTERO, V51, P448, DOI 10.3109/00365521.2015.1107752; Norlen O, 2012, WORLD J SURG, V36, P1419, DOI 10.1007/s00268-011-1296-z; O'Toole D, 2016, NEUROENDOCRINOLOGY, V103, P117, DOI 10.1159/000443169; Panzuto F, 2012, NEUROENDOCRINOLOGY, V96, P32, DOI 10.1159/000334038; Panzuto F, 2011, J CLIN ONCOL, V29, P2372, DOI 10.1200/JCO.2010.33.0688; Pape UF, 2016, NEUROENDOCRINOLOGY, V103, P144, DOI 10.1159/000443165; Pape UF, 2008, CANCER-AM CANCER SOC, V113, P256, DOI 10.1002/cncr.23549; Pelosi G, 1996, HUM PATHOL, V27, P1124, DOI 10.1016/S0046-8177(96)90303-2; Pelosi G, 2014, J THORAC ONCOL, V9, P273, DOI 10.1097/JTO.0000000000000092; Ramage JK, 2016, NEUROENDOCRINOLOGY, V103, P139, DOI 10.1159/000443166; Reid MD, 2015, MODERN PATHOL, V28, P686, DOI 10.1038/modpathol.2014.156; RINDI G, 1993, GASTROENTEROLOGY, V104, P994, DOI 10.1016/0016-5085(93)90266-F; Rindi G, 1999, GASTROENTEROLOGY, V116, P532, DOI 10.1016/S0016-5085(99)70174-5; Rindi G, 2007, VIRCHOWS ARCH, V451, P757, DOI 10.1007/s00428-007-0452-1; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Rindi G, 2012, JNCI-J NATL CANCER I, V104, P764, DOI 10.1093/jnci/djs208; Rindi G, 2010, WHO CLASSIFICATION T, V4, P13; Rosentraeger MJ, 2016, VIRCHOWS ARCH, V468, P277, DOI 10.1007/s00428-015-1890-9; Rudolph P, 1997, AM J PATHOL, V150, P1997; Scarpa A, 2010, MODERN PATHOL, V23, P824, DOI 10.1038/modpathol.2010.58; Scherubl H, 2011, WORLD J GASTRO ENDOS, V3, P133, DOI 10.4253/wjge.v3.i7.133; Sobecki M, 2016, ELIFE, V5, DOI 10.7554/eLife.13722; Sohn JH, 2015, CANCER RES TREAT, V47, P813, DOI 10.4143/crt.2014.238; Strosberg JR, 2013, J CLIN ONCOL, V31, P420, DOI 10.1200/JCO.2012.44.5924; Sugimoto S, 2016, SURG ENDOSC, V30, P4239, DOI 10.1007/s00464-015-4735-3; Tang LH, 2016, AM J SURG PATHOL, V40, P1192, DOI 10.1097/PAS.0000000000000662; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Tsukamoto S, 2008, INT J COLORECTAL DIS, V23, P1109, DOI 10.1007/s00384-008-0505-1; Vanoli A, 2017, NEUROENDOCRINOLOGY, V104, P112, DOI 10.1159/000444803; Vinik AI, 2010, PANCREAS, V39, P713, DOI 10.1097/MPA.0b013e3181ebaffd; Volante M, 2013, AM J SURG PATHOL, V37, P606, DOI 10.1097/PAS.0b013e318275d1d7; VONHERBAY A, 1991, GUT, V32, P949, DOI 10.1136/gut.32.8.949; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36; Yang ZH, 2011, AM J SURG PATHOL, V35, P853, DOI 10.1097/PAS.0b013e31821a0696	64	13	14	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					341	349		10.1007/s00428-017-2258-0			9	Pathology	Pathology	GB8UF	WOS:000429350100004	29134440				2019-10-28	
J	Coates, PJ; Nenutil, R; Holcakova, J; Nekulova, M; Podhorec, J; Svoboda, M; Vojtesek, B				Coates, Philip J.; Nenutil, Rudolf; Holcakova, Jitka; Nekulova, Marta; Podhorec, Jan; Svoboda, Marek; Vojtesek, Borivoj			p63 isoforms in triple-negative breast cancer: Delta Np63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival	VIRCHOWS ARCHIV			English	Article						Triple-negative breast cancer; TAp63; Delta Np63; PTEN; BRCA1; BRCA2; Androgen receptor	MAMMARY EPITHELIAL-CELLS; DIFFERENTIAL EXPRESSION; PROTEIN EXPRESSION; STEM-CELLS; TUMORIGENESIS; METASTASIS; P40; P53; CARCINOMA; ROLES	The TP63 gene encodes two major protein variants that differ in their N-terminal sequences and have opposing effects. In breast, Delta Np63 is expressed by immature stem/progenitor cells and mature myoepithelial/basal cells and is a characteristic feature of basal-like triple-negative breast cancers (TNBCs). The expression and potential role of TAp63 in the mammary gland and breast cancers is less clear, partly due to the lack of studies that employ p63 isoform-specific antibodies. We used immunohistochemistry with Delta Np63-specific or TAp63-specific monoclonal antibodies to investigate p63 isoforms in 236 TNBCs. TAp63, but not Delta Np63, was seen in tumour-associated lymphocytes and other stromal cells. Tumour cells showed nuclear staining for Delta Np63 in 17% of TNBCs compared to 7.3% that were positive for TAp63. Whilst most TAp63(+) tumours also contained Delta Np63(+) cells, the levels of the two isoforms were independent of each other. Delta Np63 associated with metaplastic and medullary cancers, and with a basal phenotype, whereas TAp63 associated with androgen receptor, BRCA1/2 wild-type status and PTEN positivity. Despite the proposed effects of p63 on proliferation, Ki67 did not correlate with either p63 isoform, nor did they associate with p53 mutation status. Delta Np63 showed no association with patient outcomes, whereas TAp63(+) patients showed fewer recurrences and improved overall survival. These findings indicate that both major p63 protein isoforms are expressed in TNBCs with different tumour characteristics, indicating distinct functional activities of p63 variants in breast cancer. Analysis of individual p63 isoforms provides additional information into TNBC biology, with TAp63 expression indicating improved prognosis.	[Coates, Philip J.; Nenutil, Rudolf; Holcakova, Jitka; Nekulova, Marta; Vojtesek, Borivoj] Masaryk Mem Canc Ctr, RECAMO, Zluty Kopec 7, Brno 65653, Czech Republic; [Podhorec, Jan; Svoboda, Marek] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Zluty Kopec 7, Brno 65653, Czech Republic	Coates, PJ; Vojtesek, B (reprint author), Masaryk Mem Canc Ctr, RECAMO, Zluty Kopec 7, Brno 65653, Czech Republic.	philip.coates@mou.cz; vojtesek@mou.cz		Coates, Philip/0000-0003-1518-6306	Ministry of Education, Youth and Sports, Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government [MEYS-NPSI-LO1413, LM15089]; Grant Agency of the Czech RepublicGrant Agency of the Czech Republic [GACR P206/12/G151]; MHCZ-DRO from the Ministry of Health, Czech Republic [MMCI 00209805]	This work was funded by grants MEYS-NPSI-LO1413 and Award LM15089 from the Ministry of Education, Youth and Sports, Czech Republic; GACR P206/12/G151 from the Grant Agency of the Czech Republic; and MHCZ-DRO (MMCI 00209805) from the Ministry of Health, Czech Republic. The funders did not have a role in the planning, performing or analysing the data, or in manuscript preparation or submission.	Aubry MC, 2015, MODERN PATHOL, V28, P359, DOI 10.1038/modpathol.2014.118; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; de Biase D, 2010, VIRCHOWS ARCH, V456, P395, DOI 10.1007/s00428-010-0900-1; Djelloul S, 2002, ONCOGENE, V21, P981, DOI 10.1038/sj.onc.1205253; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Henderson SA, 2014, AM J SURG PATHOL, V38, P1102, DOI 10.1097/PAS.0000000000000245; Holcakova J, 2017, BREAST CANCER RES TR, V163, P475, DOI 10.1007/s10549-017-4216-6; Hu LS, 2017, P NATL ACAD SCI USA, V114, pE3964, DOI 10.1073/pnas.1617816114; Iqbal J, 2012, HISTOPATHOLOGY, V61, P652, DOI 10.1111/j.1365-2559.2012.04255.x; Koster MI, 2006, CANCER RES, V66, P3981, DOI 10.1158/0008-5472.CAN-06-0027; Kurita T, 2005, MECH DEVELOP, V122, P1043, DOI 10.1016/j.mod.2005.04.008; Lee JJ, 2014, HUM PATHOL, V45, P1078, DOI 10.1016/j.humpath.2014.01.006; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Li N, 2008, STEM CELLS, V26, P1253, DOI 10.1634/stemcells.2007-0691; Lucijanic M, 2016, CROAT MED J, V57, P77, DOI 10.3325/cmj.2016.57.77; Mitani Y, 2011, AM J PATHOL, V179, P391, DOI 10.1016/j.ajpath.2011.03.037; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Nekulova M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2808-x; Nekulova M, 2013, VIRCHOWS ARCH, V463, P415, DOI 10.1007/s00428-013-1459-4; Nekulova M, 2011, CELL MOL BIOL LETT, V16, P296, DOI 10.2478/s11658-011-0009-9; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Orzol P, 2016, TUMOR BIOL, V37, P10133, DOI 10.1007/s13277-016-4880-x; Orzol P, 2015, HISTOL HISTOPATHOL, V30, P503, DOI 10.14670/HH-30.503; Provenzano E, 2016, HISTOPATHOLOGY, V68, P367, DOI 10.1111/his.12765; Pruneri G, 2005, J PATHOL, V206, P337, DOI 10.1002/path.1787; Rampurwala M, 2016, CLIN ADV HEMATOL ONC, V14, P186; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Rinne T, 2006, EUR J HUM GENET, V14, P904, DOI 10.1038/sj.ejhg.5201640; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sailer V, 2015, VIRCHOWS ARCH, V467, P67, DOI 10.1007/s00428-015-1766-z; Stindt MH, 2015, ONCOGENE, V34, P4300, DOI 10.1038/onc.2014.359; Su X, 2017, ONCOGENE, V36, P2377, DOI 10.1038/onc.2016.388; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Svoboda M, 2012, Klin Onkol, V25, P188; Thike AA, 2010, MODERN PATHOL, V23, P123, DOI 10.1038/modpathol.2009.145; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Wang XJ, 2017, HUM PATHOL, V64, P19, DOI 10.1016/j.humpath.2017.01.003; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Yoh KE, 2016, P NATL ACAD SCI USA, V113, pE6107, DOI 10.1073/pnas.1613417113	50	2	2	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					351	359		10.1007/s00428-018-2324-2			9	Pathology	Pathology	GB8UF	WOS:000429350100005	29484502				2019-10-28	
J	Mentzel, T; Kiss, K				Mentzel, Thomas; Kiss, Katalin			Reduced H3K27me3 expression in radiation-associated angiosarcoma of the breast	VIRCHOWS ARCHIV			English	Article						Radiation-associated vascular lesion; Radiation-associated angiosarcoma; Immunohistochemistry; H3K27me3	ATYPICAL VASCULAR-LESIONS; NERVE SHEATH TUMORS; MYC AMPLIFICATION; CUTANEOUS ANGIOSARCOMA; SURVIVAL; MARKER	The diagnosis of radiation-associated angiosarcoma is challenging and there are overlapping clinicopathological features between radiation-associated benign, atypical and malignant vascular lesions. It has been shown convincingly, that the majority of radiation-associated angiosarcomas are characterised by amplification and subsequent overexpression of MYC in contrast to benign and atypical vascular lesions. Given the fact that epigenetic changes play an important role in carcinogenesis and loss of histone H3K27 trimethylation (H3K27me3) has been found in a number of malignant neoplasms including malignant peripheral nerve sheath tumours, especially when associated with previous radiotherapy, we evaluated the immunohistochemical reaction pattern for H3K27me3 in 49 vascular lesions and control cases: normal skin and benign vascular lesions not associated with previous radiotherapy, radiation-associated benign, atypical and malignant vascular lesions and angiosarcomas not associated with previous radiotherapy. We found loss of H3K27me3 expression in most cases of radiation-associated angiosarcomas, whereas endothelial cells in benign and atypical vascular lesions arising after previous radiotherapy stained positively for H3K27me3. The sporadic angiosarcomas stained inconsistently for H3K27me3. Loss of H3K27me3 is typically seen in radiation-associated angiosarcomas, representing an additional diagnostic tool and raises questions in regard to the carcinogenesis of malignant vascular neoplasms.	[Mentzel, Thomas] Dermatopathol Bodensee, Siemensstr 6-1, D-88048 Friedrichshafen, Germany; [Kiss, Katalin] Univ Hosp, Rigshosp Copenhagen, Ctr Diagnost, Dept Pathol, Copenhagen, Denmark	Mentzel, T (reprint author), Dermatopathol Bodensee, Siemensstr 6-1, D-88048 Friedrichshafen, Germany.	mentzel@dermpath.de					Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Brenn T, 2005, AM J SURG PATHOL, V29, P983; Busam KJ, 2017, MODERN PATHOL, V30, P877, DOI 10.1038/modpathol.2017.8; Busam KJ, 2017, AM J SURG PATHOL, V41, P396, DOI 10.1097/PAS.0000000000000769; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Fernandez AP, 2012, J CUTAN PATHOL, V39, P234, DOI 10.1111/j.1600-0560.2011.01843.x; Ferrari KJ, 2014, MOL CELL, V53, P49, DOI 10.1016/j.molcel.2013.10.030; Guo TH, 2011, GENE CHROMOSOME CANC, V50, P25, DOI 10.1002/gcc.20827; He WP, 2015, NEOPLASMA, V62, P932, DOI 10.4149/neo_2015_113; Jackowski S, 2007, AM J PATHOL, V171, P338, DOI 10.2353/ajpath.2007.060589; Kiss K, 2017, MOD PATHOL A, V132A, P517; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Mentzel T, 2012, MODERN PATHOL, V25, P75, DOI 10.1038/modpathol.2011.134; Papp G, 2014, GENE CHROMOSOME CANC, V53, P168, DOI 10.1002/gcc.22128; Patton KT, 2008, AM J SURG PATHOL, V32A, P943, DOI 10.1097/PAS.0b013e31815bf8fe; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Shon W, 2014, MODERN PATHOL, V27, P509, DOI 10.1038/modpathol.2013.163	19	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					361	368		10.1007/s00428-017-2242-8			8	Pathology	Pathology	GB8UF	WOS:000429350100006	28983701				2019-10-28	
J	Birkman, EM; Mansuri, N; Kurki, S; Algars, A; Lintunen, M; Ristamaki, R; Sundstrom, J; Carpen, O				Birkman, Eva-Maria; Mansuri, Naziha; Kurki, Samu; Algars, Annika; Lintunen, Minnamaija; Ristamaki, Raija; Sundstrom, Jari; Carpen, Olli			Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics	VIRCHOWS ARCHIV			English	Article						Gastric cancer; Immunohistochemistry; In situ hybridisation; Molecular classification	EXPRESSION-BASED CLASSIFICATION; CAPECITABINE; PROTEIN	Gastric cancer is traditionally divided into intestinal and diffuse histological subtypes, but recent molecular analyses have led to novel classification proposals based on genomic alterations. While the intestinal- and diffuse-type tumours are distinguishable from each other at the molecular level, intestinal-type tumours have more diverse molecular profile. The technology required for comprehensive molecular analysis is expensive and not applicable for routine clinical diagnostics. In this study, we have used immunohistochemistry and in situ hybridisation in molecular classification of gastric adenocarcinomas with an emphasis on the intestinal subtype. A tissue microarray consisting of 244 gastric adenocarcinomas was constructed, and the tumours were divided into four subgroups based on the presence of Epstein-Barr virus, TP53 aberrations and microsatellite instability. The intestinal- and diffuse-type tumours were separately examined. The distribution of EGFR and HER2 gene amplifications was studied in the intestinal-type tumours. Epstein-Barr virus positive intestinal-type tumours were more common in male patients (p = 0.035) and most often found in the gastric corpus (p = 0.011). The majority of the intestinal-type tumours with TP53 aberrations were proximally located (p = 0.010). All tumours with microsatellite instability showed intestinal-type histology (p = 0.017) and were associated with increased overall survival both in the univariate (p = 0.040) and multivariate analysis (p = 0.015). In conclusion, this study shows that gastric adenocarcinomas can be classified into biologically and clinically different subgroups by using a simple method also applicable for clinical diagnostics.	[Birkman, Eva-Maria; Mansuri, Naziha; Sundstrom, Jari; Carpen, Olli] Univ Turku, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland; [Birkman, Eva-Maria; Lintunen, Minnamaija; Sundstrom, Jari] Turku Univ Hosp, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland; [Kurki, Samu; Carpen, Olli] Univ Turku, Auria Biobank, Kiinamyllynkatu 8, FIN-20520 Turku, Finland; [Kurki, Samu; Carpen, Olli] Turku Univ Hosp, Kiinamyllynkatu 8, FIN-20520 Turku, Finland; [Algars, Annika; Ristamaki, Raija] Turku Univ Hosp, Dept Oncol, Hameentie 11, FIN-20520 Turku, Finland; [Algars, Annika] Univ Turku, MediCity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland; [Carpen, Olli] Univ Helsinki, Res Programs Unit, Pathol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland; [Carpen, Olli] Univ Helsinki, HUSLAB, Haartmaninkatu 3, FIN-00014 Helsinki, Finland; [Carpen, Olli] Helsinki Univ Hosp, Haartmaninkatu 3, Helsinki 00014, Finland	Birkman, EM (reprint author), Univ Turku, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.; Birkman, EM (reprint author), Turku Univ Hosp, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	emabir@utu.fi			Finnish cancer organisations; Turku University Foundation	This study was supported by Finnish cancer organisations and Turku University Foundation. We thank Mr. Jaakko Liippo for help with the pictures.	Ahn S, 2017, AM J SURG PATHOL, V41, P106, DOI 10.1097/PAS.0000000000000756; Algars A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099590; Altman DG, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-51; [Anonymous], FINL DAT BANK; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Birkman EM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2456-1; Bosman FT, 2010, WHO CLASSIFICATION T; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Kim HS, 2016, ONCOTARGET, V7, P44608, DOI 10.18632/oncotarget.10115; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; lgars A, 2011, BRIT J CANCER, V105, P255; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Min L, 2017, TRANSL ONCOL, V10, P99, DOI 10.1016/j.tranon.2016.11.003; Park CK, 2016, ONCOTARGET, V7, P72099, DOI 10.18632/oncotarget.12291; Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198; Setia N, 2016, MODERN PATHOL, V29, P772, DOI 10.1038/modpathol.2016.55; Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2; Zlobec Inti, 2014, J Vis Exp, P51893, DOI 10.3791/51893	22	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					369	382		10.1007/s00428-017-2240-x			14	Pathology	Pathology	GB8UF	WOS:000429350100007	29046940	Other Gold, Green Published			2019-10-28	
J	Murakami, T; Mitomi, H; Yao, T; Saito, T; Shibuya, T; Sakamoto, N; Osada, T; Watanabe, S				Murakami, Takashi; Mitomi, Hiroyuki; Yao, Takashi; Saito, Tsuyoshi; Shibuya, Tomoyoshi; Sakamoto, Naoto; Osada, Taro; Watanabe, Sumio			Distinct histopathological characteristics in colorectal submucosal invasive carcinoma arising in sessile serrated adenoma/polyp and conventional tubular adenoma	VIRCHOWS ARCHIV			English	Article						Sessile serrated adenoma/polyp; Submucosal invasive carcinoma; Serrated neoplasia pathway; Conventional adenoma-carcinoma sequence; Histopathology	EARLY NEOPLASTIC PROGRESSION; BRAF MUTATION STATUS; MICROSATELLITE INSTABILITY; PROSPECTIVE MULTICENTER; PATHOLOGICAL FEATURES; HYPERPLASTIC POLYPS; PROXIMAL COLON; POOR SURVIVAL; CANCER; ADENOCARCINOMA	The histopathological characteristics of colorectal submucosal invasive carcinoma arising in sessile serrated adenoma/polyp (SSA/P), a rare malignant tumour, have not yet been fully elucidated. To investigate the features of such, we retrospectively analysed 40 submucosal invasive carcinomas with SSA/P (CA-SSA/P) and compared them to 129 cases of submucosal invasive carcinoma with conventional tubular adenoma (CA-AD). We additionally performed hMLH1 immunostaining. CA-SSA/Ps were significantly smaller than CA-ADs (P < 0.001). Histologically, well to moderately differentiated adenocarcinoma was predominant in both CA-SSA/Ps and CA-ADs. No significant differences in depth of invasion were found between the two groups. However, lymphatic invasion was more often found in CA-SSA/Ps (30%) than in CA-ADs (13%; P = 0.028), as was lymph node metastasis (CA-SSA/Ps, 28%; CA-ADs, 7%; P = 0.011). Furthermore, mucinous component and serrated architecture were significantly more frequent in CA-SSA/Ps (30 and 63%) than in CA-ADs (5 and 18%; P < 0.001, respectively). Tumour-infiltrating lymphocytes and Crohn-like inflammatory reaction were also more frequently found in CA-SSA/Ps (70 and 30%) than in CA-ADs (31 and 9%; P <= 0.001, respectively), whereas the opposite was true of desmoplastic reaction (CA-SSA/Ps, 35%; CA-ADs, 67%; P < 0.001). Loss of hMLH1 expression was more frequent in CA-SSA/P cases (93%) than in CA-AD cases (5%; P < 0.001). In conclusion, CA-SSA/P lesions exhibit a higher potential for lymphatic invasion and lymph node metastasis and have distinct histopathological features, including mucinous component, serrated architecture, tumour-infiltrating lymphocytes, Crohn-like inflammatory reaction, and absence of desmoplastic reaction, compared to their conventional counterparts.	[Murakami, Takashi; Shibuya, Tomoyoshi; Sakamoto, Naoto; Osada, Taro; Watanabe, Sumio] Juntendo Univ, Dept Gastroenterol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Murakami, Takashi; Yao, Takashi; Saito, Tsuyoshi] Juntendo Univ, Dept Human Pathol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan; [Mitomi, Hiroyuki] Odawara Municipal Hosp, Dept Diagnost Pathol & Lab Med, Odawara, Kanagawa, Japan	Murakami, T (reprint author), Juntendo Univ, Dept Gastroenterol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.; Murakami, T (reprint author), Juntendo Univ, Dept Human Pathol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-murakm@juntendo.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [24590429, 15K19059]	This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (#24590429 to H. Mitomi and #15K19059 to T. Murakami).	Aldridge AJ, 2001, EUR J SURG, V167, P777; Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Ban S, 2014, PATHOL INT, V64, P123, DOI 10.1111/pin.12147; Bettington M, 2017, GUT, V66, P97, DOI 10.1136/gutjnl-2015-310456; Bouwens MWE, 2014, ENDOSCOPY, V46, P225, DOI 10.1055/s-0034-1364936; Burgess NG, 2016, GUT, V65, P437, DOI 10.1136/gutjnl-2014-308603; Carr NJ, 2009, J CLIN PATHOL, V62, P516, DOI 10.1136/jcp.2008.061960; Chino A, 2016, INT J COLORECTAL DIS, V31, P343, DOI 10.1007/s00384-015-2416-2; Dhir M, 2011, INT J CANCER, V129, P1889, DOI 10.1002/ijc.25847; Dong SM, 2005, MODERN PATHOL, V18, P170, DOI 10.1038/modpathol.3800261; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita K, 2011, AM J SURG PATHOL, V35, P295, DOI 10.1097/PAS.0b013e318205df36; Gafa R, 2000, CANCER, V89, P2025, DOI 10.1002/1097-0142(20001115)89:10<2025::AID-CNCR1>3.0.CO;2-S; Garcia-Solano J, 2011, HISTOPATHOLOGY, V59, P1046, DOI 10.1111/j.1365-2559.2011.04043.x; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P132, DOI 10.1309/V8Q9KDD5AJ9LNBAG; Greenson JK, 2009, AM J SURG PATHOL, V33, P126, DOI 10.1097/PAS.0b013e31817ec2b1; Hyde A, 2010, AM J SURG PATHOL, V34, P1820, DOI 10.1097/PAS.0b013e3181f6a912; Jass JR, 2006, HISTOPATHOLOGY, V49, P121, DOI 10.1111/j.1365-2559.2006.02466.x; Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36; Kim KM, 2011, AM J SURG PATHOL, V35, P1274, DOI 10.1097/PAS.0b013e318224cd2e; Kim YH, 2008, INT J CANCER, V123, P2587, DOI 10.1002/ijc.23840; Kimura R, 2012, PATHOL INT, V62, P525, DOI 10.1111/j.1440-1827.2012.02840.x; Kobayashi H, 2011, J GASTROENTEROL, V46, P203, DOI 10.1007/s00535-010-0341-2; Lash RH, 2010, J CLIN PATHOL, V63, P681, DOI 10.1136/jcp.2010.075507; Loy TS, 2004, AM J SURG PATHOL, V28, P1460, DOI 10.1097/01.pas.0000141394.64707.02; Murakami T, 2017, GASTROINTEST ENDOSC, V85, P590, DOI 10.1016/j.gie.2016.09.018; Murakami T, 2015, MODERN PATHOL, V28, P146, DOI 10.1038/modpathol.2014.41; O'Brien MJ, 2006, AM J SURG PATHOL, V30, P1491, DOI 10.1097/01.pas.0000213313.36306.85; Pai RK, 2012, AM J SURG PATHOL, V36, P744, DOI 10.1097/PAS.0b013e31824430d7; Patil DT, 2012, MODERN PATHOL, V25, P1423, DOI 10.1038/modpathol.2012.98; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Roxburgh CSD, 2014, ANN SURG, V259, P1156, DOI 10.1097/SLA.0000000000000229; Saitoh Y, 2001, GASTROENTEROLOGY, V120, P1657, DOI 10.1053/gast.2001.24886; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sandmeier D, 2009, HISTOPATHOLOGY, V55, P206, DOI 10.1111/j.1365-2559.2009.03356.x; Sheridan TB, 2006, AM J CLIN PATHOL, V126, P564, DOI 10.1309/C7JE88VL8420V5VT; Sis B, 2005, J CLIN PATHOL, V58, P32, DOI 10.1136/jcp.2004.018705; Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038; Stefanius K, 2011, HISTOPATHOLOGY, V58, P679, DOI 10.1111/j.1365-2559.2011.03821.x; Tamaru Y, 2017, J GASTROENTEROL, V52, P1169, DOI 10.1007/s00535-017-1318-1; TANAKA S, 1995, J GASTROENTEROL, V30, P710, DOI 10.1007/BF02349636; Torlakovic E, 2003, AM J SURG PATHOL, V27, P65, DOI 10.1097/00000478-200301000-00008; Tuppurainen K, 2005, J PATHOL, V207, P285, DOI 10.1002/path.1850; Ueno H, 2013, AM J CLIN PATHOL, V139, P434, DOI 10.1309/AJCPWHUEFTGBWKE4; Wada R, 2014, MED MOL MORPHOL, V47, P123, DOI 10.1007/s00795-014-0075-y; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; Wright CL, 2003, AM J SURG PATHOL, V27, P1393, DOI 10.1097/00000478-200311000-00001; Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19	50	2	2	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					383	393		10.1007/s00428-017-2234-8			11	Pathology	Pathology	GB8UF	WOS:000429350100008	28929387				2019-10-28	
J	Mezheyeuski, A; Strell, C; Hrynchyk, I; Guren, TK; Dragomir, A; Doroshenko, T; Pashkova, O; Gorgun, J; Ruksha, K; Pfeiffer, P; Kure, EH; Sorbye, H; Edler, D; Martling, A; Glimelius, B; Ostman, A; Portyanko, A				Mezheyeuski, Artur; Strell, Carina; Hrynchyk, Ina; Guren, Tormod Kyrre; Dragomir, Anca; Doroshenko, Tatyana; Pashkova, Oksana; Gorgun, Julia; Ruksha, Kseniya; Pfeiffer, Per; Kure, Elin H.; Sorbye, Halfdan; Edler, David; Martling, Anna; Glimelius, Bengt; Ostman, Arne; Portyanko, Anna			Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer	VIRCHOWS ARCHIV			English	Article						Colorectal cancer; Cell adhesion; Claudin-2; Cancer-associated fibroblasts	DOWN-REGULATION; GROWTH; MACROPHAGES; PROGRESSION; INHIBITION; TRANSPORT; PRESSURE; PROTEINS; TRENDS; LIVER	Claudin-2 is a trans-membrane protein-component of tight junctions in epithelial cells. Elevated claudin-2 expression has been reported in colorectal cancer (CRC). The aim of this study was to investigate the expression patterns of claudin-2 in human CRC samples and analyze its association with clinical characteristics and treatment outcome. TMAs of primary tumors from two cohorts of metastatic CRC (mCRC) were used. Claudin-2 IHC staining was evaluated in a semi-quantitative manner in different regions and cell types. Claudin-2 expression was also analyzed by immunofluorescence in primary cultures of human CRC cancer-associated fibroblasts (CAFs). Initial analyses identified previously unrecognized expression patterns of claudin-2 in CAFs of human CRC. Claudin-2 expression in CAFs of the invasive margin was associated with shorter progression-free survival. Subgroup analyses demonstrated that the survival associations occurred among cases that received 5-FU+oxaliplatin combination treatment, but not in patients receiving 5-FU +/- irinotecan. The finding was validated by analyses of the independent cohort. In summary, previously unreported stromal expression of claudin-2 in CAFs of human CRC was detected together with significant association between high claudin-2 expression in CAFs and shorter survival in 5-FU+oxaliplatin-treated mCRC patients.	[Mezheyeuski, Artur; Strell, Carina; Ostman, Arne] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8 03, Stockholm, Sweden; [Mezheyeuski, Artur; Portyanko, Anna] Belarusian State Med Univ, Dept Pathol, Minsk, BELARUS; [Hrynchyk, Ina] City Clin Pathologoanat Bur, Minsk, BELARUS; [Guren, Tormod Kyrre] Oslo Univ Hosp, Dept Oncol, Oslo, Norway; [Guren, Tormod Kyrre] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway; [Dragomir, Anca] Uppsala Univ Hosp, Dept Surg Pathol, Uppsala, Sweden; [Doroshenko, Tatyana; Pashkova, Oksana] Republ Res & Prod Ctr Transfusiol & Med Biotechno, Lab Antibodies & Cytokines Biotechnol, Minsk, BELARUS; [Gorgun, Julia] Belarusian Med Acad Postgrad Educ, Dept Gastroenterol & Nutr, Minsk, BELARUS; [Ruksha, Kseniya] NN Alexandrov Natl Canc Ctr Belarus, Minsk, BELARUS; [Pfeiffer, Per] Univ Southern Denmark, Dept Oncol, Odense, Denmark; [Kure, Elin H.] Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway; [Sorbye, Halfdan] Haukeland Hosp, Dept Oncol, Bergen, Norway; [Edler, David; Martling, Anna] Karolinska Univ Hosp Solna, Dept Mol Med & Surg, S-17176 Stockholm, Sweden; [Glimelius, Bengt] Uppsala Univ, Sect Oncol, Dept Immunol Genet & Pathol, Uppsala, Sweden	Mezheyeuski, A (reprint author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8 03, Stockholm, Sweden.; Mezheyeuski, A (reprint author), Belarusian State Med Univ, Dept Pathol, Minsk, BELARUS.	artur.mezh@gmail.com		Dragomir, Anca/0000-0003-2777-8114; Pfeiffer, Per/0000-0002-2925-0586; Mezheyeuski, Artur/0000-0002-4394-2634; Hrynchyk, Ina/0000-0002-7315-5228	Swedish Cancer Society (Cancerfonden)Swedish Cancer Society; Radiumhemmets forskningsfonder; STARGET Linne-grant from Swedish Research CouncilSwedish Research Council; Svenska Institutet; Swedish Cancer SocietySwedish Cancer Society; Merck KGaA (Darmstadt, Germany); Sanofi (Oslo, Norway); Norwegian Cancer SocietyNorwegian Cancer Society	AO receives support from Swedish Cancer Society (Cancerfonden), Radiumhemmets forskningsfonder and the STARGET Linne-grant from Swedish Research Council. AM was also supported by a grant from Svenska Institutet. The collection of the patient materials and TMA production were also supported by the Swedish Cancer Society. The NORDIC-VII study was supported by Merck KGaA (Darmstadt, Germany), Sanofi (Oslo, Norway), the Norwegian Cancer Society, and the Swedish Cancer Society.	Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21; Baranowska-Kortylewicz J, 2005, CANCER RES, V65, P7824, DOI 10.1158/0008-5472.CAN-04-3991; BAXTER LT, 1989, MICROVASC RES, V37, P77, DOI 10.1016/0026-2862(89)90074-5; Elferink MAG, 2015, INT J COLORECTAL DIS, V30, P205, DOI 10.1007/s00384-014-2085-6; Garcia-Godinez A, 2014, CELL TISSUE RES, V357, P309, DOI 10.1007/s00441-014-1827-7; Gunzel D, 2012, COMPR PHYSIOL, V2, P1819, DOI 10.1002/cphy.c110045; House MG, 2010, J AM COLL SURGEONS, V210, P744, DOI 10.1016/j.jamcollsurg.2009.12.040; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kanas Gena P, 2012, Clin Epidemiol, V4, P283, DOI 10.2147/CLEP.S34285; Karagiannis GS, 2014, MOL ONCOL, V8, P178, DOI 10.1016/j.molonc.2013.10.008; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Karagkounis G, 2013, CANCER-AM CANCER SOC, V119, P4137, DOI 10.1002/cncr.28347; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13; Kojima T, 2008, LIVER INT, V28, P534, DOI 10.1111/j.1478-3231.2007.01631.x; Munson JM, 2014, CANCER MANAG RES, V6, P317, DOI 10.2147/CMAR.S65444; Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; Pietras K, 2002, CANCER RES, V62, P5476; Pietras K, 2001, CANCER RES, V61, P2929; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Soini Y, 2005, HISTOPATHOLOGY, V46, P551, DOI 10.1111/j.1365-2559.2005.02127.x; Sorbye H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131046; Tan XH, 2014, J CUTAN PATHOL, V41, P630, DOI 10.1111/cup.12332; Teng HW, 2012, J SURG ONCOL, V106, P123, DOI 10.1002/jso.23063; Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915; Van den Bossche J, 2012, SCAND J IMMUNOL, V75, P588, DOI 10.1111/j.1365-3083.2012.02689.x; van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0; Whitcomb DC, 2012, NAT GENET, V44, P1349, DOI 10.1038/ng.2466; Wongdee K, 2008, HISTOCHEM CELL BIOL, V130, P79, DOI 10.1007/s00418-008-0419-6; Zhang HR, 2015, CIRC RES, V117, P17, DOI 10.1161/CIRCRESAHA.117.305860	32	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					395	405		10.1007/s00428-017-2263-3			11	Pathology	Pathology	GB8UF	WOS:000429350100009	29134439	Green Published			2019-10-28	
J	Stanek, J				Stanek, Jerzy			Placental pathology varies in hypertensive conditions of pregnancy	VIRCHOWS ARCHIV			English	Article						Gestational hypertension; Preeclampsia; HELLP; Chronic hypertension; Superimposed preeclampsia; Placenta	LATE-ONSET PREECLAMPSIA; GESTATIONAL-AGE; LESIONS; DIAGNOSIS; VASCULOPATHY; ASSOCIATION; STILLBIRTH; DISORDERS; FREQUENCY; HYPOXIA	This study was a comprehensive analysis of placental phenotypes in hypertensive conditions of pregnancy, including recently described placental hypoxic lesions and lesions of shallow placentation. To this end, consecutive placentas from > 21 weeks pregnancies that were signed out by the author at 4 tertiary care centers on 3 continents were included. Twenty-four clinical and 50 placental phenotypes were studied in 6 groups and statistically compared: 91 cases of gestational hypertension, 187 cases of mild preeclampsia, 211 cases of severe preeclampsia, 84 cases of HELLP or eclampsia, 127 cases of chronic hypertension, and 55 cases of preeclampsia superimposed on chronic hypertension. Twenty percent of the placental and clinical phenotypes were statistically significantly different between the groups. Gestational hypertension and chronic hypertension distinguished themselves by having the highest perinatal mortality, lowest cesarean section rates, highest acute chorioamnionitis, and highest fetal vascular ectasia but conspicuously fewer differences in hypoxic and thrombotic lesions. The preeclamptic groups showed the highest rates of decidual arteriolopathy (both hypertrophic and atherosis), uterine pattern of chronic placental injury, villous infarctions, and clusters of maternal floor multinucleate trophoblasts. Based on placental pathology, severe preeclampsia may be more of a placental disease and mild preeclampsia more of a maternal disease; however, the significant overlap among the groups does not make the difference absolute, and the occurrence of decidual arteriolopathy in gestational hypertension and chronic hypertension may indicate that the conditions could be regarded as "occult preeclampsia.".	[Stanek, Jerzy] Cincinnati Childrens Hosp Med Ctr, Div Pathol, 3333 Burnet Ave, Cincinnati, OH 45229 USA	Stanek, J (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Pathol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jerzy.stanek@cchmc.org					Aurioles-Garibay A, 2014, FETAL DIAGN THER, V36, P154, DOI 10.1159/000357841; Baergen R. N., 2005, MANUAL BENIRSCHKE KA; Brosens I, 2011, AM J OBSTET GYNECOL, V204, P193, DOI 10.1016/j.ajog.2010.08.009; Cunningham FG, 2005, WILLIAMS OBSTET; Eastabrook G, 2011, BEST PRACT RES CL OB, V25, P435, DOI 10.1016/j.bpobgyn.2011.01.005; Egbor M, 2006, BJOG-INT J OBSTET GY, V113, P580, DOI 10.1111/j.1471-0528.2006.00882.x; Fox H., 2007, PATHOLOGY PLACENTA; Gibbins KJ, 2016, PLACENTA, V43, P61, DOI 10.1016/j.placenta.2016.04.020; Helfrich BB, 2017, PLACENTA, V52, P106, DOI 10.1016/j.placenta.2017.02.016; Huppertz B, 2008, HYPERTENSION, V51, P970, DOI 10.1161/HYPERTENSIONAHA.107.107607; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Kovo M, 2012, PRENATAL DIAG, V32, P632, DOI 10.1002/pd.3872; Kovo M, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.012; Kraus FT, 2004, PLACENTAL PATHOLOGY; Maloney KF, 2012, FETAL PEDIATR PATHOL, V31, P319, DOI 10.3109/15513815.2012.659391; Moldenhauer JS, 2003, AM J OBSTET GYNECOL, V189, P1173, DOI 10.1067/S0002-9378(03)00576-3; Naicker T, 2003, ACTA OBSTET GYN SCAN, V82, P722, DOI 10.1034/j.1600-0412.2003.00220.x; Nelson DB, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.09.010; Ogge G, 2011, J PERINAT MED, V39, P641, DOI 10.1515/JPM.2011.098; Parks WT, 2015, SEMIN PERINATOL, V39, P9, DOI 10.1053/j.semperi.2014.10.003; Pathak S, 2011, VIRCHOWS ARCH, V459, P565, DOI 10.1007/s00428-011-1157-z; Roberts DJ, 2008, J CLIN PATHOL, V61, P1254, DOI 10.1136/jcp.2008.055236; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Salafia CM, 1998, PLACENTA, V19, P67, DOI 10.1016/S0143-4004(98)90100-X; Sebire N J, 2005, J Obstet Gynaecol, V25, P117; Shamshirsaz AA, 2012, J PREGNANCY, DOI 10.1155/2012/374047; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)17987-2; Smulian John, 2004, J Matern Fetal Neonatal Med, V16, P287; Stanek J, 2007, PEDIATR DEVEL PATHOL, V10, P266, DOI 10.2350/06-10-0174.1; Stanek J, 2017, J OBSTET GYNAECOL RE, V43, P839, DOI 10.1111/jog.13276; Stanek J, 2014, J PERINAT MED, V42, P457, DOI 10.1515/jpm-2013-0219; Stanek J, 2014, ACTA OBSTET GYN SCAN, V93, P392, DOI 10.1111/aogs.12350; Stanek J, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.015; Stanek J, 2013, ARCH PATHOL LAB MED, V137, P706, DOI 10.5858/arpa.2011-0645-RA; Stanek J, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.03.025; Stanek J, 2012, HUM PATHOL, V43, P261, DOI 10.1016/j.humpath.2011.03.012; Stanek J, 2011, AM J CLIN PATHOL, V136, P540, DOI 10.1309/AJCPOZ73MPSPYFEZ; Stanek J, 2011, PEDIATR DEVEL PATHOL, V14, P1, DOI 10.2350/10-02-0795-OA.1; Stevens DU, 2012, PLACENTA, V33, P630, DOI 10.1016/j.placenta.2012.04.013; Vinnars MT, 2008, HYPERTENSION, V51, P1295, DOI 10.1161/HYPERTENSIONAHA.107.104844; von Dadelszen P, 2003, HYPERTENS PREGNANCY, V22, P143, DOI 10.1081/PRG-120021060; Zhang J, 1999, AM J OBSTET GYNECOL, V181, P1407, DOI 10.1016/S0002-9378(99)70384-4; Zhang PL, 2006, AM J OBSTET GYNECOL, V194, P1050, DOI 10.1016/j.ajog.2005.10.196	43	3	3	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					415	423		10.1007/s00428-017-2239-3			9	Pathology	Pathology	GB8UF	WOS:000429350100011	28971254				2019-10-28	
J	Davidson, B; Pinamonti, M; Cuevas, D; Holth, A; Zeppa, P; Hager, T; Wohlschlaeger, J; Totsch, M				Davidson, Ben; Pinamonti, Maurizio; Cuevas, Dolors; Holth, Arild; Zeppa, Pio; Hager, Thomas; Wohlschlaeger, Jeremias; Toetsch, Martin			The diagnostic role of PTEN and ARID1A in serous effusions	VIRCHOWS ARCHIV			English	Article						PTEN; ARID1A; Effusions; Immunohistochemistry; Diagnosis	HER2-POSITIVE BREAST-CANCER; MALIGNANT MESOTHELIAL CELLS; ENDOMETRIAL CARCINOMA; OVARIAN; IMMUNOHISTOCHEMISTRY; PERITONEAL; CLAUDIN-4; MARKER; TRASTUZUMAB; PAX2	The aim of this study was to analyze the diagnostic role of PTEN and ARID1A in effusion cytology. Effusions (n = 279), consisting of 226 carcinomas (70 ovarian, 64 breast, 36 lung, and 15 uterine corpus carcinomas; 41 carcinomas of other origin) and 53 malignant mesotheliomas, were analyzed for PTEN and ARID1A expression using immunohistochemistry. PTEN was preserved in 166 (59%) tumors, partially lost in 38 (14%), and absent in 75 (27%), with lower expression in malignant mesotheliomas compared to carcinomas, though not significantly (p = 0.084). ARID1A was preserved in 243 (88%) tumors, partially lost in 18 (6%), and absent in 18 (6%). The majority of tumors with absent ARID1A were ovarian carcinomas, predominantly of clear cell or low-grade serous type. Reactive mesothelial cells in carcinoma specimens were uniformly positive for both proteins. ARID1A mutation analysis showed no mutations in eight analyzed specimens negative by immunohistochemistry. Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology. Loss of PTEN is not informative of organ of origin, whereas absence of ARID1A should raise suspicion of an ovarian primary.	[Davidson, Ben; Holth, Arild] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; [Davidson, Ben] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway; [Pinamonti, Maurizio] Univ Trieste, Dept Med Surg & Hlth Sci, Unit Pathol, I-34151 Trieste, Italy; [Cuevas, Dolors] Hosp Univ Arnau de Vilanova Lleida, IRB Lleida, Lleida 25198, Spain; [Zeppa, Pio] Univ Salerno, Dept Pathol, I-84084 Salerno, Italy; [Hager, Thomas; Wohlschlaeger, Jeremias] Univ Hosp Essen, Dept Pathol, Essen, Germany; [Toetsch, Martin] Med Univ Graz, Inst Cytol, Auenbruggerpl 20-1, A-8036 Graz, Austria	Davidson, B (reprint author), Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway.; Davidson, B (reprint author), Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway.	bend@medisin.uio.no			Research Foundation at the Norwegian Radium Hospital	This work was supported by The Research Foundation at the Norwegian Radium Hospital.	Andrici J, 2016, HUM PATHOL, V51, P9, DOI 10.1016/j.humpath.2015.12.012; Balbas-Martinez C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062483; Berns K, 2016, CLIN CANCER RES, V22, P5238, DOI 10.1158/1078-0432.CCR-15-2996; Bitler BG, 2015, EXPERT OPIN THER TAR, V19, P1419, DOI 10.1517/14728222.2015.1062879; Cowell JK, 2017, INT J CANCER, V141, P1822, DOI 10.1002/ijc.30848; Davidson B, 2011, SEROUS EFFUSIONS; Davidson B, 2007, DIAGN CYTOPATHOL, V35, P756, DOI 10.1002/dc.20771; Davidson B, 2016, HUM PATHOL, V58, P123, DOI 10.1016/j.humpath.2016.08.005; Davidson B, 2016, HUM PATHOL, V47, P104, DOI 10.1016/j.humpath.2015.08.020; Davidson B, 2014, CANCER CYTOPATHOL, V122, P153, DOI 10.1002/cncy.21353; Deguchi Y, 2017, GASTRIC CANCER, V20, P416, DOI 10.1007/s10120-016-0627-z; Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208; Facchetti F, 2007, VIRCHOWS ARCH, V451, P669, DOI 10.1007/s00428-007-0448-x; Gao FF, 2012, APPL IMMUNOHISTO M M, V20, P272, DOI 10.1097/PAI.0b013e3182366531; Garg K, 2012, INT J GYNECOL PATHOL, V31, P48, DOI 10.1097/PGP.0b013e3182230d00; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Gounaris I, 2015, FUTURE ONCOL, V11, P1389, DOI 10.2217/fon.15.45; Hodges C, 2016, COLD SPRING HARB PER, V6; Jo VY, 2014, CANCER CYTOPATHOL, V122, P299, DOI 10.1002/cncy.21392; Kawai T, 2016, J CLIN PATHOL, V69, P706, DOI 10.1136/jclinpath-2015-203211; Kleinberg L, 2007, AM J CLIN PATHOL, V127, P928, DOI 10.1309/V025QRN3R9CJGNPX; Kobel M, 2013, CANCER EPIDEM BIOMAR, V22, P1677, DOI 10.1158/1055-9965.EPI-13-0391; Kobel M, 2014, HISTOPATHOLOGY, V64, P1004, DOI 10.1111/his.12349; Koo DH, 2015, TUMOR BIOL, V36, P5865, DOI 10.1007/s13277-015-3258-9; Kwan SY, 2016, ONCOTARGET, V7, P56933, DOI 10.18632/oncotarget.10921; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Loibl S, 2016, CLIN CANCER RES, V22, P2675, DOI 10.1158/1078-0432.CCR-15-0965; Maiques O, 2014, HUM PATHOL, V45, P522, DOI 10.1016/j.humpath.2013.10.018; Malaney P, 2017, CELL MOL LIFE SCI, V74, P2783, DOI 10.1007/s00018-017-2500-6; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Morel D, 2017, ANN ONCOL, V28, P254, DOI 10.1093/annonc/mdw552; Ordonez NG, 2013, MODERN PATHOL, V26, P1132, DOI 10.1038/modpathol.2013.34; Ordonez NG, 2013, MODERN PATHOL, V26, P553, DOI 10.1038/modpathol.2012.200; Takeda T, 2016, ONCOL REP, V35, P607, DOI [10.3892/or.20154421, 10.3892/or.2015.4421]; Voss MH, 2017, CLIN ONCOL; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Yuan Y, 2009, AM J SURG PATHOL, V33, P1673, DOI 10.1097/PAS.0b013e3181b6bde3	37	2	2	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					425	432		10.1007/s00428-017-2273-1			8	Pathology	Pathology	GB8UF	WOS:000429350100012	29170871				2019-10-28	
J	Brobeil, A; Wagenlehner, F; Gattenlohner, S				Brobeil, Alexander; Wagenlehner, Florian; Gattenloehner, Stefan			Expression of terminal deoxynucleotidyl transferase (TdT) in classical seminoma: a potential diagnostic pitfall	VIRCHOWS ARCHIV			English	Article						Seminona; TdT; Acute leukemia; Testis; Aberrant; Pitfall	ACUTE LYMPHOBLASTIC-LEUKEMIA; GERM-CELL TUMORS; DIFFERENTIAL-DIAGNOSIS; TESTICULAR RELAPSE; IMMUNOHISTOCHEMISTRY; ANTIBODIES; DIVERSITY; CARCINOMA; TISSUE; CD117	Seminomas are the most frequent testicular tumors and in spite of specific markers some histological subtypes can be diagnostically challenging due to the potential overlap of morphologic features and a variant antigen expression. Terminal deoxynucleotidyl transferase (TdT) is a DNA polymerase present in hematogones, thymic T cells, lymphoblastic lymphoma/leukemia (LBL), and in some cases of acute myeloid leukemia but so far has not been described to be expressed in seminomas. After observing a reactivity of TdT in one case of seminoma, we analyzed ten additional tumors by immunohistochemistry to determine their spectrum of reactivity for TdT. In all seminoma cases investigated (10/10) as well as in two tumor-associated germ cell neoplasias in situ (2/2) the TdT staining intensity was variable but was often moderate to strong and restricted to the nucleus. We conclude that TdT expression in seminomas could represent a diagnostic pitfall in the differential diagnosis of LBL, particularly because both may lack CD45 and/or CD20 expression and-concerning relapse in long-term survivors of testicular cancer-LBL is the most frequent secondary neoplasm in the patients.	[Brobeil, Alexander; Gattenloehner, Stefan] Justus Liebig Univ, Inst Pathol, D-35392 Giessen, Germany; [Brobeil, Alexander] Justus Liebig Univ, Inst Pathol, D-35385 Giessen, Germany; [Wagenlehner, Florian] Justus Liebig Univ, Dept Urol Pediat Urol & Androl, D-35392 Giessen, Germany	Brobeil, A (reprint author), Justus Liebig Univ, Inst Pathol, D-35392 Giessen, Germany.; Brobeil, A (reprint author), Justus Liebig Univ, Inst Pathol, D-35385 Giessen, Germany.	alexander.brobeil@patho.med.uni-giessen.de					Bahrami A, 2007, ARCH PATHOL LAB MED, V131, P1267; BAILEY D, 1991, MODERN PATHOL, V4, P167; Berney DM, 2016, HISTOPATHOLOGY, V69, P7, DOI 10.1111/his.12958; Blay J.Y., 2005, B CANC, V92, P13; Boujelbene N, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-90; Bromby A, 2014, TREND UROL MENS HEAL, V5, P15, DOI 10.1002/tre.373; Cabaniols JP, 2001, J EXP MED, V194, P1385, DOI 10.1084/jem.194.9.1385; Cooper SL, 2015, PEDIATR CLIN N AM, V62, P61, DOI 10.1016/j.pcl.2014.09.006; Costi R, 2013, J MED CHEM, V56, P7431, DOI 10.1021/jm4010187; DREXLER HG, 1993, LEUKEMIA, V7, P1142; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Kulkarni KP, 2010, INDIAN J CANCER, V47, P134, DOI 10.4103/0019-509X.63002; Lau SK, 2007, MODERN PATHOL, V20, P320, DOI 10.1038/modpathol.3800749; Lu J, 2011, ADV ANAT PATHOL, V18, P133, DOI 10.1097/PAP.0b013e3182026dbd; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Motea EA, 2010, BBA-PROTEINS PROTEOM, V1804, P1151, DOI 10.1016/j.bbapap.2009.06.030; Novelli M, 2010, HISTOPATHOLOGY, V57, P259, DOI 10.1111/j.1365-2559.2010.03624.x; Ozcan A, 2012, ARCH PATHOL LAB MED, V136, P1541, DOI 10.5858/arpa.2012-0072-OA; Perez-Montiel MD, 2006, AM J DERMATOPATH, V28, P105, DOI 10.1097/01.dad.0000200009.02939.cc; RITZEN EM, 1990, J REPROD IMMUNOL, V18, P117; Sahni C, 2009, LEUKEMIA LYMPHOMA, V48, P2060; SAID JW, 1988, AM J CLIN PATHOL, V89, P649, DOI 10.1093/ajcp/89.5.649; Schmoll HJ, 2010, ANN ONCOL, V21, pv140, DOI 10.1093/annonc/mdq176; Sur M, 2007, MODERN PATHOL, V20, P1113, DOI 10.1038/modpathol.3800936; Zhu JL, 2015, CANCER BIOL THER, V16, P1122, DOI 10.1080/15384047.2015.1056412	25	3	3	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					433	440		10.1007/s00428-018-2313-5			8	Pathology	Pathology	GB8UF	WOS:000429350100013	29455318				2019-10-28	
J	Volavsek, M; Blanca, A; Montironi, R; Cheng, L; Raspollini, MR; Vau, N; Fonseca, J; Pierconti, F; Lopez-Beltran, A				Volavsek, Metka; Blanca, Ana; Montironi, Rodolfo; Cheng, Liang; Raspollini, Maria R.; Vau, Nuno; Fonseca, Jorge; Pierconti, Francesco; Lopez-Beltran, Antonio			Digital versus light microscopy assessment of surgical margin status after radical prostatectomy	VIRCHOWS ARCHIV			English	Article						Prostate cancer; Radical prostatectomy; Surgical margin status; Digital microscopy; Digital pathology; Biochemical recurrence	ISUP CONSENSUS-CONFERENCE; EXTRAPROSTATIC EXTENSION; PROGNOSTIC-SIGNIFICANCE; BIOCHEMICAL RECURRENCE; INTERNATIONAL SOCIETY; PROSTATIC-CARCINOMA; CANCER; PATHOLOGY; ANTIGEN; INTEROBSERVER	Positive surgical margin (PSM) extension reported as focal or non-focal/extensive is an important pathologic prognostic parameter after radical prostatectomy. Likewise, there is limited or no agreement on how to measure and what the best cut-off points to be used in practice are. We hypothesized that digital microscopy (DM) would potentially provide a more objective way to measure PSM and better define its clinical significance. To further our knowledge, we have evaluated PSM status in 107 laparoscopic radical prostatectomies using digital and conventional light microscopy (LM). DM evaluation detected three additional PSM cases, but no differences were seen (LM vs DM; p = 0.220). Mean linear measurement correlated to biochemical recurrence (BR) (LM, p = 0.002; DM, p = 0.001). ROC analysis identified a cut-off point to assess linear measurement by LM (3.5 mm) or DM (3.2 mm), but only digital measurement was significant for BR-free survival. Our study also evaluated a cut-off ae<currency> 3 mm that was associated to BR using LM (p = 0.023) or DM (p = 0.001). Finally, the number of paraffin blocks bearing PSM correlated with BR (p < 0.001) status with either LM or DM. In conclusion, DM produces similar data than LM but shows more accurate measurements. Reporting of PSM with score of <= 3 vs. > 3 mm linear extent using LM (3.2 mm if digital microscopy is applied) might represent an important prognostic feature after radical prostatectomy. Alternatively, reporting the number of blocks with PSM 1 vs. 2 or more might also provide important prognostic data in practice.	[Volavsek, Metka] Univ Ljubljana, Inst Pathol, Fac Med, Ljubljana, Slovenia; [Blanca, Ana] Maimonides Biomed Res Inst Cordoba, Cordoba, Spain; [Montironi, Rodolfo] Polytech Univ Marche Reg Ancona, Inst Pathol Anat & Histopathol, Sch Med, United Hosp, Ancona, Italy; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; [Cheng, Liang] Indiana Univ Sch Med, Dept Urol, Indianapolis, IN USA; [Raspollini, Maria R.] Univ Hosp Careggi, Histopathol & Mol Diagnost, Florence, Italy; [Vau, Nuno] Champalimaud Clin Ctr, Urol Oncol, Lisbon, Portugal; [Fonseca, Jorge] Champalimaud Clin Ctr, Urol Clin, Lisbon, Portugal; [Pierconti, Francesco] Univ Cattolica Sacro Cuore, Agostino Gemelli Sch Med, Div Anat Pathol & Histol, Rome, Italy; [Lopez-Beltran, Antonio] Fac Med, Dept Pathol, Dept Surg, Anat Pathol Unit, Cordoba, Spain; [Lopez-Beltran, Antonio] Champalimaud Clin Ctr, Lisbon, Portugal	Lopez-Beltran, A (reprint author), Fac Med, Dept Pathol, Dept Surg, Anat Pathol Unit, Cordoba, Spain.; Lopez-Beltran, A (reprint author), Champalimaud Clin Ctr, Lisbon, Portugal.	em1lobea@uco.es	Blanca, Ana/F-6841-2016	Blanca, Ana/0000-0002-4360-4352; Lopez-Beltran, Antonio/0000-0003-3161-8164			Ahyai SA, 2010, BJU INT, V106, P478, DOI 10.1111/j.1464-410X.2009.09162.x; Babaian RJ, 2001, CANCER, V91, P1414; Buyyounouski MK, 2017, AJCC CANC STAGING MA, P715; Chan SM, 2011, PROSTATE CANCER P D, V14, P307, DOI 10.1038/pcan.2011.15; Cookson MS, 2007, J UROLOGY, V177, P540, DOI 10.1016/j.juro.2006.10.097; Emerson RE, 2005, J CLIN PATHOL, V58, P1028, DOI 10.1136/jcp.2005.025882; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Evans AJ, 2008, AM J SURG PATHOL, V32, P1503, DOI 10.1097/PAS.0b013e31817fb3a0; Evans AJ, 2017, ARCH PATHOL LAB MED, V141, P944, DOI 10.5858/arpa.2016-0074-OA; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Humphrey PA, 2016, WHO CLASSIFICATION T, P138; Kamat AM, 2003, J UROLOGY, V170, P1860, DOI 10.1097/01.ju.0000092503.45951.c2; Mann MJ, 2008, UROLOGY, V72, P1203, DOI 10.1016/j.urology.2008.04.068; Montironi R, 2016, EUR UROL FOCUS; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Rodriguez-Urrego PA, 2011, HUM PATHOL, V42, P68, DOI 10.1016/j.humpath.2010.07.001; Sengupta S, 2006, J UROLOGY, V176, P559, DOI 10.1016/j.juro.2006.03.086; Sherwin JC, 2010, J UROLOGY, V183, P1808, DOI 10.1016/j.juro.2010.01.017; Tan PH, 2011, MODERN PATHOL, V24, P48, DOI 10.1038/modpathol.2010.155; Tetu B, 2014, ARCH PATHOL LAB MED, V138, P302, DOI 10.5858/arpa.2013-0289-ED; Uchio EM, 2010, ARCH INTERN MED, V170, P1390, DOI 10.1001/archinternmed.2010.262; WELDON VE, 1995, J UROLOGY, V153, P1565, DOI 10.1016/S0022-5347(01)67462-7; Yossepowitch O, 2014, EUR UROL, V65, P303, DOI 10.1016/j.eururo.2013.07.039	26	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					451	460		10.1007/s00428-018-2296-2			10	Pathology	Pathology	GB8UF	WOS:000429350100015	29453523				2019-10-28	
J	Aubert, S; Berdelou, A; Gnemmi, V; Behal, H; Caiazzo, R; D'herbomez, M; Pigny, P; Wemeau, JL; Carnaille, B; Renaud, F; Bouchindhomme, B; Leteurtre, E; Perrais, M; Pattou, F; Do Cao, C				Aubert, Sebastien; Berdelou, Amandine; Gnemmi, Viviane; Behal, Helene; Caiazzo, Robert; D'herbomez, MichSle; Pigny, Pascal; Wemeau, Jean Louis; Carnaille, Bruno; Renaud, Florence; Bouchindhomme, Brigitte; Leteurtre, Emmanuelle; Perrais, Michael; Pattou, Francois; Do Cao, Christine			Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement	VIRCHOWS ARCHIV			English	Article						Medullary; Thyroid; Carcinoma; Node; Desmoplasia; MicroRNA	MICRORNA EXPRESSION; CANCER; MICROCARCINOMA; NORMALIZATION; METASTASES; MANAGEMENT; PROGNOSIS; APOPTOSIS; CORRELATE	Lymph node involvement (LNI) is one of the most important prognostic factors for poor survival in medullary thyroid carcinoma (MTC). At diagnosis, LNI is found in over 50% of sporadic MTCs, and especially in large tumours. Cervical lymph node dissection is therefore mandatory during MTC surgery. However, some large tumours (responsible for high preoperative basal calcitonin levels) are found to lack LNI, and can be cured definitely. Preoperative detection of these particular tumours might spare patients from undergoing extensive cervical dissection. The objective of the present retrospective study of a series of large sporadic MTCs was to identify clinical, biological and pathological factors that were predictive of LNI. Consecutive cases of large, sporadic MTCs (measuring at least 1 cm in diameter) were retrieved and reviewed. The levels of several mature microRNAs (miRs) in paraffin-embedded samples were assessed using qPCR. Of the 54 MTCs, 26 had LNI and 28 were pN0. Relative to pN0 patients, patients with LNI had a significant higher preoperative basal calcitonin level (p = 0.0074) and a greater prevalence of infiltrative margins (p < 0.0001), lymphovascular invasion (p = 0.0004), extrathyroidal extension (p < 0.0001), a higher pT stage (p = 0.0003) and more abundant desmoplastic stroma (p = 0.0006). Tumour expression levels of miR-21 (p = 0.0008) and miR-183 (p = 0.0096) were higher in the LNI group. The abundance of desmoplastic stroma (p = 0.007) and the miR-21 expression level (p = 0.0026) were independent prognostic factors for LNI. The abundance of desmoplastic stroma and high levels of miR-21 expression were strong indicators of LNI, and may thus help the surgeon to choose the extent of cervical lymph node dissection for large, sporadic MTCs with no preoperatively obvious LNI.	[Aubert, Sebastien; Gnemmi, Viviane; Renaud, Florence; Bouchindhomme, Brigitte; Leteurtre, Emmanuelle] CHRU Lille, Inst Pathol, Ctr Biol Pathol, F-59037 Lille, France; [Aubert, Sebastien; Gnemmi, Viviane; Caiazzo, Robert; Pigny, Pascal; Wemeau, Jean Louis; Carnaille, Bruno; Renaud, Florence; Leteurtre, Emmanuelle; Perrais, Michael; Pattou, Francois] Univ Lille, Fac Med, F-59045 Lille, France; [Aubert, Sebastien; Gnemmi, Viviane; Pigny, Pascal; Renaud, Florence; Leteurtre, Emmanuelle; Perrais, Michael] INSERM, JPArc, UMR 1172, Batiment Biserte, F-59045 Lille, France; [Berdelou, Amandine] IGR, Serv Cancerol Endocrinienne, F-94805 Paris, France; [Behal, Helene] CHRU Lille, Unite Biostat, Pole Sante Publ, F-59037 Lille, France; [Caiazzo, Robert; Carnaille, Bruno; Pattou, Francois] CHRU Lille, Serv Chirurg Endocrine, Hop Huriez, F-59037 Lille, France; [D'herbomez, MichSle; Pigny, Pascal] CHRU Lille, Inst Biochim, Ctr Biol Pathol Genet, F-59037 Lille, France; [Wemeau, Jean Louis; Do Cao, Christine] CHRU Lille, Serv Endocrinol, Hop Huriez, F-59037 Lille, France	Aubert, S (reprint author), CHRU Lille, Inst Pathol, Ctr Biol Pathol, F-59037 Lille, France.; Aubert, S (reprint author), Univ Lille, Fac Med, F-59045 Lille, France.; Aubert, S (reprint author), INSERM, JPArc, UMR 1172, Batiment Biserte, F-59045 Lille, France.	sebastien.aubert@chru-lille.fr	Renaud, Florence/V-5064-2019; Pattou, Francois/Y-8448-2019; caiazzo, robert/Y-9692-2019; CAO, CHRISTINE DO/M-7950-2018	Renaud, Florence/0000-0003-3614-1713; caiazzo, robert/0000-0001-5383-0540; CAO, CHRISTINE DO/0000-0002-1617-0149; Gnemmi, Viviane/0000-0001-7403-4607			Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gee HE, 2011, BRIT J CANCER, V104, P1168, DOI 10.1038/sj.bjc.6606076; Gimm O, 2013, THYROID RES, V6, DOI 10.1186/1756-6614-6-S1-S3; Glowacki F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058014; Huang YB, 2013, EUR J ENDOCRINOL, V168, P675, DOI 10.1530/EJE-12-1029; Kazaure HS, 2012, CANCER-AM CANCER SOC, V118, P620, DOI 10.1002/cncr.26283; Koperek O, 2008, HISTOPATHOLOGY, V52, P623, DOI 10.1111/j.1365-2559.2008.03002.x; Krueger JE, 2000, AM J SURG PATHOL, V24, P853, DOI 10.1097/00000478-200006000-00011; Li J, 2010, BMC EVOL BIOL, V10, DOI [10.1186/1471-2148-10-68, 10.1186/1471-2407-10-354]; Machens A, 2008, HISTOPATHOLOGY, V53, P481, DOI 10.1111/j.1365-2559.2008.03122.x; Machens A, 2008, BRIT J SURG, V95, P586, DOI 10.1002/bjs.6075; Machens A, 2010, J CLIN ENDOCR METAB, V95, P2655, DOI 10.1210/jc.2009-2368; Mian C, 2012, THYROID, V22, P890, DOI 10.1089/thy.2012.0045; Miccoli P, 2007, ENDOCR-RELAT CANCER, V14, P1099, DOI 10.1677/ERC-07-0128; Moley JF, 1999, ANN SURG, V229, P880, DOI 10.1097/00000658-199906000-00016; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Pennelli G, 2015, HUM PATHOL, V46, P50, DOI 10.1016/j.humpath.2014.09.006; Scheuba C, 2006, WORLD J SURG, V30, P853, DOI 10.1007/s00268-005-0391-4; Scollo C, 2003, J CLIN ENDOCR METAB, V88, P2070, DOI 10.1210/jc.2002-021713; Sobin LH, 2009, TNM CLASSIFICATION M; Tamagnini P, 2005, BRIT J SURG, V92, P449, DOI 10.1002/bjs.4860; Wang Y, 2014, GENE, V533, P389, DOI 10.1016/j.gene.2013.09.038; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335; Wojtas B, 2014, MOL CELL ENDOCRINOL, V388, P1, DOI 10.1016/j.mce.2014.02.011; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Yip DT, 2011, SURGERY, V150, P1168, DOI 10.1016/j.surg.2011.09.043; Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953	29	1	1	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					461	468		10.1007/s00428-018-2303-7			8	Pathology	Pathology	GB8UF	WOS:000429350100016	29388012				2019-10-28	
J	Perron, E; Pissaloux, D; Neub, A; Hohl, D; Tartar, MD; Mortier, L; Alberti, L; de la Fouchardiere, A				Perron, Emilie; Pissaloux, Daniel; Neub, Angela; Hohl, Daniel; Tartar, Marie Dominique; Mortier, Laurent; Alberti, Laurent; de la Fouchardiere, Arnaud			Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors	VIRCHOWS ARCHIV			English	Review						Melanocytic tumors; Melanoma; Desmoplastic stromal reaction; BRAF fusion	DESMOPLASTIC MELANOMA; MAPK PATHWAY; PROMOTER MUTATIONS; CANCER; INHIBITION; ACTIVATION; NEOPLASMS; MECHANISM; NEVI	The current classification of melanocytic tumors includes clinical, pathological, and molecular data. A subset of lesions remains difficult to classify according to these complex multilayer schemes. We report two cases of deeply infiltrating melanomas with a sclerosing background. The first case occurred on the back of a middle-aged man appearing clinically as a dermatofibroma. The architectural and cytological aspects resembled those of a desmoplastic melanoma but the strong expression of both melanA and HMB45, two stainings usually reported as negative in this entity, raised the question of an alternate diagnosis. The second case was a large, slowly growing, perivulvar tumor in a middle-aged woman. The morphology was complex with a central junctional spitzoid pattern associating an epidermal hyperplasia with large nests of large spindled melanocytes. The dermal component was made of deeply invasive strands and nests of nevoid unpigmented melanocytes surrounded by fibrosis; a perineural invasion was present at the periphery of the lesion. In both cases, aCGH found, among many other anomalies, a chromosomal breakpoint at the BRAF locus. RNA sequencing identified in both an AKAP9-BRAF gene fusion. A complementary resection was performed and no relapses have been observed in the respectively 15 and 6 months of follow-up. Both of these melanomas remained unclassified. We further review the variety of melanocytic tumors associated with such BRAF fusions.	[Perron, Emilie; Pissaloux, Daniel; Alberti, Laurent; de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Perron, Emilie] Univ Laval, Ctr Hosp Univ Quebec, Serv Anatomopathol, Dept Biol Med, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada; [Perron, Emilie] Univ Laval, Fac Med, Dept Biol Mol Biochim Med & Pathol, Quebec City, PQ, Canada; [Neub, Angela; Hohl, Daniel] Ctr Hosp Univ Vaudois CHUV, Serv Dermatol & Venerol, Lausanne, Switzerland; [Tartar, Marie Dominique] Hop Jean Bernard, Serv Pathol, Valenciennes, France; [Mortier, Laurent] Univ Lille, CHU Lille, INSERM, Serv Dermatol,U 1189, F-59000 Lille, France	Perron, E (reprint author), Ctr Leon Berard, Dept Biopathol, Lyon, France.; Perron, E (reprint author), Univ Laval, Ctr Hosp Univ Quebec, Serv Anatomopathol, Dept Biol Med, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.; Perron, E (reprint author), Univ Laval, Fac Med, Dept Biol Mol Biochim Med & Pathol, Quebec City, PQ, Canada.	emilie.perron.1@ulaval.ca	de la Fouchardiere, Arnaud/I-2807-2019	de la Fouchardiere, Arnaud/0000-0003-2251-8241; PISSALOUX, Daniel/0000-0003-1118-950X; MORTIER, Laurent/0000-0002-2644-1790; Perron, emilie/0000-0002-7033-8053	TEVA Innovation Canada fellowship grants	Dr. Emilie Perron gratefully acknowledges the "Bourse McLaughlin du doyen de la Faculte de medecine de l'Universite Laval" and the TEVA Innovation Canada fellowship grants.	Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Botton T, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12148; Busam KJ, 2017, AM J SURG PATHOL, V41, P396, DOI 10.1097/PAS.0000000000000769; CARLSON JA, 1995, CANCER, V75, P478, DOI 10.1002/1097-0142(19950115)75:2<478::AID-CNCR2820750211>3.0.CO;2-O; Chen LL, 2013, J AM ACAD DERMATOL, V68, P825, DOI 10.1016/j.jaad.2012.10.041; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Kay PA, 2004, INT J SURG PATHOL, V12, P17, DOI 10.1177/106689690401200103; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Lee S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11200; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Turner J, 2017, PIGM CELL MELANOMA R, V30, P53, DOI 10.1111/pcmr.12560; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116	21	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					469	476		10.1007/s00428-017-2290-0			8	Pathology	Pathology	GB8UF	WOS:000429350100017	29464327				2019-10-28	
J	Cerbelli, B; Pisano, A; Colafrancesco, S; Pignataro, MG; Biffoni, M; Berni, S; De Luca, A; Riccieri, V; Priori, R; Valesini, G; d'Amati, G; Giordano, C				Cerbelli, Bruna; Pisano, Annalinda; Colafrancesco, Serena; Pignataro, Maria Gemma; Biffoni, Marco; Berni, Silvia; De Luca, Antonia; Riccieri, Valeria; Priori, Roberta; Valesini, Guido; d'Amati, Giulia; Giordano, Carla			Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy	VIRCHOWS ARCHIV			English	Article						Myositis; Anti-synthetase syndrome; Dermatomyositis; Muscle biopsy; mtDNA damage	MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; IDIOPATHIC INFLAMMATORY MYOPATHIES; CLASSIFICATION; AUTOANTIBODIES; IMMUNE; ABNORMALITIES; PATHOLOGY; DEPLETION; FEATURES; CRITERIA	Anti-synthetase syndrome is an autoimmune disease characterized by autoantibodies toward amino acyl-tRNA synthetases (ARS), anti-Jo 1 being the most commonly detected. Muscle damage develops in up to 90% of ARS-positive patients, characterized by a necrotizing myositis restricted to the perifascicular region. This topographic distribution of muscle damage may lead to a misdiagnosis of dermatomyositis (DM) at muscle biopsy. We compared morphological, immunohistochemical, and histoenzymatic features of muscle from ARS-positive patients (n = 11) with those of DM (n = 7) providing clues for their differential diagnosis. In addition, we evaluated markers of mitochondrial damage to provide a further distinction between these two entities. Necrosis occurred in the majority of ARS patients, mainly located in the perifascicular region. It was often limited to small foci of fibers, always associated with myocyte regeneration. This last often overwhelmed necrosis, representing occasionally the main finding. In DM, necrosis/regeneration was scarce while the peculiar feature was a diffuse atrophy of perifascicular fibers. These last showed decreased cytochrome c oxidase (COX) stain and mitochondrial DNA depletion, consistent with mitochondrial dysfunction. In contrast to DM, ARS displayed scattered COX-deficient fibers, not restricted to the perifascicular region. This feature occurred in up to 91% of patients, being prominent only in two.	[Cerbelli, Bruna; Pisano, Annalinda; Pignataro, Maria Gemma; Berni, Silvia; De Luca, Antonia; d'Amati, Giulia; Giordano, Carla] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Policlin Umberto 1, Viale Regina Elena 324, I-00161 Rome, Italy; [Colafrancesco, Serena; Riccieri, Valeria; Priori, Roberta; Valesini, Guido] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Rheumatol Unit, I-00161 Rome, Italy; [Biffoni, Marco] Sapienza Univ Rome, Dept Surg Sci, I-00161 Rome, Italy	Giordano, C (reprint author), Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Policlin Umberto 1, Viale Regina Elena 324, I-00161 Rome, Italy.	carla.giordano@uniroma1.it	priori, roberta/Z-6259-2019; d'Amati, Giulia/F-1251-2011; Colafrancesco, Serena/AAB-4997-2019	priori, roberta/0000-0002-6695-1445; d'Amati, Giulia/0000-0002-6959-691X; Colafrancesco, Serena/0000-0001-7802-1192; Valesini, Guido/0000-0002-7757-8092; RICCIERI, Valeria/0000-0002-7507-5483			Alhatou MI, 2004, J MOL HISTOL, V35, P615; Allenbach Y, 2016, BRAIN, V139, DOI 10.1093/brain/aww126; BANKER BQ, 1966, MEDICINE, V45, P261, DOI 10.1097/00005792-196607000-00001; Batten F E, 1912, Proc R Soc Med, V5, P103; BROOKE MH, 1969, NEUROLOGY, V19, P378, DOI 10.1212/WNL.19.4.378; Brouwer R, 2001, ANN RHEUM DIS, V60, P116, DOI 10.1136/ard.60.2.116; CARPENTER S, 1976, NEUROLOGY, V26, P952, DOI 10.1212/WNL.26.10.952; Cavagna L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001144; Cavazzana I, 2016, J IMMUNOL METHODS, V433, P1, DOI 10.1016/j.jim.2016.02.017; Colafrancesco S, 2015, BEST PRACT RES CL RH, V29, P810, DOI 10.1016/j.berh.2016.02.005; Dalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004; Giordano C, 2011, METHODS MOL BIOL, V755, P223, DOI 10.1007/978-1-61779-163-5_18; Greenberg SA, 2005, ANN NEUROL, V57, P664, DOI 10.1002/ana.20464; Hoogendijk Jessica E, 2004, Neuromuscul Disord, V14, P337, DOI 10.1016/j.nmd.2004.02.006; Iaccarino L, 2013, AUTOIMMUN REV, V12, P363, DOI 10.1016/j.autrev.2012.06.004; Koenig M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2276; Lahoria R, 2016, BRAIN, V139, P1891, DOI 10.1093/brain/aww122; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; Mahler M, 2014, AUTOIMMUN REV, V13, P367, DOI 10.1016/j.autrev.2014.01.022; Mescam-Mancini L, 2015, BRAIN, V138, P2485, DOI 10.1093/brain/awv192; Miro O, 1998, BRIT J RHEUMATOL, V37, P1047; Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003; Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d; Pestronk A, 2011, CURR OPIN RHEUMATOL, V23, P595, DOI 10.1097/BOR.0b013e32834bab42; Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149; Senecal JL, 2017, ARTHRITIS RHEUMATOL, V69, P878, DOI 10.1002/art.40063; Temiz P, 2009, J NEUROL SCI, V278, P25, DOI 10.1016/j.jns.2008.11.010; Troyanov Y, 2005, MEDICINE, V84, P231, DOI 10.1097/01.md.0000173991.74008.b0; Troyanov Y, 2014, MEDICINE, V93, P318, DOI 10.1097/MD.0000000000000222; Uruha A, 2016, BRAIN, V139, DOI 10.1093/brain/aww125; Varadhachary AS, 2010, CURR OPIN RHEUMATOL, V22, P651, DOI 10.1097/BOR.0b013e32833f108a; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; WOO M, 1988, J NEUROL SCI, V88, P133, DOI 10.1016/0022-510X(88)90211-0	35	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					477	487		10.1007/s00428-017-2269-x			11	Pathology	Pathology	GB8UF	WOS:000429350100018	29147923				2019-10-28	
J	Bell, AH; DeMonte, F; Raza, SM; Rhines, LD; Tatsui, CE; Prieto, VG; Fuller, GN; Bell, D				Bell, Achim H.; DeMonte, Franco; Raza, Shaan M.; Rhines, Laurence D.; Tatsui, Claudio E.; Prieto, Victor G.; Fuller, Gregory N.; Bell, Diana			Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas	VIRCHOWS ARCHIV			English	Article						Chordoma; Skull base; Spine; Transcriptome; Developmental genes; Stem cells; Plasticity	EMBRYONIC STEM-CELLS; EXPRESSION; CANCER; GENES; BRACHYURY; APOPTOSIS; STRESS	Chordomas are rare, slowly growing, locally aggressive bone neoplasms that arise from embryonic remnants of the notochord, showing dual epithelial-mesenchymal differentiation. The high plasticity probably is the main reason for the high variety in phenotypes of chordoma, from its high heterogeneity on a cellular level to its subtype variations depending on tissue location, with its potential to develop from an inactive quiescent form to an aggressive cancer with extreme adaptability and resistance to drugs and other treatments. Gene expression profiles of formalin-fixed, paraffin-embedded skull chordoma, spine chordoma, and normal tissue specimens were generated and compared. Using strict criteria, we identified 222 differentially expressed transcripts unique to skull base chordoma, 261 unique to spine chordoma, and 192 common to both chordoma subtypes. Further analysis of these three groups of transcripts allowed the selection of three subsets of highly differentially expressed genes as potential biomarkers, disease drivers, and therapeutic targets in both chordoma subtypes. Immunohistochemistry revealed LMX1A to be dominant in skull base chordoma, SALL3 to be unique to spine chordoma, and T to be common to both chordoma subtypes. In both chordoma subtypes, the genes with the highest expression were predominantly development-related genes, mostly transcription factors. Our findings indicate that these developmental genes play important oncogenic roles in chordoma, mainly causing high plasticity and resistance to therapy in both these cancer subtypes but also determining their differentiation status and proliferation activity, pointing to features expected of heterogeneous stem cell-like tissues with similarities to their notochord origins.	[Bell, Achim H.; Prieto, Victor G.; Fuller, Gregory N.; Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [DeMonte, Franco; Raza, Shaan M.; Bell, Diana] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg Dept, Houston, TX 77030 USA; [Bell, Achim H.] Univ Texas MD Anderson Canc Ctr, Dept Pathol Res, Houston, TX 77030 USA; [DeMonte, Franco; Raza, Shaan M.; Rhines, Laurence D.; Tatsui, Claudio E.] Univ Texas MD Anderson Canc Ctr, Neurosurg Dept, Houston, TX 77030 USA	Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Head & Neck Surg Dept, Houston, TX 77030 USA.	diana.bell@mdanderson.org			MD Anderson	This study was supported by start-up funds from MD Anderson (DB) and presented at AACR Advances in Sarcoma, Philadelphia May 2017.	Aruga J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-79; Bell D, 2016, CANCER; Bell D, 2016, VIRCHOWS ARCH, V469, P439, DOI 10.1007/s00428-016-1985-y; Bonnomet A, 2008, ONCOGENE, V27, P3692, DOI 10.1038/sj.onc.1211035; Cha NE, 2014, TUMOR BIOL, V35, P10319, DOI 10.1007/s13277-014-2210-8; CHAMBERS PW, 1979, AM J CLIN PATHOL, V72, P765; Chao TK, 2013, GYNECOL ONCOL, V128, P475, DOI 10.1016/j.ygyno.2012.12.018; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Draper BW, 2007, DEV BIOL, V305, P589, DOI 10.1016/j.ydbio.2007.03.007; Faial T, 2015, DEVELOPMENT, V142, P2121, DOI 10.1242/dev.117838; Heng X, 2012, J MOL NEUROSCI, V46, P293, DOI 10.1007/s12031-011-9563-x; HIGINBOTHAM NL, 1967, CANCER-AM CANCER SOC, V20, P1841, DOI 10.1002/1097-0142(196711)20:11<1841::AID-CNCR2820201107>3.0.CO;2-2; Iijima K, 2012, EUR J IMMUNOL, V42, P3405, DOI 10.1002/eji.201242530; Li Q, 2016, BIOCHEM BIOPH RES CO, V475, P51, DOI 10.1016/j.bbrc.2016.05.030; Li RH, 2015, GENETICS, V201, P1341, DOI 10.1534/genetics.115.180125; Lin CC, 2017, HAEMATOLOGICA, V102, P1044, DOI 10.3324/haematol.2016.161257; Liu H, 2016, EXP MOL PATHOL, V100, P363, DOI 10.1016/j.yexmp.2015.12.002; Lorenzi L, 2017, ONCOTARGET, V8, P16463, DOI 10.18632/oncotarget.14864; Ma Zhibo, 2016, World J Biol Chem, V7, P223, DOI 10.4331/wjbc.v7.i3.223; Mangum R, 2016, CHILD NERV SYST, V32, P2439, DOI 10.1007/s00381-016-3185-0; Mardis ER, 2014, SEMIN HEMATOL, V51, P250, DOI 10.1053/j.seminhematol.2014.08.003; Moorthy SD, 2017, GENOME RES, V27, P246, DOI 10.1101/gr.210930.116; Morquette B, 2015, CELL DEATH DIFFER, V22, P612, DOI 10.1038/cdd.2014.149; Rhie SK, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0102-4; Rimkus TK, 2016, CANCERS, V8, P8; Sankar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep37412; Seifert A, 2015, WORLD J STEM CELLS, V7, P583, DOI 10.4252/wjsc.v7.i3.583; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Williams BJ, 2013, J NATL COMPR CANC NE, V11, P726, DOI 10.6004/jnccn.2013.0089; Yagi K, 2004, DEVELOPMENT, V131, P1279, DOI 10.1242/dev.01011; Yang YJ, 2017, ONCOTARGET	31	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					489	497		10.1007/s00428-017-2224-x			9	Pathology	Pathology	GB8UF	WOS:000429350100019	28844110				2019-10-28	
J	Alnajar, H; Brickman, A; Buckingham, L; Arvanitis, LD				Alnajar, Hussein; Brickman, Arlen; Buckingham, Lela; Arvanitis, Leonidas D.			Metastatic malignant PEComa of the leg with identification of ATRX mutation by next-generation sequencing	VIRCHOWS ARCHIV			English	Article							TELOMERES; EXPRESSION		[Alnajar, Hussein; Brickman, Arlen; Buckingham, Lela; Arvanitis, Leonidas D.] Rush Univ, Dept Pathol, Med Ctr, 1750 W Harrison St,Ste 570 Jelke, Chicago, IL 60612 USA	Alnajar, H (reprint author), Rush Univ, Dept Pathol, Med Ctr, 1750 W Harrison St,Ste 570 Jelke, Chicago, IL 60612 USA.	hussein_h_alnajar@rush.edu					De La Fuente R, 2011, REPRODUCTION, V142, P221, DOI 10.1530/REP-10-0380; Fadare Oluwole, 2004, World J Surg Oncol, V2, P35, DOI 10.1186/1477-7819-2-35; Flynn RL, 2015, SCIENCE, V347, P273, DOI 10.1126/science.1257216; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Koelsche C, 2016, HISTOPATHOLOGY, V68, P738, DOI 10.1111/his.12812; Lee JC, 2015, MODERN PATHOL, V28, P1064, DOI 10.1038/modpathol.2015.67; Liau JY, 2015, AM J SURG PATHOL, V39, P236, DOI 10.1097/PAS.0000000000000324; Lopez G, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0440-x; Martignoni G, 2008, VIRCHOWS ARCH, V452, P119, DOI 10.1007/s00428-007-0509-1; Peng JJE, 2010, J PEDIAT HEMATOL ONC, V32, pE136, DOI 10.1097/MPH.0b013e3181b8700b; Ratnakumar K, 2013, EPIGENETICS-US, V8, P3, DOI 10.4161/epi.23271; Selvaggi F, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-3; WHO, 2013, WHO CLASSIF TUMOURS, V46, P10, DOI [DOI 10.1097/PAT.0000000000000050, 10.1097/PAT.0000000000000050]	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					499	503		10.1007/s00428-017-2208-x			5	Pathology	Pathology	GB8UF	WOS:000429350100020	28755029				2019-10-28	
J	Hanna, EY; Abdelmeguid, ASA; Roberts, D; Bell, AH; Weber, RS; Bell, D				Hanna, Ehab Y.; Abdelmeguid, Ahmed S. A.; Roberts, Dianna; Bell, Achim H.; Weber, Randal S.; Bell, Diana			Cellular subtype may predict survival outcomes in salivary adenoid cystic carcinoma patients-a single-institution experience	VIRCHOWS ARCHIV			English	Article							MOLECULAR PORTRAITS; BREAST-TUMORS; CANCER		[Hanna, Ehab Y.; Abdelmeguid, Ahmed S. A.; Roberts, Dianna; Weber, Randal S.; Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Bell, Achim H.; Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	diana.bell@mdanderson.org	Hanna, Ehab Y/B-1593-2017	Hanna, Ehab Y/0000-0003-3241-2440	MD Anderson startup funds	This work was supported by MD Anderson startup funds (DB).	Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5; Bell D, 2016, CANCER-AM CANCER SOC, V122, P1513, DOI 10.1002/cncr.29959; Bell D, 2013, CURR OPIN OTOLARYNGO, V21, P124, DOI 10.1097/MOO.0b013e32835c05fd; Bell D, 2011, CANCER BIOL THER, V12, P569, DOI 10.4161/cbt.12.7.17008; Bell D, 2010, CANCER-AM CANCER SOC, V116, P5749, DOI 10.1002/cncr.25541; El-Naggar AK, 2017, WHO CLASSIFICATION T, P164; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Lloyd S, 2011, AM J CLIN ONCOL-CANC, V34, P76, DOI 10.1097/COC.0b013e3181d26d45; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Speight PM, 2002, ORAL DIS, V8, P229, DOI 10.1034/j.1601-0825.2002.02870.x; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553	14	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					505	512		10.1007/s00428-017-2248-2			8	Pathology	Pathology	GB8UF	WOS:000429350100021	29063189				2019-10-28	
J	Kloppel, G; La Rosa, S				Kloeppel, Gunter; La Rosa, Stefano			Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms (vol 472, pg 341, 2017)	VIRCHOWS ARCHIV			English	Correction								The authors of the above article have correct the caption for Figure 3 - namely the second sentence - clarifying the information depicted within the picture correcting the Ki67 index percentage. Figure 3 and the corrected caption can be found below.	[Kloeppel, Gunter] Tech Univ Munich, Inst Pathol, Consultat Ctr Pancreat & Endocrine Tumors, Trogerstr 18, D-81675 Munich, Germany; [La Rosa, Stefano] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, Lausanne, Switzerland	Kloppel, G (reprint author), Tech Univ Munich, Inst Pathol, Consultat Ctr Pancreat & Endocrine Tumors, Trogerstr 18, D-81675 Munich, Germany.	guenter.kloeppel@tum.de; stefano.larosa@chuv.ch					Kloppel G, 2018, VIRCHOWS ARCH, V472, P341, DOI 10.1007/s00428-017-2258-0	1	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2018	472	3					515	515		10.1007/s00428-017-2283-z			1	Pathology	Pathology	GB8UF	WOS:000429350100022	29280080	Bronze			2019-10-28	
J	Mahe, E; Pugh, T; Kamel-Reid, S				Mahe, Etienne; Pugh, Tevor; Kamel-Reid, Suzanne			T cell clonality assessment: past, present and future	JOURNAL OF CLINICAL PATHOLOGY			English	Review							RECEPTOR GENE REARRANGEMENTS; V(D)J RECOMBINATION; MYCOSIS-FUNGOIDES; IMMUNOGLOBULIN; DIAGNOSIS; LYMPHOMAS; LYMPHOPROLIFERATIONS; MECHANISMS; EVOLUTION; PRIMERS	T cell clonality testing has important clinical and research value, providing a specific and reproducible assessment of clonal diversity in T cell proliferations. Here we review the conceptual foundations of T cell clonality assays, including T cell ontogeny and T cell receptor structure and function; we also provide an introduction to T cell receptor genomics and the concept of the T cell clonotype. This is followed by a review of historical and current methods by which T cell clonality may be assayed, including current assay limitations. Some of these assay limitations have been overcome by employing next-generation sequencing (NGS)-based technologies that are becoming a mainstay of modern molecular pathology. In this vein, we provide an introduction to NGS technologies, including a review of the preanalytical, analytical and postanalytical technologies relevant to T cell clonality NGS assays.	[Mahe, Etienne] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB T2N 5A1, Canada; [Pugh, Tevor] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Kamel-Reid, Suzanne] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada	Mahe, E (reprint author), Univ Calgary, Dept Pathol & Lab Med, Calgary, AB T2N 5A1, Canada.	etienne.mahe@medportal.ca	Mahe, Etienne/P-5840-2019; Pugh, Trevor/Y-2535-2019	Mahe, Etienne/0000-0002-6559-9339; Pugh, Trevor/0000-0002-8073-5888; Kamel-Reid, Suzanne/0000-0002-4386-0292	Terry Fox Foundation/Canadian Institutes of Health Research Fellowship; Calgary Lab Services; University of Calgary Hematology Research Grants; Princess Margaret Cancer FoundationUniversity of Toronto; Canada Foundation for InnovationCanada Foundation for Innovation; Canadian Cancer Society Research Institute; Terry Fox Research Institute; Multiple Myeloma Research Foundation; Ontario Institute for Cancer Research; Pfizer CanadaPfizer	EM was supported by a Terry Fox Foundation/Canadian Institutes of Health Research Fellowship and is currently supported by Calgary Lab Services and the University of Calgary Hematology Research Grants. TP's work related to immune cell clonality testing is supported by grants from the Princess Margaret Cancer Foundation, Canada Foundation for Innovation, Canadian Cancer Society Research Institute, Terry Fox Research Institute, the Multiple Myeloma Research Foundation, and the Ontario Institute for Cancer Research. SK-R has received funding from Pfizer Canada and from the Princess Margaret Cancer Foundation.	AMAGAI M, 1990, DERMATOLOGICA, V181, P193, DOI 10.1159/000247922; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; Bagg A, 2002, J MOL DIAGN, V4, P81, DOI 10.1016/S1525-1578(10)60685-X; Behjati S, 2013, ARCH DIS CHILDHOOD-E, V98, P236, DOI 10.1136/archdischild-2013-304340; BERTNESS V, 1985, NEW ENGL J MED, V313, P534, DOI 10.1056/NEJM198508293130902; Blom B, 1999, BLOOD, V93, P3033; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bolotin DA, 2012, EUR J IMMUNOL, V42, P3073, DOI 10.1002/eji.201242517; Buermans HPJ, 2014, BBA-MOL BASIS DIS, V1842, P1932, DOI 10.1016/j.bbadis.2014.06.015; Chan D. W., 1997, Leukemia (Basingstoke), V11, P281; COSSMAN J, 1990, CRIT REV ONCOL HEMAT, V10, P267, DOI 10.1016/1040-8428(90)90035-Q; Cushman-Vokoun AM, 2010, J MOL DIAGN, V12, P787, DOI 10.2353/jmoldx.2010.090183; DOSAKA N, 1989, J INVEST DERMATOL, V93, P626, DOI 10.1111/1523-1747.ep12319746; Feng YX, 2015, GENOM PROTEOM BIOINF, V13, P4, DOI 10.1016/j.gpb.2015.01.009; Gazzola A, 2014, THER ADV HEMATOL, V5, P35, DOI 10.1177/2040620713519729; Groenen Patricia J T A, 2008, J Hematop, V1, P97, DOI 10.1007/s12308-008-0013-9; Janeway Jr C. A., 2001, IMMUNOBIOLOGY IMMUNE; Jiang H, 2006, NEW ENGL J MED, V354, P1166, DOI 10.1056/NEJMra055446; Koch U, 2011, ANNU REV CELL DEV BI, V27, P539, DOI 10.1146/annurev-cellbio-092910-154008; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Lefranc MP, 2003, LEUKEMIA, V17, P260, DOI 10.1038/sj.leu.2402637; Lefranc MP, 2003, ATLAS GENET CYTOGENE, V7, P249; Lefranc MP, 2003, ATLAS GENET CYTOGENE, V7, P252; Lefranc MP, 2003, ATLAS GENET CYTOGENE, V7, P255; Lefranc MP, 2003, ATLAS GENET CYTOGENE, V7, P245; Li SC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3793; Linnemann C, 2013, NAT MED, V19, P1534, DOI 10.1038/nm.3359; LYNCH JW, 1992, BLOOD, V79, P3293; McClure RF, 2006, LEUKEMIA, V20, P176, DOI 10.1038/sj.leu.2404049; MEIER JT, 1993, MOL CELL BIOL, V13, P1078, DOI 10.1128/MCB.13.2.1078; Mertes F, 2011, BRIEF FUNCT GENOMICS, V10, P374, DOI 10.1093/bfgp/elr033; Parra ZE, 2012, MOL BIOL EVOL, V29, P3205, DOI 10.1093/molbev/mss128; Repasky JAE, 2004, J IMMUNOL, V172, P5478, DOI 10.4049/jimmunol.172.9.5478; Rezuke WN, 1997, CLIN CHEM, V43, P1814; Sadofsky MJ, 2001, NUCLEIC ACIDS RES, V29, P1399, DOI 10.1093/nar/29.7.1399; Swerdlow SH, 2008, WHO CLASSIFICATION T; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wang MJ, 2014, IMMUNOTHERAPY-UK, V6, P1265, DOI 10.2217/imt.14.86; Yassai MB, 2009, IMMUNOGENETICS, V61, P493, DOI 10.1007/s00251-009-0383-x	41	7	7	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					195	200		10.1136/jclinpath-2017-204761			6	Pathology	Pathology	GB5HD	WOS:000429094200002	29055897	Green Published			2019-10-28	
J	Bleaney, CW; Barrow, M; Hayes, S; Ang, Y				Bleaney, Christopher William; Barrow, Mickhaiel; Hayes, Stephen; Ang, Yeng			The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus	JOURNAL OF CLINICAL PATHOLOGY			English	Review							CADHERIN GENE CDH1; GASTRIC-CANCER; PREOPERATIVE CHEMORADIATION; PROGNOSTIC VALUE; MUTATIONS; CARCINOMA; HISTOLOGY	Aim To review the current understanding of signet-ring type oesophageal adenocarcinoma including evidence for prognosis. Methods We conducted a literature search of nine healthcare literature databases for articles detailing the biology and clinical outcomes of signet-ring cell adenocarcinoma of the oesophagus. The impact of signet-ring cell morphology was analysed and detailed in written text and tabular format. Current understanding of the biology of signet-ring cell adenocarcinoma of the oesophagus was summarised. Results Signet-ring cell carcinoma was represented in 7.61% of the 18 989 cases of oesophageal carcinoma reviewed in multiple studies. The presence of signet-ring cells conferred a worse prognosis and these tumours responded differently to conventional treatments as compared with typical adenocarcinoma. Little is known about the biological features of signet-ring cell adenocarcinoma of the oesophagus. Work in gastric lesions has identified potential targets for future treatments such as CDH1 and RHOA genes. Categorisation of signet-ring cell carcinomas by the proportion of signet-ring cells within tumours differs among clinicians despite WHO criteria for classification. The current UK guidelines for histopathological reporting of oesophageal tumours do not emphasise the importance of identifying signet-ring cells. Conclusion The presence of signet-ring cells in oesophageal adenocarcinomas leads to poorer clinical outcomes. Current understanding of signet-ring cell biology in oesophageal cancer is limited.	[Bleaney, Christopher William; Hayes, Stephen; Ang, Yeng] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Barrow, Mickhaiel] Manchester Univ NHS Fdn Trust, Dept Histopathol, Manchester, Lancs, England; [Hayes, Stephen] Salford Royal NHS Fdn Trust, Dept Histopathol, Salford, Lancs, England; [Ang, Yeng] Salford Royal NHS Fdn Trust, Dept Gastroenterol, Salford M6 8HD, Lancs, England	Ang, Y (reprint author), Salford Royal NHS Fdn Trust, Dept Gastroenterol, Salford M6 8HD, Lancs, England.	yeng.ang@srft.nhs.uk					American Cancer Society, 2016, SURV RAT CANC ES STA; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BERENSON MM, 1978, CANCER, V41, P554, DOI 10.1002/1097-0142(197802)41:2<554::AID-CNCR2820410223>3.0.CO;2-V; Cancer Research UK, 2016, OES CANC SURV STAT; Chirieac LR, 2005, CLIN CANCER RES, V11, P2229, DOI 10.1158/1078-0432.CCR-04-1840; Edgren G, 2013, GUT, V62, P1406, DOI 10.1136/gutjnl-2012-302412; Enlow JM, 2013, ANN THORAC SURG, V96, P1927, DOI 10.1016/j.athoracsur.2013.06.047; Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237; Graziano F, 2003, ANN ONCOL, V14, P1705, DOI 10.1093/annonc/mdg486; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; JASS JR, 1990, CANCER, V66, P2162, DOI 10.1002/1097-0142(19901115)66:10<2162::AID-CNCR2820661020>3.0.CO;2-N; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Moinova H, 2012, CANCER EPIDEM BIOMAR, V21, P594, DOI 10.1158/1055-9965.EPI-11-1060; Nafteux PR, 2014, ANN SURG, V260, P1023, DOI 10.1097/SLA.0000000000000689; Patel VR, 2014, ANN THORAC SURG, V98, P1064, DOI 10.1016/j.athoracsur.2014.04.099; Piessen G, 2014, EJSO-EUR J SURG ONC, V40, P1746, DOI 10.1016/j.ejso.2014.04.019; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Royal College of Pathologists, 2007, STAND DAT REP CANC D; Schmidt T, 2014, BRIT J CANCER, V110, P1712, DOI 10.1038/bjc.2014.94; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Terada T, 2013, INT J CLIN EXP PATHO, V6, P191; Turner KO, 2015, ALIMENT PHARM THER, V42, P1222, DOI 10.1111/apt.13395; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Yendamuri S, 2013, CANCER-AM CANCER SOC, V119, P3156, DOI 10.1002/cncr.28099; Yoon HH, 2010, MAYO CLIN PROC, V85, P1080, DOI 10.4065/mcp.2010.0421	25	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					201	206		10.1136/jclinpath-2017-204863			6	Pathology	Pathology	GB5HD	WOS:000429094200003	29212656				2019-10-28	
J	Raposo, TP; Ebili, HO; Ilyas, M				Raposo, Teresa P.; Ebili, Henry O.; Ilyas, Mohammad			A refined method to study gene dosage changes in vitro using CRISPR/Cas9	JOURNAL OF CLINICAL PATHOLOGY			English	Article							COLORECTAL-CANCER; MUTATION DETECTION; CAS9; RNA; DNA; DELIVERY; PROTEIN; SYSTEM; CELLS	Aims Gene dosage can have a major impact on cell biology, although, hitherto, it has been difficult to study using in vitro models. We sought to refine and accelerate the development of 'gene dosage' models through using CRISPR/Cas9 (a gene editing technology) for sequential knockout of gene alleles. Methods Our method involved (1) using Cas9 nuclease mRNA rather than expression plasmids, (2) using a fluorescently labelled FAM-6 tracr complexed with guide RNA and (3) using high-resolution melting (HRM) analysis to screen for mutations. HCT116 cells, wild-type for TP53, were transfected with different molarities of FAM-6 tracr-labelled and guide RNA targeting different exons of TP53 and selected by fluorescence-activated cell sorting. Single-cell colonies were then isolated, expanded and tested for mutation in the targeted region by PCR/HRM. Results Out of 32 clones tested, 12 have shown aberrant melting by HRM, giving a targeting efficiency of 37.5%. One clone was sequenced and a heterozygous mutation found - in this case comprising a single base deletion in exon 3. mRNA sequencing confirmed the mutation was expressed, and western blotting for p53 showed the presence of both wild-type and truncated protein bands. Changes in expression of MDM-2 isoforms suggested a functional effect of the induced TP53 mutation. Conclusions We have developed an in vitro model to study TP53 gene dosage effects. The protocol is efficient and applicable to any gene. Importantly, we have used Cas9 mRNA and labelled tracr/guide RNA to isolate likely mutated cells and HRM for rapid mutation detection.	[Raposo, Teresa P.; Ebili, Henry O.; Ilyas, Mohammad] Univ Nottingham, Fac Med & Hlth Sci, Div Canc & Stem Cells, Nottingham, England; [Raposo, Teresa P.; Ebili, Henry O.; Ilyas, Mohammad] Univ Nottingham, Nottingham Mol Pathol Node, Nottingham, England; [Ebili, Henry O.] Olabisi Onabanjo Univ, Dept Morbid Anat & Histopathol, Ago Iwoye, Nigeria	Raposo, TP (reprint author), Univ Nottingham, Fac Med & Hlth Sci, Div Canc & Stem Cells, Nottingham, England.	msztp2@nottingham.ac.uk		Raposo, Teresa/0000-0003-4033-8498			Cho KH, 2006, FEBS LETT, V580, P3665, DOI 10.1016/j.febslet.2006.05.053; Ebili HO, 2017, J CLIN PATHOL, V70, P702, DOI 10.1136/jclinpath-2016-204264; Fadhil W, 2010, J CLIN PATHOL, V63, P134, DOI 10.1136/jcp.2009.070508; Findlay GM, 2014, NATURE, V513, P120, DOI 10.1038/nature13695; Garneau JE, 2010, NATURE, V468, P67, DOI 10.1038/nature09523; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kelley ML, 2016, J BIOTECHNOL, V233, P74, DOI 10.1016/j.jbiotec.2016.06.011; Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113; Kouranova E, 2016, HUM GENE THER, V27, P464, DOI 10.1089/hum.2016.009; Liang XQ, 2015, J BIOTECHNOL, V208, P44, DOI 10.1016/j.jbiotec.2015.04.024; Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103; Long KB, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26860; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Naccarati A, 2012, MUTAGENESIS, V27, P211, DOI 10.1093/mutage/ger067; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sampson TR, 2014, BIOESSAYS, V36, P34, DOI 10.1002/bies.201300135; Vossen RHAM, 2009, HUM MUTAT, V30, P860, DOI 10.1002/humu.21019; Yu X, 2016, BIOTECHNOL LETT, V38, P919, DOI 10.1007/s10529-016-2064-9; Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081	21	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					207	214		10.1136/jclinpath-2017-204558			8	Pathology	Pathology	GB5HD	WOS:000429094200004		Green Accepted			2019-10-28	
J	Phang, KC; Akhter, A; Tizen, NMS; Abd Rahman, F; Azma, RZ; Elyamany, G; Shabani-Rad, MT; Masir, N; Mansoor, A				Kean-Chang Phang; Akhter, Ariz; Tizen, Nur Maya Sabrina; Abd Rahman, Faridah; Azma, Raja Zahratul; Elyamany, Ghaleb; Shabani-Rad, Meer-Taher; Masir, Noraidah; Mansoor, Adnan			Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DIAGNOSTIC IMMUNOHISTOCHEMISTRY RECOMMENDATIONS; PARAFFIN-EMBEDDED TISSUE; GENE-EXPRESSION; MOLECULAR CLASSIFICATION; SURVIVAL; SUBTYPES; STANDARDIZATION; ASSOCIATION; MICROARRAY; THERAPY	Aims The cell of origin (COO) based molecular characterisation into germinal centre B-cell-like (GCB) and activated B-cell-like (ABC) subtypes are central to the pathogenesis and clinical course in diffuse large B-cell lymphoma (DLBCL). Globally, clinical laboratories employ pragmatic but less than ideal immunohistochemical (IHC) assay for COO classification. Novel RNA-based platforms using routine pathology samples are emerging as new gold standard and offer unique opportunities for assay standardisation for laboratories across the world. We evaluated our IHC protocols against RNA-based technologies to determine concordance; additionally, we gauged the impact of preanalytical variation on the performance of Lymph2Cx assay. Methods Diagnostic biopsies (n=104) were examined for COO classification, employing automated RNA digital quantification assay (Lymph2Cx). Results were equated against IHC-based COO categorisation. Assay performance was assessed through its impact on overall survival (OS). Results 96 (92%) informative samples were labelled as GCB (38/96; 40%) and non-GCB (58/96; 60%) by IHC evaluation. Lymph2Cx catalogued 36/96 (37%) samples as GCB, 45/96 (47%) as ABC and 15/96 (16%) as unclassified. Lymph2Cx being reference, IHC protocol revealed sensitivity of 81% for ABC and 75% for GCB categorisation and positive predictive value of 81% versus 82%, respectively. Lymph2Cx-based COO classification performed superior to Hans algorithm in predicting OS (log rank test, p=0.017 vs p=0.212). Conclusions Our report show that current IHC-based protocols for COO classification of DLBCL at UKM Malaysia are in line with previously reported results and marked variation in preanalytical factors do not critically impact Lymph2Cx assay quality.	[Kean-Chang Phang; Tizen, Nur Maya Sabrina; Abd Rahman, Faridah; Azma, Raja Zahratul; Masir, Noraidah] Univ Kebangsaan Malaysia, Dept Pathol, Kuala Lumpur, Malaysia; [Akhter, Ariz; Elyamany, Ghaleb; Shabani-Rad, Meer-Taher; Mansoor, Adnan] Univ Calgary, Dept Pathol & Lab Med, CLS, Div Hematol & Transfus Med, Calgary, AB, Canada	Mansoor, A (reprint author), Univ Calgary, Dept Pathol & Lab Med, CLS, Div Hematol & Transfus Med, Calgary, AB, Canada.	adnan.mansoor@cls.ab.ca	Laim, Nur Maya Sabrina Tizen/C-5421-2017; Sabudin, Raja Zahratul Azma Raja/W-7837-2019		UKM [UKM1.5.3.5/244/DIP-2012-10/3]; Alberta Cancer Foundation [25999]	K-CP, NMST, FAR and NM were supported by UKM grant no (UKM1.5.3.5/244/DIP-2012-10/3) while AA was supported by research grant from Alberta Cancer Foundation (grant # 25999).	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barton S, 2012, ONCOLOGIST, V17, P1562, DOI 10.1634/theoncologist.2012-0218; Batlle-Lopez A, 2016, ONCOTARGET, V7, P18036, DOI 10.18632/oncotarget.7495; Chan WC, 1997, BLOOD, V89, P3909; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; Coiffier B, 2001, CURR OPIN ONCOL, V13, P325, DOI 10.1097/00001622-200109000-00003; de Jong D, 2007, J CLIN ONCOL, V25, P805, DOI 10.1200/JCO.2006.09.4490; Gutierrez-Garcia G, 2011, BLOOD, V117, P4836, DOI 10.1182/blood-2010-12-322362; Haarer CF, 2006, ARCH PATHOL LAB MED, V130, P1819; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hicks DG, 2012, BIOTECH HISTOCHEM, V87, P14, DOI 10.3109/10520295.2011.591832; Lawrie CH, 2012, HISTOPATHOLOGY, V61, P18, DOI 10.1111/j.1365-2559.2012.04179.x; Meyer PN, 2011, J CLIN ONCOL, V29, P200, DOI 10.1200/JCO.2010.30.0368; Milanes-Yearsley M, 2002, MODERN PATHOL, V15, P1366, DOI 10.1097/01.MP.0000036345.18944.22; Nowakowski Grzegorz S, 2015, Am Soc Clin Oncol Educ Book, pe449, DOI 10.14694/EdBook_AM.2015.35.e449; O'Malley DP, 2015, ARCH PATHOL LAB MED, V139, P1094, DOI 10.5858/arpa.2014-0451-CP; Puvvada S, 2013, CANCER GENET-NY, V206, P257, DOI 10.1016/j.cancergen.2013.07.003; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Scott DW, 2015, J CLIN ONCOL, V33, P2848, DOI 10.1200/JCO.2014.60.2383; Scott DW, 2014, BLOOD, V123, P1214, DOI 10.1182/blood-2013-11-536433; Sehn LH, 2015, BLOOD, V125, P22, DOI 10.1182/blood-2014-05-577189; Swerdlow SH, 2008, WHO CLASSIFICATION T, P229; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thieblemont C, 2011, J CLIN ONCOL, V29, P4079, DOI 10.1200/JCO.2011.35.4423; Torlakovic EE, 2015, APPL IMMUNOHISTO M M, V23, P1, DOI 10.1097/PAI.0000000000000163; Torlakovic EE, 2014, APPL IMMUNOHISTO M M, V22, P241, DOI 10.1097/PAI.0000000000000069; Torlakovic EE, 2010, AM J CLIN PATHOL, V133, P354, DOI 10.1309/AJCPDYZ1XMF4HJWK; Veelken H, 2007, ANN ONCOL, V18, P931, DOI 10.1093/annonc/mdm012; Visco C, 2012, LEUKEMIA, V26, P2103, DOI 10.1038/leu.2012.83; Wang GT, 2014, BIOINFORMATICS, V30, P2377, DOI 10.1093/bioinformatics/btu296; Xue XM, 2015, LAB INVEST, V95, P113, DOI 10.1038/labinvest.2014.136	31	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					215	220		10.1136/jclinpath-2017-204548			6	Pathology	Pathology	GB5HD	WOS:000429094200005	28775174				2019-10-28	
J	Arora, K; Bal, M; Shih, A; Moy, A; Zukerberg, L; Brown, I; Liu, XL; Kelly, P; Oliva, E; Mullen, J; Ahn, S; Kim, KM; Deshpande, V				Arora, Kshitij; Bal, Munita; Shih, Angela; Moy, Andrea; Zukerberg, Lawerence; Brown, Ian; Liu, Xiuli; Kelly, Paul; Oliva, Esther; Mullen, John; Ahn, Soomin; Kim, Kyoung-Mee; Deshpande, Vikram			Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article							HEPATOCELLULAR-CARCINOMA; HEPATOID ADENOCARCINOMA; DIFFERENTIAL-DIAGNOSIS; GASTRIC CARCINOMAS; ARGINASE-1; HEPPAR-1; FEATURES; STOMACH; MARKERS; CANCER	Aims This multi-institutional study and a re-evaluation of the TCGA cohort explores the morphological spectrum, genetics and outcome of GI (gastrointestinal) hepatoid tumours, tumours expressing alpha-fetoprotein (AFP) and fetal-type (FT) GI adenocarcinomas. Methods 44 tumours with evidence of hepatocellular differentiation were evaluated for morphology as well as by immunohistochemistry for AFP, HepPar1, glypican-3 and arginase-1 and by in situ hybridisation for albumin. Three categories were defined: type I (hepatoid: morphological evidence of hepatocellular differentiation), type II (FT GI adenocarcinoma: tubular profiles and subnuclear vacuolisation, resembling fetal intestine) and type III: positive for at least two hepatocytespecific markers but lacking morphological evidence of hepatocellular differentiation. GI adenocarcinomas in the TCGA cohort were also evaluated (n=829). Results 18 cases were classified as type I, 19 as FT GI adenocarcinomas and 7 as type III (resembling conventional gastrointestinal carcinomas). Serum AFP was elevated in 92% of cases. 93% of tumours were positive for glypican-3, 90% for albumin and 89% for AFP. Arginase-1 was restricted to 35% of type 1 tumours. TCGA gastric tumours with elevated AFP expression showed morphological features of FT GI adenocarcinoma (70%) and were exclusively MSI stable. TCGA gastric adenocarcinomas with high AFP expression showed inferior survival on univariate and multivariate analysis. Conclusions FT GI adenocarcinomas show a distinctive morphological and immunohistochemical profile. Gastric adenocarcinomas with elevated expression of AFP morphologically resemble FT GI adenocarcinomas, demonstrate aggressive behaviour, independent of grade and stage, and a distinct genetic profile.	[Arora, Kshitij; Shih, Angela; Moy, Andrea; Zukerberg, Lawerence; Oliva, Esther; Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Bal, Munita] Tata Mem Hosp, Dept Pathol, Bombay, Maharashtra, India; [Brown, Ian] Envoi Pathol Unit, Kelvin Grove, Qld, Australia; [Liu, Xiuli] Cleveland Clin, Cleveland, OH 44106 USA; [Kelly, Paul] Royal Victoria Hosp, Inst Pathol, Belfast, Antrim, Ireland; [Mullen, John] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Ahn, Soomin; Kim, Kyoung-Mee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea	Deshpande, V (reprint author), Dept Pathol 55, Fruit St Warren 2, Boston, MA 02478 USA.	vdeshpande@partners.org	Brown, Ian/R-7763-2016	Brown, Ian/0000-0001-6329-2547			AIZAWA K, 1994, INT J CANCER, V58, P430, DOI 10.1002/ijc.2910580321; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; ISHIKURA H, 1985, CANCER-AM CANCER SOC, V56, P840, DOI 10.1002/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO;2-E; Kelly PJ, 2012, HISTOPATHOLOGY, V60, P1012, DOI 10.1111/j.1365-2559.2011.04129.x; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kuo PC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0586-6; Lagana S, 2015, ARCH PATHOL LAB MED, V139, P791, DOI 10.5858/arpa.2013-0249-OA; Liu XW, 2010, AM J SURG PATHOL, V34, P1465, DOI 10.1097/PAS.0b013e3181f0a873; Lugli A, 2004, AM J CLIN PATHOL, V122, P721, DOI 10.1309/KC09YTF2M4DLUY06; MOTOYAMA T, 1993, ACTA PATHOL JAPON, V43, P654; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NAGAI E, 1993, CANCER, V72, P1827, DOI 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8; Osada M, 2014, HUM PATHOL, V45, P1243, DOI 10.1016/j.humpath.2014.02.003; Radwan NA, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-149; Routhier CA, 2013, HUM PATHOL, V44, P2563, DOI 10.1016/j.humpath.2013.06.018; Sang W, 2015, TUMOR BIOL, V36, P3881, DOI 10.1007/s13277-014-3030-6; Su JS, 2013, WORLD J GASTROENTERO, V19, P321, DOI 10.3748/wjg.v19.i3.321; The International Agency for Research on Cancer, 2010, WHO CLASSIFICATION T; Timek DT, 2012, AM J CLIN PATHOL, V138, P203, DOI 10.1309/AJCPK1ZC9WNHCCMU; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Yan BC, 2010, AM J SURG PATHOL, V34, P1147, DOI 10.1097/PAS.0b013e3181e5dffa	21	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					221	227		10.1136/jclinpath-2017-204535			7	Pathology	Pathology	GB5HD	WOS:000429094200006	28814568				2019-10-28	
J	Bag, S; Dutta, D; Chaudhary, A; Sing, BC; Pal, M; Ray, AK; Banerjee, R; Paul, RR; Basak, A; Das, AK; Chatterjee, J				Bag, Swarnendu; Dutta, Debabrata; Chaudhary, Amrita; Sing, Bidhan Chandra; Pal, Mousumi; Ray, Ajoy Kumar; Banerjee, Rita; Paul, Ranjan Rashmi; Basak, Amit; Das, Amit Kumar; Chatterjee, Jyotirmoy			Identification of alpha-enolase as a prognostic and diagnostic precancer biomarker in oral submucous fibrosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; CANCER-DETECTION; E-CADHERIN; LESIONS; PROGRESSION; EXPRESSION; PROTEOMICS; DISCOVERY; MARKERS; PROLIFERATION	Aims Diagnostic ambiguities regarding the malignant potentiality of oral submucous fibrosis (OSF), an oral precancerous condition having dysplastic and non-dysplastic isoforms are the major failure for early intervention of oral squamous cell carcinoma (OSCC) patients. Our goal is to identify proteomic signatures from biopsies that can be used as precancer diagnostic marker for patient suffering from OSF. Methods The high throughput techniques adopting de novo peptide sequencing (1D SDS-PAGE coupled nanoLC MALDI tandem mass spectrometry (MS/MS)-based peptide mass fingerprint), immunohistochemistry (IHC), Western blot (WB) and real-time PCR (RT-PCR) analysis are considered for such biomarker identification and multilevel validations. Results Alpha-enolase is identified as an overexpressed protein in biopsies of oral submucous fibrosis with dysplasia (OSFWD) compared with oral submucous fibrosis without dysplasia (OSFWT) and normal oral mucosa (NOM). Total proteome analysis of an overexpressed protein band around 47 kDa of OSFWD identifies 334 peptides corresponding to 61 human proteins. Among them alpha-enolase is identified as a prime protein with highest number of peptides (44 out of 334 peptides) and sequence coverage (66.4%). Furthermore, RT-PCR, WB and IHC analysis also show mRNA and tissue level upregulation of alpha-enolase in OSFWD validating alpha-enolase as precancer marker. Conclusions This study for the first time identifies and validates alpha-enolase as a novel biomarker for early diagnosis of malignant potentiality of OSF. Hence, the identified protein marker, alpha-enolase can help in early therapeutic intervention of OSF patients leading to the reduction of patient's pain, treatment cost and enhancement of patient's quality of life.	[Bag, Swarnendu] Natl Inst Technol Sikkim, Dept Biotechnol, South Sikkim, India; [Dutta, Debabrata; Das, Amit Kumar] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India; [Chaudhary, Amrita; Chatterjee, Jyotirmoy] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India; [Sing, Bidhan Chandra] Indian Inst Technol Kharagpur, Dept Cent Res Facil, Kharagpur, W Bengal, India; [Pal, Mousumi; Paul, Ranjan Rashmi] Guru Nanak Inst Dent Sci & Res, Dept Oral & Maxillofacial Pathol, Kolkata, India; [Ray, Ajoy Kumar] Indian Inst Engn Sci & Technol, Ctr Healthcare Sci & Technol, Sibpur, India; [Banerjee, Rita] Dept Sci & Technol, New Delhi, India; [Basak, Amit] Indian Inst Technol Kharagpur, Dept Chem, Kharagpur, W Bengal, India	Das, AK (reprint author), Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India.; Chatterjee, J (reprint author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur, W Bengal, India.	amitk@hijli.iitkgp.ernet.in; jchatterjee.iitkgp@gmail.com			IAN project of IIT, Kharagpur, MHRD, Govt. of India [IIT/SRIC/SMST/IAN/2013-14/222]	This work was carried out with financial assistance from the IAN project (Sanction No.: IIT/SRIC/SMST/IAN/2013-14/222) of IIT, Kharagpur, MHRD, Govt. of India.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; ALBO D, 1994, ANN PLAS SURG, V32, P588, DOI 10.1097/00000637-199406000-00005; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Bag S, 2015, J CLIN PATHOL, V68, P605, DOI 10.1136/jclinpath-2014-202791; Bag Swarnendu, 2013, J Pathol Inform, V4, P35, DOI 10.4103/2153-3539.124006; Brinkman BMN, 2006, CURR OPIN ONCOL, V18, P228, DOI 10.1097/01.cco.0000219250.15041.f8; Bunai K, 2005, J CHROMATOGR B, V815, P227, DOI 10.1016/j.jchromb.2004.08.030; Capello M, 2011, FEBS J, V278, P1064, DOI 10.1111/j.1742-4658.2011.08025.x; Das RK, 2012, BIOTECHNOL J, V7, P602, DOI 10.1002/biot.201100013; Das RK, 2010, J CLIN PATHOL, V63, P894, DOI 10.1136/jcp.2010.078964; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Escobar-Hoyos LF, 2014, MODERN PATHOL, V27, P621, DOI 10.1038/modpathol.2013.166; Feller L L J, 2012, J CANC THERAPY, V3, P263, DOI DOI 10.4236/JCT.2012.34037; FLETCHER L, 1978, DEV BIOL, V65, P462, DOI 10.1016/0012-1606(78)90041-6; FLETCHER L, 1976, BIOCHIM BIOPHYS ACTA, V452, P245, DOI 10.1016/0005-2744(76)90077-2; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guillaud M, 2008, CANCER RES, V68, P3099, DOI 10.1158/0008-5472.CAN-07-2113; Kim CS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3130323; Kocher T, 2007, NAT METHODS, V4, P807, DOI 10.1038/NMETH1093; Kocher T, 2012, NAT PROTOC, V7, P882, DOI 10.1038/nprot.2012.036; Lei ZT, 2011, J BIOL CHEM, V286, P25435, DOI 10.1074/jbc.R111.238691; Leinonen MK, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7789; Li Y, 2004, CLIN CANCER RES, V10, P8442, DOI 10.1158/1078-0432.CCR-04-1167; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Lingen MW, 2008, ORAL ONCOL, V44, P10, DOI 10.1016/j.oraloncology.2007.06.011; Massano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038; Messadi DV, 2013, INT J ORAL SCI, V5, P59, DOI 10.1038/ijos.2013.24; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Mutter GL, 2000, J PATHOL, V190, P462, DOI 10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D; Mutter GL, 2002, J CLIN PATHOL, V55, P326, DOI 10.1136/jcp.55.5.326; Napier SS, 2008, J ORAL PATHOL MED, V37, P1, DOI 10.1111/j.1600-0714.2007.00579.x; Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195; NIKLINSKI J, 1995, EUR J CANCER PREV, V4, P129, DOI 10.1097/00008469-199504000-00002; PAHLMAN S, 1984, TUMOUR BIOL, V5, P119; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; RAJENDRAN R, 1994, B WORLD HEALTH ORGAN, V72, P985; Reichart P A, 2001, Clin Oral Investig, V5, P207, DOI 10.1007/s00784-001-0132-5; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; ROYDS JA, 1982, J PATHOL, V137, P37, DOI 10.1002/path.1711370105; Schliephake H, 2003, INT J ORAL MAX SURG, V32, P233, DOI 10.1054/ijom.2002.0383; Seidler J, 2010, PROTEOMICS, V10, P634, DOI 10.1002/pmic.200900459; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Song Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-65; Takashima M, 2005, PROTEOMICS, V5, P1686, DOI 10.1002/pmic.200401022; Wang B, 2013, CHIN J CANCER, V32, P614, DOI 10.5732/cjc.012.10219; Wu JY, 2010, ORAL ONCOL, V46, P226, DOI 10.1016/j.oraloncology.2010.01.007; Yang YH, 2005, J ORAL PATHOL MED, V34, P596, DOI 10.1111/j.1600-0714.2005.00266.x; Yardimci Gurkan, 2014, World J Clin Cases, V2, P866, DOI 10.12998/wjcc.v2.i12.866; Yasui Y, 2003, BIOSTATISTICS, V4, P449, DOI 10.1093/biostatistics/4.3.449; Zhang LW, 2012, CANCER PREV RES, V5, P1081, DOI 10.1158/1940-6207.CAPR-12-0173	50	3	3	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					228	238		10.1136/jclinpath-2017-204430			11	Pathology	Pathology	GB5HD	WOS:000429094200007	28821582				2019-10-28	
J	Beck, SC; Huissoon, AP; Collins, D; Richter, AG; Krishna, MT				Beck, Sarah C.; Huissoon, Aarnoud P.; Collins, Donna; Richter, Alex G.; Krishna, Mamidipudi T.			The concordance between component tests and clinical history in British adults with suspected pollen-food syndrome to peanut and hazelnut	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DIAGNOSTIC-VALUE; ALLERGY; SENSITIZATION; IGE; PREVALENCE; GUIDELINES; SYMPTOMS; COR	Background Mild oropharyngeal symptoms to peanut/hazelnut occur in similar to 30% of patients with pollen-food syndrome (PFS). Component tests are considered a useful adjunct to the diagnosis and may help differentiate PFS from those at a risk of anaphylaxis due to storage protein/lipid transfer protein (LTP) sensitisation. Aims To assess concordance between component tests and clinical history in suspected PFS to peanut/hazelnut in a specialist clinic. Methods Adult patients were classified into PFS (group 1, n=69) and PFS with mild systemic symptoms (group 2, n=45) based on clinical history. Specific IgE (sIgE) of >= 0.35 kUA/L was considered positive as per manufacturers' recommendation. Kappa (kappa) inter-rater agreement was calculated for concordance between clinical classification and test profiles. Results Group 1 hazelnut: 85% monosensitised to Cor a1, 12% to storage protein/s or LTP and 3% negative to all components. Group 1 peanut: 41% monosensitised to Ara h8, 44% to storage protein/s or +/- LTP and 15% negative to all components. Group 2 hazelnut: 67% monosensitised to Cor a1, 16% sensitised to storage protein/s and 17% negative to all components. Group 2 peanut: 19% monosensitised to Ara h8, 62% sensitised to storage protein/s and/or LTP and 19% negative to all components. SIgE to Ara h8 and Cor a1 were greater in group 1 versus group 2: (median (IQR) kUA/L; hazelnut: 12.1 (7.8-25.2) vs 2.4 (0.36-6.3), p<0.001; peanut: 2.4 (0.10-21.1) vs 0.3 (0-3), p<0.01)). Conclusion Concordance between component tests and clinical history for adults with PFS was good for hazelnut (kappa=0.63) but poor for peanut (kappa=-0.12). Food challenges are warranted in discordant cases for an accurate diagnosis.	[Beck, Sarah C.; Huissoon, Aarnoud P.; Collins, Donna; Krishna, Mamidipudi T.] Birmingham Heartlands Hosp, Heart England NHS Fdn Trust, Dept Allergy & Immunol, Birmingham, W Midlands, England; [Richter, Alex G.] Queen Elizabeth Hosp, Dept Immunol, Birmingham, W Midlands, England; [Richter, Alex G.; Krishna, Mamidipudi T.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England	Beck, SC (reprint author), Birmingham Heartlands Hosp, Dept Allergy & Immunol, Bordesley Green East, Birmingham B9 5SS, England.	sarah.beck@heartofengland.nhs.uk					Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Buyuktiryaki B, 2016, J ALLER CL IMM-PRACT, V4, P265, DOI 10.1016/j.jaip.2015.12.012; Calvani M, 2012, PEDIAT ALLERG IMM-UK, V23, P755, DOI 10.1111/pai.12016; Dreborg S, 1998, ALLERGY, V53, P88, DOI 10.1111/j.1398-9995.1998.tb05005.x; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P720, DOI 10.1111/cea.12412; Krishna MT, 2016, CLIN EXP ALLERGY, V46, P172, DOI 10.1111/cea.12641; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Martinet J, 2016, INT ARCH ALLERGY IMM, V169, P216, DOI 10.1159/000446181; Masthoff LJ, 2012, ALLERGY, V67, P521, DOI 10.1111/j.1398-9995.2011.02766.x; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Royal College of Physicians, 2003, ALL UNM NEED; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Skypala IJ, 2013, CLIN EXP ALLERGY, V43, P928, DOI 10.1111/cea.12104; Skypala IJ, 2011, CLIN EXP ALLERGY, V41, P1001, DOI 10.1111/j.1365-2222.2011.03759.x; Suratannon N, 2013, PEDIAT ALLERG IMM-UK, V24, P665, DOI 10.1111/pai.12125; Vieths S, 2002, ANN NY ACAD SCI, V964, P47	17	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					239	245		10.1136/jclinpath-2017-204573			7	Pathology	Pathology	GB5HD	WOS:000429094200008	28780515				2019-10-28	
J	Li, ZH; Wong, KY; Chan, GCF; Chim, CS				Li, Zhenhai; Wong, Kwan Yeung; Chan, Godfrey Chi-fung; Chim, Chor Sang			Epigenetic silencing of LPP/miR-28 in multiple myeloma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DNA METHYLATION; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; MICRORNAS; CANCER; GENES; HYPERMETHYLATION; PROLIFERATION; DYSREGULATION; TRANSCRIPTION	Aims miR-28-5-is a tumour suppressor microRNA implicated in cancers. As a CpG island is absent in miR-28-5-but present in its host gene, LPP (LIM domain containing preferred translocation partner in lipoma), we hypothesized that miR-28-5p is epigenetically silenced by promoter DNA methylation of its host gene in multiple myeloma. Methods Methylation-specific PCR, verified by quantitative bisulfite pyrosequencing, was employed to study methylation of LPP/miR-28 in healthy controls (n=10), human myeloma cell lines (HMCLs) (n=15), and primary myeloma marrow samples at diagnosis (n=49) and at relapse (n=18). Quantitative reverse transcription PCR was used to investigate expression of miR-28-5p, LPP and CCND1. Results LPP/miR-28 was completely unmethylated in all healthy controls and 12 (80%) HMCLs, but partially methylated in three (20%) HMCLs. Methylation of LPP/miR-28 correlated with low expression of miR-285p (p=0.012) and LPP (p=0.037) in HMCLs. In RPMI-8226R cells, in which LPP/miR-28 was partially methylated, 5-AzadC treatment led to demethylation of LPP/miR-28 and re-expression of both miR-28-5p (p=0.0007) and LPP (p=0.0007), whereas continuous culture without 5-AzadC restored LPP/miR-28 methylation and reduced expression of both miR-28-5p (p=0.0013) and LPP (p=0.0025). Moreover, a known miR-28-5p target, CCND1, was expressed at higher levels in HMCLs with LPP/miR-28 methylation than those without, consistent with a tumour suppressor role of miR-28-5p in myeloma. However, in primary samples, LPP/miR-28 was methylated in two (4.1%) at diagnosis, whereas none at relapse. Conclusions This is the first report of epigenetic regulation of the intronic miR-28-5p expression by promoter DNA methylation of its host gene, hence warrants further study in different cancers.	[Li, Zhenhai; Wong, Kwan Yeung; Chim, Chor Sang] Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China; [Chan, Godfrey Chi-fung] Univ Hong Kong, Queen Mary Hosp, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	Chim, CS (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China.	jcschim@hku.hk		Chim, CS/0000-0003-2427-915X	Hong Kong Blood Cancer Foundation; NSFCNational Natural Science Foundation of China [81470369]	This work was supported by Hong Kong Blood Cancer Foundation and NSFC (81470369) awarded to CSC.	Almeida MI, 2012, GASTROENTEROLOGY, V142, P886, DOI 10.1053/j.gastro.2011.12.047; Andersen M, 2015, ANTICANCER RES, V35, P6223; Athanasiou E, 2001, AM J CLIN PATHOL, V116, P535; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Chi JX, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-23; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Girardot M, 2015, ONCOGENE, V34, P1323, DOI 10.1038/onc.2014.60; Girardot M, 2010, BLOOD, V116, P437, DOI 10.1182/blood-2008-06-165985; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188; Kyle RA, 2010, LEUKEMIA, V24, P1121, DOI 10.1038/leu.2010.60; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; Lim EL, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0568-y; Liu RF, 2013, CANCER LETT, V329, P164, DOI 10.1016/j.canlet.2012.10.027; Lujambio A, 2007, CELL CYCLE, V6, P1455; Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122; Ng SB, 2011, BLOOD, V118, P4919, DOI 10.1182/blood-2011-07-364224; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Schneider C, 2014, P NATL ACAD SCI USA, V111, P8185, DOI 10.1073/pnas.1322466111; Shi XM, 2015, MOL CELL BIOCHEM, V408, P283, DOI 10.1007/s11010-015-2506-z; Wang GH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013798; Wang LQ, 2016, ONCOTARGET, V7, P946; Wang LQ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-173; Wong KY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0444-8; Wong KY, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-122; Wong KY, 2012, CARCINOGENESIS, V33, P1629, DOI 10.1093/carcin/bgs212; Wong KY, 2011, BLOOD, V118, P5901, DOI 10.1182/blood-2011-06-361022; Wong KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019027; Wong KY, 2011, EPIGENOMICS-UK, V3, P83, DOI 10.2217/EPI.10.74; Wong KY, 2011, BRIT J HAEMATOL, V154, P569, DOI 10.1111/j.1365-2141.2011.08782.x	40	3	4	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					253	258		10.1136/jclinpath-2017-204501			6	Pathology	Pathology	GB5HD	WOS:000429094200010	28775176	Green Published, Other Gold			2019-10-28	
J	Urrechaga, E; Boveda, O; Aguirre, U				Urrechaga, Eloisa; Boveda, Oihane; Aguirre, Urko			Role of leucocytes cell population data in the early detection of sepsis	JOURNAL OF CLINICAL PATHOLOGY			English	Article							INTENSIVE-CARE; SEPTIC SHOCK; NEUTROPHIL; DEFINITIONS; GUIDELINES; INFECTION; MORTALITY; ROUTINE; MARKERS; UTILITY	Aims The cell population data (CPD) parameters reported by XN analyser (Sysmex, Kobe, Japan) reflect the size and internal structure of leucocytes. We aimed to assess the clinical utility of these parameters as biomarkers for the early diagnosis of sepsis. Methods The study group (G1) included 586 controls (no quantitative or morphological alterations in the complete blood count) and 137 patients diagnosed with sepsis. The reliability of the model was evaluated using a validation group (G2) of 212 controls and 60 patients with sepsis. The optimal cut-off for the diagnosis of sepsis and the OR for CPD were established using a univariate logistic regression. A multivariate logistic regression model was then created. The OR and area under the curve were recorded. A risk stratification scale (neutrophils and monocytes NEMO)) for diagnosing sepsis was established on the basis of the coefficients of the multivariate model. Results MO-X and neutrophils fluorescence intensity (NE-SFL) were found to be the most relevant of the CPD in predicting sepsis applying multivariate analysis to G1. NEMO score was composed using the above-mentioned CPD and subsequently stratified into three risk groups: mild (<= 3), moderate (4 <= NEMO <= 5) and high (>= 6). The OR for patients with a score of 4-5 was 10 and 249 for a score of >= 6. When applied to G2, the positive predictive value was 84.8 % and the negative predictive value was 96.0%. Conclusions CPD are potentially useful for the early diagnosis of sepsis. Their values were used to compose in NEMO score can help in rapid and reliable decision making.	[Urrechaga, Eloisa; Boveda, Oihane] Hosp Galdakao Usansolo, CORE Lab, Galdakao Vizcaya, Spain; [Aguirre, Urko] Hosp Galdakao Usansolo, REDISSEC Hlth Serv Res Chron Patients Network, Res Unit, Galdakao Vizcaya, Spain	Urrechaga, E (reprint author), Hosp Galdakao Usansolo, Core Lab, Labeaga 48960, Galdakao, Spain.	eloisa.urrechagaigartua@osakidetza.net		Aguirre Larracoechea, Urko/0000-0002-8049-3030			Becker KL, 2008, CRIT CARE MED, V36, P941, DOI 10.1097/CCM.0B013E318165BABB; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brun-Buisson C, 2000, INTENS CARE MED, V26, pS64, DOI 10.1007/s001340051121; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Buoro S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.73; Chaves F, 2006, ARCH PATHOL LAB MED, V130, P378; Chaves F, 2005, AM J CLIN PATHOL, V124, P440, DOI 10.1309/LLF75W0FWQQ8TCC5; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Fan SL, 2016, CLIN CHIM ACTA, V460, P203, DOI 10.1016/j.cca.2016.07.002; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Prieto MF, 2008, MED INTENSIVA, V32, P424; Gomez JA, 2010, REV LAB CLIN, V3, P12; Guevara Ramirez P, 2012, SOC ESP BIOQ CLIN PA, V183, P8; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Lavrentieva A, 2007, BURNS, V33, P189, DOI 10.1016/j.burns.2006.07.001; Levy Mitchell M, 2003, Intensive Care Med, V29, P530; Linssen J, 2008, CYTOM PART B-CLIN CY, V74B, P295, DOI 10.1002/cyto.b.20422; Luo YL, 2013, CLIN CHIM ACTA, V422, P5, DOI 10.1016/j.cca.2013.03.026; Park DH, 2011, INT J LAB HEMATOL, V33, P391, DOI 10.1111/j.1751-553X.2011.01298.x; Park SH, 2015, INT J LAB HEMATOL, V37, P190, DOI 10.1111/ijlh.12261; Schneider HG, 2007, PATHOLOGY, V39, P383, DOI 10.1080/00313020701444564; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; van der Geest PJ, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1366-6; Vernon C, 2010, CRIT CARE CLIN, V26, P255, DOI 10.1016/j.ccc.2009.12.007; Vincent JL, 2013, EXPERT REV ANTI-INFE, V11, P265, DOI [10.1586/eri.13.9, 10.1586/ERI.13.9]; Weimann K, 2015, J INT MED RES, V43, P435, DOI 10.1177/0300060514557711	27	1	2	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					259	266		10.1136/jclinpath-2017-204524			8	Pathology	Pathology	GB5HD	WOS:000429094200011	28821583				2019-10-28	
J	Ooft, ML; van Ipenburg, JA; Sanders, ME; Kranendonk, M; Hofland, I; de Bree, R; Koljenovic, S; Willems, SM				Ooft, Marc L.; van Ipenburg, Jolique A.; Sanders, Maxime E.; Kranendonk, Mariette; Hofland, Ingrid; de Bree, Remco; Koljenovic, Senada; Willems, Stefan M.			Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							BREAST-CANCER; SIGNIFICANT PREDICTOR; DENDRITIC CELLS; POOR-PROGNOSIS; COLON-CANCER; LUNG-CANCER; INFILTRATION; SURVIVAL; PROGRESSION; METASTASIS	Aims Tumour-associated macrophages (TAMs) and regulatory T cells (Tregs) form a special niche supporting tumour progression, and both correlate with worse survival in head and neck cancers. However, the prognostic role of TAM and Tregs in nasopharyngeal carcinoma (NPC) is still unknown. Therefore, we determined differences in TAMs and Tregs in different NPC subtypes, and their prognostic significance. Methods Tissue of 91 NPCs was assessed for TAMs and Tregs by determination of CD68, CD163, CD206 and FOXP3 expression in the tumour microenvironment. Clinicopathological correlations were assessed using Pearson X2 test, Fisher's exact test, analysis of variance and Mann-Whitney U test. Survival was analysed using Kaplan-Meier curves and Cox regression. Results CD68 and FOXP3 counts were higher in Epstein-Barr virus (EBV)-positive NPC, while CD68-/FOXP3-, CD163+/FOXP3-and CD206+/FOXP3-infiltrates were more common in EBV-negative NPC. In the whole NPC group, CD68-/FOXP3-correlated with worse overall survival (OS), and after multivariate analysis high FOXP3 count showed better OS (HR 0.352, 95% CI 0.128 to 0.968). No difference in M2 counts existed between EBV-positive and negative NPC. Conclusions FOXP3, a Treg marker, seems to be an independent prognostic factor for better OS in the whole NPC group. Therefore, immune-based therapies targeting Tregs should be carefully evaluated. M2 spectrum macrophages are probably more prominent in EBV-negative NPC with also functional differences compared with EBV-positive NPC.	[Ooft, Marc L.; Sanders, Maxime E.; Kranendonk, Mariette; Willems, Stefan M.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [van Ipenburg, Jolique A.; Koljenovic, Senada] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Hofland, Ingrid] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pathol, Core Facil Mol Pathol & Biobanking, Amsterdam, Netherlands; [de Bree, Remco] Univ Med Ctr Utrecht, UMC Utrecht Canc Ctr, Dept Head & Neck Surg Oncol, Utrecht, Netherlands	Willems, SM (reprint author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	S.M.Willems-4@umcutrecht.nl					ALTUN M, 1995, INT J RADIAT ONCOL, V32, P859, DOI 10.1016/0360-3016(95)00516-2; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Costa NL, 2013, ORAL ONCOL, V49, P216, DOI 10.1016/j.oraloncology.2012.09.012; Daurkin I, 2011, CANCER RES, V71, P6400, DOI 10.1158/0008-5472.CAN-11-1261; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Fang WF, 2014, ONCOTARGET, V5, P12189, DOI 10.18632/oncotarget.2608; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; Fujii N, 2012, J ORAL PATHOL MED, V41, P444, DOI 10.1111/j.1600-0714.2012.01127.x; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; He KF, 2014, BIOMED RES INT, DOI 10.1155/2014/838632; Heinze E, 2009, INT J ONCOL, V35, P167, DOI 10.3892/ijo_00000325; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Hoebe EK, 2013, REV MED VIROL, V23, P367, DOI 10.1002/rmv.1758; Hu Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0281-z; Huang D, 2017, CANCER RES, V77, P3591, DOI [10.1158/0008-5472.can-16-2706, 10.1158/0008-5472.CAN-16-2706]; Huang HR, 2017, ACTA OTO-LARYNGOL, V137, P888, DOI 10.1080/00016489.2017.1296585; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Kaku Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087400; Kawai O, 2008, CANCER-AM CANCER SOC, V113, P1387, DOI 10.1002/cncr.23712; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kovaleva OV, 2016, ANAL CELL PATHOL, DOI 10.1155/2016/9307549; Kryczek I, 2007, CANCER RES, V67, P8900, DOI 10.1158/0008-5472.CAN-07-1866; Ladoire S, 2011, CANCER IMMUNOL IMMUN, V60, P909, DOI 10.1007/s00262-011-1046-y; Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549; Lin Jia-Ying, 2011, Chin J Cancer, V30, P280; Liu SW, 2015, BREAST CANCER RES TR, V154, P239, DOI 10.1007/s10549-015-3617-7; Lu CF, 2010, HEAD NECK-J SCI SPEC, V32, P18, DOI 10.1002/hed.21138; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marcus B, 2004, CANCER-AM CANCER SOC, V101, P2779, DOI 10.1002/cncr.20701; Markl B, 2017, J CLIN PATHOL, V70, P443, DOI 10.1136/jclinpath-2016-203978; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; MICKLEM K, 1989, BRIT J HAEMATOL, V73, P6, DOI 10.1111/j.1365-2141.1989.tb00210.x; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nguyen TDT, 2005, AM J SURG PATHOL, V29, P617, DOI 10.1097/01.pas.0000157940.80538.ec; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Petersson F, 2015, SEMIN DIAGN PATHOL, V32, P54, DOI 10.1053/j.semdp.2015.02.021; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schlereth SL, 2016, INVEST OPHTH VIS SCI, V57, P4878, DOI 10.1167/iovs.15-18552; Sheikh H, 2000, J CELL SCI, V113, P1021; Shimakage M, 2010, EXP THER MED, V1, P285, DOI 10.3892/etm_00000044; Sun Le-gang, 2008, Hua Xi Kou Qiang Yi Xue Za Zhi, V26, P591; Takeya M, 2016, PATHOL INT, V66, P491, DOI 10.1111/pin.12440; Tang KF, 2001, HUM PATHOL, V32, P42, DOI 10.1053/hupa.2001.20886; van Diest PJ, 2002, BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Wang B, 2011, ANN SURG ONCOL, V18, P2585, DOI 10.1245/s10434-011-1609-3; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang X, 2017, ONCOGENE, V36, P3048, DOI 10.1038/onc.2016.458; Wang XJ, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028077; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Xu L, 2014, ANN SURG ONCOL, V21, P3142, DOI 10.1245/s10434-014-3601-1; Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651; Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031230	56	5	5	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					267	274		10.1136/jclinpath-2017-204664			8	Pathology	Pathology	GB5HD	WOS:000429094200012	28877959				2019-10-28	
J	de Mel, S; Abid, MB; Poon, KS; Ng, SY; Poon, LM; Wang, S				de Mel, Sanjay; Abid, Muhammad Bilal; Poon, Kok-Siong; Ng, Sau-Yoke; Poon, Li-Mei; Wang, Shi			Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							WALDENSTROMS MACROGLOBULINEMIA		[de Mel, Sanjay; Abid, Muhammad Bilal; Poon, Li-Mei] Natl Univ Canc Inst Singapore, Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore; [Poon, Kok-Siong; Ng, Sau-Yoke] Natl Univ Hlth Syst, Mol Diag Ctr, Dept Lab Med, Singapore, Singapore; [Wang, Shi] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore	de Mel, S (reprint author), Natl Univ Canc Inst Singapore, Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore.	wspdm199@yahoo.com		Abid, Muhammad Bilal/0000-0002-1128-0445			BRANDT LJ, 1981, DIGEST DIS SCI, V26, P174, DOI 10.1007/BF01312238; Cioffi A, 2015, J CLIN ONCOL, V33, P1849, DOI 10.1200/JCO.2014.59.7344; Patil DT, 2011, ARCH PATHOL LAB MED, V135, P1298, DOI 10.5858/arpa.2011-0022-RA; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					284	285		10.1136/jclinpath-2017-204415			2	Pathology	Pathology	GB5HD	WOS:000429094200016	29092999				2019-10-28	
J	Jing, W; Li, XG; Peng, RY; Lv, SG; Zhang, Y; Cao, Z; Tu, JC; Ming, L				Jing, Wei; Li, Xiaogai; Peng, Ruoyu; Lv, Shaogang; Zhang, Yan; Cao, Zheng; Tu, Jiancheng; Ming, Liang			The diagnostic and prognostic significance of long noncoding RNAs expression in thyroid cancer: A systematic review and meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Thyroid cancer; LncRNAs; Prognosis; Diagnosis; Meta-analysis	POOR-PROGNOSIS; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; CARCINOMA; LNCRNA; CARCINOGENESIS; PROGRESSION; METASTASIS; MIGRATION; GENE	Objective: Thyroid cancer (TC) is the most common malignant endocrine-related cancer with an increasing trend worldwide. Therefore, it's in urgent need to find new markers for prognosis and diagnosis. Many long noncoding RNAs (lncRNAs) have been reported to be aberrantly expressed in TC, and may serve as biomarkers. Therefore, we performed this meta-analysis to systematically summarize the relationship between lncRNA expressions and TC. Methods: Sources from PubMed, Embase and Web of Science were searched. A total of 16 eligible studies including 15 on clinicopahology, 5 on prognosis and 6 on diagnosis were enrolled in our meta-analysis. Revman5.3 and Stata11.0 Software were used to conduct the meta-analysis. Results: For diagnostic value, lncRNAs could discriminate between TC and the normal, and yield a high overall sensitivity and specificity (0.80, 95% CI: 0.75-0.84; 0.80, 95% CI: 0.70-0.87). Meanwhile, their sensitivity and specificity were 0.74 (95% CI: 0.59-0.85) and 0.81 (95% CI: 0.73-0.88) respectively, when used to differentiate patients with lymph node metastasis (LNM) from without LNM. The summary receiver operator characteristic curve (sROC) showed that lncRNAs could be considered as valuable diagnostic markers for distinguishing TC patients from the normal (AUC = 0.84) and TC patients with LNM from TC patients without LNM (AUC = 0.85). Conclusions: In summary, our meta-analysis suggested that lncRNAs could function as potential diagnostic markers for TC and predict the LNM. In addition, the systematic review elaborated that lncRNAs might be as prognostic indicators in TC.	[Jing, Wei; Li, Xiaogai; Peng, Ruoyu; Lv, Shaogang; Zhang, Yan; Cao, Zheng; Ming, Liang] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Key Lab Lab Med Henan, Zhengzhou 450000, Henan, Peoples R China; [Tu, Jiancheng] Wuhan Univ, Zhongnan Hosp, Dept Lab Med, Clin Lab Med, Wuhan 430071, Hubei, Peoples R China; [Tu, Jiancheng] Wuhan Univ, Zhongnan Hosp, Ctr Gene Diag, Wuhan 430071, Hubei, Peoples R China	Ming, L (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Key Lab Lab Med Henan, Zhengzhou 450000, Henan, Peoples R China.	mingliang@zzu.edu.cn			First Affiliated Hospital of Zhengzhou University	This work was supported by the Hospital Fund of The First Affiliated Hospital of Zhengzhou University.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Fan M, 2013, EXP THER MED, V5, P1143, DOI 10.3892/etm.2013.933; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fu XM, 2017, EUR REV MED PHARMACO, V21, P3239; Guo LJ, 2017, EXP MOL PATHOL, V102, P500, DOI 10.1016/j.yexmp.2017.05.008; Huang JK, 2017, J CELL BIOCHEM, V118, P4821, DOI 10.1002/jcb.26153; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeong S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002592; Jing W, 2017, ONCOTARGET, V8, P3957, DOI 10.18632/oncotarget.13956; Jing W, 2016, BIOMED RES INT, DOI 10.1155/2016/5902678; Lan XB, 2016, TUMOR BIOL, V37, P6117, DOI 10.1007/s13277-015-4461-4; Li JH, 2017, INT J ONCOL, V50, P708, DOI 10.3892/ijo.2016.3803; Li JP, 2016, AM J CANCER RES, V6, P1099; Li N, 2017, PATHOL ONCOL RES, V23, P731, DOI 10.1007/s12253-016-0182-2; Li QH, 2017, AM J TRANSL RES, V9, P2181; Li QY, 2017, ONCOTARGET, V8, P46136, DOI 10.18632/oncotarget.17556; Li T, 2017, CELL CYCLE, V16, P224, DOI 10.1080/15384101.2016.1261768; Liao T, 2017, ONCOTARGET, V8, P238, DOI 10.18632/oncotarget.10825; Liu K., 2017, BIOSCI REP, V37; Liu N, 2017, EXP MOL PATHOL, V103, P71, DOI 10.1016/j.yexmp.2017.06.004; Liu YR, 2015, WORLD J HEPATOL, V7, P2781, DOI 10.4254/wjh.v7.i28.2781; Liyanarachchi S, 2016, J CLIN ENDOCR METAB, V101, P4005, DOI 10.1210/jc.2016-1991; Lundgren CI, 2006, CANCER, V106, P524, DOI 10.1002/cncr.21653; Molina-Vega M, 2018, ENDOCRINE, V59, P395, DOI 10.1007/s12020-017-1499-7; Pacini F, 2008, ANN ONCOL, V19, P99, DOI 10.1093/annonc/mdn115; Pan DH, 2017, ONCOTARGETS THER, V10, P3261, DOI 10.2147/OTT.S135593; Pellegriti G, 2013, J CANCER EPIDEMIOL, DOI 10.1155/2013/965212; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Priya SR, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00238; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Sun W, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0816-y; Tano Keiko, 2012, Frontiers in Genetics, V3, P219, DOI 10.3389/fgene.2012.00219; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang CH, 2015, NEOPLASMA, V62, P541, DOI 10.4149/neo_2015_065; Wang TH, 2015, ONCOTARGET, V6, P23342, DOI 10.18632/oncotarget.4344; Wang XM, 2017, J CELL BIOCHEM, V118, P4745, DOI 10.1002/jcb.26142; Wei MM, 2016, ONCOTARGET, DOI 10.18632/oncotarget.10006; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Xia SJ, 2017, ONCOTARGET, V8, P2293, DOI 10.18632/oncotarget.13725; Xiang C, 2017, ONCOTARGET, V8, P22954, DOI 10.18632/oncotarget.14578; Xie H, 2013, BIOMED RES INT, DOI 10.1155/2013/136106; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xiong XQ, 2017, BIOMED PHARMACOTHER, V93, P391, DOI 10.1016/j.biopha.2017.06.063; Yan K, 2017, CELL PHYSIOL BIOCHEM, V42, P999, DOI 10.1159/000478682; Zhang DX, 2017, INT J ENDOCRINOL, DOI 10.1155/2017/2645904; Zhang RR, 2017, ENDOCR PATHOL, V28, P7, DOI 10.1007/s12022-016-9453-4; Zhao JJ, 2016, ONCOTARGET, V7, P57903, DOI 10.18632/oncotarget.11087; Zhou H, 2017, CANC GENE THER; Zhou QY, 2016, TUMOR BIOL, V37, P3105, DOI 10.1007/s13277-015-4149-9	51	4	4	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					327	334		10.1016/j.prp.2018.01.008			8	Pathology	Pathology	GB5EK	WOS:000429085700001	29487006				2019-10-28	
J	Roh, MS; Lee, HW; Jung, SB; Kim, K; Lee, EH; Park, MI; Lee, JS; Kim, MS				Roh, Mee Sook; Lee, Hyoun Wook; Jung, Sang Bong; Kim, Kyungeun; Lee, Eun Hee; Park, Moon-il; Lee, Jae Seok; Kim, Mee-Seon			Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colorectal cancer; KRAS mutation; MicroRNA; miR-200c; Prognosis	EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; KRAS; MICRORNA; OVEREXPRESSION; MUTATIONS; SURVIVAL; MANNER; CELLS	MicroRNA-200c (miR-200c) is known to play a pivotal role in the regulation of epithelial-to-mesenchymal and mesenchymal-to-epithelial transition processes. However, the biological function of miR-200c in human carcinogenesis remains controversial. We examined the association of miR-200c expression with various clinicopathological factors, including KRAS mutation status and survival, in patients with colorectal cancer (CRC). The expression level of miR-200c was evaluated in 109 paired CRC and normal tissue samples using quantitative reverse transcription polymerase chain reaction. The KRAS mutation status of the CRC samples was determined using the PNAClamp (TM) KRAS Mutation Detection kit. Compared with the normal tissue group, miR-200c expression was significantly upregulated in the CRCs (P<.001). The expression of miR-200c was increased in CRCs with higher grade (P=.009), advanced stage (P=.042), and lymphovascular invasion (P=.003). Thirty-one CRCs (28.4%) had KRAS mutations in codon 12 or 13. CRCs with KRAS mutations had significantly higher miR-200c expression than CRCs with wild-type KRAS (P=.003). In survival analysis, high miR-200c expression was correlated with worse overall survival (P=.017) and recurrence-free survival (P=.048). Our results indicate that miR-200c is involved in tumor progression and aggressiveness in CRCs, and this oncogenic role of miR-200c may be triggered by activation of the KRAS signaling pathway.	[Roh, Mee Sook] Dong A Univ, Coll Med, Dept Pathol, Busan, South Korea; [Lee, Hyoun Wook; Lee, Eun Hee; Park, Moon-il; Lee, Jae Seok; Kim, Mee-Seon] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Pathol, 158 Paryong Ro, Chang Won 51353, South Korea; [Jung, Sang Bong] Dong Eui Inst Technol, Dept Clin Lab Sci, Busan, South Korea; [Kim, Kyungeun] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, Seoul, South Korea	Lee, HW (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Pathol, 158 Paryong Ro, Chang Won 51353, South Korea.	sudowo@naver.com			National Research Foundation of Korea (NRF) - Korean government (Ministry of Science, ICT & Future Planning) [2013R1A1A3007362]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science, ICT & Future Planning) [grant number: 2013R1A1A3007362].	Bandres E, 2007, DNA CELL BIOL, V26, P273, DOI 10.1089/dna.2006.0544; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen JM, 2014, TUMOR BIOL, V35, P6475, DOI 10.1007/s13277-014-1860-x; Diaz T, 2014, J SURG ONCOL, V109, P676, DOI 10.1002/jso.23572; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Eulalio A, 2009, RNA, V15, P21, DOI 10.1261/rna.1399509; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Hu YX, 2011, INT J CANCER, V128, P132, DOI 10.1002/ijc.25330; Hui K., 2013, GUT, V62, P1315; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Kim MK, 2014, VIRCHOWS ARCH, V465, P463, DOI 10.1007/s00428-014-1640-4; Kopp F, 2014, ONCOTARGET, V5, P185, DOI 10.18632/oncotarget.1427; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumar S, 2015, CURR DRUG TARGETS, V16, P1381, DOI 10.2174/1389450116666150325231419; Kwon MJ, 2011, PATHOL RES PRACT, V207, P762, DOI 10.1016/j.prp.2011.10.002; Lim D, 2015, CANCER EPIDEMIOL, V39, P939, DOI 10.1016/j.canep.2015.10.023; Liu XG, 2012, MED ONCOL, V29, P618, DOI 10.1007/s12032-011-9923-y; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Obrocea F, 2011, ROM J MORPHOL EMBRYO, V52, P537; Ota T, 2012, ANTICANCER RES, V32, P2271; Park YA, 2012, GYNECOL ONCOL, V124, P125, DOI 10.1016/j.ygyno.2011.09.026; Ren JJ, 2012, DIS COLON RECTUM, V55, P913, DOI 10.1097/DCR.0b013e318251d8d9; Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Song CL, 2015, ONCOTARGET, V6, P34968, DOI 10.18632/oncotarget.5198; Tsunoda T, 2011, ANTICANCER RES, V31, P2453; Wang MJ, 2012, MED ONCOL, V29, P3113, DOI 10.1007/s12032-012-0241-9; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Yokota T, 2012, ANTI-CANCER AGENT ME, V12, P163, DOI 10.2174/187152012799014968; Zhong XM, 2016, MOL CELL BIOL, V36, P2742, DOI 10.1128/MCB.00079-16	32	5	5	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					350	355		10.1016/j.prp.2018.01.005			6	Pathology	Pathology	GB5EK	WOS:000429085700004	29496312				2019-10-28	
J	Ma, ZM				Ma, Zhiming			Downregulation of SETD8 by miR-382 is involved in glioma progression	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; miR-382; SETD8; Proliferation; Migration	HISTONE METHYLTRANSFERASE SET8; CELL-PROLIFERATION; PROSTATE-CANCER; TUMOR-GROWTH; INVASION; OSTEOSARCOMA; METASTASIS; GLIOBLASTOMA; SUPPRESSES; EXPRESSION	Background: SETD8 (named PR-SET7 or KMT5a) has been reported to regulate various biological processes including carcinogenesis. However, the role of SETD8 in glioma progression has not been investigated. Method: qPCR and western blot were used to detect the expression levels of miR-382 and SETD8. MTT and wound healing assay used to detect the cell proliferation and migratory capability. A predicted target of miR-382 (SETD8) was first validated using a luciferase assay. Results: In this study, we found that SETD8 expression was evidently upregulated in glioma tissues and glioma cells, compared with the adjacent normal tissues and normal human astrocytes (NHA). Next, we showed that SETD8 evidently induced cell proliferation and migration in vitro and in vivo. In addition,dual-luciferase assays revealed that miR-382 directly regulates oncogenic SETD8 expression in U87 and 12251 cells. Finally a statistically significant inverse correlation of miR-382 and SETD8 expression was observed in 30 glioma patients. Conclusion: These data indicated that oncogenic SETD8 was regulated by miR-382 and involved glioma progression, revealing new therapeutic targets for glioma cancer.	[Ma, Zhiming] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China	Ma, ZM (reprint author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China.	mazhimingabc@163.com					Abbas T, 2010, MOL CELL, V40, P9, DOI 10.1016/j.molcel.2010.09.014; David R, 2010, NAT REV MOL CELL BIO, V11, P819, DOI 10.1038/nrm3020; DeVilbiss AW, 2015, MOL CELL BIOL, V35, P2073, DOI 10.1128/MCB.01422-14; Guo ZJ, 2012, INT J CANCER, V131, P1318, DOI 10.1002/ijc.27352; Hashemi M, 2014, TUMOR BIOL, V35, P10375, DOI 10.1007/s13277-014-2359-1; Jiang H., 2014, APSIPA T SIGNAL INFO, V3, P1, DOI DOI 10.1109/PCS.2013.6737678; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561; Milite C, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0268-4; Nieder C, 2006, CRIT REV ONCOL HEMAT, V60, P181, DOI 10.1016/j.critrevonc.2006.06.007; Qi B, 2015, WORLD J GASTROENTERO, V21, P6884, DOI 10.3748/wjg.v21.i22.6884; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takawa M, 2012, CANCER RES, V72, P3217, DOI 10.1158/0008-5472.CAN-11-3701; Tan H, 2016, INT J ONCOL, V48, P181, DOI 10.3892/ijo.2015.3241; Wang CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32921; Wang JY, 2016, MOL MED REP, V14, P537, DOI 10.3892/mmr.2016.5206; Wu XW, 2013, TUMOR BIOL, V34, P2195, DOI 10.1007/s13277-013-0756-5; Xu M, 2015, MOL THER, V23, P89, DOI 10.1038/mt.2014.197; Xu M, 2014, ONCOTARGET, V5, P9472, DOI 10.18632/oncotarget.2418; Yao LS, 2014, BIOCHEM BIOPH RES CO, V450, P692, DOI 10.1016/j.bbrc.2014.06.033; Yu GY, 2006, AM J PATHOL, V168, P597, DOI 10.2353/ajpath.2006.050620; Yu N, 2013, J BIOL CHEM, V288, P19633, DOI 10.1074/jbc.M113.475657; Zeng B, 2012, FEBS LETT, V586, P3271, DOI 10.1016/j.febslet.2012.06.049; Zhang J, 2016, BIOCHEM BIOPH RES CO, V469, P1006, DOI 10.1016/j.bbrc.2015.12.067; Zhou BG, 2016, MOL CARCINOGEN, V55, P2260, DOI 10.1002/mc.22466	25	4	4	1	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					356	360		10.1016/j.prp.2018.01.004			5	Pathology	Pathology	GB5EK	WOS:000429085700005	29487005				2019-10-28	
J	Li, XX; Guo, H; Zhou, JD; Wu, DH; Ma, JC; Wen, XM; Zhang, W; Xu, ZJ; Lin, J; Qian, J				Li, Xi-xi; Guo, Hong; Zhou, Jing-dong; Wu, De-hong; Ma, Ji-chun; Wen, Xiang-mei; Zhang, Wei; Xu, Zi-jun; Lin, Jiang; Qian, Jun			Overexpression of CTNNB1: Clinical implication in Chinese de novo acute myeloid leukemia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						CTNNB1; Expression; Prognosis; Acute myeloid leukemia	WNT/BETA-CATENIN PATHWAY; TANDEM DUPLICATION MUTATIONS; HEMATOPOIETIC STEM-CELL; BETA-CATENIN; CYTOGENETIC ABNORMALITIES; PROGNOSTIC-SIGNIFICANCE; POSTREMISSION THERAPY; SIGNALING PATHWAY; ADULT PATIENTS; GROUP-B	Activation of Wnt/beta-catenin signaling played a crucial role in tumorigenesis, and beta-catenin (CTNNB1) overexpression has been identified in numerous solid tumors. The present study was designed to determine CTNNB1 expression and its clinical significance in Chinese de novo acute myeloid leukemia (AML) patients. Real-time quantitative PCR was carried out to detect the pattern of CTNNB1 expression in 140 AML patients and 46 controls. The level of CTNNB1 transcript in AML patients was significantly up-regulated compared with controls (P < 0.001). CTNNB1(high) patients showed significantly older age than CTNNB1(low) patients (P < 0.05). The frequency of high CTNNB1 expression was significantly observed in patients with intermediate/poor karyotypes. CTNNB1(high) patients had a significantly lower complete remission (CR) rate than CTNNB1(low) patients (P = 0.004). Among cytogenetically normal AML (CN-AML), CTNNB1(high) patients presented significantly shorter overall survival (OS, P = 0.004) and leukemia-free survival (LFS, P = 0.038) than CTNNB1(low) patients. Multivariate analysis confirmed that CTNNB1 expression was an independent prognostic factor for OS among CN-AML. Moreover, CTNNB1 expression level significantly decreased after CR stage (P = 0.032) and increased in relapsed stage (P = 0.015). Our findings suggest that CTNNB1 is overexpressed and confers a poor prognosis in AML, and could be used as a biomarker in monitoring disease recurrence.	[Li, Xi-xi; Zhou, Jing-dong; Zhang, Wei; Qian, Jun] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China; [Guo, Hong; Ma, Ji-chun; Wen, Xiang-mei; Xu, Zi-jun; Lin, Jiang] Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, Zhenjiang, Jiangsu, Peoples R China; [Li, Xi-xi; Guo, Hong; Zhou, Jing-dong; Ma, Ji-chun; Wen, Xiang-mei; Zhang, Wei; Xu, Zi-jun; Lin, Jiang; Qian, Jun] Key Lab Precis Diag & Treatment Zhenjiang City, Zhenjiang, Jiangsu, Peoples R China; [Li, Xi-xi; Zhou, Jing-dong; Xu, Zi-jun] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China; [Wu, De-hong] Third Peoples Hosp KunShan City, Dept Hematol, Suzhou, Jiangsu, Peoples R China	Qian, J (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.	QianJun@jskfhn.org.cn			National Natural Science foundation of ChinaNational Natural Science Foundation of China [81270630]; Special Funds of "Ke JiaoQiang Wei" Project of Jiangsu Province; 333 Project of JiangsuProvince [BRA2016131]; Medical Innovation Teamof Jiangsu Province [CXTDB2017002]; Postgraduate Research & Practice InnovationProgram of Jiangsu Province [KYCX17_1821]; Six talent peaks project in Jiangsu Province [2015-WSN-115]; Social Development Foundation of Zhenjiang [SH2016045, SH2016046]; Key Medical Talent Program of Zhenjiang City	This work was supported by National Natural Science foundation of China (81270630), Special Funds of "Ke JiaoQiang Wei" Project of Jiangsu Province, 333 Project of JiangsuProvince (BRA2016131), Medical Innovation Teamof Jiangsu Province (CXTDB2017002), Postgraduate Research & Practice InnovationProgram of Jiangsu Province (KYCX17_1821), Six talent peaks project in Jiangsu Province (2015-WSN-115), Social Development Foundation of Zhenjiang (SH2016045, SH2016046), Key Medical Talent Program of Zhenjiang City.	Abu-Duhier FM, 2000, BRIT J HAEMATOL, V111, P190, DOI 10.1046/j.1365-2141.2000.02317.x; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Ashihara E, 2015, CANCER SCI, V106, P665, DOI 10.1111/cas.12655; Avivi I, 2005, CURR OPIN HEMATOL, V12, P62, DOI 10.1097/01.moh.0000148760.15412.df; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Chen CC, 2009, AM J HEMATOL, V84, P87, DOI 10.1002/ajh.21334; Cui DM, 2016, INT J BIOCHEM CELL B, V73, P72, DOI 10.1016/j.biocel.2016.02.007; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Estey EH, 2013, AM J HEMATOL, V88, P317, DOI 10.1002/ajh.23404; Farag SS, 2005, J CLIN ONCOL, V23, P482, DOI 10.1200/JCO.2005.06.090; Ferrara F, 2004, LANCET ONCOL, V5, P443, DOI 10.1016/S1470-2045(04)01512-8; Fu YJ, 2014, MOL BIOL REP, V41, P3907, DOI 10.1007/s11033-014-3258-7; Fu YJ, 2012, INT J BIOCHEM CELL B, V44, P770, DOI 10.1016/j.biocel.2012.01.017; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Grimwade D, 2001, BEST PRACT RES CL HA, V14, P497, DOI 10.1053/beha.2001.0152; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhnl A, 2011, BLOOD, V118, P6362, DOI 10.1182/blood-2011-04-350850; Lane SW, 2011, BLOOD, V118, P2849, DOI 10.1182/blood-2011-03-345165; Lento W., 2013, COLD SPRING HARB PER, V5, P1; Lento W., 2013, COLD SPRING HARB PER, V1; Li Y, 2013, LEUKEMIA RES, V37, P1642, DOI 10.1016/j.leukres.2013.09.022; Lin J, 2012, ANN HEMATOL, V91, P519, DOI 10.1007/s00277-011-1352-7; Lin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026906; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Moskalev EA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-213; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; National Transport Commission, 2012, NCCN CLIN PRACT GUID; Qian J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045760; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; Skrdlant L, 2016, METHODS MOL BIOL, V1421, P1, DOI 10.1007/978-1-4939-3591-8_1; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075.h8004075_4075_4083; Smith M, 2004, CRIT REV ONCOL HEMAT, V50, P197, DOI 10.1016/j.critrevonc.2003.11.002; Tickenbrock L, 2005, BLOOD, V105, P3699, DOI 10.1182/blood-2004-07-2924; Wang LL, 2014, BLOOD, V124, P1089, DOI 10.1182/blood-2014-01-552067; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wen XM, 2014, INT J CLIN EXP PATHO, V7, P6832; XU JH, 2015, PROC IEEE INT CONF, V28, P1; Xu J, 2008, BRIT J HAEMATOL, V140, P394, DOI 10.1111/j.1365-2141.2007.06914.x; Yang XF, 2013, CLIN BIOCHEM, V46, P579, DOI 10.1016/j.clinbiochem.2012.12.022; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239; Zheng J, 2008, CYTOM PART B-CLIN CY, V74B, P25, DOI 10.1002/cyto.b.20368; Zhou JD, 2015, AM J CANCER RES, V5, P1786; Zhou JD, 2015, MED ONCOL, V32, DOI [10.1007/s12032-014-0386-9, 10.1007/s12032-014-0352-6]	49	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					361	367		10.1016/j.prp.2018.01.003			7	Pathology	Pathology	GB5EK	WOS:000429085700006	29496308				2019-10-28	
J	Zhao, YN; Wang, X; Liang, FH; Zhang, WJ; Song, XT				Zhao, Yi-nuo; Wang, Xiao; Liang, Fen-hua; Zhang, Wen-jie; Song, Xiang-tao			Hyalinizing clear cell carcinoma of salivary glands: A retrospective study focused on uncommon morphology, immunohistochemistry, and detection of gene fusion using fluorescence in situ hybridization	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hyalinizing clear cell carcinoma; Salivary glands; Morphology; Immunohistochemistry; EWSR1; FISH	HIGH-GRADE TRANSFORMATION; EWSR1-ATF1 FUSION; REARRANGEMENTS; CYTOLOGY; ORIGIN; TUMOR	Aims: To investigate histological, immunohistochemical, and molecular features, especially uncommon morphology of hyalinizing clear cell carcinoma (HCCC) to expand the morphological spectrum of HCCC. Methods and results: We examined 5 cases of HCCC by histological, immunohistochemical, and molecular analysis. Generally, 5 HCCC cases shared similar characteristics, exhibiting clear to slightly eosinophilic cells arranged in cords, nests, islands, or trabeculae with a hyalinized stroma, while myxoid stroma, perineural invasion, and polygonal cells with high-grade nuclei were observed in 3 cases. Immunohistochemically, 5 cases were entirely immunoreactive for CKpan, whereas 80% HCCC cases were positive for P63, and CK14. None expressed immunoreactivity for S-100, Calponin, or GFAP. The positive rate of Ki-67 staining was about 5% in the classic area of case 3, but 40% in the high-grade area. As for the result of FISH findings, EWSR1 gene break was detected in all 5 HCCC cases. Conclusions: Our study has expanded the morphological spectrum of HCCC, and proposed the diagnosis of HCCC should be confirmed by fully analyzing histological, immunohistochemical, and molecular features practically.	[Zhao, Yi-nuo; Wang, Xiao; Liang, Fen-hua; Zhang, Wen-jie] Peoples Hosp Rizhao, Rizhao, Shandong, Peoples R China; [Song, Xiang-tao] Yantai Hosp Tradit Chinese Med, Yantai 264000, Shandong, Peoples R China	Song, XT (reprint author), Yantai Hosp Tradit Chinese Med, Yantai 264000, Shandong, Peoples R China.	xiangtaosong@163.com			Department of Pathology at People's Hospital of Rizhao; Department of Pathology at Yantai Hospital of Traditional Chinese Medicine	This work was funded by Department of Pathology at People's Hospital of Rizhao, and Department of Pathology at Yantai Hospital of Traditional Chinese Medicine.	Alali BM, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0659-7; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Boccato P, 2001, ORL J OTO-RHINO-LARY, V63, P119, DOI 10.1159/000055723; Fukuda A, 2015, AURIS NASUS LARYNX, V42, P412, DOI 10.1016/j.anl.2015.02.015; Fulciniti F, 2014, DIAGN CYTOPATHOL, V42, P63, DOI 10.1002/dc.22956; Garcia JJ, 2015, HUM PATHOL, V46, P471, DOI 10.1016/j.humpath.2014.11.010; Gon S, 2013, J CANCER RES THER, V9, P281, DOI 10.4103/0973-1482.113386; Gushi E, 2017, J CLIN DIAGN RES, V11, pZL01, DOI 10.7860/JCDR/2017/29193.10228; Hernandez-Prera JC, 2017, HEAD NECK-J SCI SPEC, V39, P503, DOI 10.1002/hed.24637; Hsieh MS, 2017, HUM PATHOL, V61, P9, DOI 10.1016/j.humpath.2016.06.029; Jeffus SK, 2017, AM J CLIN PATHOL, V148, P73, DOI [10.1093/AJCP/AQX048, 10.1093/ajcp/aqx048]; Jin RY, 2012, HEAD NECK PATHOL, V6, P389, DOI 10.1007/s12105-012-0338-7; Kim DW, 2013, J KOR ASSOC ORAL MAX, V39, P283, DOI 10.5125/jkaoms.2013.39.6.283; Lai G, 2008, EUR J HISTOCHEM, V52, P251; Milchgrub S, 2000, DIAGN CYTOPATHOL, V23, P333, DOI 10.1002/1097-0339(200011)23:5<333::AID-DC10>3.0.CO;2-R; MILCHGRUB S, 1994, AM J SURG PATHOL, V18, P74, DOI 10.1097/00000478-199401000-00007; Nagao T, 2013, HEAD NECK PATHOL, V7, pS37, DOI 10.1007/s12105-013-0458-8; Nakano T, 2015, VIRCHOWS ARCH, V466, P37, DOI 10.1007/s00428-014-1676-5; Nakashima T, 2015, J LARYNGOL OTOL, V129, pS95, DOI 10.1017/S0022215114002485; Newman WC, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.02.001; O'Sullivan-Mejia ED, 2009, HEAD NECK PATHOL, V3, P179, DOI 10.1007/s12105-009-0124-3; Roby BB, 2012, ARCH OTOLARYNGOL, V138, P207, DOI 10.1001/archoto.2011.1245a; Shah AA, 2015, HISTOPATHOLOGY, V67, P274, DOI 10.1111/his.12636; Shah AA, 2013, AM J SURG PATHOL, V37, P571, DOI 10.1097/PAS.0b013e3182772a15; Shahi M, 2017, HEAD NECK PATHOL, V11, P575, DOI 10.1007/s12105-017-0820-3; Skalova A, 2015, AM J SURG PATHOL, V39, P338, DOI 10.1097/PAS.0000000000000364; Su HK, 2015, HEAD NECK-J SCI SPEC, V37, pE19, DOI 10.1002/hed.23764; Tanguay J, 2013, HEAD NECK PATHOL, V7, P28, DOI 10.1007/s12105-013-0427-2; Weinreb I, 2013, HEAD NECK PATHOL, V7, pS20, DOI 10.1007/s12105-013-0466-8; Yamanishi T, 2015, CASE REP OTOLARYNGOL, DOI 10.1155/2015/471693; Yuan CT, 2016, DIAGN CYTOPATHOL, V44, P338, DOI 10.1002/dc.23423	31	0	0	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					380	384		10.1016/j.prp.2017.12.021			5	Pathology	Pathology	GB5EK	WOS:000429085700009	29482986				2019-10-28	
J	Li, XJ; Pang, JS; Li, YM; Ahmed, FA; He, RQ; Ma, J; Ma, FC; Chen, G				Li, Xiao-jiao; Pang, Jin-shu; Li, Yao-mei; Ahmed, Farah Abdirahman; He, Rong-quan; Ma, Jie; Ma, Fu-chao; Chen, Gang			Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ovarian cancer; Survivin; Meta-analysis; Bioinformatics study	CLINICOPATHOLOGICAL PARAMETERS; CELL-PROLIFERATION; EXPRESSION; PROGNOSIS; CARCINOMA; APOPTOSIS; TUMORS; COMBINATION; PROGRESSION; INHIBITOR	Objective: An increasing number of studies have confirmed that survivin (BIRC5) plays essential roles in ovarian cancer. Nevertheless, inconsistent or controversial results exist in some studies. In the present study, we sought to determine the clinical significance of survivin and its potential molecular pathways. Methods: The correlation between survivin (BIRC5) expression and diagnostic value, prognostic value and clinicopathological features was assessed by meta-analysis with more than 4000 patients from literature, GEO and TCGA. In addition, the potential molecular mechanism of survivin in ovarian cancer was also determined. Results: The pooled sensitivity and specificity were 0.71 (95%CI: 0.68-0.74) and 0.97 (95%CI: 0.94-0.98), respectively. The AUC of sROC was 0.8765. The results showed that there was also a significant relationship between survivin expression and poor overall survival (HR: 1.24, 95%CI: 1.14-1.35, p < 0.001), disease-free survival (HR: 1.53, 95%CI: 0.57-4.09, p < 0.001), as well as higher recurrence rate (HR: 1.11, 95%CI: 0.97-1.27). Moreover, survivin expression was also associated with tumor progression (cancerous vs. benign, OR: 11.29, 95%CI: 8.96-14.24, p < 0.001), TNM stage (III + IV vs. I + II, OR: 5.38, 95%CI: 4.16-6.97, p < 0.001), histological grades (G3 vs. G1 similar to G2, OR: 4.36, 95%CI: 3.29-5.77, p < 0.001), and lymphatic metastasis (metastasis vs. non-metastasis, 3.35, 95%CI 2.36-4.75, p < 0.001). Bioinformatics analysis revealed the 50 most frequently altered neighboring genes of survivin in OC, and then Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted. GO analysis showed that these genes were related to signal conduction, cell cycle, apoptosis, and metabolism. KEGG pathways analysis indicated that these genes were primarily enriched in mitotic prometaphase, PLK1 signaling events and the regulation of glucokinase by the glucokinase regulatory protein. Conclusion: Survivin (BIRC5) expression might become a specific but low-sensitivity biomarker in ovarian cancer patients, and its presence indicated poor prognosis and worse TNM stages. This protein might function as an oncoprotein by influencing specific pathways involving the 50 genes identified herein. Additional studies are needed to confirm these results.	[Li, Xiao-jiao; Ahmed, Farah Abdirahman] Guangxi Med Univ, Affiliated Hosp 1, Dept PET CT, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Pang, Jin-shu; Li, Yao-mei; Ahmed, Farah Abdirahman; He, Rong-quan; Ma, Jie; Ma, Fu-chao] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Ahmed, Farah Abdirahman; Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China	Ma, FC (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.	Lixiaojiao4269@126.com; mafuchao@live.cn					Athanassiadou P, 2008, PATHOL RES PRACT, V204, P241, DOI 10.1016/j.prp.2007.11.004; Ban H., 2011, CHIN J PRACT MED, V38, P79; Chen LF, 2013, INT J GYNECOL CANCER, V23, P256, DOI 10.1097/IGC.0b013e31827ad2b8; Chen Y., 2009, RES EXPRESSION ATK S; Cohen C, 2003, MODERN PATHOL, V16, P574, DOI 10.1097/01.MP.0000073868.31297.B0; Deng L., 2015, WORLD LATEST MED INF, V15, P52; Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797; Dobrzycka B, 2015, TUMOR BIOL, V36, P4157, DOI 10.1007/s13277-015-3050-x; Du JT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1553-x; Felisiak-Golabek A, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-20; Ferrandina G, 2005, BRIT J CANCER, V92, P271, DOI 10.1038/sj.bjc.6602332; Grass I., 2017, NEUROENDOCRINOLOGY, V278; Gu Y., 2016, SIGNIFICANCE PROGNOS; Jin A., 2016, CHONGQING MED, V45, P2244; Jin Z., 2017, ONCOGENE, V8, P58439; Ju LL, 2016, EUR REV MED PHARMACO, V20, P1993; Kanter M, 2016, J MOL HISTOL, V47, P145, DOI 10.1007/s10735-016-9661-8; Ketola K, 2017, CLIN CANCER RES, V23, P6923, DOI 10.1158/1078-0432.CCR-17-0901; Kleinberg L, 2007, CANCER, V109, P228, DOI 10.1002/cncr.22426; Kucukgoz G., 2013, ARCH GYNECOL OBSTET, V239, P393; Cabuk FK, 2014, TURK J PATHOL, V30, P30, DOI 10.5146/tjpath.2013.01203; Lang X., 2012, EXPRESSION SIGNIFICA; Li L., 2009, MOD MED J CHINA, V11, P24; Li W., 2014, CHINA MOD DOCTOR, V52, P21; Liguang Z., 2007, Experimental Oncology, V29, P121; Lin CK, 2009, APMIS, V117, P162, DOI 10.1111/j.1600-0463.2008.00003.x; Liu K., 2016, CHINA PRACT MED, P3; Liu L., 2014, HEILONGJIANG MED PHA, V37, P29; Liu S., 2015, SHAANXI MED J, P497; Long Q., 2015, PROG OBSTET GYNECOL, V24, P65; [陆晋荣 Lu Jinrong], 2013, [载人航天, Manned Spaceflight], V19, P17; Lu Y., 2017, J CLIN EXP MED, V16, P1373; Ma D., 2015, J INT ONCOL, V42, P313; Ma QY, 2017, ONCOL LETT, V14, P1939, DOI 10.3892/ol.2017.6373; Ma Xiang-Yi, 2004, Ai Zheng, V23, P173; Mabao Liu, 2015, 2015 Annual Reliability and Maintainability Symposium (RAMS). Proceedings, DOI 10.1109/RAMS.2015.7105199; No JH, 2011, GYNECOL OBSTET INVES, V71, P136, DOI 10.1159/000316049; Popp R, 2017, ANAL CHEM, V89, P10592, DOI 10.1021/acs.analchem.7b02934; Qian XY, 2011, APPL IMMUNOHISTO M M, V19, P126, DOI 10.1097/PAI.0b013e3181e30dcd; Ren M., 2007, EXPRESSION SIGNIFICA; Sam M., 2017, HUM EXP TOXICOL; Sankpal UT, 2016, TUMOR BIOL, V37, P14259, DOI 10.1007/s13277-016-5290-9; Shi C, 2017, ONCOL LETT, V14, P3809, DOI 10.3892/ol.2017.6647; Spaniol K, 2011, ANTI-CANCER DRUG, V22, P531, DOI 10.1097/CAD.0b013e3283454526; Sui L, 2006, ONCOL REP, V15, P773; Sui L, 2002, INT J ONCOL, V21, P315; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Takai N, 2002, INT J MOL MED, V10, P211; Teng Y, 2016, CELL PHYSIOL BIOCHEM, V39, P2341, DOI 10.1159/000447926; [王淑华 Wang Shuhua], 2005, [第四军医大学学报, Journal of the Fourth Military Medical University], V26, P1029; Wang Y., 2009, HEBEI MED J, V31, P2746; Wang Z., 2017, CANC LETT, V304-3835, P30583; Xu V., 2017, SCI REP, V7, P46060; Yin Ru-Tie, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P215; Yoshida H, 2001, INT J ONCOL, V19, P537; Zhang C., 2010, J GANNANMED U, V30, P372; Zhang Y, 2015, MOL PHARMACEUT, V12, P3137, DOI 10.1021/mp500835z; Zhao LJ, 2016, ONCOTARGET, V7, P1408, DOI 10.18632/oncotarget.6368; Zhu J, 2016, AM J TRANSL RES, V8, P4812; Zhu Q., 2009, J PRACT MED, V25, P3009	60	1	1	0	7	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					385	401		10.1016/j.prp.2017.12.020			17	Pathology	Pathology	GB5EK	WOS:000429085700010	29499854				2019-10-28	
J	Lee, VWK; Chan, KF				Lee, Victor Wai Kwan; Chan, Kui Fat			Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colon adenocarcinoma; Prognosis; Tumor budding; Poorly-differentiated cluster	COLORECTAL-CANCER; CARCINOMA; RECOMMENDATIONS; INTEROBSERVER; METAANALYSIS; PREDICTOR; CRITERIA; IMPACT; INDEX	Comparison between tumor budding (TB) and poorly-differentiated clusters (PDC) for prognostication in Stage II colon cancer was not extensively studied in literature. In this retrospective study, we assessed TB (according to the consensus statement in 2016) and PDC in 135 Stage II colon adenocarcinoma resection specimens. Counting of TB and PDC was performed on H&E slides. High-grade TB (Bd3 (>= 10 tumor buds in 0.785 mm(2))) and high-grade PDC (Grade 3 ( 10)) were found in 20% and 17% of cases respectively. High-grade TB was associated with pT4 (p = 0.008) and presence of lymphovascular invasion (p = 0.001). There was correlation between TB and PDC grades (p < 0.001), in which both grades were the same or one grade apart in majority of the cases (95%). Both TB and PDC correlated with 5-year disease-specific survival (DSS) and overall survival (OS) (DSS for TB: 89% (Bd1); 73% (Bd2); 52% (Bd3), p = 0.001) (DSS for PDC: 88% (Grade 1); 72% (Grade 2); 61% (Grade 3), p = 0.021). Survival curves of Stage II colon cancer could be further stratified by TB and PDC (log-rank tests: TB p < 0.001; PDC p = 0.009). Combining TB and PDC grades into single grading system (high-grade: Bd3 + G2, Bd2 + G3, Bd3 + G3; low-grade: other combinations) was found to have strong correlation with both 5-year DSS and OS (both p < 0.001). Our study has confirmed TB and PDC as independent prognostic factors in Stage II colon cancer, and might help selecting high-risk patients for adjuvant chemotherapy.	[Lee, Victor Wai Kwan; Chan, Kui Fat] Tuen Mun Hosp, Dept Clin Pathol, 23Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China	Lee, VWK (reprint author), Tuen Mun Hosp, Dept Clin Pathol, 23Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China.	lwk969@ha.org.hk					Barresi V, 2016, SCAND J GASTROENTERO, V51, P314, DOI 10.3109/00365521.2015.1084646; Barresi V, 2014, AM J CLIN PATHOL, V142, P375, DOI 10.1309/AJCPFEA7KA0SBBNA; Barresi V, 2014, VIRCHOWS ARCH, V464, P655, DOI 10.1007/s00428-014-1580-z; Barresi V, 2012, VIRCHOWS ARCH, V461, P621, DOI 10.1007/s00428-012-1326-8; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Betge J, 2012, ANN SURG ONCOL, V19, P3706, DOI 10.1245/s10434-012-2426-z; Cappellesso R, 2017, HUM PATHOL, V65, P62, DOI 10.1016/j.humpath.2017.04.013; Chandler I, 2008, HISTOPATHOLOGY, V52, P494, DOI 10.1111/j.1365-2559.2008.02976.x; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Hari DM, 2013, J AM COLL SURGEONS, V217, P181, DOI 10.1016/j.jamcollsurg.2013.04.018; Hong M, 2017, J KOREAN MED SCI, V32, P1595, DOI 10.3346/jkms.2017.32.10.1595; Kevans D, 2011, INT J SURG PATHOL, V19, P751, DOI 10.1177/1066896911414566; Kim JW, 2015, J KOREAN MED SCI, V30, P16, DOI 10.3346/jkms.2015.30.1.16; Kinoshita O, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0550-5; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; La Torre M, 2012, J SURG ONCOL, V106, P469, DOI 10.1002/jso.23101; Lai YH, 2014, COLORECTAL DIS, V16, P259, DOI 10.1111/codi.12454; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Nakamura T, 2008, DIS COLON RECTUM, V51, P568, DOI 10.1007/s10350-008-9192-9; Petrelli F, 2015, J Gastrointest Cancer, V46, P212, DOI 10.1007/s12029-015-9716-1; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Quah HM, 2008, DIS COLON RECTUM, V51, P503, DOI 10.1007/s10350-008-9246-z; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Rosty C, 2014, HUM PATHOL, V45, P2077, DOI 10.1016/j.humpath.2014.06.020; Santos C, 2013, COLORECTAL DIS, V15, P414, DOI 10.1111/codi.12028; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Ueno H, 2014, AM J SURG PATHOL, V38, P197, DOI 10.1097/PAS.0000000000000113; Ueno H, 2012, AM J SURG PATHOL, V36, P193, DOI 10.1097/PAS.0b013e318235edee; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55	30	4	4	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					402	407		10.1016/j.prp.2017.12.019			6	Pathology	Pathology	GB5EK	WOS:000429085700011	29487008				2019-10-28	
J	Kriegsmann, M; Harms, A; Kazdal, D; Fischer, S; Stenzinger, A; Leichsenring, J; Penzel, R; Longuespee, R; Kriegsmann, K; Muley, T; Safi, S; Warth, A				Kriegsmann, Mark; Harms, Alexander; Kazdal, Daniel; Fischer, Sebastian; Stenzinger, Albrecht; Leichsenring, Jonas; Penzel, Roland; Longuespee, Remi; Kriegsmann, Katharina; Muley, Thomas; Safi, Seyer; Warth, Arne			Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Immunohistochemistry; Ki-67; Proliferation; Adenocarcinoma; Non-small cell lung cancer; NSCLC; Digital image analysis; Driver Mutations; Lung cancer; Pathology	OF-THE-LITERATURE; BREAST-CANCER; KI-67 EXPRESSION; EGFR MUTATIONS; KRAS MUTATION; CELL; GEFITINIB; SURVIVAL; TUMORS; GENE	In the last decade it became evident that many lung adenocarcinomas (ADC) harbor key genetic alterations such as KRAS, EGFR or BRAF mutations as well as rearrangements of ROS1 or ALK that drive these tumors. In the present study we investigated whether different driver mutations of ADC result in different proliferation rates, which might have clinical impact, including resistance to therapy, recurrence and prognosis. We analyzed the proliferation index (PI) on full slides of surgically resected ADC (n = 230) with known genetic aberrations by means of immunohistochemistry and subsequent digital image analysis and correlated the results with clinicopathological variables including overall (OS) and disease free survival (DFS). We did not observe significant differences in OS or DFS regarding the KRAS or EGFR mutational status (P = 0.56). However, KRAS mutated ADC showed an increased PI compared to EGFR mutated ADC, and ADC with ALK translocations (P < 0.01). Subgroup analysis of EGFR mutated ADC showed a higher PI for tumors harboring a mutation in exon 18 and 20, compared to tumors with a mutation in exon 19 or 21. A PI of 11.5% was the best possible prognostic stratificator for OS (P = 0.01 in KRAS mutated and P < 0.01 in EGFR mutated ADC). In conclusion, the PI differs significantly among ADC with distinct driver mutations. This might explain the varying indications for a prognostic relevance of the PI observed in prior studies. Our study provides a basis for the establishment of a reliable and clinically meaningful PI threshold.	[Kriegsmann, Mark; Harms, Alexander; Kazdal, Daniel; Fischer, Sebastian; Stenzinger, Albrecht; Leichsenring, Jonas; Penzel, Roland; Longuespee, Remi; Warth, Arne] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Kriegsmann, Katharina] Heidelberg Univ, Dept Rheumatol Oncol & Hematol, Heidelberg, Germany; [Muley, Thomas] Heidelberg Univ, Thoraxklin, Translat Res Unit, Heidelberg, Germany; [Safi, Seyer] Heidelberg Univ, Thoraxklin, Dept Thorac Surg, Heidelberg, Germany; [Harms, Alexander; Kazdal, Daniel; Warth, Arne] German Ctr Lung Res, Translat Lung Res Ctr Heidelberg, Heidelberg, Germany	Kriegsmann, M (reprint author), Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, Heidelberg, Germany.	mark.kriegsmann@med.uni-heidelberg.de; Alexander.harms@med.uni-heidelberg.de; Daniel.kazdal@med.uni-heidelberg.de; Sebastian1.fischer@med.uni-heidelberg.de; Albrecht.stenzinger@med.uni-heidelberg.de; jonas.l.eichsenring@med.uni-heidelberg.de; Roland.penzel@med.uni-heidelberg.de; Remi.longuespee@med.uni-heidelberg.de; Katharina.kriegsmann@med.uni-beidelberg.de; Thomas.muley@med.uni-heidelberg.de; seyer.safi@med.uni-heidelberg.de; arne.warth@med.uni-heidelberg.de			Post-doc program of the medical faculty of the University of Heidelberg; Else Kroner-Fresenius Foundation	MK was supported by the Post-doc program of the medical faculty of the University of Heidelberg. AW was supported by an excellence grant of the Else Kroner-Fresenius Foundation.	Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Alba E, 2016, ONCOLOGIST, V21, P150, DOI 10.1634/theoncologist.2015-0312; Beau-Faller M, 2014, ANN ONCOL, V25, P126, DOI 10.1093/annonc/mdt418; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cheng C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13959; Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; E. National Cancer Institute: Surveillance and End Results Program., 2016, SEER FACT SHEET LUNG; ELSTON CW, 1993, J CLIN PATHOL, V46, P189; He M, 2012, CLIN CANCER RES, V18, P1790, DOI 10.1158/1078-0432.CCR-11-2361; Jakobsen JN, 2013, LUNG CANCER, V79, P1, DOI 10.1016/j.lungcan.2012.10.008; Kadota K, 2016, AM J SURG PATHOL, V40, P1579, DOI 10.1097/PAS.0000000000000744; Kawaguchi T, 2016, J CLIN ONCOL, V34, P2247, DOI 10.1200/JCO.2015.64.2322; Kriegsmann M, 2016, TRANSL LUNG CANCER R, V5, P552, DOI 10.21037/tlcr.2016.10.12; Ladanyi M, 2008, MODERN PATHOL, V21, pS16, DOI 10.1038/modpathol.3801018; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martin B, 2004, BRIT J CANCER, V91, P2018, DOI 10.1038/sj.bjc.6602233; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306; Shepherd FA, 2013, J CLIN ONCOL, V31, P2173, DOI 10.1200/JCO.2012.48.1390; Stalhammar G, 2016, MODERN PATHOL, V29, P318, DOI 10.1038/modpathol.2016.34; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2016, EUR RESPIR J, V47, P720, DOI 10.1183/13993003.00035-2016; Tsubochi H, 2006, ANN THORAC SURG, V82, P1198, DOI 10.1016/j.athoracsur.2006.04.069; Valous NA, 2016, MED PHYS, V43, P2936, DOI 10.1118/1.4949003; von Laffert M, 2016, PATHOLOGE, V37, P187, DOI 10.1007/s00292-016-0152-1; Warth A, 2015, PATHOLOGE, V36, P194, DOI 10.1007/s00292-015-0085-0; Warth A, 2015, PNEUMOLOGIE, V69, P477, DOI 10.1055/s-0034-1392446; Warth A, 2014, BRIT J CANCER, V111, P1222, DOI 10.1038/bjc.2014.402; Warth A, 2016, ONCOTARGET, V7, P29761, DOI 10.18632/oncotarget.8858; Warth A, 2014, HISTOPATHOLOGY, V65, P187, DOI 10.1111/his.12379; Warth A, 2014, EUR RESPIR J, V43, P872, DOI 10.1183/09031936.00018013; Warth A, 2013, VIRCHOWS ARCH, V462, P507, DOI 10.1007/s00428-013-1408-2; Warth A, 2012, HISTOPATHOLOGY, V61, P1017, DOI 10.1111/j.1365-2559.2012.04308.x; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Yasuda H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007205; Yasuda H, 2012, LANCET ONCOL, V13, pE23, DOI 10.1016/S1470-2045(11)70129-2	42	3	3	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					408	416		10.1016/j.prp.2017.12.018			9	Pathology	Pathology	GB5EK	WOS:000429085700012	29487011				2019-10-28	
J	Otsuka, H; Kohashi, K; Yoshimoto, M; Ishihara, S; Toda, Y; Yamada, Y; Yamamoto, H; Nakashima, Y; Oda, Y				Otsuka, Hiroshi; Kohashi, Kenichi; Yoshimoto, Masato; Ishihara, Shin; Toda, Yu; Yamada, Yuichi; Yamamoto, Hidetaka; Nakashima, Yasuharu; Oda, Yoshinao			Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Malignant peripheral nerve sheath tumor; H3K27me3; Neurofibromatosis type 1; Polycomb repressive complex 2; Heterochronous	METHYLATION; DIFFERENTIATION; DIAGNOSIS; MARKER; SUZ12; PRC2	The histological definitive diagnosis of malignant peripheral nerve sheath tumor (MPNST) is quite difficult because the morphological features are not specific and no useful immunohistochemical marker has been identified. Loss-of-function mutations in EED or SUZ12, which encode the core subunit of polycomb repressive complex 2 (PRC2), were reported in MPNSTs, and the mutations were shown to cause inactivation of PRC2, leading to loss of trimethylation of histone H3 at lysine 27 (H3K27me3). Immunohistochemistry of H3K27me3 is expected to be a specific marker for MPNSTs. We evaluated immunohistochemical expression of H3K27me3 in MPNSTs with heterologous components and metachronous cases of MPNSTs. Among 145 MPNST samples, 50 (34.5%) showed complete loss of staining, and 45 (31.0%) showed partial loss of staining. Regarding the backgrounds of MPNSTs, 43 patients of neurofibromatosis type 1 (NF-1)-associated MPNST demonstrated 19 (44.2%) complete and 12 (27.9%) partial loss of H3K27me3. Among MPNSTs with heterologous component, almost all of MPNSTs with epithelioid differentiation (8/9 samples, 88.9%) retained H3K27me3, and malignant Triton tumors without epithelioid component lacked H3K27me3 at high rate (91.7%). Five of 20 metachronous MPNST cases showed significantly reduced expression of H3K27me3 between primary and later-occurring tumors, but in some cases increased expression of H3K27me3 in the clinical course (such as complete loss to partial loss) was observed. If the tumors are recurrent or metastatic, H3K27me3 expression should be reduced or at least maintained because loss of H3K27me3 is due to genetic mutation of EED or SUZ12. MPNSTs, especially those associated with NF-1, can occur in heterochronous and multiple patterns, and the identification of increased expression of H3K27me3 during a patient's clinical course can be helpful for determining whether the tumors are heterochronous, multiple or not. As heterochronous and multiple tumors may show lower malignancy compared to recurrent or metastatic tumors, favorable prognosis may be expected when H3K27me3 expression is increased.6	[Otsuka, Hiroshi; Kohashi, Kenichi; Yoshimoto, Masato; Ishihara, Shin; Toda, Yu; Yamada, Yuichi; Yamamoto, Hidetaka; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan; [Otsuka, Hiroshi; Yoshimoto, Masato; Ishihara, Shin; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp					Asano N, 2017, HISTOPATHOLOGY, V70, P385, DOI 10.1111/his.13072; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; DUCATMAN BS, 1983, CANCER, V51, P1028, DOI 10.1002/1097-0142(19830315)51:6<1028::AID-CNCR2820510610>3.0.CO;2-3; Fletcher CDM, 2013, WHO CLASSIFICATION T, P187; Goldblum J. R., 2014, MALIGNANT PERIPHERAL, P855; Kamran SC, 2013, EJSO-EUR J SURG ONC, V39, P46, DOI 10.1016/j.ejso.2012.09.001; Kang YN, 2014, MODERN PATHOL, V27, P55, DOI 10.1038/modpathol.2013.115; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Pyo J. S., 2017, INT J BIOL MARKERS, V23; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z; Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Simon J. A., 2003, MUTAT RES, V647, P21; Stasik CJ, 2006, ARCH PATHOL LAB MED, V130, P1878; Vickie V. J., 2015, AM J SURG PATHOL, V39, P673; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	21	4	5	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					417	425		10.1016/j.prp.2017.12.015			9	Pathology	Pathology	GB5EK	WOS:000429085700013	29482987				2019-10-28	
J	Schmoeckel, E; Kirchner, T; Mayr, D				Schmoeckel, Elisa; Kirchner, Thomas; Mayr, Doris			SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases	PATHOLOGY RESEARCH AND PRACTICE			English	Article						SATB2; LAMN; Mucinous neoplasm in the ovary; Pseudomyxoma peritonei	IMMUNOHISTOCHEMICAL EXPRESSION; CARCINOMAS; DIAGNOSIS; ORIGIN; DISTINCTION; TRACT; CK20	The differentiation between a primary mucinous ovarian neoplasm and an extra-ovarian metastasis in the ovary is often challenging in the histopathologic practice. Among various ovarian metastases from the gastro-intestinal tract the low-grade appendiceal mucinous neoplasm (LAMN) is an important differential diagnosis to consider particularly in case of pseudomyxoma peritonei. A newly recognized marker in the routine diagnostic of a mucinous neoplasm in the ovary is SATB2 (Special AT-rich sequence-binding protein 2). The expression of SATB2 is, within cells of epithelial lineages, mainly restricted to the lower gastro-intestinal tract, indicating colorectal or appendiceal cancer origin. We report seven cases of LAMN, which clinically became apparent due to ovarian metastases in context of pseudomyxoma peritonei or at least small foci of peritoneal tumor spread. An immunohistochemical marker-panel including SATB2, CDX2, CK20, CK7, PAX8, ER and PR revealed a strong expression of SATB2 in all seven cases. On the contrary SATB2-negativity could be demonstrated in the 40 cases of mucinous borderline tumors and primary mucinous carcinomas of the ovary. The histopathologic tentative diagnosis of an ovarian metastasis of LAMN could be confirmed in the findings of the Appendix in six of seven cases. This report supports SATB2 as an additional diagnostic marker for the diagnosis of an ovarian manifestation of LAMN.	[Schmoeckel, Elisa; Kirchner, Thomas; Mayr, Doris] Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Munich, Germany	Schmoeckel, E (reprint author), Ludwig Maximilians Univ Munchen, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.	elisa.schmoeckel@med.uni-muenchen.de					Balasubramanian M, 2011, J MED GENET, V48, P290, DOI 10.1136/jmg.2010.084491; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Pinto PBC, 2012, INT J GYNECOL PATHOL, V31, P313, DOI 10.1097/PGP.0b013e31823f844d; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; de Waal YRP, 2009, INT J GYNECOL CANCER, V19, P1160, DOI 10.1111/IGC.0b013e3181b33cce; DEMOPOULOS RI, 1987, INT J GYNECOL PATHOL, V6, P166, DOI 10.1097/00004347-198706000-00008; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248; Heatley MK, 2012, J CLIN PATHOL, V65, P577, DOI 10.1136/jclinpath-2011-200407; Li ZB, 2017, AM J CLIN PATHOL, V147, P484, DOI [10.1093/ajcp/aqx023, 10.1093/AJCP/AQX023]; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; MAZUR MT, 1984, CANCER, V53, P1978, DOI 10.1002/1097-0142(19840501)53:9<1978::AID-CNCR2820530929>3.0.CO;2-1; McCluggage WG, 2012, J CLIN PATHOL, V65, P596, DOI 10.1136/jcp.2010.085688; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Moore RG, 2004, GYNECOL ONCOL, V93, P87, DOI 10.1016/j.ygyno.2003.12.039; Nonaka D, 2006, HISTOPATHOLOGY, V49, P381, DOI 10.1111/j.1365-2559.2006.02512.x; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Ronnett BM, 1997, AM J SURG PATHOL, V21, P1144, DOI 10.1097/00000478-199710000-00004; Strickland S, 2016, INT J GYNECOL PATHOL, V35, P191, DOI 10.1097/PGP.0000000000000238; Szemes M, 2006, NEUROCHEM RES, V31, P237, DOI 10.1007/s11064-005-9012-8; Vang R, 2006, MODERN PATHOL, V19, P97, DOI 10.1038/modpathol.3800510; Vang R, 2006, MODERN PATHOL, V19, P1421, DOI 10.1038/modpathol.3800698; Vang R, 2006, AM J SURG PATHOL, V30, P1130; Yang C., 2017, AM J SURG PATHOL	25	1	1	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					426	430		10.1016/j.prp.2017.12.008			5	Pathology	Pathology	GB5EK	WOS:000429085700014	29487003				2019-10-28	
J	Wang, HQ; Jie, L; Shi, HY				Wang, Hong-Qun; Jie, Li; Shi, Huai-Yin			Clinicopathological features of low-grade malignant endolymphatic sac tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Low-grade malignant endolymphatic sac tumor; Histology; Immunohistochemistry; VHL syndrome; Prognosis		Background: Low-grade malignant endolymphatic sac tumor (ELST) is a rare neoplasm, occurring in the inner ear and invading the temporal bone. This study aims to investigate the clinicopathological features of low-grade malignant ELSTs. Methods: The clinicopathological data of 21 patients with low-grade malignant ELSTs were collected and analyzed. Results: The patients were aged 16-71 years, with an average age of 40.3 years and a median age of 39 years, and the male to female ratio was 1:1.6. There were 13 cases (61.9%) of ELSTs occurring on the left side, 7 cases (33.3%) on the right side, and 1 case (4.8%) on both sides. Blood types O and B were noted in 71.4% of the patients. Immunohistochemistry showed that CK, EMA and Vim were all positive, and S-100 (71.4%, 10/14), CD56 (75.0%, 9/12), NSE (50.0%, 2/4), and GFAP (11.1%, 1/9) were also positive, while Syn, CgA, TTF-1, TG, CD34, and calcitonin were negative. The Ki-67 index was 4.3% on average. Histologically, cells were arranged in a papillary shape often with branches and abundant fibrous axial vessel. Some cells had an expanded different sized thyroid-follicle-like structure, with the follicles containing red-stained colloids and scallop-like secretary vacuoles. There were expanded cavities. Some cases were in a glandular arrangement, and a few in a nest-like, gland-cystoid arrangement. Most tumors were coated with a monolayer of cubic epithelium, a few cells were flat or columnar, with translucent cytoplasm and light staining. The nuclei were oval, nucleolus was not obvious, chromatin was delicate, and a few nucleoli were small. The tissue was prone to bleeding, with fresh and old bleeding. Approximately half of the patients had necrotic bones, and in some cases the tumor tissue had destroyed the surrounding bone. The background fibrous tissue showed hyperplasia with hyaline degeneration, some had calcification and formation of sandy-gravel bodies. The clinical manifestations were hearing reduction or loss, followed by tinnitus, and accompanied by varying degrees of cranial nerve injury. No patients died during follow-up. Conclusions: Low-grade malignant ELSTs occur most frequently on the left side, with a female preponderance. The disease progressed slowly, with no death, and but relapse in two patients in this series. These tumors are often misdiagnosed.	[Wang, Hong-Qun; Jie, Li; Shi, Huai-Yin] Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China	Shi, HY (reprint author), Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China.	shihuaiyin@sina.com					Bambakidis NC, 2004, OTOL NEUROTOL, V25, P773, DOI 10.1097/00129492-200409000-00021; Bell D, 2011, ANN DIAGN PATHOL, V15, P117, DOI 10.1016/j.anndiagpath.2010.08.009; Du J, 2015, NEUROPATHOLOGY, V35, P410, DOI 10.1111/neup.12200; Ferri E, 2014, CASE REP OTOLARYNGOL, DOI 10.1155/2014/376761; HEFFNER DK, 1989, CANCER, V64, P2292, DOI 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#; Hou ZH, 2012, ACTA OTO-LARYNGOL, V132, P329, DOI 10.3109/00016489.2011.640349; Husseini ST, 2013, AURIS NASUS LARYNX, V40, P25, DOI 10.1016/j.anl.2012.01.009; Jegannathan D, 2016, NEUROL INDIA, V64, P1336, DOI 10.4103/0028-3886.193816; Poletti AM, 2013, HEAD NECK-J SCI SPEC, V35, P1043, DOI 10.1002/hed.22962; Schittenhelm J, 2012, AM J CLIN PATHOL, V138, P85, DOI 10.1309/AJCPPRKNNL09JTLP; Sun YH, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-36; Yilmaz I, 2008, AURIS NASUS LARYNX, V35, P276, DOI 10.1016/j.anl.2007.06.009	12	1	1	1	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					431	435		10.1016/j.prp.2017.12.007			5	Pathology	Pathology	GB5EK	WOS:000429085700015	29482989				2019-10-28	
J	Ji, XN; Xue, YY; Wu, Y; Feng, F; Gao, XD				Ji, Xiaonan; Xue, Yayu; Wu, Yu; Feng, Fang; Gao, Xiangdong			High-expressed CKS2 is associated with hepatocellular carcinoma cell proliferation through down-regulating PTEN	PATHOLOGY RESEARCH AND PRACTICE			English	Article						HCC; DEGs; CKS2; Cell proliferation; CCK8; Colony formation	CYCLIN KINASE SUBUNIT-2; CLINICAL-SIGNIFICANCE; BREAST-CANCER; GENES; CHOLANGIOCARCINOMA; IDENTIFICATION; TUMORIGENESIS; RECURRENCE; PREDICTION; PROTEIN	Background: Hepatocellular carcinoma (HCC) is a product of cumulative genetic, epigenetic, somatic, and endocrine aberrations. Identifying the differentially expressed genes (DEGs) in HCC is of critical importance for diagnosis and treatment. The purpose of the present study was to screen the key genes associated with hepatocellular carcinoma and to investigate the functions underlying hepatocellular carcinoma progression. Materials and methods: The gene expression profile of GSE64041, GSE40367 and GSE60502, including 100 specimens from HCC patients and 92 specimens from normal liver controls, was downloaded from the GEO database. DEGs were screened using the online analysis tool from the GCBI website and validated by Q-PCR and Kaplan-Meier survival analysis. After knockdown by siRNA in HepG2/C3A and Bel7402 HCC cells, the CCK-8 assay and colony formation assay were used to measure the clonogenic capacity of the tumor cells. Western blotting assay was used to measure the expression of PTEN. Results: Five up-regulated genes were identified as overlapping genes associated with tumor cell activation. Upon validation by Q-PCR and Kaplan-Meier survival analysis, CKS2 was selected for further study. Although the results of CCK-8 did not show a significant difference, the colony formation assay results indicated that the silencing of CKS2 significantly inhibited cancer cell proliferation. Further study found that CKS2 knockdown induced PTEN up-regulation and may associate with P53 pathway activation. Conclusion: These findings indicated that CKS2 play a role in tumor activation and serve as a useful potential target for the treatment of HCC.	[Ji, Xiaonan; Xue, Yayu; Wu, Yu; Feng, Fang; Gao, Xiangdong] China Pharmaceut Univ, Sch Life Sci & Technol, Jiangsu Key Lab Druggabil Biopharmaceut, Nanjing 210009, Jiangsu, Peoples R China	Gao, XD (reprint author), China Pharmaceut Univ, Sch Life Sci & Technol, Jiangsu Key Lab Druggabil Biopharmaceut, Nanjing 210009, Jiangsu, Peoples R China.	jxncpu@cpu.edu.cn; 443896450@qq.com; 4022198@qq.com; j0512@126.com; xdgao@cpu.edu.cn			College Students Innovation Project for the R&D of Novel Drugs [J1310032]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81430082]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by College Students Innovation Project for the R&D of Novel Drugs (J1310032), the National Natural Science Foundation of China (No. 81430082) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bi DB, 2015, COMPUT BIOL CHEM, V56, P71, DOI 10.1016/j.compbiolchem.2015.04.001; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860; Forner A, 2012, LANCET ONCOL, V13, P750, DOI 10.1016/S1470-2045(12)70271-1; Hsu CW, 2017, J CANCER, V8, P1378, DOI 10.7150/jca.17478; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Khattar Vinayak, 2013, J Cancer Ther, V4, P1341; Lan YS, 2008, INT J CANCER, V123, P543, DOI 10.1002/ijc.23548; Makowska Z, 2016, J PATHOL CLIN RES, V2, P80, DOI 10.1002/cjp2.37; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Roessler S, 2015, INT J BIOL SCI, V11, P88, DOI 10.7150/ijbs.10583; Shen DY, 2013, LIVER INT, V33, P137, DOI 10.1111/liv.12014; Shen DY, 2010, LIVER INT, V30, P119, DOI 10.1111/j.1478-3231.2009.02106.x; Shi M, 2014, EUR J CANCER, V50, P928, DOI 10.1016/j.ejca.2013.11.026; Wang JJ, 2013, DIS ESOPHAGUS, V26, P729, DOI 10.1111/dote.12013; Wang JI, 2014, INT J CLIN EXP PATHO, V7, P8593; Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815; Wen DY, 2014, ANDROLOGIA, V46, P625, DOI 10.1111/and.12127; Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; Woo HG, 2008, CLIN CANCER RES, V14, P2056, DOI 10.1158/1078-0432.CCR-07-1473; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Yu MH, 2013, ONCOL LETT, V6, P777, DOI 10.3892/ol.2013.1456; Zhang YW, 2013, J HEPATOL, V58, P502, DOI 10.1016/j.jhep.2012.11.002	26	2	2	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					436	441		10.1016/j.prp.2017.12.006			6	Pathology	Pathology	GB5EK	WOS:000429085700016	29487004				2019-10-28	
J	Liu, X; Du, P; Han, L; Zhang, AL; Jiang, K; Zhang, QY				Liu, Xi; Du, Ping; Han, Lei; Zhang, Anling; Jiang, Kui; Zhang, Qingyu			Effects of miR-200a and FH535 combined with taxol on proliferation and invasion of gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gastric cancer; miR-200a; FH535; Taxol; EMT	EPITHELIAL-MESENCHYMAL TRANSITION; CATENIN SIGNALING PATHWAY; BETA-CATENIN; EXPRESSION; ADENOCARCINOMA; CELLS; TRANSLOCATION; PROGRESSION; SUPPRESSES; PACLITAXEL	Gastric cancer is one of the most common cancers in the world; taxol displayed modest efficacy as first-line chemotherapy for gastric cancer, conversely, it has limitations used alone. beta-catenin is a multifunctional oncogenic protein and the elevation in expression and activity of beta-catenin has been implicated in many cancers. Therefore, we assume that the inhibition of beta-catenin can enhanced the efficacy of taxol. The purpose of this study was to investigate the inhibitory effect of miR-200a mimics, FH535 combined with taxol on proliferation and invasion of human gastric cancer cell lines SGC-7901 and BGC-823. In the current study, we identified that the combination of FH535 and miR-200a with taxol had potent growth-inhibitory and pro-apoptotic effects. Further, similar results were also observed in vivo, intratumoral injection of FH535, taxol and miR-200a mimics which also delayed tumor growth in nude mice harboring subcutaneous SGC-7901 xenografts. Collectively, miR-200a and FH535 can enhance the inhibitory effect of taxol on cell proliferation and moderate the invasion of human gastric cancer.	[Liu, Xi; Jiang, Kui; Zhang, Qingyu] Tianjin Med Univ Gen Hosp, Dept Gastroenterol, 154 An Shan Rd, Tianjin 300052, Peoples R China; [Liu, Xi] Tianjin Nankai Hosp, Dept Gastroenterol, Tianjin, Peoples R China; [Du, Ping] Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Zhejiang, Peoples R China; [Han, Lei; Zhang, Anling] Minist Educ, Key Lab Neurotrauma Variat & Regenerat, Beijing, Peoples R China; [Han, Lei; Zhang, Anling] Tianjin Municipal Govt, Tianjin, Peoples R China	Zhang, QY (reprint author), Tianjin Med Univ Gen Hosp, Dept Gastroenterol, 154 An Shan Rd, Tianjin 300052, Peoples R China.	zhangqy@tijmu.edu.cn			China National Natural Scientific FundNational Natural Science Foundation of China [81172356]	This work was supported by the China National Natural Scientific Fund (Grant No.81172356).	Ajani JA, 2007, J CLIN ONCOL, V25, P3205, DOI 10.1200/JCO.2006.10.4968; Bargiela-Iparraguirre J, 2014, CELL CYCLE, V13, P3590, DOI 10.4161/15384101.2014.962952; Bauer K, 2015, J GASTRIC CANCER, V15, P10, DOI 10.5230/jgc.2015.15.1.10; Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1985, DOI 10.1002/cncr.28002; Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463; Cong NN, 2013, ONCOL REP, V29, P1579, DOI 10.3892/or.2013.2267; Dai XC, 2017, ONCOTARGET, V8, P30495, DOI 10.18632/oncotarget.13721; Das A., 2015, TUMOUR BIOL; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Gedaly R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099272; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Hamada Fumihiko, 2009, Kaibogaku Zasshi, V84, P111; Han L, 2012, CNS NEUROSCI THER, V18, P573, DOI 10.1111/j.1755-5949.2012.00344.x; He YJ, 2014, MOL MED REP, V9, P137, DOI 10.3892/mmr.2013.1774; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hu ZL, 2015, CANCER-AM CANCER SOC, V121, P214, DOI 10.1002/cncr.29039; Kim YW, 2014, DRUG DES DEV THER, V8, P293, DOI 10.2147/DDDT.S51969; Koutsaki M, 2014, CANCER LETT, V351, P173, DOI 10.1016/j.canlet.2014.05.022; Lee S. H., 2015, ONCOGENE; Leskela S, 2011, ENDOCR-RELAT CANCER, V18, P85, DOI 10.1677/ERC-10-0148; Lobert S, 2013, BIOCHEMISTRY-US, V52, P5482, DOI 10.1021/bi400340g; Saifo MS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-310; Sethi S, 2014, CLIN GENET, V86, P68, DOI 10.1111/cge.12362; Shi ZD, 2012, J NEUROIMMUNE PHARM, V7, P892, DOI 10.1007/s11481-012-9354-3; Stenner M, 2011, HISTOPATHOLOGY, V58, P1117, DOI 10.1111/j.1365-2559.2011.03805.x; Su J, 2012, INT J ONCOL, V40, P1162, DOI 10.3892/ijo.2011.1322; Trumbach D, 2015, CELL TISSUE RES, V359, P161, DOI 10.1007/s00441-014-1911-z; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wong H. R., 2015, MOL THER; Yue XA, 2010, BRAIN RES, V1366, P27, DOI 10.1016/j.brainres.2010.10.032	31	1	2	0	8	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					442	449		10.1016/j.prp.2017.12.004			8	Pathology	Pathology	GB5EK	WOS:000429085700017	29482988				2019-10-28	
J	Deng, HY; Liu, JY; Duan, XJ; Liu, YP				Deng, Huiyan; Liu, Junying; Duan, Xiaojin; Liu, Yueping			The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Adenocarcinoma; Epidermal growth factor receptor; Lung cancer; Mutation; Pathological features; Prognosis	CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; SUBTYPES	To detect the relationship of the epidermal growth factor receptor (EGFR) mutation status and the clinicopathologic features. Six hundred thirty-three patients with pathologically confirmed lung adenocarcinoma who underwent lung cancer resection surgery at the Fourth Hospital of Hebei Medical University between April 2012 and April 2015 were selected for the study. The 32 types of mutations in exons 18-21 of the EGFR gene were detected. The total EGFR mutation rate among patients with lung adenocarcinoma was 56.9%. The mutation rates were 71.2% among females and 42.8% among males (P < 0.05). Among patients with TNM stage I, II, III, and IV disease, the EGFR mutation rates were significant differences (P < 0.05). Concerning different subtypes of lung adenocarcinoma, the EGFR mutation rates were differences, and these differences were statistically significant (P < 0.05). Cox multivariate regression model analysis considering EGFR mutation status revealed that differences in TNM stage (P < 0.01), smoker status, and tumor size were statistically significant predictors. Patients with minimally invasive and lepidic adenocarcinomas were categorized as low-risk group with high EGFR mutation rate; Patients with micro-papillary and solid adenocarcinomas were categorized as high-risk with lower EGFR mutation rate, so there are different mechanisms in different types of adenocarcinomas.	[Deng, Huiyan; Liu, Junying; Liu, Yueping] Hebei Med Univ, Dept Pathol, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China; [Duan, Xiaojin] Hebei Med Univ, Dept Med Record Management, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China	Liu, YP (reprint author), Hebei Med Univ, Dept Pathol, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China.	annama@163.com					Alegre E., 2016, TUMOUR BIOL; Campbell L, 2010, EXPERT OPIN PHARMACO, V11, P1343, DOI 10.1517/14656566.2010.481283; Cha MY, 2012, J MED CHEM, V55, P2846, DOI 10.1021/jm201758g; Chen Wanqing, 2016, CA-CANCER J CLIN, V05, P149; Cheng L, 2014, INT J NANOMED, V9, P921, DOI 10.2147/IJN.S53310; Choi JR, 2016, ANN OCCUP ENVIRON ME, V28, DOI 10.1186/s40557-016-0095-2; Esteban E, 2015, CANCER EPIDEMIOL, V39, P291, DOI 10.1016/j.canep.2015.02.003; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Hsiao SH, 2014, MOL CLIN ONCOL, V2, P252, DOI 10.3892/mco.2013.232; Kuribayashi K, 2016, J CANCER RES THER, V12, P528, DOI 10.4103/0973-1482.174185; Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072; Liu C, 2014, LUNG CANCER, V86, P164, DOI 10.1016/j.lungcan.2014.08.018; Nurwidya F, 2014, RESPIR INVESTIG, V52, P82, DOI 10.1016/j.resinv.2013.07.007; Parums DV, 2014, DRUG TODAY, V50, P503, DOI 10.1358/dot.2014.50.7.2185913; Singh D., 2016, MINI REV MED CHEM; Smaill J. B., 2016, J MED CHEM; Song SY, 2014, ONCOL LETT, V7, P307, DOI 10.3892/ol.2013.1707; Sun Y, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-148; Tang Y, 2016, EXPERT REV MOL DIAGN, V16, P915, DOI 10.1080/14737159.2016.1199961; Travis WD, 2015, WHO CLASSIFICATION T; Yu DP, 2014, BIOMED REP, V2, P481, DOI 10.3892/br.2014.261	21	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					450	454		10.1016/j.prp.2017.09.008			5	Pathology	Pathology	GB5EK	WOS:000429085700018	29496311				2019-10-28	
J	Handra-Luca, A; Tissier, F				Handra-Luca, Adriana; Tissier, Frederique			Infracentimetric parathyroid cysts in hyperparathyroidemia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Parathyroid; Cyst; Hyperparathyroidism; Hypercalcemia; hyperplasia; Adenoma; Vascular malformation; Parathyroiditis; Azzopardi phenomenon; Macrophage	E-CADHERIN; EXPRESSION; PATHOLOGY; GLANDULES	Parathyroid cysts are rare, more frequently functional. Here we report 2 cases of infracentimetric parathyroid cysts identified in parathyroid adenomas resected for hyperparathyroidemia and hypercalcemia. Chronic parathyroiditis was associated. Chromogranin and E-cadherin/uvomorulin were expressed heterogeneously in the cyst lining and in parathyroid cells. In one of the cases, CD10 and CD56 were expressed by the luminal membrane of parathyroid cells. CD31 was expressed in inter parathyroid cell monocyte/macrophage membrane as well as CD68, several cells showing also CD10 and/or CD56 expression. Ki67 was expressed in sparse parathyroid cells, some of binucleated cells or with nuclear clumps. In conclusion, heterogeneous E-cadherin expression in parathyroid cells may only indirectly related to cyst formation while CD56 and CD10 seem not to relate at all. The relevance of nuclear clumps and Azzopardi phenomenon as well as of the presence of disperse monocyte/macrophage-type cells for the parathyroiditis lesions remains to be further investigated.	[Handra-Luca, Adriana] Univ Paris Nord Sorbonne Cite, GHU Avicenne, AP HP, Serv Anat Pathol, 125 Rue Stalingrad, F-93009 Bobigny, France; [Tissier, Frederique] Univ Paris 06, Sorbonne Univ, Hop Univ Pitie Salpetriere Charles Foix, AP HP, Paris, France	Handra-Luca, A (reprint author), Univ Paris Nord Sorbonne Cite, GHU Avicenne, AP HP, Serv Anat Pathol, 125 Rue Stalingrad, F-93009 Bobigny, France.	adriana.handra-luca@aphp.fr					AZZOPARDI JG, 1959, J PATHOL BACTERIOL, V78, P513, DOI 10.1002/path.1700780218; BLACK BM, 1949, SURGERY, V25, P941; Castleman B, 1935, AM J PATHOL, V11, P1; Castleman D. B., 1977, TUMORS PARATHYROID; Chan JKC, 2014, INT J SURG PATHOL, V22, P12, DOI 10.1177/1066896913517939; Fendrich V, 2009, EUR J ENDOCRINOL, V160, P695, DOI 10.1530/EJE-08-0662; Gross L, 1940, AM J PATHOL, V16, P375; Hamy A, 2002, ANN CHIR, V127, P203, DOI 10.1016/S0003-3944(01)00712-X; Janovic B. D., 1965, INT ARCH ALLER A IMM, V26, P18; KRUG J, 1991, J ENDOCRINOL, V131, P193, DOI 10.1677/joe.0.1310193; Lydiatt D D, 1993, Ear Nose Throat J, V72, P142; Rosai J., 2011, ROSAI ACKEMANS SURG; Schneider R, 2015, WORLD J SURG, V39, P2477, DOI 10.1007/s00268-015-3149-7; SELYE H, 1964, AM J PATHOL, V45, P251; SELYE H, 1964, J NUTR, V84, P97, DOI 10.1093/jn/84.2.97; Thompson RL, 1908, J MED RES, V19, P135; Thomson RL, 1908, J MED RES, V19, P121	17	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					455	458		10.1016/j.prp.2017.09.018			4	Pathology	Pathology	GB5EK	WOS:000429085700019	29496307				2019-10-28	
J	Magro, G; Angelico, G; Righi, A; Salvatorelli, L				Magro, Gaetano; Angelico, Giuseppe; Righi, Alberto; Salvatorelli, Lucia			Small round cell myofibroblastoma of the oral cavity: A tumor mimicking embryonal rhabdomyosarcoma	PATHOLOGY RESEARCH AND PRACTICE			English	Letter							MAMMARY-TYPE MYOFIBROBLASTOMA		[Magro, Gaetano; Salvatorelli, Lucia] Univ Catania, Dept Med & Surg Sci & Adv Technol, Anat Pathol, Catania, Italy; [Angelico, Giuseppe] Univ Messina, Dept Human Pathol Adult & Dev Age G Barresi, Unit Anat Pathol, Messina, Italy; [Righi, Alberto] Rizzoli Inst, Dept Pathol, Bologna, Italy	Magro, G (reprint author), Policlin Univ G Rodolico, Anat Patol, Dipartimento Sci Med & Chirurg & Tecnol Avanzate, Via S Sofia 87, I-95123 Catania, Italy.	g.magro@unict.it	Righi, Alberto/J-6028-2016	Righi, Alberto/0000-0002-1074-0155; Angelico, Giuseppe/0000-0003-4808-2052			Flucke U, 2011, MODERN PATHOL, V24, P82, DOI 10.1038/modpathol.2010.170; Howitt BE, 2016, AM J SURG PATHOL, V40, P361, DOI 10.1097/PAS.0000000000000540; Magro G, 2016, HISTOL HISTOPATHOL, V31, P1, DOI 10:14670; Magro G, 2014, HUM PATHOL, V45, P1647, DOI 10.1016/j.humpath.2014.03.020; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015; Magro G, 2012, HUM PATHOL, V43, P243, DOI 10.1016/j.humpath.2011.04.027; Magro G, 2008, PATHOL RES PRACT, V204, P837, DOI 10.1016/j.prp.2008.05.007	7	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					463	465		10.1016/j.prp.2017.12.005			3	Pathology	Pathology	GB5EK	WOS:000429085700021	29487010				2019-10-28	
J	Roy, M; Connor, J; Al-Niaimi, A; Rose, SL; Mahajan, A				Roy, Madhuchhanda; Connor, Joseph; Al-Niaimi, Ahmed; Rose, Stephen L.; Mahajan, Aparna			Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma	HUMAN PATHOLOGY			English	Article						ALDHIA1; High-grade ovarian serous carcinoma; Platinum-based therapy; Chemo-refractoriness; Cancer stem cell markers	CANCER STEM-CELLS; CLINICAL-TRIAL OUTCOMES; CA 125 KINETICS; MESENCHYMAL TRANSITION; REDUCES CHEMOTHERAPY; INHIBITION; RESISTANCE; SURVIVAL; HETEROGENEITY; TRANSPORTERS	Aldehyde dehydrogenase-1A1 (ALDH1Al), CD133, CD44, and CD24 have been reported as cancer stem cell markers in ovarian cancers. The goal of our study was to assess the prognostic significance of these markers in patients with advanced serous ovarian cancer. Formalin-fixed, paraffin-embedded tissues from 347 ovarian cancers were used to construct a microarray. Immunohistochemical studies for ALDH1A1, CD133, CD44, and CD24 were performed and scored semiquantitatively by 2 pathologists based on intensity and percent of positive immunoreactive cells. Immunohistochemistry was compared to clinical parameters and survival. Of the 347 cases, early stage disease, nonserous tumors, cases with incomplete therapy, and cores with no tumor were excluded. Immunohistochemistry was interpretable in 124 of the 136 stage III and IV ovarian serous carcinoma. ALDHIAI, CD24, and CD44 were variably detected in both tumor and stromal cells, and immunoreactivity in tumor was stronger than in stromal cells. CD133 immunoreactivity was not quantified due to nonspecific staining in tumor and stroma. Statistical analyses using chi(2) and Student t test revealed that ALDHIA1-positive (n = 53) carcinoma were 3 times more likely to demonstrate platinum refractoriness than ALDHIA1-negative (n = 71) tumors (17% vs. 6%, respectively; p = .04); however, neither progression free nor overall survival was influenced by ALDH1A1 status in this cohort. The expression of CD44 and CD24 had no clinicopathological associations in the present study. Our study supports that ALDH1A1 expression is associated with poor response to platinum-based therapy in patients with high-grade ovarian serous carcinoma. Further study of this relationship is needed to understand how this could impact clinical care. (C) 2017 Elsevier Inc. All rights reserved.	[Roy, Madhuchhanda; Connor, Joseph; Mahajan, Aparna] Univ Wisconsin Hosp & Clin, Dept Pathol, Madison, WI 53792 USA; [Al-Niaimi, Ahmed; Rose, Stephen L.] Univ Wisconsin Hosp & Clin, Dept Obstet & Gynecol, Div Gynecol Oncol, Madison, WI 53792 USA	Mahajan, A (reprint author), Dept Pathol & Lab Med, D4-208B CSC-2472,600 Highland Ave, Madison, WI 53792 USA.	AMahajan@uwhealth.org			UW Department of Pathology; UW Department of Gynecologic Oncology	This work was supported by grants from UW Departments of Pathology and Gynecologic Oncology.	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; Alniaimi AN, 2015, INT J GYNECOL CANCER, V25, P208, DOI 10.1097/IGC.0000000000000359; Barlin JN, 2013, GYNECOL ONCOL, V130, P284, DOI 10.1016/j.ygyno.2013.05.006; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Buller RE, 1996, AM J OBSTET GYNECOL, V174, P1241, DOI 10.1016/S0002-9378(96)70667-1; Burgos-Ojeda D, 2012, CANCER LETT, V322, P1, DOI 10.1016/j.canlet.2012.02.002; Chui MH, 2015, MODERN PATHOL, V28, P437, DOI 10.1038/modpathol.2014.89; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Douville J, 2009, STEM CELLS DEV, V18, P17, DOI 10.1089/scd.2008.0055; Fowler WC, 1996, AM J OBSTET GYNECOL, V174, P1253; Garson K, 2015, REPRODUCTION, V149, pR59, DOI 10.1530/REP-14-0234; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Hardin H, 2013, HUM PATHOL, V44, P1707, DOI 10.1016/j.humpath.2013.01.009; Januchowski R, 2016, INT J BIOCHEM CELL B, V78, P248, DOI 10.1016/j.biocel.2016.07.017; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P240, DOI 10.1016/j.biopha.2012.11.011; Kim IG, 2014, ONCOGENE, V33, P3908, DOI 10.1038/onc.2013.373; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kyrgiou M, 2006, JNCI-J NATL CANCER I, V98, P1655, DOI 10.1093/jnci/djj443; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Larzabal L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079798; Ledermann JA, 2010, ANN ONCOL, V21, P218, DOI 10.1093/annonc/mdq377; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Moreb JS, 2000, J PHARMACOL EXP THER, V293, P390; Ricci F, 2014, J CANC SCI THER, V6, P298, DOI [10.4172/1948-5956.1000284, DOI 10.4172/1948-5956.1000284]; Sharrow AC, 2016, GYNECOL ONCOL, V142, P341, DOI 10.1016/j.ygyno.2016.03.022; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Sugihara E, 2013, INT J CANCER, V132, P1249, DOI 10.1002/ijc.27961; Suidan RS, 2014, GYNECOL ONCOL, V134, P455, DOI 10.1016/j.ygyno.2014.07.002; Thigpen T, 2004, CANCER INVEST, V22, P21, DOI 10.1081/CNV-200030115	37	5	5	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						1	6		10.1016/j.humpath.2017.06.025			6	Pathology	Pathology	GB3PJ	WOS:000428969600001	28851663				2019-10-28	
J	Weissferdt, A; Kalhor, N; Bishop, JA; Jang, SJ; Ro, J; Petersson, F; Wu, BC; Langman, G; Bancroft, H; Bi, YL; Meng, YX; Medeiros, F; Brunnstrom, H; Spagnolo, D; Chai, SM; Laycock, A; Wakely, PE; Elmberger, G; Soares, FA; Campos, AH; Gumurdulu, D; Alvarado-Cabrero, I; Coppola, D; Correa, AM; Rice, D; Mehran, RJ; Sepesi, B; Walsh, G; Kaiser, L; Moran, CA				Weissferdt, Annikka; Kalhor, Neda; Bishop, Justin A.; Jang, Se Jin; Ro, Jae; Petersson, Fredrik; Wu, Bingcheng; Langman, Gerald; Bancroft, Hollie; Bi, Yalan; Meng, Yunxiao; Medeiros, Filomena; Brunnstrom, Hans; Spagnolo, Dominic; Chai, Siaw Ming; Laycock, Andrew; Wakely, Paul E., Jr.; Elmberger, Goran; Soares, Fernando A.; Campos, Antonio H.; Gumurdulu, Derya; Alvarado-Cabrero, Isabel; Coppola, Domenico; Correa, Arlene M.; Rice, David; Mehran, Reza J.; Sepesi, Boris; Walsh, Garrett; Kaiser, Larry; Moran, Cesar A.			Thymoma: a clinicopathological correlation of 1470 cases	HUMAN PATHOLOGY			English	Article						Thymoma; Classification; Staging; Thymus; Mediastinum	THYMIC EPITHELIAL TUMORS; FORTHCOMING 8TH EDITION; STAGING PROJECT PROPOSALS; WORLD-HEALTH-ORGANIZATION; EVIDENCE-BASED PATHOLOGY; TNM CLASSIFICATION; PROGNOSTIC-FACTORS; MALIGNANT-TUMORS; HISTOLOGIC CLASSIFICATION; SYSTEM	We present 1470 surgical resections for thymoma identified in the pathology files of 14 institutions from 11 countries with the purpose of determining and correlating a simplified histological classification of thymoma and pathological staging with clinical outcome. The study population was composed of 720 men and 750 women between the ages of 12 and 86 years (average, 54.8 years). Clinically, 137 patients (17%) had a history of myasthenia gravis, 31 patients (3.8%) of other autoimmune disease, and 55 (6.8%) patients of another neoplastic process. Surgical resection was performed in all patients. Histologically, 1284 (87.13%) cases were thymomas (World Health Organization types A, B1, and B2, and mixed histologies), and 186 (12.7%) were atypical thymomas (World Health Organization type B3). Of the entire group, 630 (42.9%) were encapsulated thymomas, and 840 (57.9%) were invasive thymomas in different stages. Follow-up information was obtained in 1339 (91%) patients, who subsequently were analyzed by univariate and multivariate statistical analysis. Follow-up ranging from 1 to 384 months was obtained (mean, 69.2 months) showing tumor recurrence in 136 patients (10.1%), whereas 227 died: 64 (28.2%) due to tumor and 163 (71.8%) due to other causes. Statistical analysis shows that separation of these tumors into thymoma and atypical thymoma is statistically significant (P = .001), whereas tumor staging into categories of encapsulated, minimally invasive, and invasion into adjacent organs offers a meaningful clinical assessment with a P = .038. Our findings suggest that our simplified histological schema and pathological staging system are excellent predictors of clinical outcome. (C) 2017 Elsevier Inc. All rights reserved.	[Weissferdt, Annikka; Kalhor, Neda; Moran, Cesar A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Bishop, Justin A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; [Jang, Se Jin] Univ Ulsan, Asan Med Ctr, Sch Med, Seoul, South Korea; [Ro, Jae] Methodist Hosp, 6535 Fannin, Houston, TX 77030 USA; [Petersson, Fredrik; Wu, Bingcheng] Natl Univ Singapore Hosp, Singapore, Singapore; [Langman, Gerald; Bancroft, Hollie] Heart England NHS Fdn Trust, Birmingham, W Midlands, England; [Bi, Yalan; Meng, Yunxiao] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China; [Bi, Yalan; Meng, Yunxiao] Beijing Union Med Coll Hosp, Beijing, Peoples R China; [Medeiros, Filomena] Ctr Hosp Lisboa Norte, Hosp Pulido Valente, Sery Anat Patol, Lisbon, Portugal; [Brunnstrom, Hans] Lund Univ, Dept Clin Sci Lund, Lab Med, Pathol, Lund, Sweden; [Spagnolo, Dominic; Chai, Siaw Ming; Laycock, Andrew] PathWest Lab Med Western Australia, Nedlands, WA, Australia; [Spagnolo, Dominic; Chai, Siaw Ming; Laycock, Andrew] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA, Australia; [Spagnolo, Dominic; Chai, Siaw Ming; Laycock, Andrew] Univ Notre Dame, Fremantle, WA, Australia; [Wakely, Paul E., Jr.] Ohio State Univ, Columbus, OH 43210 USA; [Elmberger, Goran] Pathol Orebro Univ Hosp, Dept Lab Med, Orebro, Sweden; [Soares, Fernando A.; Campos, Antonio H.] AC Camargo Canc Ctr, Sao Paulo, Brazil; [Gumurdulu, Derya] Cukurova Univ, Fac Med, Adana, Turkey; [Alvarado-Cabrero, Isabel] Mexican Oncol Hosp, Mexico City, DF, Mexico; [Coppola, Domenico] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Correa, Arlene M.; Rice, David; Mehran, Reza J.; Sepesi, Boris; Walsh, Garrett] Univ Texas MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; [Kaiser, Larry] Temple Univ, Sch Med, Philadelphia, PA 19122 USA	Moran, CA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	cesarmoran@mdanderson.org	Campos, Antonio Hugo/AAB-9287-2019; Kaiser, Larry/L-7940-2019	Campos, Antonio Hugo/0000-0001-5322-7549; Brunnstrom, Hans/0000-0001-7402-138X			Asamura Hisao, 2004, Interact Cardiovasc Thorac Surg, V3, P163, DOI 10.1016/S1569-9293(03)00265-2; Bedini AV, 2005, ANN THORAC SURG, V80, P1994, DOI 10.1016/j.athoracsur.2005.07.019; BERGH NP, 1978, ANN THORAC SURG, V25, P91, DOI 10.1016/S0003-4975(10)63498-4; BERNATZ PE, 1973, SURG CLIN N AM, V53, P885; BERNATZ PE, 1961, J THORAC CARDIOV SUR, V42, P424; Bhora FY, 2014, J THORAC ONCOL, V9, pS88, DOI 10.1097/JTO.0000000000000293; Castleman B., 1955, TUMORS THYMUS GLAND; Chalabreysse L, 2002, AM J SURG PATHOL, V26, P1605, DOI 10.1097/00000478-200212000-00008; Detterbeck FC, 2013, J THORAC ONCOL, V8, P1467, DOI 10.1097/JTO.0000000000000017; Detterbeck FC, 2013, CHINESE MED J-PEKING, V126, P2186, DOI 10.3760/cma.j.issn.0366-6999.20130177; Guerrera F, 2015, EUR J CARDIO-THORAC, V47, P1037, DOI 10.1093/ejcts/ezu410; Gupta R, 2008, ARCH PATHOL LAB MED, V132, P926, DOI 10.1043/1543-2165(2008)132[926:EPATPE]2.0.CO;2; KOGA K, 1994, PATHOL INT, V44, P359; Kondo K, 2014, J THORAC ONCOL, V9, pS81, DOI 10.1097/JTO.0000000000000291; Kondo K, 2010, J THORAC ONCOL, V5, pS352, DOI 10.1097/JTO.0b013e3181f20f3b; Marchevsky AM, 2008, CANCER-AM CANCER SOC, V112, P2780, DOI 10.1002/cncr.23492; MARINO M, 1985, VIRCHOWS ARCH A, V407, P119, DOI 10.1007/BF00737071; Marx A, 2014, J THORAC ONCOL, V9, P596, DOI 10.1097/JTO.0000000000000154; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; Moran CA, 2000, AM J CLIN PATHOL, V114, P760; Moran CA, 2012, AM J CLIN PATHOL, V137, P444, DOI 10.1309/AJCP76KEGWQKWOKA; Moran CA, 2012, AM J CLIN PATHOL, V137, P451, DOI 10.1309/AJCP36ALGUZWOSEA; Moran CA, 2010, AM J CLIN PATHOL, V134, P793, DOI 10.1309/AJCP7KBP4QQLRLXW; Moran CA, 2008, CURR TREAT OPTION ON, V9, P288, DOI 10.1007/s11864-009-0084-6; Nicholson AG, 2014, J THORAC ONCOL, V9, pS73, DOI 10.1097/JTO.0000000000000303; Regnard JF, 1996, J THORAC CARDIOV SUR, V112, P376, DOI 10.1016/S0022-5223(96)70265-9; Rieker RJ, 2002, INT J CANCER, V98, P900, DOI 10.1002/ijc.10255; Rosai J, 1999, HIST TYPING TUMOURS; Rosai J, 1975, TUMORS THYMUS 2 SERI; Safieddine N, 2014, J THORAC ONCOL, V9, P1018, DOI 10.1097/JTO.0000000000000215; Suster S, 1999, AM J CLIN PATHOL, V111, P826; Travis W. D., 2004, PATHOLOGY GENETICS; Travis WD, 2015, WHO CLASSIFICATION T; Wick MR, 2008, HEMATOL ONCOL CLIN N, V22, P527, DOI 10.1016/j.hoc.2008.03.008; WILKINS EW, 1991, ANN THORAC SURG, V51, P888, DOI 10.1016/0003-4975(91)90999-7; YAMAKAWA Y, 1991, CANCER, V68, P1984, DOI 10.1002/1097-0142(19911101)68:9<1984::AID-CNCR2820680923>3.0.CO;2-P; Zucali PA, 2013, LUNG CANCER, V79, P236, DOI 10.1016/j.lungcan.2012.11.015	37	4	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						7	15		10.1016/j.humpath.2017.08.018			9	Pathology	Pathology	GB3PJ	WOS:000428969600002	28851660				2019-10-28	
J	Sinha, N; Gaston, D; Manders, D; Goudie, M; Matsuoka, M; Xie, T; Huang, WY				Sinha, Namita; Gaston, Daniel; Manders, Daniel; Goudie, Marissa; Matsuoka, Makoto; Xie, Tao; Huang, Weei-Yuarn			Characterization of genome-wide copy number aberrations in colonic mixed adenoneuroendocrine carcinoma and neuroendocrine carcinoma reveals recurrent amplification of PTGER4 and MYC genes	HUMAN PATHOLOGY			English	Article						Mixed adenoneuroendocrine carcinoma; Neuroendocrine carcinoma; Copy number aberrations; Amphicrine carcinoma; Prostaglandin E2 receptors	EP4 RECEPTOR; CANCER; INSTABILITY; ENTITY; TUMORS	Colonic mixed adenoneuroendocrine carcinoma (MANEC) is an aggressive neoplasm with worse prognosis compared with adenocarcinoma. To gain a better understanding of the molecular features of colonic MANEC, we characterized the genome-wide copy number aberrations of 14 MANECs and 5 neuroendocrine carcinomas using the OncoScan FFPE (Affymetrix, Santa Clara, CA) assay. Compared with 269 colonic adenocarcinomas, 19 of 42 chromosomal arms of MANEC exhibited a similar frequency of major aberrant events as adenocarcinomas, and 13 chromosomal arms exhibited a higher frequency of copy number gains Among them, the most significant chromosomal arms were 5p (77% versus 13%, P =. 000012) and 8q (85% versus 33%, P =. 0018). The Genomic Identification of Significant Targets in Cancers algorithm identified 7 peaks that drive the tumorgenesis of MANEC. For all except 5p13.1, the peaks largely overlapped with those of adenocarcinoma. Two tumors exhibited MYC amplification localized in 8q24.21, and 2 tumors exhibited PTGER4 amplification localized in 5p13.1. A total of 8 tumors exhibited high copy number gain of PTGER4 and/or MYC. Whereas the frequency of MYC amplification was similar to adenocarcinoma (10.5% versus 4%, P =. 2), the frequency of PTGER4 amplification was higher than adenocarcinoma (10.5% versus 0.3%, P =. 01). Our study demonstrates similar, but also distinct, copy number aberrations in MANEC compared with adenocarcinoma and suggests an important role for the MYC pathway of colonic carcinoma with neuroendocrine differentiation. The discovery of recurrent PTGER4 amplification implies a potential of exploring targeting therapy to the prostaglandin synthesis pathways in a subset of these tumors. (C) 2017 Elsevier Inc. All rights reserved.	[Sinha, Namita; Gaston, Daniel; Manders, Daniel; Goudie, Marissa; Matsuoka, Makoto; Huang, Weei-Yuarn] Dalhousie Univ, QEII Hlth Sci Ctr, Dept Pathol, Halifax, NS B3H 1V8, Canada; [Xie, Tao] Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA 92121 USA	Huang, WY (reprint author), Queen Elizabeth 2 Hlth Sci Ctr, Div Anat Pathol, 717 Mackenzie Bldg,5788 Univ Ave, Halifax, NS B3H 1V8, Canada.; Huang, WY (reprint author), Dalhousie Univ, 717 Mackenzie Bldg,5788 Univ Ave, Halifax, NS B3H 1V8, Canada.	huangw@nshealth.ca			Nova Scotia Health Authority Research Fund; Fund for Molecular Pathology of QE II Foundation (Halifax, Nova Scotia, Canada)	This study was supported by research grants from Nova Scotia Health Authority Research Fund and Fund for Molecular Pathology of QE II Foundation (Halifax, Nova Scotia, Canada).	ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Aust DE, 2000, HUM PATHOL, V31, P109, DOI 10.1016/S0046-8177(00)80206-3; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bosman FT, 2010, WHO CLASSIFICATION T; Chappell J, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014381; Chell SD, 2006, CANCER RES, V66, P3106, DOI 10.1158/0008-5472.CAN-05-3702; Dias-Santagata D, 2010, EMBO MOL MED, V2, P146, DOI 10.1002/emmm.201000070; Furlan D, 2003, LAB INVEST, V83, P963, DOI 10.1097/01.LAB.0000079006.91414.BE; Habermann JK, 2003, CANCER GENET CYTOGEN, V147, P9, DOI 10.1016/S0165-4608(03)00219-X; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa Stefano, 2012, Cancers (Basel), V4, P11, DOI 10.3390/cancers4010011; La Rosa S, 2012, AM J SURG PATHOL, V36, P601, DOI 10.1097/PAS.0b013e318242e21c; Lee KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139727; MacQuarrie E, 2012, HUM PATHOL, V43, P1258, DOI 10.1016/j.humpath.2011.10.002; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; O'Callaghan G, 2015, BRIT J PHARMACOL, V172, P5239, DOI 10.1111/bph.13331; Olevian DC, 2016, HUM PATHOL, V49, P124, DOI 10.1016/j.humpath.2015.11.004; Sahnane N, 2015, ENDOCR-RELAT CANCER, V22, P35, DOI 10.1530/ERC-14-0410; Scardoni M, 2014, NEUROENDOCRINOLOGY, V100, P310, DOI 10.1159/000369071; Shia J, 2008, AM J SURG PATHOL, V32, P719, DOI 10.1097/PAS.0b013e318159371c; Vanacker L, 2014, ANTICANCER RES, V34, P5517; Wang Y, 2012, CANCER GENET-NY, V205, P341, DOI 10.1016/j.cancergen.2012.06.005; Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150; Xie T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042001; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195	26	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						16	25		10.1016/j.humpath.2017.08.036			10	Pathology	Pathology	GB3PJ	WOS:000428969600003	28899736				2019-10-28	
J	Jajosky, RP; Jajosky, AN; Kleven, DT; Singh, G				Jajosky, Ryan Philip; Jajosky, Audrey N.; Kleven, Daniel T.; Singh, Gurmukh			Fewer seniors from United States allopathic medical schools are filling pathology residency positions in the Main Residency Match, 2008-2017	HUMAN PATHOLOGY			English	Article						Pathology residency; Main residency match; Medical students; Pathology careers; National resident matching program; American medical schools	STUDENTS	Some pathologists have observed that fewer trainees from US medical schools are entering pathology residency. This trend was measured and further explored using Main Residency Match (MRM) data from 2008 to 2017, obtained from the National Resident Matching Program (NRMP). Over the past decade, there was an increase of 93 (508 in 2008 versus 601 in 2017, an 18.3% increase) pathology positions offered in the MRM. However, the proportion of pathology residency positions filled in the MRM which were taken by trainees from US medical schools decreased from 77.7% to 50.1% over this timespan. This was primarily due to fewer seniors from US allopathic medical schools filling pathology positions in the MRM (298 in 2008 versus 216 in 2017, a 27.5% decrease). Compared to 14 other medical specialties, pathology had the largest decline in the proportion of residency positions filled in the MRM which were taken by seniors from US allopathic medical schools (63.8% in 2008 versus 39.6% in 2017). Furthermore, pathology now has the lowest percentage of residency positions filled in the MRM, which were taken by seniors from US allopathic medical schools. The primary reason for this decline was because fewer seniors from US allopathic medical schools participated in the MRM for pathology positions (326 in 2008 versus 232 in 2017, a 28.8% decrease); however, the underlying reasons for this decline are unknown. In conclusion, over the past decade, substantially fewer seniors from US allopathic medical schools sought/filled pathology residency positions in the MRM. These findings are relevant for pathology residency recruitment, especially in the context of a projected decline in US pathologist workforce. (C) 2017 Elsevier Inc. All rights reserved.	[Jajosky, Ryan Philip] Biconcavity Inc, Lilburn, GA 30047 USA; [Jajosky, Audrey N.] Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA; [Kleven, Daniel T.; Singh, Gurmukh] Augusta Univ, Med Ctr, Augusta, GA 30912 USA	Jajosky, RP (reprint author), Biconcavity Inc, Lilburn, GA 30047 USA.	rjajosky@gmail.com					[Anonymous], 2017, RES DAT 2008 2017 MA; Biggs WS, 2013, FAM MED, V45, P647; Brooks EG, 2016, HUM PATHOL, V53, P58, DOI 10.1016/j.humpath.2016.02.006; Chu YX, 2016, HUM PATHOL, V47, P1, DOI 10.1016/j.humpath.2015.08.018; Ford J, 2015, HUM PATHOL, V46, P637, DOI 10.1016/j.humpath.2015.01.016; Ford JC, 2010, HUM PATHOL, V41, P566, DOI 10.1016/j.humpath.2009.09.012; Ford JC, 2012, CAN J PATHOL, V4, P9; Grisham S., 2017, PHYS COMPENSATION RE; Hung T, 2011, HUM PATHOL, V42, P802, DOI 10.1016/j.humpath.2010.10.018; Lingard L, 2005, J INT ACAD MED SCI E, V15, P81; Naritoku WY, 2016, ACAD PATHOL, V3, P1; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA; Van SL, 2015, HUM PATHOL, V46, P1408, DOI 10.1016/j.humpath.2015.04.016; WISECARVER JL, 1993, LAB MED, V24, P512, DOI 10.1093/labmed/24.8.512	14	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						26	32		10.1016/j.humpath.2017.11.014			7	Pathology	Pathology	GB3PJ	WOS:000428969600004	29180247				2019-10-28	
J	Piao, JJ; Chen, LY; Jin, TF; Xu, M; Quan, CJ; Lin, ZH				Piao, Junjie; Chen, Liyan; Jin, Tiefeng; Xu, Ming; Quan, Chunji; Lin, Zhenhua			Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker	HUMAN PATHOLOGY			English	Article						Paipl; Breast cancer; Growth; Prognosis; Survival	MESSENGER-RNA TRANSLATION; POLY(A)-BINDING PROTEIN; BINDING-PROTEIN; INITIATION; MODEL	Polyadenylate-binding protein-interacting protein 1 (Paipl) regulates translational initiation. Increasing evidence suggests that Paipl plays important roles in cancer development and progression. This study explored the role of Paipl in breast cancer progression and evaluated its prognostic value. The cellular location of Paipl protein was determined using immunofluorescence. Then, Paip1 protein expression was evaluated by immunohistochemical staining in 119 breast cancers and 40 normal breast tissues. The correlation between Paipl expression and the clinicopathologic features of breast cancer was evaluated using the chi(2) test, and differences in survival curves were analyzed using log-rank tests. The role of Paipl in breast cancer proliferation and cell cycle progression was identified by siRNA transfection. Paip1 was expressed mainly in the cytoplasm of cancer cells and tissues. Expression was observed in 60.5% of the breast cancers (72/119), which was significantly higher than in normal breast tissues (17.5%; 7/40). High expression of Paipl protein was associated with high histologic grade, late clinical stage, and a low survival rate. Multivariate analysis indicated that Paip1 was an independent prognostic factor. Additionally, Paipl depletion by RNAi significantly decreased cell proliferation and induced cell cycle arrest. In conclusion, our study demonstrated that Paipl promotes the growth of breast cancers and could be a prognostic biomarker and therapeutic target. (C) 2017 Elsevier Inc. All rights reserved.	[Piao, Junjie; Chen, Liyan; Lin, Zhenhua] Yanbian Univ, Coll Med, Dept Pathol, 977 Gongyuan Rd, Yanji 133002, Peoples R China; [Piao, Junjie; Chen, Liyan; Lin, Zhenhua] Yanbian Univ, Coll Med, Canc Res Ctr, 977 Gongyuan Rd, Yanji 133002, Peoples R China; [Chen, Liyan; Jin, Tiefeng; Xu, Ming; Quan, Chunji] Yanbian Univ, Coll Med, Dept Biochem & Mol Biol, Yanji 133002, Peoples R China	Lin, ZH (reprint author), Yanbian Univ, Coll Med, Dept Pathol, 977 Gongyuan Rd, Yanji 133002, Peoples R China.; Lin, ZH (reprint author), Yanbian Univ, Coll Med, Canc Res Ctr, 977 Gongyuan Rd, Yanji 133002, Peoples R China.	zhlin720@ybu.edu.cn			Special Research Project of "973 Plan"National Basic Research Program of China [2014CB560708]; National Natural Science Funds of ChinaNational Natural Science Foundation of China [61371067, 31760313]	This study was supported by grants from China. The Special Research Project of "973 Plan" (2014CB560708) and National Natural Science Funds of China (No. 61371067, 31760313).	Arveux Patrick, 2013, Rev Prat, V63, P1362; Craig AWB, 1998, NATURE, V392, P520; Derry MC, 2006, COLD SPRING HARB SYM, V71, P537, DOI 10.1101/sqb.2006.71.061; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fukada Y, 2007, BRAIN RES, V1160, P1, DOI 10.1016/j.brainres.2007.05.044; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grewal SS, 2015, BBA-GENE REGUL MECH, V1849, P898, DOI 10.1016/j.bbagrm.2014.12.005; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hershey JWB, 2015, BBA-GENE REGUL MECH, V1849, P792, DOI [10.1016/j.bbagrm.201410.005, 10.1016/j.bbagrm.2014.10.005]; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; King HA, 2016, BRIEF FUNCT GENOMICS, V15, P22, DOI 10.1093/bfgp/elu045; Lv YR, 2014, MOL CELL BIOL, V34, P4513, DOI 10.1128/MCB.00524-14; Martineau Y, 2014, MOL CELL BIOL, V34, P1046, DOI 10.1128/MCB.01079-13; Proud CG, 2015, BBA-GENE REGUL MECH, V1849, P766, DOI 10.1016/j.bbagrm.2014.10.003; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Sandoo A, 2015, VASC HEALTH RISK MAN, V11, P223, DOI 10.2147/VHRM.S69641; Scotto L, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-58; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spilka R, 2013, CANCER LETT, V340, P9, DOI 10.1016/j.canlet.2013.06.019; Tomek W, 2012, ANIM REPROD SCI, V134, P2, DOI 10.1016/j.anireprosci.2012.08.005; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Voigts-Hoffmann F, 2012, CURR OPIN STRUC BIOL, V22, P768, DOI 10.1016/j.sbi.2012.07.010; Wolin SL, 1998, METH MOL B, V77, P1	24	6	7	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						33	40		10.1016/j.humpath.2017.10.037			8	Pathology	Pathology	GB3PJ	WOS:000428969600005	29258905				2019-10-28	
J	Takayama, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH				Takayama, Takuya; Shin, Sohyun; Kang, SoYoung; Kim, Suk Jin; Kim, Won Seog; Ko, Young Hyeh			Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay	HUMAN PATHOLOGY			English	Article						Extranodal; NK/T; Lymphoma; T cell receptor; Expression; Gene rearrangement	NATURAL-KILLER-CELL; GAMMA-DELTA; CLONALITY; STRATEGY; SPECTRUM	The cellular lineage of extranodal NK/T-cell lymphoma, nasal-type (ENKTL), is determined by expression of T-cell receptor (TR) or TR gene rearrangement. In ENKTL, from TR immunohistochemistry, it may often be difficult to decide whether TR-positive cells are tumor cells or not, especially when TR is expressed in a subset of tumor cells. To analyze TR expression pattern and TR rearrangement in T lineage ENKTL, we performed double immunofluorescence staining for Epstein-Barr virus encoded small RNAs (EBER)/T-cell receptor (TCR) beta F1 and CD56/TCR beta F1 in 12 cases of ENKTL that showed TCR beta F1 expression in immunohistochemistry. TR gene rearrangement was analyzed using a commercial BIOMED-2 multiplex polymerase chain reaction system. Immunohistochemistry showed that all 12 cases expressed TCR beta F1 in a wide range of infiltrating cells from 100% to <1%. Two of them expressed both TCR beta F1 and TCR c gamma M1. EBER/TCR-beta F1 positivity was confirmed in 10 cases by double staining. One case failed to show EBER/TCR-beta F1 positive cells but showed a CD56/TCR beta F1 positive result. Among 12 cases, 5 had poor-quality DNA, 3 of them showed no polymerase chain reaction product, and 2 cases showed nonspecific peak of low height. Five of 7 cases with good DNA quality demonstrated monoclonal TR gene rearrangement. Based on TR expression and TR gene rearrangement, 10 of 12 cases of ENKTL were decided as a T-lineage tumor. In conclusion, because of common TR silence and poor DNA quality, consideration of both immunohistochemistry and TR gene rearrangement is necessary to determine the lineage of ENKTL. (C) 2017 Elsevier Inc. All rights reserved.	[Takayama, Takuya; Shin, Sohyun; Kang, SoYoung; Ko, Young Hyeh] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul 06351, South Korea; [Kim, Suk Jin; Kim, Won Seog] Sungkyunkwan Univ, Samsung Med Ctr, Dept Internal Med, Sect Hematol Oncol, Seoul 06351, South Korea; [Takayama, Takuya] Univ Ryukyus, Sch Med, Nishihara, Okinawa, Japan	Ko, YH (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 81 Irwonro, Seoul 06351, South Korea.	yhko310@skku.edu		Takayama, Takuya/0000-0001-5774-0016	National Research Foundation of Korea, Seoul, KoreaNational Research Foundation of Korea [NRF-2017R1A2B1010739]	This study was supported by a grant from the National Research Foundation of Korea, Seoul, Korea (NRF-2017R1A2B1010739).	Bonzheim I, 2004, BLOOD, V104, P3358, DOI 10.1182/blood-2004-03-1037; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Chan JKC, 2017, WHO CLASSIFICATION T, P368; CHAN JKC, 2008, WHO CLASSIFICATION T, P285; Chan JKC, 2011, AM J SURG PATHOL, V35, P1557, DOI 10.1097/PAS.0b013e318222dfcd; Garcia-Herrera A, 2011, AM J SURG PATHOL, V35, P1214, DOI 10.1097/PAS.0b013e31822067d1; Hong M, 2016, MODERN PATHOL, V29, P430, DOI 10.1038/modpathol.2016.47; Kato S, 2015, AM J SURG PATHOL, V39, P462, DOI 10.1097/PAS.0000000000000323; Ko YH, 2000, CANCER, V89, P2106, DOI 10.1002/1097-0142(20001115)89:10<2106::AID-CNCR11>3.0.CO;2-G; Kuo SY, 2011, J CLIN PATHOL, V64, P536, DOI 10.1136/jcp.2010.086637; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Liu HX, 2007, BRIT J HAEMATOL, V138, P31, DOI 10.1111/j.1365-2141.2007.06618.x; Lukowsky A, 2010, DIAGN MOL PATHOL, V19, P70, DOI 10.1097/PDM.0b013e3181b2a1b7; Rodriguez-Pinilla SM, 2013, AM J SURG PATHOL, V37, P375, DOI 10.1097/PAS.0b013e318275d1a2; Menon MP, 2015, AM J SURG PATHOL, V39, P1719, DOI 10.1097/PAS.0000000000000503; Ng CS, 1997, HUM PATHOL, V28, P1276, DOI 10.1016/S0046-8177(97)90201-X; Pongpruttipan T, 2012, AM J SURG PATHOL, V36, P481, DOI 10.1097/PAS.0b013e31824433d8; Takata K, 2015, AM J SURG PATHOL, V39, P1, DOI 10.1097/PAS.0000000000000312; Tanaka T, 2016, AM J SURG PATHOL, V40, P777, DOI 10.1097/PAS.0000000000000630; Tomita S, 2015, MODERN PATHOL, V28, P1286, DOI 10.1038/modpathol.2015.85; Yamaguchi M, 2014, CANCER SCI, V105, P1435, DOI 10.1111/cas.12526	21	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						51	58		10.1016/j.humpath.2017.12.006			8	Pathology	Pathology	GB3PJ	WOS:000428969600007	29258904				2019-10-28	
J	Liau, JY; Tsai, JH; Huang, WC; Lan, J; Hong, JB; Yuan, CT				Liau, Jau-Yu; Tsai, Jia-Huei; Huang, Wen-Chang; Lan, Jui; Hong, Jin-Bon; Yuan, Chang-Tsu			BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin	HUMAN PATHOLOGY			English	Article						Tubular apocrine adenoma; Papillary eccrine adenoma; RAS; BRAF; Syringocystadenoma papilliferum	SYRINGOCYSTADENOMA PAPILLIFERUM; ACTIVATING MUTATIONS; HIDRADENOMA; TUMOR; FUSION; BREAST; GENES; HRAS; ADENOCARCINOMA; CARCINOMAS	Tubular apocrine adenoma (TAA) and papillary eccrine adenoma (PEA) are benign sweat gland tumors. Their names imply that they exhibit apocrine and eccrine differentiation, respectively. However, morphologically they are very similar and are often indistinguishable. The molecular pathogenesis of either tumor is poorly understood at present. On the basis of an index case of nipple adenoma that was morphologically reminiscent of cutaneous TAA/PEA and harbored a BRAF(V600E) mutation, we investigated whether a similar genetic change is also present in TAA/PEA. BRAF, RAS, and PIK3CA mutation analyses, and BRAF-(V6D3E)-specific immunohistochemistry were performed for 24 TAAs/PEAs, 10 eccrine poromas, 7 apocrine cystadenomas, 2 TAA-like adenomas associated with nevus sebaceus, and one apocrine adenoma probably arising in anogenital mammary-like glands (AGMLGs). The results demonstrated that BRAF(V600E) mutations were present in TAAs (9/15, 60%) and PEAs (7/9, 78%), but not in other neoplasms. Two additional TAAs harbored KRAS(GI2D) mutations. In addition, a KRAS(GI2C) mutation was identified in one nevus sebaceus-associated TAA-like adenoma. The speculated AGMLG-related apocrine adenoma had a PIK3CA(H1047R) mutation. We concluded that activating BRAF and KRAS mutations were commonly present in TAAs/PEAs, indicating that in addition to a morphological resemblance, they are closely related genetically. Therefore, they could be considered to be united as a single entity. By contrast, the apocrine adenoma probably arising in AGMLG harbored a PIK3CA mutation, which is also commonly present in hidradenoma papilliferum. Further studies are necessary to determine whether the pathogenesis of AGMLG-related tumors is similar to breast tumors. (C) 2017 Elsevier Inc. All rights reserved.	[Liau, Jau-Yu; Tsai, Jia-Huei; Yuan, Chang-Tsu] Natl Taiwan Univ Hosp, Dept Pathol, 7 Chung Shan South Rd, Taipei 10051, Taiwan; [Liau, Jau-Yu; Tsai, Jia-Huei; Yuan, Chang-Tsu] Natl Taiwan Univ, Coll Med, Taipei 10051, Taiwan; [Liau, Jau-Yu; Tsai, Jia-Huei] Natl Taiwan Univ, Coll Med, Grad Inst Pathol, Taipei 10051, Taiwan; [Huang, Wen-Chang] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Lan, Jui] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 83301, Taiwan; [Lan, Jui] Chang Gung Univ, Coll Med, Kaohsiung 83301, Taiwan; [Hong, Jin-Bon] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei 10002, Taiwan; [Hong, Jin-Bon] Natl Taiwan Univ, Coll Med, Taipei 10002, Taiwan	Liau, JY (reprint author), Natl Taiwan Univ Hosp, Dept Pathol, 7 Chung Shan South Rd, Taipei 10051, Taiwan.	019188@ntuh.gov.tw		Hong, Jin-Bon/0000-0001-9467-6463	 [NTUH 106-N03]	Grant No.: NTUH 106-N03 (to Jau-Yu Liau).	Ang DC, 2014, MODERN PATHOL, V27, P740, DOI 10.1038/modpathol.2013.197; ANSAI S, 1989, J CUTAN PATHOL, V16, P230, DOI 10.1111/j.1600-0560.1989.tb00047.x; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Bell D, 2015, ANN DIAGN PATHOL, V19, P381, DOI 10.1016/j.anndiagpath.2015.08.002; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Coyne JD, 2000, J CUTAN PATHOL, V27, P199, DOI 10.1034/j.1600-0560.2000.027004199.x; Dashti NK, 2017, AM J SURG PATHOL, V41, P1532, DOI 10.1097/PAS.0000000000000913; Eusebi V, 2012, WHO CLASSIFICATION T, P150; Groesser L, 2016, J INVEST DERMATOL, V136, P481, DOI 10.1038/JID.2015.376; Groesser L, 2012, NAT GENET, V44, P783, DOI 10.1038/ng.2316; Harms PW, 2016, HUM PATHOL, V51, P25, DOI 10.1016/j.humpath.2015.12.015; Hsu PJ, 2003, J CUTAN PATHOL, V30, P206, DOI 10.1034/j.1600-0560.2003.00031.x; Igawa S, 2016, J DERMATOL, V43, P103, DOI 10.1111/1346-8138.13153; Levinsohn JL, 2015, J INVEST DERMATOL, V135, P2536, DOI 10.1038/jid.2015.180; Li AL, 2003, J CUTAN PATHOL, V30, P32, DOI 10.1034/j.1600-0560.2003.300106.x; Liau JY, 2017, HISTOPATHOLOGY, V70, P195, DOI 10.1111/his.13043; Liau JY, 2016, HUM PATHOL, V55, P57, DOI 10.1016/j.humpath.2016.04.014; Liau JY, 2014, MODERN PATHOL, V27, P1163, DOI 10.1038/modpathol.2013.241; McCalmont T H, 1996, Am J Dermatopathol, V18, P103; Molina-Ruiz AM, 2016, AM J SURG PATHOL, V40, P410, DOI 10.1097/PAS.0000000000000547; North JP, 2015, AM J SURG PATHOL, V39, P1347, DOI 10.1097/PAS.0000000000000463; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P113, DOI 10.1002/gcc.22315; RULON DB, 1977, ARCH DERMATOL, V113, P596, DOI 10.1001/archderm.113.5.596; Sardesai VR, 2009, INDIAN J DERMATOL VE, V75, DOI 10.4103/0378-6323.51250; Shen AS, 2015, HUM PATHOL, V46, P272, DOI 10.1016/j.humpath.2014.11.002; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; TELLECHEA O, 1995, AM J DERMATOPATH, V17, P499, DOI 10.1097/00000372-199510000-00012; Troxell ML, 2010, MODERN PATHOL, V23, P27, DOI 10.1038/modpathol.2009.142; Tsai JH, 2014, BRIT J DERMATOL, V171, P1073, DOI 10.1111/bjd.13143; UMBERT P, 1976, J CUTAN PATHOL, V3, P75, DOI 10.1111/j.1600-0560.1976.tb00850.x; Winnes M, 2007, GENE CHROMOSOME CANC, V46, P559, DOI 10.1002/gcc.20440; Wong TY, 1996, AM J DERMATOPATH, V18, P124, DOI 10.1097/00000372-199604000-00004; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x	35	4	4	2	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						59	65		10.1016/j.humpath.2017.12.002			7	Pathology	Pathology	GB3PJ	WOS:000428969600008	29241739				2019-10-28	
J	Pyo, JS; Son, BK; Oh, D; Kim, EK				Pyo, Jung-Soo; Son, Byoung Kwan; Oh, Dongwook; Kim, Eun Kyung			BRG1 is correlated with poor prognosis in colorectal cancer	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Brahma-related gene 1; Prognosis; Immunohistochemistry; Meta-analysis	SWI/SNF COMPLEX; GASTRIC CARCINOMAS; LUNG-CANCER; CELL-LINES; EXPRESSION; CHROMATIN; PROLIFERATION; MUTATIONS; COMPONENT; SURVIVAL	Brahma-related gene 1 (BRG1), a component of the chromatin-remodeling complex, regulates transcription by remodeling the chromatin structure. The present study aimed to elucidate the clinicopathological significance and prognostic role of BRG1 in colorectal cancer (CRC). We investigated the correlation between BRG1 expression and clinicopathological parameters, including prognosis, using immunohistochemistry on 266 archival paraffin-embedded CRC tissues. In addition, to confirm the prognostic role of BRG 1 in malignant tumors, we performed a meta-analysis of 9 eligible studies and the current study. BRG1 was highly expressed in 67.7% of the 266 CRCs analyzed. High BRG 1 expression significantly correlated with poor overall and recurrence-free survival (P < .001 and P < .001, respectively). The high expression of BRG1 also significantly correlated with high expression of SNAI (P < .001) but not E-cadherin (P = .432). However, there was no significant correlation between BRG1 expression and other clinicopathological parameters. The meta-analysis also demonstrated that high BRG1 expression positively correlated with poor overall and recurrence-free survival (hazard ratio 1.572, 95% confidence interval 1.106-2.235 and hazard ratio 2.050, 95% confidence interval 1.610-2.610, respectively). However, subgroup analysis based on tumor type showed that the correlation between BRG1 expression and poor prognosis was only prevalent in CRC and breast cancer. Taken together, the results of this study suggest that high BRG1 expression was associated with high SNAI expression and was significantly correlated with poor prognosis. (C) 2017 Elsevier Inc. All rights reserved.	[Pyo, Jung-Soo] Eulji Univ, Sch Med, Eulji Univ Hosp, Dept Pathol, Daejeon 35233, South Korea; [Son, Byoung Kwan; Oh, Dongwook] Eulji Univ, Sch Med, Eulji Hosp, Dept Internal Med, 68 Hangeulbiseok Ro, Seoul 01830, South Korea; [Kim, Eun Kyung] Eulji Univ, Sch Med, Eulji Hosp, Dept Pathol, Seoul 01830, South Korea	Son, BK (reprint author), Eulji Univ, Sch Med, Eulji Hosp, Dept Internal Med, 68 Hangeulbiseok Ro, Seoul 01830, South Korea.	sbk1026@eulji.ac.kr		Son, Byoung Kwan/0000-0002-9299-5476	Hanmi Pharm (Seoul, Republic of Korea) [HM-IIT-ESO-035]	This study was supported by Hanmi Pharm (HM-IIT-ESO-035: Seoul, Republic of Korea) in 2017.	Amin MB, 2016, AJCC CANC STAGING MA; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432-012-1172-8; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Do SI, 2016, ANTICANCER RES, V36, P4873, DOI 10.21873/anticanres.11051; Endo M, 2013, LIVER INT, V33, P105, DOI 10.1111/liv.12005; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Jiang W, 2017, ONCOTARGET, V8, P37423, DOI 10.18632/oncotarget.16965; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Lin H, 2010, BRIT J DERMATOL, V163, P502, DOI 10.1111/j.1365-2133.2010.09851.x; Lin ST, 2016, ONCOTARGET, V7, P86051, DOI 10.18632/oncotarget.13326; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Numata M, 2013, INT J ONCOL, V42, P403, DOI 10.3892/ijo.2012.1723; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PETO R, 1973, APPL STAT, V22, P86; Pyo JS, 2015, J CANCER RES CLIN, V141, P1181, DOI 10.1007/s00432-014-1890-1; REMMELE W, 1987, PATHOLOGE, V8, P138; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Saladi SV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-280; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Valdman A, 2003, INT J ONCOL, V22, P1003; Wang G, 2016, ONCOGENE, V35, P651, DOI 10.1038/onc.2015.124; Watanabe T, 2011, BRIT J CANCER, V104, P146, DOI 10.1038/sj.bjc.6606018; Wong AKC, 2000, CANCER RES, V60, P6171	31	5	5	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						66	73		10.1016/j.humpath.2017.12.013			8	Pathology	Pathology	GB3PJ	WOS:000428969600009	29288038				2019-10-28	
J	Piao, YS; Zhang, Y; Yue, CL; Wang, CS; Zhang, L				Piao, Yingshi; Zhang, Yuan; Yue, Changli; Wang, Chengshuo; Zhang, Luo			Immunoglobulin G4-related chronic rhinosinusitis: a pitfall in the differential diagnosis of granulomatosis with polyangiitis, Rosai-Dorfman disease, and fungal rhinosinusitis	HUMAN PATHOLOGY			English	Article						IgG4-related chronic rhinosinusitis; Plasma cell; Granulomatosis with polyangiitis; Rosai-Dorfman disease; Fungal rhinosinusitis	IGG4-RELATED SCLEROSING DISEASE; PAROTID-GLAND; SINUS; NECK; HEAD; CT	Immunoglobulin G4 (IgG4)-related chronic rhinosinusitis (CRS) has recently been proposed to be a new clinical entity of nasal disease, with no consensually agreed criteria for diagnosis. Moreover, the pathological features of IgG4-related CRS often overlap with other sinonasal inflammatory and autoimmune diseases such as granulomatosis with polyangiitis (GPA), Rosai-Dorfman disease (RDD) and fungal rhinosinusitis (FRS). We aimed to explore the specific similarities and differences in clinicopathologic features between IgG4-related CRS, and GPA, RDD and FRS, in order that these conditions can be diagnosed more accurately. Biopsy specimens collected from nasal mucosa of 20 IgG4-related CRS, 10 GPA, 10 RDD and 10 FRS patients were assessed by hematoxylin and eosin staining and immunohistochemical techniques for specific histochemical differences. The number of IgG4-positive plasma cells/high-power fields (HPF) in biopsies from IgG4-related CRS patients (mean = 79.6 +/- 51.59; range = 15/HPF to 230/HPF) was significantly higher than in biopsies from GPA (mean = 13 +/- 9.428; P<.0001) and RDD (mean = 12.5 +/- 8.267; P<.0001) patients, but not from FRS (mean = 47.4 +/- 26.48; P>.05) patients. Similarly, the ratio of IgG4/IgG-positive plasmacytes was >40% in 90% (18/20) of IgG4-related CRS patients, compared to >40% in 10% (1/10) of GPA patients, 20% (2/10) of RDD patients and 20% (2/10) of FRS patients. The sinonasal diseases GPA, RDD and FRS might present with similar histopathologic features such as the increased numbers of plasma cells and fibrosis, which are characteristic of IgG4-related CRS. A comprehensive consideration combining the clinical signs and symptoms with a histopathological assessment of IgG4-positive plasma cells may provide accurate diagnoses of these conditions. (C) 2017 Elsevier Inc. All rights reserved.	[Piao, Yingshi; Yue, Changli] Capital Med Univ, Beijing TongRen Hosp, Dept Pathol, Beijing, Peoples R China; [Piao, Yingshi; Yue, Changli] Capital Med Univ, Beijing TongRen Hosp, Beijing Key Lab Head & Neck Mol Pathol Diag, Beijing, Peoples R China; [Zhang, Yuan; Wang, Chengshuo; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China; [Zhang, Yuan; Wang, Chengshuo; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Zhang, Yuan; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Allergy, Beijing, Peoples R China	Wang, CS (reprint author), Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China.; Zhang, L (reprint author), Beijing Inst Otolaryngol, 17 HouGouHuTong, Beijing 100005, Peoples R China.	wangcs830@126.com			program for National Key R&D Program of China [2016YFC20160905200]; Changjiang Scholars and Innovative Research TeamProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT13082]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81420108009, 81570895, 81400444, 81470678, 81630023]; Special Fund of Capital Health Development [2011-1017-06, 2011-1017-02]; Special Fund of Sanitation Elite Reconstruction of Beijing [2009-2-007]; Beijing Health Bureau Program for High Level Talents [2011-3-043]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]; Capital Citizenry Health Program [z161100000116062]	This work was supported by grants from the program for National Key R&D Program of China (2016YFC20160905200), Changjiang Scholars and Innovative Research Team (IRT13082), the National Natural Science Foundation of China (81420108009, 81570895, 81400444, 81470678 and 81630023), the Special Fund of Capital Health Development (2011-1017-06,2011-1017-02), the Special Fund of Sanitation Elite Reconstruction of Beijing (2009-2-007), Beijing Health Bureau Program for High Level Talents (2011-3-043), Beijing Municipal Administration of Hospitals' Mission Plan (SML20150203) and Capital Citizenry Health Program (z161100000116062).	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Chang SY, 2012, INT J RHEUMATOL, DOI 10.1155/2012/121702; Chen TD, 2011, ARCH OTOLARYNGOL, V137, P705, DOI 10.1001/archoto.2011.52; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; FOUCAR E, 1990, SEMIN DIAGN PATHOL, V7, P19; Fujita A, 2012, RADIOGRAPHICS, V32, P1945, DOI 10.1148/rg.327125032; Grosjean P, 2007, EUR ARCH OTO-RHINO-L, V264, P461, DOI 10.1007/s00405-007-0281-5; Ikeda R, 2010, OTOLARYNG HEAD NECK, V142, P458, DOI 10.1016/j.otohns.2009.09.019; Ishida M, 2009, PATHOL INT, V59, P670, DOI 10.1111/j.1440-1827.2009.02425.x; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Kuo TT, 2009, J CUTAN PATHOL, V36, P1069, DOI 10.1111/j.1600-0560.2008.01222.x; Lindau RH, 2013, HEAD NECK-J SCI SPEC, V35, pE321, DOI 10.1002/hed.23175; Moteki H, 2011, ACTA OTO-LARYNGOL, V131, P518, DOI 10.3109/00016489.2010.533699; Nabaa B, 2012, AM J NEURORADIOL, V33, P1964, DOI [10.3174/ajnr.A3063, 10.3174/ajnr.A2495]; Piao YS, 2016, HISTOPATHOLOGY, V68, P502, DOI 10.1111/his.12775; Roberts SS, 2010, HISTOPATHOLOGY, V56, P662, DOI 10.1111/j.1365-2559.2010.03519.x; Toyoda K, 2012, AM J NEURORADIOL, V33, P2136, DOI 10.3174/ajnr.A3147; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z	18	0	1	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						82	88		10.1016/j.humpath.2017.12.011			7	Pathology	Pathology	GB3PJ	WOS:000428969600011	29288039				2019-10-28	
J	Cez, A; Brocheriou, I; Lescure, FX; Adam, C; Girard, PM; Pialoux, G; Moestrup, SK; Fellahi, S; Bastard, JP; Ronco, P; Plaisier, E				Cez, Alexandre; Brocheriou, Isabelle; Lescure, Francois-Xavier; Adam, Clovis; Girard, Pierre-Marie; Pialoux, Gilles; Moestrup, Soren K.; Fellahi, Soraya; Bastard, Jean-Philippe; Ronco, Pierre; Plaisier, Emmanuelle			Decreased expression of megalin and cubilin and altered mitochondrial activity in tenofovir nephrotoxicity	HUMAN PATHOLOGY			English	Article						Tubulopathy; Megalin; Cubilin; Nephrotoxicity; Fanconi syndrome; Tenofovir	CHRONIC KIDNEY-DISEASE; DISOPROXIL FUMARATE; ADEFOVIR; ENDOCYTOSIS; TOXICITY; THERAPY; SAFETY; CELLS; RISK; DF	Tenofovir disoproxil fumarate (TDF) is a commonly used antiretroviral drug for HIV, rarely causing Fanconi syndrome and acute kidney injury. We retrospectively analyzed the clinico pathological presentation of 20 cases of tenofovir-induced tubulopathy, and investigated the renal expression of the megalin and cubilin proteins, as well as the mitochondrial respiratory chain activity. Estimated glomerular filtration rate (eGFR) before TDF exposure was 92 ml/min/1.73m(2), decreasing to 27.5 ml/min/1.73m(2) at the time of biopsy, with 30% of patients requiring renal replacement therapy. Proximal tubular expression of megalin and cubilin was altered in 19 and 18 cases, respectively, whereas it was preserved in patients exposed to TDF without proximal tubular dysfunction and in HIV-negative patients with acute tubular necrosis. Loss of megalin/cubilin was correlated with low eGFR and high urine retinol binding protein at the time of biopsy, low eGFR at last follow-up, and was more severe in patients with multifactorial toxicity. Patients with additional nephrotoxic conditions promoting tenofovir accumulation showed a lower eGFR at presentation and at last follow-up, and more severe lesions of acute tubular necrosis, than those with isolated tenofovir toxicity. Altered mitochondrial COX activity in proximal tubules was observed and may be an early cellular alteration in tenofovir nephrotoxicity. In conclusion, altered megalin/cubilin expression represents a distinctive feature in tenofovir-induced tubulopathy, and its severity is correlated with urine retinol binding protein loss and is associated with a poor renal prognosis. Concomitant exposure to other nephrotoxic conditions severely impacts the renal presentation and outcome. (C) 2018 Elsevier Inc. All rights reserved.	[Cez, Alexandre; Ronco, Pierre; Plaisier, Emmanuelle] Tenon Hosp, APHP, Dept Nephrol & Dialysis, F-75020 Paris, France; [Cez, Alexandre; Girard, Pierre-Marie; Pialoux, Gilles; Ronco, Pierre; Plaisier, Emmanuelle] UPMC Univ Paris 06, Sorbonne Univ, Tenon Hosp, UMR S 1155, F-75020 Paris, France; [Cez, Alexandre; Brocheriou, Isabelle; Ronco, Pierre; Plaisier, Emmanuelle] INSERM, UMR S 1155, F-75020 Paris, France; [Brocheriou, Isabelle] Hop La Pitie Salpetriere, APHP, Dept Pathol, F-75020 Paris, France; [Lescure, Francois-Xavier] Hop Xavier Bichat, APHP, Dept Infect Dis, F-75018 Paris, France; [Lescure, Francois-Xavier] Univ Paris Diderot, IAME, UMR1137, Sorbonne Paris Cite, F-75018 Paris, France; [Lescure, Francois-Xavier; Pialoux, Gilles] Tenon Hosp, APHP, Dept Infect Dis, F-75020 Paris, France; [Adam, Clovis] Bicetre Hosp, APHP, Dept Pathol, F-94275 Le Kremlin Bicetre, France; [Girard, Pierre-Marie] St Antoine Hosp, APHP, Dept Infect Dis, F-75012 Paris, France; [Moestrup, Soren K.] Univ Southern Denmark, Inst Mol Med, DK-5000 Odense, Denmark; [Fellahi, Soraya; Bastard, Jean-Philippe] Tenon Hosp, APHP, Dept Biochem, F-75020 Paris, France	Plaisier, E (reprint author), Tenon Hosp, Dept Nephrol & Dialysis, 4 Rue Chine, F-75020 Paris, France.	emmanuelle.plaisier@aphp.fr	Moestrup, Soren Kragh/A-1403-2014	Moestrup, Soren Kragh/0000-0003-3862-2107	AbbottAbbott Laboratories; Gilead SciencesGilead Sciences; Merck Sharp and Dohme (MSD)Merck & Company; Janssen CilagJohnson & Johnson USAJanssen Biotech Inc; AmgenAmgen; RocheRoche Holding	F.X.L. received consultancy and lecture fees from Abbott, Gilead Sciences, and Merck Sharp and Dohme (MSD). E.P. received consultancy and lecture fees from Gilead Sciences and Janssen Cilag, research grants from Amgen, travel funding from Roche.	Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Christensen EI, 2012, PHYSIOLOGY, V27, P223, DOI 10.1152/physiol.00022.2012; Cihlar T, 2001, NUCLEOS NUCLEOT NUCL, V20, P641, DOI 10.1081/NCN-100002341; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; de Seigneux S, 2010, AM J KIDNEY DIS, V56, P117, DOI 10.1053/j.ajkd.2010.03.010; Flandre P, 2011, CLIN J AM SOC NEPHRO, V6, P1700, DOI 10.2215/CJN.09191010; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gorvin CM, 2013, P NATL ACAD SCI USA, V110, P7014, DOI 10.1073/pnas.1302063110; Herlitz LC, 2010, KIDNEY INT, V78, P1171, DOI 10.1038/ki.2010.318; Imaoka T, 2007, MOL PHARMACOL, V71, P619, DOI 10.1124/mol.106.028233; Improving Global Outcomes (KDIGO) Acute Kid-ney Injury Work Group, 2012, KIDNEY INT S, V2, P1, DOI DOI 10.1038/kisup.2012.1; Izzedine H, 2005, NEPHROL DIAL TRANSPL, V20, P743, DOI 10.1093/ndt/gfh658; Kaman A, 2003, CLIN INFECT DIS, V36, P1070; Kohler JJ, 2009, LAB INVEST, V89, P513, DOI 10.1038/labinvest.2009.14; Lebrecht D, 2009, JAIDS-J ACQ IMM DEF, V51, P258, DOI 10.1097/QAI.0b013e3181a666eb; Marcellin P, 2008, NEW ENGL J MED, V359, P2442, DOI 10.1056/NEJMoa0802878; Mocroft A, 2010, AIDS, V24, P1667, DOI [10.1097/QAD.0b013e328339fe53, 10.1097/QAD.0b013e328339fc53]; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Morelle J, 2009, CLIN NEPHROL, V71, P567; Norden AGW, 2002, J AM SOC NEPHROL, V13, P125; Peyriere H, 2004, JAIDS-J ACQ IMM DEF, V35, P269, DOI 10.1097/00126334-200403010-00007; Raggi C, 2014, HUM MOL GENET, V23, P2266, DOI 10.1093/hmg/ddt617; Ray AS, 2006, ANTIMICROB AGENTS CH, V50, P3297, DOI 10.1128/AAC.00251-06; Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043; Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f; Schooley RT, 2002, AIDS, V16, P1257, DOI 10.1097/00002030-200206140-00008; Sise ME, 2015, AIDS, V29, P941, DOI 10.1097/QAD.0000000000000628; Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2; Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586; Verhelst D, 2002, AM J KIDNEY DIS, V40, P1331, DOI 10.1053/ajkd.2002.36924; Wilmer MJ, 2008, AM J KIDNEY DIS, V51, P893, DOI 10.1053/j.ajkd.2008.03.010; Zaidan M, 2013, CLIN J AM SOC NEPHRO, V8, P930, DOI 10.2215/CJN.10051012; Zimmermann AE, 2006, CLIN INFECT DIS, V42, P283, DOI 10.1086/499048	34	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						89	101		10.1016/j.humpath.2017.12.018			13	Pathology	Pathology	GB3PJ	WOS:000428969600012	29309806				2019-10-28	
J	Mesa, H; Larson, W; Manivel, JC				Mesa, Hector; Larson, Wendy; Manivel, Juan C.			Acquired adenomatous hyperplasia of the rete testis: an immunohistochemical study of its pathogenesis	HUMAN PATHOLOGY			English	Article						Rete testis; Abnormalities; Hyperplasia; Adenoma; Senescence	CELLULAR SENESCENCE; TUMOR	Adenomatous hyperplasia of the rete testis (AHRT) is an uncommon abnormality first described by Nistal and Paniagua in 1988. Congenital and acquired forms of AHRT are recognized. We present a case of AHRT in a patient who underwent bilateral orchiectomy for penile carcinoma; he had received chemotherapy for Hodgkin lymphoma 18 years prior. Proposed causes for this disorder include developmental, hormonal, and paracrine induction by adjacent testicular tumors and exposure to chemicals, based on clinical contexts but without experimental support. We performed immunohistochemical studies using markers of cell cycle (cyclin D1, p16), proliferation (Ki-67), apoptosis (bcl2), senescence (gamma-H2AX), and androgen receptors to try to provide scientific support for or refute existing hypotheses. Our results indicate that, in this case of acquired AHRT after chemotherapy, the process is neither adenomatous nor hyperplastic but rather represents abnormal accumulation of rete testis cells with acquired senescence. Published by Elsevier Inc.	[Mesa, Hector; Larson, Wendy; Manivel, Juan C.] Minneapolis Vet Affairs Hlth Care Syst, Dept Lab Med & Pathol, Minneapolis, MN 55417 USA	Mesa, H (reprint author), Minneapolis VA Hlth Care Syst, Off BB 104, One Vet Dr, Minneapolis, MN 55417 USA.	Hector.Mesa@va.gov					Catanzariti F, 2016, ARCH ITAL UROL ANDRO, V88, P243, DOI 10.4081/aiua.2016.3.243; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gruber H, 1997, J UROLOGY, V158, P1525, DOI 10.1016/S0022-5347(01)64262-9; HARTWICK RWJ, 1991, AM J SURG PATHOL, V15, P350; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Maierhofer A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177442; Matthaios D, 2012, ONCOTARGETS THER, V5, P309, DOI 10.2147/OTT.S36995; Mesa H, 2017, HUM PATHOL, V61, P181, DOI 10.1016/j.humpath.2016.11.004; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; NISTAL M, 1988, J PATHOL, V154, P343, DOI 10.1002/path.1711540410; Nistal M, 2003, HISTOL HISTOPATHOL, V18, P741, DOI 10.14670/HH-18.741; Nistal M, 1996, AM J SURG PATHOL, V20, P1231, DOI 10.1097/00000478-199610000-00009; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; ULBRIGHT TM, 1991, AM J SURG PATHOL, V15, P66, DOI 10.1097/00000478-199101000-00008; Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x	15	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						102	107		10.1016/j.humpath.2017.09.010			6	Pathology	Pathology	GB3PJ	WOS:000428969600013	28970137				2019-10-28	
J	Meguro, S; Yamazaki, S; Matsushima, S; Kawata, K; Kawasaki, H; Tsuchida, T; Kosugi, I; Kobayashi, Y; Baba, S; Iwashita, T				Meguro, Shiori; Yamazaki, Satoru; Matsushima, Sayomi; Kawata, Kazuhito; Kawasaki, Hideya; Tsuchida, Takashi; Kosugi, Isao; Kobayashi, Yoshimasa; Baba, Satoshi; Iwashita, Toshihide			A case of a primary hepatic so-called adenosarcoma with heterotopic ossification: possibly of biliary adenofibroma origin	HUMAN PATHOLOGY			English	Article						Adenosarcoma; Biliary adenofibroma; Heterotopic ossification; Liver; Autopsy	ENDOMETRIOSIS; FEATURES; TUMOR; LIVER	We present an autopsy case of a "so-called adenosarcoma with ossification of the liver" in a 63-year-old man. Macroscopically, the well-circumscribed tumor with portal vein invasion was observed in the right lobe of the liver. The cut surface of the tumor had a solid and microcystic appearance. Microscopically, the tumor was characterized by a benign epithelial component and a malignant mesenchymal component. We believe the presence of biliary adenofibroma-like areas and the von Meyenburg complexes suggests that the tumor is possibly associated with a biliary adenofibroma. In addition, the present tumor was unique in that it showed scattered heterotopic ossification. Immunohistochemical study showed that the mesenchymal atypical spindle cells had characteristics of undifferentiated mesenchymal cells. This is the first report of a primary hepatic so-called adenosarcoma. (C) 2017 Elsevier Inc. All rights reserved.	[Meguro, Shiori; Matsushima, Sayomi; Kawasaki, Hideya; Kosugi, Isao; Iwashita, Toshihide] Hamamatsu Univ Sch Med, Dept Regenerat & Infect Pathol, Hamamatsu, Shizuoka 4313192, Japan; [Yamazaki, Satoru; Kawata, Kazuhito; Kobayashi, Yoshimasa] Hamamatsu Univ Sch Med, Dept Hepatol, Hamamatsu, Shizuoka 4313192, Japan; [Tsuchida, Takashi; Baba, Satoshi] Hamamatsu Univ Hosp, Dept Diagnost Pathol, Hamamatsu, Shizuoka 4313192, Japan	Meguro, S (reprint author), Hamamatsu Univ Sch Med, Dept Regenerat & Infect Pathol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	megu.s@hama-med.ac.jp					Amason T, 2017, AM J SURG PATHOL, V41, P499; Battula VL, 2009, HAEMATOL-HEMATOL J, V94, P173, DOI 10.3324/haematol.13740; Buhring HJ, 2007, ANN NY ACAD SCI, V1106, P262, DOI 10.1196/annals.1392.000; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Jelovsek JE, 2004, AM J OBSTET GYNECOL, V191, P1725, DOI 10.1016/j.ajog.2004.05.031; Kai K, 2012, PATHOL INT, V62, P506, DOI 10.1111/j.1440-1827.2012.02830.x; Kaminsky P, 2017, HEPATOLOGY, V65, P380, DOI 10.1002/hep.28818; N'Senda P, 2000, EUR RADIOL, V10, P1287, DOI 10.1007/s003300000322; Nakanuma Y, 2010, WHO CLASSIFICATION T, P217; Nakanuma Y, 2014, INT J HEPATOL, DOI 10.1155/2014/805973; TSUI WMS, 1993, AM J SURG PATHOL, V17, P186, DOI 10.1097/00000478-199302000-00010; Tsutsui A, 2014, CLIN J GASTROENTEROL, V7, P441, DOI 10.1007/s12328-014-0523-1; Varnholt H, 2003, AM J SURG PATHOL, V27, P693, DOI 10.1097/00000478-200305000-00014; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124	15	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						108	113		10.1016/j.humpath.2017.10.009			6	Pathology	Pathology	GB3PJ	WOS:000428969600014	29079182				2019-10-28	
J	Wang, RC; Yu, Z; Chen, F; Liao, CL; Wang, Q; Huang, XH				Wang, Rongchang; Yu, Zheng; Chen, Fan; Liao, ChunIlan; Wang, Qian; Huang, Xiaohui			Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						ARID4B; Oncogene; Prognosis; Hepatocellular carcinoma	DNA-BINDING PROTEINS; METASTASIS; FAMILY; CANCER	AT-rich interaction domain 4B (ARID4B), which belongs to the ARID family, is heavily involved in cell growth and differentiation and is closely associated with many types of tumors. However, the role of this protein in hepatocellular carcinoma (HCC) remains unknown. In this study, we used data from The Cancer Genome Atlas and Gene Expression Omnibus to analyze ARID4B expression in HCC. We subjected 15 pairs of fresh-frozen tissue samples to quantitative real-time polymerase chain reaction and Western blotting analyses to investigate ARID4B expression. We also subjected 157 formalin-fixed, paraffin-embedded HCC tissue samples to immunohistochemical analysis to detect ARID4B expression and to determine the clinical significance of ARID4B expression in HCC. The bioinformatics analysis, quantitative real-time polymerase chain reaction, and Western blotting results showed that ARID4B was highly expressed in HCC tissues compared with adjacent normal liver tissues. High ARID4B expression was strongly correlated with tumor number (P=.02), vascular invasion (P=.004), Edmondson-Steiner grades (P=.000), and tumor-node-metastasis stages (P=.001). Moreover, Kaplan-Meier and Cox proportional-hazards analyses indicated that high ARID4B expression was significantly associated with poor survival in patients with HCC and that ARID4B was an independent prognostic factor for overall survival and disease-free survival in patients with HCC. In conclusion, our results suggest that ARID4B acts as an oncogene in HCC and can therefore serve as a biomarker for the prognoses of patients with HCC. (C) 2017 Published by Elsevier Inc.	[Wang, Rongchang; Wang, Qian] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, 58 Zhong Shan Rd 2, Guangzhou 510080, Guangdong, Peoples R China; [Yu, Zheng; Chen, Fan; Huang, Xiaohui] Sun Yat Sen Univ, Affiliated Hosp 1, Gen Surg Lab, Guangzhou 510080, Guangdong, Peoples R China; [Liao, ChunIlan] Jiangxi Prov People Hosp, Anesthesia Operat Dept, Nanchang 330006, Jiangxi, Peoples R China	Wang, Q (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, 58 Zhong Shan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	wangqian_dr@126.com; hxiaohui2006@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472253, 81472258, 81572424, 81101862, 81172079, 81072047, 81201930]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2014A030313063]; Project of Guangzhou Municipal Science & Technology Planning [201607010309, 201607010164]; Science and Technology Planning Project of Guangdong Province [2016A020215047, 2017A020215016]	This work was funded by grants from the National Natural Science Foundation of China (grants 81472253, 81472258, 81572424, 81101862, 81172079, 81072047, and 81201930), the Natural Science Foundation of Guangdong Province (2014A030313063), the Project of Guangzhou Municipal Science & Technology Planning (201607010309 and 201607010164), and the Science and Technology Planning Project of Guangdong Province (2016A020215047 and 2017A020215016).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Cao JN, 2001, J NATL CANCER I, V93, P1159, DOI 10.1093/jnci/93.15.1159; Chen SR, 2015, REPRODUCTION, V149, pR159, DOI 10.1530/REP-14-0481; Cui DX, 2015, SCI REP-UK, V5, DOI 10.1038/srep10726; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Goldberger N, 2013, CANCER RES, V73, P2671, DOI 10.1158/0008-5472.CAN-12-3513; Guo M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071090; Li C, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-244; Liangpunsakul S, 2015, ALCOHOL CLIN EXP RES, V39, P556, DOI 10.1111/acer.12654; Tsai WC, 2017, J CLIN PATHOL, V70, P162, DOI 10.1136/jclinpath-2016-203804; Wang K, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-23; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; Winter SF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002735; Wu MY, 2008, JNCI-J NATL CANCER I, V100, P1247, DOI 10.1093/jnci/djn253; Wu RC, 2017, STEM CELLS, V35, P1554, DOI 10.1002/stem.2597; Wu RC, 2015, MOL ENDOCRINOL, V29, P1334, DOI 10.1210/me.2015-1089; Wu RC, 2013, P NATL ACAD SCI USA, V110, P4616, DOI 10.1073/pnas.1218318110; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	23	4	4	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						114	121		10.1016/j.humpath.2017.12.012			8	Pathology	Pathology	GB3PJ	WOS:000428969600015	29288040				2019-10-28	
J	Lintel, NJ; Luebker, SA; Lele, SM; Koepsell, SA				Lintel, Nicholas J.; Luebker, Stephen A.; Lele, Subodh M.; Koepsell, Scott A.			MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei	HUMAN PATHOLOGY			English	Article						Leiomyosarcoma; Leiomyoma; Bizarre leiomyoma; Major vault protein (MVP); Mass Spectrometry	RESISTANCE; PROTEIN; TUMORS	Morphologically, distinguishing between leiomyoma (LM) and leiomyosarcoma (LMS) is not always straightforward, especially with benign variants such as bizarre leiomyoma (BLM). To identify potential markers of malignancy in uterine smooth muscle tumors, proteomic studies were performed followed by assessment of protein expression by immunohistochemistry. Archival formalin-fixed, paraffin-embedded tissues from tumors (n = 23) diagnosed as LM, BLM, and LMS (using published criteria) were selected for the study. Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry was applied to pooled samples of formalin-fixed, paraffin-embedded LM and LMS tumor tissue to assay the relative protein quantities and look for expression patterns differentiating the 2 tumor types. A total of 592 proteins were quantified, and 10 proteins were differentially expressed between LM and LMS. Select proteins were chosen for evaluation by immunohistochemistry (IHC) based on antibody availability and biologic relevance in the literature. IHC was performed on a tissue microarray, and intensity was evaluated using imaging software. Major vault protein (MVP) and catechol O-methyltransferase had 3.05 and 13.94 times higher expression in LMS relative to LM by sequential window acquisition of all theoretical fragment ion spectra mass spectrometry, respectively. By IHC, MVP (clone 1014; Santa Cruz Biotechnology, Dallas, TX) was found to be 50% sensitive and 100% specific when comparing LMS to LM. Catechol O-methyltransferase (clone FL-271; Santa Cruz Biotechnology) had a sensitivity of 38% and a specificity of 88%. Six of 7 BLM had expression of MVP similar to LM. Immunohistochemical staining for MVP is a useful adjunct in distinguishing LMS from LM and BLM in difficult cases. (C) 2018 Elsevier Inc. All rights reserved.	[Lintel, Nicholas J.; Luebker, Stephen A.; Lele, Subodh M.; Koepsell, Scott A.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA	Lintel, NJ (reprint author), 983135 Nebraska Med Ctr, Omaha, NE 68198 USA.	Nicholas.Lintel@unmc.edu					[Anonymous], 2017, MVP MAJ VAULT PROT; Chen YL, 2016, CHINESE J PHYSIOL, V59, P331, DOI 10.4077/CJP.2016.BAF426; Crum CP, 2011, DIAGNOSTIC GYNECOLOG; D'Angelo E, 2014, SEMIN DIAGN PATHOL, V31, P216, DOI 10.1053/j.semdp.2014.03.003; Feller S, 2013, LAB INVEST, V93, p274A; Hendrickson MR, 1997, AM J SURG PATHOL, V21, P253, DOI 10.1097/00000478-199702000-00020; Ip P, 2015, LAB INVEST, V95, p291A; Jones MW, 2013, LAB INVEST, V93, p281A; Luebker SA, 2016, INT J PROTEOMICS, V2016, P1; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Toledo G, 2008, ARCH PATHOL LAB MED, V132, P595, DOI 10.1043/1543-2165(2008)132[595:SMTOTU]2.0.CO;2	12	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						122	127		10.1016/j.humpath.2017.12.020			6	Pathology	Pathology	GB3PJ	WOS:000428969600016	29307622				2019-10-28	
J	Terabe, T; Uchida, F; Nagai, H; Omori, S; Ishibashi-Kanno, N; Hasegawa, S; Yamagata, K; Gosho, M; Yanagawa, T; Bukawa, H				Terabe, Takehito; Uchida, Fumihiko; Nagai, Hiroki; Omori, Shoei; Ishibashi-Kanno, Naomi; Hasegawa, Shogo; Yamagata, Kenji; Gosho, Masahiko; Yanagawa, Toru; Bukawa, Hiroki			Expression of autophagy-related markers at the surgical margin of oral squamous cell carcinoma correlates with poor prognosis and tumor recurrence	HUMAN PATHOLOGY			English	Article						Autophagy; LC3A/B; p62; Prognosis; Oral squamous cell carcinoma; Tumor recurrence	MECHANISMS; LC3; TUMORIGENESIS; SURVIVAL; GENE	Oral squamous cell carcinoma (OSCC) is the sixth most common cancer worldwide, and is associated with poor prognosis. Autophagy is a programmed cell survival mechanism involved in physiologic processes and various diseases including cancer. However, the relationship between autophagy and cancer is controversial. Several studies have claimed that the expression of autophagy-related proteins, namely microtubule-associated protein light chain3 (LC3) and p62/SQSTM 1 (p62), is associated with poor prognosis in OSCC. In this study, we evaluated the expression of the autophagy-related markers LC3A/B and p62 by immunohistochemistry in 71 OSCC patient samples, especially focusing on surgical margins. Results were correlated with clinical characteristics. The expression of LC3A and LC3B was correlated with tumor recurrence and poor overall survival based on multivariate analysis, whereas the expression of p62 was correlated with only tumor recurrence and not prognosis. Thus, we suggest that the expression of autophagy-related markers at the surgical margins might be an indicator of local recurrence and poor prognosis in human OSCC. These results will aid in the development of new therapeutics and diagnostics for OSCC. (C) 2017 Elsevier Inc. All rights reserved.	[Terabe, Takehito; Nagai, Hiroki; Omori, Shoei] Univ Tsukuba, Grad Sch Comprehens Human Sci, Oral & Maxillofacial Surg, Clin Sci, Tsukuba, Ibaraki 3058575, Japan; [Uchida, Fumihiko; Ishibashi-Kanno, Naomi; Hasegawa, Shogo; Yamagata, Kenji; Yanagawa, Toru; Bukawa, Hiroki] Univ Tsukuba, Fac Med, Dept Oral & Maxillofacial Surg, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan; [Gosho, Masahiko] Univ Tsukuba, Fac Med, Dept Clin Trial & Clin Epidemiol, Tsukuba, Ibaraki 3058575, Japan	Bukawa, H (reprint author), Univ Tsukuba, Fac Med, Dept Oral & Maxillofacial Surg, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	bukawah-cuh@umin.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15H04917, JP15H05038, JPK20501]	This work was supported by JSPS KAKENHI [grant numbers JP15H04917, JP15H05038, JPK20501].	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI 10.1056/NEJMra1205406; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Garavello W, 2010, INT J CANCER, V127, P160, DOI 10.1002/ijc.25019; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kapoor V, 2012, BIOCHEM BIOPH RES CO, V422, P764, DOI 10.1016/j.bbrc.2012.05.079; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Malicdan MCV, 2007, AUTOPHAGY, V3, P396, DOI 10.4161/auto.4270; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12579, 10.1111/cas.12559]; Tang JY, 2013, HUM PATHOL, V44, P2558, DOI 10.1016/j.humpath.2013.06.017; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vergne I, 2006, AUTOPHAGY, V2, P175, DOI 10.4161/auto.2830; Wang YW, 2013, J ORAL PATHOL MED, V42, P557, DOI 10.1111/jop.12049; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047	35	7	7	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						156	163		10.1016/j.humpath.2017.11.019			8	Pathology	Pathology	GB3PJ	WOS:000428969600019	29241738				2019-10-28	
J	Kezlarian, BE; Cheng, L; Gupta, NS; Williamson, SR				Kezlarian, Brie E.; Cheng, Liang; Gupta, Nilesh S.; Williamson, Sean R.			Vasitis nodosa and related lesions: a modern immunohistochemical staining profile with special emphasis on novel diagnostic dilemmas	HUMAN PATHOLOGY			English	Article						Vasitis nodosa; Immunohistochemistry; Prostate cancer; GATA3; PAX8; NKX3.1	TRANSITIONAL-CELL CARCINOMAS; URINARY-BLADDER; UROTHELIAL CARCINOMA; PROSTATIC ADENOCARCINOMA; VAS-DEFERENS; GATA3; PAX8; EXPRESSION; INVASION; MARKERS	Vasitis nodosa is a benign proliferation of vas deferens epithelium, thought to be a response to trauma or obstruction, usually vasectomy. Although histologic features mimic malignancy, diagnosis is usually straightforward due to the clinical context. We analyzed 21 specimens with vasitis or epididymitis nodosa with antibodies to PAX8, CD10, p63, alpha-methyl-acyl-coA-racemase (AMACR), GATA3, prostein, NKX3.1, and prostate-specific antigen (PSA). Two diagnostically problematic cases included (1) florid bladder muscle involvement after prostatectomy and (2) involvement of the ampulla and ejaculatory duct in a radical prostatectomy specimen. Vasitis nodosa was excluded in 3 additional histologic mimics (2 post-treatment prostate cancers and 1 bladder cancer). PAX8 yielded consistent positive (100%) nuclear staining in the proliferative glands of vasitis nodosa, often stronger and more uniform than native vas deferens. CD10 labeling was common but also labeled secretions and other structures. Labeling for p63 was often basally located in glands with a multilayered appearance, but often markedly attenuated or lacking in the proliferative glands compared to native epithelium. AMACR positivity was variable but often present (19/21). PSA, prostein, and NKX3.1 were consistently negative. Rare problematic cases of vasitis nodosa include "invasion" of the ejaculatory duct at the prostate and involvement of bladder muscle after prostatectomy. The proliferative vasitis nodosa glands often have a prostate cancer like staining pattern with variable AMACR positivity and negative or patchy p63. However, reliable positivity for PAX8, patchy GATA3, and negative staining for PSA, NKX3.1, and prostein aid in distinguishing from prostate cancer and tubular variants of bladder cancer. (C) 2017 Elsevier Inc. All rights reserved.	[Kezlarian, Brie E.; Gupta, Nilesh S.; Williamson, Sean R.] Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI 48202 USA; [Kezlarian, Brie E.; Gupta, Nilesh S.; Williamson, Sean R.] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI 48202 USA; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Cheng, Liang] Indiana Univ Sch Med, Dept Urol, Indianapolis, IN 46202 USA; [Williamson, Sean R.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Williamson, SR (reprint author), Henry Ford Hosp, Dept Pathol K6, 2799 West Grand Blvd, Detroit, MI 48202 USA.	swilli25@hfhs.org					Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; BALOGH K, 1985, AM J CLIN PATHOL, V83, P426, DOI 10.1093/ajcp/83.4.426; BALOGH K, 1984, AM J CLIN PATHOL, V82, P710, DOI 10.1093/ajcp/82.6.710; Cerilli LA, 2003, AM J SURG PATHOL, V27, P469, DOI 10.1097/00000478-200304000-00006; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; DESCHRYVERKECSKEMETI K, 1987, ARCH PATHOL LAB MED, V111, P833; Easley S, 2006, J UROLOGY, V175, P1502, DOI 10.1016/S0022-5347(06)00057-7; Grote D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000316; Higgins JPT, 2007, AM J SURG PATHOL, V31, P673, DOI 10.1097/01.pas.0000213438.01278.5f; HIRSCHOWITZ L, 1988, J CLIN PATHOL, V41, P419, DOI 10.1136/jcp.41.4.419; Huang Q, 2004, HUM PATHOL, V35, P769, DOI 10.1016/j.humpath.2004.01.012; KOVI J, 1974, JAMA-J AM MED ASSOC, V228, P1519, DOI 10.1001/jama.1974.03230370017004; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Beltran AL, 2014, HISTOPATHOLOGY, V64, P872, DOI 10.1111/his.12345; Magers MJ, 2016, APPL IMMUNOHISTO M M, V24, pE50, DOI 10.1097/PAI.0000000000000326; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Oliva E, 2000, SEMIN DIAGN PATHOL, V17, P340; Ordonez NG, 2013, ADV ANAT PATHOL, V20, P352, DOI 10.1097/PAP.0b013e3182a28a68; Quick CM, 2010, HUM PATHOL, V41, P1145, DOI 10.1016/j.humpath.2010.01.010; Sakaki M, 2000, APMIS, V108, P283, DOI 10.1034/j.1600-0463.2000.d01-57.x; Sasaki K, 2009, AM J CLIN PATHOL, V132, P893, DOI 10.1309/AJCPQZX4WS8UPKGG; Tacha D, 2011, APPL IMMUNOHISTO M M, V19, P293, DOI 10.1097/PAI.0b013e3182025f66; Tong GX, 2011, AM J SURG PATHOL, V35, P1473, DOI 10.1097/PAS.0b013e318227e2ee; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Williamson SR, 2011, HISTOPATHOLOGY, V58, P811, DOI 10.1111/j.1365-2559.2010.03651.x; Young RH, 1996, AM J SURG PATHOL, V20, P1448, DOI 10.1097/00000478-199612000-00003; YOUNG RH, 1991, AM J CLIN PATHOL, V96, P635, DOI 10.1093/ajcp/96.5.635	27	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						164	170		10.1016/j.humpath.2017.12.001			7	Pathology	Pathology	GB3PJ	WOS:000428969600020	29241741				2019-10-28	
J	Brathwaite, SA; Smith, SM; Wai, L; Frankel, W; Hays, J; Yearsley, MM; Abdel-Misih, S				Brathwaite, Shayna A.; Smith, Stephen M.; Wai, Lai; Frankel, Wendy; Hays, John; Yearsley, Martha M.; Abdel-Misih, Sherif			Mixed adenoneuroendocrine carcinoma: A review of pathologic characteristics	HUMAN PATHOLOGY			English	Review						Mixed adenoneuroendocrine carcinoma; Colorectal; Neuroendocrine; Adenocarcinoma; MANEC; Carcinoid	ADENO-NEUROENDOCRINE CARCINOMA; TUMORS; ADENOCARCINOMA; APPENDIX; ENTITY; BEHAVIOR	Mixed adenoneuroendocrine carcinoma (MANEC) is a rare pathologic entity defined as a tumor exhibiting both adenocarcinoma and neuroendocrine carcinoma components. Though uncommon, these tumors show aggressive behavior and generally portend a poor prognosis. This study seeks to further define clinicopathological characteristics of MANEC to aid in accurate diagnosis and properly direct clinical management. Thirty-four confirmed MANECs were identified in our 25-year retrospective review of cases arising in the gastrointestinal tract. Various gross and microscopic variables were compared to overall survival. Tumors diagnosed at advanced stage (pT4), had a prominent mucinous component and lacked goblet cell clusters, which were all significantly associated with worse overall survival. This study supports previous findings and further elucidates clinicopathologic characteristics of MANEC. Published by Elsevier Inc.	[Brathwaite, Shayna A.; Abdel-Misih, Sherif] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA; [Smith, Stephen M.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Wai, Lai] Ohio State Univ, Wexner Med Ctr, Ctr Biostat, Columbus, OH 43210 USA; [Frankel, Wendy; Yearsley, Martha M.] Ohio State Univ, Wexner Med Ctr, Div Gastrointestinal & Liver Pathol, Dept Pathol, Columbus, OH 43210 USA; [Hays, John] Ohio State Univ, Wexner Med Ctr, Div Med Oncol, Columbus, OH 43210 USA	Abdel-Misih, S (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Surg, Div Surg Oncol, M256 Starling Loving Hall,320 West 10th Ave, Columbus, OH 43210 USA.	Sherif.Abdel-Misih@osumc.edu					Brathwaite S, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00148; Brathwaite S, 2016, ANN SURG ONCOL, V23, P2281, DOI 10.1245/s10434-016-5179-2; Capella C, 2000, SEMIN DIAGN PATHOL, V17, P91; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; Komminoth P, 2010, WHO CLASSIFICATION T; LEWIN K, 1987, AM J SURG PATHOL, V11, P71, DOI 10.1097/00000478-198700111-00007; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Roy P, 2010, WORLD J GASTRO ONCOL, V2, P251, DOI 10.4251/wjgo.v2.i6.251; Sahnane N, 2015, ENDOCR-RELAT CANCER, V22, P35, DOI 10.1530/ERC-14-0410; Sarshekeh AM, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw369.17; Scardoni M, 2014, NEUROENDOCRINOLOGY, V100, P310, DOI 10.1159/000369071; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150; Zeng YJ, 2016, ONCOTARGET, V7, P27394, DOI 10.18632/oncotarget.8423; Zeng YJ, 2014, J GASTROINTEST SURG, V18, P968, DOI 10.1007/s11605-014-2480-x	16	2	3	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						184	191		10.1016/j.humpath.2017.12.009			8	Pathology	Pathology	GB3PJ	WOS:000428969600023	29288693				2019-10-28	
J	Mengoli, MC; Cavazza, A; Zanelli, M; De Marco, L; Colby, TV; Casolari, R; Lococo, F; Rossi, G				Mengoli, Maria Cecilia; Cavazza, Alberto; Zanelli, Magda; De Marco, Loredana; Colby, Thomas V.; Casolari, Roberto; Lococo, Filippo; Rossi, Giulio			Incidental iatrogenic form of collagenized organizing pneumonia	HUMAN PATHOLOGY			English	Letter									[Mengoli, Maria Cecilia; Cavazza, Alberto; Zanelli, Magda; De Marco, Loredana] Arcispedale Santa Maria Nuova IRCCS, Unit Pathol, I-41124 Reggio Emilia, Italy; [Colby, Thomas V.] Mayo Clin, Pathol Unit, Lab Med, Scottsdale, AZ USA; [Casolari, Roberto] Univ Modena & Reggio Emilia, Dept Chem, I-41121 Modena, Italy; [Lococo, Filippo] IRCCS Arcispedale Santa Maria Nuova, Unit Thorac Surg, Reggio Emilia, Italy; [Rossi, Giulio] Reg Hosp Parini, Azienda USL Valle Aosta, Pathol Anat, I-11100 Aosta, Italy	Lococo, F (reprint author), IRCCS Arcispedale Santa Maria Nuova, Unit Thorac Surg, Reggio Emilia, Italy.	filippo_lococo@yahoo.it	Mengoli, Maria Cecilia/J-7335-2015; Cavazza, Alberto/K-2531-2018	Cavazza, Alberto/0000-0003-3590-319X; Mengoli, Maria Cecilia/0000-0002-1437-8747; zanelli, Magda/0000-0002-8733-9933			Beardsley B, 2013, J CLIN PATHOL, V66, P875, DOI 10.1136/jclinpath-2012-201342; Kawabata Y, 2010, HISTOPATHOLOGY, V56, P944, DOI 10.1111/j.1365-2559.2010.03574.x; Yousem SA, 2017, HUM PATHOL, V64, P76, DOI 10.1016/j.humpath.2017.03.018	3	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						192	193		10.1016/j.humpath.2017.10.035			2	Pathology	Pathology	GB3PJ	WOS:000428969600024	29217427				2019-10-28	
J	Andreasen, S; Stevens, E; Bjorndal, K; Homoe, P				Andreasen, Simon; Stevens, Elizabeth; Bjorndal, Kristine; Homoe, Preben			Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome	HUMAN PATHOLOGY			English	Letter							CHILDREN		[Andreasen, Simon; Stevens, Elizabeth; Homoe, Preben] Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, DK-4600 Koge, Denmark; [Andreasen, Simon; Stevens, Elizabeth] Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, DK-2100 Copenhagen, Denmark; [Bjorndal, Kristine] Odense Univ Hosp, Dept ENT Head & Neck Surg, DK-5000 Odense, Denmark	Andreasen, S (reprint author), Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, DK-4600 Koge, Denmark.; Andreasen, S (reprint author), Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, DK-2100 Copenhagen, Denmark.	Simon@Andreasen.pm		Homoe, Preben/0000-0003-2877-3518; Andreasen, Simon/0000-0002-1528-4988			Bradley P, 2007, ORL-J OTO-RHIN-LARYN, V69, P137, DOI 10.1159/000099222; Bradley PJ, 2016, ADV OTO-RHINO-LARYNG, V78, P175, DOI 10.1159/000442138; CASTRO EB, 1972, CANCER, V29, P312, DOI 10.1002/1097-0142(197202)29:2<312::AID-CNCR2820290207>3.0.CO;2-#; Stevens E, 2015, INT J PEDIATR OTORHI, V79, P1192, DOI 10.1016/j.ijporl.2015.04.035; Xu B, 2017, HUM PATHOL, V67, P37, DOI 10.1016/j.humpath.2017.07.007	5	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						193	194		10.1016/j.humpath.2017.11.021			2	Pathology	Pathology	GB3PJ	WOS:000428969600025	29288694				2019-10-28	
J	Xu, B; Katabi, N				Xu, Bin; Katabi, Nora			Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome-reply	HUMAN PATHOLOGY			English	Letter							CHILDREN; TUMORS		[Xu, Bin; Katabi, Nora] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA	Katabi, N (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.	katabin@mskcc.org		Xu, Bin/0000-0003-4638-9835			El-Naggar AK, 2017, WHO CLASSIFICATION T; Guzzo M, 2006, PEDIATR BLOOD CANCER, V47, P806, DOI 10.1002/pbc.20637; LUNA MA, 1991, ANN OTO RHINOL LARYN, V100, P869, DOI 10.1177/000348949110001016; Orvidas LJ, 2000, ARCH OTOLARYNGOL, V126, P177, DOI 10.1001/archotol.126.2.177; Stevens E, 2015, INT J PEDIATR OTORHI, V79, P1192, DOI 10.1016/j.ijporl.2015.04.035; Xu B, 2017, HUM PATHOL, V67, P37, DOI 10.1016/j.humpath.2017.07.007	6	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						194	194		10.1016/j.humpath.2017.11.022			1	Pathology	Pathology	GB3PJ	WOS:000428969600026	29288695				2019-10-28	
J	Zehnbauer, B				Zehnbauer, Barbara			Keeping Practice Recommendations in Step with Advancing Knowledge	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material									[Zehnbauer, Barbara] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Zehnbauer, B (reprint author), Emory Univ, Sch Med, 961 Castle Falls Dr NE, Atlanta, GA 30329 USA.	bzehnba@emory.edu					Lindeman NI, 2013, J MOL DIAGN, V15, P415, DOI 10.1016/j.jmoldx.2013.03.001; Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI 10.1016/j.jmoldx.2017.11.004	2	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					127	128		10.1016/j.jmoldx.2018.01.003			2	Pathology	Pathology	GA8SA	WOS:000428608800001	29360582				2019-10-28	
J	Farkas, DH				Farkas, Daniel H.			Perspectives on the Affordability of Precision Medicine	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material									[Farkas, Daniel H.] Cleveland Clin Fdn, Mol Pathol Sect, Pathol & Lab Med Inst, 9500 Euclid Ave,LL2-141, Cleveland, OH 44195 USA	Farkas, DH (reprint author), Cleveland Clin Fdn, Mol Pathol Sect, Pathol & Lab Med Inst, 9500 Euclid Ave,LL2-141, Cleveland, OH 44195 USA.	farkasd2@ccf.org					Christensen C., 1997, INNOVATORS DILEMMA N; Conic RZ, 2018, J AM ACAD DERMATOL, V78, P40, DOI 10.1016/j.jaad.2017.08.039; Hsiao SJ, 2018, J MOL DIAGN, V20, P177, DOI 10.1016/j.jmoldx.2017.10.006; Khorana AA, 2017, AM SOC CLIN ONC M JU	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					160	162		10.1016/j.jmoldx.2017.12.004			3	Pathology	Pathology	GA8SA	WOS:000428608800003	29482769				2019-10-28	
J	Ohgami, RS; Rosenwald, A; Bagg, A				Ohgami, Robert S.; Rosenwald, Andreas; Bagg, Adam			Next-Generation Sequencing for Lymphomas Perfecting a Pipeline for Personalized Pathobiologic and Prognostic Predictions	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material							CHRONIC LYMPHOCYTIC-LEUKEMIA; FOLLICULAR LYMPHOMA; VALIDATION; MUTATIONS; MALIGNANCIES; CAPTURE; GENOME; SF3B1; CELLS; GENE		[Ohgami, Robert S.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Bagg, Adam] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA	Ohgami, RS (reprint author), Stanford Univ, 300 Pasteur Dr, Stanford, CA 94304 USA.	rohgami@stanford.edu	Bagg, Adam/R-8450-2019				Cummings CA, 2016, CTS-CLIN TRANSL SCI, V9, P283, DOI 10.1111/cts.12429; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Hung SS, 2018, J MOL DIAGN, V20, P203, DOI 10.1016/j.jmoldx.2017.11.010; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kadri S, 2017, J MOL DIAGN, V19, P43, DOI 10.1016/j.jmoldx.2016.07.012; Kluk MJ, 2016, J MOL DIAGN, V18, P507, DOI 10.1016/j.jmoldx.2016.02.003; Nadeu F, 2016, BLOOD, V127, P2122, DOI 10.1182/blood-2015-07-659144; Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856; Pasqualucci L, 2014, CELL REP, V6, P130, DOI 10.1016/j.celrep.2013.12.027; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pastore A, 2015, LANCET ONCOL, V16, P1111, DOI 10.1016/S1470-2045(15)00169-2; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rosenquist R, 2017, J INTERN MED, V282, P371, DOI 10.1111/joim.12633; Samorodnitsky E, 2015, HUM MUTAT, V36, P903, DOI 10.1002/humu.22825; Samorodnitsky E, 2015, J MOL DIAGN, V17, P64, DOI 10.1016/j.jmoldx.2014.09.009; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016	18	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					163	165		10.1016/j.jmoldx.2018.01.002			3	Pathology	Pathology	GA8SA	WOS:000428608800004	29355824	Bronze			2019-10-28	
J	van Riet, J; Krol, NMG; Atmodimedjo, PN; Brosens, E; van Ijcken, WFJ; Jansen, MPHM; Martens, JWM; Looijenga, LH; Jenster, G; Dubbink, HJ; Dinjens, WNM; van de Werken, HJG				van Riet, Job; Krol, Niels M. G.; Atmodimedjo, Peggy N.; Brosens, Erwin; van Ijcken, Wilfred F. J.; Jansen, Maurice P. H. M.; Martens, John W. M.; Looijenga, Leendert H.; Jenster, Guido; Dubbink, Hendrikus J.; Dinjens, Winand N. M.; van de Werken, Harmen J. G.			SNPitty An Intuitive Web Application for Interactive B-Allele Frequency and Copy Number Visualization of Next-Generation Sequencing Data	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							GENOMIC ANALYSIS; MUTATIONS OCCUR; GENE; HETEROZYGOSITY; PATTERNS; DATABASE; LOSSES	Exploration and visualization of next-generation sequencing data are crucial for clinical diagnostics. Software allowing simultaneous visualization of multiple regions of interest coupled with dynamic heuristic filtering of genetic aberrations is, however, lacking. Therefore, the authors developed the web application SNPitty that allows interactive visualization and interrogation of variant call format files by using B-allele frequencies of single-nucleotide polymorphisms and single-nucleotide variants, coverage metrics, and copy numbers analysis results. SNPitty displays variant alleles and allelic imbalances with a focus on loss of heterozygosity and copy number variation using genome-wide heterozygous markers and somatic mutations. In addition, SNPitty is capable of generating predefined reports that summarize and highlight disease-specific targets of interest. SNPitty was validated for diagnostic interpretation of somatic events by showcasing a serial dilution series of glioma tissue. Additionally, SNPitty is demonstrated in four cancer-related scenarios encountered in daily clinical practice and on whole-exome sequencing data of peripheral blood from a Down syndrome patient. SNPitty allows detection of loss of heterozygosity, chromosomal and gene amplifications, homozygous or heterozygous deletions, somatic mutations, or any combination thereof in regions or genes of interest. Furthermore, SNPitty can be used to distinguish molecular relationships between multiple tumors from a single patient. On the basis of these data, the authors demonstrate that SNPitty is robust and user friendly in a wide range of diagnostic scenarios.	[van Riet, Job; Krol, Niels M. G.; van de Werken, Harmen J. G.] Univ Med Ctr, Erasmus MC, Canc Computat Biol Ctr, Rotterdam, Netherlands; [van Riet, Job; Jenster, Guido; van de Werken, Harmen J. G.] Univ Med Ctr, Erasmus MC, Dept Urol, Rotterdam, Netherlands; [Krol, Niels M. G.; Atmodimedjo, Peggy N.; Looijenga, Leendert H.; Dubbink, Hendrikus J.; Dinjens, Winand N. M.] Univ Med Ctr, Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Brosens, Erwin] Univ Med Ctr, Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Jansen, Maurice P. H. M.; Martens, John W. M.] Univ Med Ctr, Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands; [van Ijcken, Wilfred F. J.] Univ Med Ctr, Erasmus MC, Ctr Biom, Rotterdam, Netherlands	van de Werken, HJG (reprint author), Erasmus Univ, Canc Computat Biol Ctr, Med Ctr Rotterdam, Erasmus MC,Canc Inst,Dept Urol, BE-355,POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.vandewerken@erasmusmc.nl	Looijenga, Leendert/B-8145-2019; van ijcken, willem/N-9805-2018; van de Werken, Harmen/I-3006-2014	Looijenga, Leendert/0000-0002-8146-1911; van ijcken, willem/0000-0002-0421-8301; van de Werken, Harmen/0000-0002-9794-1477			Alves IT, 2013, HUM GENET, V132, P709, DOI 10.1007/s00439-013-1308-1; BAKER SJ, 1990, CANCER RES, V50, P7717; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Boettiger Carl, 2015, ACM SIGOPS Operating Systems Review, V49, P71; Boeva V, 2014, BIOINFORMATICS, V30, P3443, DOI 10.1093/bioinformatics/btu436; Brouwer RWW, 2012, BIOINFORMATICS, V28, P284, DOI 10.1093/bioinformatics/btr613; Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330; Dubbink HJ, 2016, J MOL DIAGN, V18, P775, DOI 10.1016/j.jmoldx.2016.06.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713; Jones S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7161; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Li F, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1733-8; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10086; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Obenchain V, 2014, BIOINFORMATICS, V30, P2076, DOI 10.1093/bioinformatics/btu168; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; R Core Team, 2017, R LANG ENV STAT COMP; R Development Core Team, 2013, R LANG ENV STAT COMP; Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177; Sato N, 2000, CANCER RES, V60, P7052; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Tate G, 2009, CANCER GENET CYTOGEN, V190, P15, DOI 10.1016/j.cancergencyto.2008.11.002; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Westesson O, 2013, BRIEF BIOINFORM, V14, P172, DOI 10.1093/bib/bbr078; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	33	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					166	176		10.1016/j.jmoldx.2017.11.011			11	Pathology	Pathology	GA8SA	WOS:000428608800005	29305224				2019-10-28	
J	Hsiao, SJ; Mansukhani, MM; Carter, MC; Sireci, AN				Hsiao, Susan J.; Mansukhani, Mahesh M.; Carter, Melissa C.; Sireci, Anthony N.			The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Transition from Stacking Codes to the Current Molecular Code Set Including Genomic Sequencing Procedures	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							PATHOLOGY	Changes in coding and coverage generate an uncertain reimbursement environment for molecular pathology laboratories. We analyzed our experience with two representative molecular oncology tests: a T-cell receptor (TCR) beta rearrangement test and a large (467-gene) cancer next-generation sequencing panel, the Columbia Combined Cancer Panel (CCCP). Before 2013, the TCR beta test was coded using stacked current procedural terminology codes and subsequently transitioned to a tier 1 code. CCCP was coded using a combination of tier 1 and 2 codes until 2015, when a new Genomic Sequencing Procedure code was adopted. A decrease in reimbursement of 61% was observed for the TCR beta test on moving from stacking to tier 1 codes. No initial increase in total rejection rate was observed, but a subsequent increase in rejection rates in 2015 and 2016 was noted. The CCCP test showed a similar decrease (48%) in reimbursement after adoption of the new Genomic Sequencing Procedure code and was accompanied by a sharp increase in rejection rates both on implementation of the new code and over time. Changes in coding can result in substantial decreases in reimbursement. This may be a barrier to patient access because of the high cost of molecular diagnostics. Revisions to the molecular code set will continue. These findings help laboratories and manufacturers prepare for the financial impact and advocate appropriately.	[Hsiao, Susan J.; Mansukhani, Mahesh M.; Carter, Melissa C.; Sireci, Anthony N.] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY USA	Sireci, AN (reprint author), Columbia Univ, Irving Med Ctr, 630 W 168th St,Ste PS17-401, New York, NY 10032 USA.	ans2133@columbia.edu					American Medical Association, 2017, CPT 2017 PROF ED; [Anonymous], 2015, CPT 2015 PROF ED; [Anonymous], 2013, CPT 2013 PROF ED; [Department of Health and Human Services Centers for Medicare & Medicaid Services], 2012, FED REGISTER, V77, P68891; Dervan AP, 2017, GENET MED, V19, P559, DOI 10.1038/gim.2016.145; Hirsch JA, 2015, J NEUROINTERV SURG, V7, P309, DOI 10.1136/neurintsurg-2014-011156; Joseph L, 2016, J MOL DIAGN, V18, P605, DOI 10.1016/j.jmoldx.2016.05.007; Klein RD, 2015, CLIN CHEM, V61, P136, DOI 10.1373/clinchem.2014.223032; Logue L Joan, 2003, Clin Leadersh Manag Rev, V17, P346; Messner DA, 2016, APPL TRANSL GENOM, V10, P19, DOI 10.1016/j.atg.2016.05.004; Sabatini LM, 2016, J MOL DIAGN, V18, P319, DOI 10.1016/j.jmoldx.2015.11.010; Sireci AN, 2017, J MOL DIAGN, V19, P277, DOI 10.1016/j.jmoldx.2016.10.008	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					177	183		10.1016/j.jmoldx.2017.10.006			7	Pathology	Pathology	GA8SA	WOS:000428608800006	29269278	Bronze			2019-10-28	
J	Yang, SR; Lin, CY; Stehr, H; Long, SR; Kong, CS; Berry, GJ; Zehnder, JL; Kunder, CA				Yang, Soo-Ryum; Lin, Chieh-Yu; Stehr, Henning; Long, Steven R.; Kong, Christina S.; Berry, Gerald J.; Zehnder, James L.; Kunder, Christian A.			Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CELL-FREE DNA; PLEURAL EFFUSION; EGFR MUTATION; CYTOLOGY SPECIMENS; TARGETED THERAPIES; CANCER PATIENTS; RESISTANCE; MECHANISMS; DISCOVERY; FREQUENCY	Cytology samples are increasingly used for comprehensive molecular testing. Although fine-needle aspirates are adequate substrates for high-throughput sequencing, the suitability of malignant body fluids remains largely unexplored. We investigated the adequacy and utility of performing targeted next-generation sequencing (NGS) on malignant effusions from patients with metastatic lung adenocarcinoma. Thirty-two effusion samples submitted for hybrid capture based NGS using a clinically validated solid tumor genotyping panel were examined. All cases showed >= 5% tumor cellularity; however, 28 (88%) provided sufficient DNA for NGS (>= 1 ng/mu L). The sequencing reads showed satisfactory quality control statistics, and the variant allele frequencies were correlated with tumor cellularity. Furthermore, pathogenic or likely pathogenic genomic alterations were identified in 26 of 28 samples (93%), whereas clinically actionable alterations were present in 18 (64%). Notably, nine patients had additional molecular testing performed on preceding or subsequent biopsy specimens, and the results across multiple samples were compared. In two patients, the NGS-based fluid analysis identified clinically actionable alterations that were not detected by other hotspot testing. In four patients treated with tyrosine kinase inhibitors, malignant fluid sequencing confirmed driver alterations from prior testing and revealed new resistance mechanisms. Hence, given adequate DNA input and tumor cellularity, comprehensive genomic profiling of malignant effusions may be used to establish mutational status at diagnosis and inform treatment resistance during targeted therapy.	[Yang, Soo-Ryum; Lin, Chieh-Yu; Stehr, Henning; Long, Steven R.; Kong, Christina S.; Berry, Gerald J.; Zehnder, James L.; Kunder, Christian A.] Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA	Kunder, CA (reprint author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.	ckunder@stanford.edu	Kunder, Christian/K-3212-2019		Department of Pathology, Stanford University School of Medicine	Supported by the Department of Pathology, Stanford University School of Medicine.	Aisner DL, 2016, ARCH PATHOL LAB MED, V140, P1206, DOI 10.5858/arpa.2016-0156-RA; Akamatsu H, 2014, J THORAC ONCOL, V9, P1048, DOI 10.1097/JTO.0000000000000203; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Cagle PT, 2012, ARCH PATHOL LAB MED, V136, P1186, DOI 10.5858/arpa.2012-0390-RA; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chiu CH, 2015, J THORAC ONCOL, V10, P793, DOI 10.1097/JTO.0000000000000504; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dudley J, 2015, ARCH PATHOL LAB MED, P139; Dudley JC, 2014, MOL DIAGN THER, V18, P409, DOI 10.1007/s40291-014-0091-6; Ettinger DS, 2016, J NATL COMPR CANC NE, V14, P255, DOI 10.6004/jnccn.2016.0031; Fang X, 2014, PULM PHARMACOL THER, V28, P41, DOI 10.1016/j.pupt.2013.05.005; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Guan Y, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027001; Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86; Hung TL, 2003, CLIN CANCER RES, V9, P2605; Husain H, 2017, MOL CANCER THER, V16, P948, DOI 10.1158/1535-7163.MCT-16-0436; Ilie M, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.11; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21597; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010; Lin J, 2014, INT J CLIN EXP PATHO, V7, P8813; Lin YT, 2016, CLIN LUNG CANCER, V17, pE77, DOI 10.1016/j.cllc.2016.03.005; Lindeman NI, 2013, ARCH PATHOL LAB MED, V137, P828, DOI 10.5858/arpa.2012-0720-OA; Liu DY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098855; Liu XQ, 2013, J CLIN PATHOL, V66, P1065, DOI 10.1136/jclinpath-2013-201728; Minari R, 2016, TRANSL LUNG CANCER R, V5, P695, DOI 10.21037/tlcr.2016.12.02; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Nakata A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13076; Newman AM, 2014, BIOINFORMATICS, V30, P3390, DOI 10.1093/bioinformatics/btu549; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Qiu T, 2015, SCI REP-UK, V5, DOI 10.1038/srep11317; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roy-Chowdhuri S, 2016, ARCH PATHOL LAB MED, V140, P1267, DOI 10.5858/arpa.2016-0091-SA; Roy-Chowdhuri S, 2016, ARCH PATHOL LAB MED, V140, P1191, DOI 10.5858/arpa.2016-0117-RA; Roy-Chowdhuri S, 2015, CANCER CYTOPATHOL, V123, P659, DOI 10.1002/cncy.21597; Saqi A, 2016, ARCH PATHOL LAB MED, V140, P1318, DOI 10.5858/arpa.2016-0125-RA; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sholl LM, 2015, J THORAC ONCOL, V10, P768, DOI 10.1097/JTO.0000000000000516; Simon GR, 2014, CLIN LUNG CANCER, V15, P21, DOI 10.1016/j.cllc.2013.11.009; Smits AJJ, 2012, CELL ONCOL, V35, P189, DOI 10.1007/s13402-012-0078-4; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90; Tian SK, 2016, ARCH PATHOL LAB MED, V140, P1200, DOI 10.5858/arpa.2016-0108-RA; Tokumo M, 2005, CLIN CANCER RES, V11, P1167; Treece AL, 2016, CANCER CYTOPATHOL, V124, P406, DOI 10.1002/cncy.21699; Tsai MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep13574; Velizheva NP, 2017, CANCER CYTOPATHOL, V125, P30, DOI 10.1002/cncy.21771; Volik S, 2016, MOL CANCER RES, V14, P898, DOI 10.1158/1541-7786.MCR-16-0044; Zou JY, 2014, J INT MED RES, V42, P1110, DOI 10.1177/0300060514539273	55	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					184	194		10.1016/j.jmoldx.2017.10.007			11	Pathology	Pathology	GA8SA	WOS:000428608800007	29269277	Bronze			2019-10-28	
J	Frans, G; Meert, W; Ten Bosch, JV; Meyts, I; Bossuyt, X; Vermeesch, JR; Hestand, MS				Frans, Glynis; Meert, Wim; Ten Bosch, Jutte van der Werff; Meyts, Isabelle; Bossuyt, Xavier; Vermeesch, Joris R.; Hestand, Matthew S.			Conventional and Single-Molecule Targeted Sequencing Method for Specific Variant Detection in IKBKG while Bypassing the IKBKGP1 Pseudogene	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							BURROWS-WHEELER TRANSFORM; PRIMARY IMMUNODEFICIENCIES; READ ALIGNMENT; DISCOVERY; FRAMEWORK; MUTATION; EXOME; NEMO	In addition to Sanger sequencing, next-generation sequencing of gene panels and exomes has emerged as a standard diagnostic tool in many laboratories. However, these captures can miss regions, have poor efficiency, or capture pseudogenes, which hamper proper diagnoses. One such example is the primary immunodeficiency-associated gene IKBKG. Its pseudogene IKBKGP1 makes traditional capture methods aspecific. We therefore developed a long-range PCR method to efficiently target IKBKG, as well as two associated genes (IRAK4 and MYD88), while bypassing the IKBKGP1 pseudogene. Sequencing accuracy was evaluated using both conventional short-read technology and a newer long-read, single-molecule sequencer. Different mapping and variant calling options were evaluated in their capability to bypass the pseudogene using both sequencing platforms. Based on these evaluations, we determined a robust diagnostic application for unambiguous sequencing and variant calling in IKBKG, IRAK4, and MYD88. This method allows rapid identification of selected primary immunodeficiency diseases in patients suffering from life-threatening invasive pyogenic bacterial infections.	[Frans, Glynis; Meyts, Isabelle; Bossuyt, Xavier] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Vermeesch, Joris R.; Hestand, Matthew S.] Katholieke Univ Leuven, Expt Immunol Lab, Dept Human Genet, Leuven, Belgium; Katholieke Univ Leuven, Childhood Immunol, Leuven, Belgium; [Meert, Wim] UZ Leuven, Genom Core, Leuven, Belgium; [Ten Bosch, Jutte van der Werff] Univ Hosp Brussels, Dept Pediat, Brussels, Belgium; [Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium	Hestand, MS (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Human Genet, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	matthew.hestand@cchmc.org	Meyts, Isabelle/Z-3295-2019; Bossuyt, Xavier/B-2085-2019	Bossuyt, Xavier/0000-0001-6856-8485	KU LeuvenKU Leuven [(SymBioSys) PFV/10/016, GOA/12/015]; Hercules Foundation [ZW11-14]; Agency for Innovation by Science and Technology (IWT)Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) [ZL36300700]	Supported by KU Leuven research grants (SymBioSys) PFV/10/016 and GOA/12/015 (J.R.V), Hercules Foundation research grant ZW11-14 (J.R.V.), and The Agency for Innovation by Science and Technology (IWT) grant ZL36300700 (X.B. and J.R.V.).	Bardaro T, 2003, HUM MUTAT, V21, P8, DOI 10.1002/humu.10150; Borras DM, 2017, HUM MUTAT, V38, P870, DOI 10.1002/humu.23223; Buermans HPJ, 2017, HUM MUTAT, V38, P310, DOI 10.1002/humu.23166; Carneiro MO, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-375; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Frans G, THESIS; Frans G, 2018, J ALLERGY CLIN IMMUN, V141, P768, DOI 10.1016/j.jaci.2017.04.017; Frans G, 2014, CRIT REV CL LAB SCI, V51, P112, DOI 10.3109/10408363.2014.881317; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Kammermeier J, 2014, J MED GENET, V51, P748, DOI 10.1136/jmedgenet-2014-102624; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Leinonen R, 2011, NUCLEIC ACIDS RES, V39, pD28, DOI 10.1093/nar/gkq967; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364; Mayor NP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127153; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mensah MA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004578; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Picard C, 2014, EUR J IMMUNOL, V44, P2854, DOI 10.1002/eji.201444669; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Smahi A, 2000, NATURE, V405, P466; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	29	5	5	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					195	202		10.1016/j.jmoldx.2017.10.005			8	Pathology	Pathology	GA8SA	WOS:000428608800008	29269280	Bronze			2019-10-28	
J	Patel, K; Nagel, M; Wesolowski, M; Dees, S; Rivera-Milla, E; Geldmacher, C; Dheda, K; Hoelscher, M; Labugger, I				Patel, Krutarth; Nagel, Matilde; Wesolowski, Maria; Dees, Stefan; Rivera-Milla, Eric; Geldmacher, Christof; Dheda, Keertan; Hoelscher, Michael; Labugger, Ines			Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis Cape Town Cohort	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							POLYMERASE-CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; NUCLEIC-ACIDS; SPUTUM INDUCTION; CLINICAL-SAMPLES; DNA; TIME; BIOMARKERS; ACCURACY; COMPLEX	Tuberculosis (TB) diagnosis among sputum-scarce patients is time consuming. Thus, a nonsputum diagnostic alternative is urgently needed. The Mycobacterium tuberculosis specific transrenal (Tr) DNA from urine is a potential target for TB diagnostics. In this study, a new urine-based Tr-DNA molecular assay was evaluated for diagnosis of pulmonary tuberculosis among 428 adults suspected of having pulmonary TB (164 HIV positive, 263 HIV negative) from Cape Town, South Africa. Tr-DNA was isolated from 4 mL of EDTA urine, and a rapid, double-stranded, primer-based PCR method was performed targeting the Mycobacterium tuberculosis specific direct repeat region. Each Tr-DNA eluate was tested in triplicate using an automated molecular analyzer with controls included in each test. With liquid culture used as the gold standard, the Tr-DNA assay showed sensitivity of 42.9% (n = 75/175; 95% CI, 35.4%-50.5%) and specificity of 88.6% (n = 210/237; 95% CI, 83.91.-92.41o). Among HIV-infected patients with TB, sensitivity and specificity were 45.2% and 89.0%, respectively. The combination of smear microscopy and Tr-DNA increased the sensitivity to 83.8% (smear microscopy alone, 75.1%), with 96.6% specificity. This study indicates that Tr-DNA has a moderate specificity with low sensitivity for diagnosis of pulmonary TB. Despite Low sensitivity, this diagnostic test may have potential in combination with smear microscopy to support TB diagnosis in HIV-endemic regions, where sputum-scarce patients are common.	[Patel, Krutarth; Nagel, Matilde; Wesolowski, Maria; Dees, Stefan; Rivera-Milla, Eric; Labugger, Ines] Alere Technol GmbH, Loebstedter St 103-105, D-07749 Jena, Germany; [Patel, Krutarth; Hoelscher, Michael] Univ Munich, Ctr Int Hlth, Munich, Germany; [Geldmacher, Christof; Hoelscher, Michael] Univ Munich, Med Ctr, Div Infect Dis & Trop Med, Munich, Germany; [Geldmacher, Christof; Hoelscher, Michael] German Ctr Infect Res, Munich, Germany; [Dheda, Keertan] Univ Cape Town, Lung Infect & Immun Unit, Dept Med, Div Pulmonol & Clin Immunol, Cape Town, South Africa; [Dheda, Keertan] Univ Cape Town, UCT Lung Inst, Cape Town, South Africa	Patel, K (reprint author), Alere Technol GmbH, Loebstedter St 103-105, D-07749 Jena, Germany.	krutarth.patel@alere.com			Alere Technologies GmbH, Jena, Germany	Supported by Alere Technologies GmbH, Jena, Germany (K.P., M.N., M.W., S.D., E.R.-M., and LL).	Alavi SM, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.19238; Amin I, 2011, BMC RES NOTES, V4, P1; Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791; Becq J, 2007, MOL BIOL EVOL, V24, P1861, DOI 10.1093/molbev/msm111; Beggs ML, 1996, J CLIN MICROBIOL, V34, P2985; Bossuyt PMM, 2012, CLIN CHEM, V58, P1636, DOI 10.1373/clinchem.2012.182576; Bryzgunova OE, 2006, ANN NY ACAD SCI, V1075, P334, DOI 10.1196/annals.1368.045; Burman WJ, 2000, CLIN INFECT DIS, V31, P1390, DOI 10.1086/317504; Cannas A, 2008, INT J TUBERC LUNG D, V12, P146; Chihota VN, 2010, INT J TUBERC LUNG D, V14, P1024; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Dheda K, 2013, RESPIROLOGY, V18, P217, DOI 10.1111/resp.12022; Doherty TM, 2009, CLIN CHEST MED, V30, P783, DOI 10.1016/j.ccm.2009.08.008; El Bali Latifa, 2014, J Biomol Tech, V25, P96, DOI 10.7171/jbt.14-2504-002; Gonzalez-Angulo Y, 2012, EUR J CLIN MICROBIOL, V31, P1619, DOI 10.1007/s10096-011-1485-6; Green C, 2009, LANCET INFECT DIS, V9, P505, DOI 10.1016/S1473-3099(09)70149-5; Huggett Jim F, 2008, BMC Res Notes, V1, P70, DOI 10.1186/1756-0500-1-70; Joel DR, 2014, INT J TUBERC LUNG D, V18, P328, DOI 10.5588/ijtld.13.0243; Kafwabulula M, 2002, INT J TUBERC LUNG D, V6, P732; KOLK AHJ, 1992, J CLIN MICROBIOL, V30, P2567; Kontanis EJ, 2006, J FORENSIC SCI, V51, P795, DOI 10.1111/j.1556-4029.2006.00182.x; Labugger I, 2017, INFECTION, V45, P269, DOI 10.1007/s15010-016-0955-2; Lessells RJ, 2011, J INFECT DIS, V204, pS1187, DOI 10.1093/infdis/jir412; Marangu D, 2015, INT J TUBERC LUNG D, V19, P1339, DOI 10.5588/ijtld.15.0209; Mayaud C, 1999, THORAX, V54, P567, DOI 10.1136/thx.54.7.567; McNerney R, 2012, J INFECT DIS, V205, pS147, DOI 10.1093/infdis/jir860; Melkonyan HS, 2008, ANN NY ACAD SCI, V1137, P73, DOI 10.1196/annals.1448.015; Milde A, 1999, INT J LEGAL MED, V112, P209, DOI 10.1007/s004140050237; Moussa OM, 2000, J UROLOGY, V164, P584, DOI 10.1016/S0022-5347(05)67427-7; Niemz A, 2012, EXPERT REV MOL DIAGN, V12, P687, DOI [10.1586/erm.12.71, 10.1586/ERM.12.71]; Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007; Pau CP, 2010, J VIROL METHODS, V164, P55, DOI 10.1016/j.jviromet.2009.11.027; Peter J, 2010, CURR OPIN PULM MED, V16, P262, DOI 10.1097/MCP.0b013e328337f23a; Peter JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039966; Rebollo MJ, 2006, DIAGN MICR INFEC DIS, V56, P141, DOI 10.1016/j.diagmicrobio.2006.03.018; Sechi LA, 1997, MOL CELL PROBE, V11, P281, DOI 10.1006/mcpr.1997.0119; Stinson KW, 2014, GLOBAL LAB INITIATIV; Storla DG, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-15; Theron G, 2011, AM J RESP CRIT CARE, V184, P132, DOI 10.1164/rccm.201101-0056OC; Torrea G, 2005, J MED MICROBIOL, V54, P39, DOI 10.1099/jmm.0.45688-0; Ullrich T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035438; Van Rie A, 2008, J CLIN MICROBIOL, V46, P897, DOI 10.1128/JCM.01553-07; Virenfeldt J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004818; Whiting PF, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-20; WHO, 2015, WHO GLOB TUB REP 201; Wood R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025098; World Health Organization, 2016, WHO GLOB TUB REP 201; Zar HJ, 2000, ARCH DIS CHILD, V82, P305, DOI 10.1136/adc.82.4.305	48	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					215	224		10.1016/j.jmoldx.2017.11.005			10	Pathology	Pathology	GA8SA	WOS:000428608800010	29269279	Bronze			2019-10-28	
J	Huho, AN; Yadak, N; Bocklage, TJ; Yang, SX				Huho, Albert N.; Yadak, Nour; Bocklage, Therese J.; Yang, Shangxin			Evaluation of Diagnostic Utility of a High-Risk Human Papillomavirus PCR Test on Formalin-Fixed, Paraffin-Embedded Head and Neck Tumor Tissues	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							SQUAMOUS-CELL CARCINOMA; OROPHARYNGEAL CANCER; POSITIVE HEAD; UNITED-STATES; HPV STATUS	The increasing prevalence of high-risk human papillomavirus (HR-HPV) associated head and neck squamous cell carcinoma (HNSCC) has prompted strong clinical demands for detecting HR-HPV directly in the tumor. Although p16 immunohistochemistry (IHC) has been the standard testing method, it has Limitations including false positivity, lack of sensitivity in low tumor cell samples such as fine-needle aspirate (FNA), and its subjectivity. We developed a modified method based on a commercial automated HR-HPV PCR assay and evaluated the performance characteristics and the diagnostic utility of this assay for direct HR-HPV detection in the HNSCC samples. HNSCC formalin-fixed, paraffin-embedded blocks were retrieved from archives including 44 excisions, 63 biopsies, and 16 FNAs. Tissue slices were trimmed from the blocks, deparaffinized, lysed, and loaded on the commercial automated platform for HR-HPV PCR. All specimens had a concurrent p16 IHC performed. The PCR assay showed high concordance with the p16 IHC (96%; 99/103) and excellent positive agreement (91.5/0) and negative agreement (100%). In addition, the PCR assay provided more conclusive results in samples with equivocal p16 IHC results. The modified commercial automated HR-HPV PCR test is a labor-efficient quick, reliable, sensitive, and specific method for detecting HR-HPV in formalin-fixed, paraffin embedded samples. This assay also showed excellent diagnostic utility in samples with equivocal p16 IHC results, including FNA cell blocks.	[Huho, Albert N.; Yadak, Nour; Bocklage, Therese J.; Yang, Shangxin] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Huho, Albert N.; Yang, Shangxin] TriCore Reference Labs, 1001 Woodward P1 NE, Albuquerque, NM 87102 USA	Yang, SX (reprint author), TriCore Reference Labs, 1001 Woodward P1 NE, Albuquerque, NM 87102 USA.	shyang@salud.unm.edu		Yang, Shangxin/0000-0001-9991-1178	Dr. Kathryn Foucar endowment funds	Supported by the Dr. Kathryn Foucar endowment funds (A.N.H.).	Abreu ALP, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-262; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Gildener-Leapman N, 2014, ORAL ONCOL, V50, P780, DOI 10.1016/j.oraloncology.2013.09.010; Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Herberhold S, 2017, MED MICROBIOL IMMUN, V206, P93, DOI 10.1007/s00430-016-0486-6; Jalaly JB, 2015, CANCER CYTOPATHOL, V123, P723, DOI 10.1002/cncy.21600; Jordan RC, 2012, AM J SURG PATHOL, V36, P945, DOI 10.1097/PAS.0b013e318253a2d1; Kerr DA, 2016, ARCH PATHOL LAB MED, V140, P844, DOI 10.5858/arpa.2015-0272-OA; Kerr DA, 2014, CANCER CYTOPATHOL, V122, P167, DOI 10.1002/cncy.21372; Lewis A, 2015, ONCOLOGY-NY, V29, P616; Lewis JS, 2012, MODERN PATHOL, V25, P1212, DOI 10.1038/modpathol.2012.79; O'Sullivan B, 2017, AJCC CANC STAGING MA, P113; Robinson M, 2012, HEAD NECK PATHOL, V6, pS83, DOI 10.1007/s12105-012-0370-7; Warner WA, 2012, CHEM BIOL DRUG DES, V80, P631, DOI 10.1111/j.1747-0285.2012.01428.x; Westra WH, 2014, ORAL ONCOL, V50, P771, DOI 10.1016/j.oraloncology.2014.05.004; Xu B, 2016, HUM PATHOL, V54, P193, DOI 10.1016/j.humpath.2016.04.002; Zaravinos A, 2014, ONCOTARGET, V5, P3956, DOI 10.18632/oncotarget.1934	21	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					232	239		10.1016/j.jmoldx.2017.11.008			8	Pathology	Pathology	GA8SA	WOS:000428608800012	29277636	Bronze			2019-10-28	
J	McEvoy, AC; Wood, BA; Ardakani, NM; Pereira, MR; Pearce, R; Cowell, L; Robinson, C; Grieu-Iacopetta, F; Spicer, AJ; Amanuel, B; Ziman, M; Gray, ES				McEvoy, Ashleigh C.; Wood, Benjamin A.; Ardakani, Nima M.; Pereira, Michelle R.; Pearce, Robert; Cowell, Lester; Robinson, Cleo; Grieu-Iacopetta, Fabienne; Spicer, Alexander J.; Amanuel, Benhur; Ziman, Melanie; Gray, Elin S.			Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues A Comparison with Sanger Sequencing and Pyrosequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							TERT PROMOTER MUTATIONS; CIRCULATING TUMOR DNA; METASTATIC MELANOMA; CUTANEOUS MELANOMA; NRAS MUTATIONS; BRAF MUTATIONS; ACQUIRED-RESISTANCE; KRAS MUTATIONS; FOLLOW-UP; CANCER	The identification of somatic mutations is crucial for guiding therapeutic decisions about personalized melanoma treatment. However, genetic analysis of tumors is usually performed on limited and often low quality DNA from tumors with low tumor cellularity and high tumor heterogeneity. Different mutation-detection platforms exist, with varying analytical sensitivities. Here we evaluated the detection of common mutations in BRAF, NRAS, and TERT promoter in 40 melanoma FFPE tissues using Droplet Digital (dd)PCR, and compared the results to the detection rates obtained by Sanger sequencing and pyrosequencing. The cellularity of tumors analyzed ranged from 5% to 50% (n = 28) and 50% to 90% (n = 12) Overall, droplet digital (dd)PCR was more sensitive, detecting mutations in 12.5% and 23% of tumors deemed as wild-type by pyrosequencing and Sanger sequencing, respectively. The increased sensitivity of ddPCR was more apparent among tumors with <50% tumor cellularity. Implementation of ddPCR-based assays may facilitate analysis of early-stage tumors and support research into improving outcomes in melanoma patients.	[McEvoy, Ashleigh C.; Pereira, Michelle R.; Pearce, Robert; Spicer, Alexander J.; Ziman, Melanie; Gray, Elin S.] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA, Australia; [Wood, Benjamin A.; Ardakani, Nima M.; Robinson, Cleo; Grieu-Iacopetta, Fabienne; Amanuel, Benhur] QEII Med Ctr, PathWest, Dept Mol Anat Pathol, Nedlands, WA, Australia; [Wood, Benjamin A.; Ardakani, Nima M.; Robinson, Cleo; Grieu-Iacopetta, Fabienne; Amanuel, Benhur; Ziman, Melanie] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia; [Robinson, Cleo] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Cowell, Lester] Levell Melanoma Clin, Hamilton Hill, WA, Australia	Gray, ES (reprint author), Edith Cowan Univ, 270 Joondalup Dr, Joondalup, WA 6027, Australia.	e.gray@ecu.edu.au	Gray, Elin/V-6707-2019	Gray, Elin/0000-0002-8613-3570	Australian Genome Research Facility (Perth, WA, Australia)	We thank the Australian Genome Research Facility (Perth, WA, Australia) for their support with Sanger sequencing.	Akincilar SC, 2016, CANCER DISCOV, V6, P1276, DOI 10.1158/2159-8290.CD-16-0177; Amanuel B, 2012, PATHOLOGY, V44, P357, DOI 10.1097/PAT.0b013e3283532565; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Beaver JA, 2014, CLIN CANCER RES, V20, P2643, DOI 10.1158/1078-0432.CCR-13-2933; Chen GL, 2015, HUM PATHOL, V46, P113, DOI 10.1016/j.humpath.2014.09.014; Colomba E, 2013, J MOL DIAGN, V15, P94, DOI 10.1016/j.jmoldx.2012.09.001; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Castro DG, 2012, BRIT J CANCER, V107, P345, DOI 10.1038/bjc.2012.259; Didelot A, 2013, CLIN CHEM, V59, P815, DOI 10.1373/clinchem.2012.193409; Dingle TC, 2013, CLIN CHEM, V59, P1670, DOI 10.1373/clinchem.2013.211045; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Garbe C, 2016, EUR J CANCER, V63, P201, DOI 10.1016/j.ejca.2016.05.005; Gessi M, 2014, NEUROPATH APPL NEURO, V40, P794, DOI 10.1111/nan.12138; Girotti MR, 2016, CANCER DISCOV, V6, P286, DOI 10.1158/2159-8290.CD-15-1336; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray ES, 2015, ONCOTARGET, V6, P42008, DOI 10.18632/oncotarget.5788; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju246; Harle A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153576; Heidenreich B, 2017, ONCOTARGET, V8, P36639, DOI 10.18632/oncotarget.16698; Heidenreich B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4401; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Hu WX, 2016, ONCOTARGET, V7, P52870, DOI 10.18632/oncotarget.9141; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Jones EL, 2013, JAMA SURG, V148, P456, DOI 10.1001/jamasurg.2013.1335; Jovanovic B, 2010, J INVEST DERMATOL, V130, P618, DOI 10.1038/jid.2009.287; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Lade-Keller J, 2013, J MOL DIAGN, V15, P70, DOI 10.1016/j.jmoldx.2012.08.003; Lamy PJ, 2015, J MOL DIAGN, V17, P366, DOI 10.1016/j.jmoldx.2015.02.004; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; Leiter U, 2012, J AM ACAD DERMATOL, V66, P37, DOI 10.1016/j.jaad.2010.09.772; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu XL, 2013, ENDOCR-RELAT CANCER, V20, P603, DOI 10.1530/ERC-13-0210; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; McEvoy AC, 2017, ONCOTARGET, V8, P78890, DOI 10.18632/oncotarget.20354; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Mourah S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120232; Nagore E, 2016, INT J CANCER, V139, P75, DOI 10.1002/ijc.30042; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3; Qu K, 2013, J MOL DIAGN, V15, P790, DOI 10.1016/j.jmoldx.2013.07.003; Reid AL, 2015, CLIN BIOCHEM, V48, P999, DOI 10.1016/j.clinbiochem.2014.12.007; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roh MR, 2017, AM J CANCER RES, V7, P134; Rubinstein JC, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-67; Sanmamed MF, 2015, CLIN CHEM, V61, P297, DOI 10.1373/clinchem.2014.230235; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198; Tschandl P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069639; Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wong SQ, 2017, JCO PRECISION ONCOLO, V1, P1; Zhao Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159004	63	5	5	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					240	252		10.1016/j.jmoldx.2017.11.009			13	Pathology	Pathology	GA8SA	WOS:000428608800013	29305225				2019-10-28	
J	Eberhardt, E; van den Kerkhof, M; Bulte, D; Mabille, D; van Bockstal, L; Monnerat, S; Alves, F; Mbui, J; Delputte, P; Cos, P; Hendrickx, S; Maes, L; Caljon, G				Eberhardt, Eline; van den Kerkhof, Magali; Bulte, Dimitri; Mabille, Dorien; van Bockstal, Lieselotte; Monnerat, Severine; Alves, Fabiana; Mbui, Jane; Delputte, Peter; Cos, Paul; Hendrickx, Sarah; Maes, Louis; Caljon, Guy			Evaluation of a Pan-Leishmania Spliced-Leader RNA Detection Method in Human Blood and Experimentally Infected Syrian Golden Hamsters	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							REAL-TIME PCR; HUMAN PATHOGENIC LEISHMANIA; REVERSE-TRANSCRIPTASE PCR; VISCERAL LEISHMANIASIS; PERIPHERAL-BLOOD; KINETOPLAST DNA; INFANTUM DNA; DONOVANI; DIAGNOSIS; GENE	Several methods have been developed for the detection of Leishmania, mostly targeting the minicircle kinetoplast DNA (kDNA). A new RNA real-time quantitative PCR (qPCR) assay was developed targeting the conserved and highly expressed spliced-leader (SL) mini-exon sequence. This study compared the limits of detection of various real-time PCR assays in hamsters infected with Leishmania infantum, in spiked human blood, and in clinical blood samples from visceral leishmaniasis patients. The SL-RNA assay showed an excellent analytical sensitivity in tissues (0.005 and 0.002 parasites per mg Liver and spleen, respectively) and was not prone to false-positive reactions. Evaluation of the SL-RNA assay on clinical samples demonstrated lower threshold cycle values than the kDNA qPCR, an excellent interrun stability of 97%, a 93% agreement with the kDNA assay, and an estimated sensitivity, specificity, and accuracy of 93.2%, 94.3%, and 93.8%, respectively. The SL-RNA qPCR assay was equally efficient for detecting Leishmania major, Leishmania tropica, Leishmania mexicana, Leishmania guayensis, Leishmania panamensis, Leishmania braziliensis, L. infantum, and Leishmania donovani and revealed similar SL-RNA levels in the different species and the occurrence of polycistronic SL-containing transcripts in Viannia species. Collectively, this single SL-RNA qPCR assay enables universal Leishmania detection and represents a particularly useful addition to the widely used kDNA assay in clinical studies in which the detection of viable parasites is pivotal to assess parasitological cure.	[Eberhardt, Eline; van den Kerkhof, Magali; Bulte, Dimitri; Mabille, Dorien; van Bockstal, Lieselotte; Delputte, Peter; Cos, Paul; Hendrickx, Sarah; Maes, Louis; Caljon, Guy] Univ Antwerp, Lab Microbiol Parasitol & Hyg, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium; [Monnerat, Severine; Alves, Fabiana] Drugs Neglected Dis Initiat, Geneva, Switzerland; [Mbui, Jane] Kenya Govt Med Res Ctr, Nairobi, Kenya	Caljon, G (reprint author), Univ Antwerp, Lab Microbiol Parasitol & Hyg, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.	caljon@uantwerpen.be	Caljon, Guy/E-1310-2017; Cos, Paul/L-9717-2015; Delputte, Peter L/A-1062-2008; Maes, Louis JRM/A-2384-2017	Caljon, Guy/0000-0002-4870-3202; Cos, Paul/0000-0003-4361-8911; Delputte, Peter L/0000-0003-3972-616X; Maes, Louis JRM/0000-0002-2324-9509; Mbui, Jane/0000-0002-8759-5689; Mabille, Dorien/0000-0003-3530-0567	Research Fund Flanders FWO project [G051812N, 11V4315N, 1189617N, 1210317N]; University of Antwerp research fund [TT-ZAPBOF 33049]; VLIR Global Minds Small Research grants project; European Union Seventh Framework Programme Africoleish grant [305178]; WHO-TDR demonstration project; Agence Francaise de Developpement grant [CZZ2062]; Department for International Development; Federal Ministry of Education and Research (BMBF) through KfW-Germany; Medicor Foundation; Medecins Sans Frontieres; Swiss Agency for Development and Cooperation [81017718]; Dutch Ministry of Foreign Affairs (Directorate-General for International Cooperation DGIS) [PDP15CH21]	Supported by the Research Fund Flanders FWO project G051812N and scholarships 11V4315N (E.E.), 1189617N (L.V.B.), and 1210317N (S.H.); the University of Antwerp research fund TT-ZAPBOF 33049 (G.C.); a VLIR Global Minds Small Research grants project (G.C.); the European Union Seventh Framework Programme Africoleish grant 305178 (Drugs for Neglected Disease Initiative); WHO-TDR demonstration project; the Agence Francaise de Developpement grant CZZ2062; Department for International Development; the Federal Ministry of Education and Research (BMBF) through KfW-Germany; the Medicor Foundation; Medecins Sans Frontieres; Swiss Agency for Development and Cooperation grant 81017718; and Dutch Ministry of Foreign Affairs (Directorate-General for International Cooperation DGIS) grant PDP15CH21.	BOOM R, 1990, J CLIN MICROBIOL, V28, P495; Bretagne S, 2001, CLIN DIAGN LAB IMMUN, V8, P828, DOI 10.1128/CDLI.8.4.828-831.2001; Brewster S, 1998, PARASITOL TODAY, V14, P437, DOI 10.1016/S0169-4758(98)01330-1; Dantas-Torres F, 2017, MOL CELL PROBE, V31, P65, DOI 10.1016/j.mcp.2016.08.006; Dereure J, 2003, J INFECTION, V47, P77, DOI 10.1016/S0163-4453(03)00002-1; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; Francino O, 2006, VET PARASITOL, V137, P214, DOI 10.1016/j.vetpar.2006.01.011; Ghasemian Mehrdad, 2016, J Parasit Dis, V40, P81, DOI 10.1007/s12639-014-0452-4; Gonzalez-Andrade P, 2014, J MOL DIAGN, V16, P400, DOI 10.1016/j.jmoldx.2014.02.006; HASSAN MQ, 1993, PARASITOLOGY, V107, P509; Hide M, 2007, PARASITOLOGY, V134, P379, DOI 10.1017/S0031182006001600; Hitakarun A, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0458-x; Keer JT, 2003, J MICROBIOL METH, V53, P175, DOI 10.1016/S0167-7012(03)00025-3; Kloehn J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004683; Lachaud L, 2000, J CLIN MICROBIOL, V38, P236; Lachaud L, 2002, J CLIN MICROBIOL, V40, P210, DOI 10.1128/JCM.40.1.210-215.2002; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; Marfurt J, 2003, DIAGN MICR INFEC DIS, V46, P115, DOI 10.1016/S0732-8893(03)00040-3; Mary C, 2004, J CLIN MICROBIOL, V42, P5249, DOI 10.1128/JCM.42.11.5249-5255.2004; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; Murray HW, 2001, INT J EXP PATHOL, V82, P249, DOI 10.1046/j.1365-2613.2001.00199.x; Nicolas L, 2002, J CLIN MICROBIOL, V40, P1666, DOI 10.1128/JCM.40.5.1666-1669.2002; Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11; Ramos A, 1996, EXP PARASITOL, V82, P242, DOI 10.1006/expr.1996.0031; Rijal S, 2013, CLIN INFECT DIS, V56, P1530, DOI 10.1093/cid/cit102; Srivastava A, 2013, J PARASITOL, V99, P145, DOI 10.1645/GE-3221.1; Stauber L. A., 1958, Rice Institute Pamphlet, V45, P80; van den Bogaart E, 2014, INT J PARASITOL-DRUG, V4, P14, DOI 10.1016/j.ijpddr.2013.11.001; van der Meide W, 2008, J CLIN MICROBIOL, V46, P73, DOI 10.1128/JCM.01416-07; VANEYS GJJM, 1992, MOL BIOCHEM PARASIT, V51, P133; WHO, 2015, KAL AZ EL PROGR REP, P2015; World Health Organization, 2010, WHO TECHN REP SER; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134	33	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					253	263		10.1016/j.jmoldx.2017.12.003			11	Pathology	Pathology	GA8SA	WOS:000428608800014	29355825				2019-10-28	
J	Wang, YL				Wang, Y. Lynn			MYD88 Mutations and Sensitivity to Ibrutinib Therapy	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Letter							CHRONIC LYMPHOCYTIC-LEUKEMIA; WALDENSTROM MACROGLOBULINEMIA; CELL LYMPHOMA; RESISTANCE; MECHANISMS		[Wang, Y. Lynn] Univ Chicago, Dept Pathol, 5841 S Maryland Ave,N316, Chicago, IL 60637 USA	Wang, YL (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,N316, Chicago, IL 60637 USA.	ylwang@bsd.uchicago.edu					Bobee V, 2017, J MOL DIAGN, V19, P892, DOI 10.1016/j.jmoldx.2017.07.007; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; Hunter ZR, 2014, BLOOD, V123, P1637, DOI 10.1182/blood-2013-09-525808; Ma J, 2014, BRIT J HAEMATOL, V166, P849, DOI 10.1111/bjh.12974; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Poulain S, 2013, BLOOD, V121, P4504, DOI 10.1182/blood-2012-06-436329; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Xu L, 2017, BLOOD, V129, P2519, DOI 10.1182/blood-2017-01-761726; Zhang SQ, 2015, BRIT J HAEMATOL, V170, P445, DOI 10.1111/bjh.13427; Zhao XH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14920	14	1	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					264	266		10.1016/j.jmoldx.2017.11.006			3	Pathology	Pathology	GA8SA	WOS:000428608800015	29482770				2019-10-28	
J	Bobee, V; Ruminy, P; Marchand, V; Viailly, PJ; Sater, AA; Veresezan, L; Drieux, F; Berard, C; Bohers, E; Mareschal, S; Dubois, S; Jais, JP; Leroy, K; Figeac, M; Picquenot, JM; Molina, TJ; Salles, G; Haioun, C; Tilly, H; Jardin, F				Bobee, Victor; Ruminy, Philippe; Marchand, Vinciane; Viailly, Pierre-Julien; Sater, Ahmad Abdel; Veresezan, Liana; Drieux, Fanny; Berard, Caroline; Bohers, Elodie; Mareschal, Sylvain; Dubois, Sydney; Jais, Jean-Philippe; Leroy, Karen; Figeac, Martin; Picquenot, Jean-Michel; Molina, Thierry J.; Salles, Gilles; Haioun, Corinne; Tilly, Herve; Jardin, Fabrice			MYD88 Mutations and Sensitivity to Ibrutinib Therapy Reply	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Letter									[Bobee, Victor; Ruminy, Philippe; Marchand, Vinciane; Viailly, Pierre-Julien; Sater, Ahmad Abdel; Veresezan, Liana; Drieux, Fanny; Bohers, Elodie; Mareschal, Sylvain; Dubois, Sydney; Picquenot, Jean-Michel; Tilly, Herve; Jardin, Fabrice] Ctr Henri Becquerel, INSERM, U1245, Team 03, Rouen, France; [Veresezan, Liana; Drieux, Fanny; Picquenot, Jean-Michel] Ctr Henri Becquerel, Dept Pathol, Rouen, France; [Berard, Caroline] Univ Normandie, UNIROUEN, LITIS Lab Informat & Traitement Informat, EA 4108, Rouen, France; [Jais, Jean-Philippe; Leroy, Karen] Hop Necker Enfants Malad, AP HP, INSERM, UMRS 872, Paris, France; [Figeac, Martin] Univ Lille, Ctr Biol & Pathol, Lille, France; [Figeac, Martin; Molina, Thierry J.] Univ Paris Descartes Sorbonne Cite, Necker Hosp, AP HP, Dept Pathol, Paris, France; [Salles, Gilles] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Lyon, France; [Haioun, Corinne] Hosp Henri Mondor, Creteil, France; [Tilly, Herve; Jardin, Fabrice] Rouen Univ Hosp, Dept Biol Hematol, Rouen, France	Ruminy, P (reprint author), Ctr Henri Becquerel, INSERM, U1245, Rue Amiens, F-76038 Rouen 1, France.	philippe.ruminy@chb.unicancer.fr	JAIS, Jean-Philippe/B-2993-2009; Salles, Gilles/Z-2336-2019	JAIS, Jean-Philippe/0000-0002-0708-8776; Salles, Gilles/0000-0002-9541-8666; jardin, fabrice/0000-0002-6804-7943; VIAILLY, Pierre-Julien/0000-0002-9636-8971; Figeac, Martin/0000-0001-8523-3708; Haioun, Corinne/0000-0003-0095-5379			Dubois S, 2017, CLIN CANCER RES, V23, P2232, DOI 10.1158/1078-0432.CCR-16-1922; Fernandez-Rodriguez C, 2014, LEUKEMIA, V28, P2104, DOI 10.1038/leu.2014.184; Kuo HP, 2016, AM J CANCER RES, V6, P2489; Rovira J, 2016, CLIN CANCER RES, V22, P2755, DOI 10.1158/1078-0432.CCR-15-1525	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					266	266		10.1016/j.jmoldx.2017.12.001			1	Pathology	Pathology	GA8SA	WOS:000428608800016	29482771				2019-10-28	
J	Zhong, Y; Dambach, DM; Maher, JM				Zhong, Yu; Dambach, Donna M.; Maher, Jonathan M.			Using Genetically Modified Rodent Models in Drug Development to Explore Target Physiology and Potential Drug Effects	VETERINARY PATHOLOGY			English	Editorial Material						transgenic models; gene editing; gene excision; CreLoxP; CrispR; drug development; C-terminal Src kinase	MOUSE MODELS; MICE; RECEPTOR; GENOME; SPECIFICITY; GENERATION		[Zhong, Yu; Dambach, Donna M.; Maher, Jonathan M.] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA	Zhong, Y (reprint author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	zhongy@gene.com					Berman-Booty LD, 2018, VET PATHOL; BRONSON SK, 1994, J BIOL CHEM, V269, P27155; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Diaz D, 2016, DRUG DISCOVERY TOXICOLOGY: FROM TARGET ASSESSMENT TO TRANSLATIONAL BIOMARKERS, P298; Doyle A, 2012, TRANSGENIC RES, V21, P327, DOI 10.1007/s11248-011-9537-3; Fitzgerald K, 2013, TOXICOL APPL PHARM, V269, P1, DOI 10.1016/j.taap.2013.02.012; Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808; Fuji RN, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3634; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Lee KY, 2013, DIABETES, V62, P864, DOI 10.2337/db12-1089; Madsen LW, 2012, ENDOCRINOLOGY, V153, P1538, DOI 10.1210/en.2011-1864; May PC, 2011, J NEUROSCI, V31, P16507, DOI 10.1523/JNEUROSCI.3647-11.2011; Ness D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066164; Papaioannou VE, 2012, VET PATHOL, V49, P64, DOI 10.1177/0300985810395725; Pich EM, 1998, ANN MED, V30, P390, DOI 10.3109/07853899809029939; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; ROBBINS J, 1993, CIRC RES, V73, P3, DOI 10.1161/01.RES.73.1.3; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Sacca R, 2010, METHODS MOL BIOL, V602, P37, DOI 10.1007/978-1-60761-058-8_3; Scearce-Levie K, 1999, ANN NY ACAD SCI, V868, P701, DOI 10.1111/j.1749-6632.1999.tb11350.x; Tsai SQ, 2014, NAT BIOTECHNOL, V32, P569, DOI 10.1038/nbt.2908; Turgeon B, 2009, PHYSIOL REV, V89, P1, DOI 10.1152/physrev.00040.2007; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zambrowicz BP, 2003, NAT REV DRUG DISCOV, V2, P38, DOI 10.1038/nrd987	25	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					193	194		10.1177/0300985817747328			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300001	29457566	Bronze			2019-10-28	
J	Mestrinho, LA				Mestrinho, Lisa A.			Current Status and Future Perspectives in Canine Oral Squamous Cell Carcinoma	VETERINARY PATHOLOGY			English	Editorial Material							DOGS; FEATURES		[Mestrinho, Lisa A.] Univ Lisbon, Interdisciplinary Ctr Res Anim Hlth CIISA, Fac Med Vet, Av Univ Tecn Lisboa, P-1300477 Lisbon, Portugal	Mestrinho, LA (reprint author), Univ Lisbon, Interdisciplinary Ctr Res Anim Hlth CIISA, Fac Med Vet, Av Univ Tecn Lisboa, P-1300477 Lisbon, Portugal.	lmestrinho@fmv.ulisboa.pt	Mestrinho, Lisa AP/F-2974-2014	Mestrinho, Lisa AP/0000-0002-2424-2106			Fitzpatrick SG, 2013, HEAD NECK PATHOL, V7, P320, DOI 10.1007/s12105-013-0444-1; Fulton AJ, 2013, JAVMA-J AM VET MED A, V243, P696, DOI 10.2460/javma.243.5.696; Liu DL, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005277; Mehrad M, 2013, AM J SURG PATHOL, V37, P1349, DOI 10.1097/PAS.0b013e318290427d; Mestrinho LA, 2017, VET COMP ONCOL, V15, P18, DOI 10.1111/vco.12134; Mestrinho LA, 2017, J VET DENT, V34, P92, DOI 10.1177/0898756417713979; Nagamine E, VET PATHOL; Nemec A, 2014, J COMP PATHOL, V150, P155, DOI 10.1016/j.jcpa.2013.07.007; Nemec A, 2012, J COMP PATHOL, V147, P111, DOI 10.1016/j.jcpa.2011.11.198; Soukup JW, 2013, J VET DENT, V30, P18, DOI 10.1177/089875641303000102; Thaiwong T, 2018, VET PATHOL, V55, P224, DOI 10.1177/0300985817741732	11	4	4	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					200	201		10.1177/0300985817732114			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300003	29457565	Bronze			2019-10-28	
J	Schott, CR; Tatiersky, LJ; Foster, RA; Wood, GA				Schott, Courtney R.; Tatiersky, Laetitia J.; Foster, Robert A.; Wood, Geoffrey A.			Histologic Grade Does Not Predict Outcome in Dogs with Appendicular Osteosarcoma Receiving the Standard of Care	VETERINARY PATHOLOGY			English	Article						anatomic site; asymmetry; biopsy; bone; disease-free survival; dogs; histology; neoplasia; grading; osteosarcoma; prognosis	LIMB-SPARING SURGERY; MAST-CELL TUMOR; CANINE OSTEOSARCOMA; PROGNOSTIC-FACTORS; IRREGULAR BONES; OSTEO-SARCOMA; AMPUTATION; DOXORUBICIN; CHEMOTHERAPY; CARBOPLATIN	Canine appendicular osteosarcoma is an aggressive bone neoplasm that imposes a short survival time. There are several published histologic grading systems for canine osteosarcoma but no universally accepted system. Location within the skeleton and therapy received are both correlated with survival time, but these factors were not always considered when the prognostic value of published grading systems was determined. Our objective was to compare 2 published histologic grading systems in a population of dogs with appendicular osteosarcoma treated with the standard of care for curative intent. Three evaluators graded 85 tumors using 2 histologic grading systems. The relationships between histologic grade as well as individual histologic features and outcome ( survival time and disease-free interval) were evaluated using Kaplan-Meier survival functions and a univariate Cox proportional hazards model. Histologic grade, as assigned by any evaluator, did not correlate with outcome. Increased number of mitotic figures per 3 randomly selected 400 x microscope fields, as assessed by 1 evaluator, was correlated with both survival time and disease-free interval; this was the only individual histologic feature that was significantly correlated with outcome for any evaluator. These findings cast doubt on the predictive value of routine histologic grading in dogs with appendicular osteosarcoma who receive amputation followed by adjuvant chemotherapy and highlight the need for better tools to predict outcome in canine appendicular osteosarcoma.	[Schott, Courtney R.; Tatiersky, Laetitia J.; Foster, Robert A.; Wood, Geoffrey A.] Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada	Wood, GA (reprint author), Univ Guelph, Dept Pathobiol, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada.	gewood@uoguelph.ca			OVC Fellowship Program; Ontario Graduate Scholarship ProgramOntario Graduate Scholarship; OVC Pet Trust	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: OVC Fellowship Program and Ontario Graduate Scholarship Program to C.R.S., and OVC Pet Trust funded the research and publication.	Bacon NJ, 2008, JAVMA-J AM VET MED A, V232, P1504, DOI 10.2460/javma.232.10.1504; BERG J, 1995, J AM VET MED ASSOC, V206, P1555; BERG J, 1992, J AM VET MED ASSOC, V200, P2005; Bergman PJ, 1996, J VET INTERN MED, V10, P76, DOI 10.1111/j.1939-1676.1996.tb02031.x; Boerman I, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-56; Broders AC, 1920, J AMER MED ASSOC, V74, P656, DOI 10.1001/jama.1920.02620100016007; Cates JMM, 2017, AM J SURG PATHOL, V41, P405, DOI 10.1097/PAS.0000000000000774; Chui MH, 2016, ARCH PATHOL LAB MED, V140, P1231, DOI 10.5858/arpa.2015-0389-OA; Chun R, 2005, J AM ANIM HOSP ASSOC, V41, P382, DOI 10.5326/0410382; Dernell WS, 1998, J AM ANIM HOSP ASSOC, V34, P11, DOI 10.5326/15473317-34-1-11; Duffy D, 2017, VET COMP ONCOL, V15, P46, DOI 10.1111/vco.12141; ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9; Fletcher C, 2013, WHO CLASSIFICATION T; Gamer M, 2012, IRR VARIOUS COEFFICI; GILLETTE SM, 1992, INT J HYPERTHER, V8, P309, DOI 10.3109/02656739209021786; HAMMER AS, 1995, J AM ANIM HOSP ASSOC, V31, P321, DOI 10.5326/15473317-31-4-321; Kent MS, 2004, J VET INTERN MED, V18, P540, DOI 10.1892/0891-6640(2004)18<540:ACADAA>2.0.CO;2; Kilpatrick SE, 2000, PEDIATR PATHOL MOL M, V19, P337, DOI 10.1080/15513810009168644; Kirpensteijn J, 2002, VET PATHOL, V39, P240, DOI 10.1354/vp.39-2-240; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Kruse MA, 2013, VET PATHOL, V50, P704, DOI 10.1177/0300985812471542; Langenbach A, 1998, J AM ANIM HOSP ASSOC, V34, P113, DOI 10.5326/15473317-34-2-113; Loukopoulos P, 2007, J COMP PATHOL, V136, P65, DOI 10.1016/j.jcpa.2006.11.005; MAULDIN GN, 1988, J VET INTERN MED, V2, P177, DOI 10.1111/j.1939-1676.1988.tb00313.x; McNiel EA, 1997, J AM VET MED ASSOC, V211, P1422; MISDORP W, 1979, JNCI-J NATL CANCER I, V62, P537, DOI 10.1093/jnci/62.3.537; Moore AS, 2007, J VET INTERN MED, V21, P783, DOI 10.1892/0891-6640(2007)21[783:DABFTT]2.0.CO;2; Morello E, 2011, VET J, V189, P268, DOI 10.1016/j.tvjl.2010.08.014; PATNAIK AK, 1984, VET PATHOL, V21, P469, DOI 10.1177/030098588402100503; Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227; Philips B, 2009, J AM ANIM HOSP ASSOC, V45, P33, DOI 10.5326/0450033; R Core Team, 2016, R LANG ENV STAT COMP; Saam DE, 2011, JAVMA-J AM VET MED A, V238, P195, DOI 10.2460/javma.238.2.195; Sabattini S, 2015, VET PATHOL, V52, P70, DOI 10.1177/0300985814521638; Schmidt AF, 2013, PREV VET MED, V112, P414, DOI 10.1016/j.prevetmed.2013.08.011; Selmic LE, 2014, J VET INTERN MED, V28, P554, DOI 10.1111/jvim.12313; SHAPIRO W, 1988, J AM VET MED ASSOC, V192, P507; Sternberg RA, 2013, J VET INTERN MED, V27, P955, DOI 10.1111/jvim.12121; Straw RC, 1996, J AM ANIM HOSP ASSOC, V32, P257, DOI 10.5326/15473317-32-3-257; THOMPSON JP, 1992, J AM VET MED ASSOC, V200, P531; Unni K K, 1984, Semin Diagn Pathol, V1, P165; Wilting J, 2011, CURR MED CHEM, V18, P5519, DOI 10.2174/092986711798347252; WITHROW SJ, 2006, WITHROW MACEWENS SMA	43	8	8	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					202	211		10.1177/0300985817747329			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300004	29284372	Bronze			2019-10-28	
J	Horta, RS; Lavalle, GE; Monteiro, LN; Souza, MCC; Cassali, GD; Araujo, RB				Horta, Rodrigo S.; Lavalle, Gleidice E.; Monteiro, Lidianne N.; Souza, Mayara C. C.; Cassali, Geovanni D.; Araujo, Roberto B.			Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features	VETERINARY PATHOLOGY			English	Article						dog; skin; mast cell tumor; mastocytoma; prognosis; clinical staging; tumor grade; mitotic count; Ki-67; c-KIT	MITOTIC INDEX; C-KIT; SURGICAL EXCISION; PROGNOSTIC INDICATOR; KI67 INDEX; LYMPH-NODE; DOGS; GRADE; EXPRESSION; SURVIVAL	Mast cell tumor (MCT) is a frequent cutaneous neoplasm in dogs that is heterogeneous in clinical presentation and biological behavior, with a variable potential for recurrence and metastasis. Accurate prediction of clinical outcomes has been challenging. The study objective was to develop a system for classification of canine MCT according to the mortality risk based on individual assessment of clinical, histologic, immunohistochemical, and molecular features. The study included 149 dogs with a histologic diagnosis of cutaneous or subcutaneous MCT. By univariate analysis, MCT metastasis and related death was significantly associated with clinical stage (P < .0001, r(P) = -0.610), history of tumor recurrence (P < .0001, r(P) = -0.550), Patnaik (P < .0001, r(P) = 0.380) and Kiupel grades (P < .0001, r(P) = -0.500), predominant organization of neoplastic cells (P < .0001, r(P) = -0.452), mitotic count (P < .0001, r(P) = -0.325), Ki-67 labeling index (P <.0001, r(P) = -0.414), KITr pattern (P = .02, r(P) = 0.207), and c-KIT mutational status (P < .0001, r(P) = -0.356). By multivariate analysis with Cox proportional hazard model, only 2 features were independent predictors of overall survival: an amendment of the World Health Organization clinical staging system (hazard ratio [95% CI]: 1.824 [1.210-4.481]; P = .01) and a history of tumor recurrence (hazard ratio [95% CI]: 9.250 [2.158-23.268]; P < .001]. From these results, we propose an amendment of the WHO staging system, a method of risk analysis, and a suggested approach to clinical and laboratory evaluation of dogs with cutaneous MCT.	[Horta, Rodrigo S.; Souza, Mayara C. C.] Univ Vila Velha, 21 Luis Jose St, BR-29102920 Vila Velha, ES, Brazil; [Lavalle, Gleidice E.; Araujo, Roberto B.] Univ Fed Minas Gerais, Vet Sch, Dept Vet Clin & Surg, Belo Horizonte, MG, Brazil; [Monteiro, Lidianne N.; Cassali, Geovanni D.] Univ Fed Minas Gerais, Biol Sci Inst, Lab Comparat Pathol, Belo Horizonte, MG, Brazil	Horta, RS (reprint author), Univ Vila Velha, 21 Luis Jose St, BR-29102920 Vila Velha, ES, Brazil.	rodrigohvet@gmail.com		Horta, Rodrigo/0000-0002-9885-4498			Abadie JJ, 1999, J AM VET MED ASSOC, V215, P1629; Avery AC, 2012, VET CLIN N AM-SMALL, V42, P97, DOI 10.1016/j.cvsm.2011.11.001; Berlato D, 2015, VET COMP ONCOL, V13, P143, DOI 10.1111/vco.12029; Blackwood L, 2012, VET COMP ONCOL, V10, pe1, DOI 10.1111/j.1476-5829.2012.00341.x; BOOKBINDER PF, 1992, J AM VET MED ASSOC, V200, P1648; BOSTOCK DE, 1973, J SMALL ANIM PRACT, V14, P27, DOI 10.1111/j.1748-5827.1973.tb06891.x; Cahalane AK, 2004, JAVMA-J AM VET MED A, V225, P401, DOI 10.2460/javma.2004.225.401; Casagrande TAC, 2015, VET COMP ONCOL, V13, P1, DOI 10.1111/vco.12010; Dobson JM, 2007, J SMALL ANIM PRACT, V48, P424, DOI 10.1111/j.1748-5827.2007.00366.x; Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x; Elston LB, 2009, VET PATHOL, V46, P362, DOI 10.1354/vp.46-2-362; Fulcher RP, 2006, JAVMA-J AM VET MED A, V228, P210, DOI 10.2460/javma.228.2.210; Giantin M, 2012, J VET DIAGN INVEST, V24, P116, DOI 10.1177/1040638711425945; da Costa RMG, 2015, VET J, V205, P5, DOI 10.1016/j.tvjl.2015.05.002; Giuliano A, 2017, J COMP PATHOL, V156, P14, DOI 10.1016/j.jcpa.2016.10.004; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P853; Hahn KA, 2008, J VET INTERN MED, V22, P1301, DOI 10.1111/j.1939-1676.2008.0190.x; Hauck ML, 2013, WITHROW MACEWENS SMA, P305; Hillman LA, 2010, JAVMA-J AM VET MED A, V237, P936, DOI 10.2460/javma.237.8.936; Kiupel M, 2004, VET PATHOL, V41, P371, DOI 10.1354/vp.41-4-371; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Krick EL, 2009, VET COMP ONCOL, V7, P130, DOI 10.1111/j.1476-5829.2009.00185.x; Leibman NF, 2000, J VET INTERN MED, V14, P583, DOI 10.1892/0891-6640(2000)014<0583:IOMMIC>2.3.CO;2; Letard S, 2008, MOL CANCER RES, V6, P1137, DOI 10.1158/1541-7786.MCR-08-0067; London CA, 2013, SMALL ANIMAL CLIN ON, P335; London CA, 2009, CLIN CANCER RES, V15, P3856, DOI 10.1158/1078-0432.CCR-08-1860; Maglennon GA, 2008, VET COMP ONCOL, V6, P268, DOI 10.1111/j.1476-5829.2008.00168.x; McNiel EA, 2006, VET COMP ONCOL, V4, P2, DOI 10.1111/j.1476-5810.2006.00085.x; Michels GM, 2002, J AM ANIM HOSP ASSOC, V38, P458, DOI 10.5326/0380458; Miller RL, 2016, VET COMP ONCOL, V14, P361, DOI 10.1111/vco.12116; O'Connell K, 2013, VET COMP ONCOL, V11, P51, DOI 10.1111/j.1476-5829.2011.00301.x; Owen LM, 1980, TNM CLASSIFICATION T, P53; PATNAIK A. K., 1984, VET PATHOL, V21, P268; Rogers KS, 1996, VET CLIN N AM-SMALL, V26, P87, DOI 10.1016/S0195-5616(96)50008-2; Romansik EM, 2007, VET PATHOL, V44, P335, DOI 10.1354/vp.44-3-335; Sabattini S, 2015, VET PATHOL, V52, P70, DOI 10.1177/0300985814521638; Scase TJ, 2006, J VET INTERN MED, V20, P151, DOI 10.1892/0891-6640(2006)20[151:CMCTCO]2.0.CO;2; Sfiligoi G, 2005, JAVMA-J AM VET MED A, V226, P1368, DOI 10.2460/javma.2005.226.1368; Stanclift RM, 2008, JAVMA-J AM VET MED A, V232, P53, DOI 10.2460/javma.232.1.53; Strefezzi RD, 2010, PESQUISA VET BRASIL, V30, P559, DOI 10.1590/S0100-736X2010000700009; Suami H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069222; Takahashi T, 1997, J VET MED SCI, V59, P995, DOI 10.1292/jvms.59.995; Takeuchi Y, 2013, VET J, V196, P492, DOI 10.1016/j.tvjl.2012.11.018; Thamm DH, 1999, J VET INTERN MED, V13, P491, DOI 10.1892/0891-6640(1999)013<0491:PAVCFC>2.3.CO;2; van Lelyveld S, 2015, J SMALL ANIM PRACT, V56, P312, DOI 10.1111/jsap.12320; Warland J, 2014, VET COMP ONCOL, V12, P287, DOI 10.1111/vco.12012; Warland J, 2015, IN PRACTICE, V37, DOI 10.1136/inp.h3440; Webster JD, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-85; Webster JD, 2006, NEOPLASIA, V8, P104, DOI 10.1593/neo.05622; Webster JD, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-32; Weishaar KM, 2014, J COMP PATHOL, V151, P329, DOI 10.1016/j.jcpa.2014.07.004; Welle MM, 2008, VET DERMATOL, V19, P321, DOI 10.1111/j.1365-3164.2008.00694.x; Zemke D, 2002, VET PATHOL, V39, P529, DOI 10.1354/vp.39-5-529	53	4	4	3	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					212	223		10.1177/0300985817747325			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300005	29338615	Bronze			2019-10-28	
J	Thaiwong, T; Sledge, DG; Collins-Webb, A; Kiupel, M				Thaiwong, Tuddow; Sledge, Dodd G.; Collins-Webb, Alexandra; Kiupel, Matti			Immunohistochemical Characterization of Canine Oral Papillary Squamous Cell Carcinoma	VETERINARY PATHOLOGY			English	Article						immunohistochemistry; dogs; oral cavity; digestive; neoplasia; squamous cell carcinoma; tissue microarrays	UPPER AERODIGESTIVE TRACT; ODONTOGENIC-TUMORS; DOGS; EXPRESSION; P63; PAPILLOMAVIRUS; AMELOBLASTOMA; HISTOGENESIS; CALRETININ; EPITHELIUM	Recently, histologic subtypes of oral squamous cell carcinoma (SCC) corresponding to the human classification scheme have been proposed for dogs. A papillary squamous cell carcinoma subtype is characterized by dominant exophytic architectural growth with limited invasion, a lower metastatic rate, and better overall survival compared with conventional SCC. Whereas most canine oral conventional SCCs are easily diagnosed by histologic examination, the diagnosis of canine oral papillary squamous cell carcinoma (COPSCC) can be challenging since the exophytic portion lacks histologic features of malignancy and appears similar to oral nonviral papillomas. In contrast, the invasive portion of COPSCC has morphologic similarities to conventional SCC and canine acanthomatous ameloblastoma. The goals of this study were to immunophenotype these 3 entities and to potentially identify discriminating markers. A panel of 17 immunohistochemical markers was investigated in tissue microarrays that included 25 COPSCCs, 10 conventional SCCs, and 10 canine acanthomatous ameloblastomas. Additionally, COPSCCs were screened for papillomavirus as a potential cause using immunohistochemistry and in situ hybridization. COPSCC had immunophenotypical similarities with conventional SCC and acanthomatous ameloblastoma, but the combined differences in immunolabeling for AE1/AE3, 34 beta E12, p63, and calretinin discriminated between the entities. Papillomavirus was not detected in any COPSCC, making a viral pathogenesis unlikely. A better understanding of the immunophenotype of COPSCC will aid in a more accurate diagnosis and potentially improve therapeutic approaches.	[Thaiwong, Tuddow; Sledge, Dodd G.; Kiupel, Matti] Michigan State Univ, Vet Diagnost Lab, 4125 Beaumont Rd 152A, Lansing, MI 48910 USA; [Collins-Webb, Alexandra] Michigan State Univ, Coll Vet Med, E Lansing, MI 48824 USA; [Kiupel, Matti] Michigan State Univ, Coll Vet Med, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA	Kiupel, M (reprint author), Michigan State Univ, Vet Diagnost Lab, 4125 Beaumont Rd 152A, Lansing, MI 48910 USA.	kiupel@dcpah.msu.edu			Merial-NIH Veterinary Scholars Summer Research Program, College of Veterinary Medicine, Michigan State University	We would like to thank the histopathology section at the Michigan State University Veterinary Diagnostic Laboratory for assistance with generation of the tissue microarrays and immunohistochemical staining and the 2013 Merial-NIH Veterinary Scholars Summer Research Program, College of Veterinary Medicine, Michigan State University for funding the summer research training of Alexandra Collins-Webb.	Alaeddini M, 2008, HISTOPATHOLOGY, V52, P299, DOI 10.1111/j.1365-2559.2007.02948.x; Anandani C, 2014, PATHOL RES INT, V2014; Arzi B, 2011, J COMP PATHOL, V145, P345, DOI 10.1016/j.jcpa.2011.03.003; Bahrami A, 2008, ARCH PATHOL LAB MED, V132, P326, DOI 10.1043/1543-2165(2008)132[326:UTTIBI]2.0.CO;2; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Cobo F, 2008, INT J SURG PATHOL, V16, P127, DOI 10.1177/1066896908314700; DeVilliers P, 2008, AM J SURG PATHOL, V32, P256, DOI 10.1097/PAS.0b013e3181452176; Ding YW, 2013, ANN DIAGN PATHOL, V17, P18, DOI 10.1016/j.anndiagpath.2012.04.005; DORN CR, 1976, J AM VET MED ASSOC, V169, P1202; Feller LL, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-31; Fulton A, 2014, VET COMP ONCOL, V12, P258, DOI 10.1111/j.1476-5829.2012.00356.x; GARDNER DG, 1993, J COMP PATHOL, V108, P47, DOI 10.1016/S0021-9975(08)80226-5; Head K. W., 2002, Tumors in domestic animals, P401, DOI 10.1002/9780470376928.ch8; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Knight CG, 2011, VET DERMATOL, V22, P570, DOI 10.1111/j.1365-3164.2011.00987.x; Kumamoto H, 2005, J ORAL PATHOL MED, V34, P220, DOI 10.1111/j.1600-0714.2005.00284.x; Mehrad M, 2013, AM J SURG PATHOL, V37, P1349, DOI 10.1097/PAS.0b013e318290427d; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Menezes RC, 2013, J CLIN MICROBIOL, V51, P206, DOI 10.1128/JCM.02123-12; Mestrinho LA, 2015, VET PATHOL, V52, P614, DOI 10.1177/0300985814547391; MILLS JHL, 1981, CAN VET J, V22, P126; Moghadam SA, 2013, BIOMED RES INT, DOI 10.1155/2013/624176; Munday JS, 2015, J VET DIAGN INVEST, V27, P221, DOI 10.1177/1040638714567191; Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600-0757.2005.00141.x; Nel S, 2011, VET PATHOL, V48, P276, DOI 10.1177/0300985810374843; Nemec A, 2014, J COMP PATHOL, V150, P155, DOI 10.1016/j.jcpa.2013.07.007; Nemec A, 2012, J COMP PATHOL, V147, P111, DOI 10.1016/j.jcpa.2011.11.198; OGILVIE GK, 1988, J AM VET MED ASSOC, V192, P933; Pereira MC, 2007, J CAN DENT ASSOC, V73, P339; Rodrigues A, 2010, VET PATHOL, V47, P964, DOI 10.1177/0300985810369899; Soukup JW, 2013, J VET DENT, V30, P18, DOI 10.1177/089875641303000102; Stapleton B L, 1996, J Vet Dent, V13, P65; Stelow EB, 2005, AM J CLIN PATHOL, V124, P96; Suarez PA, 2000, HEAD NECK-J SCI SPEC, V22, P360; Tang XH, 2013, CARCINOGENESIS, V34, P1158, DOI 10.1093/carcin/bgt021; Thompson Lester, 2006, Ear Nose Throat J, V85, P74	36	5	5	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					224	232		10.1177/0300985817741732			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300006	29262763				2019-10-28	
J	Suarez-Bonnet, A; Lara-Garcia, A; Stoll, AL; Carvalho, S; Priestnall, SL				Suarez-Bonnet, Alejandro; Lara-Garcia, Ana; Stoll, Alexander L.; Carvalho, Sofia; Priestnall, Simon L.			14-3-3 sigma Protein Expression in Canine Renal Cell Carcinomas	VETERINARY PATHOLOGY			English	Article						14-3-3 sigma; stratifin; human mammary epithelial marker 1; dogs; immunohistochemistry; cytokeratin; oncology; renal cell carcinoma; kidney; urinary; vimentin	LUNG ADENOCARCINOMA; SIGMA PROTEIN; EARLY-STAGE; PROGRESSION; CANCER; TISSUES; NEOPLASMS; STRATIFIN; TUMORS	14-3-3 sigma is a protein expressed in many epithelial tissues associated with essential cell functions, including cell-cycle control, apoptosis, and cytoskeletal integrity. There is a paucity of knowledge of the tumorigenesis of canine renal cell carcinomas (RCCs), and the histological origin of this tumor has not been established. This study analyzed the expression of 14-3-3 sigma, Ki-67, cyto-keratins, and vimentin in 40 canine RCCs. Aberrant expression of 14-3-3 sigma was demonstrated in 15 (38%) cases and was associated with a significantly shorter survival time (P < .002). In contrast to canine RCC, normal kidney did not express 14-3-3 sigma. The Ki-67 proliferation index did not show utility as a prognostic factor. The distal convoluted tubular epithelium in normal kidneys coexpressed cytokeratins and vimentin, and thus maintenance of this coexpression pattern in canine RCC suggests that most tumors arise from the distal segment of the nephron. These results suggest that 14-3-3 sigma is a potential negative prognostic factor and a possible therapeutic target.	[Suarez-Bonnet, Alejandro; Stoll, Alexander L.; Priestnall, Simon L.] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hawkshead Lane, Hatfield AL9 7TA, Herts, England; [Lara-Garcia, Ana; Carvalho, Sofia] Royal Vet Coll, Dept Oncol Serv, Hatfield, Herts, England	Suarez-Bonnet, A (reprint author), Royal Vet Coll, Dept Pathobiol & Populat Sci, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.	asuarezbonnet@rvc.ac.uk		Suarez-Bonnet, Alejandro/0000-0003-0296-5896; Priestnall, Simon/0000-0002-6027-1879	Journal of Comparative Pathology Educational Trust	Dr Alejandro Suarez-Bonnet received a travel grant from the Journal of Comparative Pathology Educational Trust to visit and develop this research in the Department of Pathobiology and Population Sciences at the Royal Veterinary College, University of London, UK.	Alpers CE, 2015, PATHOLOGIC BASIS DIS, P953; Babula JJ, 2015, J GENET GENOMICS, V42, P531, DOI 10.1016/j.jgg.2015.09.002; Bryan JN, 2006, J VET INTERN MED, V20, P1155, DOI 10.1892/0891-6640(2006)20[1155:PRNOD]2.0.CO;2; Calazans SG, 2016, PAK VET J, V36, P124; Carvalho S, VET COMP ONCOL; Chan TA, 1999, NATURE, V401, P616; Chen LW, 2013, INT J GYNECOL PATHOL, V32, P156, DOI 10.1097/PGP.0b013e31825a0353; Cianciolo R, 2015, JUBB KENNEDY PALMERS, P444; da Costa RMG, 2011, VET PATHOL, V48, P427, DOI 10.1177/0300985810381909; Edmondson EF, 2015, VET PATHOL, V52, P260, DOI 10.1177/0300985814533803; Garimella PS, 2017, CURR OPIN NEPHROL HY, V26, P136, DOI 10.1097/MNH.0000000000000299; Gayed BA, 2014, BJU INT, V113, P668, DOI 10.1111/bju.12263; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kelley LC, 1996, VET PATHOL, V33, P133, DOI 10.1177/030098589603300202; Ko S, 2014, J BREAST CANCER, V17, P207, DOI 10.4048/jbc.2014.17.3.207; Li ZM, 2009, AM J TRANSL RES, V1, P326; Lodygin D, 2006, SEMIN CANCER BIOL, V16, P214, DOI 10.1016/j.semcancer.2006.03.008; Meuten D. J., 2017, Tumors in domestic animals, P632; Meuten DJ, 2016, VET PATHOL, V53, P7, DOI 10.1177/0300985815593349; Meuten D. J., 2004, HISTOLOGICAL CLASSIF, VXI; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Mikami T, 2015, VIRCHOWS ARCH, V466, P559, DOI 10.1007/s00428-015-1735-6; Nakajima T, 2003, PATHOL INT, V53, P353, DOI 10.1046/j.1440-1827.2003.01481.x; Ngo TC, 2014, UROL ONCOL-SEMIN ORI, V32, P243, DOI 10.1016/j.urolonc.2013.07.011; Olumi AF, 2001, UROL ONCOL, V6, P63, DOI 10.1016/S1078-1439(00)00109-5; Ramos-Vara JA, 2008, J VET DIAGN INVEST, V20, P393, DOI 10.1177/104063870802000401; Schuffler PJ, 2013, J PATHOLOGY INFORM, V4, P2, DOI [10.4103/2153-3539.109804, DOI 10.4103/2153-3539.109804]; Shen JJ, 2007, MOL CARCINOGEN, V46, P331, DOI 10.1002/mc.20256; Shen SS, 2012, ARCH PATHOL LAB MED, V136, P410, DOI 10.5858/arpa.2011-0472-RA; Shiba-Ishii A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0414-1; Shiba-Ishii A, 2011, INT J CANCER, V129, P2445, DOI 10.1002/ijc.25907; Suarez-Bonnet A, 2015, UROL ONCOL, V33; Suarez-Bonnet A, 2016, J APPL ANIM RES, V44, P83, DOI 10.1080/09712119.2015.1013963; Suarez-Bonnet A, 2011, VET J, V190, P345, DOI 10.1016/j.tvjl.2010.12.015; Suarez-Bonnet A, 2010, VET J, V185, P218, DOI 10.1016/j.tvjl.2009.05.014; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; Wu YJ, 2015, CANCERS, V7, P1022, DOI 10.3390/cancers7020822; Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107251; Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012	40	2	2	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					233	240		10.1177/0300985817738097			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300007	29145797	Other Gold, Green Accepted			2019-10-28	
J	Noland, EL; Kiupel, M				Noland, Erica L.; Kiupel, Matti			Coexpression of CD3 and CD20 in Canine Enteropathy-Associated T-cell Lymphoma	VETERINARY PATHOLOGY			English	Article						CD3; CD20; PAX5; immunohistochemistry; PCR for antigen receptor rearrangement; enteropathy-associated T-cell lymphoma; EATL	OF-THE-LITERATURE; GASTROINTESTINAL LYMPHOMA; MYCOSIS-FUNGOIDES; LYMPHOCYTES	The majority of primary intestinal lymphomas in dogs are T-cell lymphomas, with enteropathy-associated T-cell lymphoma (EATL) large cell type (type 1) being the most common. While most T-cell lymphomas express the T-cell marker CD3, there is increasing evidence that some human and canine T-cell lymphomas coexpress the B-cell marker CD20. We describe 3 cases of CD3(+), CD20(+), Pax5(-) EATL type 1 in dogs. All 3 cases had clonal rearrangement of T-cell receptor gamma. Initial clinical signs included weight loss, inappetence, diarrhea, and/or vomiting. The mean age was 9 years (range 3-12). Survival was highly variable ranging from 20 days to longer than 1.6 years. Considering the different chemotherapeutic response of T-cell versus B-cell lymphomas, accurate diagnosis of lymphomas coexpressing CD3 and CD20 as EATL type 1 based on histologic features and clonality results is important. Regardless, the clinical and/or prognostic significance of neoplastic T cells expressing CD20 is unclear.	[Noland, Erica L.; Kiupel, Matti] Michigan State Univ, Dept Pathobiol & Diagnost Invest, Vet Diagnost Lab, 4125 Beaumont Rd, Lansing, MI 48910 USA	Kiupel, M (reprint author), Michigan State Univ, Dept Pathobiol & Diagnost Invest, Vet Diagnost Lab, 4125 Beaumont Rd, Lansing, MI 48910 USA.	kiupel@dcpah.msu.edu					Brachelente C, 2016, VET PATHOL, V53, P563, DOI 10.1177/0300985815604724; Carrasco V, 2015, VET PATHOL, V52, P668, DOI 10.1177/0300985814559398; Coyle KA, 2004, VET PATHOL, V41, P141, DOI 10.1354/vp.41-2-141; Harms KL, 2014, J CUTAN PATHOL, V41, P494, DOI 10.1111/cup.12299; HULTIN LE, 1993, CYTOMETRY, V14, P196, DOI 10.1002/cyto.990140212; Misra DS, 2014, INDIAN J PATHOL MICR, V57, P658, DOI 10.4103/0377-4929.142727; Moore PF, 2012, VET PATHOL, V49, P658, DOI 10.1177/0300985811404712; Munday J. S., 2017, Tumors in domestic animals, P499; Palanichamy A, 2014, J IMMUNOL, V193, P580, DOI 10.4049/jimmunol.1400118; QUINTANILLAMARTINEZ L, 1994, AM J CLIN PATHOL, V102, P483, DOI 10.1093/ajcp/102.4.483; Rahemtullah A, 2008, AM J SURG PATHOL, V32, P1593, DOI 10.1097/PAS.0b013e31817d7452; Sun T, 2004, J CLIN PATHOL, V57, P442, DOI 10.1136/jcp.2003.011734; Valli VE, 2016, JUBB KENNEDY PALMERS, P230	13	4	4	2	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					241	244		10.1177/0300985817747326			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300008	29343197	Bronze			2019-10-28	
J	Wilson-Welder, JH; Nally, JE; Alt, DP; Palmer, MV; Coatney, J; Plummer, P				Wilson-Welder, Jennifer H.; Nally, Jarlath E.; Alt, David P.; Palmer, Mitchell V.; Coatney, John; Plummer, Paul			Experimental Transmission of Bovine Digital Dermatitis to Sheep: Development of an Infection Model	VETERINARY PATHOLOGY			English	Article						animal model; digital dermatitis; Treponema; sheep; cattle; skin; foot diseases; hoof	DAIRY-CATTLE; MILK-PRODUCTION; FOOT LESIONS; DICHELOBACTER-NODOSUS; ANIMAL-WELFARE; TREPONEMES; COWS; ASSOCIATION; GOATS; IDENTIFICATION	Digital dermatitis is an infectious cause of lameness primarily affecting cattle but also described in sheep, goats, and wild elk. Digital dermatitis is a polymicrobial infection, involving several Treponema species and other anaerobic bacteria. Although the exact etiology has not been demonstrated, a number of bacterial, host, and environmental factors are thought to contribute to disease development. To study host-bacterial interactions, a reproducible laboratory model of infection is required. The objective of this study was to demonstrate key aspects of bovine digital dermatitis lesions in an easy-to-handle sheep model. Crossbred sheep were obtained from a flock free of hoof disease. Skin between the heel bulb and dewclaw was abraded before wrapping to emulate a moist, anaerobic environment. After 3 days, abraded areas were inoculated with macerated lesion material from active bovine digital dermatitis and remained wrapped. By 2 weeks postinoculation, experimentally inoculated feet developed erosive, erythematous lesions. At 4 weeks postinoculation, microscopic changes in the dermis and epidermis were consistent with those described for bovine digital dermatitis, including erosion, ulceration, hyperkeratosis, ballooning degeneration of keratinocytes, and the presence of neutrophilic infiltrates. Silver staining of lesion biopsy sections confirmed that spirochetes had penetrated the host epidermis. The model was then perpetuated by passaging lesion material from experimentally infected sheep into naive sheep. This model of bovine digital dermatitis will allow for future novel insights into pathogenic mechanisms of infection, as well as the development of improved diagnostic methods and therapeutics for all affected ruminants.	[Wilson-Welder, Jennifer H.; Nally, Jarlath E.; Alt, David P.; Palmer, Mitchell V.] ARS, Infect Bacterial Dis, Natl Anim Dis Ctr, USDA, 1920 Dayton Ave, Ames, IA 50010 USA; [Coatney, John; Plummer, Paul] Iowa State Univ, Coll Vet Med, Vet Microbiol & Prevent Med, Ames, IA USA; [Plummer, Paul] Iowa State Univ, Coll Vet Med, Vet Diagnost & Prod Med, Ames, IA USA	Wilson-Welder, JH (reprint author), ARS, Infect Bacterial Dis, Natl Anim Dis Ctr, USDA, 1920 Dayton Ave, Ames, IA 50010 USA.	jennifer.wilson-welder@ars.usda.gov	Palmer, Mitchell/R-7091-2018	Palmer, Mitchell/0000-0002-5902-3333; Wilson-Welder, Jennifer/0000-0003-3477-1631	Agriculture and Food Research Initiative Competitive Grant from the USDA National Institute of Food and Agriculture [11641835];  [5030-32000-223-00-D]	The author(s) received no financial support for the research, authorship, and/or publication of this article. JHWW, JEN, DPA, and MVP are US Department of Agriculture employees, work was completed in the course of their assigned duties in relation to project number 5030-32000-223-00-D. JC and PP were supported in part by Agriculture and Food Research Initiative Competitive Grant no. 11641835 from the USDA National Institute of Food and Agriculture. Work was completed by US Department of Agriculture employees in the course of their assigned duties in relation to project number 5030-32000-223-00-D.	Angell JW, 2015, J COMP PATHOL, V153, P212, DOI 10.1016/j.jcpa.2015.10.178; Angell JW, 2015, VET REC, V176, DOI 10.1136/vr.102978; ArgaezRodriguez FDJ, 1997, PREV VET MED, V32, P275; Bennett G, 2009, RES VET SCI, V87, P413, DOI 10.1016/j.rvsc.2009.04.001; Callis G, 2002, ANIMAL PROCESSING MA; Capion N, 2009, VET J, V182, P50, DOI 10.1016/j.tvjl.2008.05.026; Cha E, 2010, PREV VET MED, V97, P1, DOI 10.1016/j.prevetmed.2010.07.011; Choi BK, 1997, INT J SYST BACTERIOL, V47, P175, DOI 10.1099/00207713-47-1-175; Clegg SR, 2015, J CLIN MICROBIOL, V53, P88, DOI 10.1128/JCM.02276-14; Clegg SR, 2016, APPL ENVIRON MICROB, V82, P4523, DOI 10.1128/AEM.00025-16; Coatney JW, 2015, 10 INT C LAM RUM NOV; Crosby-Durrani HE, 2016, J COMP PATHOL, V154, P283, DOI 10.1016/j.jcpa.2016.04.001; DURAN SP, 1990, BRIT VET J, V146, P551; Evans NJ, 2008, VET MICROBIOL, V130, P141, DOI 10.1016/j.vetmic.2007.12.019; Evans NJ, 2012, VET MICROBIOL, V156, P102, DOI 10.1016/j.vetmic.2011.09.029; Evans NJ, 2009, INT J SYST EVOL MICR, V59, P987, DOI 10.1099/ijs.0.002287-0; Gomez A, 2015, J DAIRY SCI, V98, P4487, DOI 10.3168/jds.2014-9041; Gomez A, 2012, J DAIRY SCI, V95, P1821, DOI 10.3168/jds.2011-4754; Groenevelt M, 2015, VET REC, V176, P626, DOI 10.1136/vr.102907; Guccione J, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0726-4; Harvey David, 2013, Animals (Basel), V3, P767, DOI 10.3390/ani3030767; Jergens AE, 2007, GUT, V56, P934, DOI 10.1136/gut.2006.099242; Klitgaard K, 2013, J CLIN MICROBIOL, V51, P2212, DOI 10.1128/JCM.00320-13; Knappe-Poindecker M, 2015, ACTA VET SCAND, V57, DOI 10.1186/s13028-015-0148-5; Knappe-Poindecker M, 2014, VET MICROBIOL, V170, P375, DOI 10.1016/j.vetmic.2014.02.044; Krull AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154481; Krull AC, 2014, INFECT IMMUN, V82, P3359, DOI 10.1128/IAI.02077-14; Losinger WC, 2006, J DAIRY RES, V73, P244, DOI 10.1017/S0022029906001798; Moe KK, 2010, CLIN VACCINE IMMUNOL, V17, P376, DOI 10.1128/CVI.00464-09; Nagano Y, 2007, BRIT J BIOMED SCI, V64, P74, DOI 10.1080/09674845.2007.11732760; Nascimento LV, 2015, J CLIN MICROBIOL, V53, P1935, DOI 10.1128/JCM.03586-14; Nielsen MW, 2016, VET MICROBIOL, V186, P139, DOI 10.1016/j.vetmic.2016.03.003; Palmer MA, 2013, ANIMAL, V7, P1731, DOI 10.1017/S1751731113001274; Pringle M, 2008, ACTA VET SCAND, V50, DOI 10.1186/1751-0147-50-40; Read DH, 1998, J VET DIAGN INVEST, V10, P67, DOI 10.1177/104063879801000112; Relun A, 2013, J DAIRY SCI, V96, P2190, DOI 10.3168/jds.2012-5934; Santos TMA, 2012, FEMS MICROBIOL ECOL, V79, P518, DOI 10.1111/j.1574-6941.2011.01234.x; Sayers G, 2009, J CLIN MICROBIOL, V47, P1199, DOI 10.1128/JCM.01934-08; Sheehan DC, 1987, THEORY PRACTICE HIST; STANTON TB, 1979, APPL ENVIRON MICROB, V38, P965; Sullivan LE, 2014, VET REC, V175, P201, DOI 10.1136/vr.102269; Telfer JC, 2015, CELL IMMUNOL, V296, P76, DOI 10.1016/j.cellimm.2015.05.003; Trott DJ, 2003, J CLIN MICROBIOL, V41, P2522, DOI 10.1128/JCM.41.6.2522-2529.2003; Walker RL, 1995, VET MICROBIOL, V47, P343, DOI 10.1016/0378-1135(95)00114-X; Walker RL, 1997, AM J VET RES, V58, P744; Wilson-Welder JH, 2015, VET MED-RES REP, V6, P155, DOI 10.2147/VMRR.S62072; Wilson-Welder JH, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-280; Yano T, 2010, J VET MED SCI, V72, P379, DOI 10.1292/jvms.09-0418; Yeruham I, 2000, AUST VET J, V78, P250, DOI 10.1111/j.1751-0813.2000.tb11746.x; Zhou HT, 2010, VET J, V184, P115, DOI 10.1016/j.tvjl.2009.02.003; Zinicola M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133674	51	0	0	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					245	257		10.1177/0300985817736572			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300009	29145798	Bronze			2019-10-28	
J	Zimmerman, SM; Long, ME; Dyke, JS; Jelesijevic, TP; Michel, F; Lafontaine, ER; Hogan, RJ				Zimmerman, Shawn M.; Long, Mackenzie E.; Dyke, Jeremy S.; Jelesijevic, Tomislav P.; Michel, Frank; Lafontaine, Eric R.; Hogan, Robert J.			Use of Immunohistochemistry to Demonstrate In Vivo Expression of the Burkholderia mallei Virulence Factor BpaB During Experimental Glanders	VETERINARY PATHOLOGY			English	Article						Burkholderia mallei; glanders; animal models of human disease; mice and marmosets; virulence factor; vaccine target; immunohistochemistry	INFECTION; PSEUDOMALLEI	Burkholderia mallei causes the highly contagious and debilitating zoonosis glanders, which infects via inhalation or percutaneous inoculation and often culminates in life-threatening pneumonia and sepsis. In humans, glanders is difficult to diagnose and requires prolonged antibiotic therapy with low success rates. No vaccine exists to protect against B. mallei, and there is concern regarding its use as a bioweapon. The authors previously identified the protein BpaB as a potential target for devising therapies due to its role in adherence to host cells and the formation of biofilms in vitro and its contribution to pathogenicity in a mouse model of glanders. In the present study, the authors developed an immunostaining approach to probe tissues of experimentally infected animals and demonstrated that BpaB is produced exclusively in vivo by wild-type B. mallei in target organs from mice and marmosets. They detected the expression of BpaB by B. mallei both extracellularly and within macrophages, neutrophils, and epithelial cells in respiratory tissues (7/10 marmoset; 2/2 mouse). The authors also noted the intracellular expression of BpaB by B. mallei in macrophages in the regional lymph nodes of mice (2/2 tissues) and MALT of marmosets (4/5 tissues). It is interesting that B. mallei bacteria infecting distal organs did not express BpaB (2/2 mice; 3/3 marmosets), suggesting that the protein is not necessary for bacterial fitness in these anatomic locations. These findings underscore the value of BpaB as a target for developing medical countermeasures and provide insight into its role in pathogenesis.	[Zimmerman, Shawn M.; Dyke, Jeremy S.; Jelesijevic, Tomislav P.; Lafontaine, Eric R.; Hogan, Robert J.] Univ Georgia, Coll Vet Med, Dept Infect Dis, 501 DW Brooks Dr, Athens, GA 30602 USA; [Long, Mackenzie E.] Univ Georgia, Coll Vet Med, Vet Teaching Hosp, Athens, GA 30602 USA; [Michel, Frank; Hogan, Robert J.] Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, 501 DW Brooks Dr, Athens, GA 30602 USA	Hogan, RJ (reprint author), Univ Georgia, Coll Vet Med, Dept Infect Dis, 501 DW Brooks Dr, Athens, GA 30602 USA.; Hogan, RJ (reprint author), Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, 501 DW Brooks Dr, Athens, GA 30602 USA.	jhogan@uga.edu			National Institutes of Health National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [05 T35 OD010433-09]; Zoetis-Morris Animal Foundation Veterinary Fellowship for Advanced Study [D12ZO-902]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported, in part, by the National Institutes of Health National Center for Research Resources (05 T35 OD010433-09) to MEL and by a Zoetis-Morris Animal Foundation Veterinary Fellowship for Advanced Study (D12ZO-902) to SMZ. The funders had no input in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.	Alibek K, 1999, BIOHAZARD CHILLING T; Arun S, 1999, VET REC, V144, P255, DOI 10.1136/vr.144.10.255; Balder R, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-250; Bernhards RC, 2017, ARCH MICROBIOL, V199, P277, DOI 10.1007/s00203-016-1303-8; Bozue JA, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00021; Burtnick MN, 2010, INFECT IMMUN, V78, P88, DOI 10.1128/IAI.00985-09; Carr-Gregory B, 2007, MED ASPECTS BIOL WAR, P121; Chiang CY, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0593-3; Choh LC, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00005; David J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00080; Derbyshire JB, 2002, CAN VET J, V43, P722; Dvorak GD, 2008, JAVMA-J AM VET MED A, V233, P570, DOI 10.2460/javma.233.4.570; Estes DM, 2010, EXPERT REV ANTI-INFE, V8, P325, DOI [10.1586/eri.10.4, 10.1586/ERI.10.4]; Fritz DL, 2000, VET PATHOL, V37, P626, DOI 10.1354/vp.37-6-626; Galyov EE, 2010, ANNU REV MICROBIOL, V64, P495, DOI 10.1146/annurev.micro.112408.134030; Hatcher Christopher L, 2015, Curr Trop Med Rep, V2, P62; HOWE C, 1947, ANN INTERN MED, V26, P93, DOI 10.7326/0003-4819-26-1-93; Howe C, 1950, THE OXFORD MED, P185; Jelesijevic T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124181; Kenny DJ, 1999, ANTIMICROB AGENTS CH, V43, P2773, DOI 10.1128/AAC.43.11.2773; Kettle ANB, 2016, EQUINE VET J, V48, P654, DOI 10.1111/evj.12599; Khaki P, 2012, IRAN J MICROBIOL, V4, P3; Khan I, 2013, TRANSBOUND EMERG DIS, V60, P204, DOI 10.1111/j.1865-1682.2012.01342.x; Lafontaine ER, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-92; Lafontaine ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076804; Larsen JC, 2009, MIL MED, V174, P647, DOI 10.7205/MILMED-D-03-0808; Lehavi O, 2002, HAREFUAH, V141, P119; Lever MS, 2003, J MED MICROBIOL, V52, P1109, DOI 10.1099/jmm.0.05180-0; Lipsitz Rebecca, 2012, Emerg Infect Dis, V18, pe2, DOI 10.3201/eid1812.120638; Malik Praveen, 2015, Vet Rec Open, V2, pe000129, DOI 10.1136/vetreco-2015-000129; Malik P, 2010, INDIAN J MICROBIOL, V50, P345, DOI 10.1007/s12088-010-0027-8; Massey S, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00174; Mota RA, 2010, BRAZ J MICROBIOL, V41, P146, DOI 10.1590/S1517-838220100001000021; Neubauer H., 1997, Revue Internationale des Services de Sante des Forces Armees, V70, P258; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Podnecky NL, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00305; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Regis E., 1999, THE BIOL OF DOOM; Robins G, 1906, STUDIES ROYAL VICTOR, V1, P1; Schell MA, 2007, MOL MICROBIOL, V64, P1466, DOI 10.1111/j.1365-2958.2007.05734.x; Schell MA, 2011, J PROTEOME RES, V10, P2417, DOI 10.1021/pr1012398; SHARRER GT, 1995, AGR HIST, V69, P79; Slater J, 2013, VET REC, V173, P186, DOI 10.1136/vr.f5260; Smart JK, 1997, TXB MILITARY MED, P16; Srinivasan A, 2001, NEW ENGL J MED, V345, P256, DOI 10.1056/NEJM200107263450404; Stundick MV, 2013, VET PATHOL, V50, P877, DOI 10.1177/0300985813486812; Thibault FM, 2004, J ANTIMICROB CHEMOTH, V54, P1134, DOI 10.1093/jac/dkh471; Van Zandt KE, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-131; Viktorov Dimitry V, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS103, DOI 10.1016/S0035-9203(08)70025-7; Waag DM, 2004, BIOL WEAPONS DEFENSE, P209; Wernery U, 2011, EMERG INFECT DIS, V17, P1277, DOI 10.3201/eid1707.110222; Wheelis M, 1998, NATURE, V395, P213, DOI 10.1038/26089; Wheelis M, 1999, BIOL TOXIN WEAPONS R, P35; Willcocks SJ, 2016, CURR OPIN MICROBIOL, V29, P94, DOI 10.1016/j.mib.2015.11.007; Zimmerman SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126437	55	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					258	267		10.1177/0300985817736113			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300010	29145795	Bronze			2019-10-28	
J	Stranahan, LW; Plumlee, QD; Lawhon, SD; Cohen, ND; Bryan, LK				Stranahan, Lauren W.; Plumlee, Quinci D.; Lawhon, Sara D.; Cohen, Noah D.; Bryan, Laura K.			Rhodococcus equi Infections in Goats: Characterization of Virulence Plasmids	VETERINARY PATHOLOGY			English	Article						caseous lymphadenitis; goat; Rhodococcus equi; virulence plasmids; virulence-associated protein N	MOLECULAR EPIDEMIOLOGY	Rhodococcus equi is an uncommon cause of systemic pyogranulomatous infections in goats with macroscopic similarities to caseous lymphadenitis caused by Corynebacterium pseudotuberculosis. Caprine cases have previously been reported to be caused by avirulent R. equi strains. Six cases of R. equi infection in goats yielding 8 R. equi isolates were identified from 2000 to 2017. Lesions varied from bronchopneumonia, vertebral and humeral osteomyelitis, and subcutaneous abscesses, to disseminated infection involving the lungs, lymph nodes, and multiple visceral organs. Isolates of R. equi from infected goats were analyzed by polymerase chain reaction for R. equi virulence-associated plasmid (vap) genes. Seven of 8 isolates carried the VapN plasmid, originally characterized in bovine isolates, while 1 isolate lacked virulence plasmids and was classified as avirulent. The VapN plasmid has not been described in isolates cultured from goats.	[Stranahan, Lauren W.; Plumlee, Quinci D.; Lawhon, Sara D.; Bryan, Laura K.] Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA; [Cohen, Noah D.] Texas A&M Univ, Dept Large Anim Clin Sci, Coll Vet Med, College Stn, TX 77843 USA	Stranahan, LW (reprint author), Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA.	lstranahan@cvm.tamu.edu	Lawhon, Sara D/G-5147-2011	Lawhon, Sara D/0000-0001-9154-8909; Stranahan, Lauren/0000-0002-0746-5949; Bryan, Laura K/0000-0003-0746-9461			Bell KS, 1998, J APPL MICROBIOL, V85, P195; Bolton T, 2010, J VET DIAGN INVEST, V22, P611, DOI 10.1177/104063871002200419; Bryan LK, 2017, VET PATHOL, V54, P159, DOI 10.1177/0300985816650244; CARRIGAN MJ, 1988, AUST VET J, V65, P331, DOI 10.1111/j.1751-0813.1988.tb14522.x; Davis WP, 1999, VET PATHOL, V36, P336, DOI 10.1354/vp.36-4-336; Dorella FA, 2006, VET RES, V37, P201, DOI 10.1051/vetres:2005056; FITZGERALD SD, 1994, J VET DIAGN INVEST, V6, P105, DOI 10.1177/104063879400600121; Gonzalez-Iglesias P, 2014, VET MICROBIOL, V172, P256, DOI 10.1016/j.vetmic.2014.03.026; Jeckel S, 2011, VET REC, V169, P56, DOI 10.1136/vr.d4267; Ocampo-Sosa AA, 2007, J INFECT DIS, V196, P763, DOI 10.1086/519688; OJO MO, 1993, CAN VET J, V34, P504; PRESCOTT JF, 1991, CLIN MICROBIOL REV, V4, P20; Reuss SM, 2009, JAVMA-J AM VET MED A, V235, P855, DOI 10.2460/javma.235.7.855; Rodriguez JL, 2000, J APPL ANIM RES, V18, P149, DOI 10.1080/09712119.2000.9706336; Tkachuk-Saad O, 1998, VET REC, V143, P311, DOI 10.1136/vr.143.11.311; Valero-Rello A, 2015, INFECT IMMUN, V83, P2725, DOI 10.1128/IAI.00376-15; Witkowski L, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0712-9	17	4	4	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					273	276		10.1177/0300985817747327			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300012	29254455	Bronze			2019-10-28	
J	Yau, W; Mausbach, L; Littman, MP; Cianciolo, RE; Brown, CA				Yau, Wilson; Mausbach, Lisa; Littman, Meryl P.; Cianciolo, Rachel E.; Brown, Cathy A.			Focal Segmental Glomerulosclerosis in Related Miniature Schnauzer Dogs	VETERINARY PATHOLOGY			English	Article						dogs; kidney; primary focal segmental glomerulosclerosis; Miniature Schnauzer; proteinuria; podocyte	GLOMERULAR-DISEASE; PODOCYTES RESPONSE; RENAL BIOPSIES; ALPHA-ACTININ-4; MUTATIONS; INJURY; GLOMERULONEPHRITIDES; PROTEINURIA; FEATURES; ACTN4	Focal segmental glomerulosclerosis (FSGS) recently has been recognized as a common cause of proteinuria in dogs in general, and in Miniature Schnauzer dogs in particular. This study describes the morphologic features present in the kidneys of 8 related proteinuric Miniature Schnauzer dogs. The FSGS, characterized by solidification of portions of the capillary tuft, affected 32% to 49% of examined glomeruli in these dogs. Synechiae, often accompanied by hyalinosis, were present in 13% to 54% of glomeruli and were more prevalent in older dogs. Seven of 8 dogs had arteriolar hyalinosis. Ultrastructurally, all dogs had evidence of a podocytopathy in the absence of electron-dense deposits, glomerular basement membrane splitting, or fibrils. All dogs had multifocal to extensive podocyte foot process effacement. Other podocyte changes included microvillous transformation, the presence of vacuoles or protein resorption droplets, cytoplasmic electron-dense aggregates, and occasional binucleation. Variable amounts of intraglomerular lipid were present in all dogs. All dogs were proteinuric, with measured values for the urine protein-to-creatinine ratio ranging from 1.2 to 6.5. Azotemia was mild to absent and dogs were euthanatized at 5.1 to 14 years of age, in all cases due to nonrenal diseases. The underlying cause of FSGS in these Miniature Schnauzer dogs has yet to be determined, but contributors likely include genetic podocytopathy, lipid abnormalities, and glomerular hypertension.	[Yau, Wilson; Brown, Cathy A.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA; [Mausbach, Lisa] Wheat Ridge Anim Hosp, Wheat Ridge, CO USA; [Littman, Meryl P.] Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA; [Cianciolo, Rachel E.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA; [Brown, Cathy A.] Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA	Brown, CA (reprint author), Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA.	cathybro@uga.edu		Yau, Wilson/0000-0003-0079-9783	Gray Lady Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received financial support from the Gray Lady Foundation for the research, authorship, and/or publication of this article.	Akchurin O, 2015, PEDIATR NEPHROL, V30, P221, DOI 10.1007/s00467-014-2753-3; Aresu L, 2010, J COMP PATHOL, V143, P190, DOI 10.1016/j.jcpa.2009.12.016; Brodsky SV, 2010, HISTOL HISTOPATHOL, V25, P1379, DOI 10.14670/HH-25.1379; Brown S, 2013, J VET INTERN MED, V27, pS27, DOI 10.1111/jvim.12230; Brown S, 1996, BR VET J, V152, P1; Brown SA, 1998, J LAB CLIN MED, V131, P447, DOI 10.1016/S0022-2143(98)90146-9; BROWN SA, 1990, AM J PHYSIOL, V258, pF495; Cianciolo RE, 2016, VET PATHOL, V53, P113, DOI 10.1177/0300985815579996; Cianciolo RE, 2013, J VET INTERN MED, V27, pS10, DOI 10.1111/jvim.12226; D'Agati VD, 2008, KIDNEY INT, V73, P399, DOI 10.1038/sj.ki.5002655; D'Agati VD, 2015, HEPTINSTALLS PATHOLO, P207; D'Agati VD, 2011, NEW ENGL J MED, V365, P2398, DOI 10.1056/NEJMra1106556; FINCO DR, 1972, AM J VET RES, V33, P2447; Furrow E, 2017, VET PATHOL, V54, P484, DOI 10.1177/0300985816681412; Furrow E, 2016, VET J, V212, P83, DOI 10.1016/j.tvjl.2016.04.009; Henderson J, 2008, KIDNEY INT, V73, P741, DOI 10.1038/sj.ki.5002751; Henderson JM, 2009, J AM SOC NEPHROL, V20, P961, DOI 10.1681/ASN.2008060613; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kitiyakara C, 2003, SEMIN NEPHROL, V23, P172, DOI 10.1053/snep.2003.50025; Kriz W, 2013, AM J PHYSIOL-RENAL, V304, pF333, DOI 10.1152/ajprenal.00478.2012; Lattouf R, 2014, J HISTOCHEM CYTOCHEM, V62, P751, DOI 10.1369/0022155414545787; Littman MP, 2013, MAMM GENOME, V24, P119, DOI 10.1007/s00335-012-9445-8; MORTON LD, 1990, VET PATHOL, V27, P455, DOI 10.1177/030098589902700612; NAGATA M, 1995, NEPHRON, V70, P68, DOI 10.1159/000188546; Nagata M, 2016, KIDNEY INT, V89, P1221, DOI 10.1016/j.kint.2016.01.012; Nickeleit V, 2015, HEPTINSTALLS PATHOLO, P1395; Pollak MR, 2002, J AM SOC NEPHROL, V13, P3016, DOI 10.1097/01.ASN.0000039569.34360.5E; Schneider SM, 2013, J VET INTERN MED, V27, pS67, DOI 10.1111/jvim.12247; Shankland SJ, 2006, KIDNEY INT, V69, P2131, DOI 10.1038/sj.ki.5000410; Vaden SL, 2013, J VET EMERG CRIT CAR, V23, P174, DOI 10.1111/vec.12027; Weins A, 2007, P NATL ACAD SCI USA, V104, P16080, DOI 10.1073/pnas.0702451104; Yao J, 2004, PLOS BIOL, V2, P787, DOI 10.1371/journal.pbio.0020167	32	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					277	285		10.1177/0300985817736356			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300013	29191133	Bronze			2019-10-28	
J	Wang, P; Margolis, C; Lin, G; Buza, EL; Quick, S; Raj, K; Han, R; Giger, U				Wang, Ping; Margolis, Carol; Lin, Gloria; Buza, Elizabeth L.; Quick, Scott; Raj, Karthik; Han, Rachel; Giger, Urs			Mucopolysaccharidosis Type VI in a Great Dane Caused by a Nonsense Mutation in the ARSB Gene	VETERINARY PATHOLOGY			English	Article						arylsulfatase B; dogs; genetic diseases; hereditary disease; lysosomal storage disease; skeletal deformity	ENZYME REPLACEMENT THERAPY; ARYLSULFATASE-B DEFICIENCY; FELINE MODEL; DISORDERS; LEUKOCYTE; CATS; DOG	Mucopolysaccharidoses are inherited metabolic disorders that result from a deficiency of lysosomal enzymes required for the catabolism of glycosaminoglycans. Lysosomal glycosaminoglycan accumulation results in cell and organ dysfunction. This study characterized the phenotype and genotype of mucopolysaccharidosis VI in a Great Dane puppy with clinical signs of stunted growth, facial dysmorphia, skeletal deformities, corneal opacities, and increased respiratory sounds. Clinical and pathologic evaluations, urine glycosaminoglycan analyses, lysosomal enzyme assays, and ARSB sequencing were performed. The urine mucopolysaccharide spot test was strongly positive predominantly due to the accumulation of dermatan sulfate. Enzyme assays in leukocytes and tissues indicated a deficiency of arylsulfatase B (ARSB) activity. Histologic examination revealed cytoplasmic vacuoles in many tissues. Analysis of the exonic ARSB DNA sequences from the affected puppy compared to the published canine genome sequence revealed a homozygous nonsense mutation (c.295C>T) in exon 1, replacing glutamine with a premature stop codon (p.Gln99*), predicting no enzyme synthesis. A polymerase chain reaction-based restriction fragment length polymorphism test was established to assist with the clinical diagnosis and breeding of Great Danes. This genotyping test revealed that the clinically healthy parents and some other relatives of the puppy were heterozygous for the mutant allele, but all 200 clinically healthy dogs screened including 15 Great Danes were homozygous for the normal allele. This ARSB mutation is the fourth identified genetic variant causing canine mucopolysaccharidosis VI. Mucopolysaccharidosis VI is the first lysosomal storage disorder described in Great Danes but does not appear to be widespread in this breed.	[Wang, Ping; Margolis, Carol; Lin, Gloria; Raj, Karthik; Han, Rachel; Giger, Urs] Univ Penn, Sch Vet Med, Sect Med Genet, 3900 Delancey St,Room 4021, Philadelphia, PA 19104 USA; [Buza, Elizabeth L.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; [Quick, Scott] Qual Pet Care LLC, Monticello, NY USA	Giger, U (reprint author), Univ Penn, Sch Vet Med, Sect Med Genet, 3900 Delancey St,Room 4021, Philadelphia, PA 19104 USA.	giger@vet.upenn.edu		Raj, Karthik/0000-0001-7736-1101	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH OD 010939]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by a grant from the National Institutes of Health (NIH OD 010939).	Berman L, 2004, 2 INT C ADV CAN FEL; BERRY HK, 1987, CLIN BIOCHEM, V20, P365, DOI 10.1016/S0009-9120(87)80088-7; Brooks DA, 2005, MOL GENET METAB, V85, P236, DOI 10.1016/j.ymgme.2005.02.008; Brunelli MJ, 2016, COCHRANE DB SYST REV, V3; Byers S, 2000, PEDIATR RES, V47, P743, DOI 10.1203/00006450-200006000-00010; CHANG PL, 1981, ANAL BIOCHEM, V117, P382, DOI 10.1016/0003-2697(81)90795-8; CHANG PL, 1983, J INHERIT METAB DIS, V6, P167, DOI 10.1007/BF02310875; Crawley AC, 1998, J CLIN INVEST, V101, P109, DOI 10.1172/JCI935; Crawley AC, 1997, J CLIN INVEST, V99, P651, DOI 10.1172/JCI119208; Ferla R, 2012, MOL THER, V20, pS54; Fyfe JC, 1999, GENOMICS, V58, P121, DOI 10.1006/geno.1999.5825; Garcia A, 1996, J CLIN MICROBIOL, V34, P182; Giugliani R, 2007, PEDIATRICS, V120, P405, DOI 10.1542/peds.2006-2184; Haskins M, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P731, DOI 10.1016/B978-0-12-370491-7.00024-6; HASKINS ME, 1979, PEDIATR RES, V13, P1203, DOI 10.1203/00006450-197911000-00001; HOPWOOD JJ, 1990, MOL BIOL MED, V7, P381; JEZYK PF, 1977, SCIENCE, V198, P834, DOI 10.1126/science.144321; Jolly RD, 2012, NEW ZEAL VET J, V60, P183, DOI 10.1080/00480169.2011.642791; Karageorgeos L, 2004, HUM MUTAT, V23, P229, DOI 10.1002/humu.10313; Karageorgos L, 2007, HUM MUTAT, V28, P897, DOI 10.1002/humu.20534; Muenzer J, 2004, J PEDIATR-US, V144, pS27, DOI 10.1016/j.jpeds.2004.01.052; NEER TM, 1995, J VET INTERN MED, V9, P429, DOI 10.1111/j.1939-1676.1995.tb03306.x; Perez ML, 2015, CAN VET J, V56, P272; Ruane T, 2016, MOL GENET METAB, V117, P157, DOI 10.1016/j.ymgme.2015.10.006; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; SHEPARD N, 1976, J HISTOCHEM CYTOCHEM, V24, P621, DOI 10.1177/24.5.132503; Valayannopoulos V, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-5; Wang P, 2015, J VET INTERN MED, V29, P1022, DOI 10.1111/jvim.13569; Yogalingam G, 1998, J BIOL CHEM, V273, P13421, DOI 10.1074/jbc.273.22.13421; Yogalingam G, 1996, J BIOL CHEM, V271, P27259, DOI 10.1074/jbc.271.44.27259; Yogalingam G, 1999, BBA-MOL BASIS DIS, V1453, P284, DOI 10.1016/S0925-4439(98)00112-4; YOSHIDA M, 1993, J CLIN INVEST, V91, P1099, DOI 10.1172/JCI116268	32	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					286	293		10.1177/0300985817732115			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300014	29157190	Bronze			2019-10-28	
J	Pfankuche, VM; Jo, WK; van der Vries, E; Jungwirth, N; Lorenzen, S; Osterhaus, ADME; Baumgartner, W; Puff, C				Pfankuche, Vanessa M.; Jo, Wendy K.; van der Vries, Erhard; Jungwirth, Nicole; Lorenzen, Stephan; Osterhaus, Albert D. M. E.; Baumgaertner, Wolfgang; Puff, Christina			Neuronal Vacuolization in Feline Panleukopenia Virus Infection	VETERINARY PATHOLOGY			English	Article						cat; central nervous system; feline panleukopenia virus; immunohistochemistry; next-generation sequencing; vacuolization	PARVOVIRUS INFECTION; CEREBELLAR HYPOPLASIA; CEREBRAL NEURONS; CATS; DISEASES	Feline panleukopenia virus (FPV) infections are typically associated with anorexia, vomiting, diarrhea, neutropenia, and lymphopenia. In cases of late prenatal or early neonatal infections, cerebellar hypoplasia is reported in kittens. In addition, single cases of encephalitis are described. FPV replication was recently identified in neurons, although it is mainly found in cells with high mitotic activity. A female cat, 2 months old, was submitted to necropsy after it died with neurologic deficits. Besides typical FPV intestinal tract changes, multifocal, randomly distributed intracytoplasmic vacuoles within neurons of the thoracic spinal cord were found histologically. Next-generation sequencing identified FPV-specific sequences within the central nervous system. FPV antigen was detected within central nervous system cells, including the vacuolated neurons, via immunohistochemistry. In situ hybridization confirmed the presence of FPV DNA within the vacuolated neurons. Thus, FPV should be considered a cause for neuronal vacuolization in cats presenting with ataxia.	[Pfankuche, Vanessa M.; Jungwirth, Nicole; Baumgaertner, Wolfgang; Puff, Christina] Univ Vet Med, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany; [Pfankuche, Vanessa M.; Jo, Wendy K.; Jungwirth, Nicole; Osterhaus, Albert D. M. E.; Baumgaertner, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Jo, Wendy K.; van der Vries, Erhard; Osterhaus, Albert D. M. E.] Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany; [Lorenzen, Stephan] Bernhard Nocht Inst Trop Med, Hamburg, Germany; [Osterhaus, Albert D. M. E.] Artemis One Hlth, Utrecht, Netherlands	Puff, C (reprint author), Univ Vet Med, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany.	Christina.puff@tiho-hannover.de	Lorenzen, Stephan/C-8960-2009; Lorenzen, Stephan/S-3448-2019	Lorenzen, Stephan/0000-0003-4857-6087; Lorenzen, Stephan/0000-0003-4857-6087	Niedersachsen Research Network on Neuroinfectiology of the Ministry of Science and Culture of Lower Saxony; COMPARE project; European UnionEuropean Union (EU) [643476]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was in part supported by the Niedersachsen Research Network on Neuroinfectiology of the Ministry of Science and Culture of Lower Saxony and by the COMPARE project and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 643476.	Aeffner F, 2006, DEUT TIERARZTL WOCH, V113, P403; Aguilar-Calvo P, 2015, VIRUS RES, V207, P82, DOI 10.1016/j.virusres.2014.11.026; CSIZA CK, 1971, INFECT IMMUN, V3, P838; CSIZA CK, 1972, CORNELL VET, V62, P192; Garigliany M, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0657-0; Imran M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-493; Jo WK, 2017, J WILDLIFE DIS, V53, P921, DOI 10.7589/2016-11-246; Pfankuche VM, 2016, EMERG INFECT DIS, V22, P1310, DOI 10.3201/eid2207.152049; Poncelet L, 2016, CELL CYCLE, V15, P3482, DOI 10.1080/15384101.2016.1249546; Poncelet L, 2013, VET J, V196, P381, DOI 10.1016/j.tvjl.2012.10.019; POOLE GM, 1972, APPL MICROBIOL, V24, P663; Schaudien D, 2010, J CLIN MICROBIOL, V48, P3169, DOI 10.1128/JCM.01582-09; Schwab S, 2007, J COMP PATHOL, V136, P96, DOI 10.1016/j.jcpa.2006.11.006; Scott CA, 2008, J VIROL, V82, P513, DOI 10.1128/JVI.01677-07; Stuetzer B, 2014, VET J, V201, P150, DOI 10.1016/j.tvjl.2014.05.027; Url A, 2003, J CLIN MICROBIOL, V41, P3801, DOI 10.1128/JCM.41.8.3801-3805.2003; von Smolinski D, 2005, HISTOCHEM CELL BIOL, V124, P177, DOI 10.1007/s00418-005-0013-0	17	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					294	297		10.1177/0300985817738096			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300015	29157191				2019-10-28	
J	Alexander, KA; Laver, PN; Williams, MC; Sanderson, CE; Kanipe, C; Palmer, MV				Alexander, Kathleen A.; Laver, Peter N.; Williams, Mark C.; Sanderson, Claire E.; Kanipe, Carly; Palmer, Mitchell V.			Pathology of the Emerging Mycobacterium tuberculosis Complex Pathogen, Mycobacterium mungi, in the Banded Mongoose (Mungos mungo)	VETERINARY PATHOLOGY			English	Article						banded mongoose; emerging infectious diseases; environmental pathogen; Mycobacterium mungi; olfactory communication; transmission; tuberculosis; wildlife pathology	BOVIS INFECTION; EPIDEMIOLOGY; GRANULOMA; BCG	Wild banded mongooses (Mungos mungo) in northeastern Botswana and northwest Zimbabwe are infected with a novel Mycobacterium tuberculosis complex (MTC) pathogen, Mycobacterium mungi. We evaluated gross and histologic lesions in 62 infected mongooses (1999-2017). Many tissues contained multifocal irregular, lymphohistiocytic to granulomatous infiltrates and/or multifocal or coalescing noncaseating to caseating granulomas with variable numbers of intralesional acid-fast bacilli. Over one-third of nasal turbinates examined had submucosal lymphohistiocytic to granulomatous infiltrates, erosion and ulceration of the nasal mucosa, bony remodeling, and nasal distortion. Similar inflammatory cell infiltrates expanded the dermis of the nasal planum with frequent ulceration. However, even in cases with intact epidermis, acid-fast bacilli were present in variable numbers among dermal infiltrates and on the epidermal surface among desquamated cells and debris, most commonly in small crevices or folds. In general, tissue involvement varied among cases but was highest in lymph nodes (50/54, 93%), liver (39/53, 74%), spleen (37/51, 73%), and anal glands/sacs (6/8, 75%). Pulmonary lesions were present in 67% of sampled mongooses (35/52) but only in advanced disseminated disease. The pathological presentation of M. mungi in the banded mongoose is consistent with pathogen shedding occurring through scent-marking behaviors (urine and anal gland secretions) with new infections arising from contact with these contaminated olfactory secretions and percutaneous movement of the pathogen through breaks in the skin, nasal planum, and/or skin of the snout. Given the character and distribution of lesions and the presence of intracellular acid-fast bacilli, we hypothesize that pathogen spread occurs within the body through a hematogenous and/or lymphatic route. Features of prototypical granulomas such as multinucleated giant cells and peripheral fibrosis were rarely present in affected mongooses. Acid-fast bacilli were consistently found intracellularly, even in regions of necrosis. The mongoose genome has a unique deletion (RDImon) that includes part of the encoding region for PPE68 (Rv3873), a gene co-operonic with PE35. These proteins can influence the host's cellular immune response to mycobacterial infections, and it remains uncertain how this deletion might contribute to observed patterns of pathology. M. mungi infection in banded mongooses is characterized by both a unique transmission and exposure route, as well as accompanying pathological features, providing an opportunity to increase our understanding of MTC pathogenesis across host-pathogen systems.	[Alexander, Kathleen A.; Laver, Peter N.; Sanderson, Claire E.] Virginia Tech, Dept Fish & Wildlife Conservat, Integrated Life Sci Bldg,1981 Kraft Dr, Blacksburg, VA 24061 USA; [Alexander, Kathleen A.; Sanderson, Claire E.] Ctr Conservat African Resources Anim Communities, CARACAL, Kasane, Botswana; [Williams, Mark C.] Univ Pretoria, Sect Pathol, Dept Paraclin Sci, Fac Vet Sci, Onderstepoort, South Africa; [Kanipe, Carly] Iowa State Univ, Dept Vet Pathol, Coll Vet Med, Ames, IA USA; [Kanipe, Carly; Palmer, Mitchell V.] Natl Anim Dis Ctr, Bacterial Dis Livestock Res Unit, Ames, IA USA	Alexander, KA (reprint author), Virginia Tech, Dept Fish & Wildlife Conservat, Integrated Life Sci Bldg,1981 Kraft Dr, Blacksburg, VA 24061 USA.	kathyalx@vt.edu	Palmer, Mitchell/R-7091-2018	Palmer, Mitchell/0000-0002-5902-3333; Kanipe, Carly/0000-0001-6024-7580; Laver, Peter/0000-0001-9077-6440	Morris Animal Foundation [D14ZO-083]; National Science Foundation as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program [1518663]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5U01GM070694-13]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Morris Animal Foundation (grant D14ZO-083) and the National Science Foundation (grant 1518663) as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. K. A. Alexander was also supported in part through the National Institutes of Health and National Institute of General Medical Sciences-Models of Infectious Disease Agent Study (grant 5U01GM070694-13). The funders had no role in study design, data collection and analysis, or the decision to submit the work for publication.	Ackerman MR, 2012, PATHOLOGIC BASIS VET, P89; Alexander KA, 2016, GENOME ANNOUNC, V4; Alexander KA, 2014, MANY HOSTS MYCOBACTE; Alexander KA, 2016, MBIO, V7; Alexander KA, 2010, EMERG INFECT DIS, V16, P1296, DOI 10.3201/eid1608.100314; Amato B, 2016, RES VET SCI, V106, P116, DOI 10.1016/j.rvsc.2016.03.019; Corner LAL, 2011, J COMP PATHOL, V144, P1, DOI 10.1016/j.jcpa.2010.10.003; Coscolla M, 2013, EMERG INFECT DIS, V19, P969, DOI 10.3201/eid1906.121012; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Dippenaar A, 2015, TUBERCULOSIS, V95, P682, DOI 10.1016/j.tube.2015.10.001; Drewe JA, 2009, J COMP PATHOL, V140, P12, DOI 10.1016/j.jcpa.2008.09.004; Hunter RL, 2011, TUBERCULOSIS, V91, P497, DOI 10.1016/j.tube.2011.03.007; Jackson R, 1995, NEW ZEAL VET J, V43, P322, DOI 10.1080/00480169./1995.35913; Khan Sabina, 2017, J Lab Physicians, V9, P26, DOI 10.4103/0974-2727.187921; Lugton IW, 1998, NEW ZEAL VET J, V46, P147, DOI 10.1080/00480169.1998.36079; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Martin CJ, 2016, SEMIN IMMUNOPATHOL, V38, P213, DOI 10.1007/s00281-015-0533-1; Mostowy S, 2004, J BACTERIOL, V186, P104, DOI 10.1128/JB.186.1.104-109.2003; MUIRHEAD RH, 1974, VET REC, V95, P552; Ofori-Anyinam B, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004801; PALOMINO JC, 2007, TUBERCULOSIS 2007 BA; Parsons SDC, 2013, EMERG INFECT DIS, V19, P2004, DOI 10.3201/eid1912.130268; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; SMITH N, 1960, Tubercle, V41, P203; Tiwari B, 2014, FEBS J, V281, P1556, DOI 10.1111/febs.12723	25	1	1	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					303	309		10.1177/0300985817741730			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300017	29258402				2019-10-28	
J	Vrolyk, V; Haruna, J; Benoit-Biancamano, MO				Vrolyk, Vanessa; Haruna, Julius; Benoit-Biancamano, Marie-Odile			Neonatal and Juvenile Ocular Development in Sprague-Dawley Rats: A Histomorphological and Immunohistochemical Study	VETERINARY PATHOLOGY			English	Article						caspase-3; developmental biology; growth and development; histology; immunohistochemistry; juvenile; Ki-67; morphogenesis; neonatal; ocular; PHH3; rats; Sprague Dawley; TUNEL	RETINAL-PIGMENT EPITHELIUM; PROGRAMMED CELL-DEATH; HUMAN EYE DEVELOPMENT; OPTIC-NERVE; CORNEAL ENDOTHELIUM; CHAMBER ANGLE; PRIMARY CILIA; POSTNATAL-DEVELOPMENT; VASCULAR REGRESSION; TRABECULAR MESHWORK	As in many altricial species, rats are born with fused eyelids and markedly underdeveloped eyes. While the normal histology of the eyes of mature rats is known, the histomorphological changes occurring during postnatal eye development in this species remain incompletely characterized. This study was conducted to describe the postnatal development of ocular structures in Sprague-Dawley (SD) rats during the first month of age using histology and immunohistochemistry (IHC). Both eyes were collected from 51 SD rats at 13 time points between postnatal day (PND) 1 and PND30. Histologic examination of hematoxylin and eosin-stained sections was performed, as well as IHC for cleaved-caspase-3 and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) to evaluate apoptosis, and IHC for Ki-67 and phospho-histone-H3 to evaluate cell proliferation. Extensive ocular tissue remodeling occurred prior to the eyelid opening around PND14 and reflected the interplay between apoptosis and cell proliferation. Apoptosis was particularly remarkable in the maturing subcapsular anterior epithelium of the lens, the inner nuclear and ganglion cell layers of the developing retina, and the Harderian gland, and was involved in the regression of the hyaloid vasculature. Nuclear degradation in the newly formed secondary lens fibers was noteworthy after birth and was associated with TUNEL-positive nuclear remnants lining the lens organelle-free zone. Cell proliferation was marked in the developing retina, cornea, iris, ciliary body and Harderian gland. The rat eye reached histomorphological maturity at PND21 after a rapid phase of morphological changes characterized by the coexistence of cell death and proliferation.	[Vrolyk, Vanessa; Benoit-Biancamano, Marie-Odile] Univ Montreal, Dept Pathol & Microbiol, Fac Vet Med, St Hyacinthe, PQ H3T 1J4, Canada; [Haruna, Julius] CiToxLAB North Amer, Laval, PQ, Canada; [Benoit-Biancamano, Marie-Odile] Univ Montreal, Fac Vet Med, GREPAQ, St Hyacinthe, PQ, Canada	Benoit-Biancamano, MO (reprint author), Univ Montreal, Dept Pathol & Microbiol, Fac Vet Med, St Hyacinthe, PQ H3T 1J4, Canada.	marie-odile.benoit-biancamano@umontreal.ca			program Mitacs Accelerate; "Fonds du Centenaire" of the University of Montreal; CiToxLAB North America	The study was supported through grants from the program Mitacs Accelerate, the "Fonds du Centenaire" of the University of Montreal and from CiToxLAB North America. We are thankful to Ancuta Apreutese for her technical help, Eiko Kawamura from the Western College of Veterinary Medicine of the University of Saskatchewan for her technical support with the SEM, as well as Cedric Gordon, study director, for his general support.	Al-Hussaini H, 2008, MOL VIS, V14, P1784; Alexiades MR, 1996, DEV DYNAM, V205, P293, DOI 10.1002/(SICI)1097-0177(199603)205:3<293::AID-AJA9>3.0.CO;2-D; Ali BH, 1996, HUM EXP TOXICOL, V15, P51, DOI 10.1177/096032719601500109; Bassett EA, 2012, TRENDS NEUROSCI, V35, P565, DOI 10.1016/j.tins.2012.05.004; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Blitzer AL, 2011, P NATL ACAD SCI USA, V108, P2819, DOI 10.1073/pnas.1016702108; BLOOM GD, 1980, EXP EYE RES, V31, P129, DOI 10.1016/0014-4835(80)90074-3; Bozanic D, 2003, EUR J CELL BIOL, V82, P421, DOI 10.1078/0171-9335-00328; BRAEKEVELT CR, 1970, AM J ANAT, V127, P281, DOI 10.1002/aja.1001270305; BUSE E, 1993, ANAT EMBRYOL, V187, P259; BUTT AM, 1993, J COMP NEUROL, V338, P141, DOI 10.1002/cne.903380110; CAIRNS J E, 1959, Br J Ophthalmol, V43, P385, DOI 10.1136/bjo.43.7.385; Carleer J, 2011, BIRTH DEFECTS RES B, V92, P254, DOI 10.1002/bdrb.20310; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Cheong C, 2006, MECH AGEING DEV, V127, P633, DOI 10.1016/j.mad.2006.02.010; Chidlow G, 2011, J HISTOCHEM CYTOCHEM, V59, P884, DOI 10.1369/0022155411418115; CHUNG EH, 1992, INVEST OPHTH VIS SCI, V33, P2199; Connolly PF, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00149; CUNNINGHAM TJ, 1981, DEV BRAIN RES, V2, P203, DOI 10.1016/0165-3806(81)90032-8; Cvekl A, 2004, BIOESSAYS, V26, P374, DOI 10.1002/bies.20009; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Dorfman AL, 2010, DOC OPHTHALMOL, V120, P61, DOI 10.1007/s10633-009-9208-3; Doughty MJ, 1998, TISSUE CELL, V30, P634, DOI 10.1016/S0040-8166(98)80082-7; Duarte DM, 2015, REPROD TOXICOL, V56, P97, DOI 10.1016/j.reprotox.2015.05.005; Duarte DM, 2011, BIRTH DEFECTS RES B, V92, P353, DOI 10.1002/bdrb.20299; Dutot M, 2006, INVEST OPHTH VIS SCI, V47, P2812, DOI 10.1167/iovs.06-0224; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Endl E, 2000, EXP CELL RES, V257, P231, DOI 10.1006/excr.2000.4888; Francesconi CM, 2000, INVEST OPHTH VIS SCI, V41, P1054; Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5; Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Fujitani Y, 2006, DEVELOPMENT, V133, P4439, DOI 10.1242/dev.02598; GALLAGHER BC, 1980, AM J ANAT, V159, P475, DOI 10.1002/aja.1001590410; Gilger B.C., 2013, VET OPHTHALMOLOGY; GRIMES P, 1964, INVEST OPHTH VISUAL, V3, P566; HAMMING NA, 1977, INVEST OPHTH VIS SCI, V16, P408; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herman EH, 1996, TOXICOLOGY, V110, P71, DOI 10.1016/0300-483X(96)03337-9; HORSBURGH GM, 1987, J COMP NEUROL, V263, P553, DOI 10.1002/cne.902630407; Hubmacher D, 2014, INVEST OPHTH VIS SCI, V55, P7934, DOI 10.1167/iovs.14-15453; Inagaki K, 2014, COMPARATIVE MED, V64, P34; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289; Jahnukainen K, 2001, CANCER RES, V61, P6423; Jobling Andrew I, 2002, Clin Exp Optom, V85, P61; Joyce NC, 1998, INVEST OPHTH VIS SCI, V39, P2572; Kuhrt H, 2012, PROG RETIN EYE RES, V31, P605, DOI 10.1016/j.preteyeres.2012.08.001; Kuszak JR, 1996, MICROSC RES TECHNIQ, V33, P441, DOI 10.1002/(SICI)1097-0029(19960415)33:6<441::AID-JEMT1>3.0.CO;2-O; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P725; Laemle LK, 1999, DEV BRAIN RES, V112, P129, DOI 10.1016/S0165-3806(98)00153-9; LAI YL, 1972, EXP EYE RES, V14, P203, DOI 10.1016/0014-4835(72)90004-8; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj/cdd/4400989; Lang RA, 1997, CELL DEATH DIFFER, V4, P12, DOI 10.1038/sj.cdd.4400211; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; Liebler DC, 2005, NAT REV DRUG DISCOV, V4, P410, DOI 10.1038/nrd1720; Linden R, 1999, PROG RETIN EYE RES, V18, P133, DOI 10.1016/S1350-9462(98)00020-2; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; LING TL, 1988, DEV BRAIN RES, V44, P73, DOI 10.1016/0165-3806(88)90119-8; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Mann I., 1964, DEV HUMAN EYE; MCMENAMIN PG, 1991, EXP EYE RES, V53, P507, DOI 10.1016/0014-4835(91)90168-E; MCMENAMIN PG, 1989, CURR EYE RES, V8, P727, DOI 10.3109/02713688909025808; Meeson A, 1996, DEVELOPMENT, V122, P3929; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; Parker G. A., 2016, ATLAS HISTOLOGY JUVE; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; Qi Y, 1991, Zhonghua Yan Ke Za Zhi, V27, P295; REME C, 1983, GRAEF ARCH CLIN EXP, V221, P113, DOI 10.1007/BF02133849; REME C, 1981, DOC OPHTHALMOL, V51, P241, DOI 10.1007/BF00143888; Remick AK, 2015, TOXICOL PATHOL, V43, P1166, DOI 10.1177/0192623315595883; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SAMUELSON DA, 1984, CURR EYE RES, V3, P783, DOI 10.3109/02713688409000790; Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sevel D, 1988, Trans Am Ophthalmol Soc, V86, P178; Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216; SHIVELY JN, 1971, AM J VET RES, V32, P383; Sinha D, 2005, EXP EYE RES, V80, P323, DOI 10.1016/j.exer.2004.09.014; SMELSER GK, 1974, INVEST OPHTH VISUAL, V13, P340; SMELSER GK, 1971, AM J OPHTHALMOL, V71, P366, DOI 10.1016/0002-9394(71)90412-0; Smith R S, 2001, BMC Dev Biol, V1, P3, DOI 10.1186/1471-213X-1-3; Soellner L, 2013, REGUL TOXICOL PHARM, V65, P87, DOI 10.1016/j.yrtph.2012.10.010; Song J, 2003, INVEST OPHTH VIS SCI, V44, P548, DOI 10.1167/iovs.02-0592; STROEVA OG, 1983, INT REV CYTOL, V83, P221, DOI 10.1016/S0074-7696(08)61689-7; Verhaegen S., 1998, ASIA PACIFIC MICROS, V1, P15; Voyvodic JT, 1995, EUR J NEUROSCI, V7, P2469, DOI 10.1111/j.1460-9568.1995.tb01045.x; WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0; WEILL JC, 1979, MOL BIOL REP, V4, P207; Wride MA, 2011, PHILOS T R SOC B, V366, P1219, DOI 10.1098/rstb.2010.0324; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; Zandy AJ, 2005, J BIOL CHEM, V280, P30263, DOI 10.1074/jbc.M504007200; Zhu MD, 2000, EXP EYE RES, V70, P767, DOI 10.1006/exer.2000.0844; Zieske JD, 2004, INT J DEV BIOL, V48, P903, DOI 10.1387/ijdb.041860jz; ZIESKE JD, 1993, J CELL SCI, V106, P145	97	5	5	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					310	330		10.1177/0300985817738098			21	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300018	29157192	Bronze			2019-10-28	
J	Berman-Booty, LD; Eraslan, R; Hanumegowda, U; Cantor, GH; Bounous, DI; Janovitz, EB; Jones, BK; Buiakova, O; Hayward, M; Wee, S				Berman-Booty, Lisa D.; Eraslan, Rukiye; Hanumegowda, Umesh; Cantor, Glenn H.; Bounous, Denise I.; Janovitz, Evan B.; Jones, Beverly K.; Buiakova, Olesia; Hayward, Michael; Wee, Susan			Systemic Loss of C-terminal Src Kinase Expression Elicits Spontaneous Suppurative Inflammation in Conditional Knockout Mice	VETERINARY PATHOLOGY			English	Article						C-terminal Src kinase; enteritis; inducible knockout mouse; heart; immune modulation; inflammation; intestine; lung; pneumonia; tamoxifen	FAMILY KINASES; CONSTITUTIVE ACTIVATION; CELL DEVELOPMENT; CSK; GENE; HCK	C-terminal Src kinase (Csk) is one of the critical negative regulators of the Src family of kinases. The Src family of kinases are nonreceptor tyrosine kinases that regulate inflammation, cell proliferation, motility, and adhesion. To investigate potential histologic lesions associated with systemic loss of Csk gene activity in adult mice, conditional Csk-knockout mice were examined. Cre-mediated systemic excision of Csk induced by tamoxifen treatment resulted in multiorgan inflammation. Specifically, induction of Csk gene excision with three days of tamoxifen treatment resulted in greater than 90% gene excision. Strikingly, these mice developed enteritis that ranged from minimal and suppurative to severe, fibrinonecrosuppurative and hemorrhagic. Other inflammatory lesions included suppurative pneumonia, gastritis, and myocarditis, and increased numbers of inflammatory cells within the hepatic parenchyma. When tamoxifen treatment was reduced from three days to one day in an effort to lower the level of Csk gene excision and limit lesion development, the mice developed severe suppurative to pyogranulomatous pneumonia and minimal to mild suppurative enteritis. Lesions observed secondary to Csk gene excision suggest important roles for Csk in downregulating the proinflammatory activity of the Src family of kinases and limiting neutrophil-mediated inflammation.	[Berman-Booty, Lisa D.; Eraslan, Rukiye; Hanumegowda, Umesh; Cantor, Glenn H.; Bounous, Denise I.; Janovitz, Evan B.; Wee, Susan] Bristol Myers Squibb Co, Princeton, NJ USA; [Eraslan, Rukiye; Jones, Beverly K.; Buiakova, Olesia; Hayward, Michael] Invivotek, Hamilton, NJ USA; [Hanumegowda, Umesh] ViiV Healthcare, Wallingford, CT USA	Berman-Booty, LD (reprint author), 311 Pennington Rocky Hill Rd, Pennington, NJ 08534 USA.	Lisa.Berman-Booty@bms.com			Bristol-Myers SquibbBristol-Myers Squibb	These studies were supported by Bristol-Myers Squibb.	Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Ernst M, 2002, J EXP MED, V196, P589, DOI 10.1084/jem.20020873; Futosi K, 2016, IMMUNOL REV, V273, P121, DOI 10.1111/imr.12455; Gauld SB, 2004, ONCOGENE, V23, P8001, DOI 10.1038/sj.onc.1208075; Geahlen RL, 2004, ONCOGENE, V23, P8024, DOI 10.1038/sj.onc.1208078; Honda K, 2007, CARCINOGENESIS, V28, P2074, DOI 10.1093/carcin/bgm112; Imada S, 2016, MOL CELL BIOL, V36, P2811, DOI 10.1128/MCB.00311-16; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Lee KY, 2013, DIABETES, V62, P864, DOI 10.2337/db12-1089; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Manz BN, 2015, ELIFE, V4, DOI 10.7554/eLife.08088; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Okutani D, 2006, AM J PHYSIOL-LUNG C, V291, pL129, DOI 10.1152/ajplung.00261.2005; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; Thomas RM, 2004, IMMUNITY, V20, P181, DOI 10.1016/S1074-7613(04)00023-8; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Wilson CH, 2014, ONCOGENE, V33, P4877, DOI 10.1038/onc.2014.78; Yagi R, 2007, EMBO J, V26, P1234, DOI 10.1038/sj.emboj.7601595	23	1	1	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					331	340		10.1177/0300985817747330			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300019	29338616	Bronze			2019-10-28	
J	Sedic, M; Senn, JJ; Lynn, A; Laska, M; Smith, M; Platz, SJ; Bolen, J; Hoge, S; Bulychev, A; Jacquinet, E; Bartlett, V; Smith, PF				Sedic, Maja; Senn, Joseph J.; Lynn, Andy; Laska, Michael; Smith, Mike; Platz, Stefan J.; Bolen, Joseph; Hoge, Stephen; Bulychev, Alex; Jacquinet, Eric; Bartlett, Victoria; Smith, Peter F.			Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey	VETERINARY PATHOLOGY			English	Article						modified mRNA; lipid nanoparticle; toxicology; pharmacokinetics; drug discovery	SIRNA DELIVERY; MICE; EXPRESSION; THERAPY; ERYTHROPOIETIN; THERAPEUTICS; PROTEINS; DNA	The pharmacology, pharmacokinetics, and safety of modified mRNA formulated in lipid nanoparticles (LNPs) were evaluated after repeat intravenous infusion to rats and monkeys. In both species, modified mRNA encoding the protein for human erythropoietin (hEPO) had predictable and consistent pharmacologic and toxicologic effects. Pharmacokinetic analysis conducted following the first dose showed that measured hEPO levels were maximal at 6 hours after the end of intravenous infusion and in excess of 100-fold the anticipated efficacious exposure (17.6 ng/ml) at the highest dose tested.(24) hEPO was pharmacologically active in both the rat and the monkey, as indicated by a significant increase in red blood cell mass parameters. The primary safety-related findings were caused by the exaggerated pharmacology of hEPO and included increased hematopoiesis in the liver, spleen, and bone marrow (rats) and minimal hemorrhage in the heart (monkeys). Additional primary safety-related findings in the rat included mildly increased white blood cell counts, changes in the coagulation parameters at all doses, as well as liver injury and release of interferon gamma-inducible protein 10 in high-dose groups only. In the monkey, as seen with the parenteral administration of cationic LNPs, splenic necrosis and lymphocyte depletion were observed, accompanied with mild and reversible complement activation. These findings defined a well-tolerated dose level above the anticipated efficacious dose. Overall, these combined studies indicate that LNP-formulated modified mRNA can be administered by intravenous infusion in 2 toxicologically relevant test species and generate supratherapeutic levels of protein (hEPO) in vivo.	[Sedic, Maja; Senn, Joseph J.; Lynn, Andy; Laska, Michael; Smith, Mike; Hoge, Stephen; Bulychev, Alex; Jacquinet, Eric] Moderna Therapeut, 200 Technol Sq, Cambridge, MA 02139 USA; [Platz, Stefan J.] AstraZeneca, Melbourn, Royston, England; [Bolen, Joseph] PureTech Hlth, Boston, MA USA; [Bartlett, Victoria] Akcea Therapeut, Cambridge, MA USA; [Smith, Peter F.] Alnylam Pharmaceut Inc, Cambridge, MA USA	Senn, JJ (reprint author), Moderna Therapeut, 200 Technol Sq, Cambridge, MA 02139 USA.	Joe.Senn@modernatx.com			Moderna; AstraZenecaAstraZeneca	The author(s) received the following financial support for the research, authorship, and/or publication of this article: Moderna and AstraZeneca provided financing for this project.	Andrews DA, 2014, TOXICOL PATHOL, V42, P524, DOI 10.1177/0192623313486319; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; Barros SA, 2012, ADV DRUG DELIVER REV, V64, P1730, DOI 10.1016/j.addr.2012.06.007; Casadevall N, 2003, NEPHROL DIAL TRANSPL, V18, P37, DOI 10.1093/ndt/gfg1091; Christensen J, 2014, DRUG METAB DISPOS, V42, P431, DOI 10.1124/dmd.113.055434; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247; Frost H, 2005, TOXICOLOGY, V209, P155, DOI 10.1016/j.tox.2004.12.028; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612; Gilmore Ian R., 2006, Current Drug Delivery, V3, P147, DOI 10.2174/156720106776359159; Islam MA, 2015, BIOMATER SCI-UK, V3, P1519, DOI 10.1039/c5bm00198f; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399; Martins R, 2014, J CHROMATOGR A, V1355, P1, DOI 10.1016/j.chroma.2014.05.075; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Sorgel Fritz, 2009, BMC Clin Pharmacol, V9, P10, DOI 10.1186/1472-6904-9-10; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Tsongalis GJ, 2006, AM J CLIN PATHOL, V126, P448, DOI 10.1039/90BU6KDXANFLN4RJ; Wang YH, 2013, MOL THER, V21, P358, DOI 10.1038/mt.2012.250; Xue HY, 2015, CURR PHARM DESIGN, V21, P3140, DOI 10.2174/1381612821666150531164540; Zangi L, 2013, NAT BIOTECHNOL, V31, P898, DOI 10.1038/nbt.2682; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	30	12	12	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					341	354		10.1177/0300985817738095			14	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300020	29191134	Bronze			2019-10-28	
J	Bell, TM; Shaia, CI; Bearss, JJ				Bell, T. M.; Shaia, C., I; Bearss, J. J.			Temporal progression of lesions in guinea pigs infected with Lassa virus (vol 54, pg 549, 2017)	VETERINARY PATHOLOGY			English	Correction												Shaia, Carl/X-3555-2019	Shaia, Carl/0000-0001-8907-8821			Bell TM, 2017, VET PATHOL, V54, P549, DOI 10.1177/0300985816677153	1	0	0	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAR	2018	55	2					355	355		10.1177/0300985817753418			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GA7KF	WOS:000428514300021		Bronze			2019-10-28	
J	Ohe, C; Smith, SC; Sirohi, D; Divatia, M; de Peralta-Venturina, M; Paner, GP; Agaimy, A; Amin, MB; Argani, P; Chen, YB; Cheng, L; Colecchia, M; Comperat, E; da Cunha, IW; Epstein, JI; Gill, AJ; Hes, O; Hirsch, MS; Jochum, W; Kunju, LP; Maclean, F; Magi-Galluzzi, C; McKenney, JK; Mehra, R; Nesi, G; Osunkoya, AO; Picken, MM; Rao, P; Reuter, VE; Salles, PGD; Schultz, L; Tickoo, SK; Tomlins, SA; Trpkov, K; Amin, MB				Ohe, Chisato; Smith, Steven C.; Sirohi, Deepika; Divatia, Mukul; de Peralta-Venturina, Mariza; Paner, Gladell P.; Agaimy, Abbas; Amin, Mitual B.; Argani, Pedram; Chen, Ying-Bei; Cheng, Liang; Colecchia, Maurizio; Comperat, Eva; da Cunha, Isabela Werneck; Epstein, Jonathan I.; Gill, Anthony J.; Hes, Ondrej; Hirsch, Michelle S.; Jochum, Wolfram; Kunju, Lakshmi P.; Maclean, Fiona; Magi-Galluzzi, Cristina; McKenney, Jesse K.; Mehra, Rohit; Nesi, Gabriella; Osunkoya, Adeboye O.; Picken, Maria M.; Rao, Priya; Reuter, Victor E.; de Oliveira Salles, Paulo Guilherme; Schultz, Luciana; Tickoo, Satish K.; Tomlins, Scott A.; Trpkov, Kiril; Amin, Mahul B.			Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						renal medullary carcinoma; collecting duct carcinoma; FH-deficient renal cell carcinoma; hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma; morphology	HEREDITARY LEIOMYOMATOSIS; INTERNATIONAL-SOCIETY; UTERINE LEIOMYOMAS; KIDNEY TUMORS; EXPRESSION; FH; IMMUNOHISTOCHEMISTRY; MUTATIONS; CANCER; PAX8	Renal medullary carcinomas (RMCs) and collecting duct carcinomas (CDCs) are rare subsets of lethal high-stage, high-grade distal nephron-related adenocarcinomas with a predilection for the renal medullary region. Recent findings have established an emerging group of fumarate hydratase (FH)-deficient tumors related to hereditary leiomyomatosis and renal cell carcinoma (HLRCC-RCCs) syndrome within this morphologic spectrum. Recently developed, reliable ancillary testing has enabled consistent separation between these tumor types. Here, we present the clinicopathologic features and differences in the morphologic patterns between RMC, CDC, and FH-deficient RCC in consequence of these recent developments. This study included a total of 100 cases classified using contemporary criteria and ancillary tests. Thirty-three RMCs (SMARCB1/INI1-deficient, hemoglobinopathy), 38 CDCs (SMARCB1/INI1-retained), and 29 RCCs defined by the FH-deficient phenotype (FH-/2SC(+) or FH +/-/2SC(+) with FH mutation, regardless of HLRCC syndromic stigmata/history) were selected. The spectrum of morphologic patterns was critically evaluated, and the differences between the morphologic patterns present in the 3 groups were analyzed statistically. Twenty-five percent of cases initially diagnosed as CDC were reclassified as FH-deficient RCC on the basis of our contemporary diagnostic approach. Among the different overlapping morphologic patterns, sieve-like/cribriform and reticular/yolk sac tumor-like patterns favored RMCs, whereas intracystic papillary and tubulocystic patterns favored FH-deficient RCC. The tubulopapillary pattern favored both CDCs and FH-deficient RCCs, and the multinodular infiltrating papillary pattern favored CDCs. Infiltrating glandular and solid sheets/cords/nested patterns were not statistically different among the 3 groups. Viral inclusion-like macronucleoli, considered as a hallmark of HLRCC-RCCs, were observed significantly more frequently in FH-deficient RCCs. Despite the overlapping morphology found among these clinically aggressive infiltrating high-grade adenocarcinomas of the kidney, reproducible differences in morphology emerged between these categories after rigorous characterization. Finally, we recommend that definitive diagnosis of CDC should only be made if RMC and FH-deficient RCC are excluded.	[Ohe, Chisato; Sirohi, Deepika; de Peralta-Venturina, Mariza; Amin, Mahul B.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Smith, Steven C.] VCU Sch Med, Dept Pathol & Urol, Richmond, VA USA; [Divatia, Mukul] Cornell Univ, Dept Pathol, Houston Methodist Hosp, Weill Med Coll, Houston, TX USA; [Rao, Priya] MD Anderson Canc Ctr, Houston, TX USA; [Paner, Gladell P.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Picken, Maria M.] Loyola Univ, Dept Pathol, Maywood, IL 60153 USA; [Amin, Mitual B.] William Beaumont Hosp, Royal Oak, MI 48072 USA; [Kunju, Lakshmi P.; Mehra, Rohit] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Kunju, Lakshmi P.; Mehra, Rohit] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Argani, Pedram; Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; [Chen, Ying-Bei; Reuter, Victor E.; Tickoo, Satish K.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Cheng, Liang] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Hirsch, Michelle S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Magi-Galluzzi, Cristina; McKenney, Jesse K.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Osunkoya, Adeboye O.] Emory Univ, Sch Med, Atlanta, GA USA; [Amin, Mahul B.] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med & Urol, Memphis, TN 38163 USA; [Agaimy, Abbas] Friedrich Alexander Univ, Inst Pathol, Erlangen, Germany; [Colecchia, Maurizio] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy; [Nesi, Gabriella] Univ Florence, Div Pathol Anat, Florence, Italy; [Comperat, Eva] UPMC Paris VI, Hop Tenon, AP HP, Dept Pathol, Paris, France; [da Cunha, Isabela Werneck] AC Camargo Canc Ctr, Dept Pathol, Sao Paulo, Brazil; [de Oliveira Salles, Paulo Guilherme] Hosp Luxemburgo, Mario Penna Inst, Anat Pathol, Belo Horizonte, MG, Brazil; [Schultz, Luciana] Inst Pathol Anat, Piracicaba, Brazil; [Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, Sydney, NSW, Australia; [Gill, Anthony J.] Univ Sydney, Sydney, NSW, Australia; [Maclean, Fiona] Douglass Hanly Moir Pathol, Sydney, NSW, Australia; [Hes, Ondrej] Charles Univ Hosp, Plzen, Czech Republic; [Jochum, Wolfram] Kantonsspital, Inst Pathol, St Gallen, Switzerland; [Trpkov, Kiril] Univ Calgary, Calgary Lab Serv, Calgary, AB, Canada	Amin, MB (reprint author), Univ Tennessee, Dept Pathol & Lab Med, Hlth Sci Ctr, 930 Madison Ave,Suite 531, Memphis, TN 38163 USA.	mamin5@uthsc.edu	Cunha, Isabela/H-3013-2012; Gill, Anthony J./M-5015-2019; Colecchia, Maurizio/C-2745-2017	Cunha, Isabela/0000-0002-2029-5139; Colecchia, Maurizio/0000-0003-1914-0743	A. Alfred Taubman Medical Research Institute; Charles University Research Fund [P36]; European Regional Development FundEuropean Union (EU) [CZ.1.05/2.1.00/03.0076]; Uehara Memorial FoundationUehara Memorial Foundation	S.A.T is supported by the A. Alfred Taubman Medical Research Institute. O.H. acknowledges support of the Charles University Research Fund (project number P36) and by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund. C.O. received research fellowship training support from the Uehara Memorial Foundation. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Amin MB, 2014, AM J SURG PATHOL, V38, P871, DOI 10.1097/PAS.0000000000000222; Amin MB, 1997, ADV ANAT PATHOL, V4, P85; Amin MB, 2016, WHO CLASSIFICATION T, P31; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Calderaro J, 2012, HISTOPATHOLOGY, V61, P428, DOI 10.1111/j.1365-2559.2012.04228.x; Carvalho JC, 2012, HISTOPATHOLOGY, V60, P597, DOI 10.1111/j.1365-2559.2011.04093.x; Chen YB, 2015, MOD PATHOL S2, V28, p211A; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Elwood H, 2011, UROLOGY, V78, DOI 10.1016/j.urology.2011.04.043; Fleming S, 2016, WHO CLASSIFICATION T, P29; Gupta R, 2012, AM J SURG PATHOL, V36, P1265, DOI 10.1097/PAS.0b013e3182635954; John Nitin, 2010, Oman Med J, V25, P3, DOI 10.5001/omj.2010.2; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Karakiewicz PI, 2007, EUR UROL, V52, P1140, DOI 10.1016/j.eururo.2007.01.070; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Lehtonen HJ, 2011, FAM CANCER, V10, P397, DOI 10.1007/s10689-011-9428-z; Li G, 2005, EJSO-EUR J SURG ONC, V31, P299, DOI 10.1016/j.ejso.2004.11.009; Liu QY, 2013, AM J SURG PATHOL, V37, P368, DOI 10.1097/PAS.0b013e3182770406; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Merino MJ, 2016, WHO CLASSIFICATION T, P25; Nagai R, 2007, J BIOL CHEM, V282, P34219, DOI 10.1074/jbc.M703551200; Otero KL, 2014, MODERN PATHOL, V27, p243A; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Rao P, 2012, AM J SURG PATHOL, V36, P583, DOI 10.1097/PAS.0b013e3182417d78; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Rocca PC, 2007, MODERN PATHOL, V20, P722, DOI 10.1038/modpathol.3800828; Sirohi D, 2017, HUM PATHOL, V67, P134, DOI 10.1016/j.humpath.2017.07.006; Smith S, 2015, MODERN PATHOL, V28, p260A; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Swartz MA, 2002, UROLOGY, V60, P1083, DOI 10.1016/S0090-4295(02)02154-4; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Vocke CD, 2017, GENE CHROMOSOME CANC, V56, P484, DOI 10.1002/gcc.22452; Watanabe IC, 2007, MODERN PATHOL, V20, P914, DOI 10.1038/modpathol.3800934; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506	43	19	20	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					279	292		10.1097/PAS.0000000000001000			14	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600002	29309300				2019-10-28	
J	Ferrufino-Schmidt, MC; Medeiros, LJ; Liu, H; Clemens, MW; Hunt, KK; Laurent, C; Lofts, J; Amin, MB; Chai, SM; Morine, A; Di Napoli, A; Dogan, A; Parkash, V; Bhagat, G; Tritz, D; Quesada, AE; Pina-Oviedo, S; Hu, QL; Garcia-Gomez, FJ; Borrero, JJ; Horna, P; Thakral, B; Narbaitz, M; Hughes, RC; Yang, LJ; Fromm, JR; Wu, D; Zhang, D; Sohani, AR; Hunt, J; Vadlamani, IU; Morgan, EA; Ferry, JA; Szigeti, R; Tardio, JC; Granados, R; Dertinger, S; Offner, FA; Pircher, A; Hosry, J; Young, KH; Miranda, RN				Ferrufino-Schmidt, Maria C.; Medeiros, L. Jeffrey; Liu, Hui; Clemens, Mark W.; Hunt, Kelly K.; Laurent, Camille; Lofts, Julian; Amin, Mitual B.; Chai, Siaw Ming; Morine, Angela; Di Napoli, Arianna; Dogan, Ahmet; Parkash, Vinita; Bhagat, Govind; Tritz, Denise; Quesada, Andres E.; Pina-Oviedo, Sergio; Hu, Qinlong; Garcia-Gomez, Francisco J.; Borrero, Juan Jose; Horna, Pedro; Thakral, Beenu; Narbaitz, Marina; Hughes, R. Condon, III; Yang, Li-Jun; Fromm, Jonathan R.; Wu, David; Zhang, Da; Sohani, Aliyah R.; Hunt, John; Vadlamani, Indira U.; Morgan, Elizabeth A.; Ferry, Judith A.; Szigeti, Reka; Tardio, Juan C.; Granados, Rosario; Dertinger, Susanne; Offner, Felix A.; Pircher, Andreas; Hosry, Jeff; Young, Ken H.; Miranda, Roberto N.			Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast implant; ALCL; T-cell lymphoma; CD30; Hodgkin lymphoma; anaplastic large cell lymphoma; lymph node involvement	OF-THE-LITERATURE; UNIQUE ENTITY; MANAGEMENT; DIAGNOSIS; PATHOLOGY; SPECTRUM; CAPSULE	Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare T-cell lymphoma that arises around breast implants. Most patients manifest with periprosthetic effusion, whereas a subset of patients develops a tumor mass or lymph node involvement (LNI). The aim of this study is to describe the pathologic features of lymph nodes from patients with BI-ALCL and assess the prognostic impact of LNI. Clinical findings and histopathologic features of lymph nodes were assessed in 70 patients with BI-ALCL. LNI was defined by the histologic demonstration of ALCL in lymph nodes. Fourteen (20%) patients with BI-ALCL had LNI, all lymph nodes involved were regional, the most frequent were axillary (93%). The pattern of involvement was sinusoidal in 13 (92.9%) cases, often associated with perifollicular, interfollicular, and diffuse patterns. Two cases had Hodgkin-like patterns. The 5-year overall survival was 75% for patients with LNI and 97.9% for patients without LNI at presentation (P = 0.003). Six of 49 (12.2%) of patients with tumor confined by the capsule had LNI, compared with LNI in 8/21 (38%) patients with tumor beyond the capsule. Most patients with LNI achieved complete remission after various therapeutic approaches. Two of 14 (14.3%) patients with LNI died of disease compared with 0/56 (0%) patients without LNI. Twenty percent of patients with BI-ALCL had LNI by lymphoma, most often in a sinusoidal pattern. We conclude that BI-ALCL beyond capsule is associated with a higher risk of LNI. Involvement of lymph nodes was associated with decreased overall survival. Misdiagnosis as Hodgkin lymphoma is a pitfall.	[Ferrufino-Schmidt, Maria C.; Medeiros, L. Jeffrey; Quesada, Andres E.; Thakral, Beenu; Young, Ken H.; Miranda, Roberto N.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Unit 072, Houston, TX 77030 USA; [Clemens, Mark W.] Univ Texas MD Anderson Canc Ctr, Dept Plast Surg, Houston, TX 77030 USA; [Hunt, Kelly K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Breast Oncol, Houston, TX 77030 USA; [Hosry, Jeff] Univ Texas Hlth Sci Ctr Houston, Dept Infect Dis, Houston, TX 77030 USA; [Szigeti, Reka] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Ferrufino-Schmidt, Maria C.] Cayetano Heredia Univ, Lima, Peru; [Liu, Hui] Xuzhou Med Univ, Dept Pathol, Xuzhou, Jiangsu, Peoples R China; [Laurent, Camille] Univ Inst Canc Oncopole, Dept Pathol, CHU Purpan, Toulouse, France; [Morine, Angela] Middlemore Hosp, Auckland, New Zealand; [Lofts, Julian] Plast Surg, Auckland, New Zealand; [Amin, Mitual B.] Oakland Univ, Dept Pathol & Lab Med, William Beaumont Sch Med, Royal Oak, MI USA; [Chai, Siaw Ming] QEII Med Ctr, Dept Anat Pathol, PathWest Lab Med, Perth, WA, Australia; [Di Napoli, Arianna] Sapienza Univ Rome, Sch Med & Psychol, Dept Clin & Mol Med, Pathol Unit,St Andrea Hosp, Rome, Italy; [Dogan, Ahmet] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Bhagat, Govind] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY USA; [Bhagat, Govind] New York Presbyterian Hosp, New York, NY USA; [Parkash, Vinita] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Parkash, Vinita] Bridgeport Hosp, New Haven, CT USA; [Tritz, Denise] SSM Hlth, St Marys Hosp Jefferson City, Jefferson City, MO USA; [Pina-Oviedo, Sergio] Univ Arkansas Med Sci, Dept Pathol & Lab Serv, Little Rock, AR 72205 USA; [Hu, Qinlong] Tucson Pathol Associates, PC Carondelet St Joseph Hosp, Tucson, AZ USA; [Garcia-Gomez, Francisco J.] Virgen Macarena Univ Hosp, Dept Nucl Med, Seville, Spain; [Borrero, Juan Jose] Virgen del Rocio Univ Hosp, Dept Anat Pathol, Seville, Spain; Univ Hosp Fuenlabrada, Dept Pathol, Madrid, Spain; [Granados, Rosario] Univ Hosp Getafe, Madrid, Spain; [Horna, Pedro] Mayo Clin, Div Hematopathol, Dept Lab Med & Pathol, Rochester, MN USA; [Narbaitz, Marina] Acad Med, Dept Pathol, Inst Invest Hematol, Buenos Aires, DF, Argentina; [Narbaitz, Marina] FUNDALEU, Buenos Aires, DF, Argentina; [Hughes, R. Condon, III] Diagnost Tissue Cytol Grp, Meridian, MS USA; [Yang, Li-Jun] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Fromm, Jonathan R.; Wu, David] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Zhang, Da] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, MO USA; [Vadlamani, Indira U.] St Joseph Med Ctr, Kansas City, MO USA; [Sohani, Aliyah R.; Ferry, Judith A.] Massachusetts Gen Hosp, Dept Pathol, Springfield, MA USA; [Sohani, Aliyah R.; Ferry, Judith A.] Harvard Med Sch, Springfield, MA USA; [Morgan, Elizabeth A.] Brigham & Womens Hosp, Dept Pathol, Springfield, MA USA; [Hunt, John] Baystate Hlth, Dept Pathol, Springfield, MA USA; [Dertinger, Susanne; Offner, Felix A.] Acad Teaching Hosp Feldkirch, Dept Pathol, Feldkirch, Austria; Med Univ Innsbruck, Dept Hematol & Oncol, Innsbruck, Austria	Miranda, RN (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Unit 072, Houston, TX 77030 USA.	roberto.miranda@mdanderson.org	Gomez, Francisco Javier Garcia/D-2553-2015; Medeiros, L. Jeffrey/AAB-1018-2019; Gomez, Francisco Javier Garcia/W-2864-2019; Pircher, Andreas/L-2150-2019	Gomez, Francisco Javier Garcia/0000-0001-9307-5017; Gomez, Francisco Javier Garcia/0000-0001-9307-5017; laurent, camille/0000-0002-5375-7512; Bhagat, Govind/0000-0001-6250-048X; Borrero, Juan Jose/0000-0003-4776-1061; Ferrufino-Schmidt, Maria C./0000-0001-9303-6448			Acevedo-Banez Irene, 2015, Br J Haematol, V169, P1, DOI 10.1111/bjh.13268; Admirand JH, 2004, MODERN PATHOL, V17, P954, DOI 10.1038/modpathol.3800145; Aladily TN, 2012, AM J SURG PATHOL, V36, P1000, DOI 10.1097/PAS.0b013e31825749b1; Alobeid B, 2009, LEUKEMIA LYMPHOMA, V50, P831, DOI 10.1080/10428190902795527; Bautista-Quach MA, 2013, CLIN BREAST CANCER, V13, P492, DOI 10.1016/j.clbc.2013.08.009; Carty MJ, 2011, PLAST RECONSTR SURG, V128, p112E, DOI 10.1097/PRS.0b013e318221db96; Chai SM, 2014, DIAGN CYTOPATHOL, V42, P929, DOI 10.1002/dc.23152; Clemens MW, 2017, AESTHET SURG J, V37, P285, DOI 10.1093/asj/sjw259; Clemens MW, 2016, J CLIN ONCOL, V34, P160, DOI 10.1200/JCO.2015.63.3412; di Pompeo SF, 2015, PLAST RECONSTR SURG, V136, p144E, DOI 10.1097/PRS.0000000000001416; Doren EL, 2017, PLAST RECONSTR SURG, V139, P1042, DOI 10.1097/PRS.0000000000003282; Estes CF, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00026; Farkash Evan A, 2009, J Hematop, V2, P237, DOI 10.1007/s12308-009-0043-y; Feldman AL, 2017, WHO CLASSIFICATION T, P421; George EV, 2013, INT J CLIN EXP PATHO, V6, P1631; Ivaldi C, 2013, ANN CHIR PLAST ESTH, V58, P688, DOI 10.1016/j.anplas.2013.04.003; Kanungo A, 2006, MODERN PATHOL, V19, P25, DOI 10.1038/modpathol.3800500; Katzin WE, 2005, AM J SURG PATHOL, V29, P506, DOI 10.1097/01.pas.0000155145.60670.e4; Keech JA, 1997, PLAST RECONSTR SURG, V100, P554, DOI 10.1097/00006534-199708000-00065; Laurent C, 2016, ANN ONCOL, V27, P306, DOI 10.1093/annonc/mdv575; Locke MB, 2017, ANZ J SURG, V87, P789, DOI 10.1111/ans.13074; Miranda RM, 2018, DIAGNOSTIC PATHOLOGY, P634; Miranda RN, 2014, J CLIN ONCOL, V32, P114, DOI 10.1200/JCO.2013.52.7911; Miranda RN, 2009, ARCH PATHOL LAB MED, V133, P1383, DOI 10.1043/1543-2165-133.9.1383; Olack B, 2007, ANN PLAS SURG, V59, P56, DOI 10.1097/SAP.0b013e31804d442e; Popplewell L, 2011, LEUKEMIA LYMPHOMA, V52, P1481, DOI 10.3109/10428194.2011.574755; Story SK, 2013, ONCOLOGIST, V18, P301, DOI 10.1634/theoncologist.2012-0238; Talagas M, 2014, ACTA CYTOL, V58, P103, DOI 10.1159/000355861; Tardio JC, 2015, INT J SURG PATHOL, V23, P424, DOI 10.1177/1066896915579103; Taylor KO, 2012, PLAST RECONSTR SURG, V129, p610E, DOI 10.1097/PRS.0b013e3182450aae; Thompson PA, 2013, CURR HEMATOL MALIG R, V8, P196, DOI 10.1007/s11899-013-0164-3; Vega F, 2001, AM J CLIN PATHOL, V116, P17; Weathers WM, 2013, CAN J PLAST SURG, V21, P95, DOI 10.1177/229255031302100209	33	15	15	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					293	305		10.1097/PAS.0000000000000985			13	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600003	29194092				2019-10-28	
J	Kohashi, K; Yamamoto, H; Yamada, Y; Kinoshita, I; Taguchi, T; Iwamoto, Y; Oda, Y				Kohashi, Kenichi; Yamamoto, Hidetaka; Yamada, Yuichi; Kinoshita, Izumi; Taguchi, Tomoaki; Iwamoto, Yukihide; Oda, Yoshinao			SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						epithelioid sarcoma; SWI/SNF chromatin-remodeling complex; SMARCB1/INI1; malignant rhabdoid tumor	MALIGNANT RHABDOID TUMOR; PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; PROTEIN EXPRESSION; INI1 EXPRESSION; USEFUL TOOL; CANCER; INACTIVATION; CARCINOMA; FEATURES; TRACT	The SWI/SNF chromatin-remodeling complex, which is composed of evolutionarily conserved core subunits such as SMARCB1/INI1 (INI1), SMARCA4/BRG1 (BRG1), SMARCC1/BAF155 (BAF155), and SMARCC2/BAF170 (BAF170), can be viewed as the prototype of an epigenetic regulator of gene expression that is involved in tumor suppression. Epithelioid sarcoma, which classified as a tumor of uncertain differentiation, shows an almost complete loss of INI1. However, some cases of epithelioid sarcoma have preserved INI1, and the clinicopathologic features of these cases are uncertain. To date, there has been no investigation focused on the SWI/SNF chromatin-remodeling complex in INI1-preserved epithelioid sarcoma cases. First, an investigation of INI1 immunoexpression statuses in 60 formalin-fixed paraffin-embedded epithelioid sarcoma specimens (proximal type, 29 cases; conventional type, 31 cases) was performed. In the available INI1-preserved epithelioid sarcoma cases, we analyzed the BRG1, BAF155, and BAF170 protein expressions. INI1 preservation was observed in 6 of 29 (21%) proximal-type and 2 of 31 (6%) conventional-type epithelioid sarcoma cases. Six cases of INI1-preserved epithelioid sarcomas of proximal type were available for further immunohistochemical study. One proximal type showed loss of BAF170, and 2 proximal-type cases revealed loss of BRG1 with preservation of the other remaining core subunit proteins. One proximal-type case showed a mosaic pattern of BRG1 and loss of BAF155. However, in the remaining 2 proximal-type cases, all core subunit proteins were preserved. Overall, these results suggest that loss of expression of SWI/SNF chromatin-remodeling complex proteins has an important role in tumorigenesis. The remaining 2 INI1-preserved epithelioid sarcoma cases may have had other abnormalities causing dysfunction of SWI/SNF chromatin remodeling.	[Kohashi, Kenichi; Yamamoto, Hidetaka; Yamada, Yuichi; Kinoshita, Izumi; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan; [Taguchi, Tomoaki] Kyushu Univ, Grad Sch Med Sci, Dept Pediat Surg, Fukuoka, Japan; [Iwamoto, Yukihide] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Pathol Sci Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25293088, 26460435]	Supported by JSPS KAKENHI Grant Numbers 25293088 and 26460435.	Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Agaimy A, 2016, VIRCHOWS ARCH, V469, P321, DOI 10.1007/s00428-016-1977-y; Agaimy A, 2016, AM J SURG PATHOL, V40, P544, DOI 10.1097/PAS.0000000000000554; Agaimy A, 2015, MODERN PATHOL, V28, P248, DOI 10.1038/modpathol.2014.100; Chbani L, 2009, AM J CLIN PATHOL, V131, P222, DOI 10.1309/AJCPU98ABIPVJAIV; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Homick JL, 2013, WHO CLASSIFICATION T, P153; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Kohashi K, 2008, AM J SURG PATHOL, V32, P1168, DOI 10.1097/PAS.0b013e318161781a; Kohashi K, 2007, J CANCER RES CLIN, V133, P817, DOI 10.1007/s00432-007-0223-z; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Kohashi K, 2016, MODERN PATHOL, V29, P1232, DOI 10.1038/modpathol.2016.106; Kohashi K, 2015, HUM PATHOL, V46, P225, DOI 10.1016/j.humpath.2014.10.010; Kohashi K, 2009, HUM PATHOL, V40, P349, DOI 10.1016/j.humpath.2008.08.007; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Oda Y, 2013, WHO CLASSIFICATION T, P216; Oda Y, 2013, WHO CLASSIFICATION T, P228; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Yaniv M, 2014, CANCER GENET-NY, V207, P352, DOI 10.1016/j.cancergen.2014.03.006; Yoshida A, 2017, MODERN PATHOL, V30, P797, DOI 10.1038/modpathol.2017.11; Yoshida A, 2015, HISTOPATHOLOGY, V66, P252, DOI 10.1111/his.12460	25	6	7	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					312	318		10.1097/PAS.0000000000001011			7	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600005	29309303				2019-10-28	
J	Bishop, JA; Westra, WH				Bishop, Justin A.; Westra, William H.			MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma Evaluation of Classic, Variant, and Hybrid Forms	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						epithelial-myoepithelial carcinoma; MYB-NFIB; adenoid cystic carcinoma; hybrid carcinoma	ADENOID CYSTIC CARCINOMA; HIGH-GRADE TRANSFORMATION; CLEAR-CELL CARCINOMA; MUCOEPIDERMOID CARCINOMAS; FUSION; HEAD; NFIB; NECK; REARRANGEMENTS; EXPRESSION	Epithelial-myoepithelial carcinoma (EMC) is a malignant salivary gland neoplasm comprised of a biphasic arrangement of inner luminal ductal cells and outer myoepithelial cells. Adenoid cystic carcinoma (AdCC) is also a biphasic tumor comprised of ductal and myoepithelial cells, but these components tend to be arranged in a more cribriform pattern. The occurrence of "hybrid carcinomas" that show mixed patterns of EMC and AdCC raises questions about the relationship of these morphologically overlapping but clinically distinct tumors. AdCCs frequently harbor MYB-NFIB gene fusions. Mapping of EMCs (including hybrid forms with an AdCC component) for this fusion could help clarify the true nature of EMC as a distinct entity or simply as some variant form of AdCC. Twenty-nine cases of EMC were evaluated including 15 classic low-grade EMCs, 7 intermediate-grade EMCs, 2 EMCs with myoepithelial anaplasia, 1 EMC with high-grade transformation, and 4 hybrid EMCs with an AdCC component. Break apart fluorescence in situ hybridization for MYB was performed, as was MYB immunohistochemistry. For the hybrid carcinomas and those with high-grade transformation, the divergent tumor components were separately analyzed. A MYB translocation was identified in 5 of 28 (18%) tumors including 3 of 4 (75%) hybrid carcinomas and 2 of 7 (29%) intermediate-grade EMCs. For the positive hybrid carcinomas, the fusion was detected in both the EMC and AdCC components. The MYB fusion was not detected in any of the classic EMCs (0/15) or in any of the EMCs with myoepithelial anaplasia (0/2) or high-grade transformation (0/1). The fluorescence in situ hybridization assay was unsuccessful in 1 case. MYB immunostaining was seen in 5 of 5 fusion-positive cases, and also 9 of 23 fusion-negative tumors. Classic low-grade EMCs are genetically distinct from AdCCs in that they do not harbor MYB fusions. The presence of a MYB fusion in EMCs showing hybrid features of AdCC or exhibiting highly infiltrative growth points to a subset of these tumors that may well be true AdCCs masquerading as EMCs.	[Bishop, Justin A.; Westra, William H.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Bishop, Justin A.] UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,CS3-620, Dallas, TX 75390 USA	Bishop, JA (reprint author), UT Southwestern Med Ctr, Dept Pathol, 5323 Harry Hines Blvd,CS3-620, Dallas, TX 75390 USA.	justin.bishop@utsouthwestern.edu			National Institute of Dental and Craniofacial ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01 DE013152-11]	Supported in part by the National Institute of Dental and Craniofacial Research (R01 DE013152-11). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Amit M, 2014, HEAD NECK-J SCI SPEC, V36, P998, DOI 10.1002/hed.23405; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Bundele MM, 2017, MODERN PATHOL, V30, p322A; Chiosea SI, 2014, HEAD NECK PATHOL, V8, P146, DOI 10.1007/s12105-013-0506-4; Croitoru CM, 1999, ARCH PATHOL LAB MED, V123, P698; DONATH K, 1972, VIRCHOWS ARCH A, V356, P16, DOI 10.1007/BF00543554; Ellington CL, 2012, CANCER-AM CANCER SOC, V118, P4444, DOI 10.1002/cncr.27408; Ellis GL, 2008, EPITHELIAL MYOEPITHE, P309; Fehr A, 2011, J PATHOL, V224, P322, DOI 10.1002/path.2909; Grenko RT, 1998, ORAL SURG ORAL MED O, V86, P188, DOI 10.1016/S1079-2104(98)90124-X; Jin RY, 2012, HEAD NECK PATHOL, V6, P389, DOI 10.1007/s12105-012-0338-7; Lima FJ, 2012, OPEN DENT J, V6, P111, DOI 10.2174/1874210601206010111; Mitani Y, 2011, CLIN CANCER RES, V17, P7003, DOI 10.1158/1078-0432.CCR-11-1870; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Mosqueda-Taylor A, 2010, MED ORAL PATOL ORAL, V15, pE43, DOI 10.4317/medoral.15.e43; Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Rettig EM, 2015, LARYNGOSCOPE, V125, pE292, DOI 10.1002/lary.25356; Roy P, 2010, AM J SURG PATHOL, V34, P1258, DOI 10.1097/PAS.0b013e3181e366d2; Seethala R, 2017, WHO CLASSIFICATION H, P175; Seethala RR, 2007, AM J SURG PATHOL, V31, P44, DOI 10.1097/01.pas.0000213314.74423.d8; Seethala RR, 2013, HEAD NECK PATHOL, V7, pS77, DOI 10.1007/s12105-013-0461-0; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Seethala RR, 2009, ARCH PATHOL LAB MED, V133, P950, DOI 10.1043/1543-2165-133.6.950; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; van Weert S, 2013, ORAL ONCOL, V49, P824, DOI 10.1016/j.oraloncology.2013.05.004; Vazquez A, 2015, OTOLARYNG HEAD NECK, V153, P569, DOI 10.1177/0194599815594788; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Woo JS, 2004, J KOREAN MED SCI, V19, P462, DOI 10.3346/jkms.2004.19.3.462; Xu B, 2017, AM J SURG PATHOL, V41, P1422, DOI 10.1097/PAS.0000000000000918; Yang S, 2012, INT J ORAL MAX SURG, V41, P810, DOI 10.1016/j.ijom.2011.12.012	34	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					319	325		10.1097/PAS.0000000000000990			7	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600006	29135517	Green Accepted			2019-10-28	
J	Menguy, S; Prochazkova-Carlotti, M; Beylot-Barry, M; Saltel, F; Vergier, B; Merlio, JP; Pham-Ledard, A				Menguy, Sarah; Prochazkova-Carlotti, Martina; Beylot-Barry, Marie; Saltel, Frederic; Vergier, Beatrice; Merlio, Jean-Philippe; Pham-Ledard, Anne			PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						programmed death ligands; PD-L1; PD-L2; primary cutaneous diffuse large B-cell lymphoma leg type; M2 macro-phages	NERVOUS-SYSTEM LYMPHOMAS; DEATH LIGAND 1; GENOMIC REARRANGEMENTS; MYCOSIS-FUNGOIDES; POOR-PROGNOSIS; CANCER; RECURRENT; SURVIVAL; CLASSIFICATION; MUTATIONS	As checkpoint molecules' inhibition may represent a therapeutic option in relapsing cases, we assessed programmed death ligands' (PD-L1/PD-L2) expression in a series of 29 primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) cases. Double immunostaining for either PD-L1 or PD-L2 was associated either with PAX5 staining to evaluate tumor cells or with CD68 or CD163 staining for macrophages. The microenvironment of PCDLBCL-LT was characterized by immunostainings for CD3 (tumor-infiltrating lymphocytes), FOXP3 (regulatory T cells), programmed cell death-1, and CD33 (myeloid-derived suppressor cells). The 9p24.1 locus encoding for PD-L1/PD-L2 was evaluated by fluorescence in situ hybridization. A PD-L1 expression was observed in all cases. However, double staining with PD-L1/PAX5 identified only 1 case harboring PD-L1 expression by tumor cells. All cases displayed PD-L1 expression by numerous immune cells, characterized as CD68(+) CD163(+) M2 macrophages. A normal fluorescence in situ hybridization pattern was observed in 21 of 26 cases. Three cases (11.5%) harbored a low polysomy status including the case with PD-L1 expression by tumor cells. Interestingly, 2 cases (7.7%) exhibited a PD-L1/PD-L2 locus break-apart pattern, and PD-L2 expression by tumor cells was observed. PD-L2 expression by tumor cells was not observed in the 24 cases without 9p24.1 rearrangement. Treating patients with relapsing PCDLBCL-LT by using immune checkpoint inhibitors may have an indirect effect through immune cells, except in rare cases with 9p24.1 rearrangement leading to PD-L2 expression by tumor cells. Reprogramming tumor-associated macrophages with anticancer therapies is appealing in such lymphoma subtypes wherein M2 macrophages represent the majority of immune cells.	[Menguy, Sarah; Prochazkova-Carlotti, Martina; Beylot-Barry, Marie; Vergier, Beatrice; Merlio, Jean-Philippe; Pham-Ledard, Anne] Univ Bordeaux, Team Oncogenesis Cutaneous Lymphomas 3, INSERM, U1053, Bordeaux, France; [Saltel, Frederic] Univ Bordeaux, Team Liver Canc & Tumor Invas 1, INSERM, U1053, Bordeaux, France; [Menguy, Sarah; Vergier, Beatrice] CHU Bordeaux, Pathol Dept, Bordeaux, France; [Pham-Ledard, Anne] CHU Bordeaux, Dermatol Dept, Bordeaux, France; [Merlio, Jean-Philippe] CHU Bordeaux, Tumor Biol & Tumor Bank Dept, Bordeaux, France	Pham-Ledard, A (reprint author), Univ Bordeaux, INSERM, U1053, Team 3, F-33076 Bordeaux, France.	anne.pham@ledard.org		Prochazkova-Carlotti, Martina/0000-0002-7719-7679; Beylot-Barry, Marie/0000-0001-6150-1229	Societe Francaise de Dermatologie; Fondation pour la Recherche MedicaleFondation pour la Recherche Medicale [41078]	Supported by Societe Francaise de Dermatologie and the Fondation pour la Recherche Medicale (41078).	Aguiar PN, 2017, IMMUNOTHERAPY-UK, V9, P499, DOI 10.2217/imt-2016-0150; Anne PL, 2012, J INVEST DERMATOL, V132, P2118, DOI 10.1038/jid.2012.102; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Cetinozman F, 2014, J CUTAN PATHOL, V41, P14, DOI 10.1111/cup.12254; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Elliott LA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00086; Felcht M, 2012, BRIT J DERMATOL, V167, P348, DOI 10.1111/j.1365-2133.2012.10987.x; Genard G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00828; Georgiou K, 2016, BLOOD, V127, P3026, DOI 10.1182/blood-2015-12-686550; Gonzalez-Aguilar A, 2012, CLIN CANCER RES, V18, P5203, DOI 10.1158/1078-0432.CCR-12-0845; Grange F, 2014, JAMA DERMATOL, V150, P535, DOI 10.1001/jamadermatol.2013.7452; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Horlad H, 2016, CANCER SCI, V107, P1696, DOI 10.1111/cas.13065; Hu H, 2016, TUMOR BIOL, V37, P8657, DOI 10.1007/s13277-015-4741-z; Jullie ML, 2013, AM J SURG PATHOL, V37, P1845, DOI 10.1097/PAS.0000000000000091; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim YH, 2007, BLOOD, V110, P479, DOI 10.1182/blood-2006-10-054601; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Koens L, 2014, J INVEST DERMATOL, V134, P290, DOI 10.1038/jid.2013.265; Kraan W, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.28; Kwon D, 2016, HISTOPATHOLOGY, V68, P1079, DOI 10.1111/his.12882; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Mareschal S, 2017, J INVEST DERMATOL, V137, P1984, DOI 10.1016/j.jid.2017.04.010; Menter T, 2016, HUM PATHOL, V54, P17, DOI 10.1016/j.humpath.2016.03.005; Mitteldorf C, 2013, BRIT J DERMATOL, V169, P1212, DOI 10.1111/bjd.12579; Mitteldorf C, 2017, AM J SURG PATHOL, V41, P998, DOI 10.1097/PAS.0000000000000851; Nam SJ, 2014, LEUKEMIA LYMPHOMA, V55, P2466, DOI 10.3109/10428194.2013.879713; Pham-Ledard A, 2014, MODERN PATHOL, V27, P402, DOI 10.1038/modpathol.2013.156; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Shen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep30347; Shi M, 2014, AM J SURG PATHOL, V38, P1715, DOI 10.1097/PAS.0000000000000297; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Twa DDW, 2015, J PATHOL, V236, P136, DOI 10.1002/path.4522; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Wang JX, 2017, ONCOTARGET, V8, P5414, DOI 10.18632/oncotarget.14289; Xing W, 2016, ONCOTARGET, V7, P59976, DOI 10.18632/oncotarget.11045; Zheng X, 2017, ONCOTARGET, V8, P48436, DOI 10.18632/oncotarget.17061	46	7	7	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					326	334		10.1097/PAS.0000000000000983			9	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600007	29112015				2019-10-28	
J	Marino-Enriquez, A; Lauria, A; Przybyl, J; Ng, TL; Kowalewska, M; Debiec-Rychter, M; Ganesan, R; Sumathi, V; George, S; McCluggage, WG; Nucci, MR; Lee, CH; Fletcher, JA				Marino-Enriquez, Adrian; Lauria, Alexandra; Przybyl, Joanna; Ng, Tony L.; Kowalewska, Magdalena; Debiec-Rychter, Maria; Ganesan, Raji; Sumathi, Vaiyapuri; George, Suzanne; McCluggage, W. Glenn; Nucci, Marisa R.; Lee, Cheng-Han; Fletcher, Jonathan A.			BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						sarcoma; BCOR; internal tandem duplication endometrial stromal sarcoma; undifferentiated uterine sarcoma	CLEAR-CELL-SARCOMA; ENDOMETRIAL STROMAL SARCOMA; CYCLIN D1; KIDNEY; FUSION; REARRANGEMENT; FEATURES; MARKER	Endometrial stromal sarcomas (ESSs) are mesenchymal uterine tumors characterized by recurrent genetic events, most commonly chromosomal rearrangements, that create oncogenic gene fusions. High-grade endometrial stromal sarcomas (HG-ESSs), as defined in the 2014 World Health Organization Classification, typically contain oncogenic YWHAE-NUTM2 fusions; however, although not well characterized, there are tumors morphologically overlapping with HG-ESS that do not contain the YWHAE-NUTM2 fusions. These fusions are also found in certain pediatric primitive sarcomas, including clear cell sarcoma of the kidney and soft tissue undifferentiated round cell sarcoma of infancy. A subset of these same pediatric sarcomas lack YWHAE-NUTM2 fusions and instead have internal tandem duplications (ITDs) involving exon 15 of BCOR (BCOR ITD). We investigated the presence of BCOR ITD by targeted sequencing in a series of 31 uterine sarcomas, comprising 5 low-grade ESS, 13 uterine sarcomas diagnosed as HG-ESS, and 13 undifferentiated uterine sarcomas. BCOR ITD were present in 1 uterine sarcoma diagnosed as HG-ESS and 2 undifferentiated sarcomas with uniform nuclear features, all of which lacked any of the recurrent chromosome translocations known to occur in ESS. These 3 high-grade sarcomas with BCOR ITD affected young patients (average age, 24) and morphologically were composed of nonpleomorphic spindle cells admixed with epithelioid and round cell areas. Focal myxoid stroma was present in 2 cases. Mitotic activity was brisk, necrosis was present, and there was lymphovascular involvement in all cases. The 3 uterine sarcomas with BCOR ITD exhibited diffuse cyclin D1 immunohistoche mical expression and there was diffuse BCOR expression in the 2 cases tested. Long-term follow-up in 2 patients revealed 1 to be tumor-free after 22 years and the other to die of disease after 8 years. In conclusion, BCOR ITD is an oncogenic alternative to YWHAE-NUTM2 fusion in high-grade uterine sarcomas with uniform nuclear features. We propose that neoplasms with the morphology described and BCOR ITD be regarded as a unique subtype of high-grade uterine sarcoma, possibly within the family of endometrial stromal neoplasia.	[Marino-Enriquez, Adrian; Lauria, Alexandra; Nucci, Marisa R.; Fletcher, Jonathan A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [George, Suzanne] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA; [Przybyl, Joanna] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Ng, Tony L.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Lee, Cheng-Han] Univ Alberta, Royal Alexandra Hosp, Dept Lab Med & Pathol, Edmonton, AB, Canada; [Kowalewska, Magdalena] Maria Sklodowska Curie Mem Canc Ctr & Inst, Oncol Ctr, Dept Mol & Translat Oncol, Warsaw, Poland; [Kowalewska, Magdalena] Med Univ Warsaw, Dept Immunol Biochem & Nutr, Warsaw, Poland; [Debiec-Rychter, Maria] Katholieke Univ Leuven, Dept Human Genet, Leuven, Belgium; [Debiec-Rychter, Maria] Univ Hosp Leuven, Leuven, Belgium; [Ganesan, Raji] Birmingham Womens Hosp, Dept Histopathol, Birmingham, W Midlands, England; [Sumathi, Vaiyapuri] Royal Orthopaed Hosp, Dept Musculoskeletal Pathol, Birmingham, W Midlands, England; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland	Marino-Enriquez, A (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	dmarino@bwh.harvard.edu			Sherwood Family Research Fund	This work was supported by the Sherwood Family Research Fund (A.M.-E and J.A.F).	Astolfi A, 2015, ONCOTARGET, V6, P40934, DOI 10.18632/oncotarget.5882; Chiang S, 2017, MODERN PATHOL, V30, P1251, DOI 10.1038/modpathol.2017.42; Fehr A, 2012, J PATHOL, V227, pe5, DOI 10.1002/path.4040; Hemming ML, 2017, GYNECOL ONCOL, V145, P531, DOI 10.1016/j.ygyno.2017.03.021; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Karlsson J, 2016, GENE CHROMOSOME CANC, V55, P120, DOI 10.1002/gcc.22316; Kenny C, 2016, J PATHOL, V238, P617, DOI 10.1002/path.4693; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Kurman RJ, 2014, WHO CLASSIFICATION T; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee CH, 2014, MODERN PATHOL, V27, P751, DOI 10.1038/modpathol.2013.199; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Mirkovic J, 2015, HISTOPATHOLOGY, V67, P306, DOI 10.1111/his.12641; O'Meara E, 2012, J PATHOL, V227, P72, DOI 10.1002/path.3985; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Roy A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9891; Sciallis AP, 2014, AM J SURG PATHOL, V38, P1161, DOI 10.1097/PAS.0000000000000256; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338	22	11	11	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					335	341		10.1097/PAS.0000000000000993			7	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600008	29200103				2019-10-28	
J	Moore, EM; Swerdlow, SH; Gibson, SE				Moore, Erika M.; Swerdlow, Steven H.; Gibson, Sarah E.			Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						MEF2B; follicular lymphoma; marginal zone lymphoma; mantle cell lymphoma; diffuse large B-cell lymphoma; HGAL; LMO2; non-Hodgkin lymphoma	FOLLICULAR LYMPHOMA; IMMUNOARCHITECTURAL PATTERNS; EXPRESSION PREDICTS; LMO2; HGAL; MARKER; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; TRANSLOCATIONS; NEOPLASMS	Myocyte enhancer binding factor 2B (MEF2B) is a transcriptional activator of the BCL6 proto-oncogene in normal germinal center (GC) B-cells. Limited data exists concerning its expression in B-cell lymphomas, and comparison with other GC-associated antigens is lacking. Its role in the differential diagnosis of B-cell lymphomas, particularly in the distinction of follicular lymphoma (FL) versus marginal zone lymphoma (MZL), remains to be determined. We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL. MEF2B was positive in all FL and Burkitt lymphomas, 8/9 mantle cell lymphomas, 2/24 splenic MZL, 1/10 chronic lymphocytic leukemia/small lymphocytic lymphomas, and 38/44 diffuse large B-cell lymphoma (DLBCL), but was negative in all extranodal MZL of mucosa-associated lymphoid tissue, nodal MZL, and B-lymphoblastic lymphomas. Focusing on low-grade FL versus MZL, MEF2B was 100% sensitive and 95% specific for FL, which was similar to BCL6, but superior to LMO2 (sensitivity 87%, specificity 86%) and HGAL (sensitivity 97%, specificity 86%). Importantly, MEF2B was positive in 4/4 FL with plasmacytoid differentiation, which were CD10(-), only weakly BCL6(+), and included 1 case that lacked both LMO2 and HGAL expression. MEF2B was positive in 22/25 (88%) GC-type DLBCL, but was also positive in 16/19 (61%) non-GC-type DLBCL. MEF2B shows superior sensitivity and specificity than LMO2 and HGAL in the differential diagnosis of FL versus MZL and is particularly useful in FL with plasmacytoid differentiation, which may have morphologic and immunophenotypic overlap with MZL. MEF2B, however, is not specific for GC-derived B-cell lymphomas as it is also apparently positive in most mantle cell lymphoma and many non-GC-type DLBCL.	[Moore, Erika M.; Swerdlow, Steven H.; Gibson, Sarah E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Moore, EM (reprint author), Univ Hosp Cleveland Med Ctr, Dept Pathol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	erika.moore@uhhospitals.org		Moore, Erika/0000-0001-5387-2409			Agostinelli C, 2012, HISTOPATHOLOGY, V61, P33, DOI 10.1111/j.1365-2559.2012.04198.x; Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; Ballesteros E, 1998, AM J SURG PATHOL, V22, P201, DOI 10.1097/00000478-199802000-00008; Baseggio L, 2012, BRIT J HAEMATOL, V158, P489, DOI 10.1111/j.1365-2141.2012.09178.x; Chapman-Fredricks J, 2013, APPL IMMUNOHISTO M M, V21, P200, DOI 10.1097/PAI.0b013e31826399aa; Colomo L, 2017, AM J SURG PATHOL, V41, P877, DOI 10.1097/PAS.0000000000000839; Dufresne SD, 2010, HUM PATHOL, V41, P540, DOI 10.1016/j.humpath.2009.09.007; Dyhdalo KS, 2013, AM J CLIN PATHOL, V140, P149, DOI 10.1309/AJCPHPVH4M7MTWUN; Goteri G, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-97; Gradowski JF, 2010, MODERN PATHOL, V23, P71, DOI 10.1038/modpathol.2009.146; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Ikeda JI, 2017, HUM PATHOL, V59, P70, DOI 10.1016/j.humpath.2016.09.011; Jevremovic D, 2016, AM J CLIN PATHOL, V145, P180, DOI 10.1093/ajcp/aqv024; Krenacs D, 2015, VIRCHOWS ARCH, V467, P345, DOI 10.1007/s00428-015-1796-6; Marafioti T, 2013, HISTOPATHOLOGY, V62, P860, DOI 10.1111/his.12076; Menter T, 2015, APPL IMMUNOHISTO M M, V23, P491, DOI 10.1097/PAI.0000000000000107; Metcalf RA, 2014, HUM PATHOL, V45, P1730, DOI 10.1016/j.humpath.2014.04.004; Millar EKA, 1999, J CLIN PATHOL, V52, P849, DOI 10.1136/jcp.52.11.849; Montes-Moreno S, 2008, BLOOD, V111, P351, DOI 10.1182/blood-2007-06-094151; Natkunam Y, 2005, BLOOD, V105, P3979, DOI 10.1182/blood-2004-08-3112; Natkunam Y, 2008, J CLIN ONCOL, V26, P447, DOI 10.1200/JCO.2007.13.0690; Natkunam Y, 2007, BLOOD, V109, P1636, DOI 10.1182/blood-2006-08-039024; Palomero J, 2016, LEUKEMIA, V30, P1596, DOI 10.1038/leu.2015.355; Paterson MA, 2008, AM J CLIN PATHOL, V130, P117, DOI 10.1309/9QKE68QU7B825A3U; Salama ME, 2009, AM J CLIN PATHOL, V132, P39, DOI 10.1309/AJCPZQ1GXBBNG8OG; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; van den Brand M, 2017, HISTOPATHOLOGY, V70, P174, DOI 10.1111/his.13015; Ye HT, 2008, HAEMATOL-HEMATOL J, V93, P145, DOI 10.3324/haematol.11927; Ying CY, 2013, NAT IMMUNOL, V14, P1084, DOI 10.1038/ni.2688; Younes SF, 2011, AM J CLIN PATHOL, V135, P697, DOI 10.1309/AJCP7Z2BIBUNQPLZ; Younes SF, 2010, AM J SURG PATHOL, V34, P1266, DOI 10.1097/PAS.0b013e3181e9343d	32	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					342	350		10.1097/PAS.0000000000001015			9	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600009	29309299				2019-10-28	
J	Landau, MA; Zhu, B; Akwuole, FN; Pai, RK				Landau, Michael A.; Zhu, Benjamin; Akwuole, Frances N.; Pai, Reetesh K.			Site-specific Differences in Colonic Adenocarcinoma KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colonic adenocarcinoma; KRAS; BRAF; MSI mismatch repair; cecum; right colon; left colon; rectum; survival	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; LUNG ADENOCARCINOMA; MOLECULAR MARKERS; STAGE; SURVIVAL; INVOLVEMENT; CARCINOMA; METHYLATION; LOCATION	Recent literature indicates that adenocarcinomas of the cecum differ with respect to molecular alterations compared with noncecal proximal colon adenocarcinomas and that cecal tumor site may be a prognostically relevant variable. We compared molecular alterations, histopathologic features, and disease-specific survival in a series of 328 colonic adenocarcinomas identified over a 2-year period and stratified by tumor location (cecum, right colon, and left colon). Overall, cecal adenocarcinomas demonstrated the highest frequency of molecular abnormalities with 74% harboring either a KRAS exon 2 or 3 mutation, a BRAF mutation, or DNA mismatch repair protein deficiency. KRAS mutations were more frequently seen in the cecum compared with all other tumor sites (P = 0.03). KRAS mutations were identified in 46% of cecal adenocarcinomas compared with only 25% of adenocarcinomas of the right colon (P = 0.004). Cecal adenocarcinomas more frequently displayed adverse histopathologic features, in particular high tumor budding (31%), compared with tumors of the right colon (18%; P = 0.04) and tumors of the left colon (17%; P = 0.02). Overall stage was the most important independent predictor of disease-specific survival in the multivariable analysis; however, cecal tumor site and high tumor budding were also predictive of poor survival, particularly in patients with stage III or IV tumors. In conclusion, cecal adenocarcinomas are characterized by a high frequency of KRAS mutations compared with noncecal right colon tumors, frequently display high tumor budding, and may be a prognostically relevant variable, particularly in patients with stage III or IV disease.	[Landau, Michael A.; Zhu, Benjamin; Akwuole, Frances N.; Pai, Reetesh K.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA	Pai, RK (reprint author), Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, 200 Lothrop St,Room A-610, Pittsburgh, PA 15213 USA.	pair@upmc.edu		Landau, Michael/0000-0002-2871-5409			Barresi V, 2014, HUM PATHOL, V45, P268, DOI 10.1016/j.humpath.2013.07.046; Betge J, 2012, ANN SURG ONCOL, V19, P3706, DOI 10.1245/s10434-012-2426-z; Bhangu A, 2013, ANN SURG ONCOL, V20, P4161, DOI 10.1245/s10434-013-3104-5; Brungs D, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3255-z; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; Canney AL, 2012, HISTOPATHOLOGY, V61, P488, DOI 10.1111/j.1365-2559.2012.04250.x; Chiosea S, 2010, HUM PATHOL, V41, P1053, DOI 10.1016/j.humpath.2010.01.008; Flemer B, 2017, GUT, V66, P633, DOI 10.1136/gutjnl-2015-309595; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; Greenson JK, 2003, AM J SURG PATHOL, V27, P563, DOI 10.1097/00000478-200305000-00001; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Hayes BD, 2010, AM J SURG PATHOL, V34, P746, DOI 10.1097/PAS.0b013e3181da76b6; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kakar S, 2017, PROTOCOL EXAMINATION; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kane MF, 1997, CANCER RES, V57, P808; Koelzer VH, 2016, HUM PATHOL, V47, P4, DOI 10.1016/j.humpath.2015.08.007; Lai YH, 2014, COLORECTAL DIS, V16, P259, DOI 10.1111/codi.12454; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Meguid RA, 2008, ANN SURG ONCOL, V15, P2388, DOI 10.1245/s10434-008-0015-y; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Petrelli F, 2015, J Gastrointest Cancer, V46, P212, DOI 10.1007/s12029-015-9716-1; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Phipps AI, 2013, DIS COLON RECTUM, V56, P937, DOI 10.1097/DCR.0b013e31828f9a57; Radu OM, 2011, HUM PATHOL, V42, P1247, DOI 10.1016/j.humpath.2010.11.016; Sinicrope FA, 2015, CLIN CANCER RES, V21, P5294, DOI 10.1158/1078-0432.CCR-15-0527; Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041; Ueno H, 2013, AM J CLIN PATHOL, V139, P434, DOI 10.1309/AJCPWHUEFTGBWKE4; Wang BY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179910; Warschkow R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2412-0; Wei EK, 2017, AM J EPIDEMIOL, V185, P224, DOI 10.1093/aje/kww183; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yang J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167540; Yousem SA, 2008, AM J SURG PATHOL, V32, P1317, DOI 10.1097/PAS.0b013e31816597ca	34	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					351	358		10.1097/PAS.0000000000001004			8	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600010	29240583				2019-10-28	
J	Dodds, TJ; Lo, S; Jackett, L; Nieweg, O; Thompson, JF; Scolyer, RA				Dodds, Tristan J.; Lo, Serigne; Jackett, Louise; Nieweg, Omgo; Thompson, John F.; Scolyer, Richard A.			Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						periadnexal extension; appendageal extension melanoma; pathology; prognosis; Breslow thickness measurement	AMERICAN JOINT COMMITTEE; LENTIGO MALIGNA MELANOMA; LYMPH-NODE POSITIVITY; MITOTIC RATE; CLASSIFICATION; ULCERATION; SURVIVAL; DEPTH; TUMOR	Tumor thickness is the strongest predictor of outcome for clinically localized melanoma. Therefore, accurate assessment is critical for appropriate staging, reliable estimation of prognosis, and management. When melanoma extends alongside skin adnexal structures more deeply than the main tumor mass (periadnexal extension), it is currently unknown whether the prognosis is more accurately reflected by the deepest point of periadnexal tumor extension or the main tumor mass. This study sought to address this question. Survival outcomes of 257 primary cutaneous melanoma patients with periadnexal extension diagnosed between 2005 and 2015 and managed at Melanoma Institute Australia were identified and compared with a control cohort of 514 patients who were matched for tumor thickness, sex, age, mitotic rate, ulceration status, and year of diagnosis but lacked periadnexal extension. The incidence of periadnexal extension at Melanoma Institute Australia was 1.5% (257/16,692 cutaneous melanomas diagnosed between 2005 and 2015). The patient characteristics between the 2 groups were otherwise very similar; median Breslow thickness was 0.9 mm for the periadnexal group and 1.0 mm for the control group. The median extension beyond the Breslow thickness in the tumors with periadnexal extension was 0.45 mm (mean, 0.4 mm). Median follow-up was 46 months for the periadnexal group and 44 months for the control group. Measures of clinical outcomes all showed trends for improved survival in the periadnexal extension group; these were melanoma-specific survival (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.44, 1.38), overall survival (HR, 0.91; 95% CI, 0.59, 1.41), disease-free survival (HR, 0.68; 95% CI, 0.45, 1.03), and distant disease-free survival (HR, 0.69; 95% CI, 0.4, 1.17), although none were statistically significant. There was a higher rate of sentinel lymph node (SLN) metastasis in the periadnexal group versus the control group in patients whose tumors were > 1 mm thick (24/100 = 24% vs. 23/187 = 12.3%). Periadnexal extension was significantly associated with SLN metastasis on univariate logistic regression analysis (odds ratio [95% CI], 2.25 [1.20, 4.24], P = 0.01). If the periadnexal extension had been included in the measurement of tumor thickness, 42.8% of patients would have been upstaged to a higher American Joint Committee on Cancer T category. The findings of this study indicate that periadnexal involvement that extends more deeply than the thickness of the main tumor mass increases the risk of SLN metastasis in tumours > 1 mm thick, however, does not worsen clinical outcomes overall, and tumor thickness measurements should not include deeper foci of periadnexal tumor.	[Dodds, Tristan J.; Lo, Serigne; Jackett, Louise; Nieweg, Omgo; Thompson, John F.; Scolyer, Richard A.] Melanoma Inst Australia, Sydney, NSW, Australia; [Dodds, Tristan J.; Jackett, Louise; Scolyer, Richard A.] Univ Sydney, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Dodds, Tristan J.; Lo, Serigne; Jackett, Louise; Nieweg, Omgo; Thompson, John F.; Scolyer, Richard A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Nieweg, Omgo; Thompson, John F.] Royal Prince Alfred Hosp, Dept Melanoma & Surg Oncol, Sydney, NSW, Australia	Scolyer, RA (reprint author), Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Missenden Rd, Sydney, NSW 2050, Australia.	richard.scolyer@health.nsw.gov.au	Lo, Serigne/L-6220-2018	Lo, Serigne/0000-0001-5092-5544; Scolyer, Richard/0000-0002-8991-0013	Melanoma Foundation of the University of SydneyUniversity of Sydney; Jani Haenke Melanoma Pathology Fellowship through the BB; Miller Foundation; MIA; Australian National Health and Medical Research Council FellowshipNational Health and Medical Research Council of Australia	J.F.T. is supported by the Melanoma Foundation of the University of Sydney. T.J.D. is supported by the Jani Haenke Melanoma Pathology Fellowship through the BB and A Miller Foundation and MIA. R. A. S. is supported by an Australian National Health and Medical Research Council Fellowship.	Argenziano G, 2007, BRIT J DERMATOL, V157, P217, DOI 10.1111/j.1365-2133.2007.07972.x; Azzola MF, 2003, CANCER-AM CANCER SOC, V97, P1488, DOI 10.1002/cncr.11196; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CLARK WH, 1969, CANCER RES, V29, P705; COHEN LM, 1995, J AM ACAD DERMATOL, V33, P923, DOI 10.1016/0190-9622(95)90282-1; Cook MG, 2002, J PATHOL, V197, P188, DOI 10.1002/path.1093; Faries MB, 2017, NEW ENGL J MED, V376, P2211, DOI 10.1056/NEJMoa1613210; Farrahi F, 2005, J CUTAN PATHOL, V32, P405, DOI 10.1111/j.0303-6987.2005.00355.x; Flotte TJ, 1999, HUM PATHOL, V30, P533, DOI 10.1016/S0046-8177(99)90197-1; FUSI S, 1993, PLAST RECONSTR SURG, V91, P94, DOI 10.1097/00006534-199301000-00014; Gershenwald JE, 2017, AJCC CANC STAGING MA, V8, P563; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; in't Hout FEM, 2012, ANN SURG, V255, P1165, DOI 10.1097/SLA.0b013e31824c4b0b; Johnson TM, 1997, J AM ACAD DERMATOL, V37, P758, DOI 10.1016/S0190-9622(97)70114-2; Joosse A, 2015, ANN SURG ONCOL, V22, P1598, DOI 10.1245/s10434-014-4166-8; Lo SN, ANN SURG ONCOL UNPUB; Mandala M, 2014, VIRCHOWS ARCH, V464, P265, DOI 10.1007/s00428-013-1526-x; MCGOVERN VJ, 1973, CANCER, V32, P1446, DOI 10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8; MEIGEL WN, 1977, ARCH DERMATOL RES, V259, P1, DOI 10.1007/BF00562732; MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907; Murali R, 2012, CANCER-AM CANCER SOC, V118, P4519, DOI 10.1002/cncr.27693; Paek SC, 2007, CANCER, V109, P100, DOI 10.1002/cncr.22382; Scolyer RA, 2016, PATHOLOGY, V48, P105, DOI 10.1016/j.pathol.2015.12.011; Scolyer RA, 2013, AM J SURG PATHOL, V37, P1797, DOI 10.1097/PAS.0b013e31829d7f35; Sondak VK, 2004, ANN SURG ONCOL, V11, P247, DOI 10.1245/ASO.2004.03.044; Thompson JF, 2011, J CLIN ONCOL, V29, P2199, DOI 10.1200/JCO.2010.31.5812	26	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					359	366		10.1097/PAS.0000000000000999			8	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600011	29240580				2019-10-28	
J	Bishop, JA; Rooper, LM; Chiosea, SI; Westra, WH				Bishop, Justin A.; Rooper, Lisa M.; Chiosea, Simion I.; Westra, William H.			Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive A Pitfall in the Interpretation of Oropharyngeal Biopsies	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						clear cell carcinoma; hyalinizing clear cell carcinoma; p16; EWSR1-ATF1; human papillomavirus; HPV	MUCOEPIDERMOID CARCINOMAS; NASOPHARYNGEAL CARCINOMA; HUMAN-PAPILLOMAVIRUS; SITU-HYBRIDIZATION; EWSR1-ATF1 FUSION; NECK; HEAD; REARRANGEMENTS; TRANSLOCATION; ASSOCIATION	Clear cell carcinoma (CCC) is a low-grade malignancy that commonly arises in minor salivary glands of the oropharynx and other sites. EWSR1-ATF1 gene fusions seem to be specific for this salivary neoplasm. Testing for EWSR1-ATF1 has expanded the histologic spectrum of CCC. As one important example, many CCCs have a predominantly squamous phenotype with few clear cells, a finding that can cause confusion with squamous cell carcinoma (SqCC). P16 immunohistochemical staining to determine human papillomavirus (HPV) status has become standard practice for all oropharyngeal carcinomas showing squamous differentiation. The purpose of this study was to determine whether this practice could contribute to the difficulty in distinguishing CCC from p16-positive SqCC. The authors' surgical pathology archives were searched for cases of CCC. All cases were evaluated with p16 immunohistochemistry, high-risk HPV RNA in situ hybridization (ISH), and EWSR1 gene break-apart fluorescence ISH. Sixteen CCCs were identified. All harbored an EWSR1 rearrangement. Eleven patients were women and 5 were men. They ranged in age from 30 to 85 years (mean, 58 y). The CCCs arose in the oropharynx (tongue base or tonsil) (n = 8, 50%), oral cavity (n = 4, 25%), and nasopharynx (n = 4, 25%). Each case demonstrated clear cells, but the proportion was highly variable (10% to 90%, mean 48%), with 7 of 16 cases having <50% clear cells. Submitted diagnoses included SqCC (n = 3) and mucoepidermoid carcinoma (n = 2). Of the 3 patients diagnosed with SqCC, 1 was scheduled to undergo chemoradiation, and 1 had already completed chemoradiation. All 16 CCCs demonstrated p16 staining, with the percentage of p16-positive cells ranging from >= 70% (n = 2), 50% to 69% (n = 3), and 10% to 49% (n = 11). Staining was cytoplasmic and nuclear. All cases were negative for high-risk HPV by RNA ISH. CCCs regularly show squamous features, often lack prominent clear cell changes, frequently arise in the oropharynx, and invariably show p16 staining. These features may cause confusion with SqCC, particularly HPV-related oropharyngeal SqCC. P16 staining is not to be taken as unequivocal evidence of an HPV-related SqCC, even for carcinomas showing squamous differentiation and originating in the oropharynx. Failure to recognize this pitfall could result in overly aggressive treatment of a low-grade carcinoma.	[Bishop, Justin A.; Rooper, Lisa M.; Westra, William H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, MC 9073,5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Chiosea, Simion I.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA	Bishop, JA (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, MC 9073,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	justin.bishop@UTSouthwestern.edu		Rooper, Lisa/0000-0001-5636-9753	National Institutes of Health/National Institute of Dental and Craniofacial Research (NIH/NIDCR) Head and Neck SPORE Grant [P50 DE019032]	Supported in part by the National Institutes of Health/National Institute of Dental and Craniofacial Research (NIH/NIDCR) Head and Neck SPORE Grant P50 DE019032.	Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Beadle B, 2017, ARCH PATHOL IN PRESS; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Dogan S, 2014, HEAD NECK-J SCI SPEC, V36, P511, DOI 10.1002/hed.23318; Ellis G, 2005, WHO CLASSIFICATION T, P227; Ellis GL, 2008, ARMED FORCES I PATHO, P301; Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; Garcia-Bates TM, 2016, J IMMUNOL, V196, P2870, DOI 10.4049/jimmunol.1502027; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hsieh MS, 2017, HUM PATHOL, V61, P9, DOI 10.1016/j.humpath.2016.06.029; Ishibashi K, 2015, AM J SURG PATHOL, V39, P1479, DOI 10.1097/PAS.0000000000000507; MILCHGRUB S, 1994, AM J SURG PATHOL, V18, P74, DOI 10.1097/00000478-199401000-00007; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stenmark MH, 2014, INT J RADIAT ONCOL, V88, P580, DOI 10.1016/j.ijrobp.2013.11.246; Tanguay J, 2013, HEAD NECK PATHOL, V7, P28, DOI 10.1007/s12105-013-0427-2; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; Wenig BM, 2017, WHO CLASSIFICATION H, P168; Westra WH, 2017, WHO CLASSIFICATION H, P136	23	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					367	371		10.1097/PAS.0000000000000977			5	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600012	29076874	Green Accepted			2019-10-28	
J	Elsensohn, A; Shiu, J; Grove, N; Hosking, AM; Barr, R; de Feraudy, S				Elsensohn, Ashley; Shiu, Jessica; Grove, Narina; Hosking, Anna-Marie; Barr, Ronald; de Feraudy, Sebastien			Distinguishing Neurofibroma From Desmoplastic Melanoma The Value of p53	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						p53; desmoplastic melanoma; neurofibroma	GENE COPY NUMBER; MALIGNANT-MELANOMA; PROTEIN EXPRESSION; MUTATIONS; TUMORS; P53	Distinguishing desmoplastic melanomas (DMs) from neurofibromas (NFs) can be histologically challenging in some cases. To date, a reliable marker to differentiate the 2 entities has remained elusive. S100 subtyping and CD34 fingerprinting have been proposed, but controversy remains as to their reliability. Missense mutations in TP53 are often found in DMs, resulting in a dominant negative effect and paradoxical accumulation of the tumor suppressor protein p53. We hypothesized that p53 may be expressed differentially in DMs, making it a valuable tool in differentiating DMs from NFs. Using immunohistochemistry, we compared p53 protein expression in 20 DMs and 20 NFs retrieved from our tissue archives and stained with p53 antibody (Monoclonal, DO-7). Patients with DM included 18 men and 2 women (age, 36 to 95 y; mean, 70.5 y; median, 70 y). Fifteen (15/20) tumors occurred in head and neck area; 2 (2/20) on the trunk; and 3 (3/20) on the extremities. Patients with NF included 12 men and 8 women (age, 47 to 85 y; mean, 65.2 y; median, 69.5 y). Eleven (11/20) tumors occurred on the trunk, 6 (6/20) on the extremities, and 3 (3/20) on the head and neck area. A total of 19/20 (95%) DMs were positive for p53. DM Histo-scores ranged from 0 to 300 (mean, 203; median, 260). Nuclear accumulation of p53 was seen in all 19 positive DMs. None of the 20 NFs were positive for p53 (2-tailed t test P-value < 0.0001). Detection of p53 by immunohistochemistry can help to distinguish DMs from NFs.	[Elsensohn, Ashley; Shiu, Jessica; Hosking, Anna-Marie; de Feraudy, Sebastien] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92717 USA; [Grove, Narina] Univ Calif Irvine, Dept Pathol, Irvine, CA 92717 USA; [Barr, Ronald] Laguna Pathol Med Grp, Laguna Hills, CA USA	Elsensohn, A (reprint author), Univ Calif Irvine Hlth, 118 Med Surg 1, Irvine, CA 92697 USA.	aelsenso@uci.edu			NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001416]		Bastian BC, 2012, MCKEES PATHOLOGY SKI, P1240; Busam KJ, 2001, AM J SURG PATHOL, V25, P197, DOI 10.1097/00000478-200102000-00007; CONLEY J, 1971, CANCER, V28, P914, DOI 10.1002/1097-0142(1971)28:4<914::AID-CNCR2820280415>3.0.CO;2-E; Davison JM, 2005, CANCER-AM CANCER SOC, V103, P788, DOI 10.1002/cncr.20861; Gutzner R, 2000, HUM GENET, V107, P357, DOI 10.1007/s004390000374; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Husain S, 2013, J CUTAN PATHOL, V40, P985, DOI 10.1111/cup.12206; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Kiuru M, 2014, AM J SURG PATHOL, V38, P864, DOI 10.1097/PAS.0000000000000201; Marchenko ND, 2010, CELL DEATH DIFFER, V17, P255, DOI 10.1038/cdd.2009.173; Nonaka D, 2008, J CUTAN PATHOL, V35, P1014, DOI 10.1111/j.1600-0560.2007.00953.x; Ramos-Herberth FI, 2010, J CUTAN PATHOL, V37, P944, DOI 10.1111/j.1600-0560.2010.01568.x; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451; Yeh I, 2011, J CUTAN PATHOL, V38, P625, DOI 10.1111/j.1600-0560.2011.01700.x	16	2	2	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					372	375		10.1097/PAS.0000000000000978			4	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600013	29112020	Green Accepted			2019-10-28	
J	Salomao, MA; Lam-Himlin, D; Pai, RK				Salomao, Marcela A.; Lam-Himlin, Dora; Pai, Rish K.			Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient's Entire Set of Biopsies	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Review						Barrett esophagus; low-grade dysplasia; high-grade dysplasia; interobserver agreement	LOW-GRADE DYSPLASIA; GASTROINTESTINAL EPITHELIAL NEOPLASIA; ADENOCARCINOMA INCIDENCE; VIENNA CLASSIFICATION; OBSERVER VARIATION; PROGRESSION; PATHOLOGISTS; REPRODUCIBILITY; RISK; OVERDIAGNOSIS	The pathologic diagnosis of dysplasia in Barrett esophagus (BE) suffers from interobserver disagreement. Many of the studies demonstrating disagreement in the diagnosis of dysplasia have pathologists review individual biopsy slides in isolation. To more closely mimic daily practice, 3 pathologists reviewed hematoxylin and eosin slides made from 549 individual biopsy jars obtained from 129 unique patients with a diagnosis of BE. Each pathologist reviewed the entirety of a given patient's biopsy material. The grade of dysplasia present in each biopsy jar was given as well as an overall highest grade of dysplasia from the patient's entire set of biopsies. The interobserver agreement in the diagnosis of dysplasia per biopsy jar and per patient's set of biopsies was measured by Fleiss statistic for multiple raters. The values for each diagnosis was higher in the per patient analysis compared with the per biopsy jar analysis indicating that pathologists are more likely to agree on the overall grade of dysplasia compared with the grade in an individual biopsy jar. In the per patient analysis, the interobserver agreement in the diagnosis of nondysplastic BE and high-grade dysplasia were substantial (kappa = 0.66; 95% confidence interval [CI], 0.56-0.76 and kappa = 0.76; 95% CI, 0.66-0.86, respectively). The interobserver agreement in the diagnosis of low-grade dysplasia (LGD) was fair (kappa = 0.31; 95% CI, 0.21-0.42). When LGD and high-grade dysplasia were collapsed into 1 category of positive for dysplasia, the interobserver agreement in the per patient analysis remained substantial (kappa = 0.70; 95% CI, 0.60-0.80), suggesting that much of the disagreement in LGD is not due to lack of recognition of dysplastic Barrett's mucosa, but rather the degree of dysplasia. These results indicate that pathologists can reliably distinguish between nondysplastic BE and dysplastic BE when a patient's entire set of biopsies is reviewed as a group. When second opinions are obtained, all available slides from that endoscopic procedure should be sent for review.	[Salomao, Marcela A.; Lam-Himlin, Dora; Pai, Rish K.] Mayo Clin Arizona, Dept Pathol & Lab Med, Scottsdale, AZ USA	Pai, RK (reprint author), Mayo Clin Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	pai.rish@mayo.edu					Alikhan M, 1999, GASTROINTEST ENDOSC, V50, P23, DOI 10.1016/S0016-5107(99)70339-1; Baak JPA, 2002, J CLIN PATHOL, V55, P910, DOI 10.1136/jcp.55.12.910; Coleman HG, 2011, EUR J EPIDEMIOL, V26, P739, DOI 10.1007/s10654-011-9596-z; Curvers WL, 2010, AM J GASTROENTEROL, V105, P1523, DOI 10.1038/ajg.2010.171; Downs-Kelly E, 2008, AM J GASTROENTEROL, V103, P2333, DOI 10.1111/j.1572-0241.2008.02020.x; Duits LC, 2017, GASTROENTEROLOGY, V152, P993, DOI 10.1053/j.gastro.2016.12.008; Duits LC, 2015, GUT, V64, P700, DOI 10.1136/gutjnl-2014-307278; Hayeck TJ, 2010, DIS ESOPHAGUS, V23, P451, DOI 10.1111/j.1442-2050.2010.01054.x; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; Kaye PV, 2016, HISTOPATHOLOGY, V69, P431, DOI 10.1111/his.12956; Kaye PV, 2009, HISTOPATHOLOGY, V54, P699, DOI 10.1111/j.1365-2559.2009.03288.x; Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Pech O, 2007, SCAND J GASTROENTERO, V42, P682, DOI 10.1080/00365520601075803; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; SAGAN C, 1994, GASTROEN CLIN BIOL, V18, pD31; Sangle NA, 2015, MODERN PATHOL, V28, P758, DOI 10.1038/modpathol.2015.2; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Schlemper RJ, 2001, J GASTROENTEROL, V36, P445, DOI 10.1007/s005350170067; Shaheen NJ, 2016, AM J GASTROENTEROL, V111, P30, DOI 10.1038/ajg.2015.322; Sikkema M, 2011, AM J GASTROENTEROL, V106, P1231, DOI 10.1038/ajg.2011.153; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Spechler SJ, 2014, NEW ENGL J MED, V371, P836, DOI 10.1056/NEJMra1314704; Srivastava A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133403; Vennalaganti P, 2017, GASTROENTEROLOGY, V152, P564, DOI 10.1053/j.gastro.2016.10.041; Wani S, 2016, GASTROENTEROLOGY, V151, P822, DOI 10.1053/j.gastro.2016.09.040; Wani S, 2011, GASTROENTEROLOGY, V141, P1179, DOI 10.1053/j.gastro.2011.06.055	29	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					376	381		10.1097/PAS.0000000000000988			6	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600014	29135518				2019-10-28	
J	Cellier, L; Perron, E; Pissaloux, D; Karanian, M; Haddad, V; Alberti, L; de la Fouchardiere, A				Cellier, Lucie; Perron, Emilie; Pissaloux, Daniel; Karanian, Marie; Haddad, Veronique; Alberti, Laurent; de la Fouchardiere, Arnaud			Cutaneous Melanocytoma With CRTC1-TRIM11 Fusion Report of 5 Cases Resembling Clear Cell Sarcoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cutaneous nodule; primary dermal melanocytic tumor; CRTC1-TRIM11 fusion; low-grade melanoma; melanocytoma	PRIMARY DERMAL MELANOMA; PIGMENTED EPITHELIOID MELANOCYTOMA; TUMOR; TRIM11; DISTINCT; SUBTYPE	We report 5 cases of primary intradermal nodular unpigmented tumors with a melanocytic immunophenotype associated with a novel CRTC1-TRIM11 fusion. Clinically, the cutaneous nodules were slowly growing in 3 women and 2 men (25 to 82 y old, median, 28 y) with no specific topography. Lesion size ranged from 4 to 12 mm (median, 5 mm). The tumors were strictly located in the dermis with a nodular pattern. The cells were arranged in confluent nests and fascicules. Central fibronecrotic areas were present in 2 cases. Cells were medium to large, sometimes multinucleated, and presented a spindled and epithelioid cytology with prominent nucleoli. Cytonu-clear atypia was constant, and mitotic activity in hotspot areas ranged from 1 to 5/mm(2). Immunohistochemistry found a constant positivity with S100, MiTF, and Sox10, and a heterogenous staining by MelanA or HMB45. NTRK1 was strongly positive in 3 cases. In all cases, RNA sequencing found an invariable CRTC1(e1)-TRIM11(e2) fusion, confirmed by fluorescent in situ hybridization techniques with a TRIM11 break-apart probe. In 4/4 cases, nuclear TRIM11 expression was positive by immunohistochemistry. Fluorescent in situ hybridization techniques showed no rearrangement of NTRK1 or EWSR1, and array-comparative genomic hybridization displayed no alteration (1 case) or only a whole chromosome 7 gain (2 cases) when performed. No relapse or metastatic event was observed during follow-up [3 to 72 months (median, 14 mo)]. Cutaneous clear cell sarcoma was the main differential diagnosis. Overlapping morphologic features previously described in primary dermal melanomas and paraganglioma-like melanocytic tumors were present. The CRTC1-TRIM11 fusion appears to be specific of an unpigmented nodular tumor combining a melanocytic phenotype and low-grade tumor behavior.	[Cellier, Lucie; Perron, Emilie; Pissaloux, Daniel; Karanian, Marie; Haddad, Veronique; Alberti, Laurent; de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Perron, Emilie] Univ Laval, Univ Hosp Ctr Quebec, Dept Pathol, Quebec City, PQ, Canada; [Perron, Emilie] Univ Laval, Med Sch, Dept Mol Biol Med Biochem & Pathol, Quebec City, PQ, Canada	de la Fouchardiere, A (reprint author), Ctr Leon Berard, Dept Mol Biol, 28 Rue Laennec, F-69008 Lyon, France.	arnaud.delafouchardiere@lyon.unicancer.fr	de la Fouchardiere, Arnaud/I-2807-2019	de la Fouchardiere, Arnaud/0000-0003-2251-8241; PISSALOUX, Daniel/0000-0003-1118-950X	Bourse McLaughlin du doyen de la Faculte de medecine de l'Universite Laval; TEVA Innovation Canada	The authors thank the following French pathologists and clinicians who contributed case material and follow-up information for this study: V. Butet, H. Montaudie, F. Boukari, H. Racinet, A. Patrick, F. Le Marc'Hadour, D. Lardet, D. Raoux, E. Lucidarme, T. Wiart, J. F. Quinchon, J. Charles, N. Pinel, and E. Boudaud. The authors also thank C. Bailly, D. Ranchere-Vince, A. Lazar, A. Zembowicz, S. Billings, and F. Tirode for scientific counseling. The authors thank Elodie Legrand, Amandine Bernard, Yanis Zekri, Cyrille Py, Aurelie Houlier, Florine Dreux, and Elise Malandain for their technical help. Emilie Perron gratefully acknowledges the "Bourse McLaughlin du doyen de la Faculte de medecine de l'Universite Laval" and the TEVA Innovation Canada fellowship grants.	Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Bastian BC, 1998, CANCER RES, V58, P2170; Bowen GM, 2000, ARCH DERMATOL, V136, P1397, DOI 10.1001/archderm.136.11.1397; Cassarino DS, 2008, ARCH DERMATOL, V144, P49, DOI 10.1001/archdermatol.2007.16; Chen Y, 2017, ONCOL LETT, V14, P2125, DOI 10.3892/ol.2017.6432; Chen Y, 2017, CLIN RES HEPATOL GAS, V41, P190, DOI 10.1016/j.clinre.2016.09.010; Deyrup AT, 2004, AM J SURG PATHOL, V28, P1579, DOI 10.1097/00000478-200412000-00005; Di K, 2013, ONCOGENE, V32, P5038, DOI 10.1038/onc.2012.531; Gottardo MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111548; Kraft S, 2011, AM J SURG PATHOL, V35, P599, DOI 10.1097/PAS.0b013e31820e6093; Kyrpychova L, 2016, ANN DIAGN PATHOL, V23, P8, DOI 10.1016/j.anndiagpath.2016.04.006; Lee CC, 2009, ANN SURG ONCOL, V16, P578, DOI 10.1245/s10434-008-0272-9; Mandal RV, 2009, AM J SURG PATHOL, V33, P1778, DOI 10.1097/PAS.0b013e3181b94f3c; Mentzel T, 2005, HISTOPATHOLOGY, V46, P498, DOI 10.1111/j.1365-2559.2005.02105.x; Mottaghi-Dastjerdi N, 2014, DARU, V22, DOI 10.1186/2008-2231-22-14; Niikura T, 2003, EUR J NEUROSCI, V17, P1150, DOI 10.1046/j.1460-9568.2003.02553.x; Sidiropoulos M, 2014, J AM ACAD DERMATOL, V71, P1083, DOI 10.1016/j.jaad.2014.07.051; Sun BK, 2016, J AM ACAD DERMATOL, V75, P1263, DOI 10.1016/j.jaad.2016.08.028; Swetter SM, 2004, ARCH DERMATOL, V140, P99, DOI 10.1001/archderm.140.1.99; Teow J, 2015, ANZ J SURG, V85, P664, DOI 10.1111/ans.13116; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wang XL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0379-y; Woo JS, 2006, EMBO J, V25, P1353, DOI 10.1038/sj.emboj.7600994; Yin Y, 2016, ONCOTARGET, V7, P86755, DOI 10.18632/oncotarget.13550; Zembowicz A, 2004, AM J SURG PATHOL, V28, P31, DOI 10.1097/00000478-200401000-00002	26	5	5	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					382	391		10.1097/PAS.0000000000000996			10	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600015	29240581				2019-10-28	
J	Meredith, DM; Fletcher, CDM; Jo, VY				Meredith, David M.; Fletcher, Christopher D. M.; Jo, Vickie Y.			Chondromyxoid Fibroma Arising in Craniofacial Sites A Clinicopathologic Analysis of 25 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						chondromyxoid fibroma; bone; craniofacial; skull	SKULL BASE; SOFT-TISSUE; SPHENOID SINUS; TEMPORAL BONE; NASAL-SEPTUM; GENE FUSION; TUMOR; MYOEPITHELIOMA; JAWS	Chondromyxoid fibroma (CMF) is a rare benign tumor, usually arising in the metaphysis of long bones in young adults. Occurrence in craniofacial bones presents a particular diagnostic challenge given its unusual location and resemblance to malignant mimics. We describe the clinicopathologic features of 25 cases of craniofacial CMF identified between 1999 and 2017. Patients were 14 men and 11 women, with median age of 44 years (range, 5 to 83 y). Sites of involvement were sphenoid (7), ethmoid (5), maxilla (3), occipital (2), nasal septum (2), palatine (2), temporal (2), orbit (1), and undisclosed skull (1). Tumor size ranged from 0.8 to 6.0 cm (median, 2.0cm). Of the 21 tumors with available radiology, 15 arose on the bone surface with expansion into adjacent sinuses; 6 were intraosseous. Bony erosion/destruction was present in most (13/16) cases, and 7/12 showed calcification on imaging. Microscopically, most tumors showed a lobulated growth pattern with hypocellular central chondromyxoid areas and peripheral hypercellularity, though many samples were fragmented. Tumor cells had ovoid to tapered nuclei and abundant palely eosinophilic cytoplasm, frequently with stellate cell processes. Mitoses ranged from 0 to 2 per 10 high-power fields (median count, 0). None showed necrosis. Significant atypia was present in 2 cases, 1 of which was a previously radiated recurrence. Bone infiltration was present in 6 cases. Thirteen tumors had focal calcification, and 2 had foci of hyaline cartilage. All tumors were negative for keratin and GFAP (0/24), with frequent positivity for SMA (7/7) and occasional staining for EMA (5/24) and S-100 (2/24). Most patients underwent piecemeal excision or curettage (5/5 positive margins when reported). Follow-up data were available for 15 patients, and 5 suffered local recurrence. Craniofacial CMF poses diagnostic pitfalls including frequent aggressive radiologic features and lack of a specific immunophenotype. Tumors may recur, largely due to the difficulty of obtaining clear surgical margins in this anatomic region. Furthermore, propensity for local destruction and invasion can create significant morbidity.	[Jo, Vickie Y.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Jo, VY (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	vjo@partners.org					Agaram NP, 2015, GENE CHROMOSOME CANC, V54, P63, DOI 10.1002/gcc.22216; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P675, DOI 10.1002/gcc.22063; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Arai M, 2012, BRAIN TUMOR PATHOL, V29, P201, DOI 10.1007/s10014-012-0085-1; Baker AC, 2007, AM J SURG PATHOL, V31, P1662, DOI 10.1097/PAS.0b013e31806772ec; Baujat B, 2001, AM J OTOLARYNG, V22, P150, DOI 10.1053/ajot.2001.22582; BROWNE RM, 1977, BRIT J ORAL SURG, V15, P19, DOI 10.1016/0007-117X(77)90003-8; Bucci T, 2006, INT J ORAL MAX SURG, V35, P569, DOI 10.1016/j.ijom.2005.10.006; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Crocker M, 2010, SKULL BASE-INTERD AP, V20, P101, DOI 10.1055/s-0029-1225534; Cruz AA, 2007, OPHTHAL PLAST RECONS, V23, P427, DOI 10.1097/IOP.0b013e318146986c; DAHLIN DC, 1956, CANCER, V9, P195, DOI 10.1002/1097-0142(195601/02)9:1<195::AID-CNCR2820090121>3.0.CO;2-C; Ditta LC, 2012, OPHTHAL PLAST RECONS, V28, pE105, DOI 10.1097/IOP.0b013e31823bd1e0; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Feuvret L, 2005, ACTA ONCOL, V44, P545, DOI 10.1080/00365590500237846; Fomete Benjamin, 2014, Ann Maxillofac Surg, V4, P78, DOI 10.4103/2231-0746.133072; FRANK E, 1987, SURG NEUROL, V27, P182, DOI 10.1016/0090-3019(87)90293-X; FUJII N, 1988, J ORAL MAXIL SURG, V46, P235, DOI 10.1016/0278-2391(88)90090-0; Ghanem N, 2003, EUR J RADIOL EXTRA, V46, P21; Hammad HM, 1998, ORAL SURG ORAL MED O, V85, P293, DOI 10.1016/S1079-2104(98)90011-7; Hashimoto M, 1998, NEURORADIOLOGY, V40, P577, DOI 10.1007/s002340050647; Hornick JL, 2003, AM J SURG PATHOL, V27, P1183, DOI 10.1097/00000478-200309000-00001; Huang SC, 2015, GENE CHROMOSOME CANC, V54, P267, DOI 10.1002/gcc.22240; JAFFE HL, 1948, ARCH PATHOL, V45, P541; Jo VY, 2015, HEAD NECK PATHOL, V9, P32, DOI 10.1007/s12105-015-0618-0; Kadom N, 2009, PEDIATR RADIOL, V39, P53, DOI 10.1007/s00247-008-0999-2; Kanamaru R, 1982, No Shinkei Geka, V10, P731; Karkuzhali P, 2005, NEUROPATHOLOGY, V25, P84, DOI 10.1111/j.1440-1789.2004.00576.x; Keel SB, 1997, AM J SURG PATHOL, V21, P577, DOI 10.1097/00000478-199705000-00011; Khalatbari MR, 2012, NEUROPEDIATRICS, V43, P140, DOI 10.1055/s-0032-1307460; Khosla RK, 2015, CLEFT PALATE-CRAN J, V52, P223, DOI 10.1597/13-243; KITAMURA K, 1989, ARCH OTOLARYNGOL, V115, P384; Kurzawa P, 2013, AM J SURG PATHOL, V37, P960, DOI 10.1097/PAS.0b013e3182858a0e; LeMay DR, 1997, SURG NEUROL, V48, P148, DOI 10.1016/S0090-3019(96)00462-4; LINGEN MW, 1993, ORAL SURG ORAL MED O, V75, P615, DOI 10.1016/0030-4220(93)90236-W; LUSTMANN J, 1986, J ORAL PATHOL MED, V15, P343, DOI 10.1111/j.1600-0714.1986.tb00637.x; MARUYAMA R, 1994, PATHOL INT, V44, P857, DOI 10.1111/j.1440-1827.1994.tb01684.x; McClurg SW, 2013, HEAD NECK-J SCI SPEC, V35, pE1, DOI 10.1002/hed.21760; Mendoza M, 1998, PEDIATR RADIOL, V28, P339, DOI 10.1007/s002470050369; MIYAMOTO E, 1981, J NEUROSURG, V55, P1001, DOI 10.3171/jns.1981.55.6.1001; MORIKAWA E, 1987, Neurological Surgery, V15, P1233; MORIMURA T, 1992, AM J NEURORADIOL, V13, P1261; Morris LGT, 2009, HEAD NECK PATHOL, V3, P169, DOI 10.1007/s12105-009-0121-6; Nazeer T, 1996, SKELETAL RADIOL, V25, P779, DOI 10.1007/s002560050179; Nielsen GP, 1999, MODERN PATHOL, V12, P514; Nord KH, 2014, NAT GENET, V46, P474, DOI 10.1038/ng.2927; Otto BA, 2007, ANN OTO RHINOL LARYN, V116, P922, DOI 10.1177/000348940711601209; Park HR, 2002, ONCOL REP, V9, P1087; Pauli J, 2008, PATHOLOGY, V40, P396, DOI 10.1080/00313020802035857; RAHIMI A, 1972, CANCER-AM CANCER SOC, V30, P726, DOI 10.1002/1097-0142(197209)30:3<726::AID-CNCR2820300321>3.0.CO;2-T; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Sanchez-Romero C, 2017, HEAD NECK PATHOL; Shek TWH, 1999, J LARYNGOL OTOL, V113, P380, DOI 10.1017/S0022215100144044; Soder S, 2001, AM J CLIN PATHOL, V116, P271; Suzuki S, 1999, CLIN NEUROPATHOL, V18, P37; Tarhan NC, 2000, EUR RADIOL, V10, P1678, DOI 10.1007/s003300000323; Thomas Brian, 2011, Ear Nose Throat J, V90, pE17; TOREMALM NG, 1976, J LARYNGOL OTOL, V90, P971, DOI 10.1017/S0022215100082992; Veras EFT, 2009, ANN DIAGN PATHOL, V13, P41, DOI 10.1016/j.anndiagpath.2007.05.006; Vernon SE, 2006, AM J OTOLARYNG, V27, P406, DOI 10.1016/j.amjoto.2006.01.004; Wang B, 2009, VIRCHOWS ARCH, V455, P333; Wang C, 2000, AM J RHINOL, V14, P45, DOI 10.2500/105065800781602885; WILSON AJ, 1991, RADIOLOGY, V179, P513, DOI 10.1148/radiology.179.2.2014302; Wolf DA, 1997, ARCH PATHOL LAB MED, V121, P626; Wu CT, 1998, HUM PATHOL, V29, P438; Xu HZ, 2011, J CLIN NEUROSCI, V18, P1419, DOI 10.1016/j.jocn.2011.01.035; Yaghi NK, 2016, J NEUROL SURG REP, V77, pE23, DOI 10.1055/s-0035-1570033; Yoo YT, 2012, AURIS NASUS LARYNX, V39, P422, DOI 10.1016/j.anl.2011.10.004	70	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					392	400		10.1097/PAS.0000000000001019			9	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600016	29324473				2019-10-28	
J	Furudoi, A; Riviere, E; Lazaro, E; Furudoi, E; Viallard, JF; Parrens, M				Furudoi, Adeline; Riviere, Etienne; Lazaro, Estibaliz; Furudoi, Enio; Viallard, Jean-Francois; Parrens, Marie			Adult Primary Immune Thrombocytopenia Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						immune thrombocytopenia; splenectomy; rituximab; spleen pathology; immunochemistry	ANTIPLATELET-ANTIBODY-PRODUCTION; CELL-DEPLETING THERAPY; DENDRITIC CELLS; PLATELET COUNT; PURPURA; SPLENECTOMY; EFFICACY; SAFETY; ITP; MANAGEMENT	Immune thrombocytopenia (ITP) is an acquired antibody-mediated disease, for which splenectomy remains a curative treatment. We analyzed histology and phenotypes of ITP-splenectomy specimens from 41 adult patients, with different previous ITP-specific treatments, including B-cell-depleting rituximab (RTX) or not, in an attempt to predict splenectomy success or failure on the basis of day 56 postoperative platelet counts. RTX-naive ITP-spleen samples, compared with those from a 20-patient control trauma cohort, contained the following nonspecific, ITP-evocative, white-pulp lesions: follicular helper T-cell (programmed death-1(+) and inducible T-cell COS-timulator(+)) expansion in reactive follicles (P = 0.01 and 0.03, respectively) and regulatory T-cell (FOXP3(+)) expansion in the T-cell zone (P = 0.049). On comparing ITP-splenectomy samples that would be successful with those that would be failures, only marginal zone hyperplasia differed (P = 0.017). Indeed, 13/21 (61.9%) successful splenectomy samples exhibited marginal zone hyperplasia, as opposed to 1/9 (11.1%) failed splenectomy specimens. RTX impact on ITP-splenectomy samples was characterized by white-pulp (P = 0.03) and marginal zone atrophies (P = 0.01), and periarteriolar T-cell-zone hyperplasia (P<0.0001). The results of this novel comparative study of the histologic patterns of 41 ITP patients' evocative splenic lesions enabled clear description of different ITP morphologies and phenotypes, as a function of prior treatment and splenectomy success or failure.	[Furudoi, Adeline; Parrens, Marie] Haut Leveque Hosp, Univ Hosp Ctr Bordeaux, Pathol Dept, Bordeaux, France; [Riviere, Etienne; Viallard, Jean-Francois] Haut Leveque Hosp, Univ Hosp Ctr Bordeaux, Internal Med Dept, Bordeaux, France; [Riviere, Etienne; Lazaro, Estibaliz; Viallard, Jean-Francois] INSERM, U1034, Pessac, France; [Furudoi, Enio] Bordeaux Univ Hosp, Intens Care Unit, Pessac, France; [Furudoi, Adeline; Riviere, Etienne; Lazaro, Estibaliz; Furudoi, Enio; Viallard, Jean-Francois; Parrens, Marie] Univ Bordeaux, Med Sch, Bordeaux, France; [Parrens, Marie] Univ Bordeaux, Bariton Unit, Bordeaux, France	Furudoi, A (reprint author), CHU Bordeaux, Grp Sud, Hop Haut Leveque, Serv Pathol, Ave Magellan, F-33604 Pessac, France.	adeline.furudoi@gmail.com		Riviere, Etienne/0000-0003-0254-3394	AmgenAmgen; NovartisNovartis	J.-F.V. has served as a consultant for Amgen and Novartis, and participated on advisory boards and/or as a speaker at medical education events supported by Amgen and Novartis. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Aslam R, 2016, EXP HEMATOL, V44, P924, DOI 10.1016/j.exphem.2016.07.004; Audia S, 2017, AUTOIMMUN REV, V16, P620, DOI 10.1016/j.autrev.2017.04.012; Audia S, 2017, J AUTOIMMUN, V77, P89, DOI 10.1016/j.jaut.2016.11.002; Audia S, 2014, BLOOD, V124, P2858, DOI 10.1182/blood-2014-03-563445; Audia S, 2011, BLOOD, V118, P4394, DOI 10.1182/blood-2011-03-344051; Catani L, 2006, EXP HEMATOL, V34, P879, DOI 10.1016/j.exphem.2006.03.009; Catani L, 2013, ANN HEMATOL, V92, P67, DOI 10.1007/s00277-012-1556-5; Cuker A, 2010, HEMATOL-AM SOC HEMAT, P385, DOI 10.1182/asheducation-2010.1.385; Daridon C, 2012, BLOOD, V120, P5021, DOI 10.1182/blood-2012-04-424648; Furudoi A, 2016, AM J SURG PATHOL, V40, P958, DOI 10.1097/PAS.0000000000000661; Godeau B, 2008, BLOOD, V112, P999, DOI 10.1182/blood-2008-01-131029; HAYES MM, 1985, J CLIN PATHOL, V38, P985, DOI 10.1136/jcp.38.9.985; Khellaf M, 2005, HAEMATOL-HEMATOL J, V90, P829; Khellaf M, 2014, BLOOD, V124, P3228, DOI 10.1182/blood-2014-06-582346; Kojouri K, 2004, BLOOD, V104, P2623, DOI 10.1182/blood-2004-03-1168; Kuwana M, 2002, J IMMUNOL, V168, P3675, DOI 10.4049/jimmunol.168.7.3675; Ling Y, 2007, EUR J HAEMATOL, V79, P310, DOI 10.1111/j.1600-0609.2007.00917.x; Liu B, 2007, EUR J HAEMATOL, V78, P139, DOI 10.1111/j.1600-0609.2006.00780.x; Mahevas M, 2013, J CLIN INVEST, V123, P432, DOI 10.1172/JCI65689; MCMILLAN R, 1974, NEW ENGL J MED, V291, P812, DOI 10.1056/NEJM197410172911602; Melboucy-Belkhir S, 2016, AM J HEMATOL, V91, pE499, DOI 10.1002/ajh.24529; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Neunert C, 2011, BLOOD, V117, P4190, DOI 10.1182/blood-2010-08-302984; O'Malley DP, 2009, BENIGN REACTIVE COND, P109; Patel VL, 2012, BLOOD, V119, P5989, DOI 10.1182/blood-2011-11-393975; Provan D, 2015, ADV THER, V32, P875, DOI 10.1007/s12325-015-0251-z; Provan D, 2010, BLOOD, V115, P168, DOI 10.1182/blood-2009-06-225565; Radaelli F, 2000, HAEMATOLOGICA, V85, P1040; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Sarpatwari A, 2010, BRIT J HAEMATOL, V151, P477, DOI 10.1111/j.1365-2141.2010.08377.x; Segal JB, 2006, J THROMB HAEMOST, V4, P2377, DOI 10.1111/j.1538-7836.2006.02147.x; SEMPLE JW, 1991, BLOOD, V78, P2619; Sollazzo D, 2015, IMMUNOL LETT, V166, P63, DOI 10.1016/j.imlet.2015.04.006; Stasi R, 2008, BLOOD, V112, P1147, DOI 10.1182/blood-2007-12-129262; Vianelli N, 2005, HAEMATOLOGICA, V90, P72; Vianelli N, 2013, HAEMATOLOGICA, V98, P875, DOI 10.3324/haematol.2012.075648; Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304	37	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					401	412		10.1097/PAS.0000000000000994			12	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600017	29200102				2019-10-28	
J	Shah, KK; McHugh, JB; Folpe, AL; Patel, RM				Shah, Kabeer K.; McHugh, Jonathan B.; Folpe, Andrew L.; Patel, Rajiv M.			Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites A Clinicopathologic Analysis of 27 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						dermatofibrosarcoma protuberans; digit; acral; distal extremity	MOHS MICROGRAPHIC SURGERY; WIDE LOCAL EXCISION; TERM-FOLLOW-UP; FIBROSARCOMATOUS TRANSFORMATION; PROGNOSTIC-SIGNIFICANCE; FACTOR-XIIIA; CHILDHOOD; LESIONS; HAND; METASTASIS	Dermatofibrosarcoma protuberans (DFSP) of the distal extremities and acral sites are extremely rare and incompletely characterized. Twenty-seven DFSP occurring in these sites were retrieved from our collective archives and reevaluated. Tumors occurred in 16 males and 11 females. Median age at presentation was 42.5 years (range, 7 to 78 y). Lesions involved the foot (18 with 6 in the toes and 2 on the plantar foot), distal ankle (4), hand (4 with 2 in the thumbs), and wrist (1). All cases showed predominantly classic DFSP morphology and were diffusely CD34 positive. Myxoid change, melanin pigmented, and giant cell fibroblastoma foci were each present in 1 case, respectively. Fibrosarcomatous change was present in 3 cases. Fluorescent in situ hybridization demonstrated PDGFB gene rearrangement in 9 of 10 tested cases. Clinical follow-up was available in 21 cases (median, 36.1 mo; range, 1 to 152 mo) and revealed 4 local recurrences. Four patients underwent digital amputation for unresectable recurrent disease. An additional patient underwent multiple resections with positive margins and elected to receive imatinib mesylate therapy. After a 2-year course, the patient has no evidence of residual disease (40 mo). No metastases were documented in any of the cases studied. The natural history of DFSP of distal extremities and acral sites is similar to that of its counterparts elsewhere. A high index of suspicion, careful morphologic examination for key histologic features of DFSP, and in selected cases, molecular studies to identify the pathognomonic COL1A1-PDGFB gene fusion should facilitate the distinction of these rare, locally aggressive neoplasms from morphologic mimics that may arise in distal extremities and acral sites.	[Shah, Kabeer K.; Folpe, Andrew L.] Univ Michigan, Dept Lab Med & Pathol, Ann Arbor, MI 48109 USA; [McHugh, Jonathan B.; Patel, Rajiv M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Patel, Rajiv M.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA	Patel, RM (reprint author), 3261G Med Sci 1,1301 Catherine St,SPC 5602, Ann Arbor, MI 48109 USA.	rajivpat@med.umich.edu		PATEL, Rajiv/0000-0002-1521-4947	SARC SPORE [U54 CA168512]	Supported by the SARC SPORE grant: U54 CA168512.	Abbott JJ, 2006, AM J SURG PATHOL, V30, P436, DOI 10.1097/00000478-200604000-00002; Al-Zaid T, 2017, J CUTAN PATHOL, V44, P794, DOI 10.1111/cup.12982; BASHARA M E, 1992, Journal of Foot Surgery, V31, P160; BERLIN SJ, 1980, J AM POD ASSOC, V70, P318, DOI 10.7547/87507315-70-7-318; BONNABEAU RC, 1974, ONCOLOGY-BASEL, V29, P1; Bowne WB, 2000, CANCER, V88, P2711; BRENNER W, 1975, CANCER, V36, P1897, DOI 10.1002/1097-0142(197511)36:5<1897::AID-CNCR2820360547>3.0.CO;2-X; COHEN PR, 1994, AM J DERMATOPATH, V16, P573, DOI 10.1097/00000372-199410000-00022; COLES M, 1989, J HAND SURG-AM, V14A, P135, DOI 10.1016/0363-5023(89)90073-7; Franco JPD, 2014, AN BRAS DERMATOL, V89, P357, DOI 10.1590/abd1806-4841.20142696; DOMS SR, 1982, J AM POD ASSOC, V72, P63, DOI 10.7547/87507315-72-2-63; Erdem O, 2012, AM J DERMATOPATH, V34, P24, DOI 10.1097/DAD.0b013e3182120671; Gerlini G, 2008, PEDIATR HEMAT ONCOL, V25, P559, DOI 10.1080/08880010802235066; Gloster HM, 1996, J AM ACAD DERMATOL, V35, P82; Goldblum JR, 2000, AM J SURG PATHOL, V24, P1125, DOI 10.1097/00000478-200008000-00010; HOBBS ER, 1988, CLEV CLIN J MED, V55, P252; Hoesly PM, 2015, J AM ACAD DERMATOL, V72, P419, DOI 10.1016/j.jaad.2014.11.020; Kahn HJ, 2001, HUM PATHOL, V32, P50, DOI 10.1053/hupa.2001.21137; KRAEMER BA, 1990, ANN PLAS SURG, V25, P295, DOI 10.1097/00000637-199010000-00009; LeBoit PE, 2005, PATHOLOGY GENETICS S; Liang CA, 2014, J AM ACAD DERMATOL, V71, P781, DOI 10.1016/j.jaad.2014.03.018; Lowe GC, 2017, DERMATOL SURG, V43, P98, DOI 10.1097/DSS.0000000000000910; Martin L, 1998, BRIT J DERMATOL, V139, P719; MCKEE PH, 1991, J CUTAN PATHOL, V18, P241, DOI 10.1111/j.1600-0560.1991.tb01230.x; McNiff JM, 2005, J CUTAN PATHOL, V32, P413, DOI 10.1111/j.0303-6987.2005.00358.x; MCPEAK CJ, 1967, ANN SURG, V166, P803, DOI 10.1097/00000658-196711000-00011; Mentzel T, 2007, AM J DERMATOPATH, V29, P443, DOI 10.1097/DAD.0b013e318145413c; Miettinen M, 1999, HUM PATHOL, V30, P934, DOI 10.1016/S0046-8177(99)90247-2; Mizushima J, 1996, DERMATOLOGY, V192, P280, DOI 10.1159/000246386; Patel KU, 2008, HUM PATHOL, V39, P184, DOI 10.1016/j.humpath.2007.06.009; RABINOWITZ LG, 1994, J DERMATOL SURG ONC, V20, P655, DOI 10.1111/j.1524-4725.1994.tb00447.x; Ratner D, 1997, J AM ACAD DERMATOL, V37, P600, DOI 10.1016/S0190-9622(97)70179-8; RIZNYK P J, 1987, Journal of Foot Surgery, V26, P153; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; SCHVARCZ LW, 1977, HAND, V9, P182, DOI 10.1016/S0072-968X(77)80016-8; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Skoll PJ, 1999, ANN PLAS SURG, V42, P217; TAYLOR HB, 1962, CANCER, V15, P717, DOI 10.1002/1097-0142(196207/08)15:4<717::AID-CNCR2820150405>3.0.CO;2-2; Terrier-Lacombe MJ, 2003, AM J SURG PATHOL, V27, P27, DOI 10.1097/00000478-200301000-00004; Ugurel S, 2014, CLIN CANCER RES, V20, P499, DOI 10.1158/1078-0432.CCR-13-1411; Valdivielso-Ramos M, 2014, PEDIATR DERMATOL, V31, P676, DOI 10.1111/pde.12371; WIRMAN JA, 1981, HAND, V13, P187, DOI 10.1016/S0072-968X(81)80062-9	42	6	6	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					413	419		10.1097/PAS.0000000000000998			7	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600018	29240584				2019-10-28	
J	Suarez-Vilela, D; Izquierdo, FM; Mendez-Alvarez, JR; Velasco-Alonso, J				Suarez-Vilela, Dimas; Izquierdo, Francisco M.; Mendez-Alvarez, Jose R.; Velasco-Alonso, Julio			The Squamoid Cells in Biphasic Squamoid Alveolar Renal Carcinoma Present Cytophagocytosis (Not Emperipolesis) of Apoptotic Neutrophilic Granulocytes	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							HORIZONTAL GENE-TRANSFER; PHAGOCYTOSIS CANNIBALISM; MORPHOLOGIC VARIANT		[Suarez-Vilela, Dimas; Mendez-Alvarez, Jose R.; Velasco-Alonso, Julio] Ctr Med Asturias, Dept Pathol, Oviedo, Spain; [Izquierdo, Francisco M.] Complejo Asistencial Univ Leon, Dept Pathol, Leon, Spain	Suarez-Vilela, D (reprint author), Ctr Med Asturias, Dept Pathol, Oviedo, Spain.						Barresi V, 2015, WORLD J GASTROENTERO, V21, P5548, DOI 10.3748/wjg.v21.i18.5548; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Caruso R. A., 2012, Experimental Oncology, V34, P306; Caruso RA, 2002, ULTRASTRUCT PATHOL, V26, P315, DOI 10.1080/01913120290104593; Chartier S, 2017, AM J SURG PATHOL, V41, P1011, DOI 10.1097/PAS.0000000000000870; Cishek AC, 2014, VIRCHOWS ARCH, V465, pS157; Fornetti J, 2016, CELL DEATH DIFFER, V23, P185, DOI 10.1038/cdd.2015.82; Hes O, 2016, AM J SURG PATHOL, V40, P664, DOI 10.1097/PAS.0000000000000639; Holmgren L, 2010, BIOCHEM BIOPH RES CO, V396, P147, DOI 10.1016/j.bbrc.2010.04.026; Krajcovic M, 2012, CANCER RES, V72, P1596, DOI 10.1158/0008-5472.CAN-11-3127; Lopez Jose Ignacio, 2016, F1000Res, V5, P607, DOI 10.12688/f1000research.8451.2; Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040; Petersson F, 2012, ANN DIAGN PATHOL, V16, P459, DOI 10.1016/j.anndiagpath.2012.08.007; Troxell ML, 2016, HUM PATHOL, V57, P28, DOI 10.1016/j.humpath.2016.06.018; Trpkov K, 2017, MODERN PATHOL, V30, p264A; Yan B, 2006, BRIT J CANCER, V95, P1696, DOI 10.1038/sj.bjc.6603484	16	0	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					420	422		10.1097/PAS.0000000000000906			3	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600019	29194094				2019-10-28	
J	DeLellis, RA; Caton, M				DeLellis, Ronald A.; Caton, Mirlinda			The AFIP/ARP Atlases of Pathology Past, Present, and Future	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						AFIP; American Registry of Pathology; ARP; tumor and nontumor fascicles; atlases		The AFIP (Armed Forces Institute of Pathology) Atlases (Fascicles) have been in continuous publication for nearly 75 years and have enjoyed a highly regarded reputation for their excellence. Throughout this time period, more than 130 volumes, encompassing the 1st to 4th series have been published. Since their inception in the 1940's, the Fascicles have evolved from loose-leafed atlases illustrated with black and white images, to hardbound monographs with full color images and expansion of scope, including relevant clinical information, cytopathology, and the most recent advances in immunohistochemistry and molecular diagnostics. Each of the volumes undergoes a rigorous review process by the Editor-in-Chief, Associate Editors, members of the Editorial Advisory Board, and external reviewers. The 5th series, under the editorial direction of Drs. Elizabeth Montgomery and Jason Hornick, is well underway and will include an Epub version and a virtual slide box, in addition to the hardbound book. The Atlases of Nontumor Pathology will also continue to be published. With the closure of the AFIP in 2011, the American Registry of Pathology (ARP) has assumed full responsibility for the publication of both the Tumor and Nontumor Fascicles.	[DeLellis, Ronald A.] Rhode Isl Hosp, Dept Pathol, Lifespan Acad Med Ctr, 593 Eddy St, Providence, RI 02902 USA; [Caton, Mirlinda] Georgetown Univ, Washington, DC USA; [DeLellis, Ronald A.; Caton, Mirlinda] Amer Registry Pathol, Rockville, MD USA	DeLellis, RA (reprint author), Rhode Isl Hosp, Dept Pathol, Lifespan Acad Med Ctr, 593 Eddy St, Providence, RI 02902 USA.	rdelellis@lifespan.org					Firminger HI, 1967, TUMORS SOFT TISSUES; Henry RS, 1964, ARMED FORCES I PATHO, P319; Ishak KG, 1997, GUIDNG SURG HAND HIS, P181; King DW, 2002, ENDOCRINE DIS ATLAS; Lucke B, 1949, ATLAS TUMOR PATHOLOG; Rosai J, 1991, NONMELANOTIC TUMORS; Silverberg SS, 2004, TUMORS KIDNEY BLADDE; SOBIN LH, 1981, B WORLD HEALTH ORGAN, V59, P813; Stone P, 2011, LEGACY EXCELLENCE AR, P109; STOUT AP, 1955, AM J CLIN PATHOL, V25, P175	10	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					E28	E32		10.1097/PAS.0000000000001012			5	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600001	29309305				2019-10-28	
J	Perez-Ordonez, B				Perez-Ordonez, Bayardo			Neuroendocrine Carcinomas of the Larynx and Head and Neck: Challenges in Classification and Grading	HEAD & NECK PATHOLOGY			English	Article						Neuroendocrine carcinoma; Carcinoid tumor; Atypical carcinoid tumor; Large cell carcinoma; Small cell carcinoma; Head and neck; Larynx	SQUAMOUS-CELL CARCINOMA; TUMORS; NEOPLASMS	Primary neuroendocrine carcinomas (NECs) of the larynx and head and neck are an uncommon and heterogeneous group of neoplasms categorized by the 2017 WHO Classification of Head and Neck Tumors as: (a) well-differentiated (WD-NEC), (b) moderately-differentiated (MD-NEC), and (c) poorly-differentiated (PD-NEC) with small cell and large cell types. The classification incorporates elements of differentiation and grading and closely correlates to the 5-year disease specific survival of 100, 52.8, 19.3 and 15.3% for each diagnostic category. These survival rates are based on historical data limited by the previous lack of standard pathologic diagnostic criteria. The classification has de-emphasized the use of the terms "carcinoid" and "atypical carcinoid" as diagnostic categories. The adoption of uniform pathologic criteria for the classification of NECs of the head and neck should enable the design of high quality studies in order to understand the molecular alterations of these neoplasms.	[Perez-Ordonez, Bayardo] Toronto Gen Hosp, Univ Hlth Network, Dept Anat Pathol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada; [Perez-Ordonez, Bayardo] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Perez-Ordonez, B (reprint author), Toronto Gen Hosp, Univ Hlth Network, Dept Anat Pathol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.; Perez-Ordonez, B (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	bayardo.perez-ordonez@uhn.ca					Alos L, 2016, VIRCHOWS ARCH, V469, P277, DOI 10.1007/s00428-016-1982-1; Bapat U, 2005, EUR ARCH OTO-RHINO-L, V262, P194, DOI 10.1007/s00405-004-0788-y; Barnes L., 2005, PATHOLOGY GENETICS H, P135; Brambilla E, 2015, WHO CLASSIFICATION T, P63; Capelli M, 2007, TUMORI, V93, P499; Chung EJ, 2008, CLIN EXP OTORHINOLAR, V1, P217, DOI 10.3342/ceo.2008.1.4.217; Chung JH, 2004, LARYNGOSCOPE, V114, P1264, DOI 10.1097/00005537-200407000-00023; Davies-Husband CR, 2010, J LARYNGOL OTOL, V124, P226, DOI 10.1017/S0022215109991228; Deep NL, 2016, ANN OTO RHINOL LARYN, V125, P464, DOI 10.1177/0003489415619179; DUVALL E, 1983, J LARYNGOL OTOL, V97, P1073, DOI 10.1017/S0022215100095992; Franchi A, 2015, HEAD NECK PATHOL, V9, P107, DOI 10.1007/s12105-013-0513-5; GOLDMAN NC, 1969, ARCH OTOLARYNGOL, V90, P64; Greene L, 2005, J CLIN PATHOL, V58, P658, DOI 10.1136/jcp.2004.019927; Halmos GB, 2013, EUR ARCH OTO-RHINO-L, V270, P719, DOI 10.1007/s00405-012-2075-7; Kao HL, 2012, AM J SURG PATHOL, V36, P185, DOI 10.1097/PAS.0b013e318236d822; Kim JY, 2016, ARCH PATHOL LAB MED, V140, P437, DOI 10.5858/arpa.2015-0314-RA; Kloppel G, 2017, WHO CLASSIFICATION T, V10, P209; Kusafuka K, 2012, J CLIN PATHOL, V65, P704, DOI 10.1136/jclinpath-2012-200801; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa S, 2013, HEAD NECK PATHOL, V7, P76, DOI 10.1007/s12105-012-0379-y; Lewis JS, 2011, LARYNGOSCOPE, V121, P1187, DOI 10.1002/lary.21790; Lewis JS, 2010, HEAD NECK PATHOL, V4, P198, DOI 10.1007/s12105-010-0188-0; MILROY CM, 1991, HISTOPATHOLOGY, V18, P201, DOI 10.1111/j.1365-2559.1991.tb00827.x; OLOFSSON J, 1972, ANN OTO RHINOL LARYN, V81, P284, DOI 10.1177/000348947208100218; Pelosi G, 2017, TRANSL LUNG CANCER R, V6, P513, DOI 10.21037/tlcr.2017.09.04; Perez-Ordonez B, 2017, WHO CLASSIFICATION H, P95; SCHMIDT U, 1994, J LARYNGOL OTOL, V108, P272, DOI 10.1017/S0022215100126519; STANLEY RJ, 1986, ARCH OTOLARYNGOL, V112, P529; Thompson ED, 2016, AM J SURG PATHOL, V40, P471, DOI 10.1097/PAS.0000000000000580; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; van der Laan TP, 2015, HEAD NECK-J SCI SPEC, V37, P707, DOI 10.1002/hed.23666; Wang QY, 2014, INT J CLIN EXP PATHO, V7, P9028; WENIG BM, 1988, CANCER, V62, P2658, DOI 10.1002/1097-0142(19881215)62:12<2658::AID-CNCR2820621235>3.0.CO;2-M; WOODRUFF JM, 1991, ORL J OTO-RHINO-LARY, V53, P194, DOI 10.1159/000276219; WOODRUFF JM, 1985, AM J SURG PATHOL, V9, P771, DOI 10.1097/00000478-198511000-00001	35	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					1	8		10.1007/s12105-018-0894-6			8	Pathology	Pathology	GA6TM	WOS:000428467200001	29557536	Green Published			2019-10-28	
J	Westra, WH				Westra, William H.			Human Papillomavirus-Related Neuroendocrine Carcinomas of the Head and Neck	HEAD & NECK PATHOLOGY			English	Article						Human papillomavirus; Small cell carcinoma; Large cell neuroendocrine carcinoma; Neuroendocrine differentiation; Head and neck cancer; Non-keratinizing squamous cell carcinoma; INSM1	SMALL-CELL CARCINOMA; OROPHARYNGEAL CANCER; HPV; TUMORS; SURVIVAL; CERVIX; LUNG	Human papillomavirus (HPV)-related head and neck carcinoma (HNC) represents an important subgroup of head and neck cancer that is characterized by a consistent microscopic appearance and a favorable prognosis. A growing experience with HPV testing, however, has uncovered variants that deviate from the prototypic HPV-HNC with respect to morphology. While these HPV-HNCs may deviate morphologically from the prototype, they do not appear to stray far from the favorable clinical outcome assigned to HPV-positive status. In effect, HPV positivity trumps traditional prognostic features predicated on morphology such as tumor grade and histologic subtype when it comes to predicting clinical behavior. For the diagnostic pathologist, the pedestrian task of tumor grading and subtyping would seem to be of little prognostic or therapeutic relevance when it comes to HPV-HNC. Recognition and documentation of neuroendocrine differentiation is a most notable exception. Forms of HPV-HNC have now been reported that morphologically resemble small cell carcinoma (SCC) and large cell neuroendocrine carcinoma (LCNEC) of other sites, and that immunohistochemically exhibit neuroendocrine differentiation. Despite the presence of HPV, these SCCs and LCNECs share the same aggressive clinical behavior of their counterparts in the lung and other sites where the high grade neuroendocrine phenotype is associated with early distant spread and poor overall survival. Consequently, the high grade neuroendocrine phenotype should be regarded as an aggressive form of HPV-HNC where tumor morphology displaces HPV positivity as the most important prognostic feature.	[Westra, William H.] Mt Sinai Hosp, Icahn Sch Med, Dept Pathol, Annenberg Bldg,Room 15-54,1468 Madison Ave, New York, NY 10029 USA	Westra, WH (reprint author), Mt Sinai Hosp, Icahn Sch Med, Dept Pathol, Annenberg Bldg,Room 15-54,1468 Madison Ave, New York, NY 10029 USA.	wwestra@jhmi.edu					ABELER VM, 1994, CANCER, V73, P672, DOI 10.1002/1097-0142(19940201)73:3<672::AID-CNCR2820730328>3.0.CO;2-R; Alos L, 2016, VIRCHOWS ARCH, V469, P277, DOI 10.1007/s00428-016-1982-1; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Begum S, 2008, AM J SURG PATHOL, V32, P1044, DOI 10.1097/PAS.0b013e31816380ec; Bishop JA, 2011, AM J SURG PATHOL, V35, P1679, DOI 10.1097/PAS.0b013e3182299cde; Crowder S, 2007, SEMIN ONCOL, V34, P57, DOI 10.1053/j.seminoncol.2006.10.028; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Hatoum GF, 2009, INT J RADIAT ONCOL, V74, P477, DOI 10.1016/j.ijrobp.2008.08.014; Kraft S, 2012, AM J SURG PATHOL, V36, P321, DOI 10.1097/PAS.0b013e31823f2f17; Lewis JS, 2017, HEAD NECK PATHOL; Misawa K, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3501-x; Renner G, 2007, SEMIN ONCOL, V34, P3, DOI 10.1053/j.seminoncol.2006.10.024; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Thariat J, 2010, J CLIN PATHOL, V63, P857, DOI 10.1136/jcp.2010.078154; Thompson ED, 2016, AM J SURG PATHOL, V40, P471, DOI 10.1097/PAS.0000000000000580; Wang KL, 2006, J CHEMOTHERAPY, V18, P209, DOI 10.1179/joc.2006.18.2.209; Westra W, 2017, WHO CLASSIFICATION H; Westra WH, 2015, SEMIN DIAGN PATHOL, V32, P42, DOI 10.1053/j.semdp.2015.02.023; Wuerdemann N, 2017, ONCOL RES TREAT, V40, P320, DOI 10.1159/000477097	20	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					9	12		10.1007/s12105-018-0886-6			4	Pathology	Pathology	GA6TM	WOS:000428467200002	29556964	Green Published			2019-10-28	
J	Chernock, RD; Duncavage, EJ				Chernock, Rebecca D.; Duncavage, Eric J.			Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin	HEAD & NECK PATHOLOGY			English	Article						Salivary; Neuroendocrine carcinoma; Small cell carcinoma; Large cell neuroendocrine carcinoma; Merkel cell polyomavirus; Merkel cell carcinoma	MERKEL-CELL-CARCINOMA; PAROTID-GLAND; UNDIFFERENTIATED CARCINOMA; SUBMANDIBULAR-GLAND; SPONTANEOUS REGRESSION; POLYOMAVIRUS DNA; UNKNOWN PRIMARY; LUNG-CANCER; EXPRESSION; FEATURES	Salivary neuroendocrine carcinomas are rare and the overwhelming majority is high-grade. The parotid gland is the most commonly involved site followed by the submandibular gland. Most arise de novo but rare examples occurring as a high-grade transformation of another type of salivary gland neoplasm exist. There is significant morphologic and immunophenotypic overlap with neuroendocrine carcinomas of other sites, especially the skin. Like cutaneous neuroendocrine (or Merkel cell) carcinomas, approximately three-fourths are cytokeratin 20 positive. Cytokeratin 20 positive salivary neuroendocrine carcinomas are often referred to as being of the 'Merkel cell type' since most other non-cutaneous neuroendocrine carcinomas are cytokeratin 20 negative. Salivary neuroendocrine carcinomas may be challenging to separate from Merkel cell carcinomas of the head and neck on pathologic grounds because the latter often metastasize to the parotid gland. Clinical history is often relied upon to separate primary salivary tumors from cutaneous metastases but may not be helpful in all cases. Here we review the clinical, pathologic and molecular features of salivary neuroendocrine carcinomas focusing on high-grade major salivary gland tumors. The difficulty in separating salivary tumors from metastatic Merkel cell carcinoma will be highlighted.	[Chernock, Rebecca D.; Duncavage, Eric J.] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA; [Chernock, Rebecca D.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA	Chernock, RD (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.; Chernock, RD (reprint author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.	rchernock@path.wustl.edu					Andersson MK, 2016, ORAL ONCOL, V57, P63, DOI 10.1016/j.oraloncology.2016.04.002; Andreasen S, 2016, ONCOL REP, V35, P2177, DOI 10.3892/or.2016.4621; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Behera M, 2016, CANCER-AM CANCER SOC, V122, P50, DOI 10.1002/cncr.29674; Casas P, 2005, AURIS NASUS LARYNX, V32, P89, DOI 10.1016/j.anl.2004.11.016; Chan JKC, 1997, AM J SURG PATHOL, V21, P226, DOI 10.1097/00000478-199702000-00014; Chen KT, 2013, AM J SURG, V206, P752, DOI 10.1016/j.amjsurg.2013.02.005; Chen TT, 2011, J CLIN VIROL, V50, P125, DOI 10.1016/j.jcv.2010.10.015; Chernock RD, 2011, AM J SURG PATHOL, V35, P1806, DOI 10.1097/PAS.0b013e318236a9b0; Cheuk W, 2001, ARCH PATHOL LAB MED, V125, P228; Cimino PJ, 2014, MODERN PATHOL, V27, P1073, DOI 10.1038/modpathol.2013.235; Cimino-Mathews A, 2012, HEAD NECK PATHOL, V6, P502, DOI 10.1007/s12105-012-0376-1; Clark J, 2016, ADV OTO-RHINO-LARYNG, V78, P95, DOI 10.1159/000442129; de Biase D, 2012, HUM PATHOL, V43, P980, DOI 10.1016/j.humpath.2011.08.014; Duncavage EJ, 2009, AM J SURG PATHOL, V33, P1771, DOI 10.1097/PAS.0b013e3181ba7b73; Duncavage EJ, 2009, MODERN PATHOL, V22, P516, DOI 10.1038/modpathol.2009.3; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fisher CA, 2014, OR SURG OR MED OR PA, V118, P705, DOI 10.1016/j.oooo.2014.09.012; Fornelli A, 2001, HISTOPATHOLOGY, V39, P342, DOI 10.1046/j.1365-2559.2001.01240.x; GNEPP DR, 1990, CANCER, V66, P185, DOI 10.1002/1097-0142(19900701)66:1<185::AID-CNCR2820660133>3.0.CO;2-4; Goyal B, 2014, EXP MOL PATHOL, V97, P572, DOI 10.1016/j.yexmp.2014.10.011; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Jorcano S, 2008, CLIN TRANSL ONCOL, V10, P303, DOI 10.1007/s12094-008-0203-z; Kawaratani Hideto, 2013, J Med Case Rep, V7, P81, DOI 10.1186/1752-1947-7-81; Lee JH, 2015, INT J CLIN EXP PATHO, V8, P2987; Leroux-Kozal V, 2015, HUM PATHOL, V46, P443, DOI 10.1016/j.humpath.2014.12.001; Liu MD, 2014, ONCOL LETT, V8, P1275, DOI 10.3892/ol.2014.2258; Lombardi D, 2015, HEAD NECK PATHOL, V9, P309, DOI 10.1007/s12105-014-0573-1; MAIR S, 1989, ACTA CYTOL, V33, P164; Michaels L, 1999, AM J MED GENET, V83, P183; Moghaddam PA, 2016, AM J DERMATOPATH, V38, pE154, DOI 10.1097/DAD.0000000000000614; Mulder DC, 2010, BRIT J ORAL MAX SURG, V48, P199, DOI 10.1016/j.bjoms.2009.06.008; Nagao T, 2000, MODERN PATHOL, V13, P554, DOI 10.1038/modpathol.3880096; Nagao T, 2004, AM J SURG PATHOL, V28, P762, DOI 10.1097/01.pas.0000126776.65815.48; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Pan ZG, 2014, MODERN PATHOL, V27, P1182, DOI 10.1038/modpathol.2013.250; Petrone G, 2013, INT J SURG PATHOL, V21, P85, DOI 10.1177/1066896912446747; Prewett SL, 2015, CLIN ONCOL-UK, V27, P436, DOI 10.1016/j.clon.2015.04.007; Rodriguez JCD, 2004, ANN OTO RHINOL LARYN, V113, P55, DOI 10.1177/000348940411300113; Said-Al-Naief N, 2013, HEAD NECK PATHOL, V7, P295, DOI 10.1007/s12105-013-0431-6; Saini AT, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S72202; Shuda M, 2009, INT J CANCER, V125, P1243, DOI 10.1002/ijc.24510; Siciliano S, 2001, J ORAL MAXIL SURG, V59, P1359, DOI 10.1053/joms.2001.27535; Signorini L, 2014, J CLIN VIROL, V61, P565, DOI 10.1016/j.jcv.2014.10.012; Thompson LD, 2016, HEAD NECK PATHOL, V10, P152, DOI 10.1007/s12105-015-0645-x; Ueo T, 2005, APMIS, V113, P456, DOI 10.1111/j.1600-0463.2005.apm_231.x; Vural C, 2000, OTOLARYNG HEAD NECK, V122, P151, DOI 10.1016/S0194-5998(00)70167-7; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Yamagata K, 2016, CASE REP DENT, DOI 10.1155/2016/7462690	49	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					13	21		10.1007/s12105-018-0896-4			9	Pathology	Pathology	GA6TM	WOS:000428467200003	29556963	Green Published			2019-10-28	
J	Bell, D				Bell, Diana			Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma	HEAD & NECK PATHOLOGY			English	Article						Sinonasal neuroendocrine tumors; Sinonasal small cell carcinoma; Sinonasal large cell carcinoma; Olfactory neuroblastoma	COMPARATIVE GENOMIC HYBRIDIZATION; OF-THE-LITERATURE; MULTIMODALITY TREATMENT; MAXILLARY SINUS; CELL CARCINOMA; NASAL CAVITY; ESTHESIONEUROBLASTOMA; TUMORS; MANAGEMENT; SURVIVAL	Sinonasal tumors with neuroendocrine differentiation form a group of rare heterogeneous neoplasms of neuroectodermal and epithelial origin, consisting of olfactory neuroblastomas and neuroendocrine carcinomas. Because the natural history and biological behavior of this group of tumors vary, the morphological diagnosis coupled with grading/staging is important for prognostication, and the approach to treatment and rehabilitation is multidisciplinary. The identification of molecular abnormalities underlying these tumors is critical to the development of specific targeted therapies and the design of clinical trials.	[Bell, Diana] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Bell, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	Diana.bell@mdanderson.org					Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Augustyn A, 2014, P NATL ACAD SCI USA, V111, P14788, DOI 10.1073/pnas.1410419111; Babin E, 2006, J LARYNGOL OTOL, V120, P289, DOI 10.1017/S0022215106000594; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Bell DFA, 2017, WHO CLASSIFICATION T, P57; Bell D, 2016, HEAD NECK-J SCI SPEC, V38, pE2259, DOI 10.1002/hed.24152; Bell D, 2015, HEAD NECK PATHOL, V9, P51, DOI 10.1007/s12105-014-0547-3; Bell D, 2013, EXPERT REV ANTICANC, V13, P285, DOI [10.1586/ERA.13.1, 10.1586/era.13.1]; Berger L, 1924, B ASS FRANC CANCER, V13, P410; Bockmuhl U, 2004, BRAIN PATHOL, V14, P158, DOI 10.1111/j.1750-3639.2004.tb00048.x; Cordes B, 2009, HUM PATHOL, V40, P283, DOI 10.1016/j.humpath.2008.07.019; Czapiewski P, 2016, ONCOTARGET, V7, P52584, DOI 10.18632/oncotarget.9683; de la Vega LL, 2017, MOL CANCER RES, V15, P1551, DOI 10.1158/1541-7786.MCR-17-0135; DULGUEROV P, 1992, LARYNGOSCOPE, V102, P843, DOI 10.1288/00005537-199208000-00001; Faragalla H, 2009, ADV ANAT PATHOL, V16, P322, DOI 10.1097/PAP.0b013e3181b544cf; Fitzek MM, 2002, CANCER-AM CANCER SOC, V94, P2623, DOI 10.1002/cncr.10537; Franchi A, 2015, HEAD NECK PATHOL, V9, P107, DOI 10.1007/s12105-013-0513-5; Gay LM, 2017, ONCOLOGIST, V22, P834, DOI 10.1634/theoncologist.2016-0287; Gonzalez-Kristeller DC, 2013, GENET MOL RES, V12, P3479, DOI 10.4238/2013.September.10.4; Guled M, 2008, MODERN PATHOL, V21, P770, DOI 10.1038/modpathol.2008.57; Hendifar AE, 2017, J THORAC ONCOL, V12, P425, DOI 10.1016/j.jtho.2016.11.2222; Holbrook EH, 2011, LARYNGOSCOPE, V121, P1687, DOI 10.1002/lary.21856; Holland H, 2007, CANCER GENET CYTOGEN, V173, P89, DOI 10.1016/j.cancergencyto.2006.09.024; Holmes M, 2016, ANN DIAGN PATHOL, V22, P45, DOI 10.1016/j.anndiagpath.2016.04.001; Hyams VJ, 1982, SPECIAL TUMORS HEAD, P24; Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276; KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L; Kaur G, 2013, J CLIN NEUROSCI, V20, P275, DOI 10.1016/j.jocn.2012.05.029; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; La Rosa S, 2013, HEAD NECK PATHOL, V7, P76, DOI 10.1007/s12105-012-0379-y; Lavoie J, 2017, TRENDS MOL MED, V23, P100, DOI 10.1016/j.molmed.2016.12.010; Malouf GG, 2013, EUR J CANCER, V49, P1324, DOI 10.1016/j.ejca.2012.12.008; Mandarano M, 2017, HEAD NECK PATHOL, V11, P262, DOI 10.1007/s12105-016-0743-4; Mao L, 2009, ONCOLOGY-BASEL, V77, P231, DOI 10.1159/000236047; Mhawech P, 2004, AM J CLIN PATHOL, V122, P100, DOI 10.1309/QD0K9Q1JBH6B5GQQ; Mills SE, 2002, MODERN PATHOL, V15, P264, DOI 10.1038/modpathol.3880522; Mitchell EH, 2012, HEAD NECK-J SCI SPEC, V34, P1372, DOI 10.1002/hed.21940; MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002; Ow TJ, 2014, HEAD NECK-J SCI SPEC, V36, P524, DOI 10.1002/hed.23327; Ow TJ, 2013, NEUROSURG CLIN N AM, V24, P51, DOI 10.1016/j.nec.2012.08.005; Persson P, 2000, BIOCHEM BIOPH RES CO, V274, P22, DOI 10.1006/bbrc.2000.3090; Platek ME, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-41; Renner G, 2007, SEMIN ONCOL, V34, P3, DOI 10.1053/j.seminoncol.2006.10.024; Riaziamand SH, 2002, CANCER GENET CYTOGEN, V136, P53, DOI 10.1016/S0165-4608(01)00659-8; Rosenthal DI, 2004, CANCER-AM CANCER SOC, V101, P2567, DOI 10.1002/cncr.20693; Saade RE, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-014-0423-z; Singh L, 2015, ANN DIAGN PATHOL, V19, P391, DOI 10.1016/j.anndiagpath.2015.06.008; Su SY, 2017, HEAD NECK-J SCI SPEC, V39, P1671, DOI 10.1002/hed.24822; Su SY, 2014, INT ARCH OTORHINOLAR, V18, pS149, DOI 10.1055/s-0034-1390014; Taggart MW, 2015, ANN DIAGN PATHOL, V19, P154, DOI 10.1016/j.anndiagpath.2015.03.009; Thompson LDR, 2017, WHO CLASSIFICATION H, P21; Thompson LDR, 2012, HEAD NECK PATHOL, V6, P75, DOI 10.1007/s12105-012-0336-9; Turri-Zanoni M, 2017, ORAL ONCOL, V74, P21, DOI 10.1016/j.oraloncology.2017.09.010; Uccella S, 2017, PATHOLOGICA, V109, P14; Valli R, 2015, GENE CHROMOSOME CANC, V54, P771, DOI 10.1002/gcc.22288; van der Laan TP, 2016, ORAL ONCOL, V63, P1, DOI 10.1016/j.oraloncology.2016.10.002; Van Gompel JJ, 2012, J NEUROL SURG PART B, V73, P331, DOI 10.1055/s-0032-1321512; Venkatramani R, 2016, PEDIATR BLOOD CANCER, V63, P465, DOI 10.1002/pbc.25817	58	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					22	30		10.1007/s12105-018-0887-5			9	Pathology	Pathology	GA6TM	WOS:000428467200004	29427030	Green Published			2019-10-28	
J	Tetzlaff, MT; Nagarajan, P				Tetzlaff, Michael T.; Nagarajan, Priyadharsini			Update on Merkel Cell Carcinoma	HEAD & NECK PATHOLOGY			English	Article						Merkel cell carcinoma; Merkel cell polyoma virus; Pathogenesis; Prognostic factors; Staging	LARGE T-ANTIGEN; POTENTIAL DIAGNOSTIC PITFALL; CHRONIC LYMPHOCYTIC-LEUKEMIA; POLYOMAVIRUS INFECTION; P63 EXPRESSION; PROGNOSTIC-FACTORS; CYTOKERATIN 20; IMMUNOHISTOCHEMICAL EXPRESSION; RETINOBLASTOMA PROTEIN; HISTOLOGIC FEATURES	Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. Incidence of MCC continues to rise, and risk factors include advanced age, pale skin, chronic sun exposure, and immune suppression. Diagnosing MCC utilizes a combination of morphology and immunohistochemistry. Merkel cell polyomavirus (MCPyV) is present in approximately 70-80% of MCCs and represents a key pathogenic driver in those MCCs. In contrast, MCPyV-negative MCCs arise through progressive accumulation of ultraviolet-light induced somatic mutations. Staging of MCC proceeds according to the American Joint Commission on Cancer (AJCC) 8th Edition, which utilizes features of the primary tumor together with regional lymph node(s) (clinically and/or pathologically detected) and/or distant metastases. Many potentially useful biomarkers have been studied to refine risk stratification in MCC. In recent years, the host immune infiltrate has been leveraged as immune checkpoint blockade has emerged as an efficacious mode of treatment for patients with advanced MCC.	[Tetzlaff, Michael T.; Nagarajan, Priyadharsini] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA; [Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Translat & Mol Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA	Tetzlaff, MT (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA.; Tetzlaff, MT (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Translat & Mol Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA.	mtetzlaff@mdanderson.org					Acebo E, 2005, J EUR ACAD DERMATOL, V19, P546, DOI 10.1111/j.1468-3083.2005.01224.x; Albores-Saavedra J, 2010, J CUTAN PATHOL, V37, P20, DOI 10.1111/j.1600-0560.2009.01370.x; Andea AA, 2008, CANCER, V113, P2549, DOI 10.1002/cncr.23874; Andea AA, 2010, HUM PATHOL, V41, P1405, DOI 10.1016/j.humpath.2010.02.010; Andres C, 2009, THORAX, V64, P1007, DOI 10.1136/thx.2009.117911; Andres C, 2010, J CUTAN PATHOL, V37, P28, DOI 10.1111/j.1600-0560.2009.01352.x; Asioli S, 2007, CANCER-AM CANCER SOC, V110, P640, DOI 10.1002/cncr.22828; Asioli S, 2011, MODERN PATHOL, V24, P1451, DOI 10.1038/modpathol.2011.100; Ball NJ, 2007, J CUTAN PATHOL, V34, P612, DOI 10.1111/j.1600-0560.2006.00674.x; Becker JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.77; Becker JC, 2009, J INVEST DERMATOL, V129, P248, DOI 10.1038/jid.2008.198; Berrios C, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006020; Bhatia K, 2010, INT J CANCER, V127, P1493, DOI 10.1002/ijc.25136; Bhatia K, 2010, INT J CANCER, V126, P2240, DOI 10.1002/ijc.24676; Bhatia S, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw042; Bichakjian CK, 2017, NATL COMPREHENSIVE C; Bloom R, 2016, AUSTRALAS J DERMATOL, V57, pE114, DOI 10.1111/ajd.12325; Bobos M, 2006, AM J DERMATOPATH, V28, P99, DOI 10.1097/01.dad.0000183701.67366.c7; Boutilier R, 2001, AM J DERMATOPATH, V23, P46, DOI 10.1097/00000372-200102000-00008; Brunner M, 2010, HEAD NECK-J SCI SPEC, V32, P333, DOI 10.1002/hed.21191; Buresh CJ, 2008, AM J CLIN PATHOL, V129, P894, DOI 10.1309/R494HQ9VRDJWDY30; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Carroll TM, 2017, J INVEST DERMATOL, V137, P1187, DOI 10.1016/j.jid.2017.01.008; Cerroni L, 1997, AM J DERMATOPATH, V19, P610, DOI 10.1097/00000372-199712000-00011; Chan JKC, 1997, AM J SURG PATHOL, V21, P226, DOI 10.1097/00000478-199702000-00014; Chen KT, 2013, AM J SURG, V206, P752, DOI 10.1016/j.amjsurg.2013.02.005; D'Agostino M, 2010, J AM ACAD DERMATOL, V62, P463, DOI 10.1016/j.jaad.2009.06.023; Dong HY, 2005, AM J SURG PATHOL, V29, P687, DOI 10.1097/01.pas.0000155162.33044.4f; Duncavage EJ, 2009, AM J SURG PATHOL, V33, P1771, DOI 10.1097/PAS.0b013e3181ba7b73; Duncavage EJ, 2009, MODERN PATHOL, V22, P516, DOI 10.1038/modpathol.2009.3; Engels EA, 2002, LANCET, V359, P497, DOI 10.1016/S0140-6736(02)07668-7; Feldmeyer L, 2016, CLIN CANCER RES, V22, P5553, DOI 10.1158/1078-0432.CCR-16-0392; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fernandez-Figueras MT, 2005, HISTOPATHOLOGY, V46, P614, DOI 10.1111/j.1365-2559.2005.02140.x; Fitzgerald TL, 2015, AM SURGEON, V81, P802; Fleming KE, 2014, HUM PATHOL, V45, P952, DOI 10.1016/j.humpath.2013.12.008; Foote M, 2012, J AM ACAD DERMATOL, V67, P395, DOI 10.1016/j.jaad.2011.09.009; Garneski KM, 2009, J INVEST DERMATOL, V129, P246, DOI 10.1038/jid.2008.229; GOMEZ LG, 1983, AM J SURG PATHOL, V7, P171, DOI 10.1097/00000478-198303000-00007; Guler-Nizam E, 2009, BRIT J DERMATOL, V161, P90, DOI 10.1111/j.1365-2133.2009.09155.x; Hall BJ, 2012, J CUTAN PATHOL, V39, P911, DOI 10.1111/j.1600-0560.2012.01964.x; Hanly AJ, 2000, J CUTAN PATHOL, V27, P118, DOI 10.1034/j.1600-0560.2000.027003118.x; Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4; Harms PW, 2017, CLIN LAB MED, V37, P485, DOI 10.1016/j.cll.2017.05.004; Harms PW, 2016, MODERN PATHOL, V29, P240, DOI 10.1038/modpathol.2015.154; Harms PW, 2013, J INVEST DERMATOL, V133, P936, DOI 10.1038/jid.2012.445; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Hashimoto K, 1998, J CUTAN PATHOL, V25, P572, DOI 10.1111/j.1600-0560.1998.tb01744.x; Haymerle G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180426; Heath M, 2008, J AM ACAD DERMATOL, V58, P375, DOI 10.1016/j.jaad.2007.11.020; Hemminki K, 2012, INT J CANCER, V131, pE326, DOI 10.1002/ijc.27376; Henderson SA, 2014, J CUTAN PATHOL, V41, P846, DOI 10.1111/cup.12383; Higaki-Mori H, 2012, HUM PATHOL, V43, P2282, DOI 10.1016/j.humpath.2012.04.002; Hodgson NC, 2005, J SURG ONCOL, V89, P1, DOI 10.1002/jso.20167; Houben R, 2010, INT J CANCER, V126, P796, DOI 10.1002/ijc.24790; Hwang JHK, 2008, J CUTAN PATHOL, V35, P955, DOI 10.1111/j.1600-0560.2007.00917.x; Iacocca MV, 1998, J AM ACAD DERMATOL, V39, P882, DOI 10.1016/S0190-9622(98)70372-X; Iwasaki T, 2013, HUM PATHOL, V44, P1912, DOI 10.1016/j.humpath.2013.01.026; Jung HS, 2011, HISTOL HISTOPATHOL, V26, P1231, DOI 10.14670/HH-26.1231; Kassem A, 2008, CANCER RES, V68, P5009, DOI 10.1158/0008-5472.CAN-08-0949; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Kim J, 2008, MODERN PATHOL, V21, P764, DOI 10.1038/modpathol.2008.61; Kolhe R, 2013, INT J CLIN EXP PATHO, V6, P142; Kontochristopoulos GJ, 2000, DERMATOLOGY, V201, P123, DOI 10.1159/000018454; Kuromi T, 2017, HUM PATHOL, V69, P8, DOI 10.1016/j.humpath.2017.05.011; Leech SN, 2001, J CLIN PATHOL, V54, P727, DOI 10.1136/jcp.54.9.727; Leitz M, 2014, J MED VIROL, V86, P1813, DOI 10.1002/jmv.23808; Leroux-Kozal V, 2015, HUM PATHOL, V46, P443, DOI 10.1016/j.humpath.2014.12.001; Llombart B, 2005, HISTOPATHOLOGY, V46, P622, DOI 10.1111/j.1365-2559.2005.02158.x; Loyo M, 2010, INT J CANCER, V126, P2991, DOI 10.1002/ijc.24737; Martin B, 2013, HISTOPATHOLOGY, V62, P711, DOI 10.1111/his.12091; McNiff JM, 1999, J CUTAN PATHOL, V26, P119, DOI 10.1111/j.1600-0560.1999.tb01815.x; Mertz KD, 2013, J CUTAN PATHOL, V40, P543, DOI 10.1111/cup.12129; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P709, DOI 10.1136/jcp.2006.039917; Miraflor AP, 2016, J CUTAN PATHOL, V43, P921, DOI 10.1111/cup.12813; MOLL R, 1992, AM J PATHOL, V140, P427; Mortier L, 2003, ARCH DERMATOL, V139, P1587, DOI 10.1001/archderm.139.12.1587; Moshiri AS, 2014, J NATL COMPR CANC NE, V12, P1255, DOI 10.6004/jnccn.2014.0123; Murakami I, 2014, AM J SURG PATHOL, V38, P1627, DOI 10.1097/PAS.0000000000000279; Nardi V, 2012, CLIN CANCER RES, V18, P1227, DOI 10.1158/1078-0432.CCR-11-2308; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Nicholson SA, 2000, APPL IMMUNOHISTO M M, V8, P37, DOI 10.1097/00022744-200003000-00006; Paik JY, 2011, HUM PATHOL, V42, P1385, DOI 10.1016/j.humpath.2010.12.013; Paulson KG, 2013, J INVEST DERMATOL, V133, P642, DOI 10.1038/jid.2012.388; Paulson KG, 2011, J CLIN ONCOL, V29, P1539, DOI 10.1200/JCO.2010.30.6308; Paulson KG, 2017, J AM ACAD DERMATOL; Penn I, 1999, TRANSPLANTATION, V68, P1717, DOI 10.1097/00007890-199912150-00015; Poniecka AW, 1999, AM J DERMATOPATH, V21, P332, DOI 10.1097/00000372-199908000-00004; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Ralston J, 2008, MODERN PATHOL, V21, P1357, DOI 10.1038/modpathol.2008.118; Rekhi B, 2015, ANN DIAGN PATHOL, V19, P341, DOI 10.1016/j.anndiagpath.2015.07.006; Sastre-Garau X, 2009, J PATHOL, V218, P48, DOI 10.1002/path.2532; Sauer CM, 2017, CRIT REV ONCOL HEMAT, V116, P99, DOI 10.1016/j.critrevonc.2017.05.009; Schadendorf D, 2017, EUR J CANCER, V71, P53, DOI 10.1016/j.ejca.2016.10.022; Schirren CG, 1997, AM J DERMATOPATH, V19, P341, DOI 10.1097/00000372-199708000-00005; Schrama D, 2011, J INVEST DERMATOL, V131, P1631, DOI 10.1038/jid.2011.115; Scott MP, 1999, AM J DERMATOPATH, V21, P16, DOI 10.1097/00000372-199902000-00003; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shuda M, 2009, INT J CANCER, V125, P1243, DOI 10.1002/ijc.24510; Sidiropoulos M, 2011, AM J CLIN PATHOL, V135, P831, DOI 10.1309/AJCPLCB2Q9QXDZAA; Sihto H, 2012, CLIN CANCER RES, V18, P2872, DOI 10.1158/1078-0432.CCR-11-3020; Sihto H, 2011, CLIN CANCER RES, V17, P4806, DOI 10.1158/1078-0432.CCR-10-3363; Sihto H, 2009, JNCI-J NATL CANCER I, V101, P938, DOI 10.1093/jnci/djp139; Sirikanjanapong S, 2010, J CUTAN PATHOL, V37, P881, DOI 10.1111/j.1600-0560.2009.01407.x; Skelton HG, 1997, J AM ACAD DERMATOL, V37, P734, DOI 10.1016/S0190-9622(97)70110-5; Stetsenko GY, 2013, AM J CLIN PATHOL, V140, P838, DOI 10.1309/AJCPE4PK6CTBNQJY; Su LD, 2002, J AM ACAD DERMATOL, V46, P661, DOI 10.1067/mjd.2002.119563; Sur M, 2007, MODERN PATHOL, V20, P1113, DOI 10.1038/modpathol.3800936; Swick BL, 2013, J CUTAN PATHOL, V40, P623, DOI 10.1111/cup.12160; Tadmor T, 2012, BRIT J HAEMATOL, V157, P457, DOI 10.1111/j.1365-2141.2012.09087.x; Tarantola TI, 2013, J AM ACAD DERMATOL, V68, P433, DOI 10.1016/j.jaad.2012.07.035; Tarantola TI, 2013, J AM ACAD DERMATOL, V68, P425, DOI 10.1016/j.jaad.2012.09.036; Van Keymeulen A, 2009, J CELL BIOL, V187, P91, DOI 10.1083/jcb.200907080; Walocko FM, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0186-1; Warner CL, 2011, AM J CLIN DERMATOL, V12, P147, DOI 10.2165/11539420-000000000-00000; Wendzicki JA, 2015, CURR OPIN VIROL, V11, P38, DOI 10.1016/j.coviro.2015.01.009; Winkler JK, 2017, BRIT J DERMATOL, V176, P216, DOI 10.1111/bjd.14632; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Yang DT, 2004, J CUTAN PATHOL, V31, P254, DOI 10.1111/j.0303-6987.2003.00175.x; zur Hausen A, 2013, CANCER RES, V73, P4982, DOI 10.1158/0008-5472.CAN-13-0616	120	4	4	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					31	43		10.1007/s12105-018-0898-2			13	Pathology	Pathology	GA6TM	WOS:000428467200005	29556962	Green Published			2019-10-28	
J	Alhousami, T; Sabharwal, A; Gupta, S; Aguirre, A; Park, E; Kramer, JM				Alhousami, Thabet; Sabharwal, Amarpreet; Gupta, Shivane; Aguirre, Alfredo; Park, Etern; Kramer, Jill M.			Fibromyxoma of the Jaw: Case Report and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Fibromyxoma; Myxoma; Odontogenic; Mesenchymal tumor	ODONTOGENIC MYXOMA; SOFT-TISSUE; CHONDROMYXOID FIBROMA; TUMORS; RHABDOMYOSARCOMA; MYXOFIBROMA; RECONSTRUCTION; RESECTION; NECK; HEAD	We report a case of fibromyxoma of the mandible, a rare benign odontogenic tumor. Our patient presented in the first trimester of pregnancy with a large mass in the right body of the mandible exhibiting displacement of teeth and destruction of an extensive area of the mandibular bone. The mass was biopsied and diagnosed as a fibromyxoma. The large size of the tumor dictated a wide mandibular resection. We will review the clinical, radiographic, and histologic features of fibromyxoma and discuss its differential diagnoses. In addition, we will provide an overview of patient management. Fibromxyoma is a benign gnathic tumor that can be locally aggressive. To ensure appropriate treatment, it is important to distinguish this neoplasm from other mimickers in which myxoid, spindle mesenchymal cell proliferation is prominent.	[Alhousami, Thabet; Aguirre, Alfredo; Kramer, Jill M.] SUNY Buffalo, Univ Buffalo, Dept Oral Diagnost Sci, Sch Dent Med, Buffalo, NY 14260 USA; [Alhousami, Thabet] Umm Al Qura Univ, Dept Basic & Clin Oral Sci, Fac Dent, Mecca, Saudi Arabia; [Sabharwal, Amarpreet] SUNY Buffalo, Univ Buffalo, Dept Endodont & Periodont, Sch Dent Med, Buffalo, NY USA; [Gupta, Shivane; Park, Etern] SUNY Buffalo, Univ Buffalo, Dept Oral & Maxillofacial Surg, Sch Dent Med, Buffalo, NY USA; [Aguirre, Alfredo; Kramer, Jill M.] Immco Diagnost Inc, Buffalo, NY 14228 USA; [Kramer, Jill M.] SUNY Buffalo, Univ Buffalo, Dept Oral Biol, Sch Dent Med, 3435 Main St,211 Foster Hall, Buffalo, NY 14260 USA; [Park, Etern] Wilmington Hosp, Christiana Hlth Care Serv, Wilmington, DE 19801 USA	Kramer, JM (reprint author), SUNY Buffalo, Univ Buffalo, Dept Oral Diagnost Sci, Sch Dent Med, Buffalo, NY 14260 USA.; Kramer, JM (reprint author), Immco Diagnost Inc, Buffalo, NY 14228 USA.; Kramer, JM (reprint author), SUNY Buffalo, Univ Buffalo, Dept Oral Biol, Sch Dent Med, 3435 Main St,211 Foster Hall, Buffalo, NY 14260 USA.	jkramer@buffalo.edu	Sabharwal, Amarpreet/Z-3933-2019				ABIOSE BO, 1987, BRIT J ORAL MAX SURG, V25, P415, DOI 10.1016/0266-4356(87)90093-3; Aquillino RN, 2006, ORAL ONCOL EXTRA, V42, P133; BATSAKIS JG, 1987, ANN OTO RHINOL LARYN, V96, P618, DOI 10.1177/000348948709600527; Brannon Robert B, 2004, Oral Maxillofac Surg Clin North Am, V16, P359, DOI 10.1016/j.coms.2004.03.004; Brierley DJ, 2015, DIAGN HISTOPATHOL, V21, P370; Chaudhuri Kanad, 2016, J Oral Maxillofac Pathol, V20, P334, DOI 10.4103/0973-029X.185914; Chen CT, 1997, ANN PLAS SURG, V39, P87, DOI 10.1097/00000637-199707000-00016; Cowan ML, 2016, HEAD NECK PATHOL, V10, P161, DOI 10.1007/s12105-015-0647-8; Decoteau Corey, 2014, J Mass Dent Soc, V63, P46; Dietrich EM, 2011, CASE REP MED, DOI 10.1155/2011/238712; Downs-Kelly E, 2008, AM J SURG PATHOL, V32, P8, DOI 10.1097/PAS.0b013e3181578d5a; FARMAN AG, 1977, BRIT J ORAL SURG, V15, P3, DOI 10.1016/0007-117X(77)90002-6; GHOSH BC, 1973, CANCER, V31, P237, DOI 10.1002/1097-0142(197301)31:1<237::AID-CNCR2820310131>3.0.CO;2-F; GOLDBLATT LI, 1976, ORAL SURG ORAL MED O, V42, P206, DOI 10.1016/0030-4220(76)90125-0; Hajdu SI, 2013, CANCER-AM CANCER SOC, V119, P4058, DOI 10.1002/cncr.28319; Hammad HM, 1998, ORAL SURG ORAL MED O, V85, P293, DOI 10.1016/S1079-2104(98)90011-7; HARDER F, 1978, INT J ORAL MAXILLOF, V7, P148, DOI 10.1016/S0300-9785(78)80017-9; Haser GC, 2016, HEAD NECK-J SCI SPEC, V38, pE25, DOI 10.1002/hed.24090; Hicks J, 2002, ORAL ONCOL, V38, P450, DOI 10.1016/S1368-8375(01)00105-1; Infante-Cossio P, 2011, MED ORAL PATOL ORAL, V16, pE532, DOI 10.4317/medoral.16.e532; Iwata J, 2000, PATHOL INT, V50, P7, DOI 10.1046/j.1440-1827.2000.01001.x; Jaeger N, 2000, J ORAL PATHOL MED, V29, P129, DOI 10.1034/j.1600-0714.2000.290305.x; Jo VY, 2011, AM J CLIN PATHOL, V136, P762, DOI 10.1309/AJCPXNUC7JZSKWEU; Kaffe I, 1997, DENTOMAXILLOFAC RAD, V26, P299, DOI 10.1038/sj.dmfr.4600261; KESZLER A, 1995, J ORAL MAXIL SURG, V53, P518, DOI 10.1016/0278-2391(95)90062-4; Khatib B, 2017, INT J ORAL MAX SURG, V46, P173, DOI 10.1016/j.ijom.2016.09.018; KIM J, 1993, J ORAL MAXIL SURG, V51, P762, DOI 10.1016/S0278-2391(10)80417-3; Koseki T, 2003, DENTOMAXILLOFAC RAD, V32, P160, DOI 10.1259/dmfr/16752462; Kraft S, 2011, AM J SURG PATHOL, V35, P599, DOI 10.1097/PAS.0b013e31820e6093; Kramer IRH, 1992, HISTOLOGICAL TYPING; Kumar N, 2014, J MAXILLOFAC ORAL SU, V13, P222, DOI 10.1007/s12663-010-0107-7; Landa LE, 2002, J ORAL MAXIL SURG, V60, P704, DOI 10.1053/joms.2002.33126; LoMuzio L, 1996, ORAL SURG ORAL MED O, V82, P426; MARCOVE RC, 1964, CANCER, V17, P1209, DOI 10.1002/1097-0142(196409)17:9<1209::AID-CNCR2820170918>3.0.CO;2-N; Mehrotra D, 2008, J CLIN PEDIATR DENT, V32, P309, DOI 10.17796/jcpd.32.4.77l6553743618386; Meleti M, 2015, MED ORAL PATOL ORAL, V20, pE1, DOI 10.4317/medoral.19842; Neville BW, 2016, ORAL MAXILLOFACIAL P, P681; Nielsen GP, 1999, MODERN PATHOL, V12, P514; Orcioni GF, 2010, PATHOL RES PRACT, V206, P325, DOI 10.1016/j.prp.2009.06.002; Parham DM, 2001, MODERN PATHOL, V14, P506, DOI 10.1038/modpathol.3880339; Prescott RJ, 2008, BRIT J DERMATOL, V159, P1315, DOI 10.1111/j.1365-2133.2008.08798.x; Reddy GSP, 2013, CASE REP DENT, DOI 10.1155/2013/345479; Reddy Sridhar P, 2010, Natl J Maxillofac Surg, V1, P183, DOI 10.4103/0975-5950.79227; Said-Al-Naief N, 2006, ORAL SURG ORAL MED O, V101, P82, DOI 10.1016/j.tripleo.2005.03.034; Sato K, 2010, PATHOL INT, V60, P760, DOI 10.1111/j.1440-1827.2010.02589.x; SCHNEIDER LC, 1975, J PERIODONTOL, V46, P493, DOI 10.1902/jop.1975.46.8.493; Shah Ajaz, 2011, Natl J Maxillofac Surg, V2, P189, DOI 10.4103/0975-5950.94480; Shahoon Hossein, 2009, J Dent Res Dent Clin Dent Prospects, V3, P103, DOI 10.5681/joddd.2009.026; SLOOTWEG PJ, 1986, J MAXILLOFAC SURG, V14, P46, DOI 10.1016/S0301-0503(86)80258-2; SLOOTWEG PJ, 1985, J ORAL PATHOL MED, V14, P299, DOI 10.1111/j.1600-0714.1985.tb00497.x; STOUT AP, 1948, ANN SURG, V127, P706, DOI 10.1097/00000658-194804000-00013; THOMA KH, 1947, AM J ORTHOD ORAL SUR, V33, P532; Thompson LD, 2016, DIAGNOSTIC PATHOLOGY, P94; van Roggen JFG, 1999, HISTOPATHOLOGY, V35, P291; Williams T, 1997, ORAL MAXILLOFAC SURG, V3, P329; Wincewicz A, 2013, FOLIA HISTOCHEM CYTO, V51, P339, DOI 10.5603/FHC.2013.0046; Wright JM, 2014, HEAD NECK PATHOL, V8, P373, DOI 10.1007/s12105-014-0585-x; Wu PX, 2014, INT J CLIN EXP MED, V7, P2369; Yu YB, 2017, GROWTH HORM IGF RES, V33, P17, DOI 10.1016/j.ghir.2017.01.002; Zayet MK, 2014, IMAGNG SCI DENT, V44, P237, DOI 10.5624/isd.2014.44.3.237	60	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					44	51		10.1007/s12105-017-0823-0			8	Pathology	Pathology	GA6TM	WOS:000428467200006	28508997	Green Published			2019-10-28	
J	Lewis, JS; Chernock, RD; Bishop, JA				Lewis, J. S., Jr.; Chernock, R. D.; Bishop, J. A.			Squamous and Neuroendocrine Specific Immunohistochemical Markers in Head and Neck Squamous Cell Carcinoma: A Tissue Microarray Study	HEAD & NECK PATHOLOGY			English	Article						Oropharyngeal; Squamous cell carcinoma; p40; Neuroendocrine; Immunohistochemistry; Head and neck; Human papillomavirus	RISK HUMAN-PAPILLOMAVIRUS; IN-SITU HYBRIDIZATION; UNDIFFERENTIATED CARCINOMA; P63 IMMUNOHISTOCHEMISTRY; DIFFERENTIAL-DIAGNOSIS; CYTOKERATIN 5/6; OROPHARYNX; P40; CLASSIFICATION; DISTINCTION	The performance characteristics of neuroendocrine-specific and squamous-specific immunohistochemical markers in head and neck squamous cell carcinomas (SCC), in particular in oropharyngeal tumors in this era of human papillomavirus (HPV)-induced cases, are not well-established. The differential diagnosis for poorly differentiated SCCs, for nonkeratinizing oropharyngeal SCCs, and for other specific SCC variants such as basaloid SCC and undifferentiated (or lymphoepithelial-like) carcinomas includes neuroendocrine carcinomas. Given that neuroendocrine carcinomas of the head and neck are aggressive regardless of HPV status, separating them from SCC is critically important. In this study, we examined the neuroendocrine markers CD56, synaptophysin, and chromogranin-A along with the squamous markers p40 and cytokeratin 5/6 in a large tissue microarray cohort of oral, oropharyngeal, laryngeal, and hypopharyngeal SCCs with known HPV results by RNA in situ hybridization for the oropharyngeal tumors. Results were stratified by site and specific SCC variant. The neuroendocrine stains were rarely expressed in SCC (< 1% overall) with CD56 the least, and chromogranin-A the most, specific markers. Further, p40 and cytokeratin 5/6 were very consistently expressed in all head and neck SCC (> 98% overall), including very strong, consistent staining in oropharyngeal HPV-related nonkeratinizing SCC. Undifferentiated (or lymphoepithelial-like) carcinomas of the oropharynx are more frequently p40 or cytokeratin 5/6 negative or show only weak or focal expression. In summary, markers of neuroendocrine and squamous differentiation show very high specificity and sensitivity, respectively, across the different types of head and neck SCC.	[Lewis, J. S., Jr.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Lewis, J. S., Jr.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, TN 37232 USA; [Chernock, R. D.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Chernock, R. D.] Washington Univ, Dept Otolaryngol Head & Neck Surg, St Louis, MO USA; [Bishop, J. A.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Bishop, J. A.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA	Lewis, JS (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Lewis, JS (reprint author), Vanderbilt Univ, Med Ctr, Dept Otolaryngol, Nashville, TN 37232 USA.	james.lewis@vanderbilt.edu			NCI/NIH Cancer Center Support Grant [2P30 CA068485-14]; Vanderbilt Mouse Metabolic Phenotyping Center Grant [5U24DK059637-13]	We would like to thank Donna M. Posey for her wonderful assistance with clerical support and spreadsheet data management for the various aspects of this study. We also acknowledge the Translational Pathology Shared Resource (TPSR) supported by NCI/NIH Cancer Center Support Grant 2P30 CA068485-14 and the Vanderbilt Mouse Metabolic Phenotyping Center Grant 5U24DK059637-13.	Bates T, 2014, HEAD NECK PATHOL, V8, P127, DOI 10.1007/s12105-013-0471-y; Bishop JA, 2014, AM J SURG PATHOL, V38, P257, DOI 10.1097/PAS.0000000000000119; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Bishop JA, 2011, AM J SURG PATHOL, V35, P1679, DOI 10.1097/PAS.0b013e3182299cde; Cardesa A, 2005, WHO CLASSIFICATION T, P130; Cardesa A, 2005, WHO CLASSIFICATION T, P125; Carpenter DH, 2011, MODERN PATHOL, V24, P1306, DOI 10.1038/modpathol.2011.87; Chernock RD, 2009, HEAD NECK PATHOL, V3, P186, DOI 10.1007/s12105-009-0126-1; Chernock RD, 2012, HEAD NECK PATHOL, V6, pS41, DOI 10.1007/s12105-012-0373-4; Emanuel P, 2005, MODERN PATHOL, V18, P645, DOI 10.1038/modpathol.3800329; Fatima N, 2012, DIAGN CYTOPATHOL, V40, P943, DOI 10.1002/dc.21678; Gondim DD, 2016, AM J SURG PATHOL, V40, P1117, DOI 10.1097/PAS.0000000000000650; Kalhor N, 2006, MODERN PATHOL, V19, P1117, DOI 10.1038/modpathol.3800629; Kraft S, 2012, AM J SURG PATHOL, V36, P321, DOI 10.1097/PAS.0b013e31823f2f17; Lewis JS, 2012, HISTOPATHOLOGY, V60, P982, DOI 10.1111/j.1365-2559.2011.04169.x; Schartinger VH, 2012, J LARYNGOL OTOL, V126, P1261, DOI 10.1017/S0022215112002265; Serrano MF, 2008, HUM PATHOL, V39, P591, DOI 10.1016/j.humpath.2007.08.019; Singh L, 2014, ANN DIAGN PATHOL, V18, P261, DOI 10.1016/j.anndiagpath.2014.01.003; Singhi AD, 2010, AM J SURG PATHOL, V34, P800, DOI 10.1097/PAS.0b013e3181d9ba21; Tacha D, 2014, ARCH PATHOL LAB MED, V138, P1358, DOI 10.5858/arpa.2013-0342-OA; Tatsumori T, 2014, APPL IMMUNOHISTO M M, V22, P377, DOI 10.1097/PAI.0b013e3182980544; Thompson ED, 2016, AM J SURG PATHOL, V40, P471, DOI 10.1097/PAS.0000000000000580; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Uke M, 2010, CYTOPATHOLOGY, V21, P56, DOI 10.1111/j.1365-2303.2009.00678.x; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Wang BY, 2002, HUM PATHOL, V33, P921, DOI 10.1053/hupa.2002.126878; Westra WH, 2017, WHO CLASSIFICATION H, P136	27	3	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					62	70		10.1007/s12105-017-0825-y			9	Pathology	Pathology	GA6TM	WOS:000428467200008	28528398	Green Published			2019-10-28	
J	Stein, T; Murugan, P; Li, FQ; El Hag, MI				Stein, Tracy; Murugan, Paari; Li, Faqian; El Hag, Mohamed I.			Can Medullary Thyroid Carcinoma Arise in Thyroglossal Duct Cysts? A Search for Parafollicular C-cells in 41 Resected Cases	HEAD & NECK PATHOLOGY			English	Article						Medullary; Thyroid; Carcinoma; Thyroglossal; Parafollicular C-cells	NEUROENDOCRINE CARCINOMA; CANCER; ORIGIN; LARYNX; GLAND	Thyroglossal duct cysts (TGDCs) are present in similar to 7% of adults and develop from the midline migratory tract between the foramen cecum and anatomic location of the thyroid. Thyroid tissue can be identified in 2/3 of TGDCs, and up to 1% develop associated malignancy, 90% of which are papillary thyroid carcinoma. Cases of follicular and anaplastic carcinoma have been documented, but there are no reports of medullary thyroid carcinoma arising in a TGDC. This is presumably due to the distinct embryologic origin of parafollicular C-cells, from which medullary carcinoma arises. The goal of this study is to determine whether parafollicular C-cells are present in TGDCs. H&E sections from 41 TGDC cases were examined for thyroid tissue, thyroglossal duct remnants, ultimobranchial remnants, and parafollicular C-cells. Immunohistochemistry was performed for TTF-1 and calcitonin. Eighty three percent (34/41) of cases contained thyroid tissue on H&E and by TTF-1. No cases (0/41) had ultimobranchial remnants or parafollicular C-cells on H&E or with calcitonin. One case of papillary carcinoma in a TGDC was identified. These cases illustrate that although TGDCs often contain thyroid tissue, parafollicular C-cells are absent. Therefore, unlike other thyroid neoplasms, there is no evidence to support the possibility of medullary carcinoma arising in a TGDC.	[Stein, Tracy] Univ Minnesota, Sch Med, 420 Delaware St SE, Minneapolis, MN 55455 USA; [Murugan, Paari; Li, Faqian] Univ Minnesota, Med Ctr, Dept Pathol, 420 Delaware St SE, Minneapolis, MN 55455 USA; [El Hag, Mohamed I.] Univ Pittsburgh, Med Ctr, Dept Anat Pathol, 3459 Fifth Ave Suite E-733, Pittsburgh, PA 15213 USA	El Hag, MI (reprint author), Univ Pittsburgh, Med Ctr, Dept Anat Pathol, 3459 Fifth Ave Suite E-733, Pittsburgh, PA 15213 USA.	elhag.m@gmail.com					Chang YS, 2016, ONCOL LETT, V11, P2668, DOI 10.3892/ol.2016.4262; Chou J, 2013, SURG RADIOL ANAT, V35, P875, DOI 10.1007/s00276-013-1115-3; DESHPANDE A, 1995, J LARYNGOL OTOL, V109, P1001, DOI 10.1017/S0022215100131871; Donoghue PCJ, 2008, BIOESSAYS, V30, P530, DOI 10.1002/bies.20767; Fagman H, 2010, MOL CELL ENDOCRINOL, V323, P35, DOI 10.1016/j.mce.2009.12.008; Hirsch MS, 2004, MODERN PATHOL, V17, P631, DOI 10.1038/modpathol.3800105; Johansson E, 2015, DEVELOPMENT, V142, P3519, DOI 10.1242/dev.126581; Kwan WB, 1996, CAN J SURG, V39, P328; LIVOLSI VA, 1974, CANCER, V34, P1303, DOI 10.1002/1097-0142(197410)34:4<1303::AID-CNCR2820340442>3.0.CO;2-S; Mazzaferri EL, 2004, THYROID, V14, P335, DOI 10.1089/105072504774193140; Milojevic B, 2013, ROM J MORPHOL EMBRYO, V54, P285; Mobini J, 1974, Am Surg, V40, P290; Motamed Mehdi, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P106, DOI 10.1097/00020840-200404000-00009; Prakash, 2012, ANAT SCI INT, V87, P45, DOI 10.1007/s12565-011-0115-9; Sadat A., 2009, BANGLADESH J ANAT, V7, P94; Sameer KSM, 2012, INT J PEDIATR OTORHI, V76, P165, DOI 10.1016/j.ijporl.2011.11.025; Schmid KW, 2015, RECENT RESULTS CANC, V204, P41, DOI 10.1007/978-3-319-22542-5_2; SMETS G, 1990, VIRCHOWS ARCH A, V416, P539, DOI 10.1007/BF01600306; Thompson LDR, 2016, HEAD NECK PATHOL, V10, P465, DOI 10.1007/s12105-016-0724-7; UTIGER RD, 1994, NEW ENGL J MED, V331, P870, DOI 10.1056/NEJM199409293311309; Wei SZ, 2015, ENDOCR PATHOL, V26, P75, DOI 10.1007/s12022-015-9354-y	21	2	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					71	74		10.1007/s12105-017-0826-x			4	Pathology	Pathology	GA6TM	WOS:000428467200009	28536894	Green Published			2019-10-28	
J	Almeida, TFA; Verli, FD; dos Santos, CR; Falci, SGM; Almeida, LY; Almeida, LKY; Mesquita, ATM; Leon, JE				Araujo Almeida, Tatiana Fernandes; Verli, Flaviana Dornela; Rocha dos Santos, Cassio Roberto; Moreira Falci, Saulo Gabriel; Almeida, Luciana Yamamoto; Yamamoto Almeida, Lana Kei; Marques Mesquita, Ana Terezinha; Leon, Jorge Esquiche			Multiple Desmoplastic Cellular Neurothekeomas in Child: Report of the First Oral Case and Review of the Literature	HEAD & NECK PATHOLOGY			English	Review						Oral cavity; Cellular neurothekeoma; Desmoplastic cellular neurothekeoma; Immunohistochemistry; Child	NERVE SHEATH MYXOMA; IMMUNOHISTOCHEMICAL ANALYSIS; S-100 PROTEIN; CAVITY; TONGUE; TUMORS; FEATURES; GINGIVA; MUCOSA	Cellular neurothekeomas (CNs) are distinctive benign tumors of uncertain histogenesis, with predilection for the skin of the head and neck region. We describe the first case of multiple desmoplastic CNs (DCNs) affecting the oral cavity in a 9-year-old girl. Histopathologic evaluation showed a proliferation of spindle and epithelioid cells, forming nests and bundles, supported by exuberant fibrous stroma, as well as scattered multinucleated floret-like giant cells. The tumor cells were immunopositive for vimentin, CD63, CD56, whereas AE1/AE3, S100, CD34, alpha-SMA, GFAP, EMA, CD57 and NSE were negative. Ki-67 was < 2%. Multiple DCNs should be considered in the differential diagnosis of oral nodular lesions.	[Araujo Almeida, Tatiana Fernandes; Rocha dos Santos, Cassio Roberto; Moreira Falci, Saulo Gabriel; Marques Mesquita, Ana Terezinha] Univ Fed Vales Jequitinhonha & Mucuri, Dept Dent, Stomatol Clin, Rua Gloria,187 Campus 1, BR-39100000 Diamantina, MG, Brazil; [Verli, Flaviana Dornela] Univ Fed Vales Jequitinhonha & Mucuri, Dept Basic Sci, Pathol Lab, Diamantina, MG, Brazil; [Almeida, Luciana Yamamoto] Univ Sao Paulo FMRP USP, Med Sch Ribeirao Preto, Div Hematol, Dept Clin Med, Ribeirao Preto, SP, Brazil; [Yamamoto Almeida, Lana Kei] Univ Estadual Paulista UNESP, Araraquara Dent Sch, Dept Pediat Dent, Araraquara, SP, Brazil; [Leon, Jorge Esquiche] Univ Sao Paulo FORP USP, Sch Dent Ribeirao Preto, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Ribeirao Preto, SP, Brazil	Mesquita, ATM (reprint author), Univ Fed Vales Jequitinhonha & Mucuri, Dept Dent, Stomatol Clin, Rua Gloria,187 Campus 1, BR-39100000 Diamantina, MG, Brazil.	hanamesquita@hotmail.com	Falci, S.G.M./Q-4153-2016; Almeida, Luciana Y/C-3045-2016; Leon, Jorge Esquiche/D-7511-2013	Falci, S.G.M./0000-0001-9438-5199; Almeida, Luciana Y/0000-0001-5403-4052; Leon, Jorge Esquiche/0000-0002-9668-5870			BARNHILL RL, 1990, AM J SURG PATHOL, V14, P113, DOI 10.1097/00000478-199002000-00002; BARNHILL RL, 1991, J AM ACAD DERMATOL, V25, P80, DOI 10.1016/0190-9622(91)70177-4; Barrett AW, 2001, ORAL ONCOL, V37, P660, DOI 10.1016/S1368-8375(00)00117-2; Breuer T, 1999, ORL J OTO-RHINO-LARY, V61, P161, DOI 10.1159/000027663; D'Antonio Antonio, 2011, J Am Acad Dermatol, V65, pe57, DOI 10.1016/j.jaad.2010.12.029; de Andrade CR, 2008, MED ORAL PATOL ORAL, V13, pE540; Emami N, 2013, CASE REP OTOLARYNGOL, DOI 10.1155/2013/935435; Fetsch JF, 2005, AM J SURG PATHOL, V29, P1615, DOI 10.1097/01.pas.0000173025.87476.a4; Fetsch JF, 2007, AM J SURG PATHOL, V31, P1103, DOI 10.1097/PAS.0b013e31802d96af; GALLAGER RL, 1980, AM J CLIN PATHOL, V74, P759; Garcia-Gutierrez M, 2010, AM J DERMATOPATH, V32, P509, DOI 10.1097/DAD.0b013e3181c98f89; Gonzalez-Arriagada WA, 2010, ORAL SURG ORAL MED O, V109, pE46, DOI 10.1016/j.tripleo.2010.01.021; Hornick JL, 2007, AM J SURG PATHOL, V31, P329, DOI 10.1097/01.pas.0000213360.03133.89; HUSAIN S, 1994, AM J DERMATOPATH, V16, P496, DOI 10.1097/00000372-199410000-00004; Ishikawa M, 2016, INDIAN J DERMATOL, V61, DOI 10.4103/0019-5154.174138; Kim HJ, 2006, AM J NEURORADIOL, V27, P1823; Laskin WB, 2000, HUM PATHOL, V31, P1230, DOI 10.1053/hupa.2000.18474; Magro G, 2010, VIRCHOWS ARCH, V456, P71, DOI 10.1007/s00428-009-0859-y; Mahalingam M, 2006, J CUTAN PATHOL, V33, P51, DOI 10.1111/j.0303-6987.2006.00400.x; Nishioka M, 2009, ORAL SURG ORAL MED O, V107, pE28, DOI 10.1016/j.tripleo.2009.01.018; Pan HY, 2014, PEDIATR NEONATOL, V55, P71, DOI 10.1016/j.pedneo.2012.12.004; Penarrocha M, 2000, ORAL SURG ORAL MED O, V90, P74, DOI 10.1067/moe.2000.106335; Plaza JA, 2009, AM J DERMATOPATH, V31, P419, DOI 10.1097/DAD.0b013e3181a13afc; Prado JD, 2007, J PERIODONTOL, V78, P1639, DOI 10.1902/jop.2007.060425; RODRIGUEZPERALTO JL, 1992, J ORAL MAXIL SURG, V50, P1224, DOI 10.1016/0278-2391(92)90159-W; ROSATI L A, 1986, Applied Pathology, V4, P186; Rozza-de-Menezes RE, 2013, HEAD NECK-J SCI SPEC, V35, pE397, DOI 10.1002/hed.23361; Safadi RA, 2010, HEAD NECK PATHOL, V4, P242, DOI 10.1007/s12105-010-0183-5; SIST TC, 1979, ORAL SURG ORAL MED O, V47, P441, DOI 10.1016/0030-4220(79)90126-9; Spadari F, 2014, ACTA DERMATOVENER CR, V22, P52; Tiffee JC, 1996, ORAL SURG ORAL MED O, V82, P423, DOI 10.1016/S1079-2104(96)80308-8; Vered M, 2011, J ORAL PATHOL MED, V40, P174, DOI 10.1111/j.1600-0714.2010.00952.x; Weng YC, 2015, J DTSCH DERMATOL GES, V13, P243, DOI [10.1111/ddg.12523_suppl, 10.1111/ddg.12523]; Zedek DC, 2009, J CUTAN PATHOL, V36, P1185, DOI 10.1111/j.1600-0560.2009.01263.x	34	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					75	81		10.1007/s12105-017-0828-8			7	Pathology	Pathology	GA6TM	WOS:000428467200010	28597210	Green Published			2019-10-28	
J	Covinsky, M; Cai, ZJ; Ambelil, M; Liu, J; Zhu, H				Covinsky, Michael; Cai, Zhenjian; Ambelil, Manju; Liu, Jing; Zhu, Hui			Low Grade Carcinoma Ex-Pleomorphic Adenoma: Diagnosis and Diagnostic Challenges Caused by Fine Needle Aspiration: Report of Three Cases and Review of Literature	HEAD & NECK PATHOLOGY			English	Review						Salivary gland neoplasm; Pleomorphic adenoma; Low-grade carcinoma ex pleomorphic adenoma; Pleomorphic adenoma malignant transformation	PAROTID-GLAND; LESIONS	Low grade carcinoma ex pleomorphic adenoma (LG CXPA) is a rare low grade malignant neoplasm arising from preexisting pleomorphic adenoma (PA). LG CXPA demonstrates no overt cytological atypia, and can be difficult to distinguish from cellular PA. Invasive growth is one of the hallmarks of LG CXPA, e.g., tumor extends beyond the capsule and into adjacent non-neoplastic tissue. However, it is known that capsular and vascular invasion, as well as the presence of stroma-rich PA in soft tissue without a capsule (pseudopodia) can be seen in PA. These histological findings have no prognostic significance and are not diagnostic of malignancy. In addition, recurrent PA typically presents as numerous nodules extending into soft tissue and skeletal muscle, which again are not considered malignant features. Thus, "infiltrative growth" of LG CXPA is difficult to define and diagnosis is challenging to many practicing pathologists. In this study, we report three cases of LG CXPA. We review the diagnostic criteria for LG CXPA, and discuss the diagnostic challenges caused by fine needle aspiration (FNA) changes. FNA is widely used as a cost-effective, quick and accurate method for diagnosing salivary gland lesions. Histological changes post-FNA are usually focal and mild, and are not causes of diagnostic difficulties. According to our knowledge, this is the first report of LG CXPA complicated with FNA changes.	[Covinsky, Michael; Ambelil, Manju; Liu, Jing; Zhu, Hui] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, 6431 Fannin St, Houston, TX 77030 USA; [Cai, Zhenjian] Icahn Sch Med Mt Sinai, Dept Pathol & Lab Med, 1468 Madison Ave, New York, NY 10029 USA	Zhu, H (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, 6431 Fannin St, Houston, TX 77030 USA.	hui.zhu@uth.tmc.edu					Antony J, 2012, HEAD NECK PATHOL, V6, P1, DOI 10.1007/s12105-011-0281-z; Lopes MLDD, 2017, EUR ARCH OTO-RHINO-L, V274, P543, DOI 10.1007/s00405-016-4253-5; El-Naggar A, 2017, WHO CLASSIFICATION H; Feinstein AJ, 2016, OTOLARYNG HEAD NECK, V155, P431, DOI 10.1177/0194599816643041; Griffith CC, 2017, ARCH PATHOL LAB MED, V141, P381, DOI 10.5858/arpa.2016-0259-SA; Kong M, 2015, AM J SURG PATHOL, V39, P931, DOI 10.1097/PAS.0000000000000452; Lewis JE, 2001, HUM PATHOL, V32, P596, DOI 10.1053/hupa.2001.25000; Li SY, 2000, ARCH PATHOL LAB MED, V124, P87; Lim CM, 2015, HEAD NECK-J SCI SPEC, V37, P543, DOI 10.1002/hed.23638; Skalova A, 2017, MODERN PATHOL, V30, pS27, DOI 10.1038/modpathol.2016.167; Stennert E, 2001, LARYNGOSCOPE, V111, P2195, DOI 10.1097/00005537-200112000-00024; Wenig B., 2015, ATLAS HEAD NECK PATH	12	2	2	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					82	88		10.1007/s12105-017-0829-7			7	Pathology	Pathology	GA6TM	WOS:000428467200011	28589437	Green Published			2019-10-28	
J	McCuiston, A; Bishop, JA				McCuiston, Austin; Bishop, Justin A.			Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors	HEAD & NECK PATHOLOGY			English	Article						NKX2.2; CD99; Ewing sarcoma; Primitive neuroectodermal tumor; EWSR1-FLI1	HOMEODOMAIN TRANSCRIPTION FACTOR; FAMILY TUMORS; CARCINOMAS; DIAGNOSIS; TRACT; TERATOCARCINOSARCOMA; DIFFERENTIATION; EXPRESSION; TARGET; GENE	NKX2.2 is a new immunohistochemical marker that has been reported to be sensitive and specific for Ewing sarcoma (ES). It has not, however, been investigated specifically in the sinonasal small round blue cell tumor (SRBCT) differential diagnosis which includes many tumors specific to that site. It has also not been investigated in the newly recognized "adamantinoma-like" variant of ES. Immunohistochemistry for NKX2.2 was performed on 170 poorly differentiated sinonasal neoplasms: 73 squamous cell carcinomas (67 poorly differentiated, non-keratinizing, or basaloid types and 6 nasopharyngeal carcinomas), 46 olfactory neuroblastomas, 8 sinonasal undifferentiated carcinomas (SNUCs), 6 melanomas, 7 Ewing sarcomas, 6 SMARCB1-deficient carcinomas, 6 teratocarcinosarcomas, 5 alveolar rhabdomyosarcomas, 4 solid adenoid cystic carcinomas, 4 NK/T cell lymphomas, 3 NUT carcinomas, and 2 small cell carcinomas. NKX2.2 was positive in 7 of 7 (100%) Ewing sarcomas, including 3 adamantinoma-like variant (all diffuse, 5 strong and 2 weak). It was also positive in 5 of 6 (83%) teratocarcinosarcomas (strong, but focal), 12 of 46 (26%) olfactory neuroblastomas (diffuse, 2 strong and 10 weak), 4 of 6 melanomas (2 diffuse, 2 focal, all weak), and 1 of 2 small cell carcinomas (diffuse and strong). All squamous cell carcinomas, NUT carcinomas, SMARCB1-deficient carcinomas, SNUCs, solid adenoid cystic carcinomas, NK/T cell lymphomas, and alveolar rhabdomyosarcomas were negative. In the sinonasal SRBCT differential diagnosis, NKX2.2 is a useful and very sensitive marker for Ewing sarcoma, including the treacherous adamantinoma-like variant. At the same time, it is not entirely specific, as it will be positive in a subset of other neuroendocrine/neuroectodermal tumors. As a result, NKX2.2 must be utilized as part of an immunohistochemical panel with other markers, especially cytokeratins, melanoma markers, and CD99.	[McCuiston, Austin; Bishop, Justin A.] Johns Hopkins Univ, Dept Pathol, Sch Med, 600 N Wolfe St,Pathol Bldg,Room 401, Baltimore, MD 21287 USA; [Bishop, Justin A.] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Bishop, Justin A.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	McCuiston, A (reprint author), Johns Hopkins Univ, Dept Pathol, Sch Med, 600 N Wolfe St,Pathol Bldg,Room 401, Baltimore, MD 21287 USA.	amccuis1@jhmi.edu					Alexiev BA, 2017, PATHOL RES PRACT, V213, P422, DOI 10.1016/j.prp.2016.11.018; Bishop JA, 2016, SEMIN DIAGN PATHOL, V33, P62, DOI 10.1053/j.semdp.2015.12.001; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Bridge JA, 2010, HEAD NECK PATHOL, V4, P84, DOI 10.1007/s12105-009-0158-6; Bridge RS, 2006, MODERN PATHOL, V19, P1, DOI 10.1038/modpathol.3800486; Briscoe J, 1999, NATURE, V398, P622; Chapman-Fredricks J, 2009, APPL IMMUNOHISTO M M, V17, P207, DOI 10.1097/PAI.0b013e31818fc85c; Fadul John, 2015, Genes Cancer, V6, P129; Fatima SS, 2013, ANN DIAGN PATHOL, V17, P313, DOI 10.1016/j.anndiagpath.2013.01.003; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Hafezi S, 2011, HEAD NECK PATHOL, V5, P8, DOI 10.1007/s12105-010-0227-x; Huang Michael, 2011, Sarcoma, P863210, DOI 10.1155/2011/863210; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Llombart-Bosch A, 2009, VIRCHOWS ARCH, V455, P397, DOI 10.1007/s00428-009-0842-7; Mills SE, 2005, AM J CLIN PATHOL, V124, pS110; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Pai SA, 1998, HUM PATHOL, V29, P718, DOI 10.1016/S0046-8177(98)90281-7; Qi YC, 2001, DEVELOPMENT, V128, P2723; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Simons SA, 2016, SEMIN DIAGN PATHOL, V33, P91, DOI 10.1053/j.semdp.2015.09.010; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tilson MP, 2014, HEAD NECK PATHOL, V8, P141, DOI 10.1007/s12105-013-0496-2; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Vaccani JP, 1999, INT J PEDIATR OTORHI, V48, P209, DOI 10.1016/S0165-5876(99)00030-0; Wang YC, 2009, ENDOCR-RELAT CANCER, V16, P267, DOI 10.1677/ERC-08-0127; WEIDNER N, 1994, AM J SURG PATHOL, V18, P486, DOI 10.1097/00000478-199405000-00008; Weiss SW, 2008, ENZINGER WEISSS SOFT; Yang SD, 2013, INT J SURG PATHOL, V21, P37, DOI 10.1177/1066896912457202; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c	34	5	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					89	94		10.1007/s12105-017-0830-1			6	Pathology	Pathology	GA6TM	WOS:000428467200012	28616785	Green Published			2019-10-28	
J	Can, NT; Lingen, MW; Mashek, H; McElherne, J; Briese, R; Fitzpatrick, C; van Zante, A; Cipriani, NA				Nhu Thuy Can; Lingen, Mark W.; Mashek, Heather; McElherne, James; Briese, Renee; Fitzpatrick, Carrie; van Zante, Annemieke; Cipriani, Nicole A.			Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors	HEAD & NECK PATHOLOGY			English	Article						Salivary gland tumors; Salivary duct carcinoma; Hormone receptors; Estrogen; Progesterone; Androgen; HER-2; FISH	ANDROGEN-DEPRIVATION THERAPY; ADENOID CYSTIC CARCINOMA; IN-SITU HYBRIDIZATION; DUCT CARCINOMA; PROGESTERONE-RECEPTORS; PAROTID-GLAND; IMMUNOHISTOCHEMICAL EVALUATION; MUCOEPIDERMOID CARCINOMA; BREAST CANCERS; ESTROGEN	With the advent of targeted therapies, expression of sex hormone receptors and HER-2 in salivary gland tumors (SGTs) is of clinical interest. Previous reports of estrogen (ER) and progesterone (PR) receptor expression have varied. Androgen receptor (AR) and HER-2 overexpression are frequently reported in salivary duct carcinoma (SDC), but have not been studied systematically in other SGTs. This study examines ER, PR, AR, and HER-2 expression in SGTs. Immunohistochemistry for ER, PR, AR, and HER-2 was performed on 254 SGTs (134 malignant). ER, PR, and AR expression was scored using Allred system. HER-2 expression was scored using Dako HercepTest guidelines. FISH for HER-2 amplification was performed on select cases with HER-2 overexpression (2-3+). No SGT demonstrated strong expression of ER or PR. Combined strong AR and HER-2 expression was seen in 22 carcinomas: 14/25 SDC, 3/16 poorly differentiated, two oncocytic, and one each carcinoma ex pleomorphic adenoma, squamous cell, and intraductal carcinoma. Eighteen additional high grade carcinomas had HER-2 overexpression with absent, weak, or moderate AR expression; eight high grade carcinomas had isolated strong AR expression with 0-1+ HER-2 staining. Of 15 tested cases, six demonstrated HER-2 amplification by FISH, all of which had 3+ immunoreactivity. Neither benign nor malignant SGTs had strong expression of ER or PR. None of the benign SGTs overexpressed AR or HER-2. Coexpression of AR and HER-2 should not define SDC, but immunostaining should be considered in high grade salivary carcinomas, as some show overexpression and may benefit from targeted therapy.	[Nhu Thuy Can; Lingen, Mark W.; Cipriani, Nicole A.] Univ Chicago Med, Dept Pathol, 5841 S Maryland Ave,MC 6101, Chicago, IL 60637 USA; [Nhu Thuy Can; van Zante, Annemieke] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA; [Mashek, Heather; McElherne, James; Briese, Renee; Fitzpatrick, Carrie] Univ Chicago Med, Dept Pathol, Constitut Cytogenet & Cytogen, 5841 S Maryland Ave, Chicago, IL 60637 USA	Cipriani, NA (reprint author), Univ Chicago Med, Dept Pathol, 5841 S Maryland Ave,MC 6101, Chicago, IL 60637 USA.	nhuthuy.can@gmail.com; Mark.Lingen@uchospitals.edu; Heather.Mashek@uchospitals.edu; James.McElherne@uchospitals.edu; Renee.Briese@uchospitals.edu; cfitzpat@bsd.uchicago.edu; Annemieke.VanZante@ucsf.edu; Nicole.Cipriani@uchospitals.edu		Cipriani, Nicole/0000-0003-3092-2746			Allred DC, 1998, MODERN PATHOL, V11, P155; Alotaibi AM, 2015, J CLIN DIAGN RES, V9, pZE4, DOI 10.7860/JCDR/2015/11289.5572; Barrera JE, 2008, HEAD NECK PATHOL, V2, P13, DOI 10.1007/s12105-007-0032-3; Butler RT, 2014, HEAD NECK PATHOL, V8, P133, DOI 10.1007/s12105-013-0493-5; Clauditz TS, 2011, PATHOLOGY, V43, P459, DOI 10.1097/PAT.0b013e3283484a60; Cornolti G, 2007, ARCH OTOLARYNGOL, V133, P1031, DOI 10.1001/archotol.133.10.1031; DeRoche TC, 2008, ARCH PATHOL LAB MED, V132, P1907, DOI 10.1043/1543-2165-132.12.1907; Di Palma S, 2012, HISTOPATHOLOGY, V61, P629, DOI 10.1111/j.1365-2559.2012.04252.x; Dori S, 2000, ORAL ONCOL, V36, P450, DOI 10.1016/S1368-8375(00)00029-4; Ghazali N, 2016, OR SURG OR MED OR PA, V122, P292, DOI [10.1016/j.0000.2016.03.020, 10.1016/j.oooo.2016.03.020]; Glisson B, 2004, CLIN CANCER RES, V10, P944, DOI 10.1158/1078-0432.CCR-03-0253; Haddad R, 2003, ORAL ONCOL, V39, P724, DOI 10.1016/S1368-8375(03)00097-6; Honma N, 2014, BREAST, V23, P754, DOI 10.1016/j.breast.2014.08.003; Jaspers HCJ, 2011, J CLIN ONCOL, V29, pE473, DOI 10.1200/JCO.2010.32.8351; Kaidar-Person O, 2012, MED ONCOL, V29, P704, DOI 10.1007/s12032-011-9884-1; Limaye SA, 2013, ONCOLOGIST, V18, P294, DOI 10.1634/theoncologist.2012-0369; Locati LD, 2016, HEAD NECK-J SCI SPEC, V38, P724, DOI 10.1002/hed.23940; Locati LD, 2003, ANN ONCOL, V14, P1327, DOI 10.1093/annonc/mdg331; Masubuchi T, 2015, INT J CLIN ONCOL, V20, P35, DOI 10.1007/s10147-014-0674-6; Nabili V, 2007, HEAD NECK-J SCI SPEC, V29, P907, DOI 10.1002/hed.20614; Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841; Nasser SM, 2003, AM J CLIN PATHOL, V119, P801, DOI 10.1309/RVTP1G0Q727WJUQD; Perissinotti AJ, 2013, ANTICANCER RES, V33, P2587; Pires FR, 2004, PATHOL ONCOL RES, V10, P166, DOI 10.1007/BF03033746; Prat A, 2008, HEAD NECK-J SCI SPEC, V30, P680, DOI 10.1002/hed.20714; Press MF, 2005, CLIN CANCER RES, V11, P6598, DOI 10.1158/1078-0432.CCR-05-0636; Sharon E, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-12; SHICK PC, 1995, ORAL SURG ORAL MED O, V80, P440, DOI 10.1016/S1079-2104(05)80338-5; Simpson RHW, 2013, HEAD NECK PATHOL, V7, pS48, DOI 10.1007/s12105-013-0456-x; Skalova A, 2003, HISTOPATHOLOGY, V42, P348, DOI 10.1046/j.1365-2559.2003.01600.x; Soper MS, 2014, HEAD NECK-J SCI SPEC, V36, pE4, DOI 10.1002/hed.23383; VANDERHULST RWM, 1994, LANCET, V344, P817, DOI 10.1016/S0140-6736(94)92372-8; Vidal L, 2009, HEAD NECK-J SCI SPEC, V31, P1006, DOI 10.1002/hed.21052; Yamamoto N, 2014, AM J OTOLARYNG, V35, P731, DOI 10.1016/j.amjoto.2014.07.007	34	5	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					95	104		10.1007/s12105-017-0833-y			10	Pathology	Pathology	GA6TM	WOS:000428467200013	28681314	Green Published			2019-10-28	
J	Sowder, AM; Witt, BL; Hunt, JP				Sowder, Aleksandra M.; Witt, Benjamin L.; Hunt, Jason P.			An Update on the Risk of Lymph Node Metastasis for the Follicular Variant of Papillary Thyroid Carcinoma with the New Diagnostic Paradigm	HEAD & NECK PATHOLOGY			English	Article						Thyroid; Cancer; Lymph node; Metastasis	ULTRASONOGRAPHY; CANCER	Previous data has shown that the risk of nodal metastases is significantly greater for classical papillary thyroid carcinoma (PTC) as compared to the follicular variant (FVPTC). Given a recent change in diagnostic paradigm and definition of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) we intended to investigate if there remains a significant difference in nodal involvement between classical PTC and FVPTC. A 6-year retrospective review of all cases with FVPTC in the diagnostic line from the University of Utah/ARUP Laboratories was conducted. Two pathologists reviewed the remaining cases using the recently described histologic criteria of NIFTP to determine the total number the FVPTCs fitting the new classification paradigm. Histologic and clinical follow-up was tracked for all patients to determine the rate of nodal disease for all groups. 127 cases were identified using the above listed criteria. Forty-seven cases (37%) were classified as NIFTPs. None of the 47 patients had nodal disease either at the time of surgery or on follow-up. Twenty-eight cases met the current criteria for FVPTC (21%); of these 7/28 (25%) had evidence of nodal disease. By comparison, 17/45 (38%) of patients with mixed classical and FVPTC had nodal disease. Overall, there was no statistically significant difference in the risk of nodal metastasis between the pure FVPTC and mixed classical/FVPTC groups (p = 0.43). Our data indicates that implementing new definition for FVPTC will narrow the gap in the risk of nodal metastases between the classical PTC and FVPTC histologic subtypes.	[Sowder, Aleksandra M.; Witt, Benjamin L.] Univ Utah, Dept Pathol, Sch Med, 1950 Circle Hope Dr,N3105, Salt Lake City, UT 84112 USA; [Hunt, Jason P.] Univ Utah, Sch Med, Otolaryngol Head & Neck Surg, Salt Lake City, UT USA; [Hunt, Jason P.] Huntsman Canc Hosp, Salt Lake City, UT USA	Sowder, AM (reprint author), Univ Utah, Dept Pathol, Sch Med, 1950 Circle Hope Dr,N3105, Salt Lake City, UT 84112 USA.	aleksandra.sowder@hsc.utah.edu					Chan JKC, 2002, AM J CLIN PATHOL, V117, P16; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Daniels GH, 2011, ENDOCR PRACT, V17, P768, DOI 10.4158/EP10407.RA; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Golding A, 2017, INT J SURG ONCOL, V2017, P1; HARWOOD J, 1978, AM J SURG, V136, P107, DOI 10.1016/0002-9610(78)90209-X; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Hunt JP, 2011, ARCH OTOLARYNGOL, V137, P1141, DOI 10.1001/archoto.2011.174; Kweon SS, 2013, JPN J CLIN ONCOL, V43, P1039, DOI 10.1093/jjco/hyt102; Lin HW, 1994, CANCER, V73, P424; Lundgren CI, 2006, CANCER, V106, P524, DOI 10.1002/cncr.21653; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Moreno MA, 2011, ARCH OTOLARYNGOL, V137, P157, DOI 10.1001/archoto.2010.254; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Pearce EN, 2017, CLIN THYROIDOL, V29, P8; Pellegriti G, 2013, J CANCER EPIDEMIOL, DOI 10.1155/2013/965212; Salter KD, 2010, ARCH OTOLARYNGOL, V136, P692, DOI 10.1001/archoto.2010.112; Stulak JM, 2006, ARCH SURG-CHICAGO, V141, P489, DOI 10.1001/archsurg.141.5.489; Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015; Youngwirth LM, 2017, THYROID, V27, P626, DOI 10.1089/thy.2016.0132	20	2	2	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					105	109		10.1007/s12105-017-0835-9			5	Pathology	Pathology	GA6TM	WOS:000428467200014	28647794	Green Published			2019-10-28	
J	Cardesa, A; Nadal, A; Alos, L; Lloreta-Trull, J; Ferlito, A				Cardesa, Antonio; Nadal, Alfons; Alos, Llucia; Lloreta-Trull, Josep; Ferlito, Alfio			Sebaceous Differentiation in Squamous Cell Carcinoma of the Larynx and Adjacent Pharynx: Case Report with Review and Discussion of the Literature	HEAD & NECK PATHOLOGY			English	Review						Larynx and adjacent pharynx; Squamous cell carcinoma variants; Sebaceous differentiation; Prognosis	OF-THE-LITERATURE	Among the variants of squamous cell carcinoma (SCC) of the head and neck arising in mucosal surfaces, examples with sebaceous differentiation are exceedingly rare. We present a new case of SCC with sebaceous differentiation, developing in the larynx of a 64 year-old male, cigarette smoker and alcohol drinker. The tumor extended transglottically, metastasized to cervical lymph nodes, and killed the patient after 12 months. Comparing this case with four previously reported cases of SCC with sebaceous differentiation, two arising in the larynx and the other two in the adjacent pharynx, all five patients mostly shared the following features: appearance of the tumor in the seventh decade of life, heavy tobacco smoking, alcohol intake in three, surgery as mainstay treatment, tumor size between 2 and 4.7 cm, and regional lymph node metastases in four of them. Out of the four patients with a follow up of 12 months, two died of disease, one was alive with disease, and only one was alive without disease. One patient was lost for follow up. In conclusion, mucosal SCC with sebaceous differentiation is a very rare variant of SCC that when arising in the larynx and anatomically adjacent parts of the pharynx behaves aggressively and bears a dismal prognosis. The recognition of new cases of this entity requires special awareness of its phenotypic features and may be important for further assessment of its behavior.	[Cardesa, Antonio; Nadal, Alfons; Alos, Llucia] Univ Barcelona, Hosp Clin, Dept Anat Patol, Villarroel 170, E-08036 Barcelona, Spain; [Lloreta-Trull, Josep] DCEXS Univ Pompeu Fabra, Hosp Mar, Serv Anat Patol, Barcelona, Spain; [Ferlito, Alfio] Int Head & Neck Sci Grp, Padua, Italy	Cardesa, A (reprint author), Univ Barcelona, Hosp Clin, Dept Anat Patol, Villarroel 170, E-08036 Barcelona, Spain.	acardesa@clinic.ub.es; lalos@clinic.ub.es; anadal@clinic.ub.es; jlloreta@parcdesalutmar.cat; alfio.ferlito@uniud.it		Lloreta Trulll, Josep/0000-0003-1644-9470			Alawi F, 2005, ORAL SURG ORAL MED O, V99, P79, DOI 10.1016/j.tripleo.2004.05.007; ASSOR D, 1975, AM J CLIN PATHOL, V63, P891; Baiocco R., 1995, Pathologica (Genoa), V87, P531; BAMBIRRA EA, 1983, GASTROINTEST ENDOSC, V29, P251, DOI 10.1016/S0016-5107(83)72605-2; Ellis GL, 2008, ATLAS TUMOR PATHOL, P377; Font RL, 2006, ATLAS TUMOR PATHOL, p[15, 183]; Gnepp DR., 2005, WHO CLASSIFICATION T, P231; Gnepp DR, 2017, WHO CLASSIFICATION H, P178; Hellquist H, 2014, HISTOPATHOLOGY SALIV, P407; Ko CJ, 2010, CLIN DERMATOL, V28, P324, DOI 10.1016/j.clindermatol.2009.07.001; MARTINEZMADRIGAL F, 1991, HUM PATHOL, V22, P929, DOI 10.1016/0046-8177(91)90186-S; Miyamoto K, 1989, CANCER J, V3, P414; Ostler DA, 2010, MODERN PATHOL, V23, P567, DOI 10.1038/modpathol.2010.1; PANAYIOTIDES JG, 1995, J LARYNGOL OTOL, V109, P784, DOI 10.1017/S0022215100131329; Rowe ME, 2016, HEAD NECK-J SCI SPEC, V38, pE20, DOI 10.1002/hed.24091; RULON DB, 1974, CANCER, V33, P82, DOI 10.1002/1097-0142(197401)33:1<82::AID-CNCR2820330115>3.0.CO;2-4; Wang HJ, 2010, ORAL SURG ORAL MED O, V110, pE37, DOI 10.1016/j.tripleo.2010.04.027	17	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					118	122		10.1007/s12105-017-0839-5			5	Pathology	Pathology	GA6TM	WOS:000428467200016	28721661	Green Published			2019-10-28	
J	Rawal, SY; Rawal, YB				Rawal, Swati Y.; Rawal, Yeshwant B.			Angioleiomyoma (Vascular Leiomyoma) of the Oral Cavity	HEAD & NECK PATHOLOGY			English	Article						Oral; Vascular; Leiomyoma; Angioleiomyoma; Tumor; SMA	PALATE	A 70-year-old male presented with a slow growing, dome shaped and painless mass of the hard palate. The mass was excised. Histopathological examination confirmed the diagnosis of a angioleiomyoma (vascular leiomyoma). A leiomyoma is an uncommon benign tumor of smooth muscle differentiation. True leiomyomas of the oral cavity are rare and most oral tumors are derived from the smooth muscle of walls of blood vessels. Therefore, they are called vascular leiomyomas or angioleiomyomas. Clinically, they may resemble a myriad other conditions both benign and malignant. A definitive diagnosis depends upon histopathological examination of the biopsied tissue in correlation with the tumor cell immunohistochemistry. Tumors are excised and recurrence is rare. The histopathological findings and differential diagnosis of a case of a palatal angioleiomyoma are discussed.	[Rawal, Swati Y.] Int Med Univ, Sch Dent, Kuala Lumpur, Malaysia; [Rawal, Yeshwant B.] Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Magnuson Hlth Sci Ctr B204, 1959 NE Pacific St,Box 357133, Seattle, WA 98195 USA	Rawal, YB (reprint author), Univ Washington, Sch Dent, Dept Oral & Maxillofacial Surg, Magnuson Hlth Sci Ctr B204, 1959 NE Pacific St,Box 357133, Seattle, WA 98195 USA.	SwatiYeshwant@imu.edu.my; ybrawal@uw.edu					Brooks JK, 2002, ORAL SURG ORAL MED O, V94, P221, DOI 10.1067/moe.2002.125276; Butler RT, 2016, HEAD NECK PATHOL, V10, P286, DOI 10.1007/s12105-016-0680-2; Curran Alice E, 2004, Oral Maxillofac Surg Clin North Am, V16, P399, DOI 10.1016/j.coms.2004.03.008; Eley KA, 2012, OR SURG OR MED OR PA, V114, pE45, DOI 10.1016/j.oooo.2012.01.014; Esmeili Tara, 2005, Dent Clin North Am, V49, P223, DOI 10.1016/j.cden.2004.07.001; GOLDBLATT LI, 1977, ORAL SURG ORAL MED O, V43, P591, DOI 10.1016/0030-4220(77)90114-1; HACHISUGA T, 1984, CANCER, V54, P126, DOI 10.1002/1097-0142(19840701)54:1<126::AID-CNCR2820540125>3.0.CO;2-F; HEMANI DD, 1983, J LARYNGOL OTOL, V97, P471, DOI 10.1017/S0022215100094408; NATIELLA JR, 1982, J ORAL PATHOL MED, V11, P353, DOI 10.1111/j.1600-0714.1982.tb00177.x; Neville B. W., 2009, ORAL MAXILLOFACIAL P; Ramesh P, 2004, INT J CLIN PRACT, V58, P587, DOI 10.1111/j.1368-5031.2004.00085.x; SYANE TJ, 1986, J PERIODONTOL, V57, P433, DOI 10.1902/jop.1986.57.7.433; Tsuji T, 2014, J ORAL MAXIL SURG, V72, P920, DOI 10.1016/j.joms.2013.11.008; WALDRON CA, 1988, ORAL SURG ORAL MED O, V66, P323, DOI 10.1016/0030-4220(88)90240-X; WHITE DK, 1985, J ORAL MAXIL SURG, V43, P640, DOI 10.1016/0278-2391(85)90140-5	15	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					123	126		10.1007/s12105-017-0827-9			4	Pathology	Pathology	GA6TM	WOS:000428467200017	28589436	Green Published			2019-10-28	
J	Ginat, DT; Schulte, J; Portugal, L; Cipriani, NA				Ginat, Daniel T.; Schulte, Jefree; Portugal, Louis; Cipriani, Nicole A.			Laryngotracheal Involvement in Systemic Light Chain Amyloidosis	HEAD & NECK PATHOLOGY			English	Article						Amyloidosis; Amyloidoma; Larynx; Trachea; Radiology; Pathology	AL AMYLOIDOSIS; HEAD; NECK	Laryngotracheal amyloid deposition is an uncommon manifestation of systemic light chain amyloidosis. Diagnostic imaging, such as CT, is useful for suggesting the possibility of amyloidosis and delineating the extent of the lesions for surgical management; however, the diagnosis is confirmed with the histologic finding of amorphous eosinophilic material which stains positively for Congo red and may show apple green birefringence on polarization. These features are exemplified in this sine qua non radiology-pathology correlation article.	[Ginat, Daniel T.] Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Schulte, Jefree; Cipriani, Nicole A.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Portugal, Louis] Univ Chicago, Dept Surg, Otolaryngol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA	Ginat, DT (reprint author), Univ Chicago, Dept Radiol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dtg1@uchicago.edu			University of Chicago Office of Faculty Affairs through the Faculty Initiatives Fund for our Head and Neck Radiology-Pathology Trainee Conference	We are grateful for support received from the University of Chicago Office of Faculty Affairs through the Faculty Initiatives Fund for our Head and Neck Radiology-Pathology Trainee Conference, during which this case was presented.	Bahlis NJ, 2006, BONE MARROW TRANSPL, V38, P7, DOI 10.1038/sj.bmt.1705395; Becker M, 1998, RADIOGRAPHICS, V18, P1189, DOI 10.1148/radiographics.18.5.9747615; Cipriani NA, 2011, INT J SURG PATHOL, V19, P583, DOI 10.1177/1066896911411480; Desport E, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-54; Dogan A, 2017, ANNU REV PATHOL-MECH, V12, P277, DOI 10.1146/annurev-pathol-052016-100200; Gilad R, AJNR AM J NEURORADIO, V200, P1557; Gouvea AF, 2012, J ORAL PATHOL MED, V41, P178, DOI 10.1111/j.1600-0714.2011.01073.x; Kastritis E, 2016, BRIT J HAEMATOL, V172, P170, DOI 10.1111/bjh.13805; Ma LL, 2005, ARCH PATHOL LAB MED, V129, P215; Parmar H, 2010, AM J NEURORADIOL, V31, P1165, DOI 10.3174/ajnr.A1977; Pribitkin E, 2003, LARYNGOSCOPE, V113, P2095, DOI 10.1097/00005537-200312000-00007; Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X	12	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					127	130		10.1007/s12105-017-0831-0			4	Pathology	Pathology	GA6TM	WOS:000428467200018	28616786	Green Published			2019-10-28	
J	Jeong, HJ; Roh, J; Lee, BJ; Cho, KJ				Jeong, Hui-Jeong; Roh, Jin; Lee, Bong-Jae; Cho, Kyung-Ja			Low-Grade Papillary Schneiderian Carcinoma: A Case Report	HEAD & NECK PATHOLOGY			English	Article						Low-grade malignancy; Papillary sinonasal carcinoma; Schneiderian papilloma; Oncocytic papilloma	MALIGNANT-TRANSFORMATION; SINONASAL PAPILLOMAS; INVERTED PAPILLOMA; P53	The nasal cavity and paranasal sinuses are covered with ciliated respiratory mucosa of ectodermal origin, known as Schneiderian epithelium, which can give rise to different types of sinonasal carcinomas. A 42-year-old woman with a history of nasal polypectomy 3 years previously presented with nasal obstruction and rhinorrhea. She was found to have a papillary mass involving the left nasal cavity, and the left maxillary and ethmoidal sinuses by radiologic examination. She underwent endonasal resection under the diagnosis of oncocytic papilloma. The resected specimen showed exuberant invasive growth of papillary or inverted architectures of epithelial cells. The neoplastic cells were very bland, showing a round to polygonal shape, low nuclear-to-cytoplasmic ratio, abundant oncocytic cytoplasm, uniform nuclei, indistinct nucleoli, and scarce mitosis. The overall features were identical to those of a recent report of a low-grade papillary Schneiderian carcinoma. The main differential diagnosis is Schneiderian papilloma, and awareness of this novel entity is important for its proper treatment.	[Jeong, Hui-Jeong; Roh, Jin; Cho, Kyung-Ja] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Lee, Bong-Jae] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otorhinolaryngol, Seoul, South Korea	Cho, KJ (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	kjc@amc.seoul.kr					Anari S, 2010, J LARYNGOL OTOL, V124, P705, DOI 10.1017/S0022215110000599; Batsakis JG, 2001, ADV ANAT PATHOL, V8, P53, DOI 10.1097/00125480-200103000-00001; Bishop JA, 2017, WHO CLASSIFICATION H, P14; Buchwald C, 2001, LARYNGOSCOPE, V111, P1104, DOI 10.1097/00005537-200106000-00032; Fan GK, 2006, AM J RHINOL, V20, P360, DOI 10.2500/ajr.2006.20.2851; Franzmann MB, 1998, CANCER LETT, V128, P161, DOI 10.1016/S0304-3835(98)00058-5; Hunt JL, 2017, WHO CLASSIFICATION H, P28; Kaufman MR, 2002, LARYNGOSCOPE, V112, P1372, DOI 10.1097/00005537-200208000-00009; Lewis JS, 2015, AM J SURG PATHOL, V39, P714, DOI 10.1097/PAS.0000000000000390; Mumbuc S, 2007, J INT MED RES, V35, P237, DOI 10.1177/147323000703500208; Nudell J, 2014, HEAD NECK PATHOL, V8, P269, DOI 10.1007/s12105-014-0527-7; Vorasubin N, 2013, AM J RHINOL ALLERGY, V27, P287, DOI 10.2500/ajra.2013.27.3904	12	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					131	135		10.1007/s12105-017-0832-z			5	Pathology	Pathology	GA6TM	WOS:000428467200019	28639124	Green Published, Other Gold			2019-10-28	
J	Argyris, PP; Gopalakrishnan, R; Hu, Y; Reichenberger, EJ; Koutlas, IG				Argyris, Prokopios P.; Gopalakrishnan, Rajaram; Hu, Ying; Reichenberger, Ernst J.; Koutlas, Ioannis G.			Clinicopathologic and Molecular Characteristics of Familial Cherubism with Associated Odontogenic Tumorous Proliferations	HEAD & NECK PATHOLOGY			English	Article						Cherubism; SH3BP2; Benign giant cell lesion; Odontogenic fibroma; Hybrid COF/CGCL; Odontogenic carcinoma; Intraosseous squamous cell carcinoma; Squamous odontogenic tumor	GIANT-CELL GRANULOMA; ADAPTER PROTEIN 3BP2; OF-THE-LITERATURE; GENE CAUSES CHERUBISM; ORBITAL INVOLVEMENT; SH3BP2 CHERUBISM; ANTIGEN RECEPTOR; TURKISH FAMILY; FIBROMA; LESION	Cherubism is a rare autosomal dominant condition affecting the jaws and caused by mutations in the gene encoding for the adapter protein SH3BP2 that maps to chromosome 4p16.3. Cherubism is characterized by symmetrically developing bone lesions in the maxilla and mandible. The lesions have been radiographically and histopathologically well-described. Here, we present a family with cherubism with two of its members featuring odontogenic tumorous proliferations in association with persistent central giant cell lesions (CGCL). Specifically, the proband, a 25-year-old male, developed a radiolucent lesion characterized histologically by central odontogenic fibroma-like proliferation in association with a CGCL component, while his mother, at age 57, was diagnosed with primary intraosseous odontogenic carcinoma with areas of benign fibro-osseous lesions. In both patients the lesions occurred in the anterior mandible and presented with clinical enlargement. The son underwent incisional biopsy and did not have additional treatment. His mother underwent extensive mandibulectomy due to widespread tumor. The son has two affected children with classic cherubism while a third child at age 5, had not shown any features of the disease. Mutation analysis of three affected members resulted in the identification of a heterozygous mutation in SH3BP2 (c.1244G > C; p.Arg415Pro). To the best of our knowledge, association of cherubism with odontogenic neoplastic lesions has hitherto not been reported in the literature, thus suggesting a relationship between cherubism with disturbed odontogenesis.	[Argyris, Prokopios P.; Gopalakrishnan, Rajaram; Koutlas, Ioannis G.] Univ Minnesota, Sch Dent, Div Oral & Maxillofacial Pathol, 515 Delaware St SE 16-206B, Minneapolis, MN 55455 USA; [Hu, Ying; Reichenberger, Ernst J.] Univ Connecticut, Dept Reconstruct Sci, Farmington, CT USA	Koutlas, IG (reprint author), Univ Minnesota, Sch Dent, Div Oral & Maxillofacial Pathol, 515 Delaware St SE 16-206B, Minneapolis, MN 55455 USA.	koutl001@umn.edu					Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; ALLEN CM, 1992, ORAL SURG ORAL MED O, V73, P62, DOI 10.1016/0030-4220(92)90156-K; Battaglia A, 2000, OTOLARYNG HEAD NECK, V122, P573, DOI 10.1016/S0194-5998(00)70104-5; Beaman FD, 2004, AM J ROENTGENOL, V182, P1051, DOI 10.2214/ajr.182.4.1821051; Carroll AL, 2001, CLIN EXP OPHTHALMOL, V29, P38, DOI 10.1046/j.1442-9071.2001.00363.x; Chadwick JW, 2011, DENTOMAXILLOFAC RAD, V40, P230, DOI [10.1259/16355120, 10.1259/dmfr/16355120]; Colombo F, 2001, OPHTHALMOLOGY, V108, P1884, DOI 10.1016/S0161-6420(01)00757-6; de la Fuente MA, 2006, MOL CELL BIOL, V26, P5214, DOI 10.1128/MCB.00087-06; Dinckan N, 2012, OR SURG OR MED OR PA, V114, pE42, DOI 10.1016/j.oooo.2012.01.031; Foucault I, 2005, BLOOD, V105, P1106, DOI 10.1182/blood-2003-08-2965; Geraldo AF, 2012, ACTA MEDICA PORT, V25, P55; Hitomi G, 1996, ORAL SURG ORAL MED O, V81, P623, DOI 10.1016/S1079-2104(96)80060-6; Hyckel P, 2005, J CRANIO MAXILL SURG, V33, P61, DOI 10.1016/j.jcms.2004.07.006; Ide F, 1999, ORAL ONCOL, V35, P431, DOI 10.1016/S1368-8375(99)00010-X; Irie T, 2010, PATHOL INT, V60, P694, DOI 10.1111/j.1440-1827.2010.02583.x; Jevremovic D, 2001, J IMMUNOL, V166, P7219, DOI 10.4049/jimmunol.166.12.7219; JONES WA, 1950, J BONE JOINT SURG BR, V32, P334; Kaplan Ilana, 2007, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V103, pe35, DOI 10.1016/j.tripleo.2006.03.017; KATZ JO, 1992, J ORAL MAXIL SURG, V50, P301, DOI 10.1016/0278-2391(92)90333-U; KAWAKAMI T, 1989, J ORAL MAXIL SURG, V47, P737, DOI 10.1016/S0278-2391(89)80017-5; Ladhani S, 2003, THORAX, V58, P552, DOI 10.1136/thorax.58.6.552; Lenouvel D, 2015, J ORAL MAXIL SURG, V73, P1957, DOI 10.1016/j.joms.2015.03.069; Li BB, 2013, J CRANIOFAC SURG, V24, pE100, DOI 10.1097/SCS.0b013e3182799005; Li CY, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-84; Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600-0714.2003.00126.x; Mangion J, 1999, AM J HUM GENET, V65, P151, DOI 10.1086/302454; Meng XM, 2005, INT J ORAL MAX SURG, V34, P350, DOI 10.1016/j.ijom.2004.09.006; de Lima MDM, 2008, OTOLARYNG HEAD NECK, V139, P867, DOI 10.1016/j.otohns.2008.08.013; Naidu Aparna, 2016, Oral Surg Oral Med Oral Pathol Oral Radiol, V122, pe86, DOI 10.1016/j.oooo.2015.12.003; Neville B. W., 2016, ORAL MAXILLOFACIAL P; Odell EW, 1997, HISTOPATHOLOGY, V30, P165, DOI 10.1046/j.1365-2559.1997.d01-585.x; Papadaki ME, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-S1-S6; Preda L, 2010, MOL SYNDROMOL, V1, P87, DOI 10.1159/000314268; Reichenberger EJ, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-S1-S5; RICHARD BM, 1994, HISTOPATHOLOGY, V25, P497, DOI 10.1111/j.1365-2559.1994.tb00015.x; Sada K, 2002, BLOOD, V100, P2138, DOI 10.1182/blood-2001-12-0340; Sekerci AE, 2014, MED ORAL PATOL ORAL, V19, pE340, DOI 10.4317/medoral.19496; Silva GCC, 2007, BRIT J ORAL MAX SURG, V45, P567, DOI 10.1016/j.bjoms.2006.08.013; Taylor AM, 1999, J ORAL MAXIL SURG, V57, P1258, DOI 10.1016/S0278-2391(99)90500-1; THESLEFF I, 1995, ACTA ODONTOL SCAND, V53, P129, DOI 10.3109/00016359509005962; Tosios KI, 2008, HEAD NECK PATHOL, V2, P333, DOI 10.1007/s12105-008-0076-z; Tsodoulos S, 2014, J ORAL MAXILLOFAC SU, V72, P405; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Ueki Y, 2007, CELL, V128, P71, DOI 10.1016/j.cell.2006.10.047; Yoon JH, 2004, INT J ORAL MAX SURG, V33, P615, DOI 10.1016/j.ijom.2003.09.007; Yoshitaka T, 2014, CELL REP, V8, P1752, DOI 10.1016/j.celrep.2014.08.023; Younis RH, 2008, HEAD NECK PATHOL, V2, P222, DOI 10.1007/s12105-008-0063-4	47	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					136	144		10.1007/s12105-017-0837-7			9	Pathology	Pathology	GA6TM	WOS:000428467200020	28721660	Green Published			2019-10-28	
J	Ortega, RM; Bufalino, A; Almeida, LY; Navarro, CM; Travassos, DC; Ferrisse, TM; Carlos, R; Leon, JE				Ortega, Rose Mara; Bufalino, Andreia; Almeida, Luciana Yamamoto; Navarro, Claudia Maria; Travassos, Daphine Caxias; Ferrisse, Tulio Morandin; Carlos, Roman; Leon, Jorge Esquiche			Synchronous Polymorphous Adenocarcinoma and Canalicular Adenoma on the Upper Lip: An Unusual Presentation and Immunohistochemical Analysis	HEAD & NECK PATHOLOGY			English	Article						Minor salivary glands; Upper lip; Canalicular adenoma; Polymorphous adenocarcinoma; Multiple salivary glands tumors	LOW-GRADE ADENOCARCINOMA; OF-THE-LITERATURE; CASE SERIES	Multiple salivary gland tumors (MSGTs) are most common in the major than minor salivary glands. The most MSGTs are synchronous, either benign or malignant. A 61-year-old woman was referred presenting nine submucosal nodules, firm to fluctuant, being five nodules on the right side and four nodules on the left side of the upper lip. An incisional biopsy was performed. Hematoxylin and eosin staining was performed in 5-mu m sections for histopathologic analysis. Immunohistochemical reactions were carried out in 3-mu m sections in accordance with manufacturer's instructions. The histopathological analysis showed focal area containing low-grade polymorphous adenocarcinoma (PAC) and multiple canalicular adenomas (CAs). Immunohistochemical analysis for each lesion was carefully investigated. Here, we present an unusual case of synchronous PAC and multiple CAs of the minor salivary glands, affecting the upper lip, which appears to be the first case showing PAC and CA.	[Ortega, Rose Mara; Bufalino, Andreia; Almeida, Luciana Yamamoto; Navarro, Claudia Maria; Travassos, Daphine Caxias; Ferrisse, Tulio Morandin] Univ Estadual Paulista UNESP, Araraquara Dent Sch, Dept Diag & Surg, Oral Med, Sao Paulo, Brazil; [Carlos, Roman] Ctr Clin Cabeza & Cuello, Guatemala City, Guatemala; [Leon, Jorge Esquiche] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Stomatol Publ Oral Hlth & Forens Dent, Oral Pathol, Ribeirao Preto, SP, Brazil; [Ortega, Rose Mara] Fed Univ Juiz de Fora UFJF GV, Oral Med, Rua Israel Pinheiro 2-000, BR-35020220 Governador Valadares, MG, Brazil	Ortega, RM (reprint author), Univ Estadual Paulista UNESP, Araraquara Dent Sch, Dept Diag & Surg, Oral Med, Sao Paulo, Brazil.; Ortega, RM (reprint author), Fed Univ Juiz de Fora UFJF GV, Oral Med, Rua Israel Pinheiro 2-000, BR-35020220 Governador Valadares, MG, Brazil.	rosemara.ortega@ufjf.edu.br	Almeida, Luciana Y/C-3045-2016; Bufalino, Andreia/H-7047-2014; Leon, Jorge Esquiche/D-7511-2013; Caxias Travassos, Daphine/O-4718-2017	Almeida, Luciana Y/0000-0001-5403-4052; Bufalino, Andreia/0000-0002-6714-6253; Leon, Jorge Esquiche/0000-0002-9668-5870; Caxias Travassos, Daphine/0000-0003-4286-0714	FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [14/50256-4, 11/52090-8]; State of Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/11419-0]	The authors thank the Laboratory of Applied Immunology of the Federal University of Sao Carlos-UFSCAR, Brazil, for technical support with digital whole slides (FAPESP 14/50256-4 and 11/52090-8). Financial support came from State of Sao Paulo Research Foundation Grants 2016/11419-0 (Jorge Esquiche Leon).	Abu El-Naaj I, 2011, J ORAL MAXIL SURG, V69, P1967, DOI 10.1016/j.joms.2010.10.010; Argyris PP, 2014, OR SURG OR MED OR PA, V117, pE441, DOI 10.1016/j.oooo.2013.08.030; Fife TA, 2013, AM J OTOLARYNG, V34, P445, DOI 10.1016/j.amjoto.2013.03.012; Fonseca FP, 2015, OR SURG OR MED OR PA, V119, P566, DOI 10.1016/j.oooo.2015.01.001; Furuse Cristiane, 2003, Ann Diagn Pathol, V7, P278; KERR MA, 1992, HISTOCHEM J, V24, P811, DOI 10.1007/BF01046353; Kimple AJ, 2014, LARYNGOSCOPE, V124, P2714, DOI 10.1002/lary.24788; Rousseau A, 1999, ORAL SURG ORAL MED O, V87, P346, DOI 10.1016/S1079-2104(99)70221-0; Samar ME, 2014, INT J CLIN EXP PATHO, V7, P8205; Siqueira Carla Silva, 2013, Braz. Dent. J., V24, P542, DOI 10.1590/0103-6440201302264; Thompson LDR, 2015, HEAD NECK PATHOL, V9, P181, DOI 10.1007/s12105-014-0560-6; Tyralik D, 2013, POL J PATHOL, V64, P71, DOI 10.5114/PJP.2013.34609	12	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					145	149		10.1007/s12105-017-0838-6			5	Pathology	Pathology	GA6TM	WOS:000428467200021	28766110	Green Published			2019-10-28	
J	Jeong, HJ; Woo, CG; Lee, B; Khang, SK; Nam, SJ; Choi, J				Jeong, Hui Jeong; Woo, Chang Gok; Lee, Bora; Khang, Shin Kwang; Nam, Soo Jeong; Choi, Jene			Protein Phosphatase Magnesium-Dependent 1 delta (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						PPM1D; IDH1; Mutation; Diffuse astrocytic and oligodendroglial tumors; Supratentorial gliomas; Molecular marker	OVER-EXPRESSION; POOR-PROGNOSIS; GAIN; WIP1; P53; AMPLIFICATION; SUPPRESSOR; MUTATIONS; PATHWAY; GLIOMAS	Background: Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a p53-induced serine/threonine phosphatase, which is overexpressed in various human cancers. A recent study reported that a mutation in the PPM1D gene is associated with poor prognosis in brainstem gliomas. In this study, we evaluated the utility of PPM1D as a prognostic biomarker of adult supratentorial diffuse astrocytic and oligodendroglial tumors. Methods: To investigate PPM1D protein expression, mRNA expression, and copy number changes, immunohistochemistry, RNAscope in situ hybridization, and fluorescence in situ hybridization were performed in 84 adult supratentorial diffuse gliomas. We further analyzed clinical characteristics and overall survival (OS) according to PPM1D protein expression, and examined its correlation with other glioma biomarkers such as isocitrate dehydrogenase (IDH) mutation, and p53 expression. Results: Forty-six cases (54.8%) were PPM1D-positive. PPM1D expression levels were significantly correlated with PPM1D transcript levels (p = .035), but marginally with PPM1D gene amplification (p = .079). Patients with high-grade gliomas showed a higher frequency of PPM1D expression than those with low-grade gliomas (p < .001). Multivariate analysis demonstrated that PPM1D expression (hazard ratio [HR], 2.58; p = .032), age over 60 years (HR, 2.55; p = .018), and IDH1 mutation (HR, 0.18; p = .002) were significantly independent prognostic factors; p53 expression had no prognostic significance (p = .986). The patients with tumor expressing PPM1D showed a shorter OS (p = .003). Moreover, patients with tumor harboring wild-type IDH1 and PPM1D expression had the worst OS (p < .001). Conclusions: Our data suggest that a subset of gliomas express PPM1D; PPM1D expression is a significant marker of poor prognosis in adult supratentorial diffuse astrocytic and oligodendroglial tumors.	[Jeong, Hui Jeong; Khang, Shin Kwang; Nam, Soo Jeong; Choi, Jene] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Olymp Ro 43 Gil, Seoul 05505, South Korea; [Woo, Chang Gok] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Dept Pathol, Cheongju, South Korea; [Lee, Bora] Soonchunhyang Med Ctr, Clin Trial Ctr, Dept Biostat, Bucheon, South Korea	Choi, J (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Olymp Ro 43 Gil, Seoul 05505, South Korea.	jenec@amc.seoul.kr			Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Ministry of Health, Welfare and Family Affairs, Republic of Korea [HI15C2111]	This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Ministry of Health, Welfare and Family Affairs, Republic of Korea (HI15C2111).	Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen R, 2017, NEUROTHERAPEUTICS, V14, P284, DOI 10.1007/s13311-017-0519-x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chuman Y, 2009, J BIOCHEM, V145, P1, DOI 10.1093/jb/mvn135; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Dudgeon C, 2013, CELL CYCLE, V12, P2656, DOI 10.4161/cc.25694; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Hu Wenwei, 2010, Genes Cancer, V1, P360; Jones C, 2014, NAT REV CANCER, V14, P651, DOI 10.1038/nrc3811; Karsy M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14755; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Lambros MB, 2010, MODERN PATHOL, V23, P1334, DOI 10.1038/modpathol.2010.121; Lass U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041298; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Lee DH, 2011, TRENDS BIOCHEM SCI, V36, P569, DOI 10.1016/j.tibs.2011.08.007; Liang CH, 2012, BRAIN RES, V1444, P65, DOI 10.1016/j.brainres.2011.12.052; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Ludwig K, 2017, J NEURO-ONCOL, V134, P505, DOI 10.1007/s11060-017-2379-y; Nagpal J, 2006, ANTICANCER RES, V26, P4633; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Song JY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.252; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tabouret E, 2016, ACTA NEUROPATHOL, V132, P625, DOI 10.1007/s00401-016-1611-8; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Wang P, 2011, J SURG ONCOL, V104, P679, DOI 10.1002/jso.22004; Wang X, 2014, ANN SURG ONCOL, V21, P1337, DOI 10.1245/s10434-013-3380-0; Watanabe T, 2003, CLIN CANCER RES, V9, P4884; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yu E, 2007, BREAST CANCER RES TR, V101, P269, DOI 10.1007/s10549-006-9304-y; Zhang LW, 2014, NAT GENET, V46, P726, DOI 10.1038/ng.2995	41	0	0	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					71	78		10.4132/jptm.2017.10.21			8	Pathology	Pathology	GA3BJ	WOS:000428202100001	29046514	DOAJ Gold, Green Published			2019-10-28	
J	Espana-Ferrufino, A; Lino-Silva, LS; Salcedo-Hernandez, RA				Espana-Ferrufino, Alejandro; Lino-Silva, Leonardo S.; Salcedo-Hernandez, Rosa A.			Extramural Perineural Invasion in pT3 and pT4 Gastric Carcinomas	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Stomach neoplasms; Perineural invasion; Survival; Prognostic factor; Neoplasms	PROGNOSTIC-FACTOR; PANCREATIC-CANCER; RECTAL-CANCER; CELLS	Background: Perineural invasion (PNI) is widely studied in malignant tumors, and its prognostic significance is well demonstrated. Most studies have focused on evaluating the mural PNI (mPNI); however, extramural PNI (ePNI) may influence the prognosis in gastric cancer. We evaluated the prognostic value of ePNI compared with mPNI in gastric cancer in this observational comparative cross-sectional study. Methods: Seventy-three pT3 and pT4 gastric carcinomas with PNI were evaluated. Forty-eight (65.7%) were in the mPNI group and the remaining in the ePNI group. Results: Clinicopathologic characteristics between the two groups were similar, except for the outcomes. The 5-year disease-specific survival (DSS) rate was 64% for the mPNI group and 50% for the ePNI group (p = .039), a difference that did not remain significant in multivariate analysis. The only independent adverse prognostic factor in multivariate analysis was the presence of lymph node metastasis (hazard ratio, 1.757; 95% confidence interval, 1.082 to 2.854; p = .023). Conclusions: We demonstrated the prognostic effect of ePNI for DSS in surgically resected pT3-pT4 gastric cancer patients. ePNI could be considered in the staging and prognostic systems of gastric cancer to stratify patients with a high risk of recurrence.	[Espana-Ferrufino, Alejandro; Lino-Silva, Leonardo S.] Inst Nacl Cancerol INCan, Dept Gastrointestinal Pathol, Mexico City, DF, Mexico; [Salcedo-Hernandez, Rosa A.] Inst Nacl Cancerol INCan, Dept Surg Oncol, Mexico City, DF, Mexico	Lino-Silva, LS (reprint author), Inst Nacl Cancerol, Dept Gastrointestinal Pathol, Ave San Fernando 22 Col Secc 16, Mexico City 14080, DF, Mexico.	saul.lino.sil@gmail.com					Ayala GE, 2001, PROSTATE, V49, P213, DOI 10.1002/pros.1137; BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426; Bilici A, 2010, ANN SURG ONCOL, V17, P2037, DOI 10.1245/s10434-010-1027-y; Boyd JG, 2003, MOL NEUROBIOL, V27, P277, DOI 10.1385/MN:27:3:277; Ceyhan GO, 2010, ANN SURG, V252, P797, DOI 10.1097/SLA.0b013e3181fcab8d; Deng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088907; Duraker N, 2003, SURG TODAY, V33, P95, DOI 10.1007/s005950300020; Edge SB, 2010, AM JOINT COMMITTEE C; Fagan JJ, 1998, ARCH OTOLARYNGOL, V124, P637, DOI 10.1001/archotol.124.6.637; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; HASSAN MO, 1980, AM J SURG PATHOL, V4, P143, DOI 10.1097/00000478-198004000-00006; Jiang N, 2014, TUMOR BIOL, V35, P9429, DOI 10.1007/s13277-014-2258-5; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Luo TH, 2008, J GASTROINTEST SURG, V12, P1263, DOI 10.1007/s11605-008-0529-4; Okada Y, 2004, CLIN EXP METASTAS, V21, P285, DOI 10.1023/B:CLIN.0000046131.24625.54; Reina M A, 2000, Rev Esp Anestesiol Reanim, V47, P464; Selcukbiricik F, 2012, ASIAN PAC J CANCER P, V13, P3149, DOI 10.7314/APJCP.2012.13.7.3149; TANAKA A, 1994, CANCER-AM CANCER SOC, V73, P550, DOI 10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0; Ueno H, 2001, BRIT J SURG, V88, P994, DOI 10.1046/j.0007-1323.2001.01810.x	21	2	3	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					79	84		10.4132/jptm.2017.11.01			6	Pathology	Pathology	GA3BJ	WOS:000428202100002	29121459	DOAJ Gold, Green Published			2019-10-28	
J	Kim, MH; Song, DH; Ko, GH; Lee, JH; Kim, DC; Yang, JW; Lee, HI; An, HJ; Lee, JS				Kim, Min Hye; Song, Dae Hyun; Ko, Gyung Hyuck; Lee, Jeong Hee; Kim, Dong Chul; Yang, Jung Wook; Lee, Hyang Im; An, Hyo Jung; Lee, Jong Sil			Myoferlin Expression and Its Correlation with FIGO Histologic Grading in Early-Stage Endometrioid Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Myoferlin protein; Carcinoma; Endometrioid; FIGO grade; Immunohistochemistry; Chemotherapy	ADENOCARCINOMA; CANCER; REPRODUCIBILITY; SYSTEMS; P53	Background: For endometrioid carcinoma patients, International Federation of Gynecologists and Obstetricians (FIGO) histologic grading is very important for identifying the appropriate treatment method. However, the interobserver discrepancy with this three-tiered grading system is a serious potential problem. In this study, we used immunohistochemistry to analyze the relationship between FIGO histologic grading score and myoferlin expression. Methods: We studied the endometrioid carcinoma tissues of 60 patients from Gyeongsang National University Hospital between January 2002 and December 2009. Immunohistochemical analysis of myoferlin was performed on tissue microarray blocks from surgical specimens. Results: Myoferlin expression was observed in 58 of 60 patients. Moderate and strong myoferlin expression was observed in low-grade endometrioid carcinoma, while there was a tendency toward loss of myoferlin expression in high-grade endometrioid carcinoma (p < .001). Conclusions: Our study revealed that myoferlin loss is significantly correlated with high FIGO grade of endometrioid carcinoma.	[Kim, Min Hye; Ko, Gyung Hyuck; Lee, Jeong Hee; Kim, Dong Chul; Yang, Jung Wook; Lee, Jong Sil] Gyeongsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea; [Song, Dae Hyun; Ko, Gyung Hyuck; Lee, Jeong Hee; Kim, Dong Chul; Lee, Jong Sil] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea; [Song, Dae Hyun; Ko, Gyung Hyuck; Lee, Jeong Hee; Kim, Dong Chul; Lee, Jong Sil] Gyeongsang Inst Hlth Sci, Jinju, South Korea; [Song, Dae Hyun; Lee, Hyang Im; An, Hyo Jung] Gyeongsang Natl Univ, Dept Pathol, Changwon Hosp, Chang Won, South Korea	Lee, JS (reprint author), Gyeongsang Natl Univ, Dept Pathol, Sch Med, 15 Jinju Daero 816Beon Gil, Jinju 52727, South Korea.	jongsil25@gnu.ac.kr			Development Fund Foundation, Gyeongsang National University	This work was supported by the Development Fund Foundation, Gyeongsang National University (2015).	Abdalla N, 2016, MENOPAUSE REV, V15, P133, DOI 10.5114/pm.2016.63059; Apostolou G, 2014, DIAGN CYTOPATHOL, V42, P134, DOI 10.1002/dc.23010; Blomme A, 2017, ONCOGENE, V36, P2116, DOI 10.1038/onc.2016.369; Coenegrachts L, 2013, ONCOL REP, V29, P413, DOI 10.3892/or.2012.2178; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; Daniilidou K, 2013, J BUON, V18, P195; Dvalishvili I, 2006, Georgian Med News, P24; Guan H, 2011, INT J GYNECOL CANCER, V21, P654, DOI 10.1097/IGC.0b013e31821454f1; Kapucuoglu N, 2008, INT J GYNECOL CANCER, V18, P790, DOI 10.1111/j.1525-1438.2007.01067.x; Kashima H, 2015, GYNECOL ONCOL, V139, P338, DOI 10.1016/j.ygyno.2015.08.025; Kounelis S, 2000, MODERN PATHOL, V13, P379, DOI 10.1038/modpathol.3880062; Kumar B, 2016, ONCOTARGET, V7, P18665, DOI 10.18632/oncotarget.7625; Leung C, 2013, AM J PATHOL, V182, P1900, DOI 10.1016/j.ajpath.2013.01.041; Nishimura Y, 2005, CANCER CYTOPATHOL, V105, P8, DOI 10.1002/cncr.20787; Song DH, 2016, ONCOL LETT, V11, P998, DOI 10.3892/ol.2015.3988; Wang WS, 2013, J PROTEOMICS, V91, P453, DOI 10.1016/j.jprot.2013.06.032; Zaki MA, 2012, ANTICANCER RES, V32, P4061	17	3	3	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					93	97		10.4132/jptm.2017.11.29			5	Pathology	Pathology	GA3BJ	WOS:000428202100004	29554794	DOAJ Gold, Green Published			2019-10-28	
J	Yeong, SJ; Pak, MG; Lee, HW; Ha, SY; Roh, MS				Yeong, Son Jae; Pak, Min Gyoung; Lee, Hyoun Wook; Ha, Seung Yeon; Roh, Mee Sook			Prognostic Utility of Histological Growth Patterns of Colorectal Lung Oligometastasis	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Colorectal neoplasms; Lung; Oligometastasis; Growth pattern; Prognosis	PULMONARY METASTASES; SURGICAL RESECTION; LIVER METASTASIS; CANCER; SURVIVAL; SPREAD; TUMOR	Background: Patients with resectable colorectal lung oligometastasis (CLOM) demonstrate a heterogeneous oncological outcome. However, the parameters for predicting tumor aggressiveness have not yet been fully investigated in CLOM. This study was performed to determine the prognostic value of histological growth patterns in patients who underwent surgery for CLOM. Methods: The study included 92 patients who were diagnosed with CLOM among the first resection cases. CLOMs grow according to three histological patterns: aerogenous, pushing, and desmoplastic patterns. The growth patterns were evaluated on archival hematoxylin and eosin-stained tissue sections. Results: The aerogenous pattern was found in 29.4% (n = 27) of patients, the pushing pattern in 34.7% (n = 32), the desmoplastic pattern in 6.5% (n = 6), and a mix of two growth patterns in 29.4% (n = 27). The size of the aerogenous pattern was significantly smaller than that of metastases with other patterns (p = .033). Kaplan-Meier analysis demonstrated that patients showing an aerogenous pattern appeared to have a poorer prognosis, which was calculated from the time of diagnosis of the CLOM (p = .044). The 5-year survival rate from the diagnosis of colorectal cancer tended to be lower in patients with an aerogenous pattern than in those who had a non-aerogenous pattern; however, the difference was marginally significant (p = .051). In the multivariate Cox analysis, the aerogenous pattern appeared as an independent predictor of poor overall survival (hazard ratio, 3.122; 95% confidence interval, 1.196 to 8.145; p = .020). Conclusions: These results suggest that the growth patterns may play a part as a histology-based prognostic parameter for patients with CLOM.	[Yeong, Son Jae; Pak, Min Gyoung; Roh, Mee Sook] Dong A Univ, Coll Med, Dept Pathol, 32 Daesingongwon Ro, Busan 49201, South Korea; [Lee, Hyoun Wook] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Pathol, Chang Won, South Korea; [Ha, Seung Yeon] Gachon Univ Med & Sci, Dept Pathol, Incheon, South Korea	Roh, MS (reprint author), Dong A Univ, Coll Med, Dept Pathol, 32 Daesingongwon Ro, Busan 49201, South Korea.	msroh@dau.ac.kr			Dong-A University Research Fund	This work was supported by the Dong-A University Research Fund.	Comito T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-619; Corbin KS, 2013, J CLIN ONCOL, V31, P1384, DOI 10.1200/JCO.2012.45.9651; Dai CY, 2017, J THORAC ONCOL, V12, P1052, DOI 10.1016/j.jtho.2017.03.020; Eefsen RL, 2012, J ONCOL, DOI 10.1155/2012/907971; Iizasa T, 2006, ANN THORAC SURG, V82, P254, DOI 10.1016/j.athoracsur.2006.02.027; Inoue M, 2004, ANN THORAC SURG, V78, P238, DOI 10.1016/j.athoracsur.2004.02.017; Lee KS, 2016, J PATHOL TRANSL MED, V50, P270, DOI 10.4132/jptm.2016.03.19; Lunevicius R, 2001, J CANCER RES CLIN, V127, P193, DOI 10.1007/s004320000199; Mitry E, 2010, GUT, V59, P1383, DOI 10.1136/gut.2010.211557; Nagashima I, 1999, AM J GASTROENTEROL, V94, P739, DOI 10.1111/j.1572-0241.1999.00945.x; Nielsen K, 2014, MODERN PATHOL, V27, P1641, DOI 10.1038/modpathol.2014.4; Paku S, 1998, Pathol Oncol Res, V4, P62; Pfannschmidt J, 2007, ANN THORAC SURG, V84, P324, DOI 10.1016/j.athoracsur.2007.02.093; Rama N, 2009, EUR J CARDIO-THORAC, V35, P444, DOI 10.1016/j.ejcts.2008.10.047; Shiono S, 2005, ANN THORAC SURG, V79, P278, DOI 10.1016/j.athoracsur.2004.06.096; Terayama N, 1996, JPN J CLIN ONCOL, V26, P24, DOI 10.1093/oxfordjournals.jjco.a023174; Travis WD, 2015, WHO CLASSIFICATION T; Ueno H, 2014, AM J SURG PATHOL, V38, P1380, DOI 10.1097/PAS.0000000000000232; Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Warth A, 2017, TRANSL LUNG CANCER R, V6, P501, DOI 10.21037/tlcr.2017.06.08; Weichselbaum RR, 2011, NAT REV CLIN ONCOL, V8, P378, DOI 10.1038/nrclinonc.2011.44	22	1	1	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					98	104		10.4132/jptm.2017.12.27			7	Pathology	Pathology	GA3BJ	WOS:000428202100005	29433159	DOAJ Gold, Green Published			2019-10-28	
J	Kim, J; Lim, BJ; Hong, SW; Pyo, JY				Kim, Jisup; Lim, Beom Jin; Hong, Soon Won; Pyo, Ju Yeon			Preoperative Cytologic Diagnosis of Warthin-like Variant of Papillary Thyroid Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Warthin-like variant; Thyroid cancer; papillary; Hashimoto disease; Biopsy; fine-needle	ASPIRATION-CYTOLOGY; LYMPHOCYTIC STROMA; TUMOR	Background: Warthin-like variant of papillary thyroid carcinoma (WLV-PTC) is a relatively rare variant of papillary thyroid carcinoma with favorable prognosis. However, preoperative diagnosis using fine-needle aspiration (FNA) specimens is challenging especially with lymphocytic thyroiditis characterized by Hurthle cells and lymphocytic background. To determine a helpful cytological differential point, we compared WLV-PTC FNA findings with conventional papillary thyroid carcinoma with lymphocytic thyroiditis (PTC-LT) and conventional papillary thyroid carcinoma without lymphocytic thyroiditis (PTC) regarding infiltrating inflammatory cells and their distribution. Preoperative diagnosis or potential for WLV-PTC will be helpful for surgeons to decide the scope of operation. Methods: Of the 8,179 patients treated for papillary thyroid carcinoma between January 2007 and December 2012, 16 patients (0.2%) were pathologically confirmed as WLV-PTC and four cases were available for cytologic review. For comparison, we randomly selected six PTC-LT cases and five PTC cases during the same period. The number of intratumoral and background lymphocytes, histiocytes, neutrophils, and the presence of giant cells were evaluated and compared using conventional smear and ThinPrep preparations. Results: WLV-PTC showed extensive lymphocytic smear with incorporation of thyroid follicular tumor cell clusters and frequent histiocytes. WLV-PTC was associated with higher intratumoral and background lymphocytes and histiocytes compared with PTC-LT or PTC. The difference was more distinct in liquid-based cytology. Conclusions: The lymphocytic smear pattern and the number of inflammatory cells of WLV-PTC are different from those of PTC-LT or PTC and will be helpful for the differential diagnosis of WLV-PTC in pre-operative FNA.	[Kim, Jisup; Lim, Beom Jin; Hong, Soon Won; Pyo, Ju Yeon] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Pathol, 211 Eonju Ro, Seoul 06273, South Korea	Pyo, JY (reprint author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Pathol, 211 Eonju Ro, Seoul 06273, South Korea.	jypyo@yuhs.ac		Kim, Jisup/0000-0002-0742-5517; Lim, Beom Jin/0000-0003-2856-0133; Hong, SoonWon/0000-0002-0324-2414			APEL RL, 1995, AM J SURG PATHOL, V19, P810, DOI 10.1097/00000478-199507000-00009; Chong Yosep, 2014, Korean J Pathol, V48, P170, DOI 10.4132/KoreanJPathol.2014.48.2.170; D'antonio A, 2000, HISTOPATHOLOGY, V36, P493, DOI 10.1046/j.1365-2559.2000.00925.x; Jun HH, 2016, ANZ J SURG, V86, P492, DOI 10.1111/ans.12725; Ludvikova M, 2001, HISTOPATHOLOGY, V39, P17, DOI 10.1046/j.1365-2559.2001.01154.x; Mai KT, 2004, APPL IMMUNOHISTO M M, V12, P329, DOI 10.1097/00129039-200412000-00007; Paker I, 2012, CYTOPATHOLOGY, V23, P408, DOI 10.1111/j.1365-2303.2011.00877.x; Yousef O, 1997, ACTA CYTOL, V41, P1361	8	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					105	109		10.4132/jptm.2017.12.26			5	Pathology	Pathology	GA3BJ	WOS:000428202100006	29429327	DOAJ Gold, Green Published			2019-10-28	
J	Han, K; Ha, HJ; Kong, JS; Kim, JS; Myung, JK; Koh, JS; Park, S; Shin, MS; Song, WT; Seol, HS; Lee, SS				Han, Kanghee; Ha, Hwa-Jeong; Kong, Joon Seog; Kim, Jung-Soon; Myung, Jae Kyung; Koh, Jae Soo; Park, Sunhoo; Shin, Myung-Soon; Song, Woo-Tack; Seol, Hye Sil; Lee, Seung-Sook			Cytological Features That Differentiate Follicular Neoplasm from Mimicking Lesions	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Follicular neoplasm; Fine needle aspiration cytology; Differential diagnosis	FINE-NEEDLE-ASPIRATION; PAPILLARY THYROID-CARCINOMA; NUCLEAR FEATURES; UNDETERMINED SIGNIFICANCE; BETHESDA SYSTEM; NODULES; CYTOPATHOLOGY; CATEGORY; VARIANT; ATYPIA	Background: It is difficult to correctly diagnose follicular neoplasms (FNs) on fine-needle aspiration cytology (FNAC) because it shares many cytological features with other mimicking lesions. The aim of this study was to identify the cytological features that differentiate FNs from mimicking lesions. Methods: We included the cytological slides from 116 cases of thyroid FN diagnosed on FNAC, and included their subsequent histological diagnoses. We evaluated the cytological architectural pattern and nuclear features of the lesions according to their histological groups. Results: The final histological diagnoses of the 116 cases varied, and included 51 FNs (44%), 47 papillary thyroid carcinomas (40%) including follicular variant, and seventeen cellular nodular hyperplasias (15%). Regardless of the final histological diagnosis, microfollicular pattern was observed in most cases. On the other hand, trabecular pattern was identified in 34% of FNs, but not in any other lesions. Additionally, elongated nuclei and ground glass chromatin were found in only some papillary thyroid carcinomas. Conclusions: This study shows that the trabecular pattern is a representative cytological feature of FNs that can be used to distinguish FNs from mimicking lesions. In addition, nuclear shape and chromatin pattern can be used to further confirm the diagnosis of FNs from mimicking lesions through FNAC.	[Han, Kanghee; Ha, Hwa-Jeong; Kong, Joon Seog; Kim, Jung-Soon; Koh, Jae Soo; Shin, Myung-Soon; Song, Woo-Tack; Seol, Hye Sil] Korea Inst Radiol & Med Sci KIRAMS, Korea Canc Ctr Hosp, Dept Pathol, Seoul, South Korea; [Myung, Jae Kyung; Park, Sunhoo; Lee, Seung-Sook] Korea Inst Radiol & Med Sci KIRAMS, Lab Radiat Pathol, Seoul, South Korea	Lee, SS (reprint author), Korea Inst Radiol & Med Sci KIRAMS, Korea Canc Ctr Hosp, Lab Radiat Pathol, 75 Nowon Ro, Seoul 01812, South Korea.	sslee@kirams.re.kr			Korea Institute of Radiological and Medical Science (KIRAMS) - the Ministry of Science, ICT and Future planning, republic of Korea [1711045543, 1711045540/50476-2017]	This study was supported by a grant from the Korea Institute of Radiological and Medical Science (KIRAMS), funded by the Ministry of Science, ICT and Future planning, republic of Korea (1711045543; 1711045540/50476-2017).	Bizzarro T, 2016, CANCER CYTOPATHOL, V124, P699, DOI 10.1002/cncy.21777; Brandler TC, 2017, CANCER CYTOPATHOL, V125, P378, DOI 10.1002/cncy.21848; Cibas ES, 2009, THYROID, V19, P1159, DOI 10.1089/thy.2009.0274; Clark DP, 2005, THYROID CYTOPATHOLOG, P131; Deka L, 2017, MALAYS J PATHOL, V39, P33; Deveci M Salih, 2006, Cytojournal, V3, P9, DOI 10.1186/1742-6413-3-9; Dincer N, 2013, CYTOPATHOLOGY, V24, P385, DOI 10.1111/cyt.12021; Faquin WC, 2009, HEAD NECK PATHOL, V3, P82, DOI 10.1007/s12105-009-0104-7; Greaves TS, 2000, CANCER CYTOPATHOL, V90, P335, DOI 10.1002/1097-0142(20001225)90:6<335::AID-CNCR3>3.0.CO;2-L; HAMBERGER B, 1982, AM J MED, V73, P381, DOI 10.1016/0002-9343(82)90731-8; Ho AS, 2014, THYROID, V24, P832, DOI 10.1089/thy.2013.0317; Horne MJ, 2012, DIAGN CYTOPATHOL, V40, P410, DOI 10.1002/dc.21790; Krane JF, 2016, CANCER CYTOPATHOL, V124, P767, DOI 10.1002/cncy.21769; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Rossi ED, 2017, ADV ANAT PATHOL, V24, P45, DOI 10.1097/PAP.0000000000000135; Shi Y, 2009, CANCER CYTOPATHOL, V117, P298, DOI 10.1002/cncy.20039; Song JY, 2012, ACTA CYTOL, V56, P122, DOI 10.1159/000334200; Wu HHJ, 2012, DIAGN CYTOPATHOL, V40, P399, DOI 10.1002/dc.21754; Yang J, 2007, CANCER CYTOPATHOL, V111, P306, DOI 10.1002/cncr.22955; Yassa L, 2007, CANCER CYTOPATHOL, V111, P508, DOI 10.1002/cncr.23116; Yoo C, 2013, KOREAN J PATHOL, V47, P61, DOI 10.4132/KoreanJPathol.2013.47.1.61	23	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					110	120		10.4132/jptm.2018.01.17			11	Pathology	Pathology	GA3BJ	WOS:000428202100007	29374960	DOAJ Gold, Green Published			2019-10-28	
J	Wu, CC; Hsieh, PP				Wu, Chang-Che; Hsieh, Pin-Pen			Denosumab-Treated Giant Cell Tumor	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							BONE		[Wu, Chang-Che; Hsieh, Pin-Pen] Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan	Hsieh, PP (reprint author), Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan.	pinpenh@gmail.com					Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002; Fletcher C.D.M., 2013, WHO CLASSIFICATION T, P321; KURT AM, 1990, CANCER, V65, P1418, DOI 10.1002/1097-0142(19900315)65:6<1418::AID-CNCR2820650629>3.0.CO;2-Q; Rekhi B, 2017, PATHOL ONCOL RES, V23, P157, DOI 10.1007/s12253-016-0123-0; Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470-2045(10)70010-3; Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506; Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH-16.297	8	0	0	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					133	135		10.4132/jptm.2016.12.21			3	Pathology	Pathology	GA3BJ	WOS:000428202100011	29429326	DOAJ Gold, Green Published			2019-10-28	
J	An, HJ; Baek, HJ; Kim, JP; Kim, MH; Song, DH				An, Hyo Jung; Baek, Hye Jin; Kim, Jin Pyeong; Kim, Min Hye; Song, Dae Hyun			Fine-Needle Aspiration Cytology of Carcinosarcoma in the Salivary Gland: An Extremely Rare Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinosarcoma; Salivary glands; Biopsy; fine-needle	PAROTID-GLAND; DIAGNOSTIC-ACCURACY; METAANALYSIS; LESIONS	Carcinosarcoma of the salivary gland is an extremely rare tumor that is composed of both malignant epithelial and mesenchymal components. Diagnosing carcinosarcoma with fine-needle aspiration cytology is challenging because of its overlapping cytomorphologic characteristics with other high-grade malignant salivary gland tumors. Among the many features, including pleomorphic oncocytoid epithelial components, necrotic background, and mitoses, recognizing the singly scattered atypical spindle cells is most essential in carcinosarcoma. We present a case of a 66-year-old male patient with characteristic features of carcinosarcoma, who was successfully treated by wide local excision and subsequent radiation therapy.	[An, Hyo Jung; Song, Dae Hyun] Gyeongsang Natl Univ, Changwon Hosp, Dept Pathol, Chang Won, South Korea; [Baek, Hye Jin; Kim, Jin Pyeong; Song, Dae Hyun] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea; [Baek, Hye Jin; Kim, Jin Pyeong; Song, Dae Hyun] Gyeongsang Inst Hlth Sci, Jinju, South Korea; [Baek, Hye Jin] Gyeongsang Natl Univ, Changwon Hosp, Dept Radiol, Chang Won, South Korea; [Kim, Jin Pyeong] Gyeongsang Natl Univ, Changwon Hosp, Dept Otorhinolaryngol, Chang Won, South Korea; [Kim, Min Hye] Gyeongsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea	Song, DH (reprint author), Gyeongsang Natl Univ, Sch Med, Dept Pathol, 15 Jinju Daero 816Beon Gil, Jinju 52727, South Korea.	golgy@hanmail.net		Baek, Hye Jin/0000-0001-7349-2841			BLEIWEISS IJ, 1992, CANCER, V69, P2031, DOI 10.1002/1097-0142(19920415)69:8<2031::AID-CNCR2820690804>3.0.CO;2-3; Griffith CC, 2015, AM J CLIN PATHOL, V143, P839, DOI 10.1309/AJCPMII6OSD2HSJA; Keh SM, 2011, CLINICS PRACT, V1, P253, DOI 10.4081/cp.2011.e117; KING OH, 1967, ORAL SURG ORAL MED O, V23, P651, DOI 10.1016/0030-4220(67)90348-9; Kwon MY, 2001, ARCH PATHOL LAB MED, V125, P812; Marcotullio D, 2015, CASE REP OTOLARYNGOL, DOI 10.1155/2015/694684; Naib ZM, 1996, CYTOPATHOLOGY; Schmidt RL, 2011, AM J CLIN PATHOL, V136, P729, DOI 10.1309/AJCP2SD8RFQEUZJW; Schmidt RL, 2011, AM J CLIN PATHOL, V136, P45, DOI 10.1309/AJCPOIE0CZNAT6SQ; STEPHEN J, 1986, ORAL SURG ORAL MED O, V61, P597, DOI 10.1016/0030-4220(86)90102-7	10	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					136	139		10.4132/jptm.2017.07.27			4	Pathology	Pathology	GA3BJ	WOS:000428202100012	29281871	DOAJ Gold, Green Published			2019-10-28	
J	Barth, TFE; Moller, P; Jundt, G				Barth, T. F. E.; Moeller, P.; Jundt, G.			Cartilage, bones, chorda	PATHOLOGE			German	Editorial Material									[Barth, T. F. E.; Moeller, P.] Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany; [Jundt, G.] Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland; [Jundt, G.] Univ Spital Basel, Inst Pathol, DOSAK Referenzregister, Schonbeinstr 40, CH-4031 Basel, Switzerland	Barth, TFE; Moller, P (reprint author), Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany.; Jundt, G (reprint author), Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland.; Jundt, G (reprint author), Univ Spital Basel, Inst Pathol, DOSAK Referenzregister, Schonbeinstr 40, CH-4031 Basel, Switzerland.	thomas.barth@uniklinik-ulm.de; Peter.Moeller@uniklinik-ulm.de; gernot.jundt@unibas.ch						0	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					105	106		10.1007/s00292-018-0422-1			2	Pathology	Pathology	GA1AI	WOS:000428046700001	29492596				2019-10-28	
J	Jundt, G				Jundt, G.			Updates to the WHO classification of bone tumours	PATHOLOGE			German	Article						Bone Tumors; Osteochondromyxoma; Benign notochordal cell tumor; ISSVA-classification; Atypical cartilaginous tumour; Chondromesenchymal hamartoma	PAROSTEAL OSTEOCHONDROMATOUS PROLIFERATION; NOTOCHORDAL CELL TUMORS; PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; SUBUNGUAL EXOSTOSIS; CHONDROSARCOMA; CHONDROMATOSIS; CHORDOMA; DISEASE; GENE; ANGIOENDOTHELIOMA	The fourth edition of the WHO Classification of Soft Tissue and Bone Tumours, published in 2013, extends the approach to describe genetics and pathology of these tumours in the context of epidemiological, clinical and imaging data, which was adopted in the third edition. Added are a few new entities, reclassifications and renamings. The most important point, also of clinical relevance and with consequences for treatment, is the introduction of a stratification of bone tumours based on their biological behaviour into three groups (benign, intermediate, malignant) in analogy to soft tissue tumours.	[Jundt, G.] Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland; [Jundt, G.] Univ Spital Basel, Inst Pathol, DOSAK Referenzregister, Schonbeinstr 40, CH-4031 Basel, Switzerland	Jundt, G (reprint author), Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland.; Jundt, G (reprint author), Univ Spital Basel, Inst Pathol, DOSAK Referenzregister, Schonbeinstr 40, CH-4031 Basel, Switzerland.	gernot.jundt@unibas.ch					Andreou D, 2016, ANN SURG ONCOL, V23, P120, DOI 10.1245/s10434-015-4852-1; Berber O, 2011, J BONE JOINT SURG BR, V93B, P1118, DOI 10.1302/0301-620X.93B8.26349; Bosmuller H, 2015, PATHOLOGE, V36, P458, DOI 10.1007/s00292-015-0057-4; Broehm CJ, 2013, CANCER GENET-NY, V206, P402, DOI 10.1016/j.cancergen.2013.11.004; Bruder E, 2009, VIRCHOWS ARCH, V454, P161, DOI 10.1007/s00428-008-0709-3; Campanacci DA, 2013, J ORTHOP TRAUMATOL, V14, P101, DOI 10.1007/s10195-013-0230-6; Carney JA, 2001, AM J SURG PATHOL, V25, P164, DOI 10.1097/00000478-200102000-00004; Carter JM, 2017, AM J SURG PATHOL, V41, P39, DOI 10.1097/PAS.0000000000000766; DABSKA M, 1969, CANCER-AM CANCER SOC, V24, P503, DOI 10.1002/1097-0142(196909)24:3<503::AID-CNCR2820240311>3.0.CO;2-L; DaCambra MP, 2014, CLIN ORTHOP RELAT R, V472, P1251, DOI 10.1007/s11999-013-3345-4; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B; Fanburg-Smith JC, 1999, AM J SURG PATHOL, V23, P1004, DOI 10.1097/00000478-199909000-00002; Fetsch JF, 2003, AM J SURG PATHOL, V27, P1260, DOI 10.1097/00000478-200309000-00010; Fletcher C, 2013, WHO CLASSIFICATION T; Fletcher CD, 2002, PATHOLOGY GENETICS T; Gelderblom H, 2008, ONCOLOGIST, V13, P320, DOI 10.1634/theoncologist.2007-0237; Golden T, 2016, J BONE ONCOL, V5, P194, DOI 10.1016/j.jbo.2016.07.002; Grimer RJ, 2013, WHO CLASSIFICATION T, P244; Haroche J, 2017, LANCET ONCOL, V18, pE113, DOI 10.1016/S1470-2045(17)30031-1; Hopyan S, 2005, J PATHOL, V206, P143, DOI 10.1002/path.1761; Huang SC, 2015, AM J SURG PATHOL, V39, P1313, DOI 10.1097/PAS.0000000000000469; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; International Society for the Study of Vascular Anomalies, 2014, ISSVA CLASS VASC AN; Inyang A, 2016, AM J SURG PATHOL, V40, P587, DOI 10.1097/PAS.0000000000000613; Kyriakos M, 2003, AM J SURG PATHOL, V27, P396, DOI 10.1097/00000478-200303000-00015; Kyriakos M, 2011, SKELETAL RADIOL, V40, P1141, DOI 10.1007/s00256-011-1167-6; Ma J, 2011, PATHOL INT, V61, P382, DOI 10.1111/j.1440-1827.2011.02681.x; Matter MS, 2017, VIRCHOWS ARCH, V471, P545, DOI 10.1007/s00428-017-2173-4; Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P311, DOI 10.1097/01.coc.0000204403.13451.52; Mertens F, 2011, INT J CANCER, V128, P487, DOI 10.1002/ijc.25353; Mirra JM, 2001, SKELETAL RADIOL, V30, P698, DOI 10.1007/s002560100422; Mohr W, 2002, PATHOL RES PRACT, V198, P585, DOI 10.1078/0344-0338-00306; Romeo S, 2012, VIRCHOWS ARCH, V461, P561, DOI 10.1007/s00428-012-1306-z; Rubin BP, 2010, ARCH PATHOL LAB MED, V134, pE1, DOI 10.1043/1543-2165-134.4.e1; Schwartz RA, 2000, DERMATOLOGY, V201, P1, DOI 10.1159/000018419; Swerdlow SH, 2008, WHO CLASSIFICATION T; van de Luijtgaarden ACM, 2009, VIRCHOWS ARCH, V455, P455, DOI 10.1007/s00428-009-0845-4; Warren M, 2017, CANCER GENET-NY, V212, P13, DOI 10.1016/j.cancergen.2017.03.007; Yamaguchi T, 2005, MODERN PATHOL, V18, P1005, DOI 10.1038/modpathol.3800378; Yamaguchi T, 2004, AM J SURG PATHOL, V28, P756, DOI 10.1097/01.pas.0000126058.18669.5d; Zambrano E, 2004, AM J SURG PATHOL, V28, P1033, DOI 10.1097/01.pas.0000126642.61690.d6	42	1	1	3	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					107	116		10.1007/s00292-017-0396-4			10	Pathology	Pathology	GA1AI	WOS:000428046700002	29260299				2019-10-28	
J	Barth, TFE; von Witzleben, A; Moller, P; Scheil-Bertram, S				Barth, T. F. E.; von Witzleben, A.; Moeller, P.; Scheil-Bertram, S.			Notochordal tumors. Benign notochordal tumors and chordomas	PATHOLOGE			German	Article						Brachyury; Chordoma; Immunohistochemistry; Differential diagnosis	CELL-LINE; ECCHORDOSIS-PHYSALIPHORA; CLASSIC CHORDOMA; BRACHYURY; EXPRESSION; ENTITY; GENES; RARE	Benign notochordal tumors (BNCT) and chordomas are primary bone tumors of the spine with a predominant localization in the sacrum and clival region followed by the vertebral bodies. Besides the most common variant (NOS [not otherwise specified] with hepatoid or renal carcinoma cell-like differentiation) chordomas with chondroid, and polymorphic to anaplastic morphology are described. An unfavorable variant are pediatric chordomas with a loss of INI-1. BNCT and chordomas are characterized by the following immunohistological profile: vimentin+, cytokeratin+/-, epithelial membrane antigen (EMA)+/-, S100 protein+/-, brachyury+. This profile helps to distinguish these tumors from other lesions such as chondrosarcoma, chordoid meningioma, and metastases of carcinoma.	[Barth, T. F. E.; von Witzleben, A.; Moeller, P.; Scheil-Bertram, S.] Univ Ulm, Inst Pathol, Ulm, Germany; [Scheil-Bertram, S.] HELIOS Dr Horst Schmidt Kliniken Wiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany	Scheil-Bertram, S (reprint author), HELIOS Dr Horst Schmidt Kliniken Wiesbaden, Inst Pathol & Zytol, Ludwig Erhard Str 100, D-65199 Wiesbaden, Germany.	scheil-bertram@pathologie-wiesbaden.de					Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1; Bruederlein Silke, 2010, Sarcoma, P630129, DOI 10.1155/2010/630129; Choudhri O, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.019; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; Flanagan AM, 2013, WHO CLASSIFICATION T, P328; Freyschmidt J, 2010, KNOCHENTUMOREN KIEFE, P722; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Horbinski C, 2010, ARCH PATHOL LAB MED, V134, P1170, DOI 10.1043/2009-0380-OA.1; Hsu W, 2011, J NEUROSURG, V115, P760, DOI 10.3171/2011.5.JNS11185; Joshi VV, 2000, PEDIATR DEVEL PATHOL, V3, P184, DOI 10.1007/s100240050024; Kyriakos M, 2011, SKELETAL RADIOL, V40, P1141, DOI 10.1007/s00256-011-1167-6; Mehnert F, 2004, AM J NEURORADIOL, V25, P1851; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; Mirra JM, 2001, SKELETAL RADIOL, V30, P698, DOI 10.1007/s002560100422; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Muller H., 1858, Z RATION MED, V2, P202; Naka T, 2005, AM J CLIN PATHOL, V124, P288, DOI 10.1309/5DLWL8EA7JUDWNVL; Nelson AC, 2012, J PATHOL, V228, P274, DOI 10.1002/path.4082; Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144; Ramesh T, 2017, CUREUS, V9, DOI 10.7759/cureus.1137; Rinner B, 2012, INT J ONCOL, V40, P443, DOI 10.3892/ijo.2011.1235; Rotondo M, 2007, J NEUROL NEUROSUR PS, V78, P647, DOI 10.1136/jnnp.2006.109561; SALISBURY JR, 1993, J PATHOL, V171, P59, DOI 10.1002/path.1711710112; Scheil S, 2001, GENE CHROMOSOME CANC, V32, P203, DOI 10.1002/gcc.1184; Shen J, 2011, J CLIN NEUROSCI, V18, P96, DOI 10.1016/j.jocn.2010.03.066; Showell C, 2004, DEV DYNAM, V229, P201, DOI 10.1002/dvdy.10480; Singhal N, 2009, ANTI-CANCER DRUG, V20, P953, DOI 10.1097/CAD.0b013e328330c7f0; Stacchiotti S, 2017, ANN ONCOL, V28, P1230, DOI 10.1093/annonc/mdx054; Stacchiotti S, 2013, ANN ONCOL, V24, P1931, DOI 10.1093/annonc/mdt117; Virchow RL, 1857, UNTERSUCHUNGEN UEBER; von Witzleben A, 2015, EUR SPINE J; von Witzlebena A, 2015, CANC RES; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Yamaguchi T, 2004, HISTOPATHOLOGY, V44, P597, DOI 10.1111/j.1365-2559.2004.01877.x; Yamaguchi T, 2002, SKELETAL RADIOL, V31, P413, DOI 10.1007/s00256-002-0514-z	37	1	1	1	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					117	124		10.1007/s00292-017-0399-1			8	Pathology	Pathology	GA1AI	WOS:000428046700003	29236139				2019-10-28	
J	Luke, J; Hasenfratz, M; Moller, P; Barth, TFE				Lueke, J.; Hasenfratz, M.; Moeller, P.; Barth, T. F. E.			New aspects on giant cell tumor of bone	PATHOLOGE			German	Article						Giant cell rich lesions; Histone 3; Differential diagnosis; H3F3A mutation; Denosumab	RECURRENCE; MUTATION; CHONDROBLASTOMA; EXPRESSION; DENOSUMAB; H3F3A	A giant cell tumor of bone (GCTB) is one of the giant cell-rich lesions of bone and has to be differentiated from non-ossifying fibroma, aneurysmatic bone cyst, chondroblastoma, "brown tumor" and osteosarcoma containing giant cells. A hallmark of GCTB is the presence of the distinct histone 3 (H3F3A) mutation G34W and its detection either by sequencing methods or using immunohistochemistry with a novel antibody against this mutational site. Worrisome is the fact that under denosumab therapy a histological change of the lesions can be seen and there are first reports of sarcomas arising after therapy. When diagnosing giant cell-rich lesions, pathologists should be aware of the various differential diagnoses and morphological spectrum within GCTB.	[Lueke, J.; Hasenfratz, M.; Moeller, P.; Barth, T. F. E.] Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany	Barth, TFE (reprint author), Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany.	thomas.barth@uniklinik-ulm.de					Akpalo H, 2012, HISTOPATHOLOGY, V60, P1099, DOI 10.1111/j.1365-2559.2011.04152.x; Al-Ibraheemi A, 2016, AM J SURG PATHOL, V40, P1702, DOI 10.1097/PAS.0000000000000715; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914-017-0380-1; Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078-0432.CCR-12-0578; Broehm CJ, 2015, CASE REP MED, DOI 10.1155/2015/767198; Campanacci M, 1976, Recent Results Cancer Res, P257; Cummins CA, 1996, CLIN ORTHOP RELAT R, P245; DAHLIN DC, 1985, AM J ROENTGENOL, V144, P955, DOI 10.2214/ajr.144.5.955; De Paula AM, 2014, VIRCHOWS ARCH, V465, P487, DOI 10.1007/s00428-014-1637-z; He YF, 2017, RADIOL MED, V122, P505, DOI 10.1007/s11547-017-0746-6; Ismail FW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-25; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Khalil El Sayed Ashraf, 2004, J Egypt Natl Canc Inst, V16, P145; Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999-010-1501-7; Koelsche C, 2017, CLIN SARCOMA RES, V7, DOI 10.1186/s13569-017-0075-5; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332; MCGRATH P J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P216; Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-261; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Robinson D, 2002, PATHOBIOLOGY, V70, P333, DOI 10.1159/000071273; SANERKIN NG, 1980, CANCER, V46, P1641, DOI 10.1002/1097-0142(19801001)46:7<1641::AID-CNCR2820460725>3.0.CO;2-Z; Shooshtarizadeh T, 2016, PATHOL RES PRACT, V212, P876, DOI 10.1016/j.prp.2016.07.007; Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264-006-0215-7; West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103; Wulling M, 2003, HUM PATHOL, V34, P983, DOI 10.1053/S0046-8177(03)00413-1; Yamagishi T, 2016, PLOS ONE, V11	30	1	1	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					125	131		10.1007/s00292-017-0391-9			7	Pathology	Pathology	GA1AI	WOS:000428046700004	29110035				2019-10-28	
J	Jundt, G; Baumhoer, D				Jundt, G.; Baumhoer, D.			Chondroblastoma	PATHOLOGE			German	Article						Bone neoplasms; Chondroblastoma; Epiphyses; Immunohistochemistry; Point mutation	BENIGN CARTILAGINOUS TUMORS; CLEAR-CELL CHONDROSARCOMA; AGGRESSIVE CHONDROBLASTOMA; MALIGNANT CHONDROBLASTOMA; BONE; EXPRESSION; RECURRENT; CURETTAGE; MARKER; DOG1	Chondroblastomas are very rare benign primary bone tumors occurring preferentially in the epiphyses or apophyses of long bones in children and adolescents. In most cases the typical histological and imaging findings lead to a correct diagnosis that may be substantiated by demonstrating the highly specific point mutation in the H3F3B gene (p.K36M), either by sequencing or immunohistochemistry. Recurrences occur in 5-15% of cases, postsurgical metastatic deposits to the lungs are very rare (< 1%). Histologically "malignant" chondroblastomas have been reported as single case reports. The treatment of choice is a thorough curettage, also in the case of local relapses.	[Jundt, G.] Univ Spital Basel, Knochentumor Referenzzentrum, Schoenbeinstr 40, CH-4031 Basel, Switzerland; [Jundt, G.] Univ Spital Basel, Inst Pathol, DOSAK Zent Register, Schoenbeinstr 40, CH-4031 Basel, Switzerland	Jundt, G (reprint author), Univ Spital Basel, Knochentumor Referenzzentrum, Schoenbeinstr 40, CH-4031 Basel, Switzerland.; Jundt, G (reprint author), Univ Spital Basel, Inst Pathol, DOSAK Zent Register, Schoenbeinstr 40, CH-4031 Basel, Switzerland.	gernot.jundt@unibas.ch					Akpalo H, 2012, HISTOPATHOLOGY, V60, P1099, DOI 10.1111/j.1365-2559.2011.04152.x; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Bousdras K, 2007, HISTOPATHOLOGY, V51, P414, DOI 10.1111/j.1365-2559.2007.02777.x; Cleven AHG, 2016, HISTOPATHOLOGY, V68, P942, DOI 10.1111/his.12873; Codman EA, 2006, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000229309.90265.df; COLEMAN SS, 1966, J BONE JOINT SURG AM, VA 48, P1554, DOI 10.2106/00004623-196648080-00012; de Silva M V Chandu, 2003, Ann Diagn Pathol, V7, P205, DOI 10.1016/S1092-9134(03)00048-0; EDEL G, 1992, VIRCHOWS ARCH A, V421, P355, DOI 10.1007/BF01660984; Elek E M, 1998, Sarcoma, V2, P45, DOI 10.1080/13577149878154; Erlemann R, 2001, RADIOLOGE, V41, P548, DOI 10.1007/s001170170145; Erlemann R, 2009, RADIOLOGE, V49, P355, DOI 10.1007/s00117-008-1749-z; Farfalli GL, 2017, CLIN ORTHOP RELAT R, V475, P760, DOI 10.1007/s11999-016-4715-5; Fletcher C, 2013, WHO CLASSIFICATION T; Huang L, 2003, J CLIN PATHOL-MOL PA, V56, P116, DOI 10.1136/mp.56.2.116; HUVOS AG, 1977, CLIN ORTHOP RELAT R, P266; Jaffe HL, 1942, AM J PATHOL, V18, P969; Jambhekar NA, 1998, CANCER, V82, P675, DOI 10.1002/(SICI)1097-0142(19980215)82:4<675::AID-CNCR9>3.3.CO;2-#; Jundt G, 2008, PATHOLOGE, V29, P205, DOI 10.1007/s00292-008-0998-y; Kaim AH, 2002, SKELETAL RADIOL, V31, P88, DOI 10.1007/s00256-001-0450-3; Kilpatrick SE, 2013, WHO CLASSIFICATION T, pS262; Kirchhoff C, 2006, EUR J MED RES, V11, P128; KOLODNY A, 1927, SURG GYNECOL OBST S1, V44, P1; KURT AM, 1989, HUM PATHOL, V20, P965, DOI 10.1016/0046-8177(89)90268-2; KYRIAKOS M, 1985, CANCER, V55, P1770, DOI 10.1002/1097-0142(19850415)55:8<1770::AID-CNCR2820550825>3.0.CO;2-Q; Lehner B, 2011, ARCH ORTHOP TRAUM SU, V131, P45, DOI 10.1007/s00402-010-1099-y; McCarthy E F, 1995, Iowa Orthop J, V15, P74; Ostrowski ML, 1999, SKELETAL RADIOL, V28, P644; Posl M, 1996, HISTOPATHOLOGY, V29, P477, DOI 10.1046/j.1365-2559.1996.d01-525.x; REYES CV, 1979, AM J SURG PATHOL, V3, P449, DOI 10.1097/00000478-197910000-00007; Romeo S, 2009, ADV ANAT PATHOL, V16, P307, DOI 10.1097/PAP.0b013e3181b506a1; SEMMELINK HJF, 1990, HISTOPATHOLOGY, V16, P257, DOI 10.1111/j.1365-2559.1990.tb01112.x; Sirsat M V, 1970, J Bone Joint Surg Br, V52, P741; Soder S, 2006, PATHOLOGY, V38, P35, DOI 10.1080/00313020500455803; Suneia R, 2005, J BONE JOINT SURG BR, V87B, P974, DOI 10.1302/0301-620X.87B7.16009; Xu HR, 2015, J BONE JOINT SURG AM, V97A, P925, DOI 10.2106/JBJS.N.00992	37	2	2	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					132	138		10.1007/s00292-017-0397-3			7	Pathology	Pathology	GA1AI	WOS:000428046700005	29209799				2019-10-28	
J	Baumhoer, D				Baumhoer, D.			Pathogenesis and genetics of osteosarcoma. Current concepts and developments	PATHOLOGE			German	Article						Osteosarcoma; Chromothripsis; Copy number alterations; BRCAness; Checkpoint inhibitors	HIGH-GRADE OSTEOSARCOMA; GENOMIC REARRANGEMENT; CANCER; COMBINATION; SIGNATURES; PATTERNS; MUTATION; REPAIR; GENES	Osteosarcomas are genetically complex tumours for which the cell of origin and the molecular pathogenesis are still poorly understood. Despite intensive multimodal treatment protocols only two thirds of patients currently survive the disease which is at least partly due to the early occurring chromosomal instability resulting in marked inter- and intratumoral heterogeneity. This review article outlines the current state of osteosarcoma research with a particular focus on exome- and genome-wide sequencing analyses and potential impacts on new therapeutic opportunities.	[Baumhoer, D.] Univ Spital Basel, Knochentumor Referenzzentrum, Inst Pathol, Basel, Switzerland	Baumhoer, D (reprint author), Univ Spital Basel, Knochentumor Referenzzentrum, Inst Pathol, Basel, Switzerland.	daniel.baumhoer@usb.ch					Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Baumhoer D, 2017, PATHOLOGE, V38, P179, DOI 10.1007/s00292-017-0284-y; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Cavenee WK, 2013, WHO CLASSIFICATION T, pS388; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Engert F, 2017, ONCOTARGET, V8, P48794, DOI 10.18632/oncotarget.10720; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940; LI FP, 1988, CANCER RES, V48, P5358; Lu LC, 2014, ADV EXP MED BIOL, V804, P129, DOI 10.1007/978-3-319-04843-7_7; Malkin D, 2013, WHO CLASSIFICATION T, pS379; Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Ratti C, 2017, CLIN CANCER RES, V23, P5149, DOI 10.1158/1078-0432.CCR-16-3186; Ribi S, 2015, ONCOTARGET, V6, P7727, DOI 10.18632/oncotarget.3115; Ripperger T, 2017, AM J MED GENET A, V173, P1017, DOI 10.1002/ajmg.a.38142; Rosenberg AE, 2013, WHO CLASSIFICATION T, pS282; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Salinas-Souza C, 2015, MODERN PATHOL, V28, P1336, DOI 10.1038/modpathol.2015.91; Savage SA, 2013, NAT GENET, V45, P799, DOI 10.1038/ng.2645; Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Watkins JA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3670	31	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					139	145		10.1007/s00292-017-0365-y			7	Pathology	Pathology	GA1AI	WOS:000428046700006	28929220				2019-10-28	
J	Ostertag, H; Glombitza, S				Ostertag, H.; Glombitza, S.			The activating GNAS mutation. A survey of fibrous dysplasia, its associated syndromes, and other skeletal and extraskeletal lesions	PATHOLOGE			German	Article						Chromosomal aberration; Mutation; Myxoma; Fibrous Dysplasia; GNAS; Mazabraud; McCune Albright	MCCUNE-ALBRIGHT-SYNDROME; LIPOSCLEROSING MYXOFIBROUS TUMOR; APPENDICEAL MUCINOUS NEOPLASMS; GS-ALPHA GENE; LOW-GRADE; PRECOCIOUS PUBERTY; OSSIFYING FIBROMA; STEM-CELLS; BONE; PIGMENTATION	Fibrous dysplasia of bone is a connatal but not hereditary disease with monostotic or polyostotic manifestations and may be associated either with the extraskeletal disease McCune-Albright syndrome or with myxoma of the skeletal muscle, termed Mazabraud syndrome. The confirmation of recurrent chromosomal aberrations may lead to the conclusion that fibrous dysplasia is a neoplasia rather than a dysplastic skeletal disease. The primary cause of all forms of the described diseases is the activating GNAS mutation, which is detectable in almost all lesions. Research into the impact of this mutation has increased the understanding of these up to now solely descriptively defined diseases and also allowed easier discrimination of various fibro-osseous skeletal lesions. Current insights suggest that this mutation may also play a pivotal role in other extraskeletal neoplasias.	[Ostertag, H.; Glombitza, S.] Klinikum Reg Hannover, Pathol Inst, Haltenhoffstr 41, D-30167 Hannover, Germany	Ostertag, H (reprint author), Klinikum Reg Hannover, Pathol Inst, Haltenhoffstr 41, D-30167 Hannover, Germany.	helmut.ostertag@krh.eu					Albright F, 1937, NEW ENGL J MED, V216, P727, DOI 10.1056/NEJM193704292161701; Benhamou J, 2016, J BONE MINER RES, V31, P2167, DOI 10.1002/jbmr.2894; Carney JA, 2011, AM J SURG PATHOL, V35, P1311, DOI 10.1097/PAS.0b013e31821ec4ce; Carter JM, 2014, AM J SURG PATHOL, V38, P402, DOI 10.1097/PAS.0000000000000144; Chapurlat RD, 2008, BEST PRACT RES CL RH, V22, P55, DOI 10.1016/j.berh.2007.11.004; Dal Cin P, 2000, CANCER GENET CYTOGEN, V122, P30, DOI 10.1016/S0165-4608(00)00270-3; Deel C, 2016, ARCH PATHOL LAB MED, V140, P473, DOI 10.5858/2014-0503-RS; Demicco EG, 2010, AM J SURG PATHOL, V34, P1647, DOI 10.1097/PAS.0b013e3181f7dac6; DiCaprio MR, 2005, J BONE JOINT SURG AM, V87A, P1848, DOI 10.2106/JBJS.D.02942; Dreizin David, 2012, Am J Orthop (Belle Mead NJ), V41, P332; Fletcher CDM, 2013, WHO CLASSIFICATION T, P352; Freyschmidt J, 2010, KNOCHENTUMOREN KIEFE; Freyschmidt J, 2016, SKELETTERKRANKUNGEN; Gaujoux S, 2014, J CLIN ENDOCR METAB, V99, pE97, DOI 10.1210/jc.2013-1823; HAPPLE R, 1986, CLIN GENET, V29, P321; Hart ES, 2007, J BONE MINER RES, V22, P1468, DOI 10.1359/JBMR.070511; Henschen F., 1926, VERH DTSCH GES PATHO, V21, P93; Jasnau S, 2008, ORAL ONCOL, V44, P286, DOI 10.1016/j.oraloncology.2007.03.001; Kitagawa Y, 2011, J ORTHOP SCI, V16, P129, DOI 10.1007/s00776-010-0004-4; Kransdorf MJ, 1999, RADIOLOGY, V212, P693, DOI 10.1148/radiology.212.3.r99se40693; Kuznetsov SA, 2008, J BONE MINER RES, V23, P1731, DOI 10.1359/JBMR.080609; Lee SE, 2012, HUM PATHOL, V43, P1234, DOI 10.1016/j.humpath.2011.09.012; Lee SH, 2017, ONCOTARGET, V8, P6579, DOI 10.18632/oncotarget.14172; Lichtenstein L, 1938, ARCH SURG-CHICAGO, V36, P874, DOI 10.1001/archsurg.1938.01190230153012; Lichtenstein L, 1942, ARCH PATHOL, V33, P777; Mantovani G, 2010, MOL CELL ENDOCRINOL, V326, P15, DOI 10.1016/j.mce.2010.04.009; Mazabraud A, 1967, Presse Med, V75, P2223; McCune DJ, 1937, AM J DIS CHILD, V54, P806, DOI 10.1001/archpedi.1937.01980040110009; Okamoto S, 2002, VIRCHOWS ARCH, V440, P12, DOI 10.1007/s004280100491; Pittman ME, 2017, ARCH PATHOL LAB MED, V141, P1606, DOI 10.5858/arpa.2016-0426-RA; Pollandt K, 2001, VIRCHOWS ARCH, V439, P170, DOI 10.1007/s004280100453; RAGSDALE BD, 1993, HUM PATHOL, V24, P505, DOI 10.1016/0046-8177(93)90162-A; Ramaswamy G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45140; Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108; Remoli C, 2015, J BONE MINER RES, V30, P1030, DOI 10.1002/jbmr.2425; Riminucci M, 1999, J PATHOL, V187, P249, DOI 10.1002/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J; Riminucci M, 1997, AM J PATHOL, V151, P1587; Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899; Riminucci M, 2006, J BONE MINER RES, V21, pP125, DOI 10.1359/JBMR.06S224; Riminucci M, 2015, BONE, V70, P55, DOI 10.1016/j.bone.2014.09.009; Ritterhouse LL, 2017, MODERN PATHOL, V30, P1720, DOI 10.1038/modpathol.2017.88; Saggio I, 2014, J BONE MINER RES, V29, P2357, DOI 10.1002/jbmr.2267; Salenave S, 2014, J CLIN ENDOCR METAB, V99, P1955, DOI 10.1210/jc.2013-3826; Salinas-Souza C, 2015, MODERN PATHOL, V28, P1336, DOI 10.1038/modpathol.2015.91; Salpea P, 2014, MOL CELL ENDOCRINOL, V386, P85, DOI 10.1016/j.mce.2013.08.022; Schwarze M, 2017, ORTHOPADE, V46, P776, DOI 10.1007/s00132-017-3399-1; Shi RR, 2013, MODERN PATHOL, V26, P1023, DOI 10.1038/modpathol.2013.31; Singhi AD, 2014, HUM PATHOL, V45, P1737, DOI 10.1016/j.humpath.2014.04.018; Tabareau-Delalande F, 2015, AM J SURG PATHOL, V39, P1010, DOI 10.1097/PAS.0000000000000461; Tsai JH, 2013, AM J SURG PATHOL, V37, P1862, DOI 10.1097/PAS.0b013e3182986bb5; Tsourdi E, 2013, J CLIN ENDOCR METAB, V98, pE1381, DOI 10.1210/jc.2013-2186; Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914-015-0268-x; VOYTEK TM, 1995, AM J SURG PATHOL, V19, P775, DOI 10.1097/00000478-199507000-00005; Zauber P, 2015, HUM PATHOL, V46, P339, DOI 10.1016/j.humpath.2014.09.017; Zreik RT, 2017, HUM PATHOL, V62, P170, DOI 10.1016/j.humpath.2016.09.030	55	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					146	153		10.1007/s00292-018-0417-y			8	Pathology	Pathology	GA1AI	WOS:000428046700007	29488004				2019-10-28	
J	Specht, K; Hartmann, W				Specht, K.; Hartmann, W.			Ewing sarcomas and Ewing-like sarcomas. New aspects	PATHOLOGE			German	Article						Ewing Sarcoma; Gene rearrangement; Round cell sarcoma; Peripheral primitive neuroectodermal tumors; EWSR1	ROUND-CELL SARCOMAS; CIC-FOXO4 GENE FUSION; NEUROECTODERMAL TUMOR; SOMATIC MUTATIONS; EXPRESSION; BCOR; MARKER; REARRANGEMENTS; DIAGNOSIS; SUBTYPE	Sarcomas of the Ewing family of tumors are aggressive neoplasms occurring in bone and soft tissue of mostly children and young adults. Classical Ewing sarcomas are pathognomonically characterized by fusions between a gene of the RNA-binding TET family (EWSR1 or FUS) with a gene of the ETS-transcription family (FLI1, ERG, ETV1, ETV4 or FEV). Less frequent cases designated as Ewing-like sarcomas show different genetic rearrangements between EWSR1 and non-ETS genes (NFATC2, POU5F1, SMARCA5, PATZ, ZSG, SP3). Moreover, new molecular alterations biologically unrelated to Ewing sarcomas have recently been described in the category of undifferentiated round cell sarcomas including CIC-DUX4 fusions or BCOR alterations, each carrying unique gene expression signatures. In contrast to classical Ewing sarcomas, the morphologic spectrum of these tumor entities is much broader and includes round cell areas as well as spindled and myxoid components. The immunohistochemical profile with inconsistent CD99 positivity makes diagnosis more difficult and requires the use of a broad spectrum of antibodies and elaborate molecular work-up. Further studies for future therapeutic decision making in these newly described round cell sarcomas as well as for molecular subclassification of undifferentiated round cell sarcomas are ongoing.	[Specht, K.] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Ismaninger Str 22, D-81675 Munich, Germany; [Hartmann, W.] Univ Klinikum Munster, Gerhard Domagk Inst Pathol, Munster, Germany	Specht, K (reprint author), Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Ismaninger Str 22, D-81675 Munich, Germany.	katja.specht@tum.de	Hartmann, Wolfgang/G-1893-2017	Hartmann, Wolfgang/0000-0002-7609-5021			AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Antonescu C, 2014, HISTOPATHOLOGY, V64, P26, DOI 10.1111/his.12281; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen S, 2016, GENE CHROMOSOME CANC, V55, P340, DOI 10.1002/gcc.22336; Cohen-Gogo S, 2014, PEDIATR BLOOD CANCER, V61, P2191, DOI 10.1002/pbc.25210; Collini P, 2001, AM J SURG PATHOL, V25, P273, DOI 10.1097/00000478-200102000-00022; Damm F, 2013, BLOOD, V122, P3169, DOI 10.1182/blood-2012-11-469619; Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913; Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010; Ginsberg JP, 1999, J CLIN ONCOL, V17, P1809, DOI 10.1200/JCO.1999.17.6.1809; Goldblum JR, 2000, AM J SURG PATHOL, V24, P1174, DOI 10.1097/00000478-200008000-00023; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; Grossmann V, 2011, BLOOD, V118, P6153, DOI 10.1182/blood-2011-07-365320; Harms D, 1998, Verh Dtsch Ges Pathol, V82, P83; Hilton EN, 2007, HUM MOL GENET, V16, P1773, DOI 10.1093/hmg/ddm125; Hung YP, 2016, MODERN PATHOL, V29, P1324, DOI 10.1038/modpathol.2016.140; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Jimenez G, 2000, GENE DEV, V14, P224; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P501, DOI 10.1002/gcc.22454; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Le Deley MC, 2010, J CLIN ONCOL, V28, P1982, DOI 10.1200/JCO.2009.23.3585; Le Guellec S, 2016, MODERN PATHOL, V29, P1523, DOI 10.1038/modpathol.2016.155; Lee CJ, 2005, J NEURO-ONCOL, V73, P101, DOI 10.1007/s11060-004-4598-2; LUMADUE JA, 1994, AM J CLIN PATHOL, V102, P692, DOI 10.1093/ajcp/102.5.692; Machado I, 2016, PATHOL RES PRACT, V212, P811, DOI 10.1016/j.prp.2016.06.012; Marino-Enriquez A, 2014, INT J BIOCHEM CELL B, V53, P493, DOI 10.1016/j.biocel.2014.04.022; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Parham DM, 1999, HUM PATHOL, V30, P911, DOI 10.1016/S0046-8177(99)90244-7; Peters TL, 2015, MODERN PATHOL, V28, P575, DOI 10.1038/modpathol.2014.139; Pierron G, 2012, NAT GENET, V44, P461, DOI 10.1038/ng.1107; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Puls F, 2014, AM J SURG PATHOL, V38, P1307, DOI 10.1097/PAS.0000000000000223; Righi A, 2015, AM J SURG PATHOL, V39, P691, DOI 10.1097/PAS.0000000000000412; Romeo S, 2010, VIRCHOWS ARCH, V456, P219, DOI 10.1007/s00428-009-0854-3; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; SCHMIDT D, 1991, CANCER, V68, P2251, DOI 10.1002/1097-0142(19911115)68:10<2251::AID-CNCR2820681025>3.0.CO;2-X; Shibuya R, 2014, VIRCHOWS ARCH, V465, P599, DOI 10.1007/s00428-014-1627-1; Siegele B, 2017, AM J SURG PATHOL, V41, P423, DOI 10.1097/PAS.0000000000000772; Smith SC, 2017, HISTOPATHOLOGY, V70, P657, DOI 10.1111/his.13112; Solomon DA, 2014, AM J SURG PATHOL, V38, P1724, DOI 10.1097/PAS.0000000000000335; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Tsokos M, 1992, Perspect Pediatr Pathol, V16, P27; van der Maarel SM, 2011, TRENDS MOL MED, V17, P252, DOI 10.1016/j.molmed.2011.01.001; Wang WL, 2012, MODERN PATHOL, V25, P1378, DOI 10.1038/modpathol.2012.97; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Yamamoto Y, 2010, BLOOD, V116, P4274, DOI 10.1182/blood-2010-01-264432	56	1	1	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					154	163		10.1007/s00292-018-0421-2			10	Pathology	Pathology	GA1AI	WOS:000428046700008	29480450				2019-10-28	
J	Zustin, J; Amling, M; Crazzolara, R; Butscheidt, S; Schulz, A; Oheim, R				Zustin, J.; Amling, M.; Crazzolara, R.; Butscheidt, S.; Schulz, A.; Oheim, R.			Morphological characteristics of osteopetrosis	PATHOLOGE			German	Article						Bone density; Bone diseases; Osteoclasts; Osteopetrosis; Osteosclerosis	ADHESION DEFICIENCY-III; LEUKOCYTE ADHESION; OSTEOPROTEGERIN-LIGAND; OSTEOCLAST DIFFERENTIATION; INTEGRIN ACTIVATION; CALCIUM HOMEOSTASIS; BONE-RESORPTION; IN-VITRO; MUTATIONS; RECEPTOR	Osteopetrosis is a rare inherited bone disorder characterized by increased bone density owing to failure in bone resorption by the osteoclasts. The disease is genetically and histologically heterogeneous with a wide spectrum of microscopic findings. The histology varies from cases with a total absence of osteoclasts to bone biopsies characterized by high numbers of enlarged multinucleated osteoclasts on a background of sclerotic cancellous bone with or without additional defect of mineralization of the bone matrix. Here we present typical cases of human osteopetrosis on the basis of bone biopsies with four distinct genotypes (mutations of TNFRSF11A, TCIRG1, CNCL7, KINDLIN-3 genes) and discuss genotype-phenotype relationships. Analyzing human bone biopsies of rare skeletal disorders might improve our understanding of bone metabolism with possible implications for the clinical management of other bone diseases.	[Amling, M.; Butscheidt, S.; Oheim, R.] Univ Klinikum Hamburg Eppendorf, Inst Osteol & Biomech, Hamburg, Germany; [Crazzolara, R.] Med Univ Innsbruck, Dept Kinder & Jugendhilfe, Innsbruck, Austria; [Schulz, A.] Univ Klinikum Ulm, Univ Klin Kinder & Jugendmed, Ulm, Germany	Zustin, J (reprint author), Lademannbogen 61-63, D-22339 Hamburg, Germany.	jozefzustin@t-online.de	Schulz, Arndt P./E-2907-2010	Schulz, Arndt P./0000-0002-4927-549X			Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Barvencik F, 2014, J BONE MINER RES, V29, P982, DOI 10.1002/jbmr.2100; Coudert AE, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/372156; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109-011-0749-z; Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kilic SS, 2009, J CLIN IMMUNOL, V29, P117, DOI 10.1007/s10875-008-9226-z; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kong YY, 1999, NATURE, V397, P315; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Krause M, 2015, OSTEOPOROSIS INT, V26, P987, DOI 10.1007/s00198-014-2965-1; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978-0-387-89520-8_9; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; McDowall A, 2010, BLOOD, V115, P4834, DOI 10.1182/blood-2009-08-238709; Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Sabnis H, 2010, PEDIATR BLOOD CANCER, V55, P180, DOI 10.1002/pbc.22386; Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963; Svensson L, 2009, NAT MED, V15, P306, DOI 10.1038/nm.1931; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190	29	1	1	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					164	171		10.1007/s00292-017-0370-1			8	Pathology	Pathology	GA1AI	WOS:000428046700009	28980057				2019-10-28	
J	Hussein, K; Panning, B				Hussein, K.; Panning, B.			Reconstruction of the examination of the laryngeal carcinoma of Emperor Frederick III by Rudolf Virchow	PATHOLOGE			German	Article						Frederick III; Carcinoma; Larynx; Virchow; Waldeyer	CROWN-PRINCE FREDERICK; BRIEF-HISTORY; MEDICINE; SYPHILIS	Rudolf Virchow is one of the founders of modern pathology, and many of his ideas on inflammatory and neoplastic diseases are still valid today. Even for Virchow, determination of malignancy was not always easy. As an example, the laryngeal disease of Crown Prince Frederick William, the later Emperor Frederick III, is presented. The clinical findings at the beginning of the disease were suggestive of a carcinoma, though an inflammatory lesion was also discussed. Several attempts were made to remove the lesion bioptically, but local recurrences occurred and the first tissue samples were not examined histopathologically. Since laryngeal tumour operations had a high mortality at that time, histopathologic examinations were made in order to decide for or against an operation. The samples taken after pre-treatment did not meet Virchow's criteria for determining a carcinoma. Contrary to the present concept of a carcinoma in situ-carcinoma sequence, Virchow's concept was based on the assumption that carcinomas are not derived from the epithelium, but arise from a mesenchymal-epithelial transformation from the connective tissue. The clinical suspicion of a laryngeal carcinoma was confirmed only shortly before the patient's death and later by a post-mortem examination. The question repeatedly asked is whether Virchow should have diagnosed a carcinoma at the beginning of the disease. The answer has been the same for more than a hundred years: the clinician is dissatisfied with the histopathological diagnosis, so the pathologist is to blame.	[Hussein, K.] MHH, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Panning, B.] MHH, Klin Anasthesiol & Intens Med, Hannover, Germany	Hussein, K (reprint author), MHH, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	hussein.kais@mh-hannover.de					Androutsos G, 2002, J BUON, V7, P389; Bardeleben HA, 1888, KRANKHEIT KAISER FRI; Betlejewski Stanislaw, 2008, Otolaryngol Pol, V62, P803, DOI 10.1016/S0030-6657(08)70367-6; Bonchek LI, 2008, J LANC GEN HOSP, V3, P108; Cardesa A, 2011, VIRCHOWS ARCH, V458, P649, DOI 10.1007/s00428-011-1075-0; Davis HJ, 1908, P ROY SOC MED, V1, P46; DeVita VT, 2012, NEW ENGL J MED, V366, P2207, DOI 10.1056/NEJMra1204479; Faguet GB, 2015, INT J CANCER, V136, P2022, DOI 10.1002/ijc.29134; Fechner RE, 2002, MODERN PATHOL, V15, P221, DOI 10.1038/modpathol.3880519; Feldmann H, 2002, LARYNGO RHINO OTOL, V81, P596, DOI 10.1055/s-2002-33366; Forstl H, 2008, ACTA PSYCHIAT SCAND, V118, P499, DOI 10.1111/j.1600-0447.2008.01269.x; Haddad F S, 1999, Ann Diagn Pathol, V3, P62, DOI 10.1016/S1092-9134(99)80010-0; Hauptmann S, 2001, PATHOLOGE, V22, P291, DOI 10.1007/s002920100476; Hu YP, 2014, OTOLARYNG HEAD NECK, V150, P401, DOI 10.1177/0194599813516733; Hughes JP, 2009, J LARYNGOL OTOL, V123, P261, DOI 10.1017/S0022215108003204; Kessler R, 2011, THURING ARZTEBL, V22, P480; Kierzek A, 2013, WSPOLCZESNA ONKOL, V17, P473, DOI 10.5114/wo.2013.38908; Lahav G, 2011, ARCH OTOLARYNGOL, V137, P294, DOI 10.1001/archoto.2011.16; LAURENSON RD, 1995, J LARYNGOL OTOL, V109, P479, DOI 10.1017/S0022215100130518; LAURENSON RD, 1995, J LARYNGOL OTOL, V109, P1; Lee M, 1981, Rostrum, P1; Mackenzie M., 1871, GROWTHS LARYNX; Mackenzie M., 1888, FATAL ILLNESS FREDER; McLaren KM, 2000, HISTOPATHOLOGY, V37, P460, DOI 10.1046/j.1365-2559.2000.00998.x; MINNIGERODE B, 1986, LARYNGOSCOPE, V96, P200; PAULLEY JW, 1993, Q J MED, V86, P837; Rudert H, 2016, EUR ARCH OTO-RHINO-L, V273, P1489, DOI 10.1007/s00405-016-3912-x; Santoro A, 2011, J SKIN CANCER, DOI 10.1155/2011/370605; Schmidt A, 2006, CONTRIB MICROBIOL, V13, P1, DOI 10.1159/000092961; Sedivy R, 2015, WIEN MED WOCHENSCHR, V165, P140, DOI 10.1007/s10354-015-0351-z; Teschner M, 2012, HNO, V60, P985, DOI 10.1007/s00106-012-2542-x; Vasold M., 1990, R VIRCHOW GROSSE ARZ; Virchow R, 1887, BERL KLIN WOCHENSCHR, V25, P445; Virchow R, 1888, DEUT MED WOCHENSCHR, V8, P137; Virchow R, 1887, BERL KLIN WOCHENSCHR, V28, P634; Virchow R, 1887, BERL KLIN WOCHENSCHR, V32, P585; Virchow R, 1887, DEUT MED WOCHENSCHR, V47, P877; von Waldeyer-Hartz W, 1921, LEBENSERINNERUNGEN; Winkelmann A, 2007, CLIN ANAT, V20, P231, DOI 10.1002/ca.20400; Witt RL, 2009, J VOICE, V23, P140, DOI 10.1016/j.jvoice.2007.06.001	40	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					172	177		10.1007/s00292-017-0392-8			6	Pathology	Pathology	GA1AI	WOS:000428046700010	29147845				2019-10-28	
J	Dietmaier, W; Hummel, M				Dietmaier, W.; Hummel, M.			Quality assurance in molecular pathology	PATHOLOGE			German	Editorial Material									[Dietmaier, W.] Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany; [Hummel, M.] Charite Univ Med Berlin, Inst Pathol, Charite Campus Mitte, Virchowweg 16-17a, D-10117 Berlin, Germany	Dietmaier, W (reprint author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.; Hummel, M (reprint author), Charite Univ Med Berlin, Inst Pathol, Charite Campus Mitte, Virchowweg 16-17a, D-10117 Berlin, Germany.	wolfgang.dietmaier@klinik.uni-regensburg.de; michael.hummel@charite.de						0	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					178	180		10.1007/s00292-018-0423-0			3	Pathology	Pathology	GA1AI	WOS:000428046700011	29500523				2019-10-28	
J	Seeling, C; Hirte, C; Scheuerle, A; Moller, P; Barth, TFE				Seeling, C.; Hirte, C.; Scheuerle, A.; Moeller, P.; Barth, T. F. E.			Presacral lesion at the rima ani	PATHOLOGE			German	Editorial Material						Myxoid morphology; Immunohistochemistry; Differential diagnosis; Ependymoma; Chordoma	METASTASIS; CHORDOMA	A 26-year-old woman presented with a painful bulge at the rima ani. The tumor was located in the presacral region. Histological examination revealed a well-circumscribed biphenotypical tumor with papillary configured myxoid areas and strongly sclerosing regions. This case of a myxopapillary ependymoma is a rare example of a myxoid neoplastic lesion in the sacral region.	[Seeling, C.; Moeller, P.; Barth, T. F. E.] Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany; [Hirte, C.] Alb Fils Kliniken, Inst Pathol, Goppingen, Germany; [Scheuerle, A.] Bezirkskrankenhaus Gunzburg, Abt Neuropathol, Gunzburg, Germany	Barth, TFE (reprint author), Univ Klinikum Ulm, Inst Pathol, Albert Einstein Allee 23, D-89081 Ulm, Germany.	thomas.barth@uniklinik-ulm.de					Choudhury M, 2015, J CYTOL, V32, P42, DOI 10.4103/0970-9371.155235; Lamzabi I, 2013, APPL IMMUNOHISTO M M, V21, P485, DOI 10.1097/PAI.0b013e318283980a; von Witzleben A, 2016, EUR SPINE J, V25, P4016, DOI 10.1007/s00586-015-4242-1; von Witzleben A, 2015, CANCER RES, V75, P3823, DOI 10.1158/0008-5472.CAN-14-3270; WOLFF M, 1972, CANCER, V30, P1046, DOI 10.1002/1097-0142(197210)30:4<1046::AID-CNCR2820300427>3.0.CO;2-X	5	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					181	185		10.1007/s00292-017-0366-x			5	Pathology	Pathology	GA1AI	WOS:000428046700012	29018939				2019-10-28	
J	Mogler, C; Boxberg, M; Knebel, C; Weichert, W; Wortler, K; Specht, K				Mogler, C.; Boxberg, M.; Knebel, C.; Weichert, W.; Woertler, K.; Specht, K.			Spindle-cell osteosclerotic bone lesion with MDM2 amplification	PATHOLOGE			German	Article						Bone neoplasms; Carcinoma; Gene amplification; Stomach neoplasm; Tumor biomarker	GASTRIC CARCINOMAS; OSTEOSARCOMA; EXPRESSION; PAROSTEAL; TUMORS	This case report presents an osteosclerotic bone lesion in a 49-year-old man with MDM2 amplification. The final diagnosis shows metastasis to the bones from stomach cancer. In primary bone tumours, the MDM2 amplifications observed have been described for many other tumour entities as well, and therefore do not exclude bone metastasis from a carcinoma.	[Mogler, C.; Boxberg, M.; Weichert, W.; Specht, K.] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany; [Knebel, C.] Klinikum Rechts Der Isar, Klin & Poliklin Orthopadie & Sportorthopadie, Munich, Germany; [Woertler, K.] Klinikum Rechts Der Isar, Inst Radiol, Munich, Germany	Mogler, C (reprint author), Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany.	Carolin.Mogler@tum.de					Buyukpinarbasili N, 2016, ANN DIAGN PATHOL, V21, P29, DOI 10.1016/j.anndiagpath.2016.01.001; Crago AM, 2011, CURR OPIN ONCOL, V23, P373, DOI 10.1097/CCO.0b013e32834796e6; Duhamel LAE, 2012, HISTOPATHOLOGY, V60, P357, DOI 10.1111/j.1365-2559.2011.04023.x; Endo M, 2013, HUM PATHOL, V44, P1184, DOI 10.1016/j.humpath.2012.11.011; Grabsch HI, 2013, DIGEST SURG, V30, P150, DOI 10.1159/000350876; Gunther T, 2000, MODERN PATHOL, V13, P621, DOI 10.1038/modpathol.3880107; Hang JF, 2014, ARCH PATHOL LAB MED, V138, P694, DOI 10.5858/arpa.2013-0030-RS; Hav M, 2011, VIRCHOWS ARCH, V458, P197, DOI 10.1007/s00428-010-1012-7; Hayashi K, 2014, INT J CLIN ONCOL, V19, P731, DOI 10.1007/s10147-013-0592-z; Kim MA, 2004, HUM PATHOL, V35, P576, DOI 10.1016/j.humpath.2003.12.007; Peng DF, 2003, J PATHOL, V201, P439, DOI 10.1002/path.1459; Radig K, 1998, PATHOL RES PRACT, V194, P669, DOI 10.1016/S0344-0338(98)80125-8; Schrock AB, 2016, J THORAC ONCOL, V11, P1493, DOI 10.1016/j.jtho.2016.06.004	13	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					186	189		10.1007/s00292-017-0394-6			4	Pathology	Pathology	GA1AI	WOS:000428046700013	29209796				2019-10-28	
J	Mechtersheimer, G; Werner, M				Mechtersheimer, G.; Werner, M.			Morphological spectrum of USP6 rearranged lesions	PATHOLOGE			German	Article						Aneurysmal bone cysts; Nodular fasciitis; Molecular medicine; NIH 3T3 cells; Oncogenes	ANEURYSMAL BONE-CYST; NF-KAPPA-B; NODULAR FASCIITIS; ANCHORED MULTIPLEX; GENE REARRANGEMENT; ONCOGENE; ACTIVATION; MECHANISM; CELL; RECURRENT	USP6, also known as Tre-2 and TRE17, is an ubiquitase-specific proteinase that was identified more than two decades ago as a potential oncogene when it exhibited transforming properties upon overexpression in NIH 3T3 cells. Until recently, however, little was known about the function and the oncogenetic activation of USP6. The identification of rearrangements of the USP6 gene in aneurysmal bone cyst and in nodular fasciitis has not only led to a better understanding of the pathogenesis of these entities, but is also a useful tool in their diagnosis and differential diagnostic delineation from morphological mimics. In this review, the clinical, pathomorphological, and molecular genetic aspects of aneurysmal bone cyst and of nodular fasciitis, as well as from related lesions, are presented and discussed.	[Mechtersheimer, G.] Univ Klinikum Heidelberg, Pathol Inst, Heidelberg, Germany; [Werner, M.] HELIOS Klinikum Emil von Behring, Inst Pathol, Sarkomzentrum Berlin Brandenburg, Walterhoferstr 11, D-14165 Berlin, Germany	Werner, M (reprint author), HELIOS Klinikum Emil von Behring, Inst Pathol, Sarkomzentrum Berlin Brandenburg, Walterhoferstr 11, D-14165 Berlin, Germany.	mathias.werner@helios-kliniken.de					Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Amary MF, 2013, VIRCHOWS ARCH, V463, P97, DOI 10.1007/s00428-013-1418-0; Carter JM, 2016, MODERN PATHOL, V29, P865, DOI 10.1038/modpathol.2016.83; Dal Cin P, 2000, GENE CHROMOSOME CANC, V28, P233, DOI 10.1002/(SICI)1098-2264(200006)28:2<233::AID-GCC13>3.3.CO;2-8; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Guo RF, 2016, GENE CHROMOSOME CANC, V55, P640, DOI 10.1002/gcc.22366; Guseva NV, 2017, GENE CHROMOSOME CANC, V56, P266, DOI 10.1002/gcc.22432; [International Agency for Research on Cancer World Health Organization], 2013, WHO CLASS TUM SOFT T; Jacquot C, 2015, SKELETAL RADIOL, V44, P1695, DOI 10.1007/s00256-015-2205-6; Kumar E, 2016, J CUTAN PATHOL, V43, P1143, DOI 10.1111/cup.12828; Laaveri M, 2017, INT J ORAL MAX SURG, V46, P883, DOI 10.1016/j.ijom.2017.02.005; Lau AW, 2010, J BIOL CHEM, V285, P37111, DOI 10.1074/jbc.M110.175133; Madan B, 2016, P NATL ACAD SCI USA, V113, pE2945, DOI 10.1073/pnas.1605691113; NAKAMURA T, 1992, ONCOGENE, V7, P733; Nishio J, 2013, ONCOL LETT, V5, P12, DOI 10.3892/ol.2012.1002; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Oliveira Andre M, 2012, Front Biosci (Schol Ed), V4, P321; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; Patel NR, 2017, MODERN PATHOL, V30, P1577, DOI 10.1038/modpathol.2017.78; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; Pringle LM, 2012, ONCOGENE, V31, P3525, DOI 10.1038/onc.2011.520; Sciot R, 2000, MODERN PATHOL, V13, P1206, DOI 10.1038/modpathol.3880224; Shin C, 2016, HISTOPATHOLOGY, V69, P784, DOI 10.1111/his.13011; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; World Health Organization, 2017, WHO CLASS HEAD NECK; Ye Y, 2010, ONCOGENE, V29, P3619, DOI 10.1038/onc.2010.116; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	30	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAR	2018	39	2					191	203		10.1007/s00292-018-0430-1			13	Pathology	Pathology	GA1AI	WOS:000428046700014	29549420				2019-10-28	
J	McCluggage, WG				McCluggage, W. Glenn			Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						endometrium; uterus; staging; pathologic parameters; synchronous neoplasms	VASCULAR SPACE INVASION; LAPAROSCOPIC HYSTERECTOMY SPECIMENS; LYMPH-NODE METASTASIS; UTERINE-CERVIX; CLINICOPATHOLOGICAL ANALYSIS; PROGNOSTIC-SIGNIFICANCE; MYOMETRIAL INVASION; FALLOPIAN-TUBE; SYNCHRONOUS ENDOMETRIAL; OVARIAN INVOLVEMENT	Accurate staging of cancers is an important determinant of prognosis and guides optimal patient treatment. Although the International Collaboration on Cancer Reporting recommends that endometrial cancers (including carcinosarcomas) are pathologically staged using the International Federation of Gynecology and Obstetrics (FIGO) 2009 system, in many areas TNM [American Joint Committee on Cancer (AJCC) or Union for International Cancer Control (UICC)] staging is used or even mandated; these latter systems are based on FIGO 2009. In this review, areas of difficulty in the pathologic staging of endometrial carcinomas are covered with practical advice for the reporting pathologist. These include issues regarding the assessment of the depth of myometrial involvement (which may be rendered difficult due to a variety of factors), tumor involvement of adenomyosis, and assessment of cervical and uterine serosal involvement. Although not included in the FIGO staging system, the issue of lymphovascular space invasion (LVSI) is covered as this is of prognostic importance and there are multiple problems in the pathologic assessment of this. One important point is that tumors should not be upstaged based on the presence of LVSI alone without tissue involvement; for example, the presence of LVSI in the outer half of the myometrium or in cervical or adnexal vessels in a carcinoma with myoinvasion confined to the inner half of the myometrium is still FIGO stage IA. The issue of simultaneously occurring tumors of the endometrium and adnexa is also covered with advice on how to distinguish between synchronous independent and metastatic neoplasms of both endometrioid and nonendometrioid types. Recent molecular evidence showing that simultaneously occurring endometrioid carcinomas of the endometrium and ovary are clonal and thus probably represent metastatic disease from the endometrium to the ovary rather than synchronous independent neoplasms, as is widely assumed, is discussed.	[McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland	McCluggage, WG (reprint author), Royal Grp Hosp Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.	glenn.mccluggage@belfasttrust.hscni.net					Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x; Ali A, 2007, INT J GYNECOL PATHOL, V26, P115, DOI 10.1097/01.pgp.0000233165.56385.0b; Amezcua CA, 2006, INT J GYNECOL CANCER, V16, P1336, DOI 10.1111/j.1525-1438.2006.00528.x; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Bosse T, 2015, EUR J CANCER, V51, P1742, DOI 10.1016/j.ejca.2015.05.015; Brinkmann D, 2004, JNCI-J NATL CANCER I, V96, P1441, DOI 10.1093/jnci/djh272; CHEN KTK, 1978, ARCH PATHOL LAB MED, V108, P359; Cole AJ, 2013, ADV ANAT PATHOL, V20, P141, DOI 10.1097/PAP.0b013e31828d17cc; Creasmann WT, 2001, CME J GYNECOL ONCOL, V6, P257; Culton LK, 2006, AM J SURG PATHOL, V30, P844, DOI 10.1097/01.pas.0000209839.00467.05; Dabner M, 2012, INT J GYNECOL PATHOL, V31, P429, DOI 10.1097/PGP.0b013e31824a1de2; Desouki MM, 2014, INT J GYNECOL PATHOL, V33, P274, DOI 10.1097/PGP.0b013e31829040b5; Dewdney SB, 2014, EUR J GYNAECOL ONCOL, V35, P7; FIGO Committee on Gynecologic Oncology, 2009, INT J GYNECOL OBSTET, V106, P277; Frimer M, 2010, GYNECOL ONCOL, V119, P496, DOI 10.1016/j.ygyno.2010.08.030; GAL D, 1991, GYNECOL ONCOL, V42, P142, DOI 10.1016/0090-8258(91)90334-2; Han GM, 2014, HISTOPATHOLOGY, V64, P389, DOI 10.1111/his.12254; Hanley KZ, 2010, INT J GYNECOL PATHOL, V29, P445, DOI 10.1097/PGP.0b013e3181d81de6; HANSON MB, 1985, CANCER, V55, P1753, DOI 10.1002/1097-0142(19850415)55:8<1753::AID-CNCR2820550823>3.0.CO;2-P; Hetu V, 2009, GYNECOL OBSTET INVES, V67, P173, DOI 10.1159/000184741; Hirschowitz L, 2013, HISTOPATHOLOGY, V62, P176, DOI 10.1111/his.12058; Hirschowitz L, 2009, HISTOPATHOLOGY, V55, P478, DOI 10.1111/j.1365-2559.2009.03390.x; Hoogduin KJ, 2013, INT J GYNECOL PATHOL, V32, P122, DOI 10.1097/PGP.0b013e318253c6f6; Inoue Y, 1996, CANCER-AM CANCER SOC, V78, P1447, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1447::AID-CNCR11>3.0.CO;2-#; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jacques SM, 1998, INT J GYNECOL PATHOL, V17, P42, DOI 10.1097/00004347-199801000-00008; JACQUES SM, 1990, GYNECOL ONCOL, V37, P401, DOI 10.1016/0090-8258(90)90376-V; Jarboe EA, 2009, INT J GYNECOL PATHOL, V28, P308, DOI 10.1097/PGP.0b013e3181934390; Joehlin-Price AS, 2017, AM J SURG PATHOL, V41, P49, DOI 10.1097/PAS.0000000000000754; Jordan LB, 2002, INT J GYNECOL CANCER, V12, P42, DOI 10.1046/j.1525-1438.2002.01076.x; Kalyanasundaram K, 2010, INT J SURG PATHOL, V18, P138, DOI 10.1177/1066896908329585; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; KIM KR, 1990, AM J SURG PATHOL, V14, P925, DOI 10.1097/00000478-199010000-00005; Kitahara S, 2009, AM J SURG PATHOL, V33, P298, DOI 10.1097/PAS.0b013e31818a01bf; Kobayashi Y, 2015, INT J GYNECOL CANCER, V25, P440, DOI 10.1097/IGC.0000000000000377; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kondalsamy-Chennakesavan S, 2010, INT J GYNECOL CANCER, V20, P1217, DOI 10.1111/IGC.0b013e3181ef0a31; Koshiyama M, 2002, INT J GYNECOL PATHOL, V21, P239, DOI 10.1097/00004347-200207000-00006; Krizova A, 2011, AM J SURG PATHOL, V35, P115, DOI 10.1097/PAS.0b013e31820273dc; Lin KY, 2015, GYNECOL ONCOL, V138, P532, DOI 10.1016/j.ygyno.2015.07.012; Logani S, 2008, AM J SURG PATHOL, V32, P560, DOI 10.1097/PAS.0b013e31816098f0; Mannelqvist M, 2009, HISTOPATHOLOGY, V54, P174, DOI 10.1111/j.1365-2559.2008.03201.x; McCluggage WG, 2011, AM J SURG PATHOL, V35, P289, DOI 10.1097/PAS.0b013e3182073ac0; McCluggage WG, 2010, J CLIN PATHOL, V63, P768, DOI 10.1136/jcp.2010.080978; McKenney JK, 2005, INT J GYNECOL PATHOL, V24, P73, DOI 10.1097/01.pgp.0000148340.62017.e3; Moreno-Bueno G, 2001, DIAGN MOL PATHOL, V10, P116, DOI 10.1097/00019606-200106000-00008; Moschiano EJ, 2014, INT J GYNECOL PATHOL, V33, P268, DOI 10.1097/PGP.0b013e31829c6757; Movahedi-Lankarani S, PROTOCOL EXAMINATION; Murray SK, 2003, INT J GYNECOL PATHOL, V22, P324, DOI 10.1097/01.pgp.0000092161.33490.a9; Nascimento AF, 2003, MODERN PATHOL, V16, P22, DOI 10.1097/01.MP.0000043523.03519.FC; Nayar AG, 2008, J CLIN PATHOL, V61, P621, DOI 10.1136/jcp.2007.053504; Nicklin JL, 2000, GYNECOL ONCOL, V78, P203, DOI 10.1006/gyno.2000.5849; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Quick CM, 2012, INT J GYNECOL PATHOL, V31, P337, DOI 10.1097/PGP.0b013e31823ff422; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Scott M, 2006, MODERN PATHOL, V19, P470, DOI 10.1038/modpathol.3800556; Singh N, 2010, HISTOPATHOLOGY, V56, P277, DOI 10.1111/j.1365-2559.2009.03367.x; Song T, 2014, INT J GYNECOL CANCER, V24, P520, DOI 10.1097/IGC.0000000000000073; Srodon M, 2003, AM J SURG PATHOL, V27, P786, DOI 10.1097/00000478-200306000-00009; Stefansson IM, 2004, HISTOPATHOLOGY, V44, P472, DOI 10.1111/j.1365-2559.2004.01882.x; Tambouret R, 2003, AM J SURG PATHOL, V27, P1080, DOI 10.1097/00000478-200308000-00005; van der Putten LJM, 2017, VIRCHOWS ARCH, V470, P63, DOI 10.1007/s00428-016-2035-5; Williams JW, 2006, INT J GYNECOL PATHOL, V25, P59, DOI 10.1097/01.pgp.0000177123.78932.1d; Yamazawa K, 2001, CANCER, V91, P1777, DOI 10.1002/1097-0142(20010501)91:9<1777::AID-CNCR1196>3.0.CO;2-#; Zaino R, 2001, GYNECOL ONCOL, V83, P355, DOI 10.1006/gyno.2001.6400	65	2	2	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					71	84		10.1097/PAP.0000000000000182			14	Pathology	Pathology	FY7GZ	WOS:000427031100001	29356713				2019-10-28	
J	Joehlin-Price, AS; Garg, K				Joehlin-Price, Amy S.; Garg, Karuna			Uterine Mesenchymal Tumors: Hereditary Aspects	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						uterus; smooth muscle tumor; fumarate hydratase; HLRCC; TSC; PEComa	RENAL-CELL-CARCINOMA; SMOOTH-MUSCLE TUMORS; LYMPH-NODE LYMPHANGIOLEIOMYOMATOSIS; CANCER HLRCC SYNDROME; OF-THE-LITERATURE; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TUBEROUS SCLEROSIS; MORPHOLOGIC SPECTRUM; NEOPLASM PECOMA; LEIOMYOMAS	The topic of hereditary gynecologic malignancies readily evokes associations between Lynch syndrome and endometrial adenocarcinoma, or between BRCA mutations and tubo-ovarian serous carcinoma, but other familial associations are less well-known. Two hereditary syndromes are known to be related to uterine mesenchymal tumors: hereditary leiomyomatosis and renal cell carcinoma syndrome and the tuberous sclerosis complex. In the following review, we describe the current literature on these syndromes, summarizing their clinical, morphologic, immunophenotypic, and genetic data. It is possible that the surgical pathologic diagnosis is the first indication of a familial syndrome, thus emphasizing the importance of a pathologist's familiarity with these potentially suggestive lesions.	[Joehlin-Price, Amy S.; Garg, Karuna] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94127 USA	Garg, K (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94127 USA.	Karuna.Garg@ucsf.edu					Agaram NP, 2015, AM J SURG PATHOL, V39, P813, DOI 10.1097/PAS.0000000000000389; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; Alsolami S, 2014, INT J GYNECOL PATHOL, V33, P560, DOI 10.1097/PGP.0000000000000091; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Barker KT, 2002, BRIT J CANCER, V87, P446, DOI 10.1038/sj.bjc.6600502; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Fadare Oluwole, 2004, World J Surg Oncol, V2, P35, DOI 10.1186/1477-7819-2-35; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Garg K, 2011, AM J SURG PATHOL, V35, P1235, DOI 10.1097/PAS.0b013e318223ca01; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Hayashi T, 2011, AM J SURG PATHOL, V35, P1776, DOI 10.1097/PAS.0b013e318235edbd; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Kampjarvi K, 2016, BRIT J CANCER, V114, P1405, DOI 10.1038/bjc.2016.130; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Liang SX, 2008, INT J GYNECOL PATHOL, V27, P86, DOI 10.1097/p2p.0b013e318150df37; Lim GSD, 2011, INT J GYNECOL PATHOL, V30, P121, DOI 10.1097/PGP.0b013e3181fa5a99; Merino MJ, 2014, MODERN PATHOL, V27, p296A; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Miettinen M, 2016, AM J SURG PATHOL, V40, P1661, DOI 10.1097/PAS.0000000000000703; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rabban JT, 2015, AM J SURG PATHOL, V39, P1015, DOI 10.1097/PAS.0000000000000416; Rao Q, 2013, HISTOPATHOLOGY, V62, P642, DOI 10.1111/his.12059; Reyes C, 2014, MODERN PATHOL, V27, P1020, DOI 10.1038/modpathol.2013.215; Sanz-Ortega J, 2013, AM J SURG PATHOL, V37, P74, DOI 10.1097/PAS.0b013e31825ec16f; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P1404, DOI 10.1097/PAS.0000000000000470; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P394, DOI 10.1097/PAS.0000000000000349; Schoolmeester JK, 2014, AM J SURG PATHOL, V38, P176, DOI 10.1097/PAS.0000000000000133; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Ubago JM, 2016, AM J SURG PATHOL, V40, P923, DOI 10.1097/PAS.0000000000000646; Udager AM, 2014, AM J SURG PATHOL, V38, P567, DOI 10.1097/PAS.0000000000000127; van Spaendonck-Zwarts KY, 2012, FAM CANCER, V11, P123, DOI 10.1007/s10689-011-9491-5; Vang R, 2002, AM J SURG PATHOL, V26, P1, DOI 10.1097/00000478-200201000-00001; Ylisaukko-oja SK, 2006, INT J CANCER, V119, P283, DOI 10.1002/ijc.21798	36	0	0	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					96	105		10.1097/PAP.0000000000000175			10	Pathology	Pathology	FY7GZ	WOS:000427031100003	28945610				2019-10-28	
J	Norgan, AP; Pritt, BS				Norgan, Andrew P.; Pritt, Bobbi S.			Parasitic Infections of the Skin and Subcutaneous Tissues	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						scabies; leishmaniasis; myiasis; tungiasis	CUTANEOUS LARVA MIGRANS; DISSEMINATED ACANTHAMOEBA INFECTION; ONCHOCERCA-VOLVULUS INFECTION; LOA-LOA FILARIASIS; FREE-LIVING AMEBAS; BALAMUTHIA-MANDRILLARIS; TUNGA-PENETRANS; CLINICAL PRESENTATION; DEMODEX-FOLLICULORUM; AMPLIFICATION METHOD	A variety of arthropods, protozoa, and helminths infect the skin and subcutaneous tissues and may be identified by anatomic pathologists in standard cytology and histology preparations. The specific organisms seen vary greatly with the patient's exposure history, including travel to or residence in endemic countries. Arthropods are the most commonly encountered parasites in the skin and subcutaneous tissues and include Sarcoptes scabei, Demodex species, Tunga penetrans, and myiasis-causing fly larvae. Protozoal parasites such as Leishmania may also be common in some settings. Helminths are less often seen, and include round worms (eg, Dirofilaria spp.), tapeworms (eg, Taenia solium, Spirometra spp.), and flukes (eg, Schistosoma spp.). This review covers the epidemiologic and histopathologic features of common parasitic infections of the skin and subcutaneous tissues.	[Norgan, Andrew P.; Pritt, Bobbi S.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Pritt, Bobbi S.] Mayo Clin, Div Infect Dis, Dept Internal Med, Rochester, MN USA	Pritt, BS (reprint author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	pritt.bobbi@mayo.edu		Pritt, Bobbi/0000-0003-0261-1326			Abarzua A, 2014, INDIAN J DERMATOL VE, V80, P371, DOI 10.4103/0378-6323.136980; Abegunde AT, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011146.pub2; Akcali C, 2008, ANN ACAD MED SINGAP, V37, P435; Akilov Oleg E, 2005, J Dtsch Dermatol Ges, V3, P607, DOI 10.1111/j.1610-0387.2005.05725.x; ANDERSON RI, 1975, AM J TROP MED HYG, V24, P58, DOI 10.4269/ajtmh.1975.24.58; Antinori S, 2012, INT J INFECT DIS, V16, pE649, DOI 10.1016/j.ijid.2012.05.1023; Ariza L, 2007, REV SOC BRAS MED TRO, V40, P63, DOI 10.1590/S0037-86822007000100013; ARLIAN LG, 1988, J PARASITOL, V74, P427, DOI 10.2307/3282050; Aronson N, 2016, CLIN INFECT DIS, V63, pE202, DOI 10.1093/cid/ciw670; ASH LR, 2007, ATLAS HUMAN PARASITO; Austmann KJ, 1926, J AMER MED ASSOC, V87, P1196, DOI 10.1001/jama.1926.02680150030008; AYLESWORTH R, 1982, J AM ACAD DERMATOL, V7, P583, DOI 10.1016/S0190-9622(82)70137-9; Ayong LS, 2005, TROP MED INT HEALTH, V10, P228, DOI 10.1111/j.1365-3156.2004.01384.x; Baima B, 2002, ACTA DERM-VENEREOL, V82, P3, DOI 10.1080/000155502753600795; Bauer J, 2005, ARCH DERMATOL, V141, P643, DOI 10.1001/archderm.141.5.643; Baumrin E, 2015, JAMA-J AM MED ASSOC, V313, P298, DOI 10.1001/jama.2014.16051; Belizario V, 2016, CURR INFECT DIS REP, V18, DOI 10.1007/s11908-016-0533-x; Blackwell V, 2001, BRIT J DERMATOL, V145, P434, DOI 10.1046/j.1365-2133.2001.04406.x; Bowman DD, 2010, TRENDS PARASITOL, V26, P162, DOI 10.1016/j.pt.2010.01.005; Bravo FG, 2012, CURR INFECT DIS REP, V14, P391, DOI 10.1007/s11908-012-0266-4; BRITTON CA, 1992, AM J ROENTGENOL, V159, P51, DOI 10.2214/ajr.159.1.1609720; Bumb R A, 2006, Indian J Dermatol Venereol Leprol, V72, P224; Burbelo PD, 2008, J CLIN MICROBIOL, V46, P2298, DOI 10.1128/JCM.00490-08; BUTTNER DW, 1983, TROPENMED PARASITOL, V34, P113; CARME B, 1991, AM J TROP MED HYG, V44, P684, DOI 10.4269/ajtmh.1991.44.684; Carr PC, 2016, NEW ENGL J MED, V374, pE13, DOI 10.1056/NEJMicm1500116; Caumes E, 2000, CLIN INFECT DIS, V30, P811, DOI 10.1086/313787; Caumes E, 2002, BRIT J DERMATOL, V146, P314, DOI 10.1046/j.0007-0963.2001.04531.x; Chang OH, 2016, J CUTAN PATHOL, V43, P892, DOI 10.1111/cup.12748; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; Cho HY, 2008, J KOREAN MED SCI, V23, P731, DOI 10.3346/jkms.2008.23.4.731; Chosidow O, 2006, NEW ENGL J MED, V354, P1718, DOI 10.1056/NEJMcp052784; CHULARERK P, 1970, J PARASITOL, V56, P623, DOI 10.2307/3277640; CONVIT J, 1972, T ROY SOC TROP MED H, V66, P603, DOI 10.1016/0035-9203(72)90306-9; Criado PR, 2013, AN BRAS DERMATOL, V88, P649, DOI 10.1590/abd1806-4841.20132071; Daneshbod Y, 2011, ARCH PATHOL LAB MED, V135, P478, DOI 10.1043/2010-0069-OA.1; DAVIES HD, 1993, ARCH DERMATOL, V129, P588, DOI 10.1001/archderm.129.5.588; de Beer G, 2006, INFECT CONT HOSP EP, V27, P517, DOI 10.1086/504365; Diaz CJ, 2017, BRAZ J INFECT DIS, V21, P484, DOI 10.1016/j.bjid.2016.12.010; DOMINEY A, 1989, J AM ACAD DERMATOL, V20, P197, DOI 10.1016/S0190-9622(89)70021-9; Dong HJ, 2006, DIAGN CYTOPATHOL, V34, P232, DOI 10.1002/dc.20426; Douba MD, 2012, J EUR ACAD DERMATOL, V26, P1224, DOI 10.1111/j.1468-3083.2011.04266.x; DUKE BOL, 1993, TROP MED PARASITOL, V44, P61; DUKE BOL, 1976, TROPENMED PARASITOL, V27, P123; DUPONT A, 1988, T ROY SOC TROP MED H, V82, P730, DOI 10.1016/0035-9203(88)90218-0; Eisele M, 2003, PARASITOL RES, V90, P87, DOI [10.1007/s00436-003-0934-2, 10.1007/s00436-002-0817-y]; Enk CD, 2006, CLIN DERMATOL, V24, P176, DOI 10.1016/j.clindermatol.2005.11.008; Feldmeier H, 2012, EUR J CLIN MICROBIOL, V31, P915, DOI 10.1007/s10096-011-1404-x; Fink DL, 2011, J CLIN MICROBIOL, V49, P42, DOI 10.1128/JCM.01697-10; Forton F, 2005, J AM ACAD DERMATOL, V52, P74, DOI 10.1016/j.jaad.2004.05.034; Francesconi F, 2012, CLIN MICROBIOL REV, V25, P79, DOI 10.1128/CMR.00010-11; Gantois N, 2013, TRAVEL MED INFECT DI, V11, P366, DOI 10.1016/j.tmaid.2013.08.005; Giangaspero A, 2011, VET PARASITOL, V175, P109, DOI 10.1016/j.vetpar.2010.09.028; Global HealthDivision of Parasitic Diseases and Malaria . Centers for Disease Control and Prevention, 2016, DPDX FREE LIV AM INF; Global HealthDivision of Parasitic Diseases and Malaria . Centers for Disease Control and Prevention, 2016, DPDX SCAB; Global HealthDivision of Parasitic Diseases and Malaria . Centers for Disease Control and Prevention, 2016, DPDX TUNG; Global HealthDivision of Parasitic Diseases and Malaria . Centers for Disease Control and Prevention, 2016, DPDX LOIAS; Gobbi F, 2014, TRAVEL MED INFECT DI, V12, P713, DOI 10.1016/j.tmaid.2014.07.004; Gomez RS, 2003, BRIT J ORAL MAX SURG, V41, P115, DOI 10.1016/S0266-4356(02)00302-9; Greco JB, 2003, BRAZ J INFECT DIS, V5, P319; Hall MJR, 2016, ANNU REV ENTOMOL, V61, P159, DOI 10.1146/annurev-ento-010715-023655; Hay R, 2010, CURR OPIN INFECT DIS, V23, P103, DOI 10.1097/QCO.0b013e3283360a18; HEAD ES, 1990, ARCH DERMATOL, V126, P1475, DOI 10.1001/archderm.126.11.1475; Hewitt KA, 2015, EPIDEMIOL INFECT, V143, P1542, DOI 10.1017/S0950268814002143; Hochedez P, 2007, J TRAVEL MED, V14, P326, DOI 10.1111/j.1708-8305.2007.00148.x; HUBLER WR, 1976, ARCH DERMATOL, V112, P179, DOI 10.1001/archderm.112.2.179; Imai K, 2018, PARASITOL INT, V67, P34, DOI 10.1016/j.parint.2017.03.001; James MT, 1947, FLIES CAUSE MYIASIS; Kamgno J, 2009, AM J TROP MED HYG, V81, P1056, DOI 10.4269/ajtmh.2009.09-0356; Kandukuri S, 2015, AM J DERMATOPATH, V37, P229, DOI 10.1097/DAD.0000000000000061; KARAM M, 1987, ACTA TROP, V44, P445; Karamitros T, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv773; Kelly-Hope L, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2103-y; KLION AD, 1994, J INFECT DIS, V169, P604, DOI 10.1093/infdis/169.3.604; Klion AD, 1999, CLIN INFECT DIS, V29, P680; Kokcam I, 2005, J DERMATOL, V32, P459, DOI 10.1111/j.1346-8138.2005.tb00780.x; Kristjansson AK, 2007, J AM ACAD DERMATOL, V57, P174, DOI 10.1016/j.jaad.2007.03.018; Lagatie O, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1913-7; LASKAY T, 1995, T ROY SOC TROP MED H, V89, P273, DOI 10.1016/0035-9203(95)90537-5; Molinet FJL, 2013, MEM I OSWALDO CRUZ, V108, P293, DOI 10.1590/S0074-02762013000300006; Louis SJ, 2014, INT J DERMATOL, V53, P999, DOI 10.1111/ijd.12456; Maco V, 2013, AM J TROP MED HYG, V88, P1212, DOI 10.4269/ajtmh.12-0645; MAGNARELLI LA, 1981, AM J TROP MED HYG, V30, P894, DOI 10.4269/ajtmh.1981.30.894; Maier H, 2004, J AM ACAD DERMATOL, V50, pS26, DOI 10.1016/S0190-9622(03)01488-9; Masud H, 2009, JCPSP-J COLL PHYSICI, V19, P34, DOI 01.2009/JCPSP.3438; Mathison BA, 2014, CLIN MICROBIOL REV, V27, P48, DOI 10.1128/CMR.00008-13; McGraw TA, 2008, J AM ACAD DERMATOL, V58, P907, DOI 10.1016/j.jaad.2008.03.014; Melrose WD, 2000, T ROY SOC TROP MED H, V94, P176, DOI 10.1016/S0035-9203(00)90266-9; Meyers W. M, 2011, TOPICS PATHOLOGY PRO; Moran EM, 2017, CLIN DERMATOL, V35, P195, DOI [10.1016/j.clindermatol.2016.10.014, 10.1016/j.clindermato1.2016.10.014]; Morrison AO, 2016, AM J CLIN PATHOL, V145, P266, DOI 10.1093/ajcp/aqv081; Mouttaki T, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-420; Mukherjee A, 2012, INDIAN J MED MICROBI, V30, P356, DOI 10.4103/0255-0857.99505; MURDOCH ME, 1993, BRIT J DERMATOL, V129, P260, DOI 10.1111/j.1365-2133.1993.tb11844.x; Murdoch ME, 2010, CURR OPIN INFECT DIS, V23, P124, DOI 10.1097/QCO.0b013e328336a256; Nagsuk P, 2015, DERMATOL ONLINE J, V21, P8; NEGESSE Y, 1985, AM J TROP MED HYG, V34, P537, DOI 10.4269/ajtmh.1985.34.537; NOUTSIS C, 1994, DERMATOL CLIN, V12, P729, DOI 10.1016/S0733-8635(18)30136-0; NOVAK R, 1989, ACTA RADIOL, V30, P507; Okulicz JF, 2004, INT J DERMATOL, V43, P170, DOI 10.1111/j.1365-4632.2004.02279.x; OSUNTOKUN O, 1975, BRIT J OPHTHALMOL, V59, P166, DOI 10.1136/bjo.59.3.166; Padgett JJ, 2008, T ROY SOC TROP MED H, V102, P983, DOI 10.1016/j.trstmh.2008.03.022; Pallangyo Pedro, 2016, J Med Case Rep, V10, P354, DOI 10.1186/s13256-016-1146-6; Paltiel M, 2004, CUTIS, V73, P241; Palumbo E, 2009, AM J THER, V16, P178, DOI 10.1097/MJT.0b013e3181822e90; Pampin A, 2017, CLIN EXP DERMATOL, V42, P348, DOI 10.1111/ced.13060; Perry JD, 2017, CLIN MICROBIOL REV, V30, P449, DOI 10.1128/CMR.00097-16; Pratlong F, 2009, TROP MED INT HEALTH, V14, P1071, DOI 10.1111/j.1365-3156.2009.02336.x; Pritzker AS, 2004, J AM ACAD DERMATOL, V50, pS38, DOI 10.1016/S0190-9622(03)02090-5; Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8; Remadi L, 2016, DERMATOLOGY, V232, P752, DOI 10.1159/000456543; RIMSZA ME, 1983, PEDIATRICS, V71, P595; Robbins K, 2010, INT J DERMATOL, V49, P1092, DOI 10.1111/j.1365-4632.2010.04577.x; ROSSI MA, 1973, AM J TROP MED HYG, V22, P267, DOI 10.4269/ajtmh.1973.22.267; Royce LA, 1999, AM J TROP MED HYG, V60, P403, DOI 10.4269/ajtmh.1999.60.403; Saab M, 2015, AM J TROP MED HYG, V92, P518, DOI 10.4269/ajtmh.14-0512; Saleem K, 2007, JCPSP-J COLL PHYSICI, V17, P650; Sasaki Yu, 2016, Kansenshogaku Zasshi, V90, P73; Sherman RA, 2000, ARCH INTERN MED, V160, P2004, DOI 10.1001/archinte.160.13.2004; Singh A, 2015, INDIAN J DERMATOL VE, V81, P29, DOI 10.4103/0378-6323.148562; SLATER CA, 1994, NEW ENGL J MED, V331, P85, DOI 10.1056/NEJM199407143310204; Smith MD, 2002, ARCH PATHOL LAB MED, V126, P714; Smith SM, 2015, LANCET INFECT DIS, V15, P512, DOI 10.1016/S1473-3099(15)70146-5; Specht S, 2009, PARASITOL RES, V105, P1531, DOI 10.1007/s00436-009-1588-5; Steinberg JP, 2002, CLIN INFECT DIS, V35, pE43, DOI 10.1086/341973; Thielecke M, 2013, TRAVEL MED INFECT DI, V11, P440, DOI 10.1016/j.tmaid.2013.10.012; Trabelsi H, 2012, PATHOL BIOL, V60, P399, DOI 10.1016/j.patbio.2012.03.002; Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772; Udall DN, 2007, CLIN INFECT DIS, V44, P53, DOI 10.1086/509325; Valverde J, 2006, AM J CLIN DERMATOL, V7, P267, DOI 10.2165/00128071-200607040-00009; Verma GK, 2010, AUSTRALAS J DERMATOL, V51, P52, DOI 10.1111/j.1440-0960.2009.00594.x; Visvesvara GS, 2007, FEMS IMMUNOL MED MIC, V50, P1, DOI 10.1111/j.1574-695X.2007.00232.x; Visvesvara GS, 2010, CURR OPIN INFECT DIS, V23, P590, DOI 10.1097/QCO.0b013e32833ed78b; Wadhwa V, 2006, Indian J Med Microbiol, V24, P70; Walton SF, 2007, CLIN MICROBIOL REV, V20, P268, DOI 10.1128/CMR.00042-06; Winsett F, 2017, DERMATOL ONLINE J, V23, P3; Yadav Suresh, 2014, J Nat Sci Biol Med, V5, P194, DOI 10.4103/0976-9668.127327; Zammarchi L, 2014, ANN DERMATOL, V26, P632, DOI 10.5021/ad.2014.26.5.632; ZIMMERMAN PA, 1994, J INFECT DIS, V169, P686, DOI 10.1093/infdis/169.3.686; Zoure HGM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001210	140	2	2	2	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					106	123		10.1097/PAP.0000000000000183			18	Pathology	Pathology	FY7GZ	WOS:000427031100004	29351090				2019-10-28	
J	Heher, YK; Dintzis, SM				Heher, Yael K.; Dintzis, Suzanne M.			Disclosure of Harmful Medical Error to Patients: A Review With Recommendations for Pathologists	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						patient safety; error; disclosure; apology; pathology error; quality improvement	SURGICAL PATHOLOGY; ADVERSE EVENTS; SAFETY; LIABILITY; IMPLEMENTATION; PHYSICIANS; PROGRAM; COMMUNICATION; HOSPITALS; ATTITUDES	Harmful error is an infrequent but serious challenge in the pathology laboratory. Regulatory bodies and advocacy groups have mandated and encouraged disclosure of error to patients. Many pathologists are interested in participating in disclosure of harmful error but are ill-equipped to do so. This review of the literature with recommendations examines the current state of the patient safety movement and error disclosure as it pertains to pathology and provides a practical and explicit guide for pathologists for who, when, and how to disclose harmful pathology error to patients. The authors provide a definition of harmful pathology error, and the rationale and principles behind effective disclosure are discussed. The changing culture of medicine and its effect on pathology is examined including the trend towards increasing transparency and patient engagement. Related topics are addressed including the management of expected adverse events, barriers to disclosure, and additional resources for the implementation of disclosure programs in pathology.	[Heher, Yael K.; Dintzis, Suzanne M.] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Heher, Yael K.; Dintzis, Suzanne M.] Harvard Med Sch, Boston, MA USA; [Heher, Yael K.; Dintzis, Suzanne M.] Univ Washington, Med Ctr, Seattle, WA 98195 USA	Heher, YK (reprint author), Beth Israel Deaconess Med Ctr, Dept Pathol FN201, Qual & Safety, 330 Brookline Ave, Boston, MA 02215 USA.	ykheher@bidmc.harvard.edu					Bell SK, 2017, BMJ QUAL SAF, V26, P312, DOI 10.1136/bmjqs-2016-006020; Bell SK, 2017, BMJ QUAL SAF, V26, P262, DOI 10.1136/bmjqs-2015-004697; Bell SK, 2012, MILBANK Q, V90, P682, DOI 10.1111/j.1468-0009.2012.00679.x; Boothman RC, 2016, HEALTH SERV RES, V51, P2487, DOI 10.1111/1475-6773.12626; Boothman Richard C, 2012, Front Health Serv Manage, V28, P13; Borges JL, 1999, SELECTED NONFICTIONS, P23; Cardona DM, 2017, ARCH PATHOL LAB MED, V141, P741, DOI 10.5858/arpa.2017-0047-ED; Conway J, 2011, IHI INNOVATION SERIE; Cooper K, 2006, ARCH PATHOL LAB MED, V130, P607; Dekker S, 2007, JUST CULTURE BALANCI; Dintzis Suzanne, 2016, AMA J Ethics, V18, P802, DOI 10.1001/journalofethics.2016.18.8.medu1-1608; Dintzis SM, 2017, ARCH PATHOL LAB MED, V141, P841, DOI 10.5858/arpa.2016-0136-OA; Dintzis SM, 2011, AM J CLIN PATHOL, V135, P760, DOI 10.1309/AJCPJF1YUFG6GTFI; Dintzis SM, 2009, AM J CLIN PATHOL, V131, P463, DOI 10.1309/AJCPIO5SHDOD6URI; Etchegaray JM, 2016, HEALTH SERV RES, V51, P2600, DOI 10.1111/1475-6773.12593; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; Gallagher TH, 2007, NEW ENGL J MED, V356, P2713, DOI 10.1056/NEJMra070568; Gallagher TH, 2006, ARCH INTERN MED, V166, P1585, DOI 10.1001/archinte.166.15.1585; Gallagher TH, 2016, HEALTH SERV RES, V51, P2537, DOI 10.1111/1475-6773.12601; Gallagher TH, 2013, NEW ENGL J MED, V369, P1752, DOI 10.1056/NEJMsb1303119; Grober ED, 2005, CAN J SURG, V48, P39; Heher YK, 2017, CANCER CYTOPATHOL, V125, P79, DOI 10.1002/cncy.21819; Helmchen LA, 2016, HEALTH SERV RES, V51, P2516, DOI 10.1111/1475-6773.12610; Iedema R, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4423; Kachalia A, 2010, ANN INTERN MED, V153, P213, DOI 10.7326/0003-4819-153-4-201008170-00002; Kaldjian LC, 2008, ARCH INTERN MED, V168, P40, DOI 10.1001/archinternmed.2007.12; Kohn L, 2000, ERR IS HUMAN BUILDIN; Lambert BL, 2016, HEALTH SERV RES, V51, P2491, DOI 10.1111/1475-6773.12548; Mello MM, 2017, NEW ENGL J MED, V376, P1806, DOI 10.1056/NEJMp1701174; Mello MM, 2010, HEALTH AFFAIR, V29, P1569, DOI 10.1377/hlthaff.2009.0807; Nakhleh RE, 2008, ARCH PATHOL LAB MED, V132, P181, DOI 10.1043/1543-2165(2008)132[181:PSAERI]2.0.CO;2; Nakhleh RG, 2015, ERROR REDUCTION PREV; National Academies of Sciences Engineering and Medicine, 2015, IMPR DIAGN HLTH CAR; National Patient Safety Foundation, 2015, RCA2 IMPR ROOT CAUS; Powell SK, 2006, PROF CASE MANAG, V11, P193; Reason J, 2000, BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J, 1997, MANAGING RISKS ORG A; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Truog R. D., 2010, TALKING PATIENTS FAM; Wu AW, 2000, BRIT MED J, V320, P726, DOI 10.1136/bmj.320.7237.726; Zarbo RJ, 2005, ARCH PATHOL LAB MED, V129, P1237	41	1	1	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					124	130		10.1097/PAP.0000000000000181			7	Pathology	Pathology	FY7GZ	WOS:000427031100005	29356714				2019-10-28	
J	Felsenstein, M; Hruban, RH; Wood, LD				Felsenstein, Matthaeus; Hruban, Ralph H.; Wood, Laura D.			New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						pancreatic cancer; pancreatic ductal adenocarcinoma; cancer genome; next-generation sequencing; somatic mutation	K-RAS MUTATIONS; CIRCULATING TUMOR DNA; PHASE-III TRIAL; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; PASSENGER MUTATIONS; CLONAL EVOLUTION; STEM-CELL; GENOMIC INSTABILITY	Pancreatic cancer is an aggressive disease with a dismal prognosis in dire need of novel diagnostic and therapeutic approaches. The past decade has witnessed an explosion of data on the genetic alterations that occur in pancreatic cancer, as comprehensive next-generation sequencing analyses have been performed on samples from large cohorts of patients. These studies have defined the genomic landscape of this disease and identified novel candidates whose mutations contribute to pancreatic tumorigenesis. They have also clarified the genetic alterations that underlie multistep tumorigenesis in precursor lesions and provided insights into clonal evolution in pancreatic neoplasia. In addition to these important insights into pancreatic cancer biology, these large scale genomic studies have also provided a foundation for the development of novel early detection strategies and targeted therapies. In this review, we discuss the results of these comprehensive sequencing studies of pancreatic neoplasms, with a particular focus on how their results will impact the clinical care of patients with pancreatic cancer.	[Felsenstein, Matthaeus; Hruban, Ralph H.; Wood, Laura D.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, CRB2 Room 345,1550 Orleans St, Baltimore, MD 21231 USA	Wood, LD (reprint author), Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, CRB2 Room 345,1550 Orleans St, Baltimore, MD 21231 USA.	ldwood@jhmi.edu			NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA62924]; NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK107781]; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees); Personal Genome Diagnostics	Supported by NIH/NCI P50 CA62924; NIH/NIDDK K08 DK107781; Sol Goldman Pancreatic Cancer Research Center; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; AGA-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research; Rolfe Pancreatic Cancer Foundation; Joseph C Monastra Foundation; The Gerald O Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees).; Dr. Wood is a paid consultant for Personal Genome Diagnostics. The remaining authors have no funding or conflicts of interest to disclose.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Al-Sukhni W, 2012, J GASTROINTEST SURG, V16, P771, DOI 10.1007/s11605-011-1781-6; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Amato E, 2014, J PATHOL, V233, P217, DOI 10.1002/path.4344; American Cancer Society, 2017, CANC FACTS FIG 2015; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barber LJ, 2013, J PATHOL, V229, P422, DOI 10.1002/path.4140; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Bodoky G, 2012, INVEST NEW DRUG, V30, P1216, DOI 10.1007/s10637-011-9687-4; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bournet B, 2015, J CLIN GASTROENTEROL, V49, P50, DOI 10.1097/MCG.0000000000000053; Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; CALDAS C, 1994, CANCER RES, V54, P3568; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Canto MI, 2006, CLIN GASTROENTEROL H, V4, P766, DOI 10.1016/j.cgh.2006.02.005; Canto MI, 2013, GUT, V62, P339, DOI 10.1136/gutjnl-2012-303108; Canto MI, 2012, GASTROENTEROLOGY, V142, P796, DOI 10.1053/j.gastro.2012.01.005; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48; Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Chetty R, 2006, HUM PATHOL, V37, P212, DOI 10.1016/j.humpath.2005.11.002; Chiou SH, 2015, GENE DEV, V29, P1576, DOI 10.1101/gad.264861.115; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Cowley MJ, 2013, J HEPATO-BIL-PAN SCI, V20, P549, DOI 10.1007/s00534-013-0610-6; Crippa S, 2016, SURGERY, V159, P1041, DOI 10.1016/j.surg.2015.11.003; Dal Molin M, 2015, CLIN CANCER RES, V21, P1944, DOI 10.1158/1078-0432.CCR-14-2600; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Dreyer SB, 2017, CLIN CANCER RES, V23, P1638, DOI 10.1158/1078-0432.CCR-16-2411; Eshleman JR, 2015, CLIN GASTROENTEROL H, V13, P963, DOI 10.1016/j.cgh.2014.11.028; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Feigin ME, 2017, NAT GENET, V49, P825, DOI 10.1038/ng.3861; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Gatenby RA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6499; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Golan T, 2017, BRIT J CANCER, V116, P697, DOI 10.1038/bjc.2017.19; Gopinathan A, 2015, DIS MODEL MECH, V8, P1185, DOI 10.1242/dmm.021055; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Griffin JF, 2017, PANCREATOLOGY, V17, P490, DOI 10.1016/j.pan.2017.04.003; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hosoda W, 2017, J PATHOL, V242, P16, DOI 10.1002/path.4884; Hosoda Waki, 2016, Surg Pathol Clin, V9, P685, DOI 10.1016/j.path.2016.05.011; Hruban Ralph H, 2010, Adv Surg, V44, P293; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Huang L, 2015, NAT MED, V21, P1364, DOI 10.1038/nm.3973; Inagawa Y, 2014, CARCINOGENESIS, V35, P1840, DOI 10.1093/carcin/bgu112; Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kameta E, 2016, ONCOL LETT, V12, P3875, DOI 10.3892/ol.2016.5168; Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0; Kamphues C, 2015, PANCREAS, V44, P296, DOI 10.1097/MPA.0000000000000248; Kanda M, 2013, CLIN GASTROENTEROL H, V11, P719, DOI 10.1016/j.cgh.2012.11.016; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kisiel JB, 2015, CLIN CANCER RES, V21, P4473, DOI 10.1158/1078-0432.CCR-14-2469; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Klein F, 2017, ANTICANCER RES, V37, P735, DOI 10.21873/anticanres.11371; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Laffan TA, 2008, AM J ROENTGENOL, V191, P802, DOI 10.2214/AJR.07.3340; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Ledford H, 2015, NATURE, V520, P278, DOI 10.1038/520278a; Lee J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14686; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Lennon AM, 2014, CANCER RES, V74, P3381, DOI 10.1158/0008-5472.CAN-14-0734; Loeb LA, 2011, NAT REV CANCER, V11, P450, DOI 10.1038/nrc3063; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664; Matthaei H, 2014, AM J SURG PATHOL, V38, P360, DOI 10.1097/PAS.0000000000000117; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; McFarland CD, 2013, P NATL ACAD SCI USA, V110, P2910, DOI 10.1073/pnas.1213968110; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Miyabayashi K, 2013, CANCER RES, V73, P2221, DOI 10.1158/0008-5472.CAN-12-1453; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Nagpal G, 2014, SCI REP-UK, V4, DOI 10.1038/srep04197; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Noe Michael, 2016, Surg Pathol Clin, V9, P561, DOI 10.1016/j.path.2016.05.004; Nones K, 2014, INT J CANCER, V135, P1110, DOI 10.1002/ijc.28765; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Oshima M, 2013, ANN SURG, V258, P336, DOI 10.1097/SLA.0b013e3182827a65; Pietrasz D, 2017, CLIN CANCER RES, V23, P116, DOI 10.1158/1078-0432.CCR-16-0806; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; REDSTON MS, 1994, CANCER RES, V54, P3025; Reiter JG, 2017, NAT REV GASTRO HEPAT, V14, P7, DOI 10.1038/nrgastro.2016.190; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roberts NJ, 2016, CANCER DISCOV, V6, P166, DOI 10.1158/2159-8290.CD-15-0402; Roberts NJ, 2013, CANCER LETT, V340, P227, DOI 10.1016/j.canlet.2012.11.008; Roberts NJ, 2012, CANCER DISCOV, V2, P41, DOI 10.1158/2159-8290.CD-11-0194; Rode A, 2016, INT J CANCER, V138, P2322, DOI 10.1002/ijc.29888; Ruijs MWG, 2010, J MED GENET, V47, P421, DOI 10.1136/jmg.2009.073429; Russell R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8677; Sadakari Y, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2014.14; Sausen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8686; Schultz NA, 2012, PANCREAS, V41, P759, DOI 10.1097/MPA.0b013e31823cd9df; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Spira A, 2017, CANCER RES, V77, P1510, DOI 10.1158/0008-5472.CAN-16-2346; Springer S, 2015, GASTROENTEROLOGY, V149, P1501, DOI 10.1053/j.gastro.2015.07.041; Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tan AC, 2009, MOL ONCOL, V3, P425, DOI 10.1016/j.molonc.2009.03.004; Tanaka M, 2012, PANCREATOLOGY, V12, P183, DOI 10.1016/j.pan.2012.04.004; Tang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep13563; Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Valsangkar NP, 2012, SURGERY, V152, pS4, DOI 10.1016/j.surg.2012.05.033; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; Verna EC, 2010, CLIN CANCER RES, V16, P5028, DOI 10.1158/1078-0432.CCR-09-3209; Villarroel MC, 2011, MOL CANCER THER, V10, P3, DOI 10.1158/1535-7163.MCT-10-0893; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wang JP, 2015, ONCOTARGET, V6, P18162, DOI 10.18632/oncotarget.4216; Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111; Wang WY, 2007, J CLIN ONCOL, V25, P1417, DOI 10.1200/JCO.2006.09.2452; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002; Williams MJ, 2016, NAT GENET, V48, P238, DOI 10.1038/ng.3489; Wilson CH, 2010, ONCOGENE, V29, P4567, DOI 10.1038/onc.2010.202; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Wu S, 2016, NATURE, V529, P43, DOI 10.1038/nature16166; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yi JM, 2013, CLIN CANCER RES, V19, P6544, DOI 10.1158/1078-0432.CCR-12-3224; Young G, 2013, CANCER CYTOPATHOL, V121, P688, DOI 10.1002/cncy.21338; Yu J, 2017, GUT, V66, P1677, DOI 10.1136/gutjnl-2015-311166; Yu J, 2015, GUT, V64, P1783, DOI 10.1136/gutjnl-2014-308653; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129	166	6	6	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					131	142		10.1097/PAP.0000000000000172			12	Pathology	Pathology	FY7GZ	WOS:000427031100006	28914620	Green Accepted			2019-10-28	
J	Guo, L; Wang, Z; Anderson, CM; Doolittle, E; Kernag, S; Cotta, CV; Ondrejka, SL; Ma, XJ; Cook, JR				Guo, Ling; Wang, Zhen; Anderson, Courtney M.; Doolittle, Emerald; Kernag, Siobhan; Cotta, Claudiu V.; Ondrejka, Sarah L.; Ma, Xiao-Jun; Cook, James R.			Ultrasensitive automated RNA in situ hybridization for kappa and lambda light chain mRNA detects B-cell clonality in tissue biopsies with performance comparable or superior to flow cytometry	MODERN PATHOLOGY			English	Article							PARAFFIN-EMBEDDED-TISSUES; LYMPHOPROLIFERATIVE DISORDERS; IMMUNOGLOBULIN; EXPRESSION; CARCINOMA; IMMUNOHISTOCHEMISTRY; MALIGNANCIES; LYMPHOMAS; HPV	The assessment of B-cell clonality is a critical component of the evaluation of suspected lymphoproliferative disorders, but analysis from formalin-fixed, paraffin-embedded tissues can be challenging if fresh tissue is not available for flow cytometry. Immunohistochemical and conventional bright field in situ hybridization stains for kappa and lambda are effective for evaluation of plasma cells but are often insufficiently sensitive to detect the much lower abundance of light chains present in B-cells. We describe an ultrasensitive RNA in situ hybridization assay that has been adapted for use on an automated immunohistochemistry platform and compare results with flow cytometry in 203 consecutive tissues and 104 consecutive bone marrows. Overall, in 203 tissue biopsies, RNA in situ hybridization identified light chain-restricted B-cells in 85 (42%) vs 58 (29%) by flow cytometry. Within 83 B-cell non-Hodgkin lymphomas, RNA in situ hybridization identified restricted B-cells in 74 (89%) vs 56 (67%) by flow cytometry. B-cell clonality could be evaluated in only 23/104 (22%) bone marrow cases owing to poor RNA preservation, but evaluable cases showed 91% concordance with flow cytometry. RNA in situ hybridization allowed for recognition of biclonal/composite lymphomas not identified by flow cytometry and highlighted unexpected findings, such as coexpression of kappa and lambda RNA in 2 cases and the presence of lambda light chain RNA in a T lymphoblastic lymphoma. Automated RNA in situ hybridization showed excellent interobserver reproducibility for manual evaluation (average K=0.92), and an automated image analysis system showed high concordance (97%) with manual evaluation. Automated RNA in situ hybridization staining, which can be adopted on commonly utilized immunohistochemistry instruments, allows for the interpretation of clonality in the context of the morphological features in formalin-fixed, paraffin-embedded tissues with a clinical sensitivity similar or superior to flow cytometry.	[Guo, Ling; Wang, Zhen; Cotta, Claudiu V.; Ondrejka, Sarah L.; Cook, James R.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Lab Med, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Anderson, Courtney M.; Doolittle, Emerald; Kernag, Siobhan; Ma, Xiao-Jun] Adv Cell Diagnost, Newark, CA USA	Cook, JR (reprint author), Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Lab Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	Cookj2@ccf.org			National Cancer Institute grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [2R44CA168019-02A1]	This work was funded by the National Cancer Institute grant 2R44CA168019-02A1.	Arora K, 2016, CANCER CYTOPATHOL, V124, P203, DOI 10.1002/cncy.21629; Beck RC, 2003, DIAGN MOL PATHOL, V12, P14, DOI 10.1097/00019606-200303000-00002; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Bordeaux JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036559; Bruggemann M, 2007, LEUKEMIA, V21, P215, DOI 10.1038/sj.leu.2404481; Craig FE, 2008, BLOOD, V111, P3941, DOI 10.1182/blood-2007-11-120535; de Tute RM, 2011, HISTOPATHOLOGY, V58, P90, DOI 10.1111/j.1365-2559.2010.03703.x; Evans PAS, 2007, LEUKEMIA, V21, P207, DOI 10.1038/sj.leu.2404479; EVANS RJ, 1991, J EXP MED, V173, P305, DOI 10.1084/jem.173.2.305; GUGLIELMI P, 1991, EUR J IMMUNOL, V21, P501, DOI 10.1002/eji.1830210237; Jiwani S, 2015, INT J CLIN EXP PATHO, V8, P8536; Kim MA, 2013, HUM PATHOL, V44, P487, DOI 10.1016/j.humpath.2012.06.022; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Magro C, 2003, J CUTAN PATHOL, V30, P504, DOI 10.1034/j.1600-0560.2003.00102.x; Marshall-Taylor CE, 2002, APPL IMMUNOHISTO M M, V10, P258, DOI 10.1097/01.PAI.0000024458.81006.34; Minca EC, 2015, J CUTAN PATHOL, V42, P82, DOI 10.1111/cup.12415; National Comprehensive Cancer Network ( NCCN), 2015, NCCN CLIN PRACT GUID; Rimsza LM, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-144; Schache AG, 2013, BRIT J CANCER, V108, P1332, DOI 10.1038/bjc.2013.63; Swerdlow SH, 2013, MODERN PATHOL, V26, pS1, DOI 10.1038/modpathol.2012.177; Tubbs RR, 2013, AM J CLIN PATHOL, V140, P736, DOI 10.1309/AJCPJTWK07FSABRJ; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Virgo PF, 2012, ANN CLIN BIOCHEM, V49, P17, DOI 10.1258/acb.2011.011128; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang Z, 2013, J MOL DIAGN, V15, P210, DOI 10.1016/j.jmoldx.2012.10.003; Weiss LM, 2010, APPL IMMUNOHISTO M M, V18, P199, DOI 10.1097/PAI.0b013e3181c59a81; Xu DS, 2006, ARCH PATHOL LAB MED, V130, P853; Zaki MAA, 2011, EUR J HAEMATOL, V86, P412, DOI 10.1111/j.1600-0609.2011.01597.x	29	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					385	394		10.1038/modpathol.2017.142			10	Pathology	Pathology	FY7KC	WOS:000427040000002	29052600	Green Accepted, Bronze			2019-10-28	
J	Farshid, G; Edwards, S; Kollias, J; Gill, PG				Farshid, Gelareh; Edwards, Suzanne; Kollias, James; Gill, Peter Grantley			Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center	MODERN PATHOLOGY			English	Article							CARCINOMA IN-SITU; VACUUM-ASSISTED BIOPSY; DETECTED BREAST-LESIONS; TERM-FOLLOW-UP; CANCER RISK; MALIGNANCY; UPGRADE; TRIAL; VALIDATION; PREDICT	A needle core biopsy diagnosis of atypical ductal hyperplasia is an indication for open biopsy. The launch of randomized clinical trials of active surveillance for low-risk ductal carcinoma in situ leads to the paradoxical situation of women with low-grade ductal carcinoma in situ being observed, whereas those with atypical ductal hyperplasia have surgery. If the malignancies diagnosed after surgery for atypical ductal hyperplasia are dominated by low-risk ductal carcinoma in situ, women with atypical ductal hyperplasia may also be considered for surveillance. This 10-year prospective observational study includes women diagnosed with atypical ductal hyperplasia on core biopsy after screening mammography. We retrieved their clinical, imaging and histologic data and carried out a blind review of core biopsy histology, sub-classifying the atypical ductal hyperplasia along a spectrum from hyperplasia to ductal carcinoma in situ. Using the final surgical pathology data, we calculated: (1) The proportion and grades of ductal carcinoma in situ and invasive cancers diagnosed at open biopsy. (2) The histologic extent of the malignancy at surgery. (3) The biomarker profile and nodal status of any invasive cancers. (4) Ascertained any independent predictors of (i) any malignancy, (ii) high-risk malignancy, defined in this study as invasive cancer, or high-grade ductal carcinoma in situ, or intermediate grade ductal carcinoma in situ with any necrosis. (5) Extrapolated the above to simulate active surveillance for women with screen-detected atypical ductal hyperplasia. Between January 2005 and December 2014, 114 women, mean age 59 years (range 40-79 years) were included. Surgical pathology, available in 110 (97%), confirmed malignancy in 46 (40%). All 46 malignant cases had ductal carcinoma in situ, accompanied by invasive carcinoma in 9 (8%) women. Together, 21 (19%) women had either invasive cancer (9%), high-grade ductal carcinoma in situ (6%), or necrotizing, intermediate grade ductal carcinoma in situ (6%). Only one of nine invasive breast cancers was grade 1, 3 were multifocal, all were <= 8 mm, node negative, and ER positive but two were HER2 amplified. The mean extent of the ductal carcinoma in situ in any one specimen was 19.8 mm, median 13 mm, range 2-110 mm. Overall 32 women, 29% of the whole cohort and 70% of those 46 with malignancy, required further surgery, including mastectomy in 12 (11%). A multivariable model for predicting the likelihood of any malignancy showed a statistically significant association only with the post review subtype of atypical ductal hyperplasia, adjusting for lesion size. Independent predictors of high-risk malignancy (invasive cancer or non-low-grade ductal carcinoma in situ) were not identified. If active surveillance is adopted for screen-detected atypical ductal hyperplasia diagnosed on core biopsy, 60% of women will avoid unnecessary surgery and a further 24% would meet eligibility criteria for ductal carcinoma in situ surveillance trials. However, 18% of women will have undiagnosed invasive breast cancer or non-low-risk ductal carcinoma in situ. These women with high-risk lesions are not reliably identified pre-operatively.	[Farshid, Gelareh] Adelaide Univ, Discipline Med, BreastScreen SA, Surg Pathol, Adelaide, SA 5000, Australia; [Farshid, Gelareh] Adelaide Univ, South Australian Pathol, Frome Rd, Adelaide, SA 5000, Australia; [Farshid, Gelareh] Directorate Surg Pathol, Adelaide, SA 5000, Australia; [Edwards, Suzanne] Adelaide Univ, Sch Publ Hlth, Adelaide Hlth Technol Assessment, Adelaide, SA, Australia; [Kollias, James; Gill, Peter Grantley] Univ Adelaide, BreastScreen SA, Adelaide, SA, Australia; [Kollias, James; Gill, Peter Grantley] Univ Adelaide, Dept Surg, Adelaide, SA, Australia	Farshid, G (reprint author), Adelaide Univ, Discipline Med, BreastScreen SA, Surg Pathol, Adelaide, SA 5000, Australia.; Farshid, G (reprint author), Adelaide Univ, South Australian Pathol, Frome Rd, Adelaide, SA 5000, Australia.; Farshid, G (reprint author), Directorate Surg Pathol, Adelaide, SA 5000, Australia.	gelareh.farshid2@sa.gov.au					Allison KH, 2011, HUM PATHOL, V42, P41, DOI 10.1016/j.humpath.2010.06.011; Ancona A, 2011, RADIOL MED, V116, P276, DOI 10.1007/s11547-011-0626-9; Bendifallah S, 2012, EUR J CANCER, V48, P30, DOI 10.1016/j.ejca.2011.08.011; BreastScreen Australia B, 2015, BREASTSCREEN AUSTR A; Degnim AC, 2007, J CLIN ONCOL, V25, P2671, DOI 10.1200/JCO.2006.09.0217; Degnim AC, 2016, CANCER-AM CANCER SOC, V122, P2971, DOI 10.1002/cncr.30153; Deshaies I, 2011, BREAST, V20, P50, DOI 10.1016/j.breast.2010.06.004; Elshof LE, 2015, EUR J CANCER, V51, P1497, DOI 10.1016/j.ejca.2015.05.008; Farshid G, 2011, BRIT J CANCER, V105, P1669, DOI 10.1038/bjc.2011.466; Farshid G, 2017, BREAST CANCER RES TR, V162, P49, DOI 10.1007/s10549-016-4087-2; Farshid G, 2015, BREAST CANCER RES TR, V151, P347, DOI 10.1007/s10549-015-3388-1; Francis A, 2015, EUR J CANCER, V51, P2296, DOI 10.1016/j.ejca.2015.07.017; Gumus H, 2013, DIAGN INTERV RADIOL, V19, P91, DOI 10.4261/1305-3825.DIR.5838-12.2; Hong ZJ, 2011, EJSO-EUR J SURG ONC, V37, P758, DOI 10.1016/j.ejso.2011.06.014; Hsu HH, 2012, ULTRASCHALL MED, V33, P447, DOI 10.1055/s-0029-1245877; Khoury T, 2015, HISTOPATHOLOGY, V67, P106, DOI 10.1111/his.12635; Kim J, 2012, J BREAST CANCER, V15, P407, DOI 10.4048/jbc.2012.15.4.407; Kohr JR, 2010, RADIOLOGY, V255, P723, DOI 10.1148/radiol.09091406; Lee Andrew HS, 2016, GUIDELINES NONOPERAT; McGhan LJ, 2012, ANN SURG ONCOL, V19, P3264, DOI 10.1245/s10434-012-2575-0; Mesurolle B, 2014, AM J ROENTGENOL, V202, P1389, DOI 10.2214/AJR.13.10864; Nguyen CV, 2011, ANN SURG ONCOL, V18, P752, DOI 10.1245/s10434-010-1127-8; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; Pilewskie M, 2016, ANN SURG ONCOL, V23, P3487, DOI 10.1245/s10434-016-5268-2; Polom K, 2012, REP PRACT ONCOL RADI, V17, P129, DOI 10.1016/j.rpor.2012.03.008; Soumian S, 2013, EJSO-EUR J SURG ONC, V39, P1337, DOI 10.1016/j.ejso.2013.09.028; TAVASSOLI FA, 1990, CANCER, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O; Thomas J, 2010, BRIT J CANCER, V102, P285, DOI 10.1038/sj.bjc.6605513	28	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					395	405		10.1038/modpathol.2017.114			11	Pathology	Pathology	FY7KC	WOS:000427040000003	29099502				2019-10-28	
J	Gerdes, MJ; Gokmen-Polar, Y; Sui, YX; Pang, AS; LaPlante, N; Harris, AL; Tan, PH; Ginty, F; Badve, SS				Gerdes, Michael J.; Gokmen-Polar, Yesim; Sui, Yunxia; Pang, Alberto Santamaria; LaPlante, Nicole; Harris, Adrian L.; Tan, Puay-Hoon; Ginty, Fiona; Badve, Sunil S.			Single-cell heterogeneity in ductal carcinoma in situ of breast	MODERN PATHOLOGY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; CLINICAL ONCOLOGY/COLLEGE; INTRATUMOR HETEROGENEITY; AMERICAN SOCIETY; LOCAL RECURRENCE; CANCER; EXPRESSION; RISK; IMMUNOHISTOCHEMISTRY; RECOMMENDATIONS	Heterogeneous patterns of mutations and RNA expression have been well documented in invasive cancers. However, technological challenges have limited the ability to study heterogeneity of protein expression. This is particularly true for pre-invasive lesions such as ductal carcinoma in situ of the breast. Cell-level heterogeneity in ductal carcinoma in situ was analyzed in a single 5 mu m tissue section using a multiplexed immunofluorescence analysis of 11 disease-related markers (EGFR, HER2, HER4, S6, pmTOR, CD44v6, SLC7A5 and CD10, CD4, CD8 and CD20, plus pan-cytokeratin, pan-cadherin, DAPI, and Na+K+ATPase for cell segmentation). Expression was quantified at cell level using a single-cell segmentation algorithm. K-means clustering was used to determine co-expression patterns of epithelial cell markers and immune markers. We document for the first time the presence of epithelial cell heterogeneity within ducts, between ducts and between patients with ductal carcinoma in situ. There was moderate heterogeneity in a distribution of eight clusters within each duct (average Shannon index 0.76; range 0-1.61). Furthermore, within each patient, the average Shannon index across all ducts ranged from 0.33 to 1.02 (s.d. 0.09-0.38). As the distribution of clusters within ducts was uneven, the analysis of eight ducts might be sufficient to represent all the clusters ie within- and between-duct heterogeneity. The pattern of epithelial cell clustering was associated with the presence and type of immune infiltrates, indicating a complex interaction between the epithelial tumor and immune system for each patient. This analysis also provides the first evidence that simultaneous analysis of both the epithelial and immune/stromal components might be necessary to understand the complex milieu in ductal carcinoma in situ lesions.	[Gerdes, Michael J.; Sui, Yunxia; Pang, Alberto Santamaria; Ginty, Fiona] GE Global Res Diagnost Imaging & Biotechnol DIBT, Niskayuna, NY USA; [Gokmen-Polar, Yesim; Badve, Sunil S.] Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA; [Harris, Adrian L.] Univ Oxford, Dept Oncol, Canc & Haematol Ctr, Oxford, England; [Tan, Puay-Hoon] Singapore Gen Hosp, Div Pathol, Singapore, Singapore; [LaPlante, Nicole] Clarient NeoGen Labs, 31 Columbia, Aliso Viejo, CA 92656 USA	Gerdes, MJ; Badve, SS (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA.	gerdes@research.ge.com; sbadve@iupui.edu		Badve, Sunil/0000-0001-8861-9980; Harris, Adrian/0000-0003-1376-8409	National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA194600]; General Electric; 100 Voices of Hope and Joshua Edwards Endowed Chair	This study is supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA194600 to SS Badve and MJ Gerdes and internal funds from General Electric to F Ginty and MJ Gerdes. In addition, SS Badve is supported by 100 Voices of Hope and Joshua Edwards Endowed Chair. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Adams S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985930; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Afify A, 2008, APPL IMMUNOHISTO M M, V16, P121, DOI 10.1097/PAI.0b013e318047df6d; Altintas S, 2009, BREAST J, V15, P120, DOI 10.1111/j.1524-4741.2009.00686.x; Badve S, 1998, HUM PATHOL, V29, P915, DOI 10.1016/S0046-8177(98)90196-4; Badve S, 2015, ADV ANAT PATHOL, V22, P294, DOI 10.1097/PAP.0000000000000074; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Buckley N, 2015, ONCOTARGET, V6, P43244, DOI 10.18632/oncotarget.6525; Collins LC, 2005, MODERN PATHOL, V18, P615, DOI 10.1038/modpathol.3800360; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009; Govindan R, 2014, SCIENCE, V346, P169, DOI 10.1126/science.1259926; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI 10.1043/1543-2165-134.6.907; Hayashi K, 2017, WORLD J GASTRO ONCOL, V9, P21, DOI 10.4251/wjgo.v9.i1.21; Hollman-Hewgley D, 2014, AM J SURG PATHOL, V38, P1193, DOI 10.1097/PAS.0000000000000242; Juhasz C, 2012, NUCL MED BIOL, V39, P926, DOI 10.1016/j.nucmedbio.2012.01.010; Lari SA, 2011, J CANCER, V2, P232, DOI 10.7150/jca.2.232; Lebeau A, 2003, BREAST CANCER RES TR, V79, P187, DOI 10.1023/A:1023958324448; Lester SC, 2009, ARCH PATHOL LAB MED, V133, P13, DOI 10.1043/1543-2165-133.1.13; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Miller TJ, 2017, PATHOLOGY, V49, P24, DOI 10.1016/j.pathol.2016.09.063; Moritani S, 2002, MODERN PATHOL, V15, P397, DOI 10.1038/modpathol.3880536; Navin NE, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0452-9; Pape-Zambito D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100488; Perez EA, 2016, JAMA ONCOL, V2, P56, DOI 10.1001/jamaoncol.2015.3239; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Sidow A, 2015, TRENDS GENET, V31, P208, DOI 10.1016/j.tig.2015.02.001; Smid M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12910; Smith BD, 2015, J CLIN ONCOL, V33, P686, DOI 10.1200/JCO.2014.59.4259; Solin LJ, 2015, J CLIN ONCOL, V33, P3938, DOI 10.1200/JCO.2015.60.8588; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Sood A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87030; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Spagnolo Daniel M, 2016, J Pathol Inform, V7, P47; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Vermeulen JF, 2013, MOL IMAGING BIOL, V15, P290, DOI 10.1007/s11307-012-0605-8; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yates LR, 2012, NAT REV GENET, V13, P795, DOI 10.1038/nrg3317; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhou WJ, 2013, INT J BREAST CANCER, DOI 10.1155/2013/582134	45	6	6	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					406	417		10.1038/modpathol.2017.143			12	Pathology	Pathology	FY7KC	WOS:000427040000004	29148540	Bronze, Green Accepted			2019-10-28	
J	Griewank, KG; Wiesner, T; Murali, R; Pischler, C; Muller, H; Koelsche, C; Moller, I; Franklin, C; Cosgarea, I; Sucker, A; Schadendorf, D; Schaller, J; Horn, S; Brenn, T; Mentzel, T				Griewank, Klaus G.; Wiesner, Thomas; Murali, Rajmohan; Pischler, Carina; Mueller, Hansgeorg; Koelsche, Christian; Moeller, Inga; Franklin, Cindy; Cosgarea, Ioana; Sucker, Antje; Schadendorf, Dirk; Schaller, Joerg; Horn, Susanne; Brenn, Thomas; Mentzel, Thomas			Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles	MODERN PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; MALIGNANT FIBROUS HISTIOCYTOMA; TERT PROMOTER MUTATIONS; INDUCED P53 MUTATIONS; MELANOCYTIC TUMORS; POINT MUTATIONS; CTLA-4 BLOCKADE; PD-1 BLOCKADE; HUMAN CANCERS; CGH ANALYSIS	Atypical fibroxanthomas and pleomorphic dermal sarcomas are tumors arising in sun-damaged skin of elderly patients. They have differing prognoses and are currently distinguished using histological criteria, such as invasion of deeper tissue structures, necrosis and lymphovascular or perineural invasion. To investigate the as-yet poorly understood genetics of these tumors, 41 atypical fibroxanthomas and 40 pleomorphic dermal sarcomas were subjected to targeted next-generation sequencing approaches as well as DNA copy number analysis by comparative genomic hybridization. In an analysis of the entire coding region of 341 oncogenes and tumor suppressor genes in 13 atypical fibroxanthomas using an established hybridization-based next-generation sequencing approach, we found that these tumors harbor a large number of mutations. Gene alterations were identified in more than half of the analyzed samples in FAT1, NOTCH1/2, CDKN2A, TP53, and the TERT promoter. The presence of these alterations was verified in 26 atypical fibroxanthoma and 35 pleomorphic dermal sarcoma samples by targeted amplicon-based next-generation sequencing. Similar mutation profiles in FAT1, NOTCH1/2, CDKN2A, TP53, and the TERT promoter were identified in both atypical fibroxanthoma and pleomorphic dermal sarcoma. Activating RAS mutations (G12 and G13) identified in 3 pleomorphic dermal sarcoma were not found in atypical fibroxanthoma. Comprehensive DNA copy number analysis demonstrated a wide array of different copy number gains and losses, with similar profiles in atypical fibroxanthoma and pleomorphic dermal sarcoma. In summary, atypical fibroxanthoma and pleomorphic dermal sarcoma are highly mutated tumors with recurrent mutations in FAT1, NOTCH1/2, CDKN2A, TP53, and the TERT promoter, and a range of DNA copy number alterations. These findings suggest that atypical fibroxanthomas and pleomorphic dermal sarcomas are genetically related, potentially representing two ends of a common tumor spectrum and distinguishing these entities is at present still best performed using histological criteria.	[Griewank, Klaus G.; Moeller, Inga; Franklin, Cindy; Cosgarea, Ioana; Sucker, Antje; Schadendorf, Dirk; Horn, Susanne] Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Hufelandstr 55, D-45147 Essen, Germany; [Griewank, Klaus G.] Dermatopathol Mainz, Nieder Olm, Germany; [Wiesner, Thomas] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Murali, Rajmohan] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Pischler, Carina] Med Univ Graz, Inst Human Genet, Graz, Austria; [Mueller, Hansgeorg; Mentzel, Thomas] Dermatopathol Friedrichshafen, Friedrichshafen, Germany; [Koelsche, Christian] Heidelberg Univ, Dept Neuropathol, Heidelberg, Germany; [Koelsche, Christian] DKFZ, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Koelsche, Christian] DKFZ, DKTK, Heidelberg, Germany; [Schaller, Joerg] Dermatopathol Duisburg, Duisburg, Germany; [Brenn, Thomas] Univ Edinburgh, Western Gen Hosp, Dept Pathol, Edinburgh, Midlothian, Scotland	Griewank, KG (reprint author), Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Hufelandstr 55, D-45147 Essen, Germany.	klaus.griewank@uk-essen.de	Kolsche, Christian/Q-8854-2019; Griewank, Klaus/A-9097-2017	Brenn, Thomas/0000-0002-0089-0352; Griewank, Klaus/0000-0003-3899-9449	Mercur-Stiftung; NIH/NCI Cancer Center Support Grant [P30 CA008748]	We thank Nadine Stadler and Iris Moll for excellent technical assistance. The presented study was supported by a grant from the Mercur-Stiftung. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. The funders were not involved in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Ateenyi-Agaba C, 2004, MUTAGENESIS, V19, P399, DOI 10.1093/mutage/geh048; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x; Geigl JB, 2007, NAT PROTOC, V2, P3173, DOI 10.1038/nprot.2007.476; Griewank KG, 2014, MODERN PATHOL, V27, P502, DOI 10.1038/modpathol.2013.168; Gru AA, 2013, SEMIN DIAGN PATHOL, V30, P4, DOI 10.1053/j.semdp.2012.01.001; Hanlon A, 2017, DERMATOL SURG, V43, P431, DOI 10.1097/DSS.0000000000001000; Hartel PH, 2006, J CUTAN PATHOL, V33, P24, DOI 10.1111/j.1600-0560.2006.00492.x; Helbig D, 2016, ONCOTARGET, V7, P21763, DOI 10.18632/oncotarget.7845; Henderson MT, 2012, J AM ACAD DERMATOL, V67, P1335, DOI 10.1016/j.jaad.2012.04.013; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Iorizzo LJ, 2011, DERMATOL SURG, V37, P146, DOI 10.1111/j.1524-4725.2010.01843.x; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Krueger F., TRIM GALORE WRAPPER; Lazova R, 1997, CANCER-AM CANCER SOC, V79, P2115, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2115::AID-CNCR8>3.0.CO;2-N; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; McCalmont TH, 2012, J CUTAN PATHOL, V39, P8, DOI 10.1111/j.1600-0560.2011.01851.x; McCalmont TH, 2011, J CUTAN PATHOL, V38, P853, DOI 10.1111/j.1600-0560.2011.01802.x; McCoppin HH, 2012, DERMATOL SURG, V38, P230, DOI 10.1111/j.1524-4725.2011.02180.x; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mentzel Thomas, 2017, Surg Pathol Clin, V10, P319, DOI 10.1016/j.path.2017.01.007; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mihic-Probst D, 2004, ANTICANCER RES, V24, P19; Miller K, 2012, AM J SURG PATHOL, V36, P1317, DOI 10.1097/PAS.0b013e31825359e1; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Nowell CS, 2017, NAT REV CANCER, V17, P145, DOI 10.1038/nrc.2016.145; OZZELLO L, 1963, CANCER-AM CANCER SOC, V16, P331, DOI 10.1002/1097-0142(196303)16:3<331::AID-CNCR2820160307>3.0.CO;2-F; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Sakamoto A, 2001, HUM PATHOL, V32, P1225, DOI 10.1053/hupa.2001.28953; Sakamoto A, 2001, MODERN PATHOL, V14, P581, DOI 10.1038/modpathol.3880354; Sanchez-Martin M, 2017, BLOOD, V129, P1124, DOI 10.1182/blood-2016-09-692582; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; TOS APD, 1994, AM J PATHOL, V145, P11; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van de Nes J, 2016, J NEURO-ONCOL, V127, P435, DOI 10.1007/s11060-015-2052-2; Wang NJ, 2011, P NATL ACAD SCI USA, V108, P17761, DOI 10.1073/pnas.1114669108; Wiesner T, 2011, NAT GENET, V43, P1018, DOI 10.1038/ng.910; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	54	10	10	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					418	428		10.1038/modpathol.2017.146			11	Pathology	Pathology	FY7KC	WOS:000427040000005	29099504	Bronze			2019-10-28	
J	Chapman, J; Geyer, JT; Khanlari, M; Moul, A; Casas, C; Connor, ST; Fan, YS; Watts, JM; Swords, RT; Vega, F; Orazi, A				Chapman, Jennifer; Geyer, Julia T.; Khanlari, Mahsa; Moul, Adrienne; Casas, Carmen; Connor, Scot T.; Fan, Yao-Shan; Watts, Justin M.; Swords, Ronan T.; Vega, Francisco; Orazi, Attilio			Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia	MODERN PATHOLOGY			English	Article							MONOCYTOSIS; RUXOLITINIB; DISEASE; PHASE	Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification. In contrast, at presentation, rare cases have clinical, morphologic, and molecular genetic features truly intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. The taxonomy and natural history of these diseases are unclear. We identified cases which either: (1) fulfilled the 2008 World Health Organization criteria for primary myelofibrosis but had absolute monocytosis and, when available, chronic myelomonocytic leukemia-related mutations (ASXL1, SRSF2, TET2) or (2) fulfilled criteria of chronic myelomonocytic leukemia but had megakaryocytic proliferation and atypia, marrow fibrosis, and myeloproliferative-type driver mutations (JAK2, MPL, CALR). Patients with established primary myelofibrosis who developed monocytosis and those with chronic myelomonocytic leukemia with marrow fibrosis were excluded. By combining the pathology databases of two large institutions, six eligible cases were identified. Patients were predominantly male and elderly with monocytosis at diagnosis (average 17.5%/ 2.3 x 10(3)/mu l), organomegaly, primary myelofibrosis-like atypical megakaryocytes admixed with a variable number of chronic myelomonocytic leukemia-like hypolobated forms, variable myelodysplasia, marrow fibrosis and osteosclerosis. All had a normal karyotype and no myelodysplasia-associated cytogenetic abnormalities. Five of the patients in whom a more extensive molecular characterization was performed showed co-mutations involving JAK2 or MPL and ASXL1, SRSF2, TET2, NRAS, and/or KRAS. Disease progression has occurred in all and two have died. Rare patients present with features that overlap between primary myelofibrosis and chronic myelomonocytic leukemia and are thus difficult to classify based on current World Health Organization criteria. Biologically, these cases likely represent primary myelofibrosis with monocytosis, dysplasia, and secondary (non-driver) mutations at presentation. Alternatively, they may represent a true gray zone of neoplasms. Their clinical behavior appears aggressive and innovative therapeutic approaches may be beneficial in this particular subset.	[Chapman, Jennifer; Khanlari, Mahsa; Moul, Adrienne; Vega, Francisco] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Hematopathol, Miami, FL 33136 USA; [Geyer, Julia T.; Orazi, Attilio] Weill Cornell Med, Dept Pathol & Lab Med, Div Immunopathol, New York, NY USA; [Casas, Carmen; Connor, Scot T.; Fan, Yao-Shan] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Cytogenet, Miami, FL 33136 USA; [Watts, Justin M.; Swords, Ronan T.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Div Hematol & Oncol, Miami, FL 33136 USA	Chapman, J (reprint author), Univ Miami, Sylvester Comprehens Canc Ctr, Univ Miami Hosp, Div Hematopathol,Dept Pathol, 1400 NW 12th Ave,Suite 4046, Miami, FL 33136 USA.	jchapman@med.miami.edu					Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Boiocchi L, 2013, MODERN PATHOL, V26, P204, DOI 10.1038/modpathol.2012.165; Elliott MA, 2007, LEUKEMIA RES, V31, P1503, DOI 10.1016/j.leukres.2006.12.025; Francke S, 2017, LEUKEMIA LYMPHOMA, V58, P1271, DOI 10.1080/10428194.2016.1225209; Kong GY, 2014, J CLIN INVEST, V124, P2762, DOI 10.1172/JCI74182; Li B, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1942.1942; McGowan-Jordan J, 2016, ISCN 2016 INT SYSTEM; Nazha A, 2016, BLOOD REV, V30, P381, DOI 10.1016/j.blre.2016.04.006; Orazi A, 2008, WHO CLASSIFICATION T, P76; Orazi A, 2006, MODERN PATHOL, V19, P1536, DOI 10.1038/modpathol.3800707; Padron E, 2016, CLIN CANCER RES, V22, P3746, DOI 10.1158/1078-0432.CCR-15-2781; Patnaik MM, 2014, LEUKEMIA, V28, P2206, DOI 10.1038/leu.2014.125; Rozovski U, 2017, HAEMATOLOGICA, V102, P79, DOI 10.3324/haematol.2016.149765; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940	14	6	6	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					429	441		10.1038/modpathol.2017.148			13	Pathology	Pathology	FY7KC	WOS:000427040000006	29192651	Bronze			2019-10-28	
J	Stueck, AE; Schiano, TD; Fiel, MI				Stueck, Ashley E.; Schiano, Thomas D.; Fiel, M. Isabel			Development of a novel histologic diagnostic algorithm for hepatic graft-versus-host disease	MODERN PATHOLOGY			English	Article							BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; MINOR HISTOCOMPATIBILITY BARRIERS; CONSENSUS DEVELOPMENT PROJECT; DONOR LYMPHOCYTE INFUSION; MATCHED SIBLING DONORS; WORKING GROUP-REPORT; HUMAN RECIPIENTS; CLINICAL-TRIALS; LIVER-BIOPSY	The histopathologic diagnosis of hepatic graft-versus-host disease post bone marrow and stem cell transplantation can be challenging, but timely and unambiguous diagnosis is essential for appropriate patient management. To address this diagnostic dilemma, we identified histologic features specific for hepatic graft-versus-host disease and developed a diagnostic algorithm. Two hepatopathologists blindly evaluated 40 liver biopsies from patients with clinically and biologically confirmed graft-versus-host disease, as well as 44 controls, for percent bile duct loss, bile duct damage, intraepithelial lymphocytes, ductular reaction, acidophilic bodies/10 high power fields (HPF), cholestasis, portal and lobular inflammation, and endotheliitis. Compared with controls, graft-versus-host disease cases had significantly more bile duct loss (P < 0.0001), bile duct damage (P=0.0002), cholestasis (P < 0.0001), and acidophilic bodies/10 HPF (P=0.0006), as well as significantly less ductular reaction (P < 0.0001). Significance was maintained with a drug-induced liver injury-only control group. No histologic differences were noted in acute versus chronic graft-versus-host disease, nor cholestatic versus hepatitic types. An algorithm to predict likelihood of graft-versus-host disease was developed, with a three-tiered scoring system: 1-2 not, 3-4 probable, and 5-8 unequivocal graft-versus-host disease. This algorithm had a sensitivity of 93%, specificity of 93%, and accuracy of 92%. We identified histologic features with specificity for hepatic graft-versus-host disease and developed a simple algorithm for pathologists to predict its likelihood, distinguishing this critical diagnosis promptly from mimickers having vastly different treatments and prognoses.	[Stueck, Ashley E.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Schiano, Thomas D.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA; [Fiel, M. Isabel] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA	Stueck, AE (reprint author), Dalhousie Univ, Nova Scotia Hlth Author, 715-5788 Univ Ave, Halifax, NS B3H 2Y9, Canada.	Ashley.stueck@dal.ca					Akpek G, 2002, BLOOD, V100, P3903, DOI 10.1182/blood-2002-03-0857; ANDERSEN CB, 1993, TRANSPLANT P, V25, P1250; Beleoken E, 2013, HEPATOLOGY, V57, P689, DOI 10.1002/hep.26024; BERMAN MD, 1980, J CLIN GASTROENTEROL, V2, P53, DOI 10.1097/00004836-198003000-00009; BERNUAU D, 1980, TRANSPLANTATION, V29, P236, DOI 10.1097/00007890-198003000-00015; BESCHORNER WE, 1980, AM J PATHOL, V99, P369; Chiba T, 2005, HEPATO-GASTROENTEROL, V52, P1849; Chiba T, 2002, LIVER, V22, P514, DOI 10.1034/j.1600-0676.2002.01734.x; Davern TJ, 2011, GASTROENTEROLOGY, V141, P1665, DOI 10.1053/j.gastro.2011.07.051; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Duarte RF, 2005, BIOL BLOOD MARROW TR, V11, P805, DOI 10.1016/j.bbmt.2005.06.008; Fujii N, 2001, BONE MARROW TRANSPL, V27, P1007, DOI 10.1038/sj.bmt.1702997; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Han MAT, 2016, HEPATOLOGY, V64, p182A; Han MAT, 2015, HEPATOLOGY, V62, p1251A; Itoh S, 2000, J GASTROEN HEPATOL, V15, P443, DOI 10.1046/j.1440-1746.2000.02068.x; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Kambham N, 2014, ADV ANAT PATHOL, V21, P301, DOI 10.1097/PAP.0000000000000032; Kim BK, 2000, BONE MARROW TRANSPL, V26, P193, DOI 10.1038/sj.bmt.1702453; LERNER KG, 1974, TRANSPLANT P, V6, P367; Ma SY, 2004, BONE MARROW TRANSPL, V34, P57, DOI 10.1038/sj.bmt.1704522; Maeng H, 2004, INT J HEMATOL, V79, P501, DOI 10.1532/IJH97.A10319; Miglio F, 1989, Prog Clin Biol Res, V309, P239; Mori T, 2005, INT J HEMATOL, V81, P174, DOI 10.1532/IJH97.04159; NONOMURA A, 1991, LIVER, V11, P278; NONOMURA A, 1991, LIVER, V11, P149; Quaglia A, 2007, HISTOPATHOLOGY, V50, P727, DOI 10.1111/j.1365-2559.2007.02679.x; SHULMAN HM, 1988, HEPATOLOGY, V8, P463, DOI 10.1002/hep.1840080305; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; SNOVER DC, 1984, HEPATOLOGY, V4, P123, DOI 10.1002/hep.1840040122; Stift J, 2014, VIRCHOWS ARCH, V464, P175, DOI 10.1007/s00428-013-1528-8; Strasser SI, 2000, HEPATOLOGY, V32, P1265, DOI 10.1053/jhep.2000.20067; SUZUKI K, 1994, LAB INVEST, V70, P609; Vierling John M, 2011, Trans Am Clin Climatol Assoc, V122, P326	34	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					442	451		10.1038/modpathol.2017.151			10	Pathology	Pathology	FY7KC	WOS:000427040000007	29192646				2019-10-28	
J	Church, AJ; Calicchio, ML; Nardi, V; Skalova, A; Pinto, A; Dillon, DA; Gomez-Fernandez, CR; Manoj, N; Haimes, JD; Stahl, JA; Dela Cruz, FS; Tannenbaum-Dvir, S; Glade-Bender, JL; Kung, AL; DuBois, SG; Kozakewich, HP; Janeway, KA; Perez-Atayde, AR; Harris, MH				Church, Alanna J.; Calicchio, Monica L.; Nardi, Valentina; Skalova, Alena; Pinto, Andre; Dillon, Deborah A.; Gomez-Fernandez, Carmen R.; Manoj, Namitha; Haimes, Josh D.; Stahl, Joshua A.; Dela Cruz, Filemon S.; Tannenbaum-Dvir, Sarah; Glade-Bender, Julia L.; Kung, Andrew L.; DuBois, Steven G.; Kozakewich, Harry P.; Janeway, Katherine A.; Perez-Atayde, Antonio R.; Harris, Marian H.			Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy	MODERN PATHOLOGY			English	Article							ETV6-NTRK3 GENE FUSION; ANALOG SECRETORY CARCINOMA; MOLECULAR-DETECTION; TRANSCRIPTS; IDENTIFICATION; CHEMOTHERAPY; DIAGNOSIS; FEATURES	Infantile fibrosarcoma and congenital mesoblastic nephroma are tumors of infancy traditionally associated with the ETV6-NTRK3 gene fusion. However, a number of case reports have identified variant fusions in these tumors. In order to assess the frequency of variant NTRK3 fusions, and in particular whether the recently identified EML4-NTRK3 fusion is recurrent, 63 archival cases of infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analog secretory carcinoma and secretory breast carcinoma (tumor types that are known to carry recurrent ETV6-NTRK3 fusions) were tested with NTRK3 break-apart FISH, EML4-NTRK3 dual fusion FISH, and targeted RNA sequencing. The EML4-NTRK3 fusion was identified in two cases of infantile fibrosarcoma ( one of which was previously described), and in one case of congenital mesoblastic nephroma, demonstrating that the EML4-NTRK3 fusion is a recurrent genetic event in these related tumors. The growing spectrum of gene fusions associated with infantile fibrosarcoma and congenital mesoblastic nephroma along with the recent availability of targeted therapies directed toward inhibition of NTRK signaling argue for alternate testing strategies beyond ETV6 break- part FISH. The use of either NTRK3 FISH or next-generation sequencing will expand the number of cases in which an oncogenic fusion is identified and facilitate optimal diagnosis and treatment for patients.	[Church, Alanna J.; Kozakewich, Harry P.; Perez-Atayde, Antonio R.; Harris, Marian H.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Church, Alanna J.; Nardi, Valentina; Dillon, Deborah A.; DuBois, Steven G.; Kozakewich, Harry P.; Janeway, Katherine A.; Perez-Atayde, Antonio R.; Harris, Marian H.] Harvard Med Sch, Boston, MA USA; [Calicchio, Monica L.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Nardi, Valentina] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Skalova, Alena] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Pinto, Andre] Univ Miami, Dept Pathol, Miami, FL USA; [Dillon, Deborah A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Manoj, Namitha; Haimes, Josh D.; Stahl, Joshua A.; Kung, Andrew L.] ArcherDX, Boulder, CO USA; [Dela Cruz, Filemon S.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA; [Tannenbaum-Dvir, Sarah; Glade-Bender, Julia L.] Columbia Univ, Med Ctr, Div Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY USA; [DuBois, Steven G.; Janeway, Katherine A.] Dana Farber Boston Childrens Canc, Dept Pediat Hematol Oncol, Boston, MA USA; [DuBois, Steven G.; Janeway, Katherine A.] Blood Disorders Ctr, Boston, MA USA	Harris, MH (reprint author), Boston Childrens Hosp, Dept Pathol, Lab Mol Pediat Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	Marian.Harris@childrens.harvard.edu	Harris, Marian/R-7049-2019	Glade Bender, Julia/0000-0001-5316-6440			Adem C, 2001, MODERN PATHOL, V14, P1246, DOI 10.1038/modpathol.3880469; Argani P, 2000, MODERN PATHOL, V13, P29, DOI 10.1038/modpathol.3880006; Argani P, 2001, AM J SURG PATHOL, V25, P1461, DOI 10.1097/00000478-200111000-00021; BLOCKER S, 1987, J PEDIATR SURG, V22, P665, DOI 10.1016/S0022-3468(87)80123-9; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; CHUNG EB, 1976, CANCER, V38, P729, DOI 10.1002/1097-0142(197608)38:2<729::AID-CNCR2820380216>3.0.CO;2-Z; COFFIN CM, 1994, PEDIATR PATHOL, V14, P133, DOI 10.3109/15513819409022033; Coulibaly B, 2008, PRENATAL DIAG, V28, P773, DOI 10.1002/pd.2036; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Dubus P, 2001, J PATHOL, V193, P88; Gadd S, 2012, J PATHOL, V228, P119, DOI 10.1002/path.4010; GRIER HE, 1985, CANCER-AM CANCER SOC, V56, P1507, DOI 10.1002/1097-0142(19851001)56:7<1507::AID-CNCR2820560705>3.0.CO;2-7; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Krings G, 2017, MODERN PATHOL, V30, P1086, DOI 10.1038/modpathol.2017.32; Laetsch TW, 2017, J CLIN ONCOL, P10510; Lannon CL, 2004, J BIOL CHEM, V279, P6225, DOI 10.1074/jbc.M307388200; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Loh ML, 2002, J PEDIAT HEMATOL ONC, V24, P722, DOI 10.1097/00043426-200212000-00008; Malkan AD, 2015, PEDIATRICS, V135, P142, DOI 10.1542/peds.2014-1011; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Moreau P, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.975.975; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Orbach D, 2010, J CLIN ONCOL, V28, P318, DOI 10.1200/JCO.2009.21.9972; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SALLOUM E, 1990, MED PEDIATR ONCOL, V18, P295, DOI 10.1002/mpo.2950180408; Seethala RR, 2017, AM J SURG PATHOL, V41, P446, DOI 10.1097/PAS.0000000000000814; Sheng WQ, 2001, AM J CLIN PATHOL, V115, P348; Shukla N, 2017, JCO PRECISION ONCOL; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; SOULE EH, 1977, CANCER-AM CANCER SOC, V40, P1711, DOI 10.1002/1097-0142(197710)40:4<1711::AID-CNCR2820400447>3.0.CO;2-9; Tannenbaum-Dvir S, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000471; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Wong V, 2015, JNCI-J NATL CANCER I, V108, P1	38	22	23	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					463	473		10.1038/modpathol.2017.127			11	Pathology	Pathology	FY7KC	WOS:000427040000009	29099503	Bronze			2019-10-28	
J	Larsen, CP; Wilson, JD; Best-Rocha, A; Beggs, ML; Hennigar, RA				Larsen, Christopher P.; Wilson, Jon D.; Best-Rocha, Alejandro; Beggs, Marjorie L.; Hennigar, Randolph A.			Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy	MODERN PATHOLOGY			English	Article							HEMOLYTIC-UREMIC SYNDROME; MALIGNANT HYPERTENSION; THROMBOTIC MICROANGIOPATHY; AHUS; ABNORMALITIES; DIAGNOSIS; FAILURE	A diagnosis of thrombotic microangiopathy on kidney biopsy in a patient presenting with hypertensive emergency has historically elicited the diagnosis of malignant hypertension-associated thrombotic microangiopathy. Recent studies, however, have raised awareness that a number of these patients may actually represent atypical hemolytic uremic syndrome. To further investigate this premise, we performed next-generation sequencing to interrogate the coding regions of 29 complement and coagulation cascade genes associated with atypical hemolytic uremic syndrome in 100 non-elderly patients presenting with severe hypertension, renal failure and a kidney biopsy showing microangiopathic changes limited to the classic accelerated hypertension-associated lesion of arterial intimal edema ('mucoid intimal hyperplasia') in isolation and without accompanying glomerular microthrombi. No pathogenic or likely pathogenic variants were identified in any of the genes analyzed, although 13 patients had rare variants of uncertain significance predicted to be deleterious by all in-silico prediction methods utilized. Accordingly, this large patient cohort showed no definitive burden of disease secondary to genetic variants involving complement or coagulation pathways, which contrasts sharply with the high frequency of similar mutational events reported for atypical hemolytic uremic syndrome. Our results also inform recent data by suggesting that patients who present with severe or malignant hypertension and renal thrombotic microangiopathy may be at higher risk for atypical hemolytic uremic syndrome only if the biopsy shows more active disease that includes glomerular fibrin thrombi.	[Larsen, Christopher P.; Wilson, Jon D.; Best-Rocha, Alejandro; Beggs, Marjorie L.; Hennigar, Randolph A.] Arkana Labs, Little Rock, AR 72211 USA	Larsen, CP (reprint author), Arkana Labs, Pathol, 10810 Execut Ctr Dr,Suite 100, Little Rock, AR 72211 USA.	Chris.larsen@nephropath.com			Alexion Pharmaceuticals Inc.Fukuda Foundation for Medical TechnologyKayamori FoundationKayamori Foundation of Informational Science AdvancementSENSHIN Medical Research FoundationSasagawa Scientific Research Grant	This study was funded through an investigator initiated grant from Alexion Pharmaceuticals Inc., which has not had any influence on the results or interpretations in this article. The authors declare no conflict of interest.	Amraoui F, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-71; Asif A, 2017, J NEPHROL, V30, P347, DOI 10.1007/s40620-016-0357-7; CHURG JACOB, 1961, JOUR MT SINAI HOSP, V28, P111; Colvin RB, 2015, DIAGNOSTIC PATHOLOGY, P523; George JN, 2014, NEW ENGL J MED, V371, P654, DOI 10.1056/NEJMra1312353; HEPTINSTALL RH, 1954, BRIT HEART J, V16, P133; Jennette CJ, 2014, HEPTINSTALLS PATHOLO, P759; Larsen CP, 2016, AM J KIDNEY DIS, V67, P992, DOI 10.1053/j.ajkd.2015.11.023; Laurence J, 2016, CLIN ADV HEMATOL ONC, V14, P1; Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246; Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Shavit L, 2010, CLIN NEPHROL, V73, P147, DOI 10.2379/CNX06426; Timmermans SAMEG, 2017, KIDNEY INT, V91, P1420, DOI 10.1016/j.kint.2016.12.009; Totina A, 2013, CLIN PEDIATR, V52, P183, DOI 10.1177/0009922811412942; van den Born BJH, 2006, J HYPERTENS, V24, P2299, DOI 10.1097/01.hjh.0000249710.21146.38; van den Born BJH, 2005, HYPERTENSION, V45, P246, DOI 10.1161/01.HYP.0000151620.17905.ee; Van Laecke S, 2017, KIDNEY INT, V91, P1271, DOI 10.1016/j.kint.2017.02.025; Yu X-J, 2014, SCI WORLD J, V2014; Zhang B, 2008, HYPERTENS RES, V31, P479, DOI 10.1291/hypres.31.479	20	10	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					488	494		10.1038/modpathol.2017.154			7	Pathology	Pathology	FY7KC	WOS:000427040000011	29148534	Green Published			2019-10-28	
J	Mutzbauer, G; Maurus, K; Buszello, C; Pischimarov, J; Roth, S; Rosenwald, A; Chott, A; Geissinger, E				Mutzbauer, Grit; Maurus, Katja; Buszello, Clara; Pischimarov, Jordan; Roth, Sabine; Rosenwald, Andreas; Chott, Andreas; Geissinger, Eva			SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma	MODERN PATHOLOGY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTEIN-TYROSINE KINASE; MEDIATED PHOSPHORYLATION; SIGNALING MOLECULES; GENE-EXPRESSION; NK-CELL; MUTATIONS; ACTIVATION; ITK; PATHWAYS	Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), formerly known as type II enteropathy associated T-cell lymphoma (type II EATL), is a rare, aggressive primary intestinal T-cell lymphoma with a poor prognosis and an incompletely understood pathogenesis. We collected 40 cases of MEITL and 27 cases of EATL, formerly known as type I EATL, and comparatively investigated the T-cell receptor (TCR) itself and associated signaling molecules using immunohistochemistry, amplicon deep sequencing and bisulfite pyrosequencing. The TCR showed both an alpha beta-T-cell origin (30%) and gamma delta-T-cell derivation (55%) resulting in a predominant positive TCR phenotype in MEITL compared with the mainly silent TCR phenotype in EATL (65%). The immunohistochemical expression of the spleen tyrosine kinase (SYK) turned out to be a distinctive feature of MEITL (95%) compared with EATL (0%). Aberrant SYK overexpression in MEITL is likely caused by hypomethylation of the SYK promoter, while no common mutations in the SYK gene or in its promoter could be detected. Using amplicon deep sequencing, mutations in DNMT3A, IDH2, and TET2 were infrequent events in MEITL and EATL. Immunohistochemical expression of linker for activation of T-cells (LAT) subdivided MEITL into a LAT expressing subset (33%) and a LAT silent subset (67%) with a potentially earlier disease onset in LAT-positive MEITL.	[Mutzbauer, Grit; Maurus, Katja; Buszello, Clara; Pischimarov, Jordan; Roth, Sabine; Rosenwald, Andreas; Geissinger, Eva] Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany; [Rosenwald, Andreas; Geissinger, Eva] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Rosenwald, Andreas; Geissinger, Eva] Univ Hosp, Wurzburg, Germany; [Chott, Andreas] Wilhelminenspital Stadt Wien, Inst Pathol & Microbiol, Vienna, Austria	Geissinger, E (reprint author), Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	Geissinger@mail.uni-wuerzburg.de					Acuto O, 2008, NAT REV IMMUNOL, V8, P699, DOI 10.1038/nri2397; Archambaud C, 2009, J IMMUNOL, V182, P2680, DOI 10.4049/jimmunol.0803257; Balagopalan L, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005512; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Chan JKC, 2011, AM J SURG PATHOL, V35, P1557, DOI 10.1097/PAS.0b013e318222dfcd; Chen LG, 2008, BLOOD, V111, P2685, DOI 10.1182/blood-2006-12-062265; Chott A, 1999, AM J CLIN PATHOL, V111, pS68; Chott A, 1998, AM J PATHOL, V153, P1483, DOI 10.1016/S0002-9440(10)65736-7; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Chuang SS, 2009, AM J SURG PATHOL, V33, P1230, DOI 10.1097/PAS.0b013e3181a95c63; Couronne L, 2012, NEW ENGL J MED, V366, P95, DOI 10.1056/NEJMc1111708; Coussens NP, 2013, MOL CELL BIOL, V33, P4140, DOI 10.1128/MCB.00410-13; Deleeuw RJ, 2007, GASTROENTEROLOGY, V132, P1902, DOI 10.1053/j.gastro.2007.03.036; Devkota S, 2015, J MOL BIOL, V427, P2734, DOI 10.1016/j.jmb.2015.04.012; Dierks C, 2010, CANCER RES, V70, P6193, DOI 10.1158/0008-5472.CAN-08-3719; Facchetti F, 1999, AM J PATHOL, V154, P1037, DOI 10.1016/S0002-9440(10)65356-4; Feldman AL, 2008, LEUKEMIA, V22, P1139, DOI 10.1038/leu.2008.77; Garcia-Herrera A, 2011, AM J SURG PATHOL, V35, P1214, DOI 10.1097/PAS.0b013e31822067d1; Geissinger E, 2010, HAEMATOL-HEMATOL J, V95, P1697, DOI 10.3324/haematol.2009.021428; Ghosh D, 2012, ARTHRITIS RHEUM-US, V64, P799, DOI 10.1002/art.33375; Isaacson PG, 2008, WHO CLASSIFICATION T, P289; Keller B, 2016, J EXP MED, V213, P1185, DOI 10.1084/jem.20151110; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Ksionda O, 2012, J CELL SCI, V125, P5302, DOI 10.1242/jcs.105148; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Lasserre R, 2011, J CELL BIOL, V195, P839, DOI 10.1083/jcb.201103105; Lemonnier F, 2012, BLOOD, V120, P1466, DOI 10.1182/blood-2012-02-408542; Luo CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030087; Malissen B, 2014, NAT IMMUNOL, V15, P790, DOI 10.1038/ni.2959; Mingueneau M, 2009, IMMUNITY, V31, P197, DOI 10.1016/j.immuni.2009.05.013; Moffitt AB, 2017, J EXP MED, V214, P1371, DOI 10.1084/jem.20160894; Mutzbauer G, 2017, SYK EXPRESSION MEITL; Nairismagi ML, 2016, LEUKEMIA, V30, P1311, DOI 10.1038/leu.2016.13; Nicolae A, 2016, LEUKEMIA, V30, P2245, DOI 10.1038/leu.2016.178; Nunez-Cruz S, 2003, NAT IMMUNOL, V4, P999, DOI 10.1038/ni977; Ortiz S, 2010, EXP BIOL MED, V235, P1450, DOI 10.1258/ebm.2010.010056; Pechloff K, 2010, J EXP MED, V207, P1031, DOI 10.1084/jem.20092042; Pozzobon M, 2004, BRIT J HAEMATOL, V124, P519, DOI 10.1111/j.1365-2141.2004.04802.x; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Raca G, 2010, MOL GENET METAB, V100, P184, DOI 10.1016/j.ymgme.2010.03.004; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Roberti A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12602; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Steinberg M, 2004, BLOOD, V104, P760, DOI 10.1182/blood-2003-12-4314; Streubel B, 2006, LEUKEMIA, V20, P313, DOI 10.1038/sj.leu.2404045; Sun J, 2011, MODERN PATHOL, V24, P983, DOI 10.1038/modpathol.2011.45; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takeshita M, 2011, HISTOPATHOLOGY, V58, P395, DOI 10.1111/j.1365-2559.2011.03768.x; Tan SY, 2013, LEUKEMIA, V27, P1688, DOI 10.1038/leu.2013.41; Tan SY, 2011, LEUKEMIA, V25, P555, DOI 10.1038/leu.2010.295; Thompson MA, 2005, HUM PATHOL, V36, P494, DOI 10.1016/j.humpath.2005.03.004; Tjon JML, 2008, BLOOD, V112, P5103, DOI 10.1182/blood-2008-04-150748; Tomita S, 2015, MODERN PATHOL, V28, P1286, DOI 10.1038/modpathol.2015.85; Tse E, 2012, AM J HEMATOL, V87, P663, DOI 10.1002/ajh.23213; Wang HP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002279; Weil R, 1999, J VIROL, V73, P3709; Weissbach S, 2015, BRIT J HAEMATOL, V169, P57, DOI 10.1111/bjh.13256; Wilcox RA, 2010, LEUKEMIA, V24, P229, DOI 10.1038/leu.2009.198; Wilson AL, 2013, HUM PATHOL, V44, P1131, DOI 10.1016/j.humpath.2012.10.002	59	1	1	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					505	516		10.1038/modpathol.2017.145			12	Pathology	Pathology	FY7KC	WOS:000427040000013	29052597	Bronze			2019-10-28	
J	Rimbert, J; Tachon, G; Junca, A; Villalva, C; Karayan-Tapon, L; Tougeron, D				Rimbert, Johan; Tachon, Gaelle; Junca, Audelaure; Villalva, Claire; Karayan-Tapon, Lucie; Tougeron, David			Association between clinicopathological characteristics and RAS mutation in colorectal cancer	MODERN PATHOLOGY			English	Article							KRAS CODON 12; MICROSATELLITE INSTABILITY; BRAF MUTATION; MOLECULAR-FEATURES; PIK3CA MUTATIONS; CARCINOMA; PROGNOSIS; CETUXIMAB; SURVIVAL; NRAS	In colorectal cancer, KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations are associated with resistance to antiepidermal growth factor receptor monoclonal antibodies, and BRAF mutation is a molecular marker of poor prognosis. KRAS exon 2 and BRAF-mutated colorectal cancers have well-known distinct clinicopathological characteristics. Comparison of tumors with different RAS status (exons 2, 3, and 4 of KRAS and NRAS) based on their clinicopathological characteristics has never been established. All colorectal cancer patients with RAS and BRAF testing from 2011 to 2015 were included in this observational retrospective study. Patient and tumor characteristics were collected and correlation with RAS and BRAF status was evaluated. A total of 1735 patients with colorectal cancer were included. RAS-mutated colorectal cancers (n = 1002), compared with RAS wild-type colorectal cancers (n = 733), were significantly associated with male gender, classical adenocarcinoma subtype, well/moderately differentiated tumors, and microsatellite stable phenotype. KRAS codon 13-mutated colorectal cancers (n = 171), compared with RAS wild-type colorectal cancers, more frequently presented classical adenocarcinoma subtype and microsatellite stable phenotype. In comparison with other RAS mutations, KRAS exon 3-mutated colorectal cancers (n = 23) were associated with mucinous/rare histological subtypes and, most likely to located in the rectum. KRAS exon 4-mutated colorectal cancers (n = 33) were more frequently associated with mucinous/rare histological subtypes. There was no significant association between NRAS mutation (n = 37) and clinicopathological features. Colorectal cancers are associated with different clinicopathological features according to the type of RAS mutation. Consequently, these particular characteristics must be considered when assessing the prognostic value of RAS status in colorectal cancer.	[Rimbert, Johan; Tachon, Gaelle; Junca, Audelaure; Villalva, Claire; Karayan-Tapon, Lucie; Tougeron, David] Univ Poitiers, Fac Med & Pharmaceut Sci, Poitiers, France; [Rimbert, Johan; Tachon, Gaelle; Villalva, Claire; Karayan-Tapon, Lucie] Univ Poitiers Hosp, Dept Canc Biol, Poitiers, France; [Rimbert, Johan; Junca, Audelaure] Univ Poitiers Hosp, Dept Pathol, Poitiers, France; [Tachon, Gaelle; Karayan-Tapon, Lucie] Univ Poitiers, Cellular Therapies Brain Dis Grp, Expt & Clin Neurosci Lab, INSERM U 1084, Poitiers, France; [Tougeron, David] Univ Poitiers Hosp, Dept Gastroenterol, 2 Rue Miletrie, F-86000 Poitiers, France; [Tougeron, David] Univ Poitiers, Lab Inflammat Tissus Epitheliaux & Cytokines, EA 4331, Poitiers, France	Tougeron, D (reprint author), Univ Poitiers Hosp, Dept Gastroenterol, 2 Rue Miletrie, F-86000 Poitiers, France.	davidtougeron@hotmail.fr		tougeron, david/0000-0002-8065-9635			Ahlquist T, 2008, NEOPLASIA, V10, P680, DOI 10.1593/neo.08312; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446; Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3; Bosman FT, 2010, WHO CLASSIF TUMOURS, V3, P417; Clancy C, 2013, COLORECTAL DIS, V15, pE711, DOI 10.1111/codi.12427; Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365; Cortes U, 2015, EXP MOL PATHOL, V99, P207, DOI 10.1016/j.yexmp.2015.07.003; De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Gonsalves WI, 2014, JNCI-J NATL CANCER I, V106, P7; Hamilton SR, 2000, WHO CLASSIFICATION T, P101; Imamura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-135; Jung SB, 2012, CANCER RES TREAT, V44, P179, DOI 10.4143/crt.2012.44.3.179; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kawazoe A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1276-z; Knox RD, 2015, ANN SURG ONCOL, V22, P2988, DOI 10.1245/s10434-014-4355-5; Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046; Koochak Aghigh, 2016, Asian Pac J Cancer Prev, V17, P603; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li WB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1345-3; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Nitsche U, 2016, DIGEST SURG, V33, P157, DOI 10.1159/000443644; Piton N, 2015, CANCER EPIDEM BIOMAR, V24, P1416, DOI 10.1158/1055-9965.EPI-15-0059; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rosty C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065479; Rosty C, 2013, MODERN PATHOL, V26, P825, DOI 10.1038/modpathol.2012.240; Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619; Samara M, 2015, GENET MOL RES, V14, P16793, DOI 10.4238/2015.December.14.6; Seligmann JF, 2017, ANN ONCOL, V28, P562, DOI 10.1093/annonc/mdw645; Sinicrope FA, 2006, GASTROENTEROLOGY, V131, P729, DOI 10.1053/j.gastro.2006.06.005; Taieb J, 2014, J CLIN ONCOL, V25, P2378; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854; Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140; Zhang J., 2015, SCI REP, V5, P1, DOI DOI 10.1038/SREP18678; Zlobec I, 2010, INT J CANCER, V127, P367, DOI 10.1002/ijc.25042	42	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					517	526		10.1038/modpathol.2017.119			10	Pathology	Pathology	FY7KC	WOS:000427040000014	29052598				2019-10-28	
J	Wethkamp, N; Nordlohne, EM; Meister, V; Helwig, U; Respondek, M				Wethkamp, Nils; Nordlohne, Eva-Maria; Meister, Volker; Helwig, Ulf; Respondek, Michael			Identification of clinically relevant cytomegalovirus infections in patients with inflammatory bowel disease	MODERN PATHOLOGY			English	Article							POSITIVE ULCERATIVE-COLITIS; ANTIVIRAL THERAPY; VIRUS INFECTION; VIRAL LOAD; PCR; CMV; IMMUNOHISTOCHEMISTRY; PREVALENCE; DNA; QUANTIFICATION	Several lines of evidence indicate that cytomegalovirus infection can be substantially associated with onset of inflammatory bowel disease, especially in patients refractory to immunosuppressive treatment. As cytomegalovirus is widely spread in the population, here we present a quantitative detection system suitable to differentiate clinically relevant cytomegalovirus infection from common latent cytomegalovirus. Using a quantitative real-time PCR approach, cytomegalovirus viral load was evaluated in 917 formalin-fixed and paraffin-embedded colon biopsy samples of 136 patients diagnosed with inflammatory bowel disease. Besides initial cytomegalovirus testing, the PCR system was also used to monitor therapy response after antiviral treatment. Cytomegalovirus DNA was detected in 37 patients (27%) with varying viral loads ranging from 5 to 8.7 x 10(5) copies/10(5) cells. Thereof, 13 patients (35%) received an antiviral treatment with 12 of them going into remission (92%). Later, five patients displayed a relapse and three patients who agreed to restart antiviral treatment again showed positive therapy response. A retrospective comparison of viral loads with antiviral therapy response revealed a threshold of 600 cytomegalovirus copies/10(5) cells as indicative for clinically relevant infection. Of note, sensitivity of cytomegalovirus detection by immunohistochemistry was found to be insufficient to reliably identify antiviral therapy responders. In conclusion, quantitative real-time PCR using formalin-fixed biopsy samples is suitable for detection of cytomegalovirus infection in tissue samples of patients with inflammatory bowel disease. Moreover, it allows the definition of a viral load threshold, predictive for clinical relevance concerning antiviral therapy response.	[Wethkamp, Nils; Respondek, Michael] Practice Pathol, Mol Diagnost, Marienstr 11, D-49377 Vechta, Germany; [Nordlohne, Eva-Maria; Meister, Volker] St Marien Hosp, Gastroenterol, Med Dept, Vechta, Germany; [Helwig, Ulf] Shared Practice Internal Med, Oldenburg, Germany	Wethkamp, N (reprint author), Practice Pathol, Mol Diagnost, Marienstr 11, D-49377 Vechta, Germany.	wethkamp@pathologie-vechta.de					BERK T, 1985, AM J GASTROENTEROL, V80, P355; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Ciccocioppo R, 2015, WORLD J GASTROENTERO, V21, P1915, DOI 10.3748/wjg.v21.i6.1915; Cottone M, 2001, AM J GASTROENTEROL, V96, P773; Criscuoli V, 2004, DIGEST LIVER DIS, V36, P818, DOI 10.1016/j.dld.2004.05.013; de Saussure P, 2004, ALIMENT PHARM THER, V20, P1323, DOI 10.1111/j.1365-2036.2004.02273.x; Delvincourt M, 2014, ALIMENT PHARM THER, V39, P712, DOI 10.1111/apt.12650; Dimitroulia E, 2006, INFLAMM BOWEL DIS, V12, P879, DOI 10.1097/01.mib.0000231576.11678.57; Ganzenmueller T, 2009, J CLIN VIROL, V46, P254, DOI 10.1016/j.jcv.2009.08.008; Garrido E, 2013, WORLD J GASTROENTERO, V19, P17, DOI 10.3748/wjg.v19.i1.17; Gerna G, 2012, NEW MICROBIOL, V35, P279; Griscelli F, 2001, J CLIN MICROBIOL, V39, P4362, DOI 10.1128/JCM.39.12.4362-4369.2001; Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001; Hofkin G A, 1995, Md Med J, V44, P1047; Jones A, 2015, CLIN GASTROENTEROL H, V13, P949, DOI 10.1016/j.cgh.2014.09.042; Kambham N, 2004, AM J SURG PATHOL, V28, P365, DOI 10.1097/00000478-200403000-00009; Kandiel A, 2006, AM J GASTROENTEROL, V101, P2857, DOI 10.1111/j.1572-0241.2006.00869.x; Kim JJ, 2010, DIGEST DIS SCI, V55, P1059, DOI 10.1007/s10620-010-1126-4; Kim JW, 2014, J CROHNS COLITIS, V8, P693, DOI 10.1016/j.crohns.2013.12.014; Kim YS, 2014, GUT LIVER, V8, P643, DOI 10.5009/gnl13427; Kopylov U, 2014, WORLD J GASTROENTERO, V20, P2695, DOI 10.3748/wjg.v20.i10.2695; Kou T, 2006, DIGEST DIS SCI, V51, P1052, DOI 10.1007/s10620-006-8006-y; Lawlor G, 2010, INFLAMM BOWEL DIS, V16, P1620, DOI 10.1002/ibd.21275; Lewis JD, 2008, INFLAMM BOWEL DIS, V14, P1660, DOI 10.1002/ibd.20520; Machida U, 2000, J CLIN MICROBIOL, V38, P2536; Maconi G, 2014, EUR J GASTROEN HEPAT, V26, P1146, DOI 10.1097/MEG.0000000000000175; Matsuoka K, 2007, AM J GASTROENTEROL, V102, P331, DOI 10.1111/j.1572-0241.2006.00989.x; Mccoy MH, 2014, HUM PATHOL, V45, P48, DOI 10.1016/j.humpath.2013.07.040; Mills AM, 2013, AM J SURG PATHOL, V37, P995, DOI 10.1097/PAS.0b013e31827fcc33; Nakase H, 2010, DIGEST DIS SCI, V55, P1498, DOI 10.1007/s10620-010-1162-0; Onyeagocha C, 2009, AM J PATHOL, V175, P2034, DOI 10.2353/ajpath.2009.090471; POWELL RD, 1961, AM J MED, V30, P334, DOI 10.1016/0002-9343(61)90105-X; Rachima C, 1998, POSTGRAD MED J, V74, P486, DOI 10.1136/pgmj.74.874.486; Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013; Roblin X, 2011, AM J GASTROENTEROL, V106, P2001, DOI 10.1038/ajg.2011.202; Sager K, 2015, ALIMENT PHARM THER, V41, P725, DOI 10.1111/apt.13124; Takahashi Y, 2004, DIS COLON RECTUM, V47, P722, DOI 10.1007/s10350-003-0117-3; Vega R, 1999, AM J GASTROENTEROL, V94, P1053; Watzinger F., 2006, Molecular Aspects of Medicine, V27, P254, DOI 10.1016/j.mam.2005.12.001; WU GD, 1989, AM J GASTROENTEROL, V84, P1517; Wu XW, 2015, WORLD J GASTROENTERO, V21, P1689, DOI 10.3748/wjg.v21.i5.1689; Yoshino T, 2007, INFLAMM BOWEL DIS, V13, P1516, DOI 10.1002/ibd.20253; Zidar N, 2015, VIRCHOWS ARCH, V466, P533, DOI 10.1007/s00428-015-1741-8	44	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					527	538		10.1038/modpathol.2017.149			12	Pathology	Pathology	FY7KC	WOS:000427040000015	29192648	Bronze			2019-10-28	
J	Lambros, L; Guibourg, B; Le Flahec, G; Uguen, A				Lambros, Laetitia; Guibourg, Briac; Le Flahec, Glen; Uguen, Arnaud			The rarity of concomitant genetic alterations in lung cancer	MODERN PATHOLOGY			English	Letter							ROS1		[Lambros, Laetitia; Guibourg, Briac; Le Flahec, Glen; Uguen, Arnaud] CHRU Brest, Serv Anat & Cytol Pathol, Brest, France; [Uguen, Arnaud] INSERM, U1078, Brest, France; [Uguen, Arnaud] Univ Europeenne Bretagne, Rennes, France	Uguen, A (reprint author), CHRU Brest, Serv Anat & Cytol Pathol, Brest, France.	arnaud.uguen@chu-brest.fr					Antoine M, 2017, RECOMMANDATIONS SFP; Bubendorf L, 2016, VIRCHOWS ARCH, V469, P489, DOI 10.1007/s00428-016-2000-3; Dagogo-Jack I, 2016, ONCOLOGIST, V21, P662, DOI 10.1634/theoncologist.2016-0179; Dugay F, 2017, ONCOTARGET, V8, P53336, DOI 10.18632/oncotarget.18408; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Ju LX, 2016, LUNG CANCER, V95, P94, DOI 10.1016/j.lungcan.2016.03.005; Marchetti A, 2016, J THORAC ONCOL, V11, P487, DOI 10.1016/j.jtho.2015.12.111; Sterlacci W, 2017, VIRCHOWS ARCH, V471, P49, DOI 10.1007/s00428-017-2131-1; Tang Z, 2017, MOD PATHOL; Uguen Arnaud, 2017, J Thorac Oncol, V12, pe71, DOI 10.1016/j.jtho.2017.02.007; Van Der Steen N, 2017, CLIN LUNG CANC; van der Wekken AJ, 2017, CLIN CANCER RES, V23, P4251, DOI 10.1158/1078-0432.CCR-16-1631; Vassal G, 2015 ASCO C	13	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					539	540		10.1038/modpathol.2017.176			2	Pathology	Pathology	FY7KC	WOS:000427040000016	29515241	Bronze			2019-10-28	
J	Tang, ZY; Zhang, JJ; Chen, H; Lu, S; Cheng, J; Tang, GL; Medeiros, LJ				Tang, Zhenya; Zhang, Jianjun; Chen, Hui; Lu, Selina; Cheng, Joanne; Tang, Guilin; Medeiros, L. Jeffrey			The rarity of concomitant genetic alterations in lung cancer Reply	MODERN PATHOLOGY			English	Letter							TECHNICAL STANDARDS		[Tang, Zhenya; Lu, Selina; Cheng, Joanne; Tang, Guilin; Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Chen, Hui] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Tang, ZY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	ztang@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Bubendorf L, 2016, VIRCHOWS ARCH, V469, P489, DOI 10.1007/s00428-016-2000-3; Cooley LD, 2016, GENET MED, V18, P643, DOI 10.1038/gim.2016.51; Dugay F, 2017, ONCOTARGET, V8, P53336, DOI 10.18632/oncotarget.18408; Lambros L, MOD PATHOL; Mascarello JT, 2011, GENET MED, V13, P667, DOI 10.1097/GIM.0b013e3182227295; Michels S, 2016, J THORAC ONCOL, V11, P122, DOI 10.1016/j.jtho.2015.09.016; Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120422; Tang Z, 2017, MOD PATHOL; Tsuta K, 2014, BRIT J CANCER, V110, P1571, DOI 10.1038/bjc.2014.36	9	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					541	542		10.1038/modpathol.2017.192			2	Pathology	Pathology	FY7KC	WOS:000427040000017	29515243	Bronze			2019-10-28	
J	Hannafon, BN; Ding, WQ				Hannafon, Bethany N.; Ding, Wei-Qun			miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ	AMERICAN JOURNAL OF PATHOLOGY			English	Review							BREAST-CANCER; EXPRESSION PROFILES; MICRORNA SEQUENCE; PROMOTE; DEREGULATION; SIGNATURES; BENIGN; GENES; WOMEN; RISK	Ductal carcinoma in situ (DCIS) is defined as a proliferation of neoplastic cells within the duct of the mammary gland that have not invaded into the surrounding stroma. DCIS is considered a precursor to invasive ductal carcinoma (IDC); however, approximately half of DCIS may progress to IDC, if left untreated. Current research has shown that the genomic and transcriptomic changes are present in DCIS before the emergence of invasive disease, indicating that the malignant nature of the DCIS is defined before invasion. However, important questions remain surrounding the specific changes and processes required for malignant progression and identification of prognostic indicators of aggressiveness. miRNAs are small regulatory RNAs that can modulate gene expression by complementary binding to target mRNAs and inducing translational repression and/or mRNA degradation. In the past decade, research has shown that miRNA expression is dysregulated in IDC and that these changes are already present at the DCIS stage. Therefore, changes in miRNA expression may provide the necessary information to identify a clinical indicator of the aggressiveness of DCIS. Herein, we review the miRNA signatures identified in DCIS, describe how these signatures may be used to predict the aggressiveness of DCIS, and discuss future perspectives for DCIS biomarker discovery.	[Ding, Wei-Qun] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St,BRC 411A, Oklahoma City, OK 73104 USA; [Hannafon, Bethany N.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St,BRC 409, Oklahoma City, OK 73104 USA	Ding, WQ (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St,BRC 411A, Oklahoma City, OK 73104 USA.; Hannafon, BN (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St,BRC 409, Oklahoma City, OK 73104 USA.	bethany-hannafon@ouhsc.edu; weiqun-ding@ouhsc.edu	Hannafon, Bethany N./R-1233-2019	Hannafon, Bethany N./0000-0003-0596-9171	Presbyterian Health Foundation; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104938]; Oklahoma Center for Advancement of Science and Technology [HR17-052]	Supported by the National Institute of General Medical Sciences grant U54GM104938 (W.-Q.D.), the Presbyterian Health Foundation (W.-Q.D.), and the Oklahoma Center for Advancement of Science and Technology grant HR17-052 (B.N.H.).	Allegra Carmen J, 2009, NIH Consens State Sci Statements, V26, P1; American Cancer Society, 2015, BREAST CANC FACTS FI; Amorim M, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1025-3; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054213; Collins LC, 2005, CANCER-AM CANCER SOC, V103, P1778, DOI 10.1002/cncr.20979; Degnim AC, 2007, J CLIN ONCOL, V25, P2671, DOI 10.1200/JCO.2006.09.0217; Do Canto LM, 2016, INT J ONCOL, V48, P2071, DOI 10.3892/ijo.2016.3435; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; Haakensen VD, 2016, INT J CANCER, V139, P1117, DOI 10.1002/ijc.30142; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240; Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839; Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383; Heneghan HM, 2010, ANN SURG, V251, P499, DOI 10.1097/SLA.0b013e3181cc939f; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Khan SA, 2005, ANN SURG ONCOL, V12, P689, DOI 10.1245/ASO.2005.04.037; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Li JN, 2005, CLIN CANCER RES, V11, P8312, DOI 10.1158/1078-0432.CCR-05-1538; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin PY, 2011, EMBO MOL MED, V3, P436, DOI 10.1002/emmm.201100155; Lo PK, 2017, J BIOL CHEM, V292, P11466, DOI 10.1074/jbc.M117.775080; Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maji S, 2017, MOL CANCER RES, V15, P93, DOI 10.1158/1541-7786.MCR-16-0163; Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Ng EKO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053141; Pigati L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013515; Porter D, 2003, MOL CANCER RES, V1, P362; Resnick KE, 2009, GYNECOL ONCOL, V112, P55, DOI 10.1016/j.ygyno.2008.08.036; Rodriguez M, 2015, ONCOTARGET, V6, P40575, DOI 10.18632/oncotarget.5818; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tahiri A, 2014, CARCINOGENESIS, V35, P76, DOI 10.1093/carcin/bgt333; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Xiao DY, 2016, CANCER LETT, V376, P318, DOI 10.1016/j.canlet.2016.03.050; Yeong J, 2017, J CLIN PATHOL, V70, P102, DOI 10.1136/jclinpath-2016-204154; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013735	50	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					542	549		10.1016/j.ajpath.2017.11.003			8	Pathology	Pathology	FY4OT	WOS:000426805100001	29246496	Bronze, Green Published			2019-10-28	
J	Perry, DL; Huzella, LM; Bernbaum, JG; Holbrook, MR; Jahrling, PB; Hagen, KR; Schnell, MJ; Johnson, RF				Perry, Donna L.; Huzella, Louis M.; Bernbaum, John G.; Holbrook, Michael R.; Jahrling, Peter B.; Hagen, Katie R.; Schnell, Matthias J.; Johnson, Reed F.			Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INFECTION; PERSISTENCE; PATHOGENESIS; ACTIVATION; PREGNANCY; MONKEYS; FLUID; SEMEN; RNA	Sexual transmission of Ebola virus (EBOV) has been demonstrated more than a year after recovery from the acute phase of Ebola virus disease (EVD). The mechanisms underlying EBOV persistence and sexual transmission are not currently understood. Using the acute macaque model of EVD, we hypothesized EBOV would infect the reproductive tissues and sought to localize the infection in these tissues using immunohistochemistry and transmission electron microscopy. In four female and eight male macaques that succumbed to EVD between 6 and 9 days after EBOV challenge, we demonstrate widespread EBOV infection of the interstitial tissues and endothelium in the ovary, uterus, testis, seminal vesicle, epididymis, and prostate gland, with minimal associated tissue immune response or organ pathology. Given the widespread involvement of EBOV in the reproductive tracts of both male and female macaques, it is reasonable to surmise that our understanding of the mechanisms underlying sexual transmission of EVD and persistence of EBOV in immune-privileged sites would be facilitated by the development of a nonhuman primate model in which the macaques survived past the acute stage into convalescence.	[Perry, Donna L.; Huzella, Louis M.; Bernbaum, John G.; Holbrook, Michael R.; Jahrling, Peter B.; Hagen, Katie R.] NIAID, Integrated Res Facil, Div Intramural Res, NIH, Frederick, MD USA; [Jahrling, Peter B.; Johnson, Reed F.] NIAID, Div Clin Res, Div Intramural Res, NIH, Frederick, MD USA; [Jahrling, Peter B.; Johnson, Reed F.] NIAID, Emerging Viral Pathogens Sect, Div Intramural Res, NIH, Frederick, MD USA; [Schnell, Matthias J.] Thomas Jefferson Univ, Dept Microbiol, Philadelphia, PA 19107 USA	Perry, DL (reprint author), NIAID, Integrated Res Facil, NIH, 8200 Res Plaza, Frederick, MD 21702 USA.	perrydl@niaid.nih.gov		Schnell, Matthias/0000-0001-9040-9405	US National Institute of Allergy and Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI105204]; Jefferson Vaccine Center; NIAID Divisions of Intramural Research and Clinical Research, Department of Health and Human Services, United States; Battelle Memorial Institute; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272200700016I]	Supported by the US National Institute of Allergy and Infectious Diseases (NIAID) grant R01AI105204 (M.J.S.); the Jefferson Vaccine Center; the NIAID Divisions of Intramural Research and Clinical Research, Department of Health and Human Services, United States; and the Battelle Memorial Institute's prime contract with the NIAID under contract HHSN272200700016I.	Alazard-Dany N, 2006, J GEN VIROL, V87, P1247, DOI 10.1099/vir.0.81361-0; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Bhattacharyya S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-11; Black BO, 2015, OBSTET MED, V8, P108, DOI 10.1177/1753495X15597354; Calain P, 1999, VIROLOGY, V262, P114, DOI 10.1006/viro.1999.9915; Calain P, 2016, LANCET, V388, P659, DOI 10.1016/S0140-6736(16)31272-7; Carossino M, 2017, J VIROL, V91, DOI 10.1128/JVI.00418-17; Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305; Crozier I, 2016, J INFECT DIS, V214, P1467, DOI 10.1093/infdis/jiw079; Diallo B, 2016, CLIN INFECT DIS, V63, P1353, DOI 10.1093/cid/ciw601; Dornemann J, 2017, J INFECT DIS, V215, P171, DOI 10.1093/infdis/jiw493; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; Fischer WA, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx155; Glynn JR, 2017, LANCET INFECT DIS, V17, P645, DOI 10.1016/S1473-3099(17)30111-1; Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5; Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107; Johnson RF, 2016, J INFECT DIS, V214, pS342, DOI 10.1093/infdis/jiw231; Kuhn JH, 2017, LANCET INFECT DIS, V17, P570, DOI 10.1016/S1473-3099(17)30110-X; Ludtke A, 2016, J INFECT DIS, V214, pS275, DOI 10.1093/infdis/jiw260; Martines RB, 2015, J PATHOL, V235, P153, DOI 10.1002/path.4456; MARTINI GA, 1973, POSTGRAD MED J, V49, P542, DOI 10.1136/pgmj.49.574.542; Mate SE, 2015, NEW ENGL J MED, V373, P2448, DOI 10.1056/NEJMoa1509773; McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112; Mohan GS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003065; Muehlenbachs A, 2017, J INFECT DIS, V215, P64, DOI 10.1093/infdis/jiw206; National Research Council (US), 2011, COMM UPD GUID CAR US; Niehoff MO, 2010, REPROD TOXICOL, V29, P57, DOI 10.1016/j.reprotox.2009.09.007; Noda T, 2006, PLOS PATHOG, V2, P864, DOI 10.1371/journal.ppat.0020099; Potente M, 2017, NAT REV MOL CELL BIO, V18, P477, DOI 10.1038/nrm.2017.36; Randall RE, 2017, CURR OPIN VIROL, V23, P35, DOI 10.1016/j.coviro.2017.03.001; Sissoko D, 2017, CLIN INFECT DIS, V64, P513, DOI 10.1093/cid/ciw793; Sow MS, 2016, J INFECT DIS, V214, P1475, DOI 10.1093/infdis/jiw078; Varkey JB, 2015, NEW ENGL J MED, V372, P2423, DOI 10.1056/NEJMoa1500306; Wang H, 2016, CELL, V164, P258, DOI 10.1016/j.cell.2015.12.044; Wang L, 2017, CLIN RES HEPATOL GAS, V2017, P1, DOI DOI 10.1371/J0URNAL.P0NE.01; Wang M, 2017, J IMMUNOL, V198, P4327, DOI 10.4049/jimmunol.1700162; Warren TK, 2014, VIRUSES-BASEL, V6, P4666, DOI 10.3390/v6114666; ZAMBONI L, 1974, BIOL REPROD, V11, P251, DOI 10.1095/biolreprod11.3.251; Zeng XK, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.113; Zhang APP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002550	40	4	4	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					550	558		10.1016/j.ajpath.2017.11.004			9	Pathology	Pathology	FY4OT	WOS:000426805100002	29429544	Other Gold, Green Published			2019-10-28	
J	Esbona, K; Yi, YY; Saha, S; Yu, MG; Van Doorn, RR; Conklin, MW; Graham, DS; Wisinski, KB; Ponik, SM; Eliceiri, KW; Wilke, LG; Keely, PJ				Esbona, Karla; Yi, Yanyao; Saha, Sandeep; Yu, Menggang; Van Doorn, Rachel R.; Conklin, Matthew W.; Graham, Douglas S.; Wisinski, Kari B.; Ponik, Suzanne M.; Eliceiri, Kevin W.; Wilke, Lee G.; Keely, Patricia J.			The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SCAVENGER RECEPTOR; COX-2 EXPRESSION; CANCER; SURVIVAL; PROGRESSION; VALIDATION; CELECOXIB; DISEASE; SERUM; LOOP	Inflammation, and the organization of collagen in the breast tumor microenvironment, is an important mediator of breast tumor progression. However, a direct link between markers of inflammation, collagen organization, and patient outcome has yet to be established. A tumor microarray of 371 invasive breast carcinoma biopsy specimens was analyzed for expression of inflammatory markers, including cyclo-oxygenase 2 (COX-2), macrophages, and several collagen features in the tumor nest (TN) or the tumor-associated stroma (TS). The tumor microarray cohort included females, aged 18 to 80 years, with a median follow-up of 8.4 years. High expression of COX-2 (TN), CD68 (TS), and CD163 (TN and TS) predicted worse patient overall survival (OS). This notion was strengthened by the finding from the multivariate analysis that high numbers of CD163(+) macrophages in the TS is an independent prognostic factor. Overall collagen deposition was associated with high stomal expression of COX-2 and CD163; however, total collagen deposition was not a predictor for OS. Conversely, local collagen density, alignment and perpendicular alignment to the tumor boundary (tumor-associated collagen signature-3) were predictors of OS. These results suggest that in invasive carcinoma, the localization of inflammatory cells and aligned collagen orientation predict poor patient survival. Additional clinical studies may help validate whether therapy with selective COX-2 inhibitors alters expression of CD68 and CD163 inflammatory markers.	[Esbona, Karla; Van Doorn, Rachel R.; Conklin, Matthew W.; Ponik, Suzanne M.; Keely, Patricia J.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI USA; [Yi, Yanyao; Saha, Sandeep; Yu, Menggang] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Wilke, Lee G.] Univ Wisconsin, Dept Surg, Madison, WI USA; [Yi, Yanyao] Univ Wisconsin, Dept Stat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Graham, Douglas S.] Univ Wisconsin, Dept Informat Technol, Madison, WI USA; [Esbona, Karla; Conklin, Matthew W.; Wisinski, Kari B.; Eliceiri, Kevin W.; Wilke, Lee G.; Keely, Patricia J.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA; [Eliceiri, Kevin W.] Univ Wisconsin, Lab Opt & Computat Instrumentat, Madison, WI USA	Esbona, K (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, L5-143 Clin Sci Ctr 8550,600 Highland Ave, Madison, WI 53792 USA.	kesbona@wisc.edu	; Eliceiri, Kevin/P-8339-2015	Esbona, Karla/0000-0002-6262-0024; Conklin, Matthew/0000-0001-7087-4561; Ponik, Suzanne/0000-0003-1367-4349; Eliceiri, Kevin/0000-0001-8678-670X	Clinical and Translational Science Award program, through NIH National Center for Advancing Translational Sciences [UL1TR000427]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA142833, U01 CA143069, R01 CA179556]; University of Wisconsin-Madison Carbone Cancer Center [P30 CA014520]	Supported by the Clinical and Translational Science Award program, through NIH National Center for Advancing Translational Sciences grant UL1TR000427 (Institute for Clinical and Translational Research); and NIH grants R01 CA142833 (P.J.K.), U01 CA143069 (P.J.K.), and R01 CA179556 (P.J.K.). The University of Wisconsin-Madison Translational Research Initiatives in Pathology laboratory was, in part, supported by the University of Wisconsin-Madison Department of Pathology and Laboratory Medicine and University of Wisconsin-Madison Carbone Cancer Center grant P30 CA014520, for use of its facilities and services.	Ahn HJ, 2015, J BREAST CANCER, V18, P149, DOI 10.4048/jbc.2015.18.2.149; Ambarus CA, 2012, J IMMUNOL METHODS, V375, P196, DOI 10.1016/j.jim.2011.10.013; American Cancer Society, 2015, GLOB CANC FACTS FIG; Ansari KM, 2007, CARCINOGENESIS, V28, P2063, DOI 10.1093/carcin/bgm011; Araki Y, 2003, CANCER RES, V63, P728; Bianchini F, 2007, PROSTAG OTH LIPID M, V83, P320, DOI 10.1016/j.prostaglandins.2007.03.003; Boyd N.F., 2013, AM SOC CLIN ONCOL ED, V2013, P57, DOI DOI 10.1200/EDB00K_; Bredfeldt Jeremy S, 2014, J Pathol Inform, V5, P28, DOI 10.4103/2153-3539.139707; Bredfeldt JS, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.1.016007; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Denkert C, 2003, CANCER, V97, P2978, DOI 10.1002/cncr.11437; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Klaus HD, 2008, INT J RADIAT ONCOL, V70, P203, DOI 10.1016/j.ijrobp.2007.08.065; Esbona K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0695-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RE, 2014, WORLD J CLIN ONCOL, V5, P677, DOI 10.5306/wjco.v5.i4.677; Harris RE, 2000, CANCER RES, V60, P2101; Holmes MD, 2011, BREAST CANCER RES TR, V130, P657, DOI 10.1007/s10549-011-1651-7; Holmes MD, 2010, J CLIN ONCOL, V28, P1467, DOI 10.1200/JCO.2009.22.7918; HOLNESS CL, 1993, BLOOD, V81, P1607; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Huang W, 2013, HUM PATHOL, V44, P29, DOI 10.1016/j.humpath.2012.05.009; Jensen TO, 2009, J CLIN ONCOL, V27, P3330, DOI 10.1200/JCO.2008.19.9919; Keikhosravi A, 2014, METHOD CELL BIOL, V123, P531, DOI [10.1016/B978-0-12-420138-5.00028-8, 10.1016/11978-0-12.420138-5.00028-8]; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Kim HS, 2012, BREAST CANCER RES TR, V132, P51, DOI 10.1007/s10549-011-1521-3; Kwan ML, 2007, CANCER CAUSE CONTROL, V18, P613, DOI 10.1007/s10552-007-9003-y; Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6; Li HZ, 2015, ONCOTARGET, V6, P29637, DOI 10.18632/oncotarget.4936; Liu YM, 2017, METHODS MOL BIOL, V1627, P429, DOI 10.1007/978-1-4939-7113-8_28; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Mann JR, 2005, NAT CLIN PRACT ONCOL, V2, P202, DOI 10.1038/ncponc0140; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Misron Nurul Akmar, 2015, Asian Pac J Cancer Prev, V16, P1553; Na YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063451; Nagorsen D, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-62; Nguyen TDT, 2005, AM J SURG PATHOL, V29, P617, DOI 10.1097/01.pas.0000157940.80538.ec; Park K, 2006, EJSO-EUR J SURG ONC, V32, P1093, DOI 10.1016/j.ejso.2006.05.010; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Richards JA, 2002, CANC DRUG DISC DEV, P205; Ristimaki A, 2002, CANCER RES, V62, P632; Smyth EM, 2012, BASIC CLIN PHARM, P313; Tsai CS, 2007, INT J RADIAT ONCOL, V68, P499, DOI 10.1016/j.ijrobp.2007.01.041; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7; Wang D, 2014, INT J PHOTOENERGY, DOI 10.1155/2014/846581; Wu WKK, 2010, CANCER LETT, V295, P7, DOI 10.1016/j.canlet.2010.03.015; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449	52	6	6	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					559	573		10.1016/j.ajpath.2017.10.025			15	Pathology	Pathology	FY4OT	WOS:000426805100003	29429545	Green Published, Bronze			2019-10-28	
J	Fang, K; Law, IKM; Padua, D; Sideri, A; Huang, V; Kevil, CG; Iliopoulos, D; Pothoulakis, C				Fang, Kai; Law, Ivy Ka Man; Padua, David; Sideri, Aristea; Huang, Vanessa; Kevil, Christopher G.; Iliopoulos, Dimitrios; Pothoulakis, Charalabos			MicroRNA-31-3p Is Involved in Substance P (SP)-Associated Inflammation in Human Colonic Epithelial Cells and Experimental Colitis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RHO KINASE BLOCKADE; NF-KAPPA-B; ULCERATIVE-COLITIS; CROHNS-DISEASE; INTESTINAL INFLAMMATION; HUMAN COLONOCYTES; BOWEL-DISEASE; EXPRESSION; CANCER; NEUROKININ-1	Substance P (SP) mediates colitis. SP signaling regulates the expression of several miRNAs, including miR-31-3p, in human colonocytes. However, the role of miR-31-3p in colitis and the underlying mechanisms has not been elucidated. We performed real-time PCR analysis of miR-31-3p expression in human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) in response to SP stimulation and in NCM460 cells after IL-6, IL8, tumor necrosis factor (TNF)-alpha, and interferon-gamma exposure. Functions of miR-31-3p were tested in NCM460 NK-1R cells and the trinitrobenzene sulfonic acid (TNBS) and dextran sodium sulfate (DSS) models of colitis. Targets of miRNA-31-3p were confirmed by Western blot analysis and luciferase reporter assay. Jun N-terminal kinase inhibition decreased SP-induced miR-31-3p expression. miR-31-3p expression was increased in both TNBS- and DSS-induced colitis and human colonic biopsies from ulcerative colitis, compared with controls. Intracolonic administration of a miR-31-3p chemical inhibitor exacerbated TNBS- and DSS-induced colitis and increased colonic TNF-alpha, CXCL10, and chemokine (C-C motif) ligand 2 (CCL2) mRNA expression. Conversely, overexpression of miR-31-3p ameliorated the severity of DSS-induced colitis. Bioinformatic, luciferase reporter assay, and Western blot analyses identified RhoA as a target of miR-31-3p in NCM460 cells. Constitutive activation of RhoA led to increased expression of CCL2, IL6, TNF-alpha, and CXCL10 in NCM460-NK-1R cells on SP stimulation. Our results reveal a novel SP-miR-31-3p-RhoA pathway that protects from colitis. The use of miR-31-3p mimics may be a promising approach for colitis treatment.	[Fang, Kai; Law, Ivy Ka Man; Padua, David; Sideri, Aristea; Huang, Vanessa; Pothoulakis, Charalabos] Univ Calif Los Angeles, David Geffen Sch Med, Inflammatory Bowel Dis Ctr, Vatche & Tamar Manoukian Div Digest Dis, Los Angeles, CA 90095 USA; [Kevil, Christopher G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Syst Biomed, Vatche & Tamar Manoukian Div Digest Dis, Los Angeles, CA 90095 USA; [Iliopoulos, Dimitrios] Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71105 USA	Pothoulakis, C (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Inflammatory Bowel Dis Ctr, Div Digest Dis, 675 Charles E Young Dr,S MRL Bldg 1240, Los Angeles, CA 90095 USA.	cpothoulakis@mednet.ucla.edu		Kevil, Christopher/0000-0003-0863-7260	US Public Health ServiceUnited States Public Health Service [R01 DK47343, R01 DK60729]; Neuroendocrine Assay Core grants [P50 DK64539, R01 DK110003]; CURE: Digestive Diseases Research Center (DDRC) [P30 DK 41301]; Animal Core	Supported by US Public Health Service grants R01 DK47343 (C.P.) and R01 DK60729 (C.P.), Neuroendocrine Assay Core grants P50 DK64539 (C.P.) and R01 DK110003 (D.I.), a CURE: Digestive Diseases Research Center (DDRC) grant P30 DK 41301 Pilot and Feasibility study (K.F.), and Animal Core (C.P. and K.F.).	Assi K, 2006, IMMUNOLOGY, V118, P112, DOI 10.1111/j.1365-2567.2006.02349.x; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Chang KW, 2013, ORAL ONCOL, V49, P27, DOI 10.1016/j.oraloncology.2012.07.003; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Dai X, 2015, J BIOL CHEM, V290, P16099, DOI 10.1074/jbc.M115.659318; Fang K, 2007, CELL CYCLE, V6, P199, DOI 10.4161/cc.6.2.3740; Fang K, 2015, CELL MOL GASTROENTER, V1, P503, DOI 10.1016/j.jcmgh.2015.06.008; Fang K, 2012, INFLAMM BOWEL DIS, V18, P1411, DOI 10.1002/ibd.22842; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Goode T, 2000, GUT, V47, P387, DOI 10.1136/gut.47.3.387; Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021; He Y, 2008, ARTHRITIS RHEUM, V58, P3366, DOI 10.1002/art.23986; Iliopoulos D, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005053; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Karagiannides L, 2006, P NATL ACAD SCI USA, V103, P5207, DOI 10.1073/pnas.0600821103; Koon HW, 2008, AM J PATHOL, V173, P400, DOI 10.2353/ajpath.2008.080222; Koon HW, 2007, P NATL ACAD SCI USA, V104, P2013, DOI 10.1073/pnas.0610664104; Koon HW, 2004, J BIOL CHEM, V279, P45519, DOI 10.1074/jbc.M408523200; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001; Lapierre J, 2011, RNA, V17, P1032, DOI 10.1261/rna.2399411; Law IKM, 2015, GUT, V64, P1095, DOI 10.1136/gutjnl-2014-307329; Lieb K, 1997, J IMMUNOL, V159, P4952; Lopez-Posadas R, 2016, J CLIN INVEST, V126, P611, DOI 10.1172/JCI80997; Manceau G, 2014, CLIN CANCER RES, V20, P3338, DOI 10.1158/1078-0432.CCR-13-2750; Mingozzi F, 2007, NAT MED, V13, P419, DOI 10.1038/nm1549; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Mlcochova J, 2015, ONCOTARGET, V6, P38695, DOI 10.18632/oncotarget.5735; Nielsen OH, 2013, NEW ENGL J MED, V369, P754, DOI 10.1056/NEJMct1209614; Polytarchou C, 2015, GASTROENTEROLOGY, V149, P981, DOI 10.1053/j.gastro.2015.05.057; POTHOULAKIS C, 1994, P NATL ACAD SCI USA, V91, P947, DOI 10.1073/pnas.91.3.947; Renzi D, 2000, AM J PATHOL, V157, P1511, DOI 10.1016/S0002-9440(10)64789-X; Samperio PM, 2004, MEDIAT INFLAMM, V13, P343, DOI 10.1080/09629350400014099; Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X; Steinhoff MS, 2014, PHYSIOL REV, V94, P265, DOI 10.1152/physrev.00031.2013; Stucchi AF, 2003, AM J PHYSIOL-GASTR L, V285, pG1259, DOI 10.1152/ajpgi.00063.2003; Sun P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069424; Tansky MF, 2007, P NATL ACAD SCI USA, V104, P10691, DOI 10.1073/pnas.0703394104; Thomas Saskia, 2012, Inflammopharmacology, V20, P1, DOI 10.1007/s10787-011-0104-6; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Viennois Emilie, 2013, BMC Res Notes, V6, P360, DOI 10.1186/1756-0500-6-360; Wang CJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14553; Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016; Wu F, 2008, GASTROENTEROLOGY, V135, P1624, DOI 10.1053/j.gastro.2008.07.068; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365; Zhao DZ, 2002, BIOCHEM J, V368, P665, DOI 10.1042/BJ20020950	48	2	2	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					586	599		10.1016/j.ajpath.2017.10.023			14	Pathology	Pathology	FY4OT	WOS:000426805100005	29253460	Bronze, Green Published			2019-10-28	
J	Kennedy, L; Hargrove, L; Demieville, J; Bailey, JM; Dar, W; Polireddy, K; Chen, QZ; Rubin, MIN; Sybenga, A; DeMorrow, S; Meng, FY; Stockton, L; Alpini, G; Francis, H				Kennedy, Lindsey; Hargrove, Laura; Demieville, Jennifer; Bailey, Jennifer M.; Dar, Wasim; Polireddy, Kishore; Chen, Qingzheng; Rubin, Moises I. Nevah; Sybenga, Amelia; DeMorrow, Sharon; Meng, Fanyin; Stockton, Lindsey; Alpini, Gianfranco; Francis, Heather			Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BILE-DUCT LIGATION; LIVER DISEASE/NONALCOHOLIC STEATOHEPATITIS; HYPOTHALAMIC NEURONAL HISTAMINE; PRIMARY SCLEROSING CHOLANGITIS; INDUCED BILIARY HYPERPLASIA; NONALCOHOLIC-STEATOHEPATITIS; TARGETED DISRUPTION; CELLULAR SENESCENCE; DOWN-REGULATION; INDUCED OBESITY	Feeding a high-fat diet (HFD) coupled with sugar, mimicking a Western diet, causes fatty liver disease in mice. Histamine induces biliary proliferation and fibrosis and regulates leptin signaling. Wild-type (WT) and L-histidine decarboxylase (Hdc(-/-)) mice were fed a control diet or an HFD coupled with a high fructose corn syrup equivalent. Hematoxylin and eosin and Oil Red 0 staining were performed to determine steatosis. Biliary mass and cholangiocyte proliferation were evaluated by immunohistochemistry. Senescence and fibrosis were measured by quantitative PCR and immunohisto-chemistry. Hepatic stellate cell activation was detected by immunofluorescence. Histamine and leptin levels were measured by enzyme immunoassay. Leptin receptor (Ob-R) was evaluated by quantitative PCR. The HDC/histamine/histamine receptor axis, ductular reaction, and biliary senescence were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, or end-stage Liver disease. Hdc(-/-) HFD mice had increased steatosis compared with WT HFD mice. WT HFD mice had increased biliary mass, biliary proliferation, senescence, fibrosis, and hepatic stellate cell activation, which were reduced in HdC(-/-) HFD mice. In Hdc(-/-) HFD mice, serum leptin levels increased, whereas biliary Ob-R expression decreased. Nonalcoholic steatohepatitis patients had increased HDC/histamine/histamine receptor signaling. Hdc(-/-) HFD mice are susceptible to obesity via dysregulated Leptin/Ob-R signaling, whereas the lack of HDC protects from HFD-induced fibrosis and cholangiocyte damage. HDC/histamine/leptin signaling may be important in managing obesity-induced biliary damage.	[Kennedy, Lindsey; Demieville, Jennifer; DeMorrow, Sharon; Meng, Fanyin; Alpini, Gianfranco; Francis, Heather] Texas A&M Hlth Sci Ctr, Coll Med, Dept Res, Bryan, TX USA; [Kennedy, Lindsey; Hargrove, Laura; DeMorrow, Sharon; Alpini, Gianfranco; Francis, Heather] Texas A&M Hlth Sci Ctr, Coll Med, Cent Texas Vet Hlth Care Syst, Bryan, TX USA; [Kennedy, Lindsey; Hargrove, Laura; DeMorrow, Sharon; Alpini, Gianfranco; Francis, Heather] Texas A&M Hlth Sci Ctr, Coll Med, Dept Med Physiol, Bryan, TX USA; [Bailey, Jennifer M.; Polireddy, Kishore; Chen, Qingzheng; Rubin, Moises I. Nevah] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Div Gastroenterol, Houston, TX 77030 USA; [Dar, Wasim] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Dept Internal Med, Houston, TX 77030 USA; [Dar, Wasim] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Div Immunol & Organ Transplantat, Houston, TX 77030 USA; [Sybenga, Amelia] Baylor Scott & White Hlth, Dept Anat & Clin Pathol, Temple, TX USA; [DeMorrow, Sharon; Meng, Fanyin; Stockton, Lindsey; Alpini, Gianfranco; Francis, Heather] Baylor Scott & White Hlth Digest Dis Res Ctr, Dept Res, Temple, TX USA	Francis, H (reprint author), Texas A&M Univ, Cent Texas Vet Hlth Care Syst, Baylor Scott & White Hlth, Coll Med,Dept Med Physiol, 1901 S 1st St, Temple, TX 76504 USA.	hfrancis@medicine.tamhsc.edu		Sybenga, Amelia/0000-0001-9231-6800	US Department of Veteran's Affairs VA Merit award [1I01BX003031]; Biomedical Laboratory Research and Development Service VA Research Career Scientist Award; NIH National Institute of Diabetes and Digestive and Kidney Diseases Biomedical Laboratory Research and Development Service; PSC Partners Seeking a Cure; VA Merit awardUS Department of Veteran Affairs [5I01BX000574];  [RO1 DK108959];  [RO1 DK082435]	Supported in part by the US Department of Veteran's Affairs VA Merit award 1I01BX003031 (H.F.), Biomedical Laboratory Research and Development Service VA Research Career Scientist Award (G.A.), VA Merit award 5I01BX000574 (G.A.), NIH National Institute of Diabetes and Digestive and Kidney Diseases Biomedical Laboratory Research and Development Service and RO1 DK108959 (H.F.) and RO1 DK082435 (S.D.M.), the PSC Partners Seeking a Cure (H.F. and S.D.M.), and the Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology from Baylor Scott & White Health (G.A.). This material is the result of work supported with resources and the use of facilities at the Central Texas Veterans Health Care System (Temple, TX).	Alpini G, 1998, AM J PHYSIOL-GASTR L, V274, pG767; Aravinthan A, 2014, CELL CYCLE, V13, P1489, DOI 10.4161/cc.28471; Aravinthan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072904; Aravinthan A, 2013, J HEPATOL, V58, P549, DOI 10.1016/j.jhep.2012.10.031; Brunt EM, 2005, HEPATOL RES, V33, P68, DOI 10.1016/j.hepres.2005.09.006; Bugianesi Elisabetta, 2016, Recenti Progressi in Medicina, V107, P360, DOI 10.1701/2318.24928; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dattaroy D, 2015, AM J PHYSIOL-GASTR L, V308, pG298, DOI 10.1152/ajpgi.00346.2014; Duvnjak M, 2007, WORLD J GASTROENTERO, V13, P4539, DOI 10.3748/wjg.v13.i34.4539; Fitzgerald KR, 2013, J VASC NURS, V31, P131, DOI 10.1016/j.jvn.2013.06.004; Francis H, 2008, AM J PHYSIOL-CELL PH, V295, pC499, DOI 10.1152/ajpcell.00369.2007; Francis H, 2007, LAB INVEST, V87, P473, DOI 10.1038/labinvest.3700533; Francis H, 2012, GUT, V61, P753, DOI 10.1136/gutjnl-2011-300007; Francis HL, 2012, LAB INVEST, V92, P282, DOI 10.1038/labinvest.2011.158; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Friedman SL, 2008, TOXICOLOGY, V254, P120, DOI 10.1016/j.tox.2008.06.013; Fulop AK, 2003, ENDOCRINOLOGY, V144, P4306, DOI 10.1210/en.2003-0222; Ganz M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0552-7; Glaser S, 2014, GASTROENTEROLOGY, V146, P1795, DOI 10.1053/j.gastro.2014.02.030; Glaser SS, 2009, LAB INVEST, V89, P456, DOI 10.1038/labinvest.2009.6; Graf A, 2014, AM J PHYSIOL-GASTR L, V307, pG813, DOI 10.1152/ajpgi.00188.2014; Gutierrez-Reyes G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010231; Hargrove L, 2017, HEPATOLOGY, V65, P1991, DOI 10.1002/hep.29079; Ishizuka T, 2008, BEHAV BRAIN RES, V188, P250, DOI 10.1016/j.bbr.2007.11.001; Itateyama E, 2003, EXP BIOL MED, V228, P1132; Johnson C, 2015, DIGEST LIVER DIS, V47, P211, DOI 10.1016/j.dld.2014.12.006; Jones H, 2016, HEPATOLOGY, V64, P1202, DOI 10.1002/hep.28704; Jorgensen EA, 2007, NEUROENDOCRINOLOGY, V86, P210, DOI 10.1159/000108341; Jorgensen EA, 2006, NEUROENDOCRINOLOGY, V83, P289, DOI 10.1159/000095339; Kennedy LL, 2014, LAB INVEST, V94, P1406, DOI 10.1038/labinvest.2014.129; Masaki T, 2004, DIABETES, V53, P2250, DOI 10.2337/diabetes.53.9.2250; Masaki T, 2001, DIABETES, V50, P385, DOI 10.2337/diabetes.50.2.385; McDaniel K, 2017, HEPATOLOGY, V65, P544, DOI 10.1002/hep.28831; Mells JE, 2015, J NUTR BIOCHEM, V26, P285, DOI 10.1016/j.jnutbio.2014.11.002; Muff MA, 2006, LAB INVEST, V86, P940, DOI 10.1038/labinvest.3700448; O'Hara SP, 2011, J BIOL CHEM, V286, P30352, DOI 10.1074/jbc.M111.269464; Polyzos SA, 2009, CURR MOL MED, V9, P299, DOI 10.2174/156652409787847191; Ray D, 2015, AM J PATHOL, V185, P1061, DOI 10.1016/j.ajpath.2014.12.004; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Sasaki M, 2005, J PATHOL, V205, P451, DOI 10.1002/path.1729; Smagris E, 2016, J BIOL CHEM, V291, P10659, DOI 10.1074/jbc.M116.719955; Sorrentino P, 2005, DIGEST DIS SCI, V50, P1130, DOI 10.1007/s10620-005-2719-1; Tabibian JH, 2014, HEPATOLOGY, V59, P2263, DOI 10.1002/hep.26993; Takahashi Y, 2014, WORLD J GASTROENTERO, V20, P15539, DOI 10.3748/wjg.v20.i42.15539; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Toftegaard CL, 2003, REGUL PEPTIDES, V111, P83, DOI 10.1016/S0167-0115(02)00260-4; Wan Y, 2017, HEPATOLOGY, V66, P528, DOI 10.1002/hep.29138; Wang KY, 2010, AM J PATHOL, V177, P713, DOI 10.2353/ajpath.2010.091198; Wood JD, 2006, GUT, V55, P445, DOI 10.1136/gut.2005.079046; Yoshimatsu H, 2008, NUTRITION, V24, P827, DOI 10.1016/j.nut.2008.06.014; Yoshimatsu K, 1999, DIABETES, V48, P2286, DOI 10.2337/diabetes.48.12.2286	51	3	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					600	615		10.1016/j.ajpath.2017.11.016			16	Pathology	Pathology	FY4OT	WOS:000426805100006	29248461	Green Published, Bronze			2019-10-28	
J	Zolghadri, Y; Choudhuri, SP; Ocal, O; Layeghi-Ghalehsoukhteh, S; Berhe, F; Hale, MA; Wilkie, TM				Zolghadri, Yalda; Choudhuri, Shreoshi Pal; Ocal, Ozhan; Layeghi-Ghalehsoukhteh, Somayeh; Berhe, Feaven; Hale, Michael A.; Wilkie, Thomas M.			Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA) Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENGINEERED MOUSE MODELS; EXOCRINE INSUFFICIENCY; ACINAR-CELLS; PERIAMPULLARY CANCER; REPLACEMENT THERAPY; HORMONAL-REGULATION; ONCOGENIC KRAS; SECRETION; MICE; PROGRESSION	Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists efforts to identify better chemotherapeutics. PDA is associated with chronic pancreatitis and acinar cell dedifferentiation. This reduces enzyme production by the exocrine pancreas, resulting in digestive insufficiencies. Malabsorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition. These maladies affect quality of life and restrict treatment options for pancreatitis and PDA. Here, we characterize health benefits and risks of dietary pancreatic enzymes in three mouse models of PDA-KC, KCR8-16, and KIC. KC expresses oncogenic Kras(G12D) in pancreatic tissue whereas KCR8-16 also has deletions of the Rgs8 and Rgs16 genes. Rgs proteins inhibit the release of digestive enzymes evoked by G-protein-coupled-receptor agonists. KC and KCR8-16 mice developed dedifferentiated exocrine pancreata within 2 months of age and became malnourished, underweight, hypoglycemic, and hypothermic. KC mice adapted but KCR8-16 mice rapidly transitioned to starvation after mild metabolic challenges. Dietary pancreatic enzyme supplements reversed these symptoms in KC and KCR8-16 animals, and extended survival. Therefore, we tested the benefits of pancreatic enzymes in an aggressive mouse model of PDA (KIC). Median survival improved with dietary pancreatic enzyme supplements and was extended further when combined with warfarin and gemcitabine chemotherapy. However, dietary pancreatic enzymes stimulated tumor growth in the terminal stages of disease progression in KIC mice.	[Zolghadri, Yalda; Choudhuri, Shreoshi Pal; Ocal, Ozhan; Layeghi-Ghalehsoukhteh, Somayeh; Berhe, Feaven; Wilkie, Thomas M.] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk Dr, Dallas, TX USA; [Hale, Michael A.] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Zolghadri, Yalda; Layeghi-Ghalehsoukhteh, Somayeh] Shiraz Univ, Sch Vet Med, Dept Basic Sci, Shiraz, Iran; [Ocal, Ozhan] Bilkent Univ, Dept Mol Biol & Genet, Ankara, Turkey	Wilkie, TM (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk Dr, Dallas, TX USA.	thomas.wilkie@utsouthwestern.edu	Choudhuri, Shreoshi Pal/I-4251-2019	Ocal, Ozhan/0000-0002-4260-6778	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA161624]; NIHGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [61395]; University of Texas Southwestern Cancer Center Pilot Project Award; Ministry of Science, Research and Technology training fellowships	Supported by National Cancer Institute grants CA161624 and NIHGMS 61395 (T.M.W.); a University of Texas Southwestern Cancer Center Pilot Project Award (T.M.W.); and Ministry of Science, Research and Technology training fellowships to Shiraz University (Y.Z. and S.L.-G.).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bartel MJ, 2015, DIGEST LIVER DIS, V47, P1013, DOI 10.1016/j.dld.2015.06.015; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Chandra R, 2009, CURR OPIN GASTROEN, V25, P441, DOI 10.1097/MOG.0b013e32832e9c41; Chey WY, 2001, PANCREATOLOGY, V1, P320, DOI 10.1159/000055831; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; Damerla Venugopal, 2008, J Support Oncol, V6, P393; Dey P, 2014, ONCOTARGET, V5, P4480, DOI 10.18632/oncotarget.2041; Fieker A, 2011, CLIN EXP GASTROENTER, V4, P55, DOI 10.2147/CEG.S17634; Gooden HM, 2013, SUPPORT CARE CANCER, V21, P1835, DOI 10.1007/s00520-013-1729-3; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Hackert Thilo, 2014, Viszeralmedizin, V30, P190, DOI 10.1159/000363778; Herreros-Villanueva M, 2012, WORLD J GASTROENTERO, V18, P1286, DOI 10.3748/wjg.v18.i12.1286; Huang Jie, 2006, Comp Hepatol, V5, P8, DOI 10.1186/1476-5926-5-8; Ijichi H, 2011, WORLD J CLIN ONCOL, V2, P195, DOI 10.5306/wjco.v2.i5.195; Imrie CW, 2010, ALIMENT PHARM THER, V32, P1, DOI 10.1111/j.1365-2036.2010.04437.x; Kirane A, 2015, CANCER RES, V75, P3699, DOI 10.1158/0008-5472.CAN-14-2887-T; Krah NM, 2015, ELIFE, V4, DOI 10.7554/eLife.07125; Lanza-Jacoby S, 2013, EXP BIOL MED, V238, P787, DOI 10.1177/1535370213493727; Lashinger LM, 2013, CANCER PREV RES, V6, P1046, DOI 10.1158/1940-6207.CAPR-13-0185; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Murphy JA, 2008, GASTROENTEROLOGY, V135, P632, DOI 10.1053/j.gastro.2008.05.026; Murtaugh LC, 2015, ANNU REV PHYSIOL, V77, P229, DOI 10.1146/annurev-physiol-021014-071727; Ocal O, 2015, DIS MODEL MECH, V8, P1201, DOI 10.1242/dmm.020933; Pashkov V, 2011, J BIOL CHEM, V286, P15116, DOI 10.1074/jbc.M110.216234; Petersen OH, 2009, BRAZ J MED BIOL RES, V42, P9, DOI 10.1590/S0100-879X2009000100003; Pezzilli R, 2013, WORLD J GASTROENTERO, V19, P7930, DOI 10.3748/wjg.v19.i44.7930; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; PRZYBYLA AE, 1979, J BIOL CHEM, V254, P2154; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Tseng DSJ, 2016, PANCREAS, V45, P325, DOI 10.1097/MPA.0000000000000473; Villasenor A, 2010, DIS MODEL MECH, V3, P567, DOI 10.1242/dmm.003210; Vujasinovic M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030183; Watson L, 2010, CLIN ONCOL-UK, V22, P391, DOI 10.1016/j.clon.2010.03.004; Westphalen CB, 2012, CANCER J, V18, P502, DOI 10.1097/PPO.0b013e31827ab4c4; WILLIAMS JA, 1980, AM J PHYSIOL, V238, pG269; Williams JA, 2010, CURR OPIN GASTROEN, V26, P478, DOI 10.1097/MOG.0b013e32833d11c6; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	44	1	1	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					616	626		10.1016/j.ajpath.2017.11.014			11	Pathology	Pathology	FY4OT	WOS:000426805100007	29248457	Bronze, Green Published			2019-10-28	
J	Ramani, K; Tomasi, ML; Berlind, J; Mavila, N; Sun, ZL				Ramani, Komal; Tomasi, Maria Lauda; Berlind, Joshua; Mavila, Nirmala; Sun, Zhaoli			Role of A-Kinase Anchoring Protein Phosphorylation in Alcohol-Induced Liver Injury and Hepatic Stellate Cell Activation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							COLLAGEN-SPECIFIC CHAPERONE; IN-VITRO; EXPRESSION; FIBROSIS; CANCER; SSECKS; HSP47; DISEASE; TARGETS; GENES	Alcoholic Liver injury is associated with hepatic stellate cell (HSC) activation. A-kinase anchoring protein 12 (AKAP12) scaffolds protein kinase C and cyclin-D1, which is regulated by its phosphorylation, and spatiotemporally controls cell proliferation, invasiveness, and chemotaxis. HSC activation induces AKAP12 expression, but the role of AKAP12's scaf-folding activity in liver function is unknown. Because AKAP12 phosphorylation is enhanced in ethanol-treated HSCs, we examined AKAP12's scaffolding functions in alcohol-mediated HSC activation and liver injury. AKAP12 expression, interaction, and phosphorylation were assayed in in vitro and in vivo ethanol models and human subjects by real-time PCR, coimmunoprecipitation, immunoblotting, and phosphorylated proteomics/Phos-tag. Ethanol induced AKAP12 phosphorylation in the liver and in primary HSCs, but not in hepatocytes. AKAP12's scaffolding activity for protein kinase C/cyclin-D1 decreased in ethanol-treated HSCs but not hepatocytes. AKAP12 negatively regulated HSC activation, which was reversed by ethanol-mediated AKAP12 phosphorylation. AKAP12 interacted with heat shock protein 47 (HSP47), which chaperones collagen and induces its secretion. Ethanol inhibited AKAP12-HSP47 and induced HSP47-collagen interaction. Ethanol-induced phosphorylated AKAP12 was unable to bind to HSP47 compared with its unphosphorylated counterpart, thereby proving that ethanol-mediated phosphorylation of AKAP12 inhibited the HSP47-AKAP12 scaffold. Silencing AKAP12 facilitated the chaperoning of collagen by HSP47. Hence, AKAP12 scaffolds HSP47 and regulates collagen-HSP47 interaction. Ethanol quenches AKAP12's scaffolding activity through phosphorylation and facilitates HSC activation.	[Ramani, Komal; Tomasi, Maria Lauda; Berlind, Joshua; Mavila, Nirmala] Cedars Sinai Med Ctr, Dept Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA; [Sun, Zhaoli] Johns Hopkins Univ, Sch Med, Transplant Biol Res Ctr, Baltimore, MD USA	Ramani, K (reprint author), Cedars Sinai Med Ctr, Dept Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	ramani@cshs.org		Berlind, Joshua/0000-0001-8893-5692	NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R24AA025017]	We thank the liver research group (Cedars-Sinai Medical Center), headed by Dr. Shelly Lu, for core support; Dr. Bin Gao [National Institute on Alcohol Abuse and Alcoholism (NIAAA)] for scientific advice and samples from ethanol fed mouse model; the Kansas University Liver Bank for alcoholic liver disease samples; Dr. Hidekazu Tsukamoto (Southern California Research Center for ALPD and Cirrhosis) for scientific advice; Dr. Heping Yang (Cedars Sinai Medical Center) for providing protein extracts and paraffin-embedded slides from 10-day-old bile duct ligation mice livers and the sham controls; Dr. Zhaoli Sun [NIAAA-supported Clinical Resource for Alcoholic Hepatitis Investigations at Johns Hopkins University (R24AA025017)] for providing and processing three normal human and three alcoholic hepatitis liver samples; and the Kansas University Medical Center Liver Center tissue bank for providing three deidentified normal and three ALD liver tissues (pathologically alcoholic cirrhosis).	Akakura Shin, 2012, J Signal Transduct, V2012, P529179, DOI 10.1155/2012/529179; Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032; Brown KE, 2005, LAB INVEST, V85, P789, DOI 10.1038/labinvest.3700271; Canton DA, 2012, MOL CELL, V48, P547, DOI 10.1016/j.molcel.2012.09.002; Carnegie GK, 2009, IUBMB LIFE, V61, P394, DOI 10.1002/iub.168; Clugston RD, 2012, NUTRIENTS, V4, P356, DOI 10.3390/nu4050356; Deshpande KT, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010005; Friedman SL, 1999, ALCOHOL CLIN EXP RES, V23, P904, DOI 10.1097/00000374-199905000-00020; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Gao B, 2011, GASTROENTEROLOGY, V141, P1572, DOI 10.1053/j.gastro.2011.09.002; Gelman Irwin H, 2010, Genes Cancer, V1, P1147, DOI 10.1177/1947601910392984; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; Huang BX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061430; Kawasaki K, 2015, J BIOL CHEM, V290, P3639, DOI 10.1074/jbc.M114.592139; Kinoshita E, 2009, NAT PROTOC, V4, P1513, DOI 10.1038/nprot.2009.154; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Mavila N, 2014, HEPATOLOGY, V60, P941, DOI 10.1002/hep.27203; Ramani K, 2008, HEPATOLOGY, V47, P521, DOI 10.1002/hep.22064; Ramani K, 2015, J CELL PHYSIOL, V230, P1075, DOI 10.1002/jcp.24839; Ramani K, 2012, HEPATOLOGY, V55, P1942, DOI 10.1002/hep.25594; Ramani K, 2010, HEPATOLOGY, V51, P986, DOI 10.1002/hep.23411; Ron D, 2013, CURR TOP BEHAV NEURO, V13, P87, DOI 10.1007/7854_2011_161; Sato Y, 2008, NAT BIOTECHNOL, V26, P431, DOI 10.1038/nbt1396; Schnabl B, 2002, LAB INVEST, V82, P323, DOI 10.1038/labinvest.3780426; Shimada H, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S12; Su B, 2010, J BIOL CHEM, V285, P4578, DOI 10.1074/jbc.M109.073494; Swift B, 2010, DRUG METAB REV, V42, P446, DOI 10.3109/03602530903491881; Tomasi ML, 2016, AM J PATHOL, V186, P2326, DOI 10.1016/j.ajpath.2016.05.007; Troger J, 2012, BRIT J PHARMACOL, V166, P420, DOI 10.1111/j.1476-5381.2011.01796.x; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; Udoh US, 2015, BIOMOLECULES, V5, P2504, DOI 10.3390/biom5042504; Xia W, 2002, EXP CELL RES, V277, P139, DOI 10.1006/excr.2002.5560; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; You TG, 2013, INFLAMMATION, V36, P1415, DOI 10.1007/s10753-013-9681-4	36	1	1	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					640	655		10.1016/j.ajpath.2017.11.017			16	Pathology	Pathology	FY4OT	WOS:000426805100009	29305319	Green Published			2019-10-28	
J	Li, LY; Qian, MX; Chen, IH; Finkelstein, D; Onar-Thomas, A; Johnson, M; Calabrese, C; Bahrain, A; Lopez-Terrada, DH; Yang, JJ; Tao, WA; Zhu, LQ				Li, Liyuan; Qian, Maoxiang; Chen, I-Hsuan; Finkelstein, David; Onar-Thomas, Arzu; Johnson, Melissa; Calabrese, Christopher; Bahrain, Armita; Lopez-Terrada, Dolores H.; Yang, Jun J.; Tao, W. Andy; Zhu, Liqin			Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CANCER STEM-CELLS; HEPATIC PROGENITOR CELLS; TUMOR-INITIATING CELLS; PRIMARY LIVER-CANCER; SIGNALING PATHWAY; EXTRACELLULAR VESICLES; INTRAHEPATIC CHOLANGIOCARCINOMA; BREAST-CANCER; SELF-RENEWAL; EXPRESSION	Past studies have identified hepatic tumors with mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) characteristics that have a more aggressive behavior and a poorer prognosis than classic HCC. Whether this pathologic heterogeneity is due to a cell of origin of bipotent liver progenitors or the plasticity of cellular constituents comprising these tumors remains debated. In this study, we investigated the potential acquisition of CC-like traits during advanced development of HCC in mice. Primary and rare high-grade HCC developed in a genetic mouse model. A mouse model of highly efficient HCC invasion and metastasis by orthotopic transplantation of liver cancer organoids propagated from primary tumors in the genetic model was further developed. Invasive/metastatic tumors developed in both models closely recapitulated advanced human HCC and displayed a striking acquisition of CC related pathologic and molecular features, which was absent in the primary HCC tumors. Our study directly demonstrates the pathologic evolution of HCC during advanced tumor development, providing the first evidence that tumors with mixed HCC and CC features, or at least a subset of these tumors, represent a more advanced developmental stage of HCC. Finally, liver cancer organoid-generated high-grade tumors exhibited significantly increased extracellular vesicle secretion, suggesting that identifying tumor-specific extracellular vesicle proteins in plasma may be a promising tool for liver cancer detection.	[Li, Liyuan; Qian, Maoxiang; Yang, Jun J.; Zhu, Liqin] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Finkelstein, David; Tao, W. Andy] St Jude Childrens Res Hosp, Dept Computat Biol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Onar-Thomas, Arzu] St Jude Childrens Res Hosp, Dept Stat, 332 N Lauderdale St, Memphis, TN 38105 USA; [Johnson, Melissa; Calabrese, Christopher] St Jude Childrens Res Hosp, Dept Small Anim Clin Core, 332 N Lauderdale St, Memphis, TN 38105 USA; [Bahrain, Armita] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Chen, I-Hsuan; Tao, W. Andy] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Lopez-Terrada, Dolores H.] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; [Lopez-Terrada, Dolores H.] Baylor Coll Med, Houston, TX 77030 USA	Zhu, LQ (reprint author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	liqin.zhu@stjude.org	Bahrami, Armita/N-3262-2018; Onar-Thomas, Arzu/M-9356-2018; Tao, Andy/N-1290-2019; Zhu, Liqin/N-8126-2018	Bahrami, Armita/0000-0002-8515-2649; Zhu, Liqin/0000-0002-2346-150X	St. Jude Children's Research Hospital Comprehensive Cancer Center Developmental Funds Parent Grant [P30 CA021765]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01GM111788, 5R01GM088317]	Supported by St. Jude Children's Research Hospital Comprehensive Cancer Center Developmental Funds Parent Grant P30 CA021765 (L.Z.) and NIH grants 5R01GM088317 and 5R01GM111788 (W.A.T.).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Andersen JB, 2010, HEPATOLOGY, V51, P1401, DOI 10.1002/hep.23488; Arbelaiz A, 2017, HEPATOLOGY, V66, P1125, DOI [10.1002/hep.29291/suppinfo, 10.1002/hep.29291]; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Bock BC, 2014, CANCER RES, V74, P4671, DOI 10.1158/0008-5472.CAN-14-1424; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Calderaro J, 2017, J HEPATOL, V67, P727, DOI 10.1016/j.jhep.2017.05.014; Cancer Genome Atlas Research Network, 2017, CELL, V169, pe23; Cazals-Hatem D, 2004, J HEPATOL, V41, P292, DOI 10.1016/j.jhep.2004.04.030; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chao A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133081; Chen IH, 2017, P NATL ACAD SCI USA, V114, P3175, DOI 10.1073/pnas.1618088114; Chiba T, 2016, HEPATOL RES, V46, P50, DOI 10.1111/hepr.12548; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Cui J, 2004, WORLD J GASTROENTERO, V10, P1533; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Falkenberg N, 2016, CANCER MED-US, V5, P703, DOI 10.1002/cam4.630; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; HERREROSVILLANUEVA, 2016, ANN TRANSL MED, V4, DOI DOI 10.3978/J.ISSN.2305-5839.2015.10.39; Higashiyama M, 2012, J THORAC DIS, V4, P30, DOI 10.3978/j.issn.2072-1439.2011.05.02; Holczbauer A, 2013, GASTROENTEROLOGY, V145, P221, DOI 10.1053/j.gastro.2013.03.013; Hou Y, 2012, CELL RES, V22, P259, DOI 10.1038/cr.2011.139; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104; Julich-Haertel H, 2017, J HEPATOL, V67, P282, DOI 10.1016/j.jhep.2017.02.024; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kern DH, 1998, CANCER J SCI AM, V4, P41; Kordes C, 2007, BIOCHEM BIOPH RES CO, V352, P410, DOI 10.1016/j.bbrc.2006.11.029; Kowalik MA, 2015, ONCOTARGET, V6, P38749, DOI 10.18632/oncotarget.5501; Kuhlmann WD, 2006, INT J EXP PATHOL, V87, P343, DOI 10.1111/j.1365-2613.2006.00485.x; Lee CW, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-136; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Libbrecht L, 2006, WORLD J GASTROENTERO, V12, P6261, DOI 10.3748/wjg.v12.i39.6261; Liu CG, 2016, HEPATOLOGY, V64, P117, DOI 10.1002/hep.28509; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Merino-Azpitarte M, 2017, J HEPATOL, V67, P72, DOI 10.1016/j.jhep.2017.02.017; Okumoto K, 2004, LIVER INT, V24, P21, DOI 10.1111/j.1478-3231.2004.00882.x; Polakis P, 2000, GENE DEV, V14, P1837; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Rountree CB, 2012, HEPATOLOGY, V55, P298, DOI 10.1002/hep.24762; Salnikov AV, 2009, CANCER LETT, V275, P185, DOI 10.1016/j.canlet.2008.10.015; Schmelzer E, 2007, J EXP MED, V204, P1973, DOI 10.1084/jem.20061603; Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Shang SF, 2012, HEPATOLOGY, V55, P483, DOI 10.1002/hep.24703; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sugimachi K, 2017, ONCOLOGY-BASEL, V93, P67, DOI 10.1159/000463390; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Villanueva A, 2012, CLIN CANCER RES, V18, P1824, DOI 10.1158/1078-0432.CCR-12-0151; Wan JL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1692-0; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Wang YP, 2013, CANCER LETT, V337, P96, DOI 10.1016/j.canlet.2013.05.019; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yakaboski Elizabeth, 2014, Hepatology, V60, P419, DOI 10.1002/hep.26956; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yap LF, 2009, ONCOGENE, V28, P2524, DOI 10.1038/onc.2009.105; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zender S, 2013, CANCER CELL, V23, P784, DOI 10.1016/j.ccr.2013.04.019; Zhang F, 2008, HISTOPATHOLOGY, V52, P224, DOI 10.1111/j.1365-2559.2007.02929.x; Zhao J, 2008, GASTROENTEROLOGY, V135, P956, DOI 10.1053/j.gastro.2008.05.025; Zhu LQ, 2016, CELL, V166, P1132, DOI 10.1016/j.cell.2016.07.045; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	84	0	0	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					656	671		10.1016/j.ajpath.2017.11.013			16	Pathology	Pathology	FY4OT	WOS:000426805100010	29248454	Green Published, Bronze			2019-10-28	
J	Crossland, NA; Alvarez, X; Embers, ME				Crossland, Nicholas A.; Alvarez, Xavier; Embers, Monica E.			Late Disseminated Lyme Disease Associated Pathology and Spirochete Persistence Posttreatment in Rhesus Macaques	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NONHUMAN PRIMATE MODEL; BORRELIA-BURGDORFERI; ANTIBIOTIC-TREATMENT; ORAL DOXYCYCLINE; UNITED-STATES; MICE; NEUROBORRELIOSIS; INFECTION; INFLAMMATION; ARTHRITIS	Nonhuman primates currently serve as the best experimental model for Lyme disease because of their close genetic homology with humans and demonstration of all three phases of disease after infection with Borrelia burgdorferi. We investigated the pathology associated with late disseminated Lyme disease (12 to 13 months after tick inoculation) in doxycycline-treated (28 days; 5 mg/kg, oral, twice daily) and untreated rhesus macaques. Minimal to moderate lymphoplasmacytic inflammation, with a predilection for perivascular spaces and collagenous tissues, was observed in multiple tissues, including the cerebral leptomeninges, brainstem, peripheral nerves from both fore and hind limbs, stifle synovium and perisynovial adipose tissue, urinary bladder, skeletal muscle, myocardium, and visceral pericardium. Indirect immunofluorescence assays that combined monoclonal (outer surface protein A) and polyclonal antibodies were performed on all tissue sections that contained inflammation. Rare morphologically intact spirochetes were observed in the brains of two treated rhesus macaques, the heart of one treated rhesus macaque, and adjacent to a peripheral nerve of an untreated animal. Borrelia antigen staining of probable spirochete cross sections was also observed in heart, skeletal muscle, and near peripheral nerves of treated and untreated animals. These findings support the notion that chronic Lyme disease symptoms can be attributable to residual inflammation in and around tissues that harbor a low burden of persistent host-adapted spirochetes and/or residual antigen.	[Crossland, Nicholas A.; Embers, Monica E.] Tulane Univ Hlth Sci, Tulane Natl Primate Res Ctr, Div Bacteriol, Covington, LA USA; [Crossland, Nicholas A.; Embers, Monica E.] Tulane Univ Hlth Sci, Tulane Natl Primate Res Ctr, Div Parasitol, Covington, LA USA; [Alvarez, Xavier] Tulane Univ Hlth Sci, Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA USA	Embers, ME (reprint author), Tulane Univ Hlth Sci, Tulane Natl Primate Res Ctr, 18703 Three Rivers Rd, Covington, LA 70433 USA.	members@tulane.edu		Crossland, Nicholas/0000-0003-3873-9188	Louisiana Center of Biomedical Research Excellence in Experimental Infectious Disease Research grant [2P20-RR020159-08]; Tulane National Primate Research Center NIH [5 P51 OD 011104-56]; Bay Area Lyme Foundation; Steven and Alexandra Cohen Foundation	Supported by Louisiana Center of Biomedical Research Excellence in Experimental Infectious Disease Research grant 2P20-RR020159-08 (M.E.E.), Tulane National Primate Research Center NIH base grant 5 P51 OD 011104-56, the Bay Area Lyme Foundation (M.E.E.), and the Steven and Alexandra Cohen Foundation (M.E.E.).	Aucott JN, 2015, INFECT DIS CLIN N AM, V29, P309, DOI 10.1016/j.idc.2015.02.012; Aucott JN, 2013, INT J INFECT DIS, V17, pE443, DOI 10.1016/j.ijid.2013.01.008; Bacon Rendi Murphree, 2008, Morbidity and Mortality Weekly Report, V57, P1; Bai YH, 2004, LAB INVEST, V84, P160, DOI 10.1038/labinvest.3700024; Barthold SW, 2010, ANTIMICROB AGENTS CH, V54, P643, DOI 10.1128/AAC.00788-09; Barthold SW, 2010, ANIMAL MODELS BORREL, P547; Berende A, 2016, NEW ENGL J MED, V374, P1209, DOI 10.1056/NEJMoa1505425; Bockenstedt LK, 2012, J CLIN INVEST, V122, P2652, DOI 10.1172/JCI58813; Bockenstedt LK, 2002, J INFECT DIS, V186, P1430, DOI 10.1086/345284; Bolz DD, 2004, AUTOIMMUNITY, V37, P387, DOI 10.1080/08916930410001713098; Bugrysheva JV, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-17; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Cabello FC, 2017, ENVIRON MICROBIOL, V19, P3846, DOI 10.1111/1462-2920.13897; Cadavid D, 2004, LAB INVEST, V84, P1439, DOI 10.1038/labinvest.3700177; Cadavid D, 2003, INFECT IMMUN, V71, P7087, DOI 10.1128/IAI.71.12.7087-7098.2003; Cadavid D, 2000, LAB INVEST, V80, P1043, DOI 10.1038/labinvest.3780109; Caskey JR, 2015, ANTIMICROB AGENTS CH, V59, P6288, DOI 10.1128/AAC.00883-15; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, COMM UPD GUID CAR US; Crowley H, 2003, INFECT IMMUN, V71, P4003, DOI 10.1128/IAI.71.7.4003-4010.2003; DOTEVALL L, 1989, ANTIMICROB AGENTS CH, V33, P1078, DOI 10.1128/AAC.33.7.1078; Embers ME, 2013, JOVE-J VIS EXP, V78, P50617; Embers ME, 2007, FEMS IMMUNOL MED MIC, V50, P421, DOI 10.1111/j.1574-695X.2007.00276.x; Embers ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189071; Embers ME, 2016, CLIN VACCINE IMMUNOL, V23, P294, DOI 10.1128/CVI.00685-15; Embers ME, 2013, J MED PRIMATOL, V42, P57, DOI 10.1111/jmp.12031; Embers ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029914; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Hinckley AF, 2014, CLIN INFECT DIS, V59, P676, DOI 10.1093/cid/ciu397; Hodzic E, 2008, ANTIMICROB AGENTS CH, V52, P1728, DOI 10.1128/AAC.01050-07; Hodzic E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086907; Indest KJ, 2001, INFECT IMMUN, V69, P7083, DOI 10.1128/IAI.69.11.7083-7090.2001; Jackson CR, 2007, INT J ANTIMICROB AG, V30, P496, DOI 10.1016/j.ijantimicag.2007.07.013; Kaplan RF, 2003, NEUROLOGY, V60, P1916, DOI 10.1212/01.WNL.0000068030.26992.25; KARLSSON M, 1994, NEUROLOGY, V44, P1203, DOI 10.1212/WNL.44.7.1203; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Lazarus JJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/138069; Li X, 2013, J INFECT DIS, V208, P934, DOI 10.1093/infdis/jit269; Marques A, 2008, INFECT DIS CLIN N AM, V22, P341, DOI 10.1016/j.idc.2007.12.011; Montgomery RR, 2006, INFECT IMMUN, V74, P2468, DOI 10.1128/IAI.74.4.2468-2472.2006; Muehlenbachs A, 2016, AM J PATHOL, V186, P1195, DOI 10.1016/j.ajpath.2015.12.027; PACHNER AR, 1995, NEUROLOGY, V45, P165, DOI 10.1212/WNL.45.1.165; PHILIPP MT, 1993, INFECT IMMUN, V61, P3047; Pulzova L, 2011, SCI REP-UK, V1, DOI 10.1038/srep00086; Ramesh G, 2008, AM J PATHOL, V173, P1415, DOI 10.2353/ajpath.2008.080483; Ramesh G, 2015, AM J PATHOL, V185, P1344, DOI 10.1016/j.ajpath.2015.01.024; Sapi E, 2016, EUR J MICROBIOL IMMU, V6, P9, DOI 10.1556/1886.2015.00049; SCHWAN TG, 1988, J CLIN MICROBIOL, V26, P893; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Schwan TG, 2000, J CLIN MICROBIOL, V38, P382; Sharma B, 2015, ANTIMICROB AGENTS CH, V59, P4616, DOI 10.1128/AAC.00864-15; Stanek G, 2011, CLIN MICROBIOL INFEC, V17, P487, DOI 10.1111/j.1469-0691.2011.03492.x; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; Straubinger RK, 1997, J CLIN MICROBIOL, V35, P111; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wormser GP, 2006, CLIN INFECT DIS, V43, P1089, DOI 10.1086/508667	57	10	10	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					672	682		10.1016/j.ajpath.2017.11.005			11	Pathology	Pathology	FY4OT	WOS:000426805100011	29242055	Green Published, Other Gold			2019-10-28	
J	Ohmaru-Nakanishi, T; Asanoma, K; Fujikawa, M; Fujita, Y; Yagi, H; Onoyama, I; Hidaka, N; Sonoda, K; Kato, K				Ohmaru-Nakanishi, Takako; Asanoma, Kazuo; Fujikawa, Mai; Fujita, Yasuyuki; Yagi, Hiroshi; Onoyama, Ichiro; Hidaka, Nobuhiro; Sonoda, Kenzo; Kato, Kiyoko			Fibrosis in Preeclamptic Placentas Is Associated with Stromal Fibroblasts Activated by the Transforming Growth Factor-beta 1 Signaling Pathway	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HUMAN TERM PLACENTA; IDIOPATHIC PULMONARY-FIBROSIS; FACTOR-BETA EXPRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TGF-BETA; GENE-EXPRESSION; CARDIAC FIBROSIS; TISSUE FIBROSIS; MESSENGER-RNA	Although fibrosis is one of the most prominent pathologic features of preeclamptic (PE) placentas, its mechanism remains largely unknown. Consistent with previous reports, we observed overexpression of collagen; actin, alpha 2, smooth muscle, aorta; connective tissue growth factor; and fibronectin in PE placentas compared with control ones. To investigate the mechanism of fibrosis in PE placentas, placental fibroblasts were isolated from PE placentas or normal pregnancies at delivery. The expression of fibrosis-related factors in fibroblasts was evaluated by real-time RT-PCR, Western blotting, enzyme linked immunosorbent assay, and gene microarrays. An in vitro collagen gel contraction assay was also performed. Fibroblasts isolated from PE placentas showed higher expression levels of fibrosis-related factors compared with those from control ones. Global gene expression profiling of PE fibroblasts was contrasted with that of control ones and indicated an intimate association with transforming growth factor-beta 1 (TGFB1) signaling. Furthermore, the PE fibroblasts expressed abundant phosphorylated SMAD family member 2 and showed higher expression levels of target genes of TGFB1 signaling compared with the control ones. The PE fibroblasts also had a greater ability to contract compared with the control ones. Contractility also depended on TGFB1 signaling. Our results suggest that TGFB1 signaling is activated in the fibroblasts in PE placentas and that these active fibroblasts contribute to fibrosis.	[Ohmaru-Nakanishi, Takako; Asanoma, Kazuo; Fujikawa, Mai; Fujita, Yasuyuki; Yagi, Hiroshi; Onoyama, Ichiro; Hidaka, Nobuhiro; Sonoda, Kenzo; Kato, Kiyoko] Kyushu Univ, Fac Med Sci, Dept Obstet & Gynecol, Fukuoka, Japan	Asanoma, K (reprint author), Kyushu Univ, Fac Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	asanoma@med.kyushu-u.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15H01517, JP15K15608, JP26462529, JP17K11280]; FUKUOKA OBGYN Researcher's Charity Foundation Fund, Japan	Supported by JSPS KAKENHI grants JP15H01517 (K.K.), JP15K15608 (K.K.), and JP26462529 (K.A.), and JP17K11280 (K.A.), and the FUKUOKA OBGYN Researcher's Charity Foundation Fund, Japan (T.O.).	Abumaree MH, 2013, STEM CELL REV REP, V9, P16, DOI 10.1007/s12015-012-9385-4; Agarwal R, 2001, MOL HUM REPROD, V7, P97, DOI 10.1093/molehr/7.1.97; Ando N, 1998, AM J REPROD IMMUNOL, V40, P48; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; Bhattacharyya S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008264; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Burton GJ, 2014, PLACENTA, V35, P9, DOI 10.1016/j.placenta.2013.11.005; Caniggia I, 1997, ENDOCRINOLOGY, V138, P4977, DOI 10.1210/en.138.11.4977; Chambers RC, 2002, BIOCHEM SOC T, V30, P194, DOI 10.1042/bst0300194; Chen CP, 2005, J CLIN ENDOCR METAB, V90, P1083, DOI 10.1210/jc.2004-0803; Chen CP, 2003, PLACENTA, V24, P316, DOI 10.1053/plac.2002.0904; Cheng JC, 2013, J BIOL CHEM, V288, P33181, DOI 10.1074/jbc.M113.488866; Denys H, 2008, CANCER LETT, V266, P263, DOI 10.1016/j.canlet.2008.02.068; Devisme L, 2013, INT J GYNECOL OBSTET, V120, P165, DOI 10.1016/j.ijgo.2012.08.023; Ducray JF, 2011, EUR J OBSTET GYN R B, V156, P29, DOI 10.1016/j.ejogrb.2010.12.038; Falanga V, 2002, J CELL PHYSIOL, V191, P42, DOI 10.1002/jcp.10065; FLANDERS KC, 1995, J MOL CELL CARDIOL, V27, P805, DOI 10.1016/0022-2828(95)90087-X; Girgert R, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-19; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Hernandez-Diaz S, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2255; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hu WS, 2007, J REPROD IMMUNOL, V73, P166, DOI 10.1016/j.jri.2006.06.005; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KAUFMANN P, 1977, CELL TISSUE RES, V177, P105; Kelly T, 2012, INT REV CEL MOL BIO, V297, P83, DOI 10.1016/B978-0-12-394308-8.00003-0; Kendall RT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00123; Khaliq A, 1996, GROWTH FACTORS, V13, P243, DOI 10.3109/08977199609003225; Kucich U, 2000, ARCH BIOCHEM BIOPHYS, V374, P313, DOI 10.1006/abbi.1999.1625; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Lee HJ, 2013, J PROTEOME RES, V12, P2458, DOI 10.1021/pr301040g; Lindahl GE, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-80; Liu G, 2015, TOXICOL LETT, V232, P384, DOI 10.1016/j.toxlet.2014.11.025; Loeffler I, 2011, J AM SOC NEPHROL, V22, P649, DOI 10.1681/ASN.2010010098; Lyall F, 2001, AM J PATHOL, V159, P1827, DOI 10.1016/S0002-9440(10)63029-5; MacKenzie B, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0242-2; Madazli R, 2003, ACTA OBSTET GYN SCAN, V82, P797, DOI 10.1034/j.1600-0412.2003.00206.x; Mun JH, 2014, WOUND REPAIR REGEN, V22, P125, DOI 10.1111/wrr.12136; Nadadur RD, 2012, J APPL PHYSIOL, V113, P149, DOI 10.1152/japplphysiol.01349.2011; Oh SY, 2009, PLACENTA, V30, P981, DOI 10.1016/j.placenta.2009.08.006; Olivieri J, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-24; Ozkan ZS, 2014, J MATERN-FETAL NEO M, V27, P1513, DOI 10.3109/14767058.2013.861415; Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8; Rimon E, 2008, ENDOCRINOLOGY, V149, P2952, DOI 10.1210/en.2007-1099; Roberts JM, 2009, PLACENTA, V30, pS32, DOI 10.1016/j.placenta.2008.11.009; RUKOSUEV VS, 1990, ACTA HISTOCHEM, V89, P11, DOI 10.1016/S0065-1281(11)80308-9; Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002; Shibata S, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-6; Simpson H, 2002, PLACENTA, V23, P44, DOI 10.1053/plac.2001.0746; Sood R, 2006, P NATL ACAD SCI USA, V103, P5478, DOI 10.1073/pnas.0508035103; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Takao T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021990; Takuwa N, 2010, CARDIOVASC RES, V85, P484, DOI 10.1093/cvr/cvp312; Todros T, 2007, PLACENTA, V28, P1123, DOI 10.1016/j.placenta.2007.06.003; Ueha S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00071; Warburton D, 2013, AM J PHYSIOL-LUNG C, V304, pL83, DOI 10.1152/ajplung.00258.2012; Weel IC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157584; Wettlaufer SH, 2016, AM J RESP CELL MOL, V54, P114, DOI 10.1165/rcmb.2014-0468OC; Wolfe LM, 2014, PLACENTA, V35, P645, DOI 10.1016/j.placenta.2014.05.005; Zeisberg M, 2013, AM J PHYSIOL-CELL PH, V304, pC216, DOI 10.1152/ajpcell.00328.2012; Zhao MR, 2006, REPRODUCTION, V132, P333, DOI 10.1530/rep.1.01112	60	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					683	695		10.1016/j.ajpath.2017.11.008			13	Pathology	Pathology	FY4OT	WOS:000426805100012	29253459	Bronze			2019-10-28	
J	Paish, HL; Kalson, NS; Smith, GR; Pons, AD; Baldock, TE; Smith, N; Swist-Szulik, K; Weir, DJ; Bardgett, M; Deehan, DJ; Mann, DA; Borthwick, LA				Paish, Hannah L.; Kalson, Nicholas S.; Smith, Graham R.; Pons, Alicia del Carpio; Baldock, Thomas E.; Smith, Nicholas; Swist-Szulik, Katarzyna; Weir, David J.; Bardgett, Michelle; Deehan, David J.; Mann, Derek A.; Borthwick, Lee A.			Fibroblasts Promote Inflammation and Pain via IL-1 alpha Induction of the Monocyte Chemoattractant Chemokine (C-C Motif) Ligand 2	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TOTAL KNEE ARTHROPLASTY; NF-KAPPA-B; TUMOR NECROSIS FACTOR; RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; INTERNATIONAL CONSENSUS; FIBROTIC DISEASE; GENE-EXPRESSION; LIVER FIBROSIS; ARTHROFIBROSIS	Fibroblasts persist within fibrotic scar tissue and exhibit considerable phenotypic and functional plasticity. Herein, we hypothesized that scar-associated fibroblasts may be a source of stress induced inflammatory exacerbations and pain. To test this idea, we used a human model of surgery-induced fibrosis, total knee arthroplasty (TKA). Using a combination of tissue protein expression profiting and bioinformatics, we discovered that many months after TKA, the fibrotic joint exists in a state of unresolved chronic inflammation. Moreover, the infrapatellar fat pad, a soft tissue that becomes highly fibrotic in the post-TKA joint, expresses multiple inflammatory mediators, including the monocyte chemoattractant, chemokine (C-C motif) ligand (CCL) 2, and the innate immune trigger, IL-1 alpha. Fibroblasts isolated from the post-TKA fibrotic infrapatellar fat pad express the IL-1 alpha receptor and on exposure to IL-1 alpha polarize to a highly inflammatory state that enables them to stimulate the recruitment of monocytes. Blockade of fibroblast CCL2 or its transcriptional regulator NF-kappa B prevented IL-1 alpha induced monocyte recruitment. Clinical investigations discovered that levels of patient-reported pain in the post-TKA joint correlated with concentrations of CCL2 in the joint tissue, such that the chemokine is effectively a pain biomarker in the TKA patient. We propose that an IL-1 alpha NF-kappa B CCL2 signaling pathway, operating within scar-associated fibroblasts, may be therapeutically manipulated for alleviating inflammation and pain in fibrotic joints and other tissues.	[Paish, Hannah L.; Kalson, Nicholas S.; Smith, Graham R.; Pons, Alicia del Carpio; Smith, Nicholas; Deehan, David J.; Mann, Derek A.; Borthwick, Lee A.] Newcastle Univ, Inst Neurosci, Fibrosis Res Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Smith, Graham R.] Newcastle Univ, Inst Neurosci, Inst Cellular Med, Bioinformat Support Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Swist-Szulik, Katarzyna] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England; [Kalson, Nicholas S.; Baldock, Thomas E.; Weir, David J.; Bardgett, Michelle; Deehan, David J.] Newcastle Hosp NHS Trust, Freeman Hosp, Musculoskeletal Unit, Newcastle Upon Tyne, Tyne & Wear, England	Borthwick, LA (reprint author), Newcastle Univ, Inst Cellular Med, Fibrosis Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	lee.borthwick@newcastle.ac.uk		Bardgett, Michelle/0000-0003-1393-2010	Newcastle Surgical Training Center grant; Medical Research CouncilMedical Research Council UK (MRC) [MR/K001949/1]; Royal College of Surgeons of Edinburgh grant; Wellcome TrustWellcome Trust [204787/Z/16/Z]; National Institute for Health Research Newcastle Biomedical Research Centre grant, based at Newcastle-upon-Tyne Hospitals NHS Foundation Trust and Newcastle University	Supported by the Medical Research Council grant MR/K001949/1, Wellcome Trust grant 204787/Z/16/Z, Newcastle Surgical Training Center grant, The Royal College of Surgeons of Edinburgh grant, and the National Institute for Health Research Newcastle Biomedical Research Centre grant, based at Newcastle-upon-Tyne Hospitals NHS Foundation Trust and Newcastle University.	Abdul N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16469; Bade MJ, 2010, J ORTHOP SPORT PHYS, V40, P559, DOI 10.2519/jospt.2010.3317; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonner JC, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-15; Borthwick LA, 2016, SEMIN IMMUNOPATHOL, V38, P517, DOI 10.1007/s00281-016-0559-z; Borthwick LA, 2016, AM J TRANSPLANT, V16, P1751, DOI 10.1111/ajt.13690; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Brown CA, 2010, ORTHOPEDICS, V33, DOI 10.3928/01477447-20101021-09; BUCHAN G, 1988, CLIN EXP IMMUNOL, V73, P449; Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dixon D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16466; Endres M, 2010, OSTEOARTHR CARTILAGE, V18, P1458, DOI 10.1016/j.joca.2010.08.003; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; Flavell SJ, 2008, BRIT J PHARMACOL, V153, pS241, DOI 10.1038/sj.bjp.0707487; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Friedman J, 2010, J STAT SOFTW, V33, P1; Funakoshi-Tago M, 2011, CELL SIGNAL, V23, P363, DOI 10.1016/j.cellsig.2010.10.006; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gollwitzer H, 2006, ORTHOPADE, V35, P143, DOI 10.1007/s00132-005-0915-5; Grau Luis, 2017, Am J Orthop (Belle Mead NJ), V46, pE148; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hofmann S, 2011, KNEE SURG SPORT TR A, V19, P1442, DOI 10.1007/s00167-011-1634-6; Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334; Kalson NS, 2016, BONE JOINT J, V98B, P1479, DOI 10.1302/0301-620X.98B11.37957; Kim YS, 2016, KNEE SURG SPORT TR A, V24, P1860, DOI 10.1007/s00167-014-3199-7; Kisseleva T, 2012, P NATL ACAD SCI USA, V109, P9448, DOI 10.1073/pnas.1201840109; Kramann R, 2013, J PATHOL, V231, P273, DOI 10.1002/path.4253; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LUKACS NW, 1994, AM J PATHOL, V144, P711; Meddeb M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164117; Menetski J, 2007, NEUROSCIENCE, V149, P706, DOI 10.1016/j.neuroscience.2007.08.014; Nodzo SR, 2016, J ARTHROPLASTY, V31, P1986, DOI 10.1016/j.arth.2016.02.025; O'Connor T, 2015, ENDOCR METAB IMMUNE, V15, P105, DOI 10.2174/1871530315666150316120920; Parvizi J, 2013, BONE JOINT J, V95B, P1450, DOI 10.1302/0301-620X.95B11.33135; Petsche T S, 1999, J Am Acad Orthop Surg, V7, P119; Pujol N, 2015, ORTHOP TRAUMATOL-SUR, V101, pS179, DOI 10.1016/j.otsr.2014.06.026; Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210426; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Ruppert M, 2013, PATHOL RES PRACT, V209, P681, DOI 10.1016/j.prp.2013.05.009; Scarpa M, 2015, AM J PATHOL, V185, P1624, DOI 10.1016/j.ajpath.2015.02.018; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555; Stankovic A, 2009, BRATISL MED J, V110, P641; Struglics A, 2015, ARTHRITIS RHEUMATOL, V67, P1816, DOI 10.1002/art.39146; Suwara MI, 2014, MUCOSAL IMMUNOL, V7, P684, DOI 10.1038/mi.2013.87; Troeger JS, 2012, GASTROENTEROLOGY, V143, P1073, DOI 10.1053/j.gastro.2012.06.036; Turner NA, 2009, AM J PHYSIOL-HEART C, V297, pH1117, DOI 10.1152/ajpheart.00372.2009; Unterhauser FN, 2004, ARCH ORTHOP TRAUM SU, V124, P585, DOI 10.1007/s00402-004-0742-x; Watt FE, 2016, ARTHRITIS RHEUMATOL, V68, P2129, DOI 10.1002/art.39677; Wells RG, 2015, SEMIN LIVER DIS, V35, P97, DOI [10.1055/s-0035-1550061, 10.1055/s-0035-1554915]; White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852; White FA, 2005, P NATL ACAD SCI USA, V102, P14092, DOI 10.1073/pnas.0503496102; White L, 2016, ARCH ORTHOP TRAUM SU, V136, P701, DOI 10.1007/s00402-016-2440-x; Wilson CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083391; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443; Ye CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163515; Zarebska JM, 2017, OSTEOARTHR CARTILAGE, V25, P406, DOI 10.1016/j.joca.2016.10.008	61	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					696	714		10.1016/j.ajpath.2017.11.007			19	Pathology	Pathology	FY4OT	WOS:000426805100013	29248462	Other Gold, Green Published			2019-10-28	
J	Lee, S; Bazick, H; Chittoor-Vinod, V; Al Salihi, MO; Xia, GB; Notterpek, L				Lee, Sooyeon; Bazick, Hannah; Chittoor-Vinod, Vinita; Al Salihi, Mohammed Omar; Xia, Guangbin; Notterpek, Lucia			Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ASCORBIC-ACID TREATMENT; SCHWANN-CELLS; MOUSE MODEL; MEMBRANE-PROTEIN; NERVE MYELIN; PMP22; NEUROPATHY; AUTOPHAGY; CMT1A; GENE	A common form of hereditary autosomal dominant demyelinating neuropathy known as Charcot-Marie-Tooth disease type 1A (CMT1A) is linked with duplication of the peripheral myelin protein 22 (PMP22) gene. Although studies from animal models have led to better understanding of the pathobiology of these neuropathies, there continues to be a gap in the translation of findings from rodents to humans. Because PMP22 was originally identified in fibroblasts as growth arrest specific gene 3 (gas3) and is expressed broadly in the body, it was tested whether skin cells from neuropathic patients would display the cellular pathology observed in Schwann cells from rodent models. Dermal fibroblasts from two CMT1A pedigrees with confirmed PMP22 gene duplication were studied. Samples from age-matched non-neuropathic individuals were used as controls. CMT1A patient derived cultures contain approximately 1.5-fold elevated levels of PMP22 mRNA, exhibit reduced mitotic potential, and display intracellular protein aggregates as compared to cells from unaffected individuals. The presence of cytosolic PMP22 coincides with a decrease in proteasome activity and an increase in autophagy-lysosomat proteins, including LC3-II and LAMP1. These results indicate that the abnormalities in the subcellular processing of excess PMP22 elicit a detectable response in human CMT1A fibroblasts, a phenotype that resembles Schwann cells from neuropathic mice. These findings support the use of human CMT1A fibroblasts as a platform for therapy testing.	[Lee, Sooyeon; Bazick, Hannah; Chittoor-Vinod, Vinita; Al Salihi, Mohammed Omar; Xia, Guangbin; Notterpek, Lucia] Univ Florida, Coll Med, Dept Neurosci, 1149 S Newell Dr,POB 100244, Gainesville, FL 32611 USA; [Xia, Guangbin; Notterpek, Lucia] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA	Notterpek, L (reprint author), Univ Florida, Coll Med, Dept Neurosci, 1149 S Newell Dr,POB 100244, Gainesville, FL 32611 USA.	notterpek@ufl.edu		Bazick, Hannah/0000-0003-4668-8974	College of Medicine of the University of Florida; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS041012]	Supported in part by NIH grant NS041012 and the College of Medicine of the University of Florida (L.N.).	Amici SA, 2006, J NEUROSCI, V26, P1179, DOI 10.1523/JNEUROSCI.2618-05.2006; Ashki Negin, 2015, Critical Reviews in Oncogenesis, V20, P435, DOI 10.1615/CritRevOncog.v20.i5-6.140; Brancolini C, 2000, MOL BIOL CELL, V11, P2901, DOI 10.1091/mbc.11.9.2901; Chittoor VG, 2013, ASN NEURO, V5, DOI 10.1042/AN20130024; Chittoor-Vinod VG, 2015, ASN NEURO, V7, DOI 10.1177/1759091415569909; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538; DiVincenzo C, 2014, MOL GENET GENOM MED, V2, P522, DOI 10.1002/mgg3.106; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Fortun J, 2006, NEUROBIOL DIS, V22, P153, DOI 10.1016/j.nbd.2005.10.010; Fortun J, 2003, J NEUROSCI, V23, P10672; Fortun J, 2007, NEUROBIOL DIS, V25, P252, DOI 10.1016/j.nbd.2006.09.018; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Irobi J, 2012, NEUROMUSCULAR DISORD, V22, P699, DOI 10.1016/j.nmd.2012.04.005; Jetten AM, 2000, PROG NUCLEIC ACID RE, V64, P97, DOI 10.1016/S0079-6603(00)64003-5; Katona I, 2009, BRAIN, V132, P1734, DOI 10.1093/brain/awp113; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P806, DOI 10.1016/0005-2736(76)90050-X; Kitani-Morii F, 2017, NEUROREPORT, V28, P814, DOI 10.1097/WNR.0000000000000831; Lee S, 2014, J NEUROSCI, V34, P16140, DOI 10.1523/JNEUROSCI.1908-14.2014; Lee S, 2013, EXP GERONTOL, V48, P1085, DOI 10.1016/j.exger.2012.12.008; Levi AD, 2016, CELL TRANSPLANT, V25, P1395, DOI 10.3727/096368915X690198; Lewis RA, 2013, JAMA NEUROL, V70, P981, DOI 10.1001/jamaneurol.2013.3178; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowery J, 2016, MOL BIOL CELL, V27, P608, DOI 10.1091/mbc.E15-09-0627; Madorsky I, 2009, NEUROBIOL DIS, V34, P146, DOI 10.1016/j.nbd.2009.01.002; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; Mizushima N, 2007, AUTOPHAGY, V3, P542; Naef R, 1998, MICROSC RES TECHNIQ, V41, P359, DOI 10.1002/(SICI)1097-0029(19980601)41:5<359::AID-JEMT3>3.0.CO;2-L; Nishimura T, 1996, ACTA NEUROPATHOL, V92, P454, DOI 10.1007/s004010050546; Nobbio L, 2014, BRAIN, V137, P1614, DOI 10.1093/brain/awu071; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Notterpek L, 1997, J NEUROSCI, V17, P4190; Notterpek L, 1999, LAB ANIM SCI, V49, P588; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pareek S, 1997, J NEUROSCI, V17, P7754; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Rangaraju S, 2011, AUTOPHAGY, V7, P238, DOI 10.4161/auto.7.2.14278; Rangaraju S, 2010, J NEUROSCI, V30, P11388, DOI 10.1523/JNEUROSCI.1356-10.2010; Rao RG, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-56; Ryan MC, 2000, J NEUROCHEM, V75, P1465, DOI 10.1046/j.1471-4159.2000.0751465.x; Sakaue M, 2015, DEVELOPMENT, V142, P3188, DOI 10.1242/dev.123034; Saporta MA, 2013, NEUROL CLIN, V31, P597, DOI 10.1016/j.ncl.2013.01.009; Schneider GB, 1998, CELL ADHES COMMUN, V5, P207, DOI 10.3109/15419069809040292; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; ZOIDL G, 1995, EMBO J, V14, P1122, DOI 10.1002/j.1460-2075.1995.tb07095.x	47	2	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					728	738		10.1016/j.ajpath.2017.10.021			11	Pathology	Pathology	FY4OT	WOS:000426805100015	29246495	Green Published, Other Gold			2019-10-28	
J	Chiang, ACA; Fowler, SW; Reddy, R; Pletnikova, O; Troncoso, JC; Sherman, MA; Lesne, SE; Jankowsky, JL				Chiang, Angie C. A.; Fowler, Stephanie W.; Reddy, Rohit; Pletnikova, Olga; Troncoso, Juan C.; Sherman, Mathew A.; Lesne, Sylvain E.; Jankowsky, Joanna L.			Discrete Pools of Oligomeric Amyloid-beta Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; A-BETA; SYNAPTIC PLASTICITY; COGNITIVE RESERVE; HYPOTHETICAL MODEL; DISEASE BIOMARKERS; DYNAMIC BIOMARKERS; PROTEIN OLIGOMERS; TAU PATHOLOGY	Despite increasing appreciation that oligomeric amyloid-beta (A beta) may contribute to cognitive decline of Alzheimer disease, defining the most critical forms has been thwarted by the changeable nature of these aggregates and the varying methods used for detection. Herein, using a broad approach, we quantified A beta oligomers during the evolution of cognitive deficits in an aggressive model of A beta amyloidosis. Amyloid precursor protein/tetracycline transactivator mice underwent behavioral testing at 3, 6, 9, and 12 months of age to evaluate spatial learning and memory, followed by histologic assessment of amyloid burden and biochemical characterization of oligomeric A beta species. Transgenic mice displayed progressive impairments in acquisition and immediate recall of the trained platform location. Biochemical analysis of cortical extracts from behaviorally tested mice revealed distinct age-dependent patterns of accumulation in multiple oligomeric species. Dot blot analysis demonstrated that non fibrillar All oligomers were highly soluble and extracted into a fraction enriched for extracellular proteins, whereas prefibrillar species required high-detergent conditions to retrieve, consistent with membrane localization. Low-detergent extracts tested by 82E1 enzyme-linked immunosorbent assay confirmed the presence of bona fide All oligomers, whereas immunoprecipitation-Western blotting using high-detergent extracts revealed a variety of SDS-stable low-n species. These findings show that different A beta oligomers vary in solubility, consistent with distinct localization, and identify nonfibrillar A beta oligomer-positive aggregates as tracking most closely with cognitive decline in this model.	[Chiang, Angie C. A.; Fowler, Stephanie W.; Reddy, Rohit; Jankowsky, Joanna L.] Baylor Coll Med, Huffington Ctr Aging, Dept Neurosci, Houston, TX 77030 USA; [Jankowsky, Joanna L.] Baylor Coll Med, Huffington Ctr Aging, Dept Neurol & Neurosurg, Houston, TX 77030 USA; [Reddy, Rohit] Rice Univ, Dept Cognit Sci, Houston, TX USA; [Pletnikova, Olga; Troncoso, Juan C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Sherman, Mathew A.; Lesne, Sylvain E.] Univ Minnesota, N Bud Grossman Ctr Memory Res & Care, Inst Translat Neurosci, Dept Neurosci, Minneapolis, MN USA	Jankowsky, JL (reprint author), Baylor Coll Med, BCM295,One Baylor Plaza, Houston, TX 77030 USA.	jankowsk@bcm.edu			University of Minnesota Medical Foundation; BrightFocus FoundationBrightFocus Foundation; Robert A. and Rene E. Belfer Family Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP2 OD001734, R01 NS092615, T32 AG000183, R00 AG031293, R01 NS033249, P50AG005146, R01 AG044342, AG033655]; Gates Millennium Scholarship	Supported by NIH grants DP2 OD001734 (J.L.J.), R01 NS092615 (J.L.J.), T32 AG000183 (A.C.A.C.), R00 AG031293 (S.E.L.), R01 NS033249 (S.E.L.), R01 AG044342 (S.E.L.), P50AG005146 (J.C.T.), and AG033655 (J.C.T.), the Robert A. and Rene E. Belfer Family Foundation (J.L.J.), the Gates Millennium Scholarship (A.C.A.C.), the University of Minnesota Medical Foundation startup funds (S.E.L.), and the BrightFocus Foundation (J.C.T.).	Amar F, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2021; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Ashe KH, 2010, NEURON, V66, P631, DOI 10.1016/j.neuron.2010.04.031; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; BERG L, 1993, ARCH NEUROL-CHICAGO, V50, P349, DOI 10.1001/archneur.1993.00540040011008; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Born HA, 2014, J NEUROSCI, V34, P3826, DOI 10.1523/JNEUROSCI.5171-13.2014; Boyle PA, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00050; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Broersen K, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt36; Bushman DM, 2015, ELIFE, V4, DOI 10.7554/eLife.05116; Chetelat G, 2011, BRAIN, V134, P798, DOI 10.1093/brain/awq383; de Fiebre NC, 2006, AGE, V28, P235, DOI 10.1007/s11357-006-9027-3; De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056; Drzezga A, 2011, BRAIN, V134, P1635, DOI 10.1093/brain/awr066; Esparza TJ, 2013, ANN NEUROL, V73, P104, DOI 10.1002/ana.23748; Fowler SW, 2014, J NEUROSCI, V34, P7871, DOI 10.1523/JNEUROSCI.0572-14.2014; Han HJ, 2012, J NEUROSCI, V32, P10574, DOI 10.1523/JNEUROSCI.0893-12.2012; Harburger LL, 2007, BEHAV BRAIN RES, V185, P43, DOI 10.1016/j.bbr.2007.07.009; Hayden EY, 2017, ANAL BIOCHEM, V518, P78, DOI 10.1016/j.ab.2016.10.026; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jankowsky JL, 2005, PLOS MED, V2, P1318, DOI 10.1371/journal.pmed.0020355; Jarosz-Griffiths HH, 2016, J BIOL CHEM, V291, P3174, DOI 10.1074/jbc.R115.702704; Kawas CH, 2013, ALZHEIMERS DEMENT, V9, P199, DOI 10.1016/j.jalz.2012.06.005; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kemppainen NM, 2008, ANN NEUROL, V63, P112, DOI 10.1002/ana.21212; Kennedy KM, 2012, NEUROIMAGE, V62, P1, DOI 10.1016/j.neuroimage.2012.03.077; King DL, 2002, PHYSIOL BEHAV, V75, P627, DOI 10.1016/S0031-9384(02)00639-X; Klementieva O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14726; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Klyubin I, 2008, J NEUROSCI, V28, P4231, DOI 10.1523/JNEUROSCI.5161-07.2008; Knight EM, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000237; Larson M, 2012, J NEUROSCI, V32, P16857, DOI 10.1523/JNEUROSCI.1858-12.2012; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lesne SE, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.14021; Lesne SE, 2013, BRAIN, V136, P1383, DOI 10.1093/brain/awt062; Lian H, 2015, NEURON, V85, P101, DOI 10.1016/j.neuron.2014.11.018; Lim YY, 2014, ALZHEIMERS DEMENT, V10, P743, DOI 10.1016/j.jalz.2013.11.005; Lim YY, 2012, NEUROLOGY, V79, P1645, DOI 10.1212/WNL.0b013e31826e9ae6; Liu P, 2015, CELL REP, V11, P1760, DOI 10.1016/j.celrep.2015.05.021; Lynch MA, 2015, BRAIN RES, V1621, P197, DOI 10.1016/j.brainres.2014.08.040; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Melnikova T, 2013, J NEUROSCI, V33, P3765, DOI 10.1523/JNEUROSCI.4251-12.2013; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Monsell SE, 2014, NEUROLOGY, V83, P434, DOI 10.1212/WNL.0000000000000650; Muller-Schiffmann A, 2011, ACS CHEM NEUROSCI, V2, P242, DOI 10.1021/cn200011h; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238; Pike KE, 2011, NEUROPSYCHOLOGIA, V49, P2384, DOI 10.1016/j.neuropsychologia.2011.04.012; Rasool S, 2013, J NEUROCHEM, V126, P473, DOI 10.1111/jnc.12305; Rasool S, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-37; Rentz DM, 2010, ANN NEUROL, V67, P353, DOI 10.1002/ana.21904; Rodgers SP, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-28; Rodrigue KM, 2012, NEUROLOGY, V78, P387, DOI 10.1212/WNL.0b013e318245d295; Roe CM, 2008, ARCH NEUROL-CHICAGO, V65, P1467, DOI 10.1001/archneur.65.11.1467; Rosenberg PB, 2013, AM J GERIAT PSYCHIAT, V21, P272, DOI 10.1016/j.jagp.2012.11.016; Rudy CC, 2015, AGING DIS, V6, P131, DOI 10.14336/AD.2014.0423; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2009, NEUROBIOL DIS, V36, P293, DOI 10.1016/j.nbd.2009.07.021; Sherman MA, 2011, METHODS MOL BIOL, V670, P45, DOI 10.1007/978-1-60761-744-0_4; Sperling RA, 2013, NEUROBIOL AGING, V34, P822, DOI 10.1016/j.neurobiolaging.2012.06.014; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Szczepankiewicz O, 2015, J AM CHEM SOC, V137, P14673, DOI 10.1021/jacs.5b07849; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tomic JL, 2009, NEUROBIOL DIS, V35, P352, DOI 10.1016/j.nbd.2009.05.024; Upadhaya AR, 2012, NEUROBIOL AGING, V33, P2641, DOI 10.1016/j.neurobiolaging.2011.12.032; Upadhaya AR, 2012, J CELL MOL MED, V16, P287, DOI 10.1111/j.1582-4934.2011.01306.x; Vemuri P, 2012, ANN NEUROL, V72, P730, DOI 10.1002/ana.23665; Vemuri P, 2011, BRAIN, V134, P1479, DOI 10.1093/brain/awr049; Vickers JC, 2009, BRAIN RES BULL, V80, P217, DOI 10.1016/j.brainresbull.2009.08.004; vom Berg J, 2012, NAT MED, V18, P1812, DOI 10.1038/nm.2965; Webster SJ, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00088; Welzel AT, 2014, BIOCHEMISTRY-US, V53, P3908, DOI 10.1021/bi5003053; Willem M, 2015, NATURE, V526, P443, DOI 10.1038/nature14864; Williamson LL, 2013, BRAIN BEHAV IMMUN, V30, P186, DOI 10.1016/j.bbi.2013.01.077; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhao R, 2014, HIPPOCAMPUS, V24, P963, DOI 10.1002/hipo.22283; Zhao X, 2009, NEUROSCIENCE, V162, P933, DOI 10.1016/j.neuroscience.2009.05.018; Zheng H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-27	85	5	5	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					739	756		10.1016/j.ajpath.2017.11.011			18	Pathology	Pathology	FY4OT	WOS:000426805100016	29248459	Bronze, Green Published			2019-10-28	
J	Albertsson, AM; Zhang, XL; Vontell, R; Bi, D; Bronson, RT; Supramaniam, V; Baburamani, AA; Hua, S; Nazmi, A; Cardell, S; Zhu, CL; Cantor, H; Mallard, C; Hagberg, H; Leavenworth, JW; Wang, XY				Albertsson, Anna-Maj; Zhang, Xiaoli; Vontell, Regina; Bi, Dan; Bronson, Roderick T.; Supramaniam, Veena; Baburamani, Ana A.; Hua, Sha; Nazmi, Arshed; Cardell, Susanna; Zhu, Changlian; Cantor, Harvey; Mallard, Carina; Hagberg, Henrik; Leavenworth, Jianmei W.; Wang, Xiaoyang			gamma delta T Cells Contribute to Injury in the Developing Brain	AMERICAN JOURNAL OF PATHOLOGY			English	Article							WHITE-MATTER INJURY; MULTIPLE-SCLEROSIS; PRETERM INFANTS; PIVOTAL ROLE; INFLAMMATION; MOUSE; SKIN; REPERTOIRE; ACTIVATION; MENINGES	Brain injury in premature infants, especially periventricular leukomalacia, is an important cause of neurologic disabilities. Inflammation contributes to perinatal brain injury development, but the essential mediators that lead to early-life brain injury remain largely unknown. Neonates have reduced capacity for mounting conventional alpha beta T-cell responses. However, gamma delta T cells are already functionally competent during early development and are important in early-life immunity. We investigated the potential contribution of gamma delta T cells to preterm brain injury using postmortem brains from human preterm infants with periventricular leukomalacia and two animal models of preterm brain injury the hypoxic-ischemic mouse model and a fetal sheep asphyxia model. Large numbers of gamma delta T cells were observed in the brains of mice, sheep, and postmortem preterm infants after injury, and depletion of gamma delta T cells provided protection in the mouse model. The common gamma delta T-cell-cell-cell associated cytokines interferon-gamma and IL-17A were not detectable in the brain. Although there were increased mRNA levels of Il17f and Il22 in the mouse brains after injury, neither IL-17F nor IL-22 cytokines contributed to preterm brain injury. These findings highlight unique features of injury in the developing brain, where, unlike injury in the mature brain, gamma delta T cells function as initiators of injury independently of common gamma delta T-cell associated cytokines. This finding will help to identify therapeutic targets for preventing or treating preterm infants with brain injury.	[Albertsson, Anna-Maj; Zhang, Xiaoli; Bi, Dan; Hua, Sha; Nazmi, Arshed; Mallard, Carina; Hagberg, Henrik; Wang, Xiaoyang] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Perinatal Ctr,Dept Physiol, Gothenburg, Sweden; [Zhu, Changlian] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Neurosci, Gothenburg, Sweden; [Cardell, Susanna] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Inst Neurosci & Physiol, Gothenburg, Sweden; [Cardell, Susanna] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden; [Zhang, Xiaoli; Bi, Dan; Zhu, Changlian; Wang, Xiaoyang] Zhengzhou Univ, Affiliated Hosp 3, Dept Pediat, Zhengzhou, Henan, Peoples R China; [Zhang, Xiaoli; Zhu, Changlian] Henan Prov Key Lab Child Brain Injury, Zhengzhou, Henan, Peoples R China; [Vontell, Regina; Supramaniam, Veena; Baburamani, Ana A.; Hagberg, Henrik] St Thomas Hosp, Kings Coll London, Dept Perinatal Imaging & Hlth, Ctr Developing Brain, London, England; [Bronson, Roderick T.; Cantor, Harvey] Harvard Med Sch, Div Immunol, Dept Canc Immunol & Virol, Boston, MA USA; [Bronson, Roderick T.; Cantor, Harvey] Harvard Med Sch, Div Immunol, Dana Farber Canc Inst, Boston, MA USA; [Bronson, Roderick T.; Cantor, Harvey] Harvard Med Sch, Div Immunol, Dept Microbiol & Immunol, Boston, MA USA; [Hua, Sha] Shanghai Jiao Tong Univ, Ruijin Hosp, Med Sch, Luwan Branch,Dept Cardiovasc Med, Shanghai, Peoples R China; [Hagberg, Henrik] East Hosp, Dept Clin Sci, Gothenburg, Sweden; [Leavenworth, Jianmei W.] Univ Alabama Birmingham, Dept Neurosurg, 1600 6th Ave South,CHB118A, Birmingham, AL 35233 USA; [Leavenworth, Jianmei W.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	Leavenworth, JW (reprint author), Univ Alabama Birmingham, Dept Neurosurg, 1600 6th Ave South,CHB118A, Birmingham, AL 35233 USA.; Wang, XY (reprint author), Univ Gothenburg, Perinatal Ctr, Dept Neurosci & Physiol, Box 432, SE-40530 Gothenburg, Sweden.	jleavenworth@uabmc.edu; xiaoyang.wang@fysiologi.gu	Baburamani, Ana/J-4920-2019	Baburamani, Ana/0000-0002-7537-6534; wang, xiaoyang/0000-0001-9717-8160; Hagberg, Henrik/0000-0003-3962-1448; Mallard, Carina/0000-0001-8953-919X; Nazmi, Arshed/0000-0002-5073-2061	Science and Technology Bureau of Zhengzhou [131PCXTD621]; Department of Science and Technology of Henan Province [134200510023]; Frimurare Barnhus Foundation; Wilhelm & Martina Lundgren Foundation; Gothenburg Medical Society grant [011/14]; Swedish governmental [ALFGBG-429801, ALF-GBG:426401]; Swedish Research CouncilSwedish Research Council [VR 2013-2475, VR 2015-02493, VR 2015-06276]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [U1704281, 81771418]; Wellcome TrustWellcome Trust [WT094823]; VINNMER Marie Curie international qualification grant [2011-03458]; Chinese Scholarship CouncilChina Scholarship Council [201407040032]	Supported by Swedish Research Council grants VR 2013-2475 and VR 2015-06276 (X.W.) and VR 2015-02493 (H.H.), Swedish governmental grants ALFGBG-429801 (X.W.) and ALF-GBG:426401 (H.H.) to researchers in the public health service, VINNMER Marie Curie international qualification grant 2011-03458 (X.W.), Gothenburg Medical Society grant 011/14 (X.W.), the Frimurare Barnhus Foundation (A.N.), Wellcome Trust grant WT094823 (H.H.), the Wilhelm & Martina Lundgren Foundation (A.-M.A., X.Z., A.N., and X.W.), Chinese Scholarship Council grant 201407040032 (X.Z.), National Natural Science Foundation of China grants 81771418 (X.W.) and U1704281 (C.Z.), Department of Science and Technology of Henan Province grant 134200510023 (C.Z.), and Science and Technology Bureau of Zhengzhou grant 131PCXTD621 (C.Z.).	Albertsson AM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0153-z; Arvin AM, 2010, CURR TOP MICROBIOL, V342, P129, DOI 10.1007/82_2009_1; Back SA, 2014, GLIA, V62, P1790, DOI 10.1002/glia.22658; Blink SE, 2014, CELL IMMUNOL, V290, P39, DOI 10.1016/j.cellimm.2014.04.013; Born WK, 2010, J IMMUNOL, V184, P4055, DOI 10.4049/jimmunol.0903679; Cai YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4986; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; De Rosa SC, 2004, J IMMUNOL, V172, P1637, DOI 10.4049/jimmunol.172.3.1637; Dimova T, 2015, P NATL ACAD SCI USA, V112, pE556, DOI 10.1073/pnas.1412058112; Du XN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019583; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; Gibbons DL, 2009, EUR J IMMUNOL, V39, P1794, DOI 10.1002/eji.200939222; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Hagberg H, 2015, NAT REV NEUROL, V11, P192, DOI 10.1038/nrneurol.2015.13; Hatfield JK, 2015, CELL IMMUNOL, V297, P69, DOI 10.1016/j.cellimm.2015.06.006; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; HEIN WR, 1991, IMMUNOL TODAY, V12, P30, DOI 10.1016/0167-5699(91)90109-7; Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Netto CA, 2017, J NEUROSCI RES, V95, P409, DOI 10.1002/jnr.23828; Prinz I, 2006, NAT IMMUNOL, V7, P995, DOI 10.1038/ni1371; Ramirez-Valle F, 2015, P NATL ACAD SCI USA, V112, P8046, DOI 10.1073/pnas.1508990112; Ribeiro M, 2016, 7 INT GAMM DELT T CE; Salmaso N, 2014, NAT NEUROSCI, V17, P341, DOI 10.1038/nn.3604; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Shibata K, 2008, J IMMUNOL, V181, P5940, DOI 10.4049/jimmunol.181.9.5940; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Supramaniam V, 2013, PEDIATR RES, V73, P301, DOI 10.1038/pr.2012.186; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Vontell R, 2013, DEV NEUROSCI-BASEL, V35, P130, DOI 10.1159/000346158; Wang XY, 2007, BRAIN RES, V1144, P180, DOI 10.1016/j.brainres.2007.01.083; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Welin AK, 2007, PEDIATR RES, V61, P153, DOI 10.1203/01.pdr.0000252546.20451.1a; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; Yang D, 2014, J NEUROSCI, V34, P16467, DOI 10.1523/JNEUROSCI.2582-14.2014	44	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					757	767		10.1016/j.ajpath.2017.11.012			11	Pathology	Pathology	FY4OT	WOS:000426805100017	29248460	Green Published, Other Gold			2019-10-28	
J	Patel, M; Velagapudi, C; Burns, H; Doss, R; Lee, MJ; Mariappan, MM; Wagner, B; Arar, M; Barnes, VL; Abboud, HE; Barnes, JL				Patel, Mandakini; Velagapudi, Chakradhar; Burns, Hannah; Doss, Robert; Lee, Myung-Ja; Mariappan, Meenalakshmi M.; Wagner, Brent; Arar, Mazen; Barnes, Veronique L.; Abboud, Hanna E.; Barnes, Jeffrey L.			Mouse Metanephric Mesenchymal Cell-Derived Angioblasts Undergo Vasculogenesis in Three-Dimensional Culture	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; PLURIPOTENT STEM-CELLS; ANGIOGENESIS IN-VITRO; TYROSINE KINASE; PDGF-B; DEVELOPMENTAL EXPRESSION; VASCULAR MORPHOGENESIS; MOLECULAR-MECHANISMS; KIDNEY VASCULATURE	In vitro models for the investigation of renal vascular development are limited. We previously showed that isolated metanephric mesenchymal (MM) and ureteric bud (UB) cells grown in three-dimensional (3D) matrices formed organoids that consisted of primitive vascular structures surrounding a polarized epithelium. Here, we examined the potential of two principal effectors of vasculogenesis, vascular endothelial growth factor A (VEGF-A), and platelet-derived growth factor B chain (PDGF-BB), to stimulate MM cell differentiation. The results showed that MM cells possess angioblast characteristics by expressing phenotypic markers for endothelial and mesenchymal cells. UB cells synthesize VEGF-A and PDGF-BB proteins and RNA, whereas the MM cells express the respective cognate receptors, supporting their role in directional induction of vasculogenesis. VEGF-A stimulated proliferation of MM cells in monolayer and in 3D sponges but did not affect MM cell migration, organization, or vasculogenesis. However, PDGF-BB stimulated MM cell proliferation, migration, and vasculogenesis in monolayer and organization of the cells into primitive capillary like assemblies in 3D sea sponge scaffolds in vitro. A role for PDGF-BB in vasculogenesis in the 3D MM/UB co-culture system was validated by direct interference with PDGF-BB or PDGF receptor-beta cell interactions to implicate PDGF-BB as a primary effector of MM cell vasculogenesis. Thus, MM cells resemble early renal angioblasts that may provide an ideal platform for the investigation of renal vasculogenesis in vitro.	[Patel, Mandakini; Velagapudi, Chakradhar; Wagner, Brent; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Wagner, Brent; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Med Res Serv, San Antonio, TX 78229 USA; [Arar, Mazen] Univ Texas Hlth Sci Ctr San Antonio, Audie Murphy Mem Vet Adm Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Arar, Mazen] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [Burns, Hannah; Doss, Robert; Lee, Myung-Ja; Mariappan, Meenalakshmi M.; Barnes, Veronique L.; Barnes, Jeffrey L.] Probetex Inc, 7418 John Smith Dr,Ste A, San Antonio, TX 78229 USA	Barnes, JL (reprint author), Probetex Inc, 7418 John Smith Dr,Ste A, San Antonio, TX 78229 USA.	jlbarnes@probetex.com			NIH/National Institute of Diabetes and Digestive and Kidney Disease Small Business Technology Transfer [R42 DK077436]; Small Business Innovation Research (SBIR)United States Department of Agriculture (USDA) [R44 DK061834, R43 GM110837]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DK-102085]; Veterans Administration Merit Review Program	Supported by NIH/National Institute of Diabetes and Digestive and Kidney Disease Small Business Technology Transfer grant R42 DK077436 (J.L.B.), Small Business Innovation Research (SBIR) grants R44 DK061834 (V.L.B.), and R43 GM110837 (V.L.B.), and NIH grant R01 DK-102085 (B.W.), and the Veterans Administration Merit Review Program (J.L.B. and B.W.).	ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; Abrahamson DR, 1998, KIDNEY INT, V54, pS7, DOI 10.1046/j.1523-1755.1998.06702.x; ALPERS CE, 1992, KIDNEY INT, V42, P390, DOI 10.1038/ki.1992.300; [Anonymous], 2011, GUIDE CARE USE LAB A; Arar M, 2000, J BIOL CHEM, V275, P9527, DOI 10.1074/jbc.275.13.9527; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Barnes VL, 1999, J HISTOCHEM CYTOCHEM, V47, P787, DOI 10.1177/002215549904700608; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Chen Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12422; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Davis GE, 2011, INT REV CEL MOL BIO, V288, P101, DOI 10.1016/B978-0-12-386041-5.00003-0; Dressler GR, 2006, ANNU REV CELL DEV BI, V22, P509, DOI 10.1146/annurev.cellbio.22.010305.104340; Fabian SL, 2012, AM J PATHOL, V180, P1441, DOI 10.1016/j.ajpath.2011.12.039; Ferguson JE, 2005, ARTERIOSCL THROM VAS, V25, P2246, DOI 10.1161/01.ATV.0000183609.55154.44; Gomez RA, 1997, MICROSC RES TECHNIQ, V39, P254, DOI 10.1002/(SICI)1097-0029(19971101)39:3<254::AID-JEMT5>3.0.CO;2-K; Grandaliano G, 1998, J AM SOC NEPHROL, V9, P583; Green D, 2003, TISSUE ENG, V9, P1159, DOI 10.1089/10763270360728062; Halt KJ, 2016, KIDNEY INT, V90, P311, DOI 10.1016/j.kint.2016.02.021; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Huang CQ, 2003, DEVELOPMENT, V130, P6111, DOI 10.1242/dev.00831; Hyink DP, 1996, AM J PHYSIOL-RENAL, V270, pF886; Iruela-Arispe ML, 2009, DEV CELL, V16, P222, DOI 10.1016/j.devcel.2009.01.013; Carreres MI, 2011, J NEUROSCI, V31, P5673, DOI 10.1523/JNEUROSCI.0394-11.2011; Kanwar YS, 2004, AM J PHYSIOL-RENAL, V286, pF202, DOI 10.1152/ajprenal.00157.2003; Kim J, 1999, AM J PHYSIOL-RENAL, V276, pF498; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lanaspa MA, 2010, J BIOL CHEM, V285, P31694, DOI 10.1074/jbc.M109.093690; Lange S, 2009, CARDIOVASC RES, V81, P159, DOI 10.1093/cvr/cvn258; Le Bras A, 2010, VASC MED, V15, P321, DOI 10.1177/1358863X10371685; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Levinson R, 2003, SEMIN CELL DEV BIOL, V14, P225, DOI 10.1016/S1084-9521(03)00025-9; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lopez MLSS, 2011, J AM SOC NEPHROL, V22, P2156, DOI 10.1681/ASN.2011080818; Mathew E, 2014, J BIOL CHEM, V289, P27727, DOI 10.1074/jbc.M114.556563; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Minuth WW, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-16; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Mukherjee E, 2017, AM J PHYSIOL-RENAL, V313, pF611, DOI 10.1152/ajprenal.00136.2017; Patsch C, 2015, NAT CELL BIOL, V17, P994, DOI 10.1038/ncb3205; Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003; Ricono JM, 2009, AM J PHYSIOL-RENAL, V296, pF406, DOI 10.1152/ajprenal.90368.2008; Ricono JM, 2003, J HISTOCHEM CYTOCHEM, V51, P141, DOI 10.1177/002215540305100202; Risau W, 1992, Growth Factors, V7, P261, DOI 10.3109/08977199209046408; Robert B, 1998, AM J PHYSIOL-RENAL, V275, pF164; Robert B, 1996, AM J PHYSIOL-RENAL, V271, pF744; Rolny C, 2006, BLOOD, V108, P1877, DOI 10.1182/blood-2006-04-014894; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240; Sims-Lucas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065993; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Taguchi A, 2014, CELL STEM CELL, V14, P53, DOI 10.1016/j.stem.2013.11.010; Takasato M, 2015, NATURE, V526, P564, DOI 10.1038/nature15695; Thommen R, 1997, J CELL BIOCHEM, V64, P403; Tufro A, 1999, J AM SOC NEPHROL, V10, P2125; Velagapudi C, 2012, AM J PATHOL, V180, P819, DOI 10.1016/j.ajpath.2011.11.002; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wagner B, 2007, J AM SOC NEPHROL, V18, P2903, DOI 10.1681/ASN.2006111229; Wagner B, 2014, AM J PHYSIOL-RENAL, V306, pF85, DOI 10.1152/ajprenal.00371.2013; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamamoto T, 1997, AM J PHYSIOL-RENAL, V272, pF198; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Ye P, 2004, KIDNEY INT, V66, P1356, DOI 10.1111/j.1523-1755.2004.00897.x; Young HM, 2001, DEV BIOL, V229, P503, DOI 10.1006/dbio.2000.0100; Zheng Y, 2012, P NATL ACAD SCI USA, V109, P9342, DOI 10.1073/pnas.1201240109	70	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					768	784		10.1016/j.ajpath.2017.10.022			17	Pathology	Pathology	FY4OT	WOS:000426805100018	29269120	Bronze, Green Published			2019-10-28	
J	Gonnissen, A; Isebaert, S; Perneel, C; McKee, CM; Van Utterbeeck, F; Lerut, E; Verrill, C; Bryant, RJ; Joniau, S; Muschel, RJ; Haustermans, K				Gonnissen, Annelies; Isebaert, Sofie; Perneel, Christiaan; McKee, Chad M.; Van Utterbeeck, Filip; Lerut, Evelyne; Verrill, Clare; Bryant, Richard J.; Joniau, Steven; Muschel, Ruth J.; Haustermans, Karin			Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SONIC HEDGEHOG; RADICAL PROSTATECTOMY; SIGNALING PATHWAY; GLI3; PROGRESSION; ACTIVATION; ADENOCARCINOMA; PROLIFERATION; ASSOCIATION; SUPPRESSOR	There is an unmet clinical need for adequate biomarkers to aid risk stratification and management of prostate cancer (PCa) patients. Even within the high-risk PCa category, not all patients will invariably have a poor prognosis, and improved stratification of this heterogeneous group is needed. In this context, components of the hedgehog (Hh) pathway may have promise as biomarkers, because the available evidence suggests increased Hh pathway activity may confer a poorer outcome in advanced and castrate-resistant PCa. In this study, potential associations between Hh pathway protein expression and clinicopathological factors, including time to biochemical recurrence (BCR), were investigated using a tissue microarray constructed from benign and malignant prostate samples from 75 predominantly high-risk PCa patients who underwent radical prostatectomy. Hh signaling activity was found to differ between benign and malignant prostate tissue, with a greater amount of active Hh signaling present in malignant than benign prostate epithelium. High expression of Patched 1 in malignant prostate epithelium was found to be an independent predictor of BCR in high-risk PCa patients. Glioma-associated oncogene 1 may potentially represent a clinically useful biomarker of an aggressive tumor phenotype. Evaluation of Hh signaling activity in PCa patients may be useful for risk stratification, and epithelial Patched 1 expression, in particular, may be a prognostic marker for BCR in high-risk PCa patients.	[Gonnissen, Annelies; Isebaert, Sofie; Haustermans, Karin] Univ Leuven, KU Leuven, Dept Oncol, Lab Expt Radiotherapy, Leuven, Belgium; [Gonnissen, Annelies; Isebaert, Sofie; Haustermans, Karin] Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium; [Lerut, Evelyne] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium; [Joniau, Steven] Univ Hosp Leuven, Dept Urol, Leuven, Belgium; [Perneel, Christiaan; Van Utterbeeck, Filip] Royal Mil Acad, Dept Appl Math, Brussels, Belgium; [McKee, Chad M.; Muschel, Ruth J.] Univ Oxford, John Radcliffe Hosp, Dept Oncol, Oxford, England; [Verrill, Clare; Bryant, Richard J.] Univ Oxford, John Radcliffe Hosp, Canc Res UK Med Res Council Oxford Inst Radiat On, Oxford, England; [Verrill, Clare; Bryant, Richard J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford, England	Isebaert, S (reprint author), Katholieke Univ Leuven, Dept Oncol, Lab Expt Radiotherapy, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.	sofie.isebaert@uzleuven.be	joniau, steven/K-7655-2013	joniau, steven/0000-0003-3195-9890; Muschel, Ruth/0000-0002-5656-5970	Confidence in Concept of the Medical Research Council at University of Oxford; Cancer Research UKCancer Research UK; National Cancer Plan Action 29 Belgium grant [KPC_29_023]; National Institute for Health Research Oxford Biomedical Research Centre based at the Oxford University Hospitals National Health Service Trust; National Institute for Health ResearchNational Institute for Health Research (NIHR); University of Oxford; Academy of Medical SciencesAcademy of Medical Sciences (AMS)	Supported by the National Cancer Plan Action 29 Belgium grant KPC_29_023 (A.G. and S.I.); the Confidence in Concept of the Medical Research Council at University of Oxford and Cancer Research UK (C.M.M. and R.J.M.); the National Institute for Health Research, Cancer Research UK and the Academy of Medical Sciences (R.J.B.); and the National Institute for Health Research Oxford Biomedical Research Centre based at the Oxford University Hospitals National Health Service Trust and the University of Oxford (C.V.). K.H. is a clinical research fellow of the Research Foundation Flanders.	Azoulay S, 2008, J PATHOL, V216, P460, DOI 10.1002/path.2427; Briganti A, 2012, EUR UROL, V61, P584, DOI 10.1016/j.eururo.2011.11.043; Cigna N, 2012, AM J PATHOL, V181, P2126, DOI 10.1016/j.ajpath.2012.08.019; D'Amico AV, 2003, J CLIN ONCOL, V21, P2163, DOI 10.1200/JCO.2003.01.075; D'Amico AV, 2003, J UROLOGY, V169, P1320, DOI 10.1097/01.ju.0000049200.30192.d1; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Efstathiou E, 2013, PROSTATE, V73, P153, DOI 10.1002/pros.22550; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Goethals L, 2006, J PATHOL, V208, P607, DOI 10.1002/path.1934; Gonnissen A, 2013, INT J MOL SCI, V14, P13979, DOI 10.3390/ijms140713979; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Ibuki N, 2013, INT J CANCER, V133, P1955, DOI 10.1002/ijc.28193; Iwasaki H, 2013, CANCER SCI, V104, P328, DOI 10.1111/cas.12073; Joniau S, 2015, EUR UROL, V67, P157, DOI 10.1016/j.eururo.2014.01.020; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kim TJ, 2011, J SURG ONCOL, V104, P472, DOI 10.1002/jso.21988; Kogerman P, 1999, NAT CELL BIOL, V1, P312; Marechal R, 2015, CLIN CANCER RES, V21, P1215, DOI 10.1158/1078-0432.CCR-14-0667; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Mckee CM, 2012, J CLIN INVEST, V122, P4025, DOI 10.1172/JCI59348; Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Trnski D, 2015, BBA-MOL BASIS DIS, V1852, P2574, DOI 10.1016/j.bbadis.2015.09.005; Tzelepi V, 2011, HISTOPATHOLOGY, V58, P1037, DOI 10.1111/j.1365-2559.2011.03860.x; Van den Bergh L, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2014.11.008; Verrill C, 2016, ONCOTARGET, V7, P1107, DOI 10.18632/oncotarget.6689; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yoshizaki A, 2006, WORLD J GASTROENTERO, V12, P5687, DOI 10.3748/wjg.v12.i35.5687; Yossepowitch O, 2008, EUR UROL, V53, P950, DOI 10.1016/j.eururo.2007.10.008	34	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					795	804		10.1016/j.ajpath.2017.11.019			10	Pathology	Pathology	FY4OT	WOS:000426805100020	29339090	Bronze, Green Published			2019-10-28	
J	Alrashdi, SF; Deliyanti, D; Talia, DM; Wilkinson-Berka, JL				Alrashdi, Saeed F.; Deliyanti, Devy; Talia, Dean M.; Wilkinson-Berka, Jennifer L.			Endothelin-2 Injures the Blood-Retinal Barrier and Macroglial Muller Cells Interactions with Angiotensin II, Aldosterone, and NADPH Oxidase	AMERICAN JOURNAL OF PATHOLOGY			English	Article							VASCULAR ADVENTITIAL FIBROBLASTS; GROWTH-FACTOR; IN-VITRO; MINERALOCORTICOID RECEPTOR; ISCHEMIC RETINOPATHY; TIGHT JUNCTION; TNF-ALPHA; SYSTEM; EXPRESSION; RAT	Although increasing evidence indicates that endothelin-2 (Edn2) has distinct roles in tissue pathology, including inflammation, glial cell dysfunction, and angiogenesis, its role in the retina and the factors that regulate its actions are not fully understood. We hypothesized that Edn2 damages the blood-retinal barrier (BRB) and that this is mediated by interactions with the renin-angiotensin-aldosterone system and reactive oxygen species derived from NADPH oxidase (Nox). C57BL/6J mice received an intravitreal injection of Edn2 or control vehicle to examine the blood pressure-independent effects of Edn2. Mice administered Edn2 were randomized to receive by intraperitoneal injection treatments that inhibited the Edn type a receptor, Edn type b receptor, angiotensin type 1 receptor, mineralocorticoid receptor, or Nox isoforms 1 to 4. One month later, mice administered Edn2 exhibited breakdown of the BRB with increased vascular leakage, vascular endothelial growth factor expression, and infiltrating macrophages (Ly6C(+)CD45(high)CD11b(+)). Further, macroglial Muller cells, which influence the integrity of the BRB and prevent retinal edema, became gliotic and expressed increased levels of water (aquaporin-4) and ion (Kir4.1) channels. This Edn2-mediated retinopathy was reduced by all treatments. Complementary in vitro studies in cultured Muller cells supported these findings and demonstrated the importance of reactive oxygen species in mediating these events. In conclusion, Edn2 has detrimental effects on the BRB and Muller cells that involve interactions with the renin-angiotensin aldosterone system and Nox1/4.	[Alrashdi, Saeed F.; Deliyanti, Devy; Talia, Dean M.; Wilkinson-Berka, Jennifer L.] Monash Univ, Dept Diabet, Melbourne, Vic, Australia	Wilkinson-Berka, JL (reprint author), Monash Univ, Cent Clin Sch, Dept Diabet, Alfred Ctr, Level 5,99 Commercial Rd, Melbourne, Vic 3004, Australia.	jennifer.wilkinson-berka@monash.edu	Deliyanti, Devy/I-1562-2014	Deliyanti, Devy/0000-0002-0390-3454	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1078442]; Ministry of Education of Saudi Arabia PhD scholarship [1021389984]; JDRF postdoctoral fellowshipJuvenile Diabetes Research Foundation [3-PDF-2017-376-A-N]	Supported by the Ministry of Education of Saudi Arabia PhD scholarship 1021389984 (S.F.A.), JDRF postdoctoral fellowship 3-PDF-2017-376-A-N (D.D.), and National Health and Medical Research Council of Australia project grant 1078442 (J.L.W.-B.).	Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; An SJ, 2007, CARDIOVASC RES, V75, P702, DOI 10.1016/j.cardiores.2007.02.015; An SJ, 2006, AM J PHYSIOL-HEART C, V290, pH700, DOI 10.1152/ajpheart.00326.2005; Aoyama T, 2012, HEPATOLOGY, V56, P2316, DOI 10.1002/hep.25938; Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606; Bagnato A, 2011, BRIT J PHARMACOL, V163, P220, DOI 10.1111/j.1476-5381.2011.01217.x; Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611; Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008; Binz N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160442; Braunger BM, 2013, NEUROBIOL DIS, V50, P1, DOI 10.1016/j.nbd.2012.09.008; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9; Chen DD, 2012, HYPERTENSION, V59, P1037, DOI 10.1161/HYPERTENSIONAHA.111.183368; Dammanahalli KJ, 2008, CLIN EXP PHARMACOL P, V35, P2, DOI 10.1111/j.1440-1681.2007.04830.x; Deliyanti D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134392; Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z; Deliyanti D, 2014, ARTERIOSCL THROM VAS, V34, P2033, DOI 10.1161/ATVBAHA.114.303792; Deliyanti D, 2012, HYPERTENSION, V59, P607, DOI 10.1161/HYPERTENSIONAHA.111.188136; Deng W, 2010, CARDIOVASC RES, V88, P93, DOI 10.1093/cvr/cvq125; EMORI T, 1989, BIOCHEM BIOPH RES CO, V160, P93, DOI 10.1016/0006-291X(89)91625-2; Filipovich T, 2008, PEPTIDES, V29, P2250, DOI 10.1016/j.peptides.2008.09.002; Gien J, 2016, AM J PHYSIOL-LUNG C, V311, pL1090, DOI 10.1152/ajplung.00066.2016; Goncalves A, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24782; Goraca A, 2016, PHARMACOL REP, V68, P121, DOI 10.1016/j.pharep.2015.07.007; Gray SP, 2017, DIABETOLOGIA, V60, P927, DOI 10.1007/s00125-017-4215-5; Grimshaw MJ, 2002, EUR J IMMUNOL, V32, P2393, DOI 10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4; HINSON JP, 1991, J STEROID BIOCHEM, V40, P437, DOI 10.1016/0960-0760(91)90213-O; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010; KAWAGUCHI H, 1990, J MOL CELL CARDIOL, V22, P839, DOI 10.1016/0022-2828(90)90115-I; Kim JH, 2009, J NEUROSCI RES, V87, P653, DOI 10.1002/jnr.21884; Klipper E, 2010, ENDOCRINOLOGY, V151, P1914, DOI 10.1210/en.2009-0767; Komers R, 2016, AM J PHYSIOL-REG I, V310, pR877, DOI 10.1152/ajpregu.00425.2015; Li JM, 2010, DIABETES, V59, P1528, DOI 10.2337/db09-1057; Ling L, 2013, BRIT J PHARMACOL, V168, P283, DOI 10.1111/j.1476-5381.2011.01786.x; MAGUIRE JJ, 1995, BRIT J PHARMACOL, V115, P191, DOI 10.1111/j.1476-5381.1995.tb16338.x; Mazzocchi G, 1996, RES EXP MED, V196, P145, DOI 10.1007/BF02576836; Moravski CJ, 2003, AM J PATHOL, V162, P151, DOI 10.1016/S0002-9440(10)63806-0; Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099; Patel C, 2014, AM J PATHOL, V184, P3040, DOI 10.1016/j.ajpath.2014.07.012; Plusczyk T, 2001, DIGEST DIS SCI, V46, P1343, DOI 10.1023/A:1010640002323; Polak K, 2003, EXP EYE RES, V76, P633, DOI 10.1016/S0014-4835(02)00312-3; Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477; Sarthy VP, 2015, CURR EYE RES, V40, P1181, DOI 10.3109/02713683.2014.982828; Sjolie AK, 2011, DIABETIC MED, V28, P345, DOI 10.1111/j.1464-5491.2010.03210.x; Speciale L, 1998, IMMUNOLOGY, V93, P109; Takagi C, 1996, INVEST OPHTH VIS SCI, V37, P2504; TAKEI K, 1993, GRAEF ARCH CLIN EXP, V231, P476, DOI 10.1007/BF02044235; TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S; Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003; Vogler S, 2016, NEUROCHEM RES, V41, P2598, DOI 10.1007/s11064-016-1971-4; Wang HB, 2014, MOL VIS, V20, P231; Wilkinson-Berka JL, 2014, ANTIOXID REDOX SIGN, V20, P2726, DOI 10.1089/ars.2013.5357; Wilkinson-Berka JL, 2012, PEPTIDES, V36, P142, DOI 10.1016/j.peptides.2012.04.008; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4; Wong S, 2007, ENDOCRINOLOGY, V148, P1511, DOI 10.1210/en.2006-0965; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yang X, 2013, MOL VIS, V19, P775; ZENG ZP, 1992, J CLIN ENDOCR METAB, V74, P874, DOI 10.1210/jc.74.4.874; Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427; Zhao XJ, 2015, INVEST OPHTH VIS SCI, V56, P2773, DOI 10.1167/iovs.14-16104; Zong H, 2010, DIABETOLOGIA, V53, P2656, DOI 10.1007/s00125-010-1900-z	63	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					805	817		10.1016/j.ajpath.2017.11.009			13	Pathology	Pathology	FY4OT	WOS:000426805100021	29248456	Bronze			2019-10-28	
J	Bollen, IAE; Ehler, E; Fleischanderl, K; Bouwman, F; Kempers, L; Ricke-Hoch, M; Hilfiker-Kleiner, D; Dos Remedios, CG; Kruger, M; Vink, A; Asselbergs, FW; van Spaendonck-Zwarts, KY; Pinto, YM; Kuster, DWD; van der Velden, J				Bollen, I. A. E.; Ehler, E.; Fleischanderl, K.; Bouwman, F.; Kempers, L.; Ricke-Hoch, M.; Hilfiker-Kleiner, D.; Dos Remedios, C. G.; Kruger, M.; Vink, A.; Asselbergs, F. W.; van Spaendonck-Zwarts, K. Y.; Pinto, Y. M.; Kuster, D. W. D.; van der Velden, J.			Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease (vol 187, pg 2645, 2017)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction																Bollen IAE, 2017, AM J PATHOL, V187, P2645, DOI 10.1016/j.ajpath.2017.08.022	1	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					828	829		10.1016/j.ajpath.2018.01.003			2	Pathology	Pathology	FY4OT	WOS:000426805100023					2019-10-28	
J	Kataoka, H; Kawaguchi, M; Fukushima, T; Shimomura, T				Kataoka, Hiroaki; Kawaguchi, Makiko; Fukushima, Tsuyoshi; Shimomura, Takeshi			Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2): Emerging key players in epithelial integrity and cancer	PATHOLOGY INTERNATIONAL			English	Review						epithelial biology; growth factor; HAI-1; HAI-2; hepatocyte growth factor; HGF activator; matripase; MET; protease inhibitor; type II transmemebrane serine protease	TRANSMEMBRANE SERINE-PROTEASE; TUMOR-SUPPRESSOR ACTIVITY; FACTOR HGF ACTIVATOR; STEM-CELLS; C-MET; EPIGENETIC INACTIVATION; TYPE-1 HAI-1; TYPE-2/PLACENTAL BIKUNIN; PERICELLULAR ACTIVATION; MATRIPTASE ACTIVATION	The growth, survival, and metabolic activities of multicellular organisms at the cellular level are regulated by intracellular signaling, systemic homeostasis and the pericellular microenvironment. Pericellular proteolysis has a crucial role in processing bioactive molecules in the microenvironment and thereby has profound effects on cellular functions. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) and HAI-2 are type I transmembrane serine protease inhibitors expressed by most epithelial cells. They regulate the pericellular activities of circulating hepatocyte growth factor activator and cellular type II transmembrane serine proteases (TTSPs), proteases required for the activation of hepatocyte growth factor (HGF)/scatter factor (SF). Activated HGF/SF transduces pleiotropic signals through its receptor tyrosine kinase, MET (coded by the proto-oncogene MET), which are necessary for cellular migration, survival, growth and triggering stem cells for accelerated healing. HAI-1 and HAI-2 are also required for normal epithelial functions through regulation of TTSP-mediated activation of other proteases and protease-activated receptor 2, and also through suppressing excess degradation of epithelial junctional proteins. This review summarizes current knowledge regarding the mechanism of pericellular HGF/SF activation and highlights emerging roles of HAIs in epithelial development and integrity, as well as tumorigenesis and progression of transformed epithelial cells.	[Kataoka, Hiroaki; Kawaguchi, Makiko; Fukushima, Tsuyoshi; Shimomura, Takeshi] Miyazaki Univ, Sect Oncopathol & Regenerat Biol, Fac Med, Dept Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan	Kataoka, H (reprint author), Miyazaki Univ, Sect Oncopathol & Regenerat Biol, Fac Med, Dept Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	mejina@med.miyazaki-u.ac.jp	Fukushima, Tsuyoshi/K-4270-2019	Fukushima, Tsuyoshi/0000-0002-9350-777X	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H05175, 15K08311]	This work was supported by JSPS KAKENHI Grant Number 16H05175 (H.K.) and 15K08311 (M.K.). Hiroaki Kataoka has been announced as the winner of The Japanese Society of Pathology; Japan Pathology Award in 2017	Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Baba T, 2012, J PATHOL, V228, P181, DOI 10.1002/path.3993; Betsunoh H, 2007, CANCER SCI, V98, P491, DOI 10.1111/j.1349-7006.2007.00412.x; Carney TJ, 2007, DEVELOPMENT, V134, P3461, DOI 10.1242/dev.004556; Chen LM, 2017, ONCOTARGET, V8, P56490, DOI 10.18632/oncotarget.17009; Chen M, 2008, BBA-MOL CELL RES, V1783, P896, DOI 10.1016/j.bbamcr.2007.10.019; Cheng HX, 2009, CANCER RES, V69, P1828, DOI 10.1158/0008-5472.CAN-08-3728; Cheng MF, 2014, HISTOPATHOLOGY, V65, P24, DOI 10.1111/his.12361; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Domoto T, 2012, CANCER SCI, V103, P448, DOI 10.1111/j.1349-7006.2011.02162.x; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; Dong WJ, 2010, INT J CANCER, V127, P1526, DOI 10.1002/ijc.25161; Eigenbrot C, 2010, FEBS J, V277, P2215, DOI 10.1111/j.1742-4658.2010.07638.x; Franco FM, 2015, BIOORGAN MED CHEM, V23, P2328, DOI 10.1016/j.bmc.2015.03.072; Friis S, 2014, J BIOL CHEM, V289, P22319, DOI 10.1074/jbc.M114.574400; Fukai K, 2003, CANCER RES, V63, P8674; Fukushima T, 2011, CANCER SCI, V102, P407, DOI 10.1111/j.1349-7006.2010.01808.x; Generali D, 2007, CLIN CANCER RES, V13, P550, DOI 10.1158/1078-0432.CCR-06-1266; Hamasuna R, 2001, INT J CANCER, V93, P339, DOI 10.1002/ijc.1349; Han ZF, 2016, CHEMMEDCHEM, V11, P585, DOI 10.1002/cmdc.201500600; Han ZF, 2014, ACS MED CHEM LETT, V5, P1219, DOI 10.1021/ml500254r; Hashimoto T, 2010, FEBS J, V277, P4888, DOI 10.1111/j.1742-4658.2010.07894.x; Hayashi T, 2007, J THROMB HAEMOST, V5, P1477, DOI 10.1111/j.1538-7836.2007.02594.x; Heinz-Erian P, 2009, AM J HUM GENET, V84, P188, DOI 10.1016/j.ajhg.2009.01.004; Hoshiko S, 2013, CANCER RES, V73, P2659, DOI 10.1158/0008-5472.CAN-12-3337; Hwang S, 2015, J INVEST DERMATOL, V135, P2283, DOI 10.1038/jid.2015.160; Ishikawa T, 2017, J BIOL CHEM, V292, P20769, DOI 10.1074/jbc.M117.796789; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Itoh H, 2000, BBA-GENE STRUCT EXPR, V1491, P295, DOI 10.1016/S0167-4781(00)00029-4; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; Kanemaru A, 2017, INT J CANCER, V140, P130, DOI 10.1002/ijc.30426; Kataoka H, 2000, CANCER RES, V60, P6148; Kataoka H, 2000, J BIOL CHEM, V275, P40453, DOI 10.1074/jbc.M006412200; Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010; Kataoka H, 2000, HISTOCHEM CELL BIOL, V114, P469; Kataoka H, 2002, BIOCHEM BIOPH RES CO, V290, P1096, DOI 10.1006/bbrc.2001.6313; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kataoka H, 2000, CANCER LETT, V148, P127, DOI 10.1016/S0304-3835(99)00322-5; Kataoka H, 2010, FEBS J, V277, P2230, DOI 10.1111/j.1742-4658.2010.07640.x; Kato M, 2012, J BIOCHEM, V151, P179, DOI 10.1093/jb/mvr131; Kawaguchi M, 2016, ONCOTARGET, V7, P68614, DOI 10.18632/oncotarget.11863; Kawaguchi M, 2015, AM J PATHOL, V185, P1610, DOI 10.1016/j.ajpath.2015.02.009; Kawaguchi M, 2014, CANCERS, V6, P1890, DOI 10.3390/cancers6041890; Kawaguchi M, 2011, AM J PATHOL, V179, P1815, DOI 10.1016/j.ajpath.2011.06.038; Kawaguchi M, 2009, FEBS J, V276, P3481, DOI 10.1111/j.1742-4658.2009.07070.x; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Kohn KW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099269; Kojima K, 2011, J BIOCHEM, V150, P123, DOI 10.1093/jb/mvr075; Koschubs T, 2012, BIOCHEM J, V442, P483, DOI 10.1042/BJ20111317; Lai YJJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132163; Larsen BR, 2013, EXP CELL RES, V319, P918, DOI 10.1016/j.yexcr.2013.01.008; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Li W, 2009, CANCER RES, V69, P8395, DOI 10.1158/0008-5472.CAN-09-1995; Lin SH, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1079; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Matsumoto K, 2017, CANCER SCI, V108, P296, DOI 10.1111/cas.13156; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1998, EUR J BIOCHEM, V258, P355, DOI 10.1046/j.1432-1327.1998.2580355.x; Miyazawa K, 2010, FEBS J, V277, P2208, DOI 10.1111/j.1742-4658.2010.07637.x; Mori M, 2007, BIOL REPROD, V76, P164, DOI 10.1095/biolreprod.106.056127; MORIYAMA T, 1995, FEBS LETT, V372, P78, DOI 10.1016/0014-5793(95)00949-A; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Mukai S, 2008, FEBS J, V275, P1003, DOI 10.1111/j.1742-4658.2008.06265.x; Mukai S, 2015, HUM CELL, V28, P133, DOI 10.1007/s13577-015-0114-6; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; Nagai M, 2008, PATHOL INT, V58, P462, DOI 10.1111/j.1440-1827.2008.02255.x; Nagaike K, 2004, CANCER SCI, V95, P728, DOI 10.1111/j.1349-7006.2004.tb03253.x; Nagaike K, 2008, AM J PATHOL, V173, P1464, DOI 10.2353/ajpath.2008.071142; Nakamura K, 2011, INT J CANCER, V128, P2613, DOI 10.1002/ijc.25606; Nakamura K, 2009, INT J ONCOL, V35, P239, DOI 10.3892/ijo_00000333; Nakamura T, 2011, J GASTROEN HEPATOL, V26, P188, DOI 10.1111/j.1440-1746.2010.06549.x; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Ning T, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701636; Nonboe AW, 2017, TRAFFIC, V18, P378, DOI 10.1111/tra.12482; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1053/jhep.1997.v25.pm0008985272; Overeem AW, 2016, DIS MODEL MECH, V9, P1, DOI 10.1242/dmm.022269; Owen KA, 2010, BIOCHEM J, V426, P219, DOI 10.1042/BJ20091448; Owusu BY, 2017, ONCOTARGET, V8, P63014, DOI 10.18632/oncotarget.18260; Potgens AJG, 2003, PLACENTA, V24, P412, DOI 10.1053/plac.2002.0914; Rodgers JT, 2017, CELL REP, V19, P479, DOI 10.1016/j.celrep.2017.03.066; Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255; Sakugawa Chihiro, 2017, BMC Res Notes, V10, P674, DOI 10.1186/s13104-017-3014-x; Sales KU, 2015, ONCOGENE, V34, P288, DOI 10.1038/onc.2013.563; Sechler M, 2015, J BIOL CHEM, V290, P15610, DOI 10.1074/jbc.M114.631820; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002937; Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430; Szabo R, 2009, AM J PATHOL, V174, P2015, DOI 10.2353/ajpath.2009.090053; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanabe LM, 2017, FEBS J, V284, P1421, DOI 10.1111/febs.13971; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Tervonen TA, 2016, ONCOGENE, V35, P1832, DOI 10.1038/onc.2015.248; Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood-2009-06-230359; Tjin EPM, 2004, BLOOD, V104, P2172, DOI 10.1182/blood-2003-12-4386; Tseng IC, 2010, J BIOL CHEM, V285, P3261, DOI 10.1074/jbc.M109.055640; Turk B, 2012, EMBO J, V31, P1630, DOI 10.1038/emboj.2012.42; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wallrapp C, 2000, CANCER RES, V60, P2602; Wu CJ, 2017, J CLIN INVEST, V127, P623, DOI 10.1172/JCI88428; Yamagata Y, 2012, AM J PHYSIOL-GASTR L, V303, pG1254, DOI 10.1152/ajpgi.00107.2012; Yamauchi M, 2004, J UROLOGY, V171, P890, DOI 10.1097/01.ju.0000092861.21122.d2; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Ye JJ, 2014, CANCER SCI, V105, P44, DOI 10.1111/cas.12306; Yue DL, 2014, EXP CELL RES, V322, P149, DOI 10.1016/j.yexcr.2013.11.009; Zhang MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep36902	118	13	13	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					145	158		10.1111/pin.12647			14	Pathology	Pathology	FY0SL	WOS:000426521900001	29431273				2019-10-28	
J	Inoue, T; Nakazato, Y; Karube, Y; Maeda, S; Kobayashi, S; Chida, M				Inoue, Takashi; Nakazato, Yoshimasa; Karube, Yoko; Maeda, Sumiko; Kobayashi, Satoru; Chida, Masayuki			Mitosis count and number of cancer cells in cases of primary pulmonary adenocarcinoma: Correlations among phosphorylated histone 3, number of cancer cells, nuclear grade, pathologic features and prognosis	PATHOLOGY INTERNATIONAL			English	Article						histological classification; mitosis; nuclear grading; phosphorylated histone 3; pulmonary adenocarcinoma	LUNG ADENOCARCINOMA; MITOTIC INDEX; INTERNATIONAL ASSOCIATION; HISTOLOGIC PATTERN; STAGE; CLASSIFICATION; H3; RECURRENCE; SYSTEM; TUMORS	Immunohistochemistry findings for the phosphorylated form of histone 3 (pHH3) have been shown to be a reliable mitosis-specific marker. We evaluated the correlation between pHH3-stained mitotic figures (PHMFs) and clinical outcome, and compared the results with findings for numbers of PHMFs and cancer cells. The primary tumor was obtained from 113 patients with pulmonary adenocarcinomas (2cm maximum dimension). All specimens were stained with pHH3, then the number of cancer cells in each was determined. Cases with a cancer-cell index 1000 showed worse recurrence-free survival as compared to those with a value <1000 (P<0.001). Also, cases with a pHH3 index 0.27 showed worse recurrence-free survival as compared to <0.27 (P=0.001) and cases with a pHH3/cancer-cell index 0.001 showed worse recurrence-free survival as compared to <0.001 (P=0.002). Multivariate analysis demonstrated that pHH3/cancer-cell index was significantly correlated with prognosis, but not Ki-67 index. The number of cancer cells was also strongly correlated with progression of Noguchi's classification and WHO pathologic type. pHH3/cancer-cell index was correlated with prognosis, and those were useful for prognostic evaluation of pulmonary adenocarcinoma patients. Furthermore, cancer cell number was correlated with Noguchi's classification and WHO pathologic type.	[Inoue, Takashi; Karube, Yoko; Maeda, Sumiko; Kobayashi, Satoru; Chida, Masayuki] Dokkyo Med Univ, Dept Gen Thorac Surg, Mibu, Tochigi, Japan; [Nakazato, Yoshimasa] Dokkyo Med Univ, Dept Anat & Diagnost Pathol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan	Nakazato, Y (reprint author), Dokkyo Med Univ, Dept Anat & Diagnost Pathol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	nakazato@dokkyomed.ac.jp	Maeda, Sumiko/A-5628-2019	Chida, Masayuki/0000-0001-8502-1502	Dokkyo Medical University, Young Investigator Award in Japan [2016-12]	This work was partially supported by Dokkyo Medical University, Young Investigator Award (#2016-12) in Japan. We thank Yasuo Imai, Masaru Kojima, and Hajime Kuroda for their diagnostic assistance.	Asamura H, 1999, CHEST, V115, P1018, DOI 10.1378/chest.115.4.1018; Barletta JA, 2010, CANCER-AM CANCER SOC, V116, P659, DOI 10.1002/cncr.24831; Colman H, 2006, AM J SURG PATHOL, V30, P657, DOI 10.1097/01.pas.0000202048.28203.25; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Duhig EE, 2015, J THORAC ONCOL, V10, P673, DOI 10.1097/JTO.0000000000000446; Groome PA, 2007, J THORAC ONCOL, V2, P694, DOI 10.1097/JTO.0b013e31812d05d5; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Kadota K, 2012, MODERN PATHOL, V25, P1117, DOI 10.1038/modpathol.2012.58; Kobayashi Y, 2005, CANCER CYTOPATHOL, V105, P44, DOI 10.1002/cncr.20686; KUROKAWA T, 1994, AM J SURG PATHOL, V18, P431, DOI 10.1097/00000478-199405000-00001; Louis DN, 2016, WHO CLASSIFICATION T, P17; Motoi N, 2008, AM J SURG PATHOL, V32A, P810, DOI 10.1097/PAS.0b013e31815cb162; Nakazato Y, 2010, CANCER-AM CANCER SOC, V116, P2011, DOI 10.1002/cncr.24948; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Okudela K, 2010, AM J SURG PATHOL, V34, P243, DOI 10.1097/PAS.0b013e3181c79a6f; Petersen I, 2009, LUNG CANCER, V65, P312, DOI 10.1016/j.lungcan.2008.12.013; Ribalta T, 2004, AM J SURG PATHOL, V28, P1532, DOI 10.1097/01.pas.0000141389.06925.d5; Schimming TT, 2012, AM J DERMATOPATH, V34, P266, DOI 10.1097/DAD.0b013e31823135a3; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Tapia C, 2006, AM J SURG PATHOL, V30, P83, DOI 10.1097/01.pas.0000183572.94140.43; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsuta K, 2011, AM J CLIN PATHOL, V136, P252, DOI 10.1309/AJCPDXFOPXGEF0RP; Veras E, 2009, INT J GYNECOL PATHOL, V28, P316, DOI 10.1097/PGP.0b013e318193df97; von der Thusen JH, 2013, J THORAC ONCOL, V8, P37, DOI 10.1097/JTO.0b013e318276274e; Yamashita S, 2011, ANN THORAC CARDIOVAS, V17, P341, DOI 10.5761/atcs.oa.10.01573; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232	28	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					159	166		10.1111/pin.12635			8	Pathology	Pathology	FY0SL	WOS:000426521900002	29393583				2019-10-28	
J	Sugimura, H; Kahyo, T				Sugimura, Haruhiko; Kahyo, Tomoaki			Editorial Comment on Validation of the digital PCR system for use in tyrosine kinase inhibitor-resistant EGFR-mutant non-small-cell lung cancer	PATHOLOGY INTERNATIONAL			English	Editorial Material							IN-SITU HYBRIDIZATION; DNA; QUANTITATION; PERSPECTIVE; MUTATIONS; PATHOLOGY; ARCHIVES; TISSUE		[Sugimura, Haruhiko; Kahyo, Tomoaki] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka, Japan	Sugimura, H (reprint author), Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka, Japan.	hsugimur@hama-med.ac.jp					Do HD, 2017, CLIN CHEM, V63, P1506, DOI 10.1373/clinchem.2017.271932; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Iwaizumi Moriya, 2015, Hum Genome Var, V2, P15057, DOI 10.1038/hgv.2015.57; Kahyo T, 2017, CLIN CHIM ACTA, V475, P91, DOI 10.1016/j.cca.2017.10.015; Kanai Y, 2008, PATHOL INT, V58, P544, DOI 10.1111/j.1440-1827.2008.02270.x; Kiss MM, 2008, ANAL CHEM, V80, P8975, DOI 10.1021/ac801276c; Kiyose S, 2012, PATHOL INT, V62, P477, DOI 10.1111/j.1440-1827.2012.02832.x; Masago K, 2017, PATHOL INT IN PRESS; Meehan K, 2017, CLIN TRANSL ONCOL, V19, P606, DOI 10.1007/s12094-016-1573-2; Olmedillas-Lopez S, 2017, WORLD J GASTROENTERO, V23, P7087, DOI 10.3748/wjg.v23.i39.7087; Ottesen EA, 2006, SCIENCE, V314, P1464, DOI 10.1126/science.1131370; Postel M, 2018, EXPERT REV MOL DIAGN, V18, P7, DOI 10.1080/14737159.2018.1400384; Shibata T, 2012, PATHOL INT, V62, P647, DOI 10.1111/j.1440-1827.2012.02855.x; Sugimura H, 2016, PATHOL INT, V66, P359, DOI 10.1111/pin.12418; Sugimura H, 2010, PATHOL INT, V60, P543, DOI 10.1111/j.1440-1827.2010.02561.x; Watanabe M, 2017, EBIOMEDICINE, V21, P86, DOI 10.1016/j.ebiom.2017.06.003	16	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					174	175		10.1111/pin.12640			2	Pathology	Pathology	FY0SL	WOS:000426521900004	29437276				2019-10-28	
J	Hino, R; Motoi, N; Toda, K; Ebina, A; Yamada, K; Higuchi, M; Hirokawa, M; Ishikawa, Y				Hino, Rumi; Motoi, Noriko; Toda, Kazutoshi; Ebina, Aya; Yamada, Keiko; Higuchi, Miyoko; Hirokawa, Mitsuyoshi; Ishikawa, Yuichi			Stromal tiny black dots, like "sugar-coated", of von Kossa stain is a diagnostic clue to hyalinizing trabecular tumor of the thyroid gland	PATHOLOGY INTERNATIONAL			English	Article						calcium deposition; hyalinized trabecular tumor; thyroid tumor; von Kossa stain	PAPILLARY CARCINOMA; CELL-MEMBRANE; ADENOMA; CALCIFICATION; FIBROBLASTS; PRODUCTS; MIB-1	Hyalinizing trabecular tumor (HTT) is a rare low-grade tumor, and a prominent feature is the basement membranous stroma. We assume that such characteristic stromal findings of HTT are related to calcium deposition, and examined HTT samples by von Kossa special staining. There has been no report describing von Kossa special staining for such stroma. We collected 12 cases of HTT and 30 cases of papillary thyroid carcinoma (PTC) that had matched age, gender, tumor size, and surgical procedure characteristics as a control group. We compared the staining pattern and degree of von Kossa positivity between HTT and PTC, and a grading system of von Kossa stain was adopted to highlight differences between them. On von Kossa staining, all HTT revealed many tiny black dots around vessels in the hyalinized stroma, like sugar-coated, and a high degree of calcium deposition in most cases, whereas PTC showed sparse stromal calcification in some cases. The degree of von Kossa staining was significantly different between the two groups. This is the first report describing abundant tiny black dots, like a sugar-coated appearance, of von Kossa stain in HTT. Here, we propose this finding can be a useful diagnostic clue to HTT.	[Hino, Rumi; Motoi, Noriko; Ishikawa, Yuichi] JFCR, Inst Canc, Dept Pathol, Koto Ku, 3-8-31 Ariake, Tokyo, Japan; [Hino, Rumi] Daito Bunka Univ, Dept Sports & Hlth Sci, 560 Iwadono, Higashimathuyama, Saitama, Japan; [Motoi, Noriko] Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Toda, Kazutoshi; Ebina, Aya] JFCR, Canc Inst Hosp, Div Head & Neck, Tokyo, Japan; [Yamada, Keiko] JFCR, Canc Inst Hosp, Div Ultrasonog Examinat, Tokyo, Japan; [Higuchi, Miyoko; Hirokawa, Mitsuyoshi] Kuma Hosp, Dept Diagnost Pathol & Cytol, Chuo Ku, 8-2-35 Shimoyamate Dori, Kobe, Hyogo, Japan	Motoi, N (reprint author), Canc Inst Hosp, Div Pathol, Dept Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.; Motoi, N (reprint author), JFCR, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	nmotoi-tky@umin.ac.jp					Caraci P, 2011, HEAD NECK PATHOL, V5, P423, DOI 10.1007/s12105-011-0276-9; Carney JA, 2008, AM J SURG PATHOL, V32, P622, DOI 10.1097/PAS.0b013e3181608545; Carney JA, 2008, AM J SURG PATHOL, V32, P1877, DOI 10.1097/PAS.0b013e31817a8f1b; CARNEY JA, 1987, AM J SURG PATHOL, V11, P583, DOI 10.1097/00000478-198708000-00001; Chae IH, 2016, PATHOL RES PRACT, V212, P415, DOI 10.1016/j.prp.2016.02.014; Cheung CC, 2000, AM J SURG PATHOL, V24, P1622, DOI 10.1097/00000478-200012000-00005; Ebina A, 2014, SURGERY, V156, P1579, DOI 10.1016/j.surg.2014.08.060; Farrar EJ, 2016, BIOMATERIALS, V105, P25, DOI 10.1016/j.biomaterials.2016.07.034; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; Galgano MT, 2006, AM J SURG PATHOL, V30, P1269, DOI 10.1097/01.pas.0000209858.13035.0a; Hirokawa M, 2000, AM J SURG PATHOL, V24, P575, DOI 10.1097/00000478-200004000-00013; Howard BE, 2013, ORL J OTO-RHINO-LARY, V75, P309, DOI 10.1159/000355291; KATOH R, 1989, HISTOPATHOLOGY, V15, P211, DOI 10.1111/j.1365-2559.1989.tb03072.x; Kondo T, 2012, HUM PATHOL, V43, P932, DOI 10.1016/j.humpath.2011.08.010; Kusunoki Takeshi, 2002, Asian J Surg, V25, P304, DOI 10.1016/S1015-9584(09)60196-2; Leonardo E, 2007, APPL IMMUNOHISTO M M, V15, P220, DOI 10.1097/01.pai.0000213122.66096.f0; Lukasova V, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12357; MOLBERG K, 1994, HUM PATHOL, V25, P192, DOI 10.1016/0046-8177(94)90277-1; Ohtsuki Y, 2009, MED MOL MORPHOL, V42, P189, DOI 10.1007/s00795-008-0415-x; Rajshankar D, 2017, FASEB J, V31, P937, DOI 10.1096/fj.201600645R; Salvatore G, 2005, EUR J CANCER, V41, P816, DOI 10.1016/j.ejca.2005.01.004; Simionescu A, 2007, AM J PATHOL, V171, P116, DOI 10.2353/ajpath.2007.060930; Wiesmann HP, 2005, INT REV CYTOL, V242, P121; Xu SH, 2006, BIOPHYS J, V91, P4221, DOI [10.1529/biophysj.105.075804, 10.1529/biophysj.106.075804]	24	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					176	182		10.1111/pin.12638			7	Pathology	Pathology	FY0SL	WOS:000426521900005	29368414				2019-10-28	
J	Sarioglu, S; Kilicarslan, E; Aydin, B; Kozen, MA; Akman, F; Oztop, I; Ada, E; Ikiz, AO				Sarioglu, Sulen; Kilicarslan, Emel; Aydin, Barbaros; Kozen, Melih Arif; Akman, Fadime; Oztop, Ilhan; Ada, Emel; Ikiz, Ahmet Omer			Tumor deposits in salivary gland tumors	PATHOLOGY INTERNATIONAL			English	Article						head and neck; salivary gland; salivary gland tumors; tumor deposit	COLORECTAL-CANCER; OPTIMAL CATEGORIZATION; CARCINOMA; ANGIOTROPISM; METASTASES; PROGNOSIS; MELANOMA; HEAD	Tumor deposits (TDs), identified in different types of carcinomas are associated with poor prognosis. Salivary gland tumors were evaluated for the first time for TDs in this series. Pathological and clinical features of 25 salivary gland carcinomas primarily treated surgically including neck dissection were determined and all cases were evaluated for TDs in dissection specimens. Seven patients (28%) had TDs. There was no difference for TDs when histological type, tumor grade, tumor localization, pT, pN stage, surgical margin, lymphovascular, perineural invasion, local recurrence, distant metastatic disease and overall survival were considered. Disease-free survival rates at 12 and 24 months were 52.5%, 28.6% and 73.3%, 57.1%, for cases with and without TDs (P=0.463). Overall survival rates at 12 and 24 months for these groups were 85.7% and 57.1 versus 86.7% and 66.7% respectively (P=0.916). Mean estimated recurrence-free survival time for all cases, TD negative and TD positive cases were: 171.86, 182.72 and 82.42 months, respectively. Mean estimated overall survival time for these groups were 175.80, 186.489 and 89.70 months, respectively. TDs were described in salivary gland tumors for the first time in this series and seem to be associated with poor prognosis requiring further evaluation in larger series.	[Sarioglu, Sulen] Dokuz Eylul Univ, Dept Pathol, Sch Med, Izmir, Turkey; [Kilicarslan, Emel] Bitlis Tatvan Publ Hosp, Dept Pathol, Bitlis, Turkey; [Aydin, Barbaros; Akman, Fadime] Dokuz Eylul Univ, Dept Radiat Oncol, Sch Med, Izmir, Turkey; [Kozen, Melih Arif; Ikiz, Ahmet Omer] Dokuz Eylul Univ, Dept Otorhinolaryngol, Sch Med, Izmir, Turkey; [Oztop, Ilhan] Dokuz Eylul Univ, Dept Med Oncol, Sch Med, Izmir, Turkey; [Ada, Emel] Dokuz Eylul Univ, Dept Radiol, Sch Med, Izmir, Turkey	Sarioglu, S (reprint author), Dokuz Eylul Univ, Dept Pathol, Sch Med, Izmir, Turkey.	sulen.sarioglu@deu.edu.tr					Amin MB, 2017, AJCC CANC STAGING MA; Bentolila LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep23834; Carrillo JF, 2007, CANCER-AM CANCER SOC, V109, P2043, DOI 10.1002/cncr.22647; El-Naggar A, 2017, WHO CLASSIFICATION H; Ersen A, 2014, PATHOL RES PRACT, V210, P565, DOI 10.1016/j.prp.2014.03.006; Gabriel WB, 1935, BRIT J SURG, V23, P395, DOI 10.1002/bjs.1800239017; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Lee HS, 2013, ANN SURG ONCOL, V20, P1604, DOI 10.1245/s10434-012-2692-9; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Lugassy C, 2014, CANCER MICROENVIRON, V7, P139, DOI 10.1007/s12307-014-0156-4; Mariano FV, 2011, INT J ORAL MAX SURG, V40, P504, DOI 10.1016/j.ijom.2010.12.002; Nagayoshi K, 2014, DIS COLON RECTUM, V57, P467, DOI 10.1097/DCR.0000000000000059; Nagtegaal ID, 2007, HISTOPATHOLOGY, V51, P141, DOI 10.1111/j.1365-2559.2007.02720.x; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Puppa G, 2007, MODERN PATHOL, V20, P843, DOI 10.1038/modpathol.3800791; Rock JB, 2014, ARCH PATHOL LAB MED, V138, P636, DOI 10.5858/arpa.2013-0166-OA; Sarioglu S, 2001, PATHOL RES PRACT, V197, P483, DOI 10.1078/0344-0338-00115; Sarioglu S, 2016, HEAD NECK-J SCI SPEC, V38, pE256, DOI 10.1002/hed.23981; Seethala RR, 2011, ADV ANAT PATHOL, V18, P29, DOI 10.1097/PAP.0b013e318202645a; Sobin LH, 2009, TNM CLASSIFICATION M; Sun Z, 2012, SURGERY, V151, P871, DOI 10.1016/j.surg.2011.12.027; Tang JH, PROTOCOL EXAMINATION; Terhaard CHJ, 2004, HEAD NECK-J SCI SPEC, V26, P681, DOI 10.1002/hed.10400; Ueno H, 2007, AM J CLIN PATHOL, V127, P287, DOI 10.1309/903UT10VQ3LC7B8L; Ueno H, 2012, ANN SURG, V255, P739, DOI 10.1097/SLA.0b013e31824b4839; Walvekar RR, 2011, HEAD NECK-J SCI SPEC, V33, P225, DOI 10.1002/hed.21433; Wilmott J, 2012, HISTOPATHOLOGY, V61, P889, DOI 10.1111/j.1365-2559.2012.04279.x	27	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					183	189		10.1111/pin.12637			7	Pathology	Pathology	FY0SL	WOS:000426521900006	29465761				2019-10-28	
J	Hara, S; Hirata, M; Ito, K; Mizushima, I; Fujii, H; Yamada, K; Nagata, M; Kawano, M				Hara, Satoshi; Hirata, Masayoshi; Ito, Kiyoaki; Mizushima, Ichiro; Fujii, Hiroshi; Yamada, Kazunori; Nagata, Michio; Kawano, Mitsuhiro			Post-infectious acute glomerulonephritis with podocytopathy induced by parvovirus B19 infection	PATHOLOGY INTERNATIONAL			English	Article						collapsing glomerulopathy; endocapillary proliferative glomerulonephritis; human parvovirus B19; podocytopathy; post-infectious acute glomerulonephritis	PROLIFERATIVE GLOMERULONEPHRITIS; ASSOCIATION; TRANSPLANTATION; IMMUNOGLOBULIN; NEPHROPATHY; DISEASE	Human parvovirus B19 infection causes a variety of glomerular diseases such as post-infectious acute glomerulonephritis and collapsing glomerulopathy. Although each of these appears independently, it has not been fully determined why parvovirus B19 provokes such a variety of different glomerular phenotypes. Here, we report a 68-year-old Japanese man who showed endocapillary proliferative glomerulonephritis admixed with podocytopathy in association with parvovirus B19 infection. The patient showed acute onset of heavy proteinuria, microscopic hematuria and kidney dysfunction with arthralgia and oliguria after close contact with a person suffering from erythema infectiosum. In the kidney biopsy specimen, glomeruli revealed diffuse and global endocapillary infiltration of inflammatory cells, with some also showing tuft collapse with aberrant vacuolation, swelling, and hyperplasia of glomerular epithelial cells. Immunofluorescence revealed dense granular C3 deposition that resembled the starry sky pattern. Intravenous glucocorticoid pulse therapy followed by oral prednisolone and cyclosporine combination therapy resulted in considerable amelioration of the kidney dysfunction and urinary abnormalities. The present case reveals that parvovirus B19 infection can induce different glomerular phenotypes even in the same kidney structure. This finding may provide hints useful for the further elucidation of the pathogenesis of parvovirus B19-induced glomerular lesions.	[Hara, Satoshi; Ito, Kiyoaki; Mizushima, Ichiro; Fujii, Hiroshi; Yamada, Kazunori; Kawano, Mitsuhiro] Kanazawa Univ, Div Rheumatol, Dept Internal Med, Sch Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan; [Hirata, Masayoshi] Takaoka City Hosp, Dept Internal Med, Takaoka, Toyama, Japan; [Yamada, Kazunori] Kanazawa Univ, Dept Adv Res Community Med, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Nagata, Michio] Univ Tsukuba, Fac Med, Dept Kidney & Vasc Pathol, Tsukuba, Ibaraki, Japan	Kawano, M (reprint author), Kanazawa Univ, Div Rheumatol, Dept Internal Med, Sch Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	sk33166@gmail.com		Kawano, Mitsuhiro/0000-0003-4613-2116			Barsoum NR, 2002, AM J TRANSPLANT, V2, P425, DOI 10.1034/j.1600-6143.2002.20505.x; Batal I, 2009, MODERN PATHOL, V22, P1468, DOI 10.1038/modpathol.2009.118; Besse W, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0330-7; D'Agati VD, 2013, CLIN J AM SOC NEPHRO, V8, P399, DOI 10.2215/CJN.06100612; Diaz F, 2000, CLIN NEPHROL, V53, P237; Fujita E, 2012, HUM PATHOL, V43, P2326, DOI 10.1016/j.humpath.2012.04.004; Ieiri N, 2005, CLIN NEPHROL, V64, P249; Komatsuda A, 2000, AM J KIDNEY DIS, V36, P851; Marco H, 2016, CLIN NEPHROL, V85, P238, DOI 10.5414/CN108694; Menter T, 2013, AM J TRANSPLANT, V13, P1474, DOI 10.1111/ajt.12218; Moudgil A, 2001, KIDNEY INT, V59, P2126, DOI 10.1046/j.1523-1755.2001.00727.x; Moudgil A, 1997, TRANSPLANTATION, V64, P1847, DOI 10.1097/00007890-199712270-00037; Murer L, 2000, J AM SOC NEPHROL, V11, P1132; Nakazawa T, 2000, AM J KIDNEY DIS, V35, DOI 10.1016/S0272-6386(00)70070-9; Nasr SH, 2013, KIDNEY INT, V83, P792, DOI 10.1038/ki.2012.407; Ohtomo Y, 2003, PEDIATR NEPHROL, V18, P280, DOI 10.1007/s00467-002-1056-2; Onguru P, 2006, RENAL FAILURE, V28, P85, DOI 10.1080/08860220500461302; Ramirez JA, 2005, MEDICINA-BUENOS AIRE, V65, P333; Tanawattanacharoen S, 2000, AM J KIDNEY DIS, V35, P1166, DOI 10.1016/S0272-6386(00)70055-2; Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840	20	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					190	195		10.1111/pin.12643			6	Pathology	Pathology	FY0SL	WOS:000426521900007	29457859				2019-10-28	
J	Kawai, H; Takayashiki, N; Otani, H; Sakashita, S; Noguchi, M				Kawai, Hitomi; Takayashiki, Norio; Otani, Haruo; Sakashita, Shingo; Noguchi, Masayuki			A case of microscopic, multiple sclerosing pneumocytoma	PATHOLOGY INTERNATIONAL			English	Article						distal airway stem cell; microscopic; p63; sclerosing pneumocytoma; SP-A; terminal respiratory unit; TTF-1	AIRWAY STEM-CELLS; HEMANGIOMA; LUNG; EXPRESSION	Sclerosing pneumocytoma is a rare tumor of the lung, commonly affecting middle-aged women, and is mostly isolated. Although this tumor is thought to be derived from primitive respiratory epithelial cells, the characteristics of the precursor cells are still unknown. A 19-year-old woman presented with multiple nodules in the right lung. Partial resection of the right middle lobe was performed, and seven sclerosing pneumocytomas, including four that were microscopic, were detected. The latter showed a simple papillary pattern, and three of them consisted of only round cell-like cells (single population). Interestingly, these round cell-like cells were positive for both p63 and TTF-1, but totally negative for SP-A. On the other hand, the tumor cells of the other four sclerosing pneumocytomas showing a papillary pattern with a dual population, were diffusely positive for TTF-1 and focally positive for SP-A (only in surface cells), but negative or very focally positive for p63. It has been reported that p63-positive stem cell-like cells are present in the distal airway and have potential to differentiate into type II pneumocytes. The immunohistochemical features of these multiple microscopic lesions suggest that the p63-TTF-1 double-positive cells are candidate precursor cells of sclerosing pneumocytoma.	[Kawai, Hitomi] Univ Tsukuba, Grad Sch Comprehens Human Sci, Ibaraki, Japan; [Takayashiki, Norio] Mito Kyodo Hosp, Dept Pathol, Ibaraki, Japan; [Otani, Haruo] Mito Saiseikai Hosp, Dept Pathol, Ibaraki, Japan; [Sakashita, Shingo; Noguchi, Masayuki] Univ Tsukuba, Fac Med, Dept Pathol, Tsukuba, Ibaraki 3058575, Japan	Sakashita, S (reprint author), Univ Tsukuba, Fac Med, Dept Pathol, Tsukuba, Ibaraki 3058575, Japan.	sakashingo@hotmail.com					Amin RMS, 2008, PATHOL INT, V58, P38, DOI 10.1111/j.1440-1827.2007.02186.x; Beasly MB, 2015, WHO CLASSIFICATION T, P110; Dacic S, 2004, ARCH PATHOL LAB MED, V128, P880; Devouassoux-Shisheboran M, 2000, AM J SURG PATHOL, V24, P906, DOI 10.1097/00000478-200007000-00002; Hishida T, 2005, JPN J CLIN ONCOL, V35, P37, DOI 10.1093/jjco/hyi002; Ito Kazuhisa, 2006, Nihon Kokyuki Gakkai Zasshi, V44, P848; Jung SH, 2016, P NATL ACAD SCI USA, V113, P10672, DOI 10.1073/pnas.1606946113; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lin XY, 2012, HISTOPATHOLOGY, V61, P178, DOI 10.1111/j.1365-2559.2011.04088.x; Lin XY, 2012, VIRCHOWS ARCH, V461, P59, DOI 10.1007/s00428-012-1247-6; Maeda R, 2009, GEN THORAC CARDIOVAS, V57, P667, DOI 10.1007/s11748-009-0452-y; NAGATA N, 1985, CANCER, V55, P116, DOI 10.1002/1097-0142(19850101)55:1<116::AID-CNCR2820550119>3.0.CO;2-4; Niho S, 1998, AM J PATHOL, V152, P1065; NOGUCHI M, 1986, AM J SURG PATHOL, V10, P429, DOI 10.1097/00000478-198606000-00008; Sartori G, 2007, AM J SURG PATHOL, V31, P1512, DOI 10.1097/PAS.0b013e318032c8cc; SATOH Y, 1989, CANCER, V64, P1310, DOI 10.1002/1097-0142(19890915)64:6<1310::AID-CNCR2820640624>3.0.CO;2-S; Wang Y, 2008, J CLIN PATHOL, V61, P192, DOI 10.1136/jcp.2007.050401; Wu J, 2014, SCI REP-UK, V4, DOI 10.1038/srep06102; Zhang JY, 2014, CLIN RESPIR J, V8, P133, DOI 10.1111/crj.12048; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	20	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					196	201		10.1111/pin.12648			6	Pathology	Pathology	FY0SL	WOS:000426521900008	29451344				2019-10-28	
J	Shintaku, M; Miura, S; Asagoe, K; Yutani, C				Shintaku, Masayuki; Miura, Satoshi; Asagoe, Kohsuke; Yutani, Chikao			Chronic recurrent pulmonary thromboembolism in a patient with essential thrombocythemia, complicating acute right ventricular infarct	PATHOLOGY INTERNATIONAL			English	Letter							CORONARY-ARTERY-DISEASE; PATHOGENESIS; MECHANISMS		[Shintaku, Masayuki] Shiga Med Ctr Adults, Dept Pathol, Moriyama, Shiga, Japan; [Miura, Satoshi; Asagoe, Kohsuke] Shiga Med Ctr Adults, Dept Hematol & Oncol, Moriyama, Shiga, Japan; [Yutani, Chikao] Amagasaki Cent Hosp, Dept Pathol, Amagasaki, Hyogo, Japan	Shintaku, M (reprint author), Shiga Med Ctr Adults, Dept Pathol, Moriyama, Shiga, Japan.						FENAUX P, 1990, CANCER, V66, P549, DOI 10.1002/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6; FUSTER V, 1992, NEW ENGL J MED, V326, P242; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Guilpain P, 2008, RESPIRATION, V76, P295, DOI 10.1159/000112822; SCHEFFER MG, 1991, AM HEART J, V122, P573, DOI 10.1016/0002-8703(91)91019-J; VIRMANI R, 1979, AM J MED, V67, P498, DOI 10.1016/0002-9343(79)90800-3	6	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					202	204		10.1111/pin.12622			3	Pathology	Pathology	FY0SL	WOS:000426521900009	29318735				2019-10-28	
J	Sugawara, T; Sugita, S; Tateno, M; Yabutani, A; Segawa, K; Ito, Y; Tsujiwaki, M; Fujita, H; Ono, Y; Hasegawa, T				Sugawara, Taro; Sugita, Shintaro; Tateno, Masatoshi; Yabutani, Akira; Segawa, Keiko; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Hasegawa, Tadashi			Colonic inflammatory fibroid polyp with PDGFRA expression	PATHOLOGY INTERNATIONAL			English	Letter							TUMOR		[Sugawara, Taro; Sugita, Shintaro; Segawa, Keiko; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan; [Tateno, Masatoshi] Kushiro Red Cross Hosp, Dept Pathol, Kushiro, Hokkaido 0858512, Japan; [Yabutani, Akira] Kushiro Red Cross Hosp, Dept Med, Kushiro, Hokkaido 0858512, Japan	Sugawara, T (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.						Bui MM, 2010, CLIN COLORECTAL CANC, V9, P179, DOI 10.3816/CCC.2010.n.025; Huss S, 2012, HISTOPATHOLOGY, V61, P59, DOI 10.1111/j.1365-2559.2012.04203.x; Peterson MR, 2006, APPL IMMUNOHISTO M M, V14, P390, DOI 10.1097/01.pai.0000203038.33414.a3; Yamashita K, 2011, ENDOSCOPY, V43, pE171, DOI 10.1055/s-0030-1256289; Zhu LF, 2017, J THORAC DIS, V9, P598, DOI 10.21037/jtd.2017.02.89	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					205	206		10.1111/pin.12625			2	Pathology	Pathology	FY0SL	WOS:000426521900010	29288548				2019-10-28	
J	Meier, FA; Badrick, TC; Sikaris, KA				Meier, Frederick A.; Badrick, Tony C.; Sikaris, Kenneth A.			What's to Be Done About Laboratory Quality? Process Indicators, Laboratory Stewardship, the Outcomes Problem, Risk Assessment, and Economic Value Responding to Contemporary Global Challenges	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Clinical laboratory testing; Process quality indicators; Pre- and postanalytic testing; Risk assessment; Diagnostic error; Q-Tracks; KIMMS; FMEA	ACADEMIC-MEDICAL-CENTER; DIAGNOSTIC ERRORS; COST-EFFECTIVENESS; CARE; EXPERIENCE; IMPROVEMENT; PROGRAM; PATHOLOGY; MANAGEMENT; HISTORY	Objectives: For 50 years, structure, process, and outcomes measures have assessed health care quality. For clinical laboratories, structural quality has generally been assessed by inspection. For assessing process, quality indicators (QIs), statistical monitors of steps in the clinical laboratory total testing, have proliferated across the globe. Connections between structural and process laboratory measures and patient outcomes, however, have rarely been demonstrated. Methods: To inform further development of clinical laboratory quality systems, we conducted a selective but worldwide review of publications on clinical laboratory quality assessment. Results: Some QIs, like seven generic College of American Pathologists Q-Tracks monitors, have demonstrated significant process improvement; other measures have uncovered critical opportunities to improve test selection and result management. The College of Pathologists of Australasia Key Indicator Monitoring and Management System has deployed risk calculations, introduced from failure mode effects analysis, as surrogate measures for outcomes. Showing economic value from clinical laboratory testing quality is a challenge. Conclusions: Clinical laboratories should converge on fewer (7-14) rather than more (21-35) process monitors; monitors should cover all steps of the testing process under laboratory control and include especially high-risk specimen-quality QIs. Clinical laboratory stewardship, the combination of education interventions among clinician test orderers and report consumers with revision of test order formats and result reporting schemes, improves test ordering, but improving result reception is more difficult. Risk calculation reorders the importance of quality monitors by balancing three probabilities: defect frequency, weight of potential harm, and detection difficulty. The triple approach of (1) a more focused suite of generic consensus quality indicators, (2) more active clinical laboratory testing stewardship, and (3) integration of formal risk assessment, rather than competing with economic value, enhances it.	[Badrick, Tony C.] Bond Univ, Biomed Sci, RCPAQAP, Sydney, NSW, Australia; [Sikaris, Kenneth A.] Melbourne Pathol, Educ & Management Div, Melbourne, Vic, Australia	Meier, FA (reprint author), 3551 Windemere Dr, Ann Arbor, MI 48105 USA.	Frederickmeier4@gmail.com	Badrick, Tony/AAC-1610-2019				Kirchner MJA, 2007, CLIN CHEM LAB MED, V45, P672, DOI 10.1515/CCLM.2007.122; Ayanian JZ, 2016, NEW ENGL J MED, V375, P205, DOI 10.1056/NEJMp1605101; Badrick T, 2018, CLIN CHEM LAB MED, V56, P264, DOI 10.1515/cclm-2017-0219; Balough EP, 2015, IMPR DIAGN HLTH CAR, P9; Barth JH, 2012, ANN CLIN BIOCHEM, V49, P257, DOI 10.1258/acb.2011.011159; Barth JH, 2012, ANN CLIN BIOCHEM, V49, P9, DOI 10.1258/acb.2011.011126; Barth JH, 2011, ANN CLIN BIOCHEM, V48, P238, DOI 10.1258/acb.2010.010234; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Burke W, 2004, NAT REV GENET, V5, P955, DOI 10.1038/nrg1495; Callen J, 2011, BMJ QUAL SAF, V20, P194, DOI 10.1136/bmjqs.2010.044339; Carlson DA, 2003, LAB MED, V34, P373, DOI 10.1309/TUNGO4JCF3MVN9; Chiozza ML, 2009, CLIN CHIM ACTA, V404, P75, DOI 10.1016/j.cca.2009.03.015; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donabedian A, 2005, MILBANK Q, V83, P691, DOI 10.1111/j.1468-0009.2005.00397.x; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Douglas Mary, 1992, RISK BLAME ESSAYS CU, P3; Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757; Epner PL, 2017, CLIN BIOCHEM, V50, P622, DOI 10.1016/j.clinbiochem.2017.04.013; Epner PL, 2013, BMJ QUAL SAF, V22, pii6, DOI 10.1136/bmjqs-2012-001621; Graber ML, 2009, ADV HEALTH SCI EDUC, V14, P107, DOI 10.1007/s10459-009-9183-1; Howanitz PJ, 2014, ARCH PATHOL LAB MED, V138, P1141, DOI 10.5858/arpa.2014-0150-OA; Khoury M, 1996, MED J AUSTRALIA, V165, P128, DOI 10.5694/j.1326-5377.1996.tb124883.x; Kim JY, 2011, AM J CLIN PATHOL, V135, P108, DOI 10.1309/AJCP4GS7KSBDBACF; Kohn LT, 1999, ERR IS HUMAN BUILDIN, P25; Krasowski MD, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0137-7; Krouwer JS, 2004, ARCH PATHOL LAB MED, V128, P663; Li R, 2010, DIABETES CARE, V33, P1872, DOI 10.2337/dc10-0843; McElroy LM, 2016, BMJ QUAL SAF, V25, P329, DOI 10.1136/bmjqs-2015-004130; Meier FA, 2015, ARCH PATHOL LAB MED, V139, P762, DOI 10.5858/arpa.2014-0090-CP; Nakhleh RE, 2014, ARCH PATHOL LAB MED, V138, P1150, DOI 10.5858/arpa.2014-0148-OA; Ngo A, 2017, J APPL LAB MED, V1, P410; Plebani M, 1997, CLIN CHEM, V43, P1348; Plebani M, 2014, CLIN CHEM LAB MED, V52, P951, DOI 10.1515/cclm-2014-0142; Plebani M, 2014, BIOCHEM MEDICA, V24, P105, DOI 10.11613/BM.2014.012; Plebani M, 2013, CLIN BIOCHEM, V46, P1170, DOI 10.1016/j.clinbiochem.2012.11.028; Plebani M, 2013, CLIN CHEM LAB MED, V51, P187, DOI 10.1515/cclm-2012-0582; Procop GW, 2015, AM J CLIN PATHOL, V143, P623, DOI 10.1309/AJCPJOJ3HKEBD3TU; Reason J., 1990, HUMAN ERROR; Schiff GD, 2009, ARCH INTERN MED, V169, P1881, DOI 10.1001/archinternmed.2009.333; Sciacovelli L, 2015, CLIN CHEM LAB MED, V54, P1169; Shahangian S, 2009, AM J CLIN PATHOL, V131, P418, DOI 10.1309/AJCPJF8JI4ZLDQUE; Shcolnik W, 2012, CLIN CHEM LAB MED, V50, P1923, DOI 10.1515/cclm-2012-0357; Simundic AM, 2008, BIOCHEM MEDICA, V18, P311, DOI 10.11613/BM.2008.027; Singh H, 2012, BMJ QUAL SAF, V21, P93, DOI 10.1136/bmjqs-2011-000304; Singh H, 2009, ADV HEALTH SCI EDUC, V14, P57, DOI 10.1007/s10459-009-9177-z; Spelman D, 2015, MED J AUSTRALIA, V202, P13, DOI 10.5694/mja14.00814; Tehrani ASS, 2013, BMJ QUAL SAF, V22, P672, DOI 10.1136/bmjqs-2012-001550; Tezak Beverley, 2009, Healthc Q, V12 Spec No Patient, P80; Wachter RM, 2012, UNDERSTANDING OALIEN, P3; Wilkerson DS, 2011, LAB ADM PATHOLOGISTS, P119	50	2	2	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					186	196		10.1093/AJCP/AQX135			11	Pathology	Pathology	FW8WW	WOS:000425618700001	29471323	Bronze			2019-10-28	
J	Rubinstein, M; Hirsch, R; Bandyopadhyay, K; Madison, B; Taylor, T; Ranne, A; Linville, M; Donaldson, K; Lacbawan, F; Cornish, N				Rubinstein, Matthew; Hirsch, Robert; Bandyopadhyay, Kakali; Madison, Bereneice; Taylor, Thomas; Ranne, Anne; Linville, Millie; Donaldson, Keri; Lacbawan, Felicitas; Cornish, Nancy			Effectiveness of Practices to Support Appropriate Laboratory Test Utilization A Laboratory Medicine Best Practices Systematic Review and Meta-Analysis	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Clinical decision-making; Clinical laboratory services; Laboratory diagnosis; Laboratory medicine; Laboratory test utilization; Meta-analysis; Quality assurance; Quality improvement; Systematic review; Test ordering; Utilization management; Utilization review	PROVIDER ORDER ENTRY; CLINICAL-QUALITY INDICATORS; COMPUTER-BASED INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; DECISION-SUPPORT; PRIMARY-CARE; UTILIZATION MANAGEMENT; EDUCATIONAL INTERVENTION; DEMAND MANAGEMENT; MANAGING DEMAND	Objectives: To evaluate the effectiveness of practices used to support appropriate clinical laboratory test utilization. Methods: This review followed the Centers for Disease Control and Prevention (CDC) Laboratory Medicine Best Practices A6 cycle method. Eligible studies assessed one of the following practices for effect on outcomes relating to over- or underutilization: computerized provider order entry (CPOE), clinical decision support systems/tools (CDSS/CDST), education, feedback, test review, reflex testing, laboratory test utilization (LTU) teams, and any combination of these practices. Eligible outcomes included intermediate, systems outcomes (eg, number of tests ordered/performed and cost of tests), as well as patient-related outcomes (eg, length of hospital stay, readmission rates, morbidity, and mortality). Results: Eighty-three studies met inclusion criteria. Fifty-one of these studies could be meta-analyzed. Strength of evidence ratings for each practice ranged from high to insufficient. Conclusion: Practice recommendations are made for CPOE (specifically, modifications to existing CPOE), reflex testing, and combined practices. No recommendation for or against could be made for CDSS/CDST, education, feedback, test review, and LTU. Findings from this review serve to inform guidance for future studies.	[Rubinstein, Matthew; Madison, Bereneice; Taylor, Thomas; Ranne, Anne; Cornish, Nancy] Ctr Dis Control & Prevent, MS-G23,1600 Clifton Rd, Atlanta, GA 30333 USA; [Hirsch, Robert] Carter Consulting, Atlanta, GA USA; [Bandyopadhyay, Kakali; Linville, Millie] Deloitte Consulting, Atlanta, GA USA; [Donaldson, Keri] Penn State Univ, State Coll, PA USA; [Lacbawan, Felicitas] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA	Rubinstein, M (reprint author), Ctr Dis Control & Prevent, MS-G23,1600 Clifton Rd, Atlanta, GA 30333 USA.	ksr3@cdc.gov			CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [HHSD2002013M53968B/2002013F57569];  [200-2010-37203]	Work conducted by Kakali Bandyopadhyay and Millie Linville was supported by CDC funding for the Laboratory Medicine Best Practices Initiative to Westat-Deloitte under contract (HHSD2002013M53968B/2002013F57569). Work conducted by Robert Hirsch was supported under contract to Carter Consulting (200-2010-37203).	Calvete MDLOA, 2015, HAEMATOLOGICA, V100, P581; Aesif SW, 2015, ARCH PATHOL LAB MED, V139, P194, DOI 10.5858/arpa.2013-0693-OA; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Baird G, 2014, BIOCHEM MEDICA, V24, P223, DOI 10.11613/BM.2014.025; Baird GS, 2009, CLIN CHEM, V55, P533, DOI 10.1373/clinchem.2008.116707; Baker R, 2003, SCAND J PRIM HEALTH, V21, P219, DOI 10.1080/02813430310002995; Balogh E, 2015, COMMITTEE DIAGNOSTIC, Vxxvii, P444; Bansal P, 2001, J AM MED INFORM ASSN, P32; Baral N, 2001, TROP DOCT, V31, P155, DOI 10.1177/004947550103100314; Barazzoni F, 2002, INT J QUAL HEALTH C, V14, P321, DOI 10.1093/intqhc/14.4.321; BAREFORD D, 1990, BRIT MED J, V301, P1305, DOI 10.1136/bmj.301.6764.1305; Baricchi R, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-187; Barr J T, 1994, Clin Lab Manage Rev, V8, P526; Barth JH, 2012, ANN CLIN BIOCHEM, V49, P257, DOI 10.1258/acb.2011.011159; Barth JH, 2012, ANN CLIN BIOCHEM, V49, P9, DOI 10.1258/acb.2011.011126; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; Bates DW, 1997, ARCH INTERN MED, V157, P2501, DOI 10.1001/archinte.157.21.2501; Bindels Rianne, 2003, Inform Prim Care, V11, P69; Bonaguri C, 2011, AUTOIMMUN REV, V11, P1, DOI 10.1016/j.autrev.2011.06.006; Borenstein M., 2009, INTRO METAANALYSIS, Vxxviii, P421; Bosse HM, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0286-5; Bridges SA, 2014, J HEALTHC QUAL, V36, P46, DOI 10.1111/j.1945-1474.2012.00219.x; Brunetti M, 2011, CLIN CHEM LAB MED, V49, P617, DOI 10.1515/CCLM.2011.119; Bruns DE, 2001, CLIN CHEM, V47, P1547; Bunting PS, 2004, CLIN CHEM, V50, P321, DOI 10.1373/clinchem.2003.025098; Calderon-Margalit R, 2005, INT J QUAL HEALTH C, V17, P243, DOI 10.1093/intqhc/mzi025; Cappelletti P, 2016, INT J LAB HEMATOL, V38, P91, DOI 10.1111/ijlh.12502; Cernich JT, 2014, DIABETES, V63, pA322; Chonfhaola A, 2013, HAEMATOLOGICA, V98, P216; Christenson RH, 2011, CLIN CHEM, V57, P816, DOI 10.1373/clinchem.2010.157131; Chu KH, 2013, POSTGRAD MED J, V89, P566, DOI 10.1136/postgradmedj-2012-130833; Collins RA, 2014, AM J CLIN PATHOL, V141, P78, DOI 10.1309/AJCP1OSRTPUJE9XS; Alonso-Cerezo MC, 2009, CLIN CHEM LAB MED, V47, P1461, DOI 10.1515/CCLM.2009.335; Crawford JM, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517701067; Dawes L, 2015, BJOG-INT J OBSTET GY, V122, P237; DellaVolpe JD, 2014, HEALTHCARE, V2, P130, DOI 10.1016/j.hjdsi.2013.09.006; Dickerson JA, 2014, ARCH PATHOL LAB MED, V138, P110, DOI 10.5858/arpa.2012-0726-OA; Dolezal A, 2015, LAB INVEST, V95, p498A; DOWLING PT, 1989, ACAD MED, V64, P410, DOI 10.1097/00001888-198907000-00017; EISENBERG JM, 1977, J MED EDUC, V52, P578; Epner PL, 2013, BMJ QUAL SAF, V22, pii6, DOI 10.1136/bmjqs-2012-001621; Fang DZ, 2014, BMJ QUAL SAF, V23, P994, DOI 10.1136/bmjqs-2014-003053; Feldman LS, 2013, JAMA INTERN MED, V173, P903, DOI 10.1001/jamainternmed.2013.232; Ferrante di Ruffano L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e686; Ferraro S, 2017, CLIN BIOCHEM, V50, P555, DOI 10.1016/j.clinbiochem.2017.03.002; Froom P, 2012, AM J CLIN PATHOL, V137, P486, DOI [10.1309/AJCPLJFSS62YBAVVN, 10.1309/AJCPLJFSS62YBAWN]; Fryer AA, 2013, J CLIN PATHOL, V66, P62, DOI 10.1136/jclinpath-2011-200524; GAMA R, 1992, J CLIN PATHOL, V45, P248, DOI 10.1136/jcp.45.3.248; Gardezi SA, 2015, BMJ QUAL IMPROV REP, V4; Georgiou A, 2011, ARCH PATHOL LAB MED, V135, P495, DOI 10.1043/2010-0286-SO.1; Gilmour J, 2015, THYROID, V25, pA219; Graber ML, 2014, JT COMM J QUAL PATIE, V40, P102, DOI 10.1016/S1553-7250(14)40013-8; Hallworth MJ, 2015, CLIN CHEM, V61, P589, DOI 10.1373/clinchem.2014.232629; Harris AD, 2006, J AM MED INFORM ASSN, V13, P16, DOI 10.1197/jamia.M1749; Hauser RG, 2014, AM J CLIN PATHOL, V141, P774, DOI 10.1309/AJCPX1HIEM4KLGNU; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horn DM, 2014, J GEN INTERN MED, V29, P708, DOI 10.1007/s11606-013-2672-1; Horvath AR, 2004, CLIN CHIM ACTA, V342, P23, DOI 10.1016/j.cccn.2003.12.015; Howell Lydia Pleotis, 2014, J Pathol Inform, V5, P37, DOI 10.4103/2153-3539.141994; Huck A, 2014, CLIN CHIM ACTA, V427, P111, DOI 10.1016/j.cca.2013.09.021; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Hutton HD, 2009, ANN CLIN BIOCHEM, V46, P155, DOI 10.1258/acb.2008.008126; Hwang JI, 2002, INT J MED INFORM, V65, P213, DOI 10.1016/S1386-5056(02)00044-8; Iosfina I, 2013, AM J RESP CRIT CARE, V187; Janssens PMW, 2015, CLIN CHEM LAB MED, V53, P731, DOI 10.1515/cclm-2014-0575; Janssens PMW, 2010, CLIN CHIM ACTA, V411, P1596, DOI 10.1016/j.cca.2010.07.022; Kahan NR, 2009, AM J MANAG CARE, V15, P173; Kotecha N, 2015, AM J RESP CRIT CARE, V191; KROENKE K, 1987, MED CARE, V25, P928, DOI 10.1097/00005650-198710000-00002; Larochelle MR, 2014, J GEN INTERN MED, V29, P1468, DOI 10.1007/s11606-014-2919-5; Le RD, 2015, AM J EMERG MED, V33, P72, DOI 10.1016/j.ajem.2014.10.017; Li L, 2014, STUD HEALTH TECHNOL, V204, P74, DOI 10.3233/978-1-61499-427-5-74; Lippi G, 2015, CLIN BIOCHEM, V48, P1174, DOI 10.1016/j.clinbiochem.2015.06.006; Love SA, 2015, CLIN CHEM, V61, P498, DOI 10.1373/clinchem.2014.234310; Lum G, 2006, AM J CLIN PATHOL, V126, P190, DOI 10.1309/4X8HVJFKPHXJYMFK; MacPherson RD, 2005, ANZ J SURG, V75, P138, DOI 10.1111/j.1445-2197.2005.03316.x; May TA, 2006, AM J CLIN PATHOL, V126, P200, DOI 10.1309/WP59YM73L6CEGX2F; McKinney ZJ, 2015, TRANSFUSION, V55, P2086, DOI 10.1111/trf.13103; McNicoll L, 2015, J AM GERIATR SOC, V63, pS213; Melanson SEF, 2014, CLIN CHIM ACTA, V427, P127, DOI 10.1016/j.cca.2013.09.037; Miller CE, 2014, AM J MED GENET A, V164, P1094, DOI 10.1002/ajmg.a.36453; Minerowicz C, 2015, AM J MANAG CARE, V21, P763; Miyakis S, 2006, POSTGRAD MED J, V82, P823, DOI 10.1136/pgmj.2006.049551; Moulaert V, 2004, MED EDUC, V38, P1044, DOI 10.1111/j.1365-2929.2004.01954.x; Newman Darrell B, 2015, Perm J, V19, P49, DOI 10.7812/TPP/14-108; Nightingale P G, 1994, Qual Health Care, V3, P23, DOI 10.1136/qshc.3.1.23; Ogrinc G, 2008, QUAL SAF HEALTH CARE, V17, P13, DOI 10.1136/qshc.2008.029058; Olson Jordan, 2015, J Pathol Inform, V6, P16, DOI 10.4103/2153-3539.153916; Pageler NM, 2013, PEDIATR CRIT CARE ME, V14, P413, DOI 10.1097/PCC.0b013e318272010c; Pearl WS, 1999, ANN EMERG MED, V33, P77, DOI 10.1016/S0196-0644(99)70421-X; Plebani M, 2016, CLIN CHEM LAB MED, V54, P1881, DOI 10.1515/cclm-2016-0848; Plebani M, 2014, CLIN CHIM ACTA, V432, P15, DOI 10.1016/j.cca.2013.09.051; Plebani M, 2014, CLIN CHIM ACTA, V427, P137, DOI 10.1016/j.cca.2013.03.002; Plebani M, 2013, CLIN CHEM LAB MED, V51, P741, DOI 10.1515/cclm-2013-0075; Plebani M, 2009, CLIN CHIM ACTA, V404, P16, DOI 10.1016/j.cca.2009.03.022; Poley MJ, 2007, CLIN CHEM, V53, P213, DOI 10.1373/clinchem.2006.073908; Price CP, 2003, CLIN CHIM ACTA, V333, P147, DOI 10.1016/S0009-8981(03)00179-7; Probst CA, 2013, HEALTH PSYCHOL, V32, P995, DOI 10.1037/a0032925; Procop GW, 2015, AM J CLIN PATHOL, V143, P623, DOI 10.1309/AJCPJOJ3HKEBD3TU; Riley JD, 2015, J MOL DIAGN, V17, P225, DOI 10.1016/j.jmoldx.2015.01.003; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Roggeman N, 2014, TRANSFUSION, V54, p246A; Rohr UP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149856; Rosenbloom ST, 2005, J AM MED INFORM ASSN, V12, P546, DOI 10.1197/jamia.M1811; Roukema J, 2008, J AM MED INFORM ASSN, V15, P107, DOI 10.1197/jamia.M2164; Samuelson BT, 2015, THROMB RES, V136, P928, DOI 10.1016/j.thromres.2015.09.005; Sciacovelli L, 2017, CLIN CHEM LAB MED, V55, P1478, DOI 10.1515/cclm-2017-0412; Shahangian S, 2009, AM J CLIN PATHOL, V131, P418, DOI 10.1309/AJCPJF8JI4ZLDQUE; Shalev V, 2009, INT J MED INFORM, V78, P639, DOI 10.1016/j.ijmedinf.2009.04.011; Shirts Brian H, 2015, J Pathol Inform, V6, P9, DOI 10.4103/2153-3539.151919; Smellie WSA, 2012, ANN CLIN BIOCHEM, V49, P323, DOI 10.1258/acb.2011.011149; Solis DLE, 2015, ANN EMERG MED S1, V66, pS34; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; SPIEGEL JS, 1989, ARCH INTERN MED, V149, P549, DOI 10.1001/archinte.149.3.549; Staub LP, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-12; Staub LP, 2012, INT J TECHNOL ASSESS, V28, P52, DOI 10.1017/S0266462311000717; Tampoia M, 2007, ARCH PATHOL LAB MED, V131, P112; Thakkar RN, 2015, AM J CLIN PATHOL, V143, P393, DOI 10.1309/AJCPJS4EEM7UAUBV; Thomas RE, 2006, CLIN OUTCOMES MANAGE, V13, P472; THORNBURY JR, 1992, EUR J RADIOL, V14, P147, DOI 10.1016/0720-048X(92)90228-2; Tomlin A, 2011, BMJ QUAL SAF, V20, P282, DOI 10.1136/bmjqs.2010.048124; van Walraven C, 1998, JAMA-J AM MED ASSOC, V280, P550, DOI 10.1001/jama.280.6.550; van Walraven C, 2002, J EVAL CLIN PRACT, V8, P327, DOI 10.1046/j.1365-2753.2002.00336.x; van Wijk MAM, 2001, ANN INTERN MED, V134, P274, DOI 10.7326/0003-4819-134-4-200102200-00010; Vardy Daniel A, 2005, J Med Syst, V29, P619, DOI 10.1007/s10916-005-6130-4; Vegting IL, 2012, EUR J INTERN MED, V23, P70, DOI 10.1016/j.ejim.2011.07.003; Verstappen WHJM, 2004, ANN FAM MED, V2, P569, DOI 10.1370/afm.244; Verstappen WHJM, 2004, J CLIN EPIDEMIOL, V57, P1119, DOI 10.1016/j.jclinepi.2004.03.009; Vidyarthi AR, 2015, AM J MED QUAL, V30, P81, DOI 10.1177/1062860613517502; Waldron JL, 2014, J CLIN PATHOL, V67, P731, DOI 10.1136/jclinpath-2014-202256; Wang TJ, 2002, ARCH INTERN MED, V162, P1885, DOI 10.1001/archinte.162.16.1885; Warren JS, 2013, AM J CLIN PATHOL, V139, P289, DOI 10.1309/AJCP4G6UAUXCFTQF; Westbrook JI, 2006, J CLIN PATHOL, V59, P533, DOI 10.1136/jcp.2005.029983; White P, 2013, J LOW GENIT TRACT DI, V17, P175, DOI 10.1097/LGT.0b013e3182607137; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093; Wu AHB, 1999, CLIN CHIM ACTA, V288, P97, DOI 10.1016/S0009-8981(99)00142-4; Yeh DD, 2014, CLIN CHIM ACTA, V427, P145, DOI 10.1016/j.cca.2013.09.023; Zhi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078962	138	11	11	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					197	221		10.1093/AJCP/AQX147			25	Pathology	Pathology	FW8WW	WOS:000425618700002	29471324	Green Published			2019-10-28	
J	Broehm, CJ; Inwards, CY; Al-Ibraheemi, A; Wenger, DE; Jenkins, SM; Jin, L; Oliveira, AM; Zreik, RT; Carter, JM; Boland, JM; Fritchie, KJ				Broehm, Cory J.; Inwards, Carrie Y.; Al-Ibraheemi, Alyaa; Wenger, Doris E.; Jenkins, Sarah M.; Jin, Long; Oliveira, Andre M.; Zreik, Riyam T.; Carter, Jodi M.; Boland, Jennifer M.; Fritchie, Karen J.			Giant Cell Tumor of Bone in Patients 55 Years and Older A Study of 34 Patients	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Giant cell tumor of bone; Bone tumors; Elderly; H3F3A	FOLLOW-UP; ONCOGENES; SWEDEN; CHINA; USP6	Objectives: Most giant cell tumors of bone (GCTs) occur in patients aged 20 to 40 years. We analyzed features of GCT in patients 55 years or older. Methods: GCTs were examined for fibrosis, matrix, cystic change, histiocytes, mitoses, and necrosis. Clinical/radiologic data were collected. Results: Thirty-four (5%) of 710 GCTs occurred in patients older than 55 years (14/20 male/female; 56-83 years) in long bones (n = 24), vertebrae (n = 6), pelvis (n = 3), and metacarpal (n = 1). Imaging was classic in 26 of 27 cases; one case appeared malignant. Morphologic patterns included fibrosis (n = 29), bone formation (n = 19), cystic change (n = 8), necrosis (n = 8), foamy histiocytes (n = 7), and secondary aneurysmal bone cyst formation (n = 1). Mitoses ranged from 0 to 18 per 10 high-power fields. Six recurred; one patient developed metastasis. Four of five cases harbored H3F3A mutations. Conclusions: GCTs in patients 55 years or older share pathologic characteristics with those arising in younger adults. Fibrosis and reactive bone are common, potentially leading to diagnostic confusion in this population. No histologic features correlate with adverse outcome.	[Broehm, Cory J.; Inwards, Carrie Y.; Al-Ibraheemi, Alyaa; Jin, Long; Oliveira, Andre M.; Carter, Jodi M.; Boland, Jennifer M.; Fritchie, Karen J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Wenger, Doris E.] Mayo Clin, Dept Radiol, Rochester, MN USA; [Jenkins, Sarah M.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Zreik, Riyam T.] Baylor Scott & White Hlth, Dept Pathol, Temple, TX USA	Fritchie, KJ (reprint author), Mayo Clin, Dept Anat Pathol, Hilton 11,200 First St SW, Rochester, MN 55905 USA.	Fritchie.Karen@mayo.edu		Boland, Jennifer/0000-0002-2723-9586			Al-Ibraheemi A, 2016, AM J SURG PATHOL, V40, P1702, DOI 10.1097/PAS.0000000000000715; Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Amelio JM, 2016, CANCER EPIDEMIOL, V42, P82, DOI 10.1016/j.canep.2016.03.014; Baena-Ocampo LD, 2009, ANN DIAGN PATHOL, V13, P16, DOI 10.1016/j.anndiagpath.2008.07.005; Bandeira F, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0523-2; CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623-198769010-00018; Cantalejo FB, 2004, HISTOL HISTOPATHOL, V19, P113, DOI 10.14670/HH-19.113; DAHLIN DC, 1985, AM J ROENTGENOL, V144, P955, DOI 10.2214/ajr.144.5.955; Dorfman Czerniak B., 2015, DORFMAN CZERNIAKS BO; GOLDENBERG RR, 1970, J BONE JOINT SURG AM, VA 52, P619, DOI 10.2106/00004623-197052040-00001; Hage WD, 2000, ORTHOP CLIN N AM, V31, P515, DOI 10.1016/S0030-5898(05)70171-1; HODGES F J, 1956, Clin Orthop, V7, P82; Oliveira Júnior Roberto Clayton Lima, 2016, Rev. bras. ortop., V51, P459, DOI 10.1016/j.rboe.2016.06.004; Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815; Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999-010-1560-9; Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999-010-1501-7; LARSSON SE, 1975, J BONE JOINT SURG AM, VA 57, P167, DOI 10.2106/00004623-197557020-00007; Liede A, 2014, J BONE JOINT SURG AM, V96A, P1999, DOI 10.2106/JBJS.N.00367; Lin FS, 2016, J BONE ONCOL, V5, P38, DOI 10.1016/j.jbo.2016.02.001; McCarthy Edward F, 2009, Iowa Orthop J, V29, P79; MCDONALD DJ, 1986, J BONE JOINT SURG AM, V68A, P235, DOI 10.2106/00004623-198668020-00009; MCGRATH P J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P216; MNAYMNEH WA, 1964, J BONE JOINT SURG AM, V46, P63, DOI 10.2106/00004623-196446010-00006; Niu XH, 2015, ARCH PATHOL LAB MED, V139, P1149, DOI 10.5858/arpa.2014-0432-OA; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Phulsunga Rohit Kumar, 2016, World J Nucl Med, V15, P56, DOI 10.4103/1450-1147.167598; R Core Team, 2015, R LANG ENV STAT COMP; Rockberg J, 2015, J BONE JOINT SURG AM, V97A, P1756, DOI 10.2106/JBJS.O.00156; Roy S, 2013, EUR ARCH OTO-RHINO-L, V270, P1167, DOI 10.1007/s00405-012-2249-3; Savage Sharon A., 2011, Sarcoma, P548151, DOI 10.1155/2011/548151; Siebenrock KA, 1998, J BONE JOINT SURG BR, V80B, P43, DOI 10.1302/0301-620X.80B1.7875; Unni KK, 2010, DAHLINS BONE TUMORS, p[179, 310]; Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264-006-0215-7; WOLFE JT, 1983, J NEUROSURG, V59, P322, DOI 10.3171/jns.1983.59.2.0322	35	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					222	233		10.1093/AJCP/AQX155			12	Pathology	Pathology	FW8WW	WOS:000425618700003	29425276				2019-10-28	
J	Conant, JL; Powers, J; Sharp, G; Mead, PS; Nelson, CA				Conant, Joanna L.; Powers, Julia; Sharp, Gregory; Mead, Paul S.; Nelson, Christina A.			Lyme Disease Testing in a High-Incidence State Clinician Knowledge and Patterns	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Lyme disease; Tickborne disease; Diagnostic testing; Test interpretation	BORRELIA-BURGDORFERI; DIAGNOSIS	Objectives: Lyme disease (LD) incidence is increasing, but data suggest some clinicians are not fully aware of recommended procedures for ordering and interpreting diagnostic tests. The study objective was to assess clinicians' knowledge and practices regarding LD testing in a high-incidence region. Methods: We distributed surveys to 1,142 clinicians in the University of Vermont Medical Center region, of which 144 were completed (12.6% response rate). We also examined LD laboratory test results and logs of calls to laboratory customer service over a period of 2.5 years and 6 months, respectively. Results: Most clinicians demonstrated basic knowledge of diagnostic protocols, but many misinterpreted Western blot results. For example, 42.4% incorrectly interpreted a positive immunoglobulin M result as an overall positive test in a patient with longstanding symptoms. Many also reported receiving patient requests for unvalidated tests. \Conclusions: Additional education and modifications to LD test ordering and reporting systems would likely reduce errors and improve patient care.	[Conant, Joanna L.; Sharp, Gregory] Univ Vermont, Dept Pathol & Lab Med, Med Ctr, Burlington, VT USA; [Powers, Julia] Univ Vermont, Larner Coll Med, Burlington, VT USA; [Mead, Paul S.; Nelson, Christina A.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA	Nelson, CA (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd,Mail Stop P-02, Ft Collins, CO 80521 USA.	wje1@cdc.gov		Conant, Joanna/0000-0001-8282-7172			Aguero-Rosenfeld ME, 2005, CLIN MICROBIOL REV, V18, P484, DOI 10.1128/CMR.18.3.484-509.2005; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; Dattwyler RJ, 2014, CLIN INFECT DIS, V59, P1711, DOI 10.1093/cid/ciu705; Halperin JJ, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.10.008; Kalish RA, 2001, CLIN INFECT DIS, V33, P780, DOI 10.1086/322669; Klempner MS, 2001, AM J MED, V110, P217, DOI 10.1016/S0002-9343(00)00701-4; Moore A, 2016, EMERG INFECT DIS, V22, P1169, DOI 10.3201/eid2207.151694; Nelson C, 2015, JAMA INTERN MED, V175, P132, DOI 10.1001/jamainternmed.2014.5426; Nelson C, 2014, MMWR-MORBID MORTAL W, V63, P333; Nelson CA, 2015, EMERG INFECT DIS, V21, P1625, DOI 10.3201/eid2109.150417; Pritt BS, 2016, INT J SYST EVOL MICR, V66, P4878, DOI 10.1099/ijsem.0.001445; R Core Team, 2016, R LANG ENV STAT COMP; Stanek G, 2012, LANCET, V379, P461, DOI 10.1016/S0140-6736(11)60103-7; Steere AC, 2008, CLIN INFECT DIS, V47, P188, DOI 10.1086/589242; Vermont Department of Health, 2013, EP LYM DIS VERM	15	4	4	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					234	240		10.1093/AJCP/AQX153			7	Pathology	Pathology	FW8WW	WOS:000425618700004	29425271				2019-10-28	
J	Li, ZB; Rock, JB; Roth, R; Lehman, A; Marsh, WL; Suarez, A; Frankel, WL				Li, Zaibo; Rock, Jonathan B.; Roth, Rachel; Lehman, Amy; Marsh, William L.; Suarez, Adrian; Frankel, Wendy L.			Dual Stain With SATB2 and CK20/Villin Is Useful to Distinguish Colorectal Carcinomas From Other Tumors	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Dual immunostain; SATB2; CDX2; CK20; Villin; Colorectal tumor	INTESTINAL DIFFERENTIATION; CANCER; MARKER; CDX2; ADENOCARCINOMAS; EXPRESSION; UTILITY; ORIGIN; LIVER; CK20	Objectives: Small sample size limits the number of immunostains that may be attempted in colorectal carcinoma (CRC) biopsy specimens. We investigated the utility of dual stain with special AT-rich sequence binding protein 2 (SATB2) or caudal-type homeobox 2 (CDX2) and cytokeratin 20 (CK20) or villin in identifying CRC. Methods: Tissue microarrays with 222 CRCs and 375 other carcinomas were built. Dual stain was performed pairing nuclear stains CDX2 or SATB2 with CK20 or villin. Results: All four single stains showed excellent sensitivity (93%-99%) but variable specificity (56%-88%) for CRC. All four dual stains also showed excellent sensitivity (90%-96%) while much improved specificity (88%-98%) compared with single stains. SATB2 dual stain (with CK20 or villin) showed a higher specificity than CDX2 dual stain (with CK20 or villin) with a comparable sensitivity. Conclusions: SATB2 dual stain shows the greatest potential clinical utility in identifying CRC and is superior to CDX2 dual stain. More important, SATB2 dual stain could be helpful for specimens with limited tissues or those having a nonclassic staining pattern.	[Li, Zaibo; Rock, Jonathan B.; Roth, Rachel; Marsh, William L.; Suarez, Adrian; Frankel, Wendy L.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Lehman, Amy] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA	Frankel, WL (reprint author), Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave, Columbus, OH 43210 USA.	Wendy.Frankel@osumc.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA016058]		Bayrak R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-9; Bayrak R, 2011, PATHOL RES PRACT, V207, P156, DOI 10.1016/j.prp.2010.12.005; Bjorling E, 2008, MOL CELL PROTEOMICS, V7, P825, DOI 10.1074/mcp.M700411-MCP200; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248; Hernandez BY, 2005, HUM PATHOL, V36, P275, DOI 10.1016/j.humpath.2005.01.013; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Li ZB, 2017, AM J CLIN PATHOL, V147, P484, DOI [10.1093/ajcp/aqx023, 10.1093/AJCP/AQX023]; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; Newcombe RG, 2001, STAT MED, V20, P907, DOI 10.1002/sim.906; Newcombe RG, 1998, STAT MED, V17, P2635, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Righi A, 2015, AM J SURG PATHOL, V39, P691, DOI 10.1097/PAS.0000000000000412; Saad RS, 2011, WORLD J GASTRO SURG, V3, P159, DOI 10.4240/wjgs.v3.i11.159; Tot T, 1999, CANCER, V85, P171, DOI 10.1002/(SICI)1097-0142(19990101)85:1<171::AID-CNCR24>3.3.CO;2-M; Tot T, 2004, MED SCI MONITOR, V10, pBR139; Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575; Werling RW, 2003, AM J SURG PATHOL, V27, P303, DOI 10.1097/00000478-200303000-00003	20	2	2	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					241	246		10.1093/AJCP/AQX160			6	Pathology	Pathology	FW8WW	WOS:000425618700005	29471325	Green Published			2019-10-28	
J	Sun, SCP; Garcia, J; Hayden, JA				Sun, Su-Chieh Pamela; Garcia, JuanDavid; Hayden, Joshua A.			Repeating Critical Hematology and Coagulation Values Wastes Resources, Lengthens Turnaround Time, and Delays Clinical Action	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Critical values; Resource utilization; Laboratory management		Objectives: To determine the need and impact of repeating critical values in hematology and coagulation. Methods: We prospectively evaluated the need for repeating critical values. The cost of this practice was estimated using a workflow analysis. Retrospective chart review before and after removal of this process was performed to assess the clinical impact of removing this practice. Results: Over 95% of the repeated values remained critical and all but one of the repeats were within the expected analytical precision of the assays. The practice of repeating critical values delayed turnaround time for these results and wasted resources, most notably manpower. The delay associated with repeating hematology critical values resulted in delayed administration of blood product (RBC units). Conclusions: Repeating critical hematology and coagulation results was found to be an unnecessary process that wasted laboratory resources and lengthened turnaround time, delaying clinical intervention.	[Sun, Su-Chieh Pamela; Garcia, JuanDavid] Healthcare & Lab Advisors, Miami, FL USA; [Hayden, Joshua A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, 1300 York Ave,Box 79, New York, NY 10065 USA	Hayden, JA (reprint author), Weill Cornell Med Coll, Dept Pathol & Lab Med, 1300 York Ave,Box 79, New York, NY 10065 USA.	jah9108@med.cornell.edu		Hayden, Joshua/0000-0003-0435-9275			Chima HS, 2009, LABMEDICINE, V40, P453, DOI 10.1309/LMMY8830KBZQQBKU; Deetz CO, 2012, AM J CLIN PATHOL, V137, P20, DOI 10.1309/AJCPWPBF62YGEFOR; Lehman CM, 2014, ARCH PATHOL LAB MED, V138, P788, DOI 10.5858/arpa.2013-0140-CP; LUNDBERG GD, 1990, JAMA-J AM MED ASSOC, V263, P709, DOI 10.1001/jama.263.5.709; Niu AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080663; Onyenekwu CP, 2014, CLIN CHEM LAB MED, V52, P1739, DOI 10.1515/cclm-2014-0331; R Core Team, 2013, R LANG ENV STAT COMP; Toll AD, 2011, ARCH PATHOL LAB MED, V135, P440, DOI 10.1043/2010-0025-OA.1	8	1	1	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					247	252		10.1093/AJCP/AQX156			6	Pathology	Pathology	FW8WW	WOS:000425618700006	29425259				2019-10-28	
J	Vollmer, RT				Vollmer, Robin T.			Serum Prostate-Specific Antigen (PSA) Concentration, PSA Mass, and Obesity A Mathematical Analysis	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Hemodilution; Obesity; Plasma volume; Kinetics; PSA; PSA mass	BODY-MASS; RADICAL PROSTATECTOMY; CANCER; VOLUME; HEMODILUTION; PLASMA; MEN; DYNAMICS; DENSITY; INDEX	Objectives: To provide a mathematical background for understanding the phenomenon of analyte hemodilution using a kinetic analysis. Methods: The first assumption for this analysis is that change in concentration of any analyte, such as prostate-specific antigen (PSA), is due to the flux of the analyte from an organ into the blood minus its flux from the blood. What results is a relatively simple differential equation that emphasizes the importance of plasma volume, organ mass, and two rate constants. Results: The analyses demonstrate how serum PSA can be affected by plasma volume as well as body mass and how hemodilution due to obesity can be at least partly corrected for by expressing PSA in units of total mass or total mass density. Conclusions: At a time when obesity is prevalent, expressing analytes in units of total mass may make them relate more closely to disease status and prognosis.	[Vollmer, Robin T.] VA, Durham, NC USA; [Vollmer, Robin T.] Duke Univ, Med Ctr, Durham, NC USA	Vollmer, RT (reprint author), VA Med Ctr, Lab Med 113, 508 Fulton St, Durham, NC 27705 USA.	Robin.Vollmer@med.va.gov					Agha AH, 1996, J UROLOGY, V155, P1332, DOI 10.1016/S0022-5347(01)66259-1; Baillargeon J, 2005, CANCER-AM CANCER SOC, V103, P1092, DOI 10.1002/cncr.20856; Banez LL, 2007, JAMA-J AM MED ASSOC, V298, P2275, DOI 10.1001/jama.298.19.2275; Bryniarski P, 2011, MED SCI MONITOR, V17, pCR104, DOI 10.12659/MSM.881395; Gibson JG, 1937, J CLIN INVEST, V16, P317, DOI 10.1172/JCI100860; Grubb RL, 2009, CANCER EPIDEM BIOMAR, V18, P748, DOI 10.1158/1055-9965.EPI-08-0938; Humphrey PA, 1998, PATHOLOGY PROSTATE, P253; Kryvenko ON, 2016, UROLOGY, V90, P141, DOI 10.1016/j.urology.2015.11.042; Kryvenko ON, 2015, AM J CLIN PATHOL, V144, P271, DOI 10.1309/AJCPQL9MKQ6VDDWL; RETZLAFF JA, 1969, BLOOD-J HEMATOL, V33, P649, DOI 10.1182/blood.V33.5.649.649; Vollmer RT, 2010, AM J CLIN PATHOL, V133, P187, DOI 10.1309/AJCP3CJR3IDRCFEO; Vollmer RT, 1998, CANCER, V83, P1989, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0.CO;2-V; Vollmer RT, 2003, AM J CLIN PATHOL, V119, P80, DOI 10.1092/GMEYIBXBYUJJF3QU; Vollmer RT, 1997, J THEOR BIOL, V187, P195, DOI 10.1006/jtbi.1997.0429	14	1	1	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					262	266		10.1093/AJCP/AQX157			5	Pathology	Pathology	FW8WW	WOS:000425618700008	29425257				2019-10-28	
J	Waibel, E; Garcia, E; Kelly, M; Soles, R; Hilborne, L				Waibel, Elizabeth; Garcia, Edna; Kelly, Melissa; Soles, Ryan; Hilborne, Lee			Systematic Review of Non-ASCP Choosing Wisely Recommendations Relevant to Pathology and Laboratory Medicine	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Choosing Wisely; Pathology; Laboratory professionals; Effective test utilization; Test utilization management		Objectives: To determine non-American Society for Clinical Pathology pathology-and laboratory-related Choosing Wisely recommendations that drive effective test utilization in the laboratory. Methods: Data were collected via a two-part web-based survey distributed to a broad sample of pathologists and laboratory professionals from a variety of institutions. Results: Pathologists' most relevant recommendation: "Do not transfuse more units of blood than absolutely necessary"; highest priority: "Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7-8 g/dL in stable, noncardiac inpatients)." Laboratory professionals' most relevant recommendation: "Avoid testing for a Clostridium difficile infection in the absence of diarrhea"; highest priority: "Do not routinely transfuse stable, asymptomatic hospitalized patients with a hemoglobin level greater than 7 to 8 g/dL." Conclusions: Most of the highest priority, most relevant recommendations among those surveyed concerned utilization of blood products and transfusion management.	[Waibel, Elizabeth; Garcia, Edna] Amer Soc Clin Pathologists, Inst Sci Technol & Policy, 1225 New York Ave NW,Suite 350, Washington, DC 20005 USA; [Kelly, Melissa; Soles, Ryan] Amer Soc Clin Pathologists, Evaluat Measurement & Assessment, Chicago, IL USA; [Hilborne, Lee] Quest Diagnost, Los Angeles, CA USA	Waibel, E (reprint author), Amer Soc Clin Pathologists, Inst Sci Technol & Policy, 1225 New York Ave NW,Suite 350, Washington, DC 20005 USA.	elizabeth.waibel@ascp.org					ABIM Foundation, 2017, CLIN LISTS; ABIM Foundation, CHOOS WIS IN ABIM FD; Baird G, 2014, BIOCHEM MEDICA, V24, P223, DOI 10.11613/BM.2014.025; Cismondi F, 2013, INT J MED INFORM, V82, P345, DOI 10.1016/j.ijmedinf.2012.11.017; CMS.gov, 2016, HOSP ACQ COND RED PR; CMS.gov, 2017, CONS ASS HEALTHC PRO; Fang FC, 2017, J CLIN MICROBIOL, V55, P670, DOI 10.1128/JCM.02463-16; Health Information Research Unit Department of Health Research Methods Evidence and Impact (HEI), 2015, MCMASTER ONL RAT EV; Kelly SG, 2016, INFECT CONT HOSP EP, V37, P1395, DOI 10.1017/ice.2016.210; Lteif Louis, 2017, Hawaii J Med Public Health, V76, P59; Procop G., 2013, STRATEGIES APPROPRIA; Robson ME, 2015, J CLIN ONCOL, V33, P3660, DOI 10.1200/JCO.2015.63.0996	12	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					267	274		10.1093/AJCP/AQX159			8	Pathology	Pathology	FW8WW	WOS:000425618700009	29425260	Bronze			2019-10-28	
J	Qin, CF; Huang, YH; Feng, YF; Li, M; Guo, N; Rao, HL				Qin, Changfei; Huang, Yuhua; Feng, Yanfen; Li, Min; Guo, Na; Rao, Huilan			Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases	DIAGNOSTIC PATHOLOGY			English	Article						Lymphoma; Epstein-Barr virus (EBV); Children and Adolescents; South China	EPSTEIN-BARR-VIRUS; B-CELL LYMPHOMAS; BURKITT-LYMPHOMA; HODGKIN-LYMPHOMA; T-CELL; CLASSIFICATION; ASSOCIATION; CHILDHOOD; RISK; DISEASE	Background: The clinicopathological features and Epstein-Barr virus (EBV) infection status of lymphoma in children and adolescents in South China is under-researched. South China is a well-known high-incidence area of EBV-associated nasopharyngeal carcinoma. Methods: A cohort of 662 consecutive children and adolescents' lymphomas was retrospectively analyzed and Epstein-Barr virus encoded RNAs (EBERs) in situ hybridization was performed to detect the EBV infection. Results: The majority (501/662, 75.7%) of lymphomas in children and adolescents was Non-Hodgkin lymphoma (NHL). One hundred sixty one cases (24.3%) were Hodgkin lymphoma (HL). Of the NHL, precursor cell lymphoma, mature B-cell lymphoma and peripheral T/NK-cell lymphoma accounted for 32.0%, 41.1% and 26.9% respectively. The five common subtypes were lymphoblastic lymphoma (32.0%), Burkitt lymphoma (BL) (21.0%), anaplastic large-cell lymphoma (ALCL) (14.2%), diffuse large B-cell lymphoma (DLBCL) (13.8%) and extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (6.2%). EBV infection was detected in 58.9% classical Hodgkin lymphomas (CHLs), 21.4% mature B-cell lymphomas and 52.4% peripheral T/NK-cell lymphomas. Moreover, EBV was associated with high grade NHL including ENKTCL (100.0%), BL (30.5%) and DLBCL (17.6%). Conclusion: The high proportion of peripheral T/NK-cell lymphomas in children and adolescents in South China are presented in this study and compared to western countries due to the high percentage of ENKTCL. ENKTCL is firmly associated with EBV infection, while more than half of HL, a portion of BL and DLBCL are related to EBV infection. This study conclusively demonstrates that EBV infection is more prevalent in children and adolescents with lymphomas in South China compared to western countries.	[Qin, Changfei; Huang, Yuhua; Feng, Yanfen; Li, Min; Guo, Na; Rao, Huilan] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Qin, Changfei; Huang, Yuhua; Feng, Yanfen; Li, Min; Guo, Na; Rao, Huilan] Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China	Rao, HL (reprint author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Rao, HL (reprint author), Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China.	raohl@sysucc.org.cn			Sister Institution Network Fund of the University of Texas MD Anderson Cancer Center; Medical Scientific Research Foundation of Guangdong Province, China [A2017009]	This study was supported by Sister Institution Network Fund of the University of Texas MD Anderson Cancer Center (to Huilan Rao) and the Medical Scientific Research Foundation of Guangdong Province, China (A2017009).	Abate F, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005158; Allen CE, 2015, PEDIATR CLIN N AM, V62, P139, DOI 10.1016/j.pcl.2014.09.010; Amato T, 2016, AM J CLIN PATHOL, V145, P116, DOI [10.1093/AJCP/AQV011, 10.1093/ajcp/aqv011]; Ambinder RF, 2000, AM J PATHOL, V156, P1, DOI 10.1016/S0002-9440(10)64697-4; Ambrosio MR, 2016, HISTOPATHOLOGY, V69, P885, DOI 10.1111/his.12997; Ambrosio MR, 2014, HUM PATHOL, V45, P648, DOI 10.1016/j.humpath.2013.09.015; ARMSTRONG AA, 1993, AM J PATHOL, V142, P1683; Bigenwald C, 2017, ONCOTARGET, V8, P80073, DOI 10.18632/oncotarget.20684; Castellino SM, 2011, BLOOD, V117, P1806, DOI 10.1182/blood-2010-04-278796; Chiang AKS, 1997, INT J CANCER, V73, P332, DOI 10.1002/(SICI)1097-0215(19971104)73:3<332::AID-IJC5>3.0.CO;2-0; Cohen M, 2014, INT J CANCER, V135, P2816, DOI 10.1002/ijc.28942; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Fujita M, 2000, PATHOL INT, V50, P696; Han JY, 2014, BLOOD RES, V49, P246, DOI 10.5045/br.2014.49.4.246; Huppmann AR, 2014, AM J SURG PATHOL, V38, P316, DOI 10.1097/PAS.0000000000000107; Jaffe ES, 2008, BLOOD, V112, P4384, DOI 10.1182/blood-2008-07-077982; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Lee JH, 2014, ARCH MED RES, V45, P417, DOI 10.1016/j.arcmed.2014.06.001; Li Z, 2016, LANCET ONCOL, V17, P1240, DOI 10.1016/S1470-2045(16)30148-6; Linet MS, 2016, INT J CANCER, V138, P1862, DOI 10.1002/ijc.29924; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Magrath I, 2012, BRIT J HAEMATOL, V156, P744, DOI 10.1111/j.1365-2141.2011.09013.x; Miles RR, 2012, BRIT J HAEMATOL, V156, P730, DOI 10.1111/j.1365-2141.2011.09024.x; Minard-Colin V, 2015, J CLIN ONCOL, V33, P2963, DOI 10.1200/JCO.2014.59.5827; Mundo L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00229; Nicolae A, 2015, BLOOD, V126, P863, DOI 10.1182/blood-2015-02-630632; Oschlies I, 2011, HAEMATOL-HEMATOL J, V96, P262, DOI 10.3324/haematol.2010.030809; Pillai V, 2016, BRIT J HAEMATOL, V173, P573, DOI 10.1111/bjh.14044; Quintanilla-Martinez L, 2013, BLOOD, V122, P3101, DOI 10.1182/blood-2013-05-502203; Rowe M, 2014, CHIN J CANCER, V33, P609, DOI 10.5732/cjc.014.10190; Said J, 2015, BLOOD, V126, P827, DOI 10.1182/blood-2015-06-648097; Sandlund JT, 2016, HEMATOL-AM SOC HEMAT, P589, DOI 10.1182/asheducation-2016.1.589; Sherief LM, 2015, MOL CLIN ONCOL, V3, P139, DOI 10.3892/mco.2014.425; Swerdlow SH, 2017, IARC WHO CLASSIFICAT; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Yang QP, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-77; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Zaheen Ahmad, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212103	39	3	3	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 27	2018	13								17	10.1186/s13000-018-0693-0			8	Pathology	Pathology	FY2YQ	WOS:000426683800001	29482573	DOAJ Gold, Green Published			2019-10-28	
J	Gralewski, JH; Post, GR; van Rhee, F; Yuan, YZ				Gralewski, Jonathon H.; Post, Ginell R.; van Rhee, Frits; Yuan, Youzhong			Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing	DIAGNOSTIC PATHOLOGY			English	Article						Clonal evolution; Myeloid sarcoma; Molecular profiling; Next generation sequencing; Transdifferentiation; Plasma cell myeloma; RAS/RAF signaling pathway	ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE-MYELOMA; HISTIOCYTIC SARCOMA; PLASMABLASTIC TRANSFORMATION; FOLLICULAR LYMPHOMAS; LINEAGE CONVERSION; DIFFERENTIATION; TRANSDIFFERENTIATION; MUTATIONS; NEOPLASMS	Background: Plasma cell myeloma (PCM) is a neoplasm of terminally differentiated B lymphocytes with molecular heterogeneity. Although therapy-related myeloid neoplasms are common in plasma cell myeloma patients after chemotherapy, transdifferentiation of plasma cell myeloma into myeloid neoplasms has not been reported in literature. Here we report a very rare case of myeloid neoplasm transformed from plasma cell myeloma. Case presentation: A 60-year-old man with a history of plasma cell myeloma with IGH-MAF gene rearrangement and RAS/RAF mutations developed multiple soft tissue lesions one year following melphalan-based chemotherapy and autologous stem cell transplant. Morphological and immunohistochemical characterization of the extramedullary disease demonstrated that the tumor cells were derived from the monocyte-macrophage lineage. Next generation sequencing (NGS) studies detected similar clonal aberrations in the diagnostic plasma cell population and post-therapy neoplastic cells, including IGH-MAF rearrangement, multiple genetic mutations in RAS signaling pathway proteins, and loss of tumor suppressor genes. Molecular genetic analysis also revealed unique genomic alterations in the transformed tumor cells, including gain of NF1 and loss of TRAF3. Conclusion: To our knowledge, this is the first case of myeloid sarcoma transdifferentiated from plasma cell neoplasm. Our findings in this unique case suggest clonal evolution of plasma cell myeloma to myeloma neoplasm and the potential roles of abnormal RAS/RAF signaling pathway in lineage switch or transdifferentiation.	[Gralewski, Jonathon H.; Post, Ginell R.; Yuan, Youzhong] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [van Rhee, Frits] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA	Yuan, YZ (reprint author), Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA.	yyuan@uams.edu			University of Arkansas for Medical Sciences Department of Pathology	We thank the University of Arkansas for Medical Sciences Department of Pathology for providing funds to perform IGH gene rearrangement studies and the molecular laboratory staff who performed this assay (Stacie Delaune and Molly Robbins).	Alten J, 2015, PEDIATR BLOOD CANCER, V62, P1656, DOI 10.1002/pbc.25523; Amato T, 2016, AM J CLIN PATHOL, V145, P116, DOI [10.1093/AJCP/AQV011, 10.1093/ajcp/aqv011]; Ambrosio MR, 2014, HAEMATOLOGICA, V99, pE235, DOI 10.3324/haematol.2014.111872; Ambrosio MR, 2015, AM J CLIN PATHOL, V144, P817, DOI 10.1309/AJCP2G0VKTKPNPRR; Ambrosio MR, 2015, VIRCHOWS ARCH, V467, P471, DOI 10.1007/s00428-015-1814-8; Ansari J, 2016, EUR J HAEMATOL, V97, P9, DOI 10.1111/ejh.12755; Avet-Loiseau H, 2011, BLOOD, V117, P2009, DOI 10.1182/blood-2010-07-295105; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Boudry-Labis E, 2013, AM J HEMATOL, V88, P306, DOI 10.1002/ajh.23403; Buser L, 2014, PATHOBIOLOGY, V81, P199, DOI 10.1159/000365396; EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005; Feldman AL, 2004, LANCET ONCOL, V5, P248, DOI 10.1016/S1470-2045(04)01428-7; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; de Larrea CF, 2014, BONE MARROW TRANSPL, V49, P223, DOI 10.1038/bmt.2013.150; Fraser CR, 2009, AM J CLIN PATHOL, V132, P928, DOI 10.1309/AJCPWQ0I0DGXBMHO; Fukuchi Y, 2006, EMBO J, V25, P3398, DOI 10.1038/sj.emboj.7601199; Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416; Grogan TM, 2008, WHO CLASSIFICATION T, P356; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Kumar R, 2011, PEDIATR BLOOD CANCER, V56, P307, DOI 10.1002/pbc.22810; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Lee CK, 2003, HUM PATHOL, V34, P710, DOI 10.1016/S0046-8177(03)00181-3; Liu QQ, 2016, VIRCHOWS ARCH, V469, P233, DOI 10.1007/s00428-016-1965-2; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Mailankody S, 2011, BLOOD, V118, P4086, DOI 10.1182/blood-2011-05-355743; Michonneau D, 2014, J CLIN ONCOL, V32, pE117, DOI 10.1200/JCO.2013.49.0078; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Moore CR, 2012, LEUKEMIA, V26, P1122, DOI 10.1038/leu.2011.309; Nakajima Hideaki, 2011, Keio Journal of Medicine, V60, P47; Nguyen TDT, 2005, AM J SURG PATHOL, V29, P617, DOI 10.1097/01.pas.0000157940.80538.ec; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; Nutt SL, 1999, NATURE, V401, P556; Rawstron AC, 2008, HAEMATOL-HEMATOL J, V93, P431, DOI 10.3324/haematol.11080; Rocca BJ, 2012, HISTOL HISTOPATHOL, V27, P941, DOI 10.14670/HH-27.941; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Shinnakasu R, 2017, CURR OPIN IMMUNOL, V45, P126, DOI 10.1016/j.coi.2017.03.003; Singh ZN, 2015, CLIN CASE REP, V3, P183, DOI 10.1002/ccr3.180; Stein CK, 2017, ONCOTARGET, V8, P27854, DOI 10.18632/oncotarget.15718; Stoecker MM, 2013, ARCH PATHOL LAB MED, V137, P865, DOI 10.5858/arpa.2012-0104-RS; Takahashi E, 2013, J CLIN EXP HEMATOP, V53, P1; Thakral B, 2016, BLOOD, V128, P2475, DOI 10.1182/blood-2016-08-735795; Troppan K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123922; Vaughn John L, 2017, J Med Case Rep, V11, P92, DOI 10.1186/s13256-017-1253-z; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhao JN, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0350-9	48	1	2	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 20	2018	13								15	10.1186/s13000-018-0692-1			8	Pathology	Pathology	FX1MQ	WOS:000425816000002	29463311	DOAJ Gold, Green Published			2019-10-28	
J	van Wyk, AC; van Zyl, H; Rigby, J				van Wyk, Abraham Christoffel; van Zyl, Hennie; Rigby, Jonathan			Colonic perineurioma (benign fibroblastic polyp): case report and review of the literature	DIAGNOSTIC PATHOLOGY			English	Review						Colonic perineurioma; Fibroblastic polyp; BRAF mutation; Hemosiderin	RECTUM; MUTATIONS; FEATURES; LESIONS; TUMOR	Background: Colorectal perineuriomas are uncommon benign mucosal-based proliferations of mesenchymal cells that express perineurial markers, often associated with colonic crypts displaying a serrated/hyperplastic architecture. The vast majority of cases arise distal to the splenic flexure and have been described as sessile polyps. Using molecular analysis, BRAF mutations have been demonstrated in the serrated crypt epithelium. We report a new case of perineurioma presenting as a pedunculated polyp in the transverse colon, with prominent hemosiderin deposits in the uninvolved lamina propria that separated the perineurial proliferation from the surface epithelium, a previously unreported histological finding. By using immunohistochemistry, we demonstrated the presence of BRAF V600E mutated protein in the serrated crypt epithelium. In addition, a review of the literature on colorectal perineurioma is provided. Case presentation: A 5 mm pedunculated polyp was removed from the transverse colon of a 42 year old man who presented with epigastric pain, weight loss and rectal bleeding. A proliferation of uniform plump spindled cells expanded the lamina propria and separated serrated colonic crypts. The epithelial component closely resembled microvesicular hyperplastic polyp. Immunohistochemical stains for epithelial membrane antigen (EMA), glucose transporter 1 (GLUT1) and collagen IV were positive in the stromal proliferation. A mutation-specific monoclonal antibody directed against BRAF V600E showed positive cytoplasmic staining in the serrated crypt epithelium but not in the perineurial proliferation. Conspicuous hemosiderin deposition was seen in the inflamed lamina propria between the perineurial proliferation and the surface epithelium. Conclusion: Although the majority of colorectal perineuriomas occur in the sigmoid colon and rectum and are described as sessile polyps, colorectal perineurioma can present as a pedunculated polyp proximal to the splenic flexure as described in this case. Conspicuous hemosiderin deposition can be seen in the superficial lamina propria. BRAF mutations are limited to the serrated crypt epithelium.	[van Wyk, Abraham Christoffel; Rigby, Jonathan] Stellenbosch Univ, Tygerberg Hosp, Fac Med & Hlth Sci, Natl Hlth Lab Serv,Div Anat Pathol, Cape Town, South Africa; [van Zyl, Hennie] Karl Bremer Hosp, Dept Surg, Cape Town, South Africa	van Wyk, AC (reprint author), Stellenbosch Univ, Tygerberg Hosp, Fac Med & Hlth Sci, Natl Hlth Lab Serv,Div Anat Pathol, Cape Town, South Africa.	abraham.vanwyk@nhls.ac.za			Open Access Publication Fund of Stellenbosch University	This study was supported by the Open Access Publication Fund of Stellenbosch University.	Agaimy A, 2010, AM J SURG PATHOL, V34, P1663, DOI 10.1097/PAS.0b013e3181f4a458; Cuenllas BA, 2012, GASTROENT HEPAT-BARC, V35, P700, DOI 10.1016/j.gastrohep.2012.04.004; Bagdasaryan Robert, 2009, Med Health R I, V92, P249; Doganavsargil B, 2009, TURK J GASTROENTEROL, V20, P287, DOI 10.4318/tjg.2009.0029; Eslami-Varzaneh F, 2004, AM J SURG PATHOL, V28, P374, DOI 10.1097/00000478-200403000-00010; Fujino Y, 2014, CLIN J GASTROENTEROL, V7, P392, DOI 10.1007/s12328-014-0519-x; Gibson JA, 2009, AM J SURG PATHOL, V33, P781, DOI 10.1097/PAS.0b013e31818dd6ca; Groisman G, 2010, INT J SURG PATHOL, V18, P292, DOI 10.1177/1066896909350883; Groisman GM, 2008, AM J SURG PATHOL, V32, P1088, DOI 10.1097/PAS.0b013e318160df3f; Groisman GM, 2013, AM J SURG PATHOL, V37, P745, DOI 10.1097/PAS.0b013e318277a1a9; Groisman GM, 2006, HISTOPATHOLOGY, V48, P431, DOI 10.1111/j.1365-2559.2006.02357.x; Hornick JL, 2005, AM J SURG PATHOL, V29, P859, DOI 10.1097/01.pas.0000154130.87219.2c; Kalof AN, 2005, J CLIN GASTROENTEROL, V39, P778, DOI 10.1097/01.mcg.0000177242.51967.83; LAZARUS SS, 1978, CANCER, V41, P1823, DOI 10.1002/1097-0142(197805)41:5<1823::AID-CNCR2820410525>3.0.CO;2-J; MCCLYMONT K, 2006, PATHOL INT S, V56, pA5; Miettinen M, 2001, MODERN PATHOL, V14, P950, DOI 10.1038/modpathol.3880417; Miettinen M, 2001, AM J SURG PATHOL, V25, P846, DOI 10.1097/00000478-200107000-00002; NAKAMURA SI, 1992, AM J SURG PATHOL, V16, P772, DOI 10.1097/00000478-199208000-00005; Pai RK, 2011, AM J SURG PATHOL, V35, P1373, DOI 10.1097/PAS.0b013e318224d9df; Panarelli NC, 2015, MODERN PATHOL, V28, P740, DOI 10.1038/modpathol.2014.112; Pettus JR, 2012, MODERN PATHOL, V25, p175A; Thompson M, 2015, PATHOLOGY, V47, pS78; Vicuna Arregui M, 2008, REV ESP PATOL, V41, P271; Voltaggio L, 2015, HISTOPATHOLOGY, V66, P88, DOI 10.1111/his.12573; Yantiss RK, 2001, MODERN PATHOL, V14, P869, DOI 10.1038/modpathol.3880403; Zamecnik M, 2004, AM J SURG PATHOL, V28, P1397, DOI 10.1097/01.pas.0000141397.49460.12; Zamecnik M, 2006, AM J SURG PATHOL, V30, P1337, DOI 10.1097/01.pas.0000213278.53338.7b	27	4	4	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 20	2018	13								16	10.1186/s13000-018-0694-z			8	Pathology	Pathology	FX1MQ	WOS:000425816000003	29463272	DOAJ Gold, Green Published			2019-10-28	
J	Zheng, YL; Nong, L; Liang, L; Wang, W; Li, T				Zheng, Yalin; Nong, Lin; Liang, Li; Wang, Wei; Li, Ting			De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child	DIAGNOSTIC PATHOLOGY			English	Article						Systemic mastocytosis; Mast cell leukemia; Tryptase; CD25; KIT	ACUTE MYELOID-LEUKEMIA; MYELOMASTOCYTIC LEUKEMIA; SYSTEMIC MASTOCYTOSIS; DIAGNOSTIC-CRITERIA; CLASSIFICATION; TRYPTASE	Background: Mast cell leukemia (MCL) is a very rare form of systemic mastocytosis (SM) and accounts for less than 0.5% of all mastocytosis. The diagnosis of MCL requires the presence of SM criteria, accompanied by leukemic infiltrating of atypical mast cells (MCs) in bone marrow (BM), peripheral blood as well as extracutaneous organs. MCL is a fatal disease that almost always behaves aggressively, and the median survival time is only about six months. Herein, we present a rare case of de novo MCL without CD25 expression and KIT mutations. Case presentation: A previously healthy 13-year-old boy was referred to our hospital due to incidental discovery of an enlarged right tonsil. Diffuse infiltration of medium-sized hematopoietic blasts was found in his right tonsil, BM and multiple lymph nodes. The neoplastic cell population was subsequently revealed to exhibit differentiation towards the mast cell lineage by expressing CD117 and tryptase, but the cell population lacked expression of CD25/CD2 and the activating mutation of the KIT gene. An abnormal karyotype was identified, but no leukemia-associated fusion genes were found. Involvement of peripheral blood, bone and lung was subsequently demonstrated. The most important differential diagnosis included tryptase-positive (T+) acute myeloid leukemia, myelomastocytic leukemia and basophilic leukemia. The morphological characteristics and infiltrating patterns of the abnormal MCs supported the final diagnosis of MCL. Although intensive chemotherapy and allogeneic stem cell transplants were performed on the patient, he died 18 months after initial presentation. Conclusion: Due to its rarity, the diagnosis of MCL without typical immunophenotype and genetic aberrations is particularly challenging. Comprehensive investigation of clinical and pathological features to exclude other T+ myeloid neoplasms is necessary.	[Zheng, Yalin; Nong, Lin; Liang, Li; Wang, Wei; Li, Ting] Peking Univ, Hosp 1, Dept Pathol, 8 Xishiku St, Beijing 100034, Peoples R China	Nong, L (reprint author), Peking Univ, Hosp 1, Dept Pathol, 8 Xishiku St, Beijing 100034, Peoples R China.	06510@pkufh.cn					Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Arredondo AR, 2010, AM J HEMATOL, V85, P600, DOI 10.1002/ajh.21713; George TI, 2017, HEMATOPATHOLOGY, P911; Georgin-Lavialle S, 2013, BLOOD, V121, P1285, DOI 10.1182/blood-2012-07-442400; Horny HP, 2010, PATHOBIOLOGY, V77, P169, DOI 10.1159/000305552; Horny HP, 2014, EXPERT REV HEMATOL, V7, P431, DOI 10.1586/17474086.2014.942280; Horny HP, 2008, WHO CLASSIFICATION T, V2, P54; Joachim G., 1906, DTSCH ARCH KLIN MED, V87, P437; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P2257, DOI 10.1080/1042819021000039965; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Swerdlow SH, 2017, WHO CLASSIFICATION T, P62; Valent P, 2014, ANN ONCOL, V25, P1691, DOI 10.1093/annonc/mdu047; Wimazal F, 1999, AM J HEMATOL, V61, P66, DOI 10.1002/(SICI)1096-8652(199905)61:1<66::AID-AJH12>3.0.CO;2-3	13	0	1	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 20	2018	13								14	10.1186/s13000-018-0691-2			5	Pathology	Pathology	FX1MQ	WOS:000425816000001	29458385	DOAJ Gold, Green Published			2019-10-28	
J	Alshaikh, S; Harb, Z; Aljufairi, E; Almahari, SA				Alshaikh, Safa; Harb, Zainab; Aljufairi, Eman; Almahari, S. Ali			Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature	CYTOJOURNAL			English	Review						Bethesda; fine-needle aspiration cytology; thyroid	SYSTEM; CYTOPATHOLOGY; MALIGNANCY; LESIONS; CANCER	Background: Fine-needle aspiration cytology (FNAC) of thyroid is the initial screening test for thyroid nodules. The Bethesda system classifies thyroid FNAC into six categories. Each category is linked to a malignancy risk and has a recommended clinical management. The aim of this study is to analyze the thyroid cytology smears by Bethesda system and to correlate the diagnosis of cytopathology with histopathology, whenever surgery was done. Materials and Methods: This study presents our experience with the Bethesda system in 681 thyroid FNAs from 632 patients in the period between January 2013 and December 2016. Results: Categories were as follows: 10.1% were Category I (nondiagnostic), 68.8% Category II (benign), 12.4% were Category III (atypia of undetermined significance), 2.9% were Category IV (suspicious for follicular neoplasm), 2.6% were Category V (suspicious for malignancy), and 4.1% were Category VI (malignant). Surgery was done on 126 nodules from 119 patients with an overall rate of malignancy of 27.8% (35/126 nodules). Conclusion: The Bethesda System for Reporting Thyroid Cytopathology proved to be an excellent reporting system.	[Alshaikh, Safa; Harb, Zainab; Aljufairi, Eman; Almahari, S. Ali] Salmanyia Med Complex, Dept Pathol, Manama, Bahrain	Alshaikh, S (reprint author), Salmanyia Med Complex, Dept Pathol, Manama, Bahrain.	dr_salshaikh@hotmail.com; zfh040016@gmail.com; eman.aljufairi@gmail.com; sayed.almahari@gmail.com					Al Dawish MA, 2017, WORLD J CLIN ONCOL, V8, P151, DOI 10.5306/wjco.v8.i2.151; Melo-Uribe MA, 2015, J CYTOL, V32, P12, DOI 10.4103/0970-9371.155224; Archuletta PA, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.94274; Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Borderud SP, 2014, CANCER-AM CANCER SOC, V120, P3527, DOI 10.1002/cncr.28811; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Crippa S, 2010, AM J CLIN PATHOL, V134, P343, DOI 10.1309/AJCPXM9WIRQ8JZBJ; Cross P, 2016, GUIDANCE REPORTING T; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Jo VY, 2010, AM J CLIN PATHOL, V134, P450, DOI 10.1309/AJCP5N4MTHPAFXFB; Kapila K, 2015, ACTA CYTOL, V59, P133, DOI 10.1159/000371538; Kiernan CM, 2014, ANN SURG ONCOL, V21, P3522, DOI 10.1245/s10434-014-3743-1; Lew JI, 2011, J AM COLL SURGEONS, V213, P188, DOI 10.1016/j.jamcollsurg.2011.04.029; Mondal SK, 2013, J CYTOL, V30, P94, DOI 10.4103/0970-9371.112650; Mufti ST, 2012, INT J HEALTH SCI-IJH, V6, P159, DOI 10.12816/0005991; Nguyen Gia-Khanh, 2005, Cytojournal, V2, P12; Prathima S, 2016, THYROID RES PRACT, V13, P9; Sarkis LM, 2014, PATHOLOGY, V46, P592, DOI 10.1097/PAT.0000000000000168; Sinna EA, 2012, J EGYPT NATL CANCER, V24, P63, DOI 10.1016/j.jnci.2012.01.001; Theoharis CGA, 2009, THYROID, V19, P1215, DOI 10.1089/thy.2009.0155; Williams BA, 2013, J OTOLARYNGOL-HEAD N, V42, DOI 10.1186/1916-0216-42-61; Wong LQ, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.139725; Wu HHJ, 2012, DIAGN CYTOPATHOL, V40, P399, DOI 10.1002/dc.21754	23	2	2	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	FEB 16	2018	15								4	10.4103/cytojournal.cytojournal_32_17			7	Pathology	Pathology	FZ0VE	WOS:000427290900001	29531571	DOAJ Gold, Green Published			2019-10-28	
J	Chang, S; Hirschowitz, S; Lu, DY; Montoya, RC; Vergara-Lluri, M; Moatamed, NA				Chang, Sue; Hirschowitz, Sharon; Lu, David Y.; Montoya, Rose C.; Vergara-Lluri, Maria; Moatamed, Neda A.			Fine-needle aspiration of bilateral small round blue cell tumors in neck in a 65-year-old man: Significance of a wider differential	CYTOJOURNAL			English	Editorial Material									[Chang, Sue] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA; [Hirschowitz, Sharon; Lu, David Y.; Moatamed, Neda A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Vergara-Lluri, Maria] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; [Montoya, Rose C.] Great River Hlth Syst, Dept Pathol, West Burlington, IA USA	Chang, S (reprint author), City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA.	suchang@coh.org; shirschowitz@mednet.ucla.edu; dylu@mednet.ucla.edu; Rosecmontoya@gmail.com; maria.vergara-lluri@med.usc.edu; nmoatamed@mednet.ucla.edu		Moatamed, Neda/0000-0002-9986-8058			Chang S, 2018, CYTOJOURNAL, V15, DOI 10.4103/cytojournal.cytojournal_40_16; Chang S, 2017, CYTOJOURNAL, V14, DOI 10.4103/cytojournal.cytojournal_31_16; French CA, 2010, CANCER GENET CYTOGEN, V203, P16, DOI 10.1016/j.cancergencyto.2010.06.007; Goldblum JR, 2013, ENZINGER WEISSS SOFT; Mahooti S, 2006, CANCER CYTOPATHOL, V108, P86, DOI 10.1002/cncr.21718; Qian X., 2014, CYTOLOGY DIAGNOSTIC; Simons SA, 2016, SEMIN DIAGN PATHOL, V33, P91, DOI 10.1053/j.semdp.2015.09.010	7	1	1	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	FEB 16	2018	15								7	10.4103/cytojournal.cytojournal_41_16			4	Pathology	Pathology	FZ0VE	WOS:000427290900004	29531574	DOAJ Gold, Green Published			2019-10-28	
J	Joob, B; Wiwanitkit, V				Joob, Beuy; Wiwanitkit, Viroj			Myoepithelioma of soft tissue and diagnostic pitfall in cytology	CYTOJOURNAL			English	Letter									[Joob, Beuy] Sanitat 1 Med Acad Ctr, Bangkok, Thailand; [Wiwanitkit, Viroj] Dr DY Patil Univ, Dept Community Med, Pune, Maharashtra, India	Joob, B (reprint author), Sanitat 1 Med Acad Ctr, Bangkok, Thailand.	beuyjoob@hotmail.com; virojwiwan@hotmail.com					Bhanvadia VM, 2017, CYTOJOURNAL, V14, DOI 10.4103/cytojournal.cytojournal_45_16; Wiwanitkit V, 2001, BMC CLIN PATHOL, V1, P5, DOI DOI 10.1186/1472-6890-1-5	2	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	FEB 16	2018	15								6	10.4103/cytojournal.cytojournal_36_17			1	Pathology	Pathology	FZ0VE	WOS:000427290900003	29531573	DOAJ Gold, Green Published			2019-10-28	
J	Sharma, N; Schwartzman, JD; Gutmann, EJ; Marotti, JD; Liu, XY				Sharma, Ninu; Schwartzman, Joseph D.; Gutmann, Edward J.; Marotti, Jonathan D.; Liu, Xiaoying			Cokeromyces recurvatus in a Papanicolaou test: An exceedingly rare finding that can be mistaken for Paracoccidioides brasiliensis	CYTOJOURNAL			English	Article						Cokeromyces recurvatus; liquid-based preparations; Paracoccidioides brasiliensis	MARROW TRANSPLANT RECIPIENT; OF-THE-LITERATURE; FUNGUS	Cokeromyces recurvatus is a zygomycetes yeast form that is very rarely detected in Papanicolaou (Pap) tests, in which it typically represents an innocuous colonizer. Its morphology closely resembles that of the better known Paracoccidioides brasiliensis, which can disseminate widely and cause clinically significant disease. We present a case of C. recurvatus detected in a cervical liquid-based preparation obtained from a 38-year old healthy woman. Careful cytomorphologic evaluation, in combination with culture and molecular techniques, was utilized to make a diagnosis and prevent the misdiagnosis of P. brasiliensis.	[Sharma, Ninu; Schwartzman, Joseph D.; Gutmann, Edward J.; Marotti, Jonathan D.; Liu, Xiaoying] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Sharma, N (reprint author), Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.	ninu.sharma@hitchcock.org; joseph.d.schwartzman@hitchcock.org; Edward.j.gutmann@hitchcock.org; jonathan.d.marotti@hitchcock.org; Xiaoying.liu@hitchcock.org					Alsharif M, 2008, DIAGN CYTOPATHOL, V36, P557, DOI 10.1002/dc.20847; ALVAREZ OA, 1995, AM J GASTROENTEROL, V90, P1350; AXELROD P, 1987, J INFECT DIS, V155, P1062, DOI 10.1093/infdis/155.5.1062; Gomes MZR, 2011, CLIN MICROBIOL REV, V24, P411, DOI 10.1128/CMR.00056-10; Grooters AM, 2003, VET CLIN N AM-SMALL, V33, P695, DOI 10.1016/S0195-5616(03)00034-2; KEMNA ME, 1994, J CLIN MICROBIOL, V32, P843; MCGOUGH D A, 1990, Clinical Microbiology Newsletter, V12, P113, DOI 10.1016/0196-4399(90)90053-E; Munipalli B, 1996, J CLIN MICROBIOL, V34, P2601; Odronic SI, 2012, ARCH PATHOL LAB MED, V136, P1593, DOI 10.5858/arpa.2011-0493-CR; Paquette C, 2016, DIAGN CYTOPATHOL, V44, P419, DOI 10.1002/dc.23432; Ramani R, 2000, PEDIATR INFECT DIS J, V19, P155, DOI 10.1097/00006454-200002000-00014; Rippon JW, 1979, CLIN MICROBIOL NEWSL, V1, P4; Sheyn I, 2001, ACTA CYTOL, V45, P79, DOI 10.1159/000327191; Tsai TW, 1997, BONE MARROW TRANSPL, V19, P301, DOI 10.1038/sj.bmt.1700647	14	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	FEB 16	2018	15								5	10.4103/cytojournal.cytojournal_35_17			4	Pathology	Pathology	FZ0VE	WOS:000427290900002	29531572	DOAJ Gold, Green Published			2019-10-28	
J	Cook, RW; Middlebrook, B; Wilkinson, J; Covington, KR; Oelschlager, K; Monzon, FA; Stone, JF				Cook, Robert W.; Middlebrook, Brooke; Wilkinson, Jeff; Covington, Kyle R.; Oelschlager, Kristen; Monzon, Federico A.; Stone, John F.			Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients	DIAGNOSTIC PATHOLOGY			English	Article						Gene expression profiling; DecisionDx-Melanoma; Cutaneous melanoma; Metastasis; Analytic validity; Technical success	LYMPH-NODE BIOPSY; CUTANEOUS MELANOMA; CANCER	Background: The DecisionDx-Melanoma test provides prognostic information for patients with cutaneous melanoma (CM). Using formalin-fixed paraffin-embedded primary tumor tissue, the RT-PCR-based test classifies patients into a low-(Class 1) or high-risk (Class 2) category for recurrence based on expression of 31 genes. The current study was designed to assess the analytical validity of this test. Methods: Inter-assay, inter-instrument, and inter-operator studies were performed to evaluate reliability of the 31-gene expression test results, sample stability and reagent stability. From March 2013 through June 2016, the gene expression test was performed on 8244 CM tumors. De-identified data from Pathology Reports were used to assess technical success. Results: Robust sample and reagent stability was observed. Inter-assay concordance on 168 specimens run on 2 consecutive days was 99% and matched probability scores were significantly correlated (R-2 = 0.96). Inter-instrument concordance was 95%, and probability scores had a correlation R-2 of 0.99 (p < 0.001). From 8244 CM specimens submitted since 2013, 85% (7023) fulfilled pre-specified tumor content parameters. In these samples with sufficient tumor requirements, the technical success of the test was 98%. Conclusion: DecisionDx-Melanoma is a robust gene expression profile test that demonstrates strong reproducibility between experiments and has high technical reliability on clinical samples.	[Cook, Robert W.; Middlebrook, Brooke; Covington, Kyle R.; Monzon, Federico A.] Castle Biosci Inc, 820 S Friendswood Dr,Suite 201, Friendswood, TX 77546 USA; [Wilkinson, Jeff; Oelschlager, Kristen; Stone, John F.] 3737 N 7th St 160, Phoenix, AZ 85014 USA	Cook, RW (reprint author), Castle Biosci Inc, 820 S Friendswood Dr,Suite 201, Friendswood, TX 77546 USA.	rcook@castlebiosciences.com			Castle Biosciences, Inc.	This study was sponsored by Castle Biosciences, Inc.	Balch CM, 2010, J CLIN ONCOL, V28, P2452, DOI 10.1200/JCO.2009.27.1627; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Berger AC, 2016, CURR MED RES OPIN, V32, P1599, DOI 10.1080/03007995.2016.1192997; Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497; Dietel M, 2015, CANCER GENE THER, V22, P417, DOI 10.1038/cgt.2015.39; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Engstrom PF, 2011, J NATL COMPR CANC NE, V9, pS1; Gerami P, 2015, J AM ACAD DERMATOL, V72, P780, DOI 10.1016/j.jaad.2015.01.009; Gerami P, 2015, CLIN CANCER RES, V21, P175, DOI 10.1158/1078-0432.CCR-13-3316; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; Hsueh EC, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0520-1; Lade-Keller J, 2013, J MOL DIAGN, V15, P70, DOI 10.1016/j.jmoldx.2012.08.003; Medical Advisory Secretariat, 2010, Ont Health Technol Assess Ser, V10, P1; Morton DL, 2014, NEW ENGL J MED, V370, P599, DOI 10.1056/NEJMoa1310460; Shaikh WR, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv294; Sun F, 2010, QUALITY REGULATION C; Teutsch SM, 2009, GENET MED, V11, P3, DOI 10.1097/GIM.0b013e318184137c; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Walsh PS, 2012, J CLIN ENDOCR METAB, V97, pE2297, DOI 10.1210/jc.2012-1923; Whiteman DC, 2015, J INVEST DERMATOL, V135, P1190, DOI 10.1038/jid.2014.452	20	5	5	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 13	2018	13								13	10.1186/s13000-018-0690-3			8	Pathology	Pathology	FW1WO	WOS:000425091200001	29433548	DOAJ Gold, Green Published			2019-10-28	
J	Udall, M; Rizzo, M; Kenny, J; Doherty, J; Dahm, S; Robbins, P; Faulkner, E				Udall, Margarita; Rizzo, Maria; Kenny, Juliet; Doherty, Jim; Dahm, SueAnn; Robbins, Paul; Faulkner, Eric			PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics	DIAGNOSTIC PATHOLOGY			English	Review						Cancer; Immunotherapy; Programmed death ligand 1; Programmed cell death protein 1; PD-1; PD-L1; Test; Antibody; Diagnostic; Tests	LIGAND 1 EXPRESSION; CELL LUNG-CANCER; SQUAMOUS-CELL; IMMUNOHISTOCHEMISTRY; ASSAY; PEMBROLIZUMAB; HETEROGENEITY; CHALLENGES	Background: The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on certain lymphocytes that, with its ligand programmed death ligand 1 (PD-L1), helps to down-regulate immune responses. Many cancer types express PD-L1 and evade immune recognition via the PD-1/PD-L1 interaction. Precision therapies targeting the PD-1/PD-L1 pathway have the potential to improve response and thereby offer a novel treatment avenue to some patients with cancer. However, this new therapeutic approach requires reliable methods for identifying patients whose cancers are particularly likely to respond. Therefore, we conducted a systematic literature review assessing evidence on test validation and scoring algorithms for PD-L1 immunohistochemistry (IHC) tests that might be used to select potentially responsive patients with bladder/urothelial cell, lung, gastric, or ovarian cancers for immunotherapy treatment. Methods and results: To identify evidence on commercially available PD-L1 IHC assays, we systematically searched MEDLINE and Embase for relevant studies published between January 2010 and September 2016 and appraised abstracts from recent oncology conferences (January 2013 to November 2016). Publications that met the predefined inclusion criteria were extracted and key trends summarized. In total, 26 eligible primary studies were identified, all of which reported on the test validation metrics associated with PD-L1 IHC tests in lung cancer, most using immunohistochemistry testing. There was significant heterogeneity among the available tests for PD-L1. Specifically, no definitive cutoff for PD-L1 positivity was identifiable, with more than one threshold being reported for most antibodies. Studies also differed as to whether they evaluated tumor cells only or tumor cells and tumor-infiltrating immune cells. However, all of the tests developed and validated to support a therapeutic drug in the context of phase 2-3 clinical trials reported more than 90% inter-reader concordance. In contrast, other PD-L1 antibodies identified in the literature reported poorer concordance. Conclusions: Published validation metric data for PD-L1 tests are mainly focused on immunohistochemistry tests from studies in lung cancer. The variability in test cutoffs and standards for PD-L1 testing suggests that there is presently no standardized approach. This current variability may have implications for the uptake of precision treatments.	[Udall, Margarita; Doherty, Jim; Dahm, SueAnn; Robbins, Paul] Pfizer Inc, New York, NY 10017 USA; [Rizzo, Maria; Kenny, Juliet; Faulkner, Eric] Evidera, Metro Bldg,6th Floor,1 Butterwick, London W6 8DL, England	Udall, M (reprint author), Pfizer Inc, New York, NY 10017 USA.	Margarita.Udall@pfizer.com			Pfizer, Inc., New York, NY, USAPfizer	Funding for the design of the study, collection, analysis, interpretation of data, and writing assistance was provided by Pfizer, Inc., New York, NY, USA	Anderson SM, 2016, J CLIN ONCOL S, V34; Boyd ZS, 2015, IN INT CANC IMM C SE; Canadian Agency for Drugs and Technologies in Health (CADTH), 2010, RAP RESP REP PEER RE; Casadevall D, 2016, J CLIN ONCOL S, V34; Chaft JE, 2015, 16 WORLD C LUNG CANC; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cree IA, 2016, HISTOPATHOLOGY, V69, P177, DOI 10.1111/his.12996; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Festino L, 2016, DRUGS, V76, P925, DOI 10.1007/s40265-016-0588-x; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaule P, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9040; Gupta R, 2009, HUM PATHOL, V40, P356, DOI 10.1016/j.humpath.2008.08.008; Hiley CT, 2016, LANCET, V388, P1002, DOI 10.1016/S0140-6736(16)31340-X; Huynh TG, 2016, J THORAC ONCOL, V11, P1869, DOI 10.1016/j.jtho.2016.08.134; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Ilie M, 2016, MODERN PATHOL, V29, P1552, DOI 10.1038/modpathol.2016.149; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; Inamura K, 2016, JPN J CLIN ONCOL, V46, P935, DOI 10.1093/jjco/hyw087; Inoue Y, 2016, ONCOTARGET, V7, P32113, DOI 10.18632/oncotarget.8528; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Kowanetz M, 2015, 16 WORLD C LUNG CANC; Ma WJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0277-y; Mansfield AS, 2016, CLIN CANCER RES, V22, P2177, DOI 10.1158/1078-0432.CCR-15-2246; Marti AM, 2014, AM SOC CLIN ONC ANN; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Midha A, 2016, AM SOC CLIN ONC ANN; Phillips T, 2015, APPL IMMUNOHISTO M M, V23, P541, DOI 10.1097/PAI.0000000000000256; Rebelatto MC, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0545-8; Rivalland G, 2016, J CLIN ONCOL S, V34; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Schildhaus HU, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3031; Smith J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0494-2; U. S. Food and Drug Administration, COMP DIAGN; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA	36	31	31	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 9	2018	13								12	10.1186/s13000-018-0689-9			11	Pathology	Pathology	FW1WK	WOS:000425090800001	29426340	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, XW; Wang, HM; Li, Q; Liu, YP; Zhao, PQ; Li, T				Zhang, Xiaowei; Wang, Haiming; Li, Qian; Liu, Yunpeng; Zhao, Peiqing; Li, Tao			Differences in the expression profiles of claudin proteins in human nasopharyngeal carcinoma compared with non-neoplastic mucosa	DIAGNOSTIC PATHOLOGY			English	Article						Tight junction; Claudin-2; Claudin-5; Claudin-8; Claudin-9; Nasopharyngeal carcinoma	TIGHT JUNCTION PROTEIN; BARRIER FUNCTION; CELL POLARITY; CANCER; PHOSPHORYLATION; RECURRENCE; COMPONENTS; APOPTOSIS; TARGETS; FAMILY	Background: Several studies have suggested that claudin proteins, which are the main components of tight junction structures, are related to the regulation of cell polarity and cell differentiation. Method: To explore the expression profiles of the tight junction proteins claudin-2, -5, -8 and -9 in nasopharyngeal carcinoma, IHC (immunohistochemical analysis), Western blot and real-time PCR were used to detect the expression profiles of these claudin proteins in nasopharyngeal carcinoma tissues and in non-neoplastic mucosal tissues. Results: According to our study, the expression levels of claudin-2 and claudin-5 were reduced, while the expression of claudin-8 was increased in nasopharyngeal carcinoma tissues in comparison with non-neoplastic mucosal tissues. Correlations between claudin-2 and -5 expression and metastatic progression in nasopharyngeal carcinoma patients were also found. Conclusion: In summary, our research reveals distinct expression profiles of claudin-2, -5 and -8 in non-neoplastic mucosal tissues and nasopharyngeal carcinoma tissues. In addition, the expression of these claudin proteins was highly correlated with metastatic progression and prognosis in patients with nasopharyngeal carcinoma and had predictive value for the metastasis and survival of nasopharyngeal carcinoma patients.	[Zhang, Xiaowei; Zhao, Peiqing; Li, Tao] Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China; [Zhang, Xiaowei; Li, Qian; Zhao, Peiqing; Li, Tao] Shandong Univ, Cent Hosp Zibo, Dept Spinal Surg, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China; [Wang, Haiming] Binzhou Med Coll, Peoples Hosp Linzi Dist, Dept Gen Surg, Yantai, Shandong, Peoples R China; [Liu, Yunpeng] Jilin Univ, Hosp 1, Dept Thorac Surg, Changchun, Jilin, Peoples R China	Li, T (reprint author), Shandong Univ, Cent Hosp Zibo, Ctr Translat Med, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.; Li, T (reprint author), Shandong Univ, Cent Hosp Zibo, Dept Spinal Surg, Gongqingtuan Rd 54Hao, Zibo, Shandong, Peoples R China.	zbszxyylitao@126.com			Natural Science Foundation of Shandong ProvinceNatural Science Foundation of Shandong Province [ZR2014HM042]	This study was supported by Natural Science Foundation of Shandong Province (Code: ZR2014HM042).	Angelow S, 2008, AM J PHYSIOL-RENAL, V295, pF867, DOI 10.1152/ajprenal.90264.2008; Bernardi MA, 2012, ONCOL REP, V27, P28, DOI 10.3892/or.2011.1477; Cheung ST, 2005, CLIN CANCER RES, V11, P551; Coradini D, 2011, ACTA PHARMACOL SIN, V32, P552, DOI 10.1038/aps.2011.20; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; D'Souza T, 2007, EXP CELL RES, V313, P3364, DOI 10.1016/j.yexcr.2007.06.026; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Gao M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-205; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-186; Hsueh C, 2010, HUM PATHOL, V41, P944, DOI 10.1016/j.humpath.2010.01.005; Huang CW, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556-276X-8-480; Ikari A, 2012, BBA-MOL CELL RES, V1823, P1110, DOI 10.1016/j.bbamcr.2012.04.005; Iravani O, 2013, EXP BIOL MED, V238, P344, DOI 10.1177/1535370213477981; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Kyuno D, 2014, WORLD J GASTROENTERO, V20, P10813, DOI 10.3748/wjg.v20.i31.10813; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Lee JW, 2010, INT J CANCER, V126, P1353, DOI 10.1002/ijc.24857; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lin Z, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-133; Lu Z, 2012, FUNCTIONS CLAUDIN 7; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morohashi S, 2007, INT J MOL MED, V20, P139; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Oliveira SS, 2007, CELL MOL LIFE SCI, V64, P17, DOI 10.1007/s00018-006-6314-1; Oshima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074757; Pan XY, 2007, INT J GYNECOL CANCER, V17, P233, DOI 10.1111/j.1525-1438.2006.00748.x; Resnick MB, 2005, MODERN PATHOL, V18, P511, DOI 10.1038/modpathol.3800301; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Singh AB, 2010, J ONCOL, DOI 10.1155/2010/541957; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; Wang HM, 2015, INT J CLIN EXP PATHO, V8, P881; Wu Q, 2010, EUR J CANCER PREV, V19, P186, DOI 10.1097/CEJ.0b013e328337210e; Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112; Zhang XW, 2015, INT J CLIN EXP PATHO, V8, P5535; Zhang XW, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0600-4; Zhu JY, 2015, INT J CLIN EXP PATHO, V8, P9479	50	1	1	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	FEB 5	2018	13								11	10.1186/s13000-018-0685-0			9	Pathology	Pathology	FV1PN	WOS:000424337000001	29402318	DOAJ Gold, Green Published			2019-10-28	
J	Efared, B; Sidibe, IS; Abdoulaziz, S; Hammas, N; Chbani, L; El Fatemi, H				Efared, Boubacar; Sidibe, Ibrahim S.; Abdoulaziz, Souley; Hammas, Nawal; Chbani, Laila; El Fatemi, Hinde			Tubular Adenoma of the Breast: A Clinicopathologic Study of a Series of 9 Cases	CLINICAL MEDICINE INSIGHTS- PATHOLOGY			English	Article						Breast; tubular adenoma; pathology		Tubular adenoma of the breast is one of the most rare benign neoplasms, accounting for only 0.13% to 1.7% of all breast benign tumors. Little is known about this rare neoplasm as the current literature offers only some case reports or a few number of small series. The aim of our study is to provide some clinicopathologic features of the breast tubular adenoma. We retrospectively analyzed at our department of pathology all cases of breast tubular adenomas confirmed by immunohistochemistry over a period of 9 years (2009-2017). Nine cases of breast tubular adenoma have been recorded, with an average age of 31.44 years. Five tumors were located at the right side (55.55%), and most cases had suspicious aspects on imaging techniques (6 cases out of 9). The diagnosis has been made on 5 resected specimens (lumpectomy) and on 4 core needle biopsies. The tumor size ranged from 0.9 to 7 cm (mean size of 3.08 cm) and had well-circumscribed margins with elastic consistency. The histopathologic analysis showed a typical pattern of proliferating round and uniform tubules lined by regular epithelial cells surrounded by myoepithelial cells, packed in a small amount of stroma, highlighted by CD34 immunostaining. Tubular adenoma is a rare breast benign neoplasm of young premenopausal women. The radiologic aspects are often worrisome and only the histopathologic analysis can achieve the correct definitive diagnosis by excluding all potential differential diagnoses.	[Efared, Boubacar; Sidibe, Ibrahim S.; Hammas, Nawal; Chbani, Laila; El Fatemi, Hinde] Hassan II Univ Hosp, Dept Pathol, BP 1835,Route Sidi Harazem, Fes 30050, Morocco; [Abdoulaziz, Souley] Hassan II Univ Hosp, Dept Radiol, Fes, Morocco; [Hammas, Nawal; Chbani, Laila; El Fatemi, Hinde] Sidi Mohamed Ben Abdellah Univ, Fac Med & Pharmacol, Fes, Morocco	Efared, B (reprint author), Hassan II Univ Hosp, Dept Pathol, BP 1835,Route Sidi Harazem, Fes 30050, Morocco.	befared2013@gmail.com	Boubacar, Efared/J-7439-2019	Boubacar, Efared/0000-0002-8623-4005			Darling ML, 2000, BREAST J, V6, P252; Domoto H, 2002, PATHOL INT, V52, P244, DOI 10.1046/j.1440-1827.2002.01338.x; Dusunceli F, 2012, BREAST J, V18, P79, DOI 10.1111/j.1524-4741.2011.01186.x; Elzahaby Islam A, 2017, Breast Dis, V37, P37, DOI 10.3233/BD-160263; Huang Y, 2015, J CHEM-NY, DOI 10.1155/2015/297686; Irshad A, 2008, RADIOGRAPHICS, V28, P1399, DOI 10.1148/rg.285075743; Lakhani SREI, 2012, WHO CLASSIFICATION T; Liu GFF, 2009, INT J RADIAT ONCOL, V75, P1304, DOI 10.1016/j.ijrobp.2008.12.070; Maiorano E, 1995, PATHOL RES PRACT, V191, P1222, DOI 10.1016/S0344-0338(11)81130-1; Rovera F, 2006, BREAST J, V12, P257, DOI 10.1111/j.1075-122X.2006.00250.x; Saimura M, 2015, BREAST CANCER-TOKYO, V22, P428, DOI 10.1007/s12282-012-0375-9; Salemis Nikolaos S, 2012, J Clin Med Res, V4, P64, DOI 10.4021/jocmr746w; Sengupta Sanjay, 2015, Iran J Pathol, V10, P17; Sengupta S, 2014, N AM J MED SCI, V6, P219, DOI 10.4103/1947-2714.132940; Soo MS, 2000, AM J ROENTGENOL, V174, P757, DOI 10.2214/ajr.174.3.1740757; Spruill L, 2016, SEMIN DIAGN PATHOL, V33, P2, DOI 10.1053/j.semdp.2015.09.002; Vashi R, 2013, AM J ROENTGENOL, V200, P329, DOI 10.2214/AJR.12.9845	17	1	1	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-5557	2632-010X		CLIN MED INSIGHTS-PA	Clin. Med. Insights-Pathol.	FEB 5	2018	11								UNSP 1179555718757499	10.1177/1179555718757499			5	Pathology	Pathology	FZ5RV	WOS:000427654500001	29449780	DOAJ Gold, Green Published			2019-10-28	
J	Santos, JC; Gambeloni, RZ; Roque, AT; Oeck, S; Ribeiro, ML				Santos, Juliana C.; Gambeloni, Rafael Z.; Roque, Aline T.; Oeck, Sebastian; Ribeiro, Marcelo L.			Epigenetic Mechanisms of ATM Activation after Helicobacter pylori Infection	AMERICAN JOURNAL OF PATHOLOGY			English	Article							OXIDATIVE DNA-DAMAGE; VACUOLATING CYTOTOXIN; HISTONE MODIFICATIONS; METHYLATION; EXPRESSION; GENOTYPES; PROTEIN; RISK; VACA	Gastric cancer (GC) is the second Leading cause of cancer-related mortality worldwide. The disease develops from the accumulation of several genetic and epigenetic changes. Among other risk factors, Helicobacter pylori infection is considered the main driving factor of GC development. H. pylori infection increases DNA damage levels and leads to epigenetic dysregulation, which may favor gastric carcinogenesis. An early step in double-strand break repair is the recruitment of ataxia-telangiectasia mutated serine/threonine kinase (ATM) to the damaged site, where it plays a key role in advancing the DNA damage checkpoint process. H. pylori infection has been associated with the introduction of double-strand breaks in epithelial cells, triggering damage signaling and repair response involving ATM. Thus, the current study analyzed the effect of H. pylori infection on the DNA damage response sensor, ATM, in gastric epithelial cells and in biopsy specimens from patients with GC. In this study, we identified that H. pylori infection stimulated DNA damage, and therefore induced ATM in a virulence factor-dependent manner. In addition, we found that H. pylori might activate ATM through histone H3 and H4 hyperacetylation and DNA promoter hypomethylation. Our findings show a mechanism associating ATM signaling induction with H. pylori infection.	[Santos, Juliana C.; Gambeloni, Rafael Z.; Roque, Aline T.; Ribeiro, Marcelo L.] Sao Francisco Univ, Med Sch, Clin Pharmacol & Gastroenterol Unit, Av Sao Francisco de Assis 218, BR-12916900 Braganca Paulista, SP, Brazil; [Santos, Juliana C.] State Univ Campinas UNICAMP, Womens Hlth Hosp Prof Dr Jose Aristodemo Pinotti, Campinas, SP, Brazil; [Oeck, Sebastian] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA; [Oeck, Sebastian] Univ Duisburg Essen, Med Sch, Inst Cell Biol Canc Res, Essen, Germany	Santos, JC; Ribeiro, ML (reprint author), Sao Francisco Univ, Med Sch, Clin Pharmacol & Gastroenterol Unit, Av Sao Francisco de Assis 218, BR-12916900 Braganca Paulista, SP, Brazil.	santos.j.c@outlook.com; marcelo.ribeiro@usf.edu.br	Ribeiro, Marcelo Lima/R-8951-2019; Ribeiro, Marcelo Lima/H-8856-2013	Ribeiro, Marcelo Lima/0000-0003-4529-7832; Ribeiro, Marcelo Lima/0000-0003-4529-7832; Oeck, Sebastian/0000-0001-9695-8771; Santos, Juliana/0000-0003-4148-9570	Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/21710-0, 2015/08775-7, 2015/17768-4, 2014/11862-6]; National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq)	Supported by Sao Paulo Research Foundation grants 2011/21710-0 (J.C.S.), 2015/08775-7 (R.Z.G.), 2015/17768-4 (A.T.R.), and 2014/11862-6 (M.L.R.), and the National Council for Scientific and Technological Development (CNPq).	Abdi E, 2016, J GASTROEN HEPATOL, V31, P734, DOI 10.1111/jgh.13256; Ahn HJ, 2015, WORLD J GASTRO ONCOL, V7, P455, DOI 10.4251/wjgo.v7.i12.455; Alvarez MC, 2013, WORLD J GASTROENTERO, V19, P3043, DOI 10.3748/wjg.v19.i20.3043; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cover Timothy L, 2013, Gut Microbes, V4, P482, DOI 10.4161/gmic.26262; COVER TL, 1994, J BIOL CHEM, V269, P10566; Ding SZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009875; Escargueil AE, 2008, MUTAT RES-REV MUTAT, V658, P259, DOI 10.1016/j.mrrev.2008.01.004; Figueiredo C, 2002, J NATL CANCER I, V94, P1680; Gerhard M, 2005, GASTROENTEROLOGY, V128, P1327, DOI 10.1053/j.gastro.2005.03.018; HAAS R, 1993, MOL MICROBIOL, V8, P753, DOI 10.1111/j.1365-2958.1993.tb01618.x; Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009; Hamon MA, 2007, P NATL ACAD SCI USA, V104, P13467, DOI 10.1073/pnas.0702729104; Hanada K, 2014, INFECT IMMUN, V82, P4182, DOI 10.1128/IAI.02368-14; Jang SH, 2012, FREE RADICAL BIO MED, V52, P607, DOI 10.1016/j.freeradbiomed.2011.11.010; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kalali B, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/426309; Ladeira MSP, 2008, DIGEST DIS SCI, V53, P248, DOI 10.1007/s10620-007-9850-0; Nakajima T, 2009, INT J CANCER, V124, P905, DOI 10.1002/ijc.24018; Oeck S, 2017, RADIAT RES, V188, P114, DOI 10.1667/RR14746.1; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Reliene R, 2004, CANCER RES, V64, P5148, DOI 10.1158/0008-5472.CAN-04-0442; Sepulveda Antonia R, 2013, Curr Pathobiol Rep, V1, P9; Shin CM, 2013, INT J CANCER, V133, P2034, DOI 10.1002/ijc.28219; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Tanaka T, 2007, CELL CYCLE, V6, P371, DOI 10.4161/cc.6.3.3835; Toller IM, 2011, P NATL ACAD SCI USA, V108, P14944, DOI 10.1073/pnas.1100959108; Wang MY, 2015, FUTURE MICROBIOL, V10, P1505, DOI [10.2217/FMB.15.72, 10.2217/fmb.15.72]; WARREN JR, 1983, LANCET, V1, P1273; Xie C, 2014, ONCOL LETT, V7, P159; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; Yamaoka Y, 2010, NAT REV GASTRO HEPAT, V7, P629, DOI 10.1038/nrgastro.2010.154	33	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					329	335		10.1016/j.ajpath.2017.10.005			7	Pathology	Pathology	FT6HY	WOS:000423256300007	29128564	Bronze			2019-10-28	
J	Lin, SB; Han, YR; Jenkin, K; Lee, SJ; Sasaki, M; Klapproth, JM; He, PJ; Yun, CC				Lin, Songbai; Han, Yiran; Jenkin, Kayte; Lee, Sei-Jung; Sasaki, Maiko; Klapproth, Jan-Michael; He, Peijian; Yun, C. Chris			Lysophosphatidic Acid Receptor 1 Is Important for Intestinal Epithelial Barrier Function and Susceptibility to Colitis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TIGHT JUNCTION PERMEABILITY; INFLAMMATORY-BOWEL-DISEASE; LIGHT-CHAIN KINASE; TNF-ALPHA MODULATION; IN-VIVO; PROTEIN EXPRESSION; INTERFERON-GAMMA; RHO GTPASES; CELLS; ACTIN	Intestinal epithelial cells form a barrier that is critical in protecting the host from the hostile luminal environment. Previously, we showed that lysophosphatidic acid (LPA) receptor 1 regulates proliferation of intestinal epithelial cells, such that the absence of LPA1 mitigates the epithelial wound healing process. This study provides evidence that LPA1 is important for the maintenance of epithelial barrier integrity. The epithelial permeability, determined by fluorescently labeled dextran flux and transepithelial resistance, is increased in the intestine of mice with global deletion of Lpar1, Lpar1(-/-) (Lpa1(-/-)). Serum liposaccharide level and bacteria loads in the intestinal mucosa and peripheral organs were elevated in Lpa1(-/-) mice. Decreased claudin-4, caudin-7, and E-cadherin expression in Lpa1(-/-) mice further suggested defective apical junction integrity in these mice. Regulation of LPA1 expression in Caco-2 cells modulated epithelial permeability and the expression levels of junctional proteins. The increased epithelial permeability in Lpa1(-/-) mice correlated with increased susceptibility to an experimental model of colitis. This resulted in more severe inflammation and increased mortality compared with control mice. Treatment of Caco-2 cells with tumor necrosis factor-alpha and interferon-gamma significantly increased para-cellular permeability, which was blocked by cotreatment with LPA, but not LPA1 knockdown cells. Similarly, orally given LPA blocked tumor necrosis factor-mediated intestinal barrier defect in mice. LPA1 plays a significant role in maintenance of epithelial barrier in the intestine via regulation of apical junction integrity.	[Lin, Songbai; Han, Yiran; Jenkin, Kayte; Lee, Sei-Jung; Sasaki, Maiko; Klapproth, Jan-Michael; He, Peijian; Yun, C. Chris] Emory Univ, Sch Med, Div Digest Dis, 615 Michael St,Whitehead Bldg,Ste 201, Atlanta, GA 30324 USA; [Yun, C. Chris] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA; [Yun, C. Chris] Atlanta Vet Adm, Med Ctr, Decatur, GA USA; [Lee, Sei-Jung] Daegu Haany Univ, Dept Pharmaceut Engn, Gyongsan, South Korea; [Klapproth, Jan-Michael] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA	Yun, CC (reprint author), Emory Univ, Sch Med, Div Digest Dis, 615 Michael St,Whitehead Bldg,Ste 201, Atlanta, GA 30324 USA.	ccyun@emory.edu	Lee, Sei-Jung/V-8772-2019		VA Merit AwardUS Department of Veteran Affairs [I01BX002540]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DK071597, S10RR25679]; Integrated Cellular Imaging Shared Resources of Winship Cancer Institute of Emory University; NIH/National Cancer Institute award [P30CA138292]	Supported by the VA Merit Award I01BX002540 and NIH grant R01DK071597 (C.C.Y.). Confocal microscopic analyses were supported, in part, by the Integrated Cellular Imaging Shared Resources of Winship Cancer Institute of Emory University and NIH/National Cancer Institute award P30CA138292. Funding for the JEOL JEM-1400 electron microscope was provided by NIH grant S10RR25679.	Adachi M, 2011, DIGEST DIS SCI, V56, P2252, DOI 10.1007/s10620-011-1595-0; Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21; Al-Sadi R, 2013, AM J PATHOL, V183, P1871, DOI 10.1016/j.ajpath.2013.09.001; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; [Anonymous], 2011, GUIDE CARE USE LAB A; Bai ZB, 2013, J IMMUNOL, V190, P2036, DOI 10.4049/jimmunol.1202025; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bergstrom KS, 2012, CELL MICROBIOL, V14, P475, DOI 10.1111/j.1462-5822.2012.01750.x; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Citalan-Madrid AF, 2017, MUCOSAL IMMUNOL, V10, P1237, DOI 10.1038/mi.2016.136; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; COOPER HS, 1993, LAB INVEST, V69, P238; Cosi C, 2011, NEUROPHARMACOLOGY, V60, P1227, DOI 10.1016/j.neuropharm.2010.11.014; D'Arrigo P, 2010, MOLECULES, V15, P1354, DOI 10.3390/molecules15031354; Ehehalt R, 2010, BBA-MOL CELL BIOL L, V1801, P983, DOI 10.1016/j.bbalip.2010.05.014; Farkas AE, 2015, AM J PATHOL, V185, P2206, DOI 10.1016/j.ajpath.2015.04.023; Floege J, 2016, NAT REV NEPHROL, V12, P147, DOI 10.1038/nrneph.2015.208; Garcia-Diaz B, 2015, BRAIN STRUCT FUNCT, V220, P3701, DOI 10.1007/s00429-014-0885-7; Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018; Gkouskou KK, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00028; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; He DH, 2009, J BIOL CHEM, V284, P24123, DOI 10.1074/jbc.M109.007393; He PJ, 2015, J CLIN INVEST, V125, P3519, DOI 10.1172/JCI79552; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Hozumi H, 2013, LAB INVEST, V93, P508, DOI 10.1038/labinvest.2013.45; Imielinski M, 2009, NAT GENET, V41, P1335, DOI 10.1038/ng.489; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Khounlotham M, 2012, IMMUNITY, V37, P563, DOI 10.1016/j.immuni.2012.06.017; Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; Krieglstein CF, 2002, J CLIN INVEST, V110, P1773, DOI 10.1172/JCI200215256; Larmonier CB, 2013, AM J PHYSIOL-GASTR L, V305, pG667, DOI 10.1152/ajpgi.00189.2013; Laukoetter MG, 2007, J EXP MED, V204, P3067, DOI 10.1084/jem.20071416; Lee SJ, 2013, MOL CELL BIOL, V33, P2016, DOI 10.1128/MCB.00038-13; Li CY, 2005, J EXP MED, V202, P975, DOI 10.1084/jem.20050421; Lin SB, 2010, AM J PHYSIOL-GASTR L, V299, pG1128, DOI 10.1152/ajpgi.00321.2010; Lin SB, 2010, GASTROENTEROLOGY, V138, P649, DOI 10.1053/j.gastro.2009.09.055; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Ma TY, 2005, AM J PHYSIOL-GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004; Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003; Mackenzie A E, 2011, Front Endocrinol (Lausanne), V2, P68, DOI 10.3389/fendo.2011.00068; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Monteiro AC, 2012, ANN NY ACAD SCI, V1257, P115, DOI 10.1111/j.1749-6632.2012.06521.x; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Naydenov NG, 2016, SCI REP-UK, V6, DOI 10.1038/srep24161; No YR, 2015, AM J PHYSIOL-CELL PH, V309, pC14, DOI 10.1152/ajpcell.00067.2015; Nouri M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106335; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Panther E, 2002, J IMMUNOL, V169, P4129, DOI 10.4049/jimmunol.169.8.4129; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Poritz LS, 2007, J SURG RES, V140, P12, DOI 10.1016/j.jss.2006.07.050; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; Rahman K, 2016, GASTROENTEROLOGY, V151, P733, DOI 10.1053/j.gastro.2016.06.022; Samarin SN, 2007, MOL BIOL CELL, V18, P3429, DOI 10.1091/mbc.E07-04-0315; Schlegel N, 2011, J CELL PHYSIOL, V226, P1196, DOI 10.1002/jcp.22446; Schulze C, 1997, J NEUROCHEM, V68, P991; Segura BJ, 2004, NEUROSCIENCE, V123, P687, DOI 10.1016/j.neuroscience.2003.10.003; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Suh PG, 2008, BMB REP, V41, P415, DOI 10.5483/BMBRep.2008.41.6.415; Tanaka T, 2009, BIOSCI BIOTECH BIOCH, V73, P1293, DOI 10.1271/bbb.80813; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; Wang DD, 2016, AM J PATHOL, V186, P844, DOI 10.1016/j.ajpath.2015.11.023; Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X; Watts T, 2005, P NATL ACAD SCI USA, V102, P2916, DOI 10.1073/pnas.0500178102; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279; Zhang HC, 2007, CELL SIGNAL, V19, P261, DOI 10.1016/j.cellsig.2006.06.008; Zhang QH, 1997, MOL BIOL CELL, V8, P1415; Zhao YT, 2007, CELL SIGNAL, V19, P2329, DOI 10.1016/j.cellsig.2007.07.005	79	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					353	366		10.1016/j.ajpath.2017.10.006			14	Pathology	Pathology	FT6HY	WOS:000423256300010	29128569	Bronze, Green Published			2019-10-28	
J	Zhang, YY; Wu, HY; Yang, F; Ning, J; Li, M; Zhao, CC; Zhong, SP; Gu, KS; Wang, H				Zhang, Yiyin; Wu, Hongyang; Yang, Feng; Ning, Jie; Li, Min; Zhao, Chenchen; Zhong, Shuping; Gu, Kangsheng; Wang, Hua			Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients	AMERICAN JOURNAL OF PATHOLOGY			English	Article							POLYMERASE-III TRANSCRIPTION; NUCLEOTIDE EXCISION-REPAIR; IDENTIFICATION TEST AUDIT; BRCA1 EXPRESSION; DEPENDENT GENES; MYELOPEROXIDASE; CELLS; MICE; ADENOCARCINOMA; LANDSCAPE	Alcohol consumption likely induces gastric carcinogenesis through deregulation of RNA poLymerase (Pol) III genes and oxidative damage. Transcription factor IIB-related factor 1 (BRF1) overexpression alleviates RNA Pol III transcription inhibition through breast cancer susceptibility gene 1 (BRCA1). Myeloperoxidase (MPO) involvement in cancer is induced by alcohol-mediated oxidative damage. BRCA1/2 and MPO play key roles in DNA repair. BRCA1 and BRCA2 exert different roles in homologous recombination repair. By using human gastric cancer (GC) biopsies, we investigated the prognostic value of these proteins upon alcohol induction. In total, high expression of BRF1 (P = 0.010) and positive cell infiltration of MPO (P = 0.004) in tumor tissues as well as positive expression of BRCA1 (P < 0.001) in para-tumor tissues were more frequent in GC patients with hazardous or harmful alcohol consumption habits. BRF1 (P = 0.021), BRCA2 (P < 0.001), and MPO (P = 0.039) were independent prognostic factors for disease-free survival. BRCA1 (P = 0.005) and BRCA2 (P < 0.001) also were identified as independent prognostic factors for overall survival. Furthermore, BRCA2 was an independent unfavorable prognostic factor for disease-free survival and overall survival (P < 0.001) in GC patients who underwent platinum-based adjuvant chemotherapy. BRF1, BRCA1/2, and MPO are DNA repair related biomarkers, induced by alcohol with prognostic value in GC patients.	[Zhang, Yiyin; Wu, Hongyang; Ning, Jie; Li, Min; Zhao, Chenchen; Gu, Kangsheng; Wang, Hua] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China; [Yang, Feng] Anhui Med Univ, Basic Med Sch, Dept Pathol, Hefei, Anhui, Peoples R China; Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Zhong, Shuping] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA	Wang, H (reprint author), Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.	wanghua@ahmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81522009, 81372577]; Anhui Provincial Science and Technology Plan Project [1604b0602027]	Supported by National Natural Science Foundation of China grants 81522009 (H.Wa.) and 81372577 (H.Wa.), and Anhui Provincial Science and Technology Plan Project 1604b0602027 (K.G.).	Al-Salihi M, 2015, REDOX BIOL, V6, P218, DOI 10.1016/j.redox.2015.07.013; Amirshahrokhi K, 2015, CHEM-BIOL INTERACT, V225, P63, DOI 10.1016/j.cbi.2014.11.019; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Chen WJ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0423-5; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; Crespo-Sanjuan J, 2015, LABMEDICINE, V46, P123, DOI 10.1309/LMZJJU6BC86WUDHW; Daster S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1050574; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Droeser RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064814; Elliott SN, 1998, CAN J GASTROENTEROL, V12, P559, DOI 10.1155/1998/398384; Fang XX, 2015, EUR J CANCER, V51, P2820, DOI 10.1016/j.ejca.2015.09.010; Gungor N, 2007, FASEB J, V21, P2359, DOI 10.1096/fj.07-8163com; Johnson SAS, 2008, J BIOL CHEM, V283, P19184, DOI 10.1074/jbc.M802872200; Kim JW, 2013, CANCER CHEMOTH PHARM, V71, P1435, DOI 10.1007/s00280-013-2141-x; Li WF, 2013, TOXICOL APPL PHARM, V272, P21, DOI 10.1016/j.taap.2013.05.035; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Rajendra E, 2010, NUCLEIC ACIDS RES, V38, P82, DOI 10.1093/nar/gkp873; Rymaszewski AL, 2014, CANCERS, V6, P1111, DOI 10.3390/cancers6021111; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schults MA, 2012, MUTAT RES-FUND MOL M, V736, P75, DOI 10.1016/j.mrfmmm.2011.11.001; Tsai MC, 2005, ALCOHOL CLIN EXP RES, V29, P53, DOI 10.1097/01.ALC.0000151986.96710.E0; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Venkitaraman AR, 2014, SCIENCE, V343, P1470, DOI 10.1126/science.1252230; Veras L, 2009, J MOL BIOL, V387, P523, DOI 10.1016/j.jmb.2009.02.008; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Zhang QS, 2013, CARCINOGENESIS, V34, P28, DOI 10.1093/carcin/bgs316; Zhang ZZ, 2013, WORLD J GASTROENTERO, V19, P1968, DOI 10.3748/wjg.v19.i12.1968; Zhong Q, 2016, ONCOTARGET, V7, P6243, DOI 10.18632/oncotarget.6668; Zhong Q, 2014, ONCOTARGET, V5, P12410, DOI 10.18632/oncotarget.2678; Zhong Q, 2015, GENE, V556, P74, DOI 10.1016/j.gene.2014.11.009; Zhong SP, 2011, J BIOL CHEM, V286, P2393, DOI 10.1074/jbc.M110.192955; Zhong SP, 2009, P NATL ACAD SCI USA, V106, P12682, DOI 10.1073/pnas.0904843106	33	3	3	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					367	377		10.1016/j.ajpath.2017.10.010			11	Pathology	Pathology	FT6HY	WOS:000423256300011	29331492	Bronze, Green Published			2019-10-28	
J	Iturra, PA; Rojas, DA; Perez, FJ; Mendez, A; Ponce, CA; Bonilla, P; Bustamante, R; Rodriguez, H; Beltran, CJ; Vargas, SL				Iturra, Pablo A.; Rojas, Diego A.; Perez, Francisco J.; Mendez, Andrea; Ponce, Carolina A.; Bonilla, Paula; Bustamante, Rebeca; Rodriguez, Hector; Beltran, Carol J.; Vargas, Sergio L.			Progression of Type 2 Helper T Cell-Type Inflammation and Airway Remodeling in a Rodent Model of Naturally Acquired Subclinical Primary Pneumocystis Infection	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RAT RESPIRATORY VIRUS; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; INFANT-DEATH-SYNDROME; CARINII-PNEUMONIA; IMMUNOCOMPETENT INFANTS; EPITHELIAL-CELLS; IMMUNE-RESPONSE; UNITED-STATES; MURINE MODEL	Subclinical primary Pneumocystis infection is the most common pulmonary infection in early infancy, making it important to determine whether it damages the lung. Pneumocystis peaks at 2 to 5 months of age, when respiratory morbidity coincidently increases. We have documented that Pneumocystis increases mucus production in infant Lungs, and animal models reveal lung lesions that warrant characterization. Herein, immunocompetent rats infected at birth with Pneumocystis by cohabitation, to resemble community acquired infection, underwent lung assessments at 45, 60, and 75 days of age. Lungs fixed by vascular perfusion to prevent collapse during necropsy were used for morphometry evaluations of mucus production, airway epithelial thickening, perivascular and peribronchiolar inflammation, and structural airway remodeling. Changes in these histologic features indicate lung disease. Selected immune markers were assessed in parallel using fresh-frozen Lung tissue from sibling rats of the same cages. Sequential activation of NF-kappa B and an increased Gata3/T-bet mRNA level ratio, consistent with a type 2 helper T-cell type inflammatory response, and subacute fibrosis were recognized. Therefore, documenting subclinical Pneumocystis infection induces Lung disease in the immunocompetent host. Taken together with the peak age of primary Pneumocystis infection, results warrant investigating the clinical impact of this often subclinical infection on the severity of respiratory diseases in early infancy. This model can also be used to assess the effects of airway insults, including coinfections by recognized respiratory pathogens.	[Iturra, Pablo A.; Rojas, Diego A.; Perez, Francisco J.; Mendez, Andrea; Ponce, Carolina A.; Bonilla, Paula; Bustamante, Rebeca; Vargas, Sergio L.] Univ Chile, Univ Hosp, Sch Med, Microbiol & Mycol Program, Santiago, Chile; [Rodriguez, Hector] Univ Chile, Univ Hosp, Sch Med, Anat & Dev Biol Program, Santiago, Chile; [Beltran, Carol J.] Univ Chile, Univ Hosp, Sch Med, Biomed Sci Inst, Santiago, Chile; [Beltran, Carol J.] Univ Chile, Univ Hosp, Sch Med, Gastroenterol Div, Santiago, Chile	Vargas, SL (reprint author), Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Microbiol & Micol, Independencia 1027, Santiago 8380453, Chile.	svargas@med.uchile.cl			Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT-Chile)Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [1100225, 1140412]; Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) under ERANet LAC grant [ELAC2014/HID-0254]; FONDECYT-Chile Postdoctoral Fellow grant [3140391]; Chilean Doctoral Scholarship Fund	Supported by the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT-Chile) grants 1100225 and 1140412 (S.L.V.), Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) under ERANet LAC grant ELAC2014/HID-0254 (S.L.V.), FONDECYT-Chile Postdoctoral Fellow grant 3140391 (D.A.R.), and the Chilean Doctoral Scholarship Fund (P.A.I., F.J.P., and A.M.).	Albers TM, 2009, VET PATHOL, V46, P992, DOI 10.1354/vp.08-VP-0330-C-FL; An CL, 2003, INFECT IMMUN, V71, P2065, DOI 10.1128/IAI.71.4.2065-2070.2003; [Anonymous], 2011, GUIDE CARE USE LAB A; Beard CB, 2005, J INFECT DIS, V192, P1815, DOI 10.1086/497381; Bramson RT, 2005, RADIOLOGY, V236, P22, DOI 10.1148/radiol.2361041278; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Cohn L, 1999, J IMMUNOL, V162, P6178; Damiani C, 2011, J CLIN MICROBIOL, V49, P2000, DOI 10.1128/JCM.00249-11; Eddens T, 2016, AM J RESP CRIT CARE, V194, P807, DOI 10.1164/rccm.201511-2205OC; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; Escolar JD, 1997, ANAT REC, V247, P501; Foster SB, 2008, J ALLERGY CLIN IMMUN, V122, P159, DOI 10.1016/j.jaci.2008.04.043; Garcia CA, 2000, REV MED CHILE, V128, P425; Heil M, 2008, RESP PHYSIOL NEUROBI, V163, P214, DOI 10.1016/j.resp.2008.05.013; Henderson KS, 2012, VET PATHOL, V49, P440, DOI 10.1177/0300985811432351; Heresi GP, 1997, CLIN INFECT DIS, V25, P739, DOI 10.1086/516938; Holtzman Michael J, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS287, DOI 10.1513/AnnalsATS.201402-056AW; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; HUGHES WT, 1991, ANNU REV MED, V42, P287; Icenhour CR, 2002, EUKARYOT CELL, V1, P414, DOI 10.1128/EC.1.3.414-419.2002; Inglis TJJ, 2007, J MED MICROBIOL, V56, P1419, DOI 10.1099/jmm.0.47179-0; Kling HM, 2016, J INFECT DIS, V213, P1586, DOI 10.1093/infdis/jiw032; Kling HM, 2014, JAIDS-J ACQ IMM DEF, V65, P381, DOI 10.1097/QAI.0000000000000007; Lai HY, 2010, CURR OPIN ALLERGY CL, V10, P67, DOI 10.1097/ACI.0b013e328334643a; Larsen HH, 2007, EMERG INFECT DIS, V13, P66, DOI 10.3201/eid1301.060315; Larsen HH, 2002, J CLIN MICROBIOL, V40, P2989, DOI 10.1128/JCM.40.8.2989-2993.2002; Le TTT, 2014, J IMMUNOL, V193, P3755, DOI 10.4049/jimmunol.1302470; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Lindheimer MD, 2014, NEW ENGL J MED, V371, P1076, DOI 10.1056/NEJMc1408436; Livingston RS, 2011, COMPARATIVE MED, V61, P45; Lugade AA, 2011, ADV EXP MED BIOL, V780, P125, DOI 10.1007/978-1-4419-5632-3_11; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; Meissner NN, 2005, J IMMUNOL, V174, P5462, DOI 10.4049/jimmunol.174.9.5462; Miller RF, 2002, J CLIN MICROBIOL, V40, P1555, DOI 10.1128/JCM.40.4.1555-1557.2002; Morris A, 2004, AM J RESP CRIT CARE, V170, P408, DOI 10.1164/rccm.200401-094OC; ODRISCOLL J, 1978, J CLIN PATHOL, V31, P700, DOI 10.1136/jcp.31.7.700-a; Perez Francisco J, 2014, Results Immunol, V4, P58, DOI 10.1016/j.rinim.2014.07.001; Ponce CA, 2014, MED MYCOL CASE REP, V5, P28, DOI 10.1016/j.mmcr.2014.06.001; Ponce CA, 2010, CLIN INFECT DIS, V50, P347, DOI 10.1086/649868; Rogers DF, 2003, PEDIATR PULM, V36, P178, DOI 10.1002/ppul.10322; ROTHS JB, 1993, J EXP MED, V177, P1193, DOI 10.1084/jem.177.4.1193; SHELDON WH, 1959, AMA J DIS CHILD, V97, P287, DOI 10.1001/archpedi.1959.02070010289005; Shipley TW, 2010, J INFECT DIS, V202, P302, DOI 10.1086/653485; Siegle JS, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-14; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Swain SD, 2012, AM J RESP CELL MOL, V46, P290, DOI 10.1165/rcmb.2011-0154OC; Swain SD, 2011, INFECT IMMUN, V79, P1905, DOI 10.1128/IAI.01273-10; Tatler Amanda L, 2012, Proc Am Thorac Soc, V9, P130, DOI 10.1513/pats.201201-003AW; Tesini BL, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00850-16; Vargas SL, 2007, PEDIATR INFECT DIS J, V26, P81, DOI 10.1097/01.inf.0000247071.40739.fd; Vargas SL, 2013, CLIN INFECT DIS, V56, P171, DOI 10.1093/cid/cis870; Vargas SL, 1999, CLIN INFECT DIS, V29, P1489, DOI 10.1086/313521; Vargas SL, 2005, J INFECT DIS, V191, P122, DOI 10.1086/426451; Vargas SL, 2003, EMERG INFECT DIS, V9, P605, DOI 10.3201/eid0905.020660; VARGAS SL, 1995, J INFECT DIS, V172, P506, DOI 10.1093/infdis/172.2.506; Vargas SL, 2001, CLIN INFECT DIS, V32, P855, DOI 10.1086/319340; Vera C, 2017, EUR J PEDIATR, V176, P1619, DOI 10.1007/s00431-017-3011-z; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; Vestereng VH, 2004, J INFECT DIS, V189, P1540, DOI 10.1086/382486; Vicencio AG, 2014, PEDIATR PULM, V49, P8, DOI 10.1002/ppul.22779; Wang J, 2005, INFECT IMMUN, V73, P2766, DOI 10.1128/IAI.73.5.2766-2777.2005; Wang J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001058; Wright TW, 1999, J CLIN INVEST, V104, P1307, DOI 10.1172/JCI6688	65	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					417	431		10.1016/j.ajpath.2017.10.019			15	Pathology	Pathology	FT6HY	WOS:000423256300015	29169991	Other Gold			2019-10-28	
J	Prystaz, K; Kaiser, K; Kovtun, A; Haffner-Luntzer, M; Fischer, V; Rapp, AE; Liedert, A; Strauss, G; Waetzig, GH; -John, SR; Ignatius, A				Prystaz, Katja; Kaiser, Kathrin; Kovtun, Anna; Haffner-Luntzer, Melanie; Fischer, Verena; Rapp, Anna E.; Liedert, Astrid; Strauss, Gudrun; Waetzig, Georg H.; -John, Stefan Rose; Ignatius, Anita			Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HUMAN OSTEOCLAST FORMATION; RECEPTOR ACTIVATOR; PROINFLAMMATORY CYTOKINES; T-CELLS; B-CELL; INTERLEUKIN-6; MACROPHAGES; EXPRESSION; MICE; LIGAND	Bone healing is a complex process with closely linked phases of inflammation, regeneration, and remodeling. IL-6 may crucially regulate this process; however, the underlying mechanisms are unclear. IL-6 signals are transmitted via the transmembrane glycoprotein 130 by two distinct mechanisms: classic signaling using the membrane-anchored IL-6 receptor and trans-signaling using its soluble form. Herein, we investigated the hypothesis that IL-6 classic and trans-signaling have different functions during bone healing. To investigate fracture healing, 12-week-old C57BL/6J mice underwent a femur osteotomy. To study the function of IL-6 during the inflammatory phase, either an anti IL-6 antibody, which inhibits IL-6 classic and trans-signaling, or soluble glycoprotein 130 fusion protein, which selectively blocks trans-signaling, was injected after 30 minutes and 48 hours. To analyze IL-6 effects in the repair phase, compounds were injected from day 7 onwards. Global IL-6 inhibition in the early phase after fracture reduced systemic inflammation, the recruitment of immune cells, and bone regeneration, resulting in delayed fracture healing. Global IL-6 inhibition during the repair phase disturbed bone formation and remodeling. In contrast, inhibition of IL-6 trans-signaling exerted minor effects on the immune response and did not influence bone repair, suggesting that the classic pathway accounts for most of the effects observed after global IL-6 inhibition. Our results reveal that IL-6 classic signaling, but not IL-6 trans-signaling, is essential for bone repair.	[Prystaz, Katja; Kaiser, Kathrin; Kovtun, Anna; Haffner-Luntzer, Melanie; Fischer, Verena; Rapp, Anna E.; Liedert, Astrid; Ignatius, Anita] Univ Med Ctr Ulm, Inst Orthoped Res & Biomechan, Helmiholtzstr 14, D-89081 Ulm, Germany; [Strauss, Gudrun] Univ Med Ctr Ulm, Trauma Res Ctr Ulm, Ulm, Germany; [Strauss, Gudrun] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Waetzig, Georg H.] CONARIS Res Inst AG, Kiel, Germany; [-John, Stefan Rose] Christian Albrechts Univ Kiel, Inst Biochem, Kiel, Germany	Ignatius, A (reprint author), Univ Med Ctr Ulm, Inst Orthoped Res & Biomechan, Helmiholtzstr 14, D-89081 Ulm, Germany.	anita.ignatius@uni-ulm.de	Vikman, Anna/F-1115-2017; Ignatius, Anita/M-6012-2013; Rapp, Anna/L-8807-2016; Haffner-Luntzer, Melanie/L-3562-2019; Rose-John, Stefan/A-7998-2010	Ignatius, Anita/0000-0002-4782-1979; Rapp, Anna/0000-0001-5122-765X; Haffner-Luntzer, Melanie/0000-0002-3333-2613; Rose-John, Stefan/0000-0002-7519-3279; Vikman, Anna/0000-0001-8531-9712	German Research FoundationGerman Research Foundation (DFG) [CRC1149, INST40/491-1]	Supported by the German Research Foundation in the context of the Collaborative Research Center (CRC) Danger response, disturbance factors, and regenerative potential after acute trauma grant CRC1149, INST40/491-1 (A.I.).	Ai-Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215; Aniszewska A, 2014, ACTA NEUROBIOL EXP, V74, P424; Axmann R, 2009, ARTHRITIS RHEUM-US, V60, P2747, DOI 10.1002/art.24781; Barkhausen T, 2011, CRIT CARE MED, V39, P1407, DOI 10.1097/CCM.0b013e318211ff56; Bastian OW, 2016, CLIN IMMUNOL, V164, P78, DOI 10.1016/j.clim.2016.02.001; Bhandari M, 2003, J ORTHOP TRAUMA, V17, P353, DOI 10.1097/00005131-200305000-00006; Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004; Bottcher JP, 2014, CELL REP, V8, P1318, DOI 10.1016/j.celrep.2014.07.008; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Braida D, 2004, BEHAV BRAIN RES, V153, P423, DOI 10.1016/j.bbr.2003.12.018; Chalaris A, 2007, BLOOD, V110, P1748, DOI 10.1182/blood-2007-01-067918; Cho TJ, 2007, CALCIFIED TISSUE INT, V80, P192, DOI 10.1007/s00223-006-0240-y; Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1; Colburn NT, 2009, ARTHRITIS RHEUM-US, V60, P1694, DOI 10.1002/art.24520; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007-1719; Edwards CJ, 2010, OSTEOPOROSIS INT, V21, P1287, DOI 10.1007/s00198-010-1192-7; Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164; El Khassawna T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00562; Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002; Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756-3282(98)00040-4; Garbers C, 2011, J BIOL CHEM, V286, P42959, DOI 10.1074/jbc.M111.295758; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Haffner-Luntzer M, 2016, BRIT J PHARMACOL, V173, P2237, DOI 10.1111/bph.13503; Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE-08-0568; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hoff P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030583; Hoge J, 2013, J IMMUNOL, V190, P703, DOI 10.4049/jimmunol.1201044; Karladani AH, 2001, ARCH ORTHOP TRAUM SU, V121, P325, DOI 10.1007/s004020000252; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Kovtun A, 2016, EUR CELLS MATER, V32, P152, DOI 10.22203/eCM.v032a10; Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756-3282(02)00915-8; Loi F, 2016, BONE, V86, P119, DOI [10.1016/j.bone.2016.02.0208756-3282, 10.1016/j.bone.2016.02.020]; Lokau J, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/1785021; Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; Marusic A, 2000, LAB INVEST, V80, P1761, DOI 10.1038/labinvest.3780186; Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039; Morieri ML, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/1396398; Oei L, 2015, CURR OSTEOPOROS REP, V13, P106, DOI 10.1007/s11914-015-0260-5; Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928; Pazos P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072339; Rabe B, 2008, BLOOD, V111, P1021, DOI 10.1182/blood-2007-07-102137; Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Recknagel S, 2013, J TRAUMA ACUTE CARE, V74, P531, DOI 10.1097/TA.0b013e318278956d; Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754; Rontgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148; Rose J, 2012, INT J BIOL SCI, V8, P1237, DOI DOI 10.7150/IJBS.4989; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; Sandberg OH, 2017, BONE, V101, P129, DOI 10.1016/j.bone.2017.04.004; Sander LE, 2010, J EXP MED, V207, P1453, DOI 10.1084/jem.20091474; Sawant KV, 2016, SCI REP-UK, V6, DOI 10.1038/srep33123; Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018; Schmidt-Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004; Schumacher N, 2015, J BIOL CHEM, V290, P26059, DOI 10.1074/jbc.M115.649509; Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003; Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513; Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735; Soehnlein O, 2009, BLOOD, V114, P4613, DOI 10.1182/blood-2009-06-221630; Sun GJ, 2017, APMIS, V125, P752, DOI 10.1111/apm.12706; Sun GJ, 2017, CLIN EXP PHARMACOL P, V44, P455, DOI 10.1111/1440-1681.12719; Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185; Waetzig GH, 2012, EXPERT OPIN THER TAR, V16, P225, DOI 10.1517/14728222.2012.660307; Wallace A, 2011, J ORTHOP RES, V29, P1437, DOI 10.1002/jor.21367; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328; Wolf J, 2016, J BIOL CHEM, V291, P16186, DOI 10.1074/jbc.M116.718551; Yang SF, 2015, APMIS, V123, P975, DOI 10.1111/apm.12439; Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022	71	16	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					474	490		10.1016/j.ajpath.2017.10.011			17	Pathology	Pathology	FT6HY	WOS:000423256300019	29146294	Other Gold			2019-10-28	
J	Lehti, S; Nguyen, SD; Belevich, I; Vihinen, H; Heikkila, HM; Soliymani, R; Kakela, R; Saksi, J; Jauhiainen, M; Grabowski, GA; Kummu, O; Horkko, S; Baumann, M; Lindsberg, PJ; Jokitato, E; Kovanen, PT; Oorni, K				Lehti, Satu; Nguyen, Su D.; Belevich, Ilya; Vihinen, Helena; Heikkila, Hanna M.; Soliymani, Rabah; Kakela, Reijo; Saksi, Jani; Jauhiainen, Matti; Grabowski, Gregory A.; Kummu, Outi; Horkko, Sohvi; Baumann, Marc; Lindsberg, Perttu J.; Jokitato, Eija; Kovanen, Petri T.; Oorni, Katariina			Extracellular Lipids Accumulate in Human Carotid Arteries as Distinct Three-Dimensional Structures and Have Proinflammatory Properties	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; NLRP3 INFLAMMASOME ACTIVATION; FOAM CELL-FORMATION; SECRETORY SPHINGOMYELINASE; CHOLESTEROL CRYSTALS; PROTEOGLYCAN-BINDING; ELECTRON-MICROSCOPY; HUMAN MONOCYTES; DEFICIENT MICE	Lipid accumulation is a key characteristic of advancing atherosclerotic lesions. Herein, we analyzed the ultrastructure of the accumulated Lipids in endarterectomized human carotid atherosclerotic plaques using three-dimensional (3D) electron microscopy, a method never used in this context before. 3D electron microscopy revealed intracellular lipid droplets and extracellular Lipoprotein particles. Most of the particles were aggregated, and some connected to needle-shaped or sheet-like cholesterol crystals. Proteomic analysis of isolated extracellular Lipoprotein particles revealed that apolipoprotein B is their main protein component, indicating their origin from low-density lipoprotein, intermediate-density Lipoprotein, very-Low-density lipoprotein, lipoprotein (a), or chylomicron remnants. The particles also contained small exchangeable apolipoproteins, complement components, and immunoglobulins. Lipidomic analysis revealed differences between plasma lipoproteins and the particles, thereby indicating involvement of lipolytic enzymes in their generation. Incubation of human monocyte-derived macrophages with the isolated extracellular lipoprotein particles or with plasma lipoproteins that had been Lipolytically modified in vitro induced intracellular Lipid accumulation and triggered inflammasome activation in them. Taken together, extracellular Lipids accumulate in human carotid plaques as distinct 3D structures that include aggregated and fused lipoprotein particles and cholesterol crystals. The particles originate from plasma lipoproteins, show signs of lipolytic modifications, and associate with cholesterol crystals. By inducing intracellular cholesterol accumulation (ie, foam cell formation) and inflammasome activation, the extracellular lipoprotein particles may actively enhance atherogenesis.	[Lehti, Satu; Nguyen, Su D.; Kovanen, Petri T.; Oorni, Katariina] Wihuri Res Inst, Atherosclerosis Res Lab, Haartmaninkatu 8, Helsinki 00290, Finland; [Belevich, Ilya; Vihinen, Helena; Jokitato, Eija] Univ Helsinki, Electron Microscopy Unit, Sch Med, Helsinki, Finland; [Heikkila, Hanna M.; Saksi, Jani; Lindsberg, Perttu J.] Univ Helsinki, Inst Biotechnol, Mol Neurol, Sch Med, Helsinki, Finland; [Soliymani, Rabah; Baumann, Marc] Univ Helsinki, Sch Med, Res Programs Unit, Clin Prote Core Facil, Helsinki, Finland; [Kakela, Reijo; Oorni, Katariina] Univ Helsinki, Sch Med, Med Biochem & Dev Biol, Helsinki, Finland; [Kakela, Reijo; Oorni, Katariina] Univ Helsinki, Helsinki Univ Lipid Unit, Dept Biosci, Helsinki, Finland; [Jauhiainen, Matti] Natl Inst Hlth & Welf, Helsinki, Finland; [Jauhiainen, Matti] Minerva Fdn, Inst Med Res, Helsinki, Finland; [Grabowski, Gregory A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Grabowski, Gregory A.] Kiniksa Pharmaceut Ltd, Wellesley, MA USA; [Kummu, Outi; Horkko, Sohvi] Univ Oulu, Res Unit Biomed, Med Microbiol & Immunol, Oulu, Finland; [Horkko, Sohvi] Univ Hosp Oulu, Med Res Ctr, Oulu, Finland; [Horkko, Sohvi] Univ Hosp Oulu, Nordlab Oulu, Oulu, Finland; [Horkko, Sohvi] Univ Oulu, Oulu, Finland; [Lindsberg, Perttu J.] Univ Helsinki, Clin Neurosci, Neurol, Helsinki, Finland; [Lindsberg, Perttu J.] Helsinki Univ Hosp, Helsinki, Finland	Oorni, K (reprint author), Wihuri Res Inst, Atherosclerosis Res Lab, Haartmaninkatu 8, Helsinki 00290, Finland.	kati.oorni@wri.fi	Jokitalo, Eija/C-8375-2009; Oorni, Katariina/G-2484-2011	Jokitalo, Eija/0000-0002-4159-6934; Oorni, Katariina/0000-0002-9525-0250; Vihinen, Helena/0000-0003-3862-9237; Lindsberg, Perttu/0000-0001-7690-811X; Belevich, Ilya/0000-0003-2190-4909	Academy of FinlandAcademy of Finland [265940]; Finnish Foundation for Cardiovascular Research; Helsinki University Hospital research funds [Erityisvaltionosuus (EVO)]; Biocenter Finland	Supported by the Academy of Finland grant 265940 (K.O.), the Finnish Foundation for Cardiovascular Research (S.L. and K.O.), Helsinki University Hospital research funds [Erityisvaltionosuus (EVO)] (H.M.H., J.S., and P.J.L.), and Biocenter Finland (I.B., H.V., and E.J.). The Wihuri Research Institute is maintained by the Jenny and Antti Wihuri Foundation.	Allahverdian S, 2012, CARDIOVASC RES, V95, P165, DOI 10.1093/cvr/cvs094; Asatryan L, 2005, J LIPID RES, V46, P115, DOI 10.1194/jlr.M400306-JLR200; Babelova A, 2009, J BIOL CHEM, V284, P24035, DOI 10.1074/jbc.M109.014266; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Belevich I, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002340; Beltrami-Moreira M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152474; BOCAN TMA, 1986, AM J PATHOL, V123, P413; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; Bostrom MA, 2007, ARTERIOSCL THROM VAS, V27, P600, DOI 10.1161/01.ATV.0000257133.60884.44; Camejo G, 2002, ATHEROSCLEROSIS SUPP, V3, P3, DOI 10.1016/S1567-5688(01)00005-8; CHAO FF, 1992, J BIOL CHEM, V267, P4992; CHAO FF, 1990, AM J PATHOL, V136, P169; Chapman MJ, 2011, EUR HEART J, V32, P1345, DOI 10.1093/eurheartj/ehr112; Dai JN, 2016, ATHEROSCLEROSIS, V247, P111, DOI 10.1016/j.atherosclerosis.2016.02.010; Dasu MR, 2011, AM J PHYSIOL-ENDOC M, V300, pE145, DOI 10.1152/ajpendo.00490.2010; Davidsson P, 2010, ARTERIOSCL THROM VAS, V30, P156, DOI 10.1161/ATVBAHA.108.179317; Deerinck T.J., 2010, MICROSCOPY, P6; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Edelstein C, 2001, J LIPID RES, V42, P1664; Estruch M, 2015, BBA-MOL CELL BIOL L, V1851, P1442, DOI 10.1016/j.bbalip.2015.08.009; FILIP DA, 1987, ATHEROSCLEROSIS, V67, P199, DOI 10.1016/0021-9150(87)90280-2; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; FOLCH J, 1957, J BIOL CHEM, V226, P497; Grosheva I, 2009, ARTERIOSCL THROM VAS, V29, P1615, DOI 10.1161/ATVBAHA.109.191882; Guarino AJ, 2004, BIOCHEMISTRY-US, V43, P1685, DOI 10.1021/bi035747r; Guarino AJ, 2006, CHEM PHYS LIPIDS, V142, P33, DOI 10.1016/j.chemphyslip.2006.02.020; GUYTON JR, 1989, AM J PATHOL, V134, P705; Haimi P, 2006, ANAL CHEM, V78, P8324, DOI 10.1021/ac061390w; Hakala JK, 2003, ARTERIOSCL THROM VAS, V23, P1430, DOI 10.1161/01.ATV.0000077207.49221.06; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; Kockx M, 2008, ARTERIOSCL THROM VAS, V28, P1060, DOI 10.1161/ATVBAHA.108.164350; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KONIKOFF FM, 1992, J CLIN INVEST, V90, P1155, DOI 10.1172/JCI115935; Kozarov EV, 2005, ARTERIOSCL THROM VAS, V25, pE17, DOI 10.1161/01.ATV.0000155018.67835.1a; Kremer A, 2015, J MICROSC-OXFORD, V259, P80, DOI 10.1111/jmi.12211; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Lehti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065810; Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; Mani V, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-6; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; Nielsen LB, 1996, ATHEROSCLEROSIS, V123, P1, DOI 10.1016/0021-9150(96)05802-9; Nielsen LB, 1997, ARTERIOSCL THROM VAS, V17, P905, DOI 10.1161/01.ATV.17.5.905; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 2005, ARTERIOSCL THROM VAS, V25, P1678, DOI 10.1161/01.ATV.0000168912.42941.60; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; Plihtari R, 2010, J LIPID RES, V51, P1801, DOI 10.1194/jlr.M003103; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; Rajamaki K, 2016, ARTERIOSCL THROM VAS, V36, P1937, DOI 10.1161/ATVBAHA.115.307312; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sato H, 2008, J BIOL CHEM, V283, P33483, DOI 10.1074/jbc.M804628200; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Scifo E, 2015, J PROTEOMICS, V123, P42, DOI 10.1016/j.jprot.2015.03.038; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Singh RK, 2016, J CELL SCI, V129, P1072, DOI 10.1242/jcs.181743; SMITH EB, 1967, J ATHEROSCLER RES, V7, P171, DOI 10.1016/S0368-1319(67)80079-6; SMITH EB, 1968, J ATHEROSCLER RES, V8, P399, DOI 10.1016/S0368-1319(68)80097-3; Sneck M, 2012, J LIPID RES, V53, P1832, DOI 10.1194/jlr.M023218; Stahlman M, 2008, J LIPID RES, V49, P481, DOI 10.1194/jlr.D700025-JLR200; Nguyen SD, 2012, J LIPID RES, V53, P2115, DOI 10.1194/jlr.M028118; Sun Y, 2014, MOL GENET METAB, V112, P229, DOI 10.1016/j.ymgme.2014.04.006; TAILLEUX A, 1993, J LIPID RES, V34, P719; Torzewski M, 2004, ARTERIOSCL THROM VAS, V24, P2130, DOI 10.1161/01.ATV.0000144016.85221.66; Tsuzaki M, 2003, J ORTHOP RES, V21, P256, DOI 10.1016/S0736-0266(02)00141-9; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; van der Worp HB, 2013, NEW ENGL J MED, V369, P2359, DOI 10.1056/NEJMc1312990; Wang J, 2014, BBA-MOL BASIS DIS, V1842, P2174, DOI 10.1016/j.bbadis.2014.07.026; Webb NR, 2003, ARTERIOSCL THROM VAS, V23, P263, DOI 10.1161/01.ATV.0000051701.90972.E5; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88	77	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					525	538		10.1016/j.ajpath.2017.09.019			14	Pathology	Pathology	FT6HY	WOS:000423256300023	29154769	Bronze			2019-10-28	
J	Mirkovic, J; McFarland, M; Garcia, E; Sholl, LM; Lindeman, N; MacConaill, L; Dong, F; Hirsch, M; Nucci, MR; Quick, CM; Crum, CP; McCluggage, WG; Howitt, BE				Mirkovic, Jelena; McFarland, Marie; Garcia, Elizabeth; Sholl, Lynette M.; Lindeman, Neal; MacConaill, Laura; Dong, Fei; Hirsch, Michelle; Nucci, Marisa R.; Quick, Charles M.; Crum, Christopher P.; McCluggage, W. Glenn; Howitt, Brooke E.			Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mesonephric-like adenocarcinoma; mesonephric adenocarcinoma; endometrioid adenocarcinoma; molecular; KRAS; PIK3CA	PROBABLE WOLFFIAN ORIGIN; UTERINE CERVIX; ADNEXAL TUMOR; ENDOMETRIOID CARCINOMA; GLANDULAR LESIONS; CORPUS; CANCER; EXPRESSION; BENIGN; PAX8	Mesonephric adenocarcinoma most commonly arises in the cervix and is presumed to be derived from normal or hyperplastic mesonephric remnants. It is characterized by recurrent KRAS mutations and lack of PIK3CA/PTEN alterations. Adenocarcinomas of the uterine corpus and ovary characterized by morphologic and immunophenotypic similarities to mesonephric adenocarcinoma have been reported. The pathogenesis of these tumors, which have been designated mesonephric-like adenocarcinomas is unknown, and it has been debated whether these represent mesonephric adenocarcinomas that arise in the endometrium/ovary or endometrioid adenocarcinomas that closely mimic mesonephric adenocarcinoma. The relationship at the molecular level between mesonephric adenocarcinomas and mesonephric-like adenocarcinomas is unknown. The aim of this study was to examine the molecular alterations in mesonephric-like adenocarcinomas to identify driver mutations and potential therapeutically targetable mutations, and to determine the relationship between mesonephric-like adenocarcinomas and mesonephric adenocarcinomas using targeted next-generation sequencing. Seven mesonephric-like adenocarcinomas (4 ovarian, 3 uterine corpus) underwent targeted next-generation sequencing to detect mutations, copy number variations and structural variants in exonic regions of 300 cancer genes, and 113 selected intronic regions across 35 genes. All 7 tumors (100%) harbored canonical activating KRAS mutations (4 G12D, 3 G12V). PIK3CA activating mutations were identified in 3 of 7 (43%) cases. There were no alterations in PTEN, ARID1A, or TP53 in any of the tumors. In copy number analysis, 5 of 7 (71%) tumors exhibited 1q gain, which was accompanied by 1p loss in 2 cases. In addition, 4 of 7 (57%) tumors had chromosome 10 gain, which was accompanied by gain of chromosome 12 in 3 cases. Mesonephric-like adenocarcinomas, similar to mesonephric adenocarcinomas, are characterized by recurrent KRAS mutations, gain of 1q, lack of PTEN mutations, and gains of chromosomes 10 and 12. PIK3CA mutations, which have not previously been identified in mesonephric adenocarcinoma, were found in 3 of 7 (43%) mesonephric-like adenocarcinomas in our study. Mesonephric-like adenocarcinomas exhibit strikingly similar molecular aberrations to mesonephric adenocarcinomas, but also frequently harbor PIK3CA mutations, demonstrating biological overlap with carcinomas of both mesonephric and Mullerian (endometrioid) differentiation. Given the previously documented association with endometriosis (ovarian neoplasms) and the prominent endometrial involvement (uterine corpus neoplasms), we believe these are best regarded as of Mullerian origin and representing adenocarcinomas which differentiate along mesonephric lines; as such, we propose the term mesonephric-like Mullerian adenocarcinoma.	[Mirkovic, Jelena] Sunnybrook Hlth Sci Ctr, Dept Pathol, Toronto, ON, Canada; [McFarland, Marie; McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Garcia, Elizabeth; Sholl, Lynette M.; Lindeman, Neal; MacConaill, Laura; Dong, Fei] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hirsch, Michelle; Nucci, Marisa R.; Crum, Christopher P.; Howitt, Brooke E.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA; [MacConaill, Laura] Dana Farber Canc Inst, Boston, MA 02115 USA; [Quick, Charles M.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	Howitt, BE (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	bhowitt@partners.org		Howitt, Brooke/0000-0002-0309-6680	Department of Pathology, Brigham and Women's Hospital	Supported by the Department of Pathology, Brigham and Women's Hospital (J.G. and C.P.C.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abo RP, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1211; Bague S, 2004, AM J SURG PATHOL, V28, P601, DOI 10.1097/00000478-200405000-00006; Bournet B, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.18; BUNTINE DW, 1979, PATHOLOGY, V11, P713, DOI 10.3109/00313027909059053; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; CLEMENT PB, 1995, AM J SURG PATHOL, V19, P1158, DOI 10.1097/00000478-199510000-00006; Cossu A, 2017, INT J GYNECOL PATHOL; DAYA D, 1992, INT J GYNECOL PATHOL, V11, P122, DOI 10.1097/00004347-199204000-00006; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Devouassoux-Shisheboran M, 1999, HUM PATHOL, V30, P856, DOI 10.1016/S0046-8177(99)90148-X; Fukunaga M, 2004, ADV ANAT PATHOL, V11, P269, DOI 10.1097/01.pap.0000138141.88763.6a; Garcia EP, 2017, ARCH PATHOL LAB MED, V141, P751, DOI 10.5858/arpa.2016-0527-OA; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Goyal A, 2016, INT J GYNECOL PATHOL, V35, P167, DOI 10.1097/PGP.0000000000000222; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Huang WB, 2010, PATHOL RES PRACT, V206, P180, DOI 10.1016/j.prp.2009.04.010; Kalyanasundaram K, 2010, INT J SURG PATHOL, V18, P138, DOI 10.1177/1066896908329585; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kim SS, 2016, INT J SURG PATHOL, V24, P153, DOI 10.1177/1066896915611489; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; McCluggage WG, 2003, HISTOPATHOLOGY, V43, P144, DOI 10.1046/j.1365-2559.2003.01684.x; McFarland M, 2016, HISTOPATHOLOGY, V68, P1013, DOI 10.1111/his.12895; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Modest DP, 2016, ANN ONCOL, V27, P1746, DOI 10.1093/annonc/mdw261; Ordi J, 2001, AM J SURG PATHOL, V25, P1540, DOI 10.1097/00000478-200112000-00011; Rabban JT, 2010, AM J SURG PATHOL, V34, P137, DOI 10.1097/PAS.0b013e3181c89c98; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Roma AA, 2014, INT J GYNECOL PATHOL, V33, P624, DOI 10.1097/PGP.0000000000000088; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; Tambouret R, 2003, AM J SURG PATHOL, V27, P1080, DOI 10.1097/00000478-200308000-00005; Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184; Wani Y, 2008, INT J GYNECOL PATHOL, V27, P346, DOI [10.1097/PGP.0b013e318166067f, 10.1097/PGP.0b013618166067f]; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wu HX, 2014, INT J CLIN EXP PATHO, V7, P7012; Yemelyanova A, 2014, INT J GYNECOL PATHOL, V33, P492, DOI 10.1097/PGP.0b013e3182a54afa; YOUNG RH, 1983, AM J SURG PATHOL, V7, P125, DOI 10.1097/00000478-198303000-00002	38	10	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					227	233		10.1097/PAS.0000000000000958			7	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300010	28984674				2019-10-28	
J	Wang, KY; Li, QH; Shi, RR; Yang, DD; Zou, WL; Mu, K				Wang, Kangyu; Li, Qianhua; Shi, Ranran; Yang, Dandan; Zou, Wenlu; Mu, Kun			Increased CD105 expression is associated with disease progression in phyllodes tumors - A report of a borderline phyllodes tumor with lung metastases and a study of 54 phyllodes tumors	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							MICROVESSEL DENSITY; BREAST; CANCER; THERAPY; CD34		[Wang, Kangyu; Li, Qianhua; Yang, Dandan; Zou, Wenlu; Mu, Kun] Shandong Univ, Sch Med, Dept Pathol, Wenhuaxilu 44, Jinan 250012, Shandong, Peoples R China; [Shi, Ranran] Shandong Univ, Shandong Prov Hosp, Dept Paediat, Jinan 250021, Shandong, Peoples R China	Mu, K (reprint author), Shandong Univ, Sch Med, Dept Pathol, Wenhuaxilu 44, Jinan 250012, Shandong, Peoples R China.	mukun@sdu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81572594]	This work was supported by the National Natural Science Foundation of China [grant number 81572594].	Bauman TM, 2016, HUM PATHOL, V57, P98, DOI 10.1016/j.humpath.2016.07.005; Belkacemi Y, 2008, INT J RADIAT ONCOL, V70, P492, DOI 10.1016/j.ijrobp.2007.06.059; Ben hassouna J, 2006, AM J SURG, V192, P141, DOI 10.1016/j.amjsurg.2006.04.007; Burki TK, 2015, LANCET ONCOL, V16, pE429, DOI [10.1016/S1470-2045(15)00359-9, 10.1016/S1470-2045(15)00202-8]; Jang JH, 2012, ANN SURG ONCOL, V19, P2612, DOI 10.1245/s10434-012-2307-5; Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391; Karim RZ, 2009, BREAST, V18, P165, DOI 10.1016/j.breast.2009.03.001; Kersting C, 2006, LAB INVEST, V86, P54, DOI 10.1038/labinvest.3700358; Lenhard MS, 2008, EUR J OBSTET GYN R B, V138, P217, DOI 10.1016/j.ejogrb.2007.08.002; Lin JJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3631; Macdonald OK, 2006, CANCER-AM CANCER SOC, V107, P2127, DOI 10.1002/cncr.22228; Maity PP, 2013, MICRON, V48, P34, DOI 10.1016/j.micron.2013.02.004; Martinez LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121421; Mitus JW, 2015, WORLD J SURG; Miyata Y, 2015, PROSTATE, V75, P84, DOI 10.1002/pros.22894; Nie XM, 2011, CHINESE MED J-PEKING, V124, P4376, DOI 10.3760/cma.j.issn.0366-6999.2011.24.046; Noronha Y, 2011, INT J SURG PATHOL, V19, P152, DOI 10.1177/1066896910382009; El Ochi MR, 2016, BMC CLIN PATHOL, V16, DOI 10.1186/s12907-016-0027-7; Rowe JJ, 2015, J CLIN NEUROSCI, V22, P226, DOI 10.1016/j.jocn.2014.09.004; Suzuki-Uematsu S, 2010, BREAST CANCER-TOKYO, V17, P218, DOI 10.1007/s12282-009-0099-7; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; Tse GMK, 2004, HUM PATHOL, V35, P1053, DOI 10.1016/j.humpath.2004.01.023; Vayrynen SA, 2016, BRIT J CANCER, V114, P1334, DOI 10.1038/bjc.2016.128; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126	24	2	2	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						4	9		10.1016/j.anndiagpath.2017.04.002			6	Pathology	Pathology	FV6YY	WOS:000424729500002	29414396				2019-10-28	
J	Kechik, KA; Siar, CH				Kechik, Khamisah Awang; Siar, Chong Huat			Spatial distribution of osteopontin, CD44v6 and podoplanin in the lining epithelium of odontogenic keratocyst, and their biological relevance	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Odontogenic keratocyst; Dentigerous cyst; Radicular cyst; Osteopontin; CD44v6; Podoplanin	NERVOUS-SYSTEM LYMPHOMA; DENTIGEROUS CYSTS; EXPRESSION; TUMORS; LESIONS; CELLS	Background and aims: The odontogenic keratocyst (OKC) remains the most challenging jaw cyst to treat because of its locally-aggressive behaviour and high recurrence potential. Emerging evidence suggests that osteopontin, its receptors CD44v6 and integrin alpha(v), and podoplanin, have a role in the local invasiveness of this cyst. However the spatial distribution characteristics of these pro-invasive markers in the lining epithelium of OKC, and their association with the clinicopathologic parameters of OKC are largely unexplored. This study sought to address these issues in comparison with dentigerous cysts (DCs) and radicular cysts (RCs) and to evaluate their biological relevance. Methods: A sample consisting of 20 OKC cases, 10 DCs and 10 RCs was subjected to immunohistochemical staining for osteopontin, CD44v6 and integrin alpha(v), and podoplanin, and semiquantitative analysis was performed. Results: All factors (except integrin alpha(v)) were detected heterogeneously in the constitutive layers of the lining epithelium in all three cyst types. Key observations were significant upregulation of CD44v6 and podoplanin in OKC compared to DCs and RCs, suggesting that these protein molecules may play crucial roles in promoting local invasiveness in OKC (P < 0.05). Osteopontin underexpression and distribution patterns were indistinctive among all three cysts indicating its limited role as pro-invasive factor. Clinical parameters showed no significant correlations with all protein factors investigated. Conclusions: Present findings suggest that an osteopontin(low) CD44v6(high) and podoplanin(high) immunoprofile most probably represent epithelial signatures of OKC and are markers of local invasiveness in this cyst.	[Kechik, Khamisah Awang] Hosp Raja Permaisuri Bainun, Dent Specialist Clin, Jalan Raja Ashman, Ipoh 30450, Perak, Malaysia; [Siar, Chong Huat] Univ Malaya, Fac Dent, Dept Oral & Maxillofacial Clin Sci, Kuala Lumpur 50603, Malaysia	Kechik, KA (reprint author), Hosp Raja Permaisuri Bainun, Jalan Raja Ashman, Ipoh 30450, Perak, Malaysia.	dr.khamisah@moh.gov.my			University of Malaya Postgraduate Research FundUniversiti Malaya [P0109/2009C]; Ministry of Higher Education Malaysia Fundamental Research Grant [FP032-2015A]	This work was supported by the University of Malaya Postgraduate Research Fund [Grant No. P0109/2009C]; and the Ministry of Higher Education Malaysia Fundamental Research Grant [No. FP032-2015A].	Alaeddini M, 2009, ORAL DIS, V15, P422, DOI 10.1111/j.1601-0825.2009.01566.x; Alaeddini M, 2017, J ORAL PATHOL MED, V46, P76, DOI 10.1111/jop.12475; Astarita JL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00283; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Caetano AD, 2013, ARCH ORAL BIOL, V58, P408, DOI 10.1016/j.archoralbio.2012.06.002; de Moraes M, 2011, ARCH ORAL BIOL, V56, P1256, DOI 10.1016/j.archoralbio.2011.05.009; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; HORTON MA, 1995, ANN NY ACAD SCI, V760, P190, DOI 10.1111/j.1749-6632.1995.tb44630.x; Inoue M, 2011, IMMUNOL RES, V49, P160, DOI 10.1007/s12026-010-8179-5; Junaid A, 2007, AM J PHYSIOL-CELL PH, V292, pC919, DOI 10.1152/ajpcell.00477.2006; Martin-Villar E, 2010, MOL BIOL CELL, V21, P4387, DOI 10.1091/mbc.E10-06-0489; Masloub SM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-44; Okamoto E, 2010, J ORAL PATHOL MED, V39, P110, DOI 10.1111/j.1600-0714.2009.00851.x; OKU Y, 2008, ORAL ONCOL, P251; Oliveira DT, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-150; Philipsen HP, 2005, WHO CLASSIFICATION T, P306; Salehinejad J, 2012, PATHOL RES PRACT, V208, P410, DOI 10.1016/j.prp.2012.04.005; Speight PM, 2017, WHO CLASSIFICATION H, P234; Stoll C, 2005, J ORAL PATHOL MED, V34, P558, DOI 10.1111/j.1600-0714.2005.00352.x; Tjioe KC, 2012, ORAL DIS, V18, P673, DOI 10.1111/j.1601-0825.2012.01924.x; Tsuneki M, 2012, PATHOL RES PRACT, V208, P140, DOI 10.1016/j.prp.2011.12.016; Tun HW, 2008, BLOOD, V111, P3200, DOI 10.1182/blood-2007-10-119099; Wang YP, 2009, J FORMOS MED ASSOC, V108, P286, DOI 10.1016/S0929-6646(09)60068-1; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Yuan J, 2013, HUM PATHOL, V44, P606, DOI 10.1016/j.humpath.2012.07.007; Zhang XM, 2014, ONCOL LETT, V7, P627, DOI 10.3892/ol.2013.1764; Zlobec I, 2009, HISTOPATHOLOGY, V55, P564, DOI 10.1111/j.1365-2559.2009.03421.x; Zohar R, 1997, J CELL PHYSIOL, V170, P88; Zustin J, 2010, J ORAL PATHOL MED, V39, P115, DOI 10.1111/j.1600-0714.2009.00853.x	30	0	0	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						17	22		10.1016/j.anndiagpath.2017.08.002			6	Pathology	Pathology	FV6YY	WOS:000424729500004	29414392				2019-10-28	
J	Li, Z; Tang, YH; Xing, WJ; Dong, W; Wang, ZC				Li, Zheng; Tang, Yonghua; Xing, Wujun; Dong, Wei; Wang, Zhichou			LncRNA, CRNDE promotes osteosarcoma cell proliferation, invasion and migration by regulating Notch1 signaling and epithelial-mesenchymal transition	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Osteosarcoma; CRNDE; Cell proliferation; Invasion and migration; Notch1 signaling; EMT	LONG-NONCODING RNA; NEGATIVE PROGNOSTIC-FACTOR; EXPRESSION; CANCER; TUMORIGENESIS; PATHWAY; GROWTH; GLIOMA	Osteosarcoma is the most common bone malignancy in adolescence. Recently, the long non-coding RNAs (IncRNAs) were reported to play important roles in osteosarcoma progression. The present study examined the potential role of the IncRNA, Colorectal Neoplasia Differentially Expressed (CRNDE) and molecular mechanisms underlying osteosarcoma progression. In the present study, we identified that CRNDE was up-regulated in osteosarcoma tissues and cell lines, and CRNDE expression level was significantly higher in osteosarcoma tissues from patients with advanced stage and metastasis. Overexpression of CRNDE promoted cell growth, cell proliferation, cell invasion and migration, and increased cell population at S phase with a decreased cell population at Go/Gi phase in MG-63 cells. Knock-down of CRNDE suppressed cell growth, cell proliferation, cell invasion and migration, and decreased cell population at S phase with an increased cell population at Go/GL phase in U2OS cells. Overexpression of CRNDE was found to enhance the activity of Notchl signaling and promote epithelial-mesenchymal transition (EMT) in MG-63 cells, while knock-down of CRNDE exerted the opposite effects in U2OS cells. The in vivo results showed that knock-down of CRNDE suppressed the tumor growth in the nude mice inoculated with osteosarcoma cells, and knock-down of CRNDE also suppressed the mRNA expression of Notchl, JAG1, N-cadherin, vimentin, and increased the mRNA expression of E-cadherin in the tumor tissues. Collectively, our results indicated that CRNDE functioned as an oncogene in osteosarcoma cell lines, and CRNDE may exert its oncogenic role via regulating Notchl signaling and EMT in osteosarcoma.	[Li, Zheng; Xing, Wujun; Dong, Wei] Xian Med Univ, Affiliated Hosp 1, Dept Emergency, Xian, Shaanxi, Peoples R China; [Tang, Yonghua] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, Xian, Shaanxi, Peoples R China; [Wang, Zhichou] Xian Honghui Hosp, Dept Orthopaed Oncol, Xian 710054, Shaanxi, Peoples R China	Wang, ZC (reprint author), Xian Honghui Hosp, Dept Orthopaed Oncol, Xian 710054, Shaanxi, Peoples R China.	wzcliangjian@163.com			Research Program of the First Affiliated Hospital of Xi'an Medical University [XYFY14-31]	This study was supported by the Research Program of the First Affiliated Hospital of Xi'an Medical University (Grant No. XYFY14-31).	Acharya S., 2017, REV RNA, V8; Ali J, 2017, ORAL ONCOL, V70, P23, DOI 10.1016/j.oraloncology.2017.05.004; Cai LJ, 2017, J CELL MOL MED, V21, P2654, DOI 10.1111/jcmm.12944; Cao JQ, 2017, INT J ONCOL, V51, P1115, DOI 10.3892/ijo.2017.4110; Chen RL, 2017, ONCOTARGET, V8, P20462, DOI 10.18632/oncotarget.14726; Chen ZL, 2016, AM J CANCER RES, V6, P2299; Cheng G, 2015, ONCOL REP, V34, P987, DOI 10.3892/or.2015.4053; Davis LE, 2017, CANCER-AM CANCER SOC, V123, P3434, DOI 10.1002/cncr.30757; Dong YR, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0149-x; Esposti DD, 2016, ONCOTARGET, V7, P31862, DOI 10.18632/oncotarget.7364; Fedele M, 2017, CANCERS, V9, DOI 10.3390/cancers9100134; Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081; Hu CE, 2017, CELL PHYSIOL BIOCHEM, V42, P13, DOI 10.1159/000477107; Huan JL, 2017, AM J TRANSL RES, V9, P1977; Jing SY, 2016, EUR REV MED PHARMACO, V20, P3992; Lee HJ, 2015, BMB REP, V48, P431, DOI 10.5483/BMBRep.2015.48.8.107; Li L, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1039-6; Li YG, 2012, FEBS J, V279, P2247, DOI 10.1111/j.1742-4658.2012.08607.x; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Liu P, 2016, ONCOL LETT, V11, P1367, DOI 10.3892/ol.2015.4067; Liu T, 2016, ONCOTARGETS THER, V9, P1437, DOI 10.2147/OTT.S98268; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Monfort A, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0368; Mu XD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00143; Omer N, 2017, EUR J CANCER, V75, P98, DOI 10.1016/j.ejca.2017.01.005; Previs RA, 2015, CLIN CANCER RES, V21, P955, DOI 10.1158/1078-0432.CCR-14-0809; Sehic A, 2017, GENE, V596, P9, DOI 10.1016/j.gene.2016.10.009; Shen S, 2016, ONCOTARGET, V7, P72833, DOI 10.18632/oncotarget.12023; Szafron LM, 2015, ONCOTARGET, V6, P43897, DOI 10.18632/oncotarget.6016; Taran SJ, 2017, INDIAN J MED PAEDIAT, V38, P33, DOI 10.4103/0971-5851.203513; Wang GJ, 2017, EVID-BASED COMPL ALT, DOI 10.1155/2017/4212534; Wang GJ, 2017, AM J CANCER RES, V7, P1577; Wang SG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06353-2; Wang YL, 2015, CANCER LETT, V367, P122, DOI 10.1016/j.canlet.2015.03.027; Yamamura S, 2017, CELL MOL LIFE SCI; Yang FY, 2017, ONCOL LETT, V14, P2757, DOI 10.3892/ol.2017.6563; Yu B, 2017, ONCOTARGET, V8, P83745, DOI 10.18632/oncotarget.19407	37	25	26	7	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					19	25		10.1016/j.yexmp.2017.12.002			7	Pathology	Pathology	FV8SS	WOS:000424857700004	29246789				2019-10-28	
J	Larrieta-Carrasco, E; Flores, YN; Macias-Kauffer, LR; Ramirez-Palacios, P; Quiterio, M; Ramirez-Salazar, EG; Leon-Mimila, P; Rivera-Paredez, B; Cabrera-Alvarez, G; Canizales-Quinteros, S; Zhang, ZF; Lopez-Perez, TV; Salmeron, J; Velazquez-Cruz, R				Larrieta-Carrasco, Elena; Flores, Yvonne N.; Macias-Kauffer, Luis R.; Ramirez-Palacios, Paula; Quiterio, Manuel; Ramirez-Salazar, Eric G.; Leon-Mimila, Paola; Rivera-Paredez, Berenice; Cabrera-Alvarez, Guillermo; Canizales-Quinteros, Samuel; Zhang, Zuo-Feng; Lopez-Perez, Tania V.; Salmeron, Jorge; Velazquez-Cruz, Rafael			Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Mexican adults; Polymorphisms; Polygenic risk score	FATTY LIVER-DISEASE; GENOME-WIDE ASSOCIATION; NONALCOHOLIC STEATOHEPATITIS; MITOCHONDRIAL ABNORMALITIES; ALANINE AMINOTRANSFERASE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; COMMON VARIANTS; FUNCTION TESTS	Non-alcoholic fatty liver disease (NAFLD) is the accumulation of extra fat in liver cells not caused by alcohol. Elevated transaminase levels are common indicators of liver disease, including NAFLD. Previously, we demonstrated that PNPLA3 (rs738409), LYPLALI (rs12137855), PPPIR3B (rs4240624), and GCKR (rs780094) are associated with elevated transaminase levels in overweight/obese Mexican adults. We investigated the association between 288 SNPs identified in genome-wide association studies and risk of elevated transaminase levels in an admixed Mexican-Mestizo sample of 178 cases of NAFLD and 454 healthy controls. The rs2896019, rs12483959, and rs3810622 SNPs in PNPLA3 and rs1227756 in COL13A1 were associated with elevated alanine aminotransferase (ALT, >= 40 IU/L). A polygenic risk score (PRS) based on six SNPs in the ADIPOQ, COL13A1, PNPLA3, and SAMM50 genes was also associated with elevated ALT. Individuals carrying 9-12 risk alleles had 65.8% and 48.5% higher ALT and aspartate aminotransferase (AST) levels, respectively, than those with 1-4 risk alleles. The PRS showed the greatest risk of elevated ALT levels, with a higher level of significance than the individual variants. Our findings suggest a significant association between variants in COL13A1, ADIPOQ SAMM50, and PNPLA3, and risk of NAFLD/elevated transaminase levels in Mexican adults with an admixed ancestry. This is the first study to examine high-density single nucleotide screening for genetic variations in a Mexican-Mestizo population. The extent of the effect of these variations on the development and progression of NAFLD in Latino populations requires further analysis.	[Larrieta-Carrasco, Elena] INCMNSZ, Dept Gastroenterol, Mexico City, DF, Mexico; [Flores, Yvonne N.; Ramirez-Palacios, Paula; Rivera-Paredez, Berenice; Salmeron, Jorge] IMSS, Unidad Invest Epidemiol & Serv Salud, Blvd Benito Juarez 31 Cot Ctr, Cuernavaca, Morelos, Mexico; [Flores, Yvonne N.] UCLA, Kaiser Permanente Ctr Hlth Equ, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA; [Flores, Yvonne N.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA; [Macias-Kauffer, Luis R.; Leon-Mimila, Paola; Canizales-Quinteros, Samuel] Univ Nacl Autonoma Mexico, Fac Quim, Inst Nacl Med Genom INMEGEN, Unidad Genom Poblac Aplicada Salud, Mexico City, DF, Mexico; [Quiterio, Manuel; Salmeron, Jorge] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca, Morelos, Mexico; [Ramirez-Salazar, Eric G.] Inst Nacl Med Genom INMEGEN, Consejo Nacl Ciencia & Tecnol CONACYT, Lab Genom Metab Oseo, Mexico City, DF, Mexico; [Cabrera-Alvarez, Guillermo] IMSS Hosp Gen Reg UMF, Clin Higado, 1 Av Plan Ayala S-N, Cuernavaca, Morelos, Mexico; [Zhang, Zuo-Feng] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; [Lopez-Perez, Tania V.; Velazquez-Cruz, Rafael] Inst Nacl Med Genom INMEGEN, Lab Genom Metab Oseo, Mexico City, DF, Mexico	Velazquez-Cruz, R (reprint author), Inst Nacl Med Genom INMEGEN, Lab Genom Metab Oseo, Perifer 4809, Col Arenal Tepepan 14610, Delegacion Tlal, Mexico.	rvelazquez@inmegen.gob.mx	Ramirez-Salazar, Eric G./P-6580-2018	Ramirez-Salazar, Eric G./0000-0002-0767-9357; Macias, Luis/0000-0002-3080-2835; Ramirez-Palacios, Paula/0000-0002-2586-4396; Flores, Yvonne N./0000-0002-0601-357X; Zhang, Zuo-Feng/0000-0002-4669-3995; Leon, Paola/0000-0001-6334-1492; Salmeron, Jorge/0000-0002-5113-299X	Instituto Nacional de Medicina Genomica (INMEGEN) grant [119-11/2012/I]; Consejo Nacional de Ciencia y Tecnologia (CONACyT)Consejo Nacional de Ciencia y Tecnologia (CONACyT) [26267M, SALUD-2011-01-161930]; Instituto Mexicano del Seguro Social (IMSS) grant [FIS/IMSS/PROT/G12/1117]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5K07CA197179]; Consejo Nacional de Ciencia y Tecnologia (CONACYT) grant [CB-2013-01-221628]	This research was supported by funding from the Instituto Nacional de Medicina Genomica (INMEGEN) grant #119-11/2012/I, the Consejo Nacional de Ciencia y Tecnologia (CONACyT) grants #26267M and SALUD-2011-01-161930, and the Instituto Mexicano del Seguro Social (IMSS) grant FIS/IMSS/PROT/G12/1117. Dr. Flores was supported by NIH/NCI 5K07CA197179. The authors express their gratitude to the Mexican Health Worker Cohort Study participants, their families, and the IMSS clinicians and staff. We also acknowledge the services provided by the Microarray Core Facility at the INMEGEN (MSc. Raul Mojica Espinosa). Tania V. Lopez-Perez was supported by a Postdoctoral Fellow from the Consejo Nacional de Ciencia y Tecnologia (CONACYT) grant #CB-2013-01-221628.	Bathum L, 2001, CLIN CHEM, V47, P81; Botros Mona, 2013, Clin Biochem Rev, V34, P117; Caldwell SH, 1999, J HEPATOL, V31, P430, DOI 10.1016/S0168-8278(99)80033-6; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Chalasani N, 2010, GASTROENTEROLOGY, V139, P1567, DOI 10.1053/j.gastro.2010.07.057; Chambers JC, 2011, NAT GENET, V43, P1131, DOI 10.1038/ng.970; Chen L., 2015, HEPAT MON, V15; Clarke GM, 2011, NAT PROTOC, V6, P121, DOI 10.1038/nprot.2010.182; de Koning HD, 2012, BRIT J DERMATOL, V166, P1245, DOI 10.1111/j.1365-2133.2012.10885.x; Denova-Gutierrez E, 2016, SALUD PUBLICA MEXICO, V58, P708, DOI 10.21149/spm.v58i6.8299; Denova-Gutierrez E, 2011, J NUTR, V141, P921, DOI 10.3945/jn.110.132332; Dudbridge F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003348; Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013; Fazel Y, 2016, METABOLISM, V65, P1017, DOI 10.1016/j.metabol.2016.01.012; Flores YN, 2016, MOL BIOL REP, V43, P1359, DOI 10.1007/s11033-016-4058-z; Grove JI, 2016, ANN HEPATOL, V15, P277, DOI 10.5604/16652681.1193726; Heid IM, 2006, DIABETES, V55, P375, DOI 10.2337/diabetes.55.02.06.db05-0747; Hivert MF, 2008, DIABETES, V57, P3353, DOI 10.2337/db08-0700; Hotta K, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-172; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Jadaho SB, 2004, HEPATOLOGY, V39, P1297, DOI 10.1002/hep.20182; Jiles Ruth, 2005, Morbidity and Mortality Weekly Report, V54, P1; Johansson LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005327; Kang KS, 2013, PEDIATR GASTROENTERO, V16, P225, DOI 10.5223/pghn.2013.16.4.225; Kanth VVR, 2014, WORLD J HEPATOL, V6, P435, DOI 10.4254/wjh.v6.i6.435; Kechagias S, 2008, GUT, V57, P649, DOI 10.1136/gut.2007.131797; Kitamoto T, 2013, HUM GENET, V132, P783, DOI 10.1007/s00439-013-1294-3; Kollerits B, 2010, J MED GENET, V47, P116, DOI 10.1136/jmg.2009.066597; Kosoy R, 2009, HUM MUTAT, V30, P69, DOI 10.1002/humu.20822; Kotronen A, 2009, DIABETOLOGIA, V52, P1056, DOI 10.1007/s00125-009-1285-z; Krawczyk M, 2017, J LIPID RES, V58, P247, DOI 10.1194/jlr.P067454; Larrieta-Carrasco E, 2014, MOL BIOL REP, V41, P4705, DOI 10.1007/s11033-014-3341-0; Larrieta-Carrasco E, 2013, GENE, V520, P185, DOI 10.1016/j.gene.2013.03.038; Leon-Mimila P, 2015, EXP MOL PATHOL, V98, P178, DOI 10.1016/j.yexmp.2015.01.012; Li L., 2012, CLIN INVESTIG MED, V35; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Ma ZA, 2012, EXP DIABETES RES, DOI 10.1155/2012/703538; Macaluso FS, 2015, WORLD J GASTROENTERO, V21, P11088, DOI 10.3748/wjg.v21.i39.11088; Menzaghi C, 2007, DIABETES, V56, P1198, DOI 10.2337/db06-0506; Morales LS, 2014, SALUD PUBLICA MEXICO, V56, P197; Nalbantoglu I, 2014, WORLD J GASTROENTERO, V20, P9026, DOI 10.3748/wjg.v20.i27.9026; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rahmioglu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004435; Rector RS, 2010, J HEPATOL, V52, P727, DOI 10.1016/j.jhep.2009.11.030; RHOADS DB, 1994, HEPATOLOGY, V19, P540; Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Secretaria de Economia, 2014, PROGR NAC PROT DER C; Shang XR, 2015, J PEDIATR GASTR NUTR, V60, P669, DOI 10.1097/MPG.0000000000000662; Song G., 2016, ASS PATATIN PHOSPHOL, V33; Sookoian S, 2016, AM J CLIN NUTR, V103, P422, DOI 10.3945/ajcn.115.118695; Sookoian S, 2012, WORLD J GASTROENTERO, V18, P3775, DOI 10.3748/wjg.v18.i29.3775; Sookoian S, 2011, HEPATOLOGY, V53, P1883, DOI 10.1002/hep.24283; Speliotes EK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001324; Tatsukawa H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45049; Than N. N., 2015, ATHEROSCLEROSIS; Thapa BR, 2007, INDIAN J PEDIATR, V74, P663, DOI 10.1007/s12098-007-0118-7; Tuomisto A, 2008, CANCER RES, V68, P10324, DOI 10.1158/0008-5472.CAN-08-2582; Vazquez-Chantada M, 2013, HEPATOLOGY, V57, P505, DOI 10.1002/hep.26052; Wiegand J, 2007, Internist (Berl), V48, P154, DOI 10.1007/s00108-006-1796-3; World Health Organization, 2000, WHO TECH REP SER; Zain SM, 2012, HUM GENET, V131, P1145, DOI 10.1007/s00439-012-1141-y	64	7	7	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					50	58		10.1016/j.yexmp.2018.01.001			9	Pathology	Pathology	FV8SS	WOS:000424857700009	29307798	Green Accepted			2019-10-28	
J	Buettner, J; Joehrens, K; Klauschen, F; Hummel, M; Lenze, D; Saeger, W; Lehmann, A				Buettner, Juliane; Joehrens, Korinna; Klauschen, Frederick; Hummel, Michael; Lenze, Dido; Saeger, Wolfgang; Lehmann, Annika			Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Colorectal cancer; KRAS; Heterogeneity; Morphology; Sequencing	INTRA-TUMORAL HETEROGENEITY; ANTI-EGFR THERAPY; SIGNET-RING CELL; ACQUIRED-RESISTANCE; MOLECULAR-FEATURES; KRAS MUTATIONS; TARGETED THERAPIES; PIK3CA MUTATIONS; DRUG-RESISTANCE; EVOLUTION	Anti-EGFR-targeted therapy is used to treat metastatic colorectal cancers with RAS wild-type. However, resistance to targeted therapy is often observed and can be primary or acquired. One reason for primary resistance is the presence of mutations that are undetected due to genetic heterogeneity, which can be expressed by differences present in primary tumor and distant metastasis or recurrence or by an intratumoral heterogeneity (presence of different subclones in the investigated tumor sample). The aim of our study was to investigate if morphological heterogeneity can be an indicator of intratumoral heterogeneity. We analysed 13 samples with homogeneous and six samples with heterogeneous morphology with NGS. We were able to demonstrate that intratumoral genetic heterogeneity is present in all studied tumor samples, independent of homogeneous or heterogeneous morphology. Moreover, one sample of our cohort with morphological and genetic heterogeneity had a genetic wild-type profile in one tumor component. Therefore, we recommend to include each morphologically identifiable tumor component in the mutational analysis to not overlook resistance-inducing or potentially targetable mutations.	[Buettner, Juliane; Joehrens, Korinna; Klauschen, Frederick; Hummel, Michael; Lenze, Dido; Lehmann, Annika] Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany; [Buettner, Juliane] Provitro AG, Berlin, Germany; [Saeger, Wolfgang] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany	Buettner, J (reprint author), Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany.	juliane.buettner-patho@charite.de					Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Amaro A, 2016, CANCER METAST REV, V35, P63, DOI 10.1007/s10555-016-9606-4; Artale S, 2008, J CLIN ONCOL, V26, P4217, DOI 10.1200/JCO.2008.18.7286; Baisse B, 2001, INT J CANCER, V93, P346, DOI 10.1002/ijc.1343; Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446; Bando H, 2012, JPN J CLIN ONCOL, V42, P1146, DOI 10.1093/jjco/hys160; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bosmuller H, 2011, PATHOL RES PRACT, V207, P399, DOI 10.1016/j.prp.2011.03.004; Bozic I, 2014, P NATL ACAD SCI USA, V111, P15964, DOI 10.1073/pnas.1412075111; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Braxton DR, 2016, INT J CANCER, V139, P1546, DOI 10.1002/ijc.30196; Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Chen GL, 2016, BIOMED RES INT, DOI 10.1155/2016/9850690; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Corless CL, 2014, MODERN PATHOL, V27, pS1, DOI 10.1038/modpathol.2013.173; Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; De Smedt L, 2015, BRIT J CANCER, V113, P500, DOI 10.1038/bjc.2015.213; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Fearon E R, 1991, Princess Takamatsu Symp, V22, P37; Freeman DJ, 2008, CLIN COLORECTAL CANC, V7, P184, DOI 10.3816/CCC.2008.n.024; Graham DM, 2016, CURR COLORECT CANC R, V12, P141, DOI 10.1007/s11888-016-0312-y; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86; Inamura K, 2015, ANN SURG ONCOL, V22, P1226, DOI 10.1245/s10434-014-4159-7; Kang H, 2015, J PATHOL, V237, P355, DOI 10.1002/path.4581; Losi L, 2005, CARCINOGENESIS, V26, P916, DOI 10.1093/carcin/bgi044; Mancuso A, 2010, J CLIN ONCOL, V28, pE756, DOI 10.1200/JCO.2010.30.5011; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; McBride M, 2015, MOL ASPECTS MED, V45, P3, DOI 10.1016/j.mam.2015.05.001; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137; Muller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Normanno N, 2015, ANN ONCOL, V26, P1710, DOI 10.1093/annonc/mdv176; Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482; Parsons BL, 2013, DISCOV MED, V15, P259; Richman SD, 2011, ANAL CELL PATHOL, V34, P61, DOI 10.3233/ACP-2011-0005; Rosty C, 2013, MODERN PATHOL, V26, P825, DOI 10.1038/modpathol.2012.240; Rybinski B, 2016, ONCOTARGET, V7, P72322, DOI 10.18632/oncotarget.11875; Siravegna G, 2015, NAT MED, V21, P827, DOI 10.1038/nm0715-827b; Smolle MA, 2015, PHARMACOGENOMICS, V16, P1313, DOI 10.2217/pgs.15.83; Song QX, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0049-8; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Van Emburgh BO, 2014, MOL ONCOL, V8, P1084, DOI 10.1016/j.molonc.2014.05.003; Vermaat JS, 2012, CLIN CANCER RES, V18, P688, DOI 10.1158/1078-0432.CCR-11-1965; Watanabe T, 2011, DIS COLON RECTUM, V54, P1170, DOI 10.1097/DCR.0b013e31821d37a3; World Health Organization, 2014, WORLD CANC REPORT 20	57	3	3	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					76	81		10.1016/j.yexmp.2018.01.007			6	Pathology	Pathology	FV8SS	WOS:000424857700012	29337243				2019-10-28	
J	Islam, F; Gopalan, V; Vider, J; Lu, CT; Lam, AKY				Islam, Farhadul; Gopalan, Vinod; Vider, Jelena; Lu, Cu-tai; Lam, Alfred K. -Y.			MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Colorectal cancer; miR-142-5p; KLF6; Targeted therapy; Onco-miRNA	SQUAMOUS-CELL CARCINOMA; COLON-CANCER; EXPRESSION; OVEREXPRESSION; THERAPY; GROWTH; PREDICTION; MUTATIONS; APOPTOSIS; MIRNAS	Objectives: miR-142-5p was noted aberrantly expressed and plays important roles in different pathophysiological conditions in human. The present study aims to examine the expression of miR-142-5p and its association with clinicopathological factors in a large cohort of patients with colorectal cancer. In addition, the cellular effects of miR-142-5p and its interacting targets in colon cancer cells were investigated. Methods: Expression of miR-142-5p in colorectal cancer tissues (n = 125) and colon cancer cell lines were analysed using real-time polymerase chain reaction. In vitro assays (cell proliferation, wound healing and colony formation) were used to study the miR-142-5p induced cellular effects. Western blots were used to examine the modulation of FAM134B, KRAS, EPAS1 and KLF6 proteins expression followed by miR-142-5p expression-manipulation. Results: Significant high expression of miR-142-5p was noted in cancer tissues and cells when compared to the controls (p < 0.001). Overexpression of miR-142-5p in patients with colorectal cancer was common (72%; 90/125). miR-142-Sp overexpression was associated with cancer in the proximal colorectum and with B-ref positive patients (p = 0.05). Exogenous overexpression of miR-142-5p resulted in significantly increased cell proliferation, colony formation, and wound healing capacities, whereas inhibition of endogenous miR-142-5p led reduced cancer growth properties. The cellular effects of miR-142-5p were mediated by the modulation of tumour suppressor KLF6 expression, as the expression of miR-142-5p and KLF6 protein are inversely correlated in colon cancer cells. Conclusion: High miR-142-5p expression was associated with the biological aggressiveness of cancer. Thus, suppression of miR-142-5p could be a therapeutic strategy for patients with colorectal cancers.	[Islam, Farhadul; Gopalan, Vinod; Lam, Alfred K. -Y.] Griffith Univ, Sch Med, Canc Mol Pathol, Gold Coast, Qld 4222, Australia; [Islam, Farhadul; Gopalan, Vinod; Lam, Alfred K. -Y.] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld 4222, Australia; [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh; [Gopalan, Vinod; Vider, Jelena] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia; [Gopalan, Vinod; Vider, Jelena] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Lu, Cu-tai] Gold Coast Univ Hosp, Dept Surg, Gold Coast, Qld, Australia	Lam, AKY (reprint author), Griffith Med Sch, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	a.lam@griffith.edu.au	Vider, Jelena/B-9663-2011; Lam, Alfred/C-1652-2008	Vider, Jelena/0000-0003-1696-9812; Lam, Alfred/0000-0003-2771-564X	Griffith UniversityGriffith University; Menzies Health Institute Queensland	The project was supported by the student scholarship from Griffith University and funding from Menzies Health Institute Queensland.	Amin M, 2017, AJCC CANC STAGING MA, P251; Ben-Dov IZ, 2012, TRANSPLANTATION, V94, P1086, DOI 10.1097/TP.0b013e3182751efd; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chapnik E, 2014, ELIFE, V3, DOI 10.7554/eLife.01964; Danger R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060702; Ding S, 2012, ARTHRITIS RHEUM-US, V64, P2953, DOI 10.1002/art.34505; Gopalan V, 2016, EXP CELL RES, V348, P146, DOI 10.1016/j.yexcr.2016.09.010; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021; Islam F, 2017, HUM PATHOL, V62, P141, DOI 10.1016/j.humpath.2017.01.014; Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4; Islam F, 2017, MOL CARCINOGEN, V56, P238, DOI 10.1002/mc.22488; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jia L, 2017, BIOCHEM BIOPH RES CO, V488, P425, DOI 10.1016/j.bbrc.2017.05.074; Kramer NJ, 2015, BLOOD, V125, P3720, DOI 10.1182/blood-2014-10-603951; Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x; Li YW, 2013, MED PRIN PRACT, V22, P415, DOI 10.1159/000353562; Liu LQ, 2017, AM J TRANSL RES, V9, P2394; Liu SJ, 2017, BIOMED PHARMACOTHER, V92, P1119, DOI 10.1016/j.biopha.2017.05.134; Lou KX, 2017, ONCOL RES, V25, P65, DOI 10.3727/096504016X14719078133366; Lu XY, 2013, CELL RES, V23, P1356, DOI 10.1038/cr.2013.145; Ma ZW, 2016, ONCOTARGET, V7, P71504, DOI 10.18632/oncotarget.12229; Monroig PD, 2015, ADV DRUG DELIVER REV, V81, P104, DOI 10.1016/j.addr.2014.09.002; Nawrocki EP, 2015, NUCLEIC ACIDS RES, V43, pD130, DOI 10.1093/nar/gku1063; Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d; Shi D, 2015, INDIAN J CANCER, V52, pE47, DOI 10.4103/0019-509X.172513; Shrestha A, 2017, DEV DYNAM, V246, P285, DOI 10.1002/dvdy.24477; Sladitschek HL, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20156525; Smith RA, 2011, HUM PATHOL, V42, P500, DOI 10.1016/j.humpath.2009.09.023; Tu ML, 2017, J BONE MINER METAB, V35, P255, DOI 10.1007/s00774-016-0757-8; Venkatesan N, 2015, BIOINFORM BIOL INSIG, V9, P89, DOI 10.4137/BBI.S21742; Vychytilova-Faltejskova P, 2016, CARCINOGENESIS, V37, P941, DOI 10.1093/carcin/bgw078; Wang N, 2017, BIOMED PHARMACOTHER, V89, P1187, DOI 10.1016/j.biopha.2017.03.011; Wen D, 2015, J CONTROL RELEASE, V219, P237, DOI 10.1016/j.jconrel.2015.08.011; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yin Y, 2016, GENE, V578, P177, DOI 10.1016/j.gene.2015.12.015; Zarjou A, 2011, AM J PHYSIOL-RENAL, V301, pF793, DOI 10.1152/ajprenal.00273.2011; Zhang X, 2011, ANN ONCOL, V22, P2257, DOI 10.1093/annonc/mdq758; Zhu J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0917-6	39	9	10	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					98	107		10.1016/j.yexmp.2018.01.006			10	Pathology	Pathology	FV8SS	WOS:000424857700015	29337244				2019-10-28	
J	Zhang, M; Adeniran, AJ; Vikram, R; Tamboli, P; Pettaway, C; Bondaruk, J; Liu, JS; Baggerly, K; Czerniak, B				Zhang, Miao; Adeniran, Adebowale J.; Vikram, Raghunandan; Tamboli, Pheroze; Pettaway, Curtis; Bondaruk, Jolanta; Liu, Jinsong; Baggerly, Keith; Czerniak, Bogdan			Carcinoma of the urethra	HUMAN PATHOLOGY			English	Article						Urethral carcinoma; HPV-related cancer; Squamous urothelial; Carcinoma in situ of the urethra; Carcinoma with hybrid squamous and urothelial features; MRI imaging of urethral carcinomas	SQUAMOUS-CELL CARCINOMA; INVASIVE BLADDER-CANCER; FEMALE URETHRA; TISSUE MICROARRAY; LUMINAL SUBTYPES; PENILE; ADENOCARCINOMA; BASAL; HPV; CLASSIFICATION	Primary carcinomas of the urethra are rare and poorly understood lesions; hence, their clinical and pathologic spectrum is not completely defined. We analyzed a series of 130 primary urethral tumors and classified 106 of them as primary urethral carcinomas. The age at diagnosis of patients with primary urethral carcinomas ranged from 42 to 97 years (mean, 69.4 years; median, 70 years). There were 73 male and 33 female patients with a ratio of 2.2:1. In male patients, the tumors most frequently developed in the bulbous-membranous segment of the urethra. In female patients, the entire length of the urethra was typically involved. Microscopically, they were poorly differentiated carcinomas with hybrid squamous and urothelial features and developed from precursor intraepithelial conditions such as dysplasia and carcinoma in situ, which were frequently present in the adjacent urethral mucosa. High-risk human papilloma virus infection could be documented in 31.6% of these tumors. Follow-up information was available for 95 patients. Twenty-three patients died of the disease with a mean and median survival of 39 and 21 months, respectively. Urethral carcinomas are aggressive tumors with a high propensity for regional and distant metastases with mean and median survival of 39 and 21 months, respectively. Our observations have important implications for the management of patients with primary carcinoma of the urethra by defining them as a unique entity linked to human papilloma virus infection. (C) 2017 Elsevier Inc. All rights reserved.	[Zhang, Miao; Tamboli, Pheroze; Bondaruk, Jolanta; Liu, Jinsong; Czerniak, Bogdan] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Adeniran, Adebowale J.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA; [Vikram, Raghunandan] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA; [Pettaway, Curtis] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Baggerly, Keith] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	Czerniak, B (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 085, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bczernia@mdanderson.org			GU Bladder SPORE grant from the National Institutes of Health [P50 CA91846]	This study was supported in part by the GU Bladder SPORE grant from the National Institutes of Health (P50 CA91846/Project 1 and Core C) to B. C.	Alemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007; Amin MB, 1997, SEMIN DIAGN PATHOL, V14, P147; Amin MB, 2017, AJCC CANC STAGING MA; AMPIL FL, 1985, OBSTET GYNECOL, V66, P799; BENSON RC, 1982, GYNECOL ONCOL, V14, P313, DOI 10.1016/0090-8258(82)90105-6; BRACKEN RB, 1976, J UROLOGY, V116, P188, DOI 10.1016/S0022-5347(17)58741-8; Chaux A, 2014, HISTOPATHOLOGY, V64, P863, DOI 10.1111/his.12338; Choi W, 2014, NAT REV UROL, V11, P400, DOI 10.1038/nrurol.2014.129; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Corbishley CM, 2015, SEMIN DIAGN PATHOL, V32, P238, DOI [10.1053/j.semdp.2014.12.015, 10.1053/j.semdp:2014.12.015]; Czerniak B, 2016, ANNU REV PATHOL-MECH, V11, P149, DOI 10.1146/annurev-pathol-012513-104703; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; Dayyani F, 2014, BJU INT, V114, P25, DOI 10.1111/bju.12630; ELKON D, 1980, SOUTHERN MED J, V73, P1439, DOI 10.1097/00007611-198011000-00005; Faraj SF, 2017, VIRCHOWS ARCH, V470, P695, DOI 10.1007/s00428-017-2110-6; Gadducci A, 2012, CRIT REV ONCOL HEMAT, V83, P71, DOI 10.1016/j.critrevonc.2011.09.003; Gakis G, 2013, EUR UROL, V64, P823, DOI 10.1016/j.eururo.2013.03.044; Grivas PD, 2012, HEMATOL ONCOL CLIN N, V26, P1291, DOI 10.1016/j.hoc.2012.08.006; Hellner K, 2017, F1000RES, P6; Kawashima A, 2004, RADIOGRAPHICS, V24, pS195, DOI 10.1148/rg.24si045504; Lees BF, 2016, AM J OBSTET GYNECOL, V214, P438, DOI 10.1016/j.ajog.2015.10.147; Linxweiler M, 2015, CANCER CYTOPATHOL, V123, P219, DOI 10.1002/cncy.21512; MEIS JM, 1987, CANCER, V60, P1038, DOI 10.1002/1097-0142(19870901)60:5<1038::AID-CNCR2820600519>3.0.CO;2-#; MELICOW M M, 1978, Urology, V11, P83, DOI 10.1016/0090-4295(78)90212-1; Moch H, 2016, WHO CLASSIFICATION T; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Pechriggl EJ, 2013, ANN ANAT, V195, P260, DOI 10.1016/j.aanat.2013.01.008; Sanchez DF, 2015, SEMIN DIAGN PATHOL, V32, P198, DOI 10.1053/j.semdp.2014.12.018; Stewart SB, 2010, UROL CLIN N AM, V37, P353, DOI 10.1016/j.ucl.2010.04.014; Stratton KL, 2016, ONCOLOGY-NY, V30, P245; Suzuki K, 2001, INT J UROL, V8, P509, DOI 10.1046/j.1442-2042.2001.00361.x; TESLUK H, 1981, UROLOGY, V17, P197, DOI 10.1016/0090-4295(81)90241-7; Udager Aaron M, 2017, Surg Pathol Clin, V10, P35, DOI 10.1016/j.path.2016.10.007; Wang HM, 2002, BRAIN PATHOL, V12, P95; Yap JKW, 2017, BJOG-INT J OBSTET GY, V124, P946, DOI 10.1111/1471-0528.14560; Yvgenia R, 2005, PATHOL RES PRACT, V201, P137, DOI 10.1016/j.prp.2004.12.002; Zhang M, 2016, HUM PATHOL, V58, P138, DOI 10.1016/j.humpath.2016.07.027; Zinman LN, 2016, UROL CLIN N AM, V43, P505, DOI 10.1016/j.ucl.2016.06.011	38	3	3	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						35	44		10.1016/j.humpath.2017.08.006			10	Pathology	Pathology	FX4EC	WOS:000426024500004	28827100	Green Accepted			2019-10-28	
J	Espinosa, I; De Leo, A; D'Angelo, E; Rosa-Rosa, JM; Corominas, M; Gonzalez, A; Palacios, J; Prat, J				Espinosa, Inigo; De Leo, Antonio; D'Angelo, Emanuela; Rosa-Rosa, Juan M.; Corominas, Marina; Gonzalez, Alan; Palacios, Jose; Prat, Jaime			Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study	HUMAN PATHOLOGY			English	Article						Endometrial carcinomas; Undifferentiated/dedifferentiated carcinomas; Neuroendocrine carcinomas; POLE mutations; TP53 mutations	UNDIFFERENTIATED CARCINOMA; CANCER; TUMORS; MUTATIONS; COLON	Undifferentiated endometrial carcinoma is an aggressive type of uterine cancer, which is occasionally associated with a low-grade endometrioid carcinoma component. This combination is referred to as "dedifferentiated endometrioid endometrial carcinoma." Neuroendocrine expression may occur in undifferentiated endometrial carcinoma, but its significance in dedifferentiated endometrial carcinomas is unknown. To gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, (beta-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression. All tumors demonstrated neuroendocrine expression in >= 70% of the cells in the undifferentiated carcinoma areas. Loss of expression of at least 1 DNA mismatch repair protein was observed in 2 cases, and p53 immunoreaction was aberrant (mutated/inactivated) in one case. All carcinomas were negative for beta-catenin and maintained nuclear SMARCB1 (INI1) and ARID expression. Three tumors shared identical endometrioid molecular profile (PTENand/orP/K3CA mutations) in both components. One tumor had POLE exonuclease domain mutation in the undifferentiated component. In one case, TP53 mutation was found exclusively in the undifferentiated component. Two patients died with peritoneal carcinomatosis and abdominal metastases, respectively; one patient died of a renal failure without evidence of disease, and the last patient is alive and free of disease at 3.3 years. Dedifferentiated endometrial carcinomas with neuroendocrine features are clinically and molecularly heterogeneous tumors. Probably, these carcinomas might acquire undifferentiated phenotype through mutations in TP53 and POLE. (C) 2017 Elsevier Inc. All rights reserved.	[Espinosa, Inigo; Corominas, Marina; Gonzalez, Alan; Prat, Jaime] Autonomous Univ Barcelona, Inst Biomed Res IIB St Pau, Hosp Santa Creu & St Pau, Dept Pathol, Barcelona 08041, Spain; [De Leo, Antonio] Univ Bologna, Dept Pathol, I-40126 Bologna, Italy; [D'Angelo, Emanuela] Univ Aquila, Dept Pathol, I-67100 Laquila, Italy; [Rosa-Rosa, Juan M.; Palacios, Jose] CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Oviedo, Spain; [Palacios, Jose] Univ Alcala De Henares, IRYCIS, Hosp Univ Ramon y Cajal, Dept Pathol, Madrid 28034, Spain	Prat, J (reprint author), Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Pathol, St Quinti 87-89, Barcelona 08041, Spain.		De Leo, Antonio/V-1441-2019	De Leo, Antonio/0000-0002-3761-5135	Department of Health, Spain [FIS PI13-02477, FIS PI16-00887, FIS PI16-00902, RTICC RD06/0020/0015]; Fundacion AECC-Grupos Estables	This work was supported by Grants FIS PI13-02477, FIS PI16-00887, FIS PI16-00902 and RTICC RD06/0020/0015, Department of Health, Spain, Fundacion AECC-Grupos Estables. Tumor samples were obtained with the support of Xarxa Banc de Tumors de Catalunya (XBTC).	Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Aytac E, 2014, J VISC SURG, V151, P3, DOI 10.1016/j.jviscsurg.2013.12.007; Bakhsh S, 2016, HISTOPATHOLOGY, V68, P916, DOI 10.1111/his.12878; Bellone S, 2015, GYNECOL ONCOL, V138, P11, DOI 10.1016/j.ygyno.2015.04.027; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Church DN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju402; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hussein YR, 2015, MODERN PATHOL, V28, P505, DOI 10.1038/modpathol.2014.143; Iyoda A, 2001, CANCER-AM CANCER SOC, V91, P1992, DOI 10.1002/1097-0142(20010601)91:11<1992::AID-CNCR1224>3.0.CO;2-5; Kim HK, 2017, ONCOTARGET, V8, P73974, DOI 10.18632/oncotarget.18168; Kuhn E, 2014, AM J SURG PATHOL, V38, P660, DOI 10.1097/PAS.0000000000000166; Nelson BH, 2015, GYNECOL ONCOL, V138, P1, DOI 10.1016/j.ygyno.2015.06.004; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Pocrnich CE, 2016, AM J SURG PATHOL, V40, P577, DOI 10.1097/PAS.0000000000000633; Rosa-Rosa JM, 2016, MODERN PATHOL, V29, P1390, DOI 10.1038/modpathol.2016.132; Silva EG, 2007, PATHOLOGY, V39, P134, DOI 10.1080/00313020601159494; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057; Zaino RJ, 2014, WHO CLASSIFICATION T, P125	22	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						100	106		10.1016/j.humpath.2017.11.006			7	Pathology	Pathology	FX4EC	WOS:000426024500012	29133142				2019-10-28	
J	Xing, DY; Banet, N; Sharma, R; Vang, R; Ronnett, BM; Illei, PB				Xing, Deyin; Banet, Natalie; Sharma, Rajni; Vang, Russell; Ronnett, Brigitte M.; Illei, Peter B.			Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study	HUMAN PATHOLOGY			English	Article						Malignant mesothelioma; Peritoneum; Pax-8; Well-differentiated papillary mesothelioma; Immunohistochemistry	PAIRED BOX GENE; SEROUS CARCINOMA; EPITHELIAL TUMORS; DEVELOPING KIDNEY; THYROID-GLAND; PROLIFERATIONS; MORPHOGENESIS; DIAGNOSIS; BENIGN; ORIGIN	Serous ovarian neoplasms can overlap morphologically with peritoneal mesothelial proliferations, including well-differentiated papillary mesothelioma (WDPM) and malignant epithelioid mesothelioma (MM). Accurate histologic classification of these neoplasms is important for clinical management. The Pax-8 protein is commonly used for differentiating peritoneal MM from serous carcinoma, but the diagnostic value of Pax-8 for distinguishing WDPM from borderline or low-grade serous tumors is unknown. We used immunohistochemistry staining to assess Pax-8 expression in 33 WDPMs, 34 peritoneal MMs, 48 pleural MMs, 11 adenomatoid tumors, 5 peritoneal inclusion cysts, and 51 benign/reactive mesothelium specimens. Staining was noted in 20 WDPMs (61%), with 17 showing strong and diffuse nuclear staining and 3 patchy/focal staining. Calretinin was expressed in 33 cases (100%), whereas focal BerEP4 staining was noted in 2 of 29 cases (7%). In contrast, 4 peritoneal MM (12%) were Pax-8 positive (3 diffuse and 1 focal staining). All adenomatoid tumors and peritoneal inclusion cysts were negative for Pax-8. Of the 48 pleural MM cases, 2 (4%) showed focal weak to moderate nuclear labeling for Pax-8, and 2 cases (4%) of reactive mesothelium demonstrated focal and scattered Pax-8 staining. Pax-8 appears to be a useful marker for distinguishing MM from gynecologic malignancies but is not reliable for distinguishing WDPM from borderline or low-grade gynecologic lesions. (C) 2017 Elsevier Inc. All rights reserved.	[Xing, Deyin; Banet, Natalie; Sharma, Rajni; Vang, Russell; Ronnett, Brigitte M.; Illei, Peter B.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; [Vang, Russell; Ronnett, Brigitte M.] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21231 USA; [Illei, Peter B.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA	Illei, PB (reprint author), Johns Hopkins Univ Hosp, Dept Pathol, Weinberg Bldg,Rm 2242,401 North Broadway, Baltimore, MD 21231 USA.	pillei1@jhmi.edu		Sharma, Rajni/0000-0003-0393-0943			Baker PM, 2005, AM J CLIN PATHOL, V123, P724, DOI 10.1309/2HONVRERPP2LJDUA; Butnor KJ, 2001, AM J SURG PATHOL, V25, P1304, DOI 10.1097/00000478-200110000-00012; Chapel DB, 2017, AM J SURG PATHOL, V41, P1675, DOI 10.1097/PAS.0000000000000935; Chen XC, 2013, HISTOPATHOLOGY, V62, P805, DOI 10.1111/his.12089; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Churg A, 2000, AM J SURG PATHOL, V24, P1183; Churg A, 2014, AM J SURG PATHOL, V38, P990, DOI 10.1097/PAS.0000000000000200; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAYA D, 1990, CANCER-AM CANCER SOC, V65, P292, DOI 10.1002/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO;2-W; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Galateau-Salle F, 2004, AM J SURG PATHOL, V28, P534, DOI 10.1097/00000478-200404000-00013; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Kawai T, 2016, J CLIN PATHOL, V69, P706, DOI 10.1136/jclinpath-2015-203211; LAUCHLAN SC, 1994, INT J GYNECOL PATHOL, V13, P73, DOI 10.1097/00004347-199401000-00009; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee M, 2013, PATHOLOGY, V45, P464, DOI 10.1097/PAT.0b013e3283631cce; Lee YK, 2013, JPN J CLIN ONCOL, V43, P996, DOI 10.1093/jjco/hyt117; Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106; Malpica A, 2012, AM J SURG PATHOL, V36, P117, DOI 10.1097/PAS.0b013e3182354a79; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Mansouri A, 1999, CANCER RES, V59, p1707S; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nonaka D, 2005, CANCER, V104, P2181, DOI 10.1002/cncr.21239; Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad; Ordonez NG, 2013, MODERN PATHOL, V26, P553, DOI 10.1038/modpathol.2012.200; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1992, DEVELOPMENT, V116, P611; SCUCCHI L, 1994, ANTICANCER RES, V14, P715; Wachter DL, 2011, VIRCHOWS ARCH, V458, P593, DOI 10.1007/s00428-011-1054-5; Wang QY, 2008, J CELL MOL MED, V12, P2281, DOI 10.1111/j.1582-4934.2008.00427.x; Yemelyanova A, 2014, INT J GYNECOL PATHOL, V33, P492, DOI 10.1097/PGP.0b013e3182a54afa	34	4	5	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						160	166		10.1016/j.humpath.2017.10.036			7	Pathology	Pathology	FX4EC	WOS:000426024500019	29241740				2019-10-28	
J	Ogris, E; Sontag, E; Wadzinski, B; Narla, G				Ogris, Egon; Sontag, Estelle; Wadzinski, Brian; Narla, Goutham			Specificity of research antibodies: "trust is good, validation is better"	HUMAN PATHOLOGY			English	Letter							INACTIVATES PROTEIN PHOSPHATASE-2A; TYROSINE PHOSPHORYLATION; KINASE; 2A		[Ogris, Egon] Med Univ Vienna, Max F Perutz Labs, A-1030 Vienna, Austria; [Sontag, Estelle] Univ Newcastle, Callaghan, NSW 2308, Australia; [Wadzinski, Brian] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; [Narla, Goutham] Case Western Reserve Univ, Cleveland, OH 44106 USA	Ogris, E (reprint author), Med Univ Vienna, Max F Perutz Labs, A-1030 Vienna, Austria.	egon.ogris@meduniwien.ac.at		Ogris, Egon/0000-0001-5950-9264; Narla, Goutham/0000-0003-4098-4203			Abcam, ANI PP2A ALPH BET AN; Antibody Review, PP2A PHOSPH PY307 AN; Baker M, 2015, NATURE, V521, P274, DOI 10.1038/521274a; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chen PM, 2017, HUM PATHOL, V66, P93, DOI 10.1016/j.humpath.2017.06.001; CiteAb, SEARCH RES E155; DAMUNI Z, 1994, FEBS LETT, V352, P311, DOI 10.1016/0014-5793(94)00981-3; Epitomics, SEARCH PROD LIST PP2; GeneTex, DAT CAT NUMB GTX6106; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Labome, PP2A PHOSPH PY307; Novus Biologicals, PP2A ALPH P TYR307 A	14	2	2	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						199	201		10.1016/j.humpath.2017.12.003			3	Pathology	Pathology	FX4EC	WOS:000426024500027	29247663				2019-10-28	
J	Zhao, W; Wang, H; Xie, J; Tian, B				Zhao, Wei; Wang, Hui; Xie, Jun; Tian, Bo			A Clinicopathological Study of Small Lung Adenocarcinoma 1 cm or Less in Size: Emphasis on Histological Subtypes Associated With Lymph Node Metastasis and Recurrence	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						small lung adenocarcinoma 1 cm or less in size; adenocarcinoma in situ; minimally invasive adenocarcinoma; micropapillary pattern; lobectomy; limited resection	SIGNIFICANTLY POOR-PROGNOSIS; DISTINCT PATHOLOGICAL MARKER; LIMITED RESECTION; MICROPAPILLARY PATTERN; INTERNATIONAL-ASSOCIATION; WEDGE RESECTION; RISK PATIENTS; CANCER; LOBECTOMY; SURVIVAL	Background. The aim of this study was to assess the prognostic significance of the newly proposed 2015 World Health Organization (WHO) lung adenocarcinoma classification for patients undergoing resection for small (1 cm) lung adenocarcinoma. We also investigated whether lobectomy offers prognostic advantage over limited resection for this category of tumors. Methods. A retrospective study of resected pulmonary adenocarcinomas (n = 83) in sizes 1 cm or less was carried out in which comprehensive histologic subtyping was assessed according to the 2015 WHO classification on all consecutive patients who underwent lobectomy or limited resection between 1998 and 2012. Correlation between clinicopathologic parameters and the difference in recurrence between lobectomy and limited resection group was evaluated. Results. Our data show that the proposed 2015 WHO classification identifies histological subsets of small lung adenocarcinomas with significant differences in prognosis. No recurrence was noted for patients with adenocarcinoma in situ and minimally invasive adenocarcinoma. Invasive adenocarcinomas displayed high heterogeneity and the presence of micropapillary component of 5% or greater in adenocarcinomas was significantly related to lymph node involvement and recurrence (P < .001). Stage IA patients who underwent limited resection had a higher risk of recurrence than did those treated by lobectomy (P < .05). Conclusions. Application of the 2015 WHO classification identifies patients with adenocarcinoma in situ and minimally invasive adenocarcinoma had excellent prognosis. Micropapillary pattern was associated with high risk of lymph node metastasis and recurrence.	[Zhao, Wei; Wang, Hui; Xie, Jun; Tian, Bo] Suzhou Univ, Affiliated Hosp 3, Peoples Hosp Changzhou 1, Changzhou, Peoples R China	Zhao, W (reprint author), Suzhou Univ, Affiliated Hosp 3, Dept Pathol, Peoples Hosp Changzhou 1, Floor 3,Bldg 3,185 Juqian St, Changzhou 213003, Peoples R China.	13861017316@163.com					Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Amin MB, 2002, AM J SURG PATHOL, V26, P358, DOI 10.1097/00000478-200203000-00010; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Donington J, 2012, CHEST, V142, P1620, DOI 10.1378/chest.12-0790; DUNNILL MS, 1986, HISTOPATHOLOGY, V10, P461, DOI 10.1111/j.1365-2559.1986.tb02498.x; Edge SB, 2009, AM JOINT COMMITTEE C, P253; ERRETT LE, 1985, J THORAC CARDIOV SUR, V90, P656; Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U; Kamiya K, 2008, MODERN PATHOL, V21, P992, DOI 10.1038/modpathol.2008.79; Kates M, 2011, CHEST, V139, P491, DOI 10.1378/chest.09-2547; Landreneau RJ, 1997, J THORAC CARDIOV SUR, V113, P691, DOI 10.1016/S0022-5223(97)70226-5; Maeda R, 2009, GEN THORAC CARDIOVAS, V57, P534, DOI 10.1007/s11748-009-0436-y; Makimoto Y, 2005, HISTOPATHOLOGY, V46, P677, DOI 10.1111/j.1365-2559.2005.02126.x; Miller DL, 2002, ANN THORAC SURG, V73, P1545, DOI 10.1016/S0003-4975(02)03525-7; Miyoshi T, 2003, AM J SURG PATHOL, V27, P101, DOI 10.1097/00000478-200301000-00011; Motoi N, 2008, AM J SURG PATHOL, V32A, P810, DOI 10.1097/PAS.0b013e31815cb162; Nakamura K, 2010, JPN J CLIN ONCOL, V40, P271, DOI 10.1093/jjco/hyp156; Nitadori J, 2013, JNCI-J NATL CANCER I, V105, P1212, DOI 10.1093/jnci/djt166; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; PASTORINO U, 1991, EUR J SURG ONCOL, V17, P42; Rusch VW, 2011, J CLIN ONCOL, V29, P4313, DOI 10.1200/JCO.2011.35.2500; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; SHIMOSATO Y, 1980, AM J SURG PATHOL, V4, P365, DOI 10.1097/00000478-198008000-00005; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Sterlacci W, 2012, AM J CLIN PATHOL, V137, P946, DOI 10.1309/AJCP77KMKJXNMPMS; Travis WD, 2015, WHO CLASSIFICATION T, V7, P26; Tsutsumida H, 2007, MODERN PATHOL, V20, P638, DOI 10.1038/modpathol.3800780; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Whitson BA, 2011, ANN THORAC SURG, V92, P1943, DOI 10.1016/j.athoracsur.2011.05.091; Wisnivesky JP, 2010, ANN SURG, V251, P550, DOI 10.1097/SLA.0b013e3181c0e5f3; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232	31	3	3	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					4	11		10.1177/1066896917721649			8	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400001	28805108				2019-10-28	
J	Tan, GC; Prasad, V				Tan, Geok Chin; Prasad, Vinay			Extrarenal Wilms Tumor With Skeletal and Glial Differentiation	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Tan, Geok Chin; Prasad, Vinay] Nationwide Childrens Hosp, Columbus, OH USA; [Tan, Geok Chin] Natl Univ Malaysia, Kuala Lumpur, Malaysia	Prasad, V (reprint author), Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH 43205 USA.	vinay.prasad@nationwidechildrens.org						0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					34	34		10.1177/1066896917709946			1	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400006	28508688	Bronze			2019-10-28	
J	Baldovini, C; Sorrentino, S; Alves, CA; Piatelli, G; Garaventa, A; Morana, G; Nozza, P				Baldovini, Chiara; Sorrentino, Stefania; Alves, Cesar Augusto; Piatelli, Gianluca; Garaventa, Alberto; Morana, Giovanni; Nozza, Paolo			Congenital Myoepithelial Carcinoma of Soft Tissue Associated With Cystic Myoepithelioma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						myoepithelial carcinoma; myoepithelioma; soft tissue; congenital; cystic	NEOPLASMS; CHILDREN; TUMORS	Myoepithelial neoplasms of soft tissue represent a heterogeneous group of lesions, encompassing both benign entities as myoepithelioma (ME) and highly aggressive tumors as myoepithelial carcinoma (MEC). We describe a case of pediatric soft tissue MEC with peculiar features that may lead to misdiagnosis: congenital onset and presence of a benign component with predominant cystic structure. Few cases of congenital MEC have been reported, but the coexistence of MEC with ME is even more rare, accounting for less than 1% of myoepithelial tumors. Moreover, an extensive cystic appearance had never been described in either ME or MEC of soft tissue. Despite several predictors of poor prognosis, the patient has been showing a favorable clinical course since the administration of ICpE (ifosfamide, cisplatin, and etoposide) chemotherapy. This report provides valuable information in the differential diagnosis of cystic congenital tumors and supports a possible efficacy of adjuvant combined treatment for patients with localized disease after surgery.	[Baldovini, Chiara; Sorrentino, Stefania; Alves, Cesar Augusto; Piatelli, Gianluca; Garaventa, Alberto; Morana, Giovanni; Nozza, Paolo] Giannina Gaslini Inst, Genoa, Italy; [Alves, Cesar Augusto] Hosp Clin Sao Paulo, Sao Paulo, Brazil	Baldovini, C (reprint author), Giannina Gaslini Inst, Pathol Unit, Largo Gerolamo Gaslini 5, I-16147 Genoa, Italy.	c.baldovini@gmail.com	ALVES, CESAR/V-5958-2019; Morana, Giovanni/J-6134-2018; Sorrentino, Stefania/K-4668-2016; GARAVENTA, ALBERTO/K-5726-2016	ALVES, CESAR/0000-0001-5877-9086; Morana, Giovanni/0000-0001-8707-5969; Sorrentino, Stefania/0000-0001-7381-0133; GARAVENTA, ALBERTO/0000-0002-5368-6363			Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Bisogno G, 2014, PEDIATR BLOOD CANCER, V61, P643, DOI 10.1002/pbc.24818; Ding JH, 2016, ACTA RADIOL, V57, P837, DOI 10.1177/0284185115609364; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Gleason BC, 2007, AM J SURG PATHOL, V31, P1813, DOI 10.1097/PAS.0b013e31805f6775; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Hornick JL, 2003, AM J SURG PATHOL, V27, P1183, DOI 10.1097/00000478-200309000-00001; Jo VY, 2015, HEAD NECK PATHOL, V9, P32, DOI 10.1007/s12105-015-0618-0; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Mahdi Y, 2014, J MED CASE REP, V8, P317; Stelow EB, 2011, HEAD NECK PATHOL, V5, P31, DOI 10.1007/s12105-010-0235-x; Swain N, 2014, J ORAL MAX SURG MED, V26, P580, DOI 10.1016/j.ajoms.2013.07.014	12	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					78	83		10.1177/1066896917718936			6	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400016	28675958				2019-10-28	
J	Pennanen, M; Hagstrom, J; Heiskanen, I; Sane, T; Mustonen, H; Arola, J; Haglund, C				Pennanen, Mirkka; Hagstrom, Jaana; Heiskanen, Ilkka; Sane, Timo; Mustonen, Harri; Arola, Johanna; Haglund, Caj			C-myc expression in adrenocortical tumours	JOURNAL OF CLINICAL PATHOLOGY			English	Article							BETA-CATENIN; GENE-EXPRESSION; CELL CARCINOMA; CANCER; MALIGNANCY; SURVIVAL; PATHWAY; DIFFERENTIATION; CLASSIFICATION; ACTIVATION	Aims Widespread use of high-resolution imaging techniques and thus increased prevalence of adrenal lesions has made diagnostics of adrenocortical tumours an increasingly important clinical issue. In non-metastatic tumours, diagnosis is based on histology. New or enhanced information for clinicopathological diagnosis, revealing the malignant potential of the tumour, could emerge by means of biomarkers. The connection of proto-oncogene c-myc to adrenocortical neoplasias is poorly known, although the Wnt/beta-catenin pathway, one of the signalling pathways leading to induction of c-myc expression, has been connected to development of adrenocortical neoplasias. We studied c-myc expression in adrenocortical tumours and investigated molecules associated with the signalling pathway of c-myc, including cell cycle-related proteins p27, cyclin E and cyclin D1. Methods We studied 195 consecutive adult patients with 197 primary adrenocortical tumours. Histopathological diagnosis was determined by Weiss score and the novel Helsinki score. C-myc, cyclin D1, cyclin E and p27 expressions were determined by immunohistochemistry. Results Benign adenomas showed prominent nuclear c-myc expression comparable to that of normal adrenocortical cells, whereas carcinomas showed increased cytoplasmic expression. Strong cytoplasmic and weak nuclear c-myc expressions associated with malignancy and adverse outcome. C-myc staining did not correlate with cyclin E. Cyclin D1 correlated with cytoplasmic c-myc expression and to a lesser extent with nuclear c-myc. P27 correlated with cytoplasmic c-myc, but not with nuclear c-myc. P27 correlated with cyclin E. Conclusions Strong cytoplasmic c-myc expression and weak nuclear expression in adrenocortical tumours associated with malignancy and shorter survival.	[Pennanen, Mirkka; Hagstrom, Jaana; Arola, Johanna] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Pennanen, Mirkka; Hagstrom, Jaana; Arola, Johanna] HUSLAB, Helsinki, Finland; [Heiskanen, Ilkka; Mustonen, Harri; Haglund, Caj] Helsinki Univ Hosp, Dept Surg, Helsinki, Finland; [Heiskanen, Ilkka; Sane, Timo; Mustonen, Harri; Haglund, Caj] Univ Helsinki, Helsinki, Finland; [Sane, Timo] Helsinki Univ Hosp, Dept Med, Div Endocrinol, Helsinki, Finland; [Haglund, Caj] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland	Pennanen, M (reprint author), Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki, Finland.	mirkka.pennanen@hus.fi	Haglund, Caj/N-1240-2019; Hagstrom, Jaana/G-1468-2018	Hagstrom, Jaana/0000-0001-6079-7881; Pennanen, Mirkka/0000-0003-1714-5030; Mustonen, Harri Kalevi/0000-0001-5632-6796	Finnish Cancer Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Helsinki University Hospital Research Fund; Medicinska Understodsforeningen Liv och Halsa	This work was supported by grants from the Finnish Cancer Foundation, Sigrid Juselius Foundation, Helsinki University Hospital Research Fund and Medicinska Understodsforeningen Liv och Halsa. Funding is obtained from independent scientific foundations. We only have to report scientific results, that is, published papers.	BAI MK, 1994, ONCOLOGY, V51, P314; Berthon A, 2010, HUM MOL GENET, V19, P1561, DOI 10.1093/hmg/ddq029; Bonnet S, 2011, J CLIN ENDOCR METAB, V96, pE419, DOI 10.1210/jc.2010-1885; Calcagno DQ, 2009, ANTICANCER RES, V29, P2479; Conacci-Sorrell M, 2014, GENE DEV, V28, P689, DOI 10.1101/gad.231894.113; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Durand J, 2011, J CLIN ENDOCR METAB, V96, pE1206, DOI 10.1210/jc.2010-2143; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kouvaraki M, 2002, CANCER, V94, P2454, DOI 10.1002/cncr.10505.abs; Liu J, 1996, J ENDOCRINOL, V148, P523, DOI 10.1677/joe.0.1480523; Liu J, 1997, J ENDOCRINOL, V152, P175, DOI 10.1677/joe.0.1520175; Migita T, 2002, CANCER-AM CANCER SOC, V94, P973, DOI 10.1002/cncr.10338.abs; Nozoe T, 2006, ONCOLOGY-BASEL, V71, P402, DOI 10.1159/000108611; Parviainen H, 2013, PATHOL RES PRACT, V209, P503, DOI 10.1016/j.prp.2013.06.002; Pennanen M, 2015, HUM PATHOL, V46, P404, DOI 10.1016/j.humpath.2014.11.015; PIETILAINEN T, 1995, ANTICANCER RES, V15, P959; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; SUZUKI T, 1992, MODERN PATHOL, V5, P224; Szabo PM, 2011, HORM METAB RES, V43, P297, DOI 10.1055/s-0031-1273762; Szabo PM, 2010, ONCOGENE, V29, P3163, DOI 10.1038/onc.2010.80; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001	30	1	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					129	134		10.1136/jclinpath-2017-204503			6	Pathology	Pathology	FT1RA	WOS:000422912700006	28801349				2019-10-28	
J	Gayo, E; Polledo, L; Balseiro, A; Martinez, CP; Iglesias, MJG; Preziuso, S; Rossi, G; Marin, JFG				Gayo, E.; Polledo, L.; Balseiro, A.; Perez Martinez, C.; Garcia Iglesias, M. J.; Preziuso, S.; Rossi, G.; Garcia Marin, J. F.			Inflammatory Lesion Patterns in Target Organs of Visna/Maedi in Sheep and their Significance in the Pathogenesis and Diagnosis of the Infection	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						immunopathology; lesion pattern; sheep; visna/maedi	SMALL RUMINANT LENTIVIRUSES; CENTRAL-NERVOUS-SYSTEM; MAEDI-VISNA INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; IMMUNE-RESPONSE; ENCEPHALITIS; PARATUBERCULOSIS; CELLS	Ovine visna/maedi (VM) infection is characterized by the development of chronic inflammatory lesions in different organs, mainly in the lung, mammary gland and central nervous system (CNS), with either histiocytic or lymphocytic pattern predominance being described in the CNS. To help to understand the role of host immune response in the development of these patterns, 50 naturally-infected sheep and eight non-infected sheep from intensive milk-producing flocks were studied. The histological lesion patterns in the three main target organs in each sheep were characterized. Lesion severity was determined, including minimal lesions. A histiocytic pattern was observed in 23 sheep (46%), a lymphocytic inflammatory pattern in 19 sheep (38%) and a mixed inflammatory pattern in eight sheep (16%). Forty animals showed moderate or severe lesions (80%), while 10 had minimal lesions (20%). Moderate or severe lesions affected only one target organ in 20 sheep (50%), two organs in 14 sheep (35%) and all three target organs in six sheep (15%). Infection was confirmed by immunohistochemistry (IHC) using an antibody specific for p28 of VM virus/caprinc arthritis and encephalitis virus and by polymerase chain reaction (PCR) in all sheep. Minimal inflammatory lesions associated with positive IHC and PCR were observed. The results suggest that the development of a predominant inflammatory pattern in different organs within the same animal may be related to the host immune response. Minimal and local lesions, not considered previously, should be taken into account when formulating a differential diagnosis in affected sheep. (C) 2018 Elsevier Ltd. All rights reserved.	[Gayo, E.; Perez Martinez, C.; Garcia Iglesias, M. J.; Garcia Marin, J. F.] Univ Leon, Sch Vet Med, Anim Hlth Dept, Pathol Anat Sect, Leon, Spain; [Polledo, L.] Micros Vet, Leon, Spain; [Balseiro, A.; Preziuso, S.; Rossi, G.] SERIDA, Gijon, Spain; [Preziuso, S.; Rossi, G.] Univ Camerino, Sch Biosci & Vet Med, Camerino, Italy	Gayo, E (reprint author), Univ Leon, Sch Vet Med, Anim Hlth Dept, Pathol Anat Sect, Leon, Spain.	cgayr@unileon.es	Garcia-Iglesias, Maria Jose/I-3242-2015; Perez-Martinez, Claudia/M-4759-2013; Balseiro, Ana/O-1794-2019	Garcia-Iglesias, Maria Jose/0000-0002-7786-6561; Perez-Martinez, Claudia/0000-0001-8060-6368; Balseiro, Ana/0000-0002-5121-7264	Spanish governmentSpanish Government [LE361A12-1, FPU13/01081]	The authors thank the veterinarians who provided the case material and the Spanish government for financial support (LE361A12-1 project and FPU13/01081 grant).	Benavides J, 2006, VET REC, V158, P230, DOI 10.1136/vr.158.7.230; Benavides J, 2009, J COMP PATHOL, V140, P1, DOI 10.1016/j.jcpa.2008.07.010; Benavides J, 2013, VET J, V197, P607, DOI 10.1016/j.tvjl.2013.03.031; Blacklaws BA, 2012, COMP IMMUNOL MICROB, V35, P259, DOI 10.1016/j.cimid.2011.12.003; Butler J.E., 2015, MUCOSAL IMMUNOLOGY, P2269; CUTLIP RC, 1979, AM J VET RES, V40, P1370; DAWSON M, 1987, VET REC, V120, P451, DOI 10.1136/vr.120.19.451; de Andres D, 2005, VET MICROBIOL, V107, P49, DOI 10.1016/j.vetmic.2005.01.012; Delgado L, 2013, VET PATHOL, V50, P857, DOI 10.1177/0300985813476066; Gayo E, 2017, SMALL RUMINANT RES, V157, P27, DOI 10.1016/j.smallrumres.2017.10.008; Glaria I, 2012, VET MICROBIOL, V155, P137, DOI 10.1016/j.vetmic.2011.08.027; JUSTE RA, 1994, J COMP PATHOL, V110, P185, DOI 10.1016/S0021-9975(08)80189-2; Kim WK, 2004, J NEUROVIROL, V10, P315, DOI 10.1080/13550280490505382; LACKNER AA, 1991, AM J PATHOL, V139, P609; Leginagoikoa I, 2006, RES VET SCI, V80, P235, DOI 10.1016/j.rvsc.2005.05.003; LUJAN L, 1991, VET REC, V129, P51, DOI 10.1136/vr.129.3.51; Minguijon E, 2015, VET MICROBIOL, V181, P75, DOI 10.1016/j.vetmic.2015.08.007; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; Peterhans E, 2004, VET RES, V35, P257, DOI 10.1051/vetres:2004014; Polledo L, 2013, SMALL RUMINANT RES, V112, P224, DOI 10.1016/j.smallrumres.2012.12.010; Polledo L, 2012, J COMP PATHOL, V147, P1, DOI 10.1016/j.jcpa.2011.09.003; Polledo L, 2012, J NEUROVIROL, V18, P532, DOI 10.1007/s13365-012-0131-0; Preziuso S, 2003, EUR J HISTOCHEM, V47, P373; Ryan S, 2000, J VIROL, V74, P10096, DOI 10.1128/JVI.74.21.10096-10103.2000; Sotelo MJ, 1998, THESIS; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Thormar H, 2005, AIDS REV, V7, P233; TORSTEINSDOTTIR S, 1992, J NEUROIMMUNOL, V41, P149, DOI 10.1016/0165-5728(92)90065-S; Torsteinsdottir S, 2007, VACCINE, V25, P6713, DOI 10.1016/j.vaccine.2007.07.004	29	3	3	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						49	56		10.1016/j.jcpa.2018.01.001			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400008	29599005				2019-10-28	
J	Taube, JM; Galon, J; Sholl, LM; Rodig, SJ; Cottrell, TR; Giraldo, NA; Baras, AS; Patel, SS; Anders, RA; Rimm, DL; Cimino-Mathews, A				Taube, Janis M.; Galon, Jerome; Sholl, Lynette M.; Rodig, Scott J.; Cottrell, Tricia R.; Giraldo, Nicolas A.; Baras, Alexander S.; Patel, Sanjay S.; Anders, Robert A.; Rimm, David L.; Cimino-Mathews, Ashley			Implications of the tumor immune microenvironment for staging and therapeutics	MODERN PATHOLOGY			English	Review							RENAL-CELL CARCINOMA; CLASSICAL HODGKIN LYMPHOMA; DEATH LIGAND-1 EXPRESSION; PD-L1 B7-H1 EXPRESSION; CENTRAL-NERVOUS-SYSTEM; LONG-TERM SAFETY; SQUAMOUS-CELL; CHECKPOINT BLOCKADE; BREAST-CANCER; CLINICOPATHOLOGICAL-ANALYSIS	Characterizing the tumor immune microenvironment enables the identification of new prognostic and predictive biomarkers, the development of novel therapeutic targets and strategies, and the possibility to guide first-line treatment algorithms. Although the driving elements within the tumor microenvironment of individual primary organ sites differ, many of the salient features remain the same. The presence of a robust antitumor milieu characterized by an abundance of CD8+ cytotoxic T-cells, Th1 helper cells, and associated cytokines often indicates a degree of tumor containment by the immune system and can even lead to tumor elimination. Some of these features have been combined into an 'Immunoscore', which has been shown to complement the prognostic ability of the current TNM staging for early stage colorectal carcinomas. Features of the immune microenvironment are also potential therapeutic targets, and immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are especially promising. FDA-approved indications for anti-PD-1/PD-L1 are rapidly expanding across numerous tumor types and, in certain cases, are accompanied by companion or complimentary PD-L1 immunohistochemical diagnostics. Pathologists have direct visual access to tumor tissue and in-depth knowledge of the histological variations between and within tumor types and thus are poised to drive forward our understanding of the tumor microenvironment. This review summarizes the key components of the tumor microenvironment, presents an overview of and the challenges with PD-L1 antibodies and assays, and addresses newer candidate biomarkers, such as CD8+ cell density and mutational load. Characteristics of the local immune contexture and current pathology-related practices for specific tumor types are also addressed. In the future, characterization of the host antitumor immune response using multiplexed and multimodality biomarkers may help predict which patients will respond to immune-based therapies.	[Taube, Janis M.; Giraldo, Nicolas A.] Johns Hopkins Univ, Dept Dermatol, SOM, Baltimore, MD 21218 USA; [Taube, Janis M.; Cottrell, Tricia R.; Giraldo, Nicolas A.; Baras, Alexander S.; Anders, Robert A.; Cimino-Mathews, Ashley] Bloomberg Kimmel Inst Immunotherapy, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA; [Taube, Janis M.; Cottrell, Tricia R.; Giraldo, Nicolas A.; Baras, Alexander S.; Anders, Robert A.; Cimino-Mathews, Ashley] Johns Hopkins Univ, SOM, Dept Pathol, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA; [Taube, Janis M.; Cimino-Mathews, Ashley] Johns Hopkins Univ, SOM, Dept Oncol, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA; [Galon, Jerome] INSERM, Lab Integrat Canc Immunol, Paris, France; [Galon, Jerome] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Galon, Jerome] Univ Paris 06, UPMC, Sorbonne Univ, Ctr Rech Cordeliers, Paris, France; [Sholl, Lynette M.; Rodig, Scott J.; Patel, Sanjay S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Rimm, David L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Cimino-Mathews, A (reprint author), Bloomberg Kimmel Inst Immunotherapy, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA.; Cimino-Mathews, A (reprint author), Johns Hopkins Univ, SOM, Dept Pathol, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA.; Cimino-Mathews, A (reprint author), Johns Hopkins Univ, SOM, Dept Oncol, Weinberg Bldg,Room 2242,401N Broadway St, Baltimore, MD 21287 USA.	acimino@jhmi.edu	Galon, Jerome/G-9838-2019; Rodig, Scott/Y-3889-2019	Galon, Jerome/0000-0001-9635-1339; 	Melanoma Research Alliance; Bristol-Myers SquibbBristol-Myers Squibb; Sidney Kimmel Cancer Center Core Grant [P30 CA006973]; National Cancer Institute NIH Grant [R01 CA142779]; NIH GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 CA193145]; Center for Immuno-Oncology, Dana-Farber Cancer Institute; National Cancer Institute of France (INCa); Canceropole Ile de FranceRegion Ile-de-France; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); Cancer research for personalized medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); LabEx Immuno-oncology; Society for Immunotherapy of Cancer (SITC); Bloomberg-Kimmel Institute for Cancer Immunotherapy; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant [SU2C-AACR-DT1012]	We thank Jessica Esandrio for administrative assistance. This work was supported by the Melanoma Research Alliance (to JMT); Bristol-Myers Squibb (JMT, RAA); Sidney Kimmel Cancer Center Core Grant P30 CA006973 (to JMT, RAA); the National Cancer Institute NIH Grant R01 CA142779 (to JMT); NIH Grant T32 CA193145 (to TRC); Center for Immuno-Oncology, Dana-Farber Cancer Institute (to SJR); The National Cancer Institute of France (INCa), the Canceropole Ile de France, INSERM, the Cancer research for personalized medicine (CARPEM), Paris Alliance of Cancer Research Institutes (PACRI), the LabEx Immuno-oncology, the Society for Immunotherapy of Cancer (SITC) (to JG). We were also supported by the Bloomberg-Kimmel Institute for Cancer Immunotherapy and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Armand P, 2016, J CLIN ONCOL, V34, P3733, DOI 10.1200/JCO.2016.67.3467; Baras AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134412; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bauml J, 2017, J CLIN ONCOL, V35, P1542, DOI 10.1200/JCO.2016.70.1524; Bentz M, 2001, GENE CHROMOSOME CANC, V30, P393, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I; Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388; Boorjian SA, 2008, CLIN CANCER RES, V14, P4800, DOI 10.1158/1078-0432.CCR-08-0731; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Burugu S, 2017, BREAST CANCER-TOKYO, V24, P3, DOI 10.1007/s12282-016-0698-z; Cabillic F, 2006, CLIN EXP IMMUNOL, V146, P518, DOI 10.1111/j.1365-2249.2006.03212.x; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Chen CL, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1176653; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Cimino-Mathews A, 2015, ONCOLOGY-NY, V29, P375; Curry JL, 2017, J CUTAN PATHOL, V44, P158, DOI 10.1111/cup.12858; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Falchook GS, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0176-3; Faraj SF, 2015, UROLOGY, V85, DOI 10.1016/j.urology.2014.10.020; Feldman R, 2016, HEAD NECK-J SCI SPEC, V38, pE1625, DOI 10.1002/hed.24290; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Figel AM, 2011, AM J PATHOL, V179, P436, DOI 10.1016/j.ajpath.2011.03.011; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3500; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-1; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Giraldo NA, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-662; Giraldo NA, 2017, CLIN CANCER RES, V23, P4416, DOI 10.1158/1078-0432.CCR-16-2848; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; HERR HW, 1995, J CLIN ONCOL, V13, P1404, DOI 10.1200/JCO.1995.13.6.1404; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Inman BA, 2007, CANCER, V109, P1499, DOI 10.1002/cncr.22588; Jarvinen AK, 2008, GENE CHROMOSOME CANC, V47, P500, DOI 10.1002/gcc.20551; Johnson BE, 2016, NEW ENGL J MED, V375, P1892, DOI 10.1056/NEJMe1611003; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Johnson DB, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9517; Kadara H, 2017, ANN ONCOL, V28, P75, DOI 10.1093/annonc/mdw436; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Kaunitz GJ, 2017, AM J SURG PATHOL, V41, P1381, DOI 10.1097/PAS.0000000000000900; Kaunitz GJ, 2017, LAB INVEST, V97, P1063, DOI 10.1038/labinvest.2017.64; Kim HS, 2016, CANCER RES TREAT, V48, P527, DOI 10.4143/crt.2015.249; Kondo T, 2006, CANCER SCI, V97, P780, DOI 10.1111/j.1349-7006.2006.00231.x; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Ladoire S, 2011, J PATHOL, V224, P389, DOI 10.1002/path.2866; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lau J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14572; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lechner A, 2017, ONCOTARGET, V8, P44418, DOI 10.18632/oncotarget.17901; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8; Lipson EJ, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0228-3; Lipson EJ, 2016, NEW ENGL J MED, V374, P896, DOI 10.1056/NEJMc1509268; Lipson EJ, 2013, CANCER IMMUNOL RES, V1, P54, DOI 10.1158/2326-6066.CIR-13-0034; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; Littman DR, 2015, CELL, V162, P1186, DOI 10.1016/j.cell.2015.08.038; Lizotte PH, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89014; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384; Malm IJ, 2015, HEAD NECK-J SCI SPEC, V37, P1088, DOI 10.1002/hed.23706; Masters GA, 2015, J CLIN ONCOL, V33, P3488, DOI 10.1200/JCO.2015.62.1342; McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425; MOORE OS, 1949, CANCER, V2, P635, DOI 10.1002/1097-0142(194907)2:4<635::AID-CNCR2820020411>3.0.CO;2-Q; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; Nakanishi J, 2007, CANCER IMMUNOL IMMUN, V56, P1173, DOI 10.1007/s00262-006-0266-z; Nakano O, 2001, CANCER RES, V61, P5132; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nayak L, 2017, BLOOD, V129, P3071, DOI 10.1182/blood-2017-01-764209; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Obeid JM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1235107; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Piha-Paul SA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.1536; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Ribas A, 2015, NEW ENGL J MED, V373, P1490, DOI 10.1056/NEJMp1510079; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Rodic N, 2015, CANCER IMMUNOL RES, V3, P110, DOI 10.1158/2326-6066.CIR-14-0145; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sautes-Fridman C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00407; Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shi M, 2014, AM J SURG PATHOL, V38, P1715, DOI 10.1097/PAS.0000000000000297; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Shin SJ, 2016, ANN SURG ONCOL, V23, P694, DOI 10.1245/s10434-015-4903-7; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Socinski M, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.39; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Steidl C, 2010, BLOOD, V116, P418, DOI 10.1182/blood-2009-12-257345; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Taube JM, 2015, CLIN CANCER RES, V21, P3969, DOI 10.1158/1078-0432.CCR-15-0244; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Thompson E, 2016, MODERN PATHOL, V29, P249, DOI 10.1038/modpathol.2015.158; Thompson ED, 2017, MODERN PATHOL, V30, P1551, DOI 10.1038/modpathol.2017.79; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, CANCER IMMUNOL RES, V3, P855, DOI 10.1158/2326-6066.CIR-15-0024; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wang YH, 2009, J HUAZHONG U SCI-MED, V29, P77, DOI 10.1007/s11596-009-0116-2; Westra WH, 2008, CLIN CANCER RES, V14, P366, DOI 10.1158/1078-0432.CCR-07-1402; Winerdal ME, 2011, BJU INT, V108, P1672, DOI 10.1111/j.1464-410X.2010.10020.x; Xie XJ, 2017, EXPERT OPIN BIOL TH, V17, P701, DOI 10.1080/14712598.2017.1315100; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xylinas E, 2014, EJSO-EUR J SURG ONC, V40, P121, DOI 10.1016/j.ejso.2013.08.023; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122; Yanik EL, 2017, JAMA ONCOL, V3, P974, DOI 10.1001/jamaoncol.2017.0115; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761; Younes A, 2016, LANCET ONCOL, V17, P1283, DOI 10.1016/S1470-2045(16)30167-X; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	165	44	46	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					214	234		10.1038/modpathol.2017.156			21	Pathology	Pathology	FV7KD	WOS:000424761400001	29192647	Green Accepted, Bronze			2019-10-28	
J	Filippone, EJ; McCue, PA; Farber, JL				Filippone, Edward J.; McCue, Peter A.; Farber, John L.			Transplant glomerulopathy	MODERN PATHOLOGY			English	Review							ANTIBODY-MEDIATED REJECTION; RENAL-ALLOGRAFT REJECTION; HEPATITIS-C VIRUS; DONOR-SPECIFIC ANTIBODIES; HEMOLYTIC-UREMIC SYNDROME; NOVO THROMBOTIC MICROANGIOPATHY; INTERTUBULAR CAPILLARY CHANGES; INCOMPATIBLE KIDNEY-TRANSPLANTATION; CHRONIC HUMORAL REJECTION; ACTING ANTIVIRAL AGENTS	In the renal allograft, transplant glomerulopathy represents a morphologic lesion and not a specific diagnosis. The hallmark pathologic feature is glomerular basement membrane reduplication by light microscopy or electron microscopy in the absence of immune complex deposits. Transplant glomerulopathy results from chronic, recurring endothelial cell injury that can be mediated by HLA alloantibodies (donor-specific antibodies), various autoantibodies, cell-mediated immune injury, thrombotic microangiopathy, or chronic hepatitis C. Clinically, transplant glomerulopathy may be silent, detectable on protocol biopsy, or present with overt manifestations, including up to nephrotic range proteinuria, hypertension, and declining glomerular filtration rate. In either case, transplant glomerulopathy is associated with reduced graft survival. This review details the morphologic features of transplant glomerulopathy found on light microscopy, immunofluorescence microscopy, and electron microscopy. The pathophysiology of the causes and risk factors are discussed. Clinical manifestations are emphasized and potential therapeutic modalities are examined.	[Filippone, Edward J.] Dept Med, Div Nephrol, Philadelphia, PA USA; [McCue, Peter A.; Farber, John L.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Pathol, Philadelphia, PA 19107 USA	Filippone, EJ (reprint author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Med, 2228 South Broad St, Philadelphia, PA 19145 USA.	kidneys@comcast.net					Akalin E, 2003, AM J TRANSPLANT, V3, P1116, DOI 10.1034/j.1600-6143.2003.00151.x; Akalin E, 2007, CLIN J AM SOC NEPHRO, V2, P1261, DOI 10.2215/CJN.02420607; Al Aly Z, 2005, TRANSPL INT, V18, P800, DOI 10.1111/j.1432-2277.2005.00130.x; Alvarez-Marquez A, 2009, TRANSPLANTATION, V87, P94, DOI 10.1097/TP.0b013e31818bd790; Angaswamy N, 2014, AM J TRANSPLANT, V14, P685, DOI 10.1111/ajt.12592; Asaka M, 2000, NEPHRON, V84, P258, DOI 10.1159/000045586; Baid S, 1999, J AM SOC NEPHROL, V10, P146; Baid-Agrawal S, 2011, KIDNEY INT, V80, P879, DOI 10.1038/ki.2011.194; Banfi G, 2005, TRANSPLANTATION, V80, P1392, DOI 10.1097/01.tp.0000181167.88133.d2; Batal I, 2010, AM J TRANSPLANT, V10, P2442, DOI 10.1111/j.1600-6143.2010.03261.x; Batal I, 2008, MODERN PATHOL, V21, P1490, DOI 10.1038/modpathol.2008.152; Berdichevski RH, 2010, CLIN KIDNEY J, V3, P564, DOI 10.1093/ndtplus/sfq155; Besarani D, 2014, TRANSPLANTATION, V98, P72, DOI 10.1097/01.TP.0000443224.66960.37; Billen EVA, 2009, TRANSPLANTATION, V87, P563, DOI 10.1097/TP.0b013e3181949e37; Billing H, 2012, TRANSPL INT, V25, P1165, DOI 10.1111/j.1432-2277.2012.01544.x; BONSER RS, 1984, LANCET, V2, P1337; BUSCH GJ, 1971, HUM PATHOL, V2, P253, DOI 10.1016/S0046-8177(71)80037-0; Canaud G, 2013, AM J TRANSPLANT, V13, P2179, DOI 10.1111/ajt.12319; Cardinal H, 2017, J AM SOC NEPHROL, V28, P400, DOI 10.1681/ASN.2016070756; Carson JM, 2012, CLIN NEPHROL, V77, P79, DOI 10.5414/CN107036; Choi J, 2017, AM J TRANSPLANT, V17, P2381, DOI 10.1111/ajt.14228; Chua JS, 2015, J AM SOC NEPHROL, V26, P2239, DOI 10.1681/ASN.2014050429; Cohen D, 2012, KIDNEY INT, V81, P628, DOI 10.1038/ki.2011.497; Cornell LD, 2015, AM J TRANSPLANT, V15, P1293, DOI 10.1111/ajt.13168; Cosio FG, 1996, AM J KIDNEY DIS, V28, P752, DOI 10.1016/S0272-6386(96)90260-7; Cruzado JM, 2001, AM J TRANSPLANT, V1, P171, DOI 10.1034/j.1600-6143.2001.001002171.x; de Kort H, 2016, TRANSPLANTATION, V100, P889, DOI 10.1097/TP.0000000000000908; De Serres SA, 2016, AM J TRANSPLANT, V16, P1516, DOI 10.1111/ajt.13624; Dinavahi R, 2011, J AM SOC NEPHROL, V22, P1168, DOI 10.1681/ASN.2010111183; Dobi D, 2016, VIRCHOWS ARCH, V469, P563, DOI 10.1007/s00428-016-2010-1; Dobi D, 2016, PATHOL ONCOL RES, V22, P15, DOI 10.1007/s12253-015-9962-3; Drachenberg CB, 1997, ULTRASTRUCT PATHOL, V21, P227, DOI 10.3109/01913129709021918; Dragun D, 2005, NEW ENGL J MED, V352, P558, DOI 10.1056/NEJMoa035717; Einecke G, 2009, AM J TRANSPLANT, V9, P2520, DOI 10.1111/j.1600-6143.2009.02799.x; Fehr T, 2009, TRANSPLANTATION, V87, P1837, DOI 10.1097/TP.0b013e3181a6bac5; Filippone EJ, 2016, J IMMUNOL RES, DOI 10.1155/2016/5197396; Filippone EJ, 2015, AM J KIDNEY DIS, V66, P337, DOI 10.1053/j.ajkd.2015.03.033; Filippone EJ, 2015, CLIN TRANSPLANT, V29, P279, DOI 10.1111/ctr.12524; Filippone EJ, 2013, CLIN TRANSPLANT, V27, P790, DOI 10.1111/ctr.12258; Filippone EJ, 2013, CASE REP TRANSPLANT, V2013; Fu M, 2007, APOPTOSIS, V12, P355, DOI 10.1007/s10495-006-0581-z; GALLAY BJ, 1995, AM J KIDNEY DIS, V26, P662, DOI 10.1016/0272-6386(95)90606-1; GALLI FC, 1993, J HEART LUNG TRANSPL, V12, P440; Gasim AH, 2017, TRANSPL INT, V30, P519, DOI 10.1111/tri.12936; Gaston RS, 2010, TRANSPLANTATION, V90, P68, DOI 10.1097/TP.0b013e3181e065de; George JN, 2014, NEW ENGL J MED, V371, P654, DOI 10.1056/NEJMra1312353; Gloor JM, 2007, AM J TRANSPLANT, V7, P2124, DOI 10.1111/j.1600-6143.2007.01895.x; Gloor JM, 2006, AM J TRANSPLANT, V6, P1841, DOI 10.1111/j.1600-6143.2006.01416.x; Gough J, 2001, TRANSPLANTATION, V71, P1390, DOI 10.1097/00007890-200105270-00006; Gupta A, 2016, KIDNEY INT, V89, P217, DOI 10.1038/ki.2015.276; Haas M, 2006, AM J TRANSPLANT, V6, P1829, DOI 10.1111/j.1600-6143.2006.01356.x; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Haas M, 2011, AM J TRANSPLANT, V11, P2123, DOI 10.1111/j.1600-6143.2011.03647.x; Haas M, 2009, J AM SOC NEPHROL, V20, P197, DOI 10.1681/ASN.2008030279; Halloran PF, 2017, AM J TRANSPLANT, V17, P1754, DOI 10.1111/ajt.14200; Halloran PF, 2016, NAT REV NEPHROL, V12, P534, DOI [10.1038/nmeph.2016.85, 10.1038/nrneph.2016.85]; HAMBURGER J, 1965, LANCET, V1, P985; Hayde N, 2013, CLIN J AM SOC NEPHRO, V8, P2141, DOI 10.2215/CJN.04240413; Hayde N, 2013, TRANSPLANTATION, V95, P580, DOI 10.1097/TP.0b013e318277b2e2; Heinemann Falko M, 2006, Clin Transpl, P371; Homs S, 2009, AM J TRANSPLANT, V9, P1230, DOI 10.1111/j.1600-6143.2009.02596.x; Husain S, 2013, AM J KIDNEY DIS, V62, P352, DOI 10.1053/j.ajkd.2012.10.026; Issa N, 2008, TRANSPLANTATION, V86, P681, DOI 10.1097/TP.0b013e3181837626; Ivanyi B, 2001, MODERN PATHOL, V14, P1200, DOI 10.1038/modpathol.3880461; Ivanyi S, 2000, HUM PATHOL, V31, P1129; Jackson AM, 2015, J AM SOC NEPHROL, V26, P1161, DOI 10.1681/ASN.2013121277; Java A, 2015, TRANSPL INT, V28, P1121, DOI 10.1111/tri.12582; Jen KY, 2012, MODERN PATHOL, V25, P434, DOI 10.1038/modpathol.2011.168; JOHNSON RJ, 1994, KIDNEY INT, V46, P1700, DOI 10.1038/ki.1994.471; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; Joosten SA, 2005, AM J TRANSPLANT, V5, P383, DOI 10.1111/j.1600-6143.2005.00690.x; Joosten SA, 2002, AM J PATHOL, V160, P1301, DOI 10.1016/S0002-9440(10)62557-6; Kahwaji J, 2014, CLIN TRANSPLANT, V28, P546, DOI 10.1111/ctr.12345; Kamal L, 2015, TRANSPLANTATION, V99, P1912, DOI 10.1097/TP.0000000000000598; Kamar N, 2016, AM J TRANSPLANT, V16, P1474, DOI 10.1111/ajt.13518; Kanungo S, 2010, INT UROL NEPHROL, V42, P219, DOI 10.1007/s11255-009-9594-1; Kieran N, 2009, J AM SOC NEPHROL, V20, P2260, DOI 10.1681/ASN.2009020199; Kozakowski N, 2017, TRANSPLANTATION, V101, P395; Kozakowski N, 2015, KIDNEY INT, V88, P332, DOI 10.1038/ki.2015.64; Kulkarni S, 2017, Am J Transplant, V17, P682, DOI 10.1111/ajt.14001; Lachmann N, 2016, NEPHROL DIAL TRANSPL, V31, P1351, DOI 10.1093/ndt/gfw041; Le Quintrec M, 2008, AM J TRANSPLANT, V8, P1694, DOI 10.1111/j.1600-6143.2008.02297.x; Lesage J, 2015, TRANSPLANTATION, V99, P69, DOI 10.1097/TP.0000000000000310; Liapis G, 2012, TRANSPLANTATION, V94, P620, DOI 10.1097/TP.0b013e31825f4df4; Lin MV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158431; Lonze BE, 2014, AM J TRANSPLANT, V14, P459, DOI 10.1111/ajt.12540; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Loupy A, 2009, AM J TRANSPLANT, V9, P2561, DOI 10.1111/j.1600-6143.2009.02813.x; Lubetzky M, 2017, TRANSPLANTATION, V101, P1704, DOI 10.1097/TP.0000000000001618; Magil AB, 2005, AM J KIDNEY DIS, V45, P1084, DOI 10.1053/j.ajkd.2005.02.017; MARYNIAK RK, 1985, KIDNEY INT, V27, P799, DOI 10.1038/ki.1985.83; Mauiyyedi S, 2001, J AM SOC NEPHROL, V12, P574; Meehan SM, 2011, CLIN J AM SOC NEPHRO, V6, P395, DOI 10.2215/CJN.05870710; Mengel M, 2013, AM J TRANSPLANT, V13, P1235, DOI 10.1111/ajt.12193; Milongo D, 2017, AM J TRANSPLANT, V17, P420, DOI 10.1111/ajt.13958; MONGA G, 1990, ULTRASTRUCT PATHOL, V14, P201, DOI 10.3109/01913129009076124; MONGA G, 1992, MODERN PATHOL, V5, P125; Montgomery RA, 2016, AM J TRANSPLANT, V16, P3468, DOI 10.1111/ajt.13871; Murer L, 2000, J AM SOC NEPHROL, V11, P1132; Nagele EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060726; Nickeleit V, 2002, J AM SOC NEPHROL, V13, P242; Noris M, 2010, AM J TRANSPLANT, V10, P1517, DOI 10.1111/j.1600-6143.2010.03156.x; Orandi BJ, 2014, TRANSPLANTATION, V98, P857, DOI 10.1097/TP.0000000000000298; Patri P, 2016, KIDNEY INT, V89, P450, DOI 10.1038/ki.2015.288; Peng YF, 2005, MOL IMMUNOL, V42, P781, DOI 10.1016/j.molimm.2004.07.045; PORTER KA, 1967, LAB INVEST, V16, P153; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Regele H, 2002, J AM SOC NEPHROL, V13, P2371, DOI 10.1097/01.ASN.0000025780.03790.0F; Reinsmoen NL, 2010, TRANSPLANTATION, V90, P1473, DOI 10.1097/TP.0b013e3181fd97f1; Remport A, 2015, NEPHROL DIAL TRANSPL, V30, P1825, DOI 10.1093/ndt/gfu371; Reynolds JC, 2003, AM J KIDNEY DIS, V42, P1058, DOI 10.1053/S0272-6386(03)01019-9; Rosenstock JL, 2003, KIDNEY INT, V63, P1450, DOI 10.1046/j.1523-1755.2003.00853.x; Rostaing L, 2009, TRANSPL INT, V22, P906, DOI 10.1111/j.1432-2277.2009.00896.x; ROTH D, 1995, TRANSPLANTATION, V59, P1676, DOI 10.1097/00007890-199506270-00006; Roufosse CA, 2012, TRANSPLANTATION, V94, P269, DOI 10.1097/TP.0b013e31825774ab; Sabry AA, 2002, NEPHROL DIAL TRANSPL, V17, P239, DOI 10.1093/ndt/17.2.239; Sapir-Pichhadze R, 2015, AM J TRANSPLANT, V15, P137, DOI 10.1111/ajt.12968; Sapir-Pichhadze R, 2015, KIDNEY INT, V87, P182, DOI 10.1038/ki.2014.166; Satoskar AA, 2010, AM J TRANSPLANT, V10, P1804, DOI 10.1111/j.1600-6143.2010.03178.x; Sawinski D, 2016, AM J TRANSPLANT, V16, P1588, DOI 10.1111/ajt.13620; Schwimmer J, 2003, AM J KIDNEY DIS, V41, P471, DOI 10.1053/ajkd.2003.50058; Sethi S, 2015, J AM SOC NEPHROL, V26, P2852, DOI 10.1681/ASN.2014040406; Setoguchi K, 2008, AM J TRANSPLANT, V8, P86, DOI 10.1111/j.1600-6143.2007.02036.x; Shimizu T, 2012, CLIN TRANSPLANT, V26, P37, DOI 10.1111/j.1399-0012.2012.01639.x; SHULMAN H, 1981, NEW ENGL J MED, V305, P1392, DOI 10.1056/NEJM198112033052306; Sigdel TK, 2013, HUM IMMUNOL, V74, P1486, DOI 10.1016/j.humimm.2013.07.001; Sigdel TK, 2012, J AM SOC NEPHROL, V23, P750, DOI 10.1681/ASN.2011060596; Sijpkens YW, 2004, KIDNEY INT, V65, P2409, DOI 10.1111/j.1523-1755.2004.00662.x; Sis B, 2007, AM J TRANSPLANT, V7, P1743, DOI 10.1111/j.1600-6143.2007.01836.x; Sis B, 2012, AM J TRANSPLANT, V12, P1168, DOI 10.1111/j.1600-6143.2011.03931.x; Smith RN, 2008, AM J TRANSPLANT, V8, P1662, DOI 10.1111/j.1600-6143.2008.02303.x; Smith RN, 2012, TRANSPL IMMUNOL, V27, P107, DOI 10.1016/j.trim.2012.08.005; Sreedharanunni S, 2014, TRANSPL INT, V27, P784, DOI 10.1111/tri.12331; Stegall MD, 2011, AM J TRANSPLANT, V11, P2405, DOI 10.1111/j.1600-6143.2011.03757.x; STEHMANBREEN C, 1995, CLIN NEPHROL, V44, P141; Sun QQ, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-128; Sun QQ, 2012, KIDNEY INT, V82, P321, DOI 10.1038/ki.2012.112; Sun QQ, 2011, J AM SOC NEPHROL, V22, P246, DOI 10.1681/ASN.2010050471; Sun YBY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055027; Torres IB, 2014, CLIN TRANSPLANT, V28, P1148, DOI 10.1111/ctr.12433; VANBUREN D, 1985, SURGERY, V98, P54; Verghese PS, 2018, J NEPHROL, V31, P157, DOI 10.1007/s40620-016-0365-7; Wavamunno MD, 2007, AM J TRANSPLANT, V7, P2757, DOI 10.1111/j.1600-6143.2007.01995.x; Wiebe C, 2012, AM J TRANSPLANT, V12, P1157, DOI 10.1111/j.1600-6143.2012.04013.x; Wong W, 2004, AM J KIDNEY DIS, V44, P924, DOI 10.1053/j.ajkd.2004.05.047; Yadav B, 2015, EXP CLIN TRANSPLANT, V13, P145, DOI 10.6002/ect.2014.0188; Yang B, 2016, AM J TRANSPLANT, V16, P3416, DOI 10.1111/ajt.13866; Yang Y, 2015, J AM SOC NEPHROL, V26, P1450, DOI 10.1681/ASN.2014030287; Young BA, 1996, AM J KIDNEY DIS, V28, P561, DOI 10.1016/S0272-6386(96)90468-0; Zhao XM, 2017, TRANSPLANTATION, V101, P395, DOI 10.1097/TP.0000000000001118; Zollinger H U, 1973, Curr Top Pathol, V57, P1; Zuber J, 2012, AM J TRANSPLANT, V12, P3337, DOI 10.1111/j.1600-6143.2012.04252.x; ZWIRNER J, 1989, KIDNEY INT, V36, P1069, DOI 10.1038/ki.1989.302	153	4	5	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					235	252		10.1038/modpathol.2017.123			18	Pathology	Pathology	FV7KD	WOS:000424761400002	29027535	Bronze			2019-10-28	
J	Zieba, A; Ponten, F; Uhlen, M; Landegren, U				Zieba, Agata; Ponten, Fredrik; Uhlen, Mathias; Landegren, Ulf			In situ protein detection with enhanced specificity using DNA-conjugated antibodies and proximity ligation	MODERN PATHOLOGY			English	Article							IMMUNOHISTOCHEMISTRY; PROTEOMICS; COMPLEXES; OLIGONUCLEOTIDES; TRANSCRIPTOMICS; DIAGNOSTICS; BIOMARKER; ASSAYS; ATLAS	Antibodies are important tools in anatomical pathology and research, but the quality of in situ protein detection by immunohistochemistry greatly depends on the choice of antibodies and the abundance of the targeted proteins. Many antibodies used in scientific research do not meet requirements for specificity and sensitivity. Accordingly, methods that improve antibody performance and produce quantitative data can greatly advance both scientific investigations and clinical diagnostics based on protein expression and in situ localization. We demonstrate here protocols for antibody labeling that allow specific protein detection in tissues via bright-field in situ proximity ligation assays, where each protein molecule must be recognized by two antibodies. We further demonstrate that single polyclonal antibodies or purified serum preparations can be used for these dual recognition assays. The requirement for protein recognition by pairs of antibody conjugates can significantly improve specificity of protein detection over single-binder assays.	[Zieba, Agata; Landegren, Ulf] Uppsala Univ, BMC, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Ponten, Fredrik] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Uhlen, Mathias] KTH Royal Inst Technol, Sci Life Lab, Stockholm, Sweden	Landegren, U (reprint author), BMC, Mol Tools, Dept Immunol Genet & Pathol, Husargatan 3, S-75108 Uppsala, Sweden.; Landegren, U (reprint author), BMC, Res Grp Ulf Landegren, Husargatan 3, S-75108 Uppsala, Sweden.	Ulf.Landegren@igp.uu.se	Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056	Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation [2008:0143]; European Community's 7th Framework Program (FP7) [222635, 241481]; Swedish Research CouncilSwedish Research Council; Swedish Governmental Agency for Innovation SystemsVinnova; IngaBritt and Arne Lundberg Foundation; European Research Council under the European Union's Seventh Framework Programme (FP) / ERC GrantEuropean Research Council (ERC) [294409]; Uppsala University	This work was supported by the Knut and Alice Wallenberg Foundation (#2008:0143), the European Community's 7th Framework Program (FP7/2007-2013) under grant agreement no 222635 (AffinityProteome) 241481 (Affinomics), The Swedish Research Council, Swedish Governmental Agency for Innovation Systems, IngaBritt and Arne Lundberg Foundation, the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement n. 294409 (ProteinSeq), and Uppsala University. UL holds stock in Olink, having rights to the in situ proximity ligation assay technology. We would also like to thank Tara Hiltke at the National Cancer Institute for providing mAbs for in situ proximity ligation assay experiments.	Agaton C, 2004, J CHROMATOGR A, V1043, P33, DOI 10.1016/j.chroma.2004.06.008; Anagnostou VK, 2010, CANCER EPIDEM BIOMAR, V19, P982, DOI 10.1158/1055-9965.EPI-10-0097; Baker M, 2015, NATURE, V521, P274, DOI 10.1038/521274a; Blokzijl A, 2014, BBA-PROTEINS PROTEOM, V1844, P933, DOI 10.1016/j.bbapap.2013.07.016; Bradbury A, 2015, NATURE, V518, P27, DOI 10.1038/518027a; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; COONS AH, 1971, ANN NY ACAD SCI, V177, P5, DOI 10.1111/j.1749-6632.1971.tb35025.x; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Fritschy JM, 2008, EUR J NEUROSCI, V28, P2365, DOI 10.1111/j.1460-9568.2008.06552.x; Grannas K, 2015, J MOL BIOL, V427, P3407, DOI 10.1016/j.jmb.2015.04.015; Kamali-Moghaddam M, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-124; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Khatwani SL, 2012, BIOORGAN MED CHEM, V20, P4532, DOI 10.1016/j.bmc.2012.05.017; Kozlov IA, 2004, BIOPOLYMERS, V73, P621, DOI 10.1002/bip.20009; Lindskog C, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1686-y; Michel MC, 2009, N-S ARCH PHARMACOL, V379, P385, DOI 10.1007/s00210-009-0395-y; O'Hurley G, 2014, MOL ONCOL, V8, P783, DOI 10.1016/j.molonc.2014.03.008; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Takeda S, 2004, BIOORG MED CHEM LETT, V14, P2407, DOI 10.1016/j.bmcl.2004.03.023; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Vashist SK, 2014, SCI REP-UK, V4, DOI 10.1038/srep04407; Voskuil Jla, 2014, F1000Res, V3, P232, DOI 10.12688/f1000research.4966.2; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Zieba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013482; Zieba A, 2010, CLIN CHEM, V56, P99, DOI 10.1373/clinchem.2009.134452	28	4	4	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					253	263		10.1038/modpathol.2017.102			11	Pathology	Pathology	FV7KD	WOS:000424761400003	28937142	Bronze			2019-10-28	
J	Chaiyawat, P; Pruksakorn, D; Phanphaisarn, A; Teeyakasem, P; Klangjorhor, J; Settakorn, J				Chaiyawat, Parunya; Pruksakorn, Dumnoensun; Phanphaisarn, Areerak; Teeyakasem, Pimpisa; Klangjorhor, Jeerawan; Settakorn, Jongkolnee			Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications	MODERN PATHOLOGY			English	Article							INDUCED APOPTOSIS; LUNG METASTASES; INHIBITOR; CELLS; CANCER; DIFFERENTIATION; PROLIFERATION	Epigenetic aberrations are recognized as having pivotal roles in cancer etiology and progression. Histone deacetylases are among the most studied epigenetic modulators in various cancer types. The expression levels of class I histone deacetylase isoforms 1, 2, and 3 in patient-derived primary osteosarcoma cells (6 cases) was investigated, comparing them to normal bone graft-derived osteoblasts (6 cases) using the immunoblotting technique. Expression profiles of histone deacetylases in high-grade osteosarcoma tissue of 89 patients were examined and their association with clinicopathologic parameters and the patient survival was evaluated. Histone deacetylases were immunohistochemically stained on formalin-fixed paraffin-embedded biopsied tissue. Primary osteosarcoma cells expressed higher levels of histone deacetylase 1 and histone deacetylase 2, but lower levels of histone deacetylase 3 compared to benign osteoblasts. Overall, 82, 99, and 93% of 89 osteosarcomas showed nuclear expression of the histone deacetylase isoforms 1, 2, and 3, respectively. Low levels of histone deacetylase 1 were significantly associated with a high Enneking stage (P=0.014) and the presence of initial metastasis (P=0.040), while low levels of histone deacetylase 3 were significantly correlated with age 415 years (P=0.026). Univariate survival analysis found significantly shorter survival in the patients with a high Enneking stage (P<0.001), axial location (P=0.009), presence of initial metastasis (P<0.001),low-histone deacetylase 1 expression (P=0.038), and low-all-histone deacetylases expression (P=0.016). Multivariate survival analysis showed that only axial location (P=0.011) and low-all-histone deacetylases expression (P=0.039) were independent prognostic factors. In subgroup analysis of stage IIB patients (n=45), only axial location and low-all-histone deacetylases expression were associated with shorter survival in both univariate and multivariate analysis (axial location, P=0.008 and 0.010; low-all-HDACs, P=0.013 and 0.038, respectively). Low levels of all-histone deacetylases expression were significantly associated with advanced disease status and short survival. These findings may be a guide to future use of histone deacetylase inhibitors in osteosarcoma patients.	[Chaiyawat, Parunya; Pruksakorn, Dumnoensun; Phanphaisarn, Areerak; Teeyakasem, Pimpisa; Klangjorhor, Jeerawan] Chiang Mai Univ, Fac Med, Orthoped Lab & Res Network Ctr OLARN, Dept Orthoped, Chiang Mai, Thailand; [Pruksakorn, Dumnoensun] Chiang Mai Univ, ORTC, Excellence Ctr, Chiang Mai, Thailand; [Settakorn, Jongkolnee] Chiang Mai Univ, Fac Med, Dept Pathol, Chiang Mai 50200, Thailand	Settakorn, J (reprint author), Chiang Mai Univ, Fac Med, Dept Pathol, Chiang Mai 50200, Thailand.	jsettakorn@gmail.com		Chaiyawat, Parunya/0000-0003-0047-5578	National Science and Technology Development Agency (NSTDA) [P-15-50265]; Faculty of Medicine, Chiang Mai University; National Research University (NRU) fund; Excellence Center in Osteology Research and Training Center (ORTC)	This study was supported by the National Science and Technology Development Agency (NSTDA), code P-15-50265, Faculty of Medicine, Chiang Mai University, National Research University (NRU) fund, and the Excellence Center in Osteology Research and Training Center (ORTC). We also express our sincere thanks to Dr. G. Lamar Robert, PhD and Associate Professor Dr. Chongchit Sripun Robert, PhD, for editing the English manuscript.	Allison Daniel C., 2012, Sarcoma, P704872, DOI 10.1155/2012/704872; Bacci G, 2006, CANCER, V106, P1154, DOI 10.1002/cncr.21724; Benard A, 2015, HISTOPATHOLOGY, V66, P270, DOI 10.1111/his.12534; Blattmann C, 2013, STRAHLENTHER ONKOL, V189, P957, DOI 10.1007/s00066-013-0372-8; Bots M, 2014, BLOOD, V123, P1341, DOI 10.1182/blood-2013-03-488114; Cain Jason E., 2013, Sarcoma, P608964, DOI 10.1155/2013/608964; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Friebele Jill C, 2015, Am J Orthop (Belle Mead NJ), V44, P547; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Heymann MF, 2016, EXPERT OPIN INV DRUG, P1; Huang GX, 2014, ADV EXP MED BIOL, V804, P203, DOI 10.1007/978-3-319-04843-7_11; Hull EE, 2016, BIOMED RES INT, DOI 10.1155/2016/8797206; Koshkina NV, 2011, CANCER-AM CANCER SOC, V117, P3457, DOI 10.1002/cncr.25884; Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006-0061; Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395; McGee-Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003; Okada T, 2006, INT J CANCER, V118, P90, DOI 10.1002/ijc.21297; Pruksakorn D, 2016, INT J ONCOL, V49, P903, DOI 10.3892/ijo.2016.3601; Rao-Bindal K, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.101; Rao-Bindal K, 2013, CURR CANCER DRUG TAR, V13, P411, DOI 10.2174/1568009611313040005; Roh MS, 2004, APOPTOSIS, V9, P583, DOI 10.1023/B:APPT.0000038037.68908.6e; Seo J, 2014, J BREAST CANCER, V17, P323, DOI 10.4048/jbc.2014.17.4.323; Settakorn Jongkolnee, 2006, Journal of the Medical Association of Thailand, V89, P780; Sonnemann J, 2012, CANCER BIOL THER, V13, P417, DOI [10.4161/cbt.19293, 10.4161/cbt.13.6.19293]; Thayanithy V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043720; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wilmott JS, 2015, MODERN PATHOL, V28, P884, DOI 10.1038/modpathol.2015.34; Xie CH, 2016, ONCOTARGETS THER, V9, P4005, DOI 10.2147/OTT.S105418; Yamanegi K, 2010, ONCOL REP, V24, P1621, DOI 10.3892/or_00001026; Yu D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16991; Zhu SG, 2015, PHARM RES-DORDR, V32, P779, DOI 10.1007/s11095-013-1231-0	34	4	4	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					264	274		10.1038/modpathol.2017.125			11	Pathology	Pathology	FV7KD	WOS:000424761400004	28984297	Green Published			2019-10-28	
J	Zilberg, C; Lee, MW; Yu, B; Ashford, B; Kraitsek, S; Ranson, M; Shannon, K; Cowley, M; Iyer, NG; Palme, CE; Ch'ng, S; Low, TH; O'Toole, S; Clark, JR; Gupta, R				Zilberg, Catherine; Lee, Matthew Weicai; Yu, Bing; Ashford, Bruce; Kraitsek, Spiridoula; Ranson, Marie; Shannon, Kerwin; Cowley, Mark; Iyer, N. Gopalakrishna; Palme, Carsten E.; Ch'ng, Sydney; Low, Tsu-Hui (Hubert); O'Toole, Sandra; Clark, Jonathan R.; Gupta, Ruta			Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma	MODERN PATHOLOGY			English	Article							NORMAL HUMAN SKIN; LUNG-CANCER; RECTAL-CANCER; PHASE-II; RESISTANCE; CARCINOGENESIS; GENE; CHEMORADIOTHERAPY; CLASSIFICATION; INHIBITORS	Cutaneous squamous cell carcinoma is the second most prevalent malignancy, most frequently occurring in the head and neck (head and neck cutaneous squamous cell carcinoma). Treatment of locally advanced or metastatic disease is associated with functional morbidity and disfigurement. Underlying genetic mechanisms are poorly understood. Targeted sequencing of 48 clinically relevant genes was performed on DNA extracted from formalin-fixed and paraffin-embedded high-risk primary head and neck cutaneous squamous cell carcinomas that remained non-metastatic at minimum follow-up of 24 months. Associations of somatic mutations with clinicopathologic characteristics were evaluated and compared with those described in the literature for metastatic disease. Alterations in 44 cancer-associated genes were identified. TP53 was mutated in 100% of cases; APC, ATM, ERBB4, GNAQ, KIT, RB1 and ABL1 were altered in 60% of cases. FGFR2 mutations (40%) were exclusively seen in patients with perineural invasion. MLH1 mutations were exclusively seen in the two younger patients (<45 years). Lower incidences of NOTCH1 mutations were observed compared with that described in metastatic head and neck cutaneous squamous cell carcinoma in the literature. Somatic mutations susceptible to EGFR inhibitors, and other small molecular targeted therapeutics were seen in 60% of cases. This study provides insights into somatic mutations in non-metastatic, high-risk head and neck cutaneous squamous cell carcinoma and identifies potential therapeutic targets. Alterations in FGFR2 and NOTCH1 may have roles in local and distant disease progression.	[Zilberg, Catherine; Lee, Matthew Weicai; Yu, Bing; Palme, Carsten E.; Ch'ng, Sydney; Low, Tsu-Hui (Hubert); O'Toole, Sandra; Clark, Jonathan R.; Gupta, Ruta] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia; [Yu, Bing; Kraitsek, Spiridoula] Royal Prince Alfred Hosp, Dept Med Genom, Sydney, NSW, Australia; [Ashford, Bruce] ISLHD, Wollongong, NSW, Australia; [Ashford, Bruce; Ranson, Marie] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia; [Ashford, Bruce; Ranson, Marie] IHMRI, Wollongong, NSW, Australia; [Ranson, Marie] Ctr Oncol Educ & Res Translat CONCERT, Liverpool, Merseyside, England; [Shannon, Kerwin; Palme, Carsten E.; Ch'ng, Sydney; Low, Tsu-Hui (Hubert); Clark, Jonathan R.] Chris OBrien Lifehouse, Sydney Head & Neck Canc Inst, Sydney, NSW, Australia; [Cowley, Mark] Kinghorn Canc Ctr, Sydney, NSW, Australia; [Cowley, Mark] Garvan Inst Med Res, Sydney, NSW, Australia; [Iyer, N. Gopalakrishna] NCCS, Singhlth Duke NUS Head & Neck Ctr, Singapore, Singapore; [Cowley, Mark] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia; [O'Toole, Sandra; Gupta, Ruta] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia	Gupta, R (reprint author), Royal Prince Alfred Hosp, Dept Anat Pathol & Diagnost Oncol, Bldg 94,John Hopkins Dr, Camperdown, NSW 2050, Australia.	Ruta.Gupta@sswahs.nsw.gov.au	Cowley, Mark/K-8731-2019; Ranson, Marie/AAC-4468-2019; Ranson, Marie/A-6324-2008	Cowley, Mark/0000-0002-9519-5714; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Yu, Bing/0000-0001-6013-5220; Shannon, Kerwin/0000-0001-8538-3132; Gupta, Ruta/0000-0003-2940-313X; Low, Tsu-Hui (Hubert)/0000-0001-8958-736X	ICAP; O'Sullivan family; Tag family foundation	We gratefully acknowledge the philanthropic financial support from ICAP, the O'Sullivan family, the Tag family foundation and David Paradice for their generosity and funding assistance. The preliminary results of this study have been presented at the United States and Canadian Academy of pathologists meeting in San Antonio, USA in March 2017 and at the Australia and New Zealand Head and Neck Cancer Society 18th Annual Scientific Meeting in October 2016 Auckland, New Zealand.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al-Rohil RN, 2016, CANCER-AM CANCER SOC, V122, P249, DOI 10.1002/cncr.29738; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; Brunner M, 2015, HEAD NECK-J SCI SPEC, V37, P336, DOI 10.1002/hed.23602; Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030801; Chen HB, 2007, MOL CELL, V27, P717, DOI 10.1016/j.molcel.2007.06.028; Chu MB, 2014, J SKIN CANC, V2014, P8; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; Durinck S, 2011, CANCER DISCOV, V1, P137, DOI 10.1158/2159-8290.CD-11-0028; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Euvrard S, 2012, NEW ENGL J MED, V367, P329, DOI 10.1056/NEJMoa1204166; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Garrido MC, 2010, J INVEST DERMATOL, V130, P20, DOI 10.1038/jid.2009.334; Groth C, 2012, SEMIN CELL DEV BIOL, V23, P465, DOI 10.1016/j.semcdb.2012.01.016; Gurudutt VV, 2011, J SKIN CANCER, DOI 10.1155/2011/502723; Ismail F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021271; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kim MY, 2002, J DERMATOL SCI, V29, P1, DOI 10.1016/S0923-1811(01)00170-0; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lapke N, 2016, ONCOTARGET, V7, P44194, DOI 10.18632/oncotarget.9925; Leiser D, 2015, MOL ONCOL, V9, P1434, DOI 10.1016/j.molonc.2015.04.001; Lewis CM, 2012, CLIN CANCER RES, V18, P1435, DOI 10.1158/1078-0432.CCR-11-1951; Li CF, 2014, J CLIN PATHOL, V67, P1056, DOI 10.1136/jclinpath-2014-202551; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Marechal A, 2013, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPERSPECT.A012716; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Massarelli E, 2013, LUNG CANCER, V80, P235, DOI 10.1016/j.lungcan.2013.01.018; Maubec E, 2011, J CLIN ONCOL, V29, P3419, DOI 10.1200/JCO.2010.34.1735; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mockus SM, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-73; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Ponti G, 2005, LANCET ONCOL, V6, P980, DOI 10.1016/S1470-2045(05)70465-4; Reichrath J, 2012, ADV EXP MED BIOL, V727, P265, DOI 10.1007/978-1-4614-0899-4_20; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Silva IP, 2016, CLIN CANCER RES, V22, P2377, DOI 10.1158/1078-0432.CCR-15-1811; Snietura M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033396; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; Staples MP, 2006, MED J AUSTRALIA, V184, P6, DOI 10.5694/j.1326-5377.2006.tb00086.x; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Wu XS, 2003, MOL CELL BIOL, V23, P3320, DOI 10.1128/MCB.23.9.3320-3328.2003; Yoon G, 2016, TUMOR BIOL, V37, P10209, DOI 10.1007/s13277-016-4899-z; Yu J, 2015, GUT, V64, P636, DOI 10.1136/gutjnl-2013-306620	50	5	5	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					275	287		10.1038/modpathol.2017.128			13	Pathology	Pathology	FV7KD	WOS:000424761400005	28984303				2019-10-28	
J	Sanchez-Munoz, A; Vicioso, L; Santonja, A; Alvarez, M; Plata-Fernandez, Y; Miramon, J; Zarcos, I; Ramirez-Tortosa, CL; Montes-Torres, J; Jerez, JM; de Luque, V; Llacer, C; Fernandez-De Sousa, CE; Perez-Villa, L; Alba, E				Sanchez-Munoz, Alfonso; Vicioso, Luis; Santonja, Angela; Alvarez, Martina; Plata-Fernandez, Yessica; Miramon, Jose; Zarcos, Irene; Ramirez-Tortosa, Cesar L.; Montes-Torres, Julio; Jerez, Jose M.; de Luque, Vanessa; Llacer, Casilda; Fernandez-De Sousa, Cristina E.; Perez-Villa, Lidia; Alba, Emilio			Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes	MODERN PATHOLOGY			English	Article							PROGNOSTIC-SIGNIFICANCE; AMERICAN SOCIETY; TUMOR SUBTYPES; ONCOLOGY/COLLEGE; RECOMMENDATIONS; HETEROGENEITY; ESTROGEN; TRIAL	Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular subtypes based on a validated six-marker immunohistochemical panel and PAM50 signature in male breast cancer, and the subsequent clinical outcome of these different subtypes. We collected 67 surgical specimens of invasive male breast cancer from four different Spanish pathology laboratories. Immunohistochemical staining for the six-marker panel was performed on tissue microarrays. PAM50 subtypes were determined in a research-use-only nCounter Analysis System. We explored the association of immunohistochemical and PAM50 subtypes. Overall survival and disease-free survival were analyzed in the different subtypes of each classification. The distribution of tumor molecular subtypes according PAM50 was: 60% luminal B, 30% luminal A and 10% human epidermal growth factor receptor 2 (Her2) enriched. Only one Her2-enriched tumor was also positive by immunohistochemistry and was treated with trastuzumab. None of the tumors were basal-like. Using immunohistochemical surrogates, 51% of the tumors were luminal B, 44% luminal A, 4% triple-negative and 1% Her2-positive. The clinicopathological characteristics did not differ significantly between immunohistochemical and PAM50 subtypes. We found a significant worse overall survival in Her2-enriched compared with luminal tumors. Male breast cancer seems to be mainly a genomic luminal disease with a predominance of the luminal B subtype. In addition, we found a proportion of patients with Her2-negative by immunohistochemistry but Her2-enriched profile by PAM50 tumors with a worse outcome compared with luminal subtypes that may benefit from anti-Her2 therapies.	[Sanchez-Munoz, Alfonso; Santonja, Angela; de Luque, Vanessa; Llacer, Casilda; Fernandez-De Sousa, Cristina E.; Alba, Emilio] Hosp Univ Reg & Virgen de la Victoria, Med Oncol Serv, Malaga, Spain; [Sanchez-Munoz, Alfonso; Vicioso, Luis; Santonja, Angela; Alvarez, Martina; Montes-Torres, Julio; Jerez, Jose M.; de Luque, Vanessa; Llacer, Casilda; Fernandez-De Sousa, Cristina E.; Alba, Emilio] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Malaga, Spain; [Vicioso, Luis; Perez-Villa, Lidia] Hosp Univ Reg & Virgen de la Victoria, Dept Pathol, Malaga, Spain; [Santonja, Angela; Alvarez, Martina; de Luque, Vanessa; Fernandez-De Sousa, Cristina E.; Alba, Emilio] Univ Malaga, Lab Biol Mol Canc, Ctr Invest Med Sanitarias CIMES, Malaga, Spain; [Alvarez, Martina; Perez-Villa, Lidia] Univ Malaga, Fac Med, Dept Pathol, Malaga, Spain; [Plata-Fernandez, Yessica] Complejo Hosp Jaen, Med Oncol Serv, Jaen, Spain; [Miramon, Jose] Hosp Serrania Ronda, Med Oncol Serv, Malaga, Spain; [Zarcos, Irene] Hosp Costa del Sol, Med Oncol Serv, Malaga, Spain; [Ramirez-Tortosa, Cesar L.] Complejo Hosp Jaen, Dept Pathol, Jaen, Spain; [Montes-Torres, Julio; Jerez, Jose M.] Univ Malaga, Dept Comp Sci, Malaga, Spain	Alba, E (reprint author), Hosp Univ Virgen de la Victoria, Med Oncol Serv, Campus Teatinos S-N, Malaga 29010, Spain.	ealbac@uma.es	Ramirez-Tortosa, Cesar/F-2055-2016; Alba, Emilio/S-1435-2019	Ramirez-Tortosa, Cesar/0000-0002-3302-707X; Alba, Emilio/0000-0002-3364-2603; Santonja, Angela/0000-0001-9367-7632	PFIS-ISCIII [FI12/00489]	We gratefully acknowledge Nanostring Technologies team for providing the reagents for PAM50 subtypes determination as well as technical support, Maria Jose Lozano for her support with samples immunostaining and Jose M Roldan for the edition of the artwork. Angela Santonja has a predoctoral grant PFIS-ISCIII (FI12/00489).	Callari M, 2011, BREAST CANCER RES TR, V127, P601, DOI 10.1007/s10549-010-1015-8; Carey LA, 2016, J CLIN ONCOL, V34, P542, DOI 10.1200/JCO.2015.62.1268; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844; Farhat GN, 2011, JNCI-J NATL CANCER I, V103, P562, DOI 10.1093/jnci/djr031; Ge YM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2258; Giordano SH, 2005, ONCOLOGIST, V10, P471, DOI 10.1634/theoncologist.10-7-471; Gnant M, 2014, ANN ONCOL, V25, P339, DOI 10.1093/annonc/mdt494; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Johansson I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3116; Johansson I, 2011, BREAST CANCER RES TR, V129, P747, DOI 10.1007/s10549-010-1262-8; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korde LA, 2010, J CLIN ONCOL, V28, P2114, DOI 10.1200/JCO.2009.25.5729; Kornegoor R, 2012, MODERN PATHOL, V25, P398, DOI 10.1038/modpathol.2011.174; Leone JP, 2015, BREAST CANCER RES TR, V152, P601, DOI 10.1007/s10549-015-3488-y; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nilsson C, 2013, ACTA ONCOL, V52, P102, DOI 10.3109/0284186X.2012.711952; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840; Prat A, 2016, JAMA ONCOL, V2, P1287, DOI 10.1001/jamaoncol.2016.0922; Prat A, 2014, CLIN CANCER RES, V20, P511, DOI 10.1158/1078-0432.CCR-13-0239; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Sanchez-Munoz A, 2012, ONCOLOGY-BASEL, V83, P228, DOI 10.1159/000341537; Santonja A, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-123-07-14; Shaaban AM, 2012, BREAST CANCER RES TR, V133, P949, DOI 10.1007/s10549-011-1856-9; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Vermeulen MA, 2017, EUR J CANCER, V82, P219, DOI 10.1016/j.ejca.2017.01.034; Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yu XF, 2013, BREAST, V22, P824, DOI 10.1016/j.breast.2013.02.005	33	2	3	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					299	306		10.1038/modpathol.2017.129			8	Pathology	Pathology	FV7KD	WOS:000424761400007	28984296	Bronze			2019-10-28	
J	Tang, ZY; Zhang, JJ; Lu, XY; Wang, W; Chen, H; Robinson, MK; Cheng, J; Tang, GL; Medeiros, LJ				Tang, Zhenya; Zhang, Jianjun; Lu, Xinyan; Wang, Wei; Chen, Hui; Robinson, Melissa K.; Cheng, Joanne; Tang, Guilin; Medeiros, L. Jeffrey			Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma	MODERN PATHOLOGY			English	Article							EGFR MUTATION; CANCER; REARRANGEMENTS; INHIBITOR; SUCCESS; IMPACT; TUMORS; KRAS	In lung cancer, targetable activating alterations in cancer genes, such as EGFR, ALK, RET, ROS1 and MET, are usually mutually exclusive. Rare lung cancer cases with coexistent alterations of EGFR and ALK or EGFR mutations with RET or ROS1 rearrangements have been reported. In this study, we report 15 patients (3 men and 12 women; 14 Caucasians and 1 African American) with ages ranging from 43 to 81 years (median 60 years) with lung adenocarcinoma in which coexistent alterations of two cancer-associated genes, including ALK, ROS1, or RET rearrangement or MET amplification were present. The combination of alterations detected by fluorescence in situ hybridization included ALK combined with ROS1 (n=4), ALK with MET (n=3), ALK with RET (n=1); RET with MET (n=4), RET with ROS1 (n=2), and ROS1 combined with MET (n=1). The frequencies of involvement were similar for all 4 genes, 53% for both ALK and MET (n=8), 47% for both RET and ROS1 (n=7). Activating gene mutations were also detected by next-generation sequencing for TP53 (n=6), EGFR (n=5), KRAS(n=3) and STK11 (n=2). Nine patients reported a smoking history (8 heavy and 1 light) and 6 patients were non-smokers. These findings suggest the need for assessing a panel of genes in lung cancer. Since targetable agents are available for each of these activating alterations, treatment with more than one targeted agent may be beneficial for this rare group of patients.	[Tang, Zhenya; Lu, Xinyan; Wang, Wei; Robinson, Melissa K.; Cheng, Joanne; Tang, Guilin; Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Chen, Hui] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lu, Xinyan] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Tang, ZY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ztang@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				American Cancer Society, 2016, CANC FACTS FIG 2016, P13; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Berge EM, 2014, SEMIN ONCOL, V41, P110, DOI 10.1053/j.seminoncol.2013.12.006; Cabillic F, 2014, J THORAC ONCOL, V9, P295, DOI 10.1097/JTO.0000000000000072; Didkowska J, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.11; Falchook GS, 2016, J CLIN ONCOL, V34, pE141, DOI 10.1200/JCO.2013.50.5016; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8; Ju LX, 2016, LUNG CANCER, V95, P94, DOI 10.1016/j.lungcan.2016.03.005; Jurmeister P, 2015, LUNG CANCER, V87, P122, DOI 10.1016/j.lungcan.2014.11.018; Lee SE, 2015, MODERN PATHOL, V28, P468, DOI 10.1038/modpathol.2014.107; Lou NN, 2016, ONCOTARGET, V7, P65185, DOI 10.18632/oncotarget.11218; Mascarello JT, 2011, GENET MED, V13, P667, DOI 10.1097/GIM.0b013e3182227295; Pan YJ, 2014, LUNG CANCER, V84, P121, DOI 10.1016/j.lungcan.2014.02.007; Shea M, 2016, THER ADV RESPIR DIS, V10, P113, DOI 10.1177/1753465815617871; Subbiah V, 2015, LUNG CANCER, V89, P76, DOI 10.1016/j.lungcan.2015.04.004; Sweis RF, 2016, CUREUS, V8, DOI 10.7759/cureus.513; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56; Won JK, 2015, ANN ONCOL, V26, P348, DOI 10.1093/annonc/mdu530; Yang HS, 2014, EXP MOL PATHOL, V97, P465, DOI 10.1016/j.yexmp.2014.10.002; Yang JJ, 2014, CLIN CANCER RES, V20, P1383, DOI 10.1158/1078-0432.CCR-13-0699; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhu YC, 2016, ONCOTARGETS THER, V9, P4301, DOI 10.2147/OTT.S109415	25	3	3	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					307	312		10.1038/modpathol.2017.109			6	Pathology	Pathology	FV7KD	WOS:000424761400008	28914263				2019-10-28	
J	Miyaoka, M; Kikuti, YY; Carreras, J; Ikoma, H; Hiraiwa, S; Ichiki, A; Kojima, M; Ando, K; Yokose, T; Sakai, R; Hoshikawa, M; Tomita, N; Miura, I; Takata, K; Yoshino, T; Takizawa, J; Bea, S; Campo, E; Nakamura, N				Miyaoka, Masashi; Kikuti, Yara Y.; Carreras, Joaquim; Ikoma, Haruka; Hiraiwa, Shinichiro; Ichiki, Akifumi; Kojima, Minoru; Ando, Kiyoshi; Yokose, Tomoyuki; Sakai, Rika; Hoshikawa, Masahiro; Tomita, Naoto; Miura, Ikuo; Takata, Katsuyoshi; Yoshino, Tadashi; Takizawa, Jun; Bea, Silvia; Campo, Elias; Nakamura, Naoya			Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements	MODERN PATHOLOGY			English	Article							BURKITT-LYMPHOMA; POOR-PROGNOSIS; DLBCL PATIENTS; EXPRESSION; FEATURES; NEOPLASMS; TRANSLOCATIONS; TRANSFORMATION; PROFILES; SURVIVAL	Most high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are aggressive B-cell lymphomas. Occasional double-hit follicular lymphomas have been described but the clinicopathological features of these tumors are not well known. To clarify the characteristics of double-hit follicular lymphomas, we analyzed 10 cases of double-hit follicular lymphomas and 15 cases of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements for clinicopathological and genome-wide copy-number alterations and copy-neutral loss-of-heterozygosity profiles. For double-hit follicular lymphomas, the median age was 67.5 years (range: 48-82 years). The female/male ratio was 2.3. Eight patients presented with advanced clinical stage. The median follow-up time was 20 months (range: 1-132 months). At the end of the follow-up, 8 patients were alive, 2 patients were dead including 1 patient with diffuse large B-cell lymphoma transformation. Rearrangements of MYC/BCL2, MYC/BCL6, and MYC/BCL2/BCL6 were seen in 8, 1, and 1 cases, respectively. The partner of MYC was IGH in 6 cases. There were no cases of histological grade 1, 4 cases of grade 2, 5 cases of grade 3a, and 1 case of grade 3b. Two cases of grade 3a exhibited immunoblast-like morphology. Immunohistochemistry demonstrated 9 cases with >= 50% MYC-positive cells. There was significant difference in MYC intensity (P=0.00004) and MIB-1 positivity (P=0.001) between double-hit follicular lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. The genome profile of double-hit follicular lymphomas was comparable with conventional follicular lymphomas (GSE67385, n=198) with characteristic gains of 2p25.3-p11.1, 7p22.3-q36.3, 12q11-q24.33, and loss of 18q21.32-q23 (P < 0.05). In comparison with high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, double-hit follicular lymphomas had fewer copy-number alterations and minimal common region of gain at 2p16.1 (70%), locus also significant against conventional follicular lymphomas (P=0.0001). In summary, double-hit follicular lymphomas tended to be high-grade histology, high MYC protein expression, high MYC/IGH fusion, and minimal common region of gain at 2p16.1. Double-hit follicular lymphomas seemed to be a different disease from high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements and have an indolent clinical behavior similar to follicular lymphomas without MYC rearrangement.	[Miyaoka, Masashi; Kikuti, Yara Y.; Carreras, Joaquim; Ikoma, Haruka; Hiraiwa, Shinichiro; Nakamura, Naoya] Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan; [Ichiki, Akifumi; Kojima, Minoru; Ando, Kiyoshi] Tokai Univ, Sch Med, Dept Hematol Oncol, Isehara, Kanagawa, Japan; [Yokose, Tomoyuki] Kanagawa Canc Ctr, Dept Pathol, Yokohama, Kanagawa, Japan; [Sakai, Rika] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa, Japan; [Hoshikawa, Masahiro] St Marianna Univ, Sch Med, Dept Pathol, Kawasaki, Kanagawa, Japan; [Tomita, Naoto; Miura, Ikuo] St Marianna Univ, Sch Med, Div Hematol & Oncol, Kawasaki, Kanagawa, Japan; [Takata, Katsuyoshi; Yoshino, Tadashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama, Japan; [Takizawa, Jun] Niigata Univ, Fac Med, Dept Hematol Endocrinol & Metab, Niigata, Japan; [Bea, Silvia; Campo, Elias] Univ Barcelona, CIBER Canc CIBERONIC, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin Barcelona,Mol Pathol Lab,Dept Pathol, Barcelona, Spain; [Bea, Silvia; Campo, Elias] Univ Barcelona, CIBER Canc CIBERONIC, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin Barcelona,Mol Pathol Lab,Hematopathol U, Barcelona, Spain	Nakamura, N (reprint author), Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	naoya@is.icc.u-tokai.ac.jp	Campo, Elias/AAC-5593-2019; bea, silvia/K-7699-2014	Campo, Elias/0000-0001-9850-9793; bea, silvia/0000-0001-7192-2385; Carreras, Joaquim/0000-0002-6129-8299			Anastasia A, 2016, MEDITERR J HEMATOL I, V8, DOI 10.4084/MJHID.2016.061; Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Bouska A, 2014, BLOOD, V123, P1681, DOI 10.1182/blood-2013-05-500595; Carreras J, 2017, HISTOPATHOLOGY, V70, P595, DOI 10.1111/his.13106; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Chisholm KM, 2015, AM J SURG PATHOL, V39, P294, DOI 10.1097/PAS.0000000000000365; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Gheith S, 2014, HUM PATHOL, V45, P2359, DOI 10.1016/j.humpath.2014.07.016; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842; Kanungo A, 2006, MODERN PATHOL, V19, P25, DOI 10.1038/modpathol.3800500; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Li SY, 2016, AM J SURG PATHOL, V40, P253, DOI 10.1097/PAS.0000000000000542; Miao Y, 2016, HUM PATHOL, V58, P72, DOI 10.1016/j.humpath.2016.07.025; Molyneux EM, 2012, LANCET, V379, P1234, DOI 10.1016/S0140-6736(11)61177-X; Ott G, 2008, HAEMATOL-HEMATOL J, V93, P1773, DOI 10.3324/haematol.2008.001495; Sarkozy Clementine, 2015, Lancet Oncol, V16, pe555, DOI 10.1016/S1470-2045(15)00005-4; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Swerdlow SH, 2008, WHO CLASSIFICATION T, P265; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tomita N, 2009, HAEMATOL-HEMATOL J, V94, P935, DOI 10.3324/haematol.2008.005355; Tomita S, 2015, MODERN PATHOL, V28, P1286, DOI 10.1038/modpathol.2015.85; Wang SA, 2005, AM J SURG PATHOL, V29, P1490, DOI 10.1097/01.pas.0000172191.87176.3b; Yoshida M, 2015, PATHOL INT, V65, P519, DOI 10.1111/pin.12335	28	6	8	2	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					313	326		10.1038/modpathol.2017.134			14	Pathology	Pathology	FV7KD	WOS:000424761400009	28984304				2019-10-28	
J	Santiago, T; Clay, MR; Allen, SJ; Orr, BA				Santiago, Teresa; Clay, Michael R.; Allen, Sariah J.; Orr, Brent A.			Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma (vol 30, pg 884, 2017)	MODERN PATHOLOGY			English	Correction												Santiago, Teresa C/N-8172-2018; Orr, Brent/N-8068-2018; Clay, Michael/N-3866-2018	Santiago, Teresa C/0000-0002-2838-3619; Clay, Michael/0000-0003-1659-8927	American Lebanese Syrian Associated Charities of St Jude Children's Research HospitalAmerican Lebanese Syrian Associated Charities (ALSAC); National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 CA021765]	The authors thank the pathologists and clinicians who submitted the cases in consultation, and the support from the American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital and National Institute of Health (NIH) grant P30 CA021765.	Santiago T, 2017, MODERN PATHOL, V30, P884, DOI 10.1038/modpathol.2017.12	1	1	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					374	374		10.1038/modpathol.2017.178			1	Pathology	Pathology	FV7KD	WOS:000424761400016	29430000	Bronze			2019-10-28	
J	Park, KJ; Roma, AA				Park, Kay J.; Roma, Andres A.			Pattern based classification of endocervical adenocarcinoma: a review	PATHOLOGY			English	Review						Endocervical adenocarcinoma; risk stratification; pattern based; review	EARLY INVASIVE ADENOCARCINOMA; SQUAMOUS-CELL CARCINOMA; UTERINE CERVIX; CLINICAL-IMPLICATIONS; RADICAL HYSTERECTOMY; HUMAN-PAPILLOMAVIRUS; IN-SITU; CANCER; SYSTEM; LYMPHADENECTOMY	While endocervical adenocarcinoma is comprised of several histological subtypes, the most common subtype is human papillomavirus-associated usual type, and management of these tumours is primarily determined by FIGO (International Federation of Gynecology and Obstetrics) stage, a clinically based staging system. Early stage cervical cancer is determined by the pathological evaluation of tumour microscopic measurement (depth of invasion), which can be particularly challenging because of the lack of a defined point of origin. Yet important treatment decisions, cone versus radical surgery, are based on this imperfect system, resulting in overtreatment and related morbidities in many patients for whom it may not be necessary. There is a growing consensus, however, for a more conservative approach, one that reduces morbidity and prevents loss of fertility in these (often young) patients. This movement has been supported, in part, by the development of a morphology based risk stratification system which was devised in order to recognise those tumours that, while invasive, could potentially be treated more conservatively. In this review, we provide the reader with the background and rationale for a more conservative approach in treating endocervical adenocarcinoma, summarise the risk stratification system, and review the system's utility and reproducibility. In addition, we comment on recent updates that attempt to further refine the system. The application of this morphology based classification could help identify a subset of patients with endocervical adenocarcinoma (who would otherwise undergo radical surgery based on FIGO staging alone) that have good clinical outcomes and could be treated more conservatively.	[Park, Kay J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Roma, Andres A.] Univ Calif San Diego, Dept Anat Pathol, San Diego, CA 92103 USA	Park, KJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	parkk@mskcc.org			Memorial Sloan Kettering Cancer Center Core Grant [P30 CA008748]	Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748; PI C. Thompson). The authors state that there are no conflicts of interest to disclose.	Alvarado-Cabrero I, 2017, INT J GYNECOL PATHOL, V36, P476, DOI 10.1097/PGP.0000000000000357; [Anonymous], 2017, CLIN PRACT GUID ONC, P2017; Baalbergen A, 2011, INT J GYNECOL CANCER, V21, P1640, DOI 10.1097/IGC.0b013e3182262059; Bean SM, 2011, J LOW GENIT TRACT DI, V15, P146, DOI 10.1097/LGT.0b013e3181fb425d; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Chan PG, 2003, OBSTET GYNECOL, V102, P765, DOI 10.1016/S0029-7844(03)00696-3; Cibula D, 2015, CURR OPIN OBSTET GYN, V27, P66, DOI 10.1097/GCO.0000000000000133; Covens A, 2002, GYNECOL ONCOL, V84, P145, DOI 10.1006/gyno.2001.6493; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; Djordjevic B, 2016, INT J GYNECOL PATHOL, V35, P456, DOI 10.1097/PGP.0000000000000264; Douglas G, 2017, PATHOL RES PRACT, V213, P799, DOI 10.1016/j.prp.2017.03.008; Holloway RW, 2016, GYNECOL ONCOL, V141, P206, DOI 10.1016/j.ygyno.2016.02.018; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; KINNEY WK, 1995, GYNECOL ONCOL, V57, P3, DOI 10.1006/gyno.1995.1091; Marur S, 2016, J CLIN ONCOL; Masterson L, 2014, EUR J CANCER, V50, P2636, DOI 10.1016/j.ejca.2014.07.001; Mehra G, 2010, EJSO-EUR J SURG ONC, V36, P304, DOI 10.1016/j.ejso.2009.08.009; Okami K, 2016, INT J CLIN ONCOL, V21, P827, DOI 10.1007/s10147-016-1009-6; Ostor AG, 2000, INT J GYNECOL PATHOL, V19, P29; Paquette C, 2015, AM J SURG PATHOL, V39, P93, DOI 10.1097/PAS.0000000000000316; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Parra-Herran C, 2016, MODERN PATHOL, V29, P879, DOI 10.1038/modpathol.2016.86; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Roma AA, 2017, AM J SURG PATHOL, V41, P1205, DOI 10.1097/PAS.0000000000000822; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Roma AA, 2015, ADV ANAT PATHOL, V22, P345, DOI 10.1097/PAP.0000000000000097; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Rutgers JKL, 2016, MODERN PATHOL, V29, P1083, DOI 10.1038/modpathol.2016.94; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Takeda N, 2002, ACTA OBSTET GYN SCAN, V81, P1144, DOI 10.1034/j.1600-0412.2002.811208.x; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P314, DOI 10.1097/01.PGP.0000035801.90350.90; Zaino RJ, 2000, MODERN PATHOL, V13, P261, DOI 10.1038/modpathol.3880047	33	5	5	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					134	140		10.1016/j.pathol.2017.09.011			7	Pathology	Pathology	FX8NN	WOS:000426351600003	29241973				2019-10-28	
J	Howitt, BE; Nucci, MR				Howitt, Brooke E.; Nucci, Marisa R.			Mesonephric proliferations of the female genital tract	PATHOLOGY			English	Review						Mesonephric; Wolffian; mesonephric remnants; mesonephric hyperplasia; mesonephric carcinoma; mesonephric-like adenocarcinoma; female adnexal tumour of probably Wolffian origin	PROBABLE WOLFFIAN ORIGIN; CORD-STROMAL TUMORS; OF-THE-LITERATURE; ENDOCERVICAL GLANDULAR LESIONS; SPINDLE-CELL COMPONENT; ADNEXAL TUMOR; UTERINE CERVIX; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; IMMUNOHISTOCHEMICAL ANALYSIS	The mesonephric (Wolffian) duct regresses in females during embryological development. Remnants of this duct may persist typically along the lateral walls of the cervix, vagina, adnexa, and uterine corpus. These mesonephric epithelia may expand into hyperplastic proliferations and rarely form neoplasms. The spectrum of morphology, immunophenotype, clinical presentation, and molecular characteristics of mesonephric lesions is reviewed, with attention to distinction from entities in the differential diagnosis.	[Howitt, Brooke E.; Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA; [Howitt, Brooke E.] Stanford Sch Med, Dept Pathol, 300 Pasteur Dr H1527, Stanford, CA 94305 USA	Howitt, BE (reprint author), Stanford Sch Med, Dept Pathol, 300 Pasteur Dr H1527, Stanford, CA 94305 USA.; Nucci, MR (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA.	bhowitt@stanford.edu; mnucci@bwh.harvard.edu		Howitt, Brooke/0000-0002-0309-6680			Ando H, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0655-y; Atallah D, 2004, GYNECOL ONCOL, V95, P402, DOI 10.1016/j.ygyno.2004.07.042; AYROUD Y, 1985, INT J GYNECOL PATHOL, V4, P245, DOI 10.1097/00004347-198509000-00009; Bifulco G, 2008, INT J GYNECOL CANCER, V18, P1127, DOI 10.1111/j.1525-1438.2007.01143.x; BLACKWELL W J, 1955, Q Bull Northwest Univ Med Sch, V29, P94; Bremmer F, 2017, VIRCHOWS ARCH, V470, P421, DOI 10.1007/s00428-017-2090-6; BRESCIA RJ, 1985, CANCER, V56, P1456, DOI 10.1002/1097-0142(19850915)56:6<1456::AID-CNCR2820560638>3.0.CO;2-Z; Casey S, 2015, HISTOPATHOLOGY, V66, P420, DOI 10.1111/his.12546; Cavalcanti MS, 2017, INT J GYNECOL PATHOL, V36, P76, DOI 10.1097/PGP.0000000000000306; Chapel DB, 2017, INT J GYNECOL PATHOL; Cina SJ, 1997, MODERN PATHOL, V10, P176; CLEMENT PB, 1995, AM J SURG PATHOL, V19, P1158, DOI 10.1097/00000478-199510000-00006; Conlon N, 2015, MODERN PATHOL, V28, P1603, DOI 10.1038/modpathol.2015.115; Cossu A, 2017, INT J GYNECOL PATHOL, V36, P575, DOI 10.1097/PGP.0000000000000368; Czernobilsky B, 2011, INT J SURG PATHOL, V19, P783, DOI 10.1177/1066896909356104; DAYA D, 1994, ARCH PATHOL LAB MED, V118, P310; DAYA D, 1994, AM J CLIN PATHOL, V101, P275, DOI 10.1093/ajcp/101.3.275; de Kock L, 2017, AM J SURG PATHOL, V41, P1178, DOI 10.1097/PAS.0000000000000895; Devouassoux-Shisheboran M, 1999, HUM PATHOL, V30, P856, DOI 10.1016/S0046-8177(99)90148-X; Ersahin C, 2005, GYNECOL ONCOL, V99, P757, DOI 10.1016/j.ygyno.2005.07.010; Ervine A, 2014, HISTOPATHOLOGY, V64, P840, DOI 10.1111/his.12332; FERRY JA, 1990, AM J SURG PATHOL, V14, P1100, DOI 10.1097/00000478-199012000-00002; Fukunaga M, 2004, ADV ANAT PATHOL, V11, P269, DOI 10.1097/01.pap.0000138141.88763.6a; Goyal A, 2016, INT J GYNECOL PATHOL, V35, P167, DOI 10.1097/PGP.0000000000000222; Grayson W, 2001, AM J SURG PATHOL, V25, P338, DOI 10.1097/00000478-200103000-00008; Handoo Anil, 2005, Indian J Pathol Microbiol, V48, P20; HART WR, 1972, CANCER, V29, P106, DOI 10.1002/1097-0142(197201)29:1<106::AID-CNCR2820290117>3.0.CO;2-0; Heller DS, 2011, J REPROD MED, V56, P175; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hong S, 2017, INT J GYNECOL PATHOL; Hoogendam JP, 2017, NEW ENGL J MED, V376, pE27, DOI 10.1056/NEJMicm1609983; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; HUFFMAN JW, 1948, AM J OBSTET GYNECOL, V56, P23, DOI 10.1016/0002-9378(48)90188-4; HUGHESDON PE, 1982, J CLIN PATHOL, V35, P526, DOI 10.1136/jcp.35.5.526; JONES MA, 1993, GYNECOL ONCOL, V49, P41, DOI 10.1006/gyno.1993.1083; Kahyaoglu S, 2012, EURASIAN J MED, V44, P172, DOI 10.5152/eajm.2012.40; Kalyanasundaram K, 2010, INT J SURG PATHOL, V18, P138, DOI 10.1177/1066896908329585; KARIMINEMH, 1973, CANCER, V31, P671; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kim T, 2010, HISTOPATHOLOGY, V56, P408, DOI 10.1111/j.1365-2559.2010.03487.x; Kobel M, 2009, CANCER RES, V69, P9160, DOI 10.1158/0008-5472.CAN-09-2669; Koopman K, 2017, PATHOL INT, V67, P590, DOI 10.1111/pin.12596; LANG G, 1990, INT J GYNECOL PATHOL, V9, P145, DOI 10.1097/00004347-199004000-00006; Li CC, 2004, APMIS, V112, P390, DOI 10.1111/j.1600-0463.2004.t01-1-apm1120602.x; Li FH, 2008, INT J SURG PATHOL, V16, P222, DOI 10.1177/1066896907307034; MACKLES A, 1958, CANCER, V11, P292, DOI 10.1002/1097-0142(195803/04)11:2<292::AID-CNCR2820110210>3.0.CO;2-#; Marquette A, 2006, INT J GYNECOL CANCER, V16, P1450, DOI 10.1111/j.1525-1438.2006.00489.x; McCluggage WG, 2003, HISTOPATHOLOGY, V43, P144, DOI 10.1046/j.1365-2559.2003.01684.x; McFarland M, 2016, HISTOPATHOLOGY, V68, P1013, DOI 10.1111/his.12895; Mirkovic J, 2017, AM J SURG PATHOL; Mirkovic J, 2017, HISTOPATHOLOGY, V71, P1003, DOI 10.1111/his.13307; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Moerman P, 2016, INT J SURG PATHOL, V24, P635, DOI 10.1177/1066896916644784; Moritani S, 2002, INT J GYNECOL PATHOL, V21, P125, DOI 10.1097/00004347-200204000-00004; Nakamura K, 2014, EUR J GYNAECOL ONCOL, V35, P580; Ordi J, 2003, AM J SURG PATHOL, V27, P178, DOI 10.1097/00000478-200302000-00005; Ordi J, 2001, AM J SURG PATHOL, V25, P1540, DOI 10.1097/00000478-200112000-00011; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Perrone F, 2014, AM J SURG PATHOL, V38, P66, DOI 10.1097/PAS.0b013e31829cdbc6; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Qiu T, 2017, TAIWAN J OBSTET GYNE, V56, P382, DOI 10.1016/j.tjog.2016.12.017; RAHILLY MA, 1995, HISTOPATHOLOGY, V26, P69, DOI 10.1111/j.1365-2559.1995.tb00623.x; Rios Salete S, 2016, J Med Case Rep, V10, P147, DOI 10.1186/s13256-016-0936-1; RORAT E, 1983, INT J GYNECOL OBSTET, V21, P409, DOI 10.1016/0020-7292(83)90009-7; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; SEIDMAN JD, 1995, INT J GYNECOL PATHOL, V14, P293, DOI 10.1097/00004347-199510000-00002; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Sheyn I, 2000, ARCH PATHOL LAB MED, V124, P431; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; SNEEDEN VD, 1958, CANCER, V11, P334, DOI 10.1002/1097-0142(195803/04)11:2<334::AID-CNCR2820110217>3.0.CO;2-C; STEWART CJR, 1993, INT J GYNECOL PATHOL, V12, P264, DOI 10.1097/00004347-199307000-00011; Syriac S, 2011, INT J GYNECOL PATHOL, V30, P231, DOI 10.1097/PGP.0b013e3182005340; Tambouret R, 2003, AM J SURG PATHOL, V27, P1080, DOI 10.1097/00000478-200308000-00005; TAXY JB, 1976, CANCER, V37, P2349, DOI 10.1002/1097-0142(197605)37:5<2349::AID-CNCR2820370526>3.0.CO;2-X; Tiltman AJ, 2001, HISTOPATHOLOGY, V38, P237, DOI 10.1046/j.1365-2559.2001.01086.x; Tipps AMP, 2011, ANN DIAGN PATHOL, V15, P376, DOI 10.1016/j.anndiagpath.2010.06.004; Wagatsuma S, 1997, TOHOKU J EXP MED, V181, P371, DOI 10.1620/tjem.181.371; Wani Y, 2008, INT J GYNECOL PATHOL, V27, P346, DOI [10.1097/PGP.0b013e318166067f, 10.1097/PGP.0b013618166067f]; Welsh T, 2003, INT J GYNECOL PATHOL, V22, P121, DOI 10.1097/01.PGP.0000040028.16722.D5; Wu HX, 2014, INT J CLIN EXP PATHO, V7, P7012; YOUNG RH, 1983, AM J SURG PATHOL, V7, P125, DOI 10.1097/00000478-198303000-00002; Zhang C, 2015, AM J SURG PATHOL, V39, P1390, DOI 10.1097/PAS.0000000000000455	84	9	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					141	150		10.1016/j.pathol.2017.11.084			10	Pathology	Pathology	FX8NN	WOS:000426351600004	29269124				2019-10-28	
J	Matias-Guiu, X; Stewart, CJR				Matias-Guiu, Xavier; Stewart, Colin J. R.			Endometriosis-associated ovarian neoplasia	PATHOLOGY			English	Review						Endometriosis; tumour; endometrioid; clear cell; molecular; immunohistochemistry	CLEAR-CELL CARCINOMA; YOLK-SAC TUMOR; MUCINOUS BORDERLINE TUMORS; EPITHELIAL PAPILLARY CYSTADENOMAS; ARID1A PROTEIN EXPRESSION; CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; MICROSATELLITE INSTABILITY; DIFFERENTIAL-DIAGNOSIS; MULLERIAN-TYPE	This article reviews the most relevant pathological and molecular features of ovarian tumours that are associated with endometriosis. Endometriosis is a common condition, affecting 5-15% of all women, and it has been estimated that 0.5-1% of cases are complicated by neoplasia. The most common malignant tumours in this setting are endometrioid adenocarcinoma and clear cell adenocarcinoma, each accounting for approximately 10% of ovarian carcinomas in Western countries. A minority of cases are associated with Lynch syndrome. These carcinomas are often confined to the ovaries at presentation in which case they have relatively favourable outcomes. However, high-stage tumours, particularly clear cell carcinomas, generally have a poor prognosis and this partly reflects relative resistance to current treatment. Histological diagnosis is straightforward in the majority of cases but some variants, for example endometrioid carcinomas with sex cord-like appearances or oxyphil cells, may create diagnostic difficulty. Similarly, clear cell carcinomas can show a range of architectural and cytological patterns that overlap with other tumours, both primary and metastatic, involving the ovaries. Endometriosis-associated borderline tumours are less common, and they often show mixed patterns of differentiation (seromucinous tumours). Atypical endometriosis may represent an intermediate step in neoplastic progression and some of these lesions demonstrate immunohistological and molecular alterations similar to those observed in endometriosis-related tumours. ARID1A mutations are relatively common in all of these tumours, but each has additional characteristic molecular alterations which are likely to be of increasing clinical relevance as targeted therapies are developed. Less is known of the pathogenesis of rarer endometriosis-associated ovarian tumours including endometrioid stromal sarcoma, mesodermal (Mullerian) adenosarcoma, and carcinosarcoma. This article also briefly reviews the issue of synchronous endometrioid carcinomas of the endometrium and the ovary, including the most recent developments on pathogenesis.	[Matias-Guiu, Xavier] Univ Lleida, Hosp U Arnau de Vilanova, Dept Pathol, Lleida, Spain; [Matias-Guiu, Xavier] Univ Lleida, Hosp U Bellvitge, IDIBELL, IRBLleida, Lleida, Spain; [Matias-Guiu, Xavier] CIBERONC, Lleida, Spain; [Stewart, Colin J. R.] King Edward Mem Hosp, Dept Histopathol, Bagot Rd, Perth, WA 6008, Australia; [Stewart, Colin J. R.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia	Stewart, CJR (reprint author), King Edward Mem Hosp, Dept Histopathol, Bagot Rd, Perth, WA 6008, Australia.	colin.stewart@health.wa.gov.au	matias-guiu, xavier/C-3039-2009	matias-guiu, xavier/0000-0002-7201-6605			Abe A, 2013, HUM PATHOL, V44, P199, DOI 10.1016/j.humpath.2012.05.005; Al-Agha OM, 2011, AM J SURG PATHOL, V35, P484, DOI 10.1097/PAS.0b013e31820a406c; Anglesio MS, 2017, NEW ENGL J MED, V376, P1835, DOI 10.1056/NEJMoa1614814; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Ayhan A, 2012, INT J GYNECOL CANCER, V22, P1310, DOI 10.1097/IGC.0b013e31826b5dcc; Azueta A, 2013, HUM PATHOL, V44, P20, DOI 10.1016/j.humpath.2012.04.018; Bell KA, 2000, AM J SURG PATHOL, V24, P1465, DOI 10.1097/00000478-200011000-00002; Bennett JA, 2015, HISTOPATHOLOGY, V66, P808, DOI 10.1111/his.12514; Berton-Rigaud D, 2014, INT J GYNECOL CANCER, V24, pS55, DOI 10.1097/IGC.0000000000000228; Blanco LZ, 2017, MODERN PATHOL, V30, P563, DOI 10.1038/modpathol.2016.219; Bondza Patrick Kibangou, 2009, Front Biosci (Elite Ed), V1, P415; Brustmann H, 2013, INT J GYNECOL PATHOL, V32, P384, DOI 10.1097/PGP.0b013e318264aece; Cai KQ, 2004, HUM PATHOL, V35, P552, DOI 10.1016/j.humpath.2003.12.009; Cao DF, 2009, AM J SURG PATHOL, V33, P894, DOI 10.1097/PAS.0b013e318198177d; Carnevali IW, 2017, INT J GYNECOL PATHOL, V36, P64, DOI 10.1097/PGP.0000000000000290; Carvalho L, 2011, J MINIM INVAS GYN, V18, P419, DOI 10.1016/j.jmig.2011.03.009; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Chao A, 2016, GYNECOL ONCOL, V143, P60, DOI 10.1016/j.ygyno.2016.07.114; Chen S, 2005, MODERN PATHOL, V18, P903, DOI 10.1038/modpathol.3800366; Chene G, 2015, INT J GYNECOL OBSTET, V130, P27, DOI 10.1016/j.ijgo.2015.02.021; Cherniack AD, 2017, CANCER CELL, V31, P411, DOI 10.1016/j.ccell.2017.02.010; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; Clement PB, 2007, ADV ANAT PATHOL, V14, P241, DOI 10.1097/PAP.0b013e3180ca7d7b; del Carmen MG, 2012, GYNECOL ONCOL, V126, P481, DOI 10.1016/j.ygyno.2012.04.021; DeLair D, 2011, AM J SURG PATHOL, V35, P36, DOI 10.1097/PAS.0b013e3181ff400e; Dube V, 2005, INT J GYNECOL PATHOL, V24, P138, DOI 10.1097/01.pgp.0000152024.37482.63; Eichhorn JH, 2002, AM J SURG PATHOL, V26, P1243, DOI 10.1097/01/PAS.0000029066.53683.4B; Elvin JA, 2017, GYNECOL ONCOL REP, V20, P62, DOI 10.1016/j.gore.2017.02.007; Esheba GE, 2008, AM J SURG PATHOL, V32, P600, DOI 10.1097/PAS.0b013e31815a565a; Fadare O, 2016, AJSP-REV REP, V21, P82, DOI 10.1097/PCR.0000000000000139; Fadare O, 2015, PATHOLOGY, V47, P105, DOI 10.1097/PAT.0000000000000223; Fadare O, 2012, APPL IMMUNOHISTO M M, V20, P580, DOI 10.1097/PAI.0b013e31824973d1; Folkins AK, 2013, HISTOPATHOLOGY, V62, P2, DOI 10.1111/his.12028; Fukunaga M, 1997, HISTOPATHOLOGY, V30, P249, DOI 10.1046/j.1365-2559.1997.d01-592.x; Fukunaga M, 1998, MODERN PATHOL, V11, P784; Fukunaga M, 2006, AJSP-REV REP, V11, P38, DOI 10.1097/01.pcr.0000196558.69330.30; Gadducci A, 2014, GYNECOL ENDOCRINOL, V30, P612, DOI 10.3109/09513590.2014.926325; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Gilks CB, 2010, J ONCOL, DOI 10.1155/2010/740968; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3; Gurung A, 2013, HISTOPATHOLOGY, V62, P59, DOI 10.1111/his.12033; Hamada T, 2008, INT J GYNECOL PATHOL, V27, P199, DOI 10.1097/PGP.0b013e31815b077b; Han Guangming, 2011, Surg Pathol Clin, V4, P397, DOI 10.1016/j.path.2010.12.012; Hart WR, 2005, PATHOL INT, V55, P231, DOI 10.1111/j.1440-1827.2005.01819.x; Hoskins PJ, 2012, J CLIN ONCOL, V30, P1656, DOI 10.1200/JCO.2011.40.1646; Howitt BE, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1277308; Howitt BE, 2015, J PATHOL, V235, P37, DOI 10.1002/path.4442; Huang HN, 2014, MODERN PATHOL, V27, P983, DOI 10.1038/modpathol.2013.216; Huang W, 2016, INT J GYNECOL PATHOL, V35, P66; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Iwamoto M, 2015, HUM PATHOL, V46, P957, DOI 10.1016/j.humpath.2015.03.008; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kalloger SE, 2011, MODERN PATHOL, V24, P512, DOI 10.1038/modpathol.2010.215; Kandalaft PL, 2014, AM J CLIN PATHOL, V142, P830, DOI 10.1309/AJCP8WO2EOIAHSOF; Karnezis AN, 2013, AM J SURG PATHOL, V37, P24, DOI 10.1097/PAS.0b013e31826a5399; Karpathiou G, 2017, ANN DIAGN PATHOL, V27, P28, DOI 10.1016/j.anndiagpath.2017.01.002; Kaspar HG, 2015, ARCH PATHOL LAB MED, V139, P39, DOI 10.5858/arpa.2014-0057-RA; Kato M, 2016, MOL CLIN ONCOL, V5, P395, DOI 10.3892/mco.2016.973; Kato N, 2016, HISTOPATHOLOGY, V68, P588, DOI 10.1111/his.12783; Kikuchi N, 2017, PATHOL INT, V67, P327, DOI 10.1111/pin.12542; KIM KR, 1990, AM J SURG PATHOL, V14, P925, DOI 10.1097/00000478-199010000-00005; Kim KR, 2010, HISTOPATHOLOGY, V57, P587, DOI 10.1111/j.1365-2559.2010.03673.x; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kobel M, 2014, AM J CLIN PATHOL, V142, P735, DOI 10.1309/AJCPAVGZKA1A1HVC; Kobel M, 2010, AM J SURG PATHOL, V34, P984, DOI 10.1097/PAS.0b013e3181e1a3bb; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Kurman RJ, 2014, WHO CLASSIFICATION T; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kurman RJ, 2016, INT J GYNECOL PATHOL, V35, P78, DOI 10.1097/PGP.0000000000000266; LAGRENADE A, 1988, HUM PATHOL, V19, P1080, DOI 10.1016/S0046-8177(88)80090-X; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee KR, 2003, INT J GYNECOL PATHOL, V22, P42, DOI 10.1097/01.PGP.0000040092.04359.E9; Li Q, 2015, INT J CLIN EXP PATHO, V8, P8305; Li XD, 2016, HISTOPATHOLOGY, V69, P551, DOI 10.1111/his.12966; Lim D, 2013, PATHOLOGY, V45, P229, DOI 10.1097/PAT.0b013e32835f2264; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Lin XQ, 2008, APPL IMMUNOHISTO M M, V16, P453, DOI 10.1097/PAI.0b013e3181672574; Lu FI, 2012, INT J GYNECOL PATHOL, V31, P524, DOI 10.1097/PGP.0b013e31824fe2aa; Mabuchi S, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e31; Madore J, 2010, J PATHOL, V220, P392, DOI 10.1002/path.2659; Maeda D, 2013, ADV ANAT PATHOL, V20, P45, DOI 10.1097/PAP.0b013e31827bc24d; Maeda D, 2009, MODERN PATHOL, V22, P824, DOI 10.1038/modpathol.2009.40; Masand RP, 2013, AM J SURG PATHOL, V37, P1635, DOI 10.1097/PAS.0000000000000083; Matias Guiu X, 1990, CANCER, V65, P2001; Matias-Guiu X, 1998, HUM PATHOL, V29, P840, DOI 10.1016/S0046-8177(98)90454-3; Matsumoto T, 2015, AM J CLIN PATHOL, V144, P452, DOI 10.1309/AJCPZ5T2POOFMQVN; Matsuura Y, 2007, GYNECOL ONCOL, V104, P406, DOI 10.1016/j.ygyno.2006.08.026; May KE, 2011, HUM REPROD UPDATE, V17, P637, DOI 10.1093/humupd/dmr013; McCluggage WG, 2010, ADV ANAT PATHOL, V17, P122, DOI 10.1097/PAP.0b013e3181cfe732; McConechy MK, 2015, J PATHOL CLIN RES, V1, P173, DOI 10.1002/cjp2.18; McConechy MK, 2014, MODERN PATHOL, V27, P128, DOI 10.1038/modpathol.2013.107; MCMEEKIN DS, 1995, GYNECOL ONCOL, V59, P81, DOI 10.1006/gyno.1995.1271; Mikami Y., 2014, DIAGN HISTOPATHOL, V20, P357; Mullen MM, 2017, GYNECOL ONCOL REP, V20, P121, DOI 10.1016/j.gore.2017.04.004; Nagai Y, 2003, AM J SURG PATHOL, V27, P242, DOI 10.1097/00000478-200302000-00014; Nakonechny Quentin B, 2016, Surg Pathol Clin, V9, P189, DOI 10.1016/j.path.2016.01.003; Nathenson MJ, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0552-7; Newton CL, 2017, INT J GYNECOL PATHOL, V36, P195, DOI 10.1097/PGP.0000000000000304; Nicolae A, 2011, J CLIN PATHOL, V64, P97, DOI 10.1136/jcp.2010.085555; NILBERT M, 1995, INT J GYNECOL CANCER, V5, P61, DOI 10.1046/j.1525-1438.1995.05010061.x; Nishikimi K, 2015, HISTOPATHOLOGY, V67, P866, DOI 10.1111/his.12721; Nogales FF, 1996, AM J SURG PATHOL, V20, P1056, DOI 10.1097/00000478-199609000-00003; Nogales FF, 2014, HISTOPATHOLOGY, V65, P51, DOI 10.1111/his.12373; Offman SL, 2012, ADV ANAT PATHOL, V19, P296, DOI 10.1097/PAP.0b013e31826663b1; Ogawa S, 2000, GYNECOL ONCOL, V77, P298, DOI 10.1006/gyno.2000.5765; Okamoto A, 2014, INT J GYNECOL CANCER, V24, pS20, DOI 10.1097/IGC.0000000000000289; Oliva E, 2014, AM J SURG PATHOL, V38, P305, DOI 10.1097/PAS.0000000000000145; Ordi J, 1999, MODERN PATHOL, V12, P933; Ozcan A, 2011, AM J SURG PATHOL, V35, P1837, DOI 10.1097/PAS.0b013e31822d787c; Ozdemir DA, 2016, PATHOL ONCOL RES, V22, P593, DOI 10.1007/s12253-016-0040-2; Parker RL, 2004, AM J SURG PATHOL, V28, P285, DOI 10.1097/00000478-200403000-00001; Piscuoglio S, 2016, J PATHOL, V238, P381, DOI 10.1002/path.4675; PITMAN MB, 1994, INT J GYNECOL PATHOL, V13, P290, DOI 10.1097/00004347-199410000-00002; PRAT J, 1991, CANCER-AM CANCER SOC, V68, P2455, DOI 10.1002/1097-0142(19911201)68:11<2455::AID-CNCR2820681122>3.0.CO;2-Q; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Rabban JT, 2013, HISTOPATHOLOGY, V62, P71, DOI 10.1111/his.12052; Rahman M, 2012, HUM PATHOL, V43, P2197, DOI 10.1016/j.humpath.2012.03.011; Ramalingam P, 2004, AM J SURG PATHOL, V28, P1499, DOI 10.1097/01.pas.0000138179.87957.32; Rambau PF, 2017, AM J SURG PATHOL, V41, P685, DOI 10.1097/PAS.0000000000000812; Rauh-Hain JA, 2013, GYNECOL ONCOL, V131, P46, DOI 10.1016/j.ygyno.2013.07.097; Rodriguez IM, 2004, AM J SURG PATHOL, V28, P1311, DOI 10.1097/01.pas.0000138178.10829.b8; ROTH LM, 1982, CANCER-AM CANCER SOC, V50, P1322, DOI 10.1002/1097-0142(19821001)50:7<1322::AID-CNCR2820500718>3.0.CO;2-C; ROTH LM, 1981, CANCER-AM CANCER SOC, V48, P1838, DOI 10.1002/1097-0142(19811015)48:8<1838::AID-CNCR2820480822>3.0.CO;2-R; RUTGERS JL, 1992, MODERN PATHOL, V5, P367; RUTGERS JL, 1987, HUM PATHOL, V18, P1296, DOI 10.1016/S0046-8177(87)80418-5; RUTGERS JL, 1988, CANCER-AM CANCER SOC, V61, P340, DOI 10.1002/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U; RUTGERS JL, 1988, CANCER-AM CANCER SOC, V61, P546, DOI 10.1002/1097-0142(19880201)61:3<546::AID-CNCR2820610321>3.0.CO;2-I; Rutgers JKL, 2016, AJSP-REV REP, V21, P206, DOI 10.1097/PCR.0000000000000155; Samartzis EP, 2013, INT J MOL SCI, V14, P18824, DOI 10.3390/ijms140918824; Sangoi AR, 2008, AM J SURG PATHOL, V32, P269, DOI 10.1097/PAS.0b013e31814fa9b0; Sato N, 2000, CANCER RES, V60, P7052; Savvari P, 2009, ONKOLOGIE, V32, P517, DOI 10.1159/000226209; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Shappell HW, 2002, AM J SURG PATHOL, V26, P1529, DOI 10.1097/00000478-200212000-00001; Shu CA, 2015, GYNECOL ONCOL, V139, P236, DOI 10.1016/j.ygyno.2015.09.016; Sonoda Y, 2000, GYNECOL ONCOL, V76, P226, DOI 10.1006/gyno.1999.5681; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Stewart CJR, 2008, INT J GYNECOL PATHOL, V27, P475, DOI 10.1097/PGP.0b013e31816b5cff; Stewart CJR, 2017, HISTOPATHOLOGY, V70, P309, DOI 10.1111/his.13040; Stewart Colin J R, 2016, Surg Pathol Clin, V9, P227, DOI 10.1016/j.path.2016.01.002; Stewart CJR, 2016, HISTOPATHOLOGY, V68, P398, DOI 10.1111/his.12755; Stewart CJR, 2014, HISTOPATHOLOGY, V65, P473, DOI 10.1111/his.12406; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P31, DOI 10.1111/his.12057; Stewart CJR, 2010, CANCER CYTOPATHOL, V118, P127, DOI 10.1002/cncy.20073; Taylor J, 2015, AM J SURG PATHOL, V39, P983, DOI 10.1097/PAS.0000000000000405; TORNOS C, 1995, AM J SURG PATHOL, V19, P1343, DOI 10.1097/00000478-199512000-00001; ULBRIGHT TM, 1985, HUM PATHOL, V16, P28, DOI 10.1016/S0046-8177(85)80210-0; Vang R, 2006, INT J GYNECOL PATHOL, V25, P83, DOI 10.1097/01.pgp.0000177125.31046.fd; Veras E, 2009, AM J SURG PATHOL, V33, P844, DOI 10.1097/PAS.0b013e31819c4271; Vercellini P, 2014, NAT REV ENDOCRINOL, V10, P261, DOI 10.1038/nrendo.2013.255; Vierkoetter KR, 2014, GYNECOL ONCOL, V135, P81, DOI 10.1016/j.ygyno.2014.07.100; Vrdoljak-Mozetic D, 2006, CYTOPATHOLOGY, V17, P390, DOI 10.1111/j.1365-2303.2006.00373.x; Wang M, 2015, APPL IMMUNOHISTO M M, V23, P280, DOI 10.1097/PAI.0000000000000065; Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280; Wei JJ, 2011, INT J GYNECOL PATHOL, V30, P553, DOI 10.1097/PGP.0b013e31821f4b85; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wu CH, 2012, INT J GYNECOL PATHOL, V31, P297, DOI 10.1097/PGP.0b013e31823f8482; Wu RC, 2014, J PATHOL, V232, P473, DOI 10.1002/path.4315; Yamamoto S, 2007, AM J SURG PATHOL, V31, P999, DOI 10.1097/01.pas.0000249449.13466.3c; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Yamamoto S, 2012, VIRCHOWS ARCH, V460, P77, DOI 10.1007/s00428-011-1169-8; Yamashita Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057724; Yano T, 1999, GYNECOL OBSTET INVES, V47, P41, DOI 10.1159/000052858; Yasunaga M, 2009, HUM PATHOL, V40, P965, DOI 10.1016/j.humpath.2008.12.006; Young RH, 2001, SEMIN DIAGN PATHOL, V18, P161; YOUNG RH, 1982, AM J SURG PATHOL, V6, P513, DOI 10.1097/00000478-198209000-00003; Zhao CQ, 2008, INT J GYNECOL PATHOL, V27, P507, DOI 10.1097/PGP.0b013e31817c1b0a; Zhao CQ, 2011, J CANCER, V2, P94, DOI 10.7150/jca.2.107; Zhao SM, 2016, P NATL ACAD SCI USA, V113, P12238, DOI 10.1073/pnas.1614120113	172	13	14	4	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					190	204		10.1016/j.pathol.2017.10.006			15	Pathology	Pathology	FX8NN	WOS:000426351600008	29241974				2019-10-28	
J	Liu, WJ; Zhou, L; Liang, ZY; Zhou, WX; You, L; Zhang, TP; Zhao, YP				Liu, Wen-Jing; Zhou, Li; Liang, Zhi-Yong; Zhou, Wei-Xun; You, Lei; Zhang, Tai-Ping; Zhao, Yu-Pei			High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						G-protein-coupled receptor kinase 3; Pancreatic ductal adenocarcinoma; Prognosis; Immunohistochemistry; Tissue microarray	COUPLED RECEPTOR KINASES; LYMPH-NODE RATIO; CANCER; PROTEIN; DESENSITIZATION; CHEMOTHERAPY; BIOMARKERS; CARCINOMA	Background: It was found that G-protein-coupled receptor kinase 3 (GRK3) played key biological roles in some cancers. However, its associations with clinicopathologic features and prognosis in pancreatic ductal adenocarcinoma (PDAC) remain unknown.& para;& para; Methods and methods: Expression of GRK3 was detected, using tissue microarray-based immunohistochemistry, in paired formalin-fixed paraffin-embedded tumor and non-tumor samples from 165 patients with PDAC after curative resection, and was further correlated with clinicopathologic parameters and cancer-specific survival (CSS).& para;& para; Results: It was shown that GRK3 expression was much lower in tumor than in non-tumor tissues. Moreover, expression of GRK3 in tumor tissues was significantly associated with gender and T stage. Univariately, high GRK3 expression was predictive for favorable CSS, along with some conventional clinicopathologic variables. In multivariate Cox regression test, GRK3 expression remained to be a significant prognostic marker for PDAC. Finally, combination of GRK3 with some clinicopathologic variables, especially N stage, obtained more precise prediction for CSS.& para;& para; Conclusions: Our data suggested that expression of GRK3 was down-regulated in PDAC and was an independent prognostic factor.	[Liu, Wen-Jing; Zhou, Li; You, Lei; Zhang, Tai-Ping; Zhao, Yu-Pei] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; [Liang, Zhi-Yong; Zhou, Wei-Xun] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China	Zhang, TP; Zhao, YP (reprint author), Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China.	tpingzhang@yahoo.com; zhao8028@263.net			National Natural Science Foundation, ChinaNational Natural Science Foundation of China [81402027]	This work was supported by the National Natural Science Foundation (81402027), China.	Ahmed MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10920; Ansari D, 2011, BRIT J SURG, V98, P1041, DOI 10.1002/bjs.7574; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Billard MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152856; Chatterjee D., 2012, AM J SURG PATHOL, V36; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Golse N, 2013, PANCREAS, V42, P239, DOI 10.1097/MPA.0b013e31825f80a9; Hartwig W, 2011, ANN SURG, V254, P311, DOI 10.1097/SLA.0b013e31821fd334; Jin Y, 2017, J CANCER, V8, P1972, DOI 10.7150/jca.19201; Kato A, 2014, CHEM SENSES, V39, P771, DOI 10.1093/chemse/bju050; La Torre M, 2011, J SURG ONCOL, V104, P629, DOI 10.1002/jso.22013; Lia WL, 2014, P NATL ACAD SCI USA, V111, P1521, DOI 10.1073/pnas.1320638111; Lowe JD, 2015, MOL PHARMACOL, V88, P347, DOI 10.1124/mol.115.098293; MCCLELLAND RA, 1990, CANCER RES, V50, P3545; Mitchem JB, 2012, J AM COLL SURGEONS, V214, P46, DOI 10.1016/j.jamcollsurg.2011.10.008; Ortolan E, 2010, JNCI-J NATL CANCER I, V102, P1160, DOI 10.1093/jnci/djq256; Picozzi VJ, 2017, ANN SURG ONCOL, V24, P1722, DOI 10.1245/s10434-016-5716-z; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Righi L, 2010, J CLIN ONCOL, V28, P1534, DOI 10.1200/JCO.2009.25.9275; Robinson SM, 2012, EJSO-EUR J SURG ONC, V38, P333, DOI 10.1016/j.ejso.2011.12.020; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sang MX, 2016, ONCOTARGET, V7, P45171, DOI 10.18632/oncotarget.9359; Stanaway FF, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7679; Uesaka K, 2016, LANCET, V388, P248, DOI 10.1016/S0140-6736(16)30583-9; Winter JM, 2013, J SURG ONCOL, V107, P15, DOI 10.1002/jso.23192; Woerner BM, 2012, MOL CANCER RES, V10, P156, DOI 10.1158/1541-7786.MCR-11-0411; Zhang YJ, 2012, J GASTROINTEST SURG, V16, P1875, DOI 10.1007/s11605-012-1985-4	27	1	1	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					228	232		10.1016/j.prp.2017.11.013			5	Pathology	Pathology	GB5EL	WOS:000429085800007	29254792				2019-10-28	
J	Lee, JH; An, CH; Kim, MS; Yoo, NJ; Lee, SH				Lee, Ju Hwa; An, Chang Hyeok; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung			Rare frameshift mutations of putative tumor suppressor genes CSMDI and SLX4 in colorectal cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Letter									[Lee, Ju Hwa; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea; [An, Chang Hyeok] Catholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr			Korea Research FoundationKorea Research Foundation [2012R1A5A2047939, 2015R1D1A1A01057355]	This study was supported by grants from Korea Research Foundation (2012R1A5A2047939 and 2015R1D1A1A01057355).	Fekairi S, 2009, CELL, V138, P78, DOI 10.1016/j.cell.2009.06.029; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Lee JH, 2017, PATHOL RES PRACT, V213, P1019, DOI 10.1016/j.prp.2017.06.011; Ma CQ, 2009, CANCER BIOL THER, V8, P907, DOI 10.4161/cbt.8.10.8132; Ouyang J, 2015, MOL CELL, V57, P108, DOI 10.1016/j.molcel.2014.11.015; Sun PC, 2001, GENOMICS, V75, P17, DOI 10.1006/geno.2001.6587	6	2	2	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					325	326		10.1016/j.prp.2017.12.001			2	Pathology	Pathology	GB5EL	WOS:000429085800023	29258766				2019-10-28	
J	McDyre, BC; AbdulHameed, MDM; Permenter, MG; Dennis, WE; Baer, CE; Koontz, JM; Boyle, MH; Wallqvist, A; Lewis, JA; Ippolito, DL				McDyre, B. Claire; AbdulHameed, Mohamed Diwan M.; Permenter, Matthew G.; Dennis, William E.; Baer, Christine E.; Koontz, Jason M.; Boyle, Molly H.; Wallqvist, Anders; Lewis, John A.; Ippolito, Danielle L.			Comparative Proteomic Analysis of Liver Steatosis and Fibrosis after Oral Hepatotoxicant Administration in Sprague-Dawley Rats	TOXICOLOGIC PATHOLOGY			English	Article						bioinformatics; biomarkers; hepatic; histopathology; mechanisms of toxicity; toxicity; proteomics	ADVERSE OUTCOME PATHWAYS; GENE-EXPRESSION; OXIDATIVE STRESS; TOXICITY; INJURY; MODEL; BROMOBENZENE; PROTEINS; MICE; HISTOPATHOLOGY	The past decade has seen an increase in the development and clinical use of biomarkers associated with histological features of liver disease. Here, we conduct a comparative histological and global proteomics analysis to identify coregulated modules of proteins in the progression of hepatic steatosis or fibrosis. We orally administered the reference chemicals bromobenzene (BB) or 4,4-methylenedianiline (4,4-MDA) to male Sprague-Dawley rats for either 1 single administration or 5 consecutive daily doses. Livers were preserved for histopathology and global proteomics assessment. Analysis of liver sections confirmed a dose- and time-dependent increase in frequency and severity of histopathological features indicative of lipid accumulation after BB or fibrosis after 4,4-MDA. BB administration resulted in a dose-dependent increase in the frequency and severity of inflammation and vacuolation. 4,4-MDA administration resulted in a dose-dependent increase in the frequency and severity of periportal collagen accumulation and inflammation. Pathway analysis identified a time-dependent enrichment of biological processes associated with steatogenic or fibrogenic initiating events, cellular functions, and toxicological states. Differentially expressed protein modules were consistent with the observed histology, placing physiologically linked protein networks into context of the disease process. This study demonstrates the potential for protein modules to provide mechanistic links between initiating events and histopathological outcomes.	[McDyre, B. Claire] ORISE, Frederick, MD USA; [AbdulHameed, Mohamed Diwan M.; Wallqvist, Anders] US Army Med Res & Mat Command, Dept Def, Biotechnol High Performance Comp Software Applica, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Permenter, Matthew G.; Baer, Christine E.] Excet Inc, Frederick, MD USA; [Dennis, William E.; Koontz, Jason M.; Lewis, John A.; Ippolito, Danielle L.] USACEHR, 568 Doughten Dr, Ft Detrick, MD 21702 USA; [Boyle, Molly H.] Envigo, Somerset, NJ USA	Ippolito, DL (reprint author), USACEHR, 568 Doughten Dr, Ft Detrick, MD 21702 USA.	danielle.ippolito@gmail.com	wallqvist, anders/W-2584-2019	wallqvist, anders/0000-0002-9775-7469	US Department of Energy (DOE)United States Department of Energy (DOE); United States Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported in part by an appointment to the Postgraduate Research Participation Program at the U.S. Army Center for Environmental Health Research administered by Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy (DOE) and United States Army Medical Research and Materiel Command (USAMRMC).	Abdelmalek MF, 2010, HEPATOLOGY, V51, P1961, DOI 10.1002/hep.23535; AbdulHameed MDM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112193; Ahn JM, 2014, MOL CELL PROTEOMICS, V13, P30, DOI 10.1074/mcp.M113.028621; Alsafadi HN, 2017, AM J PHYSIOL-LUNG C, V312, pL896, DOI 10.1152/ajplung.00084.2017; Amin A, 2011, ACTA BIOCH BIOPH SIN, V43, P193, DOI 10.1093/abbs/gmq129; Angrish MM, 2016, TOXICOL SCI, V150, P261, DOI 10.1093/toxsci/kfw018; Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34; Arias IM, 1982, LIVER BIOL PATHOBIOL; Bailey WJ, 2012, TOXICOL SCI, V130, P229, DOI 10.1093/toxsci/kfs243; Beer L, 2015, SCI REP-UK, V5, DOI 10.1038/srep16662; Brunt EM, 2010, WORLD J GASTROENTERO, V16, P5286, DOI 10.3748/wjg.v16.i42.5286; BURCHAM PC, 1988, TOXICOL LETT, V44, P91, DOI 10.1016/0378-4274(88)90134-8; CASINI AF, 1985, AM J PATHOL, V118, P225; Chen K, 2008, TOXICOL APPL PHARM, V232, P190, DOI 10.1016/j.taap.2008.06.008; Chin JL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00159; DAHL JE, 1990, ARCH TOXICOL, V64, P370, DOI 10.1007/BF01973458; Ding ZB, 2011, LAB INVEST, V91, P752, DOI 10.1038/labinvest.2011.11; Dugas Tammy R, 2004, Cardiovasc Toxicol, V4, P85, DOI 10.1385/CT:4:1:85; Fuehring JI, 2015, SCI REP-UK, V5, DOI 10.1038/srep09618; Ganter B, 2005, J BIOTECHNOL, V119, P219, DOI 10.1016/j.jbiotec.2005.03.022; Green TJ, 2010, CLIN TOXICOL, V48, P787, DOI 10.3109/15563650.2010.523828; Gruys E, 2005, J Zhejiang Univ Sci B, V6, P1045, DOI 10.1631/jzus.2005.B1045; Heijne WHM, 2005, TOXICOL PATHOL, V33, P425, DOI 10.1080/01926230590958146; Horvat T, 2017, ARCH TOXICOL, V91, P1523, DOI 10.1007/s00204-016-1814-8; Ippolito DL, 2016, TOXICOL SCI, V149, P67, DOI 10.1093/toxsci/kfv214; Ishihara K, 2006, BASIC CLIN PHARMACOL, V99, P251, DOI 10.1111/j.1742-7843.2006.pto_455.x; Kawano Y, 2013, J GASTROENTEROL, V48, P434, DOI 10.1007/s00535-013-0758-5; Lettmann S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105686; Liedtke C, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-19; Luo XT, 2016, AGING DIS, V7, DOI 10.14336/AD.2015.0702; Ma L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015006; Marchesini G, 2016, HEPATOLOGY, V63, P2032, DOI 10.1002/hep.28392; Meakin PJ, 2014, MOL CELL BIOL, V34, P3305, DOI [10.1128/MCB.00677-14, 10.1128/MCB.00677-1]; Mellor CL, 2016, CHEM RES TOXICOL, V29, P203, DOI 10.1021/acs.chemrestox.5b00480; Mellor CL, 2016, CRIT REV TOXICOL, V46, P138, DOI 10.3109/10408444.2015.1089471; Munteanu M, 2016, ALIMENT PHARM THER, V44, P877, DOI 10.1111/apt.13770; National Research Council (US) Committee for the Update of the Guide for the care and Use of laboratory Animal, 2011, GUID CAR US LAB AN; National Toxicology Program, 2002, Rep Carcinog, V10, P152; National Toxicology Program, 2010, DRUGMATRIX; NAVEAU S, 1994, DIGEST DIS SCI, V39, P2426, DOI 10.1007/BF02087661; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nishikawa S, 2012, TOXICOL PATHOL, V40, P71, DOI 10.1177/0192623311422078; Oberg AL, 2008, J PROTEOME RES, V7, P225, DOI 10.1021/pr700734f; Pinzani M, 2004, DIGEST LIVER DIS, V36, P231, DOI 10.1016/j.dld.2004.01.003; Rabinowich L, 2015, BIOMED RES INT, DOI 10.1155/2015/168905; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Sanyal AJ, 2011, HEPATOL RES, V41, P670, DOI 10.1111/j.1872-034X.2011.00824.x; Shadforth IP, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-145; Shukla A, 2015, INDIAN J GASTROENTER, V34, P281, DOI 10.1007/s12664-015-0580-5; Singh D, 2015, J ETHNOPHARMACOL, V161, P186, DOI 10.1016/j.jep.2014.12.025; Tan YW, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0094264, 10.1371/journal.pone.0105192]; Tawa GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107230; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Vinken M, 2015, CHEM RES TOXICOL, V28, P1391, DOI 10.1021/acs.chemrestox.5b00208; Vinken M, 2013, TOXICOLOGY, V312, P158, DOI 10.1016/j.tox.2013.08.011; Wallace MC, 2015, LAB ANIM-UK, V49, P21, DOI 10.1177/0023677215573040; Wang SG, 2016, ONCOTARGET, V7, P17681, DOI 10.18632/oncotarget.6893; WIESNER IS, 1965, AM J DIG DIS, V10, P147, DOI 10.1007/BF02236665; Willett C, 2014, ALTEX-ALTERN ANIM EX, V31, P407, DOI http://dx.doi.org/10.14573/altex.1401283; Wong SGW, 2000, TOXICOL LETT, V116, P171, DOI 10.1016/S0378-4274(00)00218-6; Yang X, 2015, TOXICOL APPL PHARM, V284, P180, DOI 10.1016/j.taap.2015.02.013; Yoshioka H, 2017, J TOXICOL SCI, V42, P251, DOI 10.2131/jts.42.251; Zhong YG, 2015, BIOCHEM BIOPH RES CO, V468, P906, DOI 10.1016/j.bbrc.2015.11.055; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	64	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					202	223		10.1177/0192623317747549			22	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400010	29378501	Bronze			2019-10-28	
J	Almangush, A; Leivo, I; Siponen, M; Sundquist, E; Mroueh, R; Makitie, A; Soini, Y; Haglund, C; Nieminen, P; Salo, T				Almangush, Alhadi; Leivo, Ilmo; Siponen, Maria; Sundquist, Elias; Mroueh, Rayan; Makitie, Antti A.; Soini, Ylermi; Haglund, Caj; Nieminen, Pentti; Salo, Tuula			Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies	VIRCHOWS ARCHIV			English	Article						Oral tongue cancer; Tumor budding; Tumor depth; BD model; Prognosis	SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR THICKNESS; NODAL METASTASIS; PROGNOSTIC VALUE; POOR-PROGNOSIS; WORST PATTERN; STAGE; EXPRESSION; METAANALYSIS	It is of great clinical importance to identify simple prognostic markers from preoperative biopsies that could guide treatment planning. Here, we compared tumor budding (B), depth of invasion (D), and the combined scores (i.e., budding and depth of invasion (BD) histopathologic model) in preoperative biopsies and the corresponding postoperative specimens of oral tongue squamous cell carcinoma (OTSCC). Tumor budding and depth of invasion were evaluated in the pre- and postoperative samples from 100 patients treated for OTSCC. Sensitivity and specificity statistics were used. Our results showed statistically significant (P < 0.001) relationship between pre- and postoperative BD scores. There was an agreement between the pre- and postoperative BD model scores in 83 cases (83%) with 57.1% sensitivity (95% CI 39.4 to 73.7%) and 96.9% specificity (95% CI 89.3 to 99.6%). Our findings suggest that the BD model, analyzed from representative biopsies, could be used for the treatment planning of OTSCC.	[Almangush, Alhadi] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Almangush, Alhadi; Salo, Tuula] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland; [Almangush, Alhadi] Univ Misurata, Inst Dent, Misurata, Libya; [Leivo, Ilmo] Univ Turku, Dept Pathol, Turku, Finland; [Siponen, Maria; Sundquist, Elias; Salo, Tuula] Univ Oulu, Canc & Translat Med Res Unit, Oulu, Finland; [Siponen, Maria] Kuopio Univ Hosp, Dept Oral & Maxillofacial Dis, Kuopio, Finland; [Siponen, Maria] Univ Eastern Finland, Inst Dent, Kuopio, Finland; [Sundquist, Elias; Salo, Tuula] Oulu Univ Hosp, Med Res Ctr, Oulu, Finland; [Mroueh, Rayan; Makitie, Antti A.] Helsinki Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; [Mroueh, Rayan; Makitie, Antti A.; Salo, Tuula] Univ Helsinki, Helsinki, Finland; [Soini, Ylermi] Univ Eastern Finland, Dept Pathol & Forens Med, Kuopio, Finland; [Soini, Ylermi] Canc Ctr Eastern Finland, Kuopio, Finland; [Haglund, Caj] Univ Helsinki, Dept Surg, Helsinki, Finland; [Haglund, Caj] Helsinki Univ Hosp, Helsinki, Finland; [Haglund, Caj] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland; [Nieminen, Pentti] Univ Oulu, Med Informat & Stat Res Grp, Oulu, Finland; [Salo, Tuula] Univ Helsinki, Cent Hosp, Dept Pathol, HUSLAB, Helsinki, Finland	Almangush, A (reprint author), Univ Helsinki, Dept Pathol, Helsinki, Finland.; Almangush, A (reprint author), Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland.; Almangush, A (reprint author), Univ Misurata, Inst Dent, Misurata, Libya.	alhadi.almangush@helsinki.fi	Nieminen, Pentti/A-7571-2012; Haglund, Caj/N-1240-2019	Nieminen, Pentti/0000-0003-0591-586X; Salo, Tuula/0000-0001-6039-0088	Finnish Dental Society; Maritza and Reino Salonen Foundation; Finnish Cancer Society	This study was supported by the Finnish Dental Society (Alhadi Almangush), the Maritza and Reino Salonen Foundation (Ilmo Leivo), and the Finnish Cancer Society (Tuula Salo).	Almangush A, 2015, INT J ORAL MAX SURG, V44, P143, DOI 10.1016/j.ijom.2014.10.004; Almangush A, 2016, HISTOPATHOLOGY, V68, P173, DOI 10.1111/his.12781; Almangush A, 2015, VIRCHOWS ARCH, V467, P39, DOI 10.1007/s00428-015-1758-z; Almangush A, 2014, HISTOPATHOLOGY, V65, P587, DOI 10.1111/his.12471; Almangush A, 2014, HEAD NECK-J SCI SPEC, V36, P811, DOI 10.1002/hed.23380; Attramadal CG, 2015, ANTICANCER RES, V35, P6111; Barnes L., 2005, PATHOLOGY GENETICS H; Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167; Brandwein-Gensler M, 2010, AM J SURG PATHOL, V34, P676, DOI 10.1097/PAS.0b013e3181d95c37; BRYNE M, 1992, J PATHOL, V166, P375, DOI 10.1002/path.1711660409; Ganly I, 2013, CANCER-AM CANCER SOC, V119, P1168, DOI 10.1002/cncr.27872; Ganly I, 2012, CANCER-AM CANCER SOC, V118, P101, DOI 10.1002/cncr.26229; Goel V, 2016, J CLIN DIAGN RES, V10, pTC1, DOI 10.7860/JCDR/2016/17411.7905; Gujam FJA, 2015, BRIT J CANCER, V113, P1066, DOI 10.1038/bjc.2015.287; Han MW, 2015, OTOLARYNG HEAD NECK, V152, P80, DOI 10.1177/0194599814556061; Hori Y, 2017, HEAD NECK PATHOL, V11, P477, DOI 10.1007/s12105-017-0814-1; Huang SH, 2009, CANCER-AM CANCER SOC, V115, P1489, DOI 10.1002/cncr.24161; Jung J, 2009, INT J ORAL MAX SURG, V38, P653, DOI 10.1016/j.ijom.2009.01.004; Kadota K, 2014, J THORAC ONCOL, V9, P1126, DOI 10.1097/JTO.0000000000000253; Kang H, 2015, NAT REV CLIN ONCOL, V12, P11, DOI 10.1038/nrclinonc.2014.192; Karamitopoulou E, 2013, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00209; Krakhmal NV, 2015, ACTA NATURAE, V7, P17, DOI 10.32607/20758251-2015-7-2-17-28; Kumar SS, 2015, ORAL ONCOL, V51, pE87, DOI 10.1016/j.oraloncology.2015.08.010; Lodder WL, 2011, EUR RADIOL, V21, P98, DOI 10.1007/s00330-010-1891-7; Luo WR, 2012, HISTOPATHOLOGY, V61, P1072, DOI 10.1111/j.1365-2559.2012.04350.x; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Nakagawa Y, 2013, ANTICANCER RES, V33, P5023; Ng JH, 2017, HEAD NECK-J SCI SPEC, V39, P297, DOI 10.1002/hed.24589; Piazza C, 2014, CURR OPIN OTOLARYNGO, V22, P81, DOI 10.1097/MOO.0000000000000038; Preda L, 2006, EUR RADIOL, V16, P2242, DOI 10.1007/s00330-006-0263-9; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Sawazaki-Calone I, 2015, ORAL DIS, V21, P755, DOI 10.1111/odi.12343; Seki M, 2016, HEAD NECK-J SCI SPEC, V38, pE1582, DOI 10.1002/hed.24282; Sgaramella N, 2015, BRIT J CANCER, V113, P321, DOI 10.1038/bjc.2015.207; Strieder L, 2017, ORAL DIS, V23, P120, DOI 10.1111/odi.12586; Tan WJ, 2012, ORL J OTO-RHINO-LARY, V74, P264, DOI 10.1159/000343796; Taylor SM, 2010, ORAL ONCOL, V46, P38, DOI 10.1016/j.oraloncology.2009.10.005; Ueno H, 2002, CANCER, V94, P2882, DOI 10.1002/cncr.10551; Wang C, 2011, J ORAL PATHOL MED, V40, P545, DOI 10.1111/j.1600-0714.2011.01041.x; Xie N, 2015, J ORAL PATHOL MED, V44, P266, DOI 10.1111/jop.12242	40	7	7	2	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					231	236		10.1007/s00428-017-2212-1			6	Pathology	Pathology	FZ6IF	WOS:000427700600007	28766010	Green Accepted			2019-10-28	
J	Morin, DP				Morin, Daniel P.			Pacemaker failure as a cause of sudden death	VIRCHOWS ARCHIV			English	Letter									[Morin, Daniel P.] Ochsner Med Ctr, Dept Cardiol, Div Electrophysiol, 1514 Jefferson Highway, New Orleans, LA 70118 USA; [Morin, Daniel P.] Univ Queensland, Sch Med, Ochsner Clin Sch, New Orleans, LA USA	Morin, DP (reprint author), Ochsner Med Ctr, Dept Cardiol, Div Electrophysiol, 1514 Jefferson Highway, New Orleans, LA 70118 USA.; Morin, DP (reprint author), Univ Queensland, Sch Med, Ochsner Clin Sch, New Orleans, LA USA.	dmorin@ochsner.org	Morin, Daniel/M-7269-2019; Morin, Daniel P/D-6430-2014	Morin, Daniel/0000-0002-9637-9507; 			Basso C, 2017, VIRCHOWS ARCH, P1; Kirkpatrick JN, 2007, J CARDIOVASC ELECTR, V18, P478, DOI 10.1111/j.1540-8167.2007.00773.x; Saint-Martin P, 2008, J FORENSIC SCI, V53, P1160, DOI 10.1111/j.1556-4029.2008.00805.x; Sinha SK, 2016, HEART RHYTHM, V13, P1971, DOI 10.1016/j.hrthm.2016.05.023	4	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					293	293		10.1007/s00428-017-2244-6			1	Pathology	Pathology	FZ6IF	WOS:000427700600014	29080038	Bronze			2019-10-28	
J	Wiles, AB; Idowu, MO; Clevenger, CV; Powers, CN				Wiles, Austin Blackburn; Idowu, Michael O.; Clevenger, Charles V.; Powers, Celeste N.			Evaluating Nonclinical Performance of the Academic Pathologist: A Comprehensive, Scalable, and Flexible System for Leadership Use	ACADEMIC PATHOLOGY			English	Article						academic pathologist; guidance; nonclinical activity; practice leadership; promotion	PRODUCTIVITY; FACULTY; HEALTH; EXCELLENCE; PHYSICIANS	Academic pathologists perform clinical duties, as well as valuable nonclinical activities. Nonclinical activities may consist of research, teaching, and administrative management among many other important tasks. While clinical duties have many clear metrics to measure productivity, like the relative value units of Medicare reimbursement, nonclinical performance is often difficult to measure. Despite the difficulty of evaluating nonclinical activities, nonclinical productivity is used to determine promotion, funding, and inform professional evaluations of performance. In order to better evaluate the important nonclinical performance of academic pathologists, we present an evaluation system for leadership use. This system uses a Microsoft Excel workbook to provide academic pathologist respondents and reviewing leadership a transparent, easy-to-complete system that is both flexible and scalable. This system provides real-time feedback to academic pathologist respondents and a clear executive summary that allows for focused guidance of the respondent. This system may be adapted to fit practices of varying size, measure performance differently based on years of experience, and can work with many different institutional values.	[Wiles, Austin Blackburn; Idowu, Michael O.; Clevenger, Charles V.; Powers, Celeste N.] VCU Sch Med, Dept Pathol, POB 980662,1200 E Marshall St,Gateway Bldg 6-205, Richmond, VA 23298 USA	Wiles, AB (reprint author), VCU Sch Med, Dept Pathol, POB 980662,1200 E Marshall St,Gateway Bldg 6-205, Richmond, VA 23298 USA.	austin.wiles@vcuhealth.org					Akl EA, 2012, CAN MED ASSOC J, V184, pE602, DOI 10.1503/cmaj.111123; Andreae MC, 2002, ACAD MED, V77, P894, DOI 10.1097/00001888-200209000-00019; CAREY RM, 1993, ACAD MED, V68, P813, DOI 10.1097/00001888-199311000-00001; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Filler G, 2014, ACAD MED, V89, P144, DOI 10.1097/ACM.0000000000000058; Freischlag JA, 2013, AM J SURG, V206, P667, DOI 10.1016/j.amjsurg.2013.08.013; Gunderman RB, 2004, MED SCI MONITOR, V10, pRA15; Hilton C, 1997, ACAD MED, V72, P787, DOI 10.1097/00001888-199709000-00014; Holcombe RF, 2010, J ONCOL PRACT, V6, P74, DOI 10.1200/JOP.091075; Kumar RDC, 2013, ANAEST INTENS CARE M, V14, P39, DOI 10.1016/j.mpaic.2012.11.006; Ma OJ, 2017, ACAD MED, V92, P1138, DOI 10.1097/ACM.0000000000001570; Nora LM, 2000, ACAD MED, V75, P913, DOI 10.1097/00001888-200009000-00014; Nutter DO, 2000, ACAD MED, V75, P200, DOI 10.1097/00001888-200002000-00025; Pitt MB, 2017, ACAD PEDIATR, V17, P218, DOI 10.1016/j.acap.2016.10.004; PRICE P B, 1964, J Med Educ, V39, P203; Ragsdale Judith R, 2014, Hosp Pediatr, V4, P93, DOI 10.1542/hpeds.2013-0075; Raj A, 2016, ACAD MED, V91, P1074, DOI 10.1097/ACM.0000000000001251; Robinson M, 2013, J SURG EDUC, V70, P606, DOI 10.1016/j.jsurg.2013.04.013; Schindler N, 2013, J SURG EDUC, V70, P731, DOI 10.1016/j.jsurg.2013.05.002; Schindler Nancy, 2002, Acad Med, V77, P940, DOI 10.1097/00001888-200209000-00047; Schrijver I, 2016, PEERJ, V4, DOI 10.7717/peerj.1783; Scoggins CR, 2013, J AM COLL SURGEONS, V217, P46, DOI 10.1016/j.jamcollsurg.2013.01.066; Sonnino RE, 2013, AM J SURG, V206, P727, DOI 10.1016/j.amjsurg.2013.07.004	23	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	FEB 1	2018	5								UNSP 2374289518754889	10.1177/2374289518754889			7	Pathology	Pathology	GH7WE	WOS:000433787800001	29435488	DOAJ Gold, Green Published			2019-10-28	
J	Badoual, C				Badoual, Cecile			For 2018, a new editorial board for Annales de Pathologie	ANNALES DE PATHOLOGIE			French	Editorial Material									[Badoual, Cecile] Hop Europeen Georges Pompidou, Serv Anat & Cytol Pathol, 20-40 Rue Leblanc, F-75908 Paris 15, France	Badoual, C (reprint author), Hop Europeen Georges Pompidou, Serv Anat & Cytol Pathol, 20-40 Rue Leblanc, F-75908 Paris 15, France.	cecile.badoual@aphp.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					1	1		10.1016/j.annpat.2018.01.005			1	Pathology	Pathology	GE1SB	WOS:000430995900001	29407354				2019-10-28	
J	Sabourin, JC				Sabourin, Jean-Christophe			Welcome to the new editorial board!	ANNALES DE PATHOLOGIE			French	Editorial Material									[Sabourin, Jean-Christophe] CHU Charles Nicolle, Serv Anat & Cytol Pathol, 1 Rue Germont, F-76031 Rouen, France	Sabourin, JC (reprint author), CHU Charles Nicolle, Serv Anat & Cytol Pathol, 1 Rue Germont, F-76031 Rouen, France.	jean-christophe.sabourin@chu-rouen.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					2	3		10.1016/j.annpat.2018.01.006			2	Pathology	Pathology	GE1SB	WOS:000430995900002	29407355				2019-10-28	
J	Ortonne, N				Ortonne, Nicolas			Skin, a target for autoimmune, infectious and drug induced diseases	ANNALES DE PATHOLOGIE			French	Editorial Material									[Ortonne, Nicolas] Hop Henri Mondor, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France	Ortonne, N (reprint author), Hop Henri Mondor, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	nicolas.ortonne@aphp.fr		Ortonne, Nicolas/0000-0003-0111-7422				0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					4	6		10.1016/j.annpat.2017.10.013			3	Pathology	Pathology	GE1SB	WOS:000430995900003	29273281				2019-10-28	
J	Ortonne, N				Ortonne, Nicolas			Histopathology of cutaneous drug reactions	ANNALES DE PATHOLOGIE			French	Review						Cutaneous adverse reactions; Maculopapular rash; DRESS; Toxic epidermal necrolysis; Fixed drug eruption; Acute generalized exanthematic pustulosis	TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; SYSTEMIC SYMPTOMS; T-CELLS; HYPERSENSITIVITY REACTIONS; ADVERSE-REACTIONS; EOSINOPHILIA; ERUPTIONS; SPECTRUM; FEATURES	There are many different types of cutaneous adverse reactions. The most classical reactions are driven by T lymphocytes that specifically react towards a drug, with an individual genetic susceptibility linked to certain type I major histocompatibility complex alleles. These reactions are characterized by a wide variety of clinical and histopathological presentations, and a wide range of severity. The most frequent entity is the maculopapular rash, while the most aggressive forms are the Steven-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN). The histopathological alterations associated to each of these syndromes have been better described in the literature during the past 10 years, encompassing non-specific lesions, as in most drug induced maculopapular rashes, to more specific inflammatory patterns. The finding of confluent apoptotic keratinocytes with epidermal detachment is the prototypical aspect of SJS-TEN. There are however numerous pitfalls, and a similar aspect to those observed in each cutaneous drug reactions entities can be found in other diseases. DRESS syndrome can indeed present with dense and epidermotropic T-cell infiltrate, sometimes with nuclear atypias, and thus can be difficult to distinguish from a primary or secondary cutaneous T-cell lymphoma. The diagnosis of cutaneous adverse reactions relies on a clinical-pathological confrontation and requires an accurate evaluation of drug imputability. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Ortonne, Nicolas] Hop Henri Mondor, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France	Ortonne, N (reprint author), Hop Henri Mondor, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	nicolas.ortonne@aphp.fr		Ortonne, Nicolas/0000-0003-0111-7422			Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Bellon T, 2010, BRIT J DERMATOL, V162, P1014, DOI 10.1111/j.1365-2133.2009.09627.x; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; de Araujo E, 2011, EXP DERMATOL, V20, P107, DOI 10.1111/j.1600-0625.2010.01176.x; Duong TA, 2017, LANCET LOND ENGL; Dupuy A, 2017, AM J SURG P IN PRESS; Gerson D, 2008, J AM ACAD DERMATOL, V59, P995, DOI 10.1016/j.jaad.2008.09.015; Halevy S, 2010, BRIT J DERMATOL, V163, P1245, DOI 10.1111/j.1365-2133.2010.09967.x; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Mizukawa Y, 2008, BRIT J DERMATOL, V158, P1230, DOI 10.1111/j.1365-2133.2008.08516.x; Mizukawa Y, 2002, AM J PATHOL, V161, P1337, DOI 10.1016/S0002-9440(10)64410-0; Nassif A, 2004, J INVEST DERMATOL, V123, P850, DOI 10.1111/j.0022-202X.2004.23439.x; Ortonne N, 2016, BRIT J DERMATOL, V175, P1142, DOI 10.1111/bjd.14986; Ortonne N, 2015, BRIT J DERMATOL, V173, P50, DOI 10.1111/bjd.13683; Picard D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001116; Gouveia MP, 2016, BRIT J DERMATOL, V175, P1274, DOI 10.1111/bjd.14704; Posadas SJ, 2007, CLIN EXP ALLERGY, V37, P989, DOI 10.1111/j.1365-2222.2007.02742.x; Saito N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008227; Seishima M, 2006, BRIT J DERMATOL, V155, P344, DOI 10.1111/j.1365-2133.2006.07332.x; Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002; Tangamornsuksan W, 2013, JAMA DERMATOL, V149, P1025, DOI 10.1001/jamadermatol.2013.4114; Valeyrie-Allanore L, 2013, J AM ACAD DERMATOL, V68, pE29, DOI 10.1016/j.jaad.2011.10.007; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490	25	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					7	19		10.1016/j.annpat.2017.10.015			13	Pathology	Pathology	GE1SB	WOS:000430995900004	29279184				2019-10-28	
J	Marciano-Fellous, L				Marciano-Fellous, Lea			Cutaneous infections: Pathologist's role in unusual or atypical situations	ANNALES DE PATHOLOGIE			French	Review						Cutaneous infections; Atypical situation	EPIDERMODYSPLASIA-VERRUCIFORMIS; LYME BORRELIOSIS; PSEUDOLYMPHOMA; MIMICKING; CELLS; SKIN	In infectious pathology, the gold standard consists of the detection of the pathogen within the sample. Identification of the pathogen is often difficult despite the presence of few and inexpensive tools, such, as special stain, immunohistochemistry, or in situ hybridization specific of the pathogen. In infectious pathology, there are morphological signs, which can guide us towards an etiology. We present some clinicopathological examples illustrating rare or unusual situations in cutaneous infectious pathology. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Marciano-Fellous, Lea] Grp Hosp Henri Mondor, AP HP, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France	Marciano-Fellous, L (reprint author), Grp Hosp Henri Mondor, AP HP, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	Lea.marciano-fellous@aphp.fr					ASHACK RJ, 1989, J AM ACAD DERMATOL, V21, P306, DOI 10.1016/S0190-9622(89)70182-1; Champagne C, 2015, AM J DERMATOPATH, V37, P929, DOI 10.1097/DAD.0000000000000325; Delie A, 2016, ACTA CLIN BELG, V26, P1; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Heymann Warren R, 2012, J Clin Aesthet Dermatol, V5, P18; Hsu CK, 2009, J AM ACAD DERMATOL, V60, P453, DOI 10.1016/j.jaad.2008.10.058; Ichihara A, 2014, J DERMATOL, V41, P414, DOI 10.1111/1346-8138.12459; Kadam P, 2017, AM J DERMATOPATH, V39, P928, DOI 10.1097/DAD.0000000000000941; McComb ME, 2003, J AM ACAD DERMATOL, V49, pS174, DOI 10.1067/mjd.2003.329; Meymandi S, 2004, INT J DERMATOL, V43, P819, DOI 10.1111/j.1365-4632.2004.02359.x; Moon HS, 2009, AM J DERMATOPATH, V31, P846, DOI 10.1097/DAD.0b013e3181ad4f22; Nguyen KD, 2017, J AM ACAD DERMATOL, V76, P932, DOI 10.1016/j.jaad.2016.11.035; Patel T, 2010, DIS MARKERS, V29, P199, DOI 10.3233/DMA-2010-0733; Psarros G, 2012, MEDICINE, V91, P111, DOI 10.1097/MD.0b013e31824dc07a; Romero-Mate Alberto, 2012, Dermatol Online J, V18, P7; Rose C, 1999, J CUTAN PATHOL, V26, P520, DOI 10.1111/j.1600-0560.1999.tb01800.x; Skiada Anna, 2013, Skinmed, V11, P155; Stanek G, 2003, LANCET, V362, P1639, DOI 10.1016/S0140-6736(03)14798-8; Steere AC, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.90; Werner B, 2008, J CUTAN PATHOL, V35, P1100, DOI 10.1111/j.1600-0560.2007.00979.x; Zollinger T, 2010, J CUTAN PATHOL, V37, P571, DOI 10.1111/j.1600-0560.2009.01493.x	21	0	0	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					20	30		10.1016/j.annpat.2017.10.016			11	Pathology	Pathology	GE1SB	WOS:000430995900005	29287934				2019-10-28	
J	Wechsler, J				Wechsler, Janine			Humoral immune diseases: Cutaneous vasculitis and auto-immune bullous dermatoses	ANNALES DE PATHOLOGIE			French	Review						Auto-immune disease; Leucocytoclasic vasculitis; Urticaria; Lever's faciale granuloma; Erythema elevatum diutinum; Auto-immune bullous dermatosis; Pemphigoid; Epidermolysa bullous acquisita; Pemphigus; Linear IgA dermatosis; Herpetiform dermatitis	ERYTHEMA-ELEVATUM-DIUTINUM; DERMATITIS-HERPETIFORMIS; BLISTERING DISEASES; PEMPHIGUS; SKIN; IGA; PATHOGENESIS; ANTIBODIES	Humoral immunity is the cause of multiple diseases related to antibodies (IgA, IgG, IgM) produced by the patient. Two groups of diseases are identified. The first group is related to circulating antigen-antibody complexes. The antigens are various. They are often unknown. These immune complexes cause a vascular inflammation due to the complement fixation. Consequently, this group is dominated by inflammatory vasculitis. In the second group, the pathology is due to the fixation in situ of antibodies to a target antigen of the skin that is no more recognized by the patient. This group is represented by the auto-immune bullous dermatoses. (C) 2017 Published by Elsevier Masson SAS.	[Wechsler, Janine] Hop Henri Mondor, AP HP, Serv Anat & Cytol Pathol, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France	Wechsler, J (reprint author), Hop Henri Mondor, AP HP, Serv Anat & Cytol Pathol, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	wechsler.janine@gmail.com					Al-Saif F, 2016, J REPROD IMMUNOL, V116, P42, DOI 10.1016/j.jri.2016.04.286; Ali S, 2016, BRIT J DERMATOL, V174, P1022, DOI 10.1111/bjd.14351; Bagci IS, 2017, AUTOIMMUN REV, V16, P445, DOI 10.1016/j.autrev.2017.03.010; Barnadas MA, 2016, AM J DERMATOPATH, V38, P283, DOI 10.1097/DAD.0000000000000420; Brenner S, 2011, CLIN DERMATOL, V29, P455, DOI 10.1016/j.clindermatol.2011.01.016; Broussard KC, 2016, CLIN DERMATOL, V34, P205, DOI 10.1016/j.clindermatol.2015.11.006; Bulkhi A, 2017, IMMUNOL ALLERGY CLIN, V37, P95, DOI 10.1016/j.iac.2016.08.004; Carlson JA, 1996, SEMIN DIAGN PATHOL, V13, P72; Dainichi T, 2017, J DERMATOL SCI, V88, P265, DOI 10.1016/j.jdermsci.2017.07.012; de Boysson H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002957; Demirkesen C, 2017, CURR OPIN RHEUMATOL, V29, P39, DOI 10.1097/BOR.0000000000000346; Diercks Gilles F, 2017, Surg Pathol Clin, V10, P505, DOI 10.1016/j.path.2017.01.011; Diny NL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00484; Fahad Al-Saif, 2011, Indian J Dermatol, V56, P573, DOI 10.4103/0019-5154.87159; Feasel P, 2018, J CUTAN PATHOL, V45, P16, DOI 10.1111/cup.13054; Fortuna G, 2012, CLIN DERMATOL, V30, P38, DOI 10.1016/j.clindermatol.2011.03.008; Gambichler T, 2017, POSTEP DERM ALERGOL, V34, P299, DOI 10.5114/ada.2017.69307; Goyal N, 2017, INDIAN J DERMATOL VE, V83, P550, DOI 10.4103/ijdvl.IJDVL_678_16; Gru AA, 2017, SEMIN DIAGN PATHOL, V34, P285, DOI 10.1053/j.semdp.2017.04.001; Hetland LE, 2017, ACTA DERM-VENEREOL, V97, P1160, DOI 10.2340/00015555-2733; Jain R, 2008, HEAD NECK PATHOL, V2, P309, DOI 10.1007/s12105-008-0077-y; Kartan S, 2017, AM J CLIN DERMATOL, V18, P105, DOI 10.1007/s40257-016-0235-z; Kavand S, 2016, AM J CLIN PATHOL, V145, P401, DOI [10.1093/AJCP/AQW004, 10.1093/ajcp/aqw004]; Kern Malan, 2017, JAAD Case Rep, V3, P444, DOI 10.1016/j.jdcr.2017.06.033; Keyal U, 2017, AM J TRANSL RES, V9, P1956; Kim M, 2016, DRUG AGING, V33, P711, DOI 10.1007/s40266-016-0402-1; Madala Jayakiran, 2017, J Oral Maxillofac Pathol, V21, P260, DOI 10.4103/jomfp.JOMFP_143_17; Mendez-Flores S, 2016, J CUTAN PATHOL, V43, P1062, DOI 10.1111/cup.12793; Pereira AR, 2016, AN BRAS DERMATOL, V91, P35, DOI 10.1590/abd1806-4841.20164665; Fernandes KDP, 2016, AN BRAS DERMATOL, V91, P32, DOI 10.1590/abd1806-4841.20164630; Qian Y, 2016, AUTOIMMUN REV, V15, P923, DOI 10.1016/j.autrev.2016.07.005; Radonjic-Hoesli S, 2017, CLIN REV ALLERGY IMM; Reunala T, 2015, ACTA DERM-VENEREOL, V95, P917, DOI 10.2340/00015555-2162; Santoro Frank A, 2013, Dent Clin North Am, V57, P597, DOI 10.1016/j.cden.2013.06.002; Schmidt E, 2017, J INVEST DERMATOL, V137, P1199, DOI 10.1016/j.jid.2017.01.028; Vassileva S, 2014, CLIN DERMATOL, V32, P364, DOI 10.1016/j.clindermatol.2013.11.003; Yong AA, 2013, AUSTRALAS J DERMATOL, V54, P241, DOI 10.1111/j.1440-0960.2012.00921.x; Zaraa I, 2010, INT J DERMATOL, V49, P298, DOI 10.1111/j.1365-4632.2009.04195.x	38	0	0	0	2	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					31	42		10.1016/j.annpat.2017.11.003			12	Pathology	Pathology	GE1SB	WOS:000430995900006	29287933				2019-10-28	
J	Karkouche, R				Karkouche, Raymond			Cell-mediated immunity: Lupus and connective tissue diseases	ANNALES DE PATHOLOGIE			French	Review						Lupus; Classification; Histopathology; Connective tissue disease	DIRECT IMMUNOFLUORESCENCE; ERYTHEMATOSUS; CLASSIFICATION; PANNICULITIS; MULTICENTER; PERNIOSIS; SUBSETS	Lupus can present itself in a multitude of clinical and histopathological manifestations. Cutaneous lesions can be very variable either from the clinical point of view or at the microscopic scale. Signs can be specific, concerning the dermo-epidermal stage, the dermal stage or the hypodermal stage. Conversely, some manifestations can be not specific but associated to the lupus. Finally, the question of the differential diagnosis can be tricky and often requires a beam of clinical, biological and histopathological arguments. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Karkouche, Raymond] Hop Henri Mondor, AP HP, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France	Karkouche, R (reprint author), Hop Henri Mondor, AP HP, Dept Pathol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	raymond.karkouche@aphp.fr					Baima B, 2001, BRIT J DERMATOL, V144, P958, DOI 10.1046/j.1365-2133.2001.04182.x; BANGERT JL, 1984, ARCH DERMATOL, V120, P332, DOI 10.1001/archderm.120.3.332; Bosisio F, 2015, AM J SURG PATHOL, V39, P206, DOI 10.1097/PAS.0000000000000307; DAHL MV, 1983, ARCH DERMATOL, V119, P1010, DOI 10.1001/archderm.119.12.1010; Daldon PEC, 2003, J CUTAN PATHOL, V30, P443, DOI 10.1034/j.1600-0560.2003.00082.x; Fried I, 2010, J CUTAN PATHOL, V37, P91, DOI 10.1111/j.1600-0560.2009.01295.x; Fujimoto W, 2005, J DERMATOL, V32, P1021, DOI 10.1111/j.1346-8138.2005.tb00894.x; GILLIAM JN, 1981, J AM ACAD DERMATOL, V4, P471, DOI 10.1016/S0190-9622(81)80261-7; JACOBS MI, 1983, ARCH DERMATOL, V119, P883, DOI 10.1001/archderm.119.11.883; JERDAN MS, 1990, ARCH DERMATOL, V126, P52, DOI 10.1001/archderm.126.1.52; Jones SAV, 1997, CLIN EXP DERMATOL, V22, P77, DOI 10.1111/j.1365-2230.1997.tb02624.x; Karkouche R, 2017, J EUR ACAD DERMATOL, V31, P1029, DOI 10.1111/jdv.13969; Ko CJ, 2011, J CUTAN PATHOL, V38, P889, DOI 10.1111/j.1600-0560.2011.01779.x; Kuhn A, 2001, J AM ACAD DERMATOL, V45, P86, DOI 10.1067/mjd.2001.114589; Kulthanan K, 1998, INT J DERMATOL, V37, P201, DOI 10.1046/j.1365-4362.1998.00288.x; Lee HY, 2011, DERMATOLOGY, V222, P304, DOI 10.1159/000329428; Lipsker D, 2010, LUPUS, V19, P1047, DOI 10.1177/0961203310370044; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Remy-Leroux V, 2008, J AM ACAD DERMATOL, V58, P217, DOI 10.1016/j.jaad.2007.09.039; Ribero S, 2017, CLIN REV ALLERG IMMU, V53, P291, DOI 10.1007/s12016-017-8627-2; Tebbe B, 1997, ACTA DERM-VENEREOL, V77, P305; UITTO J, 1978, BRIT J DERMATOL, V98, P507, DOI 10.1111/j.1365-2133.1978.tb01936.x; West SE, 2013, JAMA DERMATOL, V149, P1314, DOI 10.1001/jamadermatol.2013.6302	23	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					43	54		10.1016/j.annpat.2017.10.012			12	Pathology	Pathology	GE1SB	WOS:000430995900007	29290386				2019-10-28	
J	Tauziede-Espariat, A; Chretien, F; Jouvion, G; Alde-Biassette, H; Hofman, P				Tauziede-Espariat, Arnault; Chretien, Fabrice; Jouvion, Gregory; Alde-Biassette, Homa; Hofman, Paul			Practices in infectious pathology in France in 2015. Results of the national survey	ANNALES DE PATHOLOGIE			French	Article						Infectious disease pathology; Expertise; Molecular pathology	EPSTEIN-BARR-VIRUS; REAL-TIME PCR; PARAFFIN-EMBEDDED TISSUE; IN-SITU HYBRIDIZATION; MYCOBACTERIUM-TUBERCULOSIS COMPLEX; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; TRANSPLANT RECIPIENTS; RESPIRATORY SYNDROME; TREPONEMA-PALLIDUM	Pathologists have been, are and will be always implicated in the diagnosis of infectious and tropical diseases. The resurgence of opportunistic infections due to the development of immunosuppressive drugs, the increase of migratory involvements draining tropical infections and the last epidemics spotlight the importance of pathologists in the field of infectious diseases. However, cancer is nowadays the first preoccupation of pathologists, which is constantly subject to evaluate diagnostic and prognostic markers and factors predictive to targeted therapy response or immunotherapy. As tumor pathology, infectious diseases require more sophisticated and rapidly changing complementary techniques, appraisals and perhaps a national network of diagnosis. The infectious pathology club committee carries out here a census of methods used in the diagnosis of infectious diseases in France in 2015 and particularly the different techniques used by laboratories to perform infectious diseases diagnosis. This will lay down the foundation of a future national organization of the infectious pathology in providing efficient services (diagnostic support, complementary tools) for the community of French pathologists in this specific domain of competence. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Tauziede-Espariat, Arnault; Chretien, Fabrice] Ctr Hosp St Anne, Lab Neuropathol, 1 Rue Cabanis, F-75014 Paris, France; [Chretien, Fabrice; Jouvion, Gregory] Inst Pasteur, Unite Histopathol Humaine & Modeles Anim, 25-28 Rue Docteur Roux, F-75015 Paris, France; [Alde-Biassette, Homa] Hop Lariboisiere, Serv Anat & Cytol Pathol, 1 Rue Ambroise Pare, F-75475 Paris, France; [Hofman, Paul] CHU Nice, Hop Pasteur, Lab Pathol Clin & Expt & Biobanque Hosp BB 0033 0, 30 Voie Romaine, F-06001 Nice 01, France	Tauziede-Espariat, A (reprint author), Ctr Hosp St Anne, Lab Neuropathol, 1 Rue Cabanis, F-75014 Paris, France.	arnault.tauziedeespariat@gmail.com	Hofman, Paul/P-7654-2018; Chretien, fabrice/D-4035-2018	Hofman, Paul/0000-0003-0431-9353; Chretien, fabrice/0000-0002-2794-1383			Abreu C, 2015, WORLD J GASTROENTERO, V21, P6491, DOI 10.3748/wjg.v21.i21.6491; Akhaddar A, 2010, WORLD NEUROSURG, V74, P346, DOI 10.1016/j.wneu.2010.05.029; Aromseree S, 2015, J CLIN VIROL, V73, P70, DOI 10.1016/j.jcv.2015.10.015; Backert S, 2016, HELICOBACTER, V21, P19, DOI 10.1111/hel.12335; Behrhof W, 2008, J CLIN PATHOL, V61, P390, DOI 10.1136/jcp.2007.046714; Borchardt J, 2016, MULT SCLER RELAT DIS, V8, P145, DOI 10.1016/j.msard.2016.03.005; Budenz CL, 2010, ANN OTO RHINOL LARYN, V119, P313, DOI 10.1177/000348941011900507; Chen CY, 2012, METHODS MOL BIOL, V903, P295, DOI 10.1007/978-1-61779-937-2_20; Chuang SS, 2014, PATHOLOGY, V46, P581, DOI 10.1097/PAT.0000000000000161; Coussement J, 2016, CLIN INFECT DIS, V63, P338, DOI 10.1093/cid/ciw241; da Silva IB, 2016, EXP PARASITOL, V165, P16, DOI 10.1016/j.exppara.2016.03.004; DeBiasi RL, 2002, J CLIN VIROL, V25, pS5; Deeb KK, 2015, ARCH PATHOL LAB MED, V139, P913, DOI 10.5858/arpa.2014-0095-OA; Dolinger David L, 2016, Int J Mycobacteriol, V5 Suppl 1, pS27, DOI 10.1016/j.ijmyco.2016.09.021; Drogari-Apiranthitou M, 2016, PATHOL RES PRACT, V212, P393, DOI 10.1016/j.prp.2016.02.010; Ellis JE, 2017, J MICROBIOL METH, V138, P12, DOI 10.1016/j.mimet.2016.09.012; Frickmann H, 2015, BIOMED RES INT, DOI 10.1155/2015/938721; Fukumoto H, 2015, INT J CLIN EXP PATHO, V8, P15479; Gasnault J, 2008, DONNEES RECENTES LEU; Goldberg B, 2015, MBIO, V6, DOI 10.1128/mBio.01888-15; HOFMAN P, 1993, BRIT HEART J, V70, P376; HOFMAN P, 1993, PATHOL RES PRACT, V189, P894; Hofman P, 2006, CURR MED CHEM, V13, P3121, DOI 10.2174/092986706778742891; Hofman P, 2017, VIRCHOWS ARCH, V470, P483, DOI 10.1007/s00428-017-2082-6; Ingrand D., 1997, Archives d'Anatomie et de Cytologie Pathologiques, V45, P127; Jacobi C, 2015, ONCOTARGET, V6, P3462, DOI 10.18632/oncotarget.3062; Kanyilmaz Gul, 2015, Asian Pac J Cancer Prev, V16, P253; Karaarslan S, 2015, POL J PATHOL, V66, P161, DOI 10.5114/PJP.2015.53013; Kerr DA, 2016, ARCH PATHOL LAB MED, V140, P844, DOI 10.5858/arpa.2015-0272-OA; Kim YN, 2015, J MOL DIAGN, V17, P597, DOI 10.1016/j.jmoldx.2015.04.005; Kolm Isabel, 2014, Dermatol Online J, V20, P22640; Le HJ, 2012, CHINESE MED J-PEKING, V125, P2109, DOI 10.3760/cma.j.issn.0366-6999.2012.12.006; Lebeaux D, 2014, EUR J CLIN MICROBIOL, V33, P689, DOI 10.1007/s10096-013-2015-5; Lecuit M, 2015, EXPERT REV MOL DIAGN, V15, P1517, DOI 10.1586/14737159.2015.1111140; Lee HS, 2011, J MOL DIAGN, V13, P390, DOI 10.1016/j.jmoldx.2011.02.004; Lefterova MI, 2015, J MOL DIAGN, V17, P623, DOI 10.1016/j.jmoldx.2015.07.004; Leroux-Kozal V, 2015, HUM PATHOL, V46, P443, DOI 10.1016/j.humpath.2014.12.001; Meghdadi H, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00675; MICHIELS JF, 1994, PATHOL RES PRACT, V190, P1089, DOI 10.1016/S0344-0338(11)80908-8; MICHIELS JF, 1993, PATHOL RES PRACT, V189, P377, DOI 10.1016/S0344-0338(11)80322-5; Mirghani H, 2016, ORAL ONCOL, V62, P101, DOI 10.1016/j.oraloncology.2016.10.009; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Mohanlal RD, 2015, AM J DERMATOPATH, V37, P530, DOI 10.1097/DAD.0000000000000363; Morbini P, 2016, HUM PATHOL, V47, P158, DOI 10.1016/j.humpath.2015.06.027; Muraosa Y, 2016, MED MYCOL, V54, P433, DOI 10.1093/mmy/myv106; Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024; Pak TR, 2015, CLIN INFECT DIS, V61, P1695, DOI 10.1093/cid/civ670; Parker J, 2017, J CLIN VIROL, V86, P20, DOI 10.1016/j.jcv.2016.11.010; Prabhu SR, 2016, J CAN DENT ASSOC, V82; Procop GW, 2001, CLIN INFECT DIS, V32, P1589, DOI 10.1086/320537; Ramdial PK, 2010, HISTOPATHOLOGY, V56, P39, DOI 10.1111/j.1365-2559.2009.03456.x; Rickerts V, 2016, FUNGAL BIOL-UK, V120, P279, DOI 10.1016/j.funbio.2015.07.002; Rochford R, 2016, CURR OPIN VIROL, V20, P28, DOI 10.1016/j.coviro.2016.08.002; Spadafora MSR, 2014, ANAL CELL PATHOL, DOI 10.1155/2014/124795; Ruangritchankul K, 2015, INT J CLIN EXP PATHO, V8, P14840; Sahm F, 2016, ACTA NEUROPATHOL, V131, P903, DOI 10.1007/s00401-015-1519-8; SantaCruz Karen S, 2016, World J Virol, V5, P31, DOI 10.5501/wjv.v5.i1.31; Schlaberg R, 2017, ARCH PATHOL LAB MED, V141, P776, DOI 10.5858/arpa.2016-0539-RA; Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006; Skalova H, 2012, Cesk Patol, V48, P161; Suh DS, 2010, ONCOL REP, V23, P751, DOI 10.3892/or_00000694; Surat G, 2014, J CLIN PATHOL, V67, P1084, DOI 10.1136/jclinpath-2014-202307; Swick BL, 2012, SEMIN CUTAN MED SURG, V31, P241, DOI 10.1016/j.sder.2012.06.009; Tauziede-Espariat A, 2016, ANN PATHOL, V36, P245, DOI 10.1016/j.annpat.2016.04.005; Thavaraj S, 2016, SEMIN DIAGN PATHOL, V33, P104, DOI 10.1053/j.semdp.2015.09.011; Toyoda M, 2015, TRANSPL INFECT DIS, V17, P838, DOI 10.1111/tid.12465; TSAI MM, 1993, MODERN PATHOL, V6, P185; Valmary-Degano S, 2013, HUM PATHOL, V44, P992, DOI 10.1016/j.humpath.2012.08.019; Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1; Wang WL, 2015, J DIGEST DIS, V16, P256, DOI 10.1111/1751-2980.12236; Wilson JW, 2012, MAYO CLIN PROC, V87, P403, DOI 10.1016/j.mayocp.2011.11.016; Win KT, 2016, APPL IMMUNOHISTO M M, V24, P105, DOI 10.1097/PAI.0000000000000162; Wroblewski LE, 2016, GASTROENTEROL CLIN N, V45, P543, DOI 10.1016/j.gtc.2016.04.010; Yajima N, 2013, INTERNAL MED, V52, P219, DOI 10.2169/internalmedicine.52.8642; Zappacosta R, 2015, ACTA CYTOL, V59, P345, DOI 10.1159/000438719	75	0	0	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					55	63		10.1016/j.annpat.2017.12.002			9	Pathology	Pathology	GE1SB	WOS:000430995900008	29317100				2019-10-28	
J	Picard, C; Fontaine, J; Chouvet, B; Balme, B; Traverse-Glehen, A				Picard, Cecile; Fontaine, Juliette; Chouvet, Brigitte; Balme, Brigitte; Traverse-Glehen, Alexandra			The key role of the pathologist in the diagnosis of syphilis: A case report	ANNALES DE PATHOLOGIE			French	Article						Secondary syphilis; Lymph node microbiopsy; Cutaneous biopsy; Lymphadenopathy		Syphilis is a resurging sexually transmitted infection linked to Treponema Pallidum. Syphilitic lymphadenitis can be present during the 3 stages of the disease. Its histological diagnosis remains challenging for the pathologist given its possible misleading aspect and its ability to mimic as well as reactional as tumoral conditions. We report the case of an HIV-infected young patient referred for suspicion of an aggressive lymphoma. Histological and immunohistochemical analysis of cervical lymphadenopathy revealed secondary syphilis. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Picard, Cecile; Fontaine, Juliette; Chouvet, Brigitte; Balme, Brigitte; Traverse-Glehen, Alexandra] Hosp Civils Lyon, Inst Pathol Multisite, Ctr Biol Sud, Ctr Hosp, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France; [Picard, Cecile; Fontaine, Juliette; Chouvet, Brigitte; Balme, Brigitte; Traverse-Glehen, Alexandra] Univ Lyon 1, 8 Ave Rockefeller, F-69003 Lyon, France	Picard, C (reprint author), Hosp Civils Lyon, Inst Pathol Multisite, Ctr Biol Sud, Ctr Hosp, 165 Chemin Grand Revoyet, F-69310 Pierre Benite, France.; Picard, C (reprint author), Univ Lyon 1, 8 Ave Rockefeller, F-69003 Lyon, France.	cecile.picard@chu-lyon.fr		Picard, Cecile/0000-0001-9284-4531			[Anonymous], 2015, B RESEAUX SURVEILLAN; Ioachim H. L., 2002, IOACHIMS LYMPH NODE; Miranda RN, 2013, ATLAS LYMPH NODE PAT; Vasiliu V, 2004, ANN PATHOL, V24, P192, DOI 10.1016/S0242-6498(04)93946-6	4	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	FEB	2018	38	1					64	67		10.1016/j.annpat.2017.10.014			4	Pathology	Pathology	GE1SB	WOS:000430995900009	29277436				2019-10-28	
J	Rainero, E				Rainero, Elena			Extracellular matrix internalization links nutrient signalling to invasive migration	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Review						extracellular matrix; integrins; vesicular trafficking; mTOR; nutrient signalling; cell metabolism	CELL-MIGRATION; INTEGRIN; FIBRONECTIN; METABOLISM; CANCER; TRAFFICKING; ENDOCYTOSIS; PROGRESSION; TURNOVER; SURVIVAL	Integrins are the key mediators of cell-extracellular matrix (ECM) interaction, linking the ECM to the actin cytoskeleton. Besides localizing at the cell surface, they can be internalized and transported back to the plasma membrane (recycled) or delivered to the late endosomes/lysosomes for degradation. We and others have shown that integrin can be endocytosed together with their ECM ligands. In this short review, I will highlight how extracellular protein (including ECM) endocytosis impinges on the activation of the mechanistic target of rapamycin (mTOR) pathway, a master regulator of cell metabolism and growth. This supports the intriguing hypothesis that ECM components may be considered as nutrient sources, primarily under soluble nutrient-depleted conditions.	[Rainero, Elena] Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield, S Yorkshire, England	Rainero, E (reprint author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield, S Yorkshire, England.	e.rainero@sheffield.ac.uk		Rainero, Elena/0000-0003-1402-8701	University of Sheffield; Royal SocietyRoyal Society of London	ER was funded by the University of Sheffield and the Royal Society.	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Christoforides C, 2012, DEV CELL, V23, P560, DOI 10.1016/j.devcel.2012.08.008; Clark K, 2005, J CELL SCI, V118, P291, DOI 10.1242/jcs.01623; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Daley WP, 2013, CURR OPIN GENET DEV, V23, P408, DOI 10.1016/j.gde.2013.05.005; De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653; Dozynkiewicz MA, 2012, DEV CELL, V22, P131, DOI 10.1016/j.devcel.2011.11.008; Georgiadou M, 2017, TRENDS CELL BIOL, V27, P703, DOI 10.1016/j.tcb.2017.06.004; Georgiadou M, 2017, J CELL BIOL, V216, P1107, DOI 10.1083/jcb.201609066; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Manninen A, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600022; Maritzen T, 2015, CELL MOL LIFE SCI, V72, P2119, DOI 10.1007/s00018-015-1855-9; McAtee CO, 2015, J BIOL CHEM, V290, P13144, DOI 10.1074/jbc.M115.647446; Muranen T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13989; Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017; Phang JM, 2015, CURR OPIN CLIN NUTR, V18, P71, DOI 10.1097/MCO.0000000000000121; Rainero E, 2015, CELL REP; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Shi F, 2008, J CELL SCI, V121, P2360, DOI 10.1242/jcs.014977; Shi F, 2011, J CELL SCI, V124, P4039, DOI 10.1242/jcs.087858; Streuli CH, 2016, MOL BIOL CELL, V27, P2885, DOI 10.1091/mbc.E15-06-0369; Theisen U, 2012, DEV CELL, V23, P1153, DOI 10.1016/j.devcel.2012.11.005; Yoon SO, 2017, MOL CELL, V67, P512, DOI 10.1016/j.molcel.2017.06.033	27	3	3	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					4	9		10.1111/iep.12265			6	Pathology	Pathology	GE0PM	WOS:000430917400001	29573490	Green Published, Green Accepted			2019-10-28	
J	Puccio, I; Khan, S; Butt, A; Graham, D; Sehgal, V; Patel, D; Novelli, M; Lovat, LB; Rodriguez-Justo, M; Hamoudi, RA				Puccio, Ignazio; Khan, Saif; Butt, Adil; Graham, David; Sehgal, Vinay; Patel, Dominic; Novelli, Marco; Lovat, Laurence B.; Rodriguez-Justo, Manuel; Hamoudi, Rifat A.			Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-kappa B activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						Barrett's oesophagus; Bcl3; immunohistochemistry; inflammatory response; nuclear factor kappa B; Survivin	ESOPHAGEAL ADENOCARCINOMA; BREAST-CANCER; APOPTOSIS; PROTEINS; PATHWAY	Non-dysplastic Barrett's oesophagus (NDBE) occurs as a consequence of an inflammatory response triggered through prolonged gastro-oesophageal reflux and it may precede the development of oesophageal adenocarcinoma. NF-kappa B activation as a result of the inflammatory response has been shown in NDBE, but the possible mechanism involved in the process is unknown. The aim of this study was to assess, using immunohistochemistry, Survivin and Bcl3 expression as potential biomarkers for NF-kappa B activation along the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. Survivin is an NF-kappa B-inducible anti-apoptotic protein, and Bcl3 is a negative regulator of NF-kappa B. There was progressive upregulation of Survivin expression along the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. Bcl3 expression was upregulated in non-dysplastic Barrett's oesophagus, low-grade, high-grade dysplasia and oesophageal adenocarcinoma when compared to squamous group. The study shows the differential expression of Bcl3 between the squamous and Barrett's stage, suggesting that Bcl3 could be a surrogate marker for early event involving constitutive NF-kappa B activation. In addition, the study suggests that NF-kappa B activation may infer resistance to apoptosis through the expression of anti-apoptotic genes such as Survivin, which showed progressive increase in expression throughout the oesophageal metaplasia-dysplasia-adenocarcinoma sequence. This ability to avoid apoptosis may underlie the persistence and malignant predisposition of Barrett's metaplasia.	[Puccio, Ignazio; Khan, Saif; Butt, Adil; Graham, David; Sehgal, Vinay; Patel, Dominic; Lovat, Laurence B.; Hamoudi, Rifat A.] UCL, Res Dept Tissue & Energy, Div Surg & Intervent Sci, London, England; [Novelli, Marco; Rodriguez-Justo, Manuel] UCL, Res Dept Pathol, London, England; [Hamoudi, Rifat A.] Univ Sharjah, Coll Med, Sharjah Inst Med Res, Sharjah, U Arab Emirates	Hamoudi, RA (reprint author), UCL, Div Surg & Intervent Sci, Wing 2-4,Cruciform Bldg,Gower St, London WC1E 6BT, England.	r.hamoudi@ucl.ac.uk	Lovat, Laurence/C-1986-2009; puccio, ignazio/F-4381-2019	Lovat, Laurence/0000-0003-4542-3915; puccio, ignazio/0000-0001-9047-2113	UCLH/UCL NIHR Biomedical Research Centre; Dangoor Education	MR-J and MN are supported by the UCLH/UCL NIHR Biomedical Research Centre. We acknowledge Dangoor Education for their support towards this work.	Abdel-Latif MMM, 2004, ANN SURG, V239, P491, DOI 10.1097/01.sla.0000118751.95179.c6; Ahlqvist K, 2013, ONCOGENE, V32, P1601, DOI 10.1038/onc.2012.175; Allred DC, 1998, MODERN PATHOL, V11, P155; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Berinstein NL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1026529; Buckley NE, 2016, ONCOTARGET, V7, P19884, DOI 10.18632/oncotarget.7865; Chen F, 1999, CLIN CHEM, V45, P7; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Garud Sagar S, 2010, Therap Adv Gastroenterol, V3, P227, DOI 10.1177/1756283X10365439; Herkenham M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-141; Hormi-Carver K, 2009, CANCER RES, V69, P672, DOI 10.1158/0008-5472.CAN-08-3703; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Li Y, 2015, MOL MED REP, V12, P2169, DOI 10.3892/mmr.2015.3579; Locke FL, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0065-1; Mak P, 2015, ONCOTARGET, V6, P40247, DOI 10.18632/oncotarget.5377; O'Riordan JM, 2005, AM J GASTROENTEROL, V100, P1257, DOI 10.1111/j.1572-0241.2005.41338.x; Pallares J, 2004, J PATHOL, V204, P569, DOI 10.1002/path.1666; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; Reissig S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15069; Saamarthy K., 2015, BMC CANCER, V15, P1; Song JX, 2008, CELL MOL IMMUNOL, V5, P239, DOI 10.1038/cmi.2008.30; Thornburg NJ, 2003, CANCER RES, V63, P8293; Wang K, 2010, BBA-MOL CELL RES, V1803, P1368, DOI 10.1016/j.bbamcr.2010.08.008; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhao H, 2016, ONCOTARGETS THER, V9, P6619, DOI 10.2147/OTT.S118184	26	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					10	14		10.1111/iep.12260			5	Pathology	Pathology	GE0PM	WOS:000430917400002	29473241	Green Published			2019-10-28	
J	Dong, WW; Li, J; Li, J; Zhang, P; Wang, ZH; Sun, W; Zhang, H				Dong, Wen-Wu; Li, Jian; Li, Jing; Zhang, Ping; Wang, Zhi-Hong; Sun, Wei; Zhang, Hao			Reduced expression of oestrogen receptor-beta is associated with tumour invasion and metastasis in oestrogen receptor-alpha-negative human papillary thyroid carcinoma	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						immunohistochemistry; oestrogen receptor-alpha; oestrogen receptor-beta; papillary thyroid cancer	BREAST-CANCER CELLS; ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; ER-BETA; PROGESTERONE-RECEPTOR; E-CADHERIN; IMMUNOHISTOCHEMICAL EXPRESSION; DIFFERENTIAL-DIAGNOSIS; PROGNOSTIC MARKER; UNITED-STATES	Oestrogens play an important role in the development and progression of papillary thyroid carcinoma (PTC) through oestrogen receptor (ER)-alpha and -beta, which may exert different or even opposing actions in PTC. The roles of ER in ER-negative PTC are still not clear. This study investigated the expression dynamics of ER beta 1 (wild-type ER) and its clinical significance in female ER alpha-negative PTC patients. ER beta 1 expression was detected in thyroid tissues of 136 female patients diagnosed with PTC. The relationships between ER beta 1 expression and clinicopathological/biological factors were also analysed in female ER alpha-negative PTC patients. The total score for ER beta 1 was significantly lower in female ER alpha-negative PTC patients with LNM or ETE when compared to those without LNM or ETE (Z = -2.923, P = 0.003 and Z = -3.441, P = 0.001). Accordingly, the total score for ER beta 1 was significantly higher in ER alpha-negative PTC patients expressing E-cadherin compared to patients negative for E-cadherin expression (Z = -2.636, P = 0.008). The total score was lower in ER alpha-negative PTC patients positive for VEGF expression compared to those negative for VEGF expression (Z = -1.914, P = 0.056). This preliminary study indicates that reduced expression of ER beta 1 in female ER alpha-negative PTC patients is associated with greater progression of the disease. This may provide insights into the underlying molecular mechanisms of ER beta 1 and could help design targeted approaches for treating or even preventing this disease.	[Dong, Wen-Wu; Zhang, Ping; Wang, Zhi-Hong; Sun, Wei; Zhang, Hao] China Med Univ, Dept Thyroid Surg, First Hosp 1, 155 Nanjing Bei St, Shenyang 110001, Liaoning, Peoples R China; [Li, Jian] Jinqiu Hosp Liaoning, Dept Surg, Shenyang, Liaoning, Peoples R China; [Li, Jing] China Med Univ, Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning, Peoples R China	Zhang, H (reprint author), China Med Univ, Dept Thyroid Surg, First Hosp 1, 155 Nanjing Bei St, Shenyang 110001, Liaoning, Peoples R China.	haozhang@cmu.edu.cn		Dong, Wenwu/0000-0001-6621-4800	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402208, 81502319]; Liaoning Province PhD Start-up Fund [20141042, 201501008]	This work was supported by National Natural Science Foundation of China [grant numbers 81402208, 81502319] and Liaoning Province PhD Start-up Fund [grant numbers 20141042, 201501008].	Ahn HY, 2015, CLIN ENDOCRINOL, V82, P300, DOI 10.1111/cen.12486; Ceresini G, 2006, THYROID, V16, P1215, DOI 10.1089/thy.2006.16.1215; Ceyran AB, 2015, INT J CLIN EXP PATHO, V8, P3670; Chantzi MI, 2013, J CANCER RES CLIN, V139, P1489, DOI 10.1007/s00432-013-1467-4; Chen D, 2015, ONCOL LETT, V10, P317, DOI 10.3892/ol.2015.3223; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Dong WW, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/941568; Dong WW, 2012, MED SCI MONITOR, V18, pBR351, DOI 10.12659/MSM.883344; Eldien MMS, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.748; Enewold L, 2009, CANCER EPIDEM BIOMAR, V18, P784, DOI 10.1158/1055-9965.EPI-08-0960; Erdem H, 2011, EXP MOL PATHOL, V90, P312, DOI 10.1016/j.yexmp.2011.01.008; Fan DH, 2015, J CLIN ENDOCR METAB, V100, pE561, DOI 10.1210/jc.2014-3257; Gruvberger-Saal SK, 2007, CLIN CANCER RES, V13, P1987, DOI 10.1158/1078-0432.CCR-06-1823; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; Hsueh C, 2011, J SURG ONCOL, V103, P395, DOI 10.1002/jso.21844; Huang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-383; Ito Y, 2014, ENDOCR J, V61, P205, DOI 10.1507/endocrj.EJ13-0403; Kanehira K, 2008, INT J CLIN EXP PATHO, V1, P435; Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lim W, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2854; Magri F, 2012, ENDOCR-RELAT CANCER, V19, P463, DOI 10.1530/ERC-11-0389; Matsuse M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41752; Mitchell B, 2016, ADV ANAT PATHOL, V23, P244, DOI 10.1097/PAP.0000000000000117; Nagataki S, 2002, THYROID, V12, P889, DOI 10.1089/105072502761016511; Novelli F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2139; Pan DH, 2017, ONCOTARGETS THER, V10, P3261, DOI 10.2147/OTT.S135593; Park C, 2014, BIOCHEM BIOPH RES CO, V450, P261, DOI 10.1016/j.bbrc.2014.05.107; Piperigkou Z, 2016, MATRIX BIOL, V56, P4, DOI 10.1016/j.matbio.2016.05.003; Poola I, 2005, CLIN CANCER RES, V11, P7579, DOI 10.1158/1078-0432.CCR-05-0728; Reese JM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-749; Rosin G, 2014, BRIT J CANCER, V111, P918, DOI 10.1038/bjc.2014.398; Rousseau C, 2004, MOL CANCER RES, V2, P523; Salajegheh A, 2013, HUM PATHOL, V44, P2204, DOI 10.1016/j.humpath.2013.04.014; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Skliris GP, 2006, BRIT J CANCER, V95, P616, DOI 10.1038/sj.bjc.6603295; Sturniolo G, 2016, EUR THYROID J, V5, P224, DOI 10.1159/000452488; Sugiura H, 2007, JPN J CLIN ONCOL, V37, P820, DOI 10.1093/jjco/hym114; Tang WW, 2016, ONCOTARGETS THER, V9, P455, DOI 10.2147/OTT.S94514; Tian X, 2008, J INT MED RES, V36, P699, DOI 10.1177/147323000803600411; Tuttle R., 2016, THYROID DIFFERENTIAT, P1024; Vaiman M, 2010, MED SCI MONITOR, V16, pBR203; Vannucchi G, 2015, EUR J ENDOCRINOL, V173, P29, DOI 10.1530/EJE-15-0054; vonWasielewski R, 1997, CANCER RES, V57, P2501; Wimberly H, 2014, BREAST CANCER RES TR, V146, P657, DOI 10.1007/s10549-014-3050-3; Yi JW, 2017, ANN SURG ONCOL, V24, P3754, DOI 10.1245/s10434-017-5780-z; Zeng Q, 2008, J PATHOL, V214, P425, DOI 10.1002/path.2297; Zhou Y, 2015, BIOCHEM BIOPH RES CO, V457, P141, DOI 10.1016/j.bbrc.2014.12.038	49	1	1	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					15	21		10.1111/iep.12266			7	Pathology	Pathology	GE0PM	WOS:000430917400003	29655286	Green Published			2019-10-28	
J	Abdel-Hamid, AAM; Atef, H; Zalata, KR; Abdel-Latif, A				Abdel-Hamid, Ahmed A. M.; Atef, Hoda; Zalata, Khaled R.; Abdel-Latif, Atef			Correlation between testicular mast cell count and spermatogenic epithelium in non-obstructive azoospermia	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						germ cell aplasia; Ki67 proliferation index; maturation arrest; non-obstructive azoospermia; sertoli cells; vimentin	MALE-INFERTILITY; MATURATION ARREST; DIFFERENT ETIOLOGIES; VARICOCELE REPAIR; PERITUBULAR CELLS; CHANGES ACCOMPANY; ONLY SYNDROME; MEN; PROLIFERATION; HYDROXYCHLOROQUINE	Although there is emerging evidence that mast cells are involved in infertility, their exact role has not been elucidated clearly. Here we carried out a retrospective case-control study to find out whether there is a correlation between mast cell (MC) count and proliferation (Ki67 index) of the spermatogenic epithelium as well as of the Sertoli cells (vimentin-positive) in non-obstructive azoospermia (NOA). We assessed MCs, Ki67 and vimentin expression in Sertoli cells in testicular biopsies of germ cell aplasia (GCA, n = 14) and maturation arrest (MA, n = 14) vs. normal spermatogenesis (n = 14) cases. There was a significant decrease in the spermatogonial Ki67 index (1.25 +/- 0.91, 4.21 +/- 1.81 vs. 39.57 +/- 3.92) and Johnsen score (2.48 +/- 0.65, 4.89 +/- 1.05 vs. 9.75 +/- 0.30) as well as a significant increase (P < 0.001) in MC count (29.00 +/- 4.11, 7.57 +/- 1.95 vs. 3.00 +/- 1.30) in seminiferous tubules of infertile cases with GCA and MA vs. controls. On the other hand, the percentage of vimentin-expressing Sertoli cells was significantly decreased (P < 0.001) in biopsies of cases with MA (35.50 +/- 15.62) compared to those of cases with GCA and controls (72.64 +/- 10.67 and 98.57 +/- 1.45 respectively). Additionally, a significant negative correlation was detected between MC count and Ki67 index as well as Johnsen score in the MA group which became more significant in the GCA group. The significant increase in MC count in the GCA group and to a lesser extent in the MA group indicates their possible role in NOA particularly at the spermatogonial proliferation level and this is supported by the significant negative correlation with the Ki67 index.	[Abdel-Hamid, Ahmed A. M.; Atef, Hoda] Mansoura Univ, Dept Histol & Cell Biol, Fac Med, Mansoura, Egypt; [Zalata, Khaled R.] Mansoura Univ, Dept Pathol, Fac Med, Mansoura, Egypt; [Abdel-Latif, Atef] Mansoura Univ, Fac Med, Mansoura Univ Hosp, Dept Gen Surg, Mansoura, Egypt	Abdel-Hamid, AAM (reprint author), Mansoura Univ, Dept Histol & Cell Biol, Fac Med, Mansoura, Egypt.	profahmadpasha@mans.edu.eg	Abdel-Hamid, Ahmed/L-3998-2016	Abdel-Hamid, Ahmed/0000-0001-5444-4609			Abdel-Hamid AAM, 2017, EXP MOL PATHOL, V102, P284, DOI 10.1016/j.yexmp.2017.02.017; Abdel-Hamid AAM, 2016, INT J EXP PATHOL, V97, P329, DOI 10.1111/iep.12196; Abdel-Hamid AAM, 2016, ACTA HISTOCHEM, V118, P560, DOI 10.1016/j.acthis.2016.06.002; Abdel-Hamid AAM, 2016, ACTA HISTOCHEM, V118, P236, DOI 10.1016/j.acthis.2016.01.004; Abdel-Hamid AAM, 2016, J MOL HISTOL, V47, P183, DOI 10.1007/s10735-016-9664-5; Adam M, 2011, HUM REPROD, V26, P2613, DOI 10.1093/humrep/der245; Allam JP, 2009, ANDROLOGIA, V41, P1, DOI 10.1111/j.1439-0272.2008.00879.x; Anniballo R, 2000, HUM REPROD, V15, P2269, DOI 10.1093/humrep/15.11.2269; Apa DD, 2002, ARCH ANDROLOGY, V48, P337, DOI 10.1080/01485010290099183; Atef E, 2016, DIGEST DIS SCI, V61, P3498, DOI 10.1007/s10620-016-4344-6; Cortes D, 2016, J PEDIATR SURG, V51, P475, DOI 10.1016/j.jpedsurg.2015.08.059; De Rooij DG, 2009, MICROSC RES TECHNIQ, V72, P580, DOI 10.1002/jemt.20699; EI-Karaksy A, 2007, ANDROLOGIA, V39, P244; Frungieri MB, 2015, REPRODUCTION, V149, pR169, DOI 10.1530/REP-14-0392; Gat Y, 2010, ANDROLOGIA, V42, P389, DOI 10.1111/j.1439-0272.2010.01083.x; Haidl G, 2011, EXPERT REV CLIN IMMU, V7, P627, DOI [10.1586/eci.11.57, 10.1586/ECI.11.57]; Hanmayyagari B., 2015, CHRISMED J HLTH RES, V2, P64; Hung AJ, 2007, J UROLOGY, V178, P608, DOI 10.1016/j.juro.2007.03.125; Ishikawa T, 2004, BJU INT, V94, P1314, DOI 10.1111/j.1464-410X.2004.05163.x; JOHNSEN S G, 1970, Hormones (Basel), V1, P2, DOI 10.1159/000178170; Kadioglu A, 2001, UROLOGY, V57, P328, DOI 10.1016/S0090-4295(00)00908-0; Kim ED, 1999, J UROLOGY, V162, P737, DOI 10.1097/00005392-199909010-00031; Mancini M., 2009, ENCY MOL MECH DIS, P1921; Manish J, 2012, INDIAN J ENDOCRINOL, V16, P512; Mayerhofer A, 2013, REPRODUCTION, V145, pR107, DOI 10.1530/REP-12-0497; Maymon BBS, 2003, FERTIL STERIL, V80, P1175, DOI 10.1016/S0015-0282(03)02161-7; Maymon BBS, 2002, FERTIL STERIL, V77, P904, DOI 10.1016/S0015-0282(02)03060-1; Meineke V, 2000, FERTIL STERIL, V74, P239, DOI 10.1016/S0015-0282(00)00626-9; NISTAL M, 1990, HISTOPATHOLOGY, V16, P173; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Steger K, 1996, INT J ANDROL, V19, P122, DOI 10.1111/j.1365-2605.1996.tb00448.x; Steger K, 1998, MOL HUM REPROD, V4, P227, DOI 10.1093/molehr/4.3.227; Takagi S, 2001, FERTIL STERIL, V76, P901, DOI 10.1016/S0015-0282(01)02732-7; Welter H, 2011, FERTIL STERIL, V96, P309, DOI 10.1016/j.fertnstert.2011.05.035; Windschuttl S, 2014, ANDROLOGY-US, V2, P615, DOI 10.1111/j.2047-2927.2014.00227.x; Yamanaka K, 2000, HUM REPROD, V15, P1543, DOI 10.1093/humrep/15.7.1543	36	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					22	28		10.1111/iep.12261			7	Pathology	Pathology	GE0PM	WOS:000430917400004	29479754	Green Published			2019-10-28	
J	Hauschildt, AT; Cora, LA; Volpato, GT; Sinzato, YK; Damasceno, DC; Americo, MF				Hauschildt, Andrieli T.; Cora, Luciana A.; Volpato, Gustavo T.; Sinzato, Yuri K.; Damasceno, Debora C.; Americo, Madileine F.			Mild diabetes: long-term effects on gastric motility evaluated in rats	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						experimental diabetes; gastric emptying; moderate hyperglycaemia; motility disorders; stomach contractions	INTERSTITIAL-CELLS; GASTROINTESTINAL TRANSIT; AUTONOMIC NEUROPATHY; MYENTERIC PLEXUS; GLUCOSE; MODEL; BIOSUSCEPTOMETRY; VALIDATION; GHRELIN; STOMACH	Moderate hyperglycaemic levels seem to be related to abnormal gastric motility in diabetes mellitus. However, experimental models designed to evaluate the relationship between motility and diabetes over time are not yet well established. Our objective was to investigate the long-term effects of mild diabetes on gastric motility in rats. Newborn male rats received streptozotocin (mild diabetes groups - MD) or vehicle (control groups C), and both groups were evaluated after 3 (C3 and MD3) and 6 months (C6 and MD6) postinduction. Mild diabetic animals (MD3 and MD6) showed moderately elevated blood glucose and decreased insulin levels compared with control (C3 and C6). Insulin secretion was enhanced in MD6 compared with MD3, most likely due to partial-cell regeneration indicated by HOMA-. In HOMA-IR, it was noticed that MD6 animals had impaired insulin response compared with MD3. Gastric emptying was faster, amplitude of contraction was stronger in MD6 compared with MD3, and in both groups, the differences were significant when compared with control animals. A significant abnormal rhythmic index was calculated for the mild diabetic groups, despite unchanged mean frequency of contraction. In conclusion, despite increased insulin levels over time, constant levels of moderate hyperglycaemia are also related to abnormal gastric motility and impairment of gastric function.	[Hauschildt, Andrieli T.; Volpato, Gustavo T.; Americo, Madileine F.] Fed Univ Mato Grosso UFMT, Barra Do Garcas, MT, Brazil; [Cora, Luciana A.] Alagoas State Univ Hlth Sci UNCISAL, Maceio, AL, Brazil; [Sinzato, Yuri K.; Damasceno, Debora C.] Sao Paulo State Univ, UNESP, Botucatu, SP, Brazil	Americo, MF (reprint author), Univ Fed Mato Grosso, BR-78600000 Barra Do Garcas, MT, Brazil.	mamerico@gmail.com	Cora, Luciana/Q-6273-2019; Sinzato, Yuri K/E-8626-2019; Damasceno, Debora C/C-7234-2012; Volpato, Gustavo Tadeu/A-5350-2013	Sinzato, Yuri K/0000-0002-2973-1099; Damasceno, Debora C/0000-0002-7003-9643; Volpato, Gustavo Tadeu/0000-0002-4753-3264; Cora, Luciana/0000-0001-8242-3653; Hauschildt, Andrieli/0000-0003-3058-0504	Mato Grosso Research Foundation (FAPEMAT) [756156/2011]	This study was partially supported by a grant from the Mato Grosso Research Foundation (FAPEMAT, Process Number 756156/2011).	American Diabetes Association, 2017, DIABETES CARE, V37, P81; Americo MF, 2007, NEUROGASTROENT MOTIL, V19, P804, DOI 10.1111/j.1365-2982.2007.00960.x; Americo MF, 2010, NEUROGASTROENT MOTIL, V22, P1340, DOI 10.1111/j.1365-2982.2010.01582.x; Ariga H, 2008, AM J PHYSIOL-REG I, V294, pR1807, DOI 10.1152/ajpregu.00785.2007; Arora S, 2009, GLOBAL J PHARM, V3, P81; Bagger JI, 2011, J CLIN ENDOCR METAB, V96, P737, DOI 10.1210/jc.2010-2435; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Beckoff K, 2001, AM J PHYSIOL-REG I, V280, pR570; Bernard C, 1999, FASEB J, V13, P1195; Bharucha AE, 2015, CLIN GASTROENTEROL H, V13, P466, DOI 10.1016/j.cgh.2014.06.034; Bharucha AE, 2009, CLIN ENDOCRINOL, V70, P415, DOI 10.1111/j.1365-2265.2008.03351.x; Calabresi MFF, 2015, NEUROGASTROENT MOTIL, V27, P1613, DOI 10.1111/nmo.12660; Camilleri M, 2010, CLIN GASTROENTEROL H, V8, P551, DOI 10.1016/j.cgh.2010.03.016; Chandrasekharan B, 2007, NEUROGASTROENT MOTIL, V19, P951, DOI 10.1111/j.1365-2982.2007.01023.x; Cora LA, 2010, EUR J PHARM BIOPHARM, V74, P67, DOI 10.1016/j.ejpb.2009.05.011; Cucchiara S, 1998, DIABETES CARE, V21, P438, DOI 10.2337/diacare.21.3.438; Cuman RKN, 2001, INFLAMM RES, V50, P460, DOI 10.1007/PL00000271; Damasceno DC, 2013, J DIABETES RES, DOI 10.1155/2013/473575; de Campos KE, 2007, LIFE SCI, V81, P1473, DOI 10.1016/j.lfs.2007.09.016; ELIASSON B, 1995, DIABETOLOGIA, V38, P79, DOI 10.1007/BF02369356; Fournel A, 2016, AM J PHYSIOL-GASTR L, V310, pG645, DOI 10.1152/ajpgi.00015.2016; FRASER RJ, 1990, DIABETOLOGIA, V33, P675, DOI 10.1007/BF00400569; Fregonesi CEPT, 2001, ARQ NEURO-PSIQUIAT, V59, P50, DOI 10.1590/S0004-282X2001000100011; Afiune LAF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179785; Gatopoulou A, 2012, EUR J INTERN MED, V23, P499, DOI 10.1016/j.ejim.2012.03.001; Green GM, 1997, DIABETOLOGIA, V40, P136, DOI 10.1007/s001250050654; Guo C, 2004, NEUROGASTROENT MOTIL, V16, P335, DOI 10.1111/j.1365-2982.2004.00524.x; He CL, 2001, GASTROENTEROLOGY, V121, P427, DOI 10.1053/gast.2001.26264; HOROWITZ M, 1993, DIABETOLOGIA, V36, P857, DOI 10.1007/BF00400362; Horvath VJ, 2006, GASTROENTEROLOGY, V130, P759, DOI 10.1053/j.gastro.2005.12.027; Ishiguchi T, 2002, AUTON NEUROSCI-BASIC, V95, P112, DOI 10.1016/S1566-0702(01)00383-6; Kunjara S, 2012, INT J EXP PATHOL, V93, P196, DOI 10.1111/j.1365-2613.2012.00818.x; Lincoln J, 2008, TZU CHI MED J, V20, P161, DOI 10.1016/S1016-3190(08)60031-2; Little TJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE647, DOI 10.1152/ajpendo.00099.2006; Long QL, 2004, WORLD J GASTROENTERO, V10, P1227; Lopez-Soldado Iliana, 2003, Exp Diabesity Res, V4, P107, DOI 10.1155/EDR.2003.107; Marathe CS, 2013, DIABETES CARE, V36, P1396, DOI 10.2337/dc12-1609; Mard S.A., 2016, NEUROGASTROENT MOTIL, V2016, P1; Marques RG, 2014, PHYSIOL MEAS, V35, P69, DOI 10.1088/0967-3334/35/1/69; Miyamoto Y, 2001, DIGEST DIS SCI, V46, P1596, DOI 10.1023/A:1010672614137; Ozaki K, 2008, J DIABETES COMPLICAT, V22, P339, DOI 10.1016/j.jdiacomp.2007.03.005; OZTURK Y, 1994, GEN PHARMACOL-VASC S, V25, P1109, DOI 10.1016/0306-3623(94)90125-2; Phillips LK, 2015, NAT REV ENDOCRINOL, V11, P112, DOI 10.1038/nrendo.2014.202; PHILLIPS WT, 1992, J NUCL MED, V33, P1496; PODCZECK F, 1995, PHARM RES-DORDR, V12, P376, DOI 10.1023/A:1016200501563; PORTHA B, 1985, DIABETES, V34, P574, DOI 10.2337/diabetes.34.6.574; Quini CC, 2012, J BIOL ENG, V6, DOI 10.1186/1754-1611-6-6; Rao SSC, 2011, NEUROGASTROENT MOTIL, V23, P8, DOI 10.1111/j.1365-2982.2010.01612.x; Rayner CK, 2005, NAT CLIN PRACT GASTR, V2, P454, DOI 10.1038/ncpgasthep0283; REDDY SN, 1987, CRIT REV BIOMED ENG, V15, P95; Rudge MVC, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-19; Dall'Agnol DJR, 2017, EXP PHYSIOL, V102, P924, DOI 10.1113/EP086267; Samsom M, 1997, GUT, V40, P641, DOI 10.1136/gut.40.5.641; Santos TMM, 2015, CELL STRESS CHAPERON, V20, P595, DOI 10.1007/s12192-015-0581-4; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; SCHMIDT RE, 1981, AM J PATHOL, V103, P210; Schvarcz E, 1997, GASTROENTEROLOGY, V113, P60, DOI 10.1016/S0016-5085(97)70080-5; Sinzato YK, 2012, EXP DIABETES RES, DOI 10.1155/2012/108163; Szarka LA, 2009, AM J PHYSIOL-GASTR L, V296, pG461, DOI 10.1152/ajpgi.90467.2008; Thomas MC, 2016, NAT REV NEPHROL, V12, P73, DOI 10.1038/nrneph.2015.173; Trahair LG, 2012, J CLIN ENDOCR METAB, V97, P844, DOI 10.1210/jc.2011-2583; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wilson RD, 2012, PHARMACOL REP, V64, P129, DOI 10.1016/S1734-1140(12)70739-9; WORLD HEALTH ORGANIZATION, 2016, GLOB REP DIAB; YOUNG AA, 1995, DIABETOLOGIA, V38, P642, DOI 10.1007/s001250050331; Zanoni JN, 1997, ARQ NEURO-PSIQUIAT, V55, P696, DOI 10.1590/S0004-282X1997000500004	66	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					29	37		10.1111/iep.12262			9	Pathology	Pathology	GE0PM	WOS:000430917400005	29479759	Green Published			2019-10-28	
J	Cheng, XW; Svensson, M; Yang, YY; Deierborg, T; Ekblad, E; Voss, U				Cheng, Xiaowen; Svensson, Martina; Yang, Yiyi; Deierborg, Tomas; Ekblad, Eva; Voss, Ulrikke			Focal, but not global, cerebral ischaemia causes loss of myenteric neurons and upregulation of vasoactive intestinal peptide in mouse ileum	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						enteric nervous system; focal cerebral ischaemia; global cerebral ischaemia; nitric oxide synthase; vasoactive intestinal peptide	ENTERIC NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; INFLAMMATORY-BOWEL-DISEASE; BLOOD-BRAIN-BARRIER; ISCHEMIA/REPERFUSION INJURY; EXPERIMENTAL STROKE; GASTROINTESTINAL-TRACT; MICROGLIAL ACTIVATION; INCREASED EXPRESSION; INTERSTITIAL-CELLS	Reduced blood flow to the brain induces cerebral ischaemia, potentially causing central injury and peripheral complications including gastrointestinal (GI) dysfunction. The pathophysiology behind GI symptoms is suspected to be neuropathy in the enteric nervous system (ENS), which is essential in regulating GI function. This study investigates if enteric neuropathy occurs after cerebral ischaemia, by analysing neuronal survival and relative numbers of vasoactive intestinal peptide (VIP) and neuronal nitric oxide synthase (nNOS) expressing neurons in mouse ileum after three types of cerebral ischaemia. Focal cerebral ischaemia, modelled by permanent middle cerebral artery occlusion (pMCAO) and global cerebral ischaemia, modelled with either transient occlusion of both common carotid arteries followed by reperfusion (GCIR) or chronic cerebral hypoperfusion (CCH) was performed on C56BL/6 mice. Sham-operated mice for each ischaemia model served as control. Ileum was collected after 1-17 weeks, depending on model, and analysed using morphometry and immunocytochemistry. For each group, intestinal mucosa and muscle layer thicknesses, neuronal numbers and relative proportions of neurons immunoreactive (IR) for nNOS or VIP were estimated. No alterations in mucosa or muscle layer thicknesses were noted in any of the groups. Loss of myenteric neurons and an increased number of VIP-IR submucous neurons were found in mouse ileum 7 days after pMCAO. None of the global ischaemia models showed any alterations in neuronal survival or relative numbers of VIP- and nNOS-IR neurons. We conclude that focal cerebral ischaemia and global cerebral ischaemia influence enteric neuronal survival differently. This is suggested to reflect differences in peripheral neuro-immune responses.	[Cheng, Xiaowen; Ekblad, Eva; Voss, Ulrikke] Lund Univ, Neurogastroenterol, Dept Expt Med Sci, Solvegatan 19,BMC B11, S-22184 Lund, Sweden; [Svensson, Martina; Yang, Yiyi; Deierborg, Tomas] Lund Univ, Neuroinflammat Units, Dept Expt Med Sci, Lund, Sweden	Cheng, XW (reprint author), Lund Univ, Neurogastroenterol, Dept Expt Med Sci, Solvegatan 19,BMC B11, S-22184 Lund, Sweden.	xiaowen.cheng@med.lu.se			Swedish Research CouncilSwedish Research Council; Swedish Stroke Association; Pahlssons Foundation; Sparbanken Fars & Frosta Foundation; Royal Physiographic Society; Faculty of Medicine, Lund University; China Scholarship CouncilChina Scholarship Council	This study was supported by the Swedish Research Council, the Swedish Stroke Association, the Pahlssons Foundation, Sparbanken Fars & Frosta Foundation, the Royal Physiographic Society and the Faculty of Medicine, Lund University. X Cheng acknowledges a PhD scholarship from the China Scholarship Council.	Abad Catalina, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P316; Arciszewski MB, 2008, REGUL PEPTIDES, V146, P218, DOI 10.1016/j.regpep.2007.09.021; Arranz A, 2008, PEPTIDES, V29, P948, DOI 10.1016/j.peptides.2008.01.019; Arranz A, 2006, ANN NY ACAD SCI, V1070, P129, DOI 10.1196/annals.1317.001; Brierley SM, 2014, NAT REV GASTRO HEPAT, V11, P611, DOI 10.1038/nrgastro.2014.103; Burguillos MA, 2015, CELL REP, V10, P1626, DOI 10.1016/j.celrep.2015.02.012; Chandrasekharan B, 2013, AM J PHYSIOL-GASTR L, V304, pG949, DOI 10.1152/ajpgi.00493.2012; Chen XM, 2014, CNS NEUROSCI THER, V20, P40, DOI 10.1111/cns.12162; Cheng XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep32893; Chu KT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-69; Clausen BH, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0203-6; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Doll DN, 2014, AGING DIS, V5, P294, DOI 10.14336/AD.2014.0500294; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Ekblad E, 2004, NEUROGASTROENT MOTIL, V16, P123, DOI 10.1111/j.1743-3150.2004.00487.x; Ekblad E, 1998, GUT, V42, P836, DOI 10.1136/gut.42.6.836; Ekelund KM, 1999, GUT, V45, P236, DOI 10.1136/gut.45.2.236; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Feng GY, 2010, REGUL PEPTIDES, V160, P121, DOI 10.1016/j.regpep.2009.11.008; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Galkin A, 2007, ESSAYS BIOCHEM, V43, P29, DOI 10.1042/bse0430029; Giaroni C, 1999, GASTROENTEROLOGY, V117, P1438, DOI 10.1016/S0016-5085(99)70295-7; Gomariz RP, 2007, PEPTIDES, V28, P1825, DOI 10.1016/j.peptides.2007.07.005; Gomariz RP, 2005, J LEUKOCYTE BIOL, V78, P491, DOI 10.1189/jlb.1004564; Gougeon PY, 2013, J NEUROSCI, V33, P3339, DOI 10.1523/JNEUROSCI.3564-12.2013; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; Hsu HL, 2009, EUR NEUROL, V62, P212, DOI 10.1159/000229018; Hsu YC, 2014, J CEREBR BLOOD F MET, V34, P668, DOI 10.1038/jcbfm.2013.244; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Khatri R, 2012, NEUROLOGY, V79, pS52, DOI 10.1212/WNL.0b013e3182697e70; Lee KM, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0652-1; Lin Z, 2004, AUTON NEUROSCI-BASIC, V114, P29, DOI 10.1016/j.autneu.2004.06.002; Lin Z, 2003, AUTON NEUROSCI-BASIC, V107, P9, DOI 10.1016/S1566-0702(03)00077-8; Liu M, 2017, BIOMED PHARMACOTHER, V85, P412, DOI 10.1016/j.biopha.2016.11.044; Liu P, 2018, J PHYSIOL SCI, V68, P121, DOI 10.1007/s12576-016-0516-6; Lomax AE, 2005, NEUROGASTROENT MOTIL, V17, P4, DOI 10.1111/j.1365-2982.2004.00607.x; Ma SB, 2015, EXP NEUROL, V272, P41, DOI 10.1016/j.expneurol.2015.05.014; Manouchehrian O, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0312-x; Mracsko E, 2010, BRAIN RES, V1321, P13, DOI 10.1016/j.brainres.2009.11.080; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Olsson T, 2003, BRAIN RES, V982, P260, DOI 10.1016/S0006-8993(03)03014-2; Padua D, 2016, J MOL NEUROSCI, V59, P203, DOI 10.1007/s12031-015-0688-1; Rivera LR, 2012, CELL TISSUE RES, V349, P565, DOI 10.1007/s00441-012-1451-3; Sand E, 2013, CELL TISSUE RES, V351, P521, DOI 10.1007/s00441-012-1534-1; Sand E, 2009, NEUROPHARMACOLOGY, V56, P522, DOI 10.1016/j.neuropharm.2008.10.007; Sandgren K, 2003, J NEUROSCI RES, V72, P595, DOI 10.1002/jnr.10612; Sandgren K, 2003, REGUL PEPTIDES, V111, P211, DOI 10.1016/S0167-0115(02)00290-2; Sandgren K, 2002, DIGEST DIS SCI, V47, P1049, DOI 10.1023/A:1015085923245; Schafer KH, 2009, ANAT REC, V292, P1940, DOI 10.1002/ar.21033; Schaller BJ, 2006, AM J GASTROENTEROL, V101, P1655, DOI 10.1111/j.1572-0241.2006.00540.x; Schulte-Herbruggen O, 2009, NEUROIMMUNOMODULAT, V16, P213, DOI 10.1159/000205514; Shibata M, 2004, STROKE, V35, P2598, DOI 10.1161/01.STR.0000143725.19053.60; Sigalet DL, 2010, NEUROGASTROENT MOTIL, V22, P1318, DOI 10.1111/j.1365-2982.2010.01585.x; Svensson M, 2016, NEUROBIOL STRESS, V5, P8, DOI 10.1016/j.ynstr.2016.09.002; Tascilar N, 2010, BRATISL MED J, V111, P194; Vasina V, 2006, AUTON NEUROSCI-BASIC, V126, P264, DOI 10.1016/j.autneu.2006.02.025; Veiga-Fernandes H, 2017, NAT IMMUNOL, V18, P116, DOI 10.1038/ni.3634; Venkataramana S, 2015, NEUROBIOL DIS, V75, P40, DOI 10.1016/j.nbd.2014.12.014; Voss U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114044; Voss U, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-30; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Wu XJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125225; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046; Zhang DM, 2016, MOL NEUROBIOL, V53, P6444, DOI 10.1007/s12035-015-9545-z	64	0	0	3	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					38	45		10.1111/iep.12263			8	Pathology	Pathology	GE0PM	WOS:000430917400006	29577471	Green Published			2019-10-28	
J	Mishra, A; Arindkar, S; Sahay, P; Kumar, JM; Upadhyay, PK; Majumdar, SS; Nagarajan, P				Mishra, Alaknanda; Arindkar, Shailendra; Sahay, Preeti; Kumar, Jerald Mahesh; Upadhyay, Pramod K.; Majumdar, Subeer S.; Nagarajan, Perumal			Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						factor 8(-/-); haemophilia A; high-fat high-fructose; metabolism; non-alcoholic fatty liver disease	COAGULATION-FACTOR VIII; HEMOPHILIA-A; ENDOTHELIAL-CELLS; LIVER-DISEASE; OBESITY; TRANSPLANTATION; PREVALENCE; OVERWEIGHT; HEPATITIS; TISSUES	Non-alcoholic fatty liver disease (NAFLD)-like conditions enhance the production and action of clotting factors in humans. However, studies examining the effect of NAFLD due to high-fat high-fructose (HFHF) diet in factor VIII-deficient (haemophilia A) animals or patients have not been reported previously. In this study, we investigated the individual role of factor VIII in the progression of diet-induced NAFLD in the factor 8(-/-) (F8(-/-)) mouse model system and its consequences on the haemophilic status of the mice. The F8(-/-) mice were fed with HFHF diet for 14 weeks. Physiological, biochemical, haematological, molecular, pathological, and immune histochemical analyses were performed to evaluate the effect of this diet. The F8(-/-) mice developed hepatic steatosis after 14 weeks HFHF diet and displayed lower energy metabolism, higher myeloid cell infiltration in the liver, decreased platelet count, upregulated de novo fatty acid synthesis, lipid accumulation, and collagen deposition. This study helps to understand the role of factor VIII in NAFLD pathogenesis and to analyse the severity and consequences of steatosis in haemophilic patients as compared to normal population. This study suggests that haemophilic animals (F8(-/-) mice) are highly prone to hepatic steatosis and thrombocytopenia.	[Mishra, Alaknanda; Arindkar, Shailendra; Sahay, Preeti; Upadhyay, Pramod K.; Majumdar, Subeer S.; Nagarajan, Perumal] Natl Inst Immunol, New Delhi, India; [Kumar, Jerald Mahesh] CSIR CCMB, Hyderabad, Andhra Pradesh, India; [Majumdar, Subeer S.] Natl Inst Anim Biotechnol, Hyderabad, Andhra Pradesh, India	Nagarajan, P (reprint author), Natl Inst Immunol, Expt Anim Facil, New Delhi 110067, India.	nagarajan@nii.ac.in	Nagarajan, Perumal/B-8736-2017	Nagarajan, Perumal/0000-0003-4557-4633	Department of Biotechnology, IndiaDepartment of Biotechnology (DBT) India	The authors wish to thank the Director, National Institute of Immunology for providing kind support with the funds originated from the Department of Biotechnology, India. The authors also wish to thank Mr. Subash Dogra for technical help in this study. We also thank Dr. S Gopalan Sampath Kumar for critical reading of the manuscript.	Amitrano L, 2002, SEMIN LIVER DIS, V22, P83, DOI 10.1055/s-2002-23205; Eckert C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00179; Enjoji M, 2012, INT J HEPATOL, DOI 10.1155/2012/925807; Everett LA, 2014, BLOOD, V123, P3697, DOI 10.1182/blood-2014-02-554501; Fahs SA, 2014, BLOOD, V123, P3706, DOI 10.1182/blood-2014-02-555151; FOLCH J, 1957, J BIOL CHEM, V226, P497; Follenzi A, 2012, BLOOD, V119, P5532, DOI 10.1182/blood-2011-07-367680; Fomin ME, 2014, J THROMB HAEMOST, V12, P1954, DOI 10.1111/jth.12750; Henrard S, 2013, HAEMATOLOGICA, V98, P1481, DOI 10.3324/haematol.2013.084038; Kawano Y, 2013, J GASTROENTEROL, V48, P434, DOI 10.1007/s00535-013-0758-5; Kiouptsi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183590; Kotronen A, 2011, LIVER INT, V31, P176, DOI 10.1111/j.1478-3231.2010.02375.x; Kumaran V, 2005, J THROMB HAEMOST, V3, P2022, DOI 10.1111/j.1538-7836.2005.01508.x; Majumdar S, 2010, HAEMOPHILIA, V16, P455, DOI 10.1111/j.1365-2516.2009.02187.x; Miyao M, 2015, LAB INVEST, V95, P1130, DOI 10.1038/labinvest.2015.95; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Revel-Vilk S, 2011, HAEMOPHILIA, V17, P689, DOI 10.1111/j.1365-2516.2010.02477.x; Tripodi A, 2014, J HEPATOL, V61, P148, DOI 10.1016/j.jhep.2014.03.013; Verma S, 2013, LIVER INT, V33, P1398, DOI 10.1111/liv.12226; Wong TE, 2011, AM J PREV MED, V41, pS369, DOI 10.1016/j.amepre.2011.09.008; Xu B, 2003, AM J PATHOL, V163, P1275, DOI 10.1016/S0002-9440(10)63487-6	21	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	FEB	2018	99	1					46	53		10.1111/iep.12264			8	Pathology	Pathology	GE0PM	WOS:000430917400007	29656466	Green Published			2019-10-28	
J	Wolfesberger, B; Fuchs-Baumgartinger, A; Gress, V; Hammer, SE; Gradner, G; Knodl, K; Tichy, A; Rutgen, BC; Beham-Schmid, C				Wolfesberger, B.; Fuchs-Baumgartinger, A.; Gress, V.; Hammer, S. E.; Gradner, G.; Knoedl, K.; Tichy, A.; Ruetgen, B. C.; Beham-Schmid, C.			World Health Organisation Classification of Lymphoid Tumours in Veterinary and Human Medicine: a Comparative Evaluation of Gastrointestinal Lymphomas in 61 Cats	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						alimentary lymphoma; cat; immunohistochemistry; WHO classification	NON-HODGKIN-LYMPHOMA; T-CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTES; FELINE LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; HISTOLOGIC CLASSIFICATION; TRACT; PHENOTYPE; CANINE; TOOL	To diagnose and classify the various entities of lymphomas, the World Health Organisation (WHO) classification is applied in human as well as in veterinary medicine. We validated the concordance of these classification systems by having a veterinary and human pathologist evaluate gastrointestinal lymphoma tissue from 61 cats. In 59% of all cases, there was a match between their respective diagnoses of the lymphoma subtype. A complete consensus between the two evaluators was obtained for all samples with a diagnosis of diffuse large B-cell lymphoma, T-cell anaplastic large cell lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. A corresponding diagnosis was also made in the majority of samples with enteropathy associated T-cell lymphoma (EATL) type II, although this subtype in cats has similarities to the 'indolent T-cell lymphoproliferative disorder of the gastrointestinal tract', a provisional entity newly added to the revised human WHO classification in 2016. Very little consensus has been found with cases of EATL type I due to the fact that most did not meet all of the criteria of human EATL I. Hence, the human pathologist assigned them to the heterogeneous group of peripheral T-cell lymphomas (not otherwise specified). Consequently, concrete guidelines and advanced immunophenotyping based on the model of human medicine are essential to differentiate these challenging entities in veterinary medicine. (C) 2017 Elsevier Ltd. All rights reserved.	[Wolfesberger, B.; Gradner, G.; Knoedl, K.] Univ Vet Med, Dept Compan Anim & Horses, Vienna, Austria; [Fuchs-Baumgartinger, A.; Hammer, S. E.; Ruetgen, B. C.] Univ Vet Med, Dept Pathobiol, Vienna, Austria; [Tichy, A.] Univ Vet Med, Dept Biomed Sci, Vienna, Austria; [Gress, V.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Beham-Schmid, C.] Med Univ Graz, Dept Pathol, Graz, Austria	Wolfesberger, B (reprint author), Univ Vet Med, Dept Compan Anim & Horses, Vienna, Austria.	Birgitt.Wolfesberger@vetmeduni.ac.at					Aki H, 2004, LEUKEMIA RES, V28, P229, DOI 10.1016/S0145-2126(03)00253-4; Barut F, 2016, J PAK MED ASSOC, V66, P905; Castro FA, 2015, J GASTROEN HEPATOL, V30, P1485, DOI 10.1111/jgh.12989; Collette SA, 2016, VET COMP ONCOL, V14, P136, DOI 10.1111/vco.12158; Delabie J, 2011, BLOOD, V118, P148, DOI 10.1182/blood-2011-02-335216; Ding WS, 2016, ACTA HAEMATOL-BASEL, V135, P21, DOI 10.1159/000437130; Ducreux M, 1998, BRIT J CANCER, V77, P511, DOI 10.1038/bjc.1998.82; Felisberto R, 2017, VET COMP ONCOL, V15, P1257, DOI 10.1111/vco.12262; Ghimire P, 2011, WORLD J GASTROENTERO, V17, P697, DOI 10.3748/wjg.v17.i6.697; Gress V, 2016, RES VET SCI, V107, P261, DOI 10.1016/j.rvsc.2016.07.004; Hammer SE, 2017, VET COMP ONCOL, V15, P1354, DOI 10.1111/vco.12277; Jaffe ES, 2008, BLOOD, V112, P4384, DOI 10.1182/blood-2008-07-077982; Jaffe ES, 2001, WHO CLASSIFICATION T, P158; Joling P, 1996, VET IMMUNOL IMMUNOP, V53, P115, DOI 10.1016/0165-2427(96)05551-1; Kahaleh M, 2002, ACTA GASTRO-ENT BELG, V65, P237; Li B, 2008, INT J HEMATOL, V87, P375, DOI 10.1007/s12185-008-0068-5; LONGACRE TA, 1990, AM J CLIN PATHOL, V93, P124, DOI 10.1093/ajcp/93.1.124; Louwerens M, 2005, J VET INTERN MED, V19, P329, DOI 10.1892/0891-6640(2005)19[329:FLITPL]2.0.CO;2; MACVEAN DW, 1978, VET PATHOL, V15, P700, DOI 10.1177/030098587801500602; Matnani R, 2017, HEMATOL ONCOL, V35, P3, DOI 10.1002/hon.2317; Moore PF, 2012, VET PATHOL, V49, P658, DOI 10.1177/0300985811404712; NAKAMURA S, 1993, CANCER-AM CANCER SOC, V71, P249, DOI 10.1002/1097-0142(19930101)71:1<249::AID-CNCR2820710138>3.0.CO;2-9; Ondrejka S, 2016, CURR HEMATOL MALIG R, V11, P504, DOI 10.1007/s11899-016-0357-7; Patterson-Kane JC, 2004, J COMP PATHOL, V130, P220, DOI 10.1016/j.jcpa.2003.09.008; Perry AM, 2013, BLOOD, V122, P3599, DOI 10.1182/blood-2013-07-512830; Pohlman LM, 2009, VET PATHOL, V46, P259, DOI 10.1354/vp.46-2-259; Radic-Kristo D, 2010, COLLEGIUM ANTROPOL, V34, P413; Roccabianca P, 2006, VET PATHOL, V43, P15, DOI 10.1354/vp.43-1-15; Santagostino SF, 2015, VET PATHOL, V52, P250, DOI 10.1177/0300985814537529; Sato H, 2014, J VET MED SCI, V76, P807, DOI 10.1292/jvms.13-0260; Shukla T, 2014, CAN J GASTROENTEROL, V28, P11, DOI 10.1155/2014/687592; Song Li-Na, 2013, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V21, P387, DOI 10.7534/j.issn.1009-2137.2013.02.026; Swerdlow SH, 2008, WHO CLASSIFICATION T, P168; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tan SY, 2013, LEUKEMIA, V27, P1688, DOI 10.1038/leu.2013.41; Vail DM, 1998, J VET INTERN MED, V12, P349, DOI 10.1111/j.1939-1676.1998.tb02134.x; Valli VE, 2011, VET PATHOL, V48, P198, DOI 10.1177/0300985810379428; Valli VE, 2000, J VET DIAGN INVEST, V12, P295, DOI 10.1177/104063870001200401; Valli VE, 2007, VET COMP HEMATOPATHO, V2007, P119; Valli VE, 2002, HISTOLOGICAL CLASSIF, P21; Valli VEO, 2016, JUBB KENNEDY PALMERS, V3, P213; Vezzali E, 2010, VET COMP ONCOL, V8, P38, DOI 10.1111/j.1476-5829.2009.00201.x; Waly NE, 2005, J COMP PATHOL, V133, P253, DOI 10.1016/j.jcpa.2005.05.004; Wolfesberger B, 2017, J FELINE MED SURG, V19, P897, DOI 10.1177/1098612X16666119; Zhou Jun, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P26, DOI 10.3760/cma.j.issn.0529-5807.2013.01.006; Zwahlen CH, 1998, J AM VET MED ASSOC, V213, P1144	46	1	1	1	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						1	10		10.1016/j.jcpa.2017.12.006			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400001	29598998				2019-10-28	
J	Morey-Matamalas, A; de Stefani, A; Corbetta, D; Grau-Roma, L; de Brot, S				Morey-Matamalas, A.; de Stefani, A.; Corbetta, D.; Grau-Roma, L.; de Brot, S.			Pulmonary Basaloid Squamous Cell Carcinoma in a Dog	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						basaloid; dog; lung; squamous cell carcinoma	DIFFERENTIAL-DIAGNOSIS; LUNG-CANCER; P63; IMMUNOHISTOCHEMISTRY; CYTOKERATINS; MARKERS; ENTITY; TUMORS	A 9-year-old neutered male crossbred dog with a 4-week history of progressive vestibulocerebellar signs was presented for necropsy examination. Gross examination revealed neoplastic growth in the lungs, thoracic lymph nodes, left kidney and cerebellum. Microscopically, the tumour consisted of an infiltrative, densely cellular, basaloid epithelial neoplastic growth with extensive areas of abrupt keratinization. Immunohistochemically, neoplastic cells expressed p63 and partially expressed cytokeratins 5/6. Based on these findings, the tumour was diagnosed as a primary pulmonary basaloid squamous cell carcinoma (BSSC) with metastasis to regional lymph nodes, kidney and brain. As far as the authors are aware, this is the first description of BSCC in an animal species. (C) 2017 Elsevier Ltd. All rights reserved.	[Morey-Matamalas, A.] Inst Res Biomed, Baldiri Reixac 10, Barcelona, Spain; [de Stefani, A.] Dick White Referrals, Six Mile Bottom, England; [Corbetta, D.; Grau-Roma, L.; de Brot, S.] Univ Nottingham, Sch Vet Med & Sci, Loughborough, England	de Brot, S (reprint author), Univ Nottingham, Sch Vet Med & Sci, Loughborough, England.	simone.debrot@nottingham.ac.uk		Grau Roma, Llorenc/0000-0002-9406-8844			Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Brambilla C, 2014, CLIN CANCER RES, V20, P5777, DOI 10.1158/1078-0432.CCR-14-0459; BRAMBILLA E, 1992, HUM PATHOL, V23, P993, DOI 10.1016/0046-8177(92)90260-A; Brunnstrom H, 2013, AM J CLIN PATHOL, V140, P37, DOI 10.1309/AJCP50RDXSCSBTBO; Cakir E, 2007, LUNG CANCER, V57, P109, DOI 10.1016/j.lungcan.2007.01.021; Crapanzano JP, 2011, DIAGN CYTOPATHOL, V39, P92, DOI 10.1002/dc.21335; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Emanuel P, 2005, MODERN PATHOL, V18, P645, DOI 10.1038/modpathol.3800329; Ewing RY, 2003, J VET DIAGN INVEST, V15, P162, DOI 10.1177/104063870301500211; Kaufmann O, 2001, AM J CLIN PATHOL, V116, P823; Marson VJ, 2004, HISTOPATHOLOGY, V45, P125, DOI 10.1111/j.1365-2559.2004.01893.x; Moro-Sibilot D, 2008, EUR RESPIR J, V31, P854, DOI 10.1183/09031936.00058507; Pelosi G, 2011, J THORAC ONCOL, V6, P1039, DOI 10.1097/JTO.0b013e318211dd16; Serrano MF, 2008, HUM PATHOL, V39, P591, DOI 10.1016/j.humpath.2007.08.019; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wang BY, 2002, HUM PATHOL, V33, P921, DOI 10.1053/hupa.2002.126878; Wang LC, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-10; Wilson D. W., 2017, Tumors in domestic animals, P467; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7	19	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						11	15		10.1016/j.jcpa.2017.12.007			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400002	29598999	Green Accepted			2019-10-28	
J	Barbon, AR; Cowen, R; Knott, C; Hughes, K; Allinson, K; Williams, CV; Routh, A				Barbon, A. Rodriguez; Cowen, R.; Knott, C.; Hughes, K.; Allinson, K.; Williams, C. V.; Routh, A.			Neoplasia in Three Aye-Ayes (Daubentonia madagascariensis)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						aye-aye; Daubentonia madagascariensis; immunohistochemistry; neoplasia	LEMUR LEMUR-CATTA; HEPATOCELLULAR-CARCINOMA; PRIMATES; GLIOMAS; BRAIN	Tumours diagnosed in three aged captive aye-ayes (Daubentonia madagascariensis), held in two different institutions, are described. A cerebral glioblastoma was diagnosed based on histological and immunohistochemical findings in one of the animals following initial presentation with bilateral mydriasis, absent papillary reflex, head tilt and ataxia. A second animal was humanely destroyed due to impaired locomotion associated with spondylosis and a post-mortem diagnosis of cholangiocarcinoma was made based on histology with further confirmation with immunohistochemical labelling for cytokeratin 7. A third aye-aye suffering from dental disease was diagnosed with an oral squamous cell carcinoma following an excisional biopsy from a non-healing wound in the lip. Due to progression of the neoplasia the animal was humanely destroyed and post-mortem examination revealed the presence on an additional unilateral phaeochromocytoma. (C) 2017 Elsevier Ltd. All rights reserved.	[Barbon, A. Rodriguez; Cowen, R.; Routh, A.] Durrell Wildlife Conservat Trust, La Profonde Rue, Trinity, Jersry, England; [Knott, C.] One Eyed Lane, Weybread, Suffolk, England; [Hughes, K.] Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge, England; [Allinson, K.] Addenbrookes Hosp, Cambridge Biomed Campus,Hills Rd, Cambridge, England; [Williams, C. V.] Duke Lemur Ctr, 3705 Erwin Rd, Durham, NC USA	Barbon, AR (reprint author), Durrell Wildlife Conservat Trust, La Profonde Rue, Trinity, Jersry, England.	alberto.barbon@durrell.org		Hughes, Katherine/0000-0002-3331-1249; Routh, Andrew/0000-0001-7459-7805			Andriaholinirina N, 2014, DAUBENTONIA MADAGASC, DOI [10.2305/IUCN.UK.2014-1.RLTS.T6302A16114609, DOI 10.2305/IUCN.UK.2014-1.RLTS.T6302A16114609]; Brandner S, 2018, J NEUROL, V265, P717, DOI 10.1007/s00415-017-8652-3; Brown DL, 2016, PATHOLOGIC BASIS VET, P454; CHANG J, 1979, LAB ANIM SCI, V29, P374; Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175; Higgins RJ, 2017, TUMORS DOMESTIC ANIM, P841; Kaufman JA, 2005, ANAT REC PART A, V287A, P1026, DOI 10.1002/ar.a.20264; Miller AD, 2012, AM COLL LAB, P325, DOI 10.1016/B978-0-12-381366-4.00006-7; Nemeth NM, 2013, J COMP PATHOL, V148, P283, DOI 10.1016/j.jcpa.2012.05.013; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207; Porter BF, 2004, VET PATHOL, V41, P424, DOI 10.1354/vp.41-4-424; Remick AK, 2009, VET PATHOL, V46, P746, DOI 10.1354/vp.08-VP-0154-R-FL; Skjulsvik AJ, 2014, INT J CLIN EXP PATHO, V7, P8905; Tezal M, 2009, CANCER EPIDEM BIOMAR, V18, P2406, DOI 10.1158/1055-9965.EPI-09-0334; Urbanska K, 2014, WSPOLCZESNA ONKOL, V18, P307, DOI 10.5114/wo.2014.40559; Wohlsein P, 1996, DEUT TIERARZTL WOCH, V103, P180; WOOD DH, 1991, RADIAT RES, V126, P132, DOI 10.2307/3577811; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	18	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						16	20		10.1016/j.jcpa.2017.12.008			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400003	29599000				2019-10-28	
J	Diaz-Delgado, J; Coimbra, AAC; dos Santos-Cirqueira, C; Sanches, TC; Guerra, JM; de Oliveira, AS; Di Loretto, C; Zwarg, T; Ressio, R; Rivas, L; Sansone, M; Nagamori, FO; Kanamura, C; Goncalves, PS; Fernandes, NCCA; Groch, KR; Catao-Dias, JL				Diaz-Delgado, J.; Coimbra, A. A. C.; dos Santos-Cirqueira, C.; Sanches, T. C.; Guerra, J. M.; de Oliveira, A. S.; Di Loretto, C.; Zwarg, T.; Ressio, R.; Rivas, L.; Sansone, M.; Nagamori, F. O.; Kanamura, C.; Goncalves, P. S.; Fernandes, N. C. C. A.; Groch, K. R.; Catao-Dias, J. L.			Parotid Salivary Gland Basal Cell Adenocarcinoma in a Big-eared Opossum (Didelphis aurita)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						carcinoma; immunohistochemistry; opossum; salivary gland	NEOPLASMS; CAT	The opossum (family Didelphidae) is a marsupial endemic to the Americas. Apart from the South American short-tailed opossum (Monodelphis domestica) and the Virginia opossum (Didelphis virginiana), there is considerable lack of knowledge about the health and diseases of most opossum species. Among these, the big-eared opossum (Didelphis aurita) is found in Argentina, Brazil and Paraguay. Natural and experimental studies have shown this species to be susceptible to infectious agents with zoonotic potential and the animals may play a role in transmission of such agents. However, neoplasia appears to be uncommon in this species. We describe the gross, microscopical and immunohistochemical features of a parotid salivary gland basal cell adenocarcinoma in a free-living big-eared opossum. This case represents the first report of salivary gland neoplasia in opossums. (C) 2017 Elsevier Ltd. All rights reserved.	[Diaz-Delgado, J.; Guerra, J. M.; Groch, K. R.; Catao-Dias, J. L.] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Patol, Av Prof Orlando Marques de Paiva 87, Sao Paulo, Brazil; [Diaz-Delgado, J.; dos Santos-Cirqueira, C.; Di Loretto, C.; Ressio, R.; Sansone, M.; Nagamori, F. O.; Kanamura, C.; Goncalves, P. S.; Fernandes, N. C. C. A.] Adolfo Lutz Inst, Ctr Patol, Av Dr Arnaldo,351-7 Andar,Sala 706, Pacaemba, Brazil; [Coimbra, A. A. C.; Sanches, T. C.; de Oliveira, A. S.; Zwarg, T.; Rivas, L.] Div Tecn Med Vet & Manejo Fauna Silvestre, 4 Portao 7A,Av Quarto Centenario, Sao Paulo, SP, Brazil	Diaz-Delgado, J (reprint author), Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Patol, Av Prof Orlando Marques de Paiva 87, Sao Paulo, Brazil.; Diaz-Delgado, J (reprint author), Adolfo Lutz Inst, Ctr Patol, Av Dr Arnaldo,351-7 Andar,Sala 706, Pacaemba, Brazil.	josue.diaz101@alu.ulpgc.es	Guerra, Juliana Mariotti/H-5310-2012; CATAO-DIAS, JOSE LUIZ/C-4897-2012; Fernandes, Natalia/H-4537-2012	Guerra, Juliana Mariotti/0000-0002-0326-7187; CATAO-DIAS, JOSE LUIZ/0000-0003-2999-3395; Fernandes, Natalia/0000-0003-4754-4200			Bacchiega TS, 2014, THESIS; Cesar MDO, 2011, THESIS; Dalmau JO, 1999, ARCH NEUROL-CHICAGO, V56, P405, DOI 10.1001/archneur.56.4.405; Eveson JW, 2005, WHO CLASSIFICATION T, P212; Hammer A, 2001, J AM ANIM HOSP ASSOC, V37, P478, DOI 10.5326/15473317-37-5-478; Horta MC, 2009, VECTOR-BORNE ZOONOT, V9, P109, DOI 10.1089/vbz.2008.0114; KOESTNER A, 1965, PATHOL VET, V2, P201, DOI 10.1177/030098586500200301; Krause WJ, 1998, ADV ANAT EMBRYOL CEL, V143, P1; Luna MA, 2006, ADV ANAT PATHOL, V13, P293, DOI 10.1097/01.pap.0000213058.74509.d3; Monteiro SRD, 2010, THESIS; Munday J. S., 2017, Tumors in domestic animals, P499; Nowak RM, 1999, WALKERS MAMMALS WORL, V1, P17; Pena HFJ, 2011, VET PARASITOL, V175, P377, DOI 10.1016/j.vetpar.2010.10.015; Pope JP, 2017, J VET DIAGN INVEST, V29, P331, DOI 10.1177/1040638717704017; Ramos-Vara JA, 2008, J VET DIAGN INVEST, V20, P393, DOI 10.1177/104063870802000401; Sozmen M, 2003, J VET MED A, V50, P399, DOI 10.1046/j.0931-184X.2003.00563.x; Uzal F.A., 2016, JUBB KENNEDY PALMERS, V2, P1, DOI [10.1016/B978-0-7020-5318-4.00007-3, DOI 10.1016/B978-0-7020-5318-4.00007-3]; Voss RS, 2009, B AM MUS NAT HIST, P1; Younes-Mhenni S, 2004, BRAIN, V127, P2331, DOI 10.1093/brain/awh247	19	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						21	25		10.1016/j.jcpa.2017.12.010			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400004	29599001				2019-10-28	
J	Kok, MK; Chambers, JK; Ushio, N; Miwa, Y; Nakayama, H; Uchida, K				Kok, M. K.; Chambers, J. K.; Ushio, N.; Miwa, Y.; Nakayama, H.; Uchida, K.			Amyloid-producing Odontoameloblastoma in a Black-tailed Prairie Dog (Cynomys ludovicianus)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						amyloid; odontogenic tumour; prairie dog	EPITHELIAL ODONTOGENIC-TUMORS; SHIH-TZU DOG; IMMUNOHISTOCHEMICAL CHARACTERIZATION; 3 CATS; PROTEIN; EXPRESSION	A 6-year-old female black-tailed prairie dog (Cynomys tudovicianus) was presented with a space-occupying lesion in the left submandibular region. On computed tomography, a low attenuating, poorly circumscribed mass infiltrated the left mandibular bone, with osteolytic change. Microscopically, the lesion was composed of odontogenic epithelium proliferating in nests and embedded in abundant dental papilla-like ectomesenchyme, including dentine and enamel. Multifocal amyloid deposition was observed. Immunohistochemically, the neoplastic epithelial cells were positive for cytokeratin (CK) AE1/AE3, CK14 and p63. Some epithelial cells were positive for amelogenin and some adjacent to the amyloid deposits co-expressed S100. The ectomesenchymal cells expressed vimentin and strong 5100 immunorcactivity was observed in odontoblast-like cells. The amyloid was immunolabelled with amelogenin. The tumour was diagnosed as amyloid-producing odontoameloblastoma. (C) 2017 Elsevier Ltd. All rights reserved.	[Kok, M. K.; Chambers, J. K.; Ushio, N.; Nakayama, H.; Uchida, K.] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo, Japan; [Miwa, Y.] Miwa Exot Anim Hosp, Toshima Ku, 1-25-5 Komagome, Tokyo, Japan	Chambers, JK (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo, Japan.	achamber@mail.ecc.u-tokyo.ac.jp		Kok, Mun Keong/0000-0001-9337-3209			ABBOTT DP, 1986, J COMP PATHOL, V96, P131, DOI 10.1016/0021-9975(86)90003-4; Aviel-Ronen S, 2000, ARCH PATHOL LAB MED, V124, P872; Boy SC, 2006, J COMP PATHOL, V135, P56, DOI 10.1016/j.jcpa.2006.03.002; BREUER W, 1994, VET PATHOL, V31, P415, DOI 10.1177/030098589403100402; Delaney MA, 2013, VET PATHOL, V50, P238, DOI 10.1177/0300985812452583; GARDNER DG, 1994, J COMP PATHOL, V111, P221, DOI 10.1016/S0021-9975(05)80001-5; Head KW, 2003, HISTOLOGICAL CLASSIF, P46; Hirayama K, 2017, VET PATHOL, V54, P218, DOI 10.1177/0300985816660746; Hirayama K, 2010, VET PATHOL, V47, P915, DOI 10.1177/0300985810375047; Kang MS, 2006, J COMP PATHOL, V134, P236, DOI 10.1016/j.jcpa.2005.09.004; Kuwamura M, 2000, J VET MED SCI, V62, P655, DOI 10.1292/jvms.62.655; Lohr CV, 2013, VET PATHOL, V50, P668, DOI 10.1177/0300985812471544; Luukko K, 1998, EUR J ORAL SCI, V106, P80, DOI 10.1111/j.1600-0722.1998.tb02157.x; Matsuura M, 2017, J MED INVESTIG, V64, P217, DOI 10.2152/jmi.64.217; MORI M, 1991, VIRCHOWS ARCH A, V418, P319, DOI 10.1007/BF01600161; Munday JS, 2017, TUMORS DOMESTIC ANIM, P530; Murphy CL, 2008, AMYLOID, V15, P89, DOI 10.1080/13506120802005965; Nosrat CA, 1997, CELL TISSUE RES, V290, P569, DOI 10.1007/s004410050962; Ohmachi T, 1996, J COMP PATHOL, V114, P305, DOI 10.1016/S0021-9975(96)80052-1; Ohshima H, 2005, ARCH ORAL BIOL, V50, P153, DOI 10.1016/j.archoralbio.2004.09.008; SAUK JJ, 1985, J ORAL PATHOL MED, V14, P133, DOI 10.1111/j.1600-0714.1985.tb00476.x; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; Takata T, 2000, VIRCHOWS ARCH, V436, P324, DOI 10.1007/s004280050454; Takeda Y, 2000, PATHOL INT, V50, P610, DOI 10.1046/j.1440-1827.2000.01087.x; Tsai YC, 2007, VET PATHOL, V44, P233, DOI 10.1354/vp.44-2-233	25	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						26	30		10.1016/j.jcpa.2017.12.002			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400005	29599002				2019-10-28	
J	de Araujo, JL; Perry, A; Wild, J; Kleinschmdit, L; Hoppes, S; Rech, RR				de Araujo, J. Leal; Perry, A.; Wild, J.; Kleinschmdit, L.; Hoppes, S.; Rech, R. R.			Ovarian Teratocarcinoma in an Emu (Dromaius novaehollandiae): Histopathological and Immunohistochemical Characterization	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						emu; malignant teratoma; ovary; teratocarcinomatosis	INTRACELOMIC TERATOMA; DUCK; RETROBULBAR	A 17-year-old female emu (Dromaius novaehollandiae) was presented for clinical evaluation due to a 3-week history of anorexia and progressive weight loss. The emu died after sedation. At necropsy examination, the ovary and the majority of the oviduct were effaced by a multinodular cystic mass and accompanied by 61 of coelomic effusion. Histopathology revealed a neoplasm composed of well-differentiated, poorly organized tissues derived from ectoderm, mesoderm and endoderm. Tissues within the neoplasm expressed glial fibrillary acidic protein, desmin and cytokeratins AE1/AE3, respectively, confirming the diagnosis of teratocarcinoma. (C) 2018 Elsevier Ltd. All rights reserved.	[de Araujo, J. Leal; Perry, A.; Rech, R. R.] Texas A&M Univ, Dept Vet Pathol, College Stn, TX 77843 USA; [Wild, J.] Texas A&M Univ, Coll Vet Med, College Stn, TX 77843 USA; [Kleinschmdit, L.] Endangered Species Res Ctr & Vet Hosp, St Louis Zoo, St Louis, MO USA; [Hoppes, S.] Texas A&M Univ, Dept Small Anim Clin Sci, College Stn, TX USA	Rech, RR (reprint author), Texas A&M Univ, Dept Vet Pathol, College Stn, TX 77843 USA.	RRech@cvm.tamu.edu	Rech, Raquel R/L-9071-2019	Rech, Raquel R/0000-0003-3768-0743			Bolte AL, 2000, AVIAN PATHOL, V29, P237, DOI 10.1080/03079450050045503; CLEMENT PB, 1991, SEMIN DIAGN PATHOL, V8, P204; Crum CP, 2010, ROBBINS COTRANS PATH, P1099; CULLEN JM, 1991, AVIAN DIS, V35, P638, DOI 10.2307/1591234; Ford SL, 2006, J AVIAN MED SURG, V20, P175, DOI 10.1647/2005-011R.1; HAMIR AN, 1985, VET REC, V117, P314, DOI 10.1136/vr.117.12.314; Hclmboldt CF, 1974, AVIAN DIS, V18, P142; Hooper CC, 2008, AVIAN PATHOL, V37, P141, DOI 10.1080/03079450801902054; Khan J, 2005, GYNECOL ONCOL, V98, P313, DOI 10.1016/j.ygyno.2005.03.048; Kusewitt D, 2016, PATHOLOGIC BASIS VET, P253; Lopez RM, 2008, AVIAN PATHOL, V37, P413, DOI 10.1080/03079450802216660; MacLachlan N, 2016, TUMOURS DOMESTIC ANI, P547; Maiti Sachchidananda, 2008, J Med Case Rep, V2, P203, DOI 10.1186/1752-1947-2-203; Manasse JL, 2015, J ZOO WILDLIFE MED, V46, P633, DOI 10.1638/2015-0054.1; Mutinelli F, 2002, AVIAN DIS, V46, P493, DOI 10.1637/0005-2086(2002)046[0493:TTIAWP]2.0.CO;2; Nader Reine, 2014, Case Rep Radiol, V2014, P189409, DOI 10.1155/2014/189409; Outwater EK, 2001, RADIOGRAPHICS, V21, P475, DOI 10.1148/radiographics.21.2.g01mr09475; Palmieri C, 2012, RES VET SCI, V93, P862, DOI 10.1016/j.rvsc.2012.01.009; Pazdzior K, 2012, AVIAN PATHOL, V41, P285, DOI 10.1080/03079457.2012.686659; REECE RL, 1993, AVIAN PATHOL, V22, P193, DOI 10.1080/03079459308418912; SCHELLING SH, 1994, J VET DIAGN INVEST, V6, P514, DOI 10.1177/104063879400600427; Schlafer D, 2016, JUBB KENNEDY PALMERS, V3, P474; Schmidt D, 2007, PATHOLOGE, V28, P203, DOI 10.1007/s00292-007-0909-7; Talerman A., 1994, BLAUSTEINS PATHOLOGY, P849	24	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						31	35		10.1016/j.jcpa.2018.01.003			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400006	29599003				2019-10-28	
J	Igwe, AO; Afonso, CL; Ezema, WS; Brown, CC; Okoye, JOA				Igwe, A. O.; Afonso, C. L.; Ezema, W. S.; Brown, C. C.; Okoye, J. O. A.			Pathology and Distribution of Velogenic Viscerotropic Newcastle Disease Virus in the Reproductive System of Vaccinated and Unvaccinated Laying Hens (Gallus gallus domesticus) by Immunohistochemical Labelling	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						immunohistochemistry; laying hens; Newcastle disease; reproductive system pathology	IN-VIVO EVALUATION; CHICKENS; ANTIBODIES; CHALLENGE; VIRULENCE; TRACT; VITRO; PATHOGENESIS; INFECTION; OVIDUCT	This study investigated the pathological changes in the reproductive system of laying hens that lead to the poor egg production and quality in Newcastle disease (ND) and the distribution of the virus in the system. Two hundred and forty Isa-Brown pullets were divided randomly into vaccinated and unvaccinated groups (n = 120 each). The vaccinated group was given Hitchner B1 vaccine at 1 day of age, La Sota vaccine at 4 weeks of age and Komarov vaccine at 9 and 16 weeks of age. At the peak of egg production, the laying hens (32 weeks old) were assigned randomly into four groups (n = 60): VC, vaccinated with ND vaccines and inoculated intramuscularly with velogenic viscerotropic ND virus (vvNDV); VU, vaccinated unchallenged; UC, unvaccinated challenged; and UU, unvaccinated unchallenged. UC hens showed depression, diarrhoea and later torticollis. Mortality in UC hens was 90%. VC hens showed mild anorexia. The body weights of the UC hens were significantly (P <0.05) lower than those of UU hens. VC and UC hens showed a significant (P <0.05) drop in egg production. Only UC hens produced abnormal eggs and initially had swollen, oedematous, hyperaemic oviducts followed by atrophy and shortening of the reproductive tract with atresia of the ovarian follicles. The histopathological changes were of necrosis of the epithelium and secretory glands. VC hens showed mild inflammatory changes in the oviduct. Immunohistochemical labelling showed extensive presence of the virus in the ovary, infundibulum, magnum, isthmus, uterus and vagina of UC hens and in the ovary of VC hens. These changes will be the cause of serious egg production problems, especially in vaccinated layers in countries where vvNDV is cnzootic. (C) 2018 Elsevier Ltd. All rights reserved.	[Igwe, A. O.] Michael Okpara Univ Agr, Dept Vet Pathol, Umudike, Abia State, Nigeria; [Afonso, C. L.] Southeast Poultry Res Lab, Exot & Emerging Avian Viral Dis Res Unit, Athens, GA USA; [Ezema, W. S.; Okoye, J. O. A.] Univ Nigeria, Dept Vet Pathol & Microbiol, Nsukka, Enugu State, Nigeria; [Brown, C. C.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA	Igwe, AO (reprint author), Michael Okpara Univ Agr, Dept Vet Pathol, Umudike, Abia State, Nigeria.	docoleji@yahoo.com			Nigerian Education Trust Fund ASTD intervention; USDA (CRIS)United States Department of Agriculture (USDA) [6612-32000-064-00D]	The authors acknowledge D. Williams-Coplin of the Southeast Poultry Research Laboratory (SEPRL), United States Department of Agriculture (USDA), for technical assistance. We thank the Management of the SEPRL, USDA, for use of their facility. We also acknowledge the assistance of Drs. Joannis, I. Shittu and H. Ularamu of the National Veterinary Research Institute, Vom, Plateau State, Nigeria, for assistance in the ELISA portion of' this work. This work was supported by the Nigerian Education Trust Fund 2011 AST&D intervention and the USDA (CRIS number 6612-32000-064-00D).	Alexander D.J., 2008, LAB MANUAL ISOLATION, P135; Alexander DJ, 1997, AVIAN PATHOL, V26, P399, DOI 10.1080/03079459708419222; Alexander DJ., 2003, DIS POULTRY, P63; ALLAN WH, 1974, VET REC, V95, P147, DOI 10.1136/vr.95.7.147; Allan WH, 1978, FAO ANIMAL PRODUCTIO, V10; BISWAL G, 1954, POULTRY SCI, V33, P880, DOI 10.3382/ps.0330880; Bwala DG, 2012, RES VET SCI, V93, P520, DOI 10.1016/j.rvsc.2011.06.023; Cardenas-Garcia S, 2015, BIOLOGICALS, V43, P136, DOI 10.1016/j.biologicals.2014.11.003; Cattoli G, 2011, J VET DIAGN INVEST, V23, P637, DOI 10.1177/1040638711407887; Cornax I, 2012, AVIAN DIS, V56, P464, DOI 10.1637/10043-122011-Reg.1; Dai YB, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-164; ECHEONWU GON, 1993, AVIAN PATHOL, V22, P383, DOI 10.1080/03079459308418928; Eze C. P., 2014, International Journal of Poultry Science, V13, P52; Ezema WS, 2016, TROP ANIM HEALTH PRO, V48, P1703, DOI 10.1007/s11250-016-1147-x; Igwe AO, 2017, J APPL ANIM RES, V46, P523, DOI 10.1080/09712119.2017.1352506; Igwe O.A., 2014, INT J POULTRY SCI, V13, P582, DOI [DOI 10.3923/ijps.2014.582.590, 10.3923/ijps.2014.582.590]; Khehra R. S., 1998, Proceedings international symposium on infectious bronchitis and pneumovirus infections in poultry, Rauischholzhausen, Germany, 15-18 June 1998., P58; LAMB RA, 2005, VIRUS TAXONOMY, P655; Mayo MA, 2002, ARCH VIROL, V147, P1655, DOI 10.1007/s007050200039; Miller P.J., 2013, DIS POULTRY, V13, P89, DOI DOI 10.1002/9781119421481.CH3.(HTTPS://D0I.0RG/); Miller PJ, 2013, DEV COMP IMMUNOL, V41, P505, DOI 10.1016/j.dci.2013.06.007; NAGY E, 1991, AVIAN DIS, V35, P585, DOI 10.2307/1591224; Nasser M, 2000, AVIAN PATHOL, V29, P27, DOI 10.1080/03079450094243; Okafor LC., 1992, BIOMETRY BASIC PRINC, P141; Okwor EC, 2016, J ANIM PLANT SCI, V26, P1226; PHILLIPS JM, 1973, VET REC, V93, P577, DOI 10.1136/vr.93.22.577; Quinn JP, 1953, POULTRY SCI, V33, P880; Raj GD, 1996, AVIAN PATHOL, V25, P649, DOI 10.1080/03079459608419172; Raj GD, 2001, AVIAN PATHOL, V30, P13, DOI 10.1080/03079450020023140; Rao MS, 2002, AVIAN PATHOL, V31, P507, DOI 10.1080/0307945021000005888; Sa ESM, 2016, J WVPA, V45, P38; Shittu I, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01716-15; Solomon P, 2012, VIRUS GENES, V44, P98, DOI 10.1007/s11262-011-0678-5; Wakamatsu N, 2006, VET PATHOL, V43, P925, DOI 10.1354/vp.43-6-925	34	4	4	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	FEB	2018	159						36	48		10.1016/j.jcpa.2017.12.009			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GD5CU	WOS:000430523400007	29599004				2019-10-28	
J	Resnik, DB; Elmore, SA				Resnik, David B.; Elmore, Susan A.			Conflict of Interest in Journal Peer Review	TOXICOLOGIC PATHOLOGY			English	Editorial Material						conflict of interest; peer review; ethics; journal policy	INTEREST DISCLOSURE POLICIES; BIOMEDICAL JOURNALS; QUALITY; EDITORS; IMPACT		[Resnik, David B.] NIEHS, NIH, Durham, NC USA; [Elmore, Susan A.] NIEHS, Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA	Elmore, SA (reprint author), NIEHS, CMPB, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	elmore@niehs.nih.gov			Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)	This research was supported (in part) by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS).	Anraku A, 2009, OPHTHALMOLOGY, V116, P1093, DOI 10.1016/j.ophtha.2008.12.053; Baggs JG, 2008, J ADV NURS, V64, P131, DOI 10.1111/j.1365-2648.2008.04816.x; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Blum JA, 2009, JAMA-J AM MED ASSOC, V302, P2230, DOI 10.1001/jama.2009.1669; Bornmann L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013345; Bosch X, 2013, EUR J CLIN INVEST, V43, P660, DOI 10.1111/eci.12090; Cho MK, 1998, JAMA-J AM MED ASSOC, V280, P243, DOI 10.1001/jama.280.3.243; Committee on Publication Ethics, 2017, COPE ETH GUID PEER R; Committee on Publication Ethics, 2016, SHORT GUID ETH ED NE; Cooper RJ, 2006, J GEN INTERN MED, V21, P1248, DOI 10.1111/j.1525-1497.2006.0598.x; Field MJ, 2009, CONFLICT INTEREST ME; Liu JJ, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4619; National Institutes of Health, 2014, NOTOD14069 NAT I HLT; Resnik DB, 2017, J OCCUP ENVIRON MED, V59, P28, DOI 10.1097/JOM.0000000000000910; Resnik DB, 2016, SCI ENG ETHICS, V22, P169, DOI 10.1007/s11948-015-9625-5; Schroter S, 2006, JAMA-J AM MED ASSOC, V295, P314, DOI 10.1001/jama.295.3.314; Shamoo Adil E., 2015, RESPONSIBLE CONDUCT; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; Wager E, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-13	20	2	2	2	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					112	114		10.1177/0192623318754792			3	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400001	29382273	Bronze, Green Accepted			2019-10-28	
J	Bolon, B				Bolon, Brad			Regulatory Forum Opinion Piece*: Effective Brain Trimming for Regulatory-type Nonclinical Toxicity Studies	TOXICOLOGIC PATHOLOGY			English	Article						best practices; brain; neuropathology; tissue trimming	GENERAL TOXICITY; NERVOUS-SYSTEM; CYNOMOLGUS MONKEY; STEREOTAXIC ATLAS; NEUROTOXICITY	Regulatory guidances for nonclinical toxicity testing require brain evaluation but do not require a specific analytical strategy. The Society of Toxicologic Pathology (STP) has produced best practice recommendations for brain sampling and processing in general toxicity (GT) studies in adult rodents and nonrodents as well as developmental neurotoxicity (DNT) studies in rodents. This article explains acceptable brain trimming strategies as described in these 2 STP documents. Figures in the DNT and GT best practices illustrate coronal brain trimming at specific levels as defined by discrete external and internal anatomic landmarks. However, the text of both best practice papers states that institutions may choose different brain trimming levels or other planes (e.g., a longitudinal orientation) as long as key structures are sampled and trimming is consistent among individuals across the study. The STP-recommended number of brain levels to evaluate (7 or 8 coronal sections for GT and DNT studies, respectively) may need to be increased if neurotoxicity is considered possible or likely based on in-life clinical findings or other risk factors (chemical structure, known mode of action, etc.).	[Bolon, Brad] GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA	Bolon, B (reprint author), GEMpath Inc, 1100 East 17th Ave,Unit M202, Longmont, CO 80504 USA.	bradgempath@aol.com					Ashwell KWS, 2008, ATLAS DEV RAT NERVOU; Bjarkam CR, 2017, BRAIN STRUCT FUNCT, V222, P2093, DOI 10.1007/s00429-016-1327-5; Bolon B, 2006, TOXICOL PATHOL, V34, P296, DOI 10.1080/01926230600713269; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; Bolon B, 2011, TOXICOL PATHOL, V39, P92, DOI 10.1177/0192623310385145; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Garman RH, 2016, TOXICOL PATHOL, V44, P14, DOI 10.1177/0192623315596858; Garman Robert H., 2003, Toxicologic Pathology, V31, P32, DOI 10.1080/01926230309781; Jordan WH, 2011, TOXICOL PATHOL, V39, P58, DOI 10.1177/0192623310391480; Organisation for Economic Co operation and Development, 1997, 424 ORG EC COOP DEV; Organisation for Economic Co operation and Development, 1995, 418 ORG EC COOP DEV; Organisation for Economic Co operation and Development, 2007, 426 ORG EC COOP DEV; Organisation for Economic Co operation and Development, 1995, 419 ORG EC COOP DEV; Organisation for Economic Co operation and Development, 2011, 443 ORG EC COOP DEV; Palazzi X., 2008, MARMOSET BRAIN STERE; Palazzi X, 2011, BEAGLE BRAIN STEREOT; Pardo ID, 2012, TOXICOL PATHOL, V40, P624, DOI 10.1177/0192623311436180; Paxinos G, 1994, ATLAS DEV RAT NERVOU; Paxinos G., 2008, RHESUS MONKEY BRAIN; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Paxinos G, 2007, ATLAS DEV MOUSE BRAI; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Rao DB, 2014, TOXICOL PATHOL, V42, P487, DOI 10.1177/0192623313501893; Singer M, 1962, BRAIN DOG SECTION; SZABO J, 1984, J COMP NEUROL, V222, P265, DOI 10.1002/cne.902220208; U.S EPA, 1998, HLTH EFF TEST GUID O; US Food and Drug Administration, 2000, REDB 2000 4 C 10 N E	28	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					115	120		10.1177/0192623317749453			6	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400002	29278994				2019-10-28	
J	Dincer, Z; Piccicuto, V; Walker, UJ; Mahl, A; McKeag, S				Dincer, Zuhal; Piccicuto, Virginie; Walker, Ursula Junker; Mahl, Andreas; McKeag, Sean			Spontaneous and Drug-induced Arteritis/Polyarteritis in the Gottingen MinipigReview	TOXICOLOGIC PATHOLOGY			English	Review						minipig; arteritis; vasculitis; drugs; spontaneous; vasoactive; immunomodulator	ENDOTHELIN; VASCULITIS; LESIONS; ARTERIOPATHY; INHIBITORS; MINOXIDIL; ARTERITIS; CORONARY; RECEPTOR	Arteritis/polyarteritis occurs spontaneously in many species used in preclinical toxicology studies. In Gottingen minipigs, arteritis/polyarteritis is an occasionally observed background change. In the minipig, this finding differs in frequency and nature from age-related polyarteritis nodosa in rats or monkeys, and Beagle pain syndrome in dogs. In minipigs, it can be present in a single small- or medium-sized artery of an organ or a few organs and is most commonly recorded in the cardiac and extracardiac blood vessels, vagina, oviduct, rectum, epididymis, spinal cord, pancreas, urinary bladder, kidneys, and stomach. The etiology is unknown although it has been considered in minipigs as well as in rats, dogs, and monkeys to be possibly immune mediated. This background change is important with respect to its nature and distribution in the minipig in order to distinguish it from drug-induced vascular changes, which might occur in similar locations and have similar morphologic features. This review summarizes the morphology, incidence, and predilection sites of arteritis as a spontaneously occurring background change and as a drug-induced vasculopathy in the minipig, and also describes the main aspects to consider when evaluating vascular changes in Gottingen minipig toxicity studies and their human relevance.	[Dincer, Zuhal; Piccicuto, Virginie; McKeag, Sean] Covance Labs Ltd, Dept Pathol, Otley Rd, Harrogate HG3 1PY, England; [Walker, Ursula Junker; Mahl, Andreas] Novartis Inst Biomed Res, Preclin Safety, Basel, Switzerland	Dincer, Z (reprint author), Covance Labs Ltd, Dept Pathol, Otley Rd, Harrogate HG3 1PY, England.	zuhal.dincer@covance.com					Albassam MA, 1998, TOXICOL PATHOL, V26, P375, DOI 10.1177/019262339802600311; Albassam MA, 1999, TOXICOL PATHOL, V27, P156, DOI 10.1177/019262339902700202; Amano J, 2015, ANN THORAC CARDIOVAS, V21, P45, DOI 10.5761/atcs.oa.13-00311; [Anonymous], 2017, MINOXIDIL; April M, 1998, AM COLL LAB, P245; Avcin T, 2008, CLIN EXP RHEUMATOL, V26, pS18; Banner KH, 2009, BRIT J PHARMACOL, V157, P892, DOI 10.1111/j.1476-5381.2009.00170.x; Belli L, 1997, EUR RADIOL, V7, P323, DOI 10.1007/s003300050159; Berridge BR, 2016, J TOXICOL PATHOL, V29, p1S, DOI [10.1293/tox.2016-I001, 10.1293/tox.29.3S-1]; Carrasco L, 2003, J COMP PATHOL, V128, P25, DOI 10.1053/jcpa.2002.0601; Chamanza R., 2012, BACKGROUND LESIONS L, P3; Clemo Frances A. S., 2003, Toxicologic Pathology, V31, P25, DOI 10.1080/01926230390174904; Dincer Z, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P305; Fajardo LF, 2002, INT J RADIAT ONCOL, V53, P714, DOI 10.1016/S0360-3016(02)02759-1; Forbess L, 2015, RHEUM DIS CLIN N AM, V41, P33, DOI 10.1016/j.rdc.2014.09.005; Frazier KS, 2015, TOXICOL PATHOL, V43, P915, DOI 10.1177/0192623315570340; Getz GS, 2012, ARTERIOSCL THROM VAS, V32, P1104, DOI 10.1161/ATVBAHA.111.237693; Grand N, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P37; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P263, DOI 10.1016/B978-0-444-53856-7.00007-5; Hamamdzic D, 2013, J DIABETES RES, DOI 10.1155/2013/761415; Helke KL, 2016, TOXICOL PATHOL, V44, P325, DOI 10.1177/0192623315611762; HERMAN EH, 1989, TOXICOL PATHOL, V17, P182, DOI 10.1177/019262338901700114; Herman EH, 1996, TOXICOLOGY, V110, P71, DOI 10.1016/0300-483X(96)03337-9; Jeppesen G, 2015, TOXICOL PATHOL, V43, P257, DOI 10.1177/0192623314538344; Jones HB, 2003, TOXICOL PATHOL, V31, P263, DOI 10.1080/01926230390204298; Lintermans LL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00504; Lombardini E. D., 2013, HASCHEK ROUSSEAUXS H, V2, P1440; Losco PE, 2004, TOXICOL PATHOL, V32, P295, DOI 10.1080/01926230490431493; Maratea KA, 2006, VET PATHOL, V43, P447, DOI 10.1354/vp.43-4-447; McInnes E. F., 2012, BACKGROUND LESIONS L, P81; Mecklenburg L, 2006, TOXICOL LETT, V163, P54, DOI 10.1016/j.toxlet.2005.09.037; Mitchell R. N., 2015, ROBBINS COTRAN PATHO, P509; Movsesian MA, 2002, EXPERT OPIN INV DRUG, V11, P1529, DOI 10.1517/13543784.11.11.1529; Percy D. H., 2007, PATHOLOGY LAB RODENT, P164; Porter BF, 2003, VET PATHOL, V40, P570, DOI 10.1354/vp.40-5-570; Robinson WF, 2016, JUBB KENNEDY PALMERS, V3, P1; Schneider MP, 2007, ANNU REV PHARMACOL, V47, P731, DOI 10.1146/annurev.pharmtox.47.120505.105134; Son Woo-Chan, 2004, J Vet Sci, V5, P147; Stephan-Gueldner M, 2000, TOXICOL LETT, V112, P531, DOI 10.1016/S0378-4274(99)00218-0; Strohmayer EA, 2011, ENDOCRIN METAB CLIN, V40, P409, DOI 10.1016/j.ecl.2011.01.011; Swindle MM, 2012, VET PATHOL, V49, P344, DOI 10.1177/0300985811402846; Teng GG, 2015, BEST PRACT RES CL RH, V29, P226, DOI 10.1016/j.berh.2015.05.007; Van Vleet J. F., 1986, SWINE CARDIOVASCULAR, V1, P121	43	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					121	130		10.1177/0192623318754791			10	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400003	29471777				2019-10-28	
J	Sharpe, ME				Sharpe, Michaela E.			T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology	TOXICOLOGIC PATHOLOGY			English	Review						immunotherapy; CAR T cells; TCR T cells; cancer; safety; cytokine release syndrome; neurotoxicity; gene modification; on-target toxicity; off-target toxicity	CHIMERIC-ANTIGEN-RECEPTOR; CYTOKINE RELEASE SYNDROME; CHRONIC LYMPHOCYTIC-LEUKEMIA; IN-VIVO PERSISTENCE; B-CELL; ADOPTIVE IMMUNOTHERAPY; GENE-THERAPY; ANTITUMOR EFFICACY; CANCER REGRESSION; ADVERSE EVENT	Gene-engineered T-cell therapies have the potential to revolutionize the treatment of cancer. These therapies have shown exceptional clinical efficacy specifically in the field of B-cell malignancies and the first products (Kymriah and Yescarta) have recently been approved in the United States for specific indications. The power of these treatments is also linked with a distinct set of toxicities both predicted and unpredicted, including off-tumor activity, cytokine release syndromes, and neurotoxicity, occasionally with fatal consequences. As these therapies begin to reach more patients, it is critical to develop the nonclinical tools to adequately determine the mechanisms driving these toxicities, to assess the safety risks of candidate products, and to develop strategies for safety management.	[Sharpe, Michaela E.] Guys Hosp, Cell & Gene Therapy Catapult, 12th Floor Tower Wing, London SE1 9RT, England	Sharpe, ME (reprint author), Guys Hosp, Cell & Gene Therapy Catapult, 12th Floor Tower Wing, London SE1 9RT, England.	michaela.sharpe@ct.catapult.org.uk		Sharpe, Michaela/0000-0002-0850-4639	UK Government through Innovate UK	The author is an employee of the Cell and Gene Therapy Catapult, which is a not-for-profit organization supported by the UK Government through Innovate UK.	Alcantar-Orozco EM, 2013, HUM GENE THER METHOD, V24, P310, DOI 10.1089/hgtb.2013.022; [Anonymous], 2017, REUTERS; [Anonymous], 2017, SPOTLIGHTPUTTING NUM; Attaf M, 2015, CLIN EXP IMMUNOL, V181, P1, DOI 10.1111/cei.12622; Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810; Barrett DM, 2013, HUM GENE THER, V24, P717, DOI 10.1089/hum.2013.075; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Bedoya F, 2017, MOL THER, V25, P314, DOI 10.1016/j.ymthe.2016.11.011; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Blankenstein T, 2012, NAT REV CANCER, V12, P307, DOI 10.1038/nrc3246; Brentjens R, 2010, MOL THER, V18, P666, DOI 10.1038/mt.2010.31; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751; Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034; Casucci M, 2015, CANCER IMMUNOL IMMUN, V64, P123, DOI 10.1007/s00262-014-1641-9; Cornetta K, 2018, MOL THER, V26, P280, DOI 10.1016/j.ymthe.2017.09.008; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Davila ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061338; Dudley ME, 2013, J CLIN ONCOL, V31, P2152, DOI 10.1200/JCO.2012.46.6441; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97; Garfall AL, 2015, NEW ENGL J MED, V373, P1040, DOI 10.1056/NEJMoa1504542; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gerry A., 2015, J IMMUNOTHER CANCER, V3, pP14; Gerry A. B., 2016, PRECLINICAL SAFETY T; Gillio-Meina C, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-0490; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Harris J, 2017, ONC LIVE; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kaiser J, 2017, SCIENCE; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kochenderfer JN, 2010, BLOOD, V116, P3875, DOI 10.1182/blood-2010-01-265041; Kowolik CM, 2006, CANCER RES, V66, P10995, DOI 10.1158/0008-5472.CAN-06-0160; Kunkele A, 2017, CLIN CANCER RES, V23, P466, DOI 10.1158/1078-0432.CCR-16-0354; Kvistborg P., 2014, ONCOIMMUNOLOGY, V1, P409; Lamers CH, 2006, J CLIN ONCOL, V24, pe20, DOI DOI 10.1200/JCO.2006.05.9964; Lamers CHJ, 2013, MOL THER, V21, P904, DOI 10.1038/mt.2013.17; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Levine BL, 2017, MOL THER-METH CLIN D, V4, P92, DOI 10.1016/j.omtm.2016.12.006; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Mackall C, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3000; Mackall C, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3040; Maher J, 2012, ISRN ONCOL, V2012, DOI DOI 10.5402/2012/278093; Mansh Matthew, 2011, Yale Journal of Biology and Medicine, V84, P381; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Morgan RA, 2013, BLOOD, V122, P3392, DOI 10.1182/blood-2013-09-527622; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Muniappan A, 2000, CANCER GENE THER, V7, P128, DOI 10.1038/sj.cgt.7700100; Muranski P, 2006, NAT CLIN PRACT ONCOL, V3, P668, DOI 10.1038/ncponc0666; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; Novartis, 2017, CTL019 NOV; Oliveira G, 2012, CURR OPIN HEMATOL, V19, P427, DOI 10.1097/MOH.0b013e32835822f5; Park JH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.7024; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Persons DA, 2011, MOL THER, V19, P229, DOI 10.1038/mt.2010.305; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Porter DL, 2014, BLOOD, V124, P1982; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Ramos CA, 2016, J CLIN INVEST, V126, P2588, DOI 10.1172/JCI86000; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Ren JT, 2017, PROTEIN CELL, V8, P634, DOI 10.1007/s13238-017-0410-x; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rouce RH, 2016, CANCER DISCOV, V6, P579, DOI 10.1158/2159-8290.CD-16-0493; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Ruella M, 2014, IMMUNOL REV, V257, P14, DOI 10.1111/imr.12136; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Santomasso B, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3019; Sarno Jessica, 2013, J Adv Pract Oncol, V4, P101; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; Sharpe M, 2015, DIS MODEL MECH, V8, P337, DOI 10.1242/dmm.018036; Taraseviciute A, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.651.651; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Treuting PM, 2010, TOXICOL PATHOL, V38, P476, DOI 10.1177/0192623310362249; Turtle CJ, 2017, J CLIN ONCOL, V35, P3010, DOI 10.1200/JCO.2017.72.8519; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; van der Stegen SJC, 2013, J IMMUNOL, V191, P4589, DOI 10.4049/jimmunol.1301523; Vonderheide RH, 2014, IMMUNOL REV, V257, P7, DOI 10.1111/imr.12143; Whilding LM, 2017, MOL THER, V25, P259, DOI 10.1016/j.ymthe.2016.10.012; Wilkie S, 2012, J CLIN IMMUNOL, V32, P1059, DOI 10.1007/s10875-012-9689-9; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhang T, 2012, J IMMUNOL, V189, P2290, DOI 10.4049/jimmunol.1103495	97	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					131	146		10.1177/0192623317752101			16	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400004	29471776	Green Published, Other Gold			2019-10-28	
J	Tirmenstein, M; Janovitz, E; Dorr, T; Song, YL; Chen, SJ; Granaldi, K; Chadwick, KD; Mangipudy, R; Graziano, M; Attalla, B; Haile, S; Czajkowski, M; Foster, JR; Bergholm, AM; Billger, M; Soderberg, M				Tirmenstein, Mark; Janovitz, Evan; Dorr, Thomas; Song, Yunling; Chen, Shen-Jue; Granaldi, Karen; Chadwick, Kristina D.; Mangipudy, Raja; Graziano, Michael; Attalla, Bassem; Haile, Solomon; Czajkowski, Melissa; Foster, John R.; Bergholm, Ann-Marie; Billger, Martin; Soderberg, Magnus			Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley Rats	TOXICOLOGIC PATHOLOGY			English	Article						N-butyl-N-(4-hydroxybutyl)-nitrosamine; rosiglitazone; sodium ascorbate; transitional cell carcinomas; tumor promoters; uracil; urinary bladder tumors	INDUCED UROLITHIASIS; CARCINOGENESIS; INITIATION; CANCER; RISK	The purpose of this study was to establish a 2-stage model of urinary bladder carcinogenesis in male Sprague-Dawley rats to identify tumor promoters. In phase 1 of the study, rats (n = 170) were administered 100 mg/kg of the tumor initiator, N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), twice weekly by oral gavage (po) for a period of 6 weeks. Phase 2 consisted of dividing rats into 4 groups (n = 40 per group) and administering one of the following for 26 weeks to identify putative tumor promoters: (1) vehicle po, (2) 25 mg/kg/day rosiglitazone po, (3) 5% dietary sodium l-ascorbate, and (4) 3% dietary uracil. Rats were necropsied after 7.5 months, and urinary bladders were evaluated by histopathology. BBN/vehicle treatments induced the development of urothelial hyperplasia (83%) and papillomas (15%) but no transitional cell carcinomas (TCCs). Rosiglitazone increased the incidence and severity of papillomas (93%) and resulted in TCC in 10% of treated rats. Uracil was the most effective tumor promoter in our study and increased the incidence of papillomas (90%) and TCC (74%). Sodium ascorbate decreased the incidence of urothelial hyperplasia (63%) and did not increase the incidence of urothelial papillomas or TCC. These data confirm the capacity of our 2-stage model to identify urinary bladder tumor promoters.	[Tirmenstein, Mark; Dorr, Thomas; Chadwick, Kristina D.; Mangipudy, Raja] Bristol Myers Squibb, Drug Safety Evaluat, One Squibb Dr, New Brunswick, NJ 08903 USA; [Tirmenstein, Mark] Allergan, Madison, NJ USA; [Janovitz, Evan] Bristol Myers Squibb, Discovery Toxicol, Pennington, NJ USA; [Song, Yunling; Chen, Shen-Jue; Granaldi, Karen] Bristol Myers Squibb, Discovery Toxicol, Princeton, NJ USA; [Graziano, Michael] Bristol Myers Squibb, Drug Safety Evaluat, Princeton, NJ USA; [Attalla, Bassem; Haile, Solomon] Montreal ULC, Charles River Labs, Senneville, PQ, Canada; [Czajkowski, Melissa] Charles River Labs Edinburgh Ltd, Dept Pathol, Tranent, E Lothian, Scotland; [Foster, John R.] ToxPath Sci Ltd, Congleton, Cheshire, England; [Bergholm, Ann-Marie; Billger, Martin; Soderberg, Magnus] AstraZeneca, IMED Biotech Unit, Drug Safety & Metab, Gothenburg, Sweden	Chadwick, KD (reprint author), Bristol Myers Squibb, Drug Safety Evaluat, One Squibb Dr, New Brunswick, NJ 08903 USA.	kristina.chadwick@bms.com					AIROLDI L, 1994, CARCINOGENESIS, V15, P2297, DOI 10.1093/carcin/15.10.2297; Buckley L. A., 2015, GENOTOXICITY CARCINO, P183; Cohen SM, 1998, INT J TOXICOL, V17, P129; DEJONG ASH, 1985, HISTOCHEM J, V17, P1119, DOI 10.1007/BF01002537; FUKUSHIMA S, 1988, CARCINOGENESIS, V9, P1203, DOI 10.1093/carcin/9.7.1203; HAGIWARA A, 1993, JPN J CANCER RES, V84, P237, DOI 10.1111/j.1349-7006.1993.tb02862.x; Iwata H, 1997, TOXICOL PATHOL, V25, P284, DOI 10.1177/019262339702500306; Lin PY, 2012, TOXICOL APPL PHARM, V259, P27, DOI 10.1016/j.taap.2011.11.016; Lubet RA, 2008, INT J CANCER, V123, P2254, DOI 10.1002/ijc.23765; MORI S, 1987, CANCER RES, V47, P3492; Nakae D, 1997, CANCER RES, V57, P1281; Oliveira MM, 2013, J APPL TOXICOL, V33, P434, DOI 10.1002/jat.1763; Parada B, 2012, INT J MOL SCI, V13, P8482, DOI 10.3390/ijms13078482; SHIRAI T, 1986, CANCER RES, V46, P2062; SHIRAI T, 1987, CANCER RES, V47, P6726; Takahashi S, 1992, TOXICOL PATHOL, V5, P151, DOI DOI 10.1293/TOX.5.151; Turner RM, 2014, BRIT J CLIN PHARMACO, V78, P258, DOI 10.1111/bcp.12306; Vasconcelos-Nobrega C, 2012, IN VIVO, V26, P727	18	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					147	157		10.1177/0192623318756004			11	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400005	29471778	Other Gold			2019-10-28	
J	Charest, PL; Vrolyk, V; Herst, P; Lessard, M; Sloboda, DM; Dalvai, M; Haruna, J; Bailey, JL; Benoit-Biancamano, MO				Charest, Phanie L.; Vrolyk, Vanessa; Herst, Pauline; Lessard, Maryse; Sloboda, Deborah M.; Dalvai, Mathieu; Haruna, Julius; Bailey, Janice L.; Benoit-Biancamano, Marie-Odile			Histomorphologic Analysis of the Late-term Rat Fetus and Placenta	TOXICOLOGIC PATHOLOGY			English	Article						anatomy; fetus; histology; placenta; Sprague-Dawley rats	POSTNATAL-DEVELOPMENT; FETAL	Histological examination of the rat placenta and fetus is uncommon. Toxicological studies mainly rely on gross examination of the fetus and on fetal and placental weights. These are often insufficient to assess the fetal and placental toxicity of xenobiotics. The small size of the fetus makes its dissection labor-intensive. Thus, our objective was to develop a simple and accurate technique to evaluate the rat fetus and placenta. Sprague-Dawley rat fetuses at gestational day 19.5 (n = 18) and their placentas (n = 32) were fixed in formalin. Placentas were cut transversally in the center. Fetuses were cut following a freehand whole-body serial sectioning diagram adapted from Wilson's method. Sections were stained with hematoxylin-eosin-phloxine-saffron, and histomorphometry was used to measure the area of the fetal placental region (27.2 +/- 1.7 mm(2)), including the labyrinth (22.2 +/- 1.0 mm(2)) and the basal zone (4.8 +/- 0.8 mm(2)). Our whole-fetus serial sectioning technique resulted in 12 precise cutting planes that fit on 3 histological slides, enabling the examination of most organs without labor-intensive dissection. Quantitative analysis of placental areas improves the understanding of the pathogenesis of treatment-related changes. This technique provides a standardized method for future research in pertinent fields such as developmental biology and toxicology.	[Charest, Phanie L.; Herst, Pauline; Lessard, Maryse; Dalvai, Mathieu; Bailey, Janice L.] Laval Univ, Fac Agr & Food Sci, Dept Anim Sci, Ctr Rech Reprod Dev & Sante Intergenerat, Quebec City, PQ, Canada; [Vrolyk, Vanessa; Benoit-Biancamano, Marie-Odile] Univ Montreal, Fac Vet Med, Dept Pathol & Microbiol, 3200 Sicotte,Pavillon CDEVQ,Off 1-34, St Hyacinthe, PQ J2S 2M2, Canada; [Sloboda, Deborah M.] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Dept Biochem & Biomed Sci, Obstet & Gynecol & Pediat, Hamilton, ON, Canada; [Haruna, Julius] CiToxLAB North Amer, Laval, PQ, Canada	Benoit-Biancamano, MO (reprint author), Univ Montreal, Fac Vet Med, Dept Pathol & Microbiol, 3200 Sicotte,Pavillon CDEVQ,Off 1-34, St Hyacinthe, PQ J2S 2M2, Canada.	marie-odile.benoit-biancamano@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was financed by the Canadian Institutes of Health Research.	BURRI PH, 1992, ANAT REC, V234, P399, DOI 10.1002/ar.1092340310; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cline JM, 2014, TOXICOL PATHOL, V42, P339, DOI 10.1177/0192623313482207; Dodge AH, 1997, MICROSC RES TECHNIQ, V39, P205, DOI 10.1002/(SICI)1097-0029(19971101)39:3<205::AID-JEMT1>3.0.CO;2-J; Fonseca BM, 2012, REPROD BIOL, V12, P97, DOI 10.1016/S1642-431X(12)60080-1; Furukawa S, 2011, J TOXICOL PATHOL, V24, P95, DOI 10.1293/tox.24.95; Marcela SG, 2012, ANAT REC, V295, P1267, DOI 10.1002/ar.22508; Hu D, 2010, INT J DEV BIOL, V54, P341, DOI 10.1387/ijdb.082768dh; Pepling ME, 2006, GENESIS, V44, P622, DOI 10.1002/dvg.20258; ROWSELL HC, 1991, CAN J VET RES, V55, P205; Russo P, 2011, COLOR ATLAS FETAL NE, P67; Swartley OM, 2016, TOXICOL PATHOL, V44, P705, DOI 10.1177/0192623316630836; Van Cruchten S, 2017, BIRTH DEFECTS RES, V109, P1540, DOI 10.1002/bdr2.1100; Vrolyk V, 2018, VET PATHOL, V55, P310, DOI 10.1177/0300985817738098; Wilson JG, 1965, TERATOLOGY PRINCIPLE, P251; Wooding P, 2008, COMP PLACENTATION ST, P185	16	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					158	168		10.1177/0192623318755135			11	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400006	29400254	Bronze			2019-10-28	
J	Balakrishnan-nair, DK; Nair, ND; Venugopal, SK; Das, VN; George, S; Abraham, MJ; Eassow, S; Alison, MR; Sainulabdeen, A; Anilkumar, TV				Balakrishnan-nair, Dhanush Krishna; Nair, Narayanan Divakaran; Venugopal, Syam Kunnekkattu; Das, Vijayan Narayana; George, Sisilamma; Abraham, Mammen John; Eassow, Saji; Alison, Malcolm Ronald; Sainulabdeen, Anoop; Anilkumar, Thapasimuthu Vijayamma			An Immunopathological Evaluation of the Porcine Cholecyst Matrix as a Muscle Repair Graft in a Male Rat Abdominal Wall Defect Model	TOXICOLOGIC PATHOLOGY			English	Article						biomaterials; safety assessment; immunopathology; irritancy scores; biocompatibility	INTESTINE SUBMUCOSA IMPLANTS; EXTRACELLULAR-MATRIX; MACROPHAGE PHENOTYPE; HOST RESPONSE; SCAFFOLD; BIOMATERIAL; REGENERATION; EFFICACY; COLLAGEN; JEJUNUM	With the increasing use of animal-based biomaterials for regenerative medical applications, the need for their safety assessment is paramount. A porcine cholecyst-derived scaffold (CDS), intended as a muscle repair graft, prepared by a nondetergent/enzymatic method was engrafted in a rat abdominal wall defect model. Host tissue-scaffold interface samples were collected 2, 8, and 16 weeks postimplantation and evaluated by histopathology, immunohistochemistry, and electron microscopy. The nature of the tissue reaction was compared with those induced by a jejunum-derived scaffold (JDS) prepared by the same method and a commercial-grade small intestinal submucosa (CSIS) scaffold. A study of the immunopathological response in major lymphoid tissues and immunophenotyping for M1 and M2 macrophages was performed at the host tissue-scaffold interface. Further, irritancy scores for CDS and JDS were determined using CSIS as the reference material. Both CDS and JDS appeared to be potential biomaterials for muscle grafts, but the former stimulated a skeletal muscle tissue remodeling response predominated by M2 macrophages. The data support the notion that biomaterials with similar biocompatibility, based on local tissue response on implantation, may cause differential immunogenicity. Additionally, CDS compared to JDS and CSIS was found to be less immunotoxic.	[Balakrishnan-nair, Dhanush Krishna; Nair, Narayanan Divakaran; Das, Vijayan Narayana; Abraham, Mammen John] Kerala Vet & Anim Sci Univ, Coll Vet & Anim Sci, Dept Vet Pathol, Mannuthy, Kerala, India; [Venugopal, Syam Kunnekkattu; Sainulabdeen, Anoop] Kerala Vet & Anim Sci Univ, Coll Vet & Anim Sci, Dept Vet Surg & Radiol, Mannuthy, Kerala, India; [George, Sisilamma] Kerala Vet & Anim Sci Univ, Dept Vet Biochem, Coll Vet & Anim Sci, Mannuthy, Kerala, India; [Eassow, Saji] Meat Prod India Ltd, Edayar, India; [Alison, Malcolm Ronald] Univ London, Barts Canc Inst, Charterhouse Sq, London, England; [Anilkumar, Thapasimuthu Vijayamma] Sree Chitra Tirunal Inst Med Sci & Technol, Div Expt Pathol, Biomed Technol Wing, Thiruvananthapuram 695012, Kerala, India	Anilkumar, TV (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Div Expt Pathol, Biomed Technol Wing, Thiruvananthapuram 695012, Kerala, India.	tvanilkumar@sctimst.ac.in			Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India, Kerala (TRC) [8144]; Kerala State Council for Science Technology and Environment [1275/2014/KSCSTE]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Part of the research work was supported by Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695012, India, Kerala (TRC project No 8144) and Kerala State Council for Science Technology and Environment (No. 1275/2014/KSCSTE).	Alicuben ET, 2014, HERNIA, V18, P705, DOI 10.1007/s10029-013-1054-2; Allman AJ, 2001, TRANSPLANTATION, V71, P1631, DOI 10.1097/00007890-200106150-00024; Anderson J, 2011, SEMIN IMMUNOPATHOL, V33, P221, DOI 10.1007/s00281-011-0244-1; Anilkumar TV, 2014, J BIOMED MATER RES B, V102, P1506, DOI 10.1002/jbm.b.33131; [Anonymous], 2006, BIOL EV MED DEV 20; [Anonymous], 2007, BIOL EV MED DEV 6; [Anonymous], 2009, BIOL EV MED DEV 1; Atala A, 2009, CURR OPIN BIOTECH, V20, P575, DOI 10.1016/j.copbio.2009.10.003; Badylak S. F., 2015, ACTA BIOMATER, V23, P17, DOI DOI 10.1016/J.ACTBIO.2015.07.016; Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264; Badylak SF, 2016, SCIENCE, V352, P298, DOI 10.1126/science.aaf7587; Bancroft JD, 2008, THEORY PRACTICE HIST; Bejjani GK, 2007, J NEUROSURG, V106, P1028, DOI 10.3171/jns.2007.106.6.1028; Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031; Burugapalli K, 2008, OBES SURG, V18, P1418, DOI 10.1007/s11695-008-9518-7; Burugapalli K, 2007, BIOMACROMOLECULES, V8, P928, DOI 10.1021/bm061088x; Burugapalli K, 2014, MACROMOL BIOSCI, V14, P244, DOI 10.1002/mabi.201300195; Burugapalli K, 2009, J BIOMAT SCI-POLYM E, V20, P1049, DOI [10.1163/156856209X444411, 10.1163/156856209X4444111]; Chan JCY, 2008, BIOMACROMOLECULES, V9, P528, DOI 10.1021/bm701055k; Chapekar MS, 1996, J BIOMED MATER RES, V33, P199, DOI 10.1002/(SICI)1097-4636(199623)33:3<199::AID-JBM10>3.0.CO;2-C; Coburn JC, 2007, J BIOMED MATER RES A, V81A, P250, DOI 10.1002/jbm.a.30943; Cohen HC, 2013, AM J PATHOL, V182, P2180, DOI 10.1016/j.ajpath.2013.02.022; Corona BT, 2016, BIOMATERIALS, V104, P238, DOI 10.1016/j.biomaterials.2016.07.020; Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057; Dziki J, 2016, NPJ REGEN MED, V1, DOI 10.1038/npjregenmed.2016.8; Elmore SA, 2012, TOXICOL PATHOL, V40, P148, DOI 10.1177/0192623311427571; Faulk DM, 2014, BIOMATERIALS, V35, P8585, DOI 10.1016/j.biomaterials.2014.06.057; Gilbert TW, 2009, J SURG RES, V152, P135, DOI 10.1016/j.jss.2008.02.013; Ho KLV, 2004, J UROLOGY, V171, P268, DOI 10.1097/01.ju.0000098680.60020.32; John TT, 2008, UROLOGY, V72, P1036, DOI 10.1016/j.urology.2008.07.043; Kajbafzadeh AM, 2014, PEDIATR SURG INT, V30, P371, DOI 10.1007/s00383-014-3474-1; Kalota SJ, 2004, J UROLOGY, V172, P1349, DOI 10.1097/01.ju.0000137867.04413.38; Kehoe S, 2012, INJURY, V43, P553, DOI 10.1016/j.injury.2010.12.030; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Longo U. G., 2012, STEM CELLS INT, V2012; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Muhamed J, 2017, J BIOMED MATER RES B, V105, P489, DOI 10.1002/jbm.b.33567; Muhamed J, 2015, J BIOMED MATER RES B, V103, P1302, DOI 10.1002/jbm.b.33296; Muhamed J, 2015, TOXICOL PATHOL, V43, P536, DOI 10.1177/0192623314550722; Nair RS, 2017, COLLOID SURFACE B, V157, P130, DOI 10.1016/j.colsurfb.2017.05.056; Olingy CE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00477-1; Petter-Puchner A, 2007, SURG ENDOSC, V21, P830, DOI 10.1007/s00464-006-9158-8; Petter-Puchner AH, 2006, SURG ENDOSC, V20, P942, DOI 10.1007/s00464-005-0568-9; Reagan WJ, 2011, TOXICOL PATHOL, V39, P435, DOI 10.1177/0192623310396907; Revi D, 2016, J BIOMATER APPL, V30, P1036, DOI 10.1177/0885328215615759; Revi D, 2013, J TISSUE ENG, V4, DOI 10.1177/2041731413518060; Rice RD, 2010, AESTHET PLAST SURG, V34, P290, DOI 10.1007/s00266-009-9449-2; Sainulabdeen A., 2017, INDIAN J VET SURG, V37, P55; Schuh JCL, 2008, TOXICOL PATHOL, V36, P63, DOI 10.1177/0192623307309926; Shakya P, 2016, SCIENTIFICA, DOI 10.1155/2016/2638371; Sicari B, 2013, METHODS MOL BIOL, V1037, P3, DOI 10.1007/978-1-62703-505-7_1; Sicari BM, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.09.45; Soiderer EE, 2004, J SURG RES, V118, P161, DOI 10.1016/S0022-4804(03)00352-4; Swinehart IT, 2016, DEV DYNAM, V245, P351, DOI 10.1002/dvdy.24379; Thevenot PT, 2011, BIOMATERIALS, V32, P8394, DOI 10.1016/j.biomaterials.2011.07.084; Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Zheng F, 2004, AM J OBSTET GYNECOL, V191, P1961, DOI 10.1016/j.ajog.2004.01.091; Zheng MH, 2005, J BIOMED MATER RES B, V73B, P61, DOI 10.1002/jbm.b.30170	59	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					169	183		10.1177/0192623317752894			15	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400007	29334850	Bronze			2019-10-28	
J	Kovi, RC; Johnson, CS; Balbo, S; Hecht, SS; O'Sullivan, MG				Kovi, Ramesh C.; Johnson, Charles S.; Balbo, Silvia; Hecht, Stephen S.; O'Sullivan, M. Gerard			Metastasis to the F344 Rat Pancreas from Lung Cancer Induced by 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol, Constituents of Tobacco Products	TOXICOLOGIC PATHOLOGY			English	Article						NNK; NNAL; smokeless tobacco; rats; pulmonary tumors; pancreatic metastasis; SP-C; CC-10; CK-19	N-NITROSAMINES; RESPIRATORY-TRACT; EXOCRINE PANCREAS; CARCINOGENICITY; TUMORS; DIFFERENTIATION; MECHANISMS; EXPRESSION; BIOMARKERS; TOXICOLOGY	Lung cancer is the most common cause of cancer-related deaths in humans worldwide. There is strong evidence that the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) play an important role in carcinogenesis caused by tobacco products. NNK and racemic NNAL are reported to induce lung and pancreatic tumors in rats. The carcinogenicity in Fischer 344 rats of NNK, NNAL, and its enantiomers (R)-NNAL and (S)-NNAL has been studied recently, and all test compounds induced significant numbers of lung tumors. We report here the detailed histopathological and immunohistochemical characterization of these tumors and their aggressive nature as shown by their metastasis locally and to the pancreas. The spectrum of treatment-related histopathological findings comprised pulmonary alveolar/bronchiolar (A/B) epithelial hyperplasia, A/B adenomas, and A/B carcinomas. A/B carcinomas frequently exhibited local invasion/metastasis within the mediastinum and thoracic cavity and distant metastasis to the pancreas that was confirmed by immunohistochemistry using the lung-specific markers prosurfactant protein-C and club (Clara) cell-10. Our observation regarding metastasis to the pancreas was an important, and unexpected, finding in this study both for the experimental animal model and potential human relevance.	[Kovi, Ramesh C.; Johnson, Charles S.; O'Sullivan, M. Gerard] Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA; [Kovi, Ramesh C.; Johnson, Charles S.; Balbo, Silvia; Hecht, Stephen S.; O'Sullivan, M. Gerard] Univ Minnesota, Masonic Canc Ctr, St Paul, MN 55108 USA; [Kovi, Ramesh C.] NIEHS, Expt Pathol Labs Inc, Cellular & Mol Pathol Branch, POB 12233, Res Triangle Pk, NC 27709 USA	O'Sullivan, MG (reprint author), Univ Minnesota, Masonic Canc Ctr Comparat Pathol Shared Resource, Room 435C AnSci VetMed Bldg,1988 Fitch Ave, St Paul, MN 55108 USA.	gos@umn.edu			U.S. National Cancer Institute grant [CA-81301]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by U.S. National Cancer Institute grant (CA-81301).	Akopyan G, 2006, INT J ONCOL, V29, P745; Balbo S, 2014, CARCINOGENESIS, V35, P2798, DOI 10.1093/carcin/bgu204; BARRETT JC, 1993, ENVIRON HEALTH PERSP, V100, P9, DOI 10.2307/3431516; BELINSKY SA, 1990, CANCER RES, V50, P3772; Bonapasta SA, 2010, BREAST CARE, V5, P170, DOI 10.1159/000314249; Boorman G., 1990, PATHOLOGY FISCHER RA, P339; DIXON D, 1991, TOXICOL PATHOL, V19, P540; Elmore SA, 2016, TOXICOL PATHOL, V44, P502, DOI 10.1177/0192623316631844; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HECHT SS, 1980, CANCER RES, V40, P4144; Hecht SS, 2002, CANCER RES, V62, P129; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Hecht SS, 1997, CARCINOGENESIS, V18, P1851, DOI 10.1093/carcin/18.9.1851; Hecht SS, 2016, ACCOUNTS CHEM RES, V49, P106, DOI 10.1021/acs.accounts.5b00472; Howroyd P, 2009, TOXICOL PATHOL, V37, P351, DOI 10.1177/0192623309332988; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1; KASPER M, 1991, HISTOCHEMISTRY, V96, P271, DOI 10.1007/BF00271547; KOKKINAKIS DM, 1989, CARCINOGENESIS, V10, P699, DOI 10.1093/carcin/10.4.699; LIJINSKY W, 1982, CANCER LETT, V16, P281, DOI 10.1016/0304-3835(82)90008-8; Niess H, 2013, J SURG ONCOL, V107, P859, DOI 10.1002/jso.23333; REAL FX, 1993, INT J CANCER, V54, P720, DOI 10.1002/ijc.2910540503; Renne R, 2009, TOXICOL PATHOL, V37, p5S, DOI 10.1177/0192623309353423; RIVENSON A, 1991, CRIT REV TOXICOL, V21, P255, DOI 10.3109/10408449109017913; RIVENSON A, 1988, CANCER RES, V48, P6912; Roethig HJ, 2009, NICOTINE TOB RES, V11, P1216, DOI 10.1093/ntr/ntp126; ROLAND CF, 1989, SURG GYNECOL OBSTET, V168, P345; Schlage WK, 1998, TOXICOL PATHOL, V26, P324, DOI 10.1177/019262339802600307; SCHULLER HM, 1994, J CANCER RES CLIN, V120, P200, DOI 10.1007/BF01372556; Showalter SL, 2008, SEMIN ONCOL, V35, P160, DOI 10.1053/j.seminoncol.2007.12.008; STANKARD CE, 1992, AM J GASTROENTEROL, V87, P1658; Stewart B, 2014, WORLD CANC REPORT; US Cancer Statistics Working Group, 2013, US CANC STAT WORK GR; Xia Y, 2011, BIOMARKERS, V16, P112, DOI 10.3109/1354750X.2010.533288; Z'graggen K, 1998, ARCH SURG-CHICAGO, V133, P413, DOI 10.1001/archsurg.133.4.413	34	0	0	4	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					184	192		10.1177/0192623317751573			9	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400008	29390940	Bronze, Green Accepted			2019-10-28	
J	Sayama, A; Okado, K; Nakamura, K; Kawaguchi, T; Iguchi, T; Makino, T; Yabe, K; Kai, K; Mori, K				Sayama, Ayako; Okado, Keiko; Nakamura, Koichi; Kawaguchi, Tatsuya; Iguchi, Takuma; Makino, Toshihiko; Yabe, Koichi; Kai, Kiyonori; Mori, Kazuhiko			UNC569-induced Morphological Changes in Pigment Epithelia and Photoreceptor Cells in the Retina through MerTK Inhibition in Mice	TOXICOLOGIC PATHOLOGY			English	Article						retina; MerTK; MerTK inhibitor; retinal pigment epithelium; phagocytosis; photoreceptor cells; miRNAs	OUTER SEGMENTS; RAT; PHAGOCYTOSIS; MICRORNAS; TOXICITY; BIOMARKERS; DYSTROPHY; INTEGRIN; RENEWAL; BINDING	Mer proto-oncogene tyrosine kinase (MerTK), which is expressed in the retinal pigment epithelium (RPE), regulates phagocytosis of shed photoreceptor outer segments (POS). To investigate the effects of drug-induced MerTK inhibition on the retina, UNC569, a specific MerTK inhibitor, was orally administered to male mice at a concentration of 60, 100, or 150 mg/kg for up to 14 days. Furthermore, MerTK inhibition in the retinal tissue sample was examined using a phosphorylation assay following a single dose of UNC569 at 100 mg/kg. In electron microscopic examination, UNC569 at 100 mg/kg or more increased phagosomes and phagolysosomes in the RPE. In addition, UNC569 at 150 mg/kg increased chromatin-condensed nuclei in the outer nuclear layer, indicating the early phase of apoptosis of photoreceptor cells. MiR-183, miR-96, and miR-124, which are enriched in photoreceptor cells, were elevated in the plasma of mice following treatment of 150-mg/kg UNC569, in conjunction with the photoreceptor lesion. Additionally, 100-mg/kg UNC569 inhibited MerTK phosphorylation in the retina. These results suggest that MerTK inhibition impaired phagocytic function of the retina, leading to accumulation of shed POS within the POS layer and increasing phagosomes and phagolysosomes in the RPE to delay POS renewal, resulting in apoptosis of photoreceptor cells.	[Sayama, Ayako; Iguchi, Takuma; Makino, Toshihiko; Yabe, Koichi; Kai, Kiyonori; Mori, Kazuhiko] Daiichi Sankyo Co Ltd, Med Safety Res Labs, Tokyo, Japan; [Okado, Keiko; Kawaguchi, Tatsuya] Daiichi Sankyo RD Novare Co Ltd, Discovery Sci & Technol Dept, Tokyo, Japan; [Nakamura, Koichi] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan	Sayama, A (reprint author), Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan.	sayama.ayako.wh@daiichisankyo.co.jp					BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462; Chen YY, 2014, EXP EYE RES, V121, P102, DOI 10.1016/j.exer.2013.12.019; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; Fielden MR, 2015, TOXICOL PATHOL, V43, P581, DOI 10.1177/0192623314553804; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Hall MO, 2005, EXP EYE RES, V81, P581, DOI 10.1016/j.exer.2005.03.017; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; ISHIKAWA T, 1970, Journal of Electron Microscopy, V19, P85; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; LaVail M M, 2001, Prog Brain Res, V131, P617; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LAVAIL MM, 1973, J CELL BIOL, V58, P650, DOI 10.1083/jcb.58.3.650; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Liu J, 2012, ACS MED CHEM LETT, V3, P129, DOI 10.1021/ml200239k; Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248; Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199; Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328; Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447; Peng QH, 2016, TOXICOL SCI, V152, P273, DOI 10.1093/toxsci/kfw085; Peng QH, 2014, J APPL TOXICOL, V34, P695, DOI 10.1002/jat.2930; Ryan D, 2006, MOL VIS, V12, P1175; Sakurai K, 2016, J APPL TOXICOL, V36, P1614, DOI 10.1002/jat.3326; Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; Shimoda K, 1999, TOXICOL LETT, V105, P9, DOI 10.1016/S0378-4274(98)00378-6; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Strauss O, 2016, EUR J PHARMACOL, V787, P84, DOI 10.1016/j.ejphar.2016.03.066; YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61	32	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					193	201		10.1177/0192623317749469			9	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400009	29310530	Bronze			2019-10-28	
J	Lenz, B; Braendli-Baiocco, A; Engelhardt, J; Fant, P; Fischer, H; Francke, S; Fukuda, R; Groters, S; Harada, T; Harleman, H; Kaufmann, W; Kustermann, S; Nolte, T; Palazzi, X; Pohlmeyer-Esch, G; Popp, A; Romeike, A; Schulte, A; Lima, BS; Tomlinson, L; Willard, J; Wood, CE; Yoshida, M				Lenz, B.; Braendli-Baiocco, A.; Engelhardt, J.; Fant, P.; Fischer, H.; Francke, S.; Fukuda, R.; Groeters, S.; Harada, T.; Harleman, H.; Kaufmann, W.; Kustermann, S.; Nolte, T.; Palazzi, X.; Pohlmeyer-Esch, G.; Popp, A.; Romeike, A.; Schulte, A.; Lima, B. Silva; Tomlinson, L.; Willard, J.; Wood, C. E.; Yoshida, M.			Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop	TOXICOLOGIC PATHOLOGY			English	Article						adversity; lysosomal accumulation; hazard; risk-benefit; risk assessment; phospholipidosis; PEGylated; antisense oligonucleotides; alpha-2u globulin; iron; lipofuscin	DRUG-INDUCED PHOSPHOLIPIDOSIS; HOST-RESISTANCE MODELS; ANTISENSE OLIGONUCLEOTIDES; CELL-DEATH; AUTOPHAGY; TRAFFICKING; METABOLISM; MOLECULES; PROTEINS; SYSTEM	Lysosomes have a central role in cellular catabolism, trafficking, and processing of foreign particles. Accumulation of endogenous and exogenous materials in lysosomes represents a common finding in nonclinical toxicity studies. Histologically, these accumulations often lack distinctive features indicative of lysosomal or cellular dysfunction, making it difficult to consistently interpret and assign adverse dose levels. To help address this issue, the European Society of Toxicologic Pathology organized a workshop where representative types of lysosomal accumulation induced by pharmaceuticals and environmental chemicals were presented and discussed. The expert working group agreed that the diversity of lysosomal accumulations requires a case-by-case weight-of-evidence approach and outlined several factors to consider in the adversity assessment, including location and type of cell affected, lysosomal contents, severity of the accumulation, and related pathological effects as evidence of cellular or organ dysfunction. Lysosomal accumulations associated with cytotoxicity, inflammation, or fibrosis were generally considered to be adverse, while those found in isolation (without morphologic or functional consequences) were not. Workshop examples highlighted the importance of thoroughly characterizing the biological context of lysosomal effects, including mechanistic data and functional in vitro readouts if available. The information provided here should facilitate greater consistency and transparency in the interpretation of lysosomal effects.	[Lenz, B.; Braendli-Baiocco, A.; Fischer, H.; Kustermann, S.] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Grenzacherstr 124,Bldg 73-307, CH-4070 Basel, Switzerland; [Engelhardt, J.] Ionis Pharmaceut Inc, Carlsbad, CA USA; [Fant, P.] Charles River Labs, Lyon, France; [Francke, S.] US FDA, CFSAN, College Pk, MD USA; [Fukuda, R.] Axcelead Drug Discovery Partners Inc, Fujisawa, Kanagawa, Japan; [Groeters, S.] BASF SE, Dept Expt Toxicol & Ecol, Ludwigshafen, Germany; [Harada, T.] Inst Environm Toxicol, Ibaraki, Japan; [Harleman, H.] Fresenius Kabi Deutschland GmbH, Global Med Clin & Regulatory Affairs, Global Preclin Dev & Management, Bad Homburg, Germany; [Kaufmann, W.] Merck, Darmstadt, Germany; [Nolte, T.; Pohlmeyer-Esch, G.] Boehringer Ingelheim Pharma GmbH & Co KG, Nonclin Drug Safety Germany, Biberach, Germany; [Palazzi, X.; Tomlinson, L.] Pfizer WRD, Global Pathol, DSRD, Groton, CT USA; [Popp, A.] AbbVie, Global Preclin Safety, Ludwigshafen, Germany; [Romeike, A.] Covance Labs Inc, Rueil Malmaison, France; [Schulte, A.] German Fed Inst Risk Assessment, Dept Chem & Prod Safety, Berlin, Germany; [Lima, B. Silva] Univ Lisbon, Dept Pharmacol Sci, Fac Pharm, Lisbon, Portugal; [Willard, J.] US FDA, CDER, Silver Spring, MD USA; [Wood, C. E.] US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA; [Yoshida, M.] Food Safety Commiss, Cabinet Off, Tokyo, Japan	Lenz, B (reprint author), F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Grenzacherstr 124,Bldg 73-307, CH-4070 Basel, Switzerland.	barbara.lenz@roche.com					Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022; BAINTON DF, 1981, J CELL BIOL, V91, pS66, DOI 10.1083/jcb.91.3.66s; Balogh GT, 2013, EUR J PHARM SCI, V49, P81, DOI 10.1016/j.ejps.2013.02.005; Baumann A, 2014, DRUG DISCOV TODAY, V19, P1623, DOI 10.1016/j.drudis.2014.06.002; Begriche K, 2011, J HEPATOL, V54, P773, DOI 10.1016/j.jhep.2010.11.006; Bellettato CM, 2010, J INHERIT METAB DIS, V33, P347, DOI 10.1007/s10545-010-9075-9; Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1006/toxs.1997.2396; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Braendli-Baiocco A, 2017, TOXICOL SCI, V157, P112, DOI 10.1093/toxsci/kfx025; Burleson GR, 2008, J IMMUNOTOXICOL, V5, P23, DOI 10.1080/15476910801897557; Carver Michael P, 2016, J Neuromuscul Dis, V3, P381; Cattley R. C., 2013, TOXICOL PATHOL, P313; Cesta MF, 2013, TOXICOL PATHOL, V41, P1068, DOI 10.1177/0192623313482057; Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963; Drevets D. A., 2015, CURR PROTOC IMMUNOL, V109; Drevets Douglas A, 2015, Curr Protoc Immunol, V109, DOI 10.1002/0471142735.im1406s109; Engelhardt JA, 2016, NUCLEIC ACID THER, V26, P199, DOI 10.1089/nat.2015.0598; Engelhardt JA, 2015, TOXICOL PATHOL, V43, P935, DOI 10.1177/0192623315570341; *EPA, 1991, EPA625391019F; Fischer H, 2000, CHIMIA, V54, P640; Fischer H., 2000, 13 EUR S QSAR PROUS, P286; Fischer H, 2012, J MED CHEM, V55, P126, DOI 10.1021/jm201082a; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Goracci L, 2013, J CHEM INF MODEL, V53, P1436, DOI 10.1021/ci400113t; Halliwell WH, 1997, TOXICOL PATHOL, V25, P53, DOI 10.1177/019262339702500111; HARD GC, 1993, ENVIRON HEALTH PERSP, V99, P313, DOI 10.2307/3431508; Harnett MM, 2017, BIOMED J, V40, P9, DOI 10.1016/j.bj.2016.12.004; Haschek WM, 2010, FUNDAMENTALS OF TOXICOLOGIC PATHOLOGY, 2ND EDITION, P1; Henry S. P., 2008, ANTISENSE DRUG TECHN, V2, P327; Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006; Ikeda K, 2008, BIOCHEM BIOPH RES CO, V377, P268, DOI 10.1016/j.bbrc.2008.09.121; Ivens IA, 2015, TOXICOL PATHOL, V43, P959, DOI 10.1177/0192623315591171; Jiang HB, 2017, CHEM COMMUN, V53, P1506, DOI 10.1039/c6cc08549k; Juliano RL, 2015, ADV DRUG DELIVER REV, V87, P35, DOI 10.1016/j.addr.2015.04.005; Kerlin R, 2016, TOXICOL PATHOL, V44, P147, DOI 10.1177/0192623315623265; Khoh-Reiter S, 2015, TOXICOL SCI, V145, P383, DOI 10.1093/toxsci/kfv059; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Kruhlak NL, 2008, TOXICOL MECH METHOD, V18, P217, DOI 10.1080/15376510701857262; Kumar V., 2015, ROBBINS COTRAN PATHO, P64; Kurz T, 2011, INT J BIOCHEM CELL B, V43, P1686, DOI 10.1016/j.biocel.2011.08.016; LEBREC H, 1994, TOXICOLOGY, V91, P179, DOI 10.1016/0300-483X(94)90143-0; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008; Logan R, 2012, EXPERT OPIN DRUG MET, V8, P943, DOI 10.1517/17425255.2012.691165; Lowe R, 2010, MOL PHARMACEUT, V7, P1708, DOI 10.1021/mp100103e; Lullmann H, 1975, CRC Crit Rev Toxicol, V4, P185; LullmannRauch R, 1996, PHARMACOL TOXICOL, V79, P109; Lundbaek JA, 2010, P NATL ACAD SCI USA, V107, P15427, DOI 10.1073/pnas.1007455107; Markovsky E, 2012, J CONTROL RELEASE, V161, P446, DOI 10.1016/j.jconrel.2011.12.021; National Toxicology Program, 2010, TECHNICAL REPORT SER, V557; Nonoyama T, 2008, J TOXICOL PATHOL, V21, P9, DOI 10.1293/tox.21.9; NOVIKOFF AB, 1976, P NATL ACAD SCI USA, V73, P2781, DOI 10.1073/pnas.73.8.2781; Palazzi X, 2016, TOXICOL PATHOL, V44, P810, DOI 10.1177/0192623316642527; Ploemen JPHTM, 2004, EXP TOXICOL PATHOL, V55, P347, DOI 10.1016/S0940-2993(04)70180-3; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; Reasor MJ, 2006, EXPERT OPIN DRUG SAF, V5, P567, DOI 10.1517/14740338.5.4.567; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Saito K, 2014, TOXICOL SCI, V141, P377, DOI 10.1093/toxsci/kfu132; Sawada H, 2005, TOXICOL SCI, V83, P282, DOI 10.1093/toxsci/kfh264; Stern ST, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-20; Sun HM, 2013, BIOORG MED CHEM LETT, V23, P4587, DOI 10.1016/j.bmcl.2013.06.034; Thompson KL, 2012, INT J TOXICOL, V31, P14, DOI 10.1177/1091581811430167; Tsukamoto S, 2008, SCIENCE, V321, P117, DOI 10.1126/science.1154822; Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015; Turk B, 2009, J BIOL CHEM, V284, P21783, DOI 10.1074/jbc.R109.023820; Willard J. W, 2010, 2010 M PHARM SCI CLI; Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649; Yano BL, 2002, TOXICOL SCI, V65, P288, DOI 10.1093/toxsci/65.2.288; Yu D., 2004, P AM ASSOC CANC RES, V45, pa644	74	2	3	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2018	46	2					224	246		10.1177/0192623317749452			23	Pathology; Toxicology	Pathology; Toxicology	GC7JM	WOS:000429969400011	29471779				2019-10-28	
J	Takaoka, RTC; Sertorio, ND; Magalini, LPJ; Dos Santos, LM; Souza, HR; Iyomasa-Pilon, MM; Possebon, L; Costa, SS; Girol, AP				Takaoka, Rodolfo T. C.; Sertorio, Nathalia D.; Magalini, Lara P. J.; Dos Santos, Leandro M.; Souza, Helena R.; Iyomasa-Pilon, Melina M.; Possebon, Lucas; Costa, Sara S.; Girol, Ana P.			Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias	PATHOLOGY RESEARCH AND PRACTICE			English	Article						ANXA1; FPR; Upper digestive tract; Tumors; Inflammation	CYCLOOXYGENASE-2 EXPRESSION; CANCER; ESOPHAGEAL; ADENOCARCINOMA; ASSOCIATION; SURVIVAL	The anti-inflammatory protein Annexin - A1 (ANXA1) is associated to tumor invasion process and its actions can be mediated by formylated peptides receptors (FPRs). Therefore, we evaluated the expression and correlation of ANXA1, FPR and cyclooxygenase - 2 (COX - 2) enzyme in esophageal and stomach inflammations and neoplasias. The study of proteins was performed by immunohistochemistry in biopsies of esophagitis, Barrett's esophagus, squamous cell carcinoma and adenocarcinoma of the esophagus, as well as gastritis, stomach polypus and gastric adenocarcinoma. The intensity of the expressions was evaluated by densitometry. The immunohistochemical and densitometric analyzes showed specificity for the FPR1 receptor and modulation of the ANXA1, COX - 2 and FPR1 expressions in the epithelial cells in the different studied conditions. Increased immunoreactivity of these proteins was observed in cases of inflammation and stomach polypus. Interestingly, moderate immunoreactivity for ANXA1 and FPR1 but increased immunolabeling for COX - 2 were observed in Barretis esophagus and esophageal adenocarcinomas. Also, there was reduced expression of ANXA1 and FPR1 in esophageal carcinoma but COX - 2 overexpression in this tumor. There was no expression of FPR2 but ANXA1 and FPR1 expressions were positively correlated in all clinical conditions studied. Positive correlation between ANXA1 and COX - 2 were also observed in inflammation conditions while negative correlation between ANXA1 and COX - 2 was observed in esophageal carcinoma. Our results demonstrate the unregulated expression of ANXA1 and COX - 2 in precursor lesions of esophageal and stomach cancers, reinforcing their involvement in gastroesophageal carcinogenesis. In addition, the data show that the actions of ANXA1 in the inflammatory and neoplastic processes of the esophagus and stomach are specifically mediated by the FPR1 receptor.	[Takaoka, Rodolfo T. C.; Sertorio, Nathalia D.; Magalini, Lara P. J.; Dos Santos, Leandro M.; Souza, Helena R.; Iyomasa-Pilon, Melina M.; Possebon, Lucas; Costa, Sara S.; Girol, Ana P.] Padre Albino Integrated Coll FIPA, Dept Phys & Biol Sci, Catanduva, SP, Brazil; [Possebon, Lucas; Girol, Ana P.] Sao Paulo State Univ, UNESP, Dept Biol, Lab Immunomorphol, Sao Jose Do Rio Preto, SP, Brazil	Girol, AP (reprint author), Integrated Coll Padre Albino Fdn FIPA, Dept Phys & Biol Sci, Rua Estudantes 225, Catanduva, SP, Brazil.	anapaulagirol@hotmail.com	Possebon, Lucas P/G-1132-2015	Possebon, Lucas P/0000-0002-7065-526X; Costa, Sara Souza/0000-0002-9359-5482			Lizarbe MA, 2013, INT J MOL SCI, V14, P2652, DOI 10.3390/ijms14022652; Boudhraa Z, 2016, CLIN SCI, V130, P205, DOI 10.1042/CS20150415; Buskens CJ, 2002, GASTROENTEROLOGY, V122, P1800, DOI 10.1053/gast.2002.33580; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Calabrese C, 2011, ALIMENT PHARM THER, V34, P982, DOI 10.1111/j.1365-2036.2011.04801.x; Cheng TY, 2014, ANTICANCER RES, V34, P2223; Cheng TY, 2012, CANCER-AM CANCER SOC, V118, P5757, DOI 10.1002/cncr.27565; DeNardo DG, 2008, CANCER CELL, V14, P7, DOI 10.1016/j.ccr.2008.06.010; France M, 2004, DIS ESOPHAGUS, V17, P136, DOI 10.1111/j.1442-2050.2004.00390.x; Gao YH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-316; Guo CM, 2013, FUTURE ONCOL, V9, P1773, DOI [10.2217/FON.13.114, 10.2217/fon.13.114]; Hafez NH, 2016, J EGYPT NATL CANCER, V28, P149, DOI 10.1016/j.jnci.2016.05.005; Han GH, 2014, INT J CLIN EXP PATHO, V7, P751; Hashimoto N, 2007, HEPATO-GASTROENTEROL, V54, P758; Hu N, 2004, CLIN CANCER RES, V10, P6013, DOI 10.1158/1078-0432.CCR-04-0317; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jorge YC, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/152860; Kanda M, 2016, WORLD J GASTROENTERO, V22, P6829, DOI 10.3748/wjg.v22.i30.6829; Kase S, 2004, PATHOBIOLOGY, V71, P84, DOI 10.1159/000074421; Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev; Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256; Martin GR, 2008, AM J PHYSIOL-GASTR L, V294, pG764, DOI 10.1152/ajpgi.00531.2007; Mussunoor S, 2008, J PATHOL, V216, P131, DOI 10.1002/path.2400; Ohno K., 2001, CANCER, V91, P1876; Paweletz CP, 2000, CANCER RES, V60, P6293; Perucci LO, 2017, EXPERT OPIN THER TAR, V21, P879, DOI 10.1080/14728222.2017.1364363; Sato Y, 2011, EXP THER MED, V2, P239, DOI 10.3892/etm.2011.210; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sun WH, 2004, WORLD J GASTROENTERO, V10, P2809; Rossi AFT, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/478138; Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209; Torres S, 2015, J CANCER EDUC, V30, P792, DOI 10.1007/s13187-015-0818-z; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Vong L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039244; Wang KL, 2006, CLIN CANCER RES, V12, P4598, DOI 10.1158/1078-0432.CCR-06-0483; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Yu GZ, 2008, CLIN EXP METASTAS, V25, P695, DOI 10.1007/s10585-008-9178-y; Zhang XY, 2017, ONCOL LETT, V13, P543, DOI 10.3892/ol.2016.5506; Zhang ZQ, 2013, WORLD J GASTROENTERO, V19, P7795, DOI 10.3748/wjg.v19.i43.7795	40	1	1	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					181	186		10.1016/j.prp.2017.12.003			6	Pathology	Pathology	GB5EL	WOS:000429085800001	29254791				2019-10-28	
J	Ilelis, F; do Amaral, NS; Alves, MR; da Costa, AABA; Calsavara, VF; Lordello, L; De Brot, L; Soares, FA; Rodrigues, IS; Rocha, RM				Ilelis, Felipe; do Amaral, Nayra Soares; Alves, Mariana Rezende; Balieiro Anastacio da Costa, Alexandre Andre; Calsavara, Vinicius Fernando; Lordello, Leonardo; De Brot, Louise; Soares, Fernando Augusto; Rodrigues, Iara Sant'Ana; Rocha, Rafael Malagoli			Prognostic value of GRIM-19, NF-kappa B and IKK2 in patients with high-grade serous ovarian cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Immunohistochemistry; Serous cystadenocarcinoma; Ovarian neoplasms; Platinum; Recurrence; Prognosis	EXPRESSION; RESISTANCE; BETA; ACTIVATION; INCREASES; DEATH; INHIBITION; PLATINUM; CELLS; CHEMORESISTANCE	Aims: High grade serous carcinoma (HGSC) is an aggressive tumour, and most patients relapse after treatment, acquiring resistance to platinum-based chemotherapy. One of the resistance mechanisms proposed is apoptosis evasion triggered by drug-related cytotoxic effect in the cell. In this context, this study aims to evaluate the protein expression of GRIM-19, NF-kappa B and IKK2, their association with chemotherapy response and to determine their prognostic values in HGSC. & para;& para;Methods: GRIM-19, NF-kappa B and IKK2 expression was evaluated by immunohistochemistry (IHC) in 71 patients with HGSC selected between 2003 and 2013, whose underwent primary debulking surgery with complete cytoreduction. Protein expression was analyzed in relation to platinum response groups, tumour progression, clinicopathological data and survival. & para;& para; Results: Positive IKK2 expression was related to resistance (p = 0.011), shorter disease-free survival (p = 0.001) and overall survival (p = 0.026) and was also a risk factor for relapse (p = 0.002) and death (p = 0.032). The association between IKK2 and NF-kappa B positivity predicted a subgroup with shorter overall survival (p = 0.004), disease-free survival (p = 0.003) and resistance to platinum-based chemotherapy (p = 0.036). NF-kappa B positivity was associated with worse overall survival (p = 0.005) and disease-free survival (p = 0.027) and was a positive predictor for relapse (p = 0.032) and death (p = 0.008). Higher expression of GRIM-19 was associated with higher disease-free survival (p = 0.039) and was a negative predictor for relapse (p = 0.046). & para;& para;Conclusions: GRIM-19 is a potential predictor of prognosis and disease recurrence in HGSC. IKK2 and NF-kappa B are related to poor prognosis and are potential predictors of response to platinum-based chemotherapy in HGSC. IHC analyses of GRIM19, IKK2 and NF-kappa B may be important in the attempt to provide prognostic values for relapse and response to treatment in patients with HGSC.	[Ilelis, Felipe; do Amaral, Nayra Soares; Alves, Mariana Rezende; Rodrigues, Iara Sant'Ana] AC Camargo Canc Ctr, Dept Invest Pathol, Lab Mol Morphol, Sao Paulo, SP, Brazil; [Balieiro Anastacio da Costa, Alexandre Andre] AC Camargo Canc Ctr, Dept Med Oncol, Sao Paulo, SP, Brazil; [Calsavara, Vinicius Fernando] AC Camargo Canc Ctr, Dept Epidemiol & Stat, Sao Paulo, SP, Brazil; [Lordello, Leonardo; De Brot, Louise; Soares, Fernando Augusto] AC Camargo Canc Ctr, Dept Anat Pathol, Sao Paulo, SP, Brazil; [Rocha, Rafael Malagoli] Univ Fed Sao Paulo, Dept Gynaecol, Lab Mol Gynaecol, Sao Paulo, SP, Brazil	Ilelis, F (reprint author), Prof Antonio Prudente St 211, BR-01509010 Sao Paulo, SP, Brazil.	felipe.ilelis1@gmail.com	Calsavara, Vinicius Fernando/G-9450-2016; ANDRADE, LOUISE/N-7669-2015	Calsavara, Vinicius Fernando/0000-0003-2332-5863; 	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Coordination for the Improvement of Higher Educational Personnel (CAPES)CAPES	We gratefully thank Sao Paulo Research Foundation (FAPESP) and Coordination for the Improvement of Higher Educational Personnel (CAPES) for financial support.	Aghajanian C, 2005, J CLIN ONCOL, V23, P5943, DOI 10.1200/JCO.2005.16.006; Alvarenga AW, 2013, J HISTOCHEM CYTOCHEM, V61, P272, DOI 10.1369/0022155413477661; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Annunziata CM, 2010, CANCER-AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190; Chang SJ, 2013, GYNECOL ONCOL, V130, P493, DOI 10.1016/j.ygyno.2013.05.040; Colombo PE, 2014, CRIT REV ONCOL HEMAT, V89, P207, DOI 10.1016/j.critrevonc.2013.08.017; Darb-Esfahani S, 2010, HISTOPATHOLOGY, V56, P727, DOI 10.1111/j.1365-2559.2010.03544.x; Davis A, 2014, GYNECOL ONCOL, V133, P624, DOI 10.1016/j.ygyno.2014.02.038; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Ebell MH, 2016, AM J PREV MED, V50, P384, DOI 10.1016/j.amepre.2015.09.023; Fan XY, 2012, MED ONCOL, V29, P3183, DOI 10.1007/s12032-012-0249-1; Gaikwad SM, 2015, INT J BIOCHEM CELL B, V61, P90, DOI 10.1016/j.biocel.2015.02.001; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Giopanou I, 2014, BIOMED RES INT, DOI 10.1155/2014/178410; Hao M, 2015, HUM PATHOL, V46, P1815, DOI 10.1016/j.humpath.2015.07.020; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Kalvakolanu DV, 2010, CYTOKINE, V52, P128, DOI 10.1016/j.cyto.2010.03.009; Kinose Y, 2015, MOL CANCER THER, V14, P909, DOI 10.1158/1535-7163.MCT-14-0696; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Prat J, 2015, J GYNECOL ONCOL, V26, P87, DOI 10.3802/jgo.2015.26.2.87; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Sakamoto K, 2013, ONCOGENE, V32, P1854, DOI 10.1038/onc.2012.192; Seo SI, 2009, APMIS, V117, P623, DOI 10.1111/j.1600-0463.2009.02506.x; Shishodia S, 2002, J BIOCHEM MOL BIOL, V35, P28; Shuang T, 2016, EXP MOL PATHOL, V100, P139, DOI 10.1016/j.yexmp.2015.11.030; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Singha B, 2015, ONCOTARGET, V6, P26347, DOI [10.18632/oncotarget.4713, 10.18632/oncotarget.4613]; Singha B, 2014, J BIOL CHEM, V289, P2687, DOI 10.1074/jbc.M113.502641; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Trillsch F, 2016, ANN ONCOL, V27, P1733, DOI 10.1093/annonc/mdw236; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Yaacoub K, 2016, CANCER LETT, V378, P150, DOI 10.1016/j.canlet.2016.05.012; Yang XK, 2004, J CANCER RES CLIN, V130, P423, DOI 10.1007/s00432-004-0556-9; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang W, 2015, MOL MED REP, V12, P2919, DOI 10.3892/mmr.2015.3757; Zhou Y, 2009, J INTERF CYTOK RES, V29, P695, DOI 10.1089/jir.2009.0003; Ziolkowska-Seta I, 2009, GYNECOL ONCOL, V112, P179, DOI 10.1016/j.ygyno.2008.09.008	38	2	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					187	194		10.1016/j.prp.2017.12.002			8	Pathology	Pathology	GB5EL	WOS:000429085800002	29254797				2019-10-28	
J	Yan, HB; Huang, JC; Chen, YR; Yao, JN; Cen, WN; Li, JY; Jiang, YF; Chen, G; Li, SH				Yan, Hai-biao; Huang, Jia-cheng; Chen, You-rong; Yao, Jian-ni; Cen, Wei-ning; Li, Jia-yi; Jiang, Yi-fan; Chen, Gang; Li, Sheng-hua			Role of miR-1 expression in clear cell renal cell carcinoma (ccRCC): A bioinformatics study based on GEO, ArrayExpress microarrays and TCGA Chao database	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MiR-1; Clear cell renal cell carcinoma; MicroRNA; Bioinformatics	SCREENING FEATURE GENES; CANCER GENOME ATLAS; LUNG-CANCER; TRANSCRIPTOME ANALYSIS; TARGETING TAGLN2; DOWN-REGULATION; BLADDER-CANCER; MICRORNA-1; CYCLE; IDENTIFICATION	Purpose: To investigate the clinical value and potential molecular mechanisms of miR-1 in clear cell renal cell carcinoma (ccRCC).& para;& para;Methods: We searched the Gene Expression Omnibus (GEO), ArrayExpress, several online publication databases and the Cancer Genome Atlas (TCGA). Continuous variable meta-analysis and diagnostic meta-analysis were conducted, both in Stata 14, to show the expression of miR-1 in ccRCC. Furthermore, we acquired the potential targets of miR-1 from datasets that transfected miR-1 into ccRCC cells, online prediction databases, differentially expressed genes from TCGA and literature. Subsequently bioinformatics analysis based on aforementioned selected target genes was conducted.& para;& para;Results: The combined effect was -0.92 with the 95% confidence interval (CI) of -1.08 to -0.77 based on fixed effect model (I-2 = 81.3%, P < 0.001). No publication bias was found in our investigation. Sensitivity analysis showed that GSE47582 and 2 TCGA studies might cause heterogeneity. After eliminating them, the combined effect was -0.47 (95%CI: -0.78, -0.16) with I-2 = 18.3%. As for the diagnostic meta-analysis, the combined sensitivity and specificity were 0.90 (95%CI: 0.61, 0.98) and 0.63 (95%CI: 0.39, 0.82). The area under the curve (AUC) in the summarized receiver operating characteristic (SROC) curve was 0.83 (95%CI: 0.80, 0.86). No publication bias was found (P = 0.15). We finally got 67 genes which were defined the promising target genes of miR-1 in ccRCC. The most three significant KEGG pathways based on the aforementioned genes were Complement and coagulation cascades, ECM-receptor interaction and Focal adhesion.& para;& para;Conclusion: The downregulation of miR-1 might play an important role in ccRCC by targeting its target genes.	[Yan, Hai-biao; Huang, Jia-cheng; Chen, You-rong; Yao, Jian-ni; Cen, Wei-ning; Li, Jia-yi; Jiang, Yi-fan; Li, Sheng-hua] Dept 1 Urol Surg, Nanning 530021, Guangxi Zhuang, Peoples R China; [Chen, Gang] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China	Li, SH (reprint author), Dept 1 Urol Surg, Nanning 530021, Guangxi Zhuang, Peoples R China.				Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi [KY2016LX034]	This study was supported by the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi (KY2016LX034); Meanwhile, we sincerely appreciated the public databases: GEO, Arrayxpress and TCGA.	Belevych AE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028324; Cai Y, 2015, INT J CLIN EXP MED, V8, P18004; Chang JTH, 2015, TRANSL RES, V166, P568, DOI 10.1016/j.trsl.2015.08.001; Chen LD, 2015, INT J CLIN EXP MED, V8, P12161; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Duan YH, 2016, INT J MOL MED, V38, P1450, DOI 10.3892/ijmm.2016.2761; Guo Y, 2017, METHODS MOL BIOL, V1627, P511, DOI 10.1007/978-1-4939-7113-8_31; Han C, 2017, BBA-GENE REGUL MECH, V1860, P227, DOI 10.1016/j.bbagrm.2016.12.004; Han C, 2014, BIOMED RES INT, DOI 10.1155/2014/428371; Hao LY, 2016, CELL PHYSIOL BIOCHEM, V38, P1267, DOI 10.1159/000443074; Jiang CM, 2015, INT J CLIN EXP MED, V8, P17321; Kawakami K, 2012, EUR J CANCER, V48, P827, DOI 10.1016/j.ejca.2011.06.030; Ke JT, 2016, SCI REP-UK, V6, DOI 10.1038/srep25194; Kim J, 2011, PATHOL INT, V61, P67, DOI 10.1111/j.1440-1827.2010.02615.x; Kolesnikov N, 2015, NUCLEIC ACIDS RES, V43, pD1113, DOI 10.1093/nar/gku1057; Kou YB, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S78974; Kumarswamy R, 2012, EUR HEART J, V33, P1067, DOI 10.1093/eurheartj/ehs043; Li Y, 2016, ONCOTARGET, V7, P81715, DOI 10.18632/oncotarget.13169; Liao JQ, 2016, AM J TRANSL RES, V8, P2438; Liu X, 2016, INT J ONCOL, V48, P243, DOI 10.3892/ijo.2015.3254; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Long GW, 2012, INT J BIOL SCI, V8, P811, DOI 10.7150/ijbs.4439; Mishima Y, 2007, CELL, V129, P247, DOI 10.1016/j.cell.2007.04.008; Mo W. B., 2017, MED RECAPITULATE, P2171; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Nohata N, 2012, ONCOTARGET, V3, P9; Nohata N, 2011, ONCOTARGET, V2, P29; Rao PK, 2010, FASEB J, V24, P3427, DOI 10.1096/fj.09-150698; Shao YJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1468, DOI 10.1159/000470649; Sun W, 2016, INT J MOL MED, V38, P466, DOI 10.3892/ijmm.2016.2657; Tominaga E, 2013, EXP CELL RES, V319, P77, DOI 10.1016/j.yexcr.2012.10.015; Wang DW, 2016, MED SCI MONITOR, V22, P2075, DOI 10.12659/MSM.898852; Wei W, 2017, AM J MED SCI, V353, P315, DOI 10.1016/j.amjms.2017.01.006; Wu SQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125087; Xiao HB, 2015, ONCOTARGET, V6, P13201, DOI 10.18632/oncotarget.3915; Yang L., 2014, J NEPHROL DIALYSIS T; Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23; Yoshino H, 2012, BIOCHEM BIOPH RES CO, V417, P588, DOI 10.1016/j.bbrc.2011.12.011; Zhang J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2928-3; Zhang K, 2016, ONCOTARGET, V7, P84178, DOI 10.18632/oncotarget.12390; Zhang ZG, 2016, MOL MED REP, V13, P5342, DOI 10.3892/mmr.2016.5188; Zhao Q, 2014, FUTURE ONCOL, V10, P49, DOI [10.2217/fon.13.242, 10.2217/FON.13.242]; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	43	2	2	1	9	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					195	206		10.1016/j.prp.2017.11.025			12	Pathology	Pathology	GB5EL	WOS:000429085800003	29258768				2019-10-28	
J	Worner, S; Mueller-Hermelink, HK; Voelker, HU				Woerner, Sonja; Mueller-Hermelink, Hans-Konrad; Voelker, Hans-Ullrich			Clinicopathologic features of adult EBV-associated B-cell lymphoproliferative disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						EBV; Lymphoproliferation; B-cell clonality; Outcome	EPSTEIN-BARR-VIRUS; INFECTIOUS-MONONUCLEOSIS; DISORDERS; PROLIFERATIONS; CLONALITY; GAMMA	In the present study, 21 cases of adult/late-onset EBV-associated lymphoproliferative disease (AELPD) with an uncertain malignant potential were investigated with regard to their histomorphology, immunophenotype, clonal rearrangement of the heavy chain (IgH) and T-cell receptor (TCR) genes and clinical course.& para;& para;The cases were histomorphologically reevaluated and assigned to one of three morphological groups: mononucleosis-like, Hodgkin-like, or polymorphous. In addition, cases with or without detectable necrosis were investigated for differences in clinical outcome.& para;& para;Overall survival was highest in the group with Hodgkin-like morphology (4/4 patients), followed by patients with mononucleosis-like phenotype (4/5 patients surviving). Cases with polymorphous morphology showed the poorest survival rates with 7/12 patients dead of disease (58%). 4/6 patients with histologically detectable necrosis died (66%), but only 4/15 patients without necrosis (27%). 11/21 cases with AELPD showed clonal rearrangement for IgH (n = 4), TCR (n = 5) or IgH + TCR (n = 2). 5/11 patients with clonal rearrangement died (45%), and this percentage was similar in all of the three subgroups.& para;& para;In conclusion, the present study shows that polymorphous morphology and detection of necrosis in AELPD are frequently linked to a fatal clinical course, whereas Hodgkin-like morphology seems to be associated with a more favourable prognosis. Clonal rearrangement of IgH or TCR is frequent in AELPD, but prognosis is unpredictable from this feature.	[Woerner, Sonja] Univ Wurzburg, Dept Pathol, Klinikum Konstanz, Wurzburg, Germany; [Mueller-Hermelink, Hans-Konrad] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Voelker, Hans-Ullrich] Univ Wurzburg, Dept Pathol, Leopoldina Krankenhaus Schweinfurt, Wurzburg, Germany	Voelker, HU (reprint author), Leopoldina Krankenhaus, Dept Pathol, Gustav Adolf Str 8, D-97422 Schweinfurt, Germany.	hvoelker@leopoldina.de					Ambrosio MR, 2015, AM J CLIN PATHOL, V144, P817, DOI 10.1309/AJCP2G0VKTKPNPRR; CHRISTENSSON B, 1987, SCAND J INFECT DIS, V19, P373, DOI 10.3109/00365548709018485; Cohen JI, 2009, ANN ONCOL, V20, P1472, DOI 10.1093/annonc/mdp064; Cohen JI, 2011, BLOOD, V117, P5835, DOI 10.1182/blood-2010-11-316745; GAILLARD F, 1992, AM J CLIN PATHOL, V98, P324, DOI 10.1093/ajcp/98.3.324; Ibrahim HAH, 2011, MODERN PATHOL, V24, P232, DOI 10.1038/modpathol.2010.186; Ichikawa A, 2013, EUR J HAEMATOL, V91, P20, DOI 10.1111/ejh.12116; Kim HJ, 2017, J PATHOL TRANSL MED, V51, P352, DOI 10.4132/jptm.2017.03.15; Kimura H, 2003, J INFECT DIS, V187, P527, DOI 10.1086/367988; Kojima M, 2007, PATHOL RES PRACT, V203, P587, DOI 10.1016/j.prp.2007.05.002; KORNSTEIN MJ, 1989, ARCH PATHOL LAB MED, V113, P481; Krafft AE, 1999, MOL DIAGN, V4, P119, DOI 10.1016/S1084-8592(99)80036-8; Malik UR, 1996, MED ONCOL, V13, P207, DOI 10.1007/BF02990933; Natkunam Y, 2017, AM J CLIN PATHOL, V147, P129, DOI 10.1093/ajcp/aqw214; Ok CY, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.82; Plumbley JA, 2002, J MOL DIAGN, V4, P37, DOI 10.1016/S1525-1578(10)60678-2; Quintanilla-Martinez L, 2000, BLOOD, V96, P443; Salama ME, 2008, PEDIATR DEVEL PATHOL, V11, P443, DOI 10.2350/07-12-0386.1; Sawada A, 2017, INT J HEMATOL, V105, P406, DOI 10.1007/s12185-017-2192-6; Schrager J., 2009, MOD PATHOL S1, V22, P285; Setsuda J, 1999, AM J PATHOL, V155, P257, DOI 10.1016/S0002-9440(10)65119-X; Wick MJ, 2002, AM J CLIN PATHOL, V117, P582, DOI 10.1309/B3WH-QWBY-YV61-CE46	22	0	0	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					207	212		10.1016/j.prp.2017.11.021			6	Pathology	Pathology	GB5EL	WOS:000429085800004	29258765				2019-10-28	
J	Roberto, GM; Engel, EE; Scrideli, CA; Tone, LG; Brassesco, MS				Roberto, Gabriela Molinari; Engel, Edgard Eduard; Scrideli, Carlos Alberto; Tone, Luiz Gonzaga; Brassesco, Maria Sol			Downregulation of miR-10B*is correlated with altered expression of mitotic kinases in osteosarcoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-10b*; Osteosarcoma; PLKs; BUBs	POLO-LIKE KINASE; KINETOCHORE LOCALIZATION; CELL-PROLIFERATION; CANCER; BUB1; OVEREXPRESSION; ANEUPLOIDY; APOPTOSIS; GROWTH; PLK3	Dysregulated mitotic kinases have frequently been associated with cancer. Changes in their expression might result from diverse mechanisms including avoidance of the tight regulation exerted by miRNAs. Herein we show that miR-10b* is downregulated in osteosarcoma samples and demonstrate its correlation with PLK1, PLK4, BUB1, and BUBR1, which are strongly intercorrelated. The selection of miRNAs that coordinately target and regulate multiple members of cancer-related pathways are particularly advantageous to tumors. Thus, even though no associations with clinical parameters were found, our data place miR-10b* as a tumor suppressor that might contribute to guarantee genomic stability, deserving further functional confirmation.	[Roberto, Gabriela Molinari] Univ Sao Paulo, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Sch Med, Ribeirao Preto, SP, Brazil; [Engel, Edgard Eduard] Univ Sao Paulo, Dept Paeditar, Ribeirao Preto Sch Med, Ribeirao Preto, SP, Brazil; [Scrideli, Carlos Alberto; Tone, Luiz Gonzaga] Univ Sao Paulo, Dept Med & Rehabil Locomotor Syst, Ribeirao Preto Sch Med, Ribeirao Preto, SP, Brazil; [Brassesco, Maria Sol] Univ Sao Paulo, Dept Biol, Fac Philosophy Sci & Letters Ribeirao Preto, Ribeirao Preto, SP, Brazil	Brassesco, MS (reprint author), Univ Sao Paulo, FFCLRP, Dept Biol, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.	solbrassesco@usp.br	Engel, Edgard Eduard/F-6835-2012; Brassesco, Maria S/D-3903-2012; Scrideli, Carlos A/D-7618-2012	Engel, Edgard Eduard/0000-0002-4047-2796; Brassesco, Maria S/0000-0003-4447-784X; Scrideli, Carlos A/0000-0001-6618-789X; Tone, Luiz Gonzaga/0000-0001-8821-4211	Fundacdo de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [<gn1> 2014/0877-3 </gn1>, <gn2> 2015/00524-5 </gn2>]	This study was supported by the Fundacdo de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant no. <GN1> 2014/0877-3 </GN1> and GMR fellow <GN2> 2015/00524-5 </GN2>.	Ando K, 2010, CANCER SCI, V101, P639, DOI 10.1111/j.1349-7006.2009.01457.x; Biagioni F, 2013, CELL CYCLE, V12, P2371, DOI 10.4161/cc.25380; Bogado RFE, 2015, ANTI-CANCER DRUG, V26, P56, DOI 10.1097/CAD.0000000000000157; Coley HM, 2012, ONCOTARGET, V3, P78; Conn CW, 2000, CANCER RES, V60, P6826; Helmke C, 2016, ONCOGENE, V35, P135, DOI 10.1038/onc.2015.105; Hu ZB, 2016, CANCER MED-US, V5, P74, DOI 10.1002/cam4.558; Jiang Shan, 2006, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V22, P29; Kazazian K., 2017, THESIS; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Li SS, 2013, MINI-REV MED CHEM, V13, P2014, DOI 10.2174/13895575113136660103; Lv HL, 2015, MOL MED REP, V12, P6789, DOI 10.3892/mmr.2015.4304; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Morales AG, 2013, CHILD NERV SYST, V29, P2241, DOI 10.1007/s00381-013-2175-8; Ou BC, 2016, CANCER LETT, V380, P457, DOI 10.1016/j.canlet.2016.07.004; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Sun L, 2015, MOL MED REP, V12, P4266, DOI 10.3892/mmr.2015.3958; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wang J, 2016, BIOMED PHARMACOTHER, V84, P947, DOI 10.1016/j.biopha.2016.09.108	21	5	5	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					213	216		10.1016/j.prp.2017.11.020			4	Pathology	Pathology	GB5EL	WOS:000429085800005	29254787				2019-10-28	
J	Li, H; Song, J; Niu, GC; Zhang, H; Guo, JB; Shih, DQ; Targan, SR; Zhang, XL				Li, Hui; Song, Jia; Niu, Guochao; Zhang, Hong; Guo, Jinbo; Shih, David Q.; Targan, Stephan R.; Zhang, Xiaolan			TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tumor necrosis factor (TNF)-like cytokine 1A (TL1A); Inflammatory bowel disease; Intestinal fibrosis; T cell transfer model	INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; TNFSF15 POLYMORPHISMS; TGF-BETA; IBD; EXPRESSION; SUSCEPTIBILITY	Tumor necrosis factor like cytokine 1A (TL1A) is a member of the TNF superfamily. Accumulating evidence demonstrated the importance of TL1A in the pathogenesis of inflammatory bowel disease (IBD) and suggested a potential role of TL1A blocking in IBD therapy. Here we aimed to explore whether the anti-TL1A antibody could ameliorate intestinal inflammation and fibrosis in IBD. A T cell transfer model of chronic colitis was induced by intraperitoneal injection of CD4(+) CD45RB(high) naive T cells isolated from either C57BL/6 wild type (WT) mice or LCK-CD2-Tl1a-GFP transgenic (L-Tg) mice into recombinase activating gene-1-deficient (RAG(-/-)) mice. The colitis model mice were treated prophylactically or therapeutically with anti-Tl1a antibody or IgG isotype control. Haematoxylin and eosin staining (H&E staining), Masson's trichrome staining (MT staining) and sirius red staining were used to detect histopathological changes in colonic tissue; immunohistochemical staining was used to detect the expressions of collagen I, collagen III, TIMP1, vimentin, alpha-SMA and TGF-beta 1/Smad3. Results showed that anti-Tl1a antibody could reduce intestinal inflammation and fibrosis by inhibiting the activation of intestinal fibroblasts and reducing the collagen synthesis in the T cell transfer model of chronic colitis. The mechanism may be related to the inhibition of TGF-1/Smad3 signaling pathway.	[Li, Hui; Song, Jia; Niu, Guochao; Zhang, Hong; Guo, Jinbo; Zhang, Xiaolan] Hebei Med Univ, Hosp 2, Dept Gastroenterol, Shijiazhuang 050035, Hebei, Peoples R China; [Shih, David Q.; Targan, Stephan R.] Cedars Sinai Med Ctr, F Widjaja Fdn, Inflammatory Bowel & Immunobiol Res Inst, Los Angeles, CA 90048 USA	Zhang, XL (reprint author), Yellow River Rd, Shijiazhuang 050035, Hebei, Peoples R China.	xiaolanzh@126.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81370501]; Projects of Science and Technology Department of Hebei Province [122077180D]; Natural Science Foundation of China from Hebei Province [H2014206446]	This work was supported by the Natural Science Foundation of China (Grant No. 81370501); Projects of Science and Technology Department of Hebei Province (Grant No. 122077180D); Natural Science Foundation of China from Hebei Province (Grant No. H2014206446).	Aiba Y, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/258164; Bamias G, 2003, J IMMUNOL, V171, P4868, DOI 10.4049/jimmunol.171.9.4868; Bernstein CN, 2010, INFLAMM BOWEL DIS, V16, P112, DOI 10.1002/ibd.21048; Burke JP, 2007, AM J GASTROENTEROL, V102, P439, DOI 10.1111/j.1572-0241.2006.01010.x; COOPER HS, 1993, LAB INVEST, V69, P238; De Salvo C, 2014, DIGEST DIS, V32, P26, DOI 10.1159/000367822; Feagan BG, 2008, GASTROENTEROLOGY, V135, P1493, DOI 10.1053/j.gastro.2008.07.069; Flier SN, 2010, J BIOL CHEM, V285, P20202, DOI 10.1074/jbc.M110.102012; Hansson T, 2002, SCAND J IMMUNOL, V56, P530, DOI 10.1046/j.1365-3083.2002.01157.x; Kakuta Y, 2006, GUT, V55, P1527, DOI 10.1136/gut.2006.100297; Louis E, 2009, DIGEST DIS, V27, P351, DOI 10.1159/000228573; Medina C, 2011, J PATHOL, V224, P461, DOI 10.1002/path.2870; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Meng XM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00082; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Owens BMJ, 2013, MUCOSAL IMMUNOL, V6, P224, DOI 10.1038/mi.2012.125; Picornell Y, 2007, INFLAMM BOWEL DIS, V13, P1333, DOI 10.1002/ibd.20223; Rieder F, 2009, NAT REV GASTRO HEPAT, V6, P228, DOI 10.1038/nrgastro.2009.31; Rieder F, 2008, J CROHNS COLITIS, V2, P279, DOI 10.1016/j.crohns.2008.05.009; Shih DQ, 2014, MUCOSAL IMMUNOL, V7, P1492, DOI 10.1038/mi.2014.37; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Takedatsu H, 2008, GASTROENTEROLOGY, V135, P552, DOI 10.1053/j.gastro.2008.04.037; Thiebaut R, 2009, AM J GASTROENTEROL, V104, P384, DOI 10.1038/ajg.2008.36; Wallace KL, 2014, WORLD J GASTROENTERO, V20, P6, DOI 10.3748/wjg.v20.i1.6; Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379; Zheng L, 2013, EUR J MICROBIOL IMMU, V3, P11, DOI 10.1556/EuJMI.3.2013.1.2	26	4	5	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					217	227		10.1016/j.prp.2017.11.017			11	Pathology	Pathology	GB5EL	WOS:000429085800006	29254800				2019-10-28	
J	Yu, N; Zhang, TG; Zhao, DH; Cao, Z; Du, J; Zhang, Q				Yu, Ning; Zhang, TingGuo; Zhao, DaHua; Cao, Zhang; Du, Jing; Zhang, Qian			CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						CIP2A; Endometrioid adenocarcinoma; Apoptosis; Proliferation; Invasion	C-MYC; CARCINOMA-CELLS; OVARIAN-CANCER; BREAST-CANCER; CYCLIN D1; EXPRESSION; SURVIVAL; PROGRESSION; BORTEZOMIB; AKT	Objective: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that stabilizes c-Myc and promotes cell proliferation and transformation. Here, we investigated the clinical significance and biological function of CIP2A in endometrial cancer.& para;& para;Method: CIP2A expression was assessed in normal endometrium, endometrial hyperplasia, endometrial atypical hyperplasia, and endometrioid adenocarcinoma tissues using immunohistochemistry, western blot, and RT-PCR. The effect of reduced CIP2A expression was assessed by siRNA knockdown in Ishikawa and An3ca endometrial cell lines. The roles of CIP2A in proliferation, apoptosis, and the cell cycle were assessed using CCK-8 assays, colony formation assays, and flow cytometry, respectively.& para;& para;Results: Our results show that CIP2A expression was higher in endometrioid adenocarcinoma tissues and cell lines. Furthermore, CIP2A siRNA significantly reduced the proliferation rate and invasion of Ishikawa and An3ca cells, and induced a significant level of apoptosis in Ishikawa cells. Moreover, CIP2A depletion resulted in reduced c-Myc and cyclin D1 protein levels, and increased caspase-3 expression.& para;& para;Conclusions: CIP2A is overexpressed in endometrioid adenocarcinoma and CIP2A promotes the malignant growth and invasion,decrease apoptosis in entometrioid adenocarcinoma cell lines. These results validate that CIP2A plays an important role in the carcinogenesis of endometrioid adenocarcinoma and establishes CIP2A as a clinically relevant oncoprotein and may presents a promising therapeutic target for cancer treatment.	[Yu, Ning; Zhang, TingGuo] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Yu, Ning; Zhao, DaHua] BinZhou Med Univ, Affiliated Hosp, Dept Pathol, Binzhou 256604, Peoples R China; [Cao, Zhang; Zhang, Qian] BinZhou Med Univ, Dept Pathol, Yantai 264003, Peoples R China; [Du, Jing] BinZhou Med Univ, Affiliated Hosp, Ctr Canc Res, Binzhou 256604, Peoples R China	Zhang, TG (reprint author), Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China.	yuning1981@163.com			Natural Science Foundation of Shandong Province, ChinaNatural Science Foundation of Shandong Province [ZR2016HL29]	This work was supported by the Natural Science Foundation of Shandong Province, China (no.ZR2016HL29).	Basile JR, 2010, CANCER BIOL THER, V10, P700, DOI 10.4161/cbt.10.7.13151; Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346; Bockelman C., 2010, CANCER BIOL THER, V13, P289; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chuan YC, 2010, ONCOGENE, V29, P1531, DOI 10.1038/onc.2009.442; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8; Fang YY, 2012, TUMOR BIOL, V33, P2299, DOI 10.1007/s13277-012-0492-2; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Howlader N, SEER CANC STAT REV 1; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kurman R.J., BLUESTEINS PATHOLOGY; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Lin YC, 2012, ORAL ONCOL, V48, P585, DOI 10.1016/j.oraloncology.2012.01.012; Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008-5472.CAN-09-0913; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Ratschiller D, 2003, J CLIN ONCOL, V21, P2085, DOI 10.1200/JCO.2003.03.103; Ren J, 2011, BRIT J CANCER, V105, P1905, DOI 10.1038/bjc.2011.492; Robanus-Maandag EC, 2003, J PATHOL, V201, P75, DOI 10.1002/path.1385; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166	28	4	4	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					233	239		10.1016/j.prp.2017.11.011			7	Pathology	Pathology	GB5EL	WOS:000429085800008	29274810				2019-10-28	
J	Jeong, JH; Kim, NY; Pyo, JS				Jeong, Jae Han; Kim, Nae Yu; Pyo, Jung-Soo			Prognostic roles of lymph node micrometastasis in non-small cell lung cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Non-small cell lung cancer; Lymph node micrometastasis; Prognosis; Meta-analysis	GENE DIAGNOSIS; TUMOR-CELLS; BONE-MARROW; SURVIVAL; IMPACT; ADENOCARCINOMA; METAANALYSIS; METASTASIS; RECURRENCE	Objective: This study aimed to confirm the prognostic roles of lymph node (LN) micrometastasis (LNMM) in non-small cell lung cancer (NSCLC) through a meta-analysis.& para;& para;Methods: This study included 2026 NSCLC cases without detection of LN metastasis in histologic examination. We investigated the detection rate of LNMM in early-stage NSCLC and analyzed the correlation between LNMM and the rates of recurrence and survival.& para;& para;Results: The range of detection rates of LNMM was 3.8-68.8% in the eligible studies. The detection rate of LNMM in early-stage NSCLC was 25.3% (95% confidence interval [CI] 19.8-31.6%). In subgroup analysis based on detection method, polymerase chain reaction method had higher detection rate than immunohistochemistry (33.7%, 95% CI 25.5-43.0% vs. 23.1%, 95% CI 18.0-29.0%). The presence of LNMM was significantly correlated with a higher recurrence rate (odds ratio 3.913, 95% CI 1.595-9.600, P = 0.003). In addition, there were significant correlations between LNMM and worse overall and disease-free survival rates (hazard ratio [HR] 2.345, 95% CI 1.863-2.951, and HR 1.606, 95% CI 1.170-2.206, respectively).& para;& para;Conclusion: Taken together, our results showed that LNMM was detected in 25.3% of NSCLCs without nodal disease through ancillary test. In addition, the presence of LNMM was significantly correlated with a higher recurrence rate and worse survival rates in early-stage NSCLC.	[Jeong, Jae Han] Chosun Univ, Chosun Univ Hosp, Dept Thorac & Cardiovasc surg, Sch Med, Gwangju, South Korea; [Kim, Nae Yu] Eulji Univ, Eulji Univ Hosp, Dept Internal Med, Sch Med, Daejeon, South Korea; [Pyo, Jung-Soo] Eulji Univ, Eulji Univ Hosp, Dept Pathol, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea; [Kim, Nae Yu; Pyo, Jung-Soo] Eulji Univ, Eulji Univ Hosp, Study Grp Metaanal, Sch Med, Daejeon, South Korea	Pyo, JS (reprint author), Eulji Univ, Eulji Univ Hosp, Dept Pathol, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea.	anapyojs@gmail.com			Chosun University	This study was supported by research funds from Chosun University, 2017.	Amin MB, 2016, AJCC CANC STAGING MA; Asamura H, 2008, J THORAC ONCOL, V3, P46, DOI 10.1097/JTO.0b013e31815e8577; Dai CH, 2013, TUMOR BIOL, V34, P1245, DOI 10.1007/s13277-013-0667-5; Deng XF, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0427-x; Dobashi K, 1997, J THORAC CARDIOV SUR, V114, P339, DOI 10.1016/S0022-5223(97)70178-8; Edge S. B., 2009, AJCC CANC STAGING MA; Goldstein NS, 2000, AM J SURG PATHOL, V24, P274, DOI 10.1097/00000478-200002000-00013; Gu CD, 2002, ANN SURG, V235, P133, DOI 10.1097/00000658-200201000-00017; Haaland B, 2014, J THORAC ONCOL, V9, P805, DOI 10.1097/JTO.0000000000000156; Izbicki JR, 1996, J THORAC CARDIOV SUR, V112, P623, DOI 10.1016/S0022-5223(96)70044-2; Kawano R, 2002, ANN THORAC SURG, V73, P1558, DOI 10.1016/S0003-4975(02)03398-2; Li J, 2013, CLIN TRANSL ONCOL, V15, P882, DOI 10.1007/s12094-013-1017-1; Li SH, 2008, WORLD J SURG, V32, P1651, DOI 10.1007/s00268-008-9560-6; Martin LW, 2016, J CLIN ONCOL, V34, P1484, DOI 10.1200/JCO.2015.63.4543; Nosotti M, 2005, CHEST, V128, P1539, DOI 10.1378/chest.128.3.1539; Osaki T, 2002, J CLIN ONCOL, V20, P2930, DOI 10.1200/JCO.2002.11.011; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Rena O, 2007, EUR J CARDIO-THORAC, V32, P863, DOI 10.1016/j.ejcts.2007.09.014; Roh MS, 2004, HISTOPATHOLOGY, V45, P580, DOI 10.1111/j.1365-2559.2004.01953.x; Rusch VW, 2011, J CLIN ONCOL, V29, P4313, DOI 10.1200/JCO.2011.35.2500; Travis WD, 2015, WHO CLASSIFICATION T; Wu J, 2001, ANN THORAC SURG, V71, P1772, DOI 10.1016/S0003-4975(01)02520-6; Yamashita T, 2010, LUNG CANCER, V70, P320, DOI 10.1016/j.lungcan.2010.02.013; Yasumoto K, 2003, ANN THORAC SURG, V76, P194, DOI 10.1016/S0003-4975(03)00130-9; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	25	2	2	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					240	244		10.1016/j.prp.2017.11.005			5	Pathology	Pathology	GB5EL	WOS:000429085800009	29129492				2019-10-28	
J	Gu, LG; Zhao, J; Zhang, SQ; Xu, WS; Ni, RZ; Liu, XJ				Gu, Liugen; Zhao, Juan; Zhang, Shiqing; Xu, Weisong; Ni, Runzhou; Liu, Xiaojuan			Runt-related transcription factor 2 (RUNX2) inhibits apoptosis of intestinal epithelial cells in Crohn's disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Crohn's disease; Intestinal epithelial cells; Apoptosis; Runx2; p53	INFLAMMATORY-BOWEL-DISEASE; COLITIS; P53; RESISTANCE; MICROBIOTA; BARRIER; STRESS; HEALTH; CANCER; MODEL	Apoptosis in intestinal epithelial cells (IECs) prevents the development of Crohn's disease (CD), a type of inflammatory bowel disease (IBD). Runt-related transcription factor 2 (Runx2) inhibits apoptosis in osteosarcoma-derived U2OS cells via down-regulating the transcriptional activity of p53. However, the expression and function of Runx2 in CD remain unclear. In this study, Runx2 protein levels were decreased in the intestinal epithelial cells (IECs) of CD patients and in a mouse 2, 4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model; in contrast, the expression levels of p53 and Bax, a p53-target gene, were increased. In a TNF-alpha-treated HT29 cell colitis model, the down-regulation of Runx2 was accompanied by the up-regulation of apoptotic markers, including cleaved caspase-3 and Bax. Furthermore, Runx2 overexpression effectively decreased TNF-alpha-induced Bax and cleaved caspase-3 expression levels. In conclusion, our data indicated that Runx2 might protect IECs from apoptosis in CD, thus revealing a novel molecular target for treating CD.	[Gu, Liugen] Nantong Univ, Affiliated Hosp 2, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Zhao, Juan; Zhang, Shiqing; Ni, Runzhou] Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Xu, Weisong] Secondary Peoples Hosp Nantong, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Liu, Xiaojuan] Nantong Univ, Dept Pathogen Biol, Nantong 226001, Jiangsu, Peoples R China	Ni, RZ (reprint author), Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.; Liu, XJ (reprint author), Nantong Univ, Dept Pathogen Biol, Nantong 226001, Jiangsu, Peoples R China.	nrz0513@sina.cn; lxj@ntu.edu.cn		ni, runzhou/0000-0001-8187-185X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81401365, 81300955]; Nantong Science and Technology Innovation Project [MS12015056, HS2013014, BK2012075, BK2011013]; 14th Six Talents Peak Project of Jiangsu Province [SWYY-058]; Priority Academic Program of Jiangsu Higher Education Institutions (PAPD)	This work was supported in part by the National Natural Science Foundation of China (Nos. 81401365 and 81300955); the Nantong Science and Technology Innovation Project (Nos. MS12015056, HS2013014, BK2012075 and BK2011013); and the 14th Six Talents Peak Project of Jiangsu Province (No. SWYY-058), a project funded by the Priority Academic Program of Jiangsu Higher Education Institutions (PAPD).	Alkim C, 2009, DIGEST DIS SCI, V54, P1979, DOI 10.1007/s10620-008-0554-x; Atreya R, 2015, NAT REV GASTRO HEPAT, V12, P67, DOI 10.1038/nrgastro.2014.201; Baczyk G, 2017, GASTROENTEROL REV, V12, P6, DOI 10.5114/pg.2016.64037; Bai JA, 2016, APOPTOSIS, V21, P1386, DOI 10.1007/s10495-016-1301-y; Bai JA, 2015, WORLD J GASTROENTERO, V21, P6180, DOI 10.3748/wjg.v21.i20.6180; Bai WX, 2017, BIOCHEM BIOPH RES CO, V485, P635, DOI 10.1016/j.bbrc.2017.02.034; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bianco AM, 2015, WORLD J GASTROENTERO, V21, P12296, DOI 10.3748/wjg.v21.i43.12296; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Browne G, 2012, BRIT J CANCER, V107, P1714, DOI 10.1038/bjc.2012.455; Cao SS, 2016, INFLAMM BOWEL DIS, V22, P984, DOI 10.1097/MIB.0000000000000660; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fumery Mathurin, 2014, Rev Prat, V64, P1210; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Hasler R., 2016, GUT, P1; Hirata Y, 2016, PHARMACOL RES, V113, P574, DOI 10.1016/j.phrs.2016.09.044; Hoivik ML, 2012, J CROHNS COLITIS, V6, P441, DOI 10.1016/j.crohns.2011.10.001; Hollenbach E, 2005, J BIOL CHEM, V280, P14981, DOI 10.1074/jbc.M500966200; Liu TJ, 2016, MOL MED REP, V13, P1156, DOI 10.3892/mmr.2015.4686; Malekzadeh MM, 2016, ARCH IRAN MED, V19, P2, DOI 0161901/AIM.003; Malki A, 2017, BIOORG CHEM, V72, P57, DOI 10.1016/j.bioorg.2017.03.010; Millar AD, 1996, GUT, V39, P407, DOI 10.1136/gut.39.3.407; Ozaki T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.127; Ozaki T, 2015, BIOMOLECULES, V5, P2854, DOI 10.3390/biom5042854; Sexton KA, 2017, INFLAMM BOWEL DIS, V23, P473, DOI 10.1097/MIB.0000000000001040; Sun SS, 2015, CANCER LETT, V361, P1, DOI 10.1016/j.canlet.2015.02.042; Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611; van der Deen M, 2013, J BIOL CHEM, V288, P21307, DOI 10.1074/jbc.M112.445890	28	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					245	252		10.1016/j.prp.2017.11.004			8	Pathology	Pathology	GB5EL	WOS:000429085800010	29129496				2019-10-28	
J	Ohashi, R; Yanagihara, K; Namimatsu, S; Sakatani, T; Takei, H; Naito, Z; Shimizu, A				Ohashi, Ryuji; Yanagihara, Keiko; Namimatsu, Shigeki; Sakatani, Takashi; Takei, Hiroyuki; Naito, Zenya; Shimizu, Akira			Osteoclast-like giant cells in invasive breast cancer predominantly possess M2-macrophage phenotype	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast carcinoma; Osteoclast-like giant cells; Macrophage phenotype	FINE-NEEDLE-ASPIRATION; MAMMARY-CARCINOMA; CRIBRIFORM CARCINOMA; MACROPHAGES; ACTIVATION; CYTOLOGY; THERAPY; LESIONS	Breast carcinoma with osteoclast-like giant cells (OGCs) is a rare tumor; however, their clinicopathological aspects remain unclear. We described the clinicopathological characteristics of 8 patients with breast carcinoma with OGCs. Immuno-phenotypes of the OGCs were comparatively examined with that of foreign body giant cells (FBGCs) in 4 cases of granulomatous reaction (GR) without cancerous elements. In most cancers, tumors displayed cribriform and tubular growth patterns. Three cases showed moderate to high nuclear grade, while all the other tumors had low nuclear grade. Six patients were estrogen receptor (ER) positive, while triple negative phenotype was identified in 2 patients. During the follow-up period, 1 patient had local recurrence of the tumor, and all the patients remained alive. All OGCs and FBGCs expressed CD68, a pan-macrophage marker. OGCs in all the breast cancers showed moderate to high expression of CD163 - a marker of M2-macrophage with protumoral function - whereas its expression in FBGCs was low to moderate (p = 0.04). CD86 - a marker of M1-macrophage with a tumoricidal activity - was positive in the OGCs of 3 breast cancers, and in the FBGCs of 3 GR cases (p = 0.15). The expression of CD163 was significantly higher than that of CD86 in the OGCs of breast cancer (p < 0.001), whereas they were comparable in the FBGCs of GR (p = 0.79). In summary, we found that breast carcinoma with OGCs mostly exhibited cribriform and tubular growth pattern, ER positivity, and predominantly possessed the M2-macrophage phenotype. However, the clinical significance of OGCs in breast cancer needs to be elucidated in further studies involving a larger number of cases.	[Ohashi, Ryuji; Namimatsu, Shigeki; Sakatani, Takashi; Naito, Zenya; Shimizu, Akira] Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan; [Yanagihara, Keiko; Takei, Hiroyuki] Nippon Med Coll Hosp, Dept Breast Surg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan; [Sakatani, Takashi; Naito, Zenya] Nippon Med Sch, Dept Integrated Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan; [Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan	Ohashi, R (reprint author), Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	r-ohashi@nms.ac.jp	Takei, Hiroyuki/AAB-1258-2019				AGNANTIS NT, 1979, AM J CLIN PATHOL, V72, P383; Cai GP, 2004, DIAGN CYTOPATHOL, V30, P396, DOI 10.1002/dc.20069; DEY P, 1993, CYTOPATHOLOGY, V4, P382, DOI 10.1111/j.1365-2303.1993.tb00119.x; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hernandez C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098458; HOLLAND R, 1984, CANCER, V53, P1963, DOI 10.1002/1097-0142(19840501)53:9<1963::AID-CNCR2820530927>3.0.CO;2-N; Jogai S, 2004, CYTOPATHOLOGY, V15, P334, DOI 10.1111/j.1365-2303.2004.00207.x; KOBAYASHI S, 1984, ACTA PATHOL JAPON, V34, P1475; Mantovani Alberto, 2004, Novartis Found Symp, V256, P137; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Ng WK, 2001, ACTA CYTOL, V45, P593, DOI 10.1159/000327870; PHILLIPSON J, 1994, ACTA CYTOL, V38, P479; Quinn JMW, 1998, J PATHOL, V184, P31, DOI 10.1002/(SICI)1096-9896(199801)184:1<31::AID-PATH962>3.0.CO;2-V; Rakha E, 2012, WHO CLASSIFICATION T, P43; Shishido-Hara Y, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-55; de Souza AWS, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1310-4; Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0; Takahashi T, 1998, ACTA CYTOL, V42, P734, DOI 10.1159/000331836; Tiainen S, 2015, HISTOPATHOLOGY, V66, P873, DOI 10.1111/his.12607; Tsuda H, 1998, JPN J CLIN ONCOL, V28, P486, DOI 10.1093/jjco/28.8.486; WARGOTZ ES, 1990, HUM PATHOL, V21, P1142, DOI 10.1016/0046-8177(90)90151-T; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Yamaguchi T, 2016, GASTRIC CANCER, V19, P1052, DOI 10.1007/s10120-015-0579-8; Zhou SL, 2014, VIRCHOWS ARCH, V464, P681, DOI 10.1007/s00428-014-1573-y	25	0	0	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					253	258		10.1016/j.prp.2017.11.002			6	Pathology	Pathology	GB5EL	WOS:000429085800011	29129494				2019-10-28	
J	Assad, DX; Borges, GA; Avelino, SR; Guerra, ENS				Assad, Daniele Xavier; Borges, Gabriel Alvares; Avelino, Samuel Ramalho; Silva Guerra, Eliete Neves			Additive cytotoxic effects of radiation and mTOR inhibitors in a cervical cancer cell line	PATHOLOGY RESEARCH AND PRACTICE			English	Article						mTOR; Cervical cancer; Radiotherapy; Apoptosis; Proliferation	MAMMALIAN TARGET; TEMSIROLIMUS; CARCINOMA; APOPTOSIS; SURVIVAL; BEVACIZUMAB; ACTIVATION; THERAPY; PATHWAY; CHEMOTHERAPY	The PI3 K/AKT/mTOR signaling pathway is frequently activated in HPV-positive cervical squamous cell cancer (CC). This study investigated the biological effects of mTOR inhibitors associated with radiotherapy in a CC cell line (HeLa). A human keratinocyte cell line (HaCaT) was used as control. Temsirolimus, everolimus, resveratrol, curcumin and epigallocatechin gallate (EGCG) were the mTOR inhibitors assessed. The 50% cell cytotoxicity rate (CC50) for each treatment was determined by MTT cell viability assay. Cells were pre-treated with mTOR inhibitors at CC50 followed by radiotherapy (RT) at 2 Gy. Cell death profile after treatment with temsirolimus, resveratrol and curcumin was assessed with flow cytometry. Everolimus, temsirolimus, EGCG, resveratrol and curcumin were cytotoxic to HeLa. Radiation induced a statistically significant (p < 0.01) supra-additive cytotoxic effect in the cervical cancer cell line when combined with mTOR inhibitors. After a 24-h treatment, EGCG and resveratrol were more cytotoxic to HeLa cells than to HaCaT cells. After 48 h of treatment, resveratrol, curcumin and everolimus were more cytotoxic to HeLa cells when compared to HaCaT cells. After 24 h, temsirolimus induced late apoptosis or necrosis in HeLa cells. Based on these data, new studies with mTOR inhibitors as treatment options for cervical cancer are recommended, mainly combined to radiotherapy.	[Assad, Daniele Xavier; Borges, Gabriel Alvares; Silva Guerra, Eliete Neves] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Campus Univ Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil; [Assad, Daniele Xavier] Hosp Sirio Libanes SGAS, 613 Conj E Bl B, BR-70200730 Brasilia, DF, Brazil; [Avelino, Samuel Ramalho] Univ Hosp Brasilia, Dept Radiat Oncol, SGAN 604-605, BR-70840901 Brasilia, DF, Brazil	Guerra, ENS (reprint author), SQN 205,Bloco H Apto 201, BR-70843080 Brasilia, DF, Brazil.	dxassad@gmail.com; gabriel_alvares_borges@hotmail.com; samuel.fismed@gmail.com; elieteneves@unb.br	GUERRA, ELIETE/E-1021-2016	GUERRA, ELIETE/0000-0002-7622-1550; Alvares Borges, Gabriel/0000-0002-6700-8782			Assad DX, 2016, ONCOL LETT, V12, P4107, DOI 10.3892/ol.2016.5157; Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162; CHANG F, 1990, J CLIN PATHOL, V43, P269, DOI 10.1136/jcp.43.4.269; Colombo N, 2012, ANN ONCOL, V23, P27, DOI 10.1093/annonc/mds268; Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825; Ekshyyan O, 2009, MOL CANCER THER, V8, P2255, DOI 10.1158/1535-7163.MCT-08-1184; Feng W, 2009, INT J CLIN EXP PATHO, V2, P249; Fouad MA, 2013, HUM EXP TOXICOL, V32, P1067, DOI 10.1177/0960327113475679; Garcia-Zepeda SP, 2013, EUR J CANCER PREV, V22, P577, DOI 10.1097/CEJ.0b013e328360345f; Hait WN, 2009, CANCER RES, V69, P1263, DOI 10.1158/0008-5472.CAN-08-3836; Helland A, 2000, INT J CANCER, V88, P217; Hellner K, 2011, J CLIN ONCOL, V29, P1785, DOI 10.1200/JCO.2010.28.2186; Horn D, 2015, EXPERT OPIN THER TAR, V19, P795, DOI 10.1517/14728222.2015.1012157; Ji J, 2010, GYNECOL ONCOL, V117, P103, DOI 10.1016/j.ygyno.2009.12.020; Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Moroney JW, 2011, CLIN CANCER RES, V17, P6840, DOI 10.1158/1078-0432.CCR-11-0666; Movva S, 2009, CANCER-AM CANCER SOC, V115, P3166, DOI 10.1002/cncr.24364; Murphy JD, 2009, CLIN CANCER RES, V15, P589, DOI 10.1158/1078-0432.CCR-08-1019; Nogueira-Rodrigues A, 2014, CANCER-AM CANCER SOC, V120, P1187, DOI 10.1002/cncr.28471; Ohara T, 2011, CANCER SCI, V102, P1344, DOI 10.1111/j.1349-7006.2011.01967.x; Piha-Paul SA, 2014, ONCOTARGET, V5, P1846, DOI 10.18632/oncotarget.1834; PIVER MS, 1988, AM J CLIN ONCOL-CANC, V11, P21, DOI 10.1097/00000421-198802000-00006; Rogers L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007583.pub2; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Serrano-Olvera A, 2015, EXPERT OPIN EMERG DR, V20, P165, DOI 10.1517/14728214.2015.1002768; Siegel R, 2013, CA-CANCER J CLIN, V2013, P63; Surviladze Z, 2013, J VIROL, V87, P2508, DOI 10.1128/JVI.02319-12; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Tinker AV, 2013, GYNECOL ONCOL, V130, P269, DOI 10.1016/j.ygyno.2013.05.008; Whitney CW, 1999, J CLIN ONCOL, V17, P1339, DOI 10.1200/JCO.1999.17.5.1339; Wu JH, 2013, CURR CANCER DRUG TAR, V13, P143, DOI 10.2174/1568009611313020004; Yokoyama M, 2004, GYNECOL ONCOL, V92, P197, DOI 10.1016/j.ygyno.2003.09.023; Zhang XY, 2008, EUR J OBSTET GYN R B, V139, P237, DOI 10.1016/j.ejogrb.2007.12.021; Zhou HY, 2010, ANTI-CANCER AGENT ME, V10, P571, DOI 10.2174/187152010793498663	35	2	2	0	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					259	262		10.1016/j.prp.2017.10.019			4	Pathology	Pathology	GB5EL	WOS:000429085800012	29103764				2019-10-28	
J	Wang, GH; Wu, PF; Zhang, LH; Fang, P; Chen, Y; Zuo, G; Wu, YQ; Wang, SH; Sun, GP				Wang, Gen-He; Wu, Peng-Fei; Zhang, Long-Hui; Fang, Ping; Chen, Yong; Zuo, Gang; Wu, Yi-Qing; Wang, Shu-Hong; Sun, Guo-Ping			Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Non-small-cell lung cancer; Thalidomide; EGFR-TKI; Acquired resistance; Erlotinib	CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; KINASE INHIBITORS; 1ST-LINE TREATMENT; OPEN-LABEL; T790M MUTATION; TUMOR-GROWTH; CHEMOTHERAPY; MULTICENTER; THERAPY	Evidences suggested that combined blockade of the VEGF and EGFR pathways can improve the treatment efficacy of non-small-cell lung cancer (NSCLC). In our previously clinical practice, we observed that thalidomide, a potent VEGF inhibitor, can significantly decrease the tumor size of one EGFR-TKI resistance patient with lung cancer cachexia. In this pilot study, we tried to assess the efficacy and toxicity of the combination therapy of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib. In all, 52 NSCLC patients with drug resistance to erlotinib were recruited and treated with this combination therapy. After treatment, 4 patients presented with partial remission (PR), 16 with stable disease (SD) and 32 with progressive disease (PD). The objective response rate (ORR) and disease control rate (DCR) was 7.7% and 38.5%, respectively. In this study, we firstly confirmed that thalidomide can reversion of erlotinib-acquired resistance with a 7 weeks median progression-free survival (PFS); besides, this combination therapy shows acceptable drug tolerance; the most common drug related adverse events were astriction, numbness and sleeve-like feeling in the limbs, no thrombosis occurred in any patient. Those evidences indicate that thalidomide may be a useful candidate for reversion of erlotinib-acquired resistance.	[Wang, Gen-He; Sun, Guo-Ping] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Anhui, Peoples R China; [Wang, Gen-He; Wu, Peng-Fei; Fang, Ping; Chen, Yong; Zuo, Gang; Wu, Yi-Qing; Wang, Shu-Hong] Huangshan City Peoples Hosp, Dept Oncol, Huangshan, Anhui, Peoples R China; [Zhang, Long-Hui] Huangshan City Peoples Hosp, Dept Resp Med, Huangshan, Anhui, Peoples R China	Sun, GP (reprint author), Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Anhui, Peoples R China.	gpsun_doc@163.com			Science and Technology Project, Huangshan City [2013KN-01]	This study is supported by Science and Technology Project, Huangshan City (Foundation No.2013KN-01).	Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bean J, 2008, CLIN CANCER RES, V14, P7519, DOI 10.1158/1078-0432.CCR-08-0151; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Johnson BE, 2013, J CLIN ONCOL, V31, P3926, DOI 10.1200/JCO.2012.47.3983; Liu Y, 2014, WSPOLCZESNA ONKOL, V18, P39, DOI 10.5114/wo.2014.40782; Lyu WW, 2016, CHINESE MED J-PEKING, V129, P320, DOI 10.4103/0366-6999.174497; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Noda S, 2016, EXPERT REV RESP MED, V10, P547, DOI 10.1586/17476348.2016.1164603; Park JS, 2017, J THORAC ONCOL, V12, pS1069; Park K, 2016, JAMA ONCOL, V2, P305, DOI 10.1001/jamaoncol.2015.4921; Patt YZ, 2005, CANCER, V103, P749, DOI 10.1002/cncr.20821; Pore N., 2006, CANC RES, V66; Rho JK, 2010, MOL CANCER THER, V9, P3233, DOI 10.1158/1535-7163.MCT-10-0625; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X; Stewart BW, 2014, WORLD CANC REPORT 20; Suda K, 2010, CLIN CANCER RES, V16, P5489, DOI 10.1158/1078-0432.CCR-10-1371; Vigeland C. L., 2016, INT J MED BIOL FRONT, V22, P19; Yamaguchi F, 2014, ONCOL LETT, V7, P357, DOI 10.3892/ol.2013.1705; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	21	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					263	267		10.1016/j.prp.2017.10.016			5	Pathology	Pathology	GB5EL	WOS:000429085800013	29108922				2019-10-28	
J	Ye, YH; Zhang, S; Chen, YP; Wang, XF; Wang, PC				Ye, Yuhong; Zhang, Sheng; Chen, Yupeng; Wang, Xingfu; Wang, Pengcheng			High ALDH1A1 expression indicates a poor prognosis in gastric neuroendocrine carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gastric neuroendocrine carcinoma; Aldehyde dehydrogenase 1A1; Cancer stem cells; Immunohistochemistry; Prognosis	CANCER STEM-CELLS; ALDEHYDE DEHYDROGENASE; RESISTANCE; TUMORS; MARKER	Objective: To evaluate the expression and prognostic significance of ALDH1A1 in gastric neuroendocrine carcinoma.& para;& para;Materials and methods: Immunohistochemical stains of ALDH1A1 were evaluated in 67 cases of gastric neuroendocrine carcinoma. The findings were correlated with clinicopathologic variables and overall survival.& para;& para;Results: Immunohistochemistry revealed positive cytoplasmic immunoreactivity in 35 of 67 (52.2%) tumors and strongly positive immunoreactivity in 14 of 67 (20.9%). Strongly positive ALDH1A1 expression, but not positive staining, was significantly associated with lymph node status, lymphovascular invasion, and ki-67 index (P = 0.039, 0.045, and 0.045, respectively). Kaplan-Meier survival curves and log-rank tests showed significantly poorer prognoses in cases of high ALDH1A1 expression compared to cases of low ALDH1A1 expression or the negative control group (MST, 17 vs. 52 months; P = 0.026). Multivariate analysis showed that high ALDH1A1 expression, lymph node metastasis, and lymphovascular invasion had significant associations with decreased overall survival (P = 0.029, 0.008, and 0.005, respectively).& para;& para;Conclusions: High ALDH1A1 expression may be a prognostic indicator of survival in patients with gastric neuroendocrine carcinoma.	[Ye, Yuhong; Zhang, Sheng; Chen, Yupeng; Wang, Xingfu; Wang, Pengcheng] Fujian Med Univ, Affiliated Hosp 1, Dept Pathol, Fuzhou 350005, Fujian, Peoples R China	Zhang, S (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Pathol, Fuzhou 350005, Fujian, Peoples R China.	zhgshg@126.com			Youth Scientific Research Project of the Fujian Provincial Health and Family Planning Commission, China [2014/2/20]	This work was funded by the Youth Scientific Research Project of the Fujian Provincial Health and Family Planning Commission, China (2014/2/20). We thank all patients, clinicians, and support staff who participated in this study.	Adhikari AS, 2011, FRONT BIOSCI-LANDMRK, V16, P1927, DOI 10.2741/3831; Ajani JA, 2014, MOL ONCOL, V8, P142, DOI 10.1016/j.molonc.2013.10.007; Avoranta ST, 2013, HUM PATHOL, V44, P966, DOI 10.1016/j.humpath.2012.10.003; Black William, 2009, Human Genomics, V4, P136; Bosman E.T., 2010, WHO CLASSIFICATION T; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Gao F, 2015, BIOCHEM BIOPH RES CO, V462, P91, DOI 10.1016/j.bbrc.2015.04.029; Garcia-Carbonero R, 2016, NEUROENDOCRINOLOGY, V103, P186, DOI 10.1159/000443172; Gaur P, 2011, GASTROENTEROLOGY, V141, P1728, DOI 10.1053/j.gastro.2011.07.037; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Kitamura H, 2013, MODERN PATHOL, V26, P117, DOI 10.1038/modpathol.2012.139; Leiros GJ, 2011, CURR PHARM BIOTECHNO, V12, P1909; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Sorbye H, 2014, CANCER-AM CANCER SOC, V120, P2814, DOI 10.1002/cncr.28721; Wakamatsu Y, 2012, PATHOL INT, V62, P112, DOI 10.1111/j.1440-1827.2011.02760.x; Xu N, 2015, CANCER EPIDEMIOL, V39, P375, DOI 10.1016/j.canep.2015.03.003; Yao JC, 2008, J CLIN ONCOL, V26, P1316, DOI 10.1200/JCO.2007.13.6374	19	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					268	272		10.1016/j.prp.2017.10.015			5	Pathology	Pathology	GB5EL	WOS:000429085800014	29103772				2019-10-28	
J	Veeravarmal, V; Austin, RD; Nagini, S; Nassar, MHM				Veeravarmal, Veeran; Austin, Ravi David; Nagini, Siddavaram; Nassar, Mohamed Hanifa Mohamed			Expression of beta 1integrin in normal epithelium, oral submucous fibrosis and oral squamous cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Atrophy; Connective tissue; Epithelium; Immunohistochemistry; Keratinocytes; Stem cells	ARECA NUT; INTEGRIN EXPRESSION; BETA(1) INTEGRIN; BREAST-CANCER; LUNG-CANCER; STEM-CELLS; IN-VITRO; KERATINOCYTES; ARECOLINE; CARCINOGENESIS	Introduction and Aims: The possible reason suggested for epithelial atrophy in oral submucous fibrosis (OSMF) is ischemia. Dysregulation in the epithelial proliferation and maturation is also thought to be a cause. The beta 1 integrin identifies the oral epithelial stem cells. The changes induced by the arecanut on these cells may result in epithelial alterations. The aim of this study is to evaluate the stem cells distribution and percentage by assessing the beta 1 integrin expression.& para;& para;Materials and methods: The study included normal oral mucosa (15 cases) and disease group (97 cases). The disease group was further subdivided into early (29 cases), moderate (34 cases), advanced OSMF (18 cases) and oral squamous cell carcinoma(OSCC) associated with OSMF (16 cases). The tissues were stained for beta 1 integrin antibodies. The positive cells and staining intensities were analysed to determine the staining index, and statistically evaluated using KW test statistics.& para;& para;Results: beta 1 integrin was observed in retepegs region and the percentage of positive cells was 14%- 30% in the control. In OSMF, the beta 1 integrin positivity was observed in basal and suprabasal layers, and the percentage was ranged from 2%-71%. beta 1 integrin expression in OSCC was observed both in central and peripheral cells and ranged from 17%-85%. On comparison, the difference in staining index among normal, OSMF and carcinomas was significant at p < 0.01. The stem cells percentage was increased both in OSMF and carcinomas. The non-dysplastic epithelium of OSMF with severe atrophy showed lowest percentage. It is inferred that absence of stem cells and proliferation may attribute for the atrophy.	[Veeravarmal, Veeran; Nassar, Mohamed Hanifa Mohamed] Annamalai Univ, Rajah Muthaih Dent Coll & Hosp, Dept Oral & Maxillofacial Pathol, Chidhambaram, Tamil Nadu, India; [Austin, Ravi David] Annamalai Univ, Rajah Muthaih Dent Coll & Hosp, Dept Oral Med & Radiol, Chidhambaram, Tamil Nadu, India; [Nagini, Siddavaram] Annamalai Univ, Dept Biochem & Biotechnol, Annamalainagar, Tamil Nadu, India	Veeravarmal, V (reprint author), Annamalai Univ, Rajah Muthaih Dent Coll & Hosp, Dept Oral & Maxillofacial Pathol, Chidhambaram, Tamil Nadu, India.	varmal.opath@yahoo.com; ravidavidaustin@gmail.com; snlabau@gmail.com; nassarmds@hotmail.com					Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; Brakebusch C, 2005, CANCER METAST REV, V24, P403, DOI 10.1007/s10555-005-5132-5; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Chang Y C, 2001, Clin Oral Investig, V5, P51, DOI 10.1007/s007840000085; Chang Y. C., 2000, DENT J, V19, P95; Chang YC, 1998, J ORAL PATHOL MED, V27, P68; Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01; Deng YT, 2009, ORAL ONCOL, V45, pE99, DOI 10.1016/j.oraloncology.2009.04.004; Desai RS, 2010, ORAL ONCOL, V46, P553, DOI 10.1016/j.oraloncology.2010.04.004; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dickhuth J, 2015, OR SURG OR MED OR PA, V120, P429, DOI 10.1016/j.oooo.2015.06.001; dos Santos PB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-104; Dyce OH, 2002, LARYNGOSCOPE, V112, P2025, DOI 10.1097/00005537-200211000-00021; Ferreira M, 2009, CANCER RES, V69, P1334, DOI 10.1158/0008-5472.CAN-08-3051; Gonzalez-Moles MA, 2013, ORAL ONCOL, V49, P738, DOI 10.1016/j.oraloncology.2013.04.002; Han JY, 2003, LUNG CANCER-J IASLC, V41, P65, DOI 10.1016/S0169-5002(03)00146-6; Haque MF, 1998, CYTOKINE, V10, P713, DOI 10.1006/cyto.1997.0342; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V85, P1; Igarashi T, 2008, ORAL DIS, V14, P413, DOI 10.1111/j.1601-0825.2007.01390.x; Izumi K, 2007, J DENT RES, V86, P341, DOI 10.1177/154405910708600408; Jeng JH, 1999, J ORAL PATHOL MED, V28, P64; Jeng JH, 2001, ORAL ONCOL, V37, P477, DOI 10.1016/S1368-8375(01)00003-3; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Lahlou H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2905; Lee PH, 2006, TOXICOLOGY, V220, P81, DOI 10.1016/j.tox.2005.07.026; Lin HC, 2014, CLIN ORAL INVEST, V18, P1277, DOI 10.1007/s00784-013-1088-y; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; Ohara T, 2009, PATHOL ONCOL RES, V15, P429, DOI 10.1007/s12253-008-9142-9; Okamura M, 2007, HUM PATHOL, V38, P1081, DOI 10.1016/j.humpath.2007.01.003; Owens DM, 2001, CANCER RES, V61, P5248; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Piwko-Czuchra A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005488; Rajendran R, 2007, Indian J Dent Res, V18, P94; Rajendran R., 2003, INDIAN J DENT RES, V15, P13; Ranganathan K, 2006, J ORAL MAXILLOFAC PA, V10, P55; REICHART PA, 1995, J ORAL PATHOL MED, V24, P241, DOI 10.1111/j.1600-0714.1995.tb01175.x; Stein E, 2007, WIEN KLIN WOCHENSCHR, V119, P318, DOI 10.1007/s00508-007-0783-6; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; SUNDQVIST K, 1989, CANCER RES, V49, P5294; Tilakaratne WM, 2006, ORAL ONCOL, V42, P561, DOI 10.1016/j.oraloncology.2005.08.005; Trivedy CR, 2002, ADDICT BIOL, V7, P115, DOI 10.1080/13556210120091482; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wamakulasuriya KAAS, 1997, ORAL DIS, V3, P286; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zhang ZC, 2012, ORAL ONCOL, V48, P1, DOI 10.1016/j.oraloncology.2011.10.004; Zhou SH, 2010, ORAL SURG ORAL MED O, V109, P575, DOI 10.1016/j.tripleo.2009.10.054; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	49	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					273	280		10.1016/j.prp.2017.10.013			8	Pathology	Pathology	GB5EL	WOS:000429085800015	29113685				2019-10-28	
J	Tandon, D; Dewangan, J; Srivastava, S; Garg, VK; Rath, IK				Tandon, Divya; Dewangan, Jayant; Srivastava, Sonal; Garg, Vivek Kumar; Rath, Srikanta Kumar			miRNA genetic variants: As potential diagnostic biomarkers for oral cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Oral squamous cell carcinoma; miRNA polymorphisms; miR-149; miR-499	SQUAMOUS-CELL CARCINOMA; CHINESE POPULATION; ASSOCIATION; MICRORNA; MIR-149; MIR-499; SUSCEPTIBILITY; POLYMORPHISMS; MIR-196A2; HEAD	MicroRNAs (miRNAs) comprise a novel class of small, non-coding endogenous RNAs that have a role in the plethora of regulatory activities by directing their target mRNAs for degradation or translational repression. Single nucleotide polymorphisms (SNPs) in miRNA genes can lead to alteration in mRNA expression, resulting in serious consequences. Detection of miRNA-polymorphisms can potentially improve diagnosis, treatment, prognosis in patients and has extreme implications in the fields of pharmacogenomics and personalization of medicine. The aim of this study is to investigate the association between miR-499 A/G and miR-149 C/T polymorphisms with susceptibility to development of Oral Squamous Cell Carcinoma (OSCC). 200 histopathologically diagnosed and confirmed samples from OSCC patients and 200 control samples from the general population were recruited for the study. All OSCC patients were graded based on their differentiation, and genetic analysis was performed by PCR-RFLP and sequencing. qRT-PCR was carried out to compare the expression of miR-499 and miR-149 in different grades of various stages of OSCC patients concerning to the controls. Further Immunohistochemistry (IHC) was performed to study the target gene of miR-499. The study shows a probable association of miR-499 A/G and miR-149 C/T with susceptibility of OSCC. Random sequencing analysis and Immunohistochemistry contribute to the result that miR-499 A/G increases the susceptibility of OSCC by targeting SOX-6. PCR- Restriction Fragment Length Polymorphism (RFLP) and multivariable logistic analysis revealed that there is a significant association between miR-149 CT + TT and CT and susceptibility of OSCC. Our study suggests that miR-499 A/G and miR-149 C/T polymorphisms may play crucial roles in susceptibility and development of OSCC in Indian population.	[Tandon, Divya; Dewangan, Jayant; Srivastava, Sonal; Rath, Srikanta Kumar] Cent Drug Res Inst, CSIR, Genotox Lab, Div Toxicol & Expt Med, Sect 10, Lucknow 226031, Uttar Pradesh, India; [Tandon, Divya] Acad Sci & Innovat Res AcSIR, New Delhi, India; [Garg, Vivek Kumar] Lucknow Canc Inst, Lucknow 226001, Uttar Pradesh, India	Rath, IK (reprint author), Cent Drug Res Inst, CSIR, Genotox Lab, Div Toxicol & Expt Med, Sect 10, Lucknow 226031, Uttar Pradesh, India.	d.tandon84@gmail.com; jayantdewangan@gmail.com; sonal.srivastava24@gmail.com; vivek_03@yahoo.co.in; skrath@cdri.res.in	Garg, Vivek Kumar/I-9688-2019	Dewangan, Jayant/0000-0002-9591-5603	Council of Scientific and Industrial Research networking project [BSC0103]; Council of Scientific and Industrial ResearchCouncil of Scientific & Industrial Research (CSIR) - India; University Grant CommissionUniversity Grants Commission, India; Indian Council of Medical ResearchIndian Council of Medical Research	This work was supported by grants from Council of Scientific and Industrial Research networking project BSC0103. D.T. acknowledges the Council of Scientific and Industrial Research for granting Senior Research Fellowship. J.D. is thankful to University Grant Commission for providing Junior Research Fellowship. One of us (S.S.) acknowledges the Indian Council of Medical Research for granting Junior Research Fellowship. CSIR-CDRI Communication number for this article is 9578.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Bourthoumieu S., 2014, J MOL GENET MED, V8, P1; Chang HT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S7-S18; Chu YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089930; Dahiya Kiran, 2016, World J Methodol, V6, P77, DOI 10.5662/wjm.v6.i1.77; Dewangan J, 2017, APOPTOSIS, V22, P1246, DOI 10.1007/s10495-017-1394-y; Dou TH, 2010, J CANCER RES CLIN, V136, P1853, DOI 10.1007/s00432-010-0844-5; Elango J Kalavathy, 2006, Asian Pac J Cancer Prev, V7, P108; Hashemi M, 2016, J ADV RES, V7, P491, DOI 10.1016/j.jare.2016.03.008; Hou YY, 2015, ORAL DIS, V21, P195, DOI 10.1111/odi.12241; Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934; Huang GL, 2013, BIOMED REP, V1, P599, DOI 10.3892/br.2013.97; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Li SC, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S1-S13; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin TT, 2011, CARCINOGENESIS, V32, P154, DOI 10.1093/carcin/bgq234; Liu XQ, 2011, CARCINOGENESIS, V32, P1798, DOI 10.1093/carcin/bgr213; Liu ZS, 2010, CANCER-AM CANCER SOC, V116, P4753, DOI 10.1002/cncr.25323; Malumbres M, 2013, MOL ASPECTS MED, V34, P863, DOI 10.1016/j.mam.2012.06.005; Miao LM, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0136-9; Nagadia R, 2013, CELL ONCOL, V36, P1, DOI 10.1007/s13402-012-0122-4; Nassiri I., 2013, J PROTEOM BIOINFORM, V6, P197; Nowak F, 2012, NAT REV CLIN ONCOL, V9, P479, DOI 10.1038/nrclinonc.2012.42; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Reis PP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-238; Su RL, 2016, INT J CLIN EXP PATHO, V9, P2192; Sushma P S, 2015, Asian Pac J Cancer Prev, V16, P7589; Vinci S, 2013, METHODS, V59, P138, DOI 10.1016/j.ymeth.2012.09.002; Wang JX, 2011, NAT MED, V17, P71, DOI 10.1038/nm.2282; Xiang Y, 2012, MOL BIOL REP, V39, P7019, DOI 10.1007/s11033-012-1532-0; Xu B, 2010, PROSTATE, V70, P467, DOI 10.1002/pros.21080; Zemani-Fodil F., 2014, J PHAMMCOGENOMICS PH, V5, P1; Zhang X, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0771-9	35	6	6	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					281	289		10.1016/j.prp.2017.10.002			9	Pathology	Pathology	GB5EL	WOS:000429085800016	29103762				2019-10-28	
J	Bhatia, A; Muthusamy, S; Giridhar, K; Goel, S				Bhatia, Alka; Muthusamy, Sasikala; Giridhar, Kriti; Goel, Sumit			Knockdown of PINCH-1 protein sensitizes the estrogen positive breast cancer cells to chemotherapy induced apoptosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Estrogen; Breast cancer; Apoptosis; PINCH-1; Chemotherapy	EXPRESSION; RESISTANCE; COMPLEX; PARVIN; ILK	Introduction: PINCH-1 is a ubiquitously expressed protein belonging to the focal adhesion protein group which has a role in cell survival, spreading, adhesion and migration. It has been implicated in pathogenesis of several cancers. In the present study we aimed to investigate the role of this protein in estrogen positive and negative breast cancer subtypes.& para;& para;Materials and methods: PINCH-1 expression was studied in two estrogen positive(T47D and MCF-7) and one estrogen negative cell lines before and after treatment with six drugs (Cyclophosphamide, Celecoxib, Doxorubicin, Paclitaxel, Etoposide and Tamoxifen). Then the protein was knocked down using siRNA against PINCH-1 and change in percentage of apoptotic cells was analysed by flow cytometry.& para;& para;Results: We observed increased but differential expression of PINCH-1 in the three breast cancer cell lines with a higher expression in estrogen positive cell lines. Knocking down of PINCH-1 led to a significant (p-value < 0.05) enhancement in apoptosis in T47D cells in response to 4/6 (cyclophosphamide, celecoxib, paclitaxel, doxorubicin) drugs. Though an increase in apoptosis was observed in MCF-7 cells also, it was not found to be significant.The MDA-MB-231 cells however, did not show significant apoptosis upon PINCH-1 knockdown.& para;& para;Conclusion: The results suggest that PINCH-1 may be playing an important role in etiopathogenesis of both subtypes breast cancer. However, enhanced apoptosis observed only in estrogen positive and not in estrogen negative cells upon PINCH-1 knockdown point towards participation of some other protein with redundant functions in the later subtype which needs to be investigated.	[Bhatia, Alka; Muthusamy, Sasikala; Giridhar, Kriti; Goel, Sumit] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India	Bhatia, A (reprint author), Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India.	alkabhatia@ymail.com			Department of Science & Technology, New Delhi, IndiaDepartment of Science & Technology (India)	Funding support for the study was provided by Department of Science & Technology, New Delhi, India.	Bocca C, 2011, MOL CELL BIOCHEM, V350, P59, DOI 10.1007/s11010-010-0682-4; Brandao RD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3409; Braun A, 2003, EXP CELL RES, V284, P239, DOI 10.1016/S0014-4827(02)00039-3; Chen K, 2008, J BIOL CHEM, V283, P2508, DOI 10.1074/jbc.M707307200; Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Dougherty GW, 2008, EUR J CELL BIOL, V87, P721, DOI 10.1016/j.ejcb.2008.02.011; Eke I, 2010, J CLIN INVEST, V120, P2516, DOI 10.1172/JCI41078; Giotopoulou N, 2015, CLIN EXP METASTAS, V32, P255, DOI 10.1007/s10585-015-9701-x; Holmqvist A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-65; Hoskin V, 2015, MOL BIOL CELL, V26, P3464, DOI 10.1091/mbc.E14-12-1584; Kovalevich J, 2011, J CELL PHYSIOL, V226, P940, DOI 10.1002/jcp.22437; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Rodriguez J.W., 2002, CANCER, V95, P1387; Rooney N, 2011, FEBS LETT, V585, P1663, DOI 10.1016/j.febslet.2011.05.014; Stanchi F, 2005, J CELL SCI, V118, P5899, DOI 10.1242/jcs.02686; Yuan Y, 2011, CYTOPATHOLOGY, V22, P22, DOI 10.1111/j.1365-2303.2010.00757.x; Zhang HZ, 2010, CHEMOTHERAPY, V56, P291, DOI 10.1159/000319953	17	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					290	295		10.1016/j.prp.2017.09.026			6	Pathology	Pathology	GB5EL	WOS:000429085800017	29079319				2019-10-28	
J	Liu, T; Zhang, H; Yang, XS; Li, XJ; Shi, Y; Niu, WD; Liu, TJ				Liu, Ting; Zhang, Hong; Yang, Xuesong; Li, Xiaojie; Shi, Yi; Niu, Weidong; Liu, Tingjiao			Study on expression of p16 and human papillomavirus 16 and 18 (E6) in OLP and its malignant transformation	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lichen planus; p16; HPV 16/18; Malignant transformation	SQUAMOUS-CELL CARCINOMA; ORAL LICHEN-PLANUS; IMMUNOHISTOCHEMICAL EXPRESSION; HPV STATUS; LESIONS; CANCER; PROTEIN; PROGRESSION; VIRUS; HEAD	Objective: The aim of this study is to investigate the expressions of p16 and HPV16/18(E6) in oral lichen planus (OLP) and malignant transformed OLP (MT-OLP).& para;& para;Study design: The expression of p16 and HPV16/18(E6) in 40 cases of OLP and 6 MT-OLP was assessed by immunohistochemical staining. Twenty four cases of normal oral mucosa were used as controls.& para;& para;Results: Compared to normal oral mucosa, the expression of p16 and HPV16/18(E6) protein increased in OLP and MT OLP. And there was a correlation between p16 expression and HPV infection in OLP and OLP malignant lesions (p < 0.0001).& para;& para;Conclusions: The expression of p16 protein might predict HPV16/18 infection in OLP. And HPV16/18(E6) infection might contribute to OLP malignant transformation.	[Liu, Ting; Zhang, Hong; Li, Xiaojie; Niu, Weidong; Liu, Tingjiao] Dalian Med Univ, Coll Stomatol, West Sect 9,South Rd Lvshun, Dalian 116044, Peoples R China; [Zhang, Hong] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China; [Liu, Ting] Nanjing Univ, Nanjing Stomatol Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China; [Yang, Xuesong] Dalian Med Univ, Dept Biochem & Mol Biol, Liaoning Prov Core Lab Glycobiol & Glycoengn, Dalian, Peoples R China; [Shi, Yi] Sichuan Univ, West China Sch Stomatol, Chengdu, Sichuan, Peoples R China	Liu, TJ (reprint author), Dalian Med Univ, Coll Stomatol, West Sect 9,South Rd Lvshun, Dalian 116044, Peoples R China.	tingjiao@dlmedu.edu.cn		Ting, Liu/0000-0003-0669-996X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81571767, 81171538]	This work was supported by National Natural Science Foundation of China (81571767 and 81171538)	Ambrosch P, 2001, VIRCHOWS ARCH, V438, P343, DOI 10.1007/s004280000368; Angiero F, 2010, ANTICANCER RES, V30, P3435; Chaudhary AK, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-22; Chen XJ, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0526-2; Debanth S, 2009, ASIA-PAC J CLIN ONCO, V5, P111, DOI 10.1111/j.1743-7563.2009.01200.x; Don K R, 2014, Indian J Dent Res, V25, P797, DOI 10.4103/0970-9290.152208; Fitzpatrick SG, 2014, J AM DENT ASSOC, V145, P45, DOI 10.14219/jada.2013.10; Gao Y, 2016, Zhonghua Kou Qiang Yi Xue Za Zhi, V51, P717, DOI 10.3760/cma.j.issn.1002-0098.2016.12.004; Gorsky M, 2011, ORAL SURG ORAL MED O, V111, P461, DOI 10.1016/j.tripleo.2010.11.007; Holmstrup P, 2010, ORAL DIS, V16, P509, DOI 10.1111/j.1601-0825.2010.01750.x; JONTELL M, 1990, J ORAL PATHOL MED, V19, P273, DOI 10.1111/j.1600-0714.1990.tb00841.x; Khot KP, 2016, CHIN J DENT RES, V19, P17, DOI 10.3290/j.cjdr.a35693; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Konig F, 2007, ANTICANCER RES, V27, P283; Laco J, 2012, NEOPLASMA, V59, P398, DOI 10.4149/neo_2012_052; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Ma JX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161339; Otero-Rey EM, 2014, ACTA ODONTOL SCAND, V72, P570, DOI 10.3109/00016357.2014.914570; Mattila R, 2012, ORAL ONCOL, V48, P980, DOI 10.1016/j.oraloncology.2012.04.009; Mohtasham Nooshin, 2010, J Oral Sci, V52, P239; Montebugnoli L, 2010, HISTOPATHOLOGY, V57, P528, DOI 10.1111/j.1365-2559.2010.03671.x; Mooren JJ, 2014, INT J CANCER, V134, P2108, DOI 10.1002/ijc.28534; Nemes JA, 2006, ORAL SURG ORAL MED O, V102, P344, DOI 10.1016/j.tripleo.2005.10.069; Ostwald C, 2003, MED MICROBIOL IMMUN, V192, P145, DOI 10.1007/s00430-002-0161-y; Pannone G, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-4; Patil S, 2014, J INT SOC PREV COMMU, V4, P61, DOI 10.4103/2231-0762.131269; Perez-Sayans M, 2011, CANCER LETT, V306, P134, DOI 10.1016/j.canlet.2011.02.039; Pol CA, 2015, INT DENT J, V65, P11, DOI 10.1111/idj.12125; Poomsawat S, 2011, J ORAL PATHOL MED, V40, P294, DOI 10.1111/j.1600-0714.2010.01001.x; Popovic B, 2010, INT J ORAL MAX SURG, V39, P909, DOI 10.1016/j.ijom.2010.05.007; Rautava J, 2012, HEAD NECK PATHOL, V6, pS3, DOI 10.1007/s12105-012-0367-2; Razavi Sayed Mohammad, 2009, Dent Res J (Isfahan), V6, P82; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Sahebjamiee Mahnaz, 2015, J Oral Maxillofac Pathol, V19, P170, DOI 10.4103/0973-029X.164528; Saini R, 2011, J CANCER RES CLIN, V137, P311, DOI 10.1007/s00432-010-0886-8; Salehinejad J, 2014, ANN DIAGN PATHOL, V18, P210, DOI 10.1016/j.anndiagpath.2014.03.009; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shintani S, 2002, ORAL ONCOL, V38, P235, DOI 10.1016/S1368-8375(01)00048-3; Singhi AD, 2010, CANCER-AM CANCER SOC, V116, P2166, DOI 10.1002/cncr.25033; Sritippho F., 2015, ASIAN PAC J CANCER P, V16, P6193; Sugerman P B, 1997, Oral Dis, V3, P130; Szarka K, 2009, ORAL MICROBIOL IMMUN, V24, P314, DOI 10.1111/j.1399-302X.2009.00516.x; Thornhill MH, 2001, ACTA ODONTOL SCAND, V59, P174, DOI 10.1080/000163501750266774; Xu RB, 2013, CANCER BIOMARK, V13, P215, DOI 10.3233/CBM-130355; Yildirim B, 2011, MED ORAL PATOL ORAL, V16, pE170, DOI 10.4317/medoral.16.e170; Yoshida T, 2011, ACTA CYTOL, V55, P413, DOI 10.1159/000331047; Zhang ZY, 2004, INT J ORAL MAX SURG, V33, P71, DOI 10.1054/ijom.2002.0443	47	0	0	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					296	302		10.1016/j.prp.2017.09.014			7	Pathology	Pathology	GB5EL	WOS:000429085800018	29254790				2019-10-28	
J	Chen, D; Qi, WJ; Zhang, PX; Zhang, YK; Liu, Y; Guan, HW; Wang, LF				Chen, Dan; Qi, Wenjing; Zhang, Pengxin; Zhang, Yunkun; Liu, Ye; Guan, Hongwei; Wang, Lifen			Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Papillary thyroid carcinoma; BRAF V600E mutation; Immunohistochemistry; Real time PCR	IMMUNOHISTOCHEMICAL DETECTION; BRAF(V600E) MUTATION; P.V600E MUTATIONS; CLINICAL UTILITY; CANCER; MELANOMA; ANTIBODIES; PROGNOSIS	Objective: The detection of BRAF V600E mutation in papillary thyroid carcinoma (PTC) may be helpful to offer diagnostic confirmation. Additionally, such detection may provide a targeted therapeutic approach for the radioactive iodine resistant patients to predict adverse outcomes. To compare the results of immunohistochemistry (IHC) method using the anti-BRAF V600E (VE1) antibody with the Quantitative real-time polymerase chain reaction (qPCR) approach in examining BRAF V600E mutation in PTC, we investigated the sensitivity and specificity of BRAF V600E (clone VE1) mouse monoclonal antibody in detecting the BRAF V600E mutation and correlated BRAF V600E mutation with clinicopathologic features in PTC.& para;& para;Methods: IHC and qPCR were performed in 40 cases of paraffin-embedded PTCs tissues. The association between BRAFV600E mutation and clinicopathologic features of PTC was assessed with the chi(2) test.& para;& para;Results: The concordance rate between IHC and qPCR analyses was 95% (38/40). The BRAF V600E (VE1) antibody has a sensitivity of 100% (34/34) and specificity of 66.67% (4/6) for detecting the mutation. Our study showed that there was no significant association of BRAF V600E mutation with the gender, age, tumor size and lymph node metastasis in PTCs.& para;& para;Conclusion: We may draw the conclusion that detection of BRAF V600E mutation by immunohistochemistry is highly sensitive and specific. Immunohistochemical detection of the mutated BRAF V600E protein in PTC may facilitate mutational analysis in the clinical setting.	[Chen, Dan; Qi, Wenjing; Zhang, Pengxin; Guan, Hongwei] Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, 222 Zhongshan Rd, Dalian 116001, Liaoning, Peoples R China; [Zhang, Yunkun; Liu, Ye; Wang, Lifen] Dalian Med Univ, Affiliated Hosp 2, Dept Pathol, 467 Zhongshan Rd, Dalian 116023, Liaoning, Peoples R China	Guan, HW (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, 222 Zhongshan Rd, Dalian 116001, Liaoning, Peoples R China.; Wang, LF (reprint author), Dalian Med Univ, Affiliated Hosp 2, Dept Pathol, 467 Zhongshan Rd, Dalian 116023, Liaoning, Peoples R China.	mudghw@aliyun.com; lifenw@163.com					Aschebrook-Kilfoy B, 2011, THYROID, V21, P125, DOI 10.1089/thy.2010.0021; Bosmuller H, 2013, HUM PATHOL, V44, P329, DOI 10.1016/j.humpath.2012.07.010; Bullock M, 2012, ENDOCR-RELAT CANCER, V19, P779, DOI 10.1530/ERC-12-0239; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Colomba E, 2013, J MOL DIAGN, V15, P94, DOI 10.1016/j.jmoldx.2012.09.001; Colonna M, 2002, EUR J CANCER, V38, P1762, DOI 10.1016/S0959-8049(02)00110-7; Crescenzi A, 2014, HORM METAB RES, V46, P370, DOI 10.1055/s-0034-1368700; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; Fisher KE, 2014, APPL IMMUNOHISTO M M, V22, P562, DOI 10.1097/PAI.0b013e3182a2f75f; Frasca F, 2008, ENDOCR-RELAT CANCER, V15, P191, DOI 10.1677/ERC-07-0212; Ghossein RA, 2013, J CLIN ENDOCR METAB, V98, pE1414, DOI 10.1210/jc.2013-1408; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Kilfoy BA, 2009, CANCER CAUSE CONTROL, V20, P525, DOI 10.1007/s10552-008-9260-4; Kim YH, 2014, HUM PATHOL, V45, P1483, DOI 10.1016/j.humpath.2014.02.025; Lade-Keller J, 2013, J MOL DIAGN, V15, P70, DOI 10.1016/j.jmoldx.2012.08.003; Lee JH, 2007, CANCER-AM CANCER SOC, V110, P38, DOI 10.1002/cncr.22754; Long GV, 2013, AM J SURG PATHOL, V37, P61, DOI 10.1097/PAS.0b013e31826485c0; McKelvie PA, 2013, PATHOLOGY, V45, P637, DOI 10.1097/PAT.0000000000000008; Moore DA, 2013, J MOL DIAGN, V15, P687, DOI 10.1016/j.jmoldx.2013.04.008; Fano MP, 2017, ENDOCRINOL DIAB NUTR, V64, P75, DOI [10.1016/j.endinu.2016.12.004, 10.1016/j.endien.2017.03.004]; Ritterhouse LL, 2015, SEMIN DIAGN PATHOL, V32, P400, DOI 10.1053/j.semdp.2015.02.010; Routhier CA, 2013, HUM PATHOL, V44, P2563, DOI 10.1016/j.humpath.2013.06.018; Rubinstein JC, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-67; Segovia IG, 2004, THYROID, V14, P277, DOI 10.1089/105072504323030933; Trovisco V, 2006, HUM PATHOL, V37, P781, DOI 10.1016/j.humpath.2006.03.013; Tufano RP, 2012, MEDICINE, V91, P274, DOI 10.1097/MD.0b013e31826a9c71; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xing M., 2011, JAMA-J AM MED ASSOC, V309, P1491; Xing MZ, 2007, ENDOCR REV, V28, P742, DOI 10.1210/er.2007-0007; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987; Xing MZ, 2004, J CLIN ENDOCR METAB, V89, P2867, DOI 10.1210/jc.2003-032050; Yip L, 2013, SURGERY, V154, P1204; Zagzag J, 2013, SURGERY, V154, P1199, DOI 10.1016/j.surg.2013.06.020; Zimmermann AK, 2014, CANCER CYTOPATHOL, V122, P48, DOI 10.1002/cncy.21352	36	7	7	0	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					303	307		10.1016/j.prp.2017.09.001			5	Pathology	Pathology	GB5EL	WOS:000429085800019	29254799				2019-10-28	
J	Qiao, G; Xia, DS; Cheng, ZY; Zhang, GB				Qiao, Gang; Xia, Dongsheng; Cheng, Zhaoyun; Zhang, Guobao			Role of Sprouty1 (Spry1) in the pathogenesis of atrial fibrosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Atrial fibrillation; Fibrosis; Spry1; TGF-beta 1; Angiotensin II	TRANSFORMING GROWTH FACTOR-BETA(1); RHEUMATIC HEART-DISEASE; EPITHELIAL-CELLS; CARDIAC FIBROSIS; TRANSGENIC MICE; FIBRILLATION; EXPRESSION; FIBROBLASTS; ACTIVATION; SUPPRESSION	Atrial fibrosis is the hallmark of atrial fibrillation (AF) dependent structure remodeling. Besides, sprouty 1 (Spry1) plays a key role in the process of fibrosis. In this study, we investigated whether Spry1 could regulate TGF-beta 1 in atrial fibrosis. Ten dogs or patients were assigned to control (n = 4) and AF group (n = 6). The left atrium of dogs or right atrial appendage of patients was taken. After that, cardiac fibroblasts were treated with or without angiotensin II (Ang II). Furthermore, cardiac fibroblasts were transfected with lentivirus of Spry1 over-expression vector, Spry1 shRNA or negative control (NC). And the protein expression of Spry1 and TGF-beta 1 was analyzed by western blot and immunohistochemistry. The results showed that TGF-beta 1 was highly expressed while Spry1 was lowly expressed in the models of human and canine with AF. Besides, the protein expression of TGF-beta 1 was up-regulated and Spry1 was down-regulated in Ang II stimulated cardiac fibroblasts. Furthermore, when Spry1 was knockdown in Ang II-induced cardiac fibroblasts. the cell proliferation and the TGF-beta 1 protein expression increased significantly, while Spry1 over-expression showed inverse results. Our results demonstrated that Spry1 may target TGF-beta 1 in regulating fibrosis. These findings may provide possible therapeutic targets in atrial fibrosis. (C) 2017 Elsevier GmbH. All rights reserved.	[Qiao, Gang; Xia, Dongsheng; Cheng, Zhaoyun; Zhang, Guobao] Zhengzhou Univ, Henan Prov Hosp, Dept Cardiovasc Surg, 7 WeiWu Rd, Zhengzhou 450003, Henan, Peoples R China	Zhang, GB (reprint author), Zhengzhou Univ, Henan Prov Hosp, Dept Cardiovasc Surg, 7 WeiWu Rd, Zhengzhou 450003, Henan, Peoples R China.	zhang_gb68@163.com					Adam O, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0278-0; Brooks WW, 2000, J MOL CELL CARDIOL, V32, P187, DOI 10.1006/jmcc.1999.1065; Cidre-Aranaz F, 2017, ONCOGENE, V36, P766, DOI 10.1038/onc.2016.244; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Dubey RK, 1997, CIRCULATION, V96, P2656, DOI 10.1161/01.CIR.96.8.2656; Edwin F, 2009, MOL PHARMACOL, V76, P679, DOI 10.1124/mol.109.055848; Everett TH, 2007, HEART RHYTHM, V4, pS24, DOI 10.1016/j.hrthm.2006.12.040; Friedrichs K, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00214; Gramley F, 2007, J CARDIOVASC ELECTR, V18, P1076, DOI 10.1111/j.1540-8167.2007.00906.x; Gramley F, 2010, INT J CARDIOL, V143, P405, DOI 10.1016/j.ijcard.2009.03.110; Gramley F, 2009, AGE, V31, P27, DOI 10.1007/s11357-008-9077-9; Gu J, 2012, EXP CELL RES, V318, P2105, DOI 10.1016/j.yexcr.2012.06.015; Guo YZ, 2016, GENE, V591, P129, DOI 10.1016/j.gene.2016.07.008; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Han Z, 2002, DEV BIOL, V252, P225, DOI 10.1006/dbio.2002.0846; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Huebert RC, 2004, PHYSIOL GENOMICS, V18, P284, DOI 10.1152/physiolgenomics.00098.2004; Khan R, 2006, IMMUNOLOGY, V118, P10, DOI 10.1111/j.1365-2567.2006.02336.x; Li DS, 2001, CIRCULATION, V104, P2608, DOI 10.1161/hc4601.099402; Li XP, 2008, MED HYPOTHESES, V70, P317, DOI 10.1016/j.mehy.2007.04.046; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Miller CL, 2011, BASIC RES CARDIOL, V106, P1023, DOI 10.1007/s00395-011-0228-2; Rosenkranz S, 2002, AM J PHYSIOL-HEART C, V283, pH1253, DOI 10.1152/ajpheart.00578.2001; Schotten U, 2011, PHYSIOL REV, V91, P265, DOI 10.1152/physrev.00031.2009; Shin EHH, 2012, MOL MED, V18, P861, DOI 10.2119/molmed.2012.00111; Siddesha JM, 2014, CELL SIGNAL, V26, P933, DOI 10.1016/j.cellsig.2014.01.005; Suenari K, 2011, BASIC RES CARDIOL, V106, P65, DOI 10.1007/s00395-010-0132-1; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tsai CT, 2011, CARDIOVASC RES, V89, P805, DOI 10.1093/cvr/cvq322; Verheule S, 2004, CIRC RES, V94, P1458, DOI 10.1161/01.RES.0000129579.59664.9d; Wakili R, 2011, J CLIN INVEST, V121, P2955, DOI 10.1172/JCI46315; Wang R, 2015, INT J CLIN EXP PATHO, V8, P14901; Wenzel S, 2001, FASEB J, V15, P2291, DOI 10.1096/fj.00-0827fje; Xiao H, 2010, CLIN CARDIOL, V33, P149, DOI 10.1002/clc.20713; Yang SS, 2011, BASIC RES CARDIOL, V106, P495, DOI 10.1007/s00395-011-0154-3; Zhang Y, 2014, MOL THER, V22, P974, DOI 10.1038/mt.2014.25; Zografos T, 2010, PACE, V33, P1270, DOI 10.1111/j.1540-8159.2010.02832.x	41	3	3	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					308	313		10.1016/j.prp.2017.04.021			6	Pathology	Pathology	GB5EL	WOS:000429085800020	29096943				2019-10-28	
J	Paluszczak, J; Kiwerska, K; Mielcarek-Kuchta, D				Paluszczak, Jaroslaw; Kiwerska, Katarzyna; Mielcarek-Kuchta, Daniela			Frequent methylation of &ITDAB2&IT, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Oral cancer; Head and neck cancer; DAB2; DNA methylation; Wnt pathway	ABERRANT HYPERMETHYLATION; EPIGENETIC INACTIVATION; LUNG-CANCER; DAB2; DISABLED-2; EXPRESSION; HEAD; INHIBITORS; PROTEIN; GENES	Background: Aberrations in Wnt signaling pathway are related to the pathogenesis of head and neck carcinomas and their activation frequently results from epigenetic alterations. This study aimed to assess the frequency of the methylation of DAB2, which acts as a negative regulator of Wnt signaling, and correlate it with clinicopathological features in a group of oral cancer patients.& para;& para;Material and methods: Forty nine patients with primary oral squamous cell carcinoma were enrolled in the study. DNA samples were isolated from surgical sections using phenol-chloroform extraction. Methylation-specific PCR was used to detect gene promoter methylation.& para;& para;Results: The analysis of the occurrence of DAB2 promoter methylation in primary oral carcinomas indicated that the gene is methylated in 70% of cases. However, no correlation was found between its methylation and TNM staging or overall survival.& para;& para;Conclusions: Our findings corroborate that DAB2 is a frequent target of epigenetic silencing in oral carcinomas and may be potentially used for tumor detection.	[Paluszczak, Jaroslaw] Poznan Univ Med Sci, Dept Pharmaceut Biochem, Ul Swiecickiego 4, PL-60781 Poznan, Poland; [Kiwerska, Katarzyna] Polish Acad Sci, Inst Human Genet, Poznan, Poland; [Mielcarek-Kuchta, Daniela] Poznan Univ Med Sci, Dept Otolaryngol & Laryngol Oncol, Poznan, Poland	Paluszczak, J (reprint author), Poznan Univ Med Sci, Dept Pharmaceut Biochem, Ul Swiecickiego 4, PL-60781 Poznan, Poland.	paluszcz@ump.edu.pl		Kiwerska, Katarzyna/0000-0002-2319-0201; Paluszczak, Jaroslaw/0000-0002-6187-7549	Department of Pharmaceutical Biochemistry; Faculty of Pharmacy, Poznan University of Medical Sciences in Poznan, Poland	The work was supported by the Department of Pharmaceutical Biochemistry and the Faculty of Pharmacy, Poznan University of Medical Sciences in Poznan, Poland.	Anupam K, 2006, WORLD J GASTROENTERO, V12, P6041, DOI 10.3748/wjg.v12.i37.6041; Du L, 2014, ONCOGENE, V33, P4307, DOI 10.1038/onc.2013.381; Finkielstein CV, 2016, BIOESSAYS, V38, pS45, DOI 10.1002/bies.201670907; Gupta B, 2016, ONCOLOGY-BASEL, V91, P13, DOI 10.1159/000446117; Gupta N, 2016, NEPAL J EPIDEMIOL, V6, P613, DOI 10.3126/nje.v6i4.17255; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; Jiang Y, 2008, ONCOGENE, V27, P1865, DOI 10.1038/sj.onc.1210829; Jiang Y, 2009, ONCOGENE, V28, P2999, DOI 10.1038/onc.2009.157; Li C, 2015, AM J MED SCI, V349, P425, DOI 10.1097/MAJ.0000000000000436; Li G, 2015, TUMOR BIOL, V36, P3949, DOI 10.1007/s13277-015-3038-6; Lindsay C, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-017-0185-3; Paluszczak J, 2017, CLIN ORAL INVEST, V21, P1777, DOI 10.1007/s00784-016-1946-5; Paluszczak J, 2015, TUMOR BIOL, V36, P2855, DOI 10.1007/s13277-014-2913-x; Paluszczak J, 2014, J ORAL PATHOL MED, V43, P652, DOI 10.1111/jop.12178; Paluszczak J, 2011, ORAL ONCOL, V47, P104, DOI 10.1016/j.oraloncology.2010.11.006; Pannone G, 2010, ONCOL REP, V24, P1035, DOI 10.3892/or_00000952; Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889; Sogabe Y, 2008, INT J ONCOL, V32, P1253; Tong JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-253; Wang WL, 2016, ONCOTARGET, V7, P71169, DOI 10.18632/oncotarget.8460; Xie XM, 2013, INT J ONCOL, V43, P1636, DOI 10.3892/ijo.2013.2084; Xu YF, 2015, CANCER LETT, V363, P146, DOI 10.1016/j.canlet.2015.04.006; Zhang ZY, 2014, PAK J MED SCI, V30, P432	23	2	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					314	317		10.1016/j.prp.2017.12.010			4	Pathology	Pathology	GB5EL	WOS:000429085800021	29254794				2019-10-28	
J	Sugiura, Y; Kanda, H; Motoi, N; Nomura, K; Inamura, K; Okada, E; Matsumoto, H; Shimoji, T; Matsumoto, S; Nakayama, J; Takazawa, Y; Ishikawa, Y; Machinami, R				Sugiura, Yoshiya; Kanda, Hiroaki; Motoi, Noriko; Nomura, Kimie; Inamura, Kentaro; Okada, Erina; Matsumoto, Haruna; Shimoji, Takashi; Matsumoto, Seiichi; Nakayama, Jun; Takazawa, Yutaka; Ishikawa, Yuichi; Machinami, Rikuo			Osteosarcoma arising in fibrous dysplasia, confirmed by mutational analysis of &ITGNAS&IT gene	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Fibrous dysplasia; Osteosarcoma; GNAS gene	MCCUNE-ALBRIGHT SYNDROME; ACTIVATING G(S)ALPHA MUTATION; STIMULATORY G-PROTEIN; GS-ALPHA GENE; BONE; CELLS	Malignancy arising in fibrous dysplasia (FD) is rare. Approximately 100 cases have been reported so far, and osteosarcoma is the most common malignancy. We report a case of osteosarcoma in a 33-year-old Japanese man with monostotic FD of the right proximal femur from the age of 16 years. Histologically, relatively well-differentiated osteosarcoma was found in the FD lesion. Immunohistochemically, the FD was negative for p53 or MDM2, and the MIB-1 index was less than 1%, whereas the osteosarcoma was positive for both p53 and MDM2, and the MIB-1 index was up to 15%. The FD and osteosarcoma were negative for CDK4. Fluorescent in situ hybridization assay showed no amplification of the MDM2 gene, indicating that the osteosarcoma was a conventional osteosarcoma, not an intraosseous well-differentiated type. The original cell of malignancy in FD is unclear. Malignancy can be potentially derived from dysplastic cells in the area of the FD or cells in the adjacent normal tissues. GNAS gene mutation has recently been reported for fibrous dysplasia and the mutation is highly specific to fibrous dysplasia among fibro-osseous lesions including osteosarcoma.& para;& para; In this case, point mutations of GNAS were found in the FD and osteosarcoma but not in the adjacent normal tissues, suggesting that osteosarcoma was derived from the spindle cells of FD. This is the first report to clearly show that osteosarcoma is derived from the spindle cells in fibrous dysplasia (FD).	[Sugiura, Yoshiya; Kanda, Hiroaki; Motoi, Noriko; Nomura, Kimie; Inamura, Kentaro; Okada, Erina; Matsumoto, Haruna; Takazawa, Yutaka; Ishikawa, Yuichi; Machinami, Rikuo] JFCR, Canc Inst Hosp, Dept Pathol, Tokyo 1358550, Japan; [Sugiura, Yoshiya; Kanda, Hiroaki; Motoi, Noriko; Nomura, Kimie; Inamura, Kentaro; Okada, Erina; Matsumoto, Haruna; Takazawa, Yutaka; Ishikawa, Yuichi; Machinami, Rikuo] JFCR, Canc Inst Hosp, Clinicopathol Ctr, Tokyo 1358550, Japan; [Sugiura, Yoshiya; Nakayama, Jun] Shinshu Univ, Dept Mol Pathol, Grad Sch Med, Matsumoto, Nagano 3908621, Japan; [Shimoji, Takashi; Matsumoto, Seiichi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Orthoped Surg, Tokyo 1358550, Japan; [Machinami, Rikuo] Kawakita Gen Hosp, Dept Pathol, Tokyo 1668588, Japan	Kanda, H (reprint author), JFCR, Canc Inst Hosp, Dept Pathol, Tokyo 1358550, Japan.; Kanda, H (reprint author), JFCR, Canc Inst Hosp, Clinicopathol Ctr, Tokyo 1358550, Japan.	kandah@jfcr.or.jp	Inamura, Kentaro/G-4229-2018	Inamura, Kentaro/0000-0001-6444-3861	Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This study was approved by the Institutional review board IRB and SRB in the Cancer Institute Hospital No. 2016-1046.The authors thank Mr. Motoyoshi Iwakoshi and Ms. Tomoyo Kakita for their technical assistances and Dr. Yasuyuki Shigematsu for his appropriate advice on English writing. This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan. We acknowledge Dr. Akihiko Yoshida for performing the FISH analysis of MDM2 gene.	Alman BA, 1996, J ORTHOPAED RES, V14, P311, DOI 10.1002/jor.1100140221; Bianco P, 2000, J BONE MINER RES, V15, P120, DOI 10.1359/jbmr.2000.15.1.120; Carter JM, 2014, AM J SURG PATHOL, V38, P402, DOI 10.1097/PAS.0000000000000144; COLEY BL, 1945, ANN SURG, V121, P872, DOI 10.1097/00000658-194506000-00012; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Hoshi Manabu, 2006, Int J Clin Oncol, V11, P229, DOI 10.1007/s10147-006-0559-4; HUVOS AG, 1972, J BONE JOINT SURG AM, VA 54, P1047, DOI 10.2106/00004623-197254050-00010; Idowu BD, 2007, HISTOPATHOLOGY, V50, P691, DOI 10.1111/j.1365-2559.2007.02676.x; ISHIDA T, 1992, PATHOL RES PRACT, V188, P757, DOI 10.1016/S0344-0338(11)80174-3; KANDA H, 1993, ONCOGENE, V8, P3047; Lee SE, 2012, HUM PATHOL, V43, P1234, DOI 10.1016/j.humpath.2011.09.012; Marie PJ, 1997, AM J PATHOL, V150, P1059; Pollandt K, 2001, VIRCHOWS ARCH, V439, P170, DOI 10.1007/s004280100453; Riminucci M, 1999, J PATHOL, V187, P249, DOI 10.1002/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J; Riminucci M, 1997, AM J PATHOL, V151, P1587; Riminucci M, 2010, J MOL ENDOCRINOL, V45, P355, DOI 10.1677/JME-10-0097; RUGGIERI P, 1994, CANCER, V73, P1411, DOI 10.1002/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T; Salinas-Souza C, 2015, MODERN PATHOL, V28, P1336, DOI 10.1038/modpathol.2015.91; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; Tabareau-Delalande F, 2015, AM J SURG PATHOL, V39, P1010, DOI 10.1097/PAS.0000000000000461; Tabareau-Delalande F, 2013, MODERN PATHOL, V26, P911, DOI 10.1038/modpathol.2012.223; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124	24	2	3	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	FEB	2018	214	2					318	324		10.1016/j.prp.2017.10.018			7	Pathology	Pathology	GB5EL	WOS:000429085800022	29268950				2019-10-28	
J	Langer, R; Becker, K				Langer, Rupert; Becker, Karen			Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy	VIRCHOWS ARCHIV			English	Review						Tumor regression grading; Histopathology; Gastric cancer; Esophageal cancer; Rectal cancer; Neoadjuvant therapy	ADVANCED RECTAL-CANCER; AMERICAN-JOINT-COMMITTEE; PATHOLOGICAL COMPLETE RESPONSE; DISEASE-FREE SURVIVAL; PREOPERATIVE CHEMORADIOTHERAPY; PROGNOSTIC-SIGNIFICANCE; PERIOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC ADENOCARCINOMA; ESOPHAGEAL ADENOCARCINOMAS; PREDICTS SURVIVAL	Neoadjuvant therapy has been successfully introduced in the treatment of locally advanced gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The effects of preoperative chemo- or radiochemotherapy can be determined by histopathological investigation of the resection specimen following this treatment. Frequent histological findings after neoadjuvant therapy include various amounts of residual tumor, inflammation, resorptive changes with infiltrates of foamy histiocytes, foreign body reactions, and scarry fibrosis. Several tumor regression grading (TRG) systems, which aim to categorize the amount of regressive changes after cytotoxic treatment in primary tumor sites, have been proposed for gastroesophageal and rectal carcinomas. These systems primarily refer to the amount of therapy-induced fibrosis in relation to the residual tumor (e.g., the Mandard, Dworak, or AJCC systems) or the estimated percentage of residual tumor in relation to the previous tumor site (e.g., the Becker, Rodel, or Rectal Cancer Regression Grading systems). TRGs provide valuable prognostic information, as in most cases, complete or subtotal tumor regression after neoadjuvant treatment is associated with better patient outcomes. This review describes the typical histopathological findings after neoadjuvant treatment, discusses the most commonly used TRG systems for gastroesophageal and rectal carcinomas, addresses the limitations and critical issues of tumor regression grading in these tumors, and describes the clinical impact of TRG.	[Langer, Rupert] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland; [Becker, Karen] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany	Langer, R (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	rupert.langer@pathology.unibe.ch		Langer, Rupert/0000-0001-9491-3609			Amin MB, 2017, AJCC CANC STAGING MA; Bateman AC, 2009, HISTOPATHOLOGY, V54, P713, DOI 10.1111/j.1365-2559.2009.03292.x; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Becker K, 2012, ANN SURG, V256, P1002, DOI 10.1097/SLA.0b013e318262a591; Becker K, 2011, ANN SURG, V253, P934, DOI 10.1097/SLA.0b013e318216f449; Blank S, 2015, GASTRIC CANCER, V18, P314, DOI 10.1007/s10120-014-0367-x; Brierley JD, 2017, TNM CLASSIFICATION M; Brucher BLDM, 2006, CANCER-AM CANCER SOC, V106, P2119, DOI 10.1002/cncr.21850; Calvo FA, 2014, J CANCER RES CLIN, V140, P1651, DOI 10.1007/s00432-014-1718-z; Chang F, 2008, AM J CLIN PATHOL, V129, P252, DOI 10.1309/CCR3QN4874YJDJJ7; Chetty R, 2012, HUM PATHOL, V43, P1917, DOI 10.1016/j.humpath.2012.01.020; Chetty R, 2012, VIRCHOWS ARCH, V460, P151, DOI 10.1007/s00428-012-1193-3; Chirieac LR, 2005, CANCER-AM CANCER SOC, V103, P1347, DOI 10.1002/cncr.20916; Cunningham D, 2017, LANCET ONCOL, V18, P357, DOI 10.1016/S1470-2045(17)30043-8; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Donohoe CL, 2013, ANN SURG, V258, P784, DOI 10.1097/SLA.0b013e3182a66588; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Fareed KR, 2009, HISTOPATHOLOGY, V55, P399, DOI 10.1111/j.1365-2559.2009.03404.x; Fernandez-Acenero MJ, 2016, VIRCHOWS ARCH, V468, P425, DOI 10.1007/s00428-015-1901-x; Fokas E, 2014, J CLIN ONCOL, V32, P1554, DOI 10.1200/JCO.2013.54.3769; Francis AM, 2013, ANN SURG, V258, P500, DOI 10.1097/SLA.0b013e3182a196f4; Glynne-Jones R, 2006, ANN ONCOL, V17, P1239, DOI 10.1093/annonc/mdl173; Gosens MJEM, 2007, CLIN CANCER RES, V13, P6617, DOI 10.1158/1078-0432.CCR-07-1197; Hav M, 2015, VIRCHOWS ARCH, V466, P517, DOI 10.1007/s00428-015-1723-x; Hornick JL, 2006, AM J SURG PATHOL, V30, P28, DOI 10.1097/01.pas.0000174011.29816.fa; Huebner M, 2012, WORLD J SURG, V36, P675, DOI 10.1007/s00268-011-1409-8; Jager T, 2017, DIS COLON RECTUM, V60, P815, DOI 10.1097/DCR.0000000000000806; Japan Esophageal Soc, 2017, ESOPHAGUS-TOKYO, V14, P1, DOI 10.1007/s10388-016-0551-7; Karamitopoulou E, 2014, AM J SURG PATHOL, V38, P1551, DOI 10.1097/PAS.0000000000000255; Kim JY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002257; Kim SH, 2016, CANCER RES TREAT, V48, P998, DOI 10.4143/crt.2015.254; Langer R, 2014, ANN SURG ONCOL, V21, P915, DOI 10.1245/s10434-013-3410-y; Langer R, 2009, MODERN PATHOL, V22, P1555, DOI 10.1038/modpathol.2009.123; Lee YC, 2013, DIS COLON RECTUM, V56, P1093, DOI 10.1097/DCR.0b013e318298e36b; Lim SB, 2012, J SURG ONCOL, V106, P659, DOI 10.1002/jso.23181; Lutz MP, 2016, EUR J CANCER, V63, P11, DOI 10.1016/j.ejca.2016.04.010; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Mace AG, 2015, DIS COLON RECTUM, V58, P32, DOI 10.1097/DCR.0000000000000266; MacGregor TP, 2012, J CLIN PATHOL, V65, P867, DOI 10.1136/jclinpath-2012-200958; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Martin ST, 2012, BRIT J SURG, V99, P918, DOI 10.1002/bjs.8702; Minsky BD, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju285; Mirza A, 2012, ISRN PATHOL, V2012, P1, DOI [10.5402/2012/519351, DOI 10.5402/2012/519351]; Moehler M, 2016, EUR J CANCER, V59, P160, DOI 10.1016/j.ejca.2016.02.020; Nakamura K, 2015, GASTRIC CANCER, V18, P597, DOI 10.1007/s10120-014-0401-z; O'Neil M, 2009, OPEN PATHOL J, V3, P91, DOI [10.2174/1874375700903020091, DOI 10.2174/1874375700903020091]; Patel UB, 2011, J CLIN ONCOL, V29, P3753, DOI 10.1200/JCO.2011.34.9068; Philippron A, 2016, SEMIN THORAC CARDIOV, V28, P549, DOI [10.1053/j.senitcvs.2016.04.003, 10.1053/j.semtcvs.2016.04.003]; Quah HM, 2008, CANCER-AM CANCER SOC, V113, P57, DOI 10.1002/cncr.23516; Reim D, 2012, ANN SURG ONCOL, V19, P2108, DOI 10.1245/s10434-011-2147-8; Rizk NP, 2007, J CLIN ONCOL, V25, P507, DOI 10.1200/JCO.2006.08.0101; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Rodel C, 2012, LANCET ONCOL, V13, P679, DOI 10.1016/S1470-2045(12)70187-0; Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467; Rombouts AJM, 2016, ANN SURG ONCOL, V23, P3593, DOI 10.1245/s10434-016-5294-0; Rosenberg R, 2008, J SURG ONCOL, V97, P8, DOI 10.1002/jso.20844; Sannier A, 2014, HISTOPATHOLOGY, V65, P623, DOI 10.1111/his.12432; Sano T, 2011, GASTRIC CANCER, V14, P97, DOI 10.1007/s10120-011-0040-6; Schmidt T, 2014, BRIT J CANCER, V110, P1712, DOI 10.1038/bjc.2014.94; Schmidt T, 2015, J NATL COMPR CANC NE, V13, P239, DOI 10.6004/jnccn.2015.0030; Schneider PM, 2005, ANN SURG, V242, P684, DOI 10.1097/01.sla.0000186170.38348.7b; Schollaert P, 2014, J GASTROINTEST SURG, V18, P894, DOI 10.1007/s11605-014-2488-2; Shia J, 2004, AM J SURG PATHOL, V28, P215, DOI 10.1097/00000478-200402000-00009; Shia J, 2011, AM J SURG PATHOL, V35, P127, DOI 10.1097/PAS.0b013e318200cf78; Swellengrebel HAM, 2014, RADIOTHER ONCOL, V112, P44, DOI 10.1016/j.radonc.2014.05.010; Swisher SG, 2005, ANN SURG, V241, P810, DOI 10.1097/01.sla.0000161983.82345.85; Thies S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00262; Tomasello G, 2017, EJSO-EUR J SURG ONC, V43, P1607, DOI 10.1016/j.ejso.2017.03.001; Trakarnsanga A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju248; Tulchinsky H, 2008, ANN SURG ONCOL, V15, P2661, DOI 10.1245/s10434-008-9892-3; Urabe M, 2016, AM J SURG PATHOL, V40, P1326, DOI 10.1097/PAS.0000000000000672; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Wu TT, 2007, AM J SURG PATHOL, V31, P58, DOI 10.1097/01.pas.0000213312.36306.cc; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597; Zhou ZR, 2014, SURG ONCOL, V23, P211, DOI 10.1016/j.suronc.2014.10.003	75	12	12	2	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					175	186		10.1007/s00428-017-2232-x			12	Pathology	Pathology	FZ6IF	WOS:000427700600001	28918544				2019-10-28	
J	Erramuzpe, A; Cortes, JM; Lopez, JI				Erramuzpe, Asier; Cortes, Jesus M.; Lopez, Jose I.			Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution	VIRCHOWS ARCHIV			English	Article						Tumor sampling; Personalized; Intratumor heterogeneity; Tumor evolution; In silico analysis; Divide and conquer algorithm; Personalized therapy	GENETIC-HETEROGENEITY; CANCER; MODEL; SELECTION	Intratumor heterogeneity (ITH) is an inherent process of tumor development that has received much attention in previous years, as it has become a major obstacle for the success of targeted therapies. ITH is also temporally unpredictable across tumor evolution, which makes its precise characterization even more problematic since detection success depends on the precise temporal snapshot at which ITH is analyzed. New and more efficient strategies for tumor sampling are needed to overcome these difficulties which currently rely entirely on the pathologist's interpretation. Recently, we showed that a new strategy, the multisite tumor sampling, works better than the routine sampling protocol for the ITH detection when the tumor time evolution was not taken into consideration. Here, we extend this work and compare the ITH detections of multisite tumor sampling and routine sampling protocols across tumor time evolution, and in particular, we provide in silico analyses of both strategies at early and late temporal stages for four different models of tumor evolution (linear, branched, neutral, and punctuated). Our results indicate that multisite tumor sampling outperforms routine protocols in detecting ITH at all different temporal stages of tumor evolution. We conclude that multisite tumor sampling is more advantageous than routine protocols in detecting intratumor heterogeneity.	[Erramuzpe, Asier] Biocruces Res Inst, Quantitat Biomed Unit, Baracaldo 48903, Spain; [Cortes, Jesus M.] Ikerbasque Basque Fdn Sci, Bilbao 48013, Spain; [Cortes, Jesus M.] Univ Basque Country UPV EHU, Dept Cell Biol & Histol, Leioa 48940, Spain; [Lopez, Jose I.] Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain; [Lopez, Jose I.] Biocruces Res Inst, Biomarkers Canc Unit, Baracaldo 48903, Spain; [Lopez, Jose I.] Univ Basque Country UPV EHU, Leioa 48940, Spain	Lopez, JI (reprint author), Cruces Univ Hosp, Dept Pathol, Plaza Cruces S-N, Baracaldo 48903, Bizkaia, Spain.; Lopez, JI (reprint author), Biocruces Res Inst, Biomarkers Canc Unit, Baracaldo 48903, Spain.; Lopez, JI (reprint author), Univ Basque Country UPV EHU, Leioa 48940, Spain.	jilpath@gmail.com	Lopez, Jose Ignacio/L-3884-2019; Cortes, Jesus/D-9949-2012	Lopez, Jose Ignacio/0000-0003-0842-5348; Cortes, Jesus/0000-0002-9059-8194; Erramuzpe Aliaga, Asier/0000-0002-9402-2184			Appierto V, 2017, SEMIN CANCER BIOL, V44, P106, DOI 10.1016/j.semcancer.2017.04.007; Baisse B, 2001, INT J CANCER, V93, P346, DOI 10.1002/ijc.1343; Bettoni F, 2017, ANN SURG, V265, pE4, DOI 10.1097/SLA.0000000000001937; Bosman FT, 2017, PATHOBIOLOGY; Cortes JM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00025; Davis A, 2017, BBA-REV CANCER, V1867, P151, DOI 10.1016/j.bbcan.2017.01.003; De la Fuente Ildefonso M, 2015, Front Mol Biosci, V2, P16, DOI 10.3389/fmolb.2015.00016; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gatenby RA, 2003, MOL CANCER THER, V2, P919; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Guarch Rosa, 2016, F1000Res, V5, P2020; Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8; Kang H, 2015, J PATHOL, V237, P355, DOI 10.1002/path.4581; Kim TM, 2014, J PATHOL, V233, P425, DOI 10.1002/path.4380; Kon R, 2015, MATH BIOSCI ENG, V12, P71, DOI 10.3934/mbe.2015.12.71; Ledgerwood LG, 2016, ONCOTARGET, V7, P27185, DOI 10.18632/oncotarget.8448; Ling SP, 2015, P NATL ACAD SCI USA, V112, pE6496, DOI 10.1073/pnas.1519556112; Lopez JI, 2017, HUM PATHOL, V64, P1, DOI 10.1016/j.humpath.2017.02.010; Lopez Jose I, 2016, F1000Res, V5, P1587, DOI 10.12688/f1000research.9091.2; Lopez Jose I, 2016, F1000Res, V5, P385, DOI 10.12688/f1000research.8196.1; Lopez JI, 2013, PATHOL RES PRACT, V209, P137, DOI 10.1016/j.prp.2013.01.007; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Morris LGT, 2016, ONCOTARGET, V7, P10051, DOI 10.18632/oncotarget.7067; Nadal C, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705749; Nagy JD, 2004, B MATH BIOL, V66, P663, DOI 10.1016/j.bulm.2003.10.001; Okegawa T, 2017, EBIOMEDICINE; Pan Y, 2017, IEEE PULSE, V8, P23, DOI 10.1109/MPUL.2016.2630838; Paracchini L., 2016, ONCOTARGET; Pearce DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep29434; Rosai J., 2011, ROSAI ACKERMANS SURG; Saraga E, 1997, J PATHOL, V181, P281, DOI 10.1002/(SICI)1096-9896(199703)181:3<281::AID-PATH777>3.0.CO;2-M; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Soultati A, 2015, CURR OPIN UROL, V25, P358, DOI 10.1097/MOU.0000000000000204; Stanta G, 2016, VIRCHOWS ARCH, V469, P371, DOI 10.1007/s00428-016-1987-9; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Williams MJ, 2016, NAT GENET, V48, P238, DOI 10.1038/ng.3489	38	4	4	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					187	194		10.1007/s00428-017-2223-y			8	Pathology	Pathology	FZ6IF	WOS:000427700600002	28842744				2019-10-28	
J	Gandara-Cortes, M; Vazquez-Boquete, A; Fernandez-Rodriguez, B; Viano, P; Insua, D; Seoane-Seoane, A; Gude, F; Gallego, R; Fraga, M; Antunez, JR; Curiel, T; Perez-Lopez, E; Garcia-Caballero, T				Gandara-Cortes, Marina; Vazquez-Boquete, Angel; Fernandez-Rodriguez, Beatriz; Viano, Patricia; Insua, Dora; Seoane-Seoane, Alejandro; Gude, Francisco; Gallego, Rosalia; Fraga, Maximo; Antunez, Jose R.; Curiel, Teresa; Perez-Lopez, Eva; Garcia-Caballero, Tomas			Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis	VIRCHOWS ARCHIV			English	Article						Breast cancer; 4-IHC; Image analysis; Biological subtypes	INTERNATIONAL EXPERT CONSENSUS; POPULATION-BASED COHORT; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; CLINICAL-PRACTICE; PRIMARY THERAPY; RECOMMENDATIONS; CLASSIFICATION; KI-67; KI67	Breast cancer is a heterogeneous disease. Surrogate classification of intrinsic subtypes of invasive carcinomas by combined immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 (4-IHC) has increased steadily since the 2011 St Gallen symposium, due to its rapid subtyping of tumors at a reasonable cost. An important step in improving 4-IHC reproducibility and reliability will be to provide reference values from the routine use of standardized 4-IHC followed by image analysis. The aims of the current study were (1) to analyze invasive breast carcinomas using standardized 4-IHC and quantitative image analysis and (2) to compare the results obtained in the classification of biological subtypes using current Ki67 and PR threshold values proposed by different authors to sub-classifying the luminal A-like and the luminal B-like (HER2-negative) subtypes. Five hundred twenty-one tumors were analyzed by standardized immunohistochemistry, with automatic image analysis, and HER2 FISH technique. Positivity for ER was found in 82.7% and for PR in 70.1% of cases. Using the Allred scoring system, hormone receptor results showed a bimodal distribution, particularly for ER. HER2 positivity was found in 15.7% of cases, and the mean Ki67 score was 32.3%. Using the most recently proposed surrogate definitions for the classification of luminal breast cancer subtypes, the percentages of different subtypes that we found were similar to those published with genomic platforms: 40.7% luminal A-like, 32.4% luminal B-like/HER2-negative, 9.8% luminal B-like/HER2-positive, 6.0% HER2-positive, and 11.1% triple negative. Standardized 4-IHC with automatic image analysis constitutes a low-cost method for surrogate definitions of biological subtypes of breast cancer that delivers accurate results in a day.	[Gandara-Cortes, Marina; Gallego, Rosalia; Garcia-Caballero, Tomas] Univ Santiago de Compostela, Sch Med, Dept Morphol Sci, Santiago De Compostela, Spain; [Gandara-Cortes, Marina] Alvaro Cunqueiro Univ Hosp, Dept Pathol, Vigo, Spain; [Vazquez-Boquete, Angel; Fernandez-Rodriguez, Beatriz; Viano, Patricia; Insua, Dora; Seoane-Seoane, Alejandro; Fraga, Maximo; Antunez, Jose R.; Garcia-Caballero, Tomas] Univ Clin Hosp, Dept Pathol, Santiago De Compostela, Spain; [Gude, Francisco] Univ Clin Hosp, Clin Epidemiol Unit, Santiago De Compostela, Spain; [Curiel, Teresa] Univ Clin Hosp, Dept Oncol, Santiago De Compostela, Spain; [Perez-Lopez, Eva] Univ Hosp Ourense, Dept Oncol, Orense, Spain	Vazquez-Boquete, A (reprint author), Univ Clin Hosp, Dept Pathol, Santiago De Compostela, Spain.	Angel.Manuel.Vazquez.Boquete@sergas.es		Fraga Rodriguez, Maximo/0000-0001-6185-9562			Abubakar M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0765-6; Allred DC, 1998, MODERN PATHOL, V11, P155; Arima N, 2016, J CLIN PATHOL, V69, P255, DOI 10.1136/jclinpath-2015-203174; Badve S, 2009, J CLIN PATHOL, V62, P6, DOI 10.1136/jcp.2008.059899; Barton S, 2012, BRIT J CANCER, V106, P1760, DOI 10.1038/bjc.2012.166; Bast RC, 2005, CLIN CANCER RES, V11, P6103, DOI 10.1158/1078-0432.CCR-04-2213; Bastien RRL, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-44; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Chan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132449; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Collins LC, 2005, AM J CLIN PATHOL, V123, P16, DOI 10.1309/HCF035N9WK40ETJ0; Cserni G, 2011, PATHOL ONCOL RES, V17, P663, DOI 10.1007/s12253-011-9366-y; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; De Maeyer L, 2008, J CLIN ONCOL, V26, P335, DOI 10.1200/JCO.2007.14.8411; Dekker TJA, 2015, BREAST CANCER RES TR, V152, P247, DOI 10.1007/s10549-015-3444-x; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Rojo MG, 2009, FOLIA HISTOCHEM CYTO, V47, P349, DOI 10.2478/v10042-008-0114-4; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Grann VR, 2005, CANCER-AM CANCER SOC, V103, P2241, DOI 10.1002/cncr.21030; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hanna WM, 2014, MODERN PATHOL, V27, P4, DOI 10.1038/modpathol.2013.103; Hayashi S, 2014, BREAST CANCER-TOKYO, V21, P47, DOI 10.1007/s12282-012-0353-2; Howlader N, 2013, SEER CANC STAT REV 1; Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8; Inwald EC, 2015, BREAST CANCER RES TR, V153, P647, DOI 10.1007/s10549-015-3572-3; Koka R, 2013, SEMIN DIAGN PATHOL, V30, P321, DOI 10.1053/j.semdp.2013.11.004; Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679; Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841; Paik S, 2005, J CLIN ONCOL, V16, P510; Phillips T, 2007, APPL IMMUNOHISTO M M, V15, P325, DOI 10.1097/01.pai.0000213135.16783.bc; Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134; Puig-Vives M, 2013, GYNECOL ONCOL, V130, P609, DOI 10.1016/j.ygyno.2013.05.039; Rakha EA, 2007, J CLIN ONCOL, V25, P4772, DOI 10.1200/JCO.2007.12.2747; Reisenbichler ES, 2013, AM J CLIN PATHOL, V140, P487, DOI 10.1309/AJCP1RF9FUIZRDPI; Rhodes A, 2009, J CLIN PATHOL, V62, P95, DOI 10.1136/jcp.2008.060723; Schneeweiss A, 2015, GEBURTSH FRAUENHEILK, V75, P574, DOI 10.1055/s-0035-1546150; Schroth W, 2016, BREAST CANCER RES TR, V155, P85, DOI 10.1007/s10549-015-3651-5; Spitale A, 2009, ANN ONCOL, V20, P628, DOI 10.1093/annonc/mdn675; Sun JZ, 2015, ONCOL LETT, V10, P1741, DOI 10.3892/ol.2015.3461; Vuong D, 2014, VIRCHOWS ARCH, V465, P1, DOI 10.1007/s00428-014-1593-7; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yao K, 2015, BREAST CANCER RES TR, V154, P81, DOI 10.1007/s10549-015-3587-9	43	5	5	3	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					195	203		10.1007/s00428-017-2194-z			9	Pathology	Pathology	FZ6IF	WOS:000427700600003	28825136				2019-10-28	
J	Flood, TA; Schieda, N; Sim, J; Breau, RH; Morash, C; Belanger, EC; Robertson, SJ				Flood, Trevor A.; Schieda, Nicola; Sim, Jordan; Breau, Rodney H.; Morash, Chris; Belanger, Eric C.; Robertson, Susan J.			Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer	VIRCHOWS ARCHIV			English	Article						Prostate; Prostate cancer; Biochemical recurrence; Gleason score; Gleason pattern; Radical prostatectomy	GLEASON PATTERN 5; NEEDLE-BIOPSY; INTRADUCTAL CARCINOMA; RETROPUBIC PROSTATECTOMY; PROGNOSTIC-SIGNIFICANCE; CRIBRIFORM PATTERN; FREE SURVIVAL; FOLLOW-UP; ADENOCARCINOMA; PROGRESSION	We assessed Gleason pattern 5 (GP5) and other prostatic adenocarcinoma (PCa) morphologies to determine their association with biochemical recurrence (BCR). A search for grade group 5 PCa with radical prostatectomy (RP) yielded 49 patients. RPs were reviewed for %GP5 and morphologies (sheets, single cells, cords, small solid cylinders, solid medium to large nests with rosette-like spaces [SMLNRS], comedonecrosis, cribriform glands, glomerulations, intraductal carcinoma of the prostate [IDC-P], and prostatic ductal adenocarcinoma [PDCa]). Prevalence of morphologies was as follows: single cells 100%, cribriform glands 98.7%, cords 85.7%, IDC-P 77.6%, comedonecrosis 53.1%, sheets 49.0%, small solid cylinders 49.0%, PDCa 44.9%, glomerulations 34.7%, and SMLNRS 14.3%. From 28 patients who were treated with RP as monotherapy, 64.3% (18/28) had BCR. Comedonecrosis, sheets, small solid cylinders, IDC-P, and PDCa were significantly associated with BCR. Number of morphologies on RP and %GP5 were higher in patients with BCR (6.8 +/- 2.1 versus 3.7 +/- 2.9%; P < 0.001 and 26.9 +/- 16.8 versus 11.4 +/- 14.1%; P = 0.02) with area under ROC curve of 0.89 (confidence intervals [CI] 0.77-1.00). Sensitivity/specificity was 77.8/80.0% for predicting BCR when ae<yen> 5 morphologies were present and 0.79 (CI 0.60-0.99) with sensitivity/specificity of 66.7/80.0% for predicting BCR when ae<yen> 15% GP5 was present. Hazard ratio for BCR was higher with increasing number of morphologies (1.23, CI 1.02-1.49; P = 0.034) but not %GP5 (0.99, CI 0.97-1.02, P = 0.622). Our results indicate that GP5 morphologies may represent a biologically heterogeneous group and that an increasing number of PCa morphologies on RP is strongly associated with an increased risk of BCR.	[Flood, Trevor A.; Sim, Jordan; Belanger, Eric C.; Robertson, Susan J.] Ottawa Hosp, Dept Pathol & Lab Med, 501 Smyth Rd,4th Floor CCW, Ottawa, ON K1H 8L6, Canada; [Schieda, Nicola] Ottawa Hosp, Dept Med Imaging, Ottawa, ON, Canada; [Breau, Rodney H.; Morash, Chris] Ottawa Hosp, Dept Urol, Ottawa, ON, Canada	Flood, TA (reprint author), Ottawa Hosp, Dept Pathol & Lab Med, 501 Smyth Rd,4th Floor CCW, Ottawa, ON K1H 8L6, Canada.	tflood@toh.on.ca		Breau, Rodney/0000-0003-2344-9022			Abern MR, 2014, CANCER-AM CANCER SOC, V120, P1656, DOI 10.1002/cncr.28647; Bach C, 2014, NAT REV UROL, V11, P342, DOI 10.1038/nrurol.2014.100; Ball MW, 2015, UROLOGY, V85, P161, DOI 10.1016/j.urology.2014.08.025; Choy B, 2016, AM J SURG PATHOL, V40, P1400, DOI 10.1097/PAS.0000000000000691; Dong F, 2013, AM J SURG PATHOL, V37, P1855, DOI 10.1097/PAS.0b013e3182a02169; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2010, MED PRIN PRACT, V19, P82, DOI 10.1159/000252842; Fajardo DA, 2011, AM J SURG PATHOL, V35, P1706, DOI 10.1097/PAS.0b013e318228571d; Fajkovic H, 2016, UROL ONCOL, V34; Flood TA, 2016, VIRCHOWS ARCH, V469, P313, DOI 10.1007/s00428-016-1981-2; Furukawa Junya, 2016, Curr Urol, V9, P67, DOI 10.1159/000442856; Gerber GS, 1997, EUR UROL, V32, P385, DOI 10.1159/000480794; Gottipati S, 2012, AM J SURG PATHOL, V36, P900, DOI 10.1097/PAS.0b013e3182495dee; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Huang Y, 2016, ASIAN J ANDROL, V18, P780, DOI 10.4103/1008-682X.156636; Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365-2559.2011.04039.x; Iczkowski KA, 2011, AM J CLIN PATHOL, V136, P98, DOI 10.1309/AJCPZ7WBU9YXSJPE; Ischia J, 2013, INT J UROL, V20, P290, DOI 10.1111/iju.12069; Kang YJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3307-4; Keefe DT, 2015, VIRCHOWS ARCH, V467, P437, DOI 10.1007/s00428-015-1809-5; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P610, DOI 10.5858/arpa.2012-0128-OA; Kweldam CF, 2017, MOD PATHOL OFF J US; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Lawrentschuk N, 2010, CURR ONCOL, V17, pS25; Meng MV, 2005, J UROLOGY, V173, P1557, DOI 10.1097/01.ju.0000154610.81916.81; Miyai K, 2014, INT J CLIN EXP PATHO, V7, P2518; Morlacco A, 2016, CRIT REV ONCOL HEMAT, V102, P135, DOI 10.1016/j.critrevonc.2016.04.011; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; Park YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25419; Ploussard G, 2011, UROLOGY, V78, P607, DOI 10.1016/j.urology.2011.05.021; Ritch CR, 2014, UROLOGY, V83, P1309, DOI 10.1016/j.urology.2014.02.023; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Roehl KA, 2004, J UROLOGY, V172, P910, DOI 10.1097/01.ju.0000134888.22332.bb; Shah RB, 2015, AM J SURG PATHOL, V39, P1242, DOI 10.1097/PAS.0000000000000442; Siadat F, 2015, PROSTATE, V75, P1277, DOI 10.1002/pros.23009; Sooriakumaran P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1502; Stephenson AJ, 2006, J CLIN ONCOL, V24, P3973, DOI 10.1200/JCO.2005.04.0756; Trudel D, 2014, EUR J CANCER, V50, P1610, DOI 10.1016/j.ejca.2014.03.009	40	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					205	212		10.1007/s00428-017-2241-9			8	Pathology	Pathology	FZ6IF	WOS:000427700600004	28975495				2019-10-28	
J	Sauvestre, F; Belleannee, G; Breal, C; Mohr, C; Fong, HI; Cossin, S; Tabrizi, R; Milpied, N; Vigouroux, S; Goussot, JF; Marty, M				Sauvestre, Fanny; Belleannee, Genevieve; Breal, Claire; Mohr, Catherine; Fong, Harold IpKan; Cossin, Sebastien; Tabrizi, Reza; Milpied, Noel; Vigouroux, Stephane; Goussot, Jean-Francois; Marty, Marion			Histologic analysis has a prognostical value in colorectal biopsies assessed for suspicion of graft-versus-host disease	VIRCHOWS ARCHIV			English	Article						Graft-versus host disease; Apoptosis; Colon; Stem cell transplantation; Mycophenolate mofetil	CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT; BONE-MARROW TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CLINICAL-TRIALS; INDUCED COLITIS; COLON BIOPSIES; RECTAL BIOPSY; DIAGNOSIS; MYCOPHENOLATE	Gastrointestinal (GI) graft-versus-host-disease (GVHD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation, but clinical and histological features are unspecific. The aim of this study was to correlate the histological GI GVHD grade with the clinical outcomes. In a retrospective study of 112 patients with clinically suspected GI GVHD, colonic biopsies were reviewed by three pathologists without knowledge of the corresponding clinical data and classified in four scores, according to the NIH Consensus Project recommendations: no GVHD, possible, probable, and unequivocal GVHD. At the end of the study, the histological and clinical data were confronted with the following results: clinical diagnosis of GI GVHD was established for 70 patients (62.5%) and histological scores correlated well with the clinical diagnosis (p < 0.001) and particularly with the prognosis (p < 0.05).When severe lesions were observed, the 1 year overall survival declined to 9%. None of the features reported in the literature to support GVHD diagnosis, eosinophil count, endocrine cells aggregate, immunohistochemical analysis (cytomegalovirus, CD123, chromogranin), did not help us for diagnosis. So routine histopathology alone without immunohistochemistry is a strong and reproducible tool to diagnose GI GVHD with the help of clinical and biological information, and most importantly, histological grading proved to be a powerful prognostic value.	[Sauvestre, Fanny; Belleannee, Genevieve; Fong, Harold IpKan; Goussot, Jean-Francois; Marty, Marion] Haut Leveque Hosp, Univ Hosp Bordeaux, Dept Pathol, Ave Magellan, F-33604 Pessac, France; [Breal, Claire; Mohr, Catherine; Tabrizi, Reza; Milpied, Noel; Vigouroux, Stephane] Haut Leveque Hosp, Univ Hosp Bordeaux, Dept Hematol, Pessac, France; [Cossin, Sebastien] Univ Bordeaux, Populat Hlth, ISPED, Bordeaux, France	Sauvestre, F (reprint author), Haut Leveque Hosp, Univ Hosp Bordeaux, Dept Pathol, Ave Magellan, F-33604 Pessac, France.	fanny.sauvestre@u-bordeaux.fr	Cossin, Sebastien/T-7132-2019	Cossin, Sebastien/0000-0002-3845-8127; Milpied, Noel/0000-0002-5177-014X; sauvestre, fanny/0000-0001-6759-0648			Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Castilla-Llorente C, 2014, BONE MARROW TRANSPL, V49, P966, DOI 10.1038/bmt.2014.69; EPSTEIN RJ, 1980, GASTROENTEROLOGY, V78, P764; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; LEE FD, 1993, J CLIN PATHOL, V46, P118, DOI 10.1136/jcp.46.2.118; Leino DG, 2012, MODERN PATHOL, V25, p167A; Lin JM, 2013, HUM PATHOL, V44, P2075, DOI 10.1016/j.humpath.2013.02.023; Lin JM, 2013, AM J SURG PATHOL, V37, P539, DOI 10.1097/PAS.0b013e318272c62a; Nguyen CV, 2008, DIGEST DIS SCI, V53, P747, DOI 10.1007/s10620-007-9904-3; Papadimitriou JC, 2003, INT J SURG PATHOL, V11, P295, DOI 10.1177/106689690301100406; Remberger M, 2011, BIOL BLOOD MARROW TR, V17, P1688, DOI 10.1016/j.bbmt.2011.05.001; Ross WA, 2005, CURR OPIN GASTROEN, V21, P64; Schulenburg A, 2004, ANN HEMATOL, V83, P101, DOI 10.1007/s00277-003-0756-4; Shidham VB, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-5; Shulman HM, 2006, BIOL BLOOD MARROW TR, V12, P31, DOI 10.1016/j.bbmt.2005.10.023; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; SNOVER DC, 1985, HUM PATHOL, V16, P387, DOI 10.1016/S0046-8177(85)80232-X; Star KV, 2013, AM J SURG PATHOL, V37, P1319, DOI 10.1097/PAS.0b013e31829ab1ef; SVILAND L, 1988, J CLIN PATHOL, V41, P148, DOI 10.1136/jcp.41.2.148; Thompson B, 2006, BONE MARROW TRANSPL, V38, P371, DOI 10.1038/sj.bmt.1705453; Washington K, 1997, AM J SURG PATHOL, V21, P1037, DOI 10.1097/00000478-199709000-00008; Washington K, 2009, HUM PATHOL, V40, P909, DOI 10.1016/j.humpath.2009.04.001	22	1	1	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					213	220		10.1007/s00428-017-2272-2			8	Pathology	Pathology	FZ6IF	WOS:000427700600005	29167990				2019-10-28	
J	Verschoor, AJ; Bovee, JVMG; Overbeek, LIH; Hogendoorn, PCW; Gelderblom, H				Verschoor, Arie J.; Bovee, J. V. M. G.; Overbeek, L. I. H.; Hogendoorn, P. C. W.; Gelderblom, H.		PALGA Grp	The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study	VIRCHOWS ARCHIV			English	Article						Gastrointestinal stromal tumours; Epidemiology; Incidence; Mutation; Pathology; Soft tissue neoplasms	CLINICAL-PRACTICE GUIDELINES; DIFFERENTIAL-DIAGNOSIS; IMATINIB MESYLATE; FOLLOW-UP; SUCCINATE-DEHYDROGENASE; PDGFRA MUTATIONS; KIT; GISTS; TRIAL; ERA	Symptomatic gastrointestinal stromal tumours (GIST) are infrequent with an incidence of 12.7 per million inhabitants in the western population. We studied whether the incidence of GIST has further increased between 2003 and 2012 and assessed the frequency of mutations, risk groups, histological subtypes and immunohistochemistry results. From PALGA, the nationwide Dutch Pathology Registry, pathology excerpts from all patients with a GIST or GIST-like tumour between 2003 and 2012 were retrieved to calculate incidence rates. Full pathology reports were retrieved of resections in 2011 and 2012 to study the frequency of mutations, risk groups, histological subtypes and immunohistochemistry results. The incidence of GIST increased to 17.7 per million inhabitants in 2012 with a median age of 67 years. Mutational analysis was performed in 33.9% of patients with a resection between 2011 and 2012 (KIT mutation 67.5%, PDGFRA 16.3%, wild-type 11.4%). The percentage of high risk patients in the different risk classifications varied from 19.9% to 38.0% depending on the used classification. Only 35.9% of patients had diagnosis or revision of pathology diagnosis within three months in a designated GIST referral centre. No increase in proportion of central pathology reviews was found. Proportion of patients with mutational analysis increased over the years. The registered incidence of GIST, 17.7 per million inhabitants in 2012 in the Netherlands, is still rising. Despite incorporation in the ESMO GIST guidelines since 2008 for mutational testing and since 2010 for central review of pathology, both are performed in a minority of patients.	[Verschoor, Arie J.; Gelderblom, H.] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Bovee, J. V. M. G.; Hogendoorn, P. C. W.] Leiden Univ, Dept Pathol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Overbeek, L. I. H.; PALGA Grp] PALGA, Randhoeve 225A, NL-3995 GA Houten, Netherlands	Verschoor, AJ (reprint author), Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	A.J.Verschoor@lumc.nl	Verschoor, Arjan/S-2655-2019; Hogendoorn, Pancras/O-6494-2019; Hogendoorn, Pancras C.W./H-5859-2015	Verschoor, Arjan/0000-0001-9972-4241; Hogendoorn, Pancras/0000-0002-1513-8104; Hogendoorn, Pancras C.W./0000-0002-1513-8104	NovartisNovartis	This work was supported by Novartis with an unconditional financial grant.	Ahmad OB, 2001, AGE STANDARDIZATION; Capocaccia R, 2015, EUR J CANC PREV; Casali PG, 2008, ANN ONCOL, V19, P35, DOI 10.1093/annonc/mdn080; Casali PG, 2010, ANN ONCOL, V21, pv98, DOI 10.1093/annonc/mdq208; Casali PG, 2014, ANN ONCOL, V25, P21, DOI 10.1093/annonc/mdu255; Casparie M, 2007, CELL ONCOL, V29, P19; Cassier PA, 2010, BRIT J CANCER, V103, P165, DOI 10.1038/sj.bjc.6605743; Cassier PA, 2012, CLIN CANCER RES, V18, P4458, DOI 10.1158/1078-0432.CCR-11-3025; Chiang NJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-102; Choi AH, 2015, J GASTROINTEST SURG, V19, P1699, DOI 10.1007/s11605-015-2860-x; Corless CL, 2014, J CLIN ONCOL, V32, P1563, DOI 10.1200/JCO.2013.51.2046; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; Debiec-Rychter M, 2006, EUR J CANCER, V42, P1093, DOI 10.1016/j.ejca.2006.01.030; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Goettsch WG, 2005, EUR J CANCER, V41, P2868, DOI 10.1016/j.ejca.2005.09.009; Gold JS, 2009, LANCET ONCOL, V10, P1045, DOI 10.1016/S1470-2045(09)70242-6; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; IKNL (Netherlands Comprehensive Cancer Organisation), 2011, DUTCH GUID DIAGN TRE; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Joensuu H, 2012, JAMA-J AM MED ASSOC, V307, P1265, DOI 10.1001/jama.2012.347; Lv MZ, 2014, GASTROENT RES PRACT, DOI 10.1155/2014/834136; Ma GL, 2015, CANCER EPIDEM BIOMAR, V24, P298, DOI 10.1158/1055-9965.EPI-14-1002; Marrari A, 2012, ARCH PATHOL LAB MED, V136, P483, DOI 10.5858/arpa.2011-0082-RA; Miettinen M, 2001, VIRCHOWS ARCH, V438, P1, DOI 10.1007/s004280000338; Miettinen M, 2002, HUM PATHOL, V33, P478, DOI 10.1053/hupa.2002.124123; Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466; Miettinen M, 2011, AM J SURG PATHOL, V35, P1712, DOI 10.1097/PAS.0b013e3182260752; Mucciarini C, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-230; Nilsson B, 2005, CANCER-AM CANCER SOC, V103, P821, DOI 10.1002/cncr.20862; Novelli M, 2010, HISTOPATHOLOGY, V57, P259, DOI 10.1111/j.1365-2559.2010.03624.x; Reichardt P, 2012, EXPERT REV ANTICANC, V12, P1053, DOI [10.1586/ERA.12.48, 10.1586/era.12.48]; Rutkowski P, 2013, ANN SURG ONCOL, V20, P2937, DOI 10.1245/s10434-013-3013-7; Sciot R, 2008, EUR J CANCER, V44, P1855, DOI 10.1016/j.ejca.2008.06.003; van Roggen JFG, 2001, J CLIN PATHOL, V54, P96, DOI 10.1136/jcp.54.2.96; Verweij J, 2003, EUR J CANCER, V39, P2006, DOI 10.1016/S0959-8049(02)00836-5; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8	38	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					221	229		10.1007/s00428-017-2285-x			9	Pathology	Pathology	FZ6IF	WOS:000427700600006	29308530	Other Gold, Green Published			2019-10-28	
J	Zidar, N; Bostjancic, E; Malgaj, M; Gale, N; Dovsak, T; Didanovic, V				Zidar, Nina; Bostjancic, Emanuela; Malgaj, Marija; Gale, Nina; Dovsak, Tadej; Didanovic, Vojko			The role of epithelial-mesenchymal transition in squamous cell carcinoma of the oral cavity	VIRCHOWS ARCHIV			English	Article						Oral carcinoma; Metastasis; Epithelial-mesenchymal transition; MicroRNA	MIR-200 FAMILY; E-CADHERIN; DOWN-REGULATION; EXPRESSION; METASTASIS; CANCER; HEAD; NECK; MICRORNAS; CATENIN	Epithelial-mesenchymal transition (EMT) has emerged as a possible mechanism of cancer metastasizing, but strong evidence for EMT involvement in human cancer is lacking. Our aim was to compare oral spindle cell carcinoma (SpCC) as an example of EMT with oral conventional squamous cell carcinoma (SCC) with and without nodal metastases to test the hypothesis that EMT contributes to metastasizing in oral SCC. Thirty cases of oral SCC with and without nodal metastasis and 15 cases of SpCC were included. Epithelial (cytokeratin, E-cadherin), mesenchymal (vimentin, N-cadherin), and stem cell markers (ALDH-1, CD44, Nanog, Sox-2) and transcription repressors (Snail, Slug, Twist) were analyzed immunohistochemically. We also analyzed the expression of microRNAs miR-141, miR-200 family, miR-205, and miR-429. SpCC exhibited loss of epithelial markers and expression of mesenchymal markers or coexpression of both up-regulation of transcription repressors and down-regulation of the investigated microRNAs. SCC showed only occasional focal expression of mesenchymal markers at the invasive front. No other differences were observed between SCC with and without nodal metastases except for a higher expression of ALDH-1 in SCC with metastases. Our results suggest that SpCC is an example of true EMT but do not support the hypothesis that EMT is involved in metastasizing of conventional SCC. Regarding oral SCC progression and metastasizing, we have been facing a shift from the initial enthusiasm for the EMT concept towards a more critical approach with "EMT-like" and "partial EMT" concepts. The real question, though, is, is there no EMT at all?.	[Zidar, Nina; Bostjancic, Emanuela; Gale, Nina] Univ Ljubljana, Inst Pathol, Fac Med, Korytkova 2, Ljubljana 1000, Slovenia; [Malgaj, Marija] Univ Clin Ctr, Dept Nephrol, Zaloska 7, Ljubljana, Slovenia; [Dovsak, Tadej; Didanovic, Vojko] Univ Clin Ctr, Dept Maxillofacial & Oral Surg, Zaloska 7, Ljubljana, Slovenia	Zidar, N (reprint author), Univ Ljubljana, Inst Pathol, Fac Med, Korytkova 2, Ljubljana 1000, Slovenia.	nina.zidar@mf.uni-lj.si					Angadi PV, 2016, INT J SURG PATHOL, V24, P696, DOI 10.1177/1066896916654763; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bryne M, 1998, Oral Dis, V4, P70; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaw SY, 2012, ORAL ONCOL, V48, P997, DOI 10.1016/j.oraloncology.2012.05.011; Chou MY, 2015, ORAL ONCOL, V51, P31, DOI 10.1016/j.oraloncology.2014.10.002; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; da Silva SD, 2015, CLIN EXP METASTAS, V32, P55, DOI 10.1007/s10585-014-9690-1; da Silva SD, 2015, CANCER, V120, P352; De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Diaz-Martin J, 2014, J PATHOL, V232, P319, DOI 10.1002/path.4289; Du LT, 2011, ORAL ONCOL, V47, P709, DOI 10.1016/j.oraloncology.2011.05.017; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kimura I, 2016, ONCOL LETT, V11, P201, DOI 10.3892/ol.2015.3833; Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5; Kokko LL, 2011, ORAL ONCOL, V47, P510, DOI 10.1016/j.oraloncology.2011.03.026; Lamouille S, 2013, CURR OPIN CELL BIOL, V25, P200, DOI 10.1016/j.ceb.2013.01.008; Latham GJ, 2010, METHODS MOL BIOL, V667, P19, DOI 10.1007/978-1-60761-811-9_2; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pectasides E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094273; Smith A, 2013, ORAL ONCOL, V49, P287, DOI 10.1016/j.oraloncology.2012.10.009; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Tarin D, 2013, CANCER METAST REV, V32, P553, DOI 10.1007/s10555-013-9438-4; Tarin D, 2012, CANCER METAST REV, V31, P21, DOI 10.1007/s10555-011-9326-8; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Watanabe M, 2014, ONCOL LETT, V7, P35; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Zhang S, 2014, ORAL ONCOL, V50, P809, DOI 10.1016/j.oraloncology.2014.06.007; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou CY, 2014, ORAL ONCOL, V50, P1144, DOI 10.1016/j.oraloncology.2014.08.018; Zidar N, 2008, VIRCHOWS ARCH, V453, P267, DOI 10.1007/s00428-008-0649-y; Zidar N, 2016, J CELL MOL MED, V20, P1813, DOI 10.1111/jcmm.12869; Zidar N, 2011, HUM PATHOL, V42, P482, DOI 10.1016/j.humpath.2010.07.020	39	4	4	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					237	245		10.1007/s00428-017-2192-1			9	Pathology	Pathology	FZ6IF	WOS:000427700600008	28699108				2019-10-28	
J	Pierry, C; Caumont, C; Blanchard, E; Brochet, C; Dournes, G; Gros, A; Bandres, T; Verdon, S; Marty, M; Begueret, H; Merlio, JP				Pierry, Clemence; Caumont, Charline; Blanchard, Elodie; Brochet, Camille; Dournes, Gael; Gros, Audrey; Bandres, Thomas; Verdon, Severine; Marty, Marion; Begueret, Hugues; Merlio, Jean-Philippe			Assessment of BRAF(V600E) mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction	VIRCHOWS ARCHIV			English	Article						Pulmonary Langerhans cell histiocytosis; BRAF mutation; Digital droplet polymerase chain reaction; Next-generation sequencing; Bronchoalveolar lavage	ERDHEIM-CHESTER DISEASE; BRAF V600E MUTATIONS; MAP2K1 MUTATIONS; HIGH PREVALENCE; FREE DNA; NEOPLASMS; IMMUNOHISTOCHEMISTRY; VEMURAFENIB; EXPRESSION; DIAGNOSIS	The neoplastic nature of pulmonary Langerhans cell histiocytosis (PLCH) is still debated. As the detection of BRAF (V600E) and MAP2K1 mutations in patients with PCLH is now considered for such assessment, the aim of our study was to evaluate digital droplet polymerase chain reaction (ddPCR) in PCLH diagnosis. We retrospectively analyzed BRAF(V600E) detection in a cohort of 42 PCLH tissues and 18 bronchoalveolar lavages (BALs) by ddPCR, immunohistochemistry, high-resolution melting PCR (HRM), and next-generation sequencing (NGS). The presence of BRAF(V600E) mutation was assessed by at least two concordant techniques to further evaluate specificity and sensitivity of each method. The BRAF (V600E) mutation prevalence was detected in 18 out of 41 cases by ddPCR, 10 out of 36 cases by HRM PCR, and 16 out of 31 cases by NGS. BRAF(V600E) immunohistochemistry sensitivity was 94%, and specificity was 79%. HRM PCR sensitivity was only 59%, and specificity was 100%. NGS sensitivity and specificity were 100% for interpretable cases (n = 31), but in 11 cases, this technique was non-contributive. The analysis of BAL samples by ddPCR revealed a BRAF(V600E) mutation both in tissue and in BAL samples in one patient, a wild-type status both in tissue and in BAL samples in two patients, and a wild-type BRAF status in BAL and a BRAF(V600E) mutation in tissue samples in four patients. The study supports the usefulness of ddPCR for BRAF status assessment in either tissue or BAL samples to increase the accuracy of PLCH diagnosis.	[Pierry, Clemence; Marty, Marion; Begueret, Hugues] CHU Bordeaux, Dept Pathol, F-33604 Bordeaux, France; [Pierry, Clemence; Caumont, Charline; Gros, Audrey; Bandres, Thomas; Verdon, Severine; Merlio, Jean-Philippe] CHU Bordeaux, Lab Tumor Biol & Tumor Biobank, F-33604 Bordeaux, France; [Caumont, Charline; Gros, Audrey; Merlio, Jean-Philippe] Univ Bordeaux, INSERM, U1053, F-33076 Bordeaux, France; [Blanchard, Elodie; Brochet, Camille] CHU Bordeaux, Dept Pneumol, F-33604 Bordeaux, France; [Dournes, Gael] Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, INSERM, U1045,CIC 1401, 146 Rue Leo Saignat, F-33076 Bordeaux, France	Merlio, JP (reprint author), CHU Bordeaux, Lab Tumor Biol & Tumor Biobank, F-33604 Bordeaux, France.; Merlio, JP (reprint author), Univ Bordeaux, INSERM, U1053, F-33076 Bordeaux, France.	jp.merlio@u-bordeaux.fr					Alayed K, 2016, HUM PATHOL, V52, P61, DOI 10.1016/j.humpath.2015.12.029; AUERSWALD U, 1991, LUNG, V169, P305, DOI 10.1007/BF02714167; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Berres ML, 2014, J EXP MED, V211, P669, DOI 10.1084/jem.20130977; Boursault L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070826; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Bubolz AM, 2014, ONCOTARGET, V5, P4060, DOI 10.18632/oncotarget.2061; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Chilosi M, 2014, LEUKEMIA LYMPHOMA, V55, P2620, DOI 10.3109/10428194.2014.887713; CHOLLET S, 1984, AM J PATHOL, V115, P225; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Dimmler A, 2017, VIRCHOWS ARCH, V470, P429, DOI 10.1007/s00428-017-2092-4; EGELER RM, 1993, CANCER, V71, P865, DOI 10.1002/1097-0142(19930201)71:3<865::AID-CNCR2820710334>3.0.CO;2-0; Egeler RM, 1998, HEMATOL ONCOL CLIN N, V12, P369, DOI 10.1016/S0889-8588(05)70516-5; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Girschikofsky M, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-72; Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; Heritier S, 2016, J CLIN ONCOL, V34, P3023, DOI 10.1200/JCO.2015.65.9508; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Hyman DM, 2015, CANCER DISCOV, V5, P64, DOI 10.1158/2159-8290.CD-14-0742; Ilie M, 2013, ANN ONCOL, V24, P742, DOI 10.1093/annonc/mds534; Ilie MI, 2014, PATHOLOGY, V46, P311, DOI 10.1097/PAT.0000000000000113; Janku F, 2014, ONCOTARGET, V5, P3607, DOI 10.18632/oncotarget.1964; Kamionek M, 2016, HISTOPATHOLOGY, V69, P499, DOI 10.1111/his.12955; Li Y, 2016, CHINESE MED J-PEKING, V129, P1384, DOI 10.4103/0366-6999.182844; Lommatzsch M, 2016, RESP MED, V119, P168, DOI 10.1016/j.rmed.2016.09.004; Mourah S, 2016, EUR RESPIR J, V47, P1785, DOI 10.1183/13993003.01677-2015; Mourah S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120232; Nelson DS, 2015, GENE CHROMOSOME CANC, V54, P361, DOI 10.1002/gcc.22247; Nelson DS, 2014, BLOOD, V123, P3152, DOI 10.1182/blood-2013-06-511139; Roden AC, 2016, ARCH PATHOL LAB MED, V140, P230, DOI 10.5858/arpa.2015-0246-RA; Roden AC, 2014, AM J SURG PATHOL, V38, P548, DOI 10.1097/PAS.0000000000000129; Sahm F, 2012, BLOOD, V120, pE28, DOI 10.1182/blood-2012-06-429597; Satoh T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033891; Swerdlow SH, 2008, WHO CLASSIFICATION T; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wei R, 2013, BIOMED REP, V1, P365, DOI 10.3892/br.2013.62; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Yousem SA, 2001, AM J SURG PATHOL, V25; Yousem SA, 2013, CHEST, V143, P1679, DOI 10.1378/chest.12-1917; YU RC, 1994, LANCET, V343, P767, DOI 10.1016/S0140-6736(94)91842-2; Zeng K, 2016, HEMATOL ONCOL; Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582	46	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					247	258		10.1007/s00428-017-2185-0			12	Pathology	Pathology	FZ6IF	WOS:000427700600009	28711990				2019-10-28	
J	Moon, A; Smith, GH; Kong, J; Rogers, TE; Ellis, CL; Farris, AB				Moon, Andres; Smith, Geoffrey H.; Kong, Jun; Rogers, Thomas E.; Ellis, Carla L.; Farris, Alton B. Brad, III			Development of CD3 cell quantitation algorithms for renal allograft biopsy rejection assessment utilizing open source image analysis software	VIRCHOWS ARCHIV			English	Article						Renal allograft; Image analysis; Immunohistochemistry; Whole slide image; Rejection	ANTIBODY-MEDIATED REJECTION; INTERSTITIAL FIBROSIS; WORKING CLASSIFICATION; BANFF CLASSIFICATION; TRANSPLANT BIOPSY; PATHOLOGY; DIAGNOSIS; STANDARDIZATION; QUANTIFICATION; NOMENCLATURE	Renal allograft rejection diagnosis depends on assessment of parameters such as interstitial inflammation; however, studies have shown interobserver variability regarding interstitial inflammation assessment. Since automated image analysis quantitation can be reproducible, we devised customized analysis methods for CD3+ T-cell staining density as a measure of rejection severity and compared them with established commercial methods along with visual assessment. Renal biopsy CD3 immunohistochemistry slides (n = 45), including renal allografts with various degrees of acute cellular rejection (ACR) were scanned for whole slide images (WSIs). Inflammation was quantitated in the WSIs using pathologist visual assessment, commercial algorithms (Aperio nuclear algorithm for CD3+ cells/mm(2) and Aperio positive pixel count algorithm), and customized open source algorithms developed in ImageJ with thresholding/positive pixel counting (custom CD3+%) and identification of pixels fulfilling "maxima" criteria for CD3 expression (custom CD3+ cells/mm(2)). Based on visual inspections of "markup" images, CD3 quantitation algorithms produced adequate accuracy. Additionally, CD3 quantitation algorithms correlated between each other and also with visual assessment in a statistically significant manner (r = 0.44 to 0.94, p = 0.003 to < 0.0001). Methods for assessing inflammation suggested a progression through the tubulointerstitial ACR grades, with statistically different results in borderline versus other ACR types, in all but the custom methods. Assessment of CD3-stained slides using various open source image analysis algorithms presents salient correlations with established methods of CD3 quantitation. These analysis techniques are promising and highly customizable, providing a form of on-slide "flow cytometry" that can facilitate additional diagnostic accuracy in tissue-based assessments.	[Moon, Andres; Smith, Geoffrey H.; Rogers, Thomas E.; Ellis, Carla L.; Farris, Alton B. Brad, III] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; [Kong, Jun] Emory Univ, Dept Bioinformat, Atlanta, GA 30322 USA; [Farris, Alton B. Brad, III] Emory Univ Hosp, 1364 Clifton Rd NE,Room H-188, Atlanta, GA 30322 USA	Farris, AB (reprint author), Emory Univ, Dept Pathol, Atlanta, GA 30322 USA.; Farris, AB (reprint author), Emory Univ Hosp, 1364 Clifton Rd NE,Room H-188, Atlanta, GA 30322 USA.	abfarri@emory.edu	Farris, Alton Brad/S-6041-2017	Farris, Alton Brad/0000-0001-5534-7763			Albarqouni S, 2016, IEEE T MED IMAGING, V35, P1313, DOI 10.1109/TMI.2016.2528120; Aperio Technologies, 2009, AP SUPP DOC; Aperio Technologies, 2009, IM AN AP; Berry GJ, 2013, J HEART LUNG TRANSPL, V32, P1147, DOI 10.1016/j.healun.2013.08.011; Cendales LC, 2008, AM J TRANSPLANT, V8, P1396, DOI 10.1111/j.1600-6143.2008.02243.x; Demetris AJ, 2016, AM J TRANSPLANT; Drachenberg CB, 2011, AM J TRANSPLANT, V11, P1792, DOI 10.1111/j.1600-6143.2011.03670.x; Farris AB, 2014, AM J TRANSPLANT, V14, P897, DOI 10.1111/ajt.12641; Farris AB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161019; Farris AB, 2011, J AM SOC NEPHROL, V22, P176, DOI 10.1681/ASN.2009091005; Farris AB, 2010, VIRCHOWS ARCH, V457, P329, DOI 10.1007/s00428-010-0948-y; Farris AB, 2017, ARCH PATHOL LAB MED, V141, P542, DOI 10.5858/arpa.2016-0265-SA; Furness PN, 2003, AM J SURG PATHOL, V27, P805, DOI 10.1097/00000478-200306000-00012; Grimm P C, 1999, Pediatr Transplant, V3, P257, DOI 10.1034/j.1399-3046.1999.00044.x; Grimm PC, 2003, J AM SOC NEPHROL, V14, P1662, DOI 10.1097/01.ASN.0000066143.02832.5E; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Janowczyk Andrew, 2016, J Pathol Inform, V7, P29, DOI 10.4103/2153-3539.186902; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Mannon RB, 2010, AM J TRANSPLANT, V10, P2066, DOI 10.1111/j.1600-6143.2010.03240.x; Meas-Yedid V, 2011, TRANSPLANTATION, V92, P890, DOI 10.1097/TP.0b013e31822d879a; Mengel M, 2007, AM J TRANSPLANT, V7, P356, DOI 10.1111/j.1600-6143.2006.01635.x; MEYER F, 1994, SIGNAL PROCESS, V38, P113, DOI 10.1016/0165-1684(94)90060-4; Nicholson ML, 1999, TRANSPLANTATION, V68, P236, DOI 10.1097/00007890-199907270-00013; Nicholson ML, 1996, BRIT J SURG, V83, P1082, DOI 10.1002/bjs.1800830813; Pape L, 2003, TRANSPLANTATION, V76, P955, DOI 10.1097/01.TP.0000078899.62040.E5; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Servais A, 2011, AM J TRANSPLANT, V11, P1456, DOI 10.1111/j.1600-6143.2011.03594.x; Servais A, 2009, AM J TRANSPLANT, V9, P2552, DOI 10.1111/j.1600-6143.2009.02803.x; Servais A, 2007, TRANSPLANTATION, V84, P1595, DOI 10.1097/01.tp.0000295749.50525.bd; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; Solez K, 2013, KIDNEY INT, V83, P201, DOI 10.1038/ki.2012.395; Solez K, 2010, CURR OPIN ORGAN TRAN, V15, P49, DOI 10.1097/MOT.0b013e328334fedb; Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019; Stewart S, 2007, J HEART LUNG TRANSPL, V26, P1229, DOI 10.1016/j.healun.2007.10.017; Sund S, 2004, NEPHROL DIAL TRANSPL, V19, P2838, DOI 10.1093/ndt/gfh490; Williams WW, 2012, NAT REV NEPHROL, V8, P110, DOI 10.1038/nrneph.2011.213; Xu J, 2016, NEUROCOMPUTING, V191, P214, DOI 10.1016/j.neucom.2016.01.034; ZACK GW, 1977, J HISTOCHEM CYTOCHEM, V25, P741, DOI 10.1177/25.7.70454	38	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					259	269		10.1007/s00428-017-2260-6			11	Pathology	Pathology	FZ6IF	WOS:000427700600010	29116389				2019-10-28	
J	Kobayashi, M; Ogawa, E; Okuyama, R; Kanno, H				Kobayashi, Mikiko; Ogawa, Eisaku; Okuyama, Ryuhei; Kanno, Hiroyuki			In vasculitis of small muscular arteries, activation of vessel-infiltrating CD8 T cells seems to be antigen-independent	VIRCHOWS ARCHIV			English	Article						Vasculitis; CD8 T cells; Innate immunity	POLYARTERITIS-NODOSA; EXPRESSION; CYTOKINES; DISEASE; MUSCLE	The etiology of polyarteritis nodosa (PAN) and localized PAN is still unknown, although a T cell-mediated immune mechanism has been considered. CD8 T cells participate not only in the antigen-dependent adaptive immune system, but also in the antigen-independent innate immune system. Non-antigen-activated CD8 T cells express a unique phenotype: granzyme B (GrB) positive /CD25 negative /programmed death-1 (PD-1) negative. The aims of this study were to assess the participation of T cells, especially innate CD8 T cells, in the development of vasculitis. Twenty-eight consecutive cases of skin biopsy specimens with cutaneous vasculitis of small muscular arteries (CVSMA) were retrieved. The series comprises of 21 cases of cutaneous arteritis, three cases of PAN, and four cases of rheumatoid vasculitis. Cases of antineutrophil cytoplasmic antibody-associated vasculitis were excluded. The phenotypes of infiltrating lymphocytes in vasculitis lesions were evaluated by immunohistochemistry. In most cases of CVSMA, the number of CD8 T cells infiltrating the intima was higher than that of CD4 T cells, and significant numbers of GrB-positive cells, which represent activated CD8 T cells, were observed. However, GrB/CD25-double-positive cells, which correspond to antigen-activated T cells, were very few in a small number of cases. Cells positive for PD-1, which is also expressed on antigen-activated CD8 T cells, were not detected. We conclude that a T cell-mediated immune mechanism, involving cytotoxic CD8 T cells, may play a role in the development of CVSMA. Low expression of CD25 in activated CD8 T cells suggests that activation was antigen-independent.	[Kobayashi, Mikiko; Kanno, Hiroyuki] Shinshu Univ, Dept Pathol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Ogawa, Eisaku; Okuyama, Ryuhei] Shinshu Univ, Dept Dermatol, Sch Med, Matsumoto, Nagano 3908621, Japan	Kanno, H (reprint author), Shinshu Univ, Dept Pathol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	hirokan@shinshu-u.ac.jp			Research on Rare and Intractable Diseases, the Ministry of Health, Labor and Welfare of Japan [nannchi-ippann-044]	This work was supported in part by grant from Research on Rare and Intractable Diseases, the Ministry of Health, Labor and Welfare of Japan (nannchi-ippann-044).	Arkin A, 1930, AM J PATHOL, V6, P401; CID MC, 1994, ARTHRITIS RHEUM-US, V37, P1055, DOI 10.1002/art.1780370711; Coll-Vinent B, 1998, ARTHRITIS RHEUM-US, V41, P435, DOI 10.1002/1529-0131(199803)41:3<435::AID-ART9>3.0.CO;2-9; Freeman BE, 2012, P NATL ACAD SCI USA, V109, P9971, DOI 10.1073/pnas.1203543109; Gurer G, 2004, RHEUMATOL INT, V24, P255, DOI 10.1007/s00296-003-0380-6; Iinuma C, 2015, INT IMMUNOL, V27, P105, DOI 10.1093/intimm/dxu088; Ishibashi M, 2008, AM J DERMATOPATH, V30, P319, DOI 10.1097/DAD.0b013e3181766190; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; KISSEL JT, 1989, ANN NEUROL, V25, P291, DOI 10.1002/ana.410250314; Lertmemongkolchai G, 2001, J IMMUNOL, V166, P1097, DOI 10.4049/jimmunol.166.2.1097; Marchi LF, 2014, INT IMMUNOPHARMACOL, V18, P228, DOI 10.1016/j.intimp.2013.12.010; Matsumoto T, 2007, CARDIOVASC PATHOL, V16, P92, DOI 10.1016/j.carpath.2006.09.005; Oudejans JJ, 1996, BLOOD, V87, P3844, DOI 10.1182/blood.V87.9.3844.bloodjournal8793844; Pagnoux C, 2010, ARTHRITIS RHEUM-US, V62, P616, DOI 10.1002/art.27240; Pryshchep O, 2008, CIRCULATION, V118, P1276, DOI 10.1161/CIRCULATIONAHA.108.789172; Sckisel GD, 2014, CLIN EXP IMMUNOL, V175, P79, DOI 10.1111/cei.12186; Suarez-Ramirez JE, 2014, MBIO, V5, DOI 10.1128/mBio.01978-14; Tietze JK, 2012, BLOOD, V119, P3073, DOI 10.1182/blood-2011-07-369736; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001	19	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					271	279		10.1007/s00428-017-2264-2			9	Pathology	Pathology	FZ6IF	WOS:000427700600011	29128969				2019-10-28	
J	Gaiser, MR; Gaiser, T				Gaiser, Maria Rita; Gaiser, Timo			Langerhans and Merkel: a nervous epidermal dispute	VIRCHOWS ARCHIV			English	Article							CELLS		[Gaiser, Maria Rita] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venerol & Allergol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany; [Gaiser, Timo] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany	Gaiser, MR (reprint author), Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venerol & Allergol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	maria.gaiser@umm.de					Koch R, 1982, Zentralbl Bakteriol Mikrobiol Hyg A, V251, P287; Banting FG, 1922, J LAB CLIN MED, V7, P464; Hausen BM, 1988, INSELN P LANGERHANS; Kallius E, 1921, ANAT ANZEIGER, V54, P40; Laguesse E, 1893, CR SOC BIOL, V5, P622; Langerhan P., 1869, THESIS; Langerhans P, 1873, TASTKORPERCHEN RETE, V9, P730; Langerhans P, 1882, ARCH MIKROSKOPISCHE, V20, P641; Langerhans P., 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI DOI 10.1007/BF01959006; Langerhans P, 1885, HDB FUR MADEIRA; Merkel F, 1880, UEBER ENDIGUNGEN SEN; Merkel F, 1875, ARCH MIKROSK ANAT, V11, P636, DOI DOI 10.1007/BF02933819; SILBERBERG I, 1973, ACTA DERM-VENEREOL, V53, P1; Taira K, 2002, J DERMATOL SCI, V30, P195, DOI 10.1016/S0923-1811(02)00104-4; Tretjakoff D, 1902, Z WISS ZOOL ABT A, V71, P625; WEISSMANN A, 1982, AM J DERMATOPATH, V4, P521	16	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					281	284		10.1007/s00428-017-2168-1			4	Pathology	Pathology	FZ6IF	WOS:000427700600012	28620786				2019-10-28	
J	Komforti, MK; Edelman, M; Fan, C; Liang, SRX				Komforti, Miglena K.; Edelman, Morris; Fan, Cathy; Liang, Sharon X.			Solid pseudopapillary neoplasm presenting as a primary ovarian mass in an eighteen-year-old female: report of a case and review of the literature	VIRCHOWS ARCHIV			English	Article							PANCREAS; TUMORS; ORIGIN		[Komforti, Miglena K.; Edelman, Morris; Fan, Cathy; Liang, Sharon X.] Northwell Hlth, Dept Pathol, New Hyde Pk, NY 11040 USA; [Komforti, Miglena K.] Northwell Hlth, Dept Pathol, 6 Ohio Dr,Suite 202, New York, NY 11042 USA	Komforti, MK (reprint author), Northwell Hlth, Dept Pathol, New Hyde Pk, NY 11040 USA.; Komforti, MK (reprint author), Northwell Hlth, Dept Pathol, 6 Ohio Dr,Suite 202, New York, NY 11042 USA.	mdzhupanova@gmail.com		Komforti, Miglena/0000-0002-1522-2541			Cheuk W, 2011, INT J GYNECOL PATHOL, V30, P539, DOI 10.1097/PGP.0b013e31821724fb; Deshpande V, 2010, AM J SURG PATHOL, V34, P1514, DOI 10.1097/PAS.0b013e3181f133e9; Hall AHS, 2016, AJSP-REV REP, V21, P227, DOI 10.1097/PCR.0000000000000157; He SQ, 2015, INT J CLIN EXP PATHO, V8, P8645; ISHIKAWA O, 1990, AM J GASTROENTEROL, V85, P597; Kim JH, 2016, AM SURGEON, V82, P308; Kloppel G, 2010, WHO CLASSIFICATION T, P327; Kominami A, 2014, PATHOL INT, V64, P460, DOI 10.1111/pin.12194; NISHIHARA K, 1993, CANCER, V71, P82, DOI 10.1002/1097-0142(19930101)71:1<82::AID-CNCR2820710114>3.0.CO;2-Y; Pratap G, 2016, INDIAN J PATHOL MICR, V59, P348, DOI 10.4103/0377-4929.188107; Reindl BA, 2014, ARCH PATHOL LAB MED, V138, P974, DOI 10.5858/arpa.2013-0184-CR; Singh K, 2017, INT J GYNECOL PATHOL; Sperti C, 2008, WORLD J GASTROENTERO, V14, P960, DOI 10.3748/wjg.14.960; Stoll LM, 2012, HUM PATHOL, V43, P1339, DOI 10.1016/j.humpath.2011.12.018; Syriac S, 2012, ANN DIAGN PATHOL, V16, P498, DOI 10.1016/j.anndiagpath.2011.04.007; Tang LH, 2005, AM J SURG PATHOL, V29, P512, DOI 10.1097/01.pas.0000155159.28530.88	16	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					285	291		10.1007/s00428-017-2231-y			7	Pathology	Pathology	FZ6IF	WOS:000427700600013	28889196				2019-10-28	
J	Basso, C; Michaud, K				Basso, Cristina; Michaud, Katarzyna			Pacemaker failure as a cause of sudden death Reply	VIRCHOWS ARCHIV			English	Letter							IMPLANTABLE ELECTRONIC DEVICES; AUTOPSY		[Basso, Cristina] Univ Padua, Sch Med, Padua, Italy; [Michaud, Katarzyna] Univ Ctr Legal Med, Lausanne, Switzerland; [Michaud, Katarzyna] Univ Ctr Legal Med, Geneva, Switzerland	Basso, C (reprint author), Univ Padua, Sch Med, Padua, Italy.	cristina.basso@unipd.it					Basso C, 2017, VIRCHOWS ARCH, V471, P691, DOI 10.1007/s00428-017-2221-0; Kirkpatrick JN, 2007, J CARDIOVASC ELECTR, V18, P478, DOI 10.1111/j.1540-8167.2007.00773.x; Mauf S, 2016, J FORENSIC SCI, V61, P988, DOI 10.1111/1556-4029.13075; Morin DP, 2017, VIRCHOWS AR IN PRESS; Sinha SK, 2016, HEART RHYTHM, V13, P1971, DOI 10.1016/j.hrthm.2016.05.023; Sinha SK, 2016, J AM COLL CARDIOL, V68, P1255, DOI 10.1016/j.jacc.2016.06.052; Tseng ZH, 2015, JAMA INTERN MED, V175, P1342, DOI 10.1001/jamainternmed.2015.2641	7	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					295	296		10.1007/s00428-017-2245-5			2	Pathology	Pathology	FZ6IF	WOS:000427700600015	29043443				2019-10-28	
J	Petronilho, SL; Montezuma, D; Vieira, R; Cunha, AL; Henrique, R; Bartosch, C				Lopes Petronilho, S.; Montezuma, D.; Vieira, R.; Cunha, A. L.; Henrique, R.; Bartosch, C.			Abstracts 29th European Congress of Pathology Abstracts (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								In Oral Free Paper Sessions, the first-author name was missing from the authorship group originally listed for Abstract OFP-04-012 (page S14), entitled "Differentiating primary pulmonary squamous cell carcinoma from squamous cell carcinoma of the cervix metastatic to the lung: Histological and immunohistochemistry study".	[Lopes Petronilho, S.; Montezuma, D.; Vieira, R.; Cunha, A. L.; Henrique, R.; Bartosch, C.] IPO Porto, Pathol, Porto, Portugal	Petronilho, SL (reprint author), IPO Porto, Pathol, Porto, Portugal.	s.petronilho@gmail.com					PETRONILHO SL, 2017, VIRCHOWS ARCH, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					297	297		10.1007/s00428-017-2251-7			1	Pathology	Pathology	FZ6IF	WOS:000427700600016		Bronze			2019-10-28	
J	Farinha, M; Montezuma, D; Pires-Luis, A; Silva, A; Castro, C; Castro, F; Abreu, J; Leal, C				Farinha, M.; Montezuma, D.; Pires-Luis, A.; Silva, A.; Castro, C.; Castro, F.; Abreu, J.; Leal, C.			Abstracts 29th European Congress of Pathology (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								In Poster Sessions, the first-author name was missing from the authorship group originally listed for Abstract PS-01-004 (page S52), entitled "Clinicopathological features of microinvasive breast cancer". The correct authorship group is shown above.	[Farinha, M.; Montezuma, D.; Pires-Luis, A.; Silva, A.; Castro, F.; Abreu, J.; Leal, C.] IPO Porto, Dept Pathol, Porto, Portugal; [Castro, C.] IPO Porto, Dept Epidemiol, Porto, Portugal	Farinha, M (reprint author), IPO Porto, Dept Pathol, Porto, Portugal.	monicadfarinha@gmail.com	Castro, Clara/M-4779-2013	Castro, Clara/0000-0001-9653-4581			FARINHA M, 2017, VIRCHOWS ARCHIV S1, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					299	299		10.1007/s00428-017-2252-6			1	Pathology	Pathology	FZ6IF	WOS:000427700600017	29143110	Bronze			2019-10-28	
J	Al-Masri, H; Ratcliffe, M; Sharpe, A; Barker, C; Scorer, P; Scott, M; Rebelatto, M; Walker, J				Al-Masri, H.; Ratcliffe, M.; Sharpe, A.; Barker, C.; Scorer, P.; Scott, M.; Rebelatto, M.; Walker, J.			Abstracts 29th European Congress of Pathology (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								Due to an error with the registration system, the following abstract was regrettably omitted from the Poster Sessions. The abstract should have been included as PS-10-021 and displayed on page S166.	[Al-Masri, H.] Hematogenix, Tinley Pk, IL 60487 USA; [Ratcliffe, M.; Sharpe, A.; Barker, C.; Scorer, P.; Scott, M.; Walker, J.] AstraZeneca, Cambridge, England; [Rebelatto, M.] MedImmune, Gaithersburg, MD USA	Al-Masri, H (reprint author), Hematogenix, Tinley Pk, IL 60487 USA.	halmasri@hematogenix.com					Al-Masri H, 2017, VIRCHOWS ARCHIV S1, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					301	301		10.1007/s00428-017-2253-5			1	Pathology	Pathology	FZ6IF	WOS:000427700600018	29196805	Bronze			2019-10-28	
J	Farinha, M; Ribeiro, J; Montezuma, D; Pires-Luis, A; Lopes, P; Sousa, H; Afonso, L; Henrique, R				Farinha, M.; Ribeiro, J.; Montezuma, D.; Pires-Luis, A.; Lopes, P.; Sousa, H.; Afonso, L.; Henrique, R.			Abstracts 29th European Congress of Pathology (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								In Poster Sessions, the first-author name was missing from the authorship group originally listed for Abstract PS-13-001 (page S176), entitled "Gastric carcinoma with lymphoid stroma: Analysis of microsatellite instability and Epstein-Barr virus status". The correct authorship group is shown above.	[Farinha, M.; Montezuma, D.; Pires-Luis, A.; Lopes, P.; Afonso, L.; Henrique, R.] IPO Porto, Dept Pathol, Porto, Portugal; [Ribeiro, J.; Sousa, H.] IPO Porto Res Ctr CI IPOP, Mol Oncol & Viral Pathol Grp, Porto, Portugal	Farinha, M (reprint author), IPO Porto, Dept Pathol, Porto, Portugal.	monicadfarinha@gmail.com	Sousa, Hugo/B-7714-2011	Sousa, Hugo/0000-0001-5795-2131			FARINHA M, 2017, VIRCHOWS ARCHIV S1, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					303	303		10.1007/s00428-017-2254-4			1	Pathology	Pathology	FZ6IF	WOS:000427700600019	29143111	Bronze			2019-10-28	
J	Mikhaleva, L; Birukov, A; Shakhpazyan, N; Vandysheva, R				Mikhaleva, L.; Birukov, A.; Shakhpazyan, N.; Vandysheva, R.			Abstracts 29th European Congress of Pathology (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								Due to an error with the registration system, the following abstract was regrettably omitted from the Poster Sessions. The abstract should have been included as PS-13-116 and displayed on page S199.	[Mikhaleva, L.; Birukov, A.; Vandysheva, R.] Inst Human Morphol, Moscow, Russia; [Shakhpazyan, N.] City Clin Hosp 31, Moscow, Russia	Mikhaleva, L (reprint author), Inst Human Morphol, Moscow, Russia.	mikhalevalm@yandex.ru					MIKHALEVA L, 2017, VIRCHOWS ARCHIV S1, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					305	305		10.1007/s00428-017-2255-3			1	Pathology	Pathology	FZ6IF	WOS:000427700600020	29143109	Bronze			2019-10-28	
J	Mikhaleva, L; Vandysheva, R; Shakhpazyan, N; Birukov, A				Mikhaleva, L.; Vandysheva, R.; Shakhpazyan, N.; Birukov, A.			Abstracts 29th European Congress of Pathology (vol 471, pg S1, 2017)	VIRCHOWS ARCHIV			English	Correction								Due to an error with the registration system, the following abstract was regrettably omitted from the Poster Sessions. The abstract should have been included as PS-13-128 and displayed on page S201.	[Mikhaleva, L.; Vandysheva, R.; Birukov, A.] Inst Human Morphol, Moscow, Russia; [Shakhpazyan, N.] City Clin Hosp 31, Moscow, Russia	Mikhaleva, L (reprint author), Inst Human Morphol, Moscow, Russia.	mikhalevalm@yandex.ru					MIKHALEVA L, 2017, VIRCHOWS ARCHIV S1, V471, pS1, DOI DOI 10.1007/S00428-017-2205-0	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	FEB	2018	472	2					307	307		10.1007/s00428-017-2256-2			1	Pathology	Pathology	FZ6IF	WOS:000427700600021	29159567	Bronze			2019-10-28	
J	Paluru, S; Ulbright, TM; Amin, M; Montironi, R; Epstein, JI				Paluru, Swetha; Ulbright, Thomas M.; Amin, Mahul; Montironi, Rodolfo; Epstein, Jonathan I.			The Morphologic Spectrum of Sertoliform Cystadenoma of the Rete Testis: A Series of 15 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						sertoliform cystadenoma; paratesticular; rete testis; adenomatous hyperplasia rete	PAGETOID SPREAD; CELL NEOPLASIA; INHIBIN; DIAGNOSIS; MARKER; TUMORS; SF1	Sertoliform cystadenoma of the rete testis (SCRT) is rare with only 9 cases reported to date in the literature, none with follow-up. Four large genitourinary pathology consult services were searched. We identified 15 cases of SCRT. Men were 21 to 84 years old (mean, 46y) and had testicular discomfort or mass. Other findings were seminoma (n=1), spermatocele (n=2), hydrocele (n=1), varicocele (n=1), and scrotal hematoma (n=1). Eight had preoperative serum tumor markers, which were normal. Tumors ranged from 0.3 to 4cm (mean, 1.5cm). All of them were well circumscribed with solid and cystic features and occupied on average, 73% of the rete (20% to 100%). The tumors were mostly confined within dilated channels of the rete testis and showed classic features consisting of: (1) tubules with well-formed lumina in 87% of cases; (2) well-formed tubules with no lumina in 87% of cases; and (3) cords/nests in hyalinized or myxoid stroma in 73% of cases. Other patterns included: (1) solid/sheet growth in 26% of cases; (2) individual cells in 13% of cases; (3) festoons in 13% of cases; (4) branching tubules in 7% of cases; and (5) papillary in 7% of cases. Cells were cuboidal with round to oval nuclei with small nucleoli, except at the periphery where projections into rete tubules had a more columnar appearance. In the festooning pattern, nuclei were pseudostratified and columnar with prominent nucleoli and nuclear grooves. In 4 cases, tumor extended into adjacent seminiferous tubules surrounded by dense peritubular fibrosis, with in some cases small cysts lined by flattened epithelium containing pale lightly granular material. All cases lacked necrosis and significant atypia. Mitoses ranged from 0 to 2 per 10 high-power field. Follow-up ranged from 4 to 170 months with mean of 97 months. For the 13 cases with information, all patients were alive, except for 3 who died of either unrelated causes (9.2 and 10y) or of unknown cause (4.8y at age 89y). We performed immunohistochemistry for steroidogenic factor 1 and inhibin in 4 of our cases, where 3 (75%) were positive for both markers. We also describe 2 additional cases which morphologically resembled SCRT but had more atypical features. This study highlights that SCRT has variable morphology. We also verify the benign nature of the lesion and its lack of association with any syndromes.	[Paluru, Swetha; Epstein, Jonathan I.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Ulbright, Thomas M.] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA; [Amin, Mahul] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; [Montironi, Rodolfo] Polytech Univ Marche Reg Ancona, Dept Pathol, Ancona, Italy	Epstein, JI (reprint author), 401 N Broadway St,Rm 2242, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Anderson RA, 2002, REPRODUCTION, V123, P779, DOI 10.1530/rep.0.1230779; Bremmer F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-23; Burns Jennifer A, 2002, Urology, V60, P344, DOI 10.1016/S0090-4295(02)01729-6; Busto Martin Luis A, 2009, Arch Esp Urol, V62, P592; Chovanec M, 2014, Klin Onkol, V27, P136; CUEVAS P, 1987, BIOCHEM BIOPH RES CO, V142, P23, DOI 10.1016/0006-291X(87)90446-3; de Santa Barbara P, 2000, DEV DYNAM, V217, P293, DOI 10.1002/(SICI)1097-0177(200003)217:3<293::AID-DVDY7>3.0.CO;2-P; Emam AT, 2012, SAUDI J KIDNEY DIS T, V23, P559; Ghosh Prithwijit, 2015, J Nat Sci Biol Med, V6, P211, DOI 10.4103/0976-9668.149125; Hagiuda Jun, 2010, Nihon Hinyokika Gakkai Zasshi, V101, P749; HARTWICK RWJ, 1991, AM J SURG PATHOL, V15, P350; HASAN NA, 1995, HISTOPATHOLOGY, V27, P391, DOI 10.1111/j.1365-2559.1995.tb01536.x; Jequier AM, 2009, REPROD BIOMED ONLINE, V18, P190, DOI 10.1016/S1472-6483(10)60255-6; Jones EC, 2000, SEMIN DIAGN PATHOL, V17, P270; JONES MA, 1997, J UROL PATHOL, V7, P47; Kacar A, 2011, PEDIATR DEVEL PATHOL, V14, P138, DOI 10.2350/10-01-0778-CR.1; Lahouti AH, 2017, INT J SURG PATHOL, V25, P555, DOI 10.1177/1066896917704304; LEE AHS, 1994, HISTOPATHOLOGY, V24, P385, DOI 10.1111/j.1365-2559.1994.tb00542.x; Mesa H, 2017, HUM PATHOL, V61, P181, DOI 10.1016/j.humpath.2016.11.004; NISTAL M, 1989, HUM PATHOL, V20, P1065, DOI 10.1016/0046-8177(89)90224-4; Nistal M, 1976, ARCH ESPAN UROL, V29, P430; Nistal M, 2011, HISTOPATHOLOGY, V58, P1019, DOI 10.1111/j.1365-2559.2011.03858.x; Ozisik G, 2003, HORM RES, V59, P94, DOI 10.1159/000067831; Ozisik G, 2002, MOL GENET METAB, V76, P85, DOI 10.1016/S1096-7192(02)00032-X; Sahnan K, 2013, BMJ CASE REP, V2013; Sinclair AM, 2006, PATHOL INT, V56, P568, DOI 10.1111/j.1440-1827.2006.02008.x; Trainer TD, 2012, HISTOLOGY PATHOLOGIS, P1014; Ulbright TM, 2008, AM J SURG PATHOL, V32, P1683, DOI 10.1097/PAS.0b013e3181788516; Ulbright TM, 2007, AM J SURG PATHOL, V31, P827, DOI 10.1097/PAS.0b013e3180309e33; Zhao CQ, 2008, INT J GYNECOL PATHOL, V27, P507, DOI 10.1097/PGP.0b013e31817c1b0a	30	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					141	149		10.1097/PAS.0000000000000997			9	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300002	29240582				2019-10-28	
J	Xerri, L; Adelaide, J; Popovici, C; Garnier, S; Guille, A; Mescam-Mancini, L; Laurent, C; Brousset, P; Coze, C; Michel, G; Chaffanet, M; Bouabdallah, R; Coso, D; Bertucci, F; Birnbaum, D				Xerri, Luc; Adelaide, Jose; Popovici, Cornel; Garnier, Severine; Guille, Arnaud; Mescam-Mancini, Lenaig; Laurent, Camille; Brousset, Pierre; Coze, Carole; Michel, Gerard; Chaffanet, Max; Bouabdallah, Reda; Coso, Diane; Bertucci, Francois; Birnbaum, Daniel			CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Langerhans cell histiocytosis; Langerhans cell sarcoma; NRAS; MAP2K1; CDKN2A/B; sequencing	ACUTE LYMPHOBLASTIC-LEUKEMIA; ERDHEIM-CHESTER DISEASE; HISTIOCYTIC SARCOMA; FOLLICULAR LYMPHOMA; LYMPHOCYTIC LYMPHOMA; SOMATIC MUTATIONS; RICHTER SYNDROME; TRANSFORMATION; NEOPLASMS; MAP2K1	Langerhans cell histiocytosis (LCH) has a mostly favorable outcome, whereas Langerhans cell sarcoma (LCS) is an aggressive tumor. It is still unclear whether any specific molecular alterations could underlie the aggressive behavior of Langerhans cell proliferations. We used targeted next-generation sequencing and array-comparative genomic hybridization to profile 22 LCH samples from different patients together with 3 LCS samples corresponding to different relapses from the same patient. The third LCS relapse was a composite tumor including both B-cell chronic lymphocytic leukemia and LCS components. The 22 LCH samples were mostly of bone origin and showed classic histophenotypical features. Array-comparative genomic hybridization showed in all 3 LCS samples a similar homozygous somatic loss affecting the CDKN2A/B locus, whereas the 17 informative LCH samples did not show any detectable abnormality. In the 3 LCS samples, targeted next-generation sequencing of 495 cancer genes detected common mutations in KMT2D/MLL2 and in both MAP2K1 and NRAS genes, whereas BRAF was not mutated. A NOTCH1 mutation was acquired in 2 LCS samples. The composite LCS/B-cell chronic lymphocytic leukemia tumor showed the same genetic profile in its 2 components. LCH samples showed mutually exclusive mutations of BRAF (8/20) and MAP2K1 (4/19), but no mutation of KMT2D, NRAS nor NOTCH1. These results suggest that CDKN2A/B deletion and/or simultaneous mutations of MAP2K1 and NRAS may underlie the aggressive behavior of Langerhans cell tumors, and thus could be useful for the diagnosis of malignancy in histiocytic neoplasms. The MAPK pathway double hit profile provides a basis for targeted therapy in LCS patients.	[Xerri, Luc; Mescam-Mancini, Lenaig] CHU Timone, APHM, Dept Biopathol & Tumor Immunol, Marseille, France; [Coze, Carole; Michel, Gerard] CHU Timone, APHM, Dept Pediat Oncol & Hematol, Marseille, France; [Xerri, Luc; Adelaide, Jose; Garnier, Severine; Guille, Arnaud; Mescam-Mancini, Lenaig; Chaffanet, Max; Bertucci, Francois; Birnbaum, Daniel] INSERM, CRCM, U1068, Paris, France; [Xerri, Luc; Adelaide, Jose; Garnier, Severine; Guille, Arnaud; Mescam-Mancini, Lenaig; Chaffanet, Max; Bertucci, Francois; Birnbaum, Daniel] CNRS, UMR7258, Paris, France; [Xerri, Luc; Adelaide, Jose; Popovici, Cornel; Garnier, Severine; Guille, Arnaud; Mescam-Mancini, Lenaig; Chaffanet, Max; Bouabdallah, Reda; Coso, Diane; Bertucci, Francois; Birnbaum, Daniel] Inst Paoli Calmettes, Marseille, France; [Xerri, Luc; Adelaide, Jose; Garnier, Severine; Guille, Arnaud; Mescam-Mancini, Lenaig; Coze, Carole; Michel, Gerard; Chaffanet, Max; Bertucci, Francois; Birnbaum, Daniel] Aix Marseille Univ, Marseille, France; [Adelaide, Jose; Garnier, Severine; Guille, Arnaud; Chaffanet, Max; Bertucci, Francois; Birnbaum, Daniel] CRCM, Dept Mol Oncol, Marseille, France; [Popovici, Cornel] Univ Inst Canc Oncopole, INSERM, U1037, Dept Oncogenet, Toulouse, France; [Bouabdallah, Reda; Coso, Diane] Univ Inst Canc Oncopole, INSERM, U1037, Dept Hematol, Toulouse, France; [Laurent, Camille; Brousset, Pierre] Univ Inst Canc Oncopole, INSERM, U1037, Dept Pathol, Toulouse, France	Xerri, L (reprint author), Inst Paoli Calmettes, Dept Biopathol, 232 Bd St Marguerite, F-13009 Marseille, France.	xerril@ipc.unicancer.fr	POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127; laurent, camille/0000-0002-5375-7512			Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Ambrosio MR, 2015, VIRCHOWS ARCH, V467, P471, DOI 10.1007/s00428-015-1814-8; Bertucci F, 2016, ONCOTARGET, V7, P27208, DOI 10.18632/oncotarget.8349; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Brunner P, 2014, LEUKEMIA, V28, P1937, DOI 10.1038/leu.2014.167; Burger JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11589; Chakraborty R, 2016, BLOOD, V128, P2533, DOI 10.1182/blood-2016-08-733790; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Chen Weiwei, 2013, N Am J Med Sci, V5, P386, DOI 10.4103/1947-2714.114172; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Durham BH, 2016, CURR OPIN HEMATOL, V23, P416, DOI 10.1097/MOH.0000000000000256; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Emile JF, 2014, BLOOD, V124, P3016, DOI 10.1182/blood-2014-04-570937; Fabbri G, 2013, J EXP MED, V210, P2273, DOI 10.1084/jem.20131448; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Fernandez-Pol S, 2016, HUM PATHOL, V55, P39, DOI 10.1016/j.humpath.2016.04.004; Fraser CR, 2009, AM J CLIN PATHOL, V132, P928, DOI 10.1309/AJCPWQ0I0DGXBMHO; Furmanczyk PS, 2012, J CUTAN PATHOL, V39, P644, DOI 10.1111/j.1600-0560.2012.01873.x; Gu YS, 2016, ONCOTARGET, V7, P29804, DOI 10.18632/oncotarget.7772; Harmon CM, 2015, ARCH PATHOL LAB MED, V139, P1211, DOI 10.5858/arpa.2015-0199-RA; Huang WT, 2016, ONCOTARGET, V7, P78355, DOI 10.18632/oncotarget.13058; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Karai LJ, 2015, AM J DERMATOPATH, V37, P854, DOI 10.1097/DAD.0000000000000318; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Kumar R, 2011, PEDIATR BLOOD CANCER, V56, P307, DOI 10.1002/pbc.22810; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liersch J, 2017, AM J DERMATOPATH, V39, P493, DOI 10.1097/DAD.0000000000000793; Liu QQ, 2016, VIRCHOWS ARCH, V469, P233, DOI 10.1007/s00428-016-1965-2; Milne P, 2017, BLOOD, V130, P167, DOI 10.1182/blood-2016-12-757823; Mourah S, 2015, BLOOD, V126, P2649, DOI 10.1182/blood-2015-06-650036; Nelson DS, 2015, GENE CHROMOSOME CANC, V54, P361, DOI 10.1002/gcc.22247; Pagni F, 2014, LEUKEMIA, V28, P1377, DOI 10.1038/leu.2014.87; Rasi S, 2016, HAEMATOLOGICA, V101, DOI 10.3324/haematol.2015.136051; Rossi D, 2016, SEMIN ONCOL, V43, P311, DOI 10.1053/j.seminoncol.2016.02.012; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Swerdlow SH, 2008, WHO CLASSIFICATION T; Waanders E, 2016, LEUKEMIA, V30, P955, DOI 10.1038/leu.2015.193; Yokokawa Y, 2015, GENE CHROMOSOME CANC, V54, P409, DOI 10.1002/gcc.22252; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017	41	3	3	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					150	159		10.1097/PAS.0000000000000989			10	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300003	29194093				2019-10-28	
J	Yang, C; Sun, L; Zhang, LX; Zhou, LX; Zhao, M; Peng, Y; Niu, DF; Li, ZW; Huang, XZ; Kang, Q; Jia, L; Lai, JP; Cao, DF				Yang, Chen; Sun, Li; Zhang, Lingxin; Zhou, Lixin; Zhao, Ming; Peng, Yan; Niu, Dongfeng; Li, Zhongwu; Huang, Xiaozheng; Kang, Qiang; Jia, Lin; Lai, Jinping; Cao, Dengfeng			Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						metastatic Krukenberg tumors; ovary; adenocarcinoma ex goblet cell carcinoid; SATB2; immunohistochemistry	RING CELL-CARCINOMA; GOBLET CELL; MUCINOUS TUMORS; EXPRESSION; STOMACH; APPENDIX; ORIGIN; DIFFERENTIATION; ADENOCARCINOMA; CYTOKERATIN-20	SATB2 is a sensitive marker for colorectal adenocarcinomas. No study has investigated its diagnostic utility in metastatic Krukenberg tumors (MKTs) of the ovary. Here we performed immunohistochemical staining SATB2 in 70 MKTs of various origins (stomach 27, colorectum 13, appendix 20 including 19 metastatic adenocarcinomas ex goblet cell carcinoids [AdexGCC] and 1 conventional poorly differentiated carcinoma with signet ring cells, breast 5, bladder 3, lung 2) to assess its diagnostic utility. We also compared SATB2 with CDX2, CK7, CK20, chromogranin, and synaptophysin in MKTs of gastric origin (MKTs-stomach), those of colorectal origin (MKTs-colorectum) and those due to appendiceal AdexGCCs (MKT-AdexGCCs) for their sensitivity and specificity to distinguish these tumors. SATB2 staining was seen in 1/27 (4%) MKTs-stomach (40% cells), 7/13 (54%) MKTs-colorectum (mean: 17% cells, median: 7%, range: 2% to 60%), and 19/19 (100%) of MKT-AdexGCCs (mean: 97% cells, median: 100%, range: 80% to 100%) (P<0.01 between any two). SATB2 staining was seen in 1/1 metastatic appendiceal poorly differentiated carcinoma with signet ring cells (5% cells), 1/3 MKTs of bladder origin (60% cells), 0/2 MKTs of pulmonary origin, and 1/5 MKTs of breast origin (10% cells). SATB2 staining was diffuse strong in MKT-AdexGCCs whereas in other MKTs it was focal and weak in the signet ring and nonsignet ring nonglandular cells and from focal weak to diffuse strong in well-formed glands. MKTs-stomach, MKTs-colorectum, and MKT-AdexGCCs showed no significant staining difference in CDX2 (100%, 100%, 100% cases, respectively; P=1.0), CK20 (96%, 100%, 100%, respectively; P=1.0), chromogranin (59%, 31%, 63%, respectively; P>0.05) or synaptophysin (59%, 63%, 84%, respectively; P>0.05) but they had significant difference in CK7 staining (93%, 8%, 42%, respectively; P<0.05). Among these 6 markers, SATB2 is the best one to distinguish MKT-AdexGCCs from MKTs-stomach (100% sensitivity, 96% specificity) and MKTs-colorectum (100% sensitivity and 100% specificity if staining more than 75% tumor cells as the cutoff). In distinguishing MKTs-stomach from MKTs-colorectum, SATB2 is not as good as CK7 which is the best marker. Our results indicate that SATB2 is a highly sensitive marker (100% sensitivity) for metastatic MKT-AdexGCCs with high specificity (100% specificity when showing strong staining in at least 75% cells) among MKTs. SATB2 is a useful marker for determining the primary sites of MKTs of the ovary.	[Yang, Chen; Zhang, Lingxin; Cao, Dengfeng] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Sun, Li; Zhou, Lixin; Niu, Dongfeng; Li, Zhongwu; Huang, Xiaozheng; Kang, Qiang; Jia, Lin] Peking Univ, Canc Hosp, Beijing Canc Hosp,Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Zhao, Ming] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Zhao, Ming] Hangzhou Med Coll, Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Peng, Yan] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Lai, Jinping] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA	Cao, DF (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Lab Lauren V Ackerman Surg Pathol, 660 S Euclid Ave Campus,POB 8118, St Louis, MO 63110 USA.	dcao@path.wustl.edu			Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO	Supported by the departmental discretional fund from Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Alcamo EA, 2008, NEURON, V57, P364, DOI 10.1016/j.neuron.2007.12.012; Alsaad KO, 2007, ENDOCR PATHOL, V18, P16, DOI 10.1007/s12022-007-0004-x; Alsaad KO, 2003, MODERN PATHOL, V16, P1189; Baker PM, 2001, AM J SURG PATHOL, V25, P557, DOI 10.1097/00000478-200105000-00001; Bartley AN, 2011, HUM PATHOL, V42, P1420, DOI 10.1016/j.humpath.2010.12.008; BOWLBY LS, 1986, GYNECOL ONCOL, V25, P376, DOI 10.1016/0090-8258(86)90090-9; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214; Pinto PBC, 2012, INT J GYNECOL PATHOL, V31, P313, DOI 10.1097/PGP.0b013e31823f844d; Chu PG, 2004, AM J CLIN PATHOL, V121, P884, DOI 10.1309/A09ERYMFR64NERDW; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Fujiyoshi Y, 2008, HISTOPATHOLOGY, V52, P305, DOI 10.1111/j.1365-2559.2007.02950.x; Giordano G, 2017, INT J SURG PATHOL, V25, P365, DOI 10.1177/1066896917691613; Groisman GM, 2004, INT J GYNECOL PATHOL, V23, P52, DOI 10.1097/01.pgp.0000101141.31270.a0; Hristov AC, 2007, AM J SURG PATHOL, V31, P1502, DOI 10.1097/PAS.0b013e31804f7aa1; Irving JA, 2006, INT J GYNECOL PATHOL, V25, P147, DOI 10.1097/01.pgp.0000185405.08556.a0; ISAACSON P, 1981, AM J SURG PATHOL, V5, P213, DOI 10.1097/00000478-198104000-00001; Jiang Y, 2011, PATHOL ONCOL RES, V17, P127, DOI 10.1007/s12253-010-9291-5; JOSHI VV, 1968, CANCER, V22, P1199, DOI 10.1002/1097-0142(196811)22:6<1199::AID-CNCR2820220616>3.0.CO;2-P; Kiyokawa T, 2006, AM J SURG PATHOL, V30, P277; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Li ZW, 2015, INT J CLIN EXP PATHO, V8, P7072; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; McCluggage WG, 2008, AM J SURG PATHOL, V32, P1373, DOI 10.1097/PAS.0b013e31816b18c1; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Park SY, 2002, HUM PATHOL, V33, P1078, DOI 10.1053/hupa.2002.129422; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Ronnett BM, 1997, AM J SURG PATHOL, V21, P1144, DOI 10.1097/00000478-199710000-00004; Stancu M, 2003, MODERN PATHOL, V16, P1189, DOI 10.1097/01.MP.0000097362.10330.B1; Strickland S, 2016, HISTOPATHOLOGY, V68, P977, DOI 10.1111/his.12899; Strickland S, 2016, INT J GYNECOL PATHOL, V35, P191, DOI 10.1097/PGP.0000000000000238; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Terada T, 2013, INT J CLIN EXP PATHO, V6, P630; Terada T, 2013, INT J CLIN EXP PATHO, V6, P703; van Eeden S, 2007, HISTOPATHOLOGY, V51, P763, DOI 10.1111/j.1365-2559.2007.02883.x; Vang R, 2006, MODERN PATHOL, V19, P1421, DOI 10.1038/modpathol.3800698; Vang R, 2006, AM J SURG PATHOL, V30, P1130; WONG PC, 1986, CANCER, V57, P751, DOI 10.1002/1097-0142(19860215)57:4<751::AID-CNCR2820570412>3.0.CO;2-G; Yang C, 2017, MODERN PATHOL, V30, p208A; Young RH, 2006, ADV ANAT PATHOL, V13, P205, DOI 10.1097/01.pap.0000213038.85704.e4	43	6	6	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					160	171		10.1097/PAS.0000000000000951			12	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300004	28914716				2019-10-28	
J	Nakano, K; Yamamoto, H; Fujiwara, M; Koga, Y; Tsuruta, S; Ihara, E; Oki, E; Nakamura, M; Ogawa, Y; Oda, Y				Nakano, Kayoko; Yamamoto, Hidetaka; Fujiwara, Minako; Koga, Yutaka; Tsuruta, Shinichi; Ihara, Eikichi; Oki, Eiji; Nakamura, Masafumi; Ogawa, Yoshihiro; Oda, Yoshinao			Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						synchronous colorectal carcinoma; mismatch repair; KRAS; BRAF	MLH1 PROMOTER HYPERMETHYLATION; MICROSATELLITE INSTABILITY; LYNCH-SYNDROME; CANCER PATHOGENESIS; DNA METHYLATION; KRAS MUTATIONS; BRAF; FEATURES; PROTEIN; HETEROGENEITY	Synchronous colorectal carcinoma (CRC) is a unique disease associated with a high prevalence (approximate to 35%) of microsatellite instability and occasionally with Lynch syndrome. The clinicopathologic and molecular features of synchronous CRC are poorly understood, particularly in Japanese patients. We examined 118 Japanese patients (236 tumors) with synchronous CRC and 117 Japanese patients (117 tumors) with solitary CRC with immunohistochemical staining for TP53 and mismatch repair (MMR) protein (MLH1, MSH2, PMS2, and MSH6) and mutation analyses of KRAS and BRAF genes. The results revealed no significant differences in clinicopathologic, histologic, and molecular findings between the synchronous and solitary CRC groups. Among the 118 synchronous CRC patients, 15 (12.7%) showed loss of MMR protein(s) expression in at least 1 tumor, whereas 103 (87.3%) showed intact expression of all 4 MMR proteins in both tumors. Of note, all patients with MMR deficiency had excellent prognoses. The 15 patients were further subdivided into 2 groups: the Concordant group, with concordant MMR loss (n=9, 7.6%) and the Discordant group, with discordant MMR loss (n=6, 5.1%). The Concordant patients showed concurrent MLH1/PMS2 loss (n=3), concurrent MSH2/MSH6 loss (n=4) and isolated MSH6 loss (n=2) in both tumors, whereas the Discordant patients showed concurrent MLH1/PMS2 loss (n=2), isolated PMS2 loss (n=2) and isolated MSH6 loss (n=2) in a single tumor. On the basis of the MMR expression pattern and BRAF mutation, the Concordant and Discordant groups were suspected to include Lynch syndrome, Lynch-like syndrome and sporadic MLH1 promoter hypermethylated CRC. In addition, KRAS mutation was present in only 1 tumor in a single patient in each group. In conclusion, the frequency of MMR protein deficiency in synchronous CRC in the Japanese population may be lower compared with the reported data from Western populations. MMR protein loss and KRAS and BRAF mutations in synchronous CRCs were heterogenous even in an individual patient.	[Nakano, Kayoko; Yamamoto, Hidetaka; Fujiwara, Minako; Koga, Yutaka; Tsuruta, Shinichi; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan; [Nakano, Kayoko; Tsuruta, Shinichi; Ihara, Eikichi; Ogawa, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Japan; [Oki, Eiji] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan; [Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Maidashi3-1-1, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp		Ihara, Eikichi/0000-0002-7070-6610			Abdel-Rahman WM, 2005, ONCOGENE, V24, P1542, DOI 10.1038/sj.onc.1208387; Aslaniaw HR, 2008, CLIN GASTROENTEROL H, V6, P1385, DOI 10.1016/j.cgh.2008.04.027; Bae JM, 2012, DIS COLON RECTUM, V55, P181, DOI 10.1097/DCR.0b013e31823c46ce; Balschun K, 2011, J MOL DIAGN, V13, P436, DOI 10.1016/j.jmoldx.2011.03.002; Bledsoe JR, 2014, AM J SURG PATHOL, V38, P1418, DOI 10.1097/PAS.0000000000000263; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Chen W, 2017, DIAGN PATHOL, V12, P1, DOI 10.1186/s13000-017-0613-8; Farchoukh L, 2016, AM J SURG PATHOL, V40, P1390, DOI 10.1097/PAS.0000000000000695; Fujita K, 2011, AM J SURG PATHOL, V35, P295, DOI 10.1097/PAS.0b013e318205df36; Goel A, 2010, GASTROENTEROLOGY, V138, P1854, DOI 10.1053/j.gastro.2010.01.035; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hayashi T, 2006, DIS COLON RECTUM, V49, pS23, DOI 10.1007/s10350-006-0722-z; Hu HK, 2013, AM J SURG PATHOL, V37, P1660, DOI 10.1097/PAS.0b013e31829623b8; Kadowaki S, 2015, WORLD J GASTROENTERO, V21, P1275, DOI 10.3748/wjg.v21.i4.1275; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kang GH, 2011, ARCH PATHOL LAB MED, V135, P698, DOI 10.1043/2010-0523-RA.1; Kato A, 2016, AM J SURG PATHOL, V40, P770, DOI 10.1097/PAS.0000000000000606; Kuan SF, 2014, HUM PATHOL, V45, P464, DOI 10.1016/j.humpath.2013.10.026; Lam AKY, 2011, AM J SURG, V202, P39, DOI 10.1016/j.amjsurg.2010.05.012; Lawes DA, 2005, BRIT J CANCER, V93, P472, DOI 10.1038/sj.bjc.6602708; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Malesci A, 2014, BRIT J CANCER, V110, P1228, DOI 10.1038/bjc.2013.827; Mas-Moya J, 2015, HUM PATHOL, V46, P1616, DOI 10.1016/j.humpath.2015.06.022; Nakaji Y, 2017, J CANCER RES CLIN, V143, P151, DOI 10.1007/s00432-016-2275-4; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; Ogino S, 2006, MODERN PATHOL, V19, P1083, DOI 10.1038/modpathol.3800618; Pai RK, 2016, AM J SURG PATHOL, V40, pE17, DOI 10.1097/PAS.0000000000000620; Roth RM, 2016, AM J CLIN PATHOL, V146, P50, DOI 10.1093/ajcp/aqw067; Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917; Southey MC, 2005, J CLIN ONCOL, V23, P6524, DOI 10.1200/JCO.2005.04.671; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3; Yuen ST, 2002, CANCER RES, V62, P6451	35	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					172	182		10.1097/PAS.0000000000000947			11	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300005	28877066				2019-10-28	
J	Mills, AM; Dill, EA; Moskaluk, CA; Dziegielewski, J; Bullock, TN; Dillon, PM				Mills, Anne M.; Dill, Erik A.; Moskaluk, Christopher A.; Dziegielewski, Jaroslaw; Bullock, Tim N.; Dillon, Patrick M.			The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						breast cancer; breast carcinoma; mismatch repair; mismatch repair deficiency; PD-L1; immunotherapy	TUMOR-INFILTRATING LYMPHOCYTES; NONPOLYPOSIS COLORECTAL-CANCER; LYNCH SYNDROME; MICROSATELLITE INSTABILITY; ENDOMETRIAL CANCER; ANTI-PD-L1 ANTIBODY; NEOANTIGEN LOAD; IMMUNE EVASION; BLOCKADE; IMMUNOHISTOCHEMISTRY	Mismatch repair (MMR) deficiency in solid tumors has recently been linked to susceptibility to immunotherapies targeting the programmed cell death-1 (PD-1)/programmed cell death-1 ligand (PD-L1) axis. Loss of MMR proteins has been shown to correlate with tumoral PD-L1 expression in colorectal and endometrial carcinomas, but the association between expression of MMR proteins and PD-L1 has not previously been studied in breast carcinoma, where MMR deficiency is less common. We assessed the relationship between PD-L1 and MMR protein expression by immunohistochemistry in 245 primary and 40 metastatic breast carcinomas. Tumoral staining for PD-L1 was positive in 12% of all cases, including 32% of triple-negative cancers. MMR deficiency was observed in 0.04% of breast cancers; the single MMR-deficient case was a high-grade, triple-negative ductal carcinoma which showed dual loss of MLH1 and PMS2 proteins and expressed PD-L1. Two ER+ carcinomas initially were scored with MMR protein loss in tissue microarray format but were subsequently shown to be MMR-intact on whole sections. Analysis of MMR gene mutation in The Cancer Genome Atlas corroborates low frequency of MMR deficiency for invasive breast cancer. MMR protein expression is therefore unlikely to show utility as a screen for immunotherapeutic vulnerability in this tumor type, and may provoke unwarranted genetic testing in patients unlikely to have a heritable cancer syndrome. PD-L1 may be a more clinically relevant biomarker for anti-PD-1/PD-L1 therapies in this setting.	[Mills, Anne M.; Dill, Erik A.; Moskaluk, Christopher A.; Bullock, Tim N.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Dziegielewski, Jaroslaw] Univ Virginia, Dept Radiat Oncol, Charlottesville, VA USA; [Dillon, Patrick M.] Univ Virginia, Dept Med, Hematol Oncol, Charlottesville, VA USA	Mills, AM (reprint author), Univ Virginia Hlth Syst, Dept Surg Pathol, 3rd Floor Hosp Expans,Room 3001,1215 Lee St, Charlottesville, VA 22908 USA.	amm7r@virginia.edu		Mills, Anne/0000-0002-2686-4857			Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; Adams S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-OT1-03-20; Adams S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.1008; Barrow E, 2013, FAM CANCER, V12, P229, DOI 10.1007/s10689-013-9615-1; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bruegl AS, 2014, CANCER PREV RES, V7, P686, DOI 10.1158/1940-6207.CAPR-13-0359; Buchanan DD, 2014, APPL CLIN GENET, V7, P183, DOI 10.2147/TACG.S48625; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chawla A, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28325; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Clarke BA, 2012, ADV ANAT PATHOL, V19, P231, DOI 10.1097/PAP.0b013e31825c6b76; Cree IA, 2016, HISTOPATHOLOGY, V69, P177, DOI 10.1111/his.12996; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; Dill EA, 2017, AM J SURG PATHOL, V41, P334, DOI 10.1097/PAS.0000000000000780; Dirix LY, CANC RES S4, V76, pS1; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Egoavil C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079737; Engel JB, 2014, ARCH GYNECOL OBSTET, V289, P141, DOI 10.1007/s00404-013-2922-9; Folkins AK, 2013, HISTOPATHOLOGY, V62, P2, DOI 10.1111/his.12028; Friedman K, 2016, MODERN PATHOL, V29, P528, DOI 10.1038/modpathol.2016.54; Frolova AI, 2015, GYNECOL ONCOL, V137, P7, DOI 10.1016/j.ygyno.2015.01.535; Funkhouser WK, 2012, J MOL DIAGN, V14, P91, DOI 10.1016/j.jmoldx.2011.11.001; Gadgeel SM, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gausachs M, 2012, EUR J HUM GENET, V20, P762, DOI 10.1038/ejhg.2011.277; Giardiello FM, 2014, AM J GASTROENTEROL, V109, P1159, DOI 10.1038/ajg.2014.186; Gottlieb CE, 2017, GYNECOL ONCOL, V144, P607, DOI 10.1016/j.ygyno.2016.12.021; Hamid O, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3012; Hampel H, 2015, GENET MED, V17, P70, DOI 10.1038/gim.2014.147; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Heald B, 2013, J CLIN ONCOL, V31, P1336, DOI 10.1200/JCO.2012.45.1674; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee V, 2016, IMMUNOTHERAPY-UK, V8, P1, DOI 10.2217/imt.15.97; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; Mills AM, 2016, AM J SURG PATHOL, V40, pE35, DOI 10.1097/PAS.0000000000000608; Mills AM, 2016, AM J SURG PATHOL, V40, P155, DOI 10.1097/PAS.0000000000000544; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Nanda R, 2017, CANC RES S, V77; Reiss KA, 2014, IMMUNOTHERAPY-UK, V6, P459, DOI 10.2217/imt.14.9; Rosenbaum MW, 2016, MODERN PATHOL, V29, P1104, DOI 10.1038/modpathol.2016.95; Schmid P, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.556; Sloan EA, 2017, AM J SURG PATHOL, V41, P326, DOI 10.1097/PAS.0000000000000783; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang MZ, 2017, ONCOTARGETS THER, V10, P1561, DOI 10.2147/OTT.S126424; Warth A, 2016, VIRCHOWS ARCH, V468, P313, DOI 10.1007/s00428-015-1892-7; Wen YH, 2012, AM J SURG PATHOL, V36, P1700, DOI 10.1097/PAS.0b013e3182627787; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	56	7	7	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					183	191		10.1097/PAS.0000000000000949			9	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300006	28914717	Green Published			2019-10-28	
J	Mills, AM; Coppock, JD; Willis, BC; Stoler, MH				Mills, Anne M.; Coppock, Joseph D.; Willis, Brian C.; Stoler, Mark H.			HPV E6/E7 mRNA In Situ Hybridization in the Diagnosis of Cervical Low-grade Squamous Intraepithelial Lesions (LSIL)	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cervical dysplasia; CIN1; squamous intraepithelial lesion; human papillomavirus; HPV; RNA in situ hybridization; E6; E7	HUMAN-PAPILLOMAVIRUS TYPE-16; TISSUE SPECIMENS; CELL CARCINOMA; NEOPLASIA; HEAD; NECK; DNA; EXPRESSION; BIOPSIES; TRIAGE	Cervical low-grade squamous intraepithelial lesions (LSIL) (aka cervical intraepithelial neoplasia, grade 1 [CIN1]) can present considerable diagnostic challenges and are associated with poor interobserver reproducibility and overdiagnosis. Furthermore, ancillary studies such as p16 immunohistochemistry have shown little utility in resolving the LSIL versus negative/reactive differential. Human papillomavirus (HPV) RNA in situ hybridization (ISH) has shown promise as a diagnostic aid in this setting, but has not been studied in a large case series. We herein investigate high-risk and low-risk HPV RNA ISH in 126 cervical biopsies originally diagnosed as LSIL/CIN1 and compare HPV RNA ISH results to expert-adjudicated morphologic diagnosis to assess whether this assay can help routine cases attain the existing gold standard of morphologic consensus diagnosis. We also assess whether this criterion standard can be further improved by integration of HPV RNA ISH results. A consensus diagnosis of intraepithelial lesion (CIN1(+)) was confirmed in 61% of cases, whereas 57% were HPV RNA(+). HPV-RNA positivity was 84% sensitive and 86% specific for an expert-adjudicated diagnosis of CIN1(+). Conversely, consensus diagnosis was 90% sensitive and 78% specific for the presence of HPV RNA. Integrating RNA ISH into morphologic review led to further reclassification of 10% of cases, resulting in 95% sensitivity and 98% specificity of HPV RNA ISH for a CIN1(+) diagnosis and 98% sensitivity and 92% specificity of CIN1(+) for the presence of HPV RNA. These findings suggest that judicious use of HPV RNA ISH can improve the accuracy of LSIL/CIN1 diagnosis for morphologically ambiguous cases.	[Mills, Anne M.; Coppock, Joseph D.; Willis, Brian C.; Stoler, Mark H.] Univ Virginia, Dept Pathol, 1215 Lee St,HEP 3rd Floor,Room 2001, Charlottesville, VA 22908 USA	Mills, AM (reprint author), Univ Virginia, Dept Pathol, 1215 Lee St,HEP 3rd Floor,Room 2001, Charlottesville, VA 22908 USA.	amm7r@virginia.edu		Mills, Anne/0000-0002-2686-4857			Bansal N, 2008, ANTICANCER RES, V28, P1763; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; Darragh TM, 2013, INT J GYNECOL PATHOL, V32, P76, DOI 10.1097/PGP.0b013e31826916c7; Evans MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091142; Fujii T, 2005, DIAGN MOL PATHOL, V14, P103, DOI 10.1097/01.pas.0000162755.84026.9f; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Guo M, 2008, J CLIN MICROBIOL, V46, P274, DOI 10.1128/JCM.01299-07; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016/j.ygyno.2003.11.035; Mills AM, 2017, AM J SURG PATHOL, V41, P607, DOI 10.1097/PAS.0000000000000800; Nakagawa S, 2000, J MED VIROL, V62, P251, DOI 10.1002/1096-9071(200010)62:2<251::AID-JMV18>3.0.CO;2-V; Schiffman M, 2003, ARCH PATHOL LAB MED, V127, P946; Selvi K, 2014, INT J SURG PATHOL, V22, P221, DOI 10.1177/1066896913496147; Stoler MH, 2015, AM J SURG PATHOL, V39, P729, DOI 10.1097/PAS.0000000000000381; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; STOLER MH, 1990, J VIROL, V64, P3310; Wright TC, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.024; Zhang WJ, 2012, INT J GYNECOL PATHOL, V31, P588, DOI 10.1097/PGP.0b013e318254349a	20	4	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					192	200		10.1097/PAS.0000000000000974			9	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300007	29112014				2019-10-28	
J	Mete, O; Gucer, H; Kefeli, M; Asa, SL				Mete, Ozgur; Gucer, Hasan; Kefeli, Mehmet; Asa, Sylvia L.			Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						angioinvasion; IGF-2; adrenal cortical carcinoma; reticulin; biomarkers; Ki67; phospho-mTOR; DAXX; tumor grade	GROWTH-FACTOR-II; ADRENOCORTICAL TUMORS; IGF-II; GENOMIC CHARACTERIZATION; PROTEIN-KINASE; HELSINKI SCORE; P53 MUTATIONS; MTOR PATHWAY; WEISS SYSTEM; DNA-DAMAGE	The diagnosis of low-grade adrenal cortical carcinoma (ACC) confined to the adrenal gland can be challenging. Although there are diagnostic and prognostic molecular tests for ACC, they remain largely unutilized. We examined the diagnostic and prognostic value of altered reticulin framework and the immunoprofile of biomarkers including IGF-2, proteins involved in cell proliferation and mitotic spindle regulation (Ki67, p53, BUB1B, HURP, NEK2), DNA damage repair (PBK, -H2AX), telomere regulation (DAX, ATRX), wnt-signaling pathway (beta-catenin) and PI3K signaling pathway (PTEN, phospho-mTOR) in a tissue microarray of 50 adenomas and 43 carcinomas that were characterized for angioinvasion as defined by strict criteria, Weiss score, and mitotic rate-based tumor grade. IGF-2 and proteins involved in cell proliferation and mitotic spindle regulation (Ki67, p53, BUB1B, HURP, NEK2), DNA damage proteins (PBK, -H2AX), regulators of telomeres (DAXX, ATRX), and beta-catenin revealed characteristic expression profiles enabling the distinction of carcinomas from adenomas. Not all biomarkers were informative in all carcinomas. IGF-2 was the most useful biomarker of malignancy irrespective of tumor grade and cytomorphologic features, as juxtanuclear Golgi-pattern IGF-2 reactivity optimized for high specificity was identified in up to 80% of carcinomas and in no adenomas. Loss rather than qualitative alterations of the reticulin framework yielded statistical difference between carcinoma and adenoma. Angioinvasion defined as tumor cells invading through a vessel wall and intravascular tumor cells admixed with thrombus proved to be the best prognostic parameter, predicting adverse outcome in the entire cohort as well as within low-grade ACCs. Low mitotic tumor grade, Weiss score, global loss of DAXX expression, and high phospho-mTOR expression correlated with disease-free survival, but Weiss score and biomarkers failed to predict adverse outcome in low-grade disease. Our results underscore the importance of careful morphologic assessment coupled with ancillary diagnostic and prognostic biomarkers of ACC.	[Mete, Ozgur; Asa, Sylvia L.] Univ Hlth Network, Dept Pathol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada; [Mete, Ozgur; Asa, Sylvia L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Mete, Ozgur; Asa, Sylvia L.] Princess Margaret Canc Ctr, Endocrine Oncol Site Grp, Toronto, ON, Canada; [Gucer, Hasan] Recep Tayyip Erdogan Univ, Dept Pathol, Rize, Turkey; [Kefeli, Mehmet] Ondokuz Mayis Univ, Dept Pathol, Samsun, Turkey	Mete, O (reprint author), Univ Hlth Network, Dept Pathol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada.	ozgur.mete2@uhn.ca	GUCER, HASAN/B-2426-2014	GUCER, HASAN/0000-0002-9122-379X; Asa, Sylvia/0000-0001-8418-5054			Ando K, 2010, CANCER SCI, V101, P639, DOI 10.1111/j.1349-7006.2009.01457.x; Arola J, 2000, ENDOCR RES, V26, P861, DOI 10.3109/07435800009048609; Assie G, 2012, MOL CELL ENDOCRINOL, V351, P111, DOI 10.1016/j.mce.2011.09.044; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Aubert S, 2002, AM J SURG PATHOL, V26, P1612, DOI 10.1097/00000478-200212000-00009; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Barbagallo F, 2009, J PATHOL, V217, P431, DOI 10.1002/path.2471; Batisse-Lignier M, 2017, ONCOGENE, V36, P4445, DOI 10.1038/onc.2017.54; Boulle N, 2000, ENDOCRINOLOGY, V141, P3127, DOI 10.1210/en.141.9.3127; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Das S, 2016, J PEDIATR SURG, V51, P1795, DOI 10.1016/j.jpedsurg.2016.07.014; De Martino MC, 2014, ENDOCR-RELAT CANCER, V21, P601, DOI 10.1530/ERC-13-0112; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Duan K, 2016, ENDOCR PATHOL, P602; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duregon E, 2017, HUM PATHOL, V62, P1, DOI 10.1016/j.humpath.2016.09.035; Duregon Eleonora, 2015, Turk Patoloji Derg, V31 Suppl 1, P98, DOI 10.5146/tjpath.2015.01317; Duregon E, 2013, AM J SURG PATHOL, V37, P1433, DOI 10.1097/PAS.0b013e31828d387b; Edgren M, 1997, ANTICANCER RES, V17, P1303; Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029; Erickson LA, 2001, ENDOCR PATHOL, V12, P429, DOI 10.1385/EP:12:4:429; Erovic BM, 2013, HEAD NECK-J SCI SPEC, V35, P35, DOI 10.1002/hed.22908; Erovic BM, 2012, ENDOCR PATHOL, V23, P221, DOI 10.1007/s12022-012-9222-y; Erovic BM, 2012, ENDOCR PATHOL, V23, P232, DOI 10.1007/s12022-012-9225-8; Espiard S, 2015, ENDOCRIN METAB CLIN, V44, P311, DOI 10.1016/j.ecl.2015.02.004; Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211; Fraenkel M, 2013, ENDOCRINE, V44, P187, DOI 10.1007/s12020-013-9878-1; Fragoso MCBV, 2012, EUR J ENDOCRINOL, V166, P61, DOI 10.1530/EJE-11-0806; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Gaston V, 2001, EUR J HUM GENET, V9, P409, DOI 10.1038/sj.ejhg.5200649; Germano A, 2017, ENDOCR PATHOL, V28, P95, DOI 10.1007/s12022-017-9473-8; Giordano TJ, 2011, AM J SURG PATHOL, V35, P471, DOI 10.1097/PAS.0b013e31820bcf21; Giordano TJ, 2010, ARCH PATHOL LAB MED, V134, P1440, DOI 10.1043/2010-0320-RA.1; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; HAN VKM, 1992, ENDOCRINOLOGY, V131, P3100, DOI 10.1210/en.131.6.3100; Hayward DG, 2010, J BIOMOL SCREEN, V15, P918, DOI 10.1177/1087057110376537; He FR, 2010, HUM PATHOL, V41, P415, DOI 10.1016/j.humpath.2009.05.016; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; ILVESMAKI V, 1993, J CLIN ENDOCR METAB, V77, P852, DOI 10.1210/jc.77.3.852; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kao J, 2006, CURR CANCER DRUG TAR, V6, P197, DOI 10.2174/156800906776842957; Kuo LJ, 2008, IN VIVO, V22, P305; Lee YK, 2009, BRIT J CANCER, V101, P504, DOI 10.1038/sj.bjc.6605161; Logarinho E, 2008, CELL CYCLE, V7, P1763, DOI 10.4161/cc.7.12.6180; McNicol AM, 1997, J PATHOL, V181, P146; Mete O, 2013, PATHOLOGY, V45, P316, DOI 10.1097/PAT.0b013e32835f45c5; Mete O, 2011, MODERN PATHOL, V24, P1545, DOI 10.1038/modpathol.2011.119; Morimoto R, 2008, ENDOCR J, V55, P49, DOI 10.1507/endocrj.K07-079; Nielsen HM, 2015, ENDOCR-RELAT CANCER, V22, P953, DOI 10.1530/ERC-15-0086; Ohashi T, 2017, BRIT J CANCER, V116, P218, DOI 10.1038/bjc.2016.394; OHGAKI H, 1993, INT J CANCER, V54, P408, DOI 10.1002/ijc.2910540310; Papotti Mauro, 2011, Hormones & Cancer, V2, P333, DOI 10.1007/s12672-011-0088-0; Papotti M, 2010, AM J SURG PATHOL, V34, P973, DOI 10.1097/PAS.0b013e3181e2b726; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Patel D, 2014, ANN SURG ONCOL, V21, P3541, DOI 10.1245/s10434-014-3768-5; Pennanen M, 2015, HUM PATHOL, V46, P404, DOI 10.1016/j.humpath.2014.11.015; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Pinto EM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7302; Pinto M, 2008, CELL ONCOL, V30, P389, DOI 10.3233/CLO-2008-0439; REINCKE M, 1994, J CLIN ENDOCR METAB, V78, P790, DOI 10.1210/jc.78.3.790; Rizzardi C, 2011, HEAD NECK-J SCI SPEC, V33, P727, DOI 10.1002/hed.21532; Ross JS, 2014, J CLIN PATHOL, V67, P968, DOI 10.1136/jclinpath-2014-202514; Sari SO, 2016, ENDOCR PATHOL, V27, P162, DOI 10.1007/s12022-016-9424-9; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Schmitt A, 2006, HISTOPATHOLOGY, V49, P298, DOI 10.1111/j.1365-2559.2006.02505.x; Song L, 2014, MOL CELL, V53, P179, DOI 10.1016/j.molcel.2013.12.022; Stojadinovic A, 2003, MODERN PATHOL, V16, P742, DOI 10.1097/01.MP.0000081730.72305.81; Stojadinovic A, 2002, J CLIN ONCOL, V20, P941, DOI 10.1200/JCO.20.4.941; Stricker TP, 2013, MODERN PATHOL, V26, P930, DOI 10.1038/modpathol.2012.242; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Tissier F, 2012, AM J SURG PATHOL, V36, P1194, DOI 10.1097/PAS.0b013e31825a6308; Volante M, 2009, HISTOPATHOLOGY, V55, P535, DOI 10.1111/j.1365-2559.2009.03423.x; Voon HPJ, 2016, NUCLEIC ACIDS RES, V44, P1496, DOI 10.1093/nar/gkw012; VOUTILAINEN R, 1987, P NATL ACAD SCI USA, V84, P1590, DOI 10.1073/pnas.84.6.1590; Wang CP, 2014, HISTOPATHOLOGY, V64, P567, DOI 10.1111/his.12283; Wang MY, 2016, ONCOTARGET, V7, P26604, DOI 10.18632/oncotarget.8445; Wasserman JD, 2012, MOL CELL ENDOCRINOL, V351, P101, DOI 10.1016/j.mce.2011.09.010; WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004; Wrighton KH, 2014, NAT REV MOL CELL BIO, V15, DOI 10.1038/nrm3759; Yamamoto Y, 2007, CANCER GENET CYTOGEN, V174, P42, DOI 10.1016/j.cancergencyto.2006.11.012; Yang JJ, 2016, J GINSENG RES, V40, P400, DOI 10.1016/j.jgr.2016.03.007; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048	85	7	8	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					201	213		10.1097/PAS.0000000000000943			13	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300008	28877067				2019-10-28	
J	Stolnicu, S; Barsan, I; Hoang, L; Patel, P; Terinte, C; Pesci, A; Aviel-Ronen, S; Kiyokawa, T; Alvarado-Cabrero, I; Pike, MC; Oliva, E; Park, KJ; Soslow, RA				Stolnicu, Simona; Barsan, Iulia; Hoang, Lien; Patel, Prusha; Terinte, Cristina; Pesci, Anna; Aviel-Ronen, Sarit; Kiyokawa, Takako; Alvarado-Cabrero, Isabel; Pike, Malcolm C.; Oliva, Esther; Park, Kay J.; Soslow, Robert A.			International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cervix; endocervical; adenocarcinoma; HPV; classification	SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS DNA; PAPILLARY SEROUS CARCINOMA; DIFFERENT HISTOLOGICAL SUBTYPES; UTERINE CERVIX; IMMUNOHISTOCHEMICAL ANALYSIS; DIFFERENTIAL-DIAGNOSIS; INTRAEPITHELIAL LESION; GASTRIC MORPHOLOGY; OVARIAN-CARCINOMA	We sought to classify endocervical adenocarcinomas (ECAs) based on morphologic features linked to etiology (ie, human papillomavirus [HPV] infection), unlike the World Health Organization 2014 classification. The International Endocervical Adenocarcinoma Criteria and Classification (IECC criteria), described herein, distinguishes between human papillomavirus-associated adenocarcinoma (HPVA), recognized by the presence of luminal mitoses and apoptosis seen at scanning magnification, and no or limited HPVA features (nonhuman papillomavirus-associated adenocarcinoma [NHPVA]). HPVAs were then subcategorized based on cytoplasmic features (mostly to provide continuity with preexisting classification schemes), whereas NHPVAs were subclassified based on established criteria (ie, gastric-type, clear cell, etc.). Complete slide sets from 409 cases were collected from 7 institutions worldwide. Tissue microarrays representing 297 cases were constructed; immunohistochemistry (p16, p53, vimentin, progesterone receptor) and chromogenic in situ hybridization using an RNA-based probe set that recognizes 18 varieties of high-risk HPV were performed to validate IECC diagnoses. The 5 most common IECC diagnoses were usual-type (HPVA) (73% of cohort), gastric-type (NHPVA) (10%), mucinous adenocarcinoma of HPVA type, including intestinal, mucinous not otherwise specified, signet-ring, and invasive stratified mucin-producing carcinoma categories (9%), clear cell carcinoma (NHPVA) (3%) and adenocarcinoma, not otherwise specified (2%). Only 3 endometrioid carcinomas were recognized and all were NHPVA. When excluding cases thought to have suboptimal tissue processing, 90% and 95% of usual-type IECC cases overexpressed p16 and were HPV+, whereas 37% and 3% of NHPVAs were p16(+) and HPV+, respectively. The 1 HPV+ gastric-type carcinoma was found to have hybrid HPVA/NHPVA features on secondary review. NHPVA tumors were larger and occurred in significantly older patients, compared with HPVA tumors (P<0.001). The high-risk HPV chromogenic in situ hybridization probe set had superior sensitivity, specificity, and positive and negative predictive values (0.955, 0.968, 0.992, 0.833, respectively) compared with p16 immunohistochemistry (0.872, 0.632, 0.907, 0.545, respectively) to identify HPV-related usual carcinoma and mucinous carcinoma. IECC reliably segregates ECAs into HPVA and NHPVA types using morphology alone. This study confirms that usual-type ECAs are the most common type worldwide and that mucinous carcinomas comprise a mixture of HPVA and NHPVA, with gastric-type carcinoma being the major NHPVA type. Endometrioid and serous carcinomas of the endocervix are extraordinarily rare. Should clinical outcomes and genomic studies continue to support these findings, we recommend replacement of the World Health Organization 2014 criteria with the IECC 2017.	[Stolnicu, Simona; Barsan, Iulia] Univ Med & Pharm Targu Mures, Dept Pathol, Targu Mures, Romania; [Terinte, Cristina] Reg Inst Oncol, Iasi, Romania; [Hoang, Lien] Vancouver Gen Hosp, Vancouver, BC, Canada; [Pesci, Anna] Osped Sacro Cuore Don Calabria, Negrar, Italy; [Aviel-Ronen, Sarit] Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Kiyokawa, Takako] Jikei Univ, Sch Med, Tokyo, Japan; [Alvarado-Cabrero, Isabel] Hosp Oncol Mexico City, Mexico City, DF, Mexico; [Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Patel, Prusha; Pike, Malcolm C.; Park, Kay J.; Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Soslow, RA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	soslowr@mskcc.org		Stolnicu, Simona/0000-0002-4459-7019	NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]	This study was funded in part through the NIH/NCI Support Grant P30 CA008748 (R.A.S., K.J.P., and M.C.P.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ajila Vidya, 2015, J Sex Transm Dis, V2015, P791024, DOI 10.1155/2015/791024; Alfsen GC, 2000, CANCER, V89, P1291, DOI 10.1002/1097-0142(20000915)89:6<1291::AID-CNCR14>3.3.CO;2-F; An HJ, 2005, MODERN PATHOL, V18, P528, DOI 10.1038/modpathol.3800316; Balci S, 2010, INT J GYNECOL PATHOL, V29, P181, DOI 10.1097/PGP.0b013e3181b70176; BeyerFinkler E, 1995, INTERVIROLOGY, V38, P173, DOI 10.1159/000150429; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; CHANG SH, 1971, AM J OBSTET GYNECOL, V110, P1015, DOI 10.1016/0002-9378(71)90559-X; Domfeh AB, 2013, MODERN PATHOL, V26, p272A; Dong F, 2015, AM J SURG PATHOL, V39, P1045, DOI 10.1097/PAS.0000000000000454; Evans MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091142; FERRY JA, 1990, AM J SURG PATHOL, V14, P1100, DOI 10.1097/00000478-199012000-00002; Gilks CB, 2008, HUM PATHOL, V39, P1239, DOI 10.1016/j.humpath.2008.01.003; Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438; Hirschowitz L, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-40; Hong X, 2007, MODERN PATHOL, V20, p201A; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Howitt BE, 2013, AM J SURG PATHOL, V37, P625, DOI 10.1097/PAS.0b013e318285be00; Hussein YR, 2016, AM J SURG PATHOL, V40, P404, DOI 10.1097/PAS.0000000000000556; IKENBERG H, 1993, GYNECOL ONCOL, V48, P56, DOI 10.1006/gyno.1993.1009; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kocken M, 2011, GYNECOL ONCOL, V122, P297, DOI 10.1016/j.ygyno.2011.05.002; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kurman RJ, 2014, WHO CLASSIFICATION T; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Lastra RR, 2016, AM J SURG PATHOL, V40, P262, DOI 10.1097/PAS.0000000000000543; Liang WS, 2014, INT J GYNECOL CANCER, V24, P329, DOI 10.1097/IGC.0000000000000049; Lim D, 2016, AM J SURG PATHOL, V40, P302, DOI 10.1097/PAS.0000000000000550; Masoudi H, 2006, HISTOPATHOLOGY, V49, P542, DOI 10.1111/j.1365-2559.2006.02510.x; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; McAlpine JN, 2017, HISTOPATHOLOGY, V71, P238, DOI 10.1111/his.13205; McCluggage WG, 2016, ADV ANAT PATHOL, V23, P58, DOI 10.1097/PAP.0000000000000095; McCluggage WG, 2010, AM J SURG PATHOL, V34, P735, DOI 10.1097/PAS.0b013e3181d6b8fd; Molijn A, 2016, INT J CANCER, V138, P409, DOI 10.1002/ijc.29722; Nelson HH, 2017, JAMA ONCOL, V3, P178, DOI 10.1001/jamaoncol.2016.4500; Nofech-Mozes S, 2010, APPL IMMUNOHISTO M M, V18, P80, DOI 10.1097/PAI.0b013e3181ae7240; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Onishi J, 2016, HUM PATHOL, V55, P174, DOI 10.1016/j.humpath.2016.05.007; Park JJ, 2000, AM J SURG PATHOL, V24, P1414, DOI 10.1097/00000478-200010000-00012; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Pirog EC, 2014, MODERN PATHOL, V27, P1559, DOI 10.1038/modpathol.2014.55; Poetsch M, 2011, VIRCHOWS ARCH, V458, P221, DOI 10.1007/s00428-010-1007-4; Reid-Nicholson M, 2006, MODERN PATHOL, V19, P1091, DOI 10.1038/modpathol.3800620; Reyes MC, 2014, MODERN PATHOL, V27, P1405, DOI 10.1038/modpathol.2013.237; Rodriguez-Carunchio L, 2015, BJOG-INT J OBSTET GY, V122, P119, DOI 10.1111/1471-0528.13071; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Schorge JO, 1999, OBSTET GYNECOL, V94, P386, DOI 10.1016/S0029-7844(99)00312-9; Sedghizadeh PP, 2016, ORAL ONCOL, V54, P15, DOI 10.1016/j.oraloncology.2016.01.002; Singh N, 2017, HISTOPATHOLOGY, V70, P56, DOI 10.1111/his.13080; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Stewart CJR, 2015, PATHOLOGY, V47, P653, DOI 10.1097/PAT.0000000000000329; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Togami S, 2015, PATHOL ONCOL RES, V21, P487, DOI 10.1007/s12253-014-9854-y; VESTERINEN E, 1989, GYNECOL ONCOL, V33, P49, DOI 10.1016/0090-8258(89)90602-1; Wada T, 2017, AM J SURG PATHOL, V41, P696, DOI 10.1097/PAS.0000000000000833; Watrowski R, 2012, ANTICANCER RES, V32, P5075; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P1, DOI 10.1097/00004347-200201000-00001; Zhou C, 1998, AM J SURG PATHOL, V22, P113, DOI 10.1097/00000478-199801000-00015	62	23	24	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					214	226		10.1097/PAS.0000000000000986			13	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300009	29135516	Green Accepted			2019-10-28	
J	Skalova, A; Vanecek, T; Martinek, P; Weinreb, I; Stevens, TM; Simpson, RHW; Hyrcza, M; Rupp, NJ; Baneckova, M; Michal, M; Slouka, D; Svoboda, T; Metelkova, A; Etebarian, A; Pavelka, J; Potts, SJ; Christiansen, J; Steiner, P; Michal, M				Skalova, Alena; Vanecek, Tomas; Martinek, Petr; Weinreb, Ilan; Stevens, Todd M.; Simpson, Roderick H. W.; Hyrcza, Martin; Rupp, Niels J.; Baneckova, Martina; Michal, Michael, Jr.; Slouka, David; Svoboda, Tomas; Metelkova, Alena; Etebarian, Arghavan; Pavelka, Jaroslav; Potts, Steven J.; Christiansen, Jason; Steiner, Petr; Michal, Michal			Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET Translocation: Report of 10 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						salivary; mammary analog secretory carcinoma; MASC; ETV6-NTRK3; ETV6-RET fusion transcript	ETV6-NTRK3 GENE FUSION; PAPILLARY THYROID-CARCINOMA; SALIVARY-GLANDS; MESOBLASTIC NEPHROMA; ANTITUMOR-ACTIVITY; LEUKEMIA; MASC; REARRANGEMENTS; ENTRECTINIB; FEATURES	ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of ETV6 have been reported in a variety of epithelial, mesenchymal, and hematological malignancies. In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for (mammary analog) secretory carcinoma, and has not been documented in any other salivary tumor type. The present study comprised a clinical, histologic, and molecular analysis of 10 cases of secretory carcinoma, with typical morphology and immunoprofile harboring a novel ETV6-RET translocation.	[Skalova, Alena; Baneckova, Martina; Michal, Michael, Jr.; Steiner, Petr; Michal, Michal] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Slouka, David] Charles Univ Prague, Fac Med Plzen, Dept Otorhinolaryngol, Plzen, Czech Republic; [Svoboda, Tomas] Charles Univ Prague, Fac Med Plzen, Dept Radiotherapy & Oncol, Oncol Clin, Plzen, Czech Republic; [Metelkova, Alena] Charles Univ Prague, Fac Med Plzen, Dept Clin Oncol, Oncol Clin, Plzen, Czech Republic; [Michal, Michael, Jr.] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Skalova, Alena; Baneckova, Martina] Biopt Lab Ltd, Plzen, Czech Republic; [Vanecek, Tomas; Martinek, Petr; Pavelka, Jaroslav; Steiner, Petr] Biopt Lab Ltd, Mol Pathol Lab, Plzen, Czech Republic; [Pavelka, Jaroslav] Univ West Bohemia, Fac Educ, Plzen, Czech Republic; [Weinreb, Ilan] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Stevens, Todd M.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA; [Simpson, Roderick H. W.] Univ Calgary, Dept Anat Pathol, Calgary, AB, Canada; [Simpson, Roderick H. W.] Foothills Med Ctr, Calgary, AB, Canada; [Hyrcza, Martin] McMaster Univ, St Josephs Healthcare & Hamilton Hlth Sci, Dept Pathol & Mol Med, Vancouver, BC, Canada; [Rupp, Niels J.] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; [Etebarian, Arghavan] Univ Tehran Med Sci, Sch Dent, Dept Oral & Maxillofacial Pathol, Tehran, Iran; [Potts, Steven J.; Christiansen, Jason] Ignyta Inc, San Diego, CA USA	Skalova, A (reprint author), Charles Univ Prague, Fac Hosp, Sikls Dept Pathol, Fac Med, E Benese 13, Plzen 30599, Czech Republic.	skalova@fnplzen.cz	Michal, Michael/I-3497-2017; Baneckova, Martina/Q-1052-2017	Michal, Michael/0000-0003-4403-7027; Baneckova, Martina/0000-0002-5829-5572	National Sustainability Program I (NPU I) [LO1503]; Ministry of Education Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [260 391]	Supported in parts by the National Sustainability Program I (NPU I) Nr. LO1503 and by the grant SVV-2017 No. 260 391 provided by the Ministry of Education Youth and Sports of the Czech Republic. The NGS analysis was in part supported by Ignyta Inc., San Diego, CA. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abe A, 2016, GENE CHROMOSOME CANC, V55, P242, DOI 10.1002/gcc.22327; Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; Brenca M, 2016, J PATHOL, V238, P543, DOI 10.1002/path.4677; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Dettloff J, 2017, HEAD NECK PATHOL, V11, P266, DOI 10.1007/s12105-016-0756-z; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Fehr A, 2011, AM J SURG PATHOL, V35, P1600, DOI 10.1097/PAS.0b013e31822832c7; Gaffney R, 2003, J MOL DIAGN, V5, P127, DOI 10.1016/S1525-1578(10)60462-X; Garcia Daniela Ribeiro Ney, 2013, Rev. Bras. Hematol. Hemoter., V35, P369, DOI 10.5581/1516-8484.20130111; Griffith C, 2011, VIRCHOWS ARCH, V459, P117, DOI 10.1007/s00428-011-1098-6; Chi HT, 2012, BIOCHEM BIOPH RES CO, V429, P87, DOI 10.1016/j.bbrc.2012.10.087; Hyrcza MD, 2015, DIAGN HISTOPATHOL, V21, P481; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Knezevich SR, 1998, CANCER RES, V58, P5046; Kralik JM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-19; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Li GG, 2017, CLIN CANCER RES, V23, P2981, DOI 10.1158/1078-0432.CCR-16-1887; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Lurquin E, 2015, HISTOPATHOLOGY, V67, P749, DOI 10.1111/his.12702; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Murphy DA, 2017, APPL IMMUNOHISTO M M, V25, P513, DOI 10.1097/PAI.0000000000000360; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Reynolds S, 2016, HEAD NECK PATHOL, V10, P405, DOI 10.1007/s12105-016-0715-8; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Sabari Joshua K, 2017, Oncoscience, V4, P23, DOI 10.18632/oncoscience.345; Seethala RR, 2017, AM J SURG PATHOL, V41, P446, DOI 10.1097/PAS.0000000000000814; Skalova A, 2017, WHO CLASSIFICATION H, P177; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Strehl S, 2008, CLIN CANCER RES, V14, P977, DOI 10.1158/1078-0432.CCR-07-4022; Su Ruijun Jeanna, 2016, Hum Pathol (N Y), V5, P6; Tannenbaum-Dvir S, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000471; Tirado CA, 2016, BIOMARK RES, V4, DOI 10.1186/s40364-016-0070-7; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Viswanatha DS, 2000, MODERN PATHOL, V13, P825, DOI 10.1038/modpathol.3880144; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568	47	23	24	5	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					234	246		10.1097/PAS.0000000000000972			13	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300011	29076873				2019-10-28	
J	Sun, Y; Lohse, C; Smyrk, T; Hobday, T; Kroneman, T; Zhang, LZ				Sun, Yu; Lohse, Christine; Smyrk, Thomas; Hobday, Timothy; Kroneman, Trynda; Zhang, Lizhi			The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						neuroendocrine tumor; small intestine; Ki-67; mitotic count; prognosis	NEURO ENDOCRINE TUMORS; CARCINOID-TUMORS; INCLUDING BRONCHOPULMONARY; LIVER METASTASES; THYMIC NEOPLASMS; POOR-PROGNOSIS; MIDGUT; MANAGEMENT; SURVIVAL; CLASSIFICATION	Tumor cell proliferation rate determined by either Ki-67 index or mitotic count (MC) has shown to be a prognostic factor for gastrointestinal neuroendocrine tumors in general, and after its incorporation in the 2010 World Health Organization tumor grading system, it has become essentially mandatory in pathology reports for all gastrointestinal neuroendocrine tumors, regardless of tumor location. Nevertheless, clinical significance for the Ki-67 index or MC has not been well demonstrated in small intestinal neuroendocrine tumor (SINET), especially those without distant metastasis, the majority of which have very low proliferation rates. We assessed the clinical behavior of 130 SINETs in relation to stage, Ki-67 index, MC, and other pathologic features. Most SINETs (86%) were grade 1 and 14% were grade 2. There were no grade 3 tumors or poorly differentiated neuroendocrine carcinomas. On multivariate analysis, age, Ki-67 index >5%, MC >10/50 high-power field, stage IV, and liver metastases were associated with increased risk of death in all patients. When both stage and grade were considered, Ki-67 index >5% was associated with a nearly 4-fold increased risk of death in stage IV cases (n=60). In contrast, Ki-67 index did not show prognostic value for patients with stages I to III disease (n=70), although MC >1/50 high-power field was significantly associated with death on multivariable analysis. Our study confirms that liver metastasis and increased tumor cell proliferation rate are independent prognostic factors for SINETs, but shows that most SINETs have a very low proliferation rate, which limits its value for predicting tumor behavior. By combining staging and grading information, we demonstrate different roles and cutoff values of Ki-67 index and MC in SINET with different stages.	[Sun, Yu] Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Lohse, Christine] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Smyrk, Thomas; Kroneman, Trynda; Zhang, Lizhi] Mayo Clin, Dept Lab & Anat Pathol, 200 First St SW, Rochester, MN 55905 USA; [Hobday, Timothy] Mayo Clin, Dept Oncol, Rochester, MN USA	Zhang, LZ (reprint author), Mayo Clin, Dept Lab & Anat Pathol, 200 First St SW, Rochester, MN 55905 USA.	zhang.lizhi@mayo.edu					Ahmed A, 2009, ENDOCR-RELAT CANCER, V16, P885, DOI 10.1677/ERC-09-0042; Akerstrom G, 2005, J SURG ONCOL, V89, P161, DOI 10.1002/jso.20188; Al-Khafaji B, 1998, HUM PATHOL, V29, P992, DOI 10.1016/S0046-8177(98)90206-4; Bilimoria KY, 2008, ANN SURG, V247, P490, DOI 10.1097/SLA.0b013e31815b9cae; Bohm J, 1996, J PATHOL, V178, P402, DOI 10.1002/(SICI)1096-9896(199604)178:4<402::AID-PATH498>3.0.CO;2-5; Bosman FT, 2010, WHO CLASSIFICATION T; Boudreaux JP, 2010, PANCREAS, V39, P753, DOI 10.1097/MPA.0b013e3181ebb2a5; Burke AP, 1997, CANCER-AM CANCER SOC, V79, P1086, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1086::AID-CNCR5>3.0.CO;2-E; CAPELLA C, 1995, VIRCHOWS ARCH, V425, P547; Chow JS, 1996, INT J EPIDEMIOL, V25, P722, DOI 10.1093/ije/25.4.722; Edge SB, 2010, AJCC CANC STAGING MA; Fata CR, 2017, AM J SURG PATHOL, V41, P128, DOI 10.1097/PAS.0000000000000751; Hamilton NA, 2012, SURGERY, V152, P107, DOI 10.1016/j.surg.2012.02.011; Jann H, 2011, CANCER-AM CANCER SOC, V117, P3332, DOI 10.1002/cncr.25855; Kim MK, 2013, J CLIN ONCOL, V31, P3776, DOI 10.1200/JCO.2013.51.1477; Landerholm K, 2011, BRIT J SURG, V98, P1617, DOI 10.1002/bjs.7649; Landry CS, 2008, AM J SURG, V196, P896, DOI 10.1016/j.amjsurg.2008.07.042; Lawrence B, 2011, ENDOCRIN METAB CLIN, V40, P1, DOI 10.1016/j.ecl.2010.12.005; Madeira I, 1998, GUT, V43, P422, DOI 10.1136/gut.43.3.422; Maggard MA, 2004, ANN SURG, V240, P117, DOI 10.1097/01.sla.0000129342.67174.67; Oberg K, 2004, ANN ONCOL, V15, P966, DOI 10.1093/annonc/mdh216; Oberg K, 2004, ACTA ONCOL, V43, P626, DOI 10.1080/02841860410018584; Oberg K, 2004, ACTA ONCOL, V43, P617, DOI 10.1080/02841860410018575; Panzuto F, 2005, ENDOCR-RELAT CANCER, V12, P1083, DOI 10.1677/ERC1.01017; Panzuto F, 2011, J CLIN ONCOL, V29, P2372, DOI 10.1200/JCO.2010.33.0688; Pape UF, 2004, ANN NY ACAD SCI, V1014, P222, DOI 10.1196/annals.1294.025; Pape UF, 2008, CANCER-AM CANCER SOC, V113, P256, DOI 10.1002/cncr.23549; Pape UF, 2008, ENDOCR-RELAT CANCER, V15, P1083, DOI 10.1677/ERC-08-0017; Plockinger U, 2004, NEUROENDOCRINOLOGY, V80, P394, DOI 10.1159/000085237; Rindi G, 2007, VIRCHOWS ARCH, V451, P757, DOI 10.1007/s00428-007-0452-1; Scarpa A, 2010, MODERN PATHOL, V23, P824, DOI 10.1038/modpathol.2010.58; Scherubl H, 2010, WORLD J GASTRO ENDOS, V2, P325, DOI 10.4253/wjge.v2.i10.325; Sobin LH, 2009, CLASSIFICATION MALIG; Steinmuller T, 2008, NEUROENDOCRINOLOGY, V87, P47, DOI 10.1159/000111037; Strosberg J, 2009, NEUROENDOCRINOLOGY, V89, P471, DOI 10.1159/000197899; Strosberg JR, 2013, J CLIN ONCOL, V31, P420, DOI 10.1200/JCO.2012.44.5924; Tomassetti P, 2006, NEUROENDOCRINOLOGY, V83, P380, DOI 10.1159/000096053; Turner GB, 2006, GUT, V55, P1586, DOI 10.1136/gut.2006.092320; Van Eeden S, 2002, HUM PATHOL, V33, P1126, DOI 10.1053/hupa.2002.129204; Volante M, 2013, AM J SURG PATHOL, V37, P606, DOI 10.1097/PAS.0b013e318275d1d7; Woltering EA, 2017, AJCC CANC STAGING MA, V2017, P375, DOI [10.1007/978-3-319-40618-3_30, DOI 10.1007/978-3-319-40618-3_30]; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377	42	5	5	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					247	255		10.1097/PAS.0000000000000968			9	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300012	29016403				2019-10-28	
J	Pillappa, R; Maleszewski, JJ; Sukov, WR; Bedroske, PP; Greipp, PT; Boland, JM; Yi, ES; Peikert, T; Aubry, MC; Roden, AC				Pillappa, Raghavendra; Maleszewski, Joseph J.; Sukov, William R.; Bedroske, Patrick P.; Greipp, Patricia T.; Boland, Jennifer M.; Yi, Eunhee S.; Peikert, Tobias; Aubry, Marie Christine; Roden, Anja C.			Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						atypical mesothelial proliferation; BAP1; CDKN2A; malignant mesothelioma	SITU HYBRIDIZATION ANALYSIS; PLEURAL MESOTHELIOMA; P16 FISH; BRCA1-ASSOCIATED PROTEIN-1; TUMOR-SUPPRESSOR; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; DELETION; BENIGN; CLASSIFICATION	Distinguishing reactive mesothelial proliferation from malignant mesothelioma (MM) can be difficult, particularly on small biopsies. In this scenario, a diagnosis of atypical mesothelial proliferation might be rendered. However, the distinction between a reactive process and MM is important for prognosis and treatment. Recently, loss of BRCA1-associated protein 1 (BAP1) expression and/or homozygous deletion of CDKN2A were identified in some MM, but not in reactive mesothelial proliferations. We studied 34 cases of atypical mesothelial proliferation from our institutional files (1993 to 2016) for BAP1 expression, deletion of CDKN2A, and clinical outcome. Fifteen of 34 patients (44%) were subsequently diagnosed with MM. BAP1 expression was lost in 6 of these 15 (40%) patients. Ten of 15 (67%) patients died of disease within a median time of 18.2 months. BAP1 expression was also lost in 1 case of probable MM. In this case atypical mesothelial proliferation was identified in the pleura during a lobectomy procedure for lung adenocarcinoma. Follow-up of 57.0 months was remarkable for visceral and parietal pleural thickening with continued unilateral effusion identified on imaging studies but no subsequent definitive diagnosis of MM. CDKN2A studies by fluorescence in situ hybridization (performed in 31 cases) found no homozygous deletion of that gene in any case. In conclusion, loss of BAP1 expression in atypical mesothelial proliferation helps to predict MM and is a useful adjunct test in these cases. Homozygous deletion of CDKN2A in mesothelial cell proliferations did not prove to be useful to predict MM in cases of atypical mesothelial proliferation.	[Pillappa, Raghavendra; Maleszewski, Joseph J.; Sukov, William R.; Bedroske, Patrick P.; Greipp, Patricia T.; Boland, Jennifer M.; Yi, Eunhee S.; Aubry, Marie Christine; Roden, Anja C.] Mayo Clin Rochester, Dept Lab Med & Pathol, Hilton 11,200 First St SW, Rochester, MN 55905 USA; [Peikert, Tobias] Mayo Clin Rochester, Div Pulm & Crit Care Med, Rochester, MN USA; [Peikert, Tobias] Mayo Clin Rochester, Dept Immunol, Rochester, MN USA	Roden, AC (reprint author), Mayo Clin Rochester, Dept Lab Med & Pathol, Hilton 11,200 First St SW, Rochester, MN 55905 USA.	roden.anja@mayo.edu		Boland, Jennifer/0000-0002-2723-9586			Attanoos RL, 2003, HISTOPATHOLOGY, V43, P231, DOI 10.1046/j.1365-2559.2003.01686.x; Borasio P, 2008, EUR J CARDIO-THORAC, V33, P307, DOI 10.1016/j.ejcts.2007.09.044; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Chiosea S, 2008, MODERN PATHOL, V21, P742, DOI 10.1038/modpathol.2008.45; Chung CTS, 2010, J CLIN PATHOL, V63, P630, DOI 10.1136/jcp.2010.076794; Churg A, 2016, ARCH PATHOL LAB MED, V140, P318, DOI 10.5858/arpa.2015-0240-SA; Churg A, 2012, ARCH PATHOL LAB MED, V136, P1217, DOI 10.5858/arpa.2012-0112-RA; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Dacic S, 2008, VIRCHOWS ARCH, V453, P627, DOI 10.1007/s00428-008-0689-3; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; Hida T, 2016, PATHOL INT, V66, P563, DOI 10.1111/pin.12453; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Hwang H, 2014, AM J SURG PATHOL, V38, P681, DOI 10.1097/PAS.0000000000000176; Hwang HC, 2016, AM J SURG PATHOL, V40, P714, DOI 10.1097/PAS.0000000000000616; Kato Y, 2007, MODERN PATHOL, V20, P215, DOI 10.1038/modpathol.3800732; King J, 2006, HISTOPATHOLOGY, V49, P561, DOI 10.1111/j.1365-2559.2006.02442.x; McGregor SM, 2015, HUM PATHOL, V46, P1670, DOI 10.1016/j.humpath.2015.06.024; Monaco SE, 2011, AM J CLIN PATHOL, V135, P619, DOI 10.1309/AJCPP5R2ZJZKCLWN; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Righi L, 2016, J THORAC ONCOL, V11, P2006, DOI 10.1016/j.jtho.2016.06.020; Romano RC, 2016, INT J SURG PATHOL, V24, P512, DOI 10.1177/1066896916648379; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sheffield BS, 2015, AM J SURG PATHOL, V39, P977, DOI 10.1097/PAS.0000000000000394; Shi M, 2011, AM J SURG PATHOL, V35, P878, DOI 10.1097/PAS.0b013e318218985b; Taioli E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145039; Takeda M, 2010, PATHOL INT, V60, P395, DOI 10.1111/j.1440-1827.2010.02534.x; van de Nes JAP, 2016, AM J SURG PATHOL, V40, P796, DOI 10.1097/PAS.0000000000000645; White AE, 2012, SCIENCE, V337, P1463, DOI 10.1126/science.1228463; Wu D, 2013, AM J CLIN PATHOL, V139, P39, DOI 10.1309/AJCPT94JVWIHBKRD	29	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					256	263		10.1097/PAS.0000000000000976			8	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300013	29076876				2019-10-28	
J	Salimian, KJ; Waters, KM; Eze, O; Pezhouh, MK; Tarabishy, Y; Shin, EJ; Canto, MI; Voltaggio, L; Montgomery, EA				Salimian, Kevan J.; Waters, Kevin M.; Eze, Ogechukwu; Pezhouh, Maryam K.; Tarabishy, Yaman; Shin, Eun-Ji; Canto, Marcia I.; Voltaggio, Lysandra; Montgomery, Elizabeth A.			Definition of Barrett Esophagus in the United States: Support for Retention of a Requirement for Goblet Cells	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Barrett esophagus; esophageal adenocarcinoma; intestinal metaplasia; columnar-lined mucosa; goblet cells	INTESTINAL METAPLASIA; COLUMNAR EPITHELIUM; CANCER-RISK; ADENOCARCINOMA; MANAGEMENT; SURVEILLANCE; DIAGNOSIS; RESECTION	Barrett esophagus (BE) predisposes patients to the development of esophageal adenocarcinoma (EAC). However, the global definition of BE is controversial. Pathologists in Europe and the United States require intestinal metaplasia (IM) within columnar-lined mucosa (CLM) in the tubular esophagus to diagnose BE, whereas in the UK and Japan only the presence of CLM is required. To aid in establishing an appropriate definition for BE, we evaluated whether IM accompanies EAC in a US patient cohort. We examined a series of 139 consecutive patients who underwent endoscopic mucosal resections or esophagectomies for EAC performed at a US tertiary care center. The resection specimens were evaluated for the presence (IM+) or absence (IM-) of IM within CLM. Ninety-seven (70%) patients were IM+. Tumors found in IM- patients tended to be advanced at the time of resection (57% pT3 or greater, IM-; 31% pT3 or greater, IM+; P=0.02) such that the tumor may have overgrown zones of IM. We hypothesized that changes as a result of neoadjuvant chemotherapy or radiation might mask preexisting IM. When evaluating this hypothesis, we found that 34 of 39 of treatment-naive patients were IM+. Two of the 5 IM- patients had prior IM+ biopsies resulting in 92% of treatment-naive patients who were IM+. In our US hospital population, CLM with IM in the tubular esophagus is found in association with EAC in 70% to 92% of patients. We believe that based on these data the United States definition of BE should continue to require the presence of IM.	[Salimian, Kevan J.; Waters, Kevin M.; Eze, Ogechukwu; Pezhouh, Maryam K.; Tarabishy, Yaman; Voltaggio, Lysandra; Montgomery, Elizabeth A.] Johns Hopkins Med Inst, Dept Pathol, Weinberg Bldg,Room 2242,401 North Broadway, Baltimore, MD 21224 USA; [Shin, Eun-Ji; Canto, Marcia I.] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; [Canto, Marcia I.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	Montgomery, EA (reprint author), Johns Hopkins Med Inst, Dept Pathol, Weinberg Bldg,Room 2242,401 North Broadway, Baltimore, MD 21224 USA.	emontgom@jhmi.edu					ALLISON PR, 1953, THORAX, V8, P87, DOI 10.1136/thx.8.2.87; BARRETT NR, 1957, SURGERY, V41, P881; Bennett C, 2015, AM J GASTROENTEROL, V110, P662, DOI 10.1038/ajg.2015.55; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Chandrasoma P, 2012, AM J SURG PATHOL, V36, P1, DOI 10.1097/PAS.0b013e31822a5a2c; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Garside R, 2006, HEALTH TECHNOL ASSES, V10, P1; Hahn HP, 2009, AM J SURG PATHOL, V33, P1006, DOI 10.1097/PAS.0b013e31819f57e9; HAYWARD JOHN, 1961, THORAX, V16, P36, DOI 10.1136/thx.16.1.36; Kelty CJ, 2007, SCAND J GASTROENTERO, V42, P1271, DOI 10.1080/00365520701420735; Kroep S, 2015, GASTROENTEROLOGY, V149, P577, DOI 10.1053/j.gastro.2015.04.045; PARAF F, 1995, AM J SURG PATHOL, V19, P183, DOI 10.1097/00000478-199502000-00007; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904; Provenzale D, 1999, AM J GASTROENTEROL, V94, P2043; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; ROSENBERG JC, 1985, CANCER, V55, P1353, DOI 10.1002/1097-0142(19850315)55:6<1353::AID-CNCR2820550632>3.0.CO;2-D; Ruol A, 2000, CANCER, V88, P2520, DOI 10.1002/1097-0142(20000601)88:11<2520::AID-CNCR13>3.0.CO;2-L; Shaheen NJ, 2016, AM J GASTROENTEROL, V111, P30, DOI 10.1038/ajg.2015.322; SKINNER DB, 1983, ANN SURG, V198, P554, DOI 10.1097/00000658-198310000-00016; Smith J, 2016, AM J SURG PATHOL, V40, P537, DOI 10.1097/PAS.0000000000000601; Spechler SJ, 2011, GASTROENTEROLOGY, V140, P1084, DOI 10.1053/j.gastro.2011.01.030; Stein Hubert J., 1993, Dysphagia, V8, P276, DOI 10.1007/BF01354551; Takubo K, 2009, HUM PATHOL, V40, P65, DOI 10.1016/j.humpath.2008.06.008	23	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					264	268		10.1097/PAS.0000000000000971			5	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300014	29016405				2019-10-28	
J	Li, YT; Gupta, G; Molofsky, A; Xie, Y; Shihabi, N; McCormick, J; Jaffe, ES				Li, Yiting; Gupta, Gunjan; Molofsky, Ari; Xie, Yi; Shihabi, Nader; McCormick, Jane; Jaffe, Elaine S.			B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						B lymphoblastic leukemia; lymphoma; MYC rearrangement; Burkitt lymphoma; terminal deoxynucleotidyl transferase; gene (TdT) rearrangement	CELL IMMUNOPHENOTYPE; FOLLICULAR LYMPHOMA; MOLECULAR ANALYSIS; MYC REARRANGEMENT; LEUKEMIA; SURFACE; LOCUS; L3; TRANSFORMATION; TRANSLOCATION	Isolated MYC rearrangement without other recurrent genetic abnormalities is rare in B lymphoblastic leukemia/lymphoma (B-ALL/LBL), with most cases reported in pediatric patients. We report 3 adult cases with lymphoblasts showing a precursor B cell immunophenotype, and isolated MYC/IGH translocation. All 3 cases occurred in male patients with initial presentation of diffuse lymphadenopathy. Cases 1 and 2 had B-ALL with significantly increased lymphoblasts in peripheral blood and bone marrow. Case 3, a patient with human immunodeficiency virus infection, had the diagnosis of B-LBL made on a retroperitoneal lymph node biopsy and had no peripheral blood or bone marrow involvement. The leukemic and lymphoma cells in all 3 cases demonstrated Burkitt lymphoma-like morphology with deeply basophilic cytoplasm and numerous cytoplasmic vacuoles. However, all 3 had immature immunophenotypes including expression of terminal deoxynucleotidyl transferase (TdT), absence of BCL6, and dim-to-negative CD45. CD20 was largely negative in 2 of 3 cases. All 3 had confirmed MYC/IGH translocation, but lacked rearrangements of BCL2 or BCL6. EBV was negative by Epstein-Barr virus encoded small RNA in situ hybridization. Treatment protocols varied, including both high-risk ALL-type (protocol 8707) and high-grade lymphoma regimens (hyper-CVAD [cyclophosphamide, vincristine, adriamycin, and dexamethasone]), but no patient achieved continuous complete remission. These cases seem to represent a distinct biological phenomenon, in which a MYC translocation may be acquired at an immature stage of differentiation, thus manifesting features of both B-ALL/LBL and Burkitt lymphoma.	[Li, Yiting; Molofsky, Ari; Xie, Yi] Univ Calif San Francisco, Dept Lab Med, San Francisco Med Ctr, San Francisco, CA 94143 USA; [Shihabi, Nader] John Muir Hlth, Dept Pathol, Pleasant Hill, CA USA; [McCormick, Jane] Contra Costa Reg Med Ctr, Martinez, CA USA; [Gupta, Gunjan] Danbury Hosp Campus, West Connecticut Healthcare Network, Dept Pathol & Lab Med, Danbury, CT USA; [Jaffe, Elaine S.] NCI, Pathol Lab, Ctr Canc Res, 10 Ctr Dr, Bethesda, MD 20892 USA	Jaffe, ES (reprint author), NCI, Pathol Lab, Ctr Canc Res, 10 Ctr Dr, Bethesda, MD 20892 USA.	elainejaffe@nih.gov		Molofsky, Ari/0000-0003-0764-3175	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 BC011070-01]		Antillon FG, 2017, CANCER-AM CANCER SOC, V123, P436, DOI 10.1002/cncr.30257; Behm F, 1999, CHILDHOOD LEUKEMIAS, P111; Bertrand P, 2007, LEUKEMIA, V21, P515, DOI 10.1038/sj.leu.2404529; Cai QQ, 2015, ONCOTARGET, V6, P38591, DOI 10.18632/oncotarget.5774; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Geyer JT, 2015, HUM PATHOL, V46, P260, DOI 10.1016/j.humpath.2014.10.021; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Gupta AA, 2004, J PEDIAT HEMATOL ONC, V26, P532, DOI 10.1097/01.mph.0000132736.31514.28; Hassan R, 2008, EUR J HAEMATOL, V80, P265, DOI 10.1111/j.1600-0609.2007.00992.x; Higa B, 2009, PATHOLOGY, V41, P495, DOI 10.1080/00313020903040988; IMAMURA N, 1990, AM J HEMATOL, V35, P216, DOI 10.1002/ajh.2830350316; Jabbour E, 2015, CANCER-AM CANCER SOC, V121, P2517, DOI 10.1002/cncr.29383; KANEKO Y, 1980, BLOOD, V56, P782; Kaplinsky C, 1998, MED PEDIATR ONCOL, V31, P36, DOI 10.1002/(SICI)1096-911X(199807)31:1<36::AID-MPO9>3.3.CO;2-Y; Kobrin C, 2006, LEUKEMIA LYMPHOMA, V47, P1523, DOI 10.1080/10428190600612909; Komrokji R, 2003, LEUKEMIA RES, V27, P561, DOI 10.1016/S0145-2126(02)00271-0; Linker C, 2002, J CLIN ONCOL, V20, P2464, DOI 10.1200/JCO.2002.07.116; Loghavi S, 2015, AM J CLIN PATHOL, V144, P393, DOI 10.1309/AJCPAN7BH5DNYWZB; Meznarich J, 2016, PEDIATR BLOOD CANCER, V63, P938, DOI 10.1002/pbc.25907; Navid F, 1999, LEUKEMIA, V13, P135, DOI 10.1038/sj.leu.2401244; Nelson BP, 2006, LEUKEMIA LYMPHOMA, V47, P1352, DOI 10.1080/10428190500473238; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; Seo JY, 2012, ANN LAB MED, V32, P289, DOI 10.3343/alm.2012.32.4.289; Shiratori S, 2011, LEUKEMIA LYMPHOMA, V52, P716, DOI 10.3109/10428194.2010.551158; Slavutsky I, 1996, LEUKEMIA LYMPHOMA, V21, P169, DOI 10.3109/10428199609067595; Swerdlow EC SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; VANKRIEKEN JHJM, 1992, LEUKEMIA LYMPHOMA, V7, P371, DOI 10.3109/10428199209049793	29	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					269	276		10.1097/PAS.0000000000000982			8	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300015	29112016	Green Accepted			2019-10-28	
J	Dalton, LW				Dalton, Leslie W.			Discordance in Pathologist Assessment of Endometrial Cancer is Informative While Level of Discordance of Molecular Classification Remains Unknown	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							CARCINOMA		[Dalton, Leslie W.] South Austin Med Ctr, Austin, TX 78704 USA	Dalton, LW (reprint author), South Austin Med Ctr, Austin, TX 78704 USA.						Dalton L, 2014, AM J SURG PATHOL, V38, P433, DOI 10.1097/PAS.0000000000000126; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Talhouk A, 2016, GYNECOL ONCOL, V143, P46, DOI 10.1016/j.ygyno.2016.07.090; van Esterik M, 2017, ONCOTARGET, V8, P25542, DOI 10.18632/oncotarget.16067	5	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					277	278		10.1097/PAS.0000000000000904			2	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300016	29176512				2019-10-28	
J	Skalova, A; Stenman, G; Simpson, RHW; Hellquist, H; Slouka, D; Svoboda, T; Bishop, JA; Hunt, JL; Nibu, KI; Rinaldo, A; Vander Poorten, V; Devaney, KO; Steiner, P; Ferlito, A				Skalova, Alena; Stenman, Goran; Simpson, Roderick H. W.; Hellquist, Henrik; Slouka, David; Svoboda, Tomas; Bishop, Justin A.; Hunt, Jennifer L.; Nibu, Ken-Ichi; Rinaldo, Alessandra; Vander Poorten, Vincent; Devaney, Kenneth O.; Steiner, Petr; Ferlito, Alfio			The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Review						salivary gland carcinoma; mammary analog secretory carcinoma; mucoepidermoid carcinoma; hyalinizing clear cell carcinoma; adenoid cystic carcinoma; salivary duct carcinoma; polymorphous adenocarcinoma; cribriform adenocarcinoma; fusion oncogenes; molecular testing	ANALOG SECRETORY CARCINOMA; ADENOID CYSTIC CARCINOMA; CLEAR-CELL-CARCINOMA; CERVICAL LYMPH-NODE; HIGH-GRADE TRANSFORMATION; ETV6-NTRK3 GENE FUSION; IN-SITU-HYBRIDIZATION; ANDROGEN DEPRIVATION THERAPY; PAPILLARY THYROID-CARCINOMA; OF-THE-LITERATURE	Salivary gland neoplasms are a morphologically heterogenous group of lesions that are often diagnostically challenging. In recent years, considerable progress in salivary gland taxonomy has been reached by the discovery of tumor type-specific fusion oncogenes generated by chromosome translocations. This review describes the clinicopathologic features of a selected group of salivary gland carcinomas with a focus on their distinctive genomic characteristics. Mammary analog secretory carcinoma is a recently described entity characterized by a t(12;15)(p13;q25) translocation resulting in an ETV6-NTRK3 fusion. Hyalinizing clear cell carcinoma is a low-grade tumor with infrequent nodal and distant metastasis, recently shown to harbor an EWSR1-ATF1 gene fusion. The CRTC1-MAML2 fusion gene resulting from a t(11;19)(q21;p13) translocation, is now known to be a feature of both low-grade and high-grade mucoepidermoid carcinomas associated with improved survival. A t(6;9)(q22-23;p23-34) translocation resulting in a MYB-NFIB gene fusion has been identified in the majority of adenoid cystic carcinomas. Polymorphous (low-grade) adenocarcinoma and cribriform adenocarcinoma of (minor) salivary gland origin are related entities with partly differing clinicopathologic and genomic profiles; they are the subject of an ongoing taxonomic debate. Polymorphous (low-grade) adenocarcinomas are characterized by hot spot point E710D mutations in the PRKD1 gene, whereas cribriform adenocarcinoma of (minor) salivary glands origin are characterized by translocations involving the PRKD1-3 genes. Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with morphologic and molecular features akin to invasive ductal carcinoma of the breast, including HER2 gene amplification, mutations of TP53, PIK3CA, and HRAS and loss or mutation of PTEN. Notably, a recurrent NCOA4-RET fusion has also been found in SDC. A subset of SDC with apocrine morphology is associated with overexpression of androgen receptors. As these genetic aberrations are recurrent they serve as powerful diagnostic tools in salivary gland tumor diagnosis, and therefore also in refinement of salivary gland cancer classification. Moreover, they are promising as prognostic biomarkers and targets of therapy.	[Skalova, Alena; Steiner, Petr] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Plzen, Czech Republic; [Slouka, David] Charles Univ Prague, Fac Med Plzen, Dept Otorhinolaryngol, Plzen, Czech Republic; [Svoboda, Tomas] Charles Univ Prague, Fac Med Plzen, Dept Radiotherapy & Oncol, Oncol Clin, Plzen, Czech Republic; [Steiner, Petr] Biopticka Lab Ltd, Mol & Genet Lab, Plzen, Czech Republic; [Stenman, Goran] Univ Gothenburg, Dept Pathol & Genet, Sahlgrenska Canc Ctr, Gothenburg, Sweden; [Simpson, Roderick H. W.; Vander Poorten, Vincent] Univ Calgary, Dept Anat Pathol, Foothills Med Ctr, Calgary, AB, Canada; [Stenman, Goran] European Salivary Gland Soc, Geneva, Switzerland; [Hellquist, Henrik] Univ Algarve, Ctr Biomed Res CBMR, Dept Biomed Sci & Med, Faro, Portugal; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Hunt, Jennifer L.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Devaney, Kenneth O.] Allegiance Hlth, Dept Pathol, Jackson, MI USA; [Nibu, Ken-Ichi] Kobe Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kobe, Hyogo, Japan; [Rinaldo, Alessandra] Univ Udine, Sch Med, Udine, Italy; [Ferlito, Alfio] Int Head & Neck Sci Grp, Padua, Italy; [Vander Poorten, Vincent] Univ Hosp Leuven, Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Vander Poorten, Vincent] Katholieke Univ Leuven, Sect Head & Neck Oncol, Dept Oncol, Leuven, Belgium	Skalova, A (reprint author), Charles Univ Prague, Fac Med, Sikls Dept Pathol, Fac Hosp, E Benese 13, Plzen 30599, Czech Republic.	skalova@fnplzen.cz		Hellquist, Henrik/0000-0003-3044-6065			Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Aman P, 2005, SEMIN CANCER BIOL, V15, P236, DOI 10.1016/j.semcancer.2005.01.009; Andersson MK, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx017; Andersson MK, 2016, ORAL ONCOL, V57, P63, DOI 10.1016/j.oraloncology.2016.04.002; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Anzick SL, 2010, GENE CHROMOSOME CANC, V49, P59, DOI 10.1002/gcc.20719; Bahrami A, 2013, HISTOPATHOLOGY, V63, P250, DOI 10.1111/his.12152; Bahrami A, 2012, HEAD NECK PATHOL, V6, P328, DOI 10.1007/s12105-012-0353-8; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Bell D, 2008, GENE CHROMOSOME CANC, V47, P309, DOI 10.1002/gcc.20534; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Brandwein-Gensler M, 2017, WHO CLASSIFICATION H, P163; Brayer KJ, 2016, CANCER DISCOV, V6, P176, DOI 10.1158/2159-8290.CD-15-0859; Brierley D, 2015, Oral Surg Oral Med Oral Pathol Oral Radiol, V120, pe174, DOI 10.1016/j.oooo.2015.02.480; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Carlson Julie, 2013, Am Soc Clin Oncol Educ Book, P257, DOI 10.1200/EdBook_AM.2013.33.257; Chen G, 2011, MODERN PATHOL, V24, P1560, DOI 10.1038/modpathol.2011.126; Chenevert J, 2011, VIRCHOWS ARCH, V458, P133, DOI 10.1007/s00428-011-1040-y; Chiosea SI, 2016, CANCER-AM CANCER SOC, V122, P3136, DOI 10.1002/cncr.30179; Chiosea SI, 2015, AM J SURG PATHOL, V39, P744, DOI 10.1097/PAS.0000000000000410; Chiosea SI, 2012, LARYNGOSCOPE, V122, P1690, DOI 10.1002/lary.22419; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Clauditz TS, 2012, DIAGN MOL PATHOL, V21, P134, DOI 10.1097/PDM.0b013e318255552c; Coca-Pelaz A, 2015, ORAL ONCOL, V51, P652, DOI 10.1016/j.oraloncology.2015.04.005; Cocek A, 2011, ONCOL LETT, V2, P135, DOI 10.3892/ol.2010.213; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Dalin MG, 2016, CLIN CANCER RES, V22, P4623, DOI 10.1158/1078-0432.CCR-16-0637; Dettloff J, 2017, HEAD NECK PATHOL, V11, P124, DOI 10.1007/s12105-016-0741-6; Di Palma S, 1999, HISTOPATHOLOGY, V35, P432; Di Palma S, 2012, HISTOPATHOLOGY, V61, P629, DOI 10.1111/j.1365-2559.2012.04252.x; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; El-Naggar A, 2017, WHO CLASSIFICATION H; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Falchook GS, 2014, HEAD NECK-J SCI SPEC, V36, pE25, DOI 10.1002/hed.23429; Fehr A, 2008, GENE CHROMOSOME CANC, V47, P203, DOI 10.1002/gcc.20522; Fehr A, 2008, CANCER GENET CYTOGEN, V180, P135, DOI 10.1016/j.cancergencyto.2007.10.007; Fehr A, 2011, AM J SURG PATHOL, V35, P1600, DOI 10.1097/PAS.0b013e31822832c7; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P123, DOI 10.1159/000055726; Flucke U, 2012, HUM PATHOL, V43, P764, DOI 10.1016/j.humpath.2011.08.004; Fonseca I, 2017, WHO CLASSIFICATION H, P167; Foo WC, 2016, CANCER CYTOPATHOL, V124, P397, DOI 10.1002/cncy.21693; Gailey MP, 2014, DIAGN CYTOPATHOL, V42, P1085, DOI 10.1002/dc.23111; Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; Gnepp DR, 2014, HEAD NECK PATHOL, V8, P42, DOI 10.1007/s12105-014-0532-x; Griffith C, 2011, VIRCHOWS ARCH, V459, P117, DOI 10.1007/s00428-011-1098-6; Griffith CC, 2017, ARCH PATHOL LAB MED, V141, P381, DOI 10.5858/arpa.2016-0259-SA; Griffith CC, 2013, AM J SURG PATHOL, V37, P1201, DOI 10.1097/PAS.0b013e3182880d5a; Hellquist H, 2016, VIRCHOWS ARCH, V469, P643, DOI 10.1007/s00428-016-2018-6; Hellquist H, 2016, ADV THER, V33, P357, DOI 10.1007/s12325-016-0298-5; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Chi HT, 2012, BIOCHEM BIOPH RES CO, V429, P87, DOI 10.1016/j.bbrc.2012.10.087; Hyrcza MD, 2015, DIAGN HISTOPATHOL, V21, P481; Ishibashi K, 2015, AM J SURG PATHOL, V39, P1479, DOI 10.1097/PAS.0000000000000507; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Jee KJ, 2013, MODERN PATHOL, V26, P213, DOI 10.1038/modpathol.2012.154; Kang H, 2017, CLIN CANCER RES, V23, P283, DOI 10.1158/1078-0432.CCR-16-0720; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kass JI, 2015, LARYNGOSCOPE, V125, pE371, DOI 10.1002/lary.25519; Katabi N, 2015, HUM PATHOL, V46, P26, DOI 10.1016/j.humpath.2014.08.017; Khan HA, 2010, HEAD NECK PATHOL, V4, P261, DOI 10.1007/s12105-010-0191-5; Khoo TK, 2017, ONCOTARGET; Knezevich SR, 1998, CANCER RES, V58, P5046; Kralik JM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-19; Laco J, 2012, VIRCHOWS ARCH, V461, P531, DOI 10.1007/s00428-012-1320-1; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Lennerz JKM, 2009, AM J SURG PATHOL, V33, P835, DOI 10.1097/PAS.0b013e318190cf5b; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Limaye SA, 2013, ONCOLOGIST, V18, P294, DOI 10.1634/theoncologist.2012-0369; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Lurquin E, 2015, HISTOPATHOLOGY, V67, P749, DOI 10.1111/his.12702; Majewska H, 2016, POL J PATHOL, V67, P84, DOI 10.5114/PJP.2016.59223; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Martins C, 2004, J MOL DIAGN, V6, P205, DOI 10.1016/S1525-1578(10)60511-9; Masubuchi T, 2015, INT J CLIN ONCOL, V20, P35, DOI 10.1007/s10147-014-0674-6; McCord C, 2012, DIAGN HISTOPATHOL, V18, P253; Michal M, 1999, HISTOPATHOLOGY, V35, P495; Michal M, 2013, HEAD NECK PATHOL, V7, pS3, DOI 10.1007/s12105-013-0457-9; Min R, 2012, INT J ORAL MAX SURG, V41, P952, DOI 10.1016/j.ijom.2012.04.023; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2014, CLIN CANCER RES, V20, P6570, DOI 10.1158/1078-0432.CCR-14-1746; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Mitelman F, 2013, MITELMAN DATABASE CH; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nakayama T, 2009, MODERN PATHOL, V22, P1575, DOI 10.1038/modpathol.2009.126; Nardi V, 2013, CLIN CANCER RES, V19, P480, DOI 10.1158/1078-0432.CCR-12-1842; Nemoto N, 2007, GENE CHROMOSOME CANC, V46, P813, DOI 10.1002/gcc.20467; O'Regan E, 2004, ORAL ONCOL, V40, P348, DOI 10.1016/j.oraloncology.2003.08.023; Okabe M, 2006, CLIN CANCER RES, V12, P3902, DOI 10.1158/1078-0432.CCR-05-2376; Okumura Y, 2011, HISTOPATHOLOGY, V59, P90, DOI 10.1111/j.1365-2559.2011.03890.x; Pagano A, 2017, DIAGN CYTOPATHOL, V45, P468, DOI 10.1002/dc.23687; Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Piscuoglio S, 2015, HISTOPATHOLOGY, V67, P529, DOI 10.1111/his.12673; Qiu WL, 2014, BIOMED RES INT, DOI 10.1155/2014/810487; Rettig EM, 2016, CANCER PREV RES, V9, P265, DOI 10.1158/1940-6207.CAPR-15-0316; Reynolds S, 2016, HEAD NECK PATHOL, V10, P405, DOI 10.1007/s12105-016-0715-8; Roden AC, 2013, HUM PATHOL, V44, P2799, DOI 10.1016/j.humpath.2013.07.031; Rotellini M, 2014, APPL IMMUNOHISTO M M, V22, P390, DOI 10.1097/PAI.0b013e3182936ea7; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Salovaara E, 2013, EUR ARCH OTO-RHINO-L, V270, P281, DOI 10.1007/s00405-012-1997-4; Seethala RR, 2007, AM J SURG PATHOL, V31, P1683, DOI 10.1097/PAS.0b013e3180dc928c; Seethala RR, 2017, AM J SURG PATHOL, V41, P446, DOI 10.1097/PAS.0000000000000814; Seethala Raja R, 2017, Surg Pathol Clin, V10, P155, DOI 10.1016/j.path.2016.11.004; Seethala Raja R, 2016, Surg Pathol Clin, V9, P339, DOI 10.1016/j.path.2016.04.002; Seethala RR, 2009, HEAD NECK PATHOL, V3, P69, DOI 10.1007/s12105-009-0102-9; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Serra A, 2007, J PEDIATR SURG, V42, DOI 10.1016/j.jpedsurg.2007.04.031; Shah AA, 2017, MODERN PATHOL, V30, P329, DOI 10.1038/modpathol.2016.180; Shah AA, 2013, AM J SURG PATHOL, V37, P571, DOI 10.1097/PAS.0b013e3182772a15; Shinomiya H, 2016, HUM PATHOL, V57, P37, DOI 10.1016/j.humpath.2016.06.016; Silver CE, 2017, J LARYNGOL OTOL, V131, P96, DOI 10.1017/S0022215116009749; Simpson RHW, 2014, VIRCHOWS ARCH, V465, P371, DOI 10.1007/s00428-014-1639-x; Simpson RHW, 2013, HEAD NECK PATHOL, V7, pS48, DOI 10.1007/s12105-013-0456-x; Skalova A, 1997, PATHOL RES PRACT, V193, P695, DOI 10.1016/S0344-0338(97)80029-5; Skalova A, 2003, HISTOPATHOLOGY, V42, P348, DOI 10.1046/j.1365-2559.2003.01600.x; Skalova A, 2017, AM J SURG P IN PRESS; Skalova A, 2012, DIAGN HISTOPATHOL, V18, P388; Skalova A, 2017, WHO CLASSIFICATION H, P177; Skalova A, 2017, AM J SURG PATHOL, V41, pE33, DOI 10.1097/PAS.0000000000000883; Skalova A, 2017, MODERN PATHOL, V30, pS27, DOI 10.1038/modpathol.2016.167; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2015, AM J SURG PATHOL, V39, P338, DOI 10.1097/PAS.0000000000000364; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2013, AM J SURG PATHOL, V37, P1743, DOI 10.1097/PAS.0000000000000065; Skalova A, 2011, AM J SURG PATHOL, V35, P1168, DOI 10.1097/PAS.0b013e31821e1f54; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Solar AA, 2009, CANCER-AM CANCER SOC, V115, P75, DOI 10.1002/cncr.23974; Soper MS, 2014, HEAD NECK-J SCI SPEC, V36, pE4, DOI 10.1002/hed.23383; Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.002; STENMAN G, 1986, CANCER GENET CYTOGEN, V22, P283, DOI 10.1016/0165-4608(86)90021-X; Stenman G, 2014, ORAL ONCOL, V50, P683, DOI 10.1016/j.oraloncology.2014.04.008; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Suarez C, 2016, AURIS NASUS LARYNX, V43, P477, DOI 10.1016/j.anl.2016.02.013; Takhar AS, 2015, J LARYNGOL OTOL, V129, P194, DOI 10.1017/S0022215114002643; Tanguay J, 2013, HEAD NECK PATHOL, V7, P28, DOI 10.1007/s12105-013-0427-2; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Von Holstein SL, 2012, ONCOL REP, V27, P1413, DOI 10.3892/or.2012.1676; Wang K, 2017, ANN ONCOL, V28, P748, DOI 10.1093/annonc/mdw689; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; Weinreb I, 2013, ADV ANAT PATHOL, V20, P367, DOI 10.1097/PAP.0b013e3182a92cc3; Weinreb I, 2009, AM J SURG PATHOL, V33, P409, DOI 10.1097/PAS.0b013e318184b36d; West RB, 2011, AM J SURG PATHOL, V35, P92, DOI 10.1097/PAS.0b013e3182002777; Williams MD, 2007, AM J SURG PATHOL, V31, P1645, DOI 10.1097/PAS.0b013e3180caa099; Xu B, 2016, AM J SURG PATHOL, V40, P1526, DOI 10.1097/PAS.0000000000000705; Yamamoto N, 2014, AM J OTOLARYNG, V35, P731, DOI 10.1016/j.amjoto.2014.07.007; Zhu SB, 2015, ARCH PATHOL LAB MED, V139, P55, DOI 10.5858/arpa.2014-0167-RA; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	161	20	20	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	FEB	2018	42	2					E11	E27		10.1097/PAS.0000000000000980			17	Pathology; Surgery	Pathology; Surgery	FZ5OH	WOS:000427643300001	29076877				2019-10-28	
J	Colin, TS; David, JO; Dennis, RP				Colin, Shearn T.; David, Orlicky J.; Dennis, Petersen R.			Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Aldehyde; Cholestasis; Oxidative stress; Cholangiocyte; Lipid peroxidation	PRIMARY BILIARY-CIRRHOSIS; FATTY LIVER-DISEASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; PROTEIN CARBONYLATION; URSODEOXYCHOLIC ACID; REACTIVE ALDEHYDES; N-ACETYLCYSTEINE; OXIDANT STRESS; KNOCKOUT MICE	Objective: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease that is characterized by severe peri-biliary tract inflammation and fibrosis, elevated oxidative stress and hepatocellular injury. A hallmark of PSC patients is the concurrent diagnosis of Inflammatory Bowel Disease occurring in approximately 70%-80% of PSC patients (PSC/IBD). The objective of this study was to determine the impact of end stage PSC/IBD on cellular antioxidant responses and the formation of protein carbonylation. Methods: Using hepatic tissue and whole cell extracts isolated from age-matched healthy humans and patients diagnosed with end stage PSC/IBD, overall inflammation, oxidative stress, and protein carbonylation were assessed by Western blotting, and immunohistochemistry. Results: Increased immunohistochemical staining for CD3 + (lymphocyte), CD68 (Kupffer cell) and myeloperoxidase (neutrophil) colocalized with the extensive Picrosirius red stained fibrosis confirming the inflammatory aspect of PSC. Importantly, the increased inflammation also colocalized with elevated periportal post-translational modification by the reactive aldehydes 4-HNE, MDA and acrolein. 4-HNE, MDA and acrolein IHC all displayed a significant component in hepatocytes adjacent to fibrotic regions. Furthermore, acrolein was also elevated within the nuclei of periportal inflammatory cells whereas MDA staining was increased in hepatocytes across the lobule. Prussian Blue staining, when compared to the positive controls (ALD, NASH), did not display any evidence of iron accumulation in PSC/IBD livers. Western analysis of PSC/IBD anti-oxidant responses revealed elevated expression of SOD2, GSTst as well as upregulation of Akt Ser473 phosphorylation. In contrast, expression of GST mu, GSTA4, catalase, Gpxl and Hsp70 were suppressed. These data were further supported by a significant decrease in measured GST pi activity. Dysregulation of anti-oxidant responses in the periportal region of the liver was supported by elevated SOD2 and GSM IHC signals in periportal hepatocytes and cholangiocytes. Expression of the Nrf2-regulated proteins HO-1, NAD(P)H quinone reductase (NQ01) and Gpxl was primarily localized to macrophages. In contrast, catalase staining decreased within periportal hepatocytes and was not evident within cholangiocytes. Conclusions: Results herein provide additional evidence that cholestasis induces significant increases in periportal oxidative stress and suggest that there are significant differences in the cellular and subcellular generation of reactive aldehydes formed during cholestatic liver injury. Furthermore, these data suggest that anti-oxidant responses are dysregulated during end-stage PSC/IBD supporting pathological data.	[Colin, Shearn T.; Dennis, Petersen R.] Univ Colorado Anschutz Med Campus, Dept Pharmaceut Sci, Aurora, CO 80045 USA; [David, Orlicky J.] Univ Colorado Anschutz Med Campus, Dept Pathol, Aurora, CO 80045 USA	Colin, TS (reprint author), Univ Colorado Denver Anschutz Med Campus, Sch Pharm, Dept Pharmaceut Sci, 12850 East Montview Blvd,Box C238, Aurora, CO 80045 USA.	Colin.Sheam@ucdenver.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37AA009300-22]; NIH/NCRR Colorado CTSI Grant [UL1 RR025780]; University of Colorado Cancer Center Grant [P30 CA046934]	This research was supported by the following grants from the National Institutes of Health; R37AA009300-22 D.R.P. The authors wish to thank E. Erin Smith, HTL(ASCP)CMQIHC of the University of Colorado Denver Cancer Center Research Histology Core for assistance in preparing histology slides. The UCDCCRHC is supported in part by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780 and the University of Colorado Cancer Center Grant (P30 CA046934).	Aboutwerat A, 2003, BBA-MOL BASIS DIS, V1637, P142, DOI 10.1016/S0925-4439(02)00225-9; Albano E, 2006, P NUTR SOC, V65, P278, DOI 10.1079/PNS2006496; Arduini Alessandro, 2012, Front Biosci (Elite Ed), V4, P2233; Aubert J, 2011, CLIN RES HEPATOL GAS, V35, P630, DOI 10.1016/j.clinre.2011.04.015; Bakhautdin B, 2014, J HEPATOL, V61, P1029, DOI 10.1016/j.jhep.2014.06.007; Bell LN, 2015, LIVER INT, V35, P263, DOI 10.1111/liv.12680; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Chen WY, 2016, CELL MOL GASTROENTER, V2, P685, DOI 10.1016/j.jcmgh.2016.05.010; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; Covey TM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013545; Damnjanovic Z, 2013, VOJNOSANIT PREGL, V70, P170, DOI 10.2298/VSP1302170D; Datz C, 2017, MINERVA ENDOCRINOL, V42, P173, DOI 10.23736/S0391-1977.16.02565-7; Eaton JE, 2013, GASTROENTEROLOGY, V145, P521, DOI 10.1053/j.gastro.2013.06.052; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; Fickert P, 2006, GASTROENTEROLOGY, V130, P465, DOI 10.1053/j.gastro.2005.10.018; Galicia-Moreno M, 2012, EUR J GASTROEN HEPAT, V24, P179, DOI 10.1097/MEG.0b013e32834f3123; Galligan JJ, 2012, CHEM RES TOXICOL, V25, P1012, DOI 10.1021/tx300002q; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Harrison-Findik DD, 2010, WORLD J HEPATOL, V2, P302, DOI 10.4254/wjh.v2.i8.302; Harrison-Findik DD, 2007, WORLD J GASTROENTERO, V13, P4925, DOI 10.3748/wjg.v13.i37.4925; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Jiang XJ, 2017, NAT REV GASTRO HEPAT, V14, P279, DOI 10.1038/nrgastro.2016.154; Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563; Karnati S, 2013, HISTOCHEM CELL BIOL, V140, P105, DOI 10.1007/s00418-013-1099-4; Kawamura K, 2000, AM J GASTROENTEROL, V95, P3596; Kryskiewicz E, 2012, J CLIN DENSITOM, V15, P233, DOI 10.1016/j.jocd.2011.09.007; Kugelmas M, 2003, LIVER TRANSPLANT, V9, P727, DOI 10.1053/jlts.2003.50143; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leung TM, 2013, J HEPATOL, V58, P395, DOI 10.1016/j.jhep.2012.08.018; Li T, 2013, INT J MED SCI, V10, P683, DOI 10.7150/ijms.5947; Ljubuncic P, 1996, GUT, V39, P475, DOI 10.1136/gut.39.3.475; Lunder A. K., 2016, GASTROENTEROLOGY; Mattar Regina Helena Guedes da Motta, 2005, J. Pediatr. (Rio J.), V81, P317, DOI 10.1590/S0021-75572005000500010; Osna NA, 2016, WORLD J GASTROENTERO, V22, P6192, DOI 10.3748/wjg.v22.i27.6192; Ozdil B, 2010, J CLIN PHARMACOL, V50, P1414, DOI 10.1177/0091270010361257; Parola M, 1996, FREE RADICAL BIO MED, V20, P351, DOI 10.1016/0891-5849(96)02055-2; Peres W, 2000, J HEPATOL, V33, P742, DOI 10.1016/S0168-8278(00)80305-0; Ronis MJJ, 2015, AM J PHYSIOL-GASTR L, V308, pG403, DOI 10.1152/ajpgi.00154.2014; Roskams T, 2003, AM J PATHOL, V163, P1301, DOI 10.1016/S0002-9440(10)63489-X; Salem T A, 2003, Egypt J Immunol, V10, P37; Salunga TL, 2007, J AUTOIMMUN, V29, P78, DOI 10.1016/j.jaut.2007.04.002; Shearn CT, 2015, FREE RADICAL BIO MED, V89, P1144, DOI 10.1016/j.freeradbiomed.2015.10.420; Shearn CT, 2013, FREE RADICAL BIO MED, V65, P680, DOI 10.1016/j.freeradbiomed.2013.07.011; Shearn CT, 2011, BIOCHEMISTRY-US, V50, P3984, DOI 10.1021/bi200029w; Shearn CT, 2017, FREE RADICAL BIO MED, V113, P280, DOI 10.1016/j.freeradbiomed.2017.10.004; Shearn CT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154152; Shearn CT, 2016, REDOX BIOL, V7, P68, DOI 10.1016/j.redox.2015.11.013; Shearn CT, 2014, J BIOL CHEM, V289, P15449, DOI 10.1074/jbc.M113.543942; Shearn CT, 2013, J NUTR BIOCHEM, V24, P1436, DOI 10.1016/j.jnutbio.2012.12.002; Shen KZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126278; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Sorrentino P, 2010, J GASTROENTEROL, V45, P1053, DOI 10.1007/s00535-010-0249-x; Sutti S, 2014, HEPATOLOGY, V59, P886, DOI 10.1002/hep.26749; Tamura S, 2007, LIVER INT, V27, P86, DOI 10.1111/j.1478-3231.2006.01395.x; Tan M, 2015, FREE RADICAL RES, V49, P935, DOI 10.3109/10715762.2015.1016020; Trivedi HD, 2017, FRONTLINE GASTROENTE, V8, P29, DOI 10.1136/flgastro-2016-100741; Vendemiale G, 2002, J HEPATOL, V37, P601, DOI 10.1016/S0168-8278(02)00234-9; Venkatesan B, 2007, J CELL PHYSIOL, V211, P457, DOI 10.1002/jcp.20953; Wang XD, 2014, GUT, V63, P1805, DOI 10.1136/gutjnl-2013-306373; Wasik U, 2017, SCI REP-UK, V7, DOI 10.1038/srep44769; Weismuller TJ, 2017, GASTROENTEROLOGY, V152, P1975, DOI 10.1053/j.gastro.2017.02.038	61	0	0	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					1	8		10.1016/j.yexmp.2017.11.012			8	Pathology	Pathology	FV8SS	WOS:000424857700001		Green Accepted			2019-10-28	
J	Masouminia, M; Ghani, HA; Foote, D; Hari, D; French, S				Masouminia, Maryam; Ghani, Hassan Abdul; Foote, Dingle; Hari, Danielle; French, Samuel			Rare presentation of the glomus tumor in the stomach	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article							BEHAVIOR		[Masouminia, Maryam; Ghani, Hassan Abdul; French, Samuel] Harbor UCLA Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90502 USA; [Foote, Dingle] Harbor UCLA Med Ctr, Dept Radiol, 1000 W Carson St, Torrance, CA 90502 USA; [Hari, Danielle] Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90502 USA	French, S (reprint author), Harbor UCLA Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90502 USA.	sfrench@labiomed.org					de Bruin AFJ, 2008, INT J SURG PATHOL, V16, P440, DOI 10.1177/1066896908316381; Devanathan M, 2015, INT J SURG CASE REP, V11, P64, DOI 10.1016/j.ijscr.2015.04.014; Dong LL, 2015, ONCOTARGETS THER, V8, P1909, DOI 10.2147/OTT.S89396; Folpe AL, 2002, WHO CLASSIFICATION T, P136; Kumar V, 2015, ROBBINS COTRAN PATHO; Lee HW, 2006, J CLIN GASTROENTEROL, V40, P717, DOI 10.1097/00004836-200609000-00011; Park YS, 2004, GASTROINTEST ENDOSC, V59, P409, DOI 10.1016/S0016-5107(03)02717-2; Pidhorecky I, 2000, ANN SURG ONCOL, V7, P705, DOI 10.1007/s10434-000-0705-6; Nascimento EFR, 2011, CASE REP SURG, DOI 10.1155/2011/371082; Thambi R, 2014, INDIAN J PATHOL MICR, V57, P509, DOI 10.4103/0377-4929.138809; Vassiliou I, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-19; Xu XD, 2010, J INT MED RES, V38, P1539, DOI 10.1177/147323001003800438	12	1	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					9	11		10.1016/j.yexmp.2017.11.016			3	Pathology	Pathology	FV8SS	WOS:000424857700002	29221662				2019-10-28	
J	Zhao, Y; Li, GH; Wang, YC; Liu, ZJ				Zhao, Yongli; Li, Guohua; Wang, Yuchuan; Liu, Zhengjuan			Alteration of Connexin43 expression in a rat model of obesity-related glomerulopathy	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Connexin43; Obesity; Obesity-related glomerulopathy; Inflammation	CHRONIC KIDNEY-DISEASE; PODOCYTE INJURY; UP-REGULATION; RENAL INJURY; PROTECTS; MICE; INFLAMMATION; ADOLESCENTS; PROGRESSION; MARKERS	It is accepted that alteration of connexin43 (Cx43) expression in glomeruli is a common pathological response in several forms of kidney diseases. To date, however the change of the Cx43 expression in obesity-related glomerulopathy (ORG) has not been reported. In this study, the alteration of Cx43 expression in the glomeruli of rat with ORG was defined. Five-week-old rats were fed with high-fat diet for 18 weeks to establish the ORG model, then the histological change of glomeruli, the foot process effacement of podocyte, the markers for podocyte injury (nephrin,podocin and WT1) and Cx43 expression in glomeruli were examined respectively. The results demonstrated metabolic disorder, hyperinsulinemia, systemic inflammation and microalbuminuria in ORG rats. There was significant hypertrophy, glomerular expansion and inflammatory cell infiltration in the kidney of ORG rats compared to the control group. Significant foot process effacement of the podocyte in the glomeruli, nephrin loss and density reduction were shown in the ORG rats, and Cx43 expression was significant upregulated in glomeruli of ORG rats compared to the control group. The results indicate the correlation of overexpressed Cx43 with the obesity related renal inflammation and suggest that Cx43 might be a potential target in the development of obesity related glomerulopathy.	[Zhao, Yongli; Li, Guohua; Wang, Yuchuan; Liu, Zhengjuan] Dalian Med Univ, Hosp 2, Dept Pediat, Dalian, Liaoning, Peoples R China	Zhao, Y (reprint author), 467 Zhongshan Rd, Dalian 116027, Liaoning, Peoples R China.	zhaoyongli79@163.com		Wang, Yuchuan/0000-0001-6533-6558	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402694]	This study was supported by the National Natural Science Foundation of China (81402694).	Abed A, 2014, KIDNEY INT, V86, P768, DOI 10.1038/ki.2014.108; Abed AB, 2015, CELL MOL LIFE SCI, V72, P2869, DOI 10.1007/s00018-015-1964-5; Balasubramaniyan V, 2013, J HEPATOL, V58, P1194, DOI 10.1016/j.jhep.2013.01.023; Bian J, 2013, J MOL ENDOCRINOL, V51, P27, DOI 10.1530/JME-12-0212; D'Agati VD, 2016, NAT REV NEPHROL, V12, P453, DOI 10.1038/nrneph.2016.75; Ding W, 2015, PEDIATR NEPHROL, V30, P1, DOI 10.1007/s00467-014-2976-3; Fernandez-Cobo M, 1998, SHOCK, V10, P97, DOI 10.1097/00024382-199808000-00003; Goknar N, 2015, PEDIATR NEPHROL, V30, P139, DOI 10.1007/s00467-014-2829-0; Hanner F, 2010, AM J PHYSIOL-REG I, V298, pR1143, DOI 10.1152/ajpregu.00808.2009; Hillis GS, 1997, J PATHOL, V182, P373; Hills CE, 2015, DIABETOLOGIA, V58, P233, DOI 10.1007/s00125-014-3427-1; Hunley Tracy E, 2010, Curr Opin Nephrol Hypertens, V19, P227, DOI 10.1097/MNH.0b013e3283374c09; Imig JD, 2012, EXP BIOL MED, V237, P1402, DOI 10.1258/ebm.2012.012225; Kandasamy Y, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-21; Kelishadi R, 2013, J RES MED SCI, V18, P178; Luo MY, 2016, OBESITY, V24, P1244, DOI 10.1002/oby.21463; Morioka T, 2013, CLIN EXP NEPHROL, V17, P191, DOI 10.1007/s10157-012-0687-2; Nieman P, 2012, PAED CHILD HEALT-CAN, V17, P205, DOI 10.1093/pch/17.4.205; Pereira SV, 2015, OBESITY, V23, P1643, DOI 10.1002/oby.21156; Pienaar Anita E, 2015, BMC Obes, V2, P2, DOI 10.1186/s40608-014-0030-4; Sawai K, 2006, NEPHROL DIAL TRANSPL, V21, P2472, DOI 10.1093/ndt/gfl260; Sekulic M, 2013, PATHOL RES INT, V2013; Sun YBY, 2015, KIDNEY INT, V88, P286, DOI 10.1038/ki.2015.121; Takenaka T, 2011, DIABETOLOGIA, V54, P2192, DOI 10.1007/s00125-011-2175-8; Toubas J, 2011, AM J PHYSIOL-RENAL, V301, pF24, DOI 10.1152/ajprenal.00255.2010; Vivante A, 2012, ARCH INTERN MED, V172, P1644, DOI 10.1001/2013.jamainternmed.85; Willebrords J, 2016, CRIT REV BIOCHEM MOL, V51, P413, DOI 10.1080/10409238.2016.1204980; Yamamoto T, 2009, RENAL URINARY PROTEO, P1; Yan QJ, 2012, FREE RADICAL BIO MED, V53, P1286, DOI 10.1016/j.freeradbiomed.2012.07.012; Yan ZC, 2013, OBESITY, V21, P538, DOI 10.1002/oby.20103; Yao YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116471; Yaoita E, 2002, AM J PATHOL, V161, P1597, DOI 10.1016/S0002-9440(10)64438-0	32	2	2	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					12	18		10.1016/j.yemp.2017.11.017			7	Pathology	Pathology	FV8SS	WOS:000424857700003	29246788				2019-10-28	
J	Olofson, AM; Tafe, LJ				Olofson, Andrea M.; Tafe, Laura J.			A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Collision tumor; Combined tumor; BRAF; Divergent differentiation; Lung cancer	SQUAMOUS-CELL CARCINOMA; ADENOSQUAMOUS CARCINOMA; NEUROENDOCRINE TUMORS; GENE	Mixed morphology lung tumors are rare; this is the second report of a combined NSCLC and atypical carcinoid tumor. Next generation sequencing was performed on both histologically distinct patterns which identified that both components harbored a BRAF p.V600E mutation. Molecular studies inform our knowledge of the biology and aid in treatment decisions for mixed morphology lung cancers.	[Tafe, Laura J.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03754 USA	Tafe, LJ (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03754 USA.	Laura.J.Tafe@hitchcock.org					Abbi KKS, 2014, AM J THER, V21, pE234, DOI 10.1097/MJT.0b013e318293b0b0; Armengol G, 2015, LUNG, V193, P303, DOI 10.1007/s00408-015-9690-1; Dragnev KH, 2014, CLIN LUNG CANCER, V15, pE37, DOI 10.1016/j.cllc.2014.01.003; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Jhuang JY, 2014, ANN THORAC SURG, V98, P695, DOI 10.1016/j.athoracsur.2013.10.035; Okazaki M, 2015, INTERNAL MED, V54, P1385, DOI 10.2169/internalmedicine.54.3846; Owens CL, 2011, INT J SURG PATHOL, V19, P273, DOI 10.1177/1066896910397883; Sen F, 1998, LUNG CANCER-J IASLC, V21, P53, DOI 10.1016/S0169-5002(98)00042-7; Simbolo M, 2017, J PATHOL, V241, P488, DOI 10.1002/path.4853; Tochigi N, 2011, AM J CLIN PATHOL, V135, P783, DOI 10.1309/AJCP08IQZAOGYLFL; Travis WD, 1998, AM J SURG PATHOL, V22, P934, DOI 10.1097/00000478-199808000-00003; Travis WD, 2015, WHO CLASSIFICATION T; Vassella E, 2015, ONCOTARGET, V6, P23905, DOI 10.18632/oncotarget.4163; Yazawa T, 2003, PATHOL INT, V53, P58, DOI 10.1046/j.1440-1827.2003.01428.x	14	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					26	28		10.1016/j.yexmp.2017.12.004			3	Pathology	Pathology	FV8SS	WOS:000424857700005	29248665				2019-10-28	
J	Hou, CM; Qu, XM; Zhang, J; Ding, TT; Han, W; Ji, GC; Zhong, ZH; Chen, H; Zhang, FM				Hou, Chun Mei; Qu, Xue Mei; Zhang, Jian; Ding, Ting Ting; Han, Wei; Ji, Guang Chuan; Zhong, Zhao Hua; Chen, He; Zhang, FengMin			Fibroblast activation proteins-alpha suppress tumor immunity by regulating T cells and tumor-associated macrophages	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Fibroblast activation protein-alpha (FAP alpha); Epithelial ovarian cancer (EOC); Regulatory T cells (Treg); CD4+CD25+Tregs; Foxp3	ANTITUMOR IMMUNITY; MICROENVIRONMENT; EXPRESSION; POLARIZATION; IMMUNOSUPPRESSION; RECRUITMENT; PLASTICITY; DIVERSITY	Fibroblast activation protein-alpha (FAP alpha) is a type-II cell-surface-bound integral transmembrane serine protease and selectively overexpressed by tumor-associated stromal fibroblasts (TAFs), which are the main components in the tumor microenvironment, in > 90% of malignant epithelial carcinomas. FAPa regulates the immunosuppression of tumor cells in the tumor microenvironment. Regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) are the major immunosuppressive cells in the tumor microenvironment. However, the effect of FAP alpha on Tregs and TAMs is unknown. The non-enzymatic function of FAP alpha on Treg and TAM was investigated. In this study, we confirm that FAP alpha can promote the generation of Tregs and TAMs, which suggests that FAP alpha plays a immunosuppressive role in the tumor microenvironment and provides evidence for FAP alpha as a potent immunotherapeutic target for cancer.	[Hou, Chun Mei; Qu, Xue Mei; Zhang, Jian; Ding, Ting Ting; Ji, Guang Chuan; Chen, He] Harbin Med Univ, Basic Med Coll, Dept Forens, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China; [Chen, He] Harbin Med Univ, Basic Med Coll, Dept Pathol, Harbin, Heilongjiang, Peoples R China; [Han, Wei] Harbin Med Univ, Hosp 1, Dept Pathol, Harbin, Heilongjiang, Peoples R China; [Zhong, Zhao Hua; Zhang, FengMin] Harbin Med Univ, Basic Med Coll, Dept Microbiol, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China	Chen, H (reprint author), Harbin Med Univ, Basic Med Coll, Dept Forens, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.; Zhang, FM (reprint author), Harbin Med Univ, Basic Med Coll, Dept Microbiol, 157 Baojian Rd, Harbin 150086, Heilongjiang, Peoples R China.	1259689040@qq.com; 392511808@qq.com; 39224637@qq.com; 1120851878@qq.com; 845731162@qq.com; Zhongzh@ems.hrbmu.edu.cn; chenhe_2008@aliyun.com; fengminzhang@ems.hrbmu.edu.cn	Zhong, Zhaohua/N-1659-2019	Zhong, Zhaohua/0000-0002-0778-5053			Arnold JN, 2014, CANCER IMMUNOL RES, V2, P121, DOI 10.1158/2326-6066.CIR-13-0150; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Chen H, 2009, EXP MOL PATHOL, V87, P189, DOI 10.1016/j.yexmp.2009.09.001; Chen X, 2016, INT IMMUNOPHARMACOL, V34, P244, DOI 10.1016/j.intimp.2016.03.009; Coffelt SB, 2009, BBA-REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004; Cui R, 2016, ONCOTARGET, V7, P50735, DOI 10.18632/oncotarget.9383; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; d'Hennezel E, 2011, METHODS MOL BIOL, V707, P199, DOI 10.1007/978-1-61737-979-6_13; Daurkin I, 2011, CANCER RES, V71, P6400, DOI 10.1158/0008-5472.CAN-11-1261; Domagala-Kulawik J, 2014, TRANSL LUNG CANCER R, V3, P15, DOI 10.3978/j.issn.2218-6751.2013.11.03; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Halvorsen EC, 2014, CANCER METAST REV, V33, P1025, DOI 10.1007/s10555-014-9529-x; He JB, 2015, SCI REP-UK, V5, DOI 10.1038/srep13110; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Howard EW, 2008, INT J CANCER, V122, P1941, DOI 10.1002/ijc.23355; Hushmendy S, 2009, NUTR RES, V29, P568, DOI 10.1016/j.nutres.2009.08.003; Iwasa S, 2005, CANCER LETT, V227, P227, DOI 10.1016/j.canlet.2004.06.031; Jiang GM, 2016, ONCOTARGET, V7, P33472, DOI 10.18632/oncotarget.8098; Kluger MS, 2011, J INVEST DERMATOL, V131, P17, DOI 10.1038/jid.2010.347; KORMAN A, 2007, J IMMUNOL S1, V178; Kovaleva OV, 2016, ANAL CELL PATHOL, DOI 10.1155/2016/9307549; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; Mantovani A, 2013, ARTERIOSCL THROM VAS, V33, P1478, DOI 10.1161/ATVBAHA.113.300168; Mentlein R, 2011, BIOL CHEM, V392, P199, DOI 10.1515/BC.2010.119; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Ostuni R, 2011, EUR J IMMUNOL, V41, P2486, DOI 10.1002/eji.201141706; Ren L, 2016, ONCOTARGET, V7, P75763, DOI 10.18632/oncotarget.12409; Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood-2008-03-144980; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Shi M, 2012, WORLD J GASTROENTERO, V18, P840, DOI 10.3748/wjg.v18.i8.840; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soave DF, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/8910520; Stanculeanu D L, 2016, J Med Life, V9, P240; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wang Y, 2016, CELL PHYSIOL BIOCHEM, V38, P306, DOI 10.1159/000438631; Wasmer MH, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00682; Wiedemann GM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1175794; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Yasuda K, 2004, IMMUNOLOGY, V111, P282, DOI 10.1111/j.1365-2567.2004.01814.x; Zhang MY, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-19	51	0	0	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					29	37		10.1016/j.yexmp.2017.12.003			9	Pathology	Pathology	FV8SS	WOS:000424857700006	29273462				2019-10-28	
J	Knific, T; Grazio, SF; Riner, TL				Knific, Tamara; Grazio, Snjeiana Frkovic; Riner, Tea LanIgnik			Detection of Aristaless-related homeobox protein in ovarian sex cord-stromal tumors	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Endometriosis; Biomarkers; Sex cord-stromal tumors; Ovarian pathologies	LASER-CAPTURE MICRODISSECTION; MID-SECRETORY ENDOMETRIUM; ECTOPIC ENDOMETRIUM; ABNORMAL GENITALIA; DIFFERENTIAL EXPRESSION; POTENTIAL BIOMARKERS; INFERTILE PATIENTS; ARX; MUTATION; CELLS	Objective: To examine the potential of ARX as a novel biomarker of ovarian endometriosis and other ovarian pathologies. Methods: The mRNA level of ARX in ovarian endometriosis and normal endometrium samples was determined by real-time PCR, while the protein level was determined by Western blotting and immunohistochemical staining. Immunohistochemical analysis was performed on nearly 200 tissue samples of different ovarian pathologies. GraphPad Prism was used for statistical analysis. Results: The expression of ARX was significantly increased in ovarian endometriosis samples as compared to normal endometrium. Also Western blotting data showed higher ARX levels in the ovarian endometriosis samples versus normal endometrium. Immunohistochemical analysis revealed that the protein is localized in the ovarian stroma and does not originate from endometriosis. Further immunohistochemical analysis performed on several different non-neoplastic and neoplastic ovarian tissue samples revealed that in the non-neoplastic ovary ARX protein is present only in the stromal cells and their derivates (luteinized stromal cells, theca and Leydig cells) and not in granulosa cells, oocites, surface epithelium or rete ovarii, while all stromal and sex cord tumors showed strong nuclear staining for ARX. All other primary or metastatic epithelial tumors of the ovary were ARX negative. Conclusions: ARX is not associated with endometriosis and cannot be used as a biomarker for ovarian endometriosis. ARX is present in ovarian stroma and cells derived from ovarian stroma as well as in all types of sex cord-stromal tumors of the ovary and could thus be used as a marker for sex cord-stromal differentiation in ovarian tumors.	[Knific, Tamara; Riner, Tea LanIgnik] Univ Ljubljana, Fac Med, Inst Biochem, Vrazov Trg 2, Ljubljana 1000, Slovenia; [Grazio, Snjeiana Frkovic] Univ Med Ctr Ljubljana, Dept Pathol, Div Obstet & Gynecol, Ljubljana 1000, Slovenia	Riner, TL (reprint author), Univ Ljubljana, Fac Med, Inst Biochem, Vrazov Trg 2, Ljubljana 1000, Slovenia.; Grazio, SF (reprint author), Univ Med Ctr Ljubljana, Dept Pathol, Div Obstet & Gynecol, Ljubljana 1000, Slovenia.	snjezana.frkovicgrazio@kclj.si; tea.lanisnik-rizner@mf.uni-lj.si			Slovenian Research AgencySlovenian Research Agency - Slovenia [J3-6799]	This study was supported by Grant J3-6799 to T.L.R. and a Young Researcher grant to T.K., both from the Slovenian Research Agency. The authors thank Spela Petelin from the Institute of Biochemistry, Faculty of Medicine, Ljubljana, for technical support with the immunohistochemistry. The contributions of Dr. V. Kocbek for the gene expression data are also acknowledged. The authors also thank Dr. Matej Bracko for selection of ovarian pathological samples and the technicians at the Department of Pathology University Medical Centre Ljubljana, Mara Deronja, Mirjam Sternad, Andrej Lesnjak, Nives Hojan, and others who prepared the tissue samples and tissue microarrays for further experiments.	Banu SK, 2008, FERTIL STERIL, V90, P972, DOI 10.1016/j.fertnstert.2007.07.1358; BYSKOV AG, 1973, J ANAT, V116, P207; Canis M, 1997, FERTIL STERIL, V67, P817; Chakravarthy H, 2017, CELL METAB, V25, P622, DOI 10.1016/j.cmet.2017.01.009; Eksioglu YZ, 2011, EPILEPSIA, V52, P984, DOI 10.1111/j.1528-1167.2011.02980.x; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Fassbender A, 2014, FERTIL STERIL, V102, DOI 10.1016/j.fertnstert.2014.07.1209; Gage BK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144100; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; Hartmann H, 2004, NEUROPEDIATRICS, V35, P157, DOI 10.1055/s-2004-817919; He H, 2009, ARTIF CELL BLOOD SUB, V37, P208, DOI 10.1080/10731190903199028; Horta M, 2015, DIAGN INTERV RADIOL, V21, P277, DOI 10.5152/dir.2015.34414; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4679, DOI 10.1210/en.139.11.4679; Hummitzsch K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055578; Kitamura K, 2002, NAT GENET, V32, P359, DOI 10.1038/ng1009; Kocbek V, 2015, J MOL DIAGN, V17, P325, DOI 10.1016/j.jmoldx.2015.01.006; Lawrie LC, 2001, J CLIN PATHOL-MOL PA, V54, P253; Matsuzaki S, 2006, FERTIL STERIL, V86, P548, DOI 10.1016/j.fertnstert.2006.02.093; Matsuzaki S, 2010, J CLIN ENDOCR METAB, V95, P3437, DOI 10.1210/jc.2009-2713; Matsuzaki S, 2010, HUM REPROD, V25, P742, DOI 10.1093/humrep/dep435; Matsuzaki S, 2009, HUM REPROD, V24, P3180, DOI 10.1093/humrep/dep306; Mills SE, 2007, HISTOLOGY PATHOLOGIS; Nnoaham KE, 2011, FERTIL STERIL, V96, P366, DOI 10.1016/j.fertnstert.2011.05.090; Rizner TL, 2014, EXPERT REV MOL DIAGN, V14, P365, DOI 10.1586/14737159.2014.899905; Sawyer HR, 2002, BIOL REPROD, V66, P1134, DOI 10.1095/biolreprod66.4.1134; Uyanik G, 2003, NEUROLOGY, V61, P232, DOI 10.1212/01.WNL.0000079371.19562.BA; Vouk K, 2012, HUM REPROD, V27, P2955, DOI 10.1093/humrep/des152; Vouk K, 2016, J STEROID BIOCHEM, V159, P60, DOI 10.1016/j.jsbmb.2016.02.023; Vouk K, 2011, J STEROID BIOCHEM, V125, P231, DOI 10.1016/j.jsbmb.2011.03.010; WHEELER JM, 1989, J REPROD MED, V34, P41; Wu Y, 2006, ENDOCRINOLOGY, V147, P232, DOI 10.1210/en.2005-0426; Wu Y, 2006, GYNECOL OBSTET INVES, V62, P148, DOI 10.1159/000093130; Zeitvogel A, 2001, AM J PATHOL, V159, P1839, DOI 10.1016/S0002-9440(10)63030-1; Zhao LY, 2016, BIOMED REP, V5, P531, DOI 10.3892/br.2016.758	34	1	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					38	44		10.1016/j.yexmp.2017.12.005			7	Pathology	Pathology	FV8SS	WOS:000424857700007	29275192				2019-10-28	
J	Nguyen, L; Masouminia, M; Mendoza, A; Samadzadeh, S; Tillman, B; Morgan, T; French, B; French, S				Luan Nguyen; Masouminia, Maryam; Mendoza, Alejandro; Samadzadeh, Sara; Tillman, Brittany; Morgan, Timothy; French, Barbara; French, Samuel			Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Tumorigenesis; Alcoholic hepatitis; Pre-cancer gene expression; Hepatocellular carcinoma (HCC)	HEPATOCELLULAR-CARCINOMA CELLS; NATURAL-HISTORY; LIVER-DISEASE; CANCER; IDENTIFICATION; PROLIFERATION; APOPTOSIS; INVASION; PATHWAY	Non-alcoholic steatohepatitis (NASH) is commonly associated with obesity, type 2 diabetes, and/or hypertriglyceridemia, while alcoholic steatohepatitis (ASH) is associated with alcohol abuse. Both NASH and ASH patients can develop cirrhosis and hepatocellular carcinoma (HCC) if left untreated. However, the rate of tumorigenesis in NASH and ASH appears to be different. Individuals with NASH progress to HCC at a rate of 0.5% annually (Lindenmeyer and McCullough, 2018), when individuals with ASH progress to HCC at a rate of 3-10% annually (Schwartz and ReMus, 2012). Thus, the objective of our study is to determine if there are differences in NASH versus ASH in the levels of different proteins expressed involved in cancer development. The method used was measuring the proteins expressed in liver biopsied sections from NASH and ASH patients using immunohistochemical staining with fluorescent antibodies and then quantitating the fluorescence intensity morphometrically. The 20 proteins tested are parts of the Ingenuity Canonical Pathway of Molecular Mechanisms of Cancer and include: RAP2B, NAIP, FYN, PAK6, SUV39H1, GNAIl, BAX, E2F3, CKDN2B, BAK1, BCL2, DIABLO, RASGRF2, GNA15, PIK3CB, BRCA1, MAP2K1, BIRC3, CDK2, and ATM. In ASH, the proteins that showed up regulated levels of expression were SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAI1. In NASH, the proteins that showed upregulated levels of expression were BAK1 and GNAI1 and the protein that showed downregulated level of expression was BCL2. Additionally, levels of expression for SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAIl were significant upregulated in ASH compared to NASH. These results showed significant differences in ASH compared to normal liver, and significant differences in ASH compared to NASH. Thus, we conclude that there are more proteins involved in tumorigenesis in ASH compared to NASH and in ASH compared to normal liver, which is consistent with the known tumor development rate in ASH and NASH.	[Luan Nguyen; Masouminia, Maryam; Mendoza, Alejandro; Samadzadeh, Sara; Tillman, Brittany; French, Barbara; French, Samuel] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Morgan, Timothy] VA Med Ctr, Long Beach, CA USA	Nguyen, L (reprint author), Harbor UCLA Med Ctr, Torrance, CA 90509 USA.	Inguyen23289@yahoo.com			NIH/AAA grant [UO-21898-05]	This study was funded by NIH/AAA grant # UO-21898-05.	Augello C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-125; Bao Shi-Ting, 2006, Hepatobiliary Pancreat Dis Int, V5, P580; Chen H, 2006, ONCOL REP, V15, P1281; Chiba T, 2015, INT J CANCER, V136, P289, DOI 10.1002/ijc.28985; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; EI-Emshaty Hoda M, 2014, Hepatogastroenterology, V61, P1393; El-Haibi CP, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-64; Elias D, 2015, PHARMACOL RES, V100, P250, DOI 10.1016/j.phrs.2015.08.010; Ferroudj S, 2016, HEPATOL RES, V46, P1264, DOI 10.1111/hepr.12675; Garcia EJ, 2002, APPL IMMUNOHISTO M M, V10, P210, DOI 10.1097/01.PAI.0000013624.57350.7F; Janku F, 2014, ONCOTARGET, V5, P3012, DOI 10.18632/oncotarget.1687; Kent LN, 2017, J CLIN INVEST, V127, P830, DOI 10.1172/JCI87583; Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075; Li KKW, 2002, LIVER, V22, P259, DOI 10.1046/j.0106-9543.2002.01629.x; Lin YW, 1998, EUR J CANCER, V34, P1789, DOI 10.1016/S0959-8049(98)00189-0; Lindenmeyer CC, 2018, CLIN LIVER DIS, V22, P11, DOI 10.1016/j.cld.2017.08.003; Liu H, 2015, ONCOTARGET, V6, P42491, DOI 10.18632/oncotarget.6382; Liu JH, 2017, INT J MED SCI, V14, P523, DOI 10.7150/ijms.19033; Liu WS, 2015, J BIOL CHEM, V290, P28489, DOI 10.1074/jbc.M115.658237; Masouminia M, 2016, EXP MOL PATHOL, V101, P81, DOI 10.1016/j.yexmp.2016.07.002; Schwartz JM, 2012, CLIN LIVER DIS, V16, P659, DOI 10.1016/j.cld.2012.08.001; To AKY, 2011, BBA-MOL CELL RES, V1813, P222, DOI 10.1016/j.bbamcr.2010.09.005; Yao Jian, 2012, Cancer Biology Medicine, V9, P234, DOI 10.7497/j.issn.2095-3941.2012.04.003; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang L, 2017, ONCOL RES, V25, P19, DOI 10.3727/096504016X14685034103914	25	4	4	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					45	49		10.1016/j.yexmp.2017.12.007			5	Pathology	Pathology	FV8SS	WOS:000424857700008	29307797	Green Accepted			2019-10-28	
J	Federica, T; Antonio, G				Federica, Taurino; Antonio, Gnoni			Systematic review of plasma-membrane ecto-ATP synthase: A new player in health and disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Ecto-ATP-synthase; Lipid metabolism; pH regulation; Angiogenesis; Extracellular ATP/ADP; IF1	HDL ENDOCYTOSIS PATHWAY; INHIBITOR PROTEIN IF1; CELL-SURFACE; BETA-SUBUNIT; BOVINE F-1-ATPASE; EXTRACELLULAR ATP; F0F1-ATP SYNTHASE; F1F0-ATP SYNTHASE; COUPLING FACTOR-6; HEPG2 CELLS	This review summarizes recent studies on plasma-membrane ecto-ATP synthase from structural and functional standpoints to possible pathophysiological roles. This review discusses significant new contributions and perspectives in the area of ecto-ATP synthase since the topic was last reviewed in 2015. Following an extensive summary of the cell types in which the ecto-ATP synthase is present, its structural and functional mechanism are discussed and physiological and pathological roles of the ecto-ATP synthase are reviewed and evaluated. Attempts to define the possible role of ecto-ATP synthase as possible target for anti-cancer and anti-obesity interventions are discussed.	[Federica, Taurino] Univ Salento, Dept Biol & Environm Sci & Technol, Lab Biochem & Mol Biol, Lecce, Italy; [Antonio, Gnoni] Univ Bari Aldo Moro, Dept Med Basic Sci Neurosci & Sense Organs, Bari, Italy	Antonio, G (reprint author), Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Policlin Pzza G Cesare 11, I-70100 Bari, Italy.	antonio.gnoni@uniba.it	; Gnoni, Antonio/C-8078-2014	Taurino, Federica/0000-0002-8489-1650; Gnoni, Antonio/0000-0001-5071-611X			ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahmad Z, 2010, CURR MED CHEM, V17, P2822, DOI 10.2174/092986710791859270; Alard JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014654; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arakaki N, 2003, MOL CANCER RES, V1, P931; Arakaki N, 2007, FEBS LETT, V581, P3405, DOI 10.1016/j.febslet.2007.06.041; Bae TJ, 2004, PROTEOMICS, V4, P3536, DOI 10.1002/pmic.200400952; Biason JV, 2011, J MOL BIOL, V406, P443, DOI 10.1016/j.jmb.2010.12.025; Bini L, 2003, BIOCHEM J, V369, P301, DOI 10.1042/BJ20020503; Borghese R, 1998, ARCH MICROBIOL, V170, P385, DOI 10.1007/s002030050657; Braschi E, 2010, CURR BIOL, V20, P1310, DOI 10.1016/j.cub.2010.05.066; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Burwick NR, 2005, J BIOL CHEM, V280, P1740, DOI 10.1074/jbc.M405947200; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Cardouat G, 2017, BBA-MOL CELL BIOL L, V1862, P832, DOI 10.1016/j.bbalip.2017.05.005; CARLSEN SA, 1981, J BIOL CHEM, V256, P8058; Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820; Cavallo A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052328; Cavallo A, 2011, J BIOENERG BIOMEMBR, V43, P349, DOI 10.1007/s10863-011-9366-3; Cavelier C, 2012, ARTERIOSCL THROM VAS, V32, P131, DOI 10.1161/ATVBAHA.111.238063; Chang HY, 2012, CANCER RES, V72, P4696, DOI 10.1158/0008-5472.CAN-12-0567; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; Chen C, 2006, J BIOL CHEM, V281, P13777, DOI 10.1074/jbc.M513369200; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; Chi SL, 2006, CANCER RES, V66, P875, DOI 10.1158/0008-5472.CAN-05-2806; Comelli M, 2016, J CELL BIOCHEM, V117, P470, DOI 10.1002/jcb.25295; Contessi S, 2007, J BIOENERG BIOMEMBR, V39, P291, DOI 10.1007/s10863-007-9091-0; Cortes-Hernandez P, 2005, BIOCHEM BIOPH RES CO, V330, P844, DOI 10.1016/j.bbrc.2005.03.064; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; Di Pancrazio F, 2004, BBA-BIOENERGETICS, V1659, P52, DOI 10.1016/j.bbabio.2004.07.009; Dolman NJ, 2005, J BIOL CHEM, V280, P15794, DOI 10.1074/jbc.M412694200; Dowling P, 2007, BBA-PROTEINS PROTEOM, V1774, P93, DOI 10.1016/j.bbapap.2006.09.014; ESSNER E, 1958, J BIOPHYS BIOCHEM CY, V4, P711, DOI 10.1083/jcb.4.6.711; Fabre ACS, 2006, CELL MOL LIFE SCI, V63, P2829, DOI 10.1007/s00018-006-6325-y; Faccenda D, 2012, INT J CELL BIOL, V2012, P1, DOI DOI 10.1155/2012/367934; Fliedner SMJ, 2015, AM J CANCER RES, V5, P1558; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Garcia J, 2011, AM J PHYSIOL-CELL PH, V301, pC44, DOI 10.1152/ajpcell.00405.2010; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Giorgio V, 2010, J BIOENERG BIOMEMBR, V42, P117, DOI 10.1007/s10863-010-9270-2; Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P13632, DOI 10.1073/pnas.0706290104; Gonzalez-Pecchi V, 2015, MICROVASC RES, V98, P9, DOI 10.1016/j.mvr.2014.11.003; Hong D, 2008, AM J PHYSIOL-CELL PH, V294, pC856, DOI 10.1152/ajpcell.00278.2007; Hong S, 2008, MICROBIOL MOL BIOL R, V72, P590, DOI 10.1128/MMBR.00016-08; Howard AD, 2011, MOL CELL BIOCHEM, V348, P155, DOI 10.1007/s11010-010-0650-z; Huang TC, 2008, J PROTEOME RES, V7, P1433, DOI 10.1021/pr700742h; Jacquet S, 2005, CELL MOL LIFE SCI, V62, P2508, DOI 10.1007/s00018-005-5194-0; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Johnson JA, 2011, CURR MED CHEM, V18, P4684; Jung KH, 2007, CANCER BIOTHER RADIO, V22, P704, DOI 10.1089/cbr.2007.369; KARASAKI S, 1972, CANCER RES, V32, P1703; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kim BW, 2004, EXP MOL MED, V36, P476, DOI 10.1038/emm.2004.60; Kim KB, 2006, PROTEOMICS, V6, P2444, DOI 10.1002/pmic.200500574; Kita T, 2015, BIOMED RES-TOKYO, V36, P115, DOI 10.2220/biomedres.36.115; Lagadic-Gossmann D, 2004, CELL DEATH DIFFER, V11, P953, DOI 10.1038/sj.cdd.4401466; Letts JA, 2017, NAT STRUCT MOL BIOL, V24, P800, DOI 10.1038/nsmb.3460; Lindqvist A, 2008, NUTR NEUROSCI, V11, P55, DOI 10.1179/147683008X301397; Lu ZJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-16; Lyly A, 2008, HUM MOL GENET, V17, P1406, DOI 10.1093/hmg/ddn028; Ma Z, 2010, ACTA BIOCH BIOPH SIN, V42, P530, DOI 10.1093/abbs/gmq063; Malaval C, 2009, CELL SIGNAL, V21, P120, DOI 10.1016/j.cellsig.2008.09.016; Mangiullo R, 2008, BBA-BIOENERGETICS, V1777, P1326, DOI 10.1016/j.bbabio.2008.08.003; Mangiullo R, 2010, BBA-BIOENERGETICS, V1797, P233, DOI 10.1016/j.bbabio.2009.10.009; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; McMahon KA, 2006, PROTEOMICS, V6, P143, DOI 10.1002/pmic.200500208; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Notari L, 2010, FEBS J, V277, P2192, DOI 10.1111/j.1742-4658.2010.07641.x; Ohta T, 2009, BBA-BIOMEMBRANES, V1788, P1099, DOI 10.1016/j.bbamem.2009.03.005; Omatsu-Kanbe M, 2006, BIOCHEM J, V393, P171, DOI 10.1042/BJ20051037; Osanai T, 2005, HYPERTENSION, V46, P1140, DOI 10.1161/01.HYP.0000186483.86750.85; Osanai T, 2012, DIABETOLOGIA, V55, P520, DOI 10.1007/s00125-011-2341-z; Osanai T, 2001, CIRCULATION, V104, P3132, DOI 10.1161/hc5001.100832; Pan J, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-211; Panfoli I, 2011, EXPERT REV PROTEOMIC, V8, P231, DOI [10.1586/EPR.11.1, 10.1586/epr.11.1]; Panfoli I, 2009, INT J BIOCHEM CELL B, V41, P2555, DOI 10.1016/j.biocel.2009.08.013; Park M, 2004, PEPTIDES, V25, P2127, DOI 10.1016/j.peptides.2004.08.022; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Quillen EE, 2006, J BIOL CHEM, V281, P20728, DOI 10.1074/jbc.M513042200; Radojkovic C, 2009, ARTERIOSCL THROM VAS, V29, P1125, DOI 10.1161/ATVBAHA.109.187997; Rai AK, 2013, J BIOENERG BIOMEMBR, V45, P569, DOI 10.1007/s10863-013-9522-z; Ravera S, 2011, CELL BIOCHEM BIOPHYS, V59, P63, DOI 10.1007/s12013-010-9112-1; Ravera S, 2011, CELL MOL NEUROBIOL, V31, P313, DOI 10.1007/s10571-010-9624-7; Ravera S, 2009, INT J BIOCHEM CELL B, V41, P1581, DOI 10.1016/j.biocel.2009.01.009; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Schmidt C, 2008, MOL PSYCHIATR, V13, P953, DOI 10.1038/sj.mp.4002077; Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012; SHI XJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P177, DOI 10.1006/abbi.1994.1487; Song KX, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/356432; Soubannier V, 2012, CURR BIOL, V22, P135, DOI 10.1016/j.cub.2011.11.057; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Taurino F, 2016, BIOCHEM J, V473, P2519, DOI 10.1042/BCJ20160065; Vacirca D, 2012, NEUROBIOL AGING, V33, P753, DOI 10.1016/j.neurobiolaging.2010.05.013; Vacirca D, 2011, J ALZHEIMERS DIS, V26, P441, DOI 10.3233/JAD-2011-110350; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vantourout P, 2008, MOL IMMUNOL, V45, P485, DOI 10.1016/j.molimm.2007.05.026; Veitonmaki N, 2004, CANCER RES, V64, P3679, DOI 10.1158/0008-5472.CAN-03-1754; Verdier C, 2013, ARCH CARDIOVASC DIS, V106, P601, DOI 10.1016/j.acvd.2013.06.052; VERSCHOOR GJ, 1977, BIOCHIM BIOPHYS ACTA, V462, P438, DOI 10.1016/0005-2728(77)90141-4; Wang JB, 2008, CANCER BIOL THER, V7, P1829, DOI 10.4161/cbt.7.11.6861; Wang TK, 2006, BBA-MOL CELL BIOL L, V1761, P1182, DOI 10.1016/j.bbalip.2006.08.009; Wang WJ, 2013, J CELL BIOCHEM, V114, P1695, DOI 10.1002/jcb.24511; Wu JH, 2015, ONCOL LETT, V10, P2075, DOI 10.3892/ol.2015.3548; Wu YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070642; Xing SL, 2012, INT J NEUROSCI, V122, P290, DOI 10.3109/00207454.2011.649867; Xing SL, 2011, CELL BIOL INT, V35, P81, DOI 10.1042/CBI20090441; Xing SL, 2013, MOL MED REP, V8, P1689, DOI 10.3892/mmr.2013.1722; Yamamoto K, 2007, AM J PHYSIOL-HEART C, V293, pH1646, DOI 10.1152/ajpheart.01385.2006; Yonally SK, 2006, MITOCHONDRION, V6, P305, DOI 10.1016/j.mito.2006.10.001; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200; Zanotti F, 2009, BIOCHEM BIOPH RES CO, V384, P43, DOI 10.1016/j.bbrc.2009.04.046; Zhang LH, 2008, J LIPID RES, V49, P1195, DOI 10.1194/jlr.M700426-JLR200; Zhang X, 2008, ACTA PHARMACOL SIN, V29, P942, DOI 10.1111/j.1745-7254.2008.00830.x	119	4	4	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					59	70		10.1016/j.yexmp.2017.12.006			12	Pathology	Pathology	FV8SS	WOS:000424857700010	29305066				2019-10-28	
J	Wahab, R; Gopalan, V; Islam, F; Mamoori, A; Lee, KTW; Lu, CT; Lam, AKY				Wahab, Riajul; Gopalan, Vinod; Islam, Farhadul; Mamoori, Afraa; Lee, Katherine Ting-Wei; Lu, Cu-Tai; Lam, Alfred King-Yin			Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						GAEC1; Immunohistochemistry; Pathology; Expression	SQUAMOUS-CELL CARCINOMA; CLINICOPATHOLOGICAL SIGNIFICANCE; P16 EXPRESSION; CANCER; MUTATIONS; SURVIVAL	Aim: GAEC1 (Gene amplified in esophageal cancer 1) is an oncogene with key regulatory roles in the pathogenesis of oesophageal and colorectal carcinomas. The aim of this study was to investigate expression profiles and clinicopathological significance of GAEC1 mRNA and protein in patients with colorectal carcinomas. Method: Matched cancer and non-cancer fresh frozen tissues were prospectively collected from 80 patients diagnosed with colorectal adenocarcinoma (39 men and 41 women). The tissues were sectioned for RNA extraction and cDNA conversion and quantified by a real-time polymerase chain reaction. GAEC1 protein expression was analysed by immunohistochemistry using a custom made GAEC1 antibody. Result GAEC1 mRNA was upregulated in majority (52%, n = 42/80) of the colorectal carcinomas when compared to the matched non-neoplastic tissues. High expression of GAEC1 mRNA as correlated with patients of younger age (p = 0.008), with lower grade carcinoma (p = 0.028), presence of synchronous adenocarcinomas (p = 0.034) and without any associated adenomas (p = 0.047). In addition, patients with high GAEC1 mRNA overexpression had a shorter survival time. Furthermore, high GAEC1 protein expression was noted among patients having perforated colorectal carcinoma (p = 0.04). Conclusion: The high expression of GAEC1 mRNA/protein as well as its correlation with multiple clinicopathological characteristics in patients with colorectal carcinoma strongly suggests that GAEC1 is a key regulator in the initiation of colorectal carcinogenesis.	[Wahab, Riajul; Gopalan, Vinod; Islam, Farhadul; Mamoori, Afraa; Lee, Katherine Ting-Wei; Lam, Alfred King-Yin] Griffith Univ, Sch Med, Menzies Hlth Inst Queensland, Canc Mol Pathol, Gold Coast, Qld, Australia; [Gopalan, Vinod] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia; [Lu, Cu-Tai] Gold Coast Hosp, Dept Surg, Gold Coast, Qld, Australia	Lam, AKY (reprint author), Griffith Med Sch, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	a.lam@griffith.edu.au	Lam, Alfred/C-1652-2008	Lam, Alfred/0000-0003-2771-564X; Lee, Katherine Ting-Wei/0000-0003-2068-7762	Griffith UniversityGriffith University	The authors would like to thank for the support of project and HDR funding from Griffith University.	Amin M, 2017, AJCC CANC STAGING MA, P251; Asano H, 2017, INT J COLORECTAL DIS, V32, P419, DOI 10.1007/s00384-016-2694-3; Chan D, 2013, WORLD J GASTROENTERO, V19, P2772, DOI 10.3748/wjg.v19.i18.2772; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005; Gopalan V, 2016, HUM PATHOL, V53, P105, DOI 10.1016/j.humpath.2016.02.016; Gopalan V, 2015, EXP CELL RES, V330, P423, DOI 10.1016/j.yexcr.2014.08.006; Gopalan V, 2014, MOL CARCINOGEN, V53, pE36, DOI 10.1002/mc.21993; Gopalan V, 2013, J CLIN PATHOL, V66, P721, DOI 10.1136/jclinpath-2013-201459; Gopalan V, 2010, HUM PATHOL, V41, P1009, DOI 10.1016/j.humpath.2009.11.014; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Islam F, 2017, HUM GENET, V136, P321, DOI 10.1007/s00439-017-1760-4; Lam AKY, 2008, PATHOLOGY, V40, P580, DOI 10.1080/00313020802320713; Lam AKY, 2008, HUM PATHOL, V39, P599, DOI 10.1016/j.humpath.2007.09.001; Lam AKY, 2014, WORLD J GASTROENTERO, V20, P6815, DOI 10.3748/wjg.v20.i22.6815; Lam AKY, 2011, AM J SURG, V202, P39, DOI 10.1016/j.amjsurg.2010.05.012; Law FBF, 2007, ONCOGENE, V26, P5877, DOI 10.1038/sj.onc.1210390; Muller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3; Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d; Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016; Tang JCO, 2001, CLIN CANCER RES, V7, P1539; Wahab R, 2017, EUR J CELL BIOL, V96, P487, DOI 10.1016/j.ejcb.2017.07.003; Yamane L, 2014, WORLD J GASTROENTERO, V20, P2634, DOI 10.3748/wjg.v20.i10.2634	24	2	2	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					71	75		10.1016/j.yexmp.2018.01.004			5	Pathology	Pathology	FV8SS	WOS:000424857700011	29337242				2019-10-28	
J	Mitchell, R; Molligan, J; Rooney, S; Cho, Y; Schon, L; Zhang, ZJ				Mitchell, Reed; Molligan, Jeremy; Rooney, Sydney; Cho, Young; Schon, Lew; Zhang, Zijun			Functionally compromised synovium-derived mesenchymal stem cells in Charcot neuroarthropathy	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Mesenchymal stem cells; Synovium; Neuroarthropathy; Diabetes	BONE-MARROW; RHEUMATOID-ARTHRITIS; STROMAL CELLS; NERVE-FIBERS; FOOT; OSTEOARTHRITIS; INFLAMMATION	Charcot neuroarthropathy (CNA) often presents as a diabetic foot complication. The role of synovial mesenchymal stem cells (syn-MSCs) in the pathogenesis of CNA is unclear. Synovial samples were collected, for isolation of syn-MSCs, from diabetic patients with CNA (n = 7) and non-diabetic patients with intra-articular fracture or normal joints (non-CNA; n = 7) during foot surgery. The syn-MSCs in the CNA and non-CNA groups were characterized comparatively. The average number of colonies formed in the CNA group was 6 +/- 3.5 per half plate (10 mm in diameter), while it was 43 +/- 21.6 in the non-CNA group (p < 0.05). The average size (pixels) of the colonies in the CNA group was smaller than that in the non-CNA group. When the colonies were stratified into high-, medium- and low-density subgroups, colonies in the high-density subgroup of the CNA group were reduced in density. Expression of PPAR-gamma, RUNX2, Sox9 and type II collagen by syn-MSCs in the CNA group was decreased during adipogenic, osteogenic and chondrogenic differentiation as compared with the non-CNA group. In conclusion, syn-MSCs in CNA joints were reduced in number, with declined differentiation potentials. The high-density subpopulation of the syn-MSCs was particularly affected by the pathology of CNA.	[Mitchell, Reed; Cho, Young; Schon, Lew; Zhang, Zijun] MedStar Union Mem Hosp, Orthobiol Lab, 201 E Univ Pkwy,Bauernschmidt Bldg,Room 763, Baltimore, MD 21218 USA; [Molligan, Jeremy] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Rooney, Sydney] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Zhang, ZJ (reprint author), MedStar Union Mem Hosp, Orthobiol Lab, 201 E Univ Pkwy,Bauernschmidt Bldg,Room 763, Baltimore, MD 21218 USA.	zijun.zhang@medstar.net		Cho, Young/0000-0002-8350-1470			Albers JW, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0473-5; Alves H, 2010, J CELL MOL MED, V14, P2729, DOI 10.1111/j.1582-4934.2009.00931.x; Arranz L, 2014, NATURE, V512, P78, DOI 10.1038/nature13383; Barbaric I, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.006; Bhattaram P., 2016, SEMIN CELL DEV BIOL; Chang TC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126537; Chisholm Kara A, 2011, J Clin Neuromuscul Dis, V13, P1, DOI 10.1097/CND.0b013e3181c6f55b; Contador D, 2015, EXP BIOL MED, V240, P1235, DOI 10.1177/1535370214566565; De Bari C, 2001, ARTHRITIS RHEUM-US, V44, P1928, DOI 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P; Dirmeier M, 2008, RHEUMATOLOGY, V47, P36, DOI 10.1093/rheumatology/kem301; Djouad F, 2005, ARTHRITIS RES THER, V7, pR1304, DOI 10.1186/ar1827; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Eljaafari A, 2012, ARTHRITIS RHEUM-US, V64, P2147, DOI 10.1002/art.34391; Fahy N, 2014, OSTEOARTHR CARTILAGE, V22, P1167, DOI 10.1016/j.joca.2014.05.021; Fox DA, 2010, RHEUM DIS CLIN N AM, V36, P311, DOI 10.1016/j.rdc.2010.02.004; Frykberg Robert G, 2006, J Foot Ankle Surg, V45, pS1; Fulber J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0294-3; Hagmann S, 2016, STEM CELLS INT, DOI 10.1155/2016/6579463; Handorf AM, 2014, J CELL PHYSIOL, V229, P162, DOI 10.1002/jcp.24428; Hanoun M, 2014, CELL STEM CELL, V15, P365, DOI 10.1016/j.stem.2014.06.020; Hastings MK, 2013, J BONE JOINT SURG AM, V95A, P1206, DOI 10.2106/JBJS.L.00250; Jones E, 2010, ANN RHEUM DIS, V69, P450, DOI 10.1136/ard.2008.106435; Klimczak A, 2016, STEM CELLS INT, DOI 10.1155/2016/4285215; Koeck FX, 2009, J ORTHOP RES, V27, P736, DOI 10.1002/jor.20807; Kurth TB, 2011, ARTHRITIS RHEUM-US, V63, P1289, DOI 10.1002/art.30234; Mareddy S, 2007, TISSUE ENG, V13, P819, DOI 10.1089/ten.2006.0180; Mareddy S, 2009, J CELL BIOCHEM, V106, P776, DOI 10.1002/jcb.22088; Matsukura Y, 2015, J ORTHOP RES, V33, P246, DOI 10.1002/jor.22753; Molligan J, 2016, J ORTHOP RES, V34, P224, DOI 10.1002/jor.22989; Rajbhandari SM, 2002, DIABETOLOGIA, V45, P1085, DOI 10.1007/s00125-002-0885-7; Ryu JS, 2014, BIOCHEM BIOPH RES CO, V447, P715, DOI 10.1016/j.bbrc.2014.04.077; Sakaguchi Y, 2005, ARTHRITIS RHEUM-US, V52, P2521, DOI 10.1002/art.21212; Sanders LJ, 2004, DIABETES-METAB RES, V20, pS4, DOI 10.1002/dmrr.451; Sengers BG, 2010, BONE, V46, P496, DOI 10.1016/j.bone.2009.10.002; Shin L, 2012, STEM CELL TRANSL MED, V1, P125, DOI [10.5966/sctm.2011-0031, 10.5966/sctm.2012-0031]; SOUDRY M, 1986, CLIN ORTHOP RELAT R, P199; Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002; Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826; Trieb K, 2016, BONE JOINT J, V98B, P1155, DOI 10.1302/0301-620X.98B9.37038; Yoshimura H, 2007, CELL TISSUE RES, V327, P449, DOI 10.1007/s00441-006-0308-z	40	1	1	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					82	88		10.1016/j.yexmp.2018.01.003			7	Pathology	Pathology	FV8SS	WOS:000424857700013	29353045				2019-10-28	
J	Amer, SM; Bhopale, KK; Kakumanu, RD; Popov, VL; Rampy, BA; El-Mehallawi, IH; Ashmawy, MM; Ansari, GAS; Kaphalia, BS				Amer, Samir M.; Bhopale, Kamlesh K.; Kakumanu, Ramu D.; Popov, Vsevolod L.; Rampy, Bill A.; El-Mehallawi, Inas H.; Ashmawy, Magdy M.; Ansari, G. A. Shakeel; Kaphalia, Bhupendra S.			Hepatic alcohol dehydrogenase deficiency induces pancreatic injury in chronic ethanol feeding model of deer mice	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Ethanol; Alcohol dehydrogenase; Deer mice; Alcoholic chronic pancreatitis; ER membrane stress; Fatty acid ethyl esters	ACID ETHYL-ESTER; ENDOPLASMIC-RETICULUM; CHOLESTEROL ESTERASE; MITOCHONDRIAL DYSFUNCTION; LIVER-DISEASE; RAT PANCREAS; METABOLISM; ACTIVATION; CELLS; SYNTHASE	The single most common cause of chronic pancreatitis (CP, a serious inflammatory disease) is chronic alcohol abuse, which impairs hepatic alcohol dehydrogenase (ADH, a major ethanol oxidizing enzyme). Previously, we found similar to 5 fold greater fatty acid ethyl esters (FAEEs), and injury in the pancreas of hepatic ADH deficient (ADH(-)) vs. hepatic normal ADH (ADH(+)) deer mice fed 3.5 g% ethanol via liquid diet daily for two months. Therefore, progression of ethanol-induced pancreatic injury was determined in ADH(-) deer mice fed ethanol for four months to delineate the mechanism and metabolic basis of alcoholic chronic pancreatitis (ACP). In addition to a substantially increased blood alcohol concentration and plasma FAEEs, significant degenerative changes, including atrophy and loss of acinar cells in some areas, ultrastructural changes evident by such features as swelling and disintegration of endoplasmic reticulum (ER) cisternae and ER stress were observed in the pancreas of ethanol-fed ADH(-) deer mice vs. ADH(+) deer mice. These changes are consistent with noted increases in pancreatic injury markers (plasma lipase, pancreatic trypsinogen activation peptide, FAEE synthase and cathepsin B) in ethanol-fed ADH(-) deer mice. Most importantly, an increased levels of pancreatic glucose regulated protein (GRP) 78 (a prominent ER stress marker) were found to be closely associated with increased phosphorylated eukaryotic initiation factor (eIF) 2 alpha signaling molecule in PKR-like ER kinase branch of unfolded protein response (UPR) as compared to X box binding protein 1S and activating transcription factor (ATF)6 - 50 kDa protein of inositol requiring enzyme 1 alpha and ATF6 branches of UPR, respectively, in ethanol-fed ADH(-) vs. ADH(+) deer mice. These results along with findings on plasma FAEEs, and pancreatic histology and injury markers suggest a metabolic basis of ethanol-induced pancreatic injury, and provide new avenues to understand metabolic basis and molecular mechanism of ACP.	[Amer, Samir M.; Bhopale, Kamlesh K.; Kakumanu, Ramu D.; Popov, Vsevolod L.; Rampy, Bill A.; Ansari, G. A. Shakeel; Kaphalia, Bhupendra S.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Amer, Samir M.; El-Mehallawi, Inas H.; Ashmawy, Magdy M.] Tanta Univ, Dept Forens Med & Clin Toxicol, Tanta, Egypt; [Rampy, Bill A.] Univ Texas Austin, Dell Med Sch, Dept Med Educ, Austin, TX 78712 USA	Kaphalia, BS (reprint author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.	bkaphali@utmb.edu			National Institute on Alcohol Abuse and Alcoholism, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA24699, AA25850]; NIEHS Center grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES06676]; Egyptian Cultural and Educational Bureau (Egypt)Egyptian Cultural & Educational Bureau [J2832]	This work is supported by grants AA24699 and AA25850 funded by National Institute on Alcohol Abuse and Alcoholism, NIH. The analysis of FAEEs was conducted in the Exposure Assessment and Biomarker Development laboratory supported by Sealy Center of Environmental Health & Medicine and NIEHS Center grant P30ES06676. Authors also acknowledge the assistance of Research Histopathology Core, UTMB. Samir Amer was supported by Egyptian Cultural and Educational Bureau (Egypt) (grant No. J2832).	Bhopale KK, 2006, ALCOHOL, V39, P179, DOI 10.1016/j.alcohol.2006.09.005; Brunner R, 2004, J CLIN GASTROENTEROL, V38, P201, DOI 10.1097/00004836-200403000-00001; Cederbaum AI, 2010, DIGEST DIS, V28, P802, DOI 10.1159/000324289; Clemens DL, 2010, WORLD J GASTROENTERO, V16, P1314, DOI 10.3748/wjg.v16.i11.1314; Fortunato F, 2006, AM J PHYSIOL-GASTR L, V290, pG232, DOI 10.1152/ajpgi.00040.2005; HABER PS, 1993, J LAB CLIN MED, V121, P759; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Herreros-Villanueva M, 2013, WORLD J GASTROENTERO, V19, P638, DOI 10.3748/wjg.v19.i5.638; Huang W, 2014, GUT, V63, P1313, DOI 10.1136/gutjnl-2012-304058; HUANG Y, 1994, BBA-LIPID LIPID MET, V1214, P317; Ji BA, 2009, J BIOL CHEM, V284, P17488, DOI 10.1074/jbc.M109.005520; Kaphalia B. S., 2001, Cellular and Molecular Biology Online Papers, V47, pOL173; Kaphalia B. S, 2011, ENCY ENV HLTH, V4, P315; Kaphalia BS, 2010, TOXICOL APPL PHARM, V246, P154, DOI 10.1016/j.taap.2010.05.002; Kaphalia BS, 1996, J TOXICOL ENV HEALTH, V49, P463, DOI 10.1080/009841096160691; Kaphalia BS, 2004, ALCOHOL, V34, P151, DOI 10.1016/j.alcohol.2004.07.013; Kaphalia BS, 2003, J BIOCHEM MOL TOXIC, V17, P338, DOI 10.1002/jbt.10097; Kaplowitz N, 2006, J GASTROEN HEPATOL, V21, pS7, DOI 10.1111/j.1440-1746.2006.04581.x; Kubisch CH, 2007, AM J PHYSIOL-GASTR L, V292, pG1804, DOI 10.1152/ajpgi.00078.2007; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; Lankisch P. G., 1998, PANCREATITIS, P377; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; Lieber CS, 1997, PHYSIOL REV, V77, P517; Lopez JM, 1996, GUT, V38, P285, DOI 10.1136/gut.38.2.285; MANAUTOU JE, 1991, TOXICOLOGY, V70, P303, DOI 10.1016/0300-483X(91)90005-L; MEZEY E, 1975, AM J CLIN NUTR, V28, P1277; NIAAA (National Institute on Alcohol Abuse and Alcoholism), 2000, ALC HLTH SERV RES; NUUTINEN H, 1983, ALCOHOL CLIN EXP RES, V7, P163, DOI 10.1111/j.1530-0277.1983.tb05432.x; PANES J, 1989, GASTROENTEROLOGY, V97, P708, DOI 10.1016/0016-5085(89)90642-2; PANES J, 1993, ALCOHOL CLIN EXP RES, V17, P48, DOI 10.1111/j.1530-0277.1993.tb00725.x; Pfutzer RH, 2002, PANCREAS, V25, P101, DOI 10.1097/01.MPA.0000020652.86805.47; PITCHUMONI CS, 1984, AM J GASTROENTEROL, V79, P382; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Rognstead R., 1979, BIOCH PHARM ETHANOL, P65; Sacks Jeffrey J, 2015, Am J Prev Med, V49, pe73, DOI 10.1016/j.amepre.2015.05.031; SHARKAWI M, 1984, LIFE SCI, V35, P2353, DOI 10.1016/0024-3205(84)90527-7; SHIGETA Y, 1984, BIOCHEM PHARMACOL, V33, P807, DOI 10.1016/0006-2952(84)90466-0; SIMSEK H, 1990, PANCREAS, V5, P401, DOI 10.1097/00006676-199007000-00005; SINGH M, 1990, GASTROENTEROLOGY, V98, P1051, DOI 10.1016/0016-5085(90)90033-W; Wang YL, 2006, PANCREAS, V32, P351, DOI 10.1097/01.mpa.0000220859.93496.e1; Werner J, 1997, GASTROENTEROLOGY, V113, P286, DOI 10.1016/S0016-5085(97)70106-9; Werner J, 2002, AM J PHYSIOL-GASTR L, V283, pG65, DOI 10.1152/ajpgi.00419.2001; WILSON JS, 1982, ALCOHOL CLIN EXP RES, V6, P117, DOI 10.1111/j.1530-0277.1982.tb05389.x; Wu H, 2008, ALCOHOL ALCOHOLISM, V43, P1, DOI 10.1093/alcalc/agm044	45	0	1	1	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	FEB	2018	104	1					89	97		10.1016/j.yexmp.2018.01.002			9	Pathology	Pathology	FV8SS	WOS:000424857700014	29337245	Green Accepted			2019-10-28	
J	McCluggage, WG; Oliva, E				McCluggage, W. Glenn; Oliva, Esther			Gynaecological pathology: problematic areas, new concepts and emerging developments	PATHOLOGY			English	Editorial Material							ENDOMETRIAL STROMAL SARCOMA; PATTERN-BASED-CLASSIFICATION; SMALL-CELL CARCINOMA; ENDOCERVICAL ADENOCARCINOMA; HIGH-GRADE; DICER1 MUTATIONS; OVARIAN METASTASES; TUMORS; NEOPLASMS; UTERINE		[McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland; [Oliva, Esther] Harvard Med Sch, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA USA	McCluggage, WG (reprint author), Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland.	glenn.mccluggage@belfasttrust.hscni.ne					Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Bartosch C, 2018, PATHOLOGY, V50, P222, DOI 10.1016/j.pathol.2017.10.010; Chang MC, 2010, INT J GYNECOL PATHOL, V29, P88, DOI 10.1097/PGP.0b013e3181acefbf; de Kock L, 2017, AM J SURG PATHOL, V41, P1178, DOI 10.1097/PAS.0000000000000895; Garg K, 2018, PATHOLOGY, V50, P238, DOI 10.1016/j.pathol.2017.10.009; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gilks CB, 2018, PATHOLOGY, V50, P214, DOI 10.1016/j.pathol.2017.10.007; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hoang L, 2018, PATHOLOGY, V50, P162, DOI 10.1016/j.pathol.2017.11.086; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Howitt BE, 2018, PATHOLOGY, V50, P141, DOI 10.1016/j.pathol.2017.11.084; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Hussein YR, 2018, PATHOLOGY, V50, P151, DOI 10.1016/j.pathol.2017.09.010; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kurman RJ, 2014, WHO CLASSIFICATION T; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Lim D, 2018, PATHOLOGY, V50, P178, DOI 10.1016/j.pathol.2017.10.008; Malpica A, 2018, PATHOLOGY, V50, P205, DOI 10.1016/j.pathol.2017.12.001; Matias-Guiu X, 2018, PATHOLOGY, V50, P190, DOI 10.1016/j.pathol.2017.10.006; McFarland M, 2016, HISTOPATHOLOGY, V68, P1013, DOI 10.1111/his.12895; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mirkovic J, 2017, AM J SURG PATHOL; Mirkovic J, 2015, MODERN PATHOL, V28, P1504, DOI 10.1038/modpathol.2015.103; Park KJ, 2018, PATHOLOGY, V50, P134, DOI 10.1016/j.pathol.2017.09.011; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Ronnett BM, 2008, AM J SURG PATHOL, V32, P1835, DOI 10.1097/PAS.0b013e3181758831; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Talia KL, 2018, PATHOLOGY, V50, P122, DOI 10.1016/j.pathol.2017.09.009; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Witkowski L, 2016, GYNECOL ONCOL, V141, P454, DOI 10.1016/j.ygyno.2016.03.013; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931	40	0	0	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					119	121		10.1016/j.pathol.2017.11.085			3	Pathology	Pathology	FX8NN	WOS:000426351600001	29258703				2019-10-28	
J	Talia, KL; McCluggage, WG				Talia, Karen L.; McCluggage, W. Glenn			The developing spectrum of gastric-type cervical glandular lesions	PATHOLOGY			English	Review						Cervix; gastric-type lesions; gastric-type adenocarcinoma; gastric-type adenocarcinoma in situ; lobular endocervical glandular hyperplasia	MINIMAL-DEVIATION ADENOCARCINOMA; PEUTZ-JEGHERS-SYNDROME; HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; RISK HUMAN-PAPILLOMAVIRUS; FEMALE GENITAL-TRACT; UTERINE CERVIX; ADENOMA-MALIGNUM; ENDOCERVICAL ADENOCARCINOMA; IMMUNOHISTOCHEMICAL ANALYSIS	Adenocarcinoma of the cervix is less common than squamous cell carcinoma, although its relative prevalence is increasing. Oncogenic (high-risk) human papillomavirus (HPV) infection is implicated in the development of approximately 90% of all cervical adenocarcinomas. Of the remaining non-HPV associated tumours, the most frequent is gastric-type adenocarcinoma (GAS), which is recognised by the World Health Organization as a form of mucinous adenocarcinoma of the cervix. Minimal deviation adenocarcinoma (MDA) of mucinous type (adenoma malignum) is considered an extremely well differentiated variant of GAS and is encompassed within the category of GAS. The concept of gastric-type cervical glandular lesions has emerged over recent decades and our understanding of the full spectrum of benign, premalignant and malignant lesions is still evolving. Established benign lesions, which are rare, include simple gastric metaplasia and lobular endocervical glandular hyperplasia (LEGH) (complex gastric metaplasia). Postulated premalignant lesions comprise atypical LEGH and gastric-type adenocarcinoma in situ (gAIS); these are probably related lesions for which the umbrella term 'gAIS' has been proposed. The term 'gastric-type' derives from the morphological resemblance of the glandular epithelium to that seen in the stomach and pancreaticobiliary tree; intestinal metaplasia with goblet cells and neuroendocrine cells are present in some cases. A gastric immunophenotype has been demonstrated using markers of pyloric gland mucin, MUC6 and HIK1083. Uncommonly, gastric-type cervical glandular lesions involve multiple sites in the female genital tract and it may be problematic to discern whether these represent independent synchronous or metastatic lesions. There is also an association between gastric-type cervical lesions and Peutz-Jeghers syndrome. Awareness of the spectrum of gastric-type lesions is important, as the diagnostic features of both gAIS and GAS, particularly well differentiated examples, may be subtle, and p16 immunohistochemistry is usually negative. GAS has a much poorer prognosis than HPV-associated cervical adenocarcinoma, with propensity for presentation at advanced stage and wide dissemination to unusual sites such as the ovary, omentum and peritoneum. Although uncommon, GAS is likely to increase in relative prevalence with the introduction of HPV vaccination and precursor lesions will not be detected by primary HPV-based screening programs.	[Talia, Karen L.] Box Hill Hosp, Dept Pathol, Nelson Rd,Box Hill, Melbourne, Vic 3128, Australia; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland	Talia, KL (reprint author), Box Hill Hosp, Dept Pathol, Nelson Rd,Box Hill, Melbourne, Vic 3128, Australia.	Karen.Talia@easternhealth.org.au					Adegoke O, 2012, J WOMENS HEALTH, V21, P1031, DOI 10.1089/jwh.2011.3385; AIHW, 2015, AIHW CANC SER, V93; Banno K, 2013, ONCOL LETT, V6, P1184, DOI 10.3892/ol.2013.1527; Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Ferguson AW, 1998, MODERN PATHOL, V11, P11; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; GILKS CB, 1989, AM J SURG PATHOL, V13, P717, DOI 10.1097/00000478-198909000-00001; Hata S, 2002, DIAGN CYTOPATHOL, V27, P80, DOI 10.1002/dc.10140; Hayashi I, 2000, AM J SURG PATHOL, V24, P559, DOI 10.1097/00000478-200004000-00010; Hirasawa A, 2012, ANN ONCOL, V23, P2990, DOI 10.1093/annonc/mds492; Holl K, 2015, INT J CANCER, V137, P2858, DOI 10.1002/ijc.29651; Howitt BE, 2013, AM J SURG PATHOL, V37, P625, DOI 10.1097/PAS.0b013e318285be00; Ichimura T, 2001, INT J GYNECOL PATHOL, V20, P220, DOI 10.1097/00004347-200107000-00003; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Ishii K, 1999, CANCER CYTOPATHOL, V87, P245, DOI 10.1002/(SICI)1097-0142(19991025)87:5<245::AID-CNCR2>3.0.CO;2-0; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kato N, 2011, PATHOL INT, V61, P369, DOI 10.1111/j.1440-1827.2011.02670.x; Kawauchi S, 2008, AM J SURG PATHOL, V32, P1807, DOI 10.1097/PAS.0b013e3181883722; Kim EN, 2017, J PATHOL TRANSL MED, V51, P159, DOI 10.4132/jptm.2016.07.01; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kondo T, 2007, HISTOPATHOLOGY, V50, P843, DOI 10.1111/j.1365-2559.2007.02705.x; Kuragaki C, 2003, LAB INVEST, V83, P35, DOI 10.1097/01.LAB.0000049821.16698.D0; Kurman RJ, 2014, WHO CLASSIFICATION T; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Liu SL, 2001, CAN MED ASSOC J, V164, P1151; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; McCluggage WG, 2016, ADV ANAT PATHOL, V23, P58, DOI 10.1097/PAP.0000000000000095; McCluggage WG, 2013, HISTOPATHOLOGY, V62, P138, DOI 10.1111/his.12012; McCluggage WG, 2010, J CLIN PATHOL, V63, P935, DOI 10.1136/jcp.2010.080150; Meserve Emily E K, 2016, Surg Pathol Clin, V9, P243, DOI 10.1016/j.path.2016.01.006; Mikami Y, 2005, HISTOPATHOLOGY, V46, P130, DOI 10.1111/j.1365-2559.2005.02057.x; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 1999, GYNECOL ONCOL, V74, P504, DOI 10.1006/gyno.1999.5462; Mikami Y, 2001, HISTOPATHOLOGY, V39, P364, DOI 10.1046/j.1365-2559.2001.01239.x; Mikami Y, 2013, ADV ANAT PATHOL, V20, P227, DOI 10.1097/PAP.0b013e31829c2d66; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x; Moat M, 2014, GYNECOL ONCOL REP, V10, P41, DOI 10.1016/j.gynor.2014.03.002; Nara M, 2007, GYNECOL ONCOL, V106, P289, DOI 10.1016/j.ygyno.2007.03.044; Nucci MR, 1999, AM J SURG PATHOL, V23, P886, DOI 10.1097/00000478-199908000-00005; Ohta Y, 2008, PATHOL RES PRACT, V204, P683, DOI 10.1016/j.prp.2008.02.009; Omori M, 2008, AM J CLIN PATHOL, V130, P585, DOI 10.1309/L8XME5JVEJ74C3F1; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Park SB, 2013, ACTA RADIOL, V54, P113, DOI 10.1258/ar.2012.120059; Pimenta JM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-553; Pirog EC, 2014, MODERN PATHOL, V27, P1559, DOI 10.1038/modpathol.2014.55; Sasajima Y, 2008, HISTOPATHOLOGY, V53, P487, DOI 10.1111/j.1365-2559.2008.03095.x; Schoolmeester JK, 2017, MAYO CLIN PROC, V92, pE7, DOI 10.1016/j.mayocp.2016.10.016; SEIDMAN JD, 1994, AM J SURG PATHOL, V18, P1205, DOI 10.1097/00000478-199412000-00003; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Stewart CJR, 2015, PATHOLOGY, V47, P653, DOI 10.1097/PAT.0000000000000329; Takatsu A, 2011, INT J GYNECOL CANCER, V21, P1287, DOI 10.1097/IGC.0b013e31821f746c; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Talia KL, 2014, AM J SURG PATHOL, V38, P289, DOI 10.1097/PAS.0000000000000139; Talia KL, 2012, INT J GYNECOL PATHOL, V31, P192, DOI 10.1097/PGP.0b013e31822c8036; Toki T, 1999, INT J GYNECOL PATHOL, V18, P215, DOI 10.1097/00004347-199907000-00005; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wada T, 2017, AM J SURG PATHOL, V41, P696, DOI 10.1097/PAS.0000000000000833; Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064; Xu JY, 2005, INT J GYNECOL PATHOL, V24, P296, DOI 10.1097/01.PGP.0000157918.36354.C1; Yoden E, 2001, J COMPUT ASSIST TOMO, V25, P94, DOI 10.1097/00004728-200101000-00017; Yuan CT, 2016, VIRCHOWS ARCH, V469, P351, DOI 10.1007/s00428-016-1978-x; Zhao SM, 2003, INT J GYNECOL PATHOL, V22, P393, DOI 10.1097/01.pgp.0000092128.10100.17	65	15	15	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					122	133		10.1016/j.pathol.2017.09.009			12	Pathology	Pathology	FX8NN	WOS:000426351600002	29233547	Bronze			2019-10-28	
J	Hussein, YR; Soslow, RA				Hussein, Yaser R.; Soslow, Robert A.			Molecular insights into the classification of high-grade endometrial carcinoma	PATHOLOGY			English	Review						Endometrial carcinoma; high-grade carcinoma; TCGA; molecular classification; POLE; microsatellite instability	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR DEFICIENCY; EXONUCLEASE DOMAIN MUTATIONS; CLEAR-CELL CARCINOMA; LYNCH-SYNDROME; MICROSATELLITE INSTABILITY; CLINICOPATHOLOGICAL SIGNIFICANCE; UNDIFFERENTIATED CARCINOMA; SEROUS CARCINOMA; GYNECOLOGIC CANCER	Endometrial carcinoma, which is associated with a mortality rate of approximately 20%, is the most common gynecological malignancy in the Western world. It is a heterogeneous disease, with multiple histotypes, each constituting a different disease entity. However, interob-server diagnostic agreement is suboptimal, particularly among the most lethal histotypes. Most recent data also indicate that histotype assignment is not independently associated with survival, while in contrast, clinicopathological risk stratification and genomic classification are significantly prognostic. Recent work has shown that there are four molecular subgroups of endometrioid carcinomas instead of the two types proposed by Bokhman in the 1970s. Carcinomas with polymerase E (POLE) exonuclease domain hotspot mutations are highly prognostically favourable; those with copy-number alterations and TP53 mutations are highly aggressive; and microsatellite unstable and 'copy-number low' endometrioid carcinomas are associated with intermediate prognoses. This review summarises the genetic foundations of the various histotypes of endometrial carcinoma and synthesises this information in the form of algorithms, or classifiers, that recapitulate genomic classification that is not only prognostic, but also potentially diagnostic and therapeutically predictive. A review of Lynch syndrome and Lynch-like syndrome is also provided.	[Hussein, Yaser R.] Morristown Med Ctr, Dept Pathol, Morristown, NJ USA; [Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Soslow, RA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	soslowr@mskcc.org					Alkushi A, 2007, MODERN PATHOL, V20, P1156, DOI 10.1038/modpathol.3800950; Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Altrabulsi B, 2005, AM J SURG PATHOL, V29, P1316, DOI 10.1097/01.pas.0000171003.72352.9a; Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; Bakhsh S, 2016, HISTOPATHOLOGY, V68, P916, DOI 10.1111/his.12878; Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75; Bilbao C, 2010, INT J RADIAT ONCOL, V76, P9, DOI 10.1016/j.ijrobp.2009.09.035; Billingsley CC, 2015, CANCER-AM CANCER SOC, V121, P386, DOI 10.1002/cncr.29046; Black D, 2006, J CLIN ONCOL, V24, P1745, DOI 10.1200/JCO.2005.04.1574; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Broaddus RR, 2006, CANCER, V106, P87, DOI 10.1002/cncr.21560; Buchanan DD, 2014, APPL CLIN GENET, V7, P183, DOI 10.2147/TACG.S48625; Carcangiu ML, 2010, INT J SURG PATHOL, V18, P21, DOI 10.1177/1066896909332117; Carethers JM, 2014, GASTROENTEROLOGY, V146, P602, DOI 10.1053/j.gastro.2014.01.041; Chen WQ, 2017, INT J GYNECOL PATHOL, V36, P128, DOI 10.1097/PGP.0000000000000291; Cherniack AD, 2017, CANCER CELL, V31, P411, DOI 10.1016/j.ccell.2017.02.010; Chiang S, 2014, SEMIN DIAGN PATHOL, V31, P205, DOI 10.1053/j.semdp.2014.03.002; Church DN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju402; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Church JM, 2014, DIS COLON RECTUM, V57, P396, DOI 10.1097/DCR.0000000000000084; Creasman WT, 2004, GYNECOL ONCOL, V95, P593, DOI 10.1016/j.ygyno.2004.08.019; De Jong AE, 2006, GASTROENTEROLOGY, V130, P665, DOI 10.1053/j.gastro.2005.11.032; Delair D, 2012, MOD PATHOL S2, V25, p265A; DeLair DF, 2017, J PATHOL, V243, P230, DOI 10.1002/path.4947; Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35; Ferguson SE, 2014, CANCER-AM CANCER SOC, V120, P3932, DOI 10.1002/cncr.28933; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Garg K, 2010, MODERN PATHOL, V23, P80, DOI 10.1038/modpathol.2009.153; Garg K, 2009, AM J SURG PATHOL, V33, P925, DOI 10.1097/PAS.0b013e318197a046; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Halperin R, 2002, EUR J GYNAECOL ONCOL, V23, P300; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hampel H, 2006, CANCER RES, V66, P7810, DOI 10.1158/0008-5472.CAN-06-1114; Hampel H, 2015, GENET MED, V17, P70, DOI 10.1038/gim.2014.147; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Hoang LN, 2016, HISTOPATHOLOGY, V69, P560, DOI 10.1111/his.12989; Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hussein YR, 2015, MODERN PATHOL, V28, P505, DOI 10.1038/modpathol.2014.143; Jung A, 2007, Verh Dtsch Ges Pathol, V91, P112; Kang SY, 2015, INT J CANCER, V136, P1568, DOI 10.1002/ijc.29133; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Kobel M, 2016, AM J SURG PATHOL, V40, P166, DOI 10.1097/PAS.0000000000000536; Kobel M, 2010, J PATHOL, V222, P191, DOI 10.1002/path.2744; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kuiper RP, 2011, HUM MUTAT, V32, P407, DOI 10.1002/humu.21446; Kurman RJ, 2014, WHO CLASSIFICATION T; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; Lancaster JM, 2015, GYNECOL ONCOL, V136, P3, DOI 10.1016/j.ygyno.2014.09.009; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Lax SF, 1998, HUM PATHOL, V29, P551, DOI 10.1016/S0046-8177(98)80002-6; Lee S, 2016, INT J GYNECOL PATHOL, V35, P209, DOI 10.1097/PGP.0000000000000251; Leenen CHM, 2012, GYNECOL ONCOL, V125, P414, DOI 10.1016/j.ygyno.2012.01.049; Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae; Lynch HT, 2011, LANCET ONCOL, V12, P5, DOI 10.1016/S1470-2045(10)70291-6; Lynch HT, 2004, DIS MARKERS, V20, P181, DOI 10.1155/2004/460240; Matias-Guiu X, 2013, HISTOPATHOLOGY, V62, P111, DOI 10.1111/his.12053; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056; McMeekin DS, 2016, J CLIN ONCOL, V34, P3062, DOI 10.1200/JCO.2016.67.8722; Memorial Sloan Kettering Cancer Center (MSKCC), 2017, END CANC NOM; Meng B, 2014, GYNECOL ONCOL, V134, P15, DOI 10.1016/j.ygyno.2014.05.006; Mensenkamp AR, 2014, GASTROENTEROLOGY, V146, P643, DOI 10.1053/j.gastro.2013.12.002; Mills AM, 2016, AM J SURG PATHOL, V40, P155, DOI 10.1097/PAS.0000000000000544; Mills AM, 2014, AM J SURG PATHOL, V38, P1501, DOI 10.1097/PAS.0000000000000321; Moline J, 2013, GYNECOL ONCOL, V130, P121, DOI 10.1016/j.ygyno.2013.04.022; Oliva Esther, 2011, Surg Pathol Clin, V4, P199, DOI 10.1016/j.path.2010.12.008; Ollikainen M, 2005, J CLIN ONCOL, V23, P4609, DOI 10.1200/JCO.2005.06.055; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Piulats JM, 2017, GYNECOL ONCOL, V145, P200, DOI 10.1016/j.ygyno.2016.12.015; Proctor L, 2017, GYNECOL ONCOL, V146, P596, DOI 10.1016/j.ygyno.2017.06.020; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; Resnick KE, 2010, GYNECOL ONCOL, V117, P234, DOI 10.1016/j.ygyno.2009.12.028; Rodriguez-Soler M, 2013, GASTROENTEROLOGY, V144, P926, DOI 10.1053/j.gastro.2013.01.044; Romero-Perez L, 2013, MODERN PATHOL, V26, P1514, DOI 10.1038/modpathol.2013.93; Rosa-Rosa JM, 2016, MODERN PATHOL, V29, P1390, DOI 10.1038/modpathol.2016.132; Ryan P, 2012, CANCER-AM CANCER SOC, V118, P681, DOI 10.1002/cncr.26323; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Samarnthai N, 2010, OBSTET GYNECOL INT, DOI 10.1155/2010/162363; Shia J, 2008, HUM PATHOL, V39, P116, DOI 10.1016/j.humpath.2007.05.022; Shih IM, 2011, AM J PATHOL, V178, P1442, DOI 10.1016/j.ajpath.2011.01.009; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Silva EG, 2006, INT J GYNECOL PATHOL, V25, P52, DOI 10.1097/01.pgp.0000183048.22588.18; Stelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Westin SN, 2008, J CLIN ONCOL, V26, P5965, DOI 10.1200/JCO.2008.18.6296; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Win AK, 2015, GUT, V64, P101, DOI 10.1136/gutjnl-2013-306567; Zighelboim I, 2007, J CLIN ONCOL, V25, P2042, DOI 10.1200/JCO.2006.08.2107	99	9	10	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					151	161		10.1016/j.pathol.2017.09.010			11	Pathology	Pathology	FX8NN	WOS:000426351600005	29246451	Bronze			2019-10-28	
J	Hoang, L; Chiang, S; Lee, CH				Hoang, Lien; Chiang, Sarah; Lee, Cheng-Han			Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations	PATHOLOGY			English	Review						Endometrial stromal sarcoma; low-grade endometrial stromal sarcoma; high-grade endometrial stromal sarcoma; undifferentiated uterine sarcoma; uterine sarcoma classification; molecular; JAZF1; YWHAE; BCOR	CLEAR-CELL-SARCOMA; INTERNAL TANDEM DUPLICATION; OF-THE-LITERATURE; HIGH-GRADE; UTERINE SARCOMAS; MESENCHYMAL TUMORS; GENE FUSION; TRANSLOCATION T(10/17)(Q22,P13); IMMUNOHISTOCHEMICAL MARKER; YWHAE-FAM22 REARRANGEMENT	Our understanding of endometrial stromal sarcomas has evolved dramatically since their earliest descriptions from over a century ago. Initial studies focused on establishing the relationship between histological appearances of endometrial stromal sarcomas and their clinical outcomes. Studies performed in the last decade have uncovered several recurrent cytogenetic aberrations occurring in low-and high-grade endometrial stromal sarcomas. Low-grade endometrial stromal sarcomas bear close histopathological resemblance to proliferative-type endometrial stroma, and approximately half harbour t(7;17)(p15;q21) resulting in JAZF1-SUZ12 gene fusion. Less common JAZF1-PHF1, EPC1-PHF1, MEAF6-PHF1, and MBTD1-CXorf67 fusions have also been reported. The term 'high-grade endometrial stromal sarcoma' was recently re-introduced in the classification of endometrial stromal tumours after the discovery of t(10; 17)(q22;p13) resulting in YWHAE-NUTM2A/B fusion and is associated with distinct morphological characteristics. This review highlights the evolution of endometrial stromal sarcoma classification schemes over time and describes the salient clinicopathological and molecular features of endometrial stromal nodule, low-grade endometrial stromal sarcoma, highgrade endometrial stromal sarcoma, and undifferentiated uterine sarcoma. It also describes the recent characterisation of endometrial stromal sarcoma with t(X;22)(p11;q13) resulting in ZC3H7B-BCOR fusion, a noteworthy entity due to its close histological resemblance to myxoid leiomyosarcoma. We also provide insights into common challenging scenarios encountered when assessing endometrial stromal lesions in daily surgical pathology practice.	[Hoang, Lien] Vancouver Gen Hosp, Dept Anat Pathol, Vancouver, BC, Canada; [Chiang, Sarah] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Lee, Cheng-Han] BC Canc Agcy, Dept Pathol, Vancouver, BC, Canada	Hoang, L (reprint author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver Gen Hosp, Dept Anat Pathol, Room 1215-910 West 10th Ave, Vancouver, BC V5Z 1M9, Canada.	Lien.Hoang@vch.ca					Abeler VM, 2011, INT J GYNECOL PATHOL, V30, P236, DOI 10.1097/PGP.0b013e318200caff; Abeler VM, 2009, HISTOPATHOLOGY, V54, P355, DOI 10.1111/j.1365-2559.2009.03231.x; Aisagbonhi O, 2017, INT J GYNECOL PATHOL; Ali RH, 2015, J CLIN PATHOL, V68, P325, DOI 10.1136/jclinpath-2014-202829; Ali RH, 2014, HUM PATHOL, V45, P2453, DOI 10.1016/j.humpath.2014.08.012; Allen AJ, 2017, GYNECOL ONCOL REP, V20, P51, DOI 10.1016/j.gore.2017.03.002; Amant F, 2014, INT J GYNECOL CANCER, V24, pS67, DOI 10.1097/IGC.0000000000000205; Amant F, 2011, ANTICANCER RES, V31, P2367; American Cancer Society, SURV RAT UT SARC STA; Astolfi A, 2015, ONCOTARGET, V6, P40934, DOI 10.18632/oncotarget.5882; Bai HM, 2014, GYNECOL ONCOL, V132, P654, DOI 10.1016/j.ygyno.2013.12.032; Baker PM, 2005, AM J SURG PATHOL, V29, P1394, DOI 10.1097/01.pas.0000172295.05527.28; BEER TW, 1995, J CLIN PATHOL, V48, P596, DOI 10.1136/jcp.48.6.596-b; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Blythe JG, 2008, UTERINE SARCOMA HIST; Brooks BE, 2004, GYNECOL ONCOL, V93, P204, DOI 10.1016/j.ygyno.2003.12.029; Busca A, 2017, INT J GYNECOL PATHOL; Caudell JJ, 2005, APPL IMMUNOHISTO M M, V13, P167, DOI 10.1097/01.pai.0000129057.38941.a1; Chan JK, 2008, BRIT J CANCER, V99, P1210, DOI 10.1038/sj.bjc.6604527; CHANG KL, 1993, INT J GYNECOL PATHOL, V12, P282, DOI 10.1097/00004347-199310000-00002; CHANG KL, 1990, AM J SURG PATHOL, V14, P415, DOI 10.1097/00000478-199005000-00002; Chew I, 2010, ADV ANAT PATHOL, V17, P113, DOI 10.1097/PAP.0b013e3181cfb7c2; Chiang S, 2017, MODERN PATHOL, V30, P1251, DOI 10.1038/modpathol.2017.42; Chiang S, 2013, HISTOPATHOLOGY, V62, P124, DOI 10.1111/his.12048; Chiang S, 2011, AM J SURG PATHOL, V35, P1364, DOI 10.1097/PAS.0b013e3182262743; Chiang S, 2011, HUM PATHOL, V42, P609, DOI 10.1016/j.humpath.2010.12.005; Chu PG, 2001, MODERN PATHOL, V14, P465, DOI 10.1038/modpathol.3880335; CLEMENT PB, 1991, HUM PATHOL, V22, P776, DOI 10.1016/0046-8177(91)90207-6; CLEMENT PB, 1992, INT J GYNECOL PATHOL, V11, P163; Clement PB, 1993, TUMORS TUMORLIKE LES; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Conklin CMJ, 2014, ADV ANAT PATHOL, V21, P383, DOI 10.1097/PAP.0000000000000046; Cossu-Rocca P, 2012, INT J GYNECOL PATHOL, V31, P570, DOI 10.1097/PGP.0b013e31824fe289; Croce S, 2013, MODERN PATHOL, V26, P1390, DOI 10.1038/modpathol.2013.69; Cuppens Tine, 2015, Sarcoma, P243298, DOI 10.1155/2015/243298; D'Angelo E, 2013, AM J SURG PATHOL, V37, P514, DOI 10.1097/PAS.0b013e318272c612; Dewaele B, 2014, INT J CANCER, V134, P1112, DOI 10.1002/ijc.28440; Dionigi A, 2002, AM J SURG PATHOL, V26, P567, DOI 10.1097/00000478-200205000-00003; EVANS HL, 1982, CANCER-AM CANCER SOC, V50, P2170, DOI 10.1002/1097-0142(19821115)50:10<2170::AID-CNCR2820501033>3.0.CO;2-K; Fadare O, 2008, ADV ANAT PATHOL, V15, P63, DOI 10.1097/PAP.0b013e31816613b0; FARHOOD AI, 1991, HUM PATHOL, V22, P224, DOI 10.1016/0046-8177(91)90154-H; Fehr A, 2012, J PATHOL, V227, pe5, DOI 10.1002/path.4040; FITKO R, 1990, INT J GYNECOL PATHOL, V9, P379, DOI 10.1097/00004347-199010000-00010; Gadducci A, 2008, CRIT REV ONCOL HEMAT, V65, P129, DOI 10.1016/j.critrevonc.2007.06.011; Gil-Benso R, 1999, VIRCHOWS ARCH, V434, P307, DOI 10.1007/s004280050346; Goodall JR, 1940, J OBSTET GYN BR COMM, V47, P13; GREENE RR, 1954, OBSTET GYNECOL, V3, P150; Gremel G, 2015, INT J CANCER, V136, P1608, DOI 10.1002/ijc.29141; HARLOW BL, 1986, J NATL CANCER I, V76, P399; HART WR, 1977, OBSTET GYNECOL, V49, P393; Hemming ML, 2017, GYNECOL ONCOL, V145, P531, DOI 10.1016/j.ygyno.2017.03.021; HENDERSON DN, 1946, AM J OBSTET GYNECOL, V52, P1000, DOI 10.1016/0002-9378(46)90418-8; Hendrickson MR, 2003, WHO CLASSIFICATION T, P233; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Hosh M, 2016, INT J GYNECOL CANCER, V26, P1098, DOI 10.1097/IGC.0000000000000720; Huang HY, 2004, AM J SURG PATHOL, V28, P224, DOI 10.1097/00000478-200402000-00010; HUNTER WC, 1956, AM J OBSTET GYNECOL, V72, P1072, DOI 10.1016/0002-9378(56)90073-4; HUNTER WC, 1958, AM J OBSTET GYNECOL, V75, P258, DOI 10.1016/0002-9378(58)90383-1; HUNTER WC, 1953, SURGERY, V34, P258; Huynh KD, 2000, GENE DEV, V14, P1810; Hwang H, 2015, J CLIN PATHOL, V68, P710, DOI 10.1136/jclinpath-2015-202915; Jung CK, 2008, MODERN PATHOL, V21, P756, DOI 10.1038/modpathol.2008.53; KAHANPAA KV, 1986, OBSTET GYNECOL, V67, P417; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Karlsson J, 2016, GENE CHROMOSOME CANC, V55, P120, DOI 10.1002/gcc.22316; Kasashima S, 2003, PATHOL INT, V53, P637, DOI 10.1046/j.1440-1827.2003.01525.x; Kempson R L, 1970, Hum Pathol, V1, P331; KEMPSON RL, 1988, SEMIN DIAGN PATHOL, V5, P172; Kenny C, 2016, J PATHOL, V238, P617, DOI 10.1002/path.4693; Kikuchi N, 2017, PATHOL INT, V67, P327, DOI 10.1111/pin.12542; Kim HS, 2015, INT J CLIN EXP PATHO, V8, P3316; Klein WM, 2003, INT J GYNECOL PATHOL, V22, P181, DOI 10.1097/01.PGP.0000040026.16722.78; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; KOSS LG, 1965, SURG GYNECOL OBSTETR, V121, P531; Kruse AJ, 2014, INT J GYNECOL CANCER, V24, P1616, DOI 10.1097/IGC.0000000000000278; Kubo T, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0615-6; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Lee CH, 2015, HISTOPATHOLOGY, V67, P1, DOI 10.1111/his.12594; Lee CH, 2014, MODERN PATHOL, V27, P751, DOI 10.1038/modpathol.2013.199; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Lee CH, 2010, ADV ANAT PATHOL, V17, P222, DOI 10.1097/PAP.0b013e3181d973c2; Leunen K, 2003, GYNECOL ONCOL, V91, P265, DOI 10.1016/S0090-8258(03)00477-3; Lewis N, 2018, MOD PATHOL IN PRESS, V31; Li H, 2007, P NATL ACAD SCI USA, V104, P20001, DOI 10.1073/pnas.0709986104; Li XD, 2016, HISTOPATHOLOGY, V69, P551, DOI 10.1111/his.12966; LIFSCHITZMERCER B, 1987, CANCER, V59, P1494, DOI 10.1002/1097-0142(19870415)59:8<1494::AID-CNCR2820590817>3.0.CO;2-V; MARCHESE MJ, 1984, GYNECOL ONCOL, V18, P299, DOI 10.1016/0090-8258(84)90041-6; Masand RP, 2013, AM J SURG PATHOL, V37, P1635, DOI 10.1097/PAS.0000000000000083; McCluggage WG, 2008, INT J GYNECOL PATHOL, V27, P555, DOI 10.1097/PGP.0b013e31817a82f9; McCluggage WG, 2001, HISTOPATHOLOGY, V39, P273, DOI 10.1046/j.1365-2559.2001.01215.x; McCluggage WG, 2001, HISTOPATHOLOGY, V38, P403, DOI 10.1046/j.1365-2559.2001.01147.x; McCluggage WG, 1996, HISTOPATHOLOGY, V29, P369, DOI 10.1111/j.1365-2559.1996.tb01421.x; MEREDITH RF, 1986, CANCER, V58, P2003, DOI 10.1002/1097-0142(19861101)58:9<2003::AID-CNCR2820580908>3.0.CO;2-2; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Micci F, 2016, GENE CHROMOSOME CANC, V55, P834, DOI 10.1002/gcc.22380; Micci F, 2014, CANCER LETT, V347, P75, DOI 10.1016/j.canlet.2014.01.030; Nakayama M, 2006, INT J GYNECOL PATHOL, V25, P70, DOI 10.1097/01.pgp.0000183047.45459.36; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Nordal RR, 1997, EUR J CANCER, V33, P907, DOI 10.1016/S0959-8049(97)00040-3; NORRIS HJ, 1966, CANCER, V19, P755, DOI 10.1002/1097-0142(196606)19:6<755::AID-CNCR2820190604>3.0.CO;2-U; Nucci MR, 2016, MODERN PATHOL, V29, pS92, DOI 10.1038/modpathol.2015.140; O'Meara E, 2012, J PATHOL, V227, P72, DOI 10.1002/path.3985; OBER WB, 1959, ANN NY ACAD SCI, V75, P568, DOI 10.1111/j.1749-6632.1959.tb44576.x; Oliva E, 2000, ADV ANAT PATHOL, V7, P257, DOI 10.1097/00125480-200007050-00001; Oliva E, 2014, WHO CLASSIFICATION T, P141; Oliva Esther, 2009, Surg Pathol Clin, V2, P679, DOI 10.1016/j.path.2009.08.023; Oliva E, 2014, INT J GYNECOL PATHOL, V33, P374, DOI 10.1097/PGP.0000000000000141; Oliva E, 2014, AM J SURG PATHOL, V38, P305, DOI 10.1097/PAS.0000000000000145; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Panagopoulos I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039354; PARK WW, 1949, J OBSTET GYN BRIT EM, V56, P759; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; PETERS WA, 1984, OBSTET GYNECOL, V63, P550; Pink D, 2006, GYNECOL ONCOL, V101, P464, DOI 10.1016/j.ygyno.2005.11.010; PROPST A, 1964, VIRCHOWS ARCH A, V337, P555, DOI 10.1007/BF00957677; PUNNETT HH, 1989, CANCER GENET CYTOGEN, V41, P123, DOI 10.1016/0165-4608(89)90116-7; Rakheja D, 2004, CANCER GENET CYTOGEN, V154, P175, DOI 10.1016/j.cancergencyto.2004.02.024; Regauer S, 2008, HISTOPATHOLOGY, V52, P780, DOI 10.1111/j.1365-2559.2008.03022.x; Reich O, 2007, CURR OPIN ONCOL, V19, P347, DOI 10.1097/CCO.0b013e3281a7ef3a; Riopel J, 2005, GYNECOL ONCOL, V96, P402, DOI 10.1016/j.ygyno.2004.10.021; Roy A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9891; Schoolmeester JK, 2013, AM J SURG PATHOL, V37, P938, DOI 10.1097/PAS.0b013e318282da9d; Schoolmeester JK, 2014, AM J SURG PATHOL, V38, P176, DOI 10.1097/PAS.0000000000000133; SCHWARTZ Z, 1985, GYNECOL ONCOL, V20, P354, DOI 10.1016/0090-8258(85)90217-3; Sciallis AP, 2014, AM J SURG PATHOL, V38, P1161, DOI 10.1097/PAS.0000000000000256; Scully RE, 1994, HIST TYPING FEMALE G; Shah VI, 2015, AM J SURG PATHOL, V39, P722, DOI 10.1097/PAS.0000000000000427; Silverberg SG, 1992, ATLAS TUMOR PATHOL, V3, P91; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; SREEKANTAIAH C, 1991, CANCER GENET CYTOGEN, V55, P163, DOI 10.1016/0165-4608(91)90073-4; Staats PN, 2009, AM J SURG PATHOL, V33, P1206, DOI 10.1097/PAS.0b013e3181a7b9cf; Stadsvold JL, 2005, GYNECOL ONCOL, V99, P243, DOI 10.1016/j.ygyno.2005.06.039; Stemme S, 2014, AM J CLIN PATHOL, V141, P133, DOI 10.1309/AJCPXD0TPYSNVI8I; Stewart CJR, 2014, HISTOPATHOLOGY, V65, P473, DOI 10.1111/his.12406; Su TF, 2014, INT J SURG PATHOL, V22, P559, DOI 10.1177/1066896913506934; Suzuki S, 2014, PATHOL RES PRACT, V210, P130, DOI 10.1016/j.prp.2013.09.009; SYMMONDS RE, 1957, AM J OBSTET GYNECOL, V73, P1054, DOI 10.1016/S0002-9378(16)37176-9; TAVASSOLI FA, 1981, HISTOPATHOLOGY, V5, P1, DOI 10.1111/j.1365-2559.1981.tb01761.x; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; WHEELOCK MC, 1953, OBSTET GYNECOL, V2, P384; Yamamoto Y, 2014, MOL CANCER RES, V12, P479, DOI 10.1158/1541-7786.MCR-13-0596; Yen MS, 2016, TAIWAN J OBSTET GYNE, V55, P625, DOI 10.1016/j.tjog.2016.07.001; Yilmaz A, 2002, AM J SURG PATHOL, V26, P1142, DOI 10.1097/01.PAS.0000022569.53433.DF; YOONESSI M, 1977, CANCER-AM CANCER SOC, V40, P898, DOI 10.1002/1097-0142(197708)40:2<898::AID-CNCR2820400246>3.0.CO;2-X; YOUNG RH, 1984, CANCER-AM CANCER SOC, V53, P1143, DOI 10.1002/1097-0142(19840301)53:5<1143::AID-CNCR2820530521>3.0.CO;2-F; Zenker FA, 1864, VERANDERUNGEN WILLKU, P84	151	12	12	3	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					162	177		10.1016/j.pathol.2017.11.086			16	Pathology	Pathology	FX8NN	WOS:000426351600006	29275929				2019-10-28	
J	Lim, D; Oliva, E				Lim, Diana; Oliva, Esther			Ovarian sex cord-stromal tumours: an update in recent molecular advances	PATHOLOGY			English	Review						Sex cord-stromal; FOXL2; DICER1; immunohistochemistry; molecular; ovary	GRANULOSA-CELL TUMORS; TERM-FOLLOW-UP; TRANSCRIPTION FACTOR FOXL2; DICER1 HOTSPOT MUTATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL MEMBRANE ANTIGEN; CLINICOPATHOLOGICAL ANALYSIS; OLLIER DISEASE; PROGNOSTIC-FACTORS; MAFFUCCI SYNDROME	Sex cord-stromal tumours (SCSTs) consist of a heterogeneous group of neoplasms with diverse clinicopathological features and biological behaviour. They often present as a diagnostic challenge as they have varied and occasionally overlapping histomorphology and some may even mimic non-SCSTs. An accurate diagnosis is important for therapeutic and prognostic purposes. The use of a panel of immunohistochemical markers which are sensitive and specific for sex cord-stromal differentiation such as alpha-inhibin, calretinin, SF-1 and FOXL2, may be helpful in confirming the cellular lineage of these tumours, but is of limited utility in distinguishing between the different tumour types within this category. Additionally, the development of new therapeutic strategies in patients with SCSTs is also hampered by the infrequent occurrence of these neoplasms. Recent molecular analyses of some SCSTs has led to the discovery of novel molecular events, which may have important diagnostic, prognostic and therapeutic implications. The salient pathological features, management issues and recently described genetic aberrations in adult and juvenile granulosa cell tumours as well as Sertoli-Leydig cell tumours are discussed in this review, with particular emphasis on the clinical significance of FOXL2 and DICER1 mutations. An in-depth understanding of the molecular pathogenesis underlying SCSTs may aid in improving tumour classification and disease prognostication and also potentially lead to the discovery of more effective treatment strategies.	[Lim, Diana] Natl Univ Singapore Hosp, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore; [Lim, Diana] Natl Univ Hlth Syst, Translat Ctr Dev & Res, Singapore, Singapore; [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Lim, D (reprint author), Natl Univ Singapore Hosp, Dept Pathol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	diana_gz_lim@nuhs.edu.sg					AGUIRRE P, 1986, ARCH PATHOL LAB MED, V110, P528; Ahmed E, 1999, AM J SURG PATHOL, V23, P1089, DOI 10.1097/00000478-199909000-00012; Akman L, 2016, J CANCER RES THER, V12, P290, DOI 10.4103/0973-1482.158037; Al-Agha OM, 2011, AM J SURG PATHOL, V35, P484, DOI 10.1097/PAS.0b013e31820a406c; Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Auguste A, 2015, HUM MOL GENET, V24, P6687, DOI 10.1093/hmg/ddv373; Bahubeshi A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002493; Bai ST, 2013, INT J SURG PATHOL, V21, P121, DOI 10.1177/1066896912454567; Benayoun BA, 2013, ONCOGENE, V32, P2739, DOI 10.1038/onc.2012.298; Benayoun BA, 2011, HUM MOL GENET, V20, P1673, DOI 10.1093/hmg/ddr042; Bessiere L, 2015, EBIOMEDICINE, V2, P421, DOI 10.1016/j.ebiom.2015.03.002; BJORKHOLM E, 1981, GYNECOL ONCOL, V11, P261, DOI 10.1016/0090-8258(81)90040-8; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Brown J, 2014, CANCER-AM CANCER SOC, V120, P344, DOI 10.1002/cncr.28421; Bryk S, 2016, GYNECOL ONCOL, V143, P571, DOI 10.1016/j.ygyno.2016.10.002; Bryk S, 2015, INT J GYNECOL CANCER, V25, P33, DOI 10.1097/IGC.0000000000000304; Busam KJ, 1998, AM J SURG PATHOL, V22, P57, DOI 10.1097/00000478-199801000-00007; Buza N, 2017, INT J GYNECOL PATHOL; Caburet S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1283-0; Cathro HP, 2005, HUM PATHOL, V36, P195, DOI 10.1016/j.humpath.2004.11.011; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Choan E, 2006, GYNECOL ONCOL, V102, P406, DOI 10.1016/j.ygyno.2006.02.034; Choong CS, 2012, TRENDS MOL MED, V18, P503, DOI 10.1016/j.molmed.2012.07.003; Cocquet J, 2002, J MED GENET, V39, P916, DOI 10.1136/jmg.39.12.916; Conlon N, 2015, MODERN PATHOL, V28, P1603, DOI 10.1038/modpathol.2015.115; COSTA MJ, 1994, HUM PATHOL, V25, P60, DOI 10.1016/0046-8177(94)90172-4; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; D'Angelo E, 2011, MODERN PATHOL, V24, P1360, DOI 10.1038/modpathol.2011.95; de Boer Carmela M, 2012, BMC Res Notes, V5, P569, DOI 10.1186/1756-0500-5-569; Deavers MT, 2003, MODERN PATHOL, V16, P584, DOI 10.1097/01.MP.0000073133.79591.A1; Din NU, 2014, ANN DIAGN PATHOL, V18, P125, DOI 10.1016/j.anndiagpath.2014.02.002; Ellsworth BS, 2003, MOL CELL ENDOCRINOL, V206, P93, DOI 10.1016/S0303-7207(03)00235-1; Erdreich-Epstein A, 2002, J PEDIAT HEMATOL ONC, V24, P229, DOI 10.1097/00043426-200203000-00015; Ertas IE, 2014, INT J CLIN ONCOL, V19, P912, DOI 10.1007/s10147-013-0630-x; EVANS AT, 1980, OBSTET GYNECOL, V55, P231; Farinola MA, 2007, INT J GYNECOL PATHOL, V26, P375, DOI 10.1097/pgp.0b013e31805c0d99; Farkkila A, 2017, J MOL DIAGN, V19, P126, DOI 10.1016/j.jmoldx.2016.08.005; Farkkila A, 2014, CANCER MED-US, V3, P526, DOI 10.1002/cam4.230; Foulkes WD, 2014, NAT REV CANCER, V14, P662, DOI 10.1038/nrc3802; Foulkes WD, 2011, HUM MUTAT, V32, P1381, DOI 10.1002/humu.21600; FOX H, 1975, CANCER, V35, P231, DOI 10.1002/1097-0142(197501)35:1<231::AID-CNCR2820350128>3.0.CO;2-O; Fox H, 2003, INT J GYNECOL CANCER, V13, P1, DOI 10.1046/j.1525-1438.2003.13050.x; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Ganesan R, 2011, INT J GYNECOL PATHOL, V30, P452, DOI 10.1097/PGP.0b013e318214b17f; Goulvent T, 2016, HISTOPATHOLOGY, V68, P279, DOI 10.1111/his.12747; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Guerrieri C, 1998, INT J GYNECOL PATHOL, V17, P266, DOI 10.1097/00004347-199807000-00012; Gui T, 2012, GYNECOL ONCOL, V127, P384, DOI 10.1016/j.ygyno.2012.07.114; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hofman S, 1998, SKELETAL RADIOL, V27, P688, DOI 10.1007/s002560050460; Irving JA, 2015, AM J SURG PATHOL, V39, P1420, DOI 10.1097/PAS.0000000000000482; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Kalfa N, 2006, J CLIN ENDOCR METAB, V91, P1842, DOI 10.1210/jc.2005-2710; Karalok A, 2016, INT J GYNECOL CANCER, V26, P619, DOI 10.1097/IGC.0000000000000659; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kato N, 2017, HUM PATHOL, V59, P41, DOI 10.1016/j.humpath.2016.09.005; Kenny SL, 2013, HISTOPATHOLOGY, V62, P667, DOI 10.1111/his.12054; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; Kim MS, 2013, HISTOPATHOLOGY, V63, P435, DOI 10.1111/his.12161; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kim T, 2010, HISTOPATHOLOGY, V56, P408, DOI 10.1111/j.1365-2559.2010.03487.x; Kommoss F, 1998, MODERN PATHOL, V11, P656; Kommoss S, 2014, HISTOPATHOLOGY, V64, P380, DOI 10.1111/his.12253; Kommoss S, 2013, MODERN PATHOL, V26, P860, DOI 10.1038/modpathol.2012.226; Kondi-Pafiti A, 2010, EUR J GYNAECOL ONCOL, V31, P94; Korach J, 2009, INT J GYNECOL CANCER, V19, P830, DOI 10.1111/IGC.0b013e3181a261d7; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Kurman RJ, 2014, WHO CLASSIFICATION T, P44; Kurman RJ, 2014, WHO CLASSIFICATION T, P54; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Lee YK, 2008, INT J GYNECOL CANCER, V18, P642, DOI 10.1111/j.1525-1438.2007.01065.x; Leung DTH, 2016, INT J BIOCHEM CELL B, V72, P51, DOI 10.1016/j.biocel.2016.01.003; Leyva-Carmona M, 2009, J PEDIAT HEMATOL ONC, V31, P304, DOI 10.1097/MPH.0b013e318196a70e; Lima JF, 2012, ARCH PATHOL LAB MED, V136, P825, DOI 10.5858/arpa.2011-0355-OA; Lin YS, 2005, GYNECOL ONCOL, V97, P68, DOI 10.1016/j.ygyno.2004.12.014; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mangili G, 2013, BRIT J CANCER, V109, P29, DOI 10.1038/bjc.2013.241; Matias-Guiu X, 1998, HUM PATHOL, V29, P840, DOI 10.1016/S0046-8177(98)90454-3; Mayr D, 2002, MODERN PATHOL, V15, P951, DOI 10.1097/01.MP.0000024290.55261.14; McCluggage WG, 2013, AM J SURG PATHOL, V37, P1450, DOI 10.1097/PAS.0b013e31828e4f55; McCluggage WG, 2001, HISTOPATHOLOGY, V38, P403, DOI 10.1046/j.1365-2559.2001.01147.x; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Meurgey A, 2017, VIRCHOWS ARCH, V470, P225, DOI 10.1007/s00428-016-2038-2; Moumne L, 2008, MOL CELL ENDOCRINOL, V282, P2, DOI 10.1016/j.mce.2007.11.006; Movahedi-Lankarani S, 2002, AM J SURG PATHOL, V26, P1477, DOI 10.1097/00000478-200211000-00010; NAKASHIMA N, 1984, ARCH PATHOL LAB MED, V108, P786; NOGALES FF, 1993, AM J SURG PATHOL, V17, P85, DOI 10.1097/00000478-199301000-00011; Nolan A, 2017, INT J GYNECOL PATHOL, V36, P568, DOI 10.1097/PGP.0000000000000377; Ohishi Y, 2007, GYNECOL ONCOL, V107, P30, DOI 10.1016/j.ygyno.2007.05.020; Oliva E, 2005, AM J SURG PATHOL, V29, P143, DOI 10.1097/01.pas.0000149692.21205.9c; Oliva E, 2007, INT J GYNECOL PATHOL, V26, P359, DOI 10.1097/pgp.0b013e318064511c; Oost EE, 2015, INT J GYNECOL PATHOL, V34, P266, DOI 10.1097/PGP.0000000000000150; Oparka R, 2012, HISTOPATHOLOGY, V60, P838, DOI 10.1111/j.1365-2559.2011.04148.x; Oseto K, 2014, J OBSTET GYNAECOL RE, V40, P1197, DOI 10.1111/jog.12324; Park M, 2010, MOL ENDOCRINOL, V24, P1024, DOI 10.1210/me.2009-0375; Pautier P, 2008, INT J GYNECOL CANCER, V18, P446, DOI 10.1111/j.1525-1438.2007.01049.x; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; PerezAtayde AR, 1996, AM J SURG PATHOL, V20, P72, DOI 10.1097/00000478-199601000-00008; PRAT J, 1982, CANCER, V50, P2465, DOI 10.1002/1097-0142(19821201)50:11<2465::AID-CNCR2820501135>3.0.CO;2-U; Ranger A, 2009, NEUROSURGERY, V65, P1106, DOI 10.1227/01.NEU.0000356984.92242.D5; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; Riopel MA, 1998, INT J GYNECOL PATHOL, V17, P46, DOI 10.1097/00004347-199801000-00009; Rishi M, 1997, AM J SURG PATHOL, V21, P583, DOI 10.1097/00000478-199705000-00012; Rosario R, 2013, GYNECOL ONCOL, V131, P325, DOI 10.1016/j.ygyno.2013.08.031; ROTH LM, 1985, CANCER, V55, P1093, DOI 10.1002/1097-0142(19850301)55:5<1093::AID-CNCR2820550526>3.0.CO;2-O; Savage P, 1998, Clin Oncol (R Coll Radiol), V10, P242, DOI 10.1016/S0936-6555(98)80008-3; Schmidt D, 2004, DEVELOPMENT, V131, P933, DOI 10.1242/dev.00969; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; SCHWARTZ HS, 1987, J BONE JOINT SURG AM, V69A, P269, DOI 10.2106/00004623-198769020-00016; Scully RE, 1999, TUMORS OVARY MALDEVE, V23; Sendur OF, 2010, RHEUMATOL INT, V30, P699, DOI 10.1007/s00296-009-0983-7; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Shim SH, 2014, ANTICANCER RES, V34, P1001; Sigismondi C, 2012, GYNECOL ONCOL, V125, P673, DOI 10.1016/j.ygyno.2012.03.024; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P257, DOI 10.1111/j.1365-2559.2012.04334.x; Stuart GCE, 2003, CURR OPIN OBSTET GYN, V15, P33, DOI 10.1097/01.gco.0000051557.77532.1b; Suri A, 2013, GYNECOL ONCOL, V131, P321, DOI 10.1016/j.ygyno.2013.08.013; SUSIL BJ, 1987, HUM PATHOL, V18, P397, DOI 10.1016/S0046-8177(87)80172-7; TALERMAN A, 1987, CANCER, V60, P3056, DOI 10.1002/1097-0142(19871215)60:12<3056::AID-CNCR2820601233>3.0.CO;2-R; TANAKA Y, 1992, AM J CLIN PATHOL, V97, P523, DOI 10.1093/ajcp/97.4.523; Tuteja G, 2007, CELL, V130, DOI 10.1016/j.cell.2007.09.005; van Meurs HS, 2014, GYNECOL ONCOL, V134, P498, DOI 10.1016/j.ygyno.2014.06.021; van Meurs HS, 2014, GYNECOL ONCOL, V134, P196, DOI 10.1016/j.ygyno.2014.03.573; VASSAL G, 1988, J CLIN ONCOL, V6, P990, DOI 10.1200/JCO.1988.6.6.990; VAZ RM, 1986, J PEDIATR-US, V108, P945, DOI 10.1016/S0022-3476(86)80936-2; Verdegaal SHM, 2011, ONCOLOGIST, V16, P1771, DOI 10.1634/theoncologist.2011-0200; Wilson MK, 2015, GYNECOL ONCOL, V138, P285, DOI 10.1016/j.ygyno.2015.05.011; Witkowski L, 2013, BRIT J CANCER, V109, P2744, DOI 10.1038/bjc.2013.637; Yang SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130429; YOUNG RH, 1982, CANCER, V50, P2448, DOI 10.1002/1097-0142(19821201)50:11<2448::AID-CNCR2820501133>3.0.CO;2-T; YOUNG RH, 1983, AM J SURG PATHOL, V7, P755, DOI 10.1097/00000478-198307080-00005; YOUNG RH, 1983, INT J GYNECOL PATHOL, V1, P325, DOI 10.1097/00004347-198301040-00002; YOUNG RH, 1984, AM J SURG PATHOL, V8, P575, DOI 10.1097/00000478-198408000-00002; YOUNG RH, 1985, AM J SURG PATHOL, V9, P543, DOI 10.1097/00000478-198508000-00001; YOUNG RH, 1994, INT J GYNECOL PATHOL, V13, P302, DOI 10.1097/00004347-199410000-00003; YOUNG RH, 1984, AM J SURG PATHOL, V8, P709, DOI 10.1097/00000478-198409000-00011; ZALOUDEK C, 1982, AM J SURG PATHOL, V6, P503, DOI 10.1097/00000478-198209000-00002; ZALOUDEK C, 1984, AM J SURG PATHOL, V8, P405, DOI 10.1097/00000478-198406000-00001; Zannoni GF, 2016, ONCOL LETT, V12, P1159, DOI 10.3892/ol.2016.4711; Zhao CQ, 2008, INT J GYNECOL PATHOL, V27, P507, DOI 10.1097/PGP.0b013e31817c1b0a; Zhao CQ, 2007, AM J SURG PATHOL, V31, P1378, DOI 10.1097/PAS.0b013e3180339961; Zhao CQ, 2007, AM J SURG PATHOL, V31, P255, DOI 10.1097/01.pas.0000213355.72638.f4; Zhao CQ, 2009, AM J SURG PATHOL, V33, P354, DOI 10.1097/PAS.0b013e318188373d	146	5	7	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					178	189		10.1016/j.pathol.2017.10.008			12	Pathology	Pathology	FX8NN	WOS:000426351600007	29275930	Bronze			2019-10-28	
J	Malpica, A; Longacre, TA				Malpica, Anais; Longacre, Teri A.			Prognostic indicators in ovarian serous borderline tumours	PATHOLOGY			English	Review						Ovary; serous borderline tumour; prognosis; implants; low-grade serous carcinoma	ATYPICAL PROLIFERATIVE TUMORS; LYMPH-NODE INVOLVEMENT; LOW-GRADE; BRAF MUTATION; MICROPAPILLARY PATTERN; CONSERVATIVE TREATMENT; STROMAL MICROINVASION; CRIBRIFORM PATTERNS; FOLLOW-UP; CARCINOMA	There have been great strides in our understanding of the serous group of borderline and malignant pelvic epithelial neoplasms in the past decade. While most serous borderline tumours have a favourable prognosis, recurrences and progression to carcinoma occur, often following a protracted clinical course. Clinical and pathological risk factors tend to co-vary, but the presence and type of extraovarian disease is the most important predictor for progression. Progression usually takes the form of low-grade serous carcinoma, although transformation to high-grade carcinoma is occasionally seen. A serous borderline - low-grade serous carcinoma pathway analogous to neoplastic transformation pathways seen in other organ systems has been proposed, based on global gene expression profiling, shared mutations in KRAS or BRAF, and in most cases, the presence of serous borderline tumour in de novo low-grade serous carcinoma. This discussion focuses on the key prognostic factors that predispose to disease progression and/or transformation to carcinoma in serous borderline tumours.	[Malpica, Anais] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Longacre, Teri A.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Malpica, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	amalpica@mdanderson.org					Burks RT, 1996, AM J SURG PATHOL, V20, P1319, DOI 10.1097/00000478-199611000-00003; Camatte S, 2002, J AM COLL SURGEONS, V195, P332, DOI 10.1016/S1072-7515(02)01250-4; Deavers MT, 2002, AM J SURG PATHOL, V26, P1129, DOI 10.1097/01.PAS.0000022581.14422.C1; Djordjevic B, 2012, AM J SURG PATHOL, V36, P955, DOI 10.1097/PAS.0b013e31825793e1; Djordjevic B, 2010, AM J SURG PATHOL, V34, P1, DOI 10.1097/PAS.0b013e3181c0a5ab; Eichhorn JH, 1999, AM J SURG PATHOL, V23, P397, DOI 10.1097/00000478-199904000-00004; Ewald-Riegler N, 2012, ONKOLOGIE, V35, P28, DOI 10.1159/000336140; Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7; Grisham RN, 2013, CANCER-AM CANCER SOC, V119, P548, DOI 10.1002/cncr.27782; Hannibal CG, 2017, GYNECOL ONCOL, V144, P174, DOI 10.1016/j.ygyno.2016.11.007; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Karlsen NMS, 2016, GYNECOL ONCOL, V142, P50, DOI 10.1016/j.ygyno.2016.05.005; Laurent I, 2008, ANN SURG ONCOL, V15, P3561, DOI 10.1245/s10434-008-0159-9; Lesieur B, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.055; Longacre TA, 2005, AM J SURG PATHOL, V29, P707, DOI 10.1097/01.pas.0000164030.82810.db; Longacre Teri A, 2011, Surg Pathol Clin, V4, P331, DOI 10.1016/j.path.2010.12.011; Matsuo K, 2015, GYNECOL ONCOL REP, V13, P36, DOI 10.1016/j.gore.2015.06.003; McKenney JK, 2006, AM J SURG PATHOL, V30, P1209, DOI 10.1097/01.pas.0000213299.11649.fa; McKenney JK, 2016, AM J SURG PATHOL, V40, P1155, DOI 10.1097/PAS.0000000000000692; McKenney JK, 2006, AM J SURG PATHOL, V30, P614, DOI 10.1097/01.pas.0000194743.33540.e6; Prat J, 2002, AM J SURG PATHOL, V26, P1111, DOI 10.1097/01.PAS.0000022626.38542.66; Rollins SE, 2006, AM J SURG PATHOL, V30, P457, DOI 10.1097/00000478-200604000-00005; Romeo M, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-13; Sangoi AR, 2008, AM J SURG PATHOL, V32, P261, DOI 10.1097/PAS.0b013e318141fc7a; Seidmam JD, 2014, WHO CLASSIFICATION T, P15; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Silva EG, 1998, INT J GYNECOL PATHOL, V17, P1, DOI 10.1097/00004347-199801000-00001; Silva EG, 2006, AM J SURG PATHOL, V30, P1367, DOI 10.1097/01.pas.0000213294.81154.95; Slomovitz BM, 2002, AM J SURG PATHOL, V26, P592, DOI 10.1097/00000478-200205000-00005; Tsang YT, 2013, J PATHOL, V231, P449, DOI 10.1002/path.4252; Uzan C, 2014, ANN ONCOL, V25, P166, DOI 10.1093/annonc/mdt430; Vang R, 2017, AM J SURG PATHOL, V41, P725, DOI 10.1097/PAS.0000000000000824; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Wong KK, 2010, AM J PATHOL, V177, P1611, DOI 10.2353/ajpath.2010.100212; Zeppernick F, 2014, AM J SURG PATHOL, V38, P1603, DOI 10.1097/PAS.0000000000000313	35	7	7	3	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					205	213		10.1016/j.pathol.2017.12.001			9	Pathology	Pathology	FX8NN	WOS:000426351600009	29289348				2019-10-28	
J	Gilks, CB; Kommoss, F				Gilks, C. Blake; Kommoss, Friedrich			Synchronous tumours of the female reproductive tract	PATHOLOGY			English	Review						Synchronous; independent primaries; metastasis; pseudometastasis	TUBAL INTRAEPITHELIAL CARCINOMA; GRADE SEROUS CARCINOMA; FALLOPIAN-TUBE; CLINICOPATHOLOGICAL ANALYSIS; LYNCH SYNDROME; PSEUDOMYXOMA PERITONEI; ENDOMETRIAL CANCER; PRIMARY NEOPLASMS; MUCINOUS OVARIAN; PAGETS-DISEASE	Many ovarian endometrioid carcinomas present with concurrent endometrial carcinoma, and these organ-confined, low-grade synchronous endometrial and ovarian tumours consistently behave as independent primary tumours, rather than a single advanced-stage carcinoma; they are associated with a very favourable prognosis and there is no need for adjuvant treatment. This phenomenon of synchronous tumours involving two or more sites within the female reproductive tract is well recognised, occurring in 1-2% of cases. Although some tumours can be recognised as metastasis, in many the relationship between the synchronous tumours is uncertain. Recently, application of next generation sequencing to synchronous endometrial and ovarian carcinomas has shed light on the relationship between these tumours, but raised more questions about the biology of this curious phenomenon. Herein, we review synchronous tumours involving more than one site in the female genital tract, discuss the pathogenesis, and offer guidelines for how to handle in routine practice.	[Gilks, C. Blake] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Gilks, C. Blake] Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada; [Kommoss, Friedrich] Inst Pathol, Friedrichshafen, Germany	Gilks, CB (reprint author), Univ British Columbia, Vancouver Coastal Hlth, Dept Pathol & Lab Med, Vancouver Gen Hosp, Rm 1253,1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada.	Blake.Gilks@vch.ca					Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; AYHAN A, 1992, EUR J OBSTET GYN R B, V45, P63, DOI 10.1016/0028-2243(92)90195-5; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bijron JG, 2013, AM J SURG PATHOL, V37, P1123, DOI 10.1097/PAS.0b013e318282da7f; Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814; Chuaqui RF, 1996, HUM PATHOL, V27, P165, DOI 10.1016/S0046-8177(96)90370-6; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; Chui MH, 2013, ADV ANAT PATHOL, V20, P378, DOI 10.1097/PAP.0b013e3182a92cf8; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; Crawford D, 1999, INT J GYNECOL PATHOL, V18, P351, DOI 10.1097/00004347-199910000-00010; Dillon JL, 2017, HUM PATHOL; EISNER RF, 1989, GYNECOL ONCOL, V33, P335, DOI 10.1016/0090-8258(89)90523-4; Euscher ED, 2005, AM J SURG PATHOL, V29, P1074; Falkenberry SS, 1996, J REPROD MED, V41, P713; Feltmate CM, 2005, CLIN CANCER RES, V11, P7651, DOI 10.1158/1078-0432.CCR-05-1008; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gilks CB, 2015, AM J SURG PATHOL, V39, P357, DOI 10.1097/PAS.0000000000000353; Girolimetti G, 2014, BIOMED RES INT, DOI 10.1155/2014/787143; Goldblum JR, 1998, AM J SURG PATHOL, V22, P170, DOI 10.1097/00000478-199802000-00004; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heitz F, 2014, INT J GYNECOL CANCER, V24, P54, DOI 10.1097/IGC.0000000000000019; HILSABECK JR, 1951, SURG CLIN N AM, V31, P995; HOLTZ F, 1982, CANCER, V50, P2438, DOI 10.1002/1097-0142(19821201)50:11<2438::AID-CNCR2820501132>3.0.CO;2-X; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kuhn E, 2016, MODERN PATHOL, V29, P1254, DOI 10.1038/modpathol.2016.101; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kuhn E, 2010, AM J SURG PATHOL, V34, P829, DOI 10.1097/PAS.0b013e3181dcede7; Kurman RJ, 2014, WHO CLASSIFICATION T, P316; Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae; Lynch HT, 2013, ANN ONCOL, V24, P83, DOI 10.1093/annonc/mdt313; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Morrison JC, 2015, AM J SURG PATHOL, V39, P442, DOI 10.1097/PAS.0000000000000352; Nakamura K, 2014, MOL CLIN ONCOL, V2, P909, DOI 10.3892/mco.2014.397; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Ronnett BM, 2008, AM J SURG PATHOL, V32, P1835, DOI 10.1097/PAS.0b013e3181758831; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Sieben NL, 2006, J PATHOL, V210, P405, DOI 10.1002/path.2074; Singh N, 2017, MOD PATHOL; Singh N, 2015, PATHOLOGY, V47, P423, DOI 10.1097/PAT.0000000000000291; Singh N, 2010, HISTOPATHOLOGY, V56, P277, DOI 10.1111/j.1365-2559.2009.03367.x; Soliman PT, 2005, J CLIN ONCOL, V23, P9344, DOI 10.1200/JCO.2005.03.5915; Szych C, 1999, AM J PATHOL, V154, P1849, DOI 10.1016/S0002-9440(10)65442-9; Takeshima N, 1998, GYNECOL ONCOL, V70, P183, DOI 10.1006/gyno.1998.5086; Tong SY, 2008, EUR J OBSTET GYN R B, V136, P78, DOI 10.1016/j.ejogrb.2006.09.010; ULBRIGHT TM, 1985, HUM PATHOL, V16, P28, DOI 10.1016/S0046-8177(85)80210-0; Vinokurova S, 2005, JNCI-J NATL CANCER I, V97, P1816, DOI 10.1093/jnci/dji428; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Watson P, 2008, INT J CANCER, V123, P444, DOI 10.1002/ijc.23508; Wilkinson EJ, 2002, HUM PATHOL, V33, P549, DOI 10.1053/hupa.2002.124788; Willis R. A., 1952, SPREAD TUMORS HUMAN; Young RH, 1998, AM J SURG PATHOL, V22, P805, DOI 10.1097/00000478-199807000-00003; YOUNG RH, 1991, AM J SURG PATHOL, V15, P415, DOI 10.1097/00000478-199105000-00001; YOUNG RH, 1988, INT J GYNECOL PATHOL, V7, P99, DOI 10.1097/00004347-198805000-00001; Young RH, 2007, ADV ANAT PATHOL, V14, P149, DOI 10.1097/PAP.0b013e3180504abf	63	2	3	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					214	221		10.1016/j.pathol.2017.10.007			8	Pathology	Pathology	FX8NN	WOS:000426351600010	29249564				2019-10-28	
J	Bartosch, C; Clarke, B; Bosse, T				Bartosch, Carla; Clarke, Blaise; Bosse, Tjalling			Gynaecological neoplasms in common familial syndromes (Lynch and HBOC)	PATHOLOGY			English	Review						Lynch; MMR; endometrial cancer; BRCA; ovarian cancer; screening	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR DEFICIENCY; TUBAL-INTRAEPITHELIAL-CARCINOMA; REDUCING SALPINGO-OOPHORECTOMY; GRADE-SEROUS-CARCINOMA; EPITHELIAL OVARIAN-CANCER; MICROSATELLITE INSTABILITY STATUS; GERMLINE MUTATION STATUS; 4 ANTIBODY PANEL; ENDOMETRIAL CANCER	Recognising hereditary predisposition in a cancer patient has implications both for the patient and the patient's kindred. For the latter, cascade germline testing can reassure those not-at-risk family members while carriers can be enrolled in cancer screening and prevention programs that are medically effective and economically sustainable for health care systems. Furthermore, in many of these syndromes, ramifications of molecular phenotypes are increasing, and it is now emerging that, in addition, they convey prognostic and predictive information. Although cancer predisposition syndromes are rare, these molecular phenotypes also occur as somatic events in sporadic cancer settings. The information obtained from these molecular phenotypes, regardless of germline or somatic origin, is being incorporated into clinical management in view of their manifold significance. Thus, increasingly, bespoke management of cancer patients involves testing for both germline and somatic mutations in tumours. Lynch syndrome and BRCA-1 and BRCA-2-associated hereditary breast and ovarian cancer are hereditary cancer syndromes frequently involving the gynaecological tract but tumours associated with similar molecular alterations may also occur sporadically. Thus, the molecular phenotype of mismatch repair deficiency, microsatellite instability or hypermutator phenotype may be attributable to germline or somatic events. Similarly, homologous recombination deficiency or 'BRCAness' in ovarian cancers may be syndromic or sporadic. While hereditary syndromes are well recognised, the prognostic and predictive implications of these molecular phenotypes have only recently been elucidated and these aspects will finally ensure that molecular screening may become standard of care. Thus, nowadays pathologists are asked to designate the molecular phenotype of these cancers and then determine whether it is due to hereditary or sporadic causes.	[Bartosch, Carla] Portuguese Oncol Inst Porto IPO Porto, Dept Pathol, Porto, Portugal; [Clarke, Blaise] Univ Hlth Network, Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Bosse, Tjalling] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands	Bosse, T (reprint author), Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands.	t.bosse@lumc.nl		Clarke, Blaise/0000-0002-2585-8391			Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; [Anonymous], 2016, PORTEC 4A RANDOMISED; Baldwin RL, 2000, CANCER RES, V60, P5329; Bao F, 2010, AM J SURG PATHOL, V34, P1798, DOI 10.1097/PAS.0b013e3181f906cc; Barrow E, 2009, CLIN GENET, V75, P141, DOI 10.1111/j.1399-0004.2008.01125.x; Bartley AN, 2012, CANCER PREV RES, V5, P320, DOI 10.1158/1940-6207.CAPR-11-0288; Bartosch C, 2016, AM J SURG PATHOL, V40, P1177, DOI 10.1097/PAS.0000000000000684; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellizzi AM, 2009, ADV ANAT PATHOL, V16, P405, DOI 10.1097/PAP.0b013e3181bb6bdc; Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Berends MJW, 2001, INT J CANCER, V92, P398, DOI 10.1002/ijc.1206; Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; Bolton KL, 2012, JAMA-J AM MED ASSOC, V307, P382, DOI 10.1001/jama.2012.20; Bonadona V, 2011, JAMA-J AM MED ASSOC, V305, P2304, DOI 10.1001/jama.2011.743; Broaddus RR, 2006, CANCER, V106, P87, DOI 10.1002/cncr.21560; Buecher B, 2017, FAM CANC; Byrne TJ, 2000, ONCOL REP, V7, P949; Carcangiu ML, 2010, INT J SURG PATHOL, V18, P21, DOI 10.1177/1066896909332117; Carlson JW, 2010, INT J GYNECOL PATHOL, V29, P310, DOI 10.1097/PGP.0b013e3181c713a8; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; Chung L, 2003, OBSTET GYNECOL, V102, P1152, DOI 10.1016/S0029-7844(03)00699-9; Clarke BA, 2012, ADV ANAT PATHOL, V19, P231, DOI 10.1097/PAP.0b013e31825c6b76; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; Committee on Practice Bulletins-Gynecology, 2014, Obstet Gynecol, V124, P1042, DOI 10.1097/01.AOG.0000456325.50739.72; de Jonge MM, 2017, EUR J CANCER, V72, P215, DOI 10.1016/j.ejca.2016.11.028; de Leeuw WJF, 2000, J PATHOL, V192, P328, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2; Downes MR, 2014, HISTOPATHOLOGY, V65, P228, DOI 10.1111/his.12386; Dudley B, 2015, AM J SURG PATHOL, V39, P1114, DOI 10.1097/PAS.0000000000000425; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; Ellison G, 2015, BMC CLIN PATHOL, V15, DOI 10.1186/s12907-015-0004-6; Endris V, 2016, VIRCHOWS ARCH, V468, P697, DOI 10.1007/s00428-016-1919-8; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fadhil W, 2012, HISTOPATHOLOGY, V60, P653, DOI 10.1111/j.1365-2559.2011.04021.x; Faquin WC, 2000, AM J CLIN PATHOL, V113, P576; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferguson SE, 2014, CANCER-AM CANCER SOC, V120, P3932, DOI 10.1002/cncr.28933; Finch A, 2006, GYNECOL ONCOL, V100, P58, DOI 10.1016/j.ygyno.2005.06.065; Finch APM, 2014, J CLIN ONCOL, V32, P1547, DOI 10.1200/JCO.2013.53.2820; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Fujiwara M, 2012, AM J SURG PATHOL, V36, P1170, DOI 10.1097/PAS.0b013e31825d9b8d; Garg K, 2013, AM J SURG PATHOL, V37, P138, DOI 10.1097/PAS.0b013e31826cabbd; Garg K, 2009, AM J SURG PATHOL, V33, P1869, DOI 10.1097/PAS.0b013e3181bc9866; Garg K, 2009, AM J SURG PATHOL, V33, P925, DOI 10.1097/PAS.0b013e318197a046; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Giuffre G, 2005, J MOL DIAGN, V7, P160, DOI 10.1016/S1525-1578(10)60542-9; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Graham RP, 2015, AM J SURG PATHOL, V39, P1370, DOI 10.1097/PAS.0000000000000459; Guillotin D, 2014, EXP CELL RES, V329, P110, DOI 10.1016/j.yexcr.2014.07.004; Gurin CC, 1999, CANCER RES, V59, P462; Hall G, 2010, PATHOLOGY, V42, P409, DOI 10.3109/00313025.2010.493871; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Hampel H, 2006, CANCER RES, V66, P7810, DOI 10.1158/0008-5472.CAN-06-1114; Hampel H, 2015, GENET MED, V17, P70, DOI 10.1038/gim.2014.147; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Han Su Jin, 2015, Obstet Gynecol Sci, V58, P106, DOI 10.5468/ogs.2015.58.2.106; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Helder-Woolderink JM, 2016, EUR J CANCER, V55, P65, DOI 10.1016/j.ejca.2015.12.005; Hjortkjaer M, 2017, INT J GYNECOL PATHOL, V36, P180, DOI 10.1097/PGP.0000000000000310; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Honore LH, 2006, INT J GYNECOL CANCER, V16, P1386, DOI 10.1111/j.1525-1438.2006.00535.x; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Ichikawa Y, 2002, JPN J CLIN ONCOL, V32, P110, DOI 10.1093/jjco/hyf026; Jarboe EA, 2009, INT J GYNECOL PATHOL, V28, P308, DOI 10.1097/PGP.0b013e3181934390; Jarvinen HJ, 2009, J CLIN ONCOL, V27, P4793, DOI 10.1200/JCO.2009.23.7784; Jensen KC, 2008, AM J SURG PATHOL, V32, P1029, DOI 10.1097/PAS.0b013e31816380c4; Joost P, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-126; Karamurzin Y, 2013, AM J SURG PATHOL, V37, P579, DOI 10.1097/PAS.0b013e3182796e27; Kato M, 2015, J GYNECOL ONCOL, V26, P40, DOI 10.3802/jgo.2015.26.1.40; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kempers MJE, 2011, LANCET ONCOL, V12, P49, DOI 10.1016/S1470-2045(10)70265-5; Ketabi Z, 2011, GYNECOL ONCOL, V121, P462, DOI 10.1016/j.ygyno.2011.02.010; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kobel M, 2017, INT J GYNECOL PATHOL, V36, P555, DOI 10.1097/PGP.0000000000000369; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kotsopoulos J, 2016, GYNECOL ONCOL, V140, P42, DOI 10.1016/j.ygyno.2015.11.009; Kuan SF, 2017, HUM PATHOL, V63, P33, DOI 10.1016/j.humpath.2017.02.003; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Lachiewicz MP, 2014, GYNECOL ONCOL, V132, P434, DOI 10.1016/j.ygyno.2013.10.033; Lancaster JM, 2015, GYNECOL ONCOL, V136, P3, DOI 10.1016/j.ygyno.2014.09.009; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Lee V, 2016, ONCOLOGIST, V21, P1200, DOI 10.1634/theoncologist.2016-0046; Ligtenberg MJL, 2013, FAM CANCER, V12, P169, DOI 10.1007/s10689-012-9591-x; Longacre TA, 2016, ENDOMETRIUM BIOMARKE; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Lu FI, 2012, INT J GYNECOL PATHOL, V31, P524, DOI 10.1097/PGP.0b013e31824fe2aa; Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae; Lynch HT, 2010, CANCER PREV RES, V3, P1371, DOI 10.1158/1940-6207.CAPR-10-0204; Mafficini A, 2016, ONCOTARGET, V7, P1076, DOI 10.18632/oncotarget.6834; Malander S, 2006, GYNECOL ONCOL, V101, P238, DOI 10.1016/j.ygyno.2005.10.029; Manchanda R, 2011, BJOG-INT J OBSTET GY, V118, P814, DOI 10.1111/j.1471-0528.2011.02920.x; Mangold E, 2005, J PATHOL, V207, P385, DOI 10.1002/path.1858; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; McLaughlin JR, 2013, JNCI-J NATL CANCER I, V105, P141, DOI 10.1093/jnci/djs494; McMeekin DS, 2016, J CLIN ONCOL, V34, P3062, DOI 10.1200/JCO.2016.67.8722; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mehrad M, 2010, ADV ANAT PATHOL, V17, P293, DOI 10.1097/PAP.0b013e3181ecdee1; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Meisel JL, 2014, ANN ONCOL, V25, P2372, DOI 10.1093/annonc/mdu461; Mensenkamp AR, 2014, GASTROENTEROLOGY, V146, P643, DOI 10.1053/j.gastro.2013.12.002; Mills AM, 2016, AM J SURG PATHOL, V40, P155, DOI 10.1097/PAS.0000000000000544; Milner R, 2013, VIRCHOWS ARCH, V462, P269, DOI 10.1007/s00428-012-1368-y; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Mojtahed A, 2011, MODERN PATHOL, V24, P1004, DOI 10.1038/modpathol.2011.55; Moore KN, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps5616; Mukhopadhyay A, 2012, CANCER RES, V72, P5675, DOI 10.1158/0008-5472.CAN-12-0324; Murphy MA, 2011, INT J CANCER, V129, P1914, DOI 10.1002/ijc.25835; Mutter RW, 2017, J PATHOL, V242, P165, DOI 10.1002/path.4890; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Najdawi F, 2017, PATHOLOGY, V49, P457, DOI 10.1016/j.pathol.2017.05.004; National Comprehensive Cancer Network, 2017, CLIN PRACT GUID ONC; NICE, 2017, MOL TEST STRAT LYNCH; Nieminen TT, 2009, CLIN CANCER RES, V15, P5772, DOI 10.1158/1078-0432.CCR-09-0506; Norquist BM, 2016, JAMA ONCOL, V2, P482, DOI 10.1001/jamaoncol.2015.5495; O'Regan T, 2013, NEW ZEAL MED J, V126, P70; ODonnell RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090604; Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536; Palma L, 2008, GYNECOL ONCOL, V111, P575, DOI 10.1016/j.ygyno.2008.08.002; Parc YR, 2000, INT J CANCER, V86, P60, DOI 10.1002/(SICI)1097-0215(20000401)86:1<60::AID-IJC9>3.0.CO;2-3; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Powell CB, 2013, GYNECOL ONCOL, V129, P364, DOI 10.1016/j.ygyno.2013.01.029; Powell CB, 2011, INT J GYNECOL CANCER, V21, P846, DOI 10.1097/IGC.0b013e31821bc7e3; Powell CB, 2005, J CLIN ONCOL, V23, P127, DOI 10.1200/JCO.2005.04.109; Rabban JT, 2015, AM J SURG PATHOL, V39, P35, DOI 10.1097/PAS.0000000000000293; Radu OM, 2011, HUM PATHOL, V42, P1247, DOI 10.1016/j.humpath.2010.11.016; Raevaara TE, 2003, GASTROENTEROLOGY, V125, P501, DOI 10.1016/S0016-5085(03)00905-3; Rafnar T, 2011, NAT GENET, V43, P1104, DOI 10.1038/ng.955; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; Rambau PF, 2016, HISTOPATHOLOGY, V69, P288, DOI 10.1111/his.12934; Ramus SJ, 2015, JNCI-J NATL CANCER I, P107; Reyes MC, 2014, MODERN PATHOL, V27, P1405, DOI 10.1038/modpathol.2013.237; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Ruszkiewicz A, 2002, PATHOLOGY, V34, P541, DOI 10.1080/0031302021000035965; Ryan P, 2012, CANCER-AM CANCER SOC, V118, P681, DOI 10.1002/cncr.26323; Salahshor S, 2001, LAB INVEST, V81, P535, DOI 10.1038/labinvest.3780262; Schmeler KM, 2006, NEW ENGL J MED, V354, P261, DOI 10.1056/NEJMoa052627; Schrader KA, 2012, OBSTET GYNECOL, V120, P235, DOI 10.1097/AOG.0b013e31825f3576; Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807; Shaw PA, 2002, INT J GYNECOL PATHOL, V21, P407, DOI 10.1097/PGP.0000035810.01856.c8; Sherman ME, 2014, J CLIN ONCOL, V32, P3275, DOI 10.1200/JCO.2013.54.1987; Shia J, 2005, AM J SURG PATHOL, V29, P96, DOI 10.1097/01.pas.0000146009.85309.3b; Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031; Shia J, 2008, HUM PATHOL, V39, P116, DOI 10.1016/j.humpath.2007.05.022; Shia J, 2013, MODERN PATHOL, V26, P131, DOI 10.1038/modpathol.2012.138; Shilpa V, 2014, TUMOR BIOL, V35, P4277, DOI 10.1007/s13277-013-1558-5; Shu CA, 2016, JAMA ONCOL, V2, P1434, DOI 10.1001/jamaoncol.2016.1820; Singh N, 2014, HISTOPATHOLOGY, V65, P149, DOI 10.1111/his.12419; Skytte AB, 2011, ACTA OBSTET GYN SCAN, V90, P593, DOI 10.1111/j.1600-0412.2011.01121.x; Sloan EA, 2017, AM J SURG PATHOL, V41, P326, DOI 10.1097/PAS.0000000000000783; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067; Stelloo E, 2017, ANN ONCOL, V28, P96, DOI 10.1093/annonc/mdw542; Stelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878; Stoffel E, 2009, GASTROENTEROLOGY, V137, P1621, DOI 10.1053/j.gastro.2009.07.039; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; van den Bos M, 2004, AM J SURG PATHOL, V28, P706, DOI 10.1097/01.pas.0000126720.49083.11; Vang R, 2012, INT J GYNECOL PATHOL, V31, P243, DOI 10.1097/PGP.0b013e31823b8831; Vierkoetter KR, 2014, GYNECOL ONCOL, V135, P81, DOI 10.1016/j.ygyno.2014.07.100; Vilkin A, 2014, HUM PATHOL, V45, P2029, DOI 10.1016/j.humpath.2014.07.005; Visvanathan K, 2011, AM J SURG PATHOL, V35, P1766, DOI 10.1097/PAS.0b013e31822f58bc; Wagner A, 2001, J MED GENET, V38, P318, DOI 10.1136/jmg.38.5.318; Wahlberg SS, 2002, CANCER RES, V62, P3485; Walsh MD, 2008, CLIN CANCER RES, V14, P1692, DOI 10.1158/1078-0432.CCR-07-1849; Walsh MD, 2012, MODERN PATHOL, V25, P722, DOI 10.1038/modpathol.2011.209; Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507; Watson N, 2007, J MOL DIAGN, V9, P472, DOI 10.2353/jmoldx.2007.060162; Watson P, 2008, INT J CANCER, V123, P444, DOI 10.1002/ijc.23508; Westin SN, 2008, J CLIN ONCOL, V26, P5965, DOI 10.1200/JCO.2008.18.6296; Wethington SL, 2013, INT J GYNECOL CANCER, V23, P1603, DOI 10.1097/IGC.0b013e3182a80ac8; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Zhang SY, 2011, GYNECOL ONCOL, V121, P353, DOI 10.1016/j.ygyno.2011.01.020	187	5	5	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					222	237		10.1016/j.pathol.2017.10.010			16	Pathology	Pathology	FX8NN	WOS:000426351600011	29287922				2019-10-28	
J	Garg, K; Karnezis, AN; Rabban, JT				Garg, Karuna; Karnezis, Anthony N.; Rabban, Joseph T.			Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation	PATHOLOGY			English	Review						Hereditary gynaecological tumours; germline mutation	SMALL-CELL CARCINOMA; PEUTZ-JEGHERS-SYNDROME; CORD-STROMAL TUMORS; ENDOCERVICAL-GLANDULAR-HYPERPLASIA; FEMALE GENITAL-TRACT; OF-THE-LITERATURE; MINIMAL DEVIATION ADENOCARCINOMA; VON-HIPPEL-LINDAU; TUBEROUS SCLEROSIS COMPLEX; DICER1 HOTSPOT MUTATIONS	The most common hereditary gynaecological tumour syndromes are hereditary breast and ovarian cancer syndrome and Lynch syndrome. However, pathologists also may encounter gynaecological tumours in women with rare hereditary syndromes. Many of these tumours exhibit distinctive gross and microscopic features that are associated with a risk for an inherited gene mutation. The sensitivity and specificity of these tumour pathology features for predicting an inherited mutation vary depending on the syndrome. By recognising these tumour features, pathologists may potentially contribute to the diagnosis of an unsuspected syndrome by recommending referral of the patient for formal risk assessment by genetic counselling. Patients additionally benefit from diagnosis of an inherited syndrome because many also carry a lifetime risk for developing primary malignancies outside of the gynaecological tract. Early diagnosis of an inherited syndrome permits early screening, detection, and management of additional malignancies associated with the syndrome. This review highlights these rare syndromes and their tumour pathology, including Peutz-Jeghers syndrome (gastric type mucinous carcinoma of the cervix; ovarian sex cord tumour with annular tubules); hereditary leiomyoma renal cell carcinoma syndrome (uterine leiomyoma); tuberous sclerosis complex (uterine PEComa; uterine lymphangioleiomyomatosis); DICER1 syndrome (ovarian Sertoli-Leydig cell tumour; cervical embryonal rhabdomyosarcoma); rhabdoid tumour predisposition syndrome 2 (small cell carcinoma of the ovary, hypercalcaemic type); Cowden syndrome (endometrial endometrioid adenocarcinoma); naevoid basal cell carcinoma syndrome (ovarian fibroma); and Von Hippel-Lindau syndrome (clear cell papillary cystadenoma of the broad ligament).	[Garg, Karuna; Rabban, Joseph T.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Karnezis, Anthony N.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada	Rabban, JT (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.	joseph.rabban@ucsf.edu					Agaram NP, 2015, AM J SURG PATHOL, V39, P813, DOI 10.1097/PAS.0000000000000389; Al-Agha OM, 2011, AM J SURG PATHOL, V35, P484, DOI 10.1097/PAS.0b013e31820a406c; Alam NA, 2005, BRIT J DERMATOL, V153, P11, DOI 10.1111/j.1365-2133.2005.06678.x; Alam NA, 2005, ARCH DERMATOL, V141, P199, DOI 10.1001/archderm.141.2.199; Anglesio MS, 2013, J PATHOL, V229, P400, DOI 10.1002/path.4135; Anjarwalla S, 2007, INT J GYNECOL CANCER, V17, P1147, DOI 10.1111/j.1525-1438.2007.00939.x; Aretz S, 2005, HUM MUTAT, V26, P513, DOI 10.1002/humu.20253; Aydin H, 2005, AM J SURG PATHOL, V29, P520, DOI 10.1097/01.pas.0000155160.36154.mL; Aydin H, 2009, AM J SURG PATHOL, V33, P289, DOI 10.1097/PAS.0b013e31817ed7a6; Baker WD, 2013, J OBSTET GYNAECOL RE, V39, P876, DOI 10.1111/j.1447-0756.2012.02052.x; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Bartman AE, 1998, J PATHOL, V186, P398; Beggs AD, 2010, GUT, V59, P975, DOI 10.1136/gut.2009.198499; Bennett JA, 2017, MODERN PATHOL, V30, P1476, DOI 10.1038/modpathol.2017.56; Biegel JA, 2014, AM J MED GENET C, V166, P350, DOI 10.1002/ajmg.c.31410; Black D, 2005, GYNECOL ONCOL, V96, P21, DOI 10.1016/j.ygyno.2004.09.024; Bouchard-Fortier G, 2016, GYNECOL ONCOL REP, V18, P4, DOI 10.1016/j.gore.2016.08.004; Brady A, 2012, INT J GYNECOL PATHOL, V31, P133, DOI 10.1097/PGP.0b013e318228f577; BRAND E, 1987, CANCER, V60, P1552, DOI 10.1002/1097-0142(19871001)60:7<1552::AID-CNCR2820600724>3.0.CO;2-W; BRUWER A, 1954, P STAFF M MAYO CLIN, V29, P168; Bubien V, 2013, J MED GENET, V50, P255, DOI 10.1136/jmedgenet-2012-101339; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Cao DF, 2009, AM J SURG PATHOL, V33, P894, DOI 10.1097/PAS.0b013e318198177d; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Carlson JW, 2007, HISTOPATHOLOGY, V51, P305, DOI 10.1111/j.1365-2559.2007.02790.x; CHEN KTK, 1986, HUM PATHOL, V17, P858, DOI 10.1016/S0046-8177(86)80208-8; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Cil AP, 2004, GYNECOL ONCOL, V94, P593, DOI 10.1016/j.ygyno.2004.05.015; Clarke BA, 2016, HISTOPATHOLOGY, V69, P727, DOI 10.1111/his.12988; Conlon N, 2016, AM J SURG PATHOL, V40, P395, DOI 10.1097/PAS.0000000000000558; Conlon N, 2015, MODERN PATHOL, V28, P1603, DOI 10.1038/modpathol.2015.115; Cox R, 2014, AM J SURG PATHOL, V38, P713, DOI 10.1097/PAS.0000000000000152; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; de Kock L, 2017, AM J SURG PATHOL, V41, P1178, DOI 10.1097/PAS.0000000000000895; de Kock L, 2014, ACTA NEUROPATHOL, V128, P111, DOI 10.1007/s00401-014-1285-z; Deavers MT, 2003, MODERN PATHOL, V16, P584, DOI 10.1097/01.MP.0000073133.79591.A1; Dehner LP, 2012, MODERN PATHOL, V25, P602, DOI 10.1038/modpathol.2011.185; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Djordjevic B, 2013, MODERN PATHOL, V26, P1401, DOI 10.1038/modpathol.2013.67; Doros LA, 2014, MODERN PATHOL, V27, P1267, DOI 10.1038/modpathol.2013.242; Edwards James M, 2012, Gynecol Oncol Case Rep, V2, P29, DOI 10.1016/j.gynor.2011.12.004; Elnaggar Adam C, 2012, Gynecol Oncol Case Rep, V3, P18, DOI 10.1016/j.gynor.2012.10.006; Eng C., 2017, GENEREVIEWS; Fadare Oluwole, 2004, World J Surg Oncol, V2, P35, DOI 10.1186/1477-7819-2-35; Farinola MA, 2007, INT J GYNECOL PATHOL, V26, P375, DOI 10.1097/pgp.0b013e31805c0d99; FERRY JA, 1994, INT J GYNECOL PATHOL, V13, P259, DOI 10.1097/00004347-199407000-00010; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Foulkes WD, 2017, CLIN CANCER RES, V23, pE62, DOI 10.1158/1078-0432.CCR-17-0595; Foulkes WD, 2014, NAT REV CANCER, V14, P662, DOI 10.1038/nrc3802; Froio E, 2008, INT J SURG PATHOL, V16, P443, DOI 10.1177/1066896908316067; Garg K, 2011, AM J SURG PATHOL, V35, P1235, DOI 10.1097/PAS.0b013e318223ca01; GERSELL DJ, 1988, AM J SURG PATHOL, V12, P145, DOI 10.1097/00000478-198802000-00008; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GILKS CB, 1989, AM J SURG PATHOL, V13, P717, DOI 10.1097/00000478-198909000-00001; Gorlin RJ, 2004, GENET MED, V6, P530, DOI 10.1097/01.GIM.0000144188.15902.C4; GORLIN RJ, 1965, CANCER-AM CANCER SOC, V18, P89, DOI 10.1002/1097-0142(196501)18:1<89::AID-CNCR2820180114>3.0.CO;2-9; Goulvent T, 2016, HISTOPATHOLOGY, V68, P279, DOI 10.1111/his.12747; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x; Hayashi T, 2011, AM J SURG PATHOL, V35, P1776, DOI 10.1097/PAS.0b013e318235edbd; Hemminki A, 1998, NATURE, V391, P184; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hirasawa A, 2012, ANN ONCOL, V23, P2990, DOI 10.1093/annonc/mds492; Hornick JL, 2008, AM J SURG PATHOL, V32, P493, DOI 10.1097/PAS.0b013e318161dc34; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Ichimura T, 2001, INT J GYNECOL PATHOL, V20, P220, DOI 10.1097/00004347-200107000-00003; Ishihara K, 1996, BIOCHEM J, V318, P409, DOI 10.1042/bj3180409; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Italiano A, 2010, ANN ONCOL, V21, P1135, DOI 10.1093/annonc/mdq044; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jelinic P, 2016, MODERN PATHOL, V29, P60, DOI 10.1038/modpathol.2015.129; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JOHNSON AD, 1986, J AM ACAD DERMATOL, V14, P371, DOI 10.1016/S0190-9622(86)70046-7; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Karanian-Philippe M, 2015, AM J SURG PATHOL, V39, P1197, DOI 10.1097/PAS.0000000000000475; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Karnezis AN, 2016, J PATHOL, V238, P389, DOI 10.1002/path.4633; Kim J, 2017, INT J CANCER, V141, P2030, DOI 10.1002/ijc.30907; Kim MS, 2013, HISTOPATHOLOGY, V63, P435, DOI 10.1111/his.12161; Kimonis VE, 1997, AM J MED GENET, V69, P299, DOI 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M; Kiuru M, 2001, AM J PATHOL, V159, P825, DOI 10.1016/S0002-9440(10)61757-9; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kommoss F, 1998, MODERN PATHOL, V11, P656; Kondo T, 2005, MODERN PATHOL, V18, P1199, DOI 10.1038/modpathol.3800403; Krueger DA, 2013, PEDIATR NEUROL, V49, P255, DOI 10.1016/j.pediatrneurol.2013.08.002; Kupryjanczyk J, 2013, POL J PATHOL, V64, P238, DOI 10.5114/PJP.2013.39331; Kuragaki C, 2003, LAB INVEST, V83, P35, DOI 10.1097/01.LAB.0000049821.16698.D0; Kurman RJ, 2014, WHO CLASSIFICATION T; Kusanagi Y, 2010, AM J PATHOL, V177, P2169, DOI 10.2353/ajpath.2010.100323; Lele SM, 2000, MODERN PATHOL, V13, P466, DOI 10.1038/modpathol.3880079; Lewis T., 1879, LATIN DICT; Li RF, 2013, AM J SURG PATHOL, V37, P344, DOI 10.1097/PAS.0b013e31826e0271; Liang SX, 2008, INT J GYNECOL PATHOL, V27, P86, DOI 10.1097/p2p.0b013e318150df37; Lim GSD, 2011, INT J GYNECOL PATHOL, V30, P121, DOI 10.1097/PGP.0b013e3181fa5a99; LINDAU ARVID, 1927, ACTA OPHTHALMOL, V4, P193; Linehan WM, 2013, CLIN CANCER RES, V19, P3345, DOI 10.1158/1078-0432.CCR-13-0304; LLOYD KM, 1963, ANN INTERN MED, V58, P136, DOI 10.7326/0003-4819-58-1-136; Mahdi H, 2015, CANCER-AM CANCER SOC, V121, P688, DOI 10.1002/cncr.29106; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Matsubara A, 2014, AM J SURG PATHOL, V38, P370, DOI 10.1097/PAS.0000000000000093; McCluggage WG, 2017, HISTOPATHOLOGY, V70, P1147, DOI 10.1111/his.13177; McCluggage WG, 2001, HISTOPATHOLOGY, V38, P403, DOI 10.1046/j.1365-2559.2001.01147.x; McCluggage WG, 2004, INT J GYNECOL PATHOL, V23, P330, DOI 10.1097/01.pgp.0000139644.38835.9d; Menko FH, 2014, FAM CANCER, V13, P637, DOI 10.1007/s10689-014-9735-2; Merino M, 2014, MOD PATHOL, V27; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Merriam-Webster, DEF ANT; Mester J, 2015, J SURG ONCOL, V111, P125, DOI 10.1002/jso.23735; Miettinen M, 2016, AM J SURG PATHOL, V40, P1661, DOI 10.1097/PAS.0000000000000703; Mikami Y, 2004, MODERN PATHOL, V17, P962, DOI 10.1038/modpathol.3800148; Mikami Y, 2009, HISTOPATHOLOGY, V54, P184, DOI 10.1111/j.1365-2559.2008.03202.x; MONTAG TW, 1986, GYNECOL ONCOL, V25, P171, DOI 10.1016/0090-8258(86)90098-3; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagahama Kiyotaka, 2013, Gynecol Oncol Case Rep, V5, P4, DOI 10.1016/j.gynor.2013.02.005; Nara M, 2007, GYNECOL ONCOL, V106, P289, DOI 10.1016/j.ygyno.2007.03.044; National Comprehensive Cancer Network, 2016, NCCN CLIN PRACT GUID; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nishio S, 2009, PATHOL RES PRACT, V205, P331, DOI 10.1016/j.prp.2008.12.002; Nogales FF, 2012, HISTOPATHOLOGY, V60, P748, DOI 10.1111/j.1365-2559.2011.04151.x; Northrup H, 2017, GENEREVIEWS; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Oost EE, 2015, INT J GYNECOL PATHOL, V34, P266, DOI 10.1097/PGP.0000000000000150; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Peutz JLA., 1921, NEDERL MAANDSCHR GEN, V10, P134; Poulsen MLM, 2010, CLIN GENET, V77, P49, DOI 10.1111/j.1399-0004.2009.01281.x; PRAT J, 1982, CANCER, V50, P2465, DOI 10.1002/1097-0142(19821201)50:11<2465::AID-CNCR2820501135>3.0.CO;2-U; Pugh TJ, 2014, ONCOGENE, V33, P5295, DOI 10.1038/onc.2014.150; Rabban JT, 2015, AM J SURG PATHOL, V39, P1015, DOI 10.1097/PAS.0000000000000416; Rabban JT, 2013, HISTOPATHOLOGY, V62, P71, DOI 10.1111/his.12052; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Rao Q, 2013, HISTOPATHOLOGY, V62, P642, DOI 10.1111/his.12059; Rednam SP, 2017, CLIN CANCER RES, V23, pE68, DOI [10.1158/1078-0432.CCR-17-0834, 10.1158/1078-0432.CCR-17-0547]; Reyes C, 2014, MODERN PATHOL, V27, P1020, DOI 10.1038/modpathol.2013.215; Riedlinger WFJ, 2005, PEDIATR DEVEL PATHOL, V8, P427, DOI 10.1007/s10024-005-0006-y; Sanz-Ortega J, 2013, AM J SURG PATHOL, V37, P74, DOI 10.1097/PAS.0b013e31825ec16f; Schmeler KM, 2009, OBSTET GYNECOL, V114, P477, DOI 10.1097/AOG.0b013e31819dade8; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P1404, DOI 10.1097/PAS.0000000000000470; Schoolmeester JK, 2015, AM J SURG PATHOL, V39, P394, DOI 10.1097/PAS.0000000000000349; Schoolmeester JK, 2014, AM J SURG PATHOL, V38, P176, DOI 10.1097/PAS.0000000000000133; Schultz KA, 2014, AJSP-REV REP, V19, P90, DOI 10.1097/PCR.0000000000000027; Schultz KAP, 2014, PEDIATR BLOOD CANCER, V61, P1695, DOI 10.1002/pbc.25092; Schultz KAP, 2011, GYNECOL ONCOL, V122, P246, DOI 10.1016/j.ygyno.2011.03.024; Scully R E, 1976, N Engl J Med, V294, P772; SCULLY RE, 1970, CANCER, V25, P1107, DOI 10.1002/1097-0142(197005)25:5<1107::AID-CNCR2820250516>3.0.CO;2-7; Scully RE, 1979, ATLAS TUMOR PATHOLOG; Seki M, 2014, CANCER RES, V74, P2742, DOI 10.1158/0008-5472.CAN-13-2470; Silva EG, 2006, INT J GYNECOL PATHOL, V25, P52, DOI 10.1097/01.pgp.0000183048.22588.18; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Sredni ST, 2015, PEDIATR DEVEL PATHOL, V18, P49, DOI 10.2350/14-07-1531-MISC.1; Stewart Colin J R, 2016, Surg Pathol Clin, V9, P227, DOI 10.1016/j.path.2016.01.002; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Utsugi K, 1999, GYNECOL ONCOL, V75, P345, DOI 10.1006/gyno.1999.5622; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; von Hippel E, 1904, ARCH OPHTHALMOL-CHIC, V59, P83, DOI DOI 10.1007/BF01994821; Wada T, 2017, AM J SURG PATHOL, V41, P696, DOI 10.1097/PAS.0000000000000833; Wagner AJ, 2010, J CLIN ONCOL, V28, P835, DOI 10.1200/JCO.2009.25.2981; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang YM, 2015, NEOPLASIA, V17, P650, DOI 10.1016/j.neo.2015.08.003; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506; Witkowski L, 2013, BRIT J CANCER, V109, P2744, DOI 10.1038/bjc.2013.637; Witkowski L, 2016, GYNECOL ONCOL, V141, P454, DOI 10.1016/j.ygyno.2016.03.013; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Xu JY, 2005, INT J GYNECOL PATHOL, V24, P296, DOI 10.1097/01.PGP.0000157918.36354.C1; Yaegashi H, 2001, PATHOL INT, V51, P896, DOI 10.1046/j.1440-1827.2001.01289.x; Yamada Y, 2011, PATHOL INT, V61, P768, DOI 10.1111/j.1440-1827.2011.02737.x; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; YOUNG RH, 1994, AM J SURG PATHOL, V18, P1102, DOI 10.1097/00000478-199411000-00004; YOUNG RH, 1982, CANCER, V50, P2448, DOI 10.1002/1097-0142(19821201)50:11<2448::AID-CNCR2820501133>3.0.CO;2-T; YOUNG RH, 1983, AM J SURG PATHOL, V7, P755, DOI 10.1097/00000478-198307080-00005; YOUNG RH, 1985, AM J SURG PATHOL, V9, P543, DOI 10.1097/00000478-198508000-00001; Zhao CQ, 2009, AM J SURG PATHOL, V33, P354, DOI 10.1097/PAS.0b013e318188373d; Zhao SM, 2003, INT J GYNECOL PATHOL, V22, P393, DOI 10.1097/01.pgp.0000092128.10100.17; Zou Y, 2015, BIOMED REP, V3, P33, DOI 10.3892/br.2014.378	192	5	5	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	FEB	2018	50	2					238	256		10.1016/j.pathol.2017.10.009			19	Pathology	Pathology	FX8NN	WOS:000426351600012	29373116				2019-10-28	
J	Batra, K; Butt, Y; Gokaslan, T; Burguete, D; Glazer, C; Torrealba, JR				Batra, Kiran; Butt, Yasmeen; Gokaslan, Tunc; Burguete, Daniel; Glazer, Craig; Torrealba, Jose R.			Pathology and radiology correlation of idiopathic interstitial pneumonias	HUMAN PATHOLOGY			English	Article						Interstitial pneumonias; Radiology and pathology; UP; NSIP; OP; AIP; Smoking-related interstitial pneumonia	HIGH-RESOLUTION CT; THIN-SECTION CT; RESPIRATORY-DISTRESS-SYNDROME; COMPUTED-TOMOGRAPHY FINDINGS; DIFFUSE ALVEOLAR DAMAGE; PULMONARY-FIBROSIS; ORGANIZING PNEUMONIA; LUNG-DISEASE; PLEUROPARENCHYMAL FIBROELASTOSIS; HYPERSENSITIVITY PNEUMONITIS	By nature, idiopathic interstitial pneumonias have been diagnosed in a multidisciplinary manner. As classifications have been subject to significant refinement over the last decade, the importance of correlating clinical, radiologic, and pathologic information to arrive at a diagnosis, which will predict prognosis in any given patient, has become increasingly recognized. In 2013, the American Thoracic Society and European Respiratory Society updated the idiopathic interstitial pneumonias classification scheme, addressing the most recent updates in the field. The purpose of this review is to highlight the correlations between radiologic and pathologic findings in idiopathic interstitial pneumonias while using updated classification schemes and naming conventions. (C) 2017 Elsevier Inc. All rights reserved.	[Batra, Kiran] Univ Texas Southwestern, Dept Radiol, Dallas, TX 75235 USA; [Butt, Yasmeen; Gokaslan, Tunc; Torrealba, Jose R.] Univ Texas Southwestern, Dept Pathol, Dallas, TX 75235 USA; [Burguete, Daniel] Univ Texas Southwestern, Sch Med, Dallas, TX 75390 USA; [Glazer, Craig] Univ Texas Southwestern, Dept Med, Pulmonol, Dallas, TX 75390 USA	Torrealba, JR (reprint author), UT Southwestern Med Ctr, William P Clements Univ Hosp, Dept Pathol, 4-246,6201 Harry Hines Blvd, Dallas, TX 75235 USA.	jose.torrealba@utsouthwestern.edu			Dr Jose Torrealba's endowment fund "University of Texas, Southwestem Medical Center, Dallas, Texas"	The work of this manuscript has been funded by Dr Jose Torrealba's endowment fund "Drs. George and Anne Race Distinguished Professor of Pathology, University of Texas, Southwestem Medical Center, Dallas, Texas."	Akira M, 2000, THORAX, V55, P854, DOI 10.1136/thorax.55.10.854; Baqir M, 2013, RESP MED, V107, P616, DOI 10.1016/j.rmed.2013.01.005; Beasley MB, 2002, ARCH PATHOL LAB MED, V126, P1064; Becker CD, 2008, MODERN PATHOL, V21, P784, DOI 10.1038/modpathol.2008.56; Borie R, 2016, RESPIROLOGY, V21, P615, DOI 10.1111/resp.12778; Bourke SJ, 2001, EUR RESPIR J, V18, p81S; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; Chung JH, 2015, CHEST, V147, P450, DOI 10.1378/chest.14-0976; Churg A, 2014, USUAL INTERSTITIAL P, P38; COLBY TV, 1992, CHEST, V102, pS38, DOI 10.1378/chest.102.1.38S; COLEMAN A, 1988, AM J SURG PATHOL, V12, P514, DOI 10.1097/00000478-198807000-00002; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; Faria IM, 2015, J BRAS PNEUMOL, V41, P231, DOI 10.1590/S1806-37132015000004544; Fell CD, 2010, AM J RESP CRIT CARE, V181, P832, DOI 10.1164/rccm.200906-0959OC; Flaherty KR, 2003, THORAX, V58, P143, DOI 10.1136/thorax.58.2.143; Frankel SK, 2004, CHEST, V126, P2007, DOI 10.1378/chest.126.6.2007; Greenberg-Wolff I, 2005, ISR MED ASSOC J, V7, P568; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Gruden JF, 2016, AM J ROENTGENOL, V206, P495, DOI 10.2214/AJR.15.15674; Gruden JF, 2016, AM J ROENTGENOL, V206, P472, DOI 10.2214/AJR.15.14525; GUERRYFORCE ML, 1987, AM REV RESPIR DIS, V135, P705; Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712; Hansell DM, 2003, SEM RESP CRIT CARE M, V24, P377; Hansell DM, 1996, RADIOLOGY, V199, P123, DOI 10.1148/radiology.199.1.8633133; HOLT RM, 1993, J COMPUT ASSIST TOMO, V17, P46, DOI 10.1097/00004728-199301000-00007; Hunninghake GW, 2003, CHEST, V124, P1215, DOI 10.1378/chest.124.4.1215; Ichikado K, 2006, RADIOLOGY, V238, P321, DOI 10.1148/radiol.2373041515; Ichikado K, 2014, SEMIN ULTRASOUND CT, V35, P39, DOI 10.1053/j.sult.2013.10.007; Johkoh T, 1999, RADIOLOGY, V211, P555, DOI 10.1148/radiology.211.2.r99ma01555; Johkoh T, 2002, RADIOLOGY, V225, P199, DOI 10.1148/radiol.2251011555; Kadoch MA, 2015, CURR PROBL DIAGN RAD, V44, P15, DOI 10.1067/j.cpradiol.2014.07.005; Katzenstein AL, 2006, KATZENSTEIN ASKINS S, P17; Katzenstein ALA, 2002, AM J SURG PATHOL, V26, P1567, DOI 10.1097/00000478-200212000-00004; KATZENSTEIN ALA, 1986, AM J SURG PATHOL, V10, P373, DOI 10.1097/00000478-198606000-00002; KATZENSTEIN ALA, 1986, AM J SURG PATHOL, V10, P256, DOI 10.1097/00000478-198604000-00004; KATZENSTEIN ALA, 1994, AM J SURG PATHOL, V18, P136, DOI 10.1097/00000478-199402000-00003; Katzenstein ALA, 2013, J CLIN PATHOL, V66, P882, DOI 10.1136/jclinpath-2012-201338; Katzenstein ALA, 2012, MODERN PATHOL, V25, pS68, DOI 10.1038/modpathol.2011.154; Kawabata Y, 2008, HISTOPATHOLOGY, V52, P194, DOI 10.1111/j.1365-2559.2007.02930.x; Kawabata Y, 2012, RESPIROLOGY, V17, P1214, DOI 10.1111/j.1440-1843.2012.02226.x; KAWANAMI O, 1983, AM J PATHOL, V110, P275; Kligerman SJ, 2013, RADIOGRAPHICS, V33, P1951, DOI 10.1148/rg.337130057; Kokosi MA, 2016, RESPIROLOGY, V21, P600, DOI 10.1111/resp.12693; Lee JS, 1998, J THORAC IMAG, V13, P199, DOI 10.1097/00005382-199807000-00007; Lohr RH, 1997, ARCH INTERN MED, V157, P1323, DOI 10.1001/archinte.157.12.1323; Lynch DA, 2005, RADIOLOGY, V236, P10, DOI 10.1148/radiol.2361031674; MacDonald SLS, 2001, RADIOLOGY, V221, P600, DOI 10.1148/radiol.2213010158; Martinez FJ, 2017, LANCET RESP MED, V5, P61, DOI 10.1016/S2213-2600(16)30325-3; Meyer KC, 2015, PNEUMONIA, V6, P67, DOI 10.15172/pneu.2015.6/648; Mueller-Mang C, 2007, RADIOGRAPHICS, V27, P595, DOI 10.1148/rg.273065130; MULLER NL, 1987, RADIOLOGY, V162, P151; Myers JL, 1998, EUR RESPIR J, V12, P1003, DOI 10.1183/09031936.98.12051003; Nagao T, 2001, RESPIRATION, V68, P151, DOI 10.1159/000050485; Noh HJ, 2014, TUBERC RESPIR DIS, V77, P184, DOI 10.4046/trd.2014.77.4.184; Obadina ET, 2013, BRIT J RADIOL, V86, DOI 10.1259/bjr.20120614; Piciucchi S, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-111; Raghu G, 2014, LANCET RESP MED, V2, P277, DOI 10.1016/S2213-2600(14)70011-6; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Reddy Taryn L, 2013, Ann Am Thorac Soc, V10, P590, DOI 10.1513/AnnalsATS.201304-088OC; Reddy TL, 2012, EUR RESPIR J, V40, P377, DOI 10.1183/09031936.00165111; REMYJARDIN M, 1993, RADIOLOGY, V189, P693, DOI 10.1148/radiology.189.3.8234692; Rosenbaum JN, 2015, HUM PATHOL, V46, P137, DOI 10.1016/j.humpath.2014.10.007; Ryerson CJ, 2013, EUR RESPIR J, V42, P750, DOI 10.1183/09031936.00131912; Ryu JH, 2001, EUR RESPIR J, V17, P122, DOI 10.1183/09031936.01.17101220; Silva CIS, 2008, RADIOLOGY, V246, P288, DOI 10.1148/radiol.2453061881; Silva CIS, 2007, AM J ROENTGENOL, V188, P334, DOI 10.2214/AJR.05.1826; Silva CIS, 2006, J THORAC IMAG, V21, P241, DOI 10.1097/01.rti.0000213554.61752.73; Souza CA, 2005, AM J ROENTGENOL, V185, P1531, DOI 10.2214/AJR.04.1599; Sumikawa H, 2014, RADIOLOGY, V272, P549, DOI 10.1148/radiol.14130853; Takishima T, 1994, BASIC CLIN ASPECTS P, P463; Tomiyama N, 2001, J COMPUT ASSIST TOMO, V25, P28, DOI 10.1097/00004728-200101000-00005; TORII K, 1994, INTERNAL MED, V33, P237; Travis WD, 2008, AM J RESP CRIT CARE, V177, P1338, DOI 10.1164/rccm.200611-1685OC; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Ujita M, 2004, RADIOLOGY, V232, P757, DOI 10.1148/radiol.2323031059; Vassallo R, 2003, CHEST, V124, P1199, DOI 10.1378/chest.124.4.1199; Vassallo R, 2008, SEMIN RESP CRIT CARE, V29, P643, DOI 10.1055/s-0028-1101274; von der Thusen JH, 2011, MODERN PATHOL, V24, P1633, DOI 10.1038/modpathol.2011.114; Walsh SLF, 2016, THORAX, V71, P45, DOI 10.1136/thoraxjnl-2015-207252; Walsh SLF, 2015, CURR OPIN PULM MED, V21, P407, DOI 10.1097/MCP.0000000000000178; Watadani T, 2013, RADIOLOGY, V266, P936, DOI 10.1148/radiol.12112516; Wild LG, 2001, J INVEST ALLERG CLIN, V11, P3; Wright JL, 2011, HISTOPATHOLOGY, V58, P517, DOI 10.1111/j.1365-2559.2010.03648.x; Yousem SA, 2006, MODERN PATHOL, V19, P1474, DOI 10.1038/modpathol.3800671; ZERHOUNI E, 1989, CHEST, V95, P901, DOI 10.1378/chest.95.4.901	85	2	2	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						1	17		10.1016/j.humpath.2017.11.009			17	Pathology	Pathology	FX4EC	WOS:000426024500001	29180253				2019-10-28	
J	Nonaka, D; Papaxoinis, G; Lamarca, A; Fulford, P; Valle, J; Chakrabarty, B				Nonaka, Daisuke; Papaxoinis, George; Lamarca, Angela; Fulford, Paul; Valle, Juan; Chakrabarty, Bipasha			A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related adenocarcinoma)	HUMAN PATHOLOGY			English	Article						Goblet cell carcinoid; Crypt cell adenocarcinoma; Appendix; Mucinous; Neuroendocrine; Amphophilic	VERMIFORM APPENDIX; ENDOCRINE DIFFERENTIATION; GASTRIC-CARCINOMA; ARGYROPHIL CELLS; TUMORS; ARGENTAFFIN; PREVALENCE; FEATURES; BEHAVIOR	Goblet cell carcinoids (GCCs) of the appendix are rare tumors, characterized by a carcinoid-like organoid growth pattern. Despite the term carcinoid, neuroendocrine features are inconspicuous, and its behavior is distinct from carcinoid. Its high-grade counterpart is designated as adenocarcinoma ex GCC. We conducted a retrospective study of 105 tumors to find prognostic values of a variety of clinicopathologic features. The tumors were subclassified as low grade, equivalent to classic type, and high grade, defined as loss of organoid pattern, and a proportion (%) of low and high grades were documented in each tumor. Correlations between survival and various clinicopathologic parameters were investigated. One-third were pure low grade, while the remainder contained variable high-grade component ranging from 5% to 95%. Neuroendocrine cell component ranged from 0% to 90% (median, 5), while mucus cell component ranged from 5% to 100% (median, 70). By univariate analysis, size, stage, high-grade component, nuclear grade, surgery, and chemotherapy correlated with cancer-related survival (CSS), and by multivariate analysis, stage (P = .001), high-grade component (P = .008), and tumor size (P = .005) correlated with CSS. There was significant difference in CSS when the cases were grouped by high-grade component: <40%, 40% to 90%, and <= 90% (P < .001). Our results indicate that staging and proportion of high-grade histology may provide important prognostic information. Neuroendocrine component was insignificant in both low- and high-grade areas. In light of our findings, this tumor type is best regarded as a variant of adenocarcinoma, and the term crypt cell adenocarcinoma more appropriately reflects the nature and origin of this tumor group. (C) 2017 Elsevier Inc. All rights reserved.	[Nonaka, Daisuke; Chakrabarty, Bipasha] Christie NHS Fdn Trust, Dept Histopathol, Manchester M20 4BX, Lancs, England; [Nonaka, Daisuke] Univ Manchester, Inst Canc Sci, Manchester M20 4BX, Lancs, England; [Papaxoinis, George; Lamarca, Angela; Valle, Juan] Christie NHS Fdn Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England; [Fulford, Paul] Christie NHS Fdn Trust, Dept Surg, Manchester M20 4BX, Lancs, England; [Valle, Juan] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Canc Studies, Manchester M20 4BX, Lancs, England	Nonaka, D (reprint author), St Thomas Hosp, Dept Cellular Pathol, 2nd Floor,North Wing,Westminster Bridge Rd, London SE1 7EH, England.	DNonaka@msn.com		Papaxoinis, George/0000-0001-6900-784X	Spanish Society of Medical Oncology (SEOM) Translational Fellowship grant; Hellenic Society of Medical Oncology (HeSMO)	A.L. was partially funded by a Spanish Society of Medical Oncology (SEOM) Translational Fellowship grant.; G.P. was awarded a grant from the Hellenic Society of Medical Oncology (HeSMO).	ABT AB, 1976, ARCH PATHOL LAB MED, V100, P301; ANDERSON NH, 1991, HISTOPATHOLOGY, V18, P61, DOI 10.1111/j.1365-2559.1991.tb00815.x; AZZOPARDI JG, 1963, J PATHOL BACTERIOL, V86, P443, DOI 10.1002/path.1700860219; BURKE AP, 1990, AM J CLIN PATHOL, V94, P27, DOI 10.1093/ajcp/94.1.27; CAPELLA C, 1980, HISTOPATHOLOGY, V4, P613, DOI 10.1111/j.1365-2559.1980.tb02957.x; Carr NJ, 2010, WHO CLASSIFICATION T, P119; COOPER PH, 1978, CANCER, V42, P2687, DOI 10.1002/1097-0142(197812)42:6<2687::AID-CNCR2820420625>3.0.CO;2-6; EDMONDS P, 1984, GASTROENTEROLOGY, V86, P302; GAGNE F, 1969, Annales d'Anatomie Pathologique, V14, P393; GIBBS NM, 1967, J CLIN PATHOL, V20, P826, DOI 10.1136/jcp.20.6.826; Hristov AC, 2007, AM J SURG PATHOL, V31, P1502, DOI 10.1097/PAS.0b013e31804f7aa1; Huang B, 2016, WORLD J GASTROENTERO, V22, P6726, DOI 10.3748/wjg.v22.i29.6726; ISAACSON P, 1981, AM J SURG PATHOL, V5, P213, DOI 10.1097/00000478-198104000-00001; Kanthan R, 2001, ARCH PATHOL LAB MED, V125, P386; KLEIN HZ, 1974, CANCER, V33, P770, DOI 10.1002/1097-0142(197403)33:3<770::AID-CNCR2820330324>3.0.CO;2-J; Lee LH, 2015, HUM PATHOL, V46, P1881, DOI 10.1016/j.humpath.2015.08.005; Olsen IH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117627; OOI A, 1988, CANCER, V62, P1096, DOI 10.1002/1097-0142(19880915)62:6<1096::AID-CNCR2820620612>3.0.CO;2-T; PARK K, 1990, GUT, V31, P322, DOI 10.1136/gut.31.3.322; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Rosai J, 2011, ROSAI ACKERMANS SURG, P714; SMITH DM, 1984, AM J SURG PATHOL, V8, P123, DOI 10.1097/00000478-198402000-00006; SUBBUSWAMY SG, 1974, CANCER-AM CANCER SOC, V34, P338, DOI 10.1002/1097-0142(197408)34:2<338::AID-CNCR2820340218>3.0.CO;2-W; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Toumpanakis C, 2007, DIS COLON RECTUM, V50, P315, DOI 10.1007/s10350-006-0762-4; ULICH TR, 1983, CANCER, V51, P1483, DOI 10.1002/1097-0142(19830415)51:8<1483::AID-CNCR2820510822>3.0.CO;2-J; van Eeden S, 2007, HISTOPATHOLOGY, V51, P763, DOI 10.1111/j.1365-2559.2007.02883.x; Waldum HL, 1998, CANCER, V83, P435, DOI 10.1002/(SICI)1097-0142(19980801)83:3<435::AID-CNCR11>3.0.CO;2-X; Wang HLL, 2009, ADV ANAT PATHOL, V16, P247, DOI 10.1097/PAP.0b013e3181a9d49a; WARKEL RL, 1978, CANCER, V42, P2781, DOI 10.1002/1097-0142(197812)42:6<2781::AID-CNCR2820420638>3.0.CO;2-B; WARNER TFCS, 1979, CANCER, V44, P1700, DOI 10.1002/1097-0142(197911)44:5<1700::AID-CNCR2820440525>3.0.CO;2-T; WATSON PH, 1987, VIRCHOWS ARCH A, V412, P175, DOI 10.1007/BF00716191; WOLFF M, 1976, CANCER, V37, P2493, DOI 10.1002/1097-0142(197605)37:5<2493::AID-CNCR2820370543>3.0.CO;2-D; Wood DA, 1967, TUMORS INTESTINE, P177	35	3	3	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						18	27		10.1016/j.humpath.2017.08.005			10	Pathology	Pathology	FX4EC	WOS:000426024500002	28823572				2019-10-28	
J	Karnik, T; Kimler, BF; Fan, F; Tawfik, O				Karnik, Tejashree; Kimler, Bruce F.; Fan, Fang; Tawfik, Ossama			PD-L1 in breast cancer: comparative analysis of 3 different antibodies	HUMAN PATHOLOGY			English	Article						Breast cancer; Invasive ductal carcinoma; Programmed cell death ligand-1; lmmunohistochemistry; Comparative analysis; Three antibodies	TUMOR-INFILTRATING LYMPHOCYTES; LIGAND 1 EXPRESSION; CELL LUNG-CANCER; POOR-PROGNOSIS; PATHWAY; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; METAANALYSIS; ACTIVATION	The interaction of programmed cell death-1 and its ligand-1 (PD-L1) serves as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of 3 different PD-L1 antibodies (Ventana SP263, Dako 22C3, and BioCare RbMCAL10 antibodies) in 136 invasive ductal carcinoma specimens including 43 primary, 48 locally metastatic, and 46 distantly metastatic diseases. PD-L1 expression was correlated with clinicopathologic parameters including tumor size, grade, lymphovascular invasion, estrogen receptor, progesterone receptor, HER2, Ki67, molecular type, and triple-negative status. There was excellent agreement between the 3 antibodies, with highly significant kappa values (P <= .001). PD-L1 expression was more likely to be associated with higher tumor grade and estrogen receptor negative, progesterone receptor negative, triple-negative, and highly proliferative tumors (P <= .001). When we studied PD-L1 expression at 0, 1%-9%, 10%-49%, and >= 50% cutoff points by the 3 antibodies, there were 20 discordant cases between the antibodies. Sixteen were of inconsequential impact as far as low and high PD-L1 expression. The 4 differences between antibodies did exhibit an interesting pattern of expression, where there was a general agreement between the BioCare and Ventana antibodies with consistently higher PD-L1 expression compared with the Dako antibody. Given the high concordance, it is not surprising that all 3 antibodies demonstrated the same associations with all pathologic and clinical parameters studied. Standardization studies to identify reliable biomarkers that help in patient selection for immune therapy to improve the risk-benefit ratio for these drugs are still needed. (C) 2017 Elsevier Inc. All rights reserved.	[Karnik, Tejashree; Fan, Fang; Tawfik, Ossama] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA; [Kimler, Bruce F.] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66160 USA	Tawfik, O (reprint author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	otawfik@kumc.edu					Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Baptista MZ, 2016, HUM PATHOL, V47, P78, DOI 10.1016/j.humpath.2015.09.006; Beckers RK, 2016, HISTOPATHOLOGY, V69, P25, DOI 10.1111/his.12904; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Dill EA, 2017, AM J SURG PATHOL, V41, P334, DOI 10.1097/PAS.0000000000000780; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Ghebeh H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-57; Ghebeh H, 2006, NEOPLASIA, V8, P190, DOI 10.1593/neo.05733; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8; Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Mori H, 2017, ONCOTARGET, V8, P15584, DOI 10.18632/oncotarget.14698; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Park IH, 2016, CLIN BREAST CANCER, V16, P51, DOI 10.1016/j.clbc.2015.07.006; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Soliman H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088557; Sun WY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0925-6; Wang CJ, 2017, BREAST J, V23, P436, DOI 10.1111/tbj.12753; Yaziji H, 2017, APPL IMMUNOHISTO M M, V25, P1, DOI 10.1097/PAI.0000000000000472	31	5	5	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						28	34		10.1016/j.humpath.2017.08.010			7	Pathology	Pathology	FX4EC	WOS:000426024500003	28843709				2019-10-28	
J	Nasri, E; Wiesen, LB; Knapik, JA; Fredenburg, KM				Nasri, Elham; Wiesen, Lisa B.; Knapik, Jacquelyn A.; Fredenburg, Kristianna M.			Eps8 expression is significantly lower in p16(+) head and neck squamous cell carcinomas (HNSCCs) compared with p16(-) HNSCCs	HUMAN PATHOLOGY			English	Article						EGFR; Eps8; Oropharyngeal squamous cell carcinoma; Oral cavity squamous cell carcinoma; p16	OROPHARYNGEAL CANCER; PROGNOSTIC-SIGNIFICANCE; HUMAN-PAPILLOMAVIRUS; SURVIVAL; EGFR; OVEREXPRESSION; GROWTH; TRANSFORMATION; ACTIVATION; MOTILITY	In vitro head and neck cancer studies have demonstrated that epidermal growth factor receptor kinase substrate 8 (Eps8) overexpression contributes to squamous carcinogenesis. Oral squamous cell carcinoma studies have correlated Eps8 expression with metastatic disease and poor prognosis. Head and neck squamous cell carcinoma (HNSCC) studies comparing its expression by anatomic site or in in vivo regional metastases have not been performed. In this study, we compared Eps8 expression in HNSCCs arising in the oral cavity (OCSCC) and oropharynx (OPSCC) along with their corresponding regional lymph node (LN) metastases. We then correlated our findings with clinicopathologic data including tumor-node-metastasis stage, p16 status, age, sex, and smoking and alcohol history. Eps8 immunohistochemistry was performed on 69 archived OCSCCs and OPSCCs, and 24 paired and 4 unpaired LNs. Expression was scored from 0 to 3. Eps8 expression was detected in 49% of combined OCSCC and OPSCC cases. We found that expression correlated with advanced tumor stage (P = .022) and p16 status (P = .032) but not with anatomic site. Notably, p16(+) HNSCCs had significantly lower Eps8 expression than p16(-) HNSCCs. No significant difference was observed between primary HNSCCs and their corresponding metastatic LNs. Neither p16 status nor anatomic site influenced Eps8 expression in regional LN metastases. In conclusion, our data offer in vivo support that, in HNSCCs, Eps8 is involved in tumor invasion but not necessarily the development of regional LN metastasis. The association between low Eps8 expression and p16(+) HNSCCs suggests that alternative signaling pathways may be used for their tumorigenesis. (C) 2017 Elsevier Inc. All rights reserved.	[Nasri, Elham; Wiesen, Lisa B.; Knapik, Jacquelyn A.; Fredenburg, Kristianna M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	Fredenburg, KM (reprint author), Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.	kfredenburg@ufl.edu					Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Chen YJ, 2008, MOL CANCER THER, V7, P1376, DOI 10.1158/1535-7163.MCT-07-2388; Chu PY, 2012, ASIA-PAC J CLIN ONCO, V8, pE77, DOI 10.1111/j.1743-7563.2011.01459.x; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Fischer CA, 2010, ANN ONCOL, V21, P1961, DOI 10.1093/annonc/mdq210; Harris SL, 2011, HEAD NECK-J SCI SPEC, V33, P1622, DOI 10.1002/hed.21650; Hertzog M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000387; Hong A, 2010, EUR J CANCER, V46, P2088, DOI 10.1016/j.ejca.2010.04.016; Kumar B, 2008, J CLIN ONCOL, V26, P3128, DOI 10.1200/JCO.2007.12.7662; Langendijk JA, 2010, ANN ONCOL, V21, P1931, DOI 10.1093/annonc/mdq439; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2013, CARCINOGENESIS, P87; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Reimers N, 2007, INT J CANCER, V120, P1731, DOI 10.1002/ijc.22355; Sgaramella N, 2015, BRIT J CANCER, V113, P321, DOI 10.1038/bjc.2015.207; Shah NG, 2009, HEAD NECK-J SCI SPEC, V31, P1544, DOI 10.1002/hed.21126; Singhi AD, 2010, CANCER-AM CANCER SOC, V116, P2166, DOI 10.1002/cncr.25033; Wang HX, 2009, CARCINOGENESIS, V30, P165, DOI 10.1093/carcin/bgn252; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Yap LF, 2009, ONCOGENE, V28, P2524, DOI 10.1038/onc.2009.105	25	5	5	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						45	51		10.1016/j.humpath.2017.10.021			7	Pathology	Pathology	FX4EC	WOS:000426024500005	29107665				2019-10-28	
J	Bean, GR; Wen, KW; Horvai, AE				Bean, Gregory R.; Wen, Kwun Wah; Horvai, Andrew E.			Adipocyte size variability in benign and malignant lipomatous tumors and morphologic mimics: a quantitative definition using digital pathology	HUMAN PATHOLOGY			English	Article						Alt/WDL; Lipoma; Adipocyte; Digital pathology; Whole-slide scanning; Image analysis	IMAGE-ANALYSIS; MOLECULAR PATHOLOGY; ADIPOSE-TISSUE; LIPOSARCOMAS; MDM2; AMPLIFICATION; CELLULARITY; DIAGNOSIS; UTILITY; CELLS	Among well-differentiated lipomatous lesions, variability in adipocyte size has been proposed as a morphologic feature of malignancy. Specifically, normal adipose tissue and benign lipomas tend to contain adipocytes of uniform size, whereas atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) is described as containing adipocytes with a conspicuous variation in cell size. However, this proposed variance has never been objectively, quantitatively correlated with diagnosis. Using whole-slide scanning combined with semiautomated digital image analysis, we aimed to quantitatively test the hypothesis that variance in adipocyte size is a feature of malignancy in well-differentiated lipomatous tumors. Whole-slide scanning was performed on representative hematoxylin and eosin stained slides selected from 130 cases representing benign (lipoma, spindle cell lipoma) and malignant lipomatous neoplasms (ALT/WDL) and morphologic mimics (normal adipose tissue, fat necrosis, fat atrophy). A previously validated, open source software package (Fiji-based Adiposoft) was used in semiautomated analysis of adipocyte size from a representative 1-cm(2) portion of each slide. Median, range, and variance of cell sizes were compared across all diagnoses. Fat atrophy demonstrated smaller adipocyte cell size compared with other diagnoses. Among the remaining diagnostic groups, no significant differences were identified in adipocyte size or variance by objective quantitative morphologic analysis. However, the maximum range of adipocyte size was significantly higher in ALT/WDL than conyentional lipoma and spindle cell lipoma. These data quantitate the morphology of ALT/WDL and its mimics and more specifically define the somewhat subjective "variability" of cell size as maximum range, rather than variance, of adipocyte size. (C) 2017 Elsevier Inc. All rights reserved.	[Bean, Gregory R.; Wen, Kwun Wah; Horvai, Andrew E.] Univ San Francisco UCSF, Dept Pathol, San Francisco, CA 94143 USA	Bean, GR (reprint author), Univ Calif San Francisco, Dept Pathol, 1825 4th St,M2372, San Francisco, CA 94143 USA.	gregory.bean@ucsf.edu					Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Chen HC, 2002, J LIPID RES, V43, P986; Clay MR, 2015, AM J SURG PATHOL, V39, P1433, DOI 10.1097/PAS.0000000000000468; Dei Tos A P, 2000, Ann Diagn Pathol, V4, P252, DOI 10.1053/adpa.2000.8133; Dei Tos AP, 2014, HISTOPATHOLOGY, V64, P38, DOI 10.1111/his.12311; DEITOS AP, 2013, WHO CLASSIFICATION T, V4, P33; Dessauvagie BF, 2015, PATHOLOGY, V47, P329, DOI 10.1097/PAT.0000000000000248; Dietel M, 2015, CANCER GENE THER, V22, P417, DOI 10.1038/cgt.2015.39; Dietel M, 2016, ONCOL RES TREAT, V39, P804, DOI 10.1159/000453085; Downs-Kelly E, 2008, AM J SURG PATHOL, V32, P8, DOI 10.1097/PAS.0b013e3181578d5a; Fagerland MW, 2009, STAT MED, V28, P1487, DOI 10.1002/sim.3561; Fukushima M, 2017, AM J SURG PATHOL, V41, P153, DOI 10.1097/PAS.0000000000000737; Galarraga M, 2012, J LIPID RES, V53, P2791, DOI 10.1194/jlr.D023788; Hameed M, 2007, CYTOGENET GENOME RES, V118, P138, DOI 10.1159/000108294; Hamilton PW, 2014, METHODS, V70, P59, DOI 10.1016/j.ymeth.2014.06.015; HIRSCH J, 1969, J LIPID RES, V10, P77; Hisaoka Masanori, 2014, J UOEH, V36, P115; Howat WJ, 2015, J PATHOL CLIN RES, V1, P18, DOI 10.1002/cjp2.3; Lee YH, 2004, J LIPID RES, V45, P1162, DOI 10.1194/jlr.D300028-JLR200; MARONI BJ, 1990, J LIPID RES, V31, P1703; McLaugblin T, 2007, DIABETOLOGIA, V50, P1707, DOI 10.1007/s00125-007-0708-y; Osman OS, 2013, ADIPOCYTE, V2, P160, DOI 10.4161/adip.24652; Powers MP, 2010, MODERN PATHOL, V23, P1307, DOI 10.1038/modpathol.2010.118; Shimada S, 2006, HUM PATHOL, V37, P1123, DOI 10.1016/j.humpath.2006.04.010; Thway K, 2012, AM J SURG PATHOL, V36, P462, DOI 10.1097/PAS.0b013e3182417330; Wang YG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023495; Yang J, 2012, OBESITY, V20, P932, DOI 10.1038/oby.2011.371	27	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						52	58		10.1016/j.humpath.2017.10.030			7	Pathology	Pathology	FX4EC	WOS:000426024500006	29128479				2019-10-28	
J	Zhang, J; Sun, J; Zhang, ZW; Liang, XL; Luo, YF; Wu, SF; Liang, ZY				Zhang, Jing; Sun, Jian; Zhang, Zhiwen; Liang, Xiaolong; Luo, Yufeng; Wu, Shafei; Liang, Zhiyong			Protein overexpression and gene amplification of cellular mesenchymal-epithelial transition factor is associated with poor prognosis in micropapillary-predominant subtype pulmonary adenocarcinoma	HUMAN PATHOLOGY			English	Article						Cellular mesenchymal-epithelial transition factor; Gene amplification; Micropapillary; Pulmonary adenocarcinoma; Prognosis	C-MET; LUNG-CANCER; EXPRESSION; CARCINOMA; SURVIVAL; PATTERN	Micropapillary-predominant subtype pulmonary adenocarcinoma (MPPAC) is a subtype of lung cancer with poor prognosis. Cellular mesenchymal-epithelial transition factor (c-MET) is a promising pharmaceutic target found to be associated with the survival of patients with pulmonary adenocarcinoma. In this study, we aimed to analyze c-MET protein overexpression and gene amplification in MPPAC samples and to elucidate their relationship with the clinicopathological characteristics of the patients. c-MET protein expression was examined by immunohistochemical analyses, and gene amplification was detected by fluorescence in situ hybridization. A total of 86 MPPAC cases were included in this study. The prevalence of c-MET protein overexpression and gene amplification were 62.8% and 10.5%, respectively. C-MET protein overexpression was significantly associated with smoking status, lymphatic and venous invasion, and tumor-node-metastasis stage (P = .014, P = .040, and P = .004, respectively), but c-MET gene amplification showed no relation with any of these characteristics. Univariate analysis revealed that pleural invasion, lymph node metastasis, lymphatic and venous invasion, tumor-node-metastasis stage, c-MET protein over expression, and c-MET gene amplification were associated with poor prognosis (P = .041, P < .001,P = .001, P <.001, P =.001 and P =.001, respectively), but only c-MET gene amplification was an independent prognostic marker (P = .04). These results indicated that c-MET is an important biomarker. Also, c-MET protein overexpression and gene amplification are highly related to poor prognosis in patients with MPPAC. (C) 2017 Elsevier Inc. All rights reserved.	[Liang, Zhiyong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China	Liang, ZY (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China.; Liang, ZY (reprint author), Peking Union Med Coll, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China.	liangzhiyong1220@yahoo.com		Sun, Jian/0000-0003-4997-2604	Chinese Academy of Medical Science Innovation Fund for Medical Science, Beijing, China [2016-I2M-1-002]	The work was supported by Chinese Academy of Medical Science Innovation Fund for Medical Science (grant 2016-I2M-1-002), Beijing, China.	Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689; Bendinelli P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.403; Cannistraci A, 2017, ONCOGENE, V36, P3718, DOI 10.1038/onc.2016.505; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; COOPER CS, 1984, CANCER RES, V44, P1; Dai CY, 2017, AM J SURG PATHOL, V41, P1212, DOI 10.1097/PAS.0000000000000901; Koga K, 2013, LUNG CANCER, V82, P413, DOI 10.1016/j.lungcan.2013.09.005; Ren XY, 2016, TUMOR BIOL, V37, P11385, DOI 10.1007/s13277-016-5010-5; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Sun WZ, 2013, ONCOTARGETS THER, V6, P1315, DOI 10.2147/OTT.S50428; Sun WZ, 2013, J BIOMED RES, V27, P220, DOI 10.7555/JBR.27.20130004; Szturz P, 2017, CRIT REV ONCOL HEMAT, V111, P39, DOI 10.1016/j.critrevonc.2017.01.004; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wohlschlager J, 2010, PATHOLOGE, V31, P355, DOI 10.1007/s00292-010-1303-4; Zhang J, 2011, HISTOPATHOLOGY, V59, P1204, DOI 10.1111/j.1365-2559.2011.04050.x; Zhang SW, 2016, STEM CELLS INT, DOI 10.1155/2016/4810734	17	0	0	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						59	65		10.1016/j.humpath.2017.10.031			7	Pathology	Pathology	FX4EC	WOS:000426024500007	29128478				2019-10-28	
J	Lubin, DJ; Mick, R; Shroff, SG; Stashek, K; Furth, EE				Lubin, Daniel J.; Mick, Rosemarie; Shroff, Stuti G.; Stashek, Kristen; Furth, Emma E.			The notch pathway is activated in neoplastic progression in esophageal squamous cell carcinoma	HUMAN PATHOLOGY			English	Article						Surgical pathology; Notch signaling; Esophageal squamous cell carcinoma; Carcinogenesis; Overall survival	CHROMOSOMAL TRANSLOCATIONS; LYMPHOBLASTIC NEOPLASMS; GENE; ADENOCARCINOMA; CANCER	The Notch signaling pathway is integral to normal human development and homeostasis and has a deterministic function on cell differentiation. Recent studies suggest aberrant Notch signaling may contribute to neoplastic progression by an increase in stem cell survival, chemoresistance, and the promotion of epithelial-to-mesenchymal transition. The goals of our study were to determine, utilizing quantitative technologies, the expression of activated Notch 1 in esophageal squamous cell carcinoma (SCC) and to determine the relationship between Notch 1 expression and various clinicopathologic parameters. Immunohistochemical staining for Notch intracellular domain (NICD) was performed on 60 consecutive cases of esophageal squamous cell carcinoma, 42 cases of benign esophageal squamous epithelium, and 13 cases of eosinophilic esophagitis diagnosed in our department from 2007 through 2015, and exact nuclear staining and nuclear characteristics were graded using the Vectra imaging system. Clinicopathologic data (gender, age at diagnosis, smoking status, tumor grade, tumor stage, tumor location, and survival) were collected for each SCC case and these were correlated with NICD staining. Cases of esophageal SCC demonstrated significantly higher NICD staining compared to cases of benign and reactive esophageal epithelium (P = .003 and .005, respectively). Among cases of esophageal SCC, nuclear NICD staining was significantly correlated with both tumor grade and stage. Following classification and regression tree analysis, esophageal SCC patients with increased NICD expression were found to be more likely to die from their disease than those with lower levels of expression. Taken together, the findings suggest that increased Notch 1 may contribute to the development and aggressiveness of esophageal SCC. (C) 2017 Elsevier Inc. All rights reserved.	[Lubin, Daniel J.; Shroff, Stuti G.; Stashek, Kristen; Furth, Emma E.] Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; [Mick, Rosemarie] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	Lubin, DJ (reprint author), Hosp Univ Penn, 6 Founders,3400 Spruce St, Philadelphia, PA 19104 USA.	Daniel.Lubin@uphs.upenn.edu					Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Forghanifard MM, 2012, ANN SURG ONCOL, V19, P743, DOI 10.1245/s10434-011-2074-8; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Huang JY, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-84; Morgan TH, 1917, AM NAT, V51, P513, DOI 10.1086/279629; Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316; Penton AL, 2012, SEMIN CELL DEV BIOL, V23, P450, DOI 10.1016/j.semcdb.2012.01.010; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; Taleb Shaghayegh, 2014, J Gastrointest Cancer, V45, P466, DOI 10.1007/s12029-014-9648-1; Wang T, 2013, TUMOUR BIOL J INT SO, V35, P1193; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106	15	5	7	3	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						66	70		10.1016/j.humpath.2017.11.004			5	Pathology	Pathology	FX4EC	WOS:000426024500008	29137934				2019-10-28	
J	Garcia, Y; Collins, AB; Stone, JR				Garcia, Yessica; Collins, A. Bernard; Stone, James R.			Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis	HUMAN PATHOLOGY			English	Article						AL amyloidosis; ATTR amyloidosis; Diagnostic rest; Sensitivity; Serum-free light chain; Biopsy size	IMMUNOGLOBULIN LIGHT-CHAIN; FINE-NEEDLE-ASPIRATION; SALIVARY-GLAND BIOPSY; RETROSPECTIVE ANALYSIS; CARDIAC AMYLOIDOSIS; TISSUE; AL; NOMENCLATURE; SECONDARY; PROTEIN	In the past, the diagnosis and typing of amyloidosis often required an invasive biopsy of an internal organ, such as the heart or kidneys. Abdominal fat pad excisional biopsy (FPEB) offers a less invasive approach, but the sensitivity of this technique has been unclear. To determine the sensitivity of FPEB for immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, we performed a retrospective clinicopathologic analysis of 97 patients who had undergone FPEB, of which 16 were positive for amyloid. The most significant pretest feature predicting a positive FPEB was a serum free light chain kappa/lambda ratio less than .5, and in this group of patients the probability of a positive biopsy was dependent on the size of the biopsy (P = .004). In FPEBs, the amyloid was present in multiple distinct patterns: pericellular, septal, medium-sized vessel, small vessel, and nodular. For patients with AL amyloidosis for which direct typing was attempted using the FPEB tissue, the amyloid was successfully typed in the FPEB in 90% of cases. The overall sensitivity of FPEB was 79% for AL amyloidosis and 12% for ATTR amyloidosis (P = .0003). In patients with AL amyloidosis, the sensitivity of FPEB was dependent on biopsy size, with small biopsies (<= 700 mm(3)) having a sensitivity of similar to 50%, and large biopsies (>700 mm(3)) having a sensitivity of similar to 100%. This study demonstrates that FPEB has high sensitivity for AL amyloidosis, and can be routinely used to type the amyloid. However, FPEB has low sensitivity for ATTR amyloidosis in our patient population. (C) 2017 Elsevier Inc. All rights reserved.	[Garcia, Yessica; Collins, A. Bernard; Stone, James R.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA	Stone, JR (reprint author), Massachusetts Gen Hosp, 149 13th St,Room 7368, Charlestown, MA 02129 USA.	jrstone@partners.org			Massachusetts General Hospital	This work was supported by Massachusetts General Hospital. There are no sources of external funding and no conflicts of interest to report.	Alishiri GH, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-43; Ansari-Lari MA, 2004, DIAGN CYTOPATHOL, V30, P178, DOI 10.1002/dc.10370; Bartle L, 1993, ARCH MED RES, V24, P189; Bogov B, 2008, HIPPOKRATIA, V12, P236; BREEDVELD FC, 1989, CLIN EXP RHEUMATOL, V7, P407; Collins AB, 2009, CARDIOVASC PATHOL, V18, P205, DOI 10.1016/j.carpath.2008.05.004; Falk RH, 2005, CIRCULATION, V112, P2047, DOI 10.1161/CIRCULATIONAHA.104.489187; Fine NM, 2014, AM J CARDIOL, V113, P1723, DOI 10.1016/j.amjcard.2014.02.030; GERTZ MA, 1988, ARCH INTERN MED, V148, P929, DOI 10.1001/archinte.148.4.929; Gillmore JD, 2016, CIRCULATION, V133, P2404, DOI 10.1161/CIRCULATIONAHA.116.021612; HACHULLA E, 1993, ARTHRITIS RHEUM, V36, P691, DOI 10.1002/art.1780360518; Halushka MK, 2015, J CARDIOVASC TRANSL, V8, P264, DOI 10.1007/s12265-015-9628-2; Ikeda S, 2011, AMYLOID, V18, P211, DOI 10.3109/13506129.2011.623199; Kourelis TV, 2017, BLOOD, V129, P299, DOI 10.1182/blood-2016-10-743997; LEE JG, 1994, SOUTHERN MED J, V87, P243, DOI 10.1097/00007611-199402000-00019; LIPSCHUTZ JH, 1995, AM J NEPHROL, V15, P431, DOI 10.1159/000168878; Maleszewski JJ, 2015, CARDIOVASC PATHOL, V24, P343, DOI 10.1016/j.carpath.2015.07.008; Maleszewski JJ, 2013, CARDIOVASC PATHOL, V22, P189, DOI 10.1016/j.carpath.2012.09.001; MALLINSON WJW, 1987, POSTGRAD MED J, V63, P105, DOI 10.1136/pgmj.63.736.105; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Olsen KE, 1999, AM J CLIN PATHOL, V111, P355; Olsen KE, 1998, BIOCHEM BIOPH RES CO, V245, P713, DOI 10.1006/bbrc.1998.8515; Paccalin M, 2005, AMYLOID, V12, P239, DOI 10.1080/13506120500351174; PELLIKKA PA, 1988, ARCH INTERN MED, V148, P662, DOI 10.1001/archinte.148.3.662; Rapezzi C, 2009, CIRCULATION, V120, P1203, DOI 10.1161/CIRCULATIONAHA.108.843334; Stoddard H, 2016, J CUTAN PATHOL, V43, P637, DOI 10.1111/cup.12724; Suzuki T, 2016, ANN HEMATOL, V95, P279, DOI 10.1007/s00277-015-2549-y; van Gameren II, 2006, ARTHRITIS RHEUM-US, V54, P2015, DOI 10.1002/art.21902; WESTERMARK P, 1989, J CLIN PATHOL, V42, P817, DOI 10.1136/jcp.42.8.817; Westermark P, 2007, AMYLOID, V14, P179, DOI 10.1080/13506120701460923; Westermark P, 2006, ACTA HISTOCHEM, V108, P209, DOI 10.1016/j.acthis.2006.03.011	31	6	6	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						71	79		10.1016/j.humpath.2017.11.001			9	Pathology	Pathology	FX4EC	WOS:000426024500009	29133141				2019-10-28	
J	Wang, DZ; Zhang, SS; Chen, YY; Hu, BY; Lu, CH				Wang, Dongzhi; Zhang, Shusen; Chen, Yuyan; Hu, Baoying; Lu, Cuihua			Low expression of NKD2 is associated with enhanced cell proliferation and poor prognosis in human hepatocellular carcinoma	HUMAN PATHOLOGY			English	Article						Cell proliferation; Doxorubicin; Hepatocellular carcinoma; NKD2; Wnt/beta-catenin	SIGNALING PATHWAY; WNT PATHWAY; CANCER; GROWTH; DIAGNOSIS; CIRRHOSIS; NAKED2; OVEREXPRESSION; INHIBITION; PREVENTION	NKD2 is a member of the Naked cuticle (Nkd) protein family and functions as a negative regulator of the Wnt signaling pathway. We investigated the prognostic value of NKD2 expression in hepatocellular carcinoma (HCC). Western blot and immunohistochemical analyses revealed that NKD2 was significantly downregulated in HCC specimens compared with adjacent nontumorous tissues. Next, we found that NKD2 expression correlated significantly with several clinicopathologic features, such as tumor grade, tumor size, and Ki-67 expression. Univariate and multivariate analyses demonstrated that NKD2 was an independent prognostic factor for the survival of HCC patients. In particular, Kaplan-Meier survival curves suggested that low NKD2 was statistically associated with poor overall survival. Furthermore, serum refeeding of cultured HCC cells led to impaired amounts of NKD2 and induced HepG2 and Huh7 cells to transition from the G(1) to the S phase. Small interfering RNA-mediated depletion of NKD2 in LO2 hepatocytes caused accelerated cell growth. To further clarify the role of NKD2 in cell cycle progression, a Flag-tagged NKD2 construct was used to overexpress NKD2 exogenously in Huh7 cells. These results showed that overexpression of NKD2 induced G(1)-phase cell cycle arrest. Reduced expression of NKD2 correlated with hyperactivation of the Wnt/beta-catenin pathway and doxorubicin resistance in HCC cells. On the basis of these findings, we conclude that NKD2 may be a novel prognostic marker and therapeutic target in HCC. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Dongzhi] Nantong Rich Hosp, Nantong 226001, Jiangsu, Peoples R China; [Zhang, Shusen] Hebei Med Univ, Affiliated Xing Tai People Hosp, Dept Resp Med, Xingtai 054000, Hebei, Peoples R China; [Zhang, Shusen; Lu, Cuihua] Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Chen, Yuyan; Hu, Baoying] Nantong Univ, Med Coll, Nantong 226001, Jiangsu, Peoples R China	Lu, CH (reprint author), Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.	lch670608@sina.com			Science and Technology Planning Project of Jiangsu Province (China) [BK20161286, 39]	This work was supported by the Science and Technology Planning Project of Jiangsu Province (BK20161286) (No 39, Beijing east road, Nanjing 210000, China).	Altekruse SF, 2014, AM J GASTROENTEROL, V109, P542, DOI 10.1038/ajg.2014.11; Ding W, 2008, P NATL ACAD SCI USA, V105, P13433, DOI 10.1073/pnas.0806298105; Gotze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981; Heidelbaugh JJ, 2006, AM FAM PHYSICIAN, V74, P756; Hu TH, 2006, BIOCHEM BIOPH RES CO, V350, P911, DOI 10.1016/j.bbrc.2006.09.121; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Huang W, 2016, PATHOL RES PRACT, V212, P171, DOI 10.1016/j.prp.2015.11.015; Jiang DW, 2015, PATHOL RES PRACT, V211, P240, DOI 10.1016/j.prp.2014.11.013; Katoh M, 2001, INT J ONCOL, V19, P963; Katoh M, 2005, ONCOL REP, V14, P1583; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kiesslich T, 2010, INT J ONCOL, V36, P49, DOI 10.3892/ijo_00000474; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Li M, 2015, FEBS LETT, V589, P1018, DOI 10.1016/j.febslet.2015.03.004; Liu Y, 2015, ONCOGENE, V34, P5524, DOI 10.1038/onc.2015.7; Mazur M, 2015, ANAL BIOCHEM, V475, P56, DOI 10.1016/j.ab.2015.01.016; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Oberti F, 1997, GASTROENTEROLOGY, V113, P1609, DOI 10.1053/gast.1997.v113.pm9352863; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Starr SP, 2011, AM FAM PHYSICIAN, V84, P1353; Tabatabai R, 2017, TARGET ONCOL, V12, P623, DOI 10.1007/s11523-017-0507-4; Tang A, 2017, ABDOM RADIOL; Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Zeng WL, 2000, NATURE, V403, P789; Zhang SS, 2015, MOL CELL BIOCHEM, V410, P1, DOI 10.1007/s11010-015-2533-9; Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429; Zhou P, 2013, PATHOL ONCOL RES, V19, P303, DOI 10.1007/s12253-012-9583-z	29	1	1	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						80	90		10.1016/j.humpath.2017.09.016			11	Pathology	Pathology	FX4EC	WOS:000426024500010	29126834				2019-10-28	
J	Zhang, XJ; Wang, W; Li, P; Wang, XD; Ni, K				Zhang, Xiaojing; Wang, Wei; Li, Peng; Wang, Xudong; Ni, Kan			High TREM2 expression correlates with poor prognosis in gastric cancer	HUMAN PATHOLOGY			English	Article						TREM2; Protein expression; mRNA expression; Gastric cancer; Prognosis	ALZHEIMERS-DISEASE; CELL-PROLIFERATION; OVEREXPRESSION; STATISTICS; EFFICACY; PATHWAY; RISK; R47H	Triggering receptor expressed on myeloid cells 2 (TREM2) is a member of the immunoglobulin superfamily and associates with TYRO protein tyrosine kinase binding protein at the cell membrane to form a receptor signaling complex. Gastric cancer (GC) is one of the most common human cancers in the world. We found that TREM2 expressions in GC and adjacent tissues were significantly different. The goal of this study was to measure TREM2 protein and mRNA expression levels in GC tissues and evaluate their value as potential prognostic markers. We analyzed TREM2 mRNA and protein expression by quantitative real-time polymerase chain reaction and immunohistochemistry, respectively, in 317 samples of GC tissue, matched normal tissue, or benign gastric lesions. The associations between TREM2 level and various clinicopathologic characteristics were assessed, and the correlation between TREM2 expression and prognosis of GC patients was analyzed using Oncomine and Kaplan-Meier Plotter online resources. TREM2 mRNA and protein expression levels were both significantly higher in GC compared with normal gastric tissues (P < .0001 and P < .001, respectively). Among the clinicopathological characteristics evaluated, differentiation (P < .05), N stage (P < .001), and TNM stage (P < .001) were all significantly associated with high TREM2 expression. TREM2 levels were inversely correlated with patient prognosis. Our data suggest that TREM2 expression could be an effective prognostic biomarker for GC. (C) 2017 Elsevier Inc. All rights reserved.	[Zhang, Xiaojing] Nantong Univ, Affiliated Hosp, Dept Clin Biobank, Nantong 226001, Jiangsu, Peoples R China; [Zhang, Xiaojing] Nantong Univ, Sch Med, Dept Pathol, Nantong 226001, Jiangsu, Peoples R China; [Wang, Wei] Nantong Univ, Affiliated Hosp, Dept Pathol, Nantong 226001, Jiangsu, Peoples R China; [Li, Peng; Ni, Kan] Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China; [Wang, Xudong] Nantong Univ, Affiliated Hosp, Dept Lab Med, Nantong 226001, Jiangsu, Peoples R China	Ni, K (reprint author), Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China.	nk85827@hotmail.com			National Natural Science Foundation of Beijing in China [81572390]; 13th Five Years Key Talent's Subsidy Project in Science and Education of Nanjing, Jiangsu Province, China [ZDRCA2016051]; Six Project of High Level Health Professionals of Nanjing, Jiangsu Province, China [LGY2016038]	This study was supported by grants from the National Natural Science Foundation of Beijing in China (81572390), the 13th Five Years Key Talent's Subsidy Project in Science and Education of Nanjing, Jiangsu Province, China (ZDRCA2016051), and Six Project of High Level Health Professionals of Nanjing, Jiangsu Province, China (LGY2016038).	Amin MB, 2017, AJCC CANC STAGING MA; Bhattacharjee S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00116; Bosman FT, 2010, WHO CLASSIFICATION T; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Cetin Bulent, 2016, J Gastrointest Cancer, V47, P125, DOI 10.1007/s12029-016-9806-8; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Coghlin C, 2016, PROTEOM CLIN APPL, V10, P532, DOI 10.1002/prca.201500079; Conteduca V, 2013, INT J ONCOL, V42, P5, DOI 10.3892/ijo.2012.1701; Fock KM, 2014, ALIMENT PHARM THER, V40, P250, DOI 10.1111/apt.12814; Huang JF, 2017, J CONTROL RELEASE, V245, P1, DOI 10.1016/j.jconrel.2016.11.024; Huang JF, 2013, AM J TRANSL RES, V5, P336; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jones Bryony, 2013, Nat Rev Neurol, V9, P5, DOI 10.1038/nrneurol.2012.254; Karsak M, 2015, ALZHEIMERS DEMENT, V11, P500; Kim HY, 2016, ONCOTARGET, V7, P49902, DOI 10.18632/oncotarget.10231; Kobayashi M, 2016, J NEUROSCI, V36, P11138, DOI 10.1523/JNEUROSCI.1238-16.2016; Li JY, 2016, ONCOTARGET, V7, P73638, DOI 10.18632/oncotarget.12039; Liao R, 2012, CANCER SCI, V103, P984, DOI 10.1111/j.1349-7006.2012.02273.x; Lill CM, 2015, ALZHEIMERS DEMENT, V11, P1407, DOI 10.1016/j.jalz.2014.12.009; Lin H, 2013, EXP MOL PATHOL, V94, P73, DOI 10.1016/j.yexmp.2012.08.004; Luis EO, 2014, NEUROBIOL AGING, V35, P2681, DOI 10.1016/j.neurobiolaging.2014.06.007; Narita Y, 2017, EXPERT OPIN DRUG SAF, V16, P319, DOI 10.1080/14740338.2017.1273348; Park JS, 2017, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00618; Roussos P, 2015, ALZHEIMERS DEMENT, V11, P1163, DOI 10.1016/j.jalz.2014.10.013; Saber M, 2017, J NEUROTRAUM, V34, P423, DOI 10.1089/neu.2016.4401; Sasaki A, 2015, NEUROGENETICS, V16, P265, DOI 10.1007/s10048-015-0451-3; Schroeter F, 2016, STEM CELL RES, V17, P553, DOI 10.1016/j.scr.2016.10.005; Sirkis DW, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0367-7; Smith AR, 2016, NEUROBIOL AGING, V47, P35, DOI 10.1016/j.neurobiolaging.2016.07.008; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang XQ, 2016, ONCOTARGET, V7, P2354, DOI 10.18632/oncotarget.6221; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Xing JJ, 2015, RES REP BIOCHEM, V5, P89, DOI 10.2147/RRBC.S58057; Yao YA, 2016, ONCOTARGET, V7, P29620, DOI 10.18632/oncotarget.8813; Zhang SL, 2016, INT J CLIN EXP PATHO, V9, P4318	36	8	9	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						91	99		10.1016/j.humpath.2017.10.026			9	Pathology	Pathology	FX4EC	WOS:000426024500011	29104108				2019-10-28	
J	Zhang, Y; Chen, PS; Yin, W; Ji, Y; Shen, Q; Ni, QF				Zhang, Yan; Chen, Peisheng; Yin, Wei; Ji, Ye; Shen, Qin; Ni, Qingfeng			Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway	HUMAN PATHOLOGY			English	Article						Nectin-4; Gastric cancer; Proliferation; Migration; PI3K/AKT pathway	TUMOR-GROWTH; LUNG-CANCER; RAC1; PROLIFERATION; METASTASIS; INHIBITION; ACTIVATION; PROGNOSIS; MOLECULES; INVASION	Nectin-4, a member of the Nectin family that includes 4 Ca+-independent immunoglobulin-like cell adhesion molecules, plays a carcinogenic role in multiple cancers. However, Nectin-4 expression and its biological role in gastric cancer (GC) remain largely unknown. In this study, quantitative real-time polymerase chain reaction, Western blotting, and immunohistochemistry were used to evaluate the expression patterns of Nectin-4 in GC specimens and cell lines. We observed that high expression of Nectin-4 in GC patients was associated with TNM stage and lymph node metastasis status, and poor prognosis. In addition, cell proliferation and cell migration assays in vitro and tumorigenicity in vivo were performed to observe the effects of up-regulation and down-regulation of Nectin-4 expression on GC cell phenotypes. In further studies, the PI3K/AKT signaling pathway was revealed to be involved in Nectin-4 mediated GC progression. These results demonstrated that Nectin-4 had a promoter effect on human GC cell growth and motility, indicating that Nectin-4 may serve as an effective therapeutic target in GC. (C) 2017 Published by Elsevier Inc.	[Zhang, Yan] Nantong Univ, Affiliated Hosp, Dept Oncol, Nantong 226001, Jiangsu, Peoples R China; [Chen, Peisheng; Yin, Wei; Ji, Ye; Ni, Qingfeng] Nantong Univ, Affiliated Hosp, Dept Gen Surg, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Shen, Qin] Nantong Univ, Med Coll, Nantong 226001, Jiangsu, Peoples R China	Ni, QF (reprint author), Nantong Univ, Affiliated Hosp, Dept Gen Surg, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.	qfni19841116@sina.com			National Natural Science Foundations for Young Scientists of China [81502053]	These studies were supported by the National Natural Science Foundations for Young Scientists of China (Grant No. 81502053).	Bousquet E, 2016, ONCOGENE, V35, P1760, DOI 10.1038/onc.2015.240; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeRycke MS, 2010, AM J CLIN PATHOL, V134, P835, DOI 10.1309/AJCPGXK0FR4MHIHB; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fabre-Lafay S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-73; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fortugno P, 2014, J INVEST DERMATOL, V134, P2146, DOI 10.1038/jid.2014.119; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Guo YN, 2015, MOL CANCER THER, V14, P2215, DOI 10.1158/1535-7163.MCT-15-0419; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Li CS, 2017, DIGEST DIS SCI, V62, P133, DOI 10.1007/s10620-016-4365-1; Lim B, 2015, CURR CLIN PHARMACOL, V10, P267, DOI 10.2174/1574884710666151020100329; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Ni QF, 2015, INT J ONCOL, V47, P1034, DOI 10.3892/ijo.2015.3072; Ni SS, 2013, INT J CLIN EXP PATHO, V6, P2887; Nishiwada S, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0144-7; Peng PK, 2016, SCI REP-UK, V6, DOI 10.1038/srep29604; Samanta D, 2015, CELL MOL LIFE SCI, V72, P645, DOI 10.1007/s00018-014-1763-4; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shankar J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132759; Slabakova E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350; Takai Y, 2001, PHYSIOL REV, V81, P153; Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Takano A, 2009, CANCER RES, V69, P6694, DOI 10.1158/0008-5472.CAN-09-0016; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.153; Zhang JX, 2017, BIOCHEM BIOPH RES CO, V482, P870, DOI 10.1016/j.bbrc.2016.11.126; Zhang YJ, 2016, CANCER LETT, V375, P179, DOI 10.1016/j.canlet.2016.02.049	32	3	4	2	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						107	116		10.1016/j.humpath.2017.10.034			10	Pathology	Pathology	FX4EC	WOS:000426024500013	29208564				2019-10-28	
J	Mayr, C; Helm, K; Jakab, M; Ritter, M; Shrestha, R; Makaju, R; Wagner, A; Pichler, M; Beyreis, M; Staettner, S; Jaeger, T; Klieser, E; Kiesslich, T; Neureiter, D				Mayr, Christian; Helm, Katharina; Jakab, Martin; Ritter, Markus; Shrestha, Rajeev; Makaju, Ramesh; Wagner, Andrej; Pichler, Martin; Beyreis, Marlena; Staettner, Stefan; Jaeger, Tarkan; Klieser, Eckhard; Kiesslich, Tobias; Neureiter, Daniel			The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer	HUMAN PATHOLOGY			English	Article						Biliary tract cancer; Epigenetics; Histone methyltransferase; G9a; H3K9me2	BREAST-CANCER; STEM-CELLS; E-CADHERIN; INHIBITOR; CARCINOMA; BIX-01294; INVASION; GROWTH; GLP; APOPTOSIS	The histone methyltransferase G9a (EHMT2) is a key enzyme for dimethylation of lysine 9 at his tone 3 (H3K9me2), a suppressive epigenetic mark. G9a is over-expressed in tumor cells and contributes to cancer aggressiveness. Biliary tract cancer (BTC) is a rare cancer with dismal prognosis due to a lack of effective therapies. Currently, there are no data on the role of G9a in BTC carcinogenesis. We analyzed G9a expression in n = 68 BTC patient specimens and correlated the data with clinicopathological and survival data. Moreover, we measured G9a expression in a panel of BTC cell lines and evaluated the cytotoxic effect of G9a inhibition in BTC cells using established small-molecule G9a inhibitors. G9a was considerably expressed in about half of BTC cases and was significantly associated with grading and tumor size. Additionally, we observed significant differences of G9a expression between growth type and tumor localization groups. G9a expression diametrically correlated with Vimentin (positive) and E-Cadherin (negative) expression. Importantly, survival analysis revealed G9a as a significant prognostic factor of poor survival in patients with BTC. In BTC cells, G9a and H3K9me2 were detectable in a cell line dependent manner on mRNA and/or protein level, respectively. Treatment of BTC cells with established small-molecule G9a inhibitors resulted in reduction of cell viability as well as reduced G9a and H3K9me2 protein levels. The present study strongly suggests that G9a contributes to BTC carcinogenesis and may represent a potential prognostic factor as well as a therapeutic target. (C) 2017 Elsevier Inc. All rights reserved.	[Mayr, Christian; Helm, Katharina; Ritter, Markus; Beyreis, Marlena; Kiesslich, Tobias] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Lab Tumour Biol & Expt Therapies TREAT, A-5020 Salzburg, Austria; [Mayr, Christian; Wagner, Andrej; Kiesslich, Tobias] Paracelsus Med Univ, Dept Internal Med 1, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria; [Helm, Katharina; Jakab, Martin; Ritter, Markus; Beyreis, Marlena] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Lab Funct & Mol Membrane Physiol FMMP, A-5020 Salzburg, Austria; [Ritter, Markus] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Ludwig Boltzmann Cluster Arthrit & Rehabil, Dept Radon Therapy Res, A-5020 Salzburg, Austria; [Shrestha, Rajeev] Kathmandu Univ, Dhulikhel Hosp, Dept Res & Dev, Canc Res Unit, Dhulikhel 45200, Nepal; [Makaju, Ramesh] Kathmandu Univ Hosp, Dhulikhel Hosp, Dept Pathol, Dhulikhel 45200, Nepal; [Pichler, Martin] Med Univ Graz, Dept Internal Med, Div Oncol, A-8036 Graz, Austria; [Pichler, Martin] UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Staettner, Stefan] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria; [Jaeger, Tarkan] Paracelsus Med Univ, Dept Surg, Salzburger Landeskliniken SALK, A-5020 Salzburg, Austria; [Klieser, Eckhard; Neureiter, Daniel] Paracelsus Med Univ, Salzburger Landeskliniken SALK, Inst Pathol, Canc Cluster Salzburg, A-5020 Salzburg, Austria	Neureiter, D (reprint author), Paracelsus Med Univ, Salzburger Landeskliniken SALK, Inst Pathol, Canc Cluster Salzburg, A-5020 Salzburg, Austria.	ch.mayr@salk.at; katharina.helm@stud.pmu.ac.at; martin.jakab@pmu.ac.at; markus.ritter@pmu.ac.at; rmaleku@hotmail.com; makajuram@yahoo.com; and.wagner@salk.at; martin.pichler@medunigraz.at; marlena.beyreis@pmu.ac.at; stefan.staettner@tirol-kliniken.at; ta.jaeger@salk.at; e.klieser@salk.at; t.kiesslich@salk.at; d.neureiter@salk.at	Stattner, Stefan/F-7470-2016; Jager, Tarkan/P-8966-2015	Stattner, Stefan/0000-0002-5226-7597; Ritter, Markus/0000-0001-7346-7750; Mayr, Christian/0000-0003-1898-8363; Jager, Tarkan/0000-0002-2390-0226; Kiesslich, Tobias/0000-0001-5403-9478	Oesterreichische Nationalbank (Austrian Central Bank) [14842]; Paracelsus Medical University Salzburg [A12-02-006-KIE]	This study was supported by funds of the Oesterreichische Nationalbank (Austrian Central Bank, Anniversary Fund, project number: 14842) and the research fund of the Paracelsus Medical University Salzburg (grant No. A12-02-006-KIE).	Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Cui J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-014-0149-x; Curry E, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0118-9; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Guo AS, 2016, MOL MED REP, V14, P4613, DOI 10.3892/mmr.2016.5815; Hsiao SM, 2015, ANN SURG ONCOL, V22, pS1556, DOI 10.1245/s10434-015-4379-5; Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.65; Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Lin XL, 2016, ONCOL REP, V35, P3041, DOI 10.3892/or.2016.4692; Liu F, 2013, J MED CHEM, V56, P8931, DOI 10.1021/jm401480r; Mayr C, 2016, BIOMED RES INT, DOI 10.1155/2016/4805270; Mayr C, 2016, ONCOTARGET, V7, P745, DOI 10.18632/oncotarget.6378; Mayr C, 2015, ANTICANCER RES, V35, P4697; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Oh SY, 2015, MOL CELLS, V38, P528, DOI 10.14348/molcells.2015.0026; Pang ALY, 2014, ONCOL LETT, V7, P1819, DOI 10.3892/ol.2014.2034; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Savickiene J, 2014, LEUKEMIA RES, V38, P822, DOI 10.1016/j.leukres.2014.04.003; Urbas R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122053; Valle JW, 2014, ANN ONCOL, V25, P391, DOI 10.1093/annonc/mdt540; Wagner A, 2015, HEPATOLOGY, V62, P1456, DOI 10.1002/hep.27905; Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015; Wu H, 2011, CELL RES, V21, P365, DOI 10.1038/cr.2010.157; Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y; Zhong XW, 2015, HISTOPATHOLOGY, V66, P192, DOI 10.1111/his.12456	35	3	3	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						117	126		10.1016/j.humpath.2017.11.003			10	Pathology	Pathology	FX4EC	WOS:000426024500014	29133140				2019-10-28	
J	Chianchiano, P; Pezhouh, MK; Kim, A; Luchini, C; Cameron, A; Weiss, MJ; He, J; Voltaggio, L; Oshima, K; Anders, RA; Wood, LD				Chianchiano, Peter; Pezhouh, Maryam Kherad; Kim, Amy; Luchini, Claudio; Cameron, Andrew; Weiss, Matthew J.; He, Jin; Voltaggio, Lysandra; Oshima, Kiyoko; Anders, Robert A.; Wood, Laura D.			Distinction of intrahepatic metastasis from multi centric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations	HUMAN PATHOLOGY			English	Article						Multifocal hepatocellular carcinoma; Multicentric carcinogenesis; Intrahepatic metastasis; Sanger sequencing; Next-generation sequencing	CLONAL ORIGIN; SOMATIC MUTATIONS; RECURRENCE; RESECTION; PROMOTER; TUMORS	Patients with hepatocellular carcinoma (HCC) frequently have multiple anatomically distinct tumors. In these patients, multifocal HCC could represent intrahepatic metastases (IMs) of a single cancer or multidentric carcinogenesis (MC) with multiple independent neoplasms. To determine the frequency and clinical implications of these 2 possibilities, we performed histological and molecular analysis of 70 anatomically distinct HCCs from 24 patients. We assayed mutations in the TERT promoter region by Sanger sequencing and used next-generation sequencing to analyze the entire coding regions of 7 well-characterized HCC driver genes based on shared or discordant mutations in these genes, we classified the HCCs in each patient as IM, MC, or indeterminate. Mutations in the TERT promoter were the most common alteration in our cohort, present in 71% of tumors analyzed. Mutations in the remaining genes occurred in less than 20% of analyzed tumors. We were able to determine the relatedness in 58% of the patients analyzed: MC occurred in 41% of patients, with 33% with exclusively MC and 8% with both MC and IM. IM occurred exclusively in 17% of patients, whereas the remainder were indeterminate. This study highlights the utility of molecular analyses to determine relatedness in multifocal HCC; however, targeted sequencing can only resolve this distinction in approximately 60% of patients with multifocal HCC. (C) 2017 Elsevier Inc. All rights reserved.	[Chianchiano, Peter; Pezhouh, Maryam Kherad; Voltaggio, Lysandra; Oshima, Kiyoko; Anders, Robert A.; Wood, Laura D.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; [Kim, Amy] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21231 USA; [Luchini, Claudio] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, I-37134 Verona, Italy; [Cameron, Andrew; Weiss, Matthew J.; He, Jin] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; [Wood, Laura D.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Wood, LD (reprint author), CRB2 Room 345,1550 Orleans St, Baltimore, MD 21231 USA.	ldwood@jhmi.edu	Luchini, Claudio/O-2187-2019; Luchini, Claudio/Q-4922-2016	Luchini, Claudio/0000-0003-4901-4908; Luchini, Claudio/0000-0003-4901-4908; He, Jin/0000-0001-9149-2247	National Institutes of Health/National Cancer Institute (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA62924]; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD) [K08 DK107781]; Buffone Family Gastrointestinal Cancer Research Fund (Baltimore, MD); Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention (Baltimore, MD); Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award (Philadelphia, PA)	The authors acknowledge the following sources of support (all to L. D. W.): National Institutes of Health/National Cancer Institute P50 CA62924 (Bethesda, MD); National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases K08 DK107781 (Bethesda, MD); Buffone Family Gastrointestinal Cancer Research Fund (Baltimore, MD); Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention (Baltimore, MD); Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award (Philadelphia, PA).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Borie F, 2008, J SURG ONCOL, V98, P505, DOI 10.1002/jso.21159; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hodges KB, 2010, CANCER-AM CANCER SOC, V116, P4078, DOI 10.1002/cncr.25258; IKEDA K, 1993, CANCER, V71, P19, DOI 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I; Jiang WQ, 2017, ONCOTARGET, V8, P5016, DOI 10.18632/oncotarget.14018; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Miao RY, 2014, J HEPATOL, V61, P840, DOI 10.1016/j.jhep.2014.05.025; Morimoto O, 2003, J HEPATOL, V39, P215, DOI 10.1016/S0168-8278(03)00233-2; NAGASUE N, 1993, GASTROENTEROLOGY, V105, P488, DOI 10.1016/0016-5085(93)90724-Q; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Ng IOL, 2003, J PATHOL, V199, P345, DOI 10.1002/path.1287; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shi JY, 2016, ONCOTARGET, V7, P2867, DOI 10.18632/oncotarget.6558; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Torrecilla S, 2017, J HEPATOL, V67, P1222, DOI 10.1016/j.jhep.2017.08.013; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; TSUDA H, 1992, CANCER RES, V52, P1504; Wang B, 2013, J AM COLL SURGEONS, V217, P1054, DOI 10.1016/j.jamcollsurg.2013.07.402; Wu RC, 2014, J PATHOL, V232, P473, DOI 10.1002/path.4315	23	8	8	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						127	134		10.1016/j.humpath.2017.11.011			8	Pathology	Pathology	FX4EC	WOS:000426024500015	29180252	Green Accepted			2019-10-28	
J	Le Flahec, G; Badic, B; Guibourg, B; Doucet, L; Bail, JP; Marcorelles, P; Schick, U; Uguen, A				Le Flahec, Glen; Badic, Bogdan; Guibourg, Briac; Doucet, Laurent; Bail, Jean-Pierre; Marcorelles, Pascale; Schick, Ulrike; Uguen, Arnaud			Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Mismatch repair deficiency; PD-1; PD-L1; Tumor immune microenvironment	MICROSATELLITE INSTABILITY; PD-L1 EXPRESSION; BRAF MUTATION; LUNG-CANCER; SOLID TUMORS; IMMUNOTHERAPY; BLOCKADE; PEMBROLIZUMAB; ANTIBODY; SAFETY	Mismatch repair deficient (dMMR) colorectal cancers (CRCs) are good responders to anti programmed cell death ligand-1 (PD-L1) immunotherapy, but the value of PD-L1 testing remains unclear. We studied PD-L1 expression and the tumor immune microenvironment in dMMR CRC as a model of good responders to immunotherapy. We examined 35 dMMR and 34 mismatch repair proficient (pMMR) CRCs using immune cell markers (CD3, CD4, CD8, CD20, CD68, and FOXP3) as well as programmed cell death receptor-1 (PD-1) and PD-L1 immunohistochemistry staining in whole tumor specimens and tissue micro array slides to compare 4 PD-L1 immunohistochemistry clones (SP142, EIL3N, 22C3, and 28.8). We observed no 'significant difference in PD-L1 expression between dMMR and pMMR CRCs. Only 2 dMMR tumors had membranous PD-L1 staining. Expression of PD-L1 was greater in stromal immune cells of dMMR CRC, which also contained more numerous intraepithelial (CD3(+), CD8+, FOXP3(+), and PD-1(+)) and stromal (CD8(+), PD-1(+)) lymphocytes than did pMMR tumors. Immune cell quantification discriminated better between dMMR and pMMR tumors than did PD-L1 expression. Tumor heterogeneity and variations in PD-L1 expression were noted with different antibodies, especially for PD-L1(+) immune cells, which were more numerous at the invasion margin. Given the poor correlation with mismatch repair status and technical limitations, the value of PD-L1 testing to accompany the development of anti PD-1/PD-L1 immunotherapy remains unclear. Further clinical trials are required to determine which parameters are valuable predictive biomarkers of the response to immunotherapy among mismatch repair status, PD-L1 expression, and immune cell quantification in CRC. (C) 2017 Elsevier Inc. All rights reserved.	[Le Flahec, Glen; Guibourg, Briac; Doucet, Laurent; Marcorelles, Pascale; Uguen, Arnaud] CHRU Brest, Serv Anat & Cytol Pathol, F-29220 Brest, France; [Badic, Bogdan; Bail, Jean-Pierre] CHRU Brest, Serv Chirurg Viscerale, F-29220 Brest, France; [Bail, Jean-Pierre; Marcorelles, Pascale; Schick, Ulrike; Uguen, Arnaud] Univ Europeenne Bretagne, F-29220 Brest, France; [Schick, Ulrike] CHRU Brest, Serv Radiotherapie, F-29220 Brest, France; [Uguen, Arnaud] INSERM, U1078, F-29220 Brest, France	Uguen, A (reprint author), Univ Hosp Morvan, Dept Pathol, 2 Ave Foch, F-29609 Brest, France.	arnaud.uguen@chu-brest.fr		Badic, Bogdan/0000-0003-4608-8960	Omnium group	We are grateful to Professor Jean-Baptiste Nousbaum for his valuable advice on this work, to the local tumor tissue biobank BB-0033-00037 (CRB Sante/Tumorotheque de Brest) for their collaboration in this study, and to the Omnium group for financial support.	Balar AV, 2017, CANCER IMMUNOL IMMUN, V66, P551, DOI 10.1007/s00262-017-1954-6; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Diggs LP, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0093-8; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Inaguma S, 2017, MODERN PATHOL, V30, P278, DOI 10.1038/modpathol.2016.185; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim JH, 2016, BRIT J CANCER, V115, P490, DOI 10.1038/bjc.2016.211; Koganemaru S, 2017, CANCER SCI, V108, P853, DOI 10.1111/cas.13229; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee KS, 2017, CANCER IMMUNOL IMMUN, V66, P927, DOI 10.1007/s00262-017-1999-6; Lee LH, 2016, MODERN PATHOL, V29, P1433, DOI 10.1038/modpathol.2016.139; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Masugi Y, 2017, GUT, V66, P1463, DOI 10.1136/gutjnl-2016-311421; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rosenbaum MW, 2016, MODERN PATHOL, V29, P1104, DOI 10.1038/modpathol.2016.95; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	35	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						135	143		10.1016/j.humpath.2017.09.019			9	Pathology	Pathology	FX4EC	WOS:000426024500016	29208565				2019-10-28	
J	Kasajima, A; Papotti, M; Itoa, W; Brizzi, MP; La Salvia, A; Rapa, I; Tachibana, T; Yazdani, S; Sasano, H; Volante, M				Kasajima, Atsuko; Papotti, Mauro; Itoa, Wataru; Brizzi, Maria Pia; La Salvia, Anna; Rapa, Ida; Tachibana, Tomoyoshi; Yazdani, Samaneh; Sasano, Hironobu; Volante, Marco			High intertaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs	HUMAN PATHOLOGY			English	Article						Neuroendocrine neoplasm; Somatostatin receptor 2A; Somatostatin receptor 5; Immunohistochemistry; Harmonization	NEUROENDOCRINE NEOPLASMS; 2A IMMUNOHISTOCHEMISTRY; TUMORS; EXPRESSION; SCINTIGRAPHY; REASSESSMENT; OCTREOTIDE; SUBTYPES; SCORE	Monoclonal antibodies to somatostatin receptors 2A (SSTR2A, UMB-1) and 5 (SSTR5, UMB-4) were reported to be highly reliable for immunohistochemical detection of these receptors in neuroendocrine neoplasms. However, the standardization of either the immunohistochemical procedure and the methods of evaluation has yet to be established. Fifty-two tissues from 38 patients with neuroendocrine neoplasm were retrieved from 2 institutions in Italy and Japan. The tissues were immunostained using 3 staining methodologies: 1 automated and 2 manual protocols from the Italian and Japanese institutions. The slides were independently evaluated by 3 observers (2 experienced pathologists and 1 medical student) using 3 scoring systems (Volante-Score, HER2-Score, and H-Score). The scores obtained from the staining methods were highly correlated with each other (r > 0.85, P < .0001). Especially, the Volante- and HER2-Scores were highly concordant (r >= 0.95, P <= 0001). Very high interobserver agreement was obtained irrespective of the method used and the experience of the evaluator, with the best concordance obtained by experienced pathologists evaluating automated system-stained slides (SSTR2A, r > 0.97; SSTR5, r > 0.96). HER2- and H-Scores were reliable to represent the characteristics of the patients. SSTR2A expression evaluated by the HER2-Score was significantly associated with clinical efficacy to somatostatin analogs (P = .04). SSTRs determination is an easily standardizable tool in different laboratories and is highly reproducible irrespective of the method of evaluation used. Given the positive association with clinical efficacy to somatostatin analogs, as well as the simple and widespread use, HER2-Score can be proposed as a standard evaluation procedure of SSTR2A and SSTR5 expression in neuroendocrine neoplasms. (C) 2017 Elsevier Inc. All rights reserved.	[Kasajima, Atsuko; Itoa, Wataru; Tachibana, Tomoyoshi; Yazdani, Samaneh; Sasano, Hironobu] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; [Kasajima, Atsuko] Tech Univ Munich, Dept Pathol, D-81675 Munich, Germany; [Papotti, Mauro; Rapa, Ida; Volante, Marco] Univ Turin, San Luigi Hosp, Dept Oncol, I-10043 Turin, Italy; [Papotti, Mauro] Citta Salute Hosp, I-10126 Turin, Italy; [Brizzi, Maria Pia; La Salvia, Anna] San Luigi Hosp, Oncol Unit, I-10043 Turin, Italy; [Kasajima, Atsuko] Tech Univ Munich, Dept Pathol, Trogerstr 18, D-81675 Munich, Germany	Kasajima, A (reprint author), Tohoku Univ, Dept Pathol, Aoba Ku, Seiryo Machi 1-1, Sendai, Miyagi 9808574, Japan.	kasajima@patholo2.med.tohoku.ac.jp; mauro.papotti@unito.it; wataru.ito.r5@dc.tohoku.ac.jp; brizzimariapia@gmail.com; annalasal@tiscali.it; ida.rapa@unito.it; tachibana.tomoyoshi@gmail.com; samin632003.samaneh@gmail.com; hsasano@patholo2.med.tohoku.ac.jp; marco.volante@unito.it			Japanese Ministry of Education, Culture, Sports, Science, and Technology (JSPS KAKENHI)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP26460413]; Alexander von Humboldt FoundationAlexander von Humboldt Foundation	This work was partly supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (JSPS KAKENHI grant JP26460413) and funding provided by the Alexander von Humboldt Foundation to A. K., Sendai, Miyagi, Japan.	Basturk O, 2014, AM J SURG PATHOL, V38, P437, DOI 10.1097/PAS.0000000000000169; Binderup T, 2010, J NUCL MED, V51, P704, DOI 10.2967/jnumed.109.069765; Bosman FT, 2010, WHO CLASSIFICATION T; Fischer T, 2008, J CLIN ENDOCR METAB, V93, P4519, DOI 10.1210/jc.2008-1063; Gatto F, 2013, J CLIN ENDOCR METAB, V98, pE66, DOI 10.1210/jc.2012-2609; Gonzalez B, 2014, ENDOCRINOL NUTR, V61, P523, DOI 10.1016/j.endonu.2014.05.006; Korner M, 2012, AM J SURG PATHOL, V36, P242, DOI 10.1097/PAS.0b013e31823d07f3; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; Kwekkeboom DJ, 1996, J NUCL MED, V37, P886; Lloyd RV, 2017, WHO CLASSIFICATION T; Lupp A, 2011, NEUROENDOCRINOLOGY, V94, P255, DOI 10.1159/000329876; Milione M, 2017, NEUROENDOCRINOLOGY, V104, P85, DOI 10.1159/000445165; Naswa N, 2014, CLIN NUCL MED, V39, pE27, DOI 10.1097/RLU.0b013e31827a216b; Rinke A, 2017, NEUROENDOCRINOLOGY, V104, P26, DOI 10.1159/000443612; Song KB, 2016, PANCREAS, V45, P187, DOI 10.1097/MPA.0000000000000493; Sorbye H, 2014, CANCER-AM CANCER SOC, V120, P2814, DOI 10.1002/cncr.28721; Specht E, 2015, HISTOPATHOLOGY, V67, P368, DOI 10.1111/his.12662; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Travis WD, 2015, WHO CLASSIFICATION T; van Adrichem RCS, 2016, NEUROENDOCRINOLOGY, V103, P560, DOI 10.1159/000441604; Velayoudom-Cephise FL, 2013, ENDOCR-RELAT CANCER, V20, P649, DOI 10.1530/ERC-13-0027; Volante M, 2007, MODERN PATHOL, V20, P1172, DOI 10.1038/modpathol.3800954	23	8	8	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						144	152		10.1016/j.humpath.2017.11.008			9	Pathology	Pathology	FX4EC	WOS:000426024500017	29180250				2019-10-28	
J	Thway, K; Mentzel, T; Perrett, CM; Calonje, E				Thway, Khin; Mentzel, Thomas; Perrett, Conal M.; Calonje, Eduardo			Multicentric visceral epithelioid hemangioendothelioma, with extremity dermal deposits, unusual late recurrence on the nasal bridge, and TFE3 gene rearrangement	HUMAN PATHOLOGY			English	Article						Epithelioid hemangioendothelioma; Face; Metastatic; Multifocal; WWTR1-CAMTA1; YAP1-TFE3; Gene rearrangement; Sarcoma	SARCOMA-LIKE HEMANGIOENDOTHELIOMA; PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; FUSION; FOSB; EXPRESSION; VARIANT; MARKER; MIMICS; CAMTA1; TUMOR	Epithelioid hemangioendothelioma (EHE) is a malignant neoplasm with vascular differentiation that most frequently occurs within soft tissues, bone, lung, and liver. It is histologically typified by epithelioid or spindle cells present singly or in cords or clusters, many with cytoplasmic vacuoles that can contain intraluminal erythrocytes (in keeping with primitive vascular differentiation), within myxohyaline or sclerotic matrix. Up to 50% present with synchronous lesions as multifocal disease. The WWTR1-CAMTA1 fusion has been demonstrated in EHEs at a variety of sites and is considered to represent its genetic hallmark. We describe a case of EHE in a patient who initially presented with multiple liver and pulmonary deposits, was found to have a soft tissue lesion in the foot, and then presented with further lesions on the nasal bridge and the arm approximately 6 years after initial presentation. Interestingly, the case showed diffuse CAMTA1 expression but negative TFE3 immunohistochemically, but in contrast showed TFE3 gene rearrangement with fluorescence in situ hybridization but no evidence of WWTR1-CAMTA1 translocation. The clinical behavior of EHE is unpredictable, and this case highlights unusual anatomic, immunohistochemical, and molecular cytogenetic findings. Characterization of the genetics of EHE is important because targeted therapies toward products of the specific WWTR1-CAMTA1 gene fusion may have an impact in the near future. (C) 2017 Elsevier Inc. All rights reserved.	[Thway, Khin] Royal Marsden Hosp, Sarcoma Unit, London SW3 6JJ, England; [Mentzel, Thomas] Inst Dermatopathol, Dermatohistopathol Gemeinschaftslab, D-88048 Friedrichshafen, Germany; [Perrett, Conal M.] Univ Coll London Hosp, Dept Dermatol, London NW1 2BU, England; [Calonje, Eduardo] St Thomas Hosp, St Johns Inst Dermatol, London SE1 7EH, England	Thway, K (reprint author), Royal Marsden NHS Fdn Trust, Sarcoma Unit, 203 Fulham Rd, London SW3 6JJ, England.	khin.thway@rmh.nhs.uk			NIHR Royal Marsden/ICR Biomedical Research Centre	We acknowledge support from the NIHR Royal Marsden/ICR Biomedical Research Centre.	Amary MF, 2013, SKELETAL RADIOL, V42, P947, DOI 10.1007/s00256-013-1577-8; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Billings SD, 2003, AM J SURG PATHOL, V27, P48, DOI 10.1097/00000478-200301000-00006; Billings SD, 2011, AM J SURG PATHOL, V35, P1088, DOI 10.1097/PAS.0b013e31821caf1c; Chen CH, 2009, DERMATOL SURG, V35, P150, DOI 10.1111/j.1524-4725.2008.34398.x; Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; Errani C, 2012, CANCER GENET-NY, V205, P12, DOI 10.1016/j.cancergen.2011.10.008; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Fisher C., 2011, BIOPSY INTERPRETATIO, P430; Flucke U, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-131; Folpe AL, 2001, AM J SURG PATHOL, V25, P1061, DOI 10.1097/00000478-200108000-00011; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Lau K, 2011, CHEST, V140, P1312, DOI 10.1378/chest.11-0039; Lee SJ, 2016, ONCOTARGET, V7, P7480, DOI 10.18632/oncotarget.7060; Mehrabi A, 2006, CANCER, V107, P2108, DOI 10.1002/cncr.22225; Mentzel T, 1997, AM J SURG PATHOL, V21, P363, DOI 10.1097/00000478-199704000-00001; Miettinen M, 2013, AM J SURG PATHOL, V37, P1580, DOI 10.1097/PAS.0b013e31828de23a; MIRRA JM, 1992, CANCER-AM CANCER SOC, V69, P1382, DOI 10.1002/1097-0142(19920315)69:6<1382::AID-CNCR2820690614>3.0.CO;2-Y; Puls F, 2015, VIRCHOWS ARCH, V466, P473, DOI 10.1007/s00428-015-1730-y; Shibuya R, 2015, HISTOPATHOLOGY, V67, P827, DOI 10.1111/his.12713; Suchak R, 2011, AM J SURG PATHOL, V35, P60, DOI 10.1097/PAS.0b013e3181fee872; Sugita S, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0530-2; Tanas MR, 2016, ONCOGENE, V35, P929, DOI 10.1038/onc.2015.148; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; Trombetta D, 2011, CANCER GENET-NY, V204, P211, DOI 10.1016/j.cancergen.2011.01.002; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; WEISS SW, 1982, CANCER, V50, P970, DOI 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z	29	0	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						153	159		10.1016/j.humpath.2017.08.020			7	Pathology	Pathology	FX4EC	WOS:000426024500018	28855107				2019-10-28	
J	Kohsaka, S; Saito, T; Akaike, K; Suehara, Y; Hayashi, T; Takagi, T; Kaneko, K; Ueno, T; Kojima, S; Kohashi, K; Mano, H; Oda, Y; Yao, T				Kohsaka, Shinji; Saito, Tsuyoshi; Akaike, Keisuke; Suehara, Yoshiyuki; Hayashi, Takuo; Takagi, Tatsuya; Kaneko, Kazuo; Ueno, Toshihide; Kojima, Shinya; Kohashi, Ken-ichi; Mano, Hiroyuki; Oda, Yoshinao; Yao, Takashi			Pediatric soft tissue tumor of the upper arm with LMNA-NTRK1 fusion	HUMAN PATHOLOGY			English	Article						NTRK1 fusion; Pediatric soft tissue tumor; Fibrosarcoma; Inflammatory myofibroblastic tumor; Molecular target therapjftumor	INFLAMMATORY MYOFIBROBLASTIC TUMORS; NTRK1 GENE FUSIONS; COLORECTAL-CANCER; SUBSET; REARRANGEMENTS; RESISTANCE; ETV6-NTRK3; PATIENT; ALK	A 6-year-old girl was admitted to our hospital because of the presence of a slow-growing tumor in her right elbow. Biopsy specimens showed a round to spindle cell neoplasm with uncertain malignant potential, leading to the decision of surgical resection. Histologically, the resected tumor was encapsulated by fibrous tissue but focally invaded the surrounding skeletal muscles. The tumor was composed of ganglion cell like short spindle cells with lymphocytic infiltration in the collagenous background. Tumor cells with large bizarre nuclei were occasionally observed, and multinucleated giant cells were scattered at the periphery. Hemangiopericytoma-like patterns and adipose tissue elements were not evident, and mitotic figures were rarely observed (<1 per 10 high-power fields). Immunohistochemically, the tumor cells were positive for S-100 and CD34 and focally positive for epithelial membrane antigen and AE1/AE3. RNA sequencing and subsequent reverse-transcription polymerase chain reaction revealed alternative splicing forms of LMNA-NTRK1 fusion (Ex2-Ex10 and Ex2-Ex15). (C) 2017 Elsevier Inc. All rights reserved.	[Kohsaka, Shinji] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo 1130033, Japan; [Saito, Tsuyoshi; Akaike, Keisuke; Hayashi, Takuo; Yao, Takashi] Juntendo Univ, Sch Med, Dept Human Pathol, Tokyo 1138421, Japan; [Akaike, Keisuke; Suehara, Yoshiyuki; Takagi, Tatsuya; Kaneko, Kazuo] Juntendo Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1138421, Japan; [Ueno, Toshihide; Kojima, Shinya; Mano, Hiroyuki] Univ Tokyo, Grad Sch Med, Dept Cellular Signaling, Tokyo 1130033, Japan; [Kohashi, Ken-ichi; Oda, Yoshinao] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka 8128582, Japan; [Mano, Hiroyuki] Natl Canc Ctr, Tokyo 1040045, Japan	Saito, T (reprint author), Juntendo Univ, Sch Med, Dept Human Pathol, Tokyo 1138421, Japan.	tysaitou@juntendo.ac.jp			Japan Agency for Medical Research and DevelopmentJapan Agency for Medical Research and Development (AMED); Ministry of Education, Science, Sports, and Culture, Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17K08730]	This study was supported in part by a grant, Leading Advanced Projects for Medical Innovation, from the Japan Agency for Medical Research and Development and by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture (#17K08730), Tokyo, Japan.	Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Akaike K, 2015, HUM PATHOL, V46, P347, DOI 10.1016/j.humpath.2014.11.018; Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Doebele RC, 2015, CANCER DISCOV, V5, P1049, DOI 10.1158/2159-8290.CD-15-0443; Flucke U, 2017, GENE CHROMOSOME CANC, V56, P663, DOI 10.1002/gcc.22470; Fuse MJ, 2017, MOL CANCER THER, V16, P2130, DOI 10.1158/1535-7163.MCT-16-0909; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Khotskaya YB, 2017, PHARMACOL THERAPEUT, V173, P58, DOI 10.1016/j.pharmthera.2017.02.006; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lee SJ, 2015, ONCOTARGET, V6, P39028, DOI 10.18632/oncotarget.5494; McPherson A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001138; Park DY, 2016, ONCOTARGET, V7, P8399, DOI 10.18632/oncotarget.6724; Pavlick D, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26433; Pinney SS, 2016, DERMATOL ONLINE J, V22; Ross JS, 2014, ONCOLOGIST, V19, P235, DOI 10.1634/theoncologist.2013-0352; Russo M, 2016, CANCER DISCOV, V6, P36, DOI 10.1158/2159-8290.CD-15-0940; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wong V, 2015, J NATL CANC I; Yamamoto H, 2016, HISTOPATHOLOGY, V69, P72, DOI 10.1111/his.12910; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	21	4	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						167	173		10.1016/j.humpath.2017.08.017			7	Pathology	Pathology	FX4EC	WOS:000426024500020	28851664				2019-10-28	
J	Tordjman, M; Ouachee, M; Bonnard, A; Tilea, B; Yakouben, K; Viala, J; Peuchmaur, M; Berrebi, D				Tordjman, Mickael; Ouachee, Marie; Bonnard, Arnaud; Tilea, Bogdana; Yakouben, Karima; Viala, Jerome; Peuchmaur, Michel; Berrebi, Dominique			Small bowel stenosis: a manifestation of chronic graft-versus-host disease in children?	HUMAN PATHOLOGY			English	Article						Graft-versus-host disease; Small bowel stenosis; Children; NOD2; Surgery	TRANSPLANTATION; PATHOLOGY; SURGERY; GVHD	Digestive graft-versus-host disease (GVHD) is a frequent complication after bone marrow transplantation, but small bowel obstruction is an extremely rare event. We present herein the first pediatric series of 4 cases of small bowel obstruction after bone marrow transplantation with detailed gross, histological data and their genetic status of the NOD2 gene. All patients had a history of severe acute GVHD treated by immunosuppressive agents and/or infliximab (in 3 cases). Acute or progressively worsening abdominal pain accompanied by small bowel occlusion occurred 5-16 months after graft, and computed tomographic scan revealed multiple small intestinal stenoses. Failure of intensive medical treatment led to surgical resection of affected loops. Stigmata of acute (apoptosis of crypts and satellitosis) and chronic GVHD features (submucosal fibrosis and serosae sclerolipomatosis), as well as extensive ulcerations, were observed in all ileal specimens. NOD2 mutation was found in only 1 patient. The follow-up showed successful outcome after surgery. (C) 2017 Elsevier Inc. All rights reserved.	[Tordjman, Mickael; Peuchmaur, Michel; Berrebi, Dominique] Robert Debre Hosp, APHP, Dept Pathol, F-75019 Paris, France; [Ouachee, Marie; Yakouben, Karima] Robert Debre Hosp, APHP, Hematol Dept, F-75019 Paris, France; [Bonnard, Arnaud] Robert Debre Hosp, APHP, Gen Surg Dept, F-75019 Paris, France; [Bonnard, Arnaud; Viala, Jerome; Peuchmaur, Michel; Berrebi, Dominique] Diderot Paris 7 Univ SPC, Paris, France; [Tilea, Bogdana] Robert Debre Hosp, APHP, Dept Imaging, F-75019 Paris, France; [Viala, Jerome] Robert Debre Hosp, APHP, Gastroenterol Dept, F-75019 Paris, France	Tordjman, M (reprint author), Hop Univ Robert Debre, APHP, Serv Pathol, 48 Blvd Serurier, F-75019 Paris, France.	mickael_tordjman@hotmail.com					Baird K, 2010, PEDIATR CLIN N AM, V57, P297, DOI 10.1016/j.pcl.2009.11.003; de Serre NPM, 2002, BONE MARROW TRANSPL, V29, P223, DOI 10.1038/sj/bmt/1703329; Evans J, 1998, DIS COLON RECTUM, V41, P1573, DOI 10.1007/BF02237309; Gavel G, 2003, BONE MARROW TRANSPL, V32, P1097, DOI 10.1038/sj.bmt.1704282; Herr AL, 2004, TRANSPLANTATION, V77, P1617, DOI 10.1097/01.TP.0000127251.16608.8F; Holler E, 2004, BLOOD, V104, P889, DOI 10.1182/blood-2003-10-3543; Jung C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052223; Louis E, 2007, ACTA GASTRO-ENT BELG, V70, P15; Shulman HM, 2015, BIOL BLOOD MARROW TR, V21, P589, DOI 10.1016/j.bbmt.2014.12.031; SPENCER GD, 1986, HUM PATHOL, V17, P621, DOI 10.1016/S0046-8177(86)80135-6; Trabulo D, 2015, WORLD J GASTROENTERO, V21, P9217, DOI 10.3748/wjg.v21.i30.9217; Washington K, 2009, HUM PATHOL, V40, P909, DOI 10.1016/j.humpath.2009.04.001; Xu CF, 2008, WORLD J GASTROENTERO, V14, P2262, DOI 10.3748/wjg.14.2262; Yoon Ju Young, 2012, Korean J Hematol, V47, P142, DOI 10.5045/kjh.2012.47.2.142	14	1	1	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						174	179		10.1016/j.humpath.2017.08.034			6	Pathology	Pathology	FX4EC	WOS:000426024500021	28899741				2019-10-28	
J	El Behery, R; Laurini, JA; Weisenburger, DD; Smith, LM; Dave, BJ; Yuan, J; Fu, K; Chan, WC; Nathwani, BN; Bierman, PJ; Bociek, RG; Vose, JM; Armitage, JO; Greiner, TC; Aoun, P				El Behery, Radwa; Laurini, Javier A.; Weisenburger, Dennis D.; Smith, Lynette M.; Dave, Bhavana J.; Yuan, Jane; Fu, Kai; Chan, Wing C.; Nathwani, Bharat N.; Bierman, Phillip J.; Bociek, Robert G.; Vose, Julie M.; Armitage, James O.; Greiner, Timothy C.; Aoun, Patricia			Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma	HUMAN PATHOLOGY			English	Article						Follicular large cleaved cell lymphoma; Follicular lymphoma; Large cleaved cell; Large centrocyte; Non-Hodgkin lymphoma	FREE SURVIVAL; GRADE; CLASSIFICATION; PROLIFERATION; CHEMOTHERAPY; RITUXIMAB; IMPROVES; INDEX	The World Health Organization classification of lymphoma recommends the subdivision of follicular lymphoma (FL) into 3 grades (FL1-3) based on the average number of centroblasts per high-power field in the neoplastic follicles, but does not recognize a form of FL characterized by a predominance of large cleaved cells (centrocytes) without enough centroblasts to meet the World Health Organization criteria for FL3. We have classified such cases as follicular large cleaved cell lymphoma (FLC) and, herein, describe the pathologic and clinical features of 72 cases of this entity. The features of FLC include a follicular growth pattern with pale follicles at low magnification and frequent follicular and/or interfollicular fibrosis. Cytologically, the cells are predominantly large cleaved cells with moderately coarse to fine chromatin, absent or inconspicuous nucleoli, and small to moderate amounts of pale cytoplasm. The mean nuclear diameter of the large cleaved cells was 10.1 mu, approximately twice that of small lymphocytes and similar to centroblasts. The t(14;18) was present in 83% of the cases, and a high proportion expressed BCL2 (84%), BCL6 (100%), and CD10 (88%) and had high Ki67 proliferation (81%). The clinical features of patients with FLC were similar to those with other types of FL, and survival was excellent with anthracycline-based chemotherapy plus rituximab. FLC is a variant of follicular lymphoma which should be recognized in future lymphoma classifications because the diagnosis of FLC may be important for the selection of therapy. (C) 2017 Elsevier Inc. All rights reserved.	[El Behery, Radwa] LabCorp, Integrated Oncol, Ctr Specialty & Clin Testing, Phoenix, AZ 85040 USA; [Laurini, Javier A.] Univ S Alabama, Dept Pathol, Mobile, AL 33617 USA; [Weisenburger, Dennis D.; Chan, Wing C.; Nathwani, Bharat N.; Aoun, Patricia] City Hope Natl Med Ctr, Dept Pathol, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE 68198 USA; [Dave, Bhavana J.] Univ Nebraska Med Ctr, Munroe Meyer Inst, Omaha, NE 68198 USA; [Yuan, Jane; Fu, Kai; Greiner, Timothy C.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Bierman, Phillip J.; Bociek, Robert G.; Vose, Julie M.; Armitage, James O.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA	Aoun, P (reprint author), City Hope Natl Med Ctr, Dept Pathol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	paaoun@coh.org					Dave BJ, 2004, CANCER GENET CYTOGEN, V153, P115, DOI 10.1016/j.cancergencyto.2004.01.008; Ganti AK, 2006, ANN ONCOL, V17, P920, DOI 10.1093/annonc/mdl039; Gu K, 2009, MODERN PATHOL, V22, P1251, DOI 10.1038/modpathol.2009.81; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hans CP, 2003, BLOOD, V101, P2363, DOI 10.1182/blood-2002-07-2298; Harris NL, 2008, WHO CLASSIFICATION T, P220; Horn H, 2011, HAEMATOL-HEMATOL J, V96, P1327, DOI 10.3324/haematol.2011.042531; Howlader N, 2016, SEER CANC STAT REV 1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klapper W, 2007, J CLIN ONCOL, V25, P3330, DOI 10.1200/JCO.2006.10.5833; LUKES RJ, 1975, BRIT J CANCER, V31, P1; Mann R B, 1983, Hematol Oncol, V1, P187; Nathwani BN, 2001, PATHOLOGY GENETICS T, P162; Overman MJ, 2008, ANN ONCOL, V19, P553, DOI 10.1093/annonc/mdm511; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROSENBERG SA, 1982, CANCER, V49, P2112; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Wang SA, 2005, AM J SURG PATHOL, V29, P1490, DOI 10.1097/01.pas.0000172191.87176.3b; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Yuan J, 2017, CL LYMPH MYELOM LEUK, V17, P488, DOI 10.1016/j.clml.2017.06.006	20	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						180	190		10.1016/j.humpath.2017.11.002			11	Pathology	Pathology	FX4EC	WOS:000426024500022	29170017				2019-10-28	
J	Pizzi, M; Chaviano, F; Rugge, M; Orazi, A				Pizzi, Marco; Chaviano, Felicia; Rugge, Massimo; Orazi, Attilio			A lucky mistake: the splenic glands of Marcello Malpighi	HUMAN PATHOLOGY			English	Article						Spleen; Marcello Malpighi; History of medicine; White pulp; Red pulp; Epistemology	PHYSIOLOGY; DISEASE; HISTORY; SPLEEN; CELLS	Marcello Malpighi (1628-1694) is one of the most important anatomists and physicians in the history of medicine. His contributions to the understanding of human anatomy and physiology span from the first description of capillary circulation to a thorough analysis of the structure and function of body glands. Malpighi believed that most organs consisted of glandular structures, whose distribution and microscopic features determine each organ-specific function. He also applied this view to the study of spleen anatomy, which he recognized as composed of 2 distinct anatomic compartments (ie, the red and the white pulp). Malpighi's observations on the structure and function of the spleen were first published in 1666 in De Viscerum Structura. In this paper, we pay tribute to this work, presenting Malpighi's theory of the spleen as a glandular organ. The rationale of Malpighi's view and its value for contemporary pathologists and medical researchers will also be elucidated. (C) 2017 Elsevier Inc. All rights reserved.	[Pizzi, Marco; Rugge, Massimo] Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, I-35100 Padua, Italy; [Chaviano, Felicia] Weill Cornell Med Coll, New York, NY 10065 USA; [Orazi, Attilio] Weill Cornell Med Coll, Hematol Lab, Dept Pathol & Lab Med, New York, NY 10065 USA	Pizzi, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Via A Gabelli 61, I-35121 Padua, PD, Italy.	marcopizzi2002@yahoo.it					Boerhaave H., 1735, I MED USU ANNUAE EXE; Caldani LMA, 1791, I ANATOMICAE; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; De le Boe F., 1681, OPERA MEDICA; Gray H, 1854, STRUCTURE USE SPLEEN; Gross CG, 2011, CORTEX, V47, P903, DOI 10.1016/j.cortex.2011.04.005; Malpighi M, 1967, OPERE SCELTE; Malpighi M., 1666, VISCERUM STRUCTURA E; McClusky DA, 1999, WORLD J SURG, V23, P311; Mezzogiorno A, 1997, AM J NEPHROL, V17, P269, DOI 10.1159/000169112; Morgagni GB, 1764, OPERA OMNIA; OKEANE JC, 1989, CANCER, V63, P1539; Pivkin IV, 2016, P NATL ACAD SCI USA, V113, P7804, DOI 10.1073/pnas.1606751113; Pizzi M, 2017, HUM PATHOL, V60, P95, DOI 10.1016/j.humpath.2016.09.028; Verheyen P., 1734, CORPORIS HUMANI ANTO	15	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						191	195		10.1016/j.humpath.2017.11.007			5	Pathology	Pathology	FX4EC	WOS:000426024500023	29175516				2019-10-28	
J	Zhou, DX; Wu, YY; Jiang, H; Luan, JJ				Zhou, Dexi; Wu, Yuanyuan; Jiang, Hui; Luan, Jiajie			IMP3: a potential diagnostic and therapeutic biomarker for cancers	HUMAN PATHOLOGY			English	Letter							BREAST-CANCER; EXPRESSION		[Zhou, Dexi; Wu, Yuanyuan; Jiang, Hui; Luan, Jiajie] Wannan Med Coll, Dept Pharm, Yijishan Hosp, Wuhu 241001, Anhui, Peoples R China	Zhou, DX (reprint author), Wannan Med Coll, Dept Pharm, Yijishan Hosp, Wuhu 241001, Anhui, Peoples R China.	zhoudexiahmu@163.com; wangyaqin1ahmu@163.com					Bhargava S, 2017, CANC BIOL T IN PRESS; Bhargava S, 2017, ONCOTARGET, V8, P40469, DOI 10.18632/oncotarget.17118; Er LM, 2017, ONCOL LETT, V13, P2391, DOI 10.3892/ol.2017.5735; Massironi S, 2017, ENDOCRINE, V58, P360, DOI 10.1007/s12020-017-1249-x; Ohashi R, 2017, ANN DIAGN PATHOL, V31, P30, DOI 10.1016/j.anndiagpath.2017.05.015; Samanta S, 2016, ONCOGENE, V35, P1111, DOI 10.1038/onc.2015.164; Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319; Sasaki M, 2017, HUM PATHOL, V62, P152, DOI 10.1016/j.humpath.2016.12.028; Su P, 2014, INT J CLIN EXP PATHO, V7, P3008; Wei QZ, 2017, HUM PATHOL, V64, P137, DOI 10.1016/j.humpath.2017.03.013	10	0	0	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						196	196		10.1016/j.humpath.2017.08.037			1	Pathology	Pathology	FX4EC	WOS:000426024500024	28958580				2019-10-28	
J	Ree, HJ; Ko, YH; Yang, SW				Ree, Howe J.; Ko, Young-Hyeh; Yang, Seok Woo			Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma	HUMAN PATHOLOGY			English	Letter							CELLS		[Ree, Howe J.] Namsan Lotte Castle IRIS 101 603, 35 Sogong Ro, Seoul 04632, South Korea; [Ko, Young-Hyeh] Samsung Med Ctr, Dept Pathol, Seoul 06351, South Korea; [Yang, Seok Woo] Yonsei MokGu Clin, Ahndong City, Gyeungsangbookd, South Korea	Ree, HJ (reprint author), Namsan Lotte Castle IRIS 101 603, 35 Sogong Ro, Seoul 04632, South Korea.	howejree@gmail.com; yhko@skku.edu; soplab@naver.com					Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Passalidou E, 2003, BRIT J CANCER, V88, P553, DOI 10.1038/sj.bjc.6600742; REE H, 1975, HUM PATHOL, V6, P363, DOI 10.1016/S0046-8177(75)80098-0; REE HJ, 1982, CANCER-AM CANCER SOC, V48, P1636, DOI 10.1002/1097-0142(19820415)49:8<1636::AID-CNCR2820490818>3.0.CO;2-4; REE HJ, 1978, CANCER, V41, P1500, DOI 10.1002/1097-0142(197804)41:4<1500::AID-CNCR2820410439>3.0.CO;2-X; REE HJ, 1982, J SURG ONCOL, V21, P61, DOI 10.1002/jso.2930210116; Xerri L, 2017, HUM PATHOL, V64, P128, DOI 10.1016/j.humpath.2017.03.023	7	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						197	198		10.1016/j.humpath.2017.09.017			2	Pathology	Pathology	FX4EC	WOS:000426024500025	29129542				2019-10-28	
J	Xerri, L; Huet, S; Salles, G				Xerri, Luc; Huet, Sarah; Salles, Gilles			Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma-reply	HUMAN PATHOLOGY			English	Letter							VASCULARIZATION PREDICTS; PROGNOSTIC IMPACT; MACROPHAGES		[Xerri, Luc] Aix Marseille Univ, Dept Biopathol & Tumor Immunol, Inst Paoli Calmettes, UM105,CRCM,Inserm,U1068,CNRS,UMR7258, F-13009 Marseille, France; [Huet, Sarah; Salles, Gilles] Hosp Civils Lyon, Ctr Rech Cancerol Lyon, Fac Med Lyon Sud Charles Merieux, INSERM1052,CNRS 5286,Lab Hematol, F-69495 Pierre Benite, France	Xerri, L (reprint author), Aix Marseille Univ, Dept Biopathol & Tumor Immunol, Inst Paoli Calmettes, UM105,CRCM,Inserm,U1068,CNRS,UMR7258, F-13009 Marseille, France.	xerril@ipc.unicancer.fr	Salles, Gilles/Z-2336-2019				Ager A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008791; Clear AJ, 2010, BLOOD, V115, P5053, DOI 10.1182/blood-2009-11-253260; Farinha P, 2010, HAEMATOL-HEMATOL J, V95, P2157, DOI 10.3324/haematol.2009.021766; Koster A, 2005, CLIN CANCER RES, V11, P154; Kridel R, 2015, CLIN CANCER RES, V21, P3428, DOI 10.1158/1078-0432.CCR-14-3253; Xerri L, 2017, HUM PATHOL, V64, P128, DOI 10.1016/j.humpath.2017.03.023	6	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	FEB	2018	72						198	199		10.1016/j.humpath.2017.09.018			2	Pathology	Pathology	FX4EC	WOS:000426024500026	29126835				2019-10-28	
J	Prayson, RA				Prayson, Richard A.			Reflecting on the Autopsy in the Training of New Residents	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material						Autopsy; Resident training; Reflection; Humanism	MEDICAL-STUDENTS		[Prayson, Richard A.] Cleveland Clin, Cleveland, OH 44106 USA	Prayson, RA (reprint author), Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA.	praysor@ccf.org					Bertman SL, 1989, CLIN ANAT, V2, P103, DOI DOI 10.1002/CA.980020207; Martyn H, 2013, ANAT SCI EDUC, V6, P410, DOI 10.1002/ase.1372; PENNEY JC, 1985, J MED EDUC, V60, P58; Tschernig T, 2000, ANAT REC, V261, P11; Weurlander M, 2012, INT J MED EDUC, V3, P63, DOI 10.5116/ijme.4f75.fb65	5	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					96	97		10.1093/AJCP/AQX140			2	Pathology	Pathology	FW8XI	WOS:000425619900001	29385415				2019-10-28	
J	Chavez, JA; Brat, DJ; Hunter, SB; Vega, JV; Guarner, J				Chavez, Jesus A.; Brat, Daniel J.; Hunter, Steven B.; Vega, Jose Velazquez; Guarner, Jeannette			Practical Diagnostic Approach to the Presence of Hyphae in Neuropathology Specimens With Three Illustrative Cases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Hypha; Hyphae; Septate; Mold; Pauciseptated; Septated; Dematiaceous; Histopathology	INVASIVE FUNGAL-INFECTIONS; CROSS-REACTIVITY; IMMUNOCOMPROMISED PATIENTS; SCEDOSPORIUM-PROLIFICANS; FUSARIUM SPP.; CULTURE; IDENTIFICATION; INFLATUM; IMMUNOHISTOCHEMISTRY; PHEOHYPHOMYCOSIS	Objectives: Early and accurate diagnosis remains crucial in the therapeutic management of invasive central nervous system fungal infections. Different molds have intrinsic resistance to antifungal agents; thus, morphologic differentiation is helpful to clinicians. Methods: Using three examples, we present a guide on how to approach neuropathology specimens where hyphae are identified on initial histologic examination. Results: Hyphae can be classified into three basic groups: hyaline pauciseptated, hyaline septated, and pigmented or dematiaceous. The hyaline pauciseptated group includes the order of the Mucorales (previously Zygomyces) and is frequent in patients with decompensated diabetes and severe neutropenia. Aspergillus species constitutes the most frequently isolated mold in the hyaline septated group. However, other invasive hyaline septated molds include Fusarium species, which is frequently resistant to multiple antifungals, and Candida species Last, dematiaceous molds, although infrequent, can be found in neuropathology specimens, as happened during the outbreak of Exserohilum associated with manufacturing practices in a compound pharmacy. Conclusions: Categorizing hyphae into the three groups described allows pathologists to provide information that is useful for infectious disease treatment with an inclusive differential diagnosis of diverse fungal genera that share the same morphological features.	[Chavez, Jesus A.] Ohio State Univ, Wexner Med Ctr, Dept Pathol & Lab Med, Columbus, OH 43210 USA; [Brat, Daniel J.; Hunter, Steven B.; Vega, Jose Velazquez; Guarner, Jeannette] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Guarner, J (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Emory Univ Hosp,Div Infect Dis Pathol, Room H183,1364 Clifton Rd NE, Atlanta, GA 30322 USA.	jguarne@emory.edu	Guarner, Jeannette/B-8273-2013				Chandrasekar P, 2010, EUR J HAEMATOL, V84, P281, DOI 10.1111/j.1600-0609.2009.01391.x; COX J, 1992, AM J NEURORADIOL, V13, P1489; Cummings JR, 2007, DIAGN MICR INFEC DIS, V59, P113, DOI 10.1016/j.diagmicrobio.2007.04.022; de Lucas EM, 2006, EUR RADIOL, V16, P496, DOI 10.1007/s00330-005-2869-8; DIXON DM, 1987, J MED VET MYCOL, V25, P97; Gamaletsou MN, 2012, CURR INFECT DIS REP, V14, P423, DOI 10.1007/s11908-012-0272-6; GARI M, 1985, SABOURAUDIA, V23, P371; Guarner J, 2011, CLIN MICROBIOL REV, V24, P247, DOI 10.1128/CMR.00053-10; Harris DE, 1997, NEUROIMAG CLIN N AM, V7, P187; Hennequin C, 1999, J CLIN MICROBIOL, V37, P3586; Hofman V, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-1; MADRIGAL V, 1995, EUR J CLIN MICROBIOL, V14, P601, DOI 10.1007/BF01690733; Marzolf G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152475; Mayayo E, 1999, J MED MICROBIOL, V48, P363, DOI 10.1099/00222615-48-4-363; McNeil MM, 2001, CLIN INFECT DIS, V33, P641, DOI 10.1086/322606; Metan G, 2012, REV IBEROAM MICOL, V29, P169, DOI 10.1016/j.riam.2011.07.003; Millon L, 2013, CLIN INFECT DIS, V56, pE95, DOI 10.1093/cid/cit094; Nakayama Haruo, 2010, Nihon Ishinkin Gakkai Zasshi, V51, P31; Nucci M, 2007, CLIN MICROBIOL REV, V20, P695, DOI 10.1128/CMR.00014-07; Pagano Livio, 2005, Expert Rev Anti Infect Ther, V3, P775, DOI 10.1586/14787210.3.5.775; PHILLIPS P, 1987, HUM PATHOL, V18, P1015, DOI 10.1016/S0046-8177(87)80218-6; RABODONIRINA M, 1994, CLIN INFECT DIS, V19, P138, DOI 10.1093/clinids/19.1.138; REED JA, 1993, J HISTOCHEM CYTOCHEM, V41, P1217, DOI 10.1177/41.8.8331285; Revankar SG, 2006, INFECT DIS CLIN N AM, V20, P609, DOI 10.1016/j.idc.2006.06.004; Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000; Rinaldi MG, 1996, DERMATOL CLIN, V14, P147, DOI 10.1016/S0733-8635(05)70335-1; Ruangritchankul K, 2015, INT J CLIN EXP PATHO, V8, P14840; Ruchel R, 1995, MYCOSES, V38, P473; Sangoi AR, 2009, AM J CLIN PATHOL, V131, P364, DOI 10.1309/AJCP99OOOZSNISCZ; Schofield CM, 2007, BURNS, V33, P341, DOI 10.1016/j.burns.2006.08.040; Schuetz AN, 2009, APPL IMMUNOHISTO M M, V17, P524, DOI 10.1097/PAI.0b013e3181a38e05; Sharifipour F, 2009, TRANSPL P, V41, P1654, DOI 10.1016/j.transproceed.2009.02.072; Sharma A, 2015, SAUDI J KIDNEY DIS T, V26, P1253, DOI 10.4103/1319-2442.168664; Sundaram C, 2014, INDIAN J PATHOL MICR, V57, P217, DOI 10.4103/0377-4929.134666; Suri P, 2014, J CLIN DIAGN RES, V8, pDD1, DOI 10.7860/JCDR/2014/7444.4216; Tarrand JJ, 2003, AM J CLIN PATHOL, V119, P854, DOI [10.1309/EXBVYAUPENBM285Y, 10.1309/EXBV-YAUP-ENBM-285Y]; Taxy JB, 2009, AM J CLIN PATHOL, V132, P86, DOI 10.1309/AJCP9HTH9NRPMYCT; Tortorano AM, 2014, CLIN MICROBIOL INFEC, V20, P27, DOI 10.1111/1469-0691.12465; Tortorano AM, 2012, J CLIN MICROBIOL, V50, P1051, DOI 10.1128/JCM.05946-11; WOOD GM, 1992, CLIN INFECT DIS, V14, P1027, DOI 10.1093/clinids/14.5.1027	40	0	0	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					98	104		10.1093/AJCP/AQX144			7	Pathology	Pathology	FW8XI	WOS:000425619900002	29365030				2019-10-28	
J	Liu, L; Wheeler, SE; Venkataramanan, R; Rymer, JA; Pizon, AF; Lynch, MJ; Tamama, K				Liu, Li; Wheeler, Sarah E.; Venkataramanan, Raman; Rymer, Jacqueline A.; Pizon, Anthony F.; Lynch, Michael J.; Tamama, Kenichi			Newly Emerging Drugs of Abuse and Their Detection Methods An ACLPS Critical Review	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Clinical chemistry; Gas chromatography-mass spectrometry; Designer drugs; Toxicology; Substance abuse detection	CHROMATOGRAPHY-MASS-SPECTROMETRY; DESIGNER DRUG; CHRONIC PAIN; HUMAN URINE; QUANTITATIVE MEASUREMENT; UNITED-STATES; LC-MS/MS; PART 2; FENTANYL; U-47700	Objectives: Illicit drug abuse has reached an epidemic level in the United States. Drug overdose has become the leading cause of injury-related deaths since 2008 due to the recent surge of opioid overdose by heroin, controlled prescription drugs, and nonmethadone synthetic opioids. Synthetic designer drugs such as synthetic cathinones ("bath salts") and synthetic cannabinoids ("Spice" and "K2") continue to emerge and attract recreational users. Methods: The emergence of new drugs of abuse poses a steep challenge for clinical toxicology laboratories. Limited information about the emerging drugs and their metabolism, "rebranding" of the illicit drugs, and a lack of Food and Drug Administration-approved screening methods for these drugs contribute to this difficulty. Here we review detection methods that can aid in identifying emerging drugs of abuse. Results: One promising approach is the utilization of untargeted drug screening by mass spectrometry. Historically, gas chromatography-mass spectrometry has been the gold standard. Conclusions: Liquid chromatography-tandem mass spectrometry and liquid chromatography-high-resolution mass spectrometry offer improved detection capability of new drugs with simplified sample preparation, making it the new standard.	[Liu, Li; Wheeler, Sarah E.; Venkataramanan, Raman; Tamama, Kenichi] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Liu, Li; Wheeler, Sarah E.; Venkataramanan, Raman; Rymer, Jacqueline A.; Tamama, Kenichi] Univ Pittsburgh, Presbyterian Hosp, Med Ctr, Clin Labs, Pittsburgh, PA 15213 USA; [Venkataramanan, Raman; Tamama, Kenichi] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Venkataramanan, Raman] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Pizon, Anthony F.; Lynch, Michael J.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Div Med Toxicol, Pittsburgh, PA USA; [Lynch, Michael J.] Pittsburgh Poison Control Ctr, Pittsburgh, PA USA; [Tamama, Kenichi] UPMC, Childrens Hosp Pittsburgh, Clin Lab, Pittsburgh, PA USA	Tamama, K (reprint author), 3550 Terrace St,S737 Scaife Hall, Pittsburgh, PA 15261 USA.	tamamakj@upmc.edu					Ammann D, 2012, J ANAL TOXICOL, V36, P381, DOI 10.1093/jat/bks049; [Anonymous], 2015, 2015 NAT DRUG THREAT; Auwarter V, 2009, J MASS SPECTROM, V44, P832, DOI 10.1002/jms.1558; Boyer EW, 2007, AM J ADDICTION, V16, DOI 10.1080/10550490701525368; Brents LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021917; BRITTAIN RT, 1973, BRIT J PHARMACOL, V49, pP158; Castaneto MS, 2014, DRUG ALCOHOL DEPEN, V144, P12, DOI 10.1016/j.drugalcdep.2014.08.005; Cherry Shane V, 2017, J Cardiothorac Vasc Anesth, V31, pe13, DOI 10.1053/j.jvca.2016.07.038; Christo PJ, 2011, PAIN PHYSICIAN, V14, P123; Cinosi E, 2015, BIOMED RES INT, DOI 10.1155/2015/968786; Cone EJ, 2009, POSTGRAD MED, V121, P91, DOI 10.3810/pgm.2009.07.2035; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Crespi C, 2016, CASE REP PSYCHIAT, V2016; Domanski K, 2017, CLIN TOXICOL, V55, P46, DOI 10.1080/15563650.2016.1209763; Eiden C, 2013, CLIN TOXICOL, V51, P899, DOI 10.3109/15563650.2013.847187; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Grigoryev A, 2011, J CHROMATOGR B, V879, P1126, DOI 10.1016/j.jchromb.2011.03.034; Hammett-Stabler CA, 2002, CLIN CHIM ACTA, V315, P125, DOI 10.1016/S0009-8981(01)00714-8; Harper N, 1976, US patent, Patent No. [3975443, 3, 975,443]; HARPER NJ, 1974, J MED CHEM, V17, P1188, DOI 10.1021/jm00257a012; Hudson S, 2011, DRUG TEST ANAL, V3, P466, DOI 10.1002/dta.268; Kacinko SL, 2011, J ANAL TOXICOL, V35, P386, DOI 10.1093/anatox/35.7.386; Kaye AD, 2017, PAIN PHYSICIAN, V20, pS111; Liu L, 2013, CLIN CHEM S, V59, pA131; Macher AM, 2013, DRUG TEST ANAL, V5, P130, DOI 10.1002/dta.1371; Manda VK, 2014, PLANTA MED, V80, P568, DOI 10.1055/s-0034-1368444; MAURER HH, 1992, J CHROMATOGR-BIOMED, V580, P3, DOI 10.1016/0378-4347(92)80526-V; Melanson SEF, 2012, J ANAL TOXICOL, V36, P201, DOI 10.1093/jat/bks003; Mercado MC, 2018, PAIN MED, V19, P511, DOI 10.1093/pm/pnx015; Meyer MR, 2010, J MASS SPECTROM, V45, P1426, DOI 10.1002/jms.1859; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moran CL, 2011, ANAL CHEM, V83, P4228, DOI 10.1021/ac2005636; Mueller DM, 2012, ANAL BIOANAL CHEM, V402, P2141, DOI 10.1007/s00216-011-5678-8; Nagai H, 2014, INT J CARDIOL, V172, P263, DOI 10.1016/j.ijcard.2013.12.262; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Peterson BL, 2015, J ANAL TOXICOL, V39, P642, DOI 10.1093/jat/bkv091; Philipp AA, 2011, ANAL BIOANAL CHEM, V400, P127, DOI 10.1007/s00216-010-4464-3; Prosser JM, 2012, J MED TOXICOL, V8, P33, DOI 10.1007/s13181-011-0193-z; Regester LE, 2015, J ANAL TOXICOL, V39, P144, DOI 10.1093/jat/bku133; Rojek S, 2016, FORENSIC TOXICOL, V34, P403, DOI 10.1007/s11419-016-0309-x; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P369, DOI 10.1007/s12024-016-9795-8; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Singh D, 2016, BRAIN RES BULL, V126, P41, DOI 10.1016/j.brainresbull.2016.05.004; Sobolevsky T, 2010, FORENSIC SCI INT, V200, P141, DOI 10.1016/j.forsciint.2010.04.003; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Spiller HA, 2011, CLIN TOXICOL, V49, P499, DOI 10.3109/15563650.2011.590812; Strathmann FG, 2011, AM J CLIN PATHOL, V136, P609, DOI 10.1309/AJCPW0TA8OBBNGCK; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; The Drug Enforcement Administration's (DEA) Special Testing and Research Laboratory's Emerging Trends Program, DEA SPEC TEST RES LA; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Trecki J, 2015, NEW ENGL J MED, V373, P103, DOI 10.1056/NEJMp1505328; U.S. Department of Justice Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; Uchiyama N, 2013, FORENSIC TOXICOL, V31, P223, DOI 10.1007/s11419-013-0182-9; Uchiyama N, 2009, CHEM PHARM BULL, V57, P439, DOI 10.1248/cpb.57.439; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; Wu AH, 2012, CLIN TOXICOL, V50, P733, DOI 10.3109/15563650.2012.713108; Zhang YV, 2016, CLIN LAB MED, V36, P635, DOI 10.1016/j.cll.2016.07.001	59	8	9	1	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					105	116		10.1093/AJCP/AQX138			12	Pathology	Pathology	FW8XI	WOS:000425619900003	29385414	Bronze			2019-10-28	
J	Ahn, H; Kim, H; Abdul, R; Kim, Y; Sim, J; Choi, D; Paik, SS; Shin, SJ; Kim, DH; Jang, K				Ahn, Hyein; Kim, Hyunsung; Abdul, Rehman; Kim, Yesul; Sim, Jongmin; Choi, Dongho; Paik, Seung Sam; Shin, Su-Jin; Kim, Dong-Hoon; Jang, Kiseok			Overexpression of Forkhead Box O3a and Its Association With Aggressive Phenotypes and Poor Prognosis in Human Hepatocellular Carcinoma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Forkhead box O3A protein (FoxO3A); Hepatocellular carcinoma; Immunohistochemistry; Prognosis	FOXO3A; CANCER; APOPTOSIS; PROTEINS; AKT	Objectives: Recent research has demonstrated that forkhead box O3a (FoxO3a) may function as an oncogenic transcription factor. We sought to validate the clinicopathologic significance of FoxO3a expression in hepatocellular carcinoma (HCC). Methods: Western blotting and immunohistochemistry were used to determine FoxO3a expression. In vitro cell proliferation and migration assays were performed in a HepG2 cell line. Results: FoxO3a was overexpressed in 121 (64.71%) cases of HCC. FoxO3a overexpression was associated with aggressive phenotypes of HCC, such as histologic grade (P < .001), stage (P = .031), and small vessel invasion (P < .001). FoxO3a overexpression was also correlated with poor disease-free survival in both univariate and multivariate survival analyses (P = .001 and P = .018, respectively). Downregulation of FoxO3a in a HepG2 cell line inhibited cell proliferation and migration. Conclusions: These results suggest a role for FoxO3a in HCC progression and support the potential use as a prognostic biomarker.	[Ahn, Hyein] Konyang Univ, Coll Med, Dept Pathol, Daejeon, South Korea; [Kim, Hyunsung; Abdul, Rehman; Kim, Yesul; Paik, Seung Sam; Shin, Su-Jin; Jang, Kiseok] Hanyang Univ, Coll Med, Dept Pathol, 222 Wangsimni Ro, Seoul 04763, South Korea; [Choi, Dongho] Hanyang Univ, Coll Med, Dept Surg, Seoul, South Korea; [Sim, Jongmin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Kim, Dong-Hoon] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, Seoul, South Korea	Jang, K (reprint author), Hanyang Univ, Coll Med, Dept Pathol, 222 Wangsimni Ro, Seoul 04763, South Korea.	medartisan@hanyang.ac.kr	REHMAN, ABDUL/L-7934-2018; Jang, Kiseok/C-9769-2015	REHMAN, ABDUL/0000-0003-4223-4545; Jang, Kiseok/0000-0002-6585-3990	National Research Foundation of Korea (NRF) - Korean - government (MSIP) [2015R1C1A1A01056091]	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean - government (MSIP) (No. 2015R1C1A1A01056091).	Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Chen MF, 2008, INT J RADIAT ONCOL, V71, P1220, DOI 10.1016/j.ijrobp.2008.02.077; Dhanasekaran R, 2012, HEPATIC MED-EVID RES, V4, P19, DOI 10.2147/HMER.S16316; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Habashy HO, 2011, BREAST CANCER RES TR, V129, P11, DOI 10.1007/s10549-010-1161-z; Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Liang C, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-14; Liu Hong-Bin, 2015, Asian Pac J Cancer Prev, V16, P1443; Lu MD, 2009, PATHOL ONCOL RES, V15, P679, DOI 10.1007/s12253-009-9171-z; Luo YH, 2015, INT J CLIN EXP MED, V8, P10235; Marlow LA, 2012, J CELL SCI, V125, P4253, DOI 10.1242/jcs.097428; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Park SH, 2015, ONCOTARGET, V6, P44819, DOI 10.18632/oncotarget.6264; Shou Z, 2012, J CANCER RES CLIN, V138, P585, DOI 10.1007/s00432-011-1125-7; Shukla S, 2009, INT J ONCOL, V34, P1613, DOI 10.3892/ijo_00000291; Sisci D, 2013, CELL CYCLE, V12, P3405, DOI 10.4161/cc.26421; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Yang XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078158; Yu S, 2015, INT J CLIN EXP PATHO, V8, P2963; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010	26	2	2	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					117	127		10.1093/AJCP/AQX132			11	Pathology	Pathology	FW8XI	WOS:000425619900004	29365018				2019-10-28	
J	Din, NU; Ahmad, Z; Zreik, R; Horvai, A; Folpe, AL; Fritchie, K				Din, Nasir Ud; Ahmad, Zubair; Zreik, Riyam; Horvai, Andrew; Folpe, Andrew L.; Fritchie, Karen			Abdominopelvic and Retroperitoneal Low-Grade Fibromyxoid Sarcoma A Clinicopathologic Study of 13 Cases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Low-grade fibromyxoid sarcoma; Abdomen; Pelvis; Retroperitoneal; MUC4	SCLEROSING EPITHELIOID FIBROSARCOMA; SMALL-BOWEL MESENTERY; SPINDLE-CELL TUMOR; OF-THE-LITERATURE; DESMOID TUMORS; GIANT ROSETTES; GENE; MUTATIONS; FUSION; COLON	Objectives: Low-grade fibromyxoid sarcoma (LGFMS) is a rare tumor often arising in the lower extremities. Only rare examples in the abdominal cavity, pelvis, and retroperitoneum have been reported. Methods: Thirteen cases of abdominopelvic and retroperitoneal LGFMS were retrieved. MUC4, Actin, ALK, ss-catenin, desmin, DOG1, KIT, S100 protein, and STAT6 testing was performed, and a subset was tested for FUS rearrangement. Results: Sites included intra-abdominal/abdominal wall (four cases), retroperitoneum (three cases), pelvis (three cases), small bowel (two cases), and kidney (one case) (median size, 15 cm; age range, 5-61 years). Tumors harbored spindled cells with mild to moderate atypia, displaying alternating myxoid nodules and hyalinized areas. All cases were positive for MUC4, and five (of five) cases tested harbored FUS rearrangement. Variable positivity for DOG1 (four of 10) and actin (two of 10) was identified. Six tumors recurred, and one patient developed metastasis. Conclusion: LGFMS arising in these central locations exhibits similar clinicopathologic features to its counterpart in the extremities. LGFMS at these sites may show limited immunoreactivity for DOG1 and actin.	[Din, Nasir Ud; Ahmad, Zubair] Aga Khan Univ Hosp, Dept Pathol & Lab Med, Karachi, Pakistan; [Zreik, Riyam] Scott & White Med Ctr, Dept Pathol, Temple, TX USA; [Horvai, Andrew] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Folpe, Andrew L.; Fritchie, Karen] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	Din, NU (reprint author), Aga Khan Univ Hosp, Dept Pathol & Lab Med, Karachi, Pakistan.	nasir.uddin@aku.edu					Alatise OI, 2013, AFR HEALTH SCI, V13, P736, DOI 10.4314/ahs.v13i3.31; Alevizopoulos A, 2012, CASE REP NEPHROL DIA, V2, P87, DOI 10.1159/000341191; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004; Fujii S, 2008, RADIAT MED, V26, P244, DOI 10.1007/s11604-007-0214-7; Goldblum JR, 2013, ENZINGER WEISSS SOFT, P324; Guillou L, 2007, AM J SURG PATHOL, V31, P1387, DOI 10.1097/PAS.0b013e3180321959; Harish K, 2003, BMC Surg, V3, P7, DOI 10.1186/1471-2482-3-7; Kim KJ, 2014, JPN J RADIOL, V32, P360, DOI 10.1007/s11604-014-0305-1; Koishi A, 2003, J OBSTET GYNAECOL RE, V29, P388, DOI 10.1111/j.1341-8076.2003.00133.x; Konecna J, 2015, INT J SURG CASE REP, V14, P40, DOI 10.1016/j.ijscr.2015.06.022; Laurini JA, 2011, AM J SURG PATHOL, V35, P1069, DOI 10.1097/PAS.0b013e31821bc17a; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lee AF, 2011, HUM PATHOL, V42, P1804, DOI 10.1016/j.humpath.2011.01.023; Matsuyama A, 2008, DIAGN MOL PATHOL, V17, P237, DOI 10.1097/PDM.0b013e318166d205; Mendoza AS, 2015, EXP MOL PATHOL, V98, P300, DOI 10.1016/j.yexmp.2015.02.007; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; MIYAKI M, 1993, CANCER RES, V53, P5079; Park IJ, 2007, DIGEST LIVER DIS, V39, P274, DOI 10.1016/j.dld.2006.01.015; Rubinstein JC, 2014, PEDIATR DEVEL PATHOL, V17, P321, DOI 10.2350/14-05-1487-CR.1; Singh K, 2012, INDIAN J SURG, V74, P351, DOI 10.1007/s12262-012-0415-x; Thway K, 2015, INT J SURG PATHOL, V23, P454, DOI 10.1177/1066896915593801; Vasudevan G, 2014, J INTERDISCIPL HISTO, V2, P228	24	2	2	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					128	134		10.1093/AJCP/AQX137			7	Pathology	Pathology	FW8XI	WOS:000425619900005	29385413				2019-10-28	
J	Haskell, GT; Liu, YJJ; Chen, H; Chen, BY; Meyer, RG; Yuhas, JA; Geiersbach, KB				Haskell, Gloria T.; Liu, Yajuan J.; Chen, Hui; Chen, Beiyun; Meyer, Reid G.; Yuhas, Jason A.; Geiersbach, Katherine B.			Integrated Analysis of HER2 Copy Number by Cytogenomic Microarray in Breast Cancers With Nonclassical In Situ Hybridization Results	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						HER2; Breast cancer; Copy number	PATHOLOGISTS GUIDELINE RECOMMENDATIONS; AMERICAN-SOCIETY; CLINICAL-ONCOLOGY/COLLEGE; COLLEGE; PERCENTAGE; UPDATE; TUMORS	Objectives: To develop and test an integrated approach to human epidermal growth factor receptor 2 (HER2) copy number analysis in breast cancer using in situ hybridization (ISH) and cytogenomic microarray (CMA). Methods: CMA was performed on four clinical breast cancer samples with nonclassical patterns of HER2 ISH results. Integrated analysis was performed by correlating the data from pathology review, ISH, and CMA. Results: Integrated analysis provided a more comprehensive view of the genomic copy number landscape that informed HER2 copy number analysis, but ISH provided essential data in all cases. Conclusions: CMA can be helpful for clarifying HER2 amplification status in breast cancer. However, uncertainties over tumor percentage, clonal heterogeneity, and varying ploidy levels present challenges for genomic methods such as CMA. Accurate interpretation of HER2 copy number by CMA requires correlation with the pathology and ISH data.	[Haskell, Gloria T.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Liu, Yajuan J.] Univ Washington, Sch Med, Dept Pathol, Clin Cytogen Lab,Ctr Precis Diagnost, Seattle, WA 98195 USA; [Chen, Hui] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chen, Beiyun] Mayo Clin, Div Anat Pathol, Dept Lab Med & Pathol, Rochester, MN USA; [Meyer, Reid G.; Yuhas, Jason A.; Geiersbach, Katherine B.] Mayo Clin, Div Lab Genet & Genom, Dept Lab Med & Pathol, Rochester, MN USA	Geiersbach, KB (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	geiersbach.katherine@mayo.edu			Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN	Supported by the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.	Ballard M, 2017, MODERN PATHOL, V30, P227, DOI 10.1038/modpathol.2016.175; Cooley LD, 2013, GENET MED, V15, P484, DOI 10.1038/gim.2013.49; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Geiersbach KB, 2016, AM J CLIN PATHOL, V146, P439, DOI [10.1093/AJCP/AQW130, 10.1093/ajcp/aqw130]; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Press MF, 2016, J CLIN ONCOL, V34, P3518, DOI 10.1200/JCO.2016.66.6693; Shah MV, 2016, J CLIN ONCOL, V34, P3502, DOI 10.1200/JCO.2015.61.8983; Smits AJJ, 2014, MODERN PATHOL, V27, P168, DOI 10.1038/modpathol.2013.134; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Viray H, 2013, ARCH PATHOL LAB MED, V137, P1545, DOI 10.5858/arpa.2012-0561-CP; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	14	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					135	147		10.1093/AJCP/AQX143			13	Pathology	Pathology	FW8XI	WOS:000425619900006	29385416	Bronze			2019-10-28	
J	Fang, H; Chiu, A; Reichard, KK				Fang, Hong; Chiu, April; Reichard, Kaaren K.			Crystal-Storing Histiocytosis in Bone Marrow A Clinicopathologic Study of Eight Cases and Review of the Literature	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Crystal-storing histiocytosis; Bone marrow; Lymphoproliferative; Plasma cell; Myeloma	B-CELL LYMPHOMA; MARGINAL-ZONE LYMPHOMA; MIMICKING ADULT RHABDOMYOMA; CHARCOT-LEYDEN CRYSTALS; FINE-NEEDLE-ASPIRATION; CENTRAL-NERVOUS-SYSTEM; KAPPA LIGHT-CHAIN; MULTIPLE-MYELOMA; LYMPHOPROLIFERATIVE DISORDER; MONOCLONAL GAMMOPATHY	Objectives: We report the clinicopathologic characteristics of eight cases of crystal-storing histiocytosis (CSH) with bone marrow (BM) involvement (BM-CSH) and review CSH cases published in the English literature. Methods: We queried our pathology database for BM cases with CSH mentioned in the final diagnosis/comments from June 2011 to August 2016. Results: Eight cases of BM-CSH were identified. The underlying diagnoses consisted predominantly of plasma cell disorders (88%) associated with monotypic. light chain. In BM aspirates, crystals within histiocytes exhibited a morphologic spectrum including brightly eosinophilic, needle-like, or globule-like. In BM core biopsies, the histiocytes were often in aggregates with intracellular needle-like and/or globular, refractile inclusions. Conclusions: BM-CSH is a rare phenomenon and exhibits a heterogeneous crystalline and histiocytic appearance warranting accurate recognition to avoid misinterpretation of a granulomatous condition or storage disorder. In addition, prompt assessment for an underlying B-cell lymphoma or clonal plasmacytic neoplasm is indicated.	[Fang, Hong; Chiu, April; Reichard, Kaaren K.] Mayo Clin, Div Hematopathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Reichard, KK (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	reichard.kaaren@mayo.edu					Alayed KM, 2010, PATHOLOGY, V42, P85, DOI 10.3109/00313020903434652; Aline-Fardin A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001247; Baird SM, 2015, LEUKEMIA LYMPHOMA, V56, P3233, DOI 10.3109/10428194.2015.1036261; Balakrishna J, 2016, HEAD NECK-J SCI SPEC, V38, pE95, DOI 10.1002/hed.24321; Bosman C, 1998, ARCH PATHOL LAB MED, V122, P920; Campomanes AGD, 2009, CORNEA, V28, P1081, DOI 10.1097/ICO.0b013e318199f73b; Chaudhary S, 2014, BREAST J, V20, P539, DOI 10.1111/tbj.12307; Costanzi C, 2012, MULT SCLER RELAT DIS, V1, P95, DOI 10.1016/j.msard.2011.12.003; Coupland SE, 2002, OPHTHALMOLOGY, V109, P105, DOI 10.1016/S0161-6420(01)00837-5; Perez DED, 2012, ANN DIAGN PATHOL, V16, P527, DOI 10.1016/j.anndiagpath.2011.05.004; Lastours V, 2006, J RHEUMATOL, V33, P2354; Dogan S, 2012, HEAD NECK PATHOL, V6, P111, DOI 10.1007/s12105-011-0326-3; Duquesne A, 2013, HUM PATHOL, V44, P927, DOI 10.1016/j.humpath.2012.10.012; El Hamel C, 2010, NEPHROL DIAL TRANSPL, V25, P2982, DOI 10.1093/ndt/gfq129; Fairweather PM, 2006, AM J SURG PATHOL, V30, P262, DOI 10.1097/01.pas.0000178093.99889.f7; Farooq U, 2009, ANN HEMATOL, V88, P807, DOI 10.1007/s00277-008-0660-z; Friedman MT, 1996, ARCH PATHOL LAB MED, V120, P1133; Galed-Placed I, 2006, ACTA CYTOL, V50, P539, DOI 10.1159/000326010; Gao FF, 2011, ACTA CYTOL, V55, P302, DOI 10.1159/000324558; Garcia JF, 1998, HISTOPATHOLOGY, V33, P459, DOI 10.1046/j.1365-2559.1998.00531.x; Harada M, 1996, HUM PATHOL, V27, P84, DOI 10.1016/S0046-8177(96)90143-4; Hu XX, 2012, EUR J HAEMATOL, V89, P183, DOI 10.1111/j.1600-0609.2012.01800.x; Ionescu DN, ARCH PATHOL LAB MED; Isono Yoshiaki, 2016, Nihon Shokakibyo Gakkai Zasshi, V113, P968, DOI 10.11405/nisshoshi.113.968; Johnson Mahlon, 2013, Surg Neurol Int, V4, P112, DOI 10.4103/2152-7806.117412; Jones D, 1996, ARCH PATHOL LAB MED, V120, P978; Jones D, 1999, HUM PATHOL, V30, P1441, DOI 10.1016/S0046-8177(99)90166-1; Joo M, 2007, HISTOPATHOLOGY, V51, P116, DOI 10.1111/j.1365-2559.2007.02710.x; Kaminsky I A, 2011, AJNR Am J Neuroradiol, V32, pE26, DOI 10.3174/ajnr.A1983; Kanagal-Shamanna R, 2016, HISTOPATHOLOGY, V68, P482, DOI 10.1111/his.12768; KAPADIA SB, 1993, AM J SURG PATHOL, V17, P461, DOI 10.1097/00000478-199305000-00004; Kar Rakhee, 2008, Indian J Hematol Blood Transfus, V24, P63, DOI 10.1007/s12288-008-0030-y; Kaufmann O, 1996, PATHOL RES PRACT, V192, P1148, DOI 10.1016/S0344-0338(96)80036-7; Kawano N, 2013, J CLIN EXP HEMATOP, V53, P241, DOI 10.3960/jslrt.53.241; Keane C, 2008, Br J Haematol, V141, P750, DOI 10.1111/j.1365-2141.2008.07131.x; Khurram SA, 2011, ORAL SURG ORAL MED O, V111, P494, DOI 10.1016/j.tripleo.2010.12.019; Ko HM, 2012, DIAGN CYTOPATHOL, V40, P916, DOI 10.1002/dc.21677; Kokuho N, 2017, HUM PATHOL, V65, P180, DOI 10.1016/j.humpath.2016.10.028; Kusakabe T, 2007, VIRCHOWS ARCH, V450, P103, DOI 10.1007/s00428-006-0323-1; Lebeau A, 2002, BLOOD, V100, P1817, DOI 10.1182/blood.V100.5.1817.h81702001817_1817_1827; Lee JS, 2015, AM J CLIN PATHOL, V143, P300, DOI 10.1309/AJCPC7RWYPYG8UGY; Lee WS, 2009, AM J MED SCI, V338, P421, DOI 10.1097/MAJ.0b013e3181ad3feb; Lesesve JF, 2011, CYTOPATHOLOGY, V22, P207, DOI 10.1111/j.1365-2303.2010.00823.x; Lewis JT, 2007, AM J SURG PATHOL, V31, P481, DOI 10.1097/01.pas.0000213420.46127.9c; Li JJ, 2015, J CUTAN PATHOL, V42, P136, DOI 10.1111/cup.12413; Li Zeng-Shan, 2011, J Med Case Rep, V5, P53, DOI 10.1186/1752-1947-5-53; Llobet M, 1997, DIAGN CYTOPATHOL, V17, P148, DOI 10.1002/(SICI)1097-0339(199708)17:2<148::AID-DC12>3.0.CO;2-G; Loghavi S, 2015, BLOOD, V125, P2445, DOI 10.1182/blood-2015-01-623082; Mittal R, 2015, ACTA OPHTHALMOL, V93, pE602, DOI 10.1111/aos.12682; Miura TES, 2013, MOL GENET METAB, V110, P414, DOI 10.1016/j.ymgme.2013.08.001; Nagaharu Keiki, 2016, Rinsho Ketsueki, V57, P1032, DOI 10.11406/rinketsu.57.1032; Orr BA, 2014, CLIN NEUROPATHOL, V33, P23, DOI 10.5414/NP300645; Pais AV, 2004, LEPROSY REV, V75, P171; Papla B, 2004, VIRCHOWS ARCH, V445, P83, DOI 10.1007/s00428-004-1031-3; Park SH, 2010, KOREAN J LAB MED, V30, P580, DOI 10.3343/kjlm.2010.30.6.580; Pitman SD, 2006, ARCH PATHOL LAB MED, V130, P1077; Pock L, 2006, INT J DERMATOL, V45, P1408, DOI 10.1111/j.1365-4632.2006.02919.x; Prasad ML, 1998, AM J SURG PATHOL, V22, P1148, DOI 10.1097/00000478-199809000-00015; Radhakrishnan S, 2014, OPHTHAL PLAST RECONS, V30, pE67, DOI 10.1097/IOP.0b013e31829c41f7; Rodriguez FJ, 2008, LAB INVEST, V88, P1024, DOI 10.1038/labinvest.2008.72; Rossi G, 2013, AM J SURG PATHOL, V37, P906, DOI 10.1097/PAS.0b013e31827b1618; Rossi G, 2010, HISTOPATHOLOGY, V56, P403, DOI 10.1111/j.1365-2559.2010.03481.x; Sailey CJ, 2009, ARCH PATHOL LAB MED, V133, P1861, DOI 10.1043/1543-2165-133.11.1861; Saluja K, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.134439; Schaefer HE, 1996, PATHOL RES PRACT, V192, P1152, DOI 10.1016/S0344-0338(96)80037-9; Sethi S, 2002, AM J KIDNEY DIS, V39, P183, DOI 10.1053/ajkd.2002.29914; Shah S, 2016, KIDNEY INT, V89, P507, DOI 10.1016/j.kint.2015.12.012; Singh H, 2013, INDIAN J PHARMACOL, V45, P197, DOI 10.4103/0253-7613.108323; Stokes MB, 2006, KIDNEY INT, V70, P597, DOI 10.1038/sj.ki.5001524; Sukpanichnant S, 2000, AM J SURG PATHOL, V24, P129, DOI 10.1097/00000478-200001000-00016; Sun Yanyu, 2003, Ann Diagn Pathol, V7, P47, DOI 10.1053/adpa.2003.50008; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Szeto W, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw004; Tahara K, 2014, JPN J RADIOL, V32, P296, DOI 10.1007/s11604-014-0302-4; TAKAHASHI K, 1987, ACTA PATHOL JAPON, V37, P141; Thakral B, 2014, BLOOD, V123, P3540, DOI 10.1182/blood-2014-03-565788; Tholouli Eleni, 2005, Br J Haematol, V128, P412, DOI 10.1111/j.1365-2141.2004.05362.x; Thorson P, 2000, ARCH PATHOL LAB MED, V124, P460; Todd WU, 2010, DIAGN CYTOPATHOL, V38, P274, DOI 10.1002/dc.21193; Uthamalingam P, 2017, INT J SURG PATHOL; Vaid A, 2014, J CLIN PATHOL, V67, P740, DOI 10.1136/jclinpath-2014-202247; Watanabe H, 2015, PATHOL INT, V65, P38, DOI 10.1111/pin.12229; Weichman K, 2006, BONE MARROW TRANSPL, V38, P339, DOI 10.1038/sj.bmt.1705447; Weisberger James, 2004, Br J Haematol, V124, P696, DOI 10.1046/j.1365-2141.2003.04695.x; Woehrer A, 2015, CLIN NEUROPATHOL, V34, P4, DOI 10.5414/NP300847; Wu CK, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0584-8; YAMAMOTO T, 1991, ARCH PATHOL LAB MED, V115, P351; Yano Y, 2013, CLIN J GASTROENTEROL, V6, P237, DOI 10.1007/s12328-013-0388-8; Yu SC, 2013, BRIT J HAEMATOL, V160, P419, DOI 10.1111/bjh.12149; Zardawi IM, 2013, HISTOPATHOLOGY, V62, P967, DOI 10.1111/his.12102; Zhang C, 2013, ARCH PATHOL LAB MED, V137, P1199, DOI 10.5858/arpa.2013-0252-CR; Zioni F, 2004, TUMORI J, V90, P348	92	5	5	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					148	163		10.1093/AJCP/AQX150			16	Pathology	Pathology	FW8XI	WOS:000425619900007	29385417				2019-10-28	
J	Goyal, T; Thakral, B; Wang, SA; Bueso-Ramos, CE; Shi, M; Jevremovic, D; Morice, WG; Zhang, QY; George, TI; Foucar, KK; Bhattacharyya, S; Bagg, A; Rogers, HJ; Bodo, J; Durkin, L; Hsi, ED				Goyal, Tanu; Thakral, Beenu; Wang, Sa A.; Bueso-Ramos, Carlos E.; Shi, Min; Jevremovic, Dragan; Morice, William G.; Zhang, Qian-Yun; George, Tracy I.; Foucar, Kathryn K.; Bhattacharyya, Siddharth; Bagg, Adam; Rogers, Heesun J.; Bodo, Juraj; Durkin, Lisa; Hsi, Eric D.			T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas A Study From the Bone Marrow Pathology Group	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						T-LGL leukemia; B-cell lymphoma; Diffuse large B-cell lymphoma	LGL LEUKEMIA; PROLIFERATIONS; DISORDERS	Objective: T-cell large granular lymphocytic (T-LGL) leukemia is associated with B-cell lymphomas (BCLs), especially small BCLs. We aimed to explore and expand upon its association with BCLs. Methods: We retrospectively studied clinicopathologic features of T-LGL leukemia patients with coexisting BCL from January 2001 to December 2016. Results: Among 432 patients with T-LGL leukemia, 22 (5.1%) had an associated B-cell non-Hodgkin lymphoma. Thirteen (59%) patients had large and nine (41%) had small BCL. T-LGL leukemia occurred synchronously with BCL in five, preceded BCL in three, and followed BCL in 14 patients. Anemia was the most common cytopenia (68%). Only one patient had a history of rheumatoid arthritis. Conclusion: To our knowledge, this is the first multicenter study looking at the spectrum and incidence of BCLs in patients with T-LGL leukemia and highlights its association with large BCLs (3% of T-LGL leukemias).	[Goyal, Tanu; Rogers, Heesun J.; Bodo, Juraj; Durkin, Lisa; Hsi, Eric D.] Cleveland Clin, Cleveland, OH 44106 USA; [Thakral, Beenu; Wang, Sa A.; Bueso-Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Shi, Min; Jevremovic, Dragan; Morice, William G.] Mayo Clin, Rochester, MN USA; [Zhang, Qian-Yun; George, Tracy I.; Foucar, Kathryn K.] Univ New Mexico, Albuquerque, NM 87131 USA; [Bhattacharyya, Siddharth; Bagg, Adam] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA	Hsi, ED (reprint author), Cleveland Clin, Dept Lab Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hsie@ccf.org	Bagg, Adam/R-8450-2019	Jevremovic, Dragan/0000-0002-1792-5822			Alfano G, 2017, NEPHROL DIAL TRANSPL, V32, P730; Anoop P, 2010, BRIT J HAEMATOL, V148, P337, DOI 10.1111/j.1365-2141.2009.07932.x; Bockorny B, 2014, LEUKEMIA LYMPHOMA, V55, P1399, DOI 10.3109/10428194.2013.831090; Broome H Elizabeth, 2011, Clin Adv Hematol Oncol, V9, P958; GENTILE TC, 1994, BLOOD, V84, P2315; Gill H, 2012, BONE MARROW TRANSPL, V47, P952, DOI 10.1038/bmt.2011.212; Howard MT, 2010, AM J CLIN PATHOL, V133, P936, DOI 10.1309/AJCPIIL1Y5QXTIBP; Lamy T, 2003, SEMIN HEMATOL, V40, P185, DOI 10.1016/S0037-1963(03)00133-1; Lamy T, 2017, BLOOD, V129, P1082, DOI 10.1182/blood-2016-08-692590; National Cancer Institute, SURV EP END REPROG; Nawaz Ubaid, 2011, Clin Adv Hematol Oncol, V9, P956; Papadaki T, 2003, LEUKEMIA RES, V27, P85, DOI 10.1016/S0145-2126(02)00128-5; Papadaki T, 2002, LEUKEMIA RES, V26, P597, DOI 10.1016/S0145-2126(01)00183-7; Papadaki T, 2002, LEUKEMIA, V16, P2167, DOI 10.1038/sj.leu.2402643; Shah MV, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.59; Singleton TP, 2015, AM J CLIN PATHOL, V144, P137, DOI 10.1309/AJCPJ57YTEGLIUOI; Sokol L, 2006, ONCOLOGIST, V11, P263, DOI 10.1634/theoncologist.11-3-263; Viny A, 2008, LEUKEMIA LYMPHOMA, V49, P932, DOI 10.1080/10428190801932635; Xie XY, 2000, LEUKEMIA LYMPHOMA, V37, P97, DOI 10.3109/10428190009057632; Zhang RR, 2010, HEMATOL ONCOL, V28, P105, DOI 10.1002/hon.917	20	3	3	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					164	171		10.1093/AJCP/AQX146			8	Pathology	Pathology	FW8XI	WOS:000425619900008	29365010				2019-10-28	
J	Riou, J; Szuberski, J; Godart, C; Wajcman, H; Oliveira, JL; Hoyer, JD; Bardakdjian-Michau, J				Riou, Jean; Szuberski, Jessica; Godart, Christian; Wajcman, Henri; Oliveira, Jennifer L.; Hoyer, James D.; Bardakdjian-Michau, Josiane			Precision of CAPILLARYS 2 for the Detection of Hemoglobin Variants Based on Their Migration Positions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Capillary electrophoresis; Hemoglobinopathies; CAPILLARYS 2	PERFORMANCE LIQUID-CHROMATOGRAPHY; CATION-EXCHANGE HPLC; ZONE-ELECTROPHORESIS; MASS-SPECTROMETRY; BIORAD VARIANT; A(2); DIAGNOSIS; IDENTIFICATION; SYSTEM; QUANTIFICATION	Objectives: In this report, we evaluated utility of the capillary electrophoresis (CE) migration position of the CAPILLARYS 2 CE instrument. Methods: The precision of this x-axis number was determined on a selection of common hemoglobin (Hb) variants (Hb S, Hb C, Hb D-Punjab, Hb E, Hb Hope), and the reproducibility of this number was evaluated by comparing the results obtained by two large reference laboratories on 81 Hb variants. Additionally, the CE migration position is given for a total of 409 Hb variants. Results: The x-axis migration position showed excellent intra-and interassay precision. Comparison of Hb variants seen by both laboratories showed that 83% had a difference in migration position of 1 unit or less. Only three rare Hb variants showed a difference of more than 2 units. Conclusion: In summary, the CE migration position is a reproducible value and can be used as an aid in the identification of Hb variants.	[Riou, Jean; Godart, Christian; Bardakdjian-Michau, Josiane] Henri Mondor Hosp, Dept Biochem Genet, Creteil, France; [Wajcman, Henri] Henri Mondor Hosp, INSERM, Unit U955, Creteil, France; [Szuberski, Jessica; Oliveira, Jennifer L.; Hoyer, James D.] Mayo Clin, Div Hematopathol, 200 1st St SW, Rochester, MN 55905 USA	Hoyer, JD (reprint author), Mayo Clin, Div Hematopathol, 200 1st St SW, Rochester, MN 55905 USA.	jhoyer@mayo.edu					Bain BJ, 2001, HEMOGLOBINOPATHY DIA, P206; BASSET P, 1978, BLOOD, V51, P971; Borbely N, 2013, J CLIN PATHOL, V66, P29, DOI 10.1136/jclinpath-2012-200946; Cotton F, 1999, CLIN CHEM, V45, P237; FERRANTI P, 1994, METHOD ENZYMOL, V231, P45; FERRANTI P, 1991, ANAL BIOCHEM, V194, P1, DOI 10.1016/0003-2697(91)90143-H; Fucharoen S, 1998, CLIN CHEM, V44, P740; Gosselin RC, 2011, INT J LAB HEMATOL, V33, P159, DOI 10.1111/j.1751-553X.2010.01260.x; Greene DN, 2012, CLIN CHIM ACTA, V413, P1232, DOI 10.1016/j.cca.2012.03.027; Gulbis B, 2003, ANN CLIN BIOCHEM, V40, P659, DOI 10.1258/000456303770367261; Harteveld CL, 2014, INT J LAB HEMATOL, V36, P1, DOI 10.1111/ijlh.12108; Head CE, 2004, J CLIN PATHOL, V57, P276, DOI 10.1136/jcp.2003.008037; Higgins T, 2009, CLIN BIOCHEM, V42, P701, DOI 10.1016/j.clinbiochem.2009.01.004; Hoyer JD, 2005, CLIN CHEM, V51, P1303, DOI 10.1373/clinchem.2005.049577; Jenkins M, 2003, CLIN CHEM LAB MED, V41, P747, DOI 10.1515/CCLM.2003.114; Jenkins MA, 1997, J CAPILLARY ELECTROP, V4, P137; Joutovsky A, 2004, CLIN CHEM, V50, P1736, DOI 10.1373/clinchem.2004.034991; Keren DF, 2008, AM J CLIN PATHOL, V130, P824, DOI 10.1309/AJCPQY80HZWHHGZF; Keren DF, 2012, AM J CLIN PATHOL, V137, P660, DOI 10.1309/AJCPOF8V0JJOPSVF; Kleinert P, 2008, CLIN CHEM, V54, P69, DOI 10.1373/clinchem.2007.089961; Louahabi A, 2006, CLIN CHEM LAB MED, V44, P340, DOI 10.1515/CCLM.2006.059; Mais DD, 2009, AM J CLIN PATHOL, V132, P34, DOI 10.1309/AJCPP50JIXXZVLSS; Mario N, 1999, CLIN CHEM, V45, P285; OU CN, 1993, CLIN CHEM, V39, P820; Ou CN, 2001, CLIN CHIM ACTA, V313, P187, DOI 10.1016/S0009-8981(01)00672-6; Riou J, 1997, CLIN CHEM, V43, P34; SAHIN A, 1995, J CHROMATOGR A, V709, P121; SCHNEIDER RG, 1978, HEMOGLOBIN, V2, P417, DOI 10.3109/03630267809007076; Shihabi ZK, 2005, ELECTROPHORESIS, V26, P581, DOI 10.1002/elps.200410043; Suh DD, 1996, CLIN CHEM, V42, P1113; Szuberski J, 2012, INT J LAB HEMATOL, V34, P594, DOI 10.1111/j.1751-553X.2012.01440.x; TAN GB, 1993, J CLIN PATHOL, V46, P852, DOI 10.1136/jcp.46.9.852; Van Delft P, 2009, INT J LAB HEMATOL, V31, P484, DOI 10.1111/j.1751-553X.2009.01158.x; Wajcman H, 2001, HEMOGLOBIN, V25, P169, DOI 10.1081/HEM-100104026; Wang JH, 2006, ELECTROPHORESIS, V27, P3108, DOI 10.1002/elps.200500833; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; Winichagoon P, 2008, TRANSL RES, V152, P178, DOI 10.1016/j.trsl.2008.08.004; Yang ZH, 2009, AM J CLIN PATHOL, V131, P42, DOI 10.1309/AJCPD0PJGFT0SXMK	38	3	3	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					172	180		10.1093/AJCP/AQX148			9	Pathology	Pathology	FW8XI	WOS:000425619900009	29365076				2019-10-28	
J	Norgan, AP; Suman, VJ; Brown, CL; Flotte, TJ; Mounajjed, T				Norgan, Andrew P.; Suman, Vera J.; Brown, Charlene L.; Flotte, Thomas J.; Mounajjed, Taofic			Comparison of a Medical-Grade Monitor vs Commercial Off-the-Shelf Display for Mitotic Figure Enumeration and Small Object (Helicobacter pylori) Detection	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Informatics; Monitor; Calibration; Mitotic figure; Helicobacter; Dermatopathology; Gastrointestinal	VIRTUAL PATHOLOGY SLIDES; OBSERVER PERFORMANCE; CONSUMER-GRADE; COLOR DISPLAYS; ACCURACY; SEARCH	Objectives: To examine the performance of a commercial off-the-shelf (COTS) monitor vs a medical-grade (MG) monitor for small object enumeration in standardized digital pathology images. Methods: Pathologists reviewed 35 melanoma or 35 gastric biopsy images using the MG and COTS displays, with a 2-week washout period. Mitotic figure or Helicobacter pylori burden enumerations were compared with reference values reported by an expert subspecialist pathologist using a light microscope. Subjective evaluations of image color, brightness, and overall quality were also obtained. Results: There was substantial agreement between the mitotic counts obtained by the evaluating pathologists between monitors and the reference mitotic figure or H pylori burden assessments. Six of the nine evaluating pathologists subjectively evaluated the monitors as substantially similar. Conclusions: These findings are consistent with previous studies demonstrating that color calibration has limited impact on diagnostic accuracy and suggest that noncalibrated displays could be considered for fine assessment tasks.	[Norgan, Andrew P.; Brown, Charlene L.; Flotte, Thomas J.; Mounajjed, Taofic] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Suman, Vera J.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA	Norgan, AP (reprint author), Mayo Clin, Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	norgan.andrew@mayo.edu		Flotte, Thomas/0000-0001-5691-8249			Badano A, 2015, J DIGIT IMAGING, V28, P41, DOI 10.1007/s10278-014-9721-0; Bautista Pinky A, 2014, J Pathol Inform, V5, P4, DOI 10.4103/2153-3539.126153; Campbell WS, 2015, HUM PATHOL, V46, P1945, DOI 10.1016/j.humpath.2015.08.016; Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; D'Haene N, 2013, PROG BIOMED OPT IMAG, V8676, P1; Farahani Navid, 2016, J Pathol Inform, V7, P22, DOI 10.4103/2153-3539.181766; Fetterly KA, 2008, J DIGIT IMAGING, V21, P193, DOI 10.1007/s10278-007-9022-y; Kallio-Pulkkinen S, 2015, DENTOMAXILLOFAC RAD, V44, DOI 10.1259/dmfr.20140365; Kallio-Pulkkinen S, 2014, OR SURG OR MED OR PA, V118, P135, DOI 10.1016/j.oooo.2014.04.005; Kimpe T, 2016, MED PHYS, V43, P5009, DOI 10.1118/1.4959544; Krupinski EA, 2012, J DIGIT IMAGING, V25, P738, DOI 10.1007/s10278-012-9479-1; Krupinski EA, 2009, J DIGIT IMAGING, V22, P363, DOI 10.1007/s10278-008-9156-6; Malon C, 2012, ANAL CELL PATHOL, V35, P97, DOI 10.3233/ACP-2011-0029; Randell R, 2015, J DIGIT IMAGING, V28, P68, DOI 10.1007/s10278-014-9726-8; Revie WC, 2014, ANAL CELL PATHOL, V2014, P1; Salazar AJ, 2014, AM J ROENTGENOL, V202, P1272, DOI 10.2214/AJR.13.11509; Sharma G, 2011, J PATHOL INFORM, V2, pS44; Yadav K Shailaja, 2012, J Contemp Dent Pract, V13, P339	18	1	1	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	FEB	2018	149	2					181	185		10.1093/AJCP/AQX154			5	Pathology	Pathology	FW8XI	WOS:000425619900010	29365023				2019-10-28	
J	Kanai, Y; Nishihara, H; Miyagi, Y; Tsuruyama, T; Taguchi, K; Katoh, H; Takeuchi, T; Gotoh, M; Kuramoto, J; Arai, E; Ojima, H; Shibuya, A; Yoshida, T; Akahane, T; Kasajima, R; Morita, K; Inazawa, J; Sasaki, T; Fukayama, M; Oda, Y				Kanai, Yae; Nishihara, Hiroshi; Miyagi, Yohei; Tsuruyama, Tatsuhiro; Taguchi, Kenichi; Katoh, Hiroto; Takeuchi, Tomoyo; Gotoh, Masahiro; Kuramoto, Junko; Arai, Eri; Ojima, Hidenori; Shibuya, Ayako; Yoshida, Teruhiko; Akahane, Toshiaki; Kasajima, Rika; Morita, Kei-ichi; Inazawa, Johji; Sasaki, Takeshi; Fukayama, Masashi; Oda, Yoshinao			The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses	PATHOLOGY INTERNATIONAL			English	Article						biobank; empirical analysis; genome research; pathological tissue sample; sample collection and storage	HUMAN CANCERS; CELL; CONSORTIUM; FORMALIN; MEDICINE	Genome research using appropriately collected pathological tissue samples is expected to yield breakthroughs in the development of biomarkers and identification of therapeutic targets for diseases such as cancers. In this connection, the Japanese Society of Pathology (JSP) has developed The JSP Guidelines on the Handling of Pathological Tissue Samples for Genomic Research based on an abundance of data from empirical analyses of tissue samples collected and stored under various conditions. Tissue samples should be collected from appropriate sites within surgically resected specimens, without disturbing the features on which pathological diagnosis is based, while avoiding bleeding or necrotic foci. They should be collected as soon as possible after resection: at the latest within about 3h of storage at 4 degrees C. Preferably, snap-frozen samples should be stored in liquid nitrogen (about -180 degrees C) until use. When intending to use genomic DNA extracted from formalin-fixed paraffin-embedded tissue, 10% neutral buffered formalin should be used. Insufficient fixation and overfixation must both be avoided. We hope that pathologists, clinicians, clinical laboratory technicians and biobank operators will come to master the handling of pathological tissue samples based on the standard operating procedures in these Guidelines to yield results that will assist in the realization of genomic medicine.	[Kanai, Yae; Kuramoto, Junko; Arai, Eri; Ojima, Hidenori] Keio Univ, Dept Pathol, Sch Med, Tokyo, Japan; [Nishihara, Hiroshi] Hokkaido Univ, Dept Translat Pathol, Grad Sch Med, Sapporo, Hokkaido, Japan; [Miyagi, Yohei; Kasajima, Rika] Kanagawa Canc Ctr, Mol Pathol & Genet Div, Res Inst, Yokohama, Kanagawa, Japan; [Tsuruyama, Tatsuhiro] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto, Japan; [Taguchi, Kenichi] Kyushu Natl Canc Ctr, Dept Pathol, Fukuoka, Japan; [Katoh, Hiroto] Tokyo Med & Dent Univ, Med Res Inst, Dept Genom Pathol, Tokyo, Japan; [Takeuchi, Tomoyo] Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki, Japan; [Gotoh, Masahiro; Yoshida, Teruhiko] Natl Canc Ctr, Fundamental Innovat Oncol Core, Res Inst, Tokyo, Japan; [Shibuya, Ayako] Japanese Soc Pathol, Tokyo, Japan; [Akahane, Toshiaki] Hokuto Hosp, Dept Pathol, Obihiro, Hokkaido, Japan; [Morita, Kei-ichi; Inazawa, Johji] Tokyo Med & Dent Univ, Bioresource Res Ctr, Tokyo, Japan; [Sasaki, Takeshi; Fukayama, Masashi] Univ Tokyo, Dept Pathol, Grad Sch Med, Tokyo, Japan; [Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan	Kanai, Y (reprint author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	ykanai@keio.jp			Tailor-Made Medical Treatment Program - Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [17km0305003h0005]	This article was supported by "The Tailor-Made Medical Treatment Program (17km0305003h0005)" which is a project sponsored by the Japan Agency for Medical Research and Development (AMED). The authors are grateful to the many technical staff working in our laboratories for their laborious work, clinicians for approving the usage of tissue samples for this study, and members of the Advisory Council for developing The Guidelines on the Handling of Pathological Tissue Samples for Genomic Research, Drs. Hitoshi Nakagama (NCBN), Daisuke Matsubara (BBJ), Shumpei Niida (NCBN), Yu-ichi Goto (NCBN), Katsushige Yamashiro (NHO), Norihiro Teramoto (NHO), Chiyoe Kitagawa (NHO), Yasuhiro Matsumura (JCOG), Dai Shida (JCOG), Kenichi Nakamura (JCOG), Hajime Okita (JCCG), Eizo Hiyama (JCCG), Takashi Komori (JCCG), Yoshio Miki (JCA) and Atsushi Ochiai (JCA), for critical discussion and constructive suggestions.	[Anonymous], 2016, NCI BEST PRACT BIOSP; Arai E, 2015, INT J CANCER, V137, P2589, DOI 10.1002/ijc.29630; Arai E, 2014, INT J CANCER, V135, P1330, DOI 10.1002/ijc.28768; Belloni B, 2013, J CLIN PATHOL, V66, P124, DOI 10.1136/jclinpath-2012-200983; Bonthron DT, 2017, J PATHOL, V241, P119, DOI 10.1002/path.4849; Chen GL, 2014, MOL DIAGN THER, V18, P587, DOI 10.1007/s40291-014-0115-2; Chuang IC, 2016, PATHOL INT, V66, P288, DOI 10.1111/pin.12408; Fukuda H, 2010, JPN J CLIN ONCOL, V40, P881, DOI 10.1093/jjco/hyq135; Gerston KF, 2004, HUM PATHOL, V35, P571, DOI 10.1016/j.humpath.2004.01.009; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Hattori K, 2017, PATHOL INT, V67, P447, DOI 10.1111/pin.12564; Hirata M, 2017, J EPIDEMIOL, V27, pS22, DOI 10.1016/j.je.2016.12.006; Kanai Y, 2008, PATHOL INT, V58, P544, DOI 10.1111/j.1440-1827.2008.02270.x; Kanai Y, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00024; Matsubara A, 2014, PATHOL INT, V64, P39, DOI 10.1111/pin.12131; Oda Y, 2017, PATHOL INT, V67, P435, DOI 10.1111/pin.12565; Olson JE, 2014, CLIN GENET, V86, P50, DOI 10.1111/cge.12370; Organisation for Economic Co-operation and Development, 2007, OECD BEST PRACT GUID; PLANK J, 1952, Zentralbl Allg Pathol, V89, P252; Porta-Pardo E, 2017, NAT METHODS, V14, P782, DOI [10.1038/nmeth.4364, 10.1038/NMETH.4364]; Quinn AM, 2015, J THORAC ONCOL, V10, P784, DOI 10.1097/JTO.0000000000000473; Sakamoto Y, 2017, PATHOL INT, V67, P453, DOI 10.1111/pin.12566; Sato I, 2016, BIOPRESERV BIOBANK, V14, P45, DOI 10.1089/bio.2015.0051; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schneider G, 2017, NAT REV CANCER, V17, P239, DOI 10.1038/nrc.2017.5; Sugimura H, 2016, PATHOL INT, V66, P359, DOI 10.1111/pin.12418; Wada R, 2016, PATHOL INT, V66, P431, DOI 10.1111/pin.12431; WHO, 2006, BIOR MAN LAB BIOS GU; Wilson-Grady JT, 2013, METHODS, V61, P277, DOI 10.1016/j.ymeth.2013.03.031; World Health Organization, 2004, LAB BIOS MAN; Zhou JH, 2015, ARCH PATHOL LAB MED, V139, P812, DOI 10.5858/arpa.2014-0261-RA	31	7	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					63	90		10.1111/pin.12631			28	Pathology	Pathology	FV9QR	WOS:000424923700001	29431262	Green Published, Other Gold			2019-10-28	
J	Yamada, S; Guo, X				Yamada, Sohsuke; Guo, Xin			Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease	PATHOLOGY INTERNATIONAL			English	Review						animal model; chronic inflammatory disease; human PRDX4 transgenic mice (Tg); metabolic syndrome; peroxiredoxin (PRDX) 4	REGULATING KINASE 1; PANCREATIC BETA-CELLS; HIGH-FRUCTOSE DIET; HISTAMINE-RECEPTORS; OXIDATIVE STRESS; MACROPHAGE APOPTOSIS; DIABETIC-RATS; KAPPA-B; PROTECTS; STEATOHEPATITIS	The peroxiredoxin (PRDX) family, a new family of proteins with a pivotal antioxidative function, is ubiquitously synthesized and abundantly identified in various organisms. In contrast to the intracellular localization of other family members (PRDX1/2/3/5/6), PRDX4 is the only known secretory form and protects against oxidative damage by scavenging reactive oxygen species in both the intracellular (especially the endoplasmic reticulum) compartments and the extracellular space. We generated unique human PRDX4 (hPRDX4) transgenic (Tg) mice on a C57BL/6J background and investigated the critical and diverse protective roles of PRDX4 against diabetes mellitus, atherosclerosis, insulin resistance, and nonalcoholic fatty liver disease (NAFLD) as well as evaluated its role in the intestinal function in various animal models. Our published data have shown that PRDX4 helps prevent the progression of metabolic syndrome by reducing local and systemic oxidative stress and synergistically suppressing steatosis, inflammatory reactions, and/or apoptotic activity. These observations suggest that Tg mice may be a useful animal model for studying the relevance of oxidative stress on inflammation and the dysregulation of lipid/bile acid/glucose metabolism upon the progression of human metabolic syndrome, and that specific accelerators of PRDX4 may be useful as therapeutic agents for ameliorating various chronic inflammatory diseases.	[Yamada, Sohsuke; Guo, Xin] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Uchinada, Kanazawa, Ishikawa 9200293, Japan; [Guo, Xin] Hebei Med Univ, Lab Pathol, Hebei Canc Inst, Hosp 4, Shijiazhuang, Hebei, Peoples R China	Yamada, S (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Uchinada, Kanazawa, Ishikawa 9200293, Japan.	sohsuke@kanazawa-med.ac.jp			MSD Life Science Foundation; Public Interest Incorporated Foundation, Japan; Ministry of Education, Culture, Sports, Science and Technology, Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24790394, 16K08750]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402490]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2016206170]; high-level talent support project of Hebei Province [CG2015003011]	This work was supported in part by a grant from the MSD Life Science Foundation, Public Interest Incorporated Foundation, Japan (to S.Y.); by Grants-in-Aid for Scientific Research (24790394 and 16K08750) from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (to S.Y.); and by grants from National Natural Science Foundation of China (Number 81402490), Natural Science Foundation of Hebei Province (Number H2016206170), and high-level talent support project of Hebei Province (Number CG2015003011) (to X.G.). We would like to thank Hiroko Isagai, Hana Nishimura, and Naoko Tasaki for their expert technical assistance.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Busserolles J, 2003, J NUTR, V133, P1903; Cao ZB, 2011, J BIOL CHEM, V286, P42257, DOI 10.1074/jbc.M111.298810; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Ding Y, 2010, ANTIOXID REDOX SIGN, V13, P1477, DOI 10.1089/ars.2010.3137; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Fujii J, 2015, FREE RADICAL BIO MED, V83, P373, DOI 10.1016/j.freeradbiomed.2015.01.025; Gateva A, 2016, CLIN ENDOCRINOL, V85, P551, DOI 10.1111/cen.13135; Getz GS, 2012, ARTERIOSCL THROM VAS, V32, P1104, DOI 10.1161/ATVBAHA.111.237693; Giguere P, 2007, FEBS LETT, V581, P3863, DOI 10.1016/j.febslet.2007.07.011; Guo X, 2012, ANTIOXID REDOX SIGN, V17, P1362, DOI 10.1089/ars.2012.4549; Gurgul E, 2004, DIABETES, V53, P2271, DOI 10.2337/diabetes.53.9.2271; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Iqbal J, 2009, AM J PHYSIOL-ENDOC M, V296, pE1183, DOI 10.1152/ajpendo.90899.2008; Iuchi Y, 2009, BIOCHEM J, V419, P149, DOI 10.1042/BJ20081526; Iuliano L, 2001, LIPIDS, V36, pS41, DOI 10.1007/s11745-001-0680-1; Jagadeesha DK, 2005, AM J PHYSIOL-HEART C, V289, pH1047, DOI 10.1152/ajpheart.01071.2004; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 2005, TRENDS MOL MED, V11, P571, DOI 10.1016/j.molmed.2005.10.006; Kasai H., 2008, GENES ENV, V30, P33, DOI DOI 10.3123/JEMSGE.30.33; Kita Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043056; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Ku YP, 2009, ACTA HISTOCHEM, V111, P138, DOI 10.1016/j.acthis.2008.05.008; Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125-007-0886-7; Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323; Luo J, 1998, METABOLISM, V47, P663, DOI 10.1016/S0026-0495(98)90027-0; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Mellor K, 2010, NUTRITION, V26, P842, DOI 10.1016/j.nut.2009.08.017; Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848; Mouzaki M, 2013, HEPATOLOGY, V58, P120, DOI 10.1002/hep.26319; Nabeshima A, 2013, ANTIOXID REDOX SIGN, V19, P1983, DOI 10.1089/ars.2012.4946; Nawata A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152549; Neuschwander-Tetri BA, 2005, AM J MED SCI, V330, P326, DOI 10.1097/00000441-200512000-00011; Ortis F, 2008, DIABETOLOGIA, V51, P1213, DOI 10.1007/s00125-008-0999-7; Rhee SG, 2012, J BIOL CHEM, V287, P4403, DOI 10.1074/jbc.R111.283432; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sasaguri Y, 2005, CIRC RES, V96, P974, DOI 10.1161/01.RES.0000166325.00383.ed; Sasaguri Yasuyuki, 2004, J Atheroscler Thromb, V11, P122; Sato Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep02456; Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200; Syn WK, 2009, CLIN LIVER DIS, V13, P565, DOI 10.1016/j.cld.2009.07.003; Tabas I, 2009, ANN NY ACAD SCI, V1173, pE40, DOI 10.1111/j.1749-6632.2009.04957.x; Tanimoto A, 2006, TRENDS CARDIOVAS MED, V16, P280, DOI 10.1016/j.tcm.2006.06.001; Tasaki T, 2013, AM J PATHOL, V182, P597, DOI 10.1016/j.ajpath.2012.10.008; Vallejo SJH, 2009, AM J PHYSIOL-GASTR L, V296, pG782, DOI 10.1152/ajpgi.90324.2008; Wang KY, 2011, ARTERIOSCL THROM VAS, V31, P800, DOI 10.1161/ATVBAHA.110.215228; Wang KY, 2010, AM J PATHOL, V177, P713, DOI 10.2353/ajpath.2010.091198; Wong CM, 2000, ANTIOXID REDOX SIGN, V2, P507, DOI 10.1089/15230860050192288; Yamada S, 2008, AM J PATHOL, V172, P1419, DOI 10.2353/ajpath.2008.070604; Yamada S, 2017, HISTOL HISTOPATHOL, V32, P433, DOI 10.14670/HH-11-840; Yamada S, 2016, PATHOL INT, V66, P661, DOI 10.1111/pin.12477; Yamada S, 2016, PATHOL INT, V66, P376, DOI 10.1111/pin.12423; Yamada S, 2015, PATHOL INT, V65, P67, DOI 10.1111/pin.12246; Yamada S, 2013, PATHOL INT, V63, P435, DOI 10.1111/pin.12091; Yamada Sohsuke, 2012, Journal of UOEH, V34, P27; Yamada S, 2011, ARTERIOSCL THROM VAS, V31, P1555, DOI 10.1161/ATVBAHA.111.227140; Yu HX, 2011, ARTERIOSCL THROM VAS, V31, P2402, DOI 10.1161/ATVBAHA.111.235622; Zhang L, 2010, ATHEROSCLEROSIS, V211, P146, DOI 10.1016/j.atherosclerosis.2010.01.023; Zito E, 2015, FREE RADICAL BIO MED, V83, P299, DOI 10.1016/j.freeradbiomed.2015.01.011	61	5	5	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					91	101		10.1111/pin.12634			11	Pathology	Pathology	FV9QR	WOS:000424923700002	29341349				2019-10-28	
J	Mizutani, H; Ono, S; Ushiku, T; Kudo, Y; Ikemura, M; Kageyama, N; Yamamichi, N; Fujishiro, M; Someya, T; Fukayama, M; Koike, K; Onodera, H				Mizutani, Hiroya; Ono, Satoshi; Ushiku, Tetsuo; Kudo, Yotaro; Ikemura, Masako; Kageyama, Natsuko; Yamamichi, Nobutake; Fujishiro, Mitsuhiro; Someya, Takao; Fukayama, Masashi; Koike, Kazuhiko; Onodera, Hiroshi			Transparency-enhancing technology allows three-dimensional assessment of gastrointestinal mucosa: A porcine model	PATHOLOGY INTERNATIONAL			English	Article						gastrointestinal Tract; laser scanning microscopy; 3-D imaging	SQUAMOUS-CELL CARCINOMA; ENDOSCOPY; BRAIN	Although high-resolution three-dimensional imaging of endoscopically resected gastrointestinal specimens can help elucidating morphological features of gastrointestinal mucosa or tumor, there are no established methods to achieve this without breaking specimens apart. We evaluated the utility of transparency-enhancing technology for three-dimensional assessment of gastrointestinal mucosa in porcine models. Esophagus, stomach, and colon mucosa samples obtained from a sacrificed swine were formalin-fixed and paraffin-embedded, and subsequently deparaffinized for analysis. The samples were fluorescently stained, optically cleared using transparency-enhancing technology: ilLUmination of Cleared organs to IDentify target molecules method (LUCID), and visualized using laser scanning microscopy. After observation, all specimens were paraffin-embedded again and evaluated by conventional histopathological assessment to measure the impact of transparency-enhancing procedures. As a result, microscopic observation revealed horizontal section views of mucosa at deeper levels and enabled the three-dimensional image reconstruction of glandular and vascular structures. Besides, paraffin-embedded specimens after transparency-enhancing procedures were all assessed appropriately by conventional histopathological staining. These results suggest that transparency-enhancing technology may be feasible for clinical application and enable the three-dimensional structural analysis of endoscopic resected specimen non-destructively. Although there remain many limitations or problems to be solved, this promising technology might represent a novel histopathological method for evaluating gastrointestinal cancers.	[Mizutani, Hiroya; Ono, Satoshi; Kudo, Yotaro; Kageyama, Natsuko; Yamamichi, Nobutake; Fujishiro, Mitsuhiro; Koike, Kazuhiko] Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Ushiku, Tetsuo; Ikemura, Masako; Fukayama, Masashi] Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Fujishiro, Mitsuhiro] Univ Tokyo, Dept Endoscopy & Endoscop Surg, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Someya, Takao; Onodera, Hiroshi] Univ Tokyo, Dept Elect & Elect Engn, Bunkyo Ku, Tokyo, Japan; [Someya, Takao; Onodera, Hiroshi] Univ Tokyo, Photon Sci Ctr, Bunkyo Ku, Tokyo, Japan; [Someya, Takao] Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo, Japan	Ono, S (reprint author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Tokyo 1138655, Japan.	satoshi-tky@umin.ac.jp	Someya, Takao/H-3052-2015	Someya, Takao/0000-0003-3051-1138	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K09474]	This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (C) Grant number 17K09474.	Aoyagi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116280; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Gotoda T, 2000, GASTRIC CANCER, V3, P219, DOI DOI 10.1007/PL00011720; Gotoda Takuji, 2014, Gastrointest Endosc Clin N Am, V24, P213, DOI 10.1016/j.giec.2013.11.009; Inoue H, 2015, ANN GASTROENTEROL, V28, P41; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Kodashima S, 2010, WORLD J GASTROENTERO, V16, P1043, DOI 10.3748/wjg.v16.i9.1043; Muto M, 2010, J CLIN ONCOL, V28, P1566, DOI 10.1200/JCO.2009.25.4680; Saito Yutaka, 2014, Gastrointest Endosc Clin N Am, V24, P245, DOI 10.1016/j.giec.2013.11.005; Sekitani T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11425; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Staudt T, 2007, MICROSC RES TECHNIQ, V70, P1, DOI 10.1002/jemt.20396; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Uedo N, 2012, ANN GASTROENTEROL, V25, P281	16	4	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					102	108		10.1111/pin.12627			7	Pathology	Pathology	FV9QR	WOS:000424923700003	29341375				2019-10-28	
J	Yamanegi, K; Yamada, N; Nakasho, K; Nishiura, H				Yamanegi, Koji; Yamada, Naoko; Nakasho, Keiji; Nishiura, Hiroshi			Participation of delta annexin A3 in the ribosomal protein S19 C-terminus-dependent inhibitory mechanism of the neutrophil C5a receptor through delta lactoferrin	PATHOLOGY INTERNATIONAL			English	Article						C5a receptor; delta annexin A3; delta lactoferrin; neutrophils; ribosomal protein S19	SIGNAL-REGULATED KINASE; MEMBRANE-BINDING; CELLS; A1; APOPTOSIS; PATHWAY; DIFFERENTIATION; INTERNALIZATION; INFLAMMATION; DYNAMICS	Although C5a receptor (C5aR) interacting with its agonist C5a promotes acute inflammation during the initiation phase, the roles of the recycling C5aR during the resolution phase are still unclear. We found that C5aR interacted with its antagonist/agonist ribosomal protein S19 (RP S19) polymer or a RP S19 polymer functional analogue S-tagged C5a/RP S19, which connects an RP S19 C-terminus (IAGQVAAANKKH) to the S-tagged C5a C-terminus, promoted acute inflammation at the resolution phase via an activation of the apoptosis-inducing transcription factor delta lactoferrin (Lf) in neutrophils and the membrane mobilizing factor full-length annexin A3 (ANXA3) in macrophages. To confirm the antagonistic system of the recycling C5aR, S-tagged Lf-coupled BrCN-activated Sepharose 4B beads were incubated with cytoplasmic proteins and identified a neutrophil-specific ANXA3 via pull-down experiments. The S-tagged C5a/RP S19-induced agonistic functions in macrophage-like cells that were differentiated from human promyelocytic leukemia HL-60 cells by phorbol-12-myristate-13-acetate were suppressed by Lf and ANXA3 co-overexpression. ANXA3 seems to participate in the antagonistic system of the neutrophil C5aR involving IAGQVAAANKKH and Lf. Most likely, ANXA3 works as antagonist for the recycling C5aR on neutrophils during the resolution phase of acute inflammation.	[Yamanegi, Koji; Yamada, Naoko; Nakasho, Keiji; Nishiura, Hiroshi] Hyogo Coll Med, Dept Pathol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan	Nishiura, H (reprint author), Hyogo Coll Med, Dept Pathol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	hi-nishiura@hyo-med.ac.jp			Ministry of Education, Culture, Sports, Science, and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [26462863]; Hyogo College of Medicine	Peripheral blood was collected from healthy volunteers who provided written consent according to a protocol approved by the Research Ethics Committee of Hyogo College of Medicine (No.1793) in accordance with the Helsinki Declaration of 1975, as revised in 2002. Thank you Mrs. Yoko Sasa and Yasuko Yagaki for arranging this manuscript. This work was supported by a Grand-in Aid for Scientific Research (C) [26462863] from the Ministry of Education, Culture, Sports, Science, and Technology and a Grand-in Aid for Researchers, Hyogo College of Medicine, 2015.	Belvedere R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-961; Blume KE, 2012, J IMMUNOL, V188, P135, DOI 10.4049/jimmunol.1004073; Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Donohue MP, 2014, PROTEINS, V82, P2936, DOI 10.1002/prot.24623; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Koselj-Kajtna M, 2002, TRANSPLANT P, V34, P3001, DOI 10.1016/S0041-1345(02)03514-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECABEC V, 1992, BIOCHEM BIOPH RES CO, V189, P1471, DOI 10.1016/0006-291X(92)90240-L; Lee HY, 2010, FEMS IMMUNOL MED MIC, V59, P108, DOI 10.1111/j.1574-695X.2010.00668.x; Martin M, 2012, J BIOL CHEM, V287, P33733, DOI 10.1074/jbc.M112.341339; Michaud-Levesque J, 2007, BIOL CHEM, V388, P747, DOI 10.1515/BC.2007.081; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332; Nishiura H, 2015, IMMUNOBIOLOGY, V220, P1085, DOI 10.1016/j.imbio.2015.05.006; Nishiura H, 2014, EXP MOL PATHOL, V97, P241, DOI 10.1016/j.yexmp.2014.07.010; Nishiura H, 2013, ADV EXP MED BIOL, V735, P111, DOI 10.1007/978-1-4614-4118-2_7; Nishiura H, 2011, J BIOCHEM, V150, P271, DOI 10.1093/jb/mvr067; Nishiura H, 2009, LAB INVEST, V89, P676, DOI 10.1038/labinvest.2009.27; Ota Y, 2011, EXP MOL PATHOL, V90, P19, DOI 10.1016/j.yexmp.2010.11.008; Perianayagam MC, 2004, EUR J CLIN INVEST, V34, P50, DOI 10.1111/j.1365-2362.2004.01273.x; Pupjalis D, 2011, EMBO MOL MED, V3, P102, DOI 10.1002/emmm.201000113; Ray Kausik, 2015, Prog Mol Biol Transl Sci, V132, P127, DOI 10.1016/bs.pmbts.2015.02.006; Rosengarth A, 2003, J MOL BIOL, V326, P1317, DOI 10.1016/S0022-2836(03)00027-5; Sopkova J, 2002, PROTEIN SCI, V11, P1613, DOI 10.1110/ps.4230102; Trevani AS, 1996, LAB INVEST, V74, P711; Tsao FHC, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-44; Yamanegi K, 2017, IMMUNOBIOLOGY, V222, P738, DOI 10.1016/j.imbio.2017.02.001; Yang JJ, 1996, AM J PATHOL, V149, P1617; ZINZAR S, 1989, LEUKEMIA RES, V13, P23, DOI 10.1016/0145-2126(89)90027-1	30	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					109	116		10.1111/pin.12626			8	Pathology	Pathology	FV9QR	WOS:000424923700004	29288518				2019-10-28	
J	Donizy, P; Kaczorowski, M; Biecek, P; Halon, A; Matkowski, R				Donizy, Piotr; Kaczorowski, Maciej; Biecek, Przemyslaw; Halon, Agnieszka; Matkowski, Rafal			Nuclear pseudoinclusions in melanoma cells: prognostic fact or artifact? The possible role of Golgi phosphoprotein 3 overexpression in nuclear pseudoinclusions generation	PATHOLOGY INTERNATIONAL			English	Article						GOLPH3; melanoma; nuclear inclusions	PAPILLARY THYROID-CARCINOMA; INTRANUCLEAR INCLUSIONS; SPITZ NEVI; PITFALL; GROOVES; MTOR	Nuclear pseudoinclusions (NPIs) are classically found in papillary thyroid carcinoma and meningioma. Although NPIs have been described in melanocytic lesions, there is no systematic analysis of potential relationship between NPIs and other clinicopathological characteristics of melanoma. We examined the presence of NPIs in H&E-stained tissue sections form 96 melanomas and analyzed statistical associations with important clinicopathological parameters and tissue immunoreactivity for selected proteins involved in epithelial-mesenchymal transition (SPARC, N-cadherin), cell adhesion and mobility (ALCAM, ADAM-10), regulation of mitosis (PLK1), cell survival (FOXP1) and functioning of Golgi apparatus (GOLPH3, GP73). NPIs were observed in 20% of melanomas and their presence correlated with high mitotic rate and ulceration of the tumor, but not with Breslow thickness, histologic type, or presence of metastases. We observed a significant correlation with shorter cancer-specific survival, but not disease-free survival. Presence of NPIs was related to high expression of GOLPH3 in melanoma cells, whereas their absence was linked to enhanced immunoreactivity of GOLPH3 in tumor-associated macrophages. NPIs are not an uncommon finding in skin melanoma and their diagnostic and prognostic utility could be helpful in the daily routine histopathological practice. The possible explanation of NPI generation is associated with enhanced activity of Golgi apparatus in melanoma cells.	[Donizy, Piotr; Kaczorowski, Maciej; Halon, Agnieszka] Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, Borowska 213, PL-50556 Wroclaw, Poland; [Biecek, Przemyslaw] Warsaw Univ Technol, Fac Math & Informat Sci, Koszykowa 75, PL-00662 Warsaw, Poland; [Matkowski, Rafal] Wroclaw Med Univ, Dept Oncol, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland; [Matkowski, Rafal] Lower Silesian Canc Ctr, Pl Hirszfelda 12, PL-53413 Wroclaw, Poland	Donizy, P (reprint author), Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, Borowska 213, PL-50556 Wroclaw, Poland.	piotrdonizy@wp.pl		Kaczorowski, Maciej/0000-0002-7787-9952; Biecek, Przemyslaw/0000-0001-8423-1823	Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [ST.B130.16.049]	This research was financed through a statutory subsidy by the Polish Ministry of Science and Higher Education as a part of grant ST.B130.16.049 (record number in the Simple system).	Arora SK, 2012, DIAGN CYTOPATHOL, V40, P741, DOI 10.1002/dc.21714; BRUNNING RD, 1976, AM J CLIN PATHOL, V66, P10, DOI 10.1093/ajcp/66.1.10; Bussolati G, 1997, HISTOPATHOLOGY, V31, P400, DOI 10.1046/j.1365-2559.1997.3020895.x; Das DK, 2005, DIAGN CYTOPATHOL, V32, P264, DOI 10.1002/dc.20233; Donizy P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101619; Donizy P, 2015, ANAL CELL PATHOL, DOI 10.1155/2015/975436; Donizy P, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0331-z; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Ip YT, 2010, INT J SURG PATHOL, V18, P465, DOI 10.1177/1066896910385342; Kaczorowski M, 2017, J CUTAN PATHOL, V44, P819, DOI 10.1111/cup.12985; LEDUC EH, 1959, J BIOPHYS BIOCHEM CY, V6, P427, DOI 10.1083/jcb.6.3.427; Lee JH, 2008, ARCH PATHOL LAB MED, V132, P940, DOI 10.1043/1543-2165(2008)132[940:CSONGA]2.0.CO;2; Petrilli G, 2017, AM J SURG PATHOL, V41, P140, DOI 10.1097/PAS.0000000000000763; Pieniazek M, 2016, BIOMARK MED, V10, P975, DOI 10.2217/bmm-2016-0133; ROSE DSC, 1995, J CLIN PATHOL, V48, P676, DOI 10.1136/jcp.48.7.676; Scott KL, 2009, NATURE, V459, P1085, DOI 10.1038/nature08109; SOBEL HJ, 1969, ARCH PATHOL, V87, P179; Solomon A, 2002, DIAGN CYTOPATHOL, V27, P143, DOI 10.1002/dc.10156; Valdebran M, 2016, J AM ACAD DERMATOL, V75, P1032, DOI 10.1016/j.jaad.2016.06.051; Verardino GC, 2015, AN BRAS DERMATOL, V90, P91, DOI 10.1590/abd1806-4841.20153310; Yang SW, 2003, YONSEI MED J, V44, P816, DOI 10.3349/ymj.2003.44.5.816; Yoshida T, 1999, Brain Tumor Pathol, V16, P86, DOI 10.1007/BF02478908	22	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					117	122		10.1111/pin.12629			6	Pathology	Pathology	FV9QR	WOS:000424923700005	29377340				2019-10-28	
J	Kim, MJ; McCroskey, Z; Piao, YC; Belcheva, A; Truong, L; Kurtin, PJ; Ro, JY				Kim, Moon Joo; McCroskey, Zulfia; Piao, Yingchao; Belcheva, Anna; Luan Truong; Kurtin, Paul J.; Ro, Jae Y.			Spheroid-type of AL amyloid deposition associated with colonic adenocarcinoma: A case report with literature review	PATHOLOGY INTERNATIONAL			English	Review						colonic adenocarcinoma; electron microscope; Liesegang rings; spheroid-type amyloid	OF-THE-LITERATURE; LOCALIZED AMYLOIDOSIS; UTERINE CERVIX; CARCINOMA; JEJUNUM; SERIES; TUMOR	We report a colonic adenocarcinoma associated with diffuse submucosal deposition of a peculiar spheroid-type amyloid identified in the colon, terminal ileum, and appendix. A 65-year-old woman with past medical histories of hypertension, and chronic obstructive pulmonary disease, presented to the emergency room with cramping abdominal pain and nausea. A computed tomography (CT) scan of abdomen showed right colonic volvulus. Emergency right hemicolectomy was performed. The specimen showed colonic adenocarcinoma with focal submucosal invasion (pT1) arising from a villotubular adenoma. A diffuse submucosal spheroid-type amyloid deposition (resembling corpora amylacea-like structures with Liesegang ring formation) was identified in the colon, ileum, and appendix. Electron microscopy examination of this unusual spheroidal-type material further confirmed the presence of amyloid fibrils. Analysis by liquid chromatography-mass spectrometry detected AL (lambda) type amyloidosis in this specimen. Tests for monoclonal gammopathy were not performed because patient consent was not obtained. In tissue section evaluation, however, no plasma cell neoplasm was identified. Cases with isolated AL amyloid deposition in the gastrointestinal tract have been reported rarely, and there is no case report of colonic adenocarcinoma associated with primary amyloid deposition in the English literature.	[Kim, Moon Joo; McCroskey, Zulfia; Piao, Yingchao; Luan Truong; Ro, Jae Y.] Cornell Univ, Dept Pathol & Genom Med, Houston Methodist Hosp, Weill Med Coll, 6565 Fannin St, Houston, TX 77030 USA; [Belcheva, Anna] Cornell Univ, Dept Internal Med, Weill Med Coll, Houston, TX 77030 USA; [Kurtin, Paul J.] Mayo Clin, Div Hematopathol, Coll Med, Rochester, MN USA	Ro, JY (reprint author), Cornell Univ, Dept Pathol & Genom Med, Houston Methodist Hosp, Weill Med Coll, 6565 Fannin St, Houston, TX 77030 USA.	jaero@houstonmethodist.org					Acebo E, 1999, PATHOLOGY, V31, P8, DOI 10.1080/003130299105449; AHO HJ, 1992, INT J GYNECOL PATHOL, V11, P150, DOI 10.1097/00004347-199204000-00009; Biewend ML, 2006, AMYLOID, V13, P135, DOI 10.1080/13506120600876773; Cowan AJ, 2013, HAEMATOLOGICA, V98, P141, DOI 10.3324/haematol.2012.068155; HAMAYA K, 1989, ACTA PATHOL JAPON, V39, P207; LANDOLT AM, 1987, ARCH PATHOL LAB MED, V111, P453; LOOI LM, 1991, HISTOPATHOLOGY, V19, P169, DOI 10.1111/j.1365-2559.1991.tb00008.x; Merlini G, 2004, J INTERN MED, V255, P159, DOI 10.1046/j.1365-2796.2003.01262.x; MIURA K, 1993, AM J CLIN PATHOL, V100, P561, DOI 10.1093/ajcp/100.5.561; Mosqueda-Taylor A, 2014, HEAD NECK PATHOL, V8, P421, DOI 10.1007/s12105-014-0586-9; Pambuccian SE, 1997, AM J SURG PATHOL, V21, P179, DOI 10.1097/00000478-199702000-00007; Rowe K, 2017, CUREUS, V9, DOI 10.7759/cureus.1228; SHIMIZU S, 1986, Gastroenterologia Japonica, V21, P513; Val-Bernal JF, 1999, INT J GYNECOL PATHOL, V18, P188, DOI 10.1097/00004347-199904000-00018; WILLIAMS ED, 1966, J CLIN PATHOL, V19, P103, DOI 10.1136/jcp.19.2.103; YOUSUF M, 1992, HEPATO-GASTROENTEROL, V39, P267	16	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					123	127		10.1111/pin.12618			5	Pathology	Pathology	FV9QR	WOS:000424923700006	29222812				2019-10-28	
J	Kimura, N; Hasegawa, M; Hiroshima, K				Kimura, Noriko; Hasegawa, Masaru; Hiroshima, Kenzo			SMARCB1/INI1/BAF47-deficient pleural malignant mesothelioma with rhabdoid features	PATHOLOGY INTERNATIONAL			English	Article						BAP-1; pleural mesothelioma; p16 FISH; rhabdoid tumor; SMARCB1; INI1; BAF47	SMARCA4-DEFICIENT THORACIC SARCOMA; SOFT-TISSUE SARCOMAS; TUMOR; EXPRESSION; DIAGNOSIS; CELLS	Malignant mesothelioma (MM) with rhabdoid features is an MM variant. Fifteen cases have been reported previously, all of which were combined with other types of MM. Herein, we report an autopsy case of pleural MM with monomorphic rhabdoid features. The patient was a 62-year-old male without a history of asbestos exposure. An autopsy revealed a soft, granular tumor that replaced the entire left pleura and had invaded to the diaphragm and lower lobe of the lung. The tumor cells, which had eosinophilic plump cytoplasm and eccentric nuclei, were loosely cohesive. Immunohistochemistry showed that the cells were diffusely positive for calretinin, D2-40, vimentin, CAM5.2, and AE1/AE3; and negative for WT-1, TTF-1, CK7, CEA, desmin, CD34, BCL-2, S100 protein, and p40. Neither homozygous deletion of p16 nor BAP-1 protein loss was observed. Loss of INI1/BAF47 protein, an indicator of malignant rhabdoid tumor, was observed. Therefore, MM with rhabdoid features was confirmed.	[Kimura, Noriko] Natl Hosp Org Hakodate Hosp, Dept Diagnost Pathol, 18-16 Kawahara, Hakodate, Hokkaido, Japan; [Kimura, Noriko] Natl Hosp Org Hakodate Hosp, Dept Clin Res, Div Pathol, Hakodate, Hokkaido, Japan; [Hasegawa, Masaru] Natl Hosp Org Hakodate Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Dept Pathol KH, Yachiyo Med Ctr, Yachiyo, Japan; [Hasegawa, Masaru] Sapporo City Gen Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan	Kimura, N (reprint author), Natl Hosp Org Hakodate Hosp, Dept Diagnost Pathol, 18-16 Kawahara, Hakodate, Hokkaido, Japan.; Kimura, N (reprint author), Natl Hosp Org Hakodate Hosp, Clin Res Pathol Div, 18-16 Kawahara, Hakodate, Hokkaido, Japan.	kimura-path@hnh.hosp.go.jp					Comin CE, 2014, TUMORI, V100, P559, DOI 10.1700/1660.18182; Galateau-Salle F., 2015, WHO CLASSIFICATION T, P156; GONZALEZCRUSSI F, 1982, CANCER-AM CANCER SOC, V49, P2365, DOI 10.1002/1097-0142(19820601)49:11<2365::AID-CNCR2820491125>3.0.CO;2-I; HAAS JE, 1981, HUM PATHOL, V12, P646, DOI 10.1016/S0046-8177(81)80050-0; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Kuwamoto S, 2017, HUM PATHOL, V70, P92, DOI 10.1016/j.humpath.2017.05.024; Matsukuma S, 1996, PATHOL INT, V46, P389, DOI 10.1111/j.1440-1827.1996.tb03627.x; McGregor SM, 2015, HUM PATHOL, V46, P1670, DOI 10.1016/j.humpath.2015.06.024; Oda Y, 2006, PATHOL INT, V56, P287, DOI 10.1111/j.1440-1827.2006.01962.x; Oita S, 2015, PEDIATRIC REP, V7, DOI 10.4081/pr.2015.5578; Ordonez NG, 2006, MODERN PATHOL, V19, P373, DOI 10.1038/modpathol.3800543; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Sauter JL, 2017, MODERN PATHOL, V30, P1422, DOI 10.1038/modpathol.2017.61; TSUNEYOSHI M, 1987, VIRCHOWS ARCH A, V411, P509, DOI 10.1007/BF00713281; Wang J, 2016, HUM PATHOL, V55, P83, DOI 10.1016/j.humpath.2016.04.018; Wu D, 2013, AM J CLIN PATHOL, V139, P39, DOI 10.1309/AJCPT94JVWIHBKRD; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x	17	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					128	132		10.1111/pin.12623			5	Pathology	Pathology	FV9QR	WOS:000424923700007	29316066				2019-10-28	
J	Tando, S; Nagao, T; Kayano, K; Fushiki, S; Itoh, K				Tando, So; Nagao, Toshitaka; Kayano, Kaori; Fushiki, Shinji; Itoh, Kyoko			High-grade transformation/dedifferentiation of an adenoid cystic carcinoma of the minor salivary gland to myoepithelial carcinoma	PATHOLOGY INTERNATIONAL			English	Article						Adenoid cystic carcinoma (ACC); high-grade transformation (HGT); dedifferentiation; Myoepithelial carcinoma	LACRIMAL GLAND; TRANSFORMATION; DEDIFFERENTIATION	High-grade transformation (HGT)/dedifferentiation is an unusual phenomenon in salivary gland carcinomas. Here we report a case of adenoid cystic carcinoma (ACC) with HGT/dedifferentiation to myoepithelial carcinoma, occurring in the epipharynx of a 42-year-old woman. The surgically resected tumor was a pedunculated mass, 31x25mm in size, which had two histologically distinct carcinomatous areas, including a high-grade sarcomatoid area composed of pleomorphic spindle cells and an area consisting of low-grade typical ACC. These two components gradually changed from the low-grade to the high-grade component. MIB-1 index in the low-grade and high-grade component was 15% and 50%, respectively. An immunohistochemical profile of the high-grade component showed immunoreactivity for -SMA, p63, calponin and focal S100, as well as for several cytokeratin markers, which were compatible with the features of myoepithelial carcinoma. In contrast, the immunohistochemical profile of the low-grade component coincided with that of typical ACC. This HGT/dedifferentiation to myoepithelial carcinoma is extremely rare. The pathogenesis of HGT/dedifferentiation in salivary gland carcinomas still remains largely unknown, regardless of the presence or absence of myoepithelial differentiation. Further studies are required due to the more aggressive biological behavior and poorer prognosis associated with ACC with HGT/dedifferentiation, compared with conventional ACC.	[Tando, So; Itoh, Kyoko] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pathol & Appl Neurobiol, Kyoto, Japan; [Nagao, Toshitaka] Tokyo Med Univ, Dept Anat Pathol, Sch Med, Tokyo, Japan; [Kayano, Kaori] Kyoto Chubu Med Ctr, Dept Otolaryngol, Kyoto, Japan; [Fushiki, Shinji] Kyoto Prefectural Univ Med, Ctr Qual Assurance Res & Dev, Kyoto, Japan; [Fushiki, Shinji] Kyoto Chubu Med Ctr, Dept Diagnost Pathol, Kyoto, Japan	Itoh, K (reprint author), Kyoto Prefectural Univ Med, Dept Pathol & Appl Neurobiol, Grad Sch Med Sci, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	kxi14@koto.kpu-m.ac.jp					Argyris PP, 2013, HEAD NECK PATHOL, V7, P85, DOI 10.1007/s12105-012-0383-2; Chau YP, 2001, HUM PATHOL, V32, P1403, DOI 10.1053/hupa.2001.28966; Cheuk W, 1999, AM J SURG PATHOL, V23, P465, DOI 10.1097/00000478-199904000-00012; Du F, 2016, ANN DIAGN PATHOL, V22, P12, DOI 10.1016/j.anndiagpath.2016.03.001; Hellquist H, 2016, VIRCHOWS ARCH, V469, P643, DOI 10.1007/s00428-016-2018-6; Hellquist H, 2016, ADV THER, V33, P357, DOI 10.1007/s12325-016-0298-5; Ishida M, 2013, HUM PATHOL, V44, P1700, DOI 10.1016/j.humpath.2012.12.015; Mizokami H, 2002, AURIS NASUS LARYNX, V29, P77, DOI 10.1016/S0385-8146(01)00117-1; Nagao T, 2003, MODERN PATHOL, V16, P1265, DOI 10.1097/01.MP.0000097366.88165.08; Nagao T, 2013, HEAD NECK PATHOL, V7, pS37, DOI 10.1007/s12105-013-0458-8; Panarelli JF, 2011, OPHTHAL PLAST RECONS, V27, pE119, DOI 10.1097/IOP.0b013e318201cb90; Piana S, 2002, ARCH PATHOL LAB MED, V126, P1104; Roy P, 2010, AM J SURG PATHOL, V34, P1258, DOI 10.1097/PAS.0b013e3181e366d2; Seethala RR, 2007, AM J SURG PATHOL, V31, P1683, DOI 10.1097/PAS.0b013e3180dc928c; Seethala RR, 2011, ADV ANAT PATHOL, V18, P29, DOI 10.1097/PAP.0b013e318202645a; Stenman G, 2017, WHO CLASSIFICATION H, P164; Sternlicht MD, 1997, MED HYPOTHESES, V48, P37, DOI 10.1016/S0306-9877(97)90022-0; SZANTO PA, 1984, CANCER, V54, P1062, DOI 10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E; Terasaki M, 2000, Brain Tumor Pathol, V17, P159, DOI 10.1007/BF02484288	19	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					133	138		10.1111/pin.12624			6	Pathology	Pathology	FV9QR	WOS:000424923700008	29287310				2019-10-28	
J	Ichimata, S; Aoyagi, D; Kobayashi, M; Sugihara, T; Nishio, A; Maruyama, M; Shiozawa, S				Ichimata, Shojiro; Aoyagi, Daiju; Kobayashi, Mikiko; Sugihara, Takehiko; Nishio, Akihito; Maruyama, Masafumi; Shiozawa, Satoshi			Early-stage idiopathic mesenteric phlebosclerosis incidentally combined with adenocarcinoma of the ascending colon: A report of two cases	PATHOLOGY INTERNATIONAL			English	Letter									[Ichimata, Shojiro; Kobayashi, Mikiko] Shinshu Univ, Dept Pathol, Sch Med, Matsumoto, Nagano, Japan; [Ichimata, Shojiro; Aoyagi, Daiju; Shiozawa, Satoshi] Saku Cent Hosp Adv Care Ctr, Dept Pathol, Saku, Japan; [Kobayashi, Mikiko] Nagano Red Cross Hosp, Dept Pathol, Nagano, Japan; [Sugihara, Takehiko] Saku Cent Hosp Adv Care Ctr, Dept Digest Surg, Saku, Japan; [Nishio, Akihito] Nagano Red Cross Hosp, Dept Surg Gastroenterol, Nagano, Japan; [Maruyama, Masafumi] Nagano Red Cross Hosp, Dept Gastroenterol, Nagano, Japan	Ichimata, S (reprint author), Shinshu Univ, Dept Pathol, Sch Med, Matsumoto, Nagano, Japan.; Ichimata, S (reprint author), Saku Cent Hosp Adv Care Ctr, Dept Pathol, Saku, Japan.			Ichimata, Shojiro/0000-0002-7305-8137	Chubu Division of The Japanese Society of Pathology	Shojiro Ichimata won the Chubu Division of The Japanese Society of Pathology Slide Conference Young Researchers' Award.	Kakimoto T, 2017, J JPN COLL SURG, V42, P274, DOI DOI 10.4030/jjcs.42.274; Shimizu S, 2016, I TO CHO, V51, P483; Shimizu S, 2017, J GASTROENTEROL, V52, P308, DOI 10.1007/s00535-016-1218-9; Yao T, 2012, GASTROENTEROL ENDOSC, V54, P415; Yen TS, 2015, WORLD J GASTROENTERO, V21, P8148, DOI 10.3748/wjg.v21.i26.8148	5	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					139	141		10.1111/pin.12614			3	Pathology	Pathology	FV9QR	WOS:000424923700009	29280316				2019-10-28	
J	Segawa, K; Sugita, S; Sugawara, T; Ito, Y; Tsujiwaki, M; Fujita, H; Ono, Y; Kobayashi, K; Hirobe, M; Yoshida, M; Hasegawa, T				Segawa, Keiko; Sugita, Shintaro; Sugawara, Taro; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Kobayashi, Kou; Hirobe, Megumi; Yoshida, Makoto; Hasegawa, Tadashi			Multiple gastrointestinal stromal tumors involving extragastrointestinal sites in neurofibromatosis type 1	PATHOLOGY INTERNATIONAL			English	Letter									[Segawa, Keiko; Sugita, Shintaro; Sugawara, Taro; Ito, Yumika; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan; [Kobayashi, Kou; Hirobe, Megumi] Sapporo Med Univ, Sch Med, Dept Urol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan; [Yoshida, Makoto] Sapporo Med Univ, Sch Med, Dept Med Oncol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan	Segawa, K (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.						Etit D, 2017, BALK MED J, V34, P168, DOI 10.4274/balkanmedj.2015.1331; Maertens O, 2006, HUM MOL GENET, V15, P1015, DOI 10.1093/hmg/ddl016; Malhotra A, 2012, J GASTROINTEST ONCOL, V3, P373, DOI 10.3978/j.issn.2078-6891.2012.034; Miettinen M, 2006, AM J SURG PATHOL, V30, P90, DOI 10.1097/01.pas.0000176433.81079.bd; Valencia E, 2014, ANTICANCER RES, V34, P5609	5	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	FEB	2018	68	2					142	144		10.1111/pin.12620			3	Pathology	Pathology	FV9QR	WOS:000424923700010	29222828				2019-10-28	
J	Guerra, F; Vegni, A; Perna, F; Messerini, L; Coratti, A				Guerra, Francesco; Vegni, Alessandra; Perna, Federico; Messerini, Luca; Coratti, Andrea			Primary jejunal interdigitating dendritic cell sarcoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Letter							CD34 EXPRESSION; MELANOMA		[Guerra, Francesco; Vegni, Alessandra; Perna, Federico; Messerini, Luca; Coratti, Andrea] Careggi Univ Hosp, Florence, Italy	Guerra, F (reprint author), Careggi Univ Hosp, Florence, Italy.	fra.guerra.mail@gmail.com	Messerini, Luca/AAB-3356-2019	Guerra, Francesco/0000-0003-2891-4659			Breza TS, 2005, J CUTAN PATHOL, V32, P685, DOI 10.1111/j.0303-6987.2005.00367.x; Hoang MP, 2001, J CUTAN PATHOL, V28, P508, DOI 10.1034/j.1600-0560.2001.281003.x; Magro CM, 2017, ANN DIAGN PATHO 0220; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Pisacane AM, 2007, CELL ONCOL, V29, P59; Shan SJ, 2014, AM J DERMATOPATHOL; Thway K, 2016, ANN DIAGN PATHOL, V25, P64, DOI 10.1016/j.anndiagpath.2016.09.013	7	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						1	3		10.1016/j.anndiagpath.2017.08.001			3	Pathology	Pathology	FV6YY	WOS:000424729500001	29414390				2019-10-28	
J	Nuovo, G; Amann, V; Williams, J; Vandiver, P; Quinonez, M; Fadda, P; Paniccia, B; Mezache, L; Mikhail, A				Nuovo, Gerard; Amann, Vicky; Williams, James; Vandiver, Paige; Quinonez, Maria; Fadda, Paolo; Paniccia, Bernard; Mezache, Louisa; Mikhail, Adel			Increased expression of importin-beta, exportin-5 and nuclear transportable proteins in Alzheimer's disease aids anatomic pathologists in its diagnosis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Co-expression; Importin; Exportin; Alzheimer's disease	AMYOTROPHIC-LATERAL-SCLEROSIS; DOWN-SYNDROME; CANCER; P53; APOPTOSIS; DEMENTIA; NEURODEGENERATION; LOCALIZATION; NEURONS; STRESS	Understanding the metabolic profile of neurons with the hyperphosphorylated tau protein characteristic of Alzheimer's disease is essential to unraveling new potential therapies and diagnostics for the surgical pathologist. We stratified 75 brain tissues from Alzheimer's disease into hyperphosphorylated tau positive or negative and did co-expression analyses and qRTPCR for importin-beta and exportin-5 plus several bcl2 family members and compared the data to controls, Down's dementia and Parkinson's disease. There was a significant increase in the expression of importin-13 and exportin-5 in Alzheimer's disease relative to the three other categories (each p value < 0.0001) where each protein co-localized with hyperphosphorylated tau. Both apoptotic and antiapoptotic proteins were each significantly increased in Alzheimer's disease relative to the three other groups. Neurons with hyperphosphorylated tau in Alzheimer's disease have the profile of metabolically active cells including increased exportin-5 and importin-beta mRNA and proteins which indicates that immunohistochemistry testing of these proteins may aid the surgical pathologist in making a definitive diagnosis.	[Nuovo, Gerard; Fadda, Paolo; Mezache, Louisa] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Nuovo, Gerard; Amann, Vicky; Williams, James; Vandiver, Paige; Quinonez, Maria; Paniccia, Bernard; Mikhail, Adel] GNOME Diagnost Lab, Powell, OH 43065 USA	Nuovo, G (reprint author), Phylogeny Lab, 1476 Manning Pkwy, Powell, OH 43065 USA.	nuovo.1@osu.edu			Alzheimer's Drug Discovery Foundation [20160204]	The authors appreciate the photomicroscopy/computer work provided by Dr. Margaret Nuovo. The work is supported by a grant from the Alzheimer's Drug Discovery Foundation (grant # 20160204).	Chu CT, 2007, J NEUROPATH EXP NEUR, V66, P873, DOI 10.1097/nen.0b013e318156a3d7; Costa CA, 2003, J BIOL CHEM, V278, P37330; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Iwasaki YW, 2013, RNA, V19, P490, DOI 10.1261/rna.036608.112; Jamil S, 2005, BIOCHEM J, V387, P659, DOI 10.1042/BJ20041596; Jones EL, 2008, DEMENT GERIATR COGN, V26, P199, DOI 10.1159/000152044; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kinoshita Y, 2009, J NEUROPATH EXP NEUR, V68, P1184, DOI 10.1097/NEN.0b013e3181bc3bec; Lee H, 2006, BRAIN RES, V1124, P1, DOI 10.1016/j.brainres.2006.09.084; METUZALS J, 1988, J NEUROCYTOL, V17, P827, DOI 10.1007/BF01216709; Mezache L, 2015, APPL IMMUNOHISTO M M, V23, P615, DOI 10.1097/PAI.0000000000000147; Nuovo G, 2017, ANN DIAGN PATHOL, V28, P24, DOI 10.1016/j.anndiagpath.2017.02.006; Nuovo GJ, 2012, MODERN PATHOL, V25, P1333, DOI 10.1038/modpathol.2012.95; Patel VP, 2011, INT J CLIN EXP PATHO, V4, P215; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Seidl R, 1999, NEUROSCI LETT, V260, P9, DOI 10.1016/S0304-3940(98)00945-8; Sheffield LG, 2006, J NEUROPATH EXP NEUR, V65, P45, DOI 10.1097/01.jnen.0000195939.40410.08; Shigeyasu K, 2017, CLIN CANCER RES, V23, P1312, DOI 10.1158/1078-0432.CCR-16-1023; Wang Y, 2010, GENE, V451, P23, DOI 10.1016/j.gene.2009.11.006; Winkler J, 2014, HEPATOLOGY, V60, P884, DOI 10.1002/hep.27207; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Zhang JH, 2006, ACTA NEUROPATHOL, V112, P673, DOI 10.1007/s00401-006-0130-4	24	3	3	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						10	16		10.1016/j.anndiagpath.2017.08.003			7	Pathology	Pathology	FV6YY	WOS:000424729500003	29414391				2019-10-28	
J	Martinez-Ramirez, M; Coral-Vazquez, RM; Tenorio, A; Mendez, JP; Benitez-Granados, J; Asis, AM; Cuevas, SR; Reyes, CD; Erazo-Valle, A; Canto, P				Martinez-Ramirez, Monica; Mauricio Coral-Vazquez, Ramon; Tenorio, Alberto; Pablo Mendez, Juan; Benitez-Granados, Jesus; Maffuz Asis, Antonio; Rodriguez Cuevas, Sergio; Dominguez Reyes, Carlos; Erazo-Valle, Aura; Canto, Patricia			Complete sequence of the ATP6 and ND3 mitochondrial genes in breast cancer tissue of postmenopausal women with different body mass indexes	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Breast cancer; ATP6; ND3; Somatic mutations; BMI; Postmenopausal Mexican-Mestizo women	DNA MUTATIONS; OBESITY; STRESS; METAANALYSIS; POPULATION; PROGNOSIS; MORTALITY; DIAGNOSIS; SURVIVAL; DAMAGE	Due to the fact that mitochondrial defects and oxidative stress have been related with obesity and breast cancer is more aggressive in women with obesity, we investigated if postmenopausal Mexican-Mestizo women with breast cancer presented somatic mutations in the sequence of the ATP6 and/or ND3 genes. Twenty one postmenopausal Mexican-Mestizo women with breast cancer who underwent mastectomy or breast conserving surgery were studied. Height and weight were used to calculate body mass index. DNA from tumor tissue samples and blood leukocytes was amplified by polymerase chain reaction and sequenced the ATP6 and ND3 mitochondrial genes. Ages ranged from 46 to 82. According to World Health Organization criteria among the 21 women, 7 had a normal BMI, 7 were overweight and 7 had obesity. In regard to the molecular study, after sequencing the coding region of ATP6 and ND3 genes of the DNA obtained from both leukocytes and tumor tissue, we did not find somatic mutations. All of the changes that we found in both genes were polymorphisms: in ATP6, we identified in ten patients 3 non-synonymous nucleotide changes and in ND3 we observed that six patients presented polymorphisms, three of them were synonymous and two non-synonymous. To our knowledge, this constitutes the first report where the complete sequence of the ATP6 and ND3 genes has been analyzed in postmenopausal Mexican-Mestizo women with breast cancer and diverse BMI. Our results differ with those reported in Caucasian and Asian populations, possibly due to ethnic differences.	[Martinez-Ramirez, Monica; Pablo Mendez, Juan; Benitez-Granados, Jesus; Canto, Patricia] Univ Nacl Autonoma Mexico, Fac Med, Unidad Invest Obesidad, Mexico City 14000, DF, Mexico; [Mauricio Coral-Vazquez, Ramon] Inst Politecn Nacl, Escuela Super Med, Secc Posgrad & Invest, Mexico City, DF, Mexico; [Mauricio Coral-Vazquez, Ramon; Erazo-Valle, Aura] Inst Seguridad & Serv Sociales Trabajadores Estad, Ctr Med Nacl 20 Noviembre, Subdirecc Ensefianza & Invest, Mexico City, DF, Mexico; [Tenorio, Alberto; Maffuz Asis, Antonio; Rodriguez Cuevas, Sergio; Dominguez Reyes, Carlos] FUCAM, Inst Enfermedades Mama, Mexico City, DF, Mexico; [Pablo Mendez, Juan; Canto, Patricia] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Ciln Obesidad, Vasco Quiroga 15, Mexico City 14000, DF, Mexico	Canto, P (reprint author), Univ Nacl Autonoma Mexico, Fac Med, Unidad Invest Obesidad, Mexico City 14000, DF, Mexico.; Canto, P (reprint author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Ciln Obesidad, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	ipcanto@unam.mx		Coral, Ramon/0000-0001-6126-2002	Programa de Investigacion Cientifica y Tecnologica del Institute de Seguridad y Servicios Sociales de los Trabajadores del Estado [E015]	This work was partially supported by Programa de Investigacion Cientifica y Tecnologica del Institute de Seguridad y Servicios Sociales de los Trabajadores del Estado (Grant #E015).	Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554; Bekker-Mendez C, 1998, SCAND J RHEUMATOL, V27, P373; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carmichael AR, 2006, OBES REV, V7, P333, DOI 10.1111/j.1467-789X.2006.00261.x; Chan DSM, 2014, ANN ONCOL, V25, P1901, DOI 10.1093/annonc/mdu042; Cheraghi Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051446; Czarnecka AM, 2006, J APPL GENET, V47, P67, DOI 10.1007/BF03194602; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Francis A, 2013, MITOCHONDRION, V13, P559, DOI 10.1016/j.mito.2013.08.004; Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946; Ghaffarpour M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-21; Grzybowska-Szatkowska L, 2014, MOL MED REP, V10, P1772, DOI 10.3892/mmr.2014.2471; Grzybowska-Szatkowska L, 2014, J APPL GENET, V55, P173, DOI 10.1007/s13353-013-0190-9; Jackson AL, 1998, P NATL ACAD SCI USA, V95, P12468, DOI 10.1073/pnas.95.21.12468; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9; Kamineni A, 2013, CANCER CAUSE CONTROL, V24, P305, DOI 10.1007/s10552-012-0115-7; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; LISKER R, 1990, HUM BIOL, V62, P791; Luporsi E, 2012, BREAST CANCER RES TR, V132, P895, DOI 10.1007/s10549-011-1837-z; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Medina-Gomez G, 2012, BEST PRACT RES CL EN, V26, P791, DOI 10.1016/j.beem.2012.06.002; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Parekh N, 2012, ANNU REV NUTR, V32, P311, DOI 10.1146/annurev-nutr-071811-150713; Parrella P, 2001, CANCER RES, V61, P7623; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Singh RK, 2014, SCI REP-UK, V4, DOI 10.1038/srep06571; Sultana GNN, 2012, CHIN J CANCER, V31, P449, DOI 10.5732/cjc.012.10024; Tan DJ, 2002, CANCER RES, V62, P972; Thapa S, 2016, BREAST CANCER-TOKYO, V23, P607, DOI 10.1007/s12282-015-0611-1; Wallace DC, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0267; Zhu WZ, 2005, CARCINOGENESIS, V26, P145, DOI 10.1093/carcin/bgh282	36	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						23	27		10.1016/j.anndiagpath.2017.09.001			5	Pathology	Pathology	FV6YY	WOS:000424729500005	29414393				2019-10-28	
J	Nuovo, G; Tran, H; Gutierrez, A; Fadda, P; Pichiorri, F; Caserta, E; Hofmeister, CC; Chesi, M; Bergsagel, PL; Morris, D; Shi, Q; Coffey, M; Thirukkumaran, C				Nuovo, Gerard; Tran, Hue; Gutierrez, Andres; Fadda, Paolo; Pichiorri, Flavia; Caserta, Enrico; Hofmeister, Craig C.; Chesi, Marta; Bergsagel, P. Leif; Morris, Don; Shi, Qiao; Coffey, Matt; Thirukkumaran, Chandini			Importin-beta and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Infection biomarkers; Importin; Exportin; Reovirus; Oncolysis; Multiple myeloma	NUCLEAR TRANSPORT; MULTIPLE-MYELOMA; MOUSE MODEL; PROTEIN; ACTIVATION	Acute reoviral infection has been extensively studied given the virus's propensity to target malignant cells and activate caspase-3 mediated apoptosis. Reovirus infection of malignant N1E-115 mouse neuroblastoma cells led to significant increased expression of importing) and exportin-5 mRNAs (qRTPCR) and proteins (immunohistochemistry) which was partially blocked by small interfering LNA oligomers directed against the reoviral genome. Co-expression analysis showed that the N1E-115 cells that contained reoviral capsid protein had accumulated importing) and exportin-5, as well as activated caspase 3. Reoviral oncolysis using a syngeneic mouse model of multiple myeloma similarly induced a significant increase in importing) and exportin-5 proteins that were co-expressed with reoviral capsid protein and caspase-3. Apoptotic proteins (BAD, BIM, PUMA, NOXA, BAK, BAX) were increased with infection and co-localized with reoviral capsid protein. Surprisingly. the antiapoptotic MCL1 and bcl2 were also increased and co-localized with the capsid protein suggesting that it was the balance of pro-apoptotic molecules that correlated with activation of caspase-3. In summary, productive reoviral infection is strongly correlated with elevated importing) and exportin-5 levels which may serve as biomarkers of the disease in clinical specimens.	[Nuovo, Gerard; Fadda, Paolo] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Hofmeister, Craig C.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA; [Nuovo, Gerard] Phylogeny Med Lab, Powell, OH USA; [Pichiorri, Flavia; Caserta, Enrico] City Hope Med Ctr, Duarte, CA USA; [Morris, Don; Shi, Qiao; Thirukkumaran, Chandini] Univ Calgary, Tom Baker Canc Ctr, 1331,29th St NW, Calgary, AB, Canada; [Chesi, Marta; Bergsagel, P. Leif] Mayo Clin, Scottsdale, AZ USA; [Tran, Hue; Gutierrez, Andres; Coffey, Matt] Oncolyt Biotech Inc, Calgary, AB, Canada	Nuovo, G (reprint author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	nuovo.1@osu.edu			Alzheimer's disease Drug Discovery Foundation [20160204]; Cancer Research Society of Canada, Oncolytics Biotech Inc.	Alzheimer's disease Drug Discovery Foundation (20160204); Cancer Research Society of Canada, Oncolytics Biotech Inc.	Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Benavente J, 2007, VIRUS RES, V123, P105, DOI 10.1016/j.virusres.2006.09.005; Berger AK, 2017, J VIROL, V91, DOI 10.1128/JVI.02404-16; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Chesi M, 2016, NAT MED, V22, P1411, DOI 10.1038/nm.4229; Chesi M, 2012, BLOOD, V120, P376, DOI 10.1182/blood-2012-02-412783; Chu CT, 2007, J NEUROPATH EXP NEUR, V66, P873, DOI 10.1097/nen.0b013e318156a3d7; Demart S, 2003, EXP CELL RES, V291, P484, DOI 10.1016/j.yexcr.2003.07.011; Fraser JE, 2014, J INFECT DIS, V210, P1780, DOI 10.1093/infdis/jiu319; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Iwasaki YW, 2013, RNA, V19, P490, DOI 10.1261/rna.036608.112; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jamil S, 2005, BIOCHEM J, V387, P659, DOI 10.1042/BJ20041596; Johansson M, 2001, J GEN VIROL, V82, P735, DOI 10.1099/0022-1317-82-4-735; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kinoshita Y, 2009, J NEUROPATH EXP NEUR, V68, P1184, DOI 10.1097/NEN.0b013e3181bc3bec; Magri ME, 2015, SCI TOTAL ENVIRON, V520, P213, DOI 10.1016/j.scitotenv.2015.03.035; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Malik P, 2012, J BIOL CHEM, V287, P12277, DOI 10.1074/jbc.M111.331777; Mezache L, 2017, APPL IMMUNOHISTO M M, V25, P100, DOI 10.1097/PAI.0000000000000298; Nuovo GJ, 2012, MODERN PATHOL, V25, P1333, DOI 10.1038/modpathol.2012.95; Patel VP, 2011, INT J CLIN EXP PATHO, V4, P215; Samson A, 2016, GUT; Shigeyasu K, 2017, CLIN CANCER RES, V23, P1312, DOI 10.1158/1078-0432.CCR-16-1023; Stiff A, 2016, MOL CANCER THER, V15, P830, DOI 10.1158/1535-7163.MCT-15-0240-T; Thirukkumaran C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168233; Thirukkumaran CM, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-541; Thirukkumaran CM, 2012, CLIN CANCER RES, V18, P4962, DOI 10.1158/1078-0432.CCR-11-3085; Thirukkumaran CM, 2010, CANCER RES, V70, P2435, DOI 10.1158/0008-5472.CAN-09-2408; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Vanessa Bernstein, 2017, AACR 2017 P; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032	35	2	2	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						28	34		10.1016/j.anndiagpath.2017.10.001			7	Pathology	Pathology	FV6YY	WOS:000424729500006	29414394				2019-10-28	
J	Seok, JY; An, J; Cho, HY; Kim, Y; Ha, SY				Seok, Jae Yeon; An, Jungsuk; Cho, Hyun Yee; Kim, Younghye; Ha, Seung Yeon			Nuclear features of papillary thyroid carcinoma: Comparison of Core needle biopsy and thyroidectomy specimens	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Core Needle Biopsy; Thyroid; Papillary Carcinoma; Thyroidectomy	UNDETERMINED SIGNIFICANCE; FOLLICULAR NEOPLASM; BETHESDA SYSTEM; ASPIRATION; NODULES; DIAGNOSIS; CYTOPATHOLOGY; METAANALYSIS; MALIGNANCY; LYMPHOMA	Background: Core needle biopsy (CNB) has been used as an alternative or a complementary method for diagnosis of thyroid nodules. However, morphological analysis of the nuclear features of papillary thyroid carcinoma (PTC) cells obtained via CNB remains unclear. Hence, we examined the differences between the PTC nuclear features in CNB and thyroidectomy specimens. Methods: Ten PTC patients, who underwent both CNB and thyroidectomy, were selected. Microscopic photographs of three representative areas of the PTC and adjacent parenchyma were taken. Ten cells per photograph were chosen, and 1200 cells were evaluated (300 PTC and 300 follicular cells in the CNB and thyroidectomy specimens, respectively). The area, circumference, major axis, and minor axis were measured using an image analyzer. Detailed nuclear features (size and shape, membrane irregularity, chromatin characteristics) were scored using a 3-point scale. Results: The mean nuclear area, circumference, major axis, and minor axis of PTC cells in the CNB specimen were 1.76, 1.34, 1.34, and 1.29 times larger than those of the follicular cells (p < 0.001); similar results were seen in the thyroidectomy specimens (2.04, 1.41, 1.37, and 1.37: p < 0.001). Comparative analysis revealed that these parameters were significantly smaller in the CNB specimens than those in the thyroidectomy specimens (p < 0.001). Nuclear grades were also lower in the former owing to poor chromatin characteristics (clearing and margination) (p < 0.01). Conclusion: Considering that the PTC nuclei in CNB specimens are smaller with fewer irregularities and less clear than those in thyroidectomy specimens, we need to emphasize caution when using CNB specimens for diagnosis.	[Seok, Jae Yeon; An, Jungsuk; Cho, Hyun Yee; Kim, Younghye; Ha, Seung Yeon] Gachon Univ, Gil Med Ctr, Dept Pathol, 1198 Guwol Dong, Incheon 405760, South Korea	Ha, SY (reprint author), Gachon Univ, Gil Med Ctr, Dept Pathol, 1198 Guwol Dong, Incheon 405760, South Korea.	syha@gilhospital.com			National Research Foundation of Korea (NRF) - Korea government (MSIP; Ministry of Science, ICT gz Future Planning) [2017R1C1B5075617]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP; Ministry of Science, ICT gz Future Planning) (No. 2017R1C1B5075617).	Bergeron M, 2014, EUR THYROID J, V3, P130, DOI 10.1159/000360985; Chen BHT, 2015, ENDOCR PRACT, V21, P128, DOI 10.4158/EP14303.OR; Choi SH, 2016, OTOLARYNG HEAD NECK, V154, P618, DOI 10.1177/0194599816629632; Choi SH, 2014, EUR RADIOL, V24, P2819, DOI 10.1007/s00330-014-3325-4; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Ha EJ, 2017, EUR RADIOL, V27, P1186, DOI 10.1007/s00330-016-4461-9; Ha EJ, 2016, EUR RADIOL, V26, P1031, DOI 10.1007/s00330-015-3921-y; Hahn SY, 2017, CLIN ENDOCRINOL, V86, P444, DOI 10.1111/cen.13263; Jung CK, 2015, J PATHOL TRANSL MED, V49, P288, DOI 10.4132/jptm.2015.06.04; Kakiuchi Y, 2015, AM J FOREN MED PATH, V36, P207, DOI 10.1097/PAF.0000000000000172; Kim M, 2017, J PATHOL TRANSL MED, V51, P410, DOI 10.4132/jptm.2017.04.05; Lee KH, 2014, ANN SURG ONCOL, V21, P2326, DOI 10.1245/s10434-014-3568-y; Lee SH, 2014, ANN SURG ONCOL, V21, P1870, DOI 10.1245/s10434-013-3365-z; Min HS, 2014, APMIS, V122, P993, DOI 10.1111/apm.12244; Na DG, 2012, THYROID, V22, P468, DOI 10.1089/thy.2011.0185; Nasrollah N, 2014, ENDOCRINE, V45, P79, DOI 10.1007/s12020-013-9979-x; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Novoa E, 2012, HEAD NECK-J SCI SPEC, V34, P1497, DOI 10.1002/hed.21821; Park KT, 2011, HEAD NECK-J SCI SPEC, V33, P160, DOI 10.1002/hed.21414; Pyo JS, 2016, J PATHOL TRANSL MED, V50, P217, DOI 10.4132/jptm.2016.02.15; Sharma A, 2016, THYROID, V26, P1061, DOI 10.1089/thy.2016.0095; Suh CH, 2016, ENDOCRINE, V54, P315, DOI 10.1007/s12020-016-0991-9; Suh CH, 2016, THYROID, V26, P395, DOI 10.1089/thy.2015.0404; Trimboli P, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-61; Yeon JS, 2013, RADIOLOGY, V268, P274, DOI 10.1148/radiol.13122247; Yi KS, 2015, THYROID, V25, P657, DOI 10.1089/thy.2014.0596; Yoon JH, 2015, J PATHOL TRANSL MED, V49, P230, DOI 10.4132/jptm.2015.03.21; Yoon RG, 2014, THYROID, V24, P1612, DOI 10.1089/thy.2014.0140; Zhang MB, 2014, CLIN IMAG, V38, P434, DOI 10.1016/j.clinimag.2014.03.010	29	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						35	40		10.1016/j.anndiagpath.2017.09.002			6	Pathology	Pathology	FV6YY	WOS:000424729500007	29414395				2019-10-28	
J	Foda, AM; Aziz, AA; Mohamed, MA				Foda, Abd Al-Rahman Mohammad; Aziz, Azza Abdel; Mohamed, Mie Ali			Colorectal signet ring cell carcinoma: Influence of EGFR, E-cadherin and MMP-13 expression on clinicopathological features and prognosis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Colorectal signet ring carcinoma; EGFR; E-cadherin; MMP-13; Prognosis	IN-SITU HYBRIDIZATION; MATRIX METALLOPROTEINASES; CANCER; COLON; ADENOCARCINOMA; OUTCOMES; THERAPY	Signet ring cell carcinoma (SRCC) is unique rare subtype of mucin-producing colorectal adenocarcinoma characterized by presence of signet ring cells, in > 50% of the tumor tissue. This study aims to investigate expression of EGFR, E-cadherin and MMP-13 expression on clinicopathological features of signet ring cell type and its prognostic effect using manual tissue microarray technique. In this work, we studied tumor tissue specimens from 150 patients with colorectal cancer cases among which 19 cases of SRCC. High density manual tissue microarrays were constructed using modified mechanical pencil tips technique and immunohistochemistry for EGFR, E-cadherin and MMP-13 expression was done. We found that SRCC was significantly associated with younger age and more frequency of LN metastasis than all other groups. SRCC was also significantly associated with annular gross picture, more depth of invasion, advanced stage, more lymphovascular emboli, more perineural invasion and less arousal from an overlying adenoma. In conclusion, colorectal SRCC has distinctive clinicopathological and histological features with different unique mechanisms of carcinogenesis and more aggressive biologic behavior than other colorectal carcinoma subtypes. Negative/low expressions of EGFR and E-cadherin and MMP-13 were found in SRCC with no effect on the prognosis.	[Foda, Abd Al-Rahman Mohammad; Aziz, Azza Abdel; Mohamed, Mie Ali] Mansoura Univ, Fac Med, Pathol Dept, Mansoura, Egypt	Mohamed, MA (reprint author), Mansoura Univ, Fac Med, Pathol Dept, Mansoura, Egypt.	mieali@mans.edu.eg	Abdel-Aziz, Azza/W-9980-2019	Abdel-Aziz, Azza/0000-0003-4403-7123			Bibeau F, 2006, VIRCHOWS ARCH, V449, P281, DOI 10.1007/s00428-006-0247-9; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borger ME, 2007, J PATHOL, V212, P278, DOI 10.1002/path.2181; Cabibi D, 2009, ANTICANCER RES, V29, P4417; Chu PG, 2004, AM J CLIN PATHOL, V121, P884, DOI 10.1309/A09ERYMFR64NERDW; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Ding J, 2013, DIGEST DIS SCI, V58, P1581, DOI 10.1007/s10620-012-2552-2; El-Bahrawy MA, 2001, HUM PATHOL, V32, P1216, DOI 10.1053/hupa.2001.28948; Foda AA, 2014, AM J CANC EPIDEMIOL, V2, P10; Foda AM, 2013, ANN DIAGN PATHOL, V17, P347, DOI 10.1016/j.anndiagpath.2013.04.003; Foda AM, 2013, APPL IMMUNOHISTO M M, V21, P271, DOI 10.1097/PAI.0b013e318268a93f; Hamilton SR, 2010, WHO CLASSIFICATION T, P132; Hyngstrom JR, 2012, ANN SURG ONCOL, V19, P2814, DOI 10.1245/s10434-012-2321-7; Kang HJ, 2005, DIS COLON RECTUM, V48, P1161, DOI 10.1007/s10350-004-0932-1; Khoursheed MA, 2003, SURG-J R COLL SURG E, V1, P86, DOI 10.1016/S1479-666X(03)80121-X; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Leeman MF, 2002, J CLIN PATHOL, V55, P758, DOI 10.1136/jcp.55.10.758; Lin H-H, 2012, J SOC COLON RECTAL S, V23, P151; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482; Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137; Rosivatz E, 2004, INT J CANCER, V111, P711, DOI 10.1002/ijc.20317; Rundhaug JE, 2003, CLIN CANCER RES, V9, P551; Sasaki S, 1998, JPN J CLIN ONCOL, V28, P202, DOI 10.1093/jjco/28.3.202; Sauer T, 2005, HISTOPATHOLOGY, V47, P560, DOI 10.1111/j.1365-2559.2005.02252.x; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Shebl AM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-117; Shiozaki H, 1993, Hum Cell, V6, P94; Song W, 2009, CHINESE MED J-PEKING, V122, P1486, DOI 10.3760/cma.j.issn.0366-6999.2009.13.002; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Sung CO, 2008, MODERN PATHOL, V21, P1533, DOI 10.1038/modpathol.2008.170; Tsanou E, 2008, ANTICANCER RES, V28, P3815	32	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						41	46		10.1016/j.anndiagpath.2017.10.003			6	Pathology	Pathology	FV6YY	WOS:000424729500008	29414397				2019-10-28	
J	Ku, NK; Pullarkat, ST; Kim, YS; Cheng, L; O'Malley, D				Ku, Nam K.; Pullarkat, Sheeja T.; Kim, Young S.; Cheng, Liang; O'Malley, Dennis			Use of CD42b immunohistochemical stain for the detection of Histoplasma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Histoplasma; Fungus; CD42b; GPlb; 14-3-3 proteins; Immunohistochemistry	FUNGAL-INFECTIONS; IDENTIFICATION; DIAGNOSIS	In pathologic specimen, Histoplasma capsulatwn can frequently be identified by morphology and special stains such as GMS and PAS. Incidentally, we noted unusual staining of the platelet associated marker CD42b/GPlb expressed on the surface of fungal organisms. Evaluation of additional cases demonstrated that a majority of histoplasmosis cases (15/18 cases; 83%) showed positive staining with CD42b/GP1b, comparable to GMS stain results. Other platelet associated markers such as Factor VIII and CD61 showed no or rare expression (1/18 cases with Factor VIII). Studies have shown that 14-3-3 proteins bind directly to cytoplasmic domain of CD42b/GP1b. Significant homology is seen between fungal and human 14-3-3 proteins which may represent a molecular basis for our observation. Our study demonstrated that CD42b/GPlb staining by immunohistochemistry can aid in detection of Histoplasma organisms. Further studies with organisms with similar morphologic features such as Blastomyces and Leishmania may demonstrate a diagnostic utility in speciating organisms.	[Ku, Nam K.] Univ Calif Davis, Dept Pathol, Sacramento, CA 95817 USA; [Pullarkat, Sheeja T.] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA; [Kim, Young S.] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA; [Cheng, Liang] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA; [O'Malley, Dennis] Neogenomics, 31 Columbia, Aliso Viejo, CA 92656 USA; [O'Malley, Dennis] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	O'Malley, D (reprint author), Neogenomics, 31 Columbia, Aliso Viejo, CA 92656 USA.	nkku@ucdavis.edu; spullarkat@mednet.ucla.edu; yokim@coh.org; lcheng@iupui.edu; dennis.omalley@neogenomics.com					Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1; Eyzaguirre E, 2008, ARCH PATHOL LAB MED, V132, P424, DOI 10.1043/1543-2165(2008)132[424:AOITI]2.0.CO;2; Gale AJ, 2011, TOXICOL PATHOL, V39, P273, DOI 10.1177/0192623310389474; Guarner J, 2011, CLIN MICROBIOL REV, V24, P247, DOI 10.1128/CMR.00053-10; Guimaraes AJ, 2006, BRAZ J MICROBIOL, V37, P1, DOI 10.1590/S1517-83822006000100001; Kauffman CA, 2007, CLIN MICROBIOL REV, V20, P115, DOI 10.1128/CMR.00027-06; Kumar R, 2017, EUR J CELL BIOL, V96, P206, DOI 10.1016/j.ejcb.2017.02.006; Sangoi AR, 2009, AM J CLIN PATHOL, V131, P364, DOI 10.1309/AJCP99OOOZSNISCZ; Zhang W, INT J MOL SCI	10	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						47	50		10.1016/j.anndiagpath.2017.10.002			4	Pathology	Pathology	FV6YY	WOS:000424729500009	29414398				2019-10-28	
J	Maedler, C; Arnason, T; Dorreen, A; Sapp, H; Castonguay, M; Murphy, J; Selegean, S; Huan, WY				Maedler, Chelsea; Arnason, Thomas; Dorreen, Alastair; Sapp, Heidi; Castonguay, Mathieu; Murphy, Joanne; Selegean, Sorin; Huan, Weei-Yuarn			Goblet cell carcinoid of the appendix - An interobserver variability study using two proposed classification systems	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Appendix; Goblet cell carcinoid; Classification; Carcinoid	TUMORS; ADENOCARCINOMA; FEATURES; BEHAVIOR	Goblet cell carcinoid (GCC) is an uncommon tumor of the vermiform appendix. Due to a broad spectrum of morphological differentiation, subclassification and grading of GCCs remains an area of controversy. Two separate systems have proposed classifying GCC tumors into three (classical GCC; adenocarcinoma ex-GCC, signet ring cell type; adenocarcinoma ex-GCC, poorly differentiated carcinoma type) OR two subgroups (low and high grade GCC) based on morphological criteria. We independently compared the inter-observer variability associated with each classification system. Overall, both systems had moderate interobserver agreement, with the two-tiered system (kappa = 0.54) performing slightly better than the three-tiered system (kappa = 0.42). GI-specialist pathologists had substantial agreement for both two and three-tiered systems (kappa = 0.65 vs. 0.65). Non-GI trained pathologists had lower overall agreement than GI trained pathologists, but their agreement was better using the two-tiered system (kappa = 0.44) than the three-tiered system (kappa = 0.22). A sub-analysis of 6 cases with a high rate of discordant classification revealed several challenges that exist in applying current criteria, including differentiating "goblet" vs. "signet ring" cell morphology, applying a 1 mm(2) criteria to multifocal non-contiguous glandular and single infiltrating cell architecture, differentiating fibro-inflammatory stroma from desmoplastic stroma, and solid architecture in cases with abundant extracellular mucin, and distinguishing "reactive" nuclear atypia from true "cytologic atypia". Despite these challenges, the study identified better agreement among GI pathologists than non-GI trained pathologists. While GI pathologist review may be helpful, further research on objective classification criteria remains an area of interest.	[Maedler, Chelsea; Arnason, Thomas; Sapp, Heidi; Castonguay, Mathieu; Murphy, Joanne; Selegean, Sorin; Huan, Weei-Yuarn] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Dorreen, Alastair] Dalhousie Univ, Dept Med, Halifax, NS, Canada	Huan, WY (reprint author), Queen Elizabeth 2 Hlth Sci Ctr, Div Anat Pathol, Halifax, NS B3H 1V8, Canada.; Huan, WY (reprint author), Dalhousie Univ, 717,Mackenzie Bldg,5788 Univ Ave, Halifax, NS B3H 1V8, Canada.	huangw@nshealth.ca					ABT AB, 1976, ARCH PATHOL LAB MED, V100, P301; Bucher P, 2005, WORLD J SURG, V29, P1436, DOI 10.1007/s00268-005-7958-y; BURKE AP, 1990, AM J CLIN PATHOL, V94, P27, DOI 10.1093/ajcp/94.1.27; BUTLER JA, 1994, AM J SURG, V168, P685, DOI 10.1016/S0002-9610(05)80145-X; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Lee KS, 2013, EUR J RADIOL, V82, P85, DOI 10.1016/j.ejrad.2012.05.038; Lee LH, 2015, HUM PATHOL, V46, P1881, DOI 10.1016/j.humpath.2015.08.005; McGory ML, 2005, DIS COLON RECTUM, V48, P2264, DOI 10.1007/s10-005-0196-4; Pape UF, 2012, NEUROENDOCRINOLOGY, V95, P135, DOI 10.1159/000335629; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Rossi RE, 2015, SURG ONCOL, V24, P47, DOI 10.1016/j.suronc.2015.01.001; Roy P, 2010, WORLD J GASTRO ONCOL, V2, P251, DOI 10.4251/wjgo.v2.i6.251; Senn Stephen, 2011, Res Synth Methods, V2, P221, DOI 10.1002/jrsm.50; SUBBUSWAMY SG, 1974, CANCER-AM CANCER SOC, V34, P338, DOI 10.1002/1097-0142(197408)34:2<338::AID-CNCR2820340218>3.0.CO;2-W; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Turaga KK, 2012, ANN SURG ONCOL, V19, P1379, DOI 10.1245/s10434-012-2238-1; Wang HLL, 2009, ADV ANAT PATHOL, V16, P247, DOI 10.1097/PAP.0b013e3181a9d49a	18	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						51	55		10.1016/j.anndiagpath.2017.11.001			5	Pathology	Pathology	FV6YY	WOS:000424729500010	29414399				2019-10-28	
J	Magro, CM; Kazi, N; Sisinger, AE				Magro, Cynthia M.; Kazi, Najiyah; Sisinger, Aimee E.			Primary cutaneous histiocytic sarcoma: A report of five cases with primary cutaneous involvement and review of the literature	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Histiocytic sarcoma; Monocytic differentiation; B cell ontogeny; Underlying myeloproliferative disease	FOLLICULAR LYMPHOMA; MALIGNANT HISTIOCYTOSIS; CLONAL EVOLUTION; TRANSDIFFERENTIATION; LEUKEMIA; ORIGIN; SKIN	Introduction: Histiocytic sarcoma is an extremely rare hematologic malignancy of histiocytic origin. Five cases of primary cutaneous histiocytic sarcoma are presented. Materials and methods: Cases of primary cutaneous histiocytic sarcoma were identified using a natural language search from the dermatopathology data base of Cornell University. Results: There was a male predominance (4 males and 1 female) ranging in age from 33 years to 92 years (mean age of 73 years); all presented with a solitary nodule which involved the head and neck area in four and thigh in one. The 73-year-old male had chronic myeloproliferative disorder. Biopsies showed a nonepitheliotropic dermal-based atypical large cell histiocytoid appearing infiltrate dermis showing positivity for common leukocyte antigen, CD4, CD14, CD68, CD163, CD2, CD11c, and lysozyme. Markers of terminal histiocytic differentiation such as 5100, langerin, MXA, and CD83 were not seen. In two of the cases there was evidence of extracutaneous dissemination. The treatment in three of the cases was wide excision; there was no evidence of recurrent or metastatic disease. One case was given palliative radiation; the patient died. The other patient with underlying myelodysplastic syndrome died within a few weeks of initial cutaneous presentation. Conclusion: HS must be differentiated from other malignant histiocytoid lesions. Staining for common leukocyte antigen and CD163 are the most reliable markers allowing this distinction. Patients who present with primary involvement of the skin may have a favorable outcome but only if treated relatively early in the course of the disease with complete excision.	[Magro, Cynthia M.] Weill Cornell Med Ctr, 1300 York Ave, New York, NY 10065 USA; [Kazi, Najiyah] Columbia Univ, Med Ctr, 630 West 168th St, New York, NY USA; [Sisinger, Aimee E.] Ohio State Univ, Wexner Med Ctr, 452 West 10th Ave, Columbus, OH 43210 USA	Magro, CM (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave,F-309, New York, NY 10065 USA.	cym2003@med.cornell.edu; aimee.sisinger@osumc.edu					ARAI E, 1993, J CUTAN PATHOL, V20, P115, DOI 10.1111/j.1600-0560.1993.tb00226.x; Brunner P, 2014, LEUKEMIA, V28, P1937, DOI 10.1038/leu.2014.167; Chen W, 2009, AM J SURG PATHOL, V33, P863, DOI 10.1097/PAS.0b013e31819287b8; Copie-Bergman C, 1998, AM J SURG PATHOL, V22, P1386, DOI 10.1097/00000478-199811000-00009; DeMers NM, 2009, J DERMATOL CASE REP, V3, P4, DOI 10.3315/jdcr.2009.1024; Escandell I, 2017, J AM ACAD DERMATOL, V76, pS5, DOI 10.1016/j.jaad.2016.03.038; Feldman AL, 2008, BLOOD, V111, P5433, DOI 10.1182/blood-2007-11-124792; Fernandez-Pol S, 2016, HUM PATHOL, V55, P39, DOI 10.1016/j.humpath.2016.04.004; LAVABREBERTRAND T, 1989, NOUV REV FR HEMATOL, V31, P345; Liu YR, 2013, LEUKEMIA RES, V37, P737, DOI 10.1016/j.leukres.2013.03.009; Liu Y, 2013, ADV MATH PHYS, DOI 10.1155/2013/787891; MARSHALL ME, 1981, ARCH DERMATOL, V117, P278, DOI 10.1001/archderm.117.5.278; Mlika Mona, 2015, Tunis Med, V93, P427; Nakamura K, 2016, J DERMATOL, V43, P721, DOI 10.1111/1346-8138.13246; Newman B, 2007, J AM ACAD DERMATOL, V56, P302, DOI 10.1016/j.jaad.2006.06.010; RALFKIAER E, 1990, J PATHOL, V160, P9, DOI 10.1002/path.1711600105; Schnettler K, 2009, REV MED CHILE, V137, P547, DOI [10.4067/S0034-98872009000400014, /S0034-98872009000400014]; SORIA C, 1992, AM J DERMATOPATH, V14, P511, DOI 10.1097/00000372-199212000-00004; Trevisan F, 2013, AN BRAS DERMATOL, V88, P807, DOI 10.1590/abd1806-4841.20132070; Tsujimura H, 2014, INT J HEMATOL, V100, P507, DOI 10.1007/s12185-014-1630-y; Verma A, 2015, INDIAN J PATHOL MICR, V58, P537, DOI 10.4103/0377-4929.168860; Wang ED, 2010, LEUKEMIA LYMPHOMA, V51, P802, DOI 10.3109/10428191003699845; Zeng WF, 2011, J CUTAN PATHOL, V38, P999, DOI 10.1111/j.1600-0560.2011.01769.x; Zhang D, 2010, LEUKEMIA LYMPHOMA, V51, P739, DOI 10.3109/10428191003774978; Zhang D, 2009, INT J HEMATOL, V89, P529, DOI 10.1007/s12185-009-0300-y	25	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						56	62		10.1016/j.anndiagpath.2017.10.004			7	Pathology	Pathology	FV6YY	WOS:000424729500011	29414400				2019-10-28	
J	Gawelek, KL; Gales, JM; Prayson, RA				Gawelek, K. L.; Gales, J. M.; Prayson, R. A.			Hamartia in hippocampal sclerosis-associated mesial temporal lobe epilepsy	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Hamartia; Hippocampal sclerosis; Epilepsy; Focal cortical dysplasia	AMMONS HORN SCLEROSIS; HOC TASK-FORCE; CONSENSUS CLASSIFICATION; DIAGNOSTIC METHODS; ILAE COMMISSION; NEUROPATHOLOGY; EXPERIENCE; PATHOLOGY; PATTERNS; BCL-2	Hamartia are small collections of rounded glioneuronal cells that are thought to be due to aberrant cell migration. Their presence has been recognized in association with mesial temporal lobe epilepsy; their prevalence among cases of hippocampal sclerosis (HS) and any potential association with patient demographics and outcomes is unknown. This study examines hamartia in a series of 292 patients with pathologically confirmed HS. Medical records were reviewed for pertinent patient clinical information (follow-up mean 5 years). Hamartia were identified in 96 cases (33%) and were seen primarily in the amygdala (n = 88) and less commonly in the hippocampus (n = 10) and temporal lobe (n = 4). A statistically significant relationship was found between the presence of hamartia and male gender, younger age of seizure onset, and history of childhood febrile seizures and developmental delay. It is unclear if these associations represent a real association or are a result of the underlying pathologies related to chronic epilepsy. At follow-up, there were no significant differences between patients who had hamartia and those who lacked this finding. Hamartia were observed in all subtypes of HS and there was a significant difference found in subtype distribution as well as proportion of cases between subtypes, but no association with any specific subtype overall. The presence of hamartia was not associated with the coexistence of focal cortical dysplasia or any specific histologic pattern of dysplasia. Hamartia are a common concomitant finding in HS and indicates evidence of aberrant cell migration in the hippocampal and para-hippocampal regions in these patients.	[Gawelek, K. L.; Gales, J. M.; Prayson, R. A.] Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA	Prayson, RA (reprint author), Cleveland Clin, Dept Anat Pathol, L25,9500 Euclid Ave, Cleveland, OH 44195 USA.	praysor@ccf.org					ARMSTRONG DD, 1993, J NEUROPATH EXP NEUR, V52, P433, DOI 10.1097/00005072-199309000-00001; Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220; Blumcke I, 2012, BRAIN PATHOL, V22, P402, DOI 10.1111/j.1750-3639.2012.00583.x; Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x; Blumcke I, 2002, BRAIN PATHOL, V12, P199; Blumcke I, 1999, J COMP NEUROL, V414, P437, DOI 10.1002/(SICI)1096-9861(19991129)414:4<437::AID-CNE2>3.0.CO;2-3; Chung Sajun, 2014, Korean J Pediatr, V57, P384, DOI 10.3345/kjp.2014.57.9.384; de Tisi J, 2011, LANCET, V378, P1388, DOI 10.1016/S0140-6736(11)60890-8; Frater JL, 2000, ARCH PATHOL LAB MED, V124, P545; Gales JM, 2017, HUM PATHOL, V63, P79, DOI 10.1016/j.humpath.2017.02.013; Kasper BS, 1999, J NEUROPATH EXP NEUR, V58, P22, DOI 10.1097/00005072-199901000-00003; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Meencke H J, 1996, Epilepsy Res Suppl, V12, P335; Novy J, 2013, BRAIN, V136, P3187, DOI 10.1093/brain/awt117; PLATE KH, 1993, ACTA NEUROPATHOL, V86, P433; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Thom M, 2014, NEUROPATH APPL NEURO, V40, P520, DOI 10.1111/nan.12150; Thom M, 2009, J NEUROPATH EXP NEUR, V68, P928, DOI 10.1097/NEN.0b013e3181b05d67; WOLF HK, 1995, J NEUROPATH EXP NEUR, V54, P245, DOI 10.1097/00005072-199503000-00011; WOLF HK, 1993, J NEUROPATH EXP NEUR, V52, P499, DOI 10.1097/00005072-199309000-00008; Yachnis AT, 1997, J NEUROPATH EXP NEUR, V56, P186, DOI 10.1097/00005072-199702000-00010; Yachnis AT, 2000, J NEUROPATH EXP NEUR, V59, P113, DOI 10.1093/jnen/59.2.113	22	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	FEB	2018	32						63	66		10.1016/j.anndiagpath.2017.08.004			4	Pathology	Pathology	FV6YY	WOS:000424729500012	28888331				2019-10-28	
J	Adams, TA; Vail, PJ; Ruiz, A; Mollaee, M; McCue, PA; Knudsen, ES; Witkiewicz, AK				Adams, Thomas A.; Vail, Paris J.; Ruiz, Amanda; Mollaee, Mehri; McCue, Peter A.; Knudsen, Erik S.; Witkiewicz, Agnieszka K.			Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer	MODERN PATHOLOGY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; DISEASE-FREE SURVIVAL; T-CELL INFILTRATION; PD-L1 EXPRESSION; POOR-PROGNOSIS; MCT4; MACROPHAGES; IMMUNOTHERAPY; CHEMOTHERAPY; ASSOCIATION	Cancer biology is influenced by the tumor microenvironment, which impacts disease prognosis and therapeutic interventions. The inter-relationship of tumor-infiltrating lymphocytes, immune response regulators, and a glycolytic tumor environment was evaluated in a cohort of 183 largely consecutive patients with triple negative breast cancer diagnosis. High levels of tumor-infiltrating lymphocytes were associated with improved survival of triple negative breast cancer cases. However, elevated levels of PD-L1, CD163, and FOXP3 were individually associated with significantly decreased overall survival. These three determinants were significantly correlated, and could serve to differentiate the prognostic significance of tumor-infiltrating lymphocytes. Interestingly, a glycolytic tumor environment, as determined by the expression of MCT4 in the tumor stroma, was associated with the immune evasive environment and poor prognosis. Clustering of all markers defined four distinct triple negative breast cancer subtypes that harbored prognostic significance in multivariate analysis. Immune and metabolic markers stratified triple negative breast cancer into subtypes that have prognostic significance and implications for therapies targeting immune checkpoints and tumor metabolism.	[Adams, Thomas A.; Witkiewicz, Agnieszka K.] Univ Arizona, Dept Pathol, Tucson, AZ USA; [Vail, Paris J.; Ruiz, Amanda; Knudsen, Erik S.; Witkiewicz, Agnieszka K.] Univ Arizona, Ctr Canc, 1515 N Campbell Ave,4963, Tucson, AZ 85724 USA; [Mollaee, Mehri; McCue, Peter A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Witkiewicz, AK (reprint author), Univ Arizona, Ctr Canc, 1515 N Campbell Ave,4963, Tucson, AZ 85724 USA.	awitki@email.arizona.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA163863, CA188650]	This work was supported by NIH grants to AKW (CA163863) and ESK (CA188650).	Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bobisse S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.17; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Cimino-Mathews A, 2015, ONCOLOGY-NY, V29, P375; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dieci MV, 2015, ANN ONCOL, V26, P1518, DOI 10.1093/annonc/mdv241; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; Disis Mary L, 2015, Am Soc Clin Oncol Educ Book, pe25, DOI 10.14694/EdBook_AM.2015.35.e25; Doyen J, 2014, BIOCHEM BIOPH RES CO, V451, P54, DOI 10.1016/j.bbrc.2014.07.050; Garcia-Teijido P, 2016, CLIN MED INSIGHTS-ON, V10, P31, DOI 10.4137/CMO.S34540; Gillies RJ, 2015, CANCER J, V21, P88, DOI 10.1097/PPO.0000000000000102; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573; Harris LN, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1622; Hutcheson J, 2016, CLIN CANCER RES, V22, P3606, DOI 10.1158/1078-0432.CCR-15-1883; Knudsen ES, 2017, CLIN CANCER RES, V23, P4429, DOI 10.1158/1078-0432.CCR-17-0162; Krishnamurti U, 2017, HUM PATHOL, V64, P7, DOI 10.1016/j.humpath.2017.01.004; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Li XX, 2016, AM J CLIN PATHOL, V146, P496, DOI [10.1093/ajcp/aqw134, 10.1093/AJCP/AQW134]; Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8; Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Luen SJ, 2017, PATHOLOGY, V49, P141, DOI 10.1016/j.pathol.2016.10.010; Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103; Marme F, 2016, ONCOL RES TREAT, V39, P335, DOI 10.1159/000446340; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Millar EKA, 2009, J CLIN ONCOL, V27, P4701, DOI 10.1200/JCO.2008.21.7075; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Morris GJ, 2007, CANCER, V110, P876, DOI 10.1002/cncr.22836; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; Perez EA, 2016, JAMA ONCOL, V2, P56, DOI 10.1001/jamaoncol.2015.3239; Pilon-Thomas S, 2016, CANCER RES, V76, P1381, DOI 10.1158/0008-5472.CAN-15-1743; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; R Core Team, 2014, LANG ENV STAT COMP; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Renner K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00248; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schlosser HA, 2014, IMMUNOTHERAPY-UK, V6, P973, DOI 10.2217/imt.14.58; Shigehisa Kitano AI, 2015, J CLIN CELL IMMUNOLO, V06, P2, DOI DOI 10.4172/2155-9899.1000322; Singer K, 2011, INT J CANCER, V128, P2085, DOI 10.1002/ijc.25543; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Thike AA, 2010, MODERN PATHOL, V23, P123, DOI 10.1038/modpathol.2009.145; Wang K, 2016, ONCOTARGET, V7, P44288, DOI 10.18632/oncotarget.9988; Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530; Yam C, 2017, ONCOLOGIST, V22, P1086, DOI 10.1634/theoncologist.2017-0095; Yawen Guo PY, 2016, PLOS ONE, V11	58	11	11	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					288	298		10.1038/modpathol.2017.126			11	Pathology	Pathology	FV7KD	WOS:000424761400006	28984302	Bronze, Green Accepted			2019-10-28	
J	Hu, ZH; Sun, Y; Schlette, EJ; Tang, GL; Li, SY; Xu, J; Yin, CC; Young, KH; Patel, KP; Miranda, RN; Goswami, M; Wang, M; Jorgensen, JL; Medeiros, LJ; Wang, SA				Hu, Zhihong; Sun, Yi; Schlette, Ellen J.; Tang, Guilin; Li, Shaoying; Xu, Jie; Yin, C. Cameron; Young, Ken H.; Patel, Keyur Pravinchandra; Miranda, Roberto N.; Goswami, Maitrayee; Wang, Michael; Jorgensen, Jeffrey L.; Medeiros, L. Jeffrey; Wang, Sa A.			CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course	MODERN PATHOLOGY			English	Article							FLOW-CYTOMETRY; LYMPHOPROLIFERATIVE DISORDERS; DIFFERENTIAL-DIAGNOSIS; MOLECULAR PATHOGENESIS; LYMPHOCYTIC-LEUKEMIA; NEOPLASMS; OVEREXPRESSION; GLYCOPROTEIN; INVOLVEMENT; VARIANT	CD200, a marker currently utilized in the diagnosis of B-cell lymphoma, is uniformly positive in chronic lymphocytic leukemia/chronic lymphocytic leukemia, and is usually absent in mantle cell lymphoma. Over a 6 year-period, of 668 mantle cell lymphoma assessed by flow cytometry, CD200 expression was detected in 25 patients (similar to 4%). All 25 patients had bone marrow involvement; however, 11 (44%) patients had no nodal or extranodal disease and belonged to non-nodal leukemic variant mantle cell lymphoma. Morphologically, bone marrow showed an unusual interstitial infiltrative pattern in 14/25 (56%) and small round cells resembling chronic lymphocytic leukemia in 9/25 (36%). CD23 was positive in 19/25 (76%) patients; and SOX11 was only positive in 5/21(24%). All 4 patients tested showed IGHV mutations. With a median follow-up of 23 months, 12/24 (50%) patients were not treated. These clinicopathological features were significantly different from 154 randomly chosen CD200-negative mantle cell lymphoma patients, in SOX11 positivity (24% versus 74%, P < 0.0001), CD23 expression (76% versus 8%, P < 0.0001), a non-nodal leukemic presentation (44% versus 2%, P < 0.001), and therapy requirement (50% versus 92%, P < 0.0001). This is the first study to show that CD200 expression in mantle cell lymphoma, though uncommon, identifies a subgroup of mantle cell lymphoma patients with characteristic pathological features, frequent non-nodal leukemic variant, and an indolent clinical course.	[Hu, Zhihong; Sun, Yi; Schlette, Ellen J.; Tang, Guilin; Li, Shaoying; Xu, Jie; Yin, C. Cameron; Young, Ken H.; Patel, Keyur Pravinchandra; Miranda, Roberto N.; Goswami, Maitrayee; Jorgensen, Jeffrey L.; Medeiros, L. Jeffrey; Wang, Sa A.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Unit 72, Houston, TX 77030 USA	Wang, SA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,Unit 72, Houston, TX 77030 USA.	swang5@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Alapat D, 2012, AM J CLIN PATHOL, V137, P93, DOI 10.1309/AJCP59UORCYZEVQO; BARCLAY AN, 1986, BIOCHEM SOC SYMP, P149; Brunetti L, 2009, BRIT J HAEMATOL, V145, P665, DOI 10.1111/j.1365-2141.2009.07644.x; Vegliante MC, 2013, BLOOD, V121, P2175, DOI 10.1182/blood-2012-06-438937; Challagundla P, 2014, AM J CLIN PATHOL, V142, P837, DOI [10.1309/AJCPBV9ELXCOECVL, 10.1309/AJCPBV9ELXC0ECVL]; Chapman-Fredricks J, 2014, ANN DIAGN PATHOL, V18, P214, DOI 10.1016/j.anndiagpath.2014.03.006; Dreyling M, 2015, LEUKEMIA LYMPHOMA, V56, P866, DOI 10.3109/10428194.2014.940584; El Desoukey NA, 2012, J INVEST MED, V60, P56, DOI 10.2310/JIM.0b013e31823908f9; Espinet B, 2014, CLIN CANCER RES, V20, P1007, DOI 10.1158/1078-0432.CCR-13-1077; Fernandez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419; Ferrando AA, 2013, BLOOD, V121, P2169, DOI 10.1182/blood-2013-02-480418; Furtado M, 2011, HAEMATOL-HEMATOL J, V96, P1086, DOI 10.3324/haematol.2011.047357; Gallo M, 2016, VIRCHOWS ARCH, V469, P697, DOI 10.1007/s00428-016-2016-8; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Hu ZH, 2017, AM J SURG PATHOL, V41, P216, DOI 10.1097/PAS.0000000000000758; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Menter T, 2015, J CLIN PATHOL, V68, P473, DOI 10.1136/jclinpath-2015-202862; O'Malley DP, 2017, ANN DIAGN PATHOL, V26, P57, DOI 10.1016/j.anndiagpath.2016.09.016; Onciu M, 2001, AM J CLIN PATHOL, V116, P886; Ondrejka SL, 2011, HAEMATOL-HEMATOL J, V96, P1121, DOI 10.3324/haematol.2010.036277; Palomero J, 2016, LEUKEMIA, V30, P1596, DOI 10.1038/leu.2015.355; Palumbo GA, 2009, LEUKEMIA RES, V33, P1212, DOI 10.1016/j.leukres.2009.01.017; Pillai V, 2013, AM J CLIN PATHOL, V140, P536, DOI 10.1309/AJCPEBK31VQQNDDR; Sander B, 2016, VIRCHOWS ARCH, V468, P245, DOI 10.1007/s00428-015-1840-6; Sandes AF, 2014, CYTOM PART B-CLIN CY, V86, P98, DOI 10.1002/cyto.b.21128; Schmid M, 2013, INT SYSTEM HUMAN CYT; Swerdlow SH, 2008, WHO CLASSIFICATION T, P229; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tandon B, 2011, MODERN PATHOL, V24, P1433, DOI 10.1038/modpathol.2011.103; Vogt N, 2016, LEUKEMIA LYMPHOMA, P1; Wong KK, 2010, J LEUKOCYTE BIOL, V88, P361, DOI 10.1189/jlb.1009686; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Yabe M, 2017, AM J SURG PATHOL, V41, P82, DOI 10.1097/PAS.0000000000000743	33	13	14	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					327	336		10.1038/modpathol.2017.135			10	Pathology	Pathology	FV7KD	WOS:000424761400010	28984300	Bronze			2019-10-28	
J	Graham, RP; Yasir, S; Fritchie, KJ; Reid, MD; Greipp, PT; Folpe, AL				Graham, Rondell P.; Yasir, Saba; Fritchie, Karen J.; Reid, Michelle D.; Greipp, Patricia T.; Folpe, Andrew L.			Polypoid fibroadipose tumors of the esophagus: 'giant fibrovascular polyp' or liposarcoma? A clinicopathological and molecular cytogenetic study of 13 cases	MODERN PATHOLOGY			English	Article							ATYPICAL LIPOMATOUS TUMOR; DIFFERENTIATED LIPOSARCOMA	Giant fibrovascular polyp of the esophagus is a descriptive diagnostic term intended to encompass rare, large, polypoid esophageal masses composed of fibroadipose tissue. Despite sometimes dramatic clinical presentations, they have historically been considered to represent reactive, non-neoplastic proliferations. Recently, however, a small number of reports have described well-differentiated liposarcomas of the esophagus, mimicking giant fibrovascular polyps. In order to clarify the relationship between esophageal liposarcoma and giant fibrovascular polyp, we retrieved esophageal cases coded as 'giant fibrovascular polyp,' 'lipoma' and ` liposarcoma' from our archives and re-examined their clinicopathologic features and MDM2 amplification status. Thirteen cases were identified (lipoma (n=1), giant fibrovascular polyp (n=5), well-differentiated liposarcoma (n=3), dedifferentiated liposarcoma (n=3)). The tumors ranged from 5.2 to 19.5 cm and arose predominantly in the cervical esophagus. All consisted chiefly of mature adipose tissue, with a variable component of fibrous septa. In all cases, close inspection of these fibrous septa showed them to contain an increased number of slightly enlarged spindled cells with irregular, hyperchromatic nuclei, similar to those seen in some well-differentiated liposarcomas. Three cases, all previously classified as dedifferentiated liposarcoma, showed in addition solid zones of non-lipogenic spindle cell sarcoma. By fluorescence in situ hybridization (FISH), all cases showed MDM2 amplification, confirming diagnoses as well-differentiated (N=10) and dedifferentiated (N=3) liposarcoma. Clinical follow-up (8 cases, range 22-156 months, median 33 months) showed 3 patients with local recurrences (1 well-differentiated and 2 dedifferentiated liposarcomas), 1 patient with liver metastases (dedifferentiated liposarcoma) and 2 deaths from disease (both dedifferentiated liposarcomas). These results suggest that the great majority of large, polypoid, fat-containing masses of the esophagus represent well and dedifferentiated liposarcoma, rather than 'giant fibrovascular polyps.' We suggest that the diagnosis of 'giant fibrovascular polyp' should be made with great caution in the esophagus, and only after careful morphological study and MDM2 FISH has excluded the possibility of liposarcoma.	[Graham, Rondell P.; Yasir, Saba; Fritchie, Karen J.; Folpe, Andrew L.] Mayo Clin, Div Anat Pathol, Rochester, MN USA; [Graham, Rondell P.; Greipp, Patricia T.] Mayo Clin, Div Lab Genom, Rochester, MN USA; [Reid, Michelle D.] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Folpe, AL (reprint author), Mayo Clin, Dept Anat Pathol, Hilton 11 200 First St SW,1135,E Weatherhill Dr, Rochester, MN 55905 USA.	folpe.andrew@mayo.edu		Graham, Rondell/0000-0002-8686-4867	Division of Anatomic Pathology Research committee	We thank Darlene Knutson, Ryan Knudson and Sara Kloft-Nelson for excellent technical work on fluorescence in situ hybridization. We would also like to thank the Division of Anatomic Pathology Research committee for funding support.	Beylergil V, 2014, CLIN NUCL MED, V39, P288, DOI 10.1097/RLU.0000000000000358; Boland JM, 2010, AM J SURG PATHOL, V34, P837, DOI 10.1097/PAS.0b013e3181dbf2f7; Boni A, 2013, HUM PATHOL, V44, P1165, DOI 10.1016/j.humpath.2012.10.023; CHI PSH, 1950, ARCH SURG-CHICAGO, V60, P92, DOI 10.1001/archsurg.1950.01250010108010; Iriarte G, 1997, Dis Esophagus, V10, P69; Jakowski JD, 2009, ANN DIAGN PATHOL, V13, P263, DOI 10.1016/j.anndiagpath.2008.04.004; Lee KN, 1996, AM J ROENTGENOL, V166, P730, DOI 10.2214/ajr.166.3.8623675; Levine MS, 1996, AM J ROENTGENOL, V166, P781, DOI 10.2214/ajr.166.4.8610549; Lewin K, 1995, TUMORS ESOPHAGUS STO; McQueen C, 2010, ADV ANAT PATHOL, V17, P38, DOI 10.1097/PAP.0b013e3181bb6b35; OWENS JJ, 1994, ANN OTO RHINOL LARYN, V103, P838; Park JS, 2014, CLIN ENDOSC, V47, P101, DOI 10.5946/ce.2014.47.1.101; Riva Giuseppe, 2016, J Gastrointest Cancer, V47, P135, DOI 10.1007/s12029-016-9808-6; Sargent RL, 2006, ARCH PATHOL LAB MED, V130, P725; Stout AP, 1957, TUMORS ESOPHAGUS ATL, P25; Sweeney T, 2011, ANZ J SURG, V81, P845, DOI 10.1111/j.1445-2197.2011.05877.x; Torres-Mora J, 2012, CASE REP GASTROINTES, DOI 10.1155/2012/141693; Valiuddin HM, 2016, WORLD J GASTRO ONCOL, V8, P835, DOI 10.4251/wjgo.v8.i12.835; Ward MA, 2018, SURG ENDOSC, V32, P1066, DOI 10.1007/s00464-017-5664-0; Yu ZX, 2012, HUM PATHOL, V43, P293, DOI 10.1016/j.humpath.2011.04.022	20	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					337	342		10.1038/modpathol.2017.140			6	Pathology	Pathology	FV7KD	WOS:000424761400011	28984298				2019-10-28	
J	Nelson, AC; Boone, J; Cartwright, D; Thyagarajan, B; Kincaid, R; Lambert, AP; Karnuth, K; Henzler, C; Yohe, S				Nelson, Andrew C.; Boone, Jamie; Cartwright, David; Thyagarajan, Bharat; Kincaid, Robyn; Lambert, Aaron P.; Karnuth, Kylene; Henzler, Christine; Yohe, Sophia			Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity	MODERN PATHOLOGY			English	Article							GENETIC-HETEROGENEITY; CANCER; KRAS; BRAF; SURVIVAL; PIK3CA; METASTASES; RAS	Intra-tumoral genomic heterogeneity is a well-established biologic property of human malignancies with emerging roles in cancer progression and therapy resistance. However, its impact on the clinical utility of genomic testing in patient management remains unclear. Furthermore, best practices to account for heterogeneity in the provision of highly accurate, clinically valid molecular testing have yet to be firmly established. Genomic biomarkers for the management of colorectal carcinoma are both well-established (ie, KRAS, NRAS) and emerging (BRAF, PIK3CA, and others) in respect to therapy selection and clinical trial eligibility. Critically, standard colorectal carcinoma management requires the exclusion of KRAS and NRAS mutations; thus optimal procedures to control for potential intra-tumoral heterogeneity are clinically important. Here, we assessed heterogeneity among three intra-tumoral sites within 99 colorectal carcinomas cases on a CLIA-validated oncology next generation sequencing assay and examined whether a pooling strategy overcame any discordant results. Overall, 11% of cases demonstrated discordant mutation results between sites; 2% of cases were discrepant for mutations within RAS genes while the remainder was discrepant in PIK3CA. Half of the discrepant cases were associated with borderline tumor cellularity assessment. Further, a sample pooling strategy across all three sites successfully detected the relevant mutation in all but one case. Our results indicate that intra-tumoral genomic heterogeneity of clinically relevant genes within colorectal carcinoma is a relatively infrequent occurrence and that a simple strategy to pool DNA from several tumor sites with adequate cellularity minimizes the risk of false negative results even further to ensure optimal patient management.	[Nelson, Andrew C.; Boone, Jamie; Cartwright, David; Thyagarajan, Bharat; Henzler, Christine; Yohe, Sophia] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Kincaid, Robyn; Lambert, Aaron P.; Karnuth, Kylene] M Hlth, Mol Diagnost Lab, Minneapolis, MN USA	Yohe, S (reprint author), Univ Minnesota, Med Ctr, Dept Lab Med & Pathol, MMC Box Mayo 609,420 Delaware St SE, Minneapolis, MN 55455 USA.	slymp96@yahoo.com	Yohe, Sophia/O-2331-2013	Yohe, Sophia/0000-0003-2235-9930			Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Baisse B, 2001, INT J CANCER, V93, P346, DOI 10.1002/ijc.1343; Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Bouchahda M, 2016, EUR J CANCER, V68, P163, DOI 10.1016/j.ejca.2016.09.011; Buob D, 2012, DIGEST DIS SCI, V57, P1271, DOI 10.1007/s10620-011-2023-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Jones HG, 2017, WORLD J SURG, V41, P1375, DOI 10.1007/s00268-016-3860-z; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lin EI, 2015, ONCOTARGET, V6, P42334, DOI 10.18632/oncotarget.5997; Losi L, 2005, CARCINOGENESIS, V26, P916, DOI 10.1093/carcin/bgi044; Maurel J, 2015, CURR CANCER DRUG TAR, V15, P703, DOI 10.2174/156800961508151001102822; National Comprehensive Cancer Network (NCCN), NCCN CAT EV CONS; Oltedal S, 2011, INT J COLORECTAL DIS, V26, P1271, DOI 10.1007/s00384-011-1233-5; Richman SD, 2011, ANAL CELL PATHOL, V34, P61, DOI 10.3233/ACP-2011-0005; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345; Suzuki Y, 2017, MOL ONCOL, V11, P124, DOI 10.1002/1878-0261.12012; Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036; Viray H, 2013, ARCH PATHOL LAB MED, V137, P1545, DOI 10.5858/arpa.2012-0561-CP; Watanabe T, 2011, DIS COLON RECTUM, V54, P1170, DOI 10.1097/DCR.0b013e31821d37a3; Yang RD, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0251-2	22	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					343	349		10.1038/modpathol.2017.120			7	Pathology	Pathology	FV7KD	WOS:000424761400012	29027537	Bronze			2019-10-28	
J	Zuo, T; Wong, S; Buza, N; Hui, P				Zuo, Tao; Wong, Serena; Buza, Natalia; Hui, Pei			KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome	MODERN PATHOLOGY			English	Article							ATYPICAL PROLIFERATIVE TUMORS; PERITONEAL IMPLANTS; RAS MUTATIONS; CARCINOMAS; BRAF; OVARY	In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. Forty-two implants of serous borderline tumor from 39 patients were included (invasive implants/low-grade serous carcinoma, n=20; non-invasive implants, n=22). KRAS mutation was found in 12 of 20 invasive implants (60%) and 3 of 22 non-invasive implants (14%). BRAF V600E mutation was found in 1 of 22 non-invasive implants (5%) and none in invasive implants (0%). Invasive implants were more frequently associated with higher stage disease. Nine of 14 patients (64%) with KRAS mutation were found to have stage IIIC disease, while 5 of 24 patients (20%) without the mutation had stage IIIC disease. Patients with invasive implants had higher recurrence rate compared to those with non-invasive implants (60 vs 14 %, P=0.0003, log-rank test) and worse disease-specific survival (P=0.0008, log-rank test). Regardless of the histological subtypes, patients with KRAS mutation positive implants had significantly higher recurrence rate than those without the mutation (71 vs 21%, P=0.0021, log-rank test) and an unfavorable disease-specific survival (P=0.0104, log-rank test). In conclusion, compared to those with non-invasive implants, patients with invasive implants present with higher stage of the disease, higher recurrence rate and worse survival. KRAS mutation, but not BRAF V600E mutation, is significantly associated with invasive implants of serous borderline tumor. Regardless of the histological subtypes of the implants, KRAS mutation is a significant prognostic indicator for high risk of tumor recurrence and worse disease-specific survival.	[Zuo, Tao; Wong, Serena; Buza, Natalia; Hui, Pei] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Hui, P (reprint author), Yale Sch Med, Dept Pathol, BML254B,310 Cedar St, New Haven, CT 06510 USA.	pei.hui@yale.edu					Ahn G, 2016, AM J SURG PATHOL, V40, P1165, DOI 10.1097/PAS.0000000000000693; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Ardighieri L, 2014, J PATHOL, V232, P16, DOI 10.1002/path.4293; BELL DA, 1988, CANCER, V62, P2212, DOI 10.1002/1097-0142(19881115)62:10<2212::AID-CNCR2820621024>3.0.CO;2-W; Bell KA, 2001, AM J SURG PATHOL, V25, P419, DOI 10.1097/00000478-200104000-00001; Dillon DA, 2000, CANCER J, V6, P294; Hannibal CG, 2014, GYNECOL ONCOL, V134, P267, DOI 10.1016/j.ygyno.2014.06.002; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Krzystyniak J, 2016, ANN ONCOL, V27, P4, DOI 10.1093/annonc/mdw083; Malpica A, 2016, ANN ONCOL, V27, P16, DOI 10.1093/annonc/mdw089; MCCAUGHEY WTE, 1984, HISTOPATHOLOGY, V8, P195, DOI 10.1111/j.1365-2559.1984.tb02336.x; McKenney JK, 2016, AM J SURG PATHOL, V40, P1155, DOI 10.1097/PAS.0000000000000692; Perincheri S, 2015, EXPERT REV MOL DIAGN, V15, P375, DOI 10.1586/14737159.2015.986102; Seidman JD, 2014, WHO CLASSIFICATION T, P17; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Tsang YT, 2013, J PATHOL, V231, P449, DOI 10.1002/path.4252; Vang R, 2017, AM J SURG PATHOL, V41, P725, DOI 10.1097/PAS.0000000000000824; Zhong HH, 2013, DIAGN MOL PATHOL, V22, P52, DOI 10.1097/PDM.0b013e318263f092	20	1	1	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					350	357		10.1038/modpathol.2017.121			8	Pathology	Pathology	FV7KD	WOS:000424761400013	29027536	Bronze			2019-10-28	
J	Hu, SM; Hinson, JL; Matnani, R; Cibull, ML; Karabakhtsian, RG				Hu, Shaomin; Hinson, Jeff L.; Matnani, Rahul; Cibull, Michael L.; Karabakhtsian, Rouzan G.			Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma	MODERN PATHOLOGY			English	Article							MAMMAGLOBIN EXPRESSION; CLEAR-CELL; P53 GENE; CANCERS; ADENOCARCINOMAS; PROFILES; MUTATION; OUTCOMES; PTEN	Histologic subclassification of high-grade endometrial carcinomas can sometimes be a diagnostic challenge when based on histomorphology alone. Here we utilized immunohistochemical markers to determine the immunophenotype in histologically ambiguous high-grade endometrial carcinomas that were initially diagnosed as pure or mixed high-grade endometrioid carcinoma, aiming to determine the utility of selected immunohistochemical panel in accurate classification of these distinct tumor types, while correlating these findings with the clinical outcome. A total of 43 high-grade endometrial carcinoma cases initially classified as pure high-grade endometrioid carcinoma (n=32), mixed high-grade endometrioid carcinoma/serous carcinoma (n=9) and mixed high-grade endometrioid carcinoma/clear cell carcinoma (n=2) were retrospectively stained with a panel of immunostains, including antibodies for p53, p16, estrogen receptor, and mammaglobin. Clinical follow-up data were obtained, and stage-to-stage disease outcomes were compared for different tumor types. Based on aberrant staining for p53 and p16, 17/43 (40%) of the high-grade endometrial carcinoma cases initially diagnosed as high-grade endometrioid carcinoma were re-classified as serous carcinoma. All 17 cases showed negative staining for mammaglobin, while estrogen receptor was positive in only 6 (35%) cases. The remaining 26 cases of high-grade endometrioid carcinoma showed wild-type staining for p53 in 25 (96%) cases, patchy staining for p16 in 20 (77%) cases, and were positive for mammaglobin and estrogen receptor in 8 (31%) and 19 (73%) cases, respectively, thus the initial diagnosis of high-grade endometrioid carcinoma was confirmed in these cases. In addition, the patients with re-classified serous carcinoma had advanced clinical stages at diagnosis and poorer overall survival on clinical follow-up compared to that of the remaining 26 high-grade endometrioid carcinoma cases. These results indicate that selected immunohistochemical panel, including p53, p16, and mammaglobin can be helpful in reaching accurate diagnosis in cases of histomorphologically ambiguous endometrial carcinomas, and can assist in providing guidance for appropriate therapeutic options for the patients.	[Hu, Shaomin; Karabakhtsian, Rouzan G.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol & Lab Med, Bronx, NY 10461 USA; [Hinson, Jeff L.; Matnani, Rahul; Cibull, Michael L.; Karabakhtsian, Rouzan G.] Univ Kentucky, Med Ctr, Chandler Hosp, Dept Pathol & Lab Med, Lexington, KY USA	Karabakhtsian, RG (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, 1825 Eastchester Rd, Bronx, NY 10461 USA.	rkarabak@montefiore.org					Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Boruta DM, 2009, GYNECOL ONCOL, V115, P142, DOI 10.1016/j.ygyno.2009.06.011; Chan JK, 2003, GYNECOL ONCOL, V90, P181, DOI 10.1016/S0090-8258(03)00195-1; Chen WQ, 2017, INT J GYNECOL PATHOL, V36, P128, DOI 10.1097/PGP.0000000000000291; Chiang S, 2014, SEMIN DIAGN PATHOL, V31, P205, DOI 10.1053/j.semdp.2014.03.002; Creasman WT, 2004, GYNECOL ONCOL, V95, P593, DOI 10.1016/j.ygyno.2004.08.019; Darvishian T, 2004, AM J SURG PATHOL, V28, P1568, DOI 10.1097/00000478-200412000-00004; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Garg K, 2010, MODERN PATHOL, V23, P80, DOI 10.1038/modpathol.2009.153; Gatius S, 2016, MODERN PATHOL, V29, pS45, DOI 10.1038/modpathol.2015.141; Geels YP, 2015, GYNECOL ONCOL, V137, P245, DOI 10.1016/j.ygyno.2015.03.007; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Hagemann IS, 2013, HUM PATHOL, V44, P628, DOI 10.1016/j.humpath.2012.07.013; Hamilton CA, 2006, BRIT J CANCER, V94, P642, DOI 10.1038/sj.bjc.6603012; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; KING SA, 1995, CANCER, V75, P2700, DOI 10.1002/1097-0142(19950601)75:11<2700::AID-CNCR2820751110>3.0.CO;2-I; Malpica A, 2016, MODERN PATHOL, V29, pS29, DOI 10.1038/modpathol.2015.142; McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056; Moore KN, 2011, CLIN OBSTET GYNECOL, V54, P278, DOI 10.1097/GRF.0b013e318218c755; Onuma K, 2008, INT J GYNECOL PATHOL, V27, P418, DOI 10.1097/PGP.0b013e31815d05ec; Pallares J, 2005, MODERN PATHOL, V18, P719, DOI 10.1038/modpathol.3800347; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Rutgers JKL, 2015, FUTURE ONCOL, V11, P3207, DOI 10.2217/fon.15.262; Setiawan VW, 2013, J CLIN ONCOL, V31, P2607, DOI 10.1200/JCO.2012.48.2596; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; Soslow RA, 1998, INT J GYNECOL PATHOL, V17, P129, DOI 10.1097/00004347-199804000-00006; Soslow RA, 2007, AM J SURG PATHOL, V31, P979, DOI 10.1097/PAS.0b013e31802ee494; Soslow RA, 2013, HISTOPATHOLOGY, V62, P89, DOI 10.1111/his.12029; Tashiro H, 1997, AM J PATHOL, V150, P177; Tashiro H, 1997, AM J PATHOL, V150, P75; Thomas S, 2016, ARCH PATHOL LAB MED, V140, P836, DOI 10.5858/arpa.2015-0220-OA; Ueda SM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.075; Ussakli C, 2016, POL J PATHOL, V67, P221, DOI [10.5114/PJP.2016.63773, 10.5114/pjp.2016.63773]; Wei JJ, 2013, ARCH PATHOL LAB MED, V137, P1574, DOI 10.5858/arpa.2012-0445-OA; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5	37	1	1	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					358	364		10.1038/modpathol.2017.131			7	Pathology	Pathology	FV7KD	WOS:000424761400014	28984301	Bronze			2019-10-28	
J	Perrone, ME; Chang, A; Henriksen, KJ				Perrone, Marie E.; Chang, Anthony; Henriksen, Kammi J.			Medical renal diseases are frequent but often unrecognized in adult autopsies	MODERN PATHOLOGY			English	Article							TUMOR NEPHRECTOMY SPECIMENS; CHRONIC KIDNEY-DISEASE; HEPATITIS-C VIRUS; CELL TRANSPLANTATION; NEPHROPATHY; PATHOLOGY; SPECTRUM; SERIES; POPULATION; PREVALENCE	Kidney diseases affect many hospitalized patients and contribute to morbidity and mortality. Therefore, kidney disease should be prevalent, but the frequency and spectrum of medical renal pathology in autopsy specimens has not been well documented. We sought to determine the spectrum of medical renal pathology in adult autopsy specimens and the frequency of overlooked diagnoses. We reviewed the hematoxylin-and eosin-stained kidney sections from 140 adult autopsies performed at a large teaching hospital over a 2-year period. Fifty-eight cases (41%) had findings warranting further analysis, including alterations in glomerular matrix and/or cellularity, atypical or pigmented casts, thrombi, tubulointerstitial or vascular inflammation, or deposition of amorphous material. After additional studies and clinical correlation, the pathologic changes in 43 cases (31%) were categorized as follows: diabetic nephropathy, bile cast nephropathy, thrombotic microangiopathy, infection-related glomerulonephritis, focal necrotizing/crescentic glomerulonephritis, oxalate nephropathy, light-chain cast nephropathy, amyloidosis, urate nephropathy, hemosiderosis, antineutrophil cytoplasmic antibody-associated vasculitis, polyoma virus nephropathy, atheroembolic disease, and nephrocalcinosis. These diagnoses were not reported in 26 (60%) cases during the initial autopsy evaluation. This study demonstrates that medical renal diseases are common in autopsy cases, but significant diagnoses can be easily overlooked. Autopsy kidney specimens are a rich source of renal pathology and their evaluation should be emphasized in anatomic pathology residency training. Ultimately, our understanding of how kidney disease contributes to morbidity and mortality will benefit from accurate recognition of renal pathology in autopsy specimens.	[Perrone, Marie E.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Chang, Anthony; Henriksen, Kammi J.] Univ Chicago, Dept Pathol, 5841 South Maryland Ave,Room S-630 MC 6101, Chicago, IL 60637 USA	Henriksen, KJ (reprint author), Univ Chicago, Dept Pathol, 5841 South Maryland Ave,Room S-630 MC 6101, Chicago, IL 60637 USA.	kammi.henriksen@uchospitals.edu		Chang, Anthony/0000-0002-6877-5510			Arase Y, 1998, INTERNAL MED, V37, P836, DOI 10.2169/internalmedicine.37.836; Bernardi FDC, 2005, J CLIN PATHOL, V58, P1261, DOI 10.1136/jcp.2005.027953; Bijol V, 2006, AM J SURG PATHOL, V30, P575, DOI 10.1097/01.pas.0000194296.74097.87; Bijol Vanesa, 2014, Surg Pathol Clin, V7, P291, DOI 10.1016/j.path.2014.04.001; Brinkerhoff BT, 2016, MODERN PATHOL, V29, P637, DOI 10.1038/modpathol.2016.61; Buettner M, 2014, AM J KIDNEY DIS, V63, P945, DOI 10.1053/j.ajkd.2014.01.428; Chang A, 2007, CLIN J AM SOC NEPHRO, V2, P1014, DOI 10.2215/CJN.01700407; El Seisi S, 2003, BIOL BLOOD MARROW TR, V9, P683, DOI 10.1016/S1083-8791(03)00243-X; Faria TV, 2010, RENAL FAILURE, V32, P918, DOI 10.3109/0886022X.2010.502278; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gopalani A, 2001, AM J MED SCI, V322, P57, DOI 10.1097/00000441-200108000-00001; Hara S, 2016, HUM PATHOL, V55, P164, DOI 10.1016/j.humpath.2016.05.010; Henriksen KJ, 2009, ARCH PATHOL LAB MED, V133, P1012, DOI 10.1043/1543-2165-133.7.1012; Henriksen KJ, 2007, AM J SURG PATHOL, V31, P1703, DOI 10.1097/PAS.0b013e31804ca63e; Henriksen KJ, 2017, DIAG HISTOPATHOL, V23, P117; Herrera GA, 2004, ARCH PATHOL LAB MED, V128, P875; Ivanyi B, 1991, ARCH PATHOL LAB MED, V79, P517; Klessens CQF, 2016, KIDNEY INT, V90, P149, DOI 10.1016/j.kint.2016.01.023; Kocovski L, 2009, J FORENSIC SCI, V54, P439, DOI 10.1111/j.1556-4029.2008.00956.x; Monga G, 1997, MODERN PATHOL, V10, P159; Nakayama EE, 2001, AM J KIDNEY DIS, V38, P26, DOI 10.1053/ajkd.2001.25177; Nasr SH, 2006, KIDNEY INT, V70, P2148, DOI 10.1038/sj.ki.5001990; Nasr SH, 2008, CLIN J AM SOC NEPHRO, V3, P1676, DOI 10.2215/CJN.02940608; Nasr SH, 2007, NEPHROL DIAL TRANSPL, V22, P1228, DOI 10.1093/ndt/gfl838; Nichols L, 2012, ARCH PATHOL LAB MED, V136, P1552, DOI 10.5858/arpa.2011-0521-OA; Laparra MCN, 2010, NEFROLOGIA, V30, P420, DOI 10.3265/Nefrologia.pre2010.Jun.10456; Niizuma S, 2011, RENAL FAILURE, V33, P847, DOI 10.3109/0886022X.2011.605531; Ohashi R, 2014, PATHOL INT, V64, P443, DOI 10.1111/pin.12192; Paueksakon Paisit, 2014, Surg Pathol Clin, V7, P321, DOI 10.1016/j.path.2014.04.008; Roulson J, 2005, HISTOPATHOLOGY, V47, P551, DOI 10.1111/j.1365-2559.2005.02243.x; Salvatore SP, 2013, ARCH PATHOL LAB MED, V137, P531, DOI 10.5858/arpa.2012-0070-OA; Saran R, 2016, AM J KIDNEY DIS, V67, pS1, DOI 10.1053/j.ajkd.2015.12.014; Shahinian V, 2000, AM J KIDNEY DIS, V35, P884, DOI 10.1016/S0272-6386(00)70259-9; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Thomas R, 2008, PRIMARY CARE, V35, P329, DOI 10.1016/j.pop.2008.01.008; TROSTLE DC, 1988, ARTHRITIS RHEUM, V31, P393, DOI 10.1002/art.1780310311; Troxell ML, 2014, ADV ANAT PATHOL, V21, P330, DOI 10.1097/PAP.0000000000000034; UEDA K, 1976, J CHRON DIS, V29, P159, DOI 10.1016/0021-9681(76)90043-6; Usta U, 2014, SAUDI MED J, V35, P1331; van Slambrouck CM, 2013, KIDNEY INT, V84, P192, DOI 10.1038/ki.2013.78; Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487; Wyatt CM, 2009, KIDNEY INT, V75, P428, DOI 10.1038/ki.2008.604; Xu Jiaquan, 2016, Natl Vital Stat Rep, V64, P1	43	1	2	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2018	31	2					365	373		10.1038/modpathol.2017.122			9	Pathology	Pathology	FV7KD	WOS:000424761400015	28984299				2019-10-28	
J	Agaimy, A; Hartmann, A				Agaimy, A.; Hartmann, A.			Head and Neck Neoplasms News from the WHO-Classification of 2017	PATHOLOGE			German	Editorial Material									[Agaimy, A.; Hartmann, A.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Agaimy, A; Hartmann, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de; Arndt.Hartmann@uk-erlangen.de						0	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					1	2		10.1007/s00292-018-0419-9			2	Pathology	Pathology	FV3CN	WOS:000424445600001	29387917	Bronze			2019-10-28	
J	Weichert, W; Ihrler, S; Boxberg, M; Agaimy, A; Mollenhauer, M; Hartmann, A				Weichert, W.; Ihrler, S.; Boxberg, M.; Agaimy, A.; Mollenhauer, M.; Hartmann, A.			Morphology of non cutaneous head and neck squamous cell carcinoma	PATHOLOGE			German	Article						Squamous cell carcinoma; Human papilloma virus; Leukoplakia; Dsyplasia; Tumor staging	PROLIFERATIVE VERRUCOUS LEUKOPLAKIA; INTRAEPITHELIAL LESIONS; UNKNOWN PRIMARY; LARYNGEAL; CANCER; PROPOSAL; ENTITY	Head and neck squamous cell carcinoma (HNSCC) is by far the most frequent malignant tumor in this anatomic region. Today, HNSCC is divided into two morphologically, molecularly and clinically fundamentally different entities: conventional and virus-associated (HPV/EBV) neoplasms. Premalignant lesions of nonvirus-associated HNSCC include conventional leukoplakia, dysplasia and proliferative verrucous hyperplasia with an increasing risk for malignant transformation. The morphology of HNSCC comprises a spectrum of growth patterns. In addition, special types of HNSCC must be delineated. Recently, for virus-associated HNSCC, some important clinicopathological specifics have become relevant including a separate staging system for these neoplasms. For non-virus associated HNSCC, new grading procedures have been proposed, which significantly impact on prognosis. These issues will be discussed in this review.	[Weichert, W.; Boxberg, M.; Mollenhauer, M.] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany; [Ihrler, S.] Lab Dermatohistol & Oralpathol, Munich, Germany; [Agaimy, A.; Hartmann, A.] Univ Klinikum Erlangen, Inst Pathol, Erlangen, Germany	Weichert, W (reprint author), Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany.	wilko.weichert@tum.de					Agaimy A, 2016, PATHOLOGE, V37, P285, DOI 10.1007/s00292-016-0173-9; Becker N, DTSCH KREBSFORSCHUNG; Boxberg M, 2017, HISTOPATHOLOGY, V70, P1125, DOI 10.1111/his.13173; El-Naggar AK, 2017, WHO CLASSIFICATION H, V4; Gale N, 2016, ADV ANAT PATHOL, V23, P84, DOI 10.1097/PAP.0000000000000106; Gale N, 2009, HISTOPATHOLOGY, V54, P639, DOI 10.1111/j.1365-2559.2008.03111.x; Goldenberg D, 2008, HEAD NECK-J SCI SPEC, V30, P898, DOI 10.1002/hed.20796; Kang H, 2015, NAT REV CLIN ONCOL, V12, P11, DOI 10.1038/nrclinonc.2014.192; Kuribayashi Y, 2015, ORAL ONCOL, V51, P1020, DOI 10.1016/j.oraloncology.2015.09.004; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Mollenhauer M, 2014, PATHOLOGE, V35, P127, DOI 10.1007/s00292-013-1852-4; Munde A, 2016, J CANCER RES THER, V12, P469, DOI 10.4103/0973-1482.151443; Neid M, 2009, HNO, V57, P181, DOI 10.1007/s00106-008-1884-x; Pentenero M, 2014, BRIT J DERMATOL, V170, P1039, DOI 10.1111/bjd.12853; Spielmann PM, 2010, EUR ARCH OTO-RHINO-L, V267, P423, DOI 10.1007/s00405-009-1013-9; Stenzinger A, 2014, ONKOLOGE, V20, P116, DOI 10.1007/s00761-013-2584-z; Tinhofer I, 2015, EUR J CANCER, V51, P514, DOI 10.1016/j.ejca.2014.12.018; van Hulst AM, 2016, HEAD NECK-J SCI SPEC, V38, pE2284, DOI 10.1002/hed.24185; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; Wittekind C, 2017, TNM KLASSIFIKATION M; Zengel P, 2012, VIRCHOWS ARCH, V461, P283, DOI 10.1007/s00428-012-1290-3	21	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					3	10		10.1007/s00292-017-0395-5			8	Pathology	Pathology	FV3CN	WOS:000424445600002	29209797				2019-10-28	
J	Ihrler, S; Guntinas-Lichius, O; Haas, C; Mollenhauer, M				Ihrler, S.; Guntinas-Lichius, O.; Haas, C.; Mollenhauer, M.			Updates on tumours of the salivary glands. 2017 WHO classification	PATHOLOGE			German	Article						World Health Organization; Salivary gland neoplasms; Pleomorphic adenoma; Carcinoma; Molecular pathology	EX PLEOMORPHIC ADENOMA; CLEAR-CELL-CARCINOMA; DUCT CARCINOMA; IN-SITU; EMPHASIS; FUSION; LYMPHADENOMA; VARIANTS; LESIONS	In the new 2017 WHO classification, a reduction of the high number of entities of salivary carcinomas was implemented. There is only one new carcinoma entity: secretory carcinoma. There is a slight increase of reactive and benign entities by the inclusion of rare and well-established, but so far not included, lesions. Furthermore, there are some conceptual changes and pure changes in terminology. The impact of molecular findings is increasing and is so far restricted to diagnostic aspects.	[Ihrler, S.; Haas, C.] Lab Dermatohistol & Oralpathol, Bayerstr 69, D-80335 Munich, Germany; [Ihrler, S.] Ludwig Maximilians Univ Munchen, Pathol Inst, Munich, Germany; [Guntinas-Lichius, O.] Univ Klinikum Jena, Klin Hals Nasen & Ohrenheilkunde, Jena, Germany; [Mollenhauer, M.] Tech Univ Munich, Inst Pathol, Munich, Germany	Ihrler, S (reprint author), Lab Dermatohistol & Oralpathol, Bayerstr 69, D-80335 Munich, Germany.	Ihrler@dermpath-muenchen.de	Guntinas-Lichius, Orlando/L-1871-2016	Guntinas-Lichius, Orlando/0000-0001-9671-0784			Agaimy A, 2013, AM J SURG PATHOL, V37, P128, DOI 10.1097/PAS.0b013e31826731e0; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Barnes L, 2005, WORD HLTH ORG CLASSI; Chenevert J, 2012, MODERN PATHOL, V25, P919, DOI 10.1038/modpathol.2012.57; Di Palma S, 2013, HEAD NECK PATHOL, V7, pS68, DOI 10.1007/s12105-013-0454-z; Di Palma S, 2012, HISTOPATHOLOGY, V61, P629, DOI 10.1111/j.1365-2559.2012.04252.x; El- Naggar AK, 2017, WORLD HLTH ORG CLASS; Fehr A, 2011, AM J SURG PATHOL, V35, P1600, DOI 10.1097/PAS.0b013e31822832c7; Flucke U, 2011, MODERN PATHOL, V24, P1444, DOI 10.1038/modpathol.2011.108; Ihrler S, 2014, PATHOLOGE, V35, P476, DOI 10.1007/s00292-014-1929-8; Ihrler S, 2009, PATHOLOGE, V30, P446, DOI 10.1007/s00292-009-1204-6; Ihrler S, 2017, VIRCHOWS ARCH, V470, P601, DOI 10.1007/s00428-017-2106-2; Keller G, 2017, ORAL ONCOL, V68, P103, DOI 10.1016/j.oraloncology.2017.02.018; Petersson F, 2013, HEAD NECK PATHOL, V7, pS97, DOI 10.1007/s12105-013-0465-9; Seethala RR, 2012, MODERN PATHOL, V25, P26, DOI 10.1038/modpathol.2011.135; Shah AA, 2013, AM J SURG PATHOL, V37, P571, DOI 10.1097/PAS.0b013e3182772a15; Simpson RHW, 2008, HISTOPATHOLOGY, V53, P416, DOI 10.1111/j.1365-2559.2008.03135.x; Simpson RHW, 2013, HEAD NECK PATHOL, V7, pS48, DOI 10.1007/s12105-013-0456-x; Skalova A, 2015, AM J SURG PATHOL, V39, P338, DOI 10.1097/PAS.0000000000000364; Skalova A, 2011, AM J SURG PATHOL, V35, P1168, DOI 10.1097/PAS.0b013e31821e1f54; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Weiler C, 2012, VIRCHOWS ARCH, V460, P467, DOI 10.1007/s00428-012-1225-z; Weiler C, 2011, HISTOPATHOLOGY, V59, P741, DOI 10.1111/j.1365-2559.2011.03937.x; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096; Weinreb I, 2013, HEAD NECK PATHOL, V7, pS20, DOI 10.1007/s12105-013-0466-8; Williams L, 2015, AM J SURG PATHOL, V39, P705, DOI 10.1097/PAS.0000000000000413	27	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					11	17		10.1007/s00292-017-0407-5			7	Pathology	Pathology	FV3CN	WOS:000424445600003	29372306				2019-10-28	
J	Agaimy, A; Haller, F; Hartmann, A				Agaimy, A.; Haller, F.; Hartmann, A.			Sinonasal tumors. News from the WHO with special reference to mesenchymal entities	PATHOLOGE			German	Article						Adamantinoma; Ewing sarcoma; Genetic markers; Sinonasal undifferentiated carcinoma; SMARCB1 protein	SOLITARY FIBROUS TUMOR; NUT MIDLINE CARCINOMAS; BETA-CATENIN; RHABDOMYOBLASTIC DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA; NUCLEAR EXPRESSION; SARCOMA; TRACT; HEMANGIOPERICYTOMA; MUTATIONS	The last two decades have seen significant advances in the pathology of sinonasal tract neoplasms. This was the consequence of the availability of several innovative diagnostic tools, which resulted in a dynamic evolution of entities and splitting of newly defined or conceptualized entities and subtypes that have been included in the spectrum of old heterogeneous diseases. Most of these new tumor subtypes have distinctive demographic, clinicopathologic, and biological characteristics with prognostic and therapeutic implications for individual patients. NUT carcinoma (NUT midline carcinoma) was separated from the spectrum of sinonasal undifferentiated carcinoma (SNUC) and is defined by specific recurrent translocation. On the other hand, the recently described SMARCB1-deficient carcinoma (while probably representing a distinctive clinicopathologic entity) remained as a variant in the SNUC spectrum. A new neoplasm in the spectrum of non-keratinizing carcinomas is the human papillomavirus(HPV)-related adenoid-cystic-like sinonasal carcinoma with its distinctive, albeit diverse, morphology. In the group of small round-cell malignancies, adamantinoma-like Ewing sarcoma has been delineated as an important diagnostic pitfall given its prominent epithelial differentiation. Inclusion of the biphenotypic (myoneural) sinonasal sarcoma (BSS) as a low-grade malignancy defined by recurrent PAX3/MAML3-translocation represents an important feature of the new WHO classification given the distinctive biological behavior of this low-grade non-metastasizing rare entity, which has been uniformly misclassified as a peripheral nerve sheath tumor or leiomyosarcoma in the past. Recognition of CTNNB1 mutations and STAT6/NAB2 gene fusions as defining genetic markers for sinonasal hemangioaEuro/glomangiopericytoma and solitary fibrous tumors, respectively, represents another important achievement in recent years. This review summarizes the new aspects in the WHO classification and also addresses recently described entities that have not been included in the WHO classification.	[Agaimy, A.; Haller, F.; Hartmann, A.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Abraham SC, 2001, AM J PATHOL, V158, P1073, DOI 10.1016/S0002-9440(10)64054-0; Agaimy A, 2018, PATHOLOGE; Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy Abbas, 2016, Cesk Patol, V52, P146; Agaimy A, 2014, HISTOPATHOLOGY, V65, P667, DOI 10.1111/his.12452; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Barthelmess S, 2014, AM J PATHOL, V184, P1209, DOI 10.1016/j.ajpath.2013.12.016; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; de Bree E, 2014, HEAD NECK-J SCI SPEC, V36, P1517, DOI 10.1002/hed.23496; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; El-Naggar A, 2017, WHO CLASSIFICATION H; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French C, 2014, NAT REV CANCER, V14, P149, DOI 10.1038/nrc3659; FRIERSON HF, 1986, AM J SURG PATHOL, V10, P771, DOI 10.1097/00000478-198611000-00004; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Jo VY, 2017, MODERN PATHOL, V30, P650, DOI 10.1038/modpathol.2016.239; Kasper B, 2017, ANN ONCOL, V28, P2399, DOI 10.1093/annonc/mdx323; Konukiewitz B, 2018, PATHOLOGE; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Stelow EB, 2009, ADV ANAT PATHOL, V16, P92, DOI 10.1097/PAP.0b013e31819923e4; Thompson LDR, 2017, HEAD NECK PATHOL; Thompson LDR, 2017, MODERN PATHOL, V30, pS1, DOI 10.1038/modpathol.2016.119; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989	30	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					18	26		10.1007/s00292-018-0415-0			9	Pathology	Pathology	FV3CN	WOS:000424445600004	29396607				2019-10-28	
J	Konukiewitz, B; Agaimy, A; Weichert, W; Kloppel, G				Konukiewitz, B.; Agaimy, A.; Weichert, W.; Kloeppel, G.			Neuroendocrine neoplasms of the head and neck	PATHOLOGE			German	Article						Carcinoid; Neuroendocrine tumor; Neuroendocrine carcinoma; Olfactory neuroblastoma; Paraganglioma	OLFACTORY NEUROBLASTOMA; SINONASAL TRACT; EXPRESSION; TUMORS; WELL; CLASSIFICATION; CARCINOMAS; PANCREAS; GRADE; CELL	Common to all neuroendocrine neoplasms (NENs), irrespective of their site of origin, is the expression of synaptophysin and chromogranin A. NENs of the head and neck region derive either from epithelial or neural/neuroectodermal tissues. The epithelial-type NENs express cytokeratins and include the well-differentiated typical and atypical carcinoids (also called low- and intermediate-grade neuroendocrine carcinomas by WHO), the poorly differentiated high-grade neuroendocrine carcinomas of small and large cell type and the mixed neuroendocrine-nonneuroendocrine neoplasms. The neural-neuroectodermal-type NENs comprise olfactory neuroblastoma and paraganglioma, each of them with distinct clinicopathological characteristics. Olfactory neuroblastomas show a spectrum of histologic differentiation and are prognostically classified by Hyams grading. Paragangliomas often occur multiple and show a familial background. Most head and neck NENs occur in the upper respiratory system. Their diagnosis follows the general guidelines for NENs, focusing on immunohistochemical profiling. Molecular examinations are so far only required in individual cases.	[Konukiewitz, B.; Weichert, W.; Kloeppel, G.] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany; [Agaimy, A.] Univ Klinikum Erlangen, Inst Pathol, Erlangen, Germany	Konukiewitz, B (reprint author), Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany.	b.konukiewitz@tum.de					Agaimy A, 2013, MODERN PATHOL, V26, P995, DOI 10.1038/modpathol.2013.40; Argani P, 1998, AM J SURG PATHOL, V22, P391, DOI 10.1097/00000478-199804000-00002; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Bell D, 2016, HEAD NECK-J SCI SPEC, V38, pE2259, DOI 10.1002/hed.24152; Benn DE, 2015, ENDOCR-RELAT CANCER, V22, pT91, DOI 10.1530/ERC-15-0268; Cardesa A, 2009, PATHOLOGIE KOPF HALS, P47; El-Naggar A, 2017, WHO CLASSIFICATION H; ELKON D, 1979, CANCER, V44, P1087, DOI 10.1002/1097-0142(197909)44:3<1087::AID-CNCR2820440343>3.0.CO;2-A; Erlenbach-Wunsch K, 2014, PATHOLOGY, V46, P289, DOI 10.1097/PAT.0000000000000091; Ferlito A, 2009, HEAD NECK-J SCI SPEC, V31, P1634, DOI 10.1002/hed.21162; Gale N, 2009, PATHOLOGIE KOPF HALS, P237; Hermann G, 2011, VIRCHOWS ARCH, V459, P147, DOI 10.1007/s00428-011-1118-6; Hyams VJ, 1988, TUMORS UPPER RESP TR; Kaur G, 2013, J CLIN NEUROSCI, V20, P275, DOI 10.1016/j.jocn.2012.05.029; Kimura N, 2017, WHO CLASSIFICATION H, P277; Kloppel G, 2011, ENDOCR-RELAT CANCER, V18, pS1, DOI 10.1530/ERC-11-0013; Kloppel G, 2016, PATHOLOGY HEAD NECK, P515; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Kraft S, 2012, AM J SURG PATHOL, V36, P321, DOI 10.1097/PAS.0b013e31823f2f17; Lloyd RV, 2017, WHO CLASSIFICATION T; Mendenhall WM, 2011, HEAD NECK-J SCI SPEC, V33, P1530, DOI 10.1002/hed.21524; Papathomas TG, 2015, MODERN PATHOL, V28, P807, DOI 10.1038/modpathol.2015.41; Rindi G, 2010, WHO CLASSIFICATION T; Shah K, 2016, HEAD NECK PATHOL, V10, P85, DOI 10.1007/s12105-016-0696-7; Tang LH, 2016, AM J SURG PATHOL, V40, P1192, DOI 10.1097/PAS.0000000000000662; Thompson LDR, 2009, HEAD NECK PATHOL, V3, P252, DOI 10.1007/s12105-009-0125-2; Travis WD, 2015, WHO CLASSIFICATION T; Turner JH, 2012, HEAD NECK-J SCI SPEC, V34, P877, DOI 10.1002/hed.21830; Wooff JC, 2011, AM J SURG PATHOL, V35, P1786, DOI 10.1097/PAS.0b013e3182363b78; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36	30	2	2	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					27	34		10.1007/s00292-017-0404-8			8	Pathology	Pathology	FV3CN	WOS:000424445600005	29313083				2019-10-28	
J	Baumhoer, D				Baumhoer, D.			Odontogenic tumours and bone tumours of the jaw. Changes in the new WHO classification	PATHOLOGE			German	Article						Ameloblastoma; Bone neoplasms; Head and neck neoplasms; Odontogenic Tumors; World Health Organization	MUTATIONS; NEOPLASM	At the beginning of 2017, the fourth edition of the WHO Classification of Head and Neck Tumours was published, 12 years after the previous version. Notably, various changes introduced in the third edition have been revised so in some aspects the current classification has more similarities to the second edition of 1992 than to the third edition. A central goal of the editors was to create a classification that can be used worldwide. Molecular findings have therefore been included and updated but are not mandatory for establishing a diagnosis. This article discusses and comments on the most important changes implemented in the classification of gnathic lesions.	[Baumhoer, D.] Univ Basel, Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland; [Baumhoer, D.] Univ Basel, Univ Spital Basel, DOSAK Referenzregister Inst Pathol, Schonbeinstr 40, CH-4031 Basel, Switzerland	Baumhoer, D (reprint author), Univ Basel, Univ Spital Basel, Knochentumor Referenzzentrum, Schonbeinstr 40, CH-4031 Basel, Switzerland.; Baumhoer, D (reprint author), Univ Basel, Univ Spital Basel, DOSAK Referenzregister Inst Pathol, Schonbeinstr 40, CH-4031 Basel, Switzerland.	daniel.baumhoer@usb.ch					Baumhoer D, 2017, PATHOLOGE; Baumhoer D, 2014, ORAL ONCOL, V50, P147, DOI 10.1016/j.oraloncology.2013.10.017; Bilodeau EA, 2013, AM J SURG PATHOL, V37, P1001, DOI 10.1097/PAS.0b013e31828a6727; Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078-0432.CCR-14-1069; Brunner P, 2015, ORAL ONCOL, V51, pE77, DOI 10.1016/j.oraloncology.2015.07.010; Buchner A, 2013, OR SURG OR MED OR PA, V116, P598, DOI 10.1016/j.oooo.2013.06.039; Dong Q, 2010, ARCH PATHOL LAB MED, V134, P271, DOI 10.1043/1543-2165-134.2.271; El-Naggar AK, 2017, WHO CLASSIFICATION H, V9, P213; Faden DL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw190; Gorlin RJ, 2006, WHO CLASSIFICATION T, P285; Hanisch M, 2017, INT J ORAL MAXILLOFA; Heikinheimo K., 2017, WHO CLASSIFICATION H, P215; Koutlas IG, 2008, AM J SURG PATHOL, V32, P1613, DOI 10.1097/PAS.0b013e31817a8a58; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Mosqueda-Taylor A, 2014, HISTOPATHOLOGY, V65, P606, DOI 10.1111/his.12451; Muller S, 2017, WHO CLASSIFICATION H, P222; Odell EW, 2017, WHO CLASSIFICATION H, P206; Pereira NB, 2016, J ORAL PATHOL MED, V45, P780, DOI 10.1111/jop.12443; Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029; Qu JF, 2015, ORAL ONCOL, V51, P40, DOI 10.1016/j.oraloncology.2014.09.016; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070995; Speight PM, 2017, WHO CLASSIFICATION H, P234; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Van Heerden WFP, 2017, WHO CLASSIFICATION H, P228; Wright JM, 2017, WHO CLASSIFICATION H, P214; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Wright JM, 2014, HEAD NECK PATHOL, V8, P373, DOI 10.1007/s12105-014-0585-x	27	1	1	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					35	41		10.1007/s00292-017-0398-2			7	Pathology	Pathology	FV3CN	WOS:000424445600006	29242956				2019-10-28	
J	Agaimy, A; Weichert, W; Haller, F; Hartmann, A				Agaimy, A.; Weichert, W.; Haller, F.; Hartmann, A.			Diagnostic and predictive molecular pathology of head and neck neoplasms	PATHOLOGE			German	Article						Head and neck neoplasms; Molecular pathology; Genetic translocation; Squamous cell carcinoma; SMARCB1 protein	SQUAMOUS-CELL CARCINOMA; BIPHENOTYPIC SINONASAL SARCOMA; SALIVARY-GLANDS; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; MUTATIONS; HPV; HEMANGIOPERICYTOMA; FUSIONS; TUMOR	As a result of some seminal observations as well as a consequence of increasing use of modern and innovative molecular diagnostic technologies, a variety of new genetic aberrations have been discovered in head and neck neoplasms of different anatomic locations and histogenetic origins. These advances resulted in the establishment of new molecularly defined disease entities. On the other hand, some of these new genetic biomarkers paved the way to potentially promising novel therapeutic opportunities. Diverse old (well known in other entities) and newly discovered translocations and gene fusions represent the leading subgroup of these genetic aberrations. They have been detected not only in malignant epithelial neoplasms (carcinomas) of the salivary glands, but also in carcinomas from other head and neck sites as well as diverse mesenchymal tumors. In addition to these gene fusions, several activating mutations (such as CTNNB1 in sinonasal glomangiopericytoma) as well as inactivating mutations or deletions (like SMARCB1 loss in sinonasal carcinomas) were detected as new molecular markers. In the present review we summarize the relevant molecular alterations in topographically and histopathologically distinct tumors of the head and neck region with emphasis on recently established molecular markers.	[Agaimy, A.; Haller, F.; Hartmann, A.] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Weichert, W.] Tech Univ Munich, Inst Pathol, Munich, Germany	Agaimy, A (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Abraham SC, 2001, AM J PATHOL, V158, P1073, DOI 10.1016/S0002-9440(10)64054-0; Agaimy A, 2017, HEAD NECK PATHOL, V11, P541, DOI 10.1007/s12105-017-0783-4; Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2016, ADV ANAT PATHOL, V23, P1, DOI 10.1097/PAP.0000000000000104; Agaimy A, 2014, HISTOPATHOLOGY, V65, P667, DOI 10.1111/his.12452; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bishop JA, 2018, AM J SURG PATHOL, V42, P130, DOI 10.1097/PAS.0000000000000932; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Chung CH, 2014, J CLIN ONCOL, V32, P3930, DOI 10.1200/JCO.2013.54.5228; de la Vega LL, 2017, MOL CANCER RES, V15, P1551, DOI 10.1158/1541-7786.MCR-17-0135; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; El-Naggar A, 2017, WHO CLASSIFICATION H; French C, 2014, NAT REV CANCER, V14, P149, DOI 10.1038/nrc3659; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; Haderlein M, 2017, STRAHLENTHER ONKOL, V193, P961, DOI 10.1007/s00066-017-1196-8; Haller F, 2015, AM J PATHOL, V185, P563, DOI 10.1016/j.ajpath.2014.10.019; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Ihrler S, 2018, NEUES TUMOREN SPEICH; Jo VY, 2017, MODERN PATHOL, V30, P650, DOI 10.1038/modpathol.2016.239; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Mirghani H, 2015, INT J CANCER, V136, P1494, DOI 10.1002/ijc.28847; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Skalova A, 2015, AM J SURG PATHOL, V39, P338, DOI 10.1097/PAS.0000000000000364; Skalova A, 2013, AM J SURG PATHOL, V37, P1743, DOI 10.1097/PAS.0000000000000065; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Walter V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056823; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568; Weichert W, 2018, PATHOLOGE; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096	30	1	1	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					42	47		10.1007/s00292-018-0416-z			6	Pathology	Pathology	FV3CN	WOS:000424445600007	29383488				2019-10-28	
J	Schmid, KW; Synoracki, S; Dralle, H; Wittekind, C				Schmid, K. W.; Synoracki, S.; Dralle, H.; Wittekind, C.			Proposal for an extended pTNM classification of thyroid carcinoma. Commentary on deficits of the 8th edition of the TNM classification (German version)	PATHOLOGE			German	Article						Carcinoma; Papillary thyroid cancer; Prognosis; Thyroid neoplasms; Tumor staging	MINIMAL EXTRATHYROIDAL EXTENSION; EXTRANODAL EXTENSION; PAPILLARY; CANCER; ASSOCIATION; SURVIVAL; MANAGEMENT; CAPSULE; DISEASE; TUMORS	In the 8th edition of the TNM classification of thyroid carcinomas, which was introduced in 2017, carcinomas with minimal extrathyroidal extension are no longer mentioned, which might cause problems. These tumors were explicitly categorized in previous TNM classifications (5-7th editions). Studies on the prognostic relevance of minimal extrathyroidal extension have shown conflicting results. Moreover, the vast majority of these studies retrospectively analyzed only subgroups of thyroid carcinomas (e.g. differentiated thyroid carcinoma, papillary thyroid carcinoma). The proposed subcategorization of the current TNM classification (8th edition) ensures the continuity of the parameter minimal extrathyroidal extension within the TNM categorization of thyroid carcinomas and also offers the possibility to prospectively analyze in a standardized manner the potential biological relevance of minimal extrathyroidal extension in relation to tumor categories (T/pT category).	[Schmid, K. W.; Synoracki, S.] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany; [Dralle, H.] Univ Duisburg Essen, Univ Klinikum Essen, Klin Allgemeinchirurg Viszeral & Transplant Chiru, Essen, Germany; [Wittekind, C.] Univ Klinikum Leipzig, Inst Pathol, Leipzig, Germany; [Schmid, K. W.] Westdeutsch Tumorzentrum Essen WTZ, Essen, Germany	Schmid, KW (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.	kw.schmid@uk-essen.de					Al-Qurayshi Z, 2017, ENDOCR-RELAT CANCER, V24, P221, DOI 10.1530/ERC-16-0509; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Brierley JD, 2016, TNM CLASSIFICATION M, P51; Clain JB, 2014, THYROID, V24, P951, DOI 10.1089/thy.2013.0557; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Dralle H, 2013, LANGENBECK ARCH SURG, V398, P347, DOI 10.1007/s00423-013-1057-6; Goffredo P, 2013, ANN SURG ONCOL, V20, P767, DOI 10.1245/s10434-012-2697-4; Greene F, 2003, TNM SUPPLEMENT COMME; Hermann M, 2010, CHIRURG, V81, P627, DOI 10.1007/s00104-009-1884-8; Ito Y, 2006, WORLD J SURG, V30, P780, DOI 10.1007/s00268-005-0270-z; Jin BJ, 2015, ORAL ONCOL, V51, P759, DOI 10.1016/j.oraloncology.2015.05.010; Lloyd R, 2017, TUMOURS THYROID GLAN, pS65; Machens A, 2015, EJSO-EUR J SURG ONC, V41, P766, DOI 10.1016/j.ejso.2014.10.049; Mete O, 2010, ANN SURG ONCOL, V17, P386, DOI 10.1245/s10434-009-0832-7; Moon HJ, 2011, ANN SURG ONCOL, V18, P1916, DOI 10.1245/s10434-011-1556-z; Musholt TJ, 2011, LANGENBECK ARCH SURG, V396, P639, DOI 10.1007/s00423-011-0774-y; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Park S, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5745; Radowsky JS, 2014, THYROID, V24, P241, DOI 10.1089/thy.2012.0567; Roh JL, 2017, J SURG ONCOL, V116, P450, DOI 10.1002/jso.24713; Rosai J, 2003, INT J SURG PATHOL, V11, P249, DOI 10.1177/106689690301100401; Schmid KW, 2006, VIRCHOWS ARCH, V448, P385, DOI 10.1007/s00428-006-0162-0; Schmid KW, 2003, PATHOLOGE, V24, P338, DOI 10.1007/s00292-003-0653-6; Schmid KW, 2016, PATHOLOGIE, pS631; Sobin L, 2009, TNM CLASSIFICATION M, P58; Sobin LH, 2002, TNM CLASSIFICATION M, P52; Sobin LH, 1997, TNM CLASSIFICATION M, P47; Su HK, 2016, THYROID, V26, P512, DOI 10.1089/thy.2015.0508; Synoracki S, 2017, CHIRURG, V88, P740, DOI 10.1007/s00104-017-0461-9	30	1	1	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					49	56		10.1007/s00292-017-0410-x			8	Pathology	Pathology	FV3CN	WOS:000424445600008	29372307				2019-10-28	
J	Marquardt, K; Ziemke, P				Marquardt, K.; Ziemke, P.			Munich Nomenclature III: classification according to risk. Follow-up for conspicuous squamous findings	PATHOLOGE			German	Article						Cervical cytology; Cervical cancer screening; CIN; Munich Nomenclature III; Management strategies		The present study evaluates the risk of progression of cytologic diagnoses which do not require immediate therapy but do need follow-up. The presented data can contribute to risk-adapted management strategies, according to Munich Nomenclature III. Between January 2014 and March 2016, 3396 women were diagnosed as group II-p, IIID1, III-p, IIID2, IVa-p, IVb-p, and VaEurop and represent the study population. Follow-up information on all subsequent cytologic and histologic findings were collected up to July 2017. For the initial cytologic diagnosis, the cumulative risk of CIN2+ or CIN3+ and the risk for persistent pathologic findings was calculated. The cumulative risk of CIN2+ for initial findings II-p, IIID1, III-p, and IIID2 is calculated as 7.3, 17.1, 46.3, and 62.4%, respectively, after a mean observation period of 24.4, 21.1, 15.6, and 14.3 months. The cumulative risk of CIN3+ (%) is determined as 5.0, 9.3, 37.6, and 45.8. For persistent cytologic diagnoses II-p, IIID1, III-p, and IIID2, the risk of CIN2+ increases significantly after the second result (0 to 3.6, 0.21 to 3.6, 7.2 to 58.3, and 8.1 to 64.7%). Risk of CIN2+ and CIN3+ for group III-p is significantly higher for women < 35 years and < 30 years compared with women of higher age. There are no significant age-dependent differences for findings II-p, IIID1, and IIID2. The Munich Nomenclature III classifies cytologic findings according to risk. The diagnostic groups of the Munich Nomenclature III provide a solid basis for a risk-adapted clinical management, if the cytologic history of the individual patient is taken into account.	[Marquardt, K.] Praxis Pathol, Gustrower Str 34, D-19055 Schwerin, Germany	Marquardt, K (reprint author), Praxis Pathol, Gustrower Str 34, D-19055 Schwerin, Germany.	katrin.marquardt.schwerin@gmail.com					Griesser H, 2015, FRAUENARZT, V56, P10; GRIESSER H, 2013, FRAUENARZT, V11, P2; Kassenarztlichen Bundesvereinigung, 2014, AKTUALISIERTE FASSUN, V33-34, P1434; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS36, DOI 10.1097/LGT.0b013e3182854253; Kuhn W, 2015, GYN, V20, P25; Marquardt K, 2017, FRAUENARZT, V58, P706; Stoler MH, 2011, INT J CANCER, V128, P1354, DOI 10.1002/ijc.25470	7	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					57	64		10.1007/s00292-017-0382-x			8	Pathology	Pathology	FV3CN	WOS:000424445600009	28993907	Other Gold			2019-10-28	
J	Hrudka, J; Eis, V; Sach, J; Klezl, P; Schilling, S; Bandke, D				Hrudka, J.; Eis, V.; Sach, J.; Klezl, P.; Schilling, S.; Bandke, D.			Two synchronous malignancies in a single nephrectomy specimen	PATHOLOGE			German	Article						Kidney tumour; Nephrectomy; Adenocarcinoma; Metastasis; Kidney adenocarcinoma	RENAL-CELL CARCINOMA; TUMOR-METASTASIS; ADENOCARCINOMA; CANCER; LUNG	We report a case of a 65-year-old man examined for hematuria and neurologic symptoms. Radiologically a tumour of the kidney was suspected, with metastatic involvement of the brain and both lungs. The urologists then performed a cytoreductive nephrectomy. In histopathological examination of the nephrectomy specimen a clear cell renal cell carcinoma (clear cell RCC) was found. However, an additional focus of a high-grade adenocarcinoma was discovered that turned out to be a metastasis of a poor differentiated lung adenocarcinoma. This diagnosis was supported by positive TTF1 and napsin-A as well as good clinical correlations. The article summarizes the differential diagnostic considerations of poor differentiated adenocarcinoma of the kidney, aimed at gross and microscopic morphology, immunohistochemistry and clinical-pathological correlation. A review of literature about a tumour-in-tumour metastasis is included.	[Hrudka, J.; Eis, V.; Sach, J.] Karls Univ, Univ Krankenhaus Kralovske Vinohrady, Inst Pathol, Med Fak 3, Srobarova 1150-50, Prague 10034, Czech Republic; [Klezl, P.] Karls Univ, Univ Krankenhaus Kralovske Vinohrady, Med Fak 3, Urol Klin, Prague, Czech Republic; [Schilling, S.] Klinikum Furth, Inst Pathol, Furth, Germany; [Bandke, D.] Kepler Univ Klinikum, Inst Pathol & Mikrobiol, Neuromed Campus, Linz, Austria	Hrudka, J (reprint author), Karls Univ, Univ Krankenhaus Kralovske Vinohrady, Inst Pathol, Med Fak 3, Srobarova 1150-50, Prague 10034, Czech Republic.	jan.hrudka@gmail.com					Berent W., 1902, ZENTRALBL ALLG PATHO, V13, P406; CAMPBELL LV, 1968, CANCER, V22, P635, DOI 10.1002/1097-0142(196809)22:3<635::AID-CNCR2820220320>3.0.CO;2-O; Dulskas A, 2015, ONCOL LETT, V10, P1191, DOI 10.3892/ol.2015.3290; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; Huo ZJ, 2015, INT J CLIN EXP PATHO, V8, P15417; Inatomi H, 1996, Int J Urol, V3, P155, DOI 10.1111/j.1442-2042.1996.tb00503.x; Mahnken AH, 2000, ROFO-FORTSCHR RONTG, V172, P1011, DOI 10.1055/s-2000-9221; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Moch H., 2016, WHO CLASSIFICATION T, V8, P11; Perrin C, 2011, ANN PATHOL, V31, P399, DOI 10.1016/j.annpat.2011.06.007; Petraki C, 2003, INT J SURG PATHOL, V11, P127, DOI 10.1177/106689690301100214; Reis HG, 2011, PATHOLOGE, V32, P349, DOI 10.1007/s00292-010-1414-y; SELLA A, 1987, UROLOGY, V30, P35, DOI 10.1016/0090-4295(87)90568-1; Tauchi-Nishi P, 2014, ANAL QUANT CYTOPATHO, V36, P345; Ye JQ, 2011, APPL IMMUNOHISTO M M, V19, P313, DOI 10.1097/PAI.0b013e318205b059	15	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					65	70		10.1007/s00292-017-0401-y			6	Pathology	Pathology	FV3CN	WOS:000424445600010	29209798				2019-10-28	
J	Baumhoer, D; Holler, S				Baumhoer, D.; Holler, S.			Cystic lesions of the jaws	PATHOLOGE			German	Article						Odontogenic cysts; Keratocysts; Ameloblastoma; Aneurysmal bone cyst; Classification	ODONTOGENIC KERATOCYST; AMELOBLASTOMA; MUTATIONS; TUMORS	Cystic lesions of the jaws comprise a spectrum of inflammatory, developmental and neoplastic changes that can clinically appear strikingly similar. Squamous cell metaplasia due to superinfection can further blur the histologic hallmarks of the individual lesions. In this article an overview of the most important differential diagnoses and the novelties of the latest World Health Organisation (WHO) classification on head and neck tumours released in early 2017 is provided. In contrast to the previous edition, odontogenic cysts have been re-introduced and several changes in terminology and taxonomy have been complemented.	[Baumhoer, D.; Holler, S.] Univ Basel, Univ Spital Basel, Knochentumor Referenzzentrum Inst Pathol, Basel, Switzerland	Baumhoer, D (reprint author), Univ Basel, Univ Spital Basel, Knochentumor Referenzzentrum Inst Pathol, Basel, Switzerland.						Agaram NP, 2004, ARCH PATHOL LAB MED, V128, P313; Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078-0432.CCR-14-1069; Brunner P, 2015, ORAL ONCOL, V51, pE77, DOI 10.1016/j.oraloncology.2015.07.010; Chrcanovic BR, 2017, ORAL DIS; Dong Q, 2010, ARCH PATHOL LAB MED, V134, P271, DOI 10.1043/1543-2165-134.2.271; Faden DL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw190; Gorlin RJ, 2006, WHO CLASSIFICATION T, P285; Henley J, 2005, HISTOPATHOLOGY, V47, P582, DOI 10.1111/j.1365-2559.2005.02267.x; Jordan RC, 2017, WHO CLASSIFICATION H, P258; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Malcic A, 2008, J ORAL PATHOL MED, V37, P294, DOI 10.1111/j.1600-0714.2007.00622.x; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Pavelic B, 2001, J ORAL PATHOL MED, V30, P569, DOI 10.1034/j.1600-0714.2001.300911.x; Pereira NB, 2016, J ORAL PATHOL MED, V45, P780, DOI 10.1111/jop.12443; Philipsen HP, 2004, J ORAL PATHOL MED, V33, P147, DOI 10.1111/j.0904-2512.2004.00139.x; Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029; Qu JF, 2015, ORAL ONCOL, V51, P40, DOI 10.1016/j.oraloncology.2014.09.016; Raubenheimer E, 2017, WHO CLASSIFICATION H, P259; Raubenheimer E, 2017, WHO CLASSIFICATION H, P256; Shear M, 2007, CYSTS ORAL MAXILLOFA; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070995; Speight P, 2017, WHO CLASSIFICATION H, P232; Speight PM, 2017, WHO CLASSIFICATION H, P234; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Vered M, 2017, WHO CLASSIFICATION H, P217; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Yukimori A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180224	27	0	0	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	FEB	2018	39	1					71	84		10.1007/s00292-017-0402-x			14	Pathology	Pathology	FV3CN	WOS:000424445600011	29322252				2019-10-28	
J	Gardner, K				Gardner, Kevin			The Science of Cancer Health Disparities A Young Discipline with an Old Heritage	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material									[Gardner, Kevin] NCI, Ctr Canc Res, Genet Branch, Bethesda, MD 20892 USA; [Gardner, Kevin] Natl Inst Minor Hlth & Hlth Disparities, Bethesda, MD USA; [Gardner, Kevin] Columbia Univ, Med Ctr, New York, NY USA	Gardner, K (reprint author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, 460 W 168th St,Room 14, New York, NY 10032 USA.	k1g2160@cumc.columbia.edu			Intramural Research Programs of the NIH; National Cancer Institute research grant [ZIA-BC010847]; Center for Cancer ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); National Institute on Minority Health and Health Disparities research grant [ZIA-MD000005]	Supported by the Intramural Research Programs of the NIH, National Cancer Institute research grant ZIA-BC010847 (KG.), Center for Cancer Research, and National Institute on Minority Health and Health Disparities research grant ZIA-MD000005 (K.G.).	Augustus GJ, 2018, AM J PATHOL, V188, P291, DOI 10.1016/j.ajpath.2017.07.023; Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061; Bean WB, 1950, W OSLER APHORISMS, P93; Berg K, 2005, AM J HUM GENET, V77, P519; Brown TM, 2006, AM J PUBLIC HEALTH, V96, P2104, DOI 10.2105/AJPH.2005.078436; Byun JS, 2018, AM J PATHOL, V188, P317, DOI 10.1016/j.ajpath.2017.10.009; Caulfield T, 2009, GENOME MED, V1, DOI 10.1186/gm8; Dietze EC, 2018, AM J PATHOL, V188, P280, DOI 10.1016/j.ajpath.2017.09.018; Heckler M., 1985, REPORT SECRETARYS TA; Jiagge E, 2018, AM J PATHOL, V188, P271, DOI 10.1016/j.ajpath.2017.06.020; Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214; Smith CJ, 2018, AM J PATHOL, V188, P304, DOI 10.1016/j.ajpath.2017.06.019; Virchow R., 1985, COLLECTED ESSAYS PUB	13	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					268	270		10.1016/j.ajpath.2017.08.037			3	Pathology	Pathology	FT6HY	WOS:000423256300001	29137949	Green Published, Bronze			2019-10-28	
J	Jiagge, E; Chitale, D; Newman, LA				Jiagge, Evelyn; Chitale, Dhananjay; Newman, Lisa A.			Triple-Negative Breast Cancer, Stem Cells, and African Ancestry	AMERICAN JOURNAL OF PATHOLOGY			English	Review							ALDEHYDE DEHYDROGENASE 1; WHITE AMERICAN PATIENTS; SOCIOECONOMIC-STATUS; GHANAIAN WOMEN; MAMMARY-GLAND; MOLECULAR SUBTYPES; ALDH1 EXPRESSION; INCIDENCE RATES; TUMOR SUBTYPES; RISK-FACTORS	Triple-negative breast cancers (TNBCs) are more common among African-ancestry populations, such as African Americans and western, sub-Saharan Africans, compared with European-ancestry populations. This phenotype prevalence contributes to disparities in breast cancer outcomes between African Americans and White Americans. Breast cancer stem cells represent the tumor subpopulation involved in metastatic virulence, and ongoing research seeks to characterize the extent to which TNBC versus non-TNBC stem cells may differ. This review summarizes the existing literature regarding TNBCs and stem cells as they pertain to the burden of breast cancer among African-ancestry populations. Additional research related to variations in somatic tumor genomics between the African-American and White-American populations is also summarized. This review furthermore explores the history of insights regarding breast cancer disparities related to racial/ethnic identity, socioeconomic status, and tumor biology.	[Jiagge, Evelyn] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Jiagge, Evelyn] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; [Chitale, Dhananjay] Henry Ford Hlth Syst, Int Ctr Study Breast Canc Subtypes, Dept Pathol, Detroit, MI USA; [Newman, Lisa A.] Henry Ford Hlth Sys, Int Ctr Study Breast Canc Subtypes, Dept Surg, Detroit, MI USA; Henry Ford Canc Inst, 2799 W Grand Blvd, Detroit, MI 48202 USA	Newman, LA (reprint author), Henry Ford Canc Inst, 2799 W Grand Blvd, Detroit, MI 48202 USA.; Newman, LA (reprint author), Henry Ford Hlth Syst, Int Ctr Study Breast Canc Sub types, 2799 W Grand Blvd, Detroit, MI 48202 USA.	lnewman1@hfhs.org		Chitale, Dhananjay/0000-0002-4421-6431	 [HFHS F11047]	Supported in part by Susan G. Komen for the Cure Komen Scholars Leadership grant HFHS F11047 (L.A.N.).	Ademuyiwa F, 2017, BREAST CANCER RES TR, V161, P491, DOI 10.1007/s10549-016-4062-y; Aiad HA, 2014, APMIS, V122, P976, DOI 10.1111/apm.12241; Akinyemiju T, 2015, BREAST CANCER RES TR, V153, P211, DOI 10.1007/s10549-015-3528-7; Akinyemiju TF, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1282-2; Albain KS, 2009, JNCI-J NATL CANCER I, V101, P984, DOI 10.1093/jnci/djp175; Amirikia KC, 2011, CANCER-AM CANCER SOC, V117, P2747, DOI 10.1002/cncr.25862; Amoury M, 2016, CANCER LETT, V372, P201, DOI 10.1016/j.canlet.2016.01.027; Baquet CR, 2008, J NATL MED ASSOC, V100, P480, DOI 10.1016/S0027-9684(15)31294-3; Bennis Sanae, 2012, BMC Res Notes, V5, P436, DOI 10.1186/1756-0500-5-436; Bigby JA, 2005, CANCER CAUSE CONTROL, V16, P35, DOI 10.1007/s10552-004-1263-1; Brewster AM, 2014, LANCET ONCOL, V15, pE625, DOI 10.1016/S1470-2045(14)70364-X; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Campbell MC, 2014, CURR OPIN GENET DEV, V29, P120, DOI 10.1016/j.gde.2014.09.003; Chang EA, 2015, SCI REP-UK, V5, DOI 10.1038/srep15234; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chlebowski RT, 2005, JNCI-J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064; Dawood S, 2009, J CLIN ONCOL, V27, P220, DOI 10.1200/JCO.2008.17.9952; Der EM, 2015, BREAST J, V21, P627, DOI 10.1111/tbj.12527; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Deshpande AD, 2009, J SURG RES, V153, P105, DOI 10.1016/j.jss.2008.05.020; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farhana L, 2015, CANC MED, V5, P1268; Field LA, 2012, CANCER-AM CANCER SOC, V118, P1334, DOI 10.1002/cncr.26405; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goyal S, 2016, WORLD J STEM CELLS, V8, P279, DOI 10.4252/wjsc.v8.i9.279; Grunda Jessica M, 2012, BMC Res Notes, V5, P248, DOI 10.1186/1756-0500-5-248; Guler G, 2012, MODERN PATHOL, V25, P949, DOI 10.1038/modpathol.2012.37; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; HOSHINO K, 1967, NATURE, V213, P193, DOI 10.1038/213193a0; Huo DZ, 2017, JAMA ONCOL, V3, P1654, DOI 10.1001/jamaoncol.2017.0595; Huo DZ, 2009, J CLIN ONCOL, V27, P4515, DOI 10.1200/JCO.2008.19.6873; Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349; Jiagge E, 2016, ANN SURG ONCOL, V23, P3843, DOI 10.1245/s10434-016-5420-z; Jiagge E, 2015, ANN SURG ONCOL, V22, P734, DOI 10.1245/s10434-014-4345-7; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Keenan T, 2015, J CLIN ONCOL, V33, P3621, DOI 10.1200/JCO.2015.62.2126; Kohler BA, 2015, JNCI-J NATL CANCER I, V107, P1975, DOI DOI 10.1093/JNCI/DJV048; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Kroenke CH, 2014, BREAST CANCER RES TR, V144, P689, DOI 10.1007/s10549-014-2899-5; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin CY, 2016, HISTOPATHOLOGY, V68, P119, DOI 10.1111/his.12868; Lindner R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071915; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Liu Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-444; Lund MJ, 2009, BREAST CANCER RES TR, V113, P357, DOI 10.1007/s10549-008-9926-3; Luo M, 2015, METHODS MOL BIOL, V1293, P1, DOI 10.1007/978-1-4939-2519-3_1; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Ly M, 2012, ONCOLOGY-BASEL, V83, P257, DOI 10.1159/000341541; Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Nakshatri H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13526; Nalwoga H, 2010, BRIT J CANCER, V102, P369, DOI 10.1038/sj.bjc.6605488; Newman LA, 2006, J CLIN ONCOL, V24, P1342, DOI 10.1200/JCO.2005.03.3472; Newman LA, 2002, CANCER-AM CANCER SOC, V94, P2844, DOI 10.1002/cncr.10575; Newman LA, 2017, JAMA SURG, V152, P485, DOI 10.1001/jamasurg.2017.0005; Newman LA, 2016, J CLIN ONCOL, V34, P1013, DOI 10.1200/JCO.2015.65.1877; Newman LA, 2015, BREAST J, V21, P133, DOI 10.1111/tbj.12369; Newman LA, 2015, ANN SURG ONCOL, V22, P874, DOI 10.1245/s10434-014-4279-0; Nwafor CC, 2015, NIGER J CLIN PRACT, V18, P553, DOI 10.4103/1119-3077.156905; O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533; Ohene-Yeboah M, 2012, Ghana Med J, V46, P8; Olsson E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-418; Pang J, 2012, BREAST CANCER RES TR, V135, P59, DOI 10.1007/s10549-012-2055-z; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Proctor E, 2015, ANN SURG ONCOL, V22, P3831, DOI 10.1245/s10434-015-4455-x; Rais G, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-35; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sachdev JC, 2010, BREAST CANCER-BASIC, V4, P23; Salhia B, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-44; Schwartz T, 2013, CANCER-AM CANCER SOC, V119, P488, DOI 10.1002/cncr.27737; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Stewart PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082460; Sweeney C, 2014, CANCER EPIDEM BIOMAR, V23, P714, DOI 10.1158/1055-9965.EPI-13-1023; Tannenbaum SL, 2013, CANCER CAUSE CONTROL, V24, P1705, DOI 10.1007/s10552-013-0246-5; Tian N, 2012, WOMEN HEALTH ISS, V22, pE267, DOI 10.1016/j.whi.2011.11.007; Weigand A, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0688-2; Wicha MS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1540; Yang F, 2016, INT J BIOL SCI, V12, P1568, DOI 10.7150/ijbs.16874; Yang X, 2017, ONCOTARGET, V8, P10675, DOI 10.18632/oncotarget.12893	83	5	5	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					271	279		10.1016/j.ajpath.2017.06.020			9	Pathology	Pathology	FT6HY	WOS:000423256300002	29137951	Bronze			2019-10-28	
J	Dietze, EC; Chavez, TA; Seewaldt, VL				Dietze, Eric C.; Chavez, Tanya A.; Seewaldt, Victoria L.			Obesity and Triple-Negative Breast Cancer Disparities, Controversies, and Biology	AMERICAN JOURNAL OF PATHOLOGY			English	Review							AFRICAN-AMERICAN WOMEN; BODY-MASS INDEX; METABOLICALLY HEALTHY OBESITY; CLINICAL-IMPLICATIONS; WAIST CIRCUMFERENCE; AMBER CONSORTIUM; SKELETAL-MUSCLE; ADIPOSE-TISSUE; UNITED-STATES; RISK-FACTORS	Once considered a problem of Western nations, obesity (body mass index >= 30 kg/m(2)) has rapidly increased since the 1970s to become a major threat to world health. Since 1970, the face of obesity has changed from a disease of affluence and abundance to a disease of poverty. During the last 10 years, studies have mechanistically linked obesity and an obese tumor microenvironment with signaling pathways that predict aggressive breast cancer biology. For example, in the United States, African American women are more Likely than non-Hispanic European American women to be obese and to be diagnosed with triple-negative breast cancer (TNBC). In 2008, the Carolina Breast Study found that obesity (increased waist/hip ratio) was linked to an increased incidence of TNBC in premenopausal and postmenopausal African American women. Subsequently, several groups have investigated the potential link between obesity and TNBC in African American women. To date, the data are complex and sometimes contradictory. We review epidemiologic studies that investigated the potential association among obesity, metabolic syndrome, and TNBC in African American women and mechanistic studies that link insulin signaling to the obese breast microenvironment, tissue inflammation, and aggressive TNBC biology.	[Dietze, Eric C.; Chavez, Tanya A.; Seewaldt, Victoria L.] City Hope Natl Med Ctr, Dept Populat Sci, Ctr Comprehens Canc, Duarte, CA USA	Seewaldt, VL (reprint author), City Hope Natl Med Ctr, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.	vseewaldt@coh.org			NIH/National Cancer Institute grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA155664, R01CA158668, R01CA170851, R01CA192914, U01CA189283, P30CA033572]	Supported by NIH/National Cancer Institute grants R01CA155664, R01CA158668, R01CA170851, R01CA192914, U01CA189283 (V.L.S.), and P30CA033572.	Achilike I, 2015, INT J OBESITY, V39, P228, DOI 10.1038/ijo.2014.113; AdamsCampbell LL, 1996, OBES RES, V4, P451, DOI 10.1002/j.1550-8528.1996.tb00253.x; Albain KS, 2009, JNCI-J NATL CANCER I, V101, P984, DOI 10.1093/jnci/djp175; Ambrosone CB, 2009, J ONCOL, DOI 10.1155/2009/871250; AUSTIN H, 1979, INT J CANCER, V24, P541, DOI 10.1002/ijc.2910240504; Bandera EV, 2015, BREAST CANCER RES TR, V150, P655, DOI 10.1007/s10549-015-3353-z; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Beaulac J, 2009, PREV CHRONIC DIS, V6; Bernstein Leslie, 2003, Cancer, V97, P222, DOI 10.1002/cncr.11014; Berstad P, 2010, CANCER EPIDEM BIOMAR, V19, P1532, DOI 10.1158/1055-9965.EPI-10-0025; Bluher M, 2014, EUR J ENDOCRINOL, V171, pR209, DOI 10.1530/EJE-14-0540; Bluher S, 2014, METABOLISM, V63, P1084, DOI 10.1016/j.metabol.2014.06.009; Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Carroll JF, 2008, OBESITY, V16, P600, DOI 10.1038/oby.2007.92; Chiu M, 2011, DIABETES CARE, V34, P1741, DOI 10.2337/dc10-2300; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cummins S, 2006, INT J EPIDEMIOL, V35, P100, DOI 10.1093/ije/dyi276; Cummins S, 2002, BRIT MED J, V325, P436, DOI 10.1136/bmj.325.7361.436; D'Esposito V, 2016, ONCOTARGET, V7, P24495, DOI 10.18632/oncotarget.8336; Danforth DN, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3429; Davis AA, 2012, INT J BREAST CANCER, DOI 10.1155/2012/809291; Dawood S, 2009, J CLIN ONCOL, V27, P220, DOI 10.1200/JCO.2008.17.9952; Dean-Colomb W, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.22014; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dias JJ, 2013, J HEALTH CARE POOR U, V24, P206, DOI 10.1353/hpu.2013.0018; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goedecke JH, 2013, J OBES, DOI 10.1155/2013/952916; Gomez-Ambrosi J, 2014, DIABETES CARE, V37, P2813, DOI 10.2337/dc14-0937; Gordon V, 2013, CLIN CANCER RES, V19, P3738, DOI 10.1158/1078-0432.CCR-12-0274; Greenup R, 2013, ANN SURG ONCOL, V20, P3254, DOI 10.1245/s10434-013-3205-1; Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T; Hawkes C, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-4; Heo M, 2013, INT J OBESITY, V37, P1154, DOI 10.1038/ijo.2012.201; Herrmann W, 1982, Z Gesamte Inn Med, V37, P43; Heymsfield SB, 2016, OBES REV, V17, P262, DOI 10.1111/obr.12358; Hoyer D, 2011, DIABETOLOGIA, V54, P2795, DOI 10.1007/s00125-011-2275-5; Iqbal J, 2012, HISTOPATHOLOGY, V61, P652, DOI 10.1111/j.1365-2559.2012.04255.x; Johnson JL, 2010, ENDOCR PRACT, V16, P47, DOI 10.4158/EP09031.OR; Kelly TL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007038; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621; King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346; Kriegsmann M, 2014, ONCOTARGET, V5, P9952, DOI 10.18632/oncotarget.2481; Kwan ML, 2014, AM J EPIDEMIOL, V179, P95, DOI 10.1093/aje/kwt233; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Lund MJ, 2009, BREAST CANCER RES TR, V113, P357, DOI 10.1007/s10549-008-9926-3; Malik VS, 2013, NAT REV ENDOCRINOL, V9, P13, DOI 10.1038/nrendo.2012.199; Massihnia D, 2016, ONCOTARGET, V7, P60712, DOI 10.18632/oncotarget.10858; Mathew H, 2016, METABOLISM, V65, P73, DOI 10.1016/j.metabol.2015.10.019; McDaniel JM, 2017, ONCOTARGET, V8, P8226, DOI 10.18632/oncotarget.14153; Mcgee SA, 2013, CANCER EPIDEM BIOMAR, V22, P1227, DOI 10.1158/1055-9965.EPI-12-1432; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; Morris GJ, 2007, CANCER, V110, P876, DOI 10.1002/cncr.22836; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; NELSON DA, 1991, AM J PHYS ANTHROPOL, V86, P507, DOI 10.1002/ajpa.1330860406; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; Ogden CL, 2016, JAMA-J AM MED ASSOC, V315, P2292, DOI 10.1001/jama.2016.6361; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Palmer JR, 2007, CANCER EPIDEM BIOMAR, V16, P1795, DOI 10.1158/1055-9965.EPI-07-0336; Palmer JR, 2014, CANCER CAUSE CONTROL, V25, P309, DOI 10.1007/s10552-013-0332-8; Perez-Perez A, 2017, CYTOKINE GROWTH F R, V35, P71, DOI 10.1016/j.cytogfr.2017.03.001; Phillips CM, 2013, REV ENDOCR METAB DIS, V14, P219, DOI 10.1007/s11154-013-9252-x; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rahman M, 2009, METABOLISM, V58, P1329, DOI 10.1016/j.metabol.2009.04.017; Rangel MC, 2016, BREAST CANCER RES TR, V156, P211, DOI 10.1007/s10549-016-3746-7; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Rose DP, 2012, ENDOCR-RELAT CANCER, V19, pR225, DOI 10.1530/ERC-12-0203; Rosenberg L, 1995, J Am Med Womens Assoc (1972), V50, P56; SCHATZKIN A, 1987, J NATL CANCER I, V78, P213; Seidell JC, 2016, NAT REV ENDOCRINOL, V12, DOI 10.1038/nrendo.2016.121; Shaver TM, 2016, CANCER RES, V76, P4850, DOI 10.1158/0008-5472.CAN-16-0058; Shen Y, 2007, BREAST CANCER RES TR, V102, P347, DOI 10.1007/s10549-006-9337-2; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Silva AM, 2010, AM J HUM BIOL, V22, P76, DOI 10.1002/ajhb.20956; Sims EAH, 2001, METABOLISM, V50, P1499, DOI 10.1053/meta.2001.27213; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stark A, 2010, CANCER-AM CANCER SOC, V116, P4926, DOI 10.1002/cncr.25276; Stead LA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2242; Sundaram Sneha, 2013, J Carcinog, V12, P19, DOI 10.4103/1477-3163.119606; Ueng SH, 2012, INT J CLIN EXP PATHO, V5, P806; Velho S, 2010, EUR J CLIN NUTR, V64, P1043, DOI 10.1038/ejcn.2010.114; Vona-Davis L, 2009, J WOMENS HEALTH, V18, P883, DOI 10.1089/jwh.2008.1127; Wang ZM, 2001, AM J HUM BIOL, V13, P612; Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320; Whitacre PT, 2009, PUBL HLTH EFF FOOD D; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Woodward WA, 2006, CANCER, V107, P2662, DOI 10.1002/cncr.22281; World Health Organization, 2011, WAIST CIRCUMFERENCE; Xu H, 2014, CLIN CHEM, V60, P122, DOI 10.1373/clinchem.2013.207167; Zhu KM, 2005, ANN EPIDEMIOL, V15, P123, DOI 10.1016/j.annepidem.2004.05.011	99	14	14	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					280	290		10.1016/j.ajpath.2017.09.018			11	Pathology	Pathology	FT6HY	WOS:000423256300003	29128565	Bronze, Green Published			2019-10-28	
J	Augustus, GJ; Ellis, NA				Augustus, Gaius J.; Ellis, Nathan A.			Colorectal Cancer Disparity in African Americans Risk Factors and Carcinogenic Mechanisms	AMERICAN JOURNAL OF PATHOLOGY			English	Review							GENOME-WIDE ASSOCIATION; VITAMIN-D STATUS; MICROSATELLITE INSTABILITY; COLON-CANCER; 25-HYDROXYVITAMIN D; PROGNOSTIC-SIGNIFICANCE; CAUCASIAN PATIENTS; DIETARY PATTERNS; METHYLATED GENES; UNITED-STATES	African Americans have the highest incidence and mortality rates of colorectal cancer (CRC) of any ethnic group in the United States. Although some of these disparities can be explained by differences in access to care, cancer screening, and other socioeconomic factors, disparities remain after adjustment for these factors. Consequently, an examination of recent advances in the understanding of ethnicity-specific factors, including genetic and environmental factors relating to risk of CRC, the biology of CRC progression, and the changes in screening and mortality, is important for evaluating our progress toward eliminating the disparities. An overarching Limitation in this field is the number and sample size of studies performed to characterize the etiological bases of CRC incidence and mortality in African Americans. Despite this limitation, significant differences in etiology are manifest in many studies. These differences need validation, and their impacts on disparities need more detailed investigation. Perhaps most heartening, improvements in CRC screening can be attributed to the smallest difference in CRC incidence between African Americans and whites since the late 1980s. Cancer mortality, however, remains a persistent difference.	[Augustus, Gaius J.] Univ Arizona, Canc Biol Grad Interdisciplinary Program, 1515 N Campbell Ave, Tucson, AZ 85724 USA; [Ellis, Nathan A.] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA; [Ellis, Nathan A.] Univ Arizona, Dept Cellular & Mol Med, 1515 N Campbell Ave, Tucson, AZ 85724 USA	Augustus, GJ (reprint author), Univ Arizona, Canc Biol Grad Interdisciplinary Program, 1515 N Campbell Ave, Tucson, AZ 85724 USA.; Ellis, NA (reprint author), Univ Arizona, Dept Cellular & Mol Med, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	gaiusjaugustus@email.arizona.edu; naellis@email.arizona.edu			National Cancer Institute grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA153060, P30 CA023074]; Cancer Biology Training grant [T32 CA009213]	Supported by National Cancer Institute grants U01 CA153060 and P30 CA023074 (N.A.E.) and the Cancer Biology Training grant T32 CA009213 (G.J.A.).	Agrawal S, 2005, AM J GASTROENTEROL, V100, P515, DOI 10.1111/j.1572-0241.2005.41829.x; Ahmad II, 2016, J CLIN GASTROENTEROL, V50, P644, DOI 10.1097/MCG.0000000000000497; Alexander D, 2005, CANCER-AM CANCER SOC, V103, P2163, DOI 10.1002/cncr.21021; Alexander D, 2004, CANCER-AM CANCER SOC, V101, P66, DOI 10.1002/cncr.20337; Alexander Dominik D., 2007, Cancer Biomarkers, V3, P301; Alleyne D, 2017, J STEROID BIOCHEM, V168, P49, DOI 10.1016/j.jsbmb.2017.02.001; Ananthakrishnan AN, 2015, CANCER EPIDEM BIOMAR, V24, P198, DOI 10.1158/1055-9965.EPI-14-0897; Ashktorab H, 2005, INT J CANCER, V116, P914, DOI 10.1002/ijc.21062; Ashktorab H, 2003, CLIN CANCER RES, V9, P1112; Ashktorab H, 2016, GASTROENT RES PRACT, DOI 10.1155/2016/2102674; Ashktorab H, 2016, DIGEST DIS SCI, V61, P3026, DOI 10.1007/s10620-016-4207-1; Ashktorab H, 2016, ONCOTARGET, V7, P34546, DOI 10.18632/oncotarget.8945; Ashktorab H, 2015, CANCER-AM CANCER SOC, V121, P34, DOI 10.1002/cncr.28922; Ashktorab H, 2014, EPIGENETICS-US, V9, P503, DOI 10.4161/epi.27644; Ashktorab H, 2013, EPIGENETICS-US, V8, P807, DOI 10.4161/epi.25497; Ashktorab H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025314; Ashktorab H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008879; Baron JA, 2015, NEW ENGL J MED, V373, P1519, DOI 10.1056/NEJMoa1500409; Barry EL, 2016, JAMA ONCOL, V10; Bovell LC, 2013, CLIN CANCER RES, V19, P3955, DOI 10.1158/1078-0432.CCR-12-3302; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Brim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082185; Brim H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040392; Brim H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-68; Carethers JM, 2015, DIGEST DIS SCI, V60, P711, DOI 10.1007/s10620-014-3443-5; Carethers JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100461; Cekaite L, 2012, NEOPLASIA, V14, P868, DOI 10.1593/neo.121094; Chan DSM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020456; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P290, DOI 10.3322/caac.21340; Devaraj B, 2010, J GASTROINTEST SURG, V14, P1521, DOI 10.1007/s11605-010-1340-6; Dimou A, 2009, WORLD J GASTROENTERO, V15, P3734, DOI 10.3748/wjg.15.3734; Drewes JL, 2016, BRIT J CANCER, V115, P273, DOI 10.1038/bjc.2016.189; Eaton AM, 2005, CANCER EPIDEM BIOMAR, V14, P2023, DOI 10.1158/1055-9965.EPI-05-0131; Fatemi M, 2014, CANCER-AM CANCER SOC, V120, P172, DOI 10.1002/cncr.28316; Fichera A, 2007, J SURG RES, V142, P239, DOI 10.1016/j.jss.2007.02.038; Fiscella K, 2011, CANCER-AM CANCER SOC, V117, P1061, DOI 10.1002/cncr.25647; Flood DM, 2000, CANCER CAUSE CONTROL, V11, P403, DOI 10.1023/A:1008955722425; Gaillard T, 2009, ETHNIC DIS, V19, pS1; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Giovannucci E, 2009, ANN EPIDEMIOL, V19, P84, DOI 10.1016/j.annepidem.2007.12.002; Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328; Grant WB, 2012, DERM-ENDOCRINOL, V4, P85, DOI 10.4161/derm.19667; Grizzle WE, 2002, INT J CANCER, V97, P403, DOI 10.1002/ijc.1617; Guda K, 2015, P NATL ACAD SCI USA, V112, P1149, DOI 10.1073/pnas.1417064112; Guindalini RSC, 2015, GASTROENTEROLOGY, V149, P1446, DOI 10.1053/j.gastro.2015.07.052; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202; Haugen AC, 2008, CANCER RES, V68, P8465, DOI 10.1158/0008-5472.CAN-08-0002; Hines RB, 2009, CANCER-AM CANCER SOC, V115, P5798, DOI 10.1002/cncr.24598; Hiraki LT, 2013, CANCER EPIDEM BIOMAR, V22, P2037, DOI 10.1158/1055-9965.EPI-13-0209; Holick MF, 2008, AM J CLIN NUTR, V87, p1080S; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hulur I, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1292-z; Inra JA, 2015, GENET MED, V17, P815, DOI 10.1038/gim.2014.199; Iyengar NM, 2015, ANNU REV MED, V66, P297, DOI 10.1146/annurev-med-050913-022228; James AS, 2006, AM J HEALTH BEHAV, V30, P720, DOI 10.5993/AJHB.30.6.17; Jiao S, 2014, HUM MOL GENET, V23, P3898, DOI 10.1093/hmg/ddu087; Jones BA, 2009, CANCER EPIDEMIOL, V33, P249, DOI 10.1016/j.canep.2009.08.004; Jovov B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030168; Kang M, 2013, CANCER BIOMARK, V13, P359, DOI 10.3233/CBM-130366; Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719; Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032; Kupfer SS, 2014, CARCINOGENESIS, V35, P2025, DOI 10.1093/carcin/bgu088; Kupfer SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026123; Kupfer SS, 2010, GASTROENTEROLOGY, V139, P1677, DOI 10.1053/j.gastro.2010.07.038; Kupfer SS, 2017, MOL BASIS HUMAN CANC, P381; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lemire M, 2015, HUM GENET, V134, P1249, DOI 10.1007/s00439-015-1598-6; LePane CA, 2011, GASTROENTEROL RES, V4, P43, DOI 10.4021/gr291e; Li E, 2014, INT J ONCOL, V45, P587, DOI 10.3892/ijo.2014.2469; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Manne U, 2000, INT J CANCER, V89, P423, DOI 10.1002/1097-0215(20000920)89:5<423::AID-IJC5>3.0.CO;2-T; Manne U, 2004, CLIN CANCER RES, V10, P1743, DOI 10.1158/1078-0432.CCR-03-0037; Manne U, 2000, CLIN CANCER RES, V6, P4017; Manne U, 1998, CANCER-AM CANCER SOC, V83, P2456, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2456::AID-CNCR8>3.0.CO;2-5; MATSUOKA LY, 1991, ARCH DERMATOL, V127, P536, DOI 10.1001/archderm.127.4.536; Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012; Moradi T, 1998, EUR J CANCER PREV, V7, P117; O'Keefe SJD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7342; Oberg AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020465; Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182; Peeters PJHL, 2015, DIABETES CARE, V38, P495, DOI 10.2337/dc14-1175; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705; Pibiri F, 2014, CANCER CAUSE CONTROL, V25, P561, DOI 10.1007/s10552-014-0361-y; Polite BN, 2006, J CLIN ONCOL, V24, P2179, DOI 10.1200/JCO.2005.05.4775; Potter JD, 2015, CANCER EPIDEM BIOMAR, V24, P323, DOI 10.1158/1055-9965.EPI-14-1327; Poulsen MLM, 2008, CURR GENOMICS, V9, P420, DOI 10.2174/138920208785699562; Powe BD, 2010, AM J HEALTH PROMOT, V25, P92, DOI [10.4278/ajhp.080826-LIT-162, 10.4278/ajhp.080826-L11.162]; Rabeneck L, 2003, AM J GASTROENTEROL, V98, P471, DOI 10.1016/S0002-9270(02)05928-2; Rex DK, 2009, AM J GASTROENTEROL, V104, P739, DOI 10.1038/ajg.2009.104; Ridlon JM, 2016, GUT MICROBES, V7, P22, DOI 10.1080/19490976.2015.1127483; Satia JA, 2009, NUTR CANCER, V61, P179, DOI 10.1080/01635580802419806; Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Slattery ML, 2007, CANCER EPIDEM BIOMAR, V16, P2752, DOI 10.1158/1055-9965.EPI-07-2611; Sylvester BE, 2012, CLIN CANCER RES, V18, P350, DOI 10.1158/1078-0432.CCR-11-1397; Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026; Tsai CJ, 2012, DIGEST DIS SCI, V57, P2497, DOI 10.1007/s10620-012-2198-0; Tsuei J, 2014, EXP BIOL MED, V239, P1489, DOI 10.1177/1535370214538743; Varadan V, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0192-9; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Wang HS, 2017, INT J CANCER, V140, P2728, DOI 10.1002/ijc.30687; Wang HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5613; Wang HS, 2013, HUM MOL GENET, V22, P5048, DOI 10.1093/hmg/ddt337; Wang X, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1278-z; WANG ZF, 2016, JNCI-J NATL CANCER I, V65, DOI DOI 10.7498/APS.65.164203; Weber TK, 1999, JAMA-J AM MED ASSOC, V281, P2316, DOI 10.1001/jama.281.24.2316; Willett WC, 2013, ANNU REV PUBL HEALTH, V34, P77, DOI 10.1146/annurev-publhealth-031811-124646; Williams CD, 2009, CANCER EPIDEM BIOMAR, V18, P1552, DOI 10.1158/1055-9965.EPI-08-1146; Woolcott CG, 2010, CANCER EPIDEM BIOMAR, V19, P130, DOI 10.1158/1055-9965.EPI-09-0475; Xicola RM, 2014, CLIN CANCER RES, V20, P4962, DOI 10.1158/1078-0432.CCR-14-0353; Yazici C, 2017, GUT, V66, P1983, DOI 10.1136/gutjnl-2016-313321; Zeng CJ, 2016, GASTROENTEROLOGY, V150, P1633, DOI 10.1053/j.gastro.2016.02.076; Zheng XE, 2013, J STEROID BIOCHEM, V136, P280, DOI 10.1016/j.jsbmb.2012.09.018	116	7	7	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					291	303		10.1016/j.ajpath.2017.07.023			13	Pathology	Pathology	FT6HY	WOS:000423256300004	29128568	Green Published			2019-10-28	
J	Smith, CJ; Minas, TZ; Ambs, S				Smith, Cheryl J.; Minas, Tsion Z.; Ambs, Stefan			Analysis of Tumor Biology to Advance Cancer Health Disparity Research	AMERICAN JOURNAL OF PATHOLOGY			English	Review							GENOME-WIDE ASSOCIATION; AGGRESSIVE PROSTATE-CANCER; AFRICAN-AMERICAN WOMEN; BREAST-CANCER; GENE-EXPRESSION; RACIAL DISPARITIES; DNA METHYLATION; SUSCEPTIBILITY LOCI; CPG HYPERMETHYLATION; RECEPTOR STATUS	Cancer mortality rates in the United States continue to decline. Reductions in tobacco use, uptake of preventive measures, adoption of early detection methods, and better treatments have resulted in improved cancer outcomes for men and women. Despite this progress, some population groups continue to experience an excessive cancer burden when compared with other population groups. One of the most prominent cancer health disparities exists in prostate cancer. Prostate cancer mortality rates are highest among men of African ancestry when compared with other men, both in the United States and globally. This disparity and other cancer health disparities are largely explained by differences in access to health care, diet, lifestyle, cultural barriers, and disparate exposures to carcinogens and pathogens. Dietary and lifestyle factors, pathogens, and ancestry-related factors can modify tumor biology and induce a more aggressive disease. There are numerous examples of how environmental exposures, like tobacco, chronic stress, or dietary factors, induce an adverse tumor biology, leading to a more aggressive disease and decreased patient survival. Because of population differences in the exposure to these risk factors, they can be the cause of cancer disparities. In this review, we will summarize recent advances in our understanding of prostate and breast cancer disparities in the United States and discuss how the analysis of tumor biology can advance health disparity research.	[Smith, Cheryl J.; Minas, Tsion Z.; Ambs, Stefan] NCI, Lab Human Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Ambs, S (reprint author), NCI, Lab Human Carcinogenesis, Bldg 37,Room 3050B, Bethesda, MD 20892 USA.	ambss@mail.nih.gov		Ambs, Stefan/0000-0001-7651-9309	Intramural Research Program of the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); Center for Cancer Research grants [ZIA BC 010499, ZIA BC 010624, ZIA BC 010887]	Supported by the Intramural Research Program of the NIH, the National Cancer Institute, and the Center for Cancer Research grants ZIA BC 010499, ZIA BC 010624, and ZIA BC 010887.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Adisa CA, 2012, ANN AFR MED, V11, P169, DOI 10.4103/1596-3519.96880; Adkins RM, 2011, BIRTH DEFECTS RES A, V91, P728, DOI 10.1002/bdra.20770; Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; Aizer AA, 2014, CANCER-AM CANCER SOC, V120, P1532, DOI 10.1002/cncr.28617; Al Olama AA, 2014, NAT GENET, V46, P1103, DOI 10.1038/ng.3094; Albain KS, 2009, JNCI-J NATL CANCER I, V101, P984, DOI 10.1093/jnci/djp175; Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599; Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Baylin SB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019505; Berndt SI, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7889; Byers T, 2010, ANNU REV PUBL HEALTH, V31, P121, DOI 10.1146/annurev.publhealth.121208.131047; Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363; Cappetta M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1461-0; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chen F, 2013, HUM GENET, V132, P39, DOI 10.1007/s00439-012-1214-y; Chen F, 2011, EUR J HUM GENET, V19, P243, DOI 10.1038/ejhg.2010.185; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043; Cole SW, 2011, P NATL ACAD SCI USA, V108, P3080, DOI 10.1073/pnas.1014218108; Conway K, 2015, CANCER EPIDEM BIOMAR, V24, P921, DOI 10.1158/1055-9965.EPI-14-1228; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; D'Arcy M, 2015, BREAST CANCER RES TR, V152, P437, DOI 10.1007/s10549-015-3474-4; Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P290, DOI 10.3322/caac.21340; Devaney JM, 2015, EPIGENETICS-US, V10, P319, DOI 10.1080/15592294.2015.1022019; Eastham JA, 1998, J NATL CANCER I, V90, P756, DOI 10.1093/jnci/90.10.756; Enokida H, 2006, CANCER-AM CANCER SOC, V106, P79, DOI 10.1002/cncr.21577; Enokida H, 2005, INT J CANCER, V116, P174, DOI 10.1002/ijc.21017; Entringer S, 2011, P NATL ACAD SCI USA, V108, pE513, DOI 10.1073/pnas.1107759108; Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630; Faisal FA, 2016, EUR UROL, V70, P14, DOI 10.1016/j.eururo.2015.09.031; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Fejerman L, 2008, CANCER RES, V68, P9723, DOI 10.1158/0008-5472.CAN-08-2039; Feng Y, 2014, HUM MOL GENET, V23, P5518, DOI 10.1093/hmg/ddu252; Feng ZH, 2012, P NATL ACAD SCI USA, V109, P7013, DOI 10.1073/pnas.1203930109; Field LA, 2012, CANCER-AM CANCER SOC, V118, P1334, DOI 10.1002/cncr.26405; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561; Giri VN, 2016, SEMIN ONCOL, V43, P560, DOI 10.1053/j.seminoncol.2016.08.001; Glynn SA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-626; Glynn SA, 2010, J CLIN INVEST, V120, P3843, DOI 10.1172/JCI42059; Gurel B, 2014, CANCER EPIDEM BIOMAR, V23, P847, DOI 10.1158/1055-9965.EPI-13-1126; Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015; Haiman CA, 2011, NAT GENET, V43, P1210, DOI 10.1038/ng.985; Haiman CA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001387; Haiman CA, 2011, NAT GENET, V43, P570, DOI 10.1038/ng.839; Hair BY, 2015, CANCER EPIDEM BIOMAR, V24, P580, DOI 10.1158/1055-9965.EPI-14-1017; Hardiman G, 2016, PHARMACOGENOMICS, V17, P1129, DOI 10.2217/pgs-2016-0025; Hausauer AK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1839; Hershman D, 2005, J CLIN ONCOL, V23, P6639, DOI 10.1200/JCO.2005.12.633; Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112; Huo DZ, 2016, HUM MOL GENET, V25, P4835, DOI 10.1093/hmg/ddw305; Huo DZ, 2012, CARCINOGENESIS, V33, P835, DOI 10.1093/carcin/bgs093; Huo DZ, 2009, J CLIN ONCOL, V27, P4515, DOI 10.1200/JCO.2008.19.6873; Jatoi I, 2003, CANCER, V98, P894, DOI 10.1002/cncr.11604; Jin WF, 2012, GENOME RES, V22, P519, DOI 10.1101/gr.124784.111; Jones BA, 2004, CANCER, V101, P1293, DOI 10.1002/cncr.20500; Jones J, 2012, AM J PATHOL, V181, P1836, DOI 10.1016/j.ajpath.2012.08.008; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kakarala M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-191; Keenan T, 2015, J CLIN ONCOL, V33, P3621, DOI 10.1200/JCO.2015.62.2126; Khani F, 2014, CLIN CANCER RES, V20, P4925, DOI 10.1158/1078-0432.CCR-13-2265; Khera A, 2005, J AM COLL CARDIOL, V46, P464, DOI 10.1016/j.jacc.2005.04.051; Klink JC, 2013, WORLD J UROL, V31, P1497, DOI 10.1007/s00345-013-1065-8; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LEWIS CE, 1995, J LEUKOCYTE BIOL, V57, P747; Lindner R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071915; Lu DH, 2016, CLIN CANCER RES, V22, P765, DOI 10.1158/1078-0432.CCR-15-0101; Lutgendorf SK, 2009, BRAIN BEHAV IMMUN, V23, P176, DOI 10.1016/j.bbi.2008.04.155; Magi-Galluzzi C, 2011, PROSTATE, V71, P489, DOI 10.1002/pros.21265; Mariotto AB, 2007, CANCER, V109, P1877, DOI 10.1002/cncr.22607; Martin DN, 2013, CURR OPIN ONCOL, V25, P235, DOI 10.1097/CCO.0b013e32835eb5d1; Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531; Maskarinec G, 2004, ETHNIC DIS, V14, P431; Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Menashe I, 2009, J NATL CANCER I, V101, P993, DOI 10.1093/jnci/djp176; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; Mukhtar RA, 2011, BREAST CANCER RES TR, V130, P635, DOI 10.1007/s10549-011-1646-4; Mundbjerg K, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1129-3; Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573; O'Keefe Eileen B, 2015, Front Public Health, V3, P51, DOI 10.3389/fpubh.2015.00051; Odedina Folakemi T, 2009, Infect Agent Cancer, V4 Suppl 1, pS2, DOI 10.1186/1750-9378-4-S1-S2; Osborn VW, 2016, TUMORI, V102, P65, DOI 10.5301/tj.5000424; Palm D, 2006, INT J CANCER, V118, P2744, DOI 10.1002/ijc.21723; Park NJ, 2013, ONCOL NURS FORUM, V40, P490, DOI 10.1188/13.ONF.40-05AP; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; Petrovics G, 2015, EBIOMEDICINE, V2, P1957, DOI 10.1016/j.ebiom.2015.10.028; Pietro Giuliano Di, 2016, Int Neurourol J, V20, pS112; Pirie A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0570-7; Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197; Powell IJ, 2013, CANCER EPIDEM BIOMAR, V22, P891, DOI 10.1158/1055-9965.EPI-12-1238; Powell IJ, 2010, J UROLOGY, V183, P1792, DOI 10.1016/j.juro.2010.01.015; Prueitt RL, 2016, CANCER RES, V76, P1055, DOI 10.1158/0008-5472.CAN-14-3630; Purrington KS, 2014, CARCINOGENESIS, V35, P1012, DOI 10.1093/carcin/bgt404; Robbins C, 2007, GENOME RES, V17, P1717, DOI 10.1101/gr.6782707; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rose AE, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-70; Rosen P, 2012, NAT REV UROL, V9, P131, DOI 10.1038/nrurol.2012.10; Ruiz-Narvaez EA, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00170; Sawe RT, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2204-6; Shariff-Marco S, 2010, AM J PUBLIC HEALTH, V100, P364, DOI 10.2105/AJPH.2009.163899; SHUCH B, 2004, J CLIN ONCOL, V22, P4673; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Silber JH, 2013, JAMA-J AM MED ASSOC, V310, P389, DOI 10.1001/jama.2013.8272; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Smith CJ, 2017, CANCER EPIDEM BIOMAR, V26, P845, DOI 10.1158/1055-9965.EPI-16-1027; Starks AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057361; Storey JD, 2007, AM J HUM GENET, V80, P502, DOI 10.1086/512017; Taylor TR, 2007, AM J EPIDEMIOL, V166, P46, DOI 10.1093/aje/kwm056; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; THOMAS DB, 1987, CANCER RES, V47, P5771; Tosoian JJ, 2017, EUR UROL, V71, P697, DOI 10.1016/j.eururo.2016.07.026; Tyson MD, 2014, MAYO CLIN PROC, V89, P300, DOI 10.1016/j.mayocp.2013.11.001; Van Dyke AL, 2009, CYTOKINE, V46, P236, DOI 10.1016/j.cyto.2009.02.003; Vidal AC, 2017, ONCOTARGET, V8, P71393, DOI 10.18632/oncotarget.10690; Vin-Raviv N, 2013, JNCI-J NATL CANCER I, V105, P563, DOI 10.1093/jnci/djt024; Volden PA, 2013, CANCER PREV RES, V6, P634, DOI 10.1158/1940-6207.CAPR-12-0458; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; WEIDNER N, 1995, AM J PATHOL, V147, P9; Williams JB, 2009, CANCER PREV RES, V2, P850, DOI 10.1158/1940-6207.CAPR-08-0238; Zeigler-Johnson CM, 2008, CAN J UROL, V15, P4056; Zhang L, 2016, CANCER RES, V76, P6290, DOI 10.1158/0008-5472.CAN-16-0087; Zhang W, 2008, AM J HUM GENET, V82, P631, DOI 10.1016/j.ajhg.2007.12.015; Zhao SS, 2017, CLIN CANCER RES, V23, P311, DOI 10.1158/1078-0432.CCR-16-0549	135	8	8	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					304	316		10.1016/j.ajpath.2017.06.019			13	Pathology	Pathology	FT6HY	WOS:000423256300005	29137948	Green Published, Bronze			2019-10-28	
J	Byun, JS; Park, S; Caban, A; Jones, A; Gardner, K				Byun, Jung S.; Park, Samson; Caban, Ambar; Jones, Alana; Gardner, Kevin			Linking Race, Cancer Outcomes, and Tissue Repair	AMERICAN JOURNAL OF PATHOLOGY			English	Review							EPITHELIAL-MESENCHYMAL-TRANSITION; FATTY LIVER-DISEASE; APOL1 RISK VARIANTS; BREAST-CANCER; KIDNEY-DISEASE; STEM-CELLS; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; AFRICAN-AMERICAN	The burden of cancer in the United States is unevenly spread across its different populations, with stark differences in both disease prevalence and outcome on the basis of race and ethnicity. Although a large portion of these differences can be explained by a variety of sociobehavioral and socioeconomic factors, even after these exposures are taken into consideration, considerable disparities persist. In this review, we explore a conceptual framework of biological theories and unifying concepts, based on an evolutionary perspective, that may help better define common guiding principles for exploration of under Lying causes of cancer health disparities. The ultimate goal of this conceptual perspective is to outline approaches that may aid in establishing integrated pathway and processes analyses to provide useful insights to guide the development of future interventions. These interventions will improve outcome, increase prevention, and ultimately eliminate all disparities.	[Byun, Jung S.; Caban, Ambar; Jones, Alana; Gardner, Kevin] Natl Inst Minor Hlth & Hlth Dispar, Bethesda, MD USA; NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Gardner, Kevin] Columbia Univ, Med Ctr, New York, NY 10032 USA	Gardner, K (reprint author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, Room 14-460 W,168th St, New York, NY 10032 USA.; Gardner, K (reprint author), Columbia Univ, Med Ctr, New York, NY 10032 USA.	klg2160@cumc.columbia.edu		Jones, Alana/0000-0003-3827-2426	Intramural Research Programs of the NIH; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); Center for Cancer Research grant [ZIA-BC010847]; National Institute on Minority Health and Health Disparities grant [ZIA-MD000005]	Supported by the Intramural Research Programs of the NIH, National Cancer Institute, Center for Cancer Research grant ZIA-BC010847 (J.S.B., S.P., and K.G.), and National Institute on Minority Health and Health Disparities grant ZIA-MD000005 (J.S.B., A.C., A.J., and K.G.).	Aad G, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.022301; Akaiwa H, 1919, J MED RES, V40, P311; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Alter NM, 1925, AM J PATHOL, V1, P511; Andreoli SP, 2004, ADV RENAL REPLACE TH, V11, P105, DOI 10.1053/j.arrt.2003.10.015; Anton K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035036; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Beckerman P, 2017, NAT MED, V23, P429, DOI 10.1038/nm.4287; BERGER U, 1991, CANCER RES, V51, P239; Bertrand KA, 2017, CANCER EPIDEM BIOMAR, V26, P270, DOI 10.1158/1055-9965.EPI-16-0692; Byun JS, 2013, AM J PATHOL, V182, P1055, DOI 10.1016/j.ajpath.2013.01.009; Catherino WH, 2013, SEMIN REPROD MED, V31, P370, DOI 10.1055/s-0033-1348896; Cavazza A, 2009, INT J SURG PATHOL, V17, P219, DOI 10.1177/1066896909333748; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chang EA, 2015, SCI REP-UK, V5, DOI 10.1038/srep15234; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; Dovas A, 2013, J MICROSC-OXFORD, V251, P261, DOI 10.1111/j.1365-2818.2012.03667.x; DUSTAN HP, 1995, HYPERTENSION, V26, P858, DOI 10.1161/01.HYP.26.6.858; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Edwards DRV, 2014, HUM GENET, V133, P1513, DOI 10.1007/s00439-014-1490-9; Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631; Farhana L, 2016, CANCER MED-US, V5, P1268, DOI 10.1002/cam4.690; Faupel-Badger JM, 2013, JNCI-J NATL CANCER I, V105, P166, DOI 10.1093/jnci/djs505; Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691; Freytes DO, 2013, J CELL BIOCHEM, V114, P220, DOI 10.1002/jcb.24357; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; Goyal S, 2016, WORLD J STEM CELLS, V8, P279, DOI 10.4252/wjsc.v8.i9.279; Guan MJ, 2016, HUM GENET, V135, P1251, DOI 10.1007/s00439-016-1714-2; Guo QC, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89206; Guo QC, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010010; Haddow A, 1972, Adv Cancer Res, V16, P181; Haerian MS, 2011, J GASTROEN HEPATOL, V26, P1475, DOI 10.1111/j.1440-1746.2011.06831.x; He YJ, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12326; Hinz B, 2016, CURR RES TRANSL MED, V64, P171, DOI 10.1016/j.retram.2016.09.003; Hinz B, 2016, EXP EYE RES, V142, P56, DOI 10.1016/j.exer.2015.07.009; Iannuzzi MC, 2005, GENES IMMUN, V6, P509, DOI 10.1038/sj.gene.6364235; Iyengar NM, 2017, CANCER PREV RES, V10, P235, DOI 10.1158/1940-6207.CAPR-16-0314; Iyengar NM, 2016, CLIN CANCER RES, V22, P2283, DOI 10.1158/1078-0432.CCR-15-2239; Jumper N, 2015, HISTOL HISTOPATHOL, V30, P1033, DOI 10.14670/HH-11-624; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karan D, 2009, CANCER RES, V69, P2, DOI 10.1158/0008-5472.CAN-08-1230; Keeling BH, 2013, MED HYPOTHESES, V81, P908, DOI 10.1016/j.mehy.2013.08.009; Kessler MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12521; Kisseleva T, 2017, HEPATOLOGY, V65, P1039, DOI 10.1002/hep.28948; Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049; Kopp JB, 2008, NAT GENET, V40, P1175, DOI 10.1038/ng.226; Koru-Sengul T, 2016, BREAST CANCER RES TR, V158, P113, DOI 10.1007/s10549-016-3847-3; Krenkel O, 2017, NAT REV IMMUNOL, V17, P306, DOI 10.1038/nri.2017.11; Kupfer SS, 2014, CARCINOGENESIS, V35, P2025, DOI 10.1093/carcin/bgu088; Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034; Loeb L, 1920, J MED RES, V41, P247; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Mamoori A, 2016, BIOL CELL, V108, P51, DOI 10.1111/boc.201500062; Mann DA, 2014, HEPATOLOGY, V60, P1418, DOI 10.1002/hep.27131; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mari Walid, 2015, J Am Coll Clin Wound Spec, V7, P1, DOI 10.1016/j.jccw.2016.10.001; Marshall LM, 1997, OBSTET GYNECOL, V90, P967, DOI 10.1016/S0029-7844(97)00534-6; Martin DN, 2013, CURR OPIN ONCOL, V25, P235, DOI 10.1097/CCO.0b013e32835eb5d1; Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; Mirsaeidi M, 2015, CHEST, V147, P438, DOI 10.1378/chest.14-1120; Mishra PJ, 2009, CANCER RES, V69, P1255, DOI 10.1158/0008-5472.CAN-08-3562; Montanari M, 2017, ONCOTARGET, V8, P35376, DOI 10.18632/oncotarget.15686; Nakazawa M, 2017, J STEROID BIOCHEM, V166, P84, DOI 10.1016/j.jsbmb.2016.05.007; Ng K, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju345; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Nwosu ZC, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00191; O'Brien J, 2009, J MAMMARY GLAND BIOL, V14, P145, DOI 10.1007/s10911-009-9118-8; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Olabisi OA, 2016, P NATL ACAD SCI USA, V113, P830, DOI 10.1073/pnas.1522913113; Palmer JR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju237; Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345; Perumpail RB, 2015, DIGEST DIS SCI, V60, P3142, DOI 10.1007/s10620-015-3821-7; Petrick JL, 2016, J CLIN ONCOL, V34, P1787, DOI 10.1200/JCO.2015.64.7412; Pibiri F, 2014, CANCER CAUSE CONTROL, V25, P561, DOI 10.1007/s10552-014-0361-y; Pocha C, 2015, SEMIN LIVER DIS, V35, P304, DOI 10.1055/s-0035-1562949; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Power ML, 2012, PHYSIOL BEHAV, V106, P22, DOI 10.1016/j.physbeh.2011.09.011; Power ML, 2009, EVOLUTION OBESITY; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Prueitt RL, 2016, CANCER RES, V76, P1055, DOI 10.1158/0008-5472.CAN-14-3630; RELMAN AS, 1982, NEW ENGL J MED, V306, P1290, DOI 10.1056/NEJM198205273062109; Rombouts K, 2010, DIGEST DIS, V28, P229, DOI 10.1159/000282094; Rosset S, 2011, NAT REV NEPHROL, V7, P313, DOI 10.1038/nrneph.2011.52; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Rybicki BA, 1997, AM J EPIDEMIOL, V145, P234; Salinas CA, 2008, CANCER EPIDEM BIOMAR, V17, P1203, DOI 10.1158/1055-9965.EPI-07-2811; SARTWELL PE, 1976, ANN NY ACAD SCI, V278, P368, DOI 10.1111/j.1749-6632.1976.tb47047.x; Satish L, 2004, WOUND REPAIR REGEN, V12, P183, DOI 10.1111/j.1067-1927.2004.012111.x; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Schedin P, 2007, J MAMMARY GLAND BIOL, V12, P71, DOI 10.1007/s10911-007-9039-3; Schedin P, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2235; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Seeman TE, 2001, P NATL ACAD SCI USA, V98, P4770, DOI 10.1073/pnas.081072698; Sekhon K, 2016, ONCOTARGET, V7, P67597, DOI 10.18632/oncotarget.11708; Shaker SA, 2011, APPL IMMUNOHISTO M M, V19, P153, DOI 10.1097/PAI.0b013e3181efa2ef; Shany S, 2016, ANTICANCER RES, V36, P6225, DOI 10.21873/anticanres.11216; Shih B, 2010, ARCH DERMATOL RES, V302, P319, DOI 10.1007/s00403-009-1014-y; Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Slattery ML, 2014, CANCER CAUSE CONTROL, V25, P293, DOI 10.1007/s10552-013-0331-9; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Smith CJ, 2017, CANCER EPIDEM BIOMAR, V26, P845, DOI 10.1158/1055-9965.EPI-16-1027; Spaeth EL, 2013, CANCER RES, V73, P5347, DOI 10.1158/0008-5472.CAN-13-0087; STERLING P, 1981, SOC SCI MED-MED PSYC, V15, P3, DOI 10.1016/S0277-9536(81)80005-6; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tampe B, 2014, NEPHROL DIAL TRANSPL, V29, P72, DOI 10.1093/ndt/gft025; Taran FA, 2010, FERTIL STERIL, V94, P1500, DOI 10.1016/j.fertnstert.2009.08.037; Trivanovic D, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/7314016; Tzouvelekis A, 2015, BIOCHEM CELL BIOL, V93, P159, DOI 10.1139/bcb-2014-0126; Virchow R., 1858, CELLULARPATHOLOGIE I; Wahab SMR, 2017, CLIN COLORECTAL CANC, V16, P93, DOI 10.1016/j.clcc.2017.01.011; Westney GE, 2006, CLIN CHEST MED, V27, P453, DOI 10.1016/j.ccm.2006.04.002; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897	133	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					317	328		10.1016/j.ajpath.2017.10.009			12	Pathology	Pathology	FT6HY	WOS:000423256300006	29137950	Bronze, Green Published			2019-10-28	
J	Kwong, EML; Ho, JCH; Lau, MCC; You, MS; Jiang, YJ; Tse, WKF				Kwong, Ernest Man Lok; Ho, Jeff Cheuk Hin; Lau, Marco Chi Chung; You, May-Su; Jiang, Yun-Jin; Tse, William Ka Fai			Restoration of polr1c in Early Embryogenesis Rescues the Type 3 Treacher Collins Syndrome Facial Malformation Phenotype in Zebrafish	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MANDIBULOFACIAL DYSOSTOSIS; DEUBIQUITYLATING ENZYMES; GENE; P53; PATHOGENESIS; MODEL; ABNORMALITIES; MORPHOLINOS; PREVENTION; DISEASE	Treacher Collins syndrome (TCS) is a rare congenital birth disorder (1 in 50,000 live births) characterized by severe craniofacial defects. Recently, the authors' group unfolded the pathogenesis of polr1c Type 3 TCS by using the zebrafish model. Facial development depends on the neural crest cells, in which polr1c plays a role in regulating their expression. In this study, the authors aimed to identify the functional time window of polr1c in TCS by the use of photo-morpholino to restore the polr1c expression at different time points. Results suggested that the restoration of polr1c at 8 hours after fertilization could rescue the TCS facial malformation phenotype by correcting the neural crest cell expression, reducing the cell death, and normalizing the p53 mRNA expression level in the rescued morphants. However, such recovery could not be reproduced if the polr1c is restored after 30 hours after fertilization.	[Kwong, Ernest Man Lok; Ho, Jeff Cheuk Hin; Lau, Marco Chi Chung] Hong Kong Baptist Univ, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China; [You, May-Su; Jiang, Yun-Jin] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Tse, William Ka Fai] Kyushu Univ, Fac Agr, Fukuoka, Japan	Tse, WKF (reprint author), Kyushu Univ, Fac Agr, Promot Ctr Int Educ & Res, Fukuoka 8128581, Japan.	kftse@agr.kyushu-u.ac.jp	TSE, KA FAI WILLIAM/C-9384-2012	TSE, KA FAI WILLIAM/0000-0002-3738-0460	Japan Society for the Promotion of Science Bilateral Open Partnership Joint Research Project [AJ179064]; National Health Research Institutes, TaiwanNational Health Research Institutes - Taiwan [MG-105-PP-12, MG-106-PP-11]; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 105-2311-B-400-001, MOST 106-2319-B-400-002, MOST 106-2311-B-400-003-MY3]	Supported by the Japan Society for the Promotion of Science Bilateral Open Partnership Joint Research Project AJ179064 (W.K.F.T.), National Health Research Institutes, Taiwan, grants MG-105-PP-12 and MG-106-PP-11, and the Ministry of Science and Technology, Taiwan, grants MOST 105-2311-B-400-001, MOST 106-2319-B-400-002, and MOST 106-2311-B-400-003-MY3 (Y.-J.J.).	Collins ET, 1900, T OPHTHAL SOC UK, V20, P190; Das A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002710; Dauwerse JG, 2011, NAT GENET, V43, P20, DOI 10.1038/ng.724; Deng W, 2015, J BIOMED NANOTECHNOL, V11, P2111, DOI 10.1166/jbn.2015.2171; Dixon J, 1996, NAT GENET, V12, P130; Dixon J, 2006, P NATL ACAD SCI USA, V103, P13403, DOI 10.1073/pnas.0603730103; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eberhart JK, 2008, NAT GENET, V40, P290, DOI 10.1038/ng.82; Fong HCH, 2016, CHEMOSPHERE, V164, P413, DOI 10.1016/j.chemosphere.2016.08.073; HERRING SW, 1979, AM J MED GENET, V3, P225, DOI 10.1002/ajmg.1320030303; Jones NC, 2008, NAT MED, V14, P125, DOI 10.1038/nm1725; Kadakia S, 2014, INT J PEDIATR OTORHI, V78, P893, DOI 10.1016/j.ijporl.2014.03.006; Kamel G, 2013, DEV BIOL, V381, P423, DOI 10.1016/j.ydbio.2013.06.012; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lau MCC, 2016, BBA-MOL BASIS DIS, V1862, P1147, DOI 10.1016/j.bbadis.2016.03.005; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; McKeown SJ, 2008, NAT MED, V14, P115, DOI 10.1038/nm0208-115; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plomp RG, 2016, PLAST RECONSTR SURG, V137, P191, DOI 10.1097/PRS.0000000000001896; POSWILLO D, 1975, BRIT J ORAL SURG, V13, P1, DOI 10.1016/0007-117X(75)90019-0; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sakai D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10328; Saxena A, 2013, ELIFE, V2, DOI 10.7554/eLife.00336; Seth A, 2013, DIS MODEL MECH, V6, P1080, DOI 10.1242/dmm.011346; Solomon KS, 2003, DEVELOPMENT, V130, P929, DOI 10.1242/dev.00308; Su PH, 2006, J FORMOS MED ASSOC, V105, P518, DOI 10.1016/S0929-6646(09)60194-7; Swartz ME, 2011, DEV DYNAM, V240, P2204, DOI 10.1002/dvdy.22713; Tallafuss A, 2012, DEVELOPMENT, V139, P1691, DOI 10.1242/dev.072702; Tse WKF, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-637; Tse WKF, 2016, INT J BIOCHEM CELL B, V81, P44, DOI 10.1016/j.biocel.2016.10.016; Tse WKF, 2012, METHODS MOL BIOL, V815, P321, DOI 10.1007/978-1-61779-424-7_24; Vincent M, 2016, GENET MED, V18, P49, DOI 10.1038/gim.2015.29; Watt KEN, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006187; WILEY MJ, 1983, ACTA ANAT, V116, P180; Yelick PC, 2002, CRIT REV ORAL BIOL M, V13, P308, DOI 10.1177/154411130201300402; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	36	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					336	342		10.1016/j.ajpath.2017.10.004			7	Pathology	Pathology	FT6HY	WOS:000423256300008	29128566	Bronze			2019-10-28	
J	Bornfeldt, KE; Kramer, F; Batorsky, A; Choi, J; Hudkins, KL; Tontonoz, P; Alpers, CE; Kanter, JE				Bornfeldt, Karin E.; Kramer, Farah; Batorsky, Anna; Choi, Jinkuk; Hudkins, Kelly L.; Tontonoz, Peter; Alpers, Charles E.; Kanter, Jenny E.			A Novel Type 2 Diabetes Mouse Model of Combined Diabetic Kidney Disease and Atherosclerosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LOWERING LDL CHOLESTEROL; EPITHELIAL-CELLS; KNOCKOUT MICE; RENAL-DISEASE; NEPHROPATHY; PROGRESSION; EXPRESSION; INJURY; IDOL	Diabetic kidney disease and atherosclerotic disease are major causes of morbidity and mortality associated with type 2 diabetes (T2D), and diabetic kidney disease is a major cardiovascular risk factor. The black and tan, brachyury (BTBR) mouse strain with leptin deficiency (Lep(ob)) has emerged as one of the best models of human diabetic kidney disease. However, no T2D mouse model of combined diabetic kidney disease and atherosclerosis exists. Our goal was to generate such a model. To this end, the Low density lipoprotein (LDL) receptor was targeted for degradation via inducible degrader of the LDL receptor (IDOL) overexpression, using Liver-targeted adenoassociated virus serotype DJ/8 (AAV-DJ/8) in BTBR wild-type and BTBR Lep(ob) mice. Liver-targeted IDOL-AAV-DJ/8 increased plasma LDL cholesterol compared with the control enhanced green fluorescent protein AAV-DJ/8. IDOL-induced dyslipidemia caused formation of atherosclerotic lesions of an intermediate stage, which contained both macrophages and smooth muscle cells. BTBR Lep(ob) mice exhibited diabetic kidney disease. IDOL-induced dyslipidemia worsened albuminuria and glomerular macrophage accumulation but had no effect on mesangial expansion or podocyte numbers. Thus, by inducing hepatic degradation of the LDL receptor, we generated a T2D model of combined kidney disease and atherosclerosis. This model provides a new tool to study mechanisms, interactions, and treatment strategies of kidney disease and atherosclerosis in T2D.	[Bornfeldt, Karin E.; Kramer, Farah; Kanter, Jenny E.] Univ Washington, Sch Med, Dept Med, UW Med Diabet Inst, Seattle, WA 98195 USA; [Bornfeldt, Karin E.; Batorsky, Anna; Hudkins, Kelly L.; Alpers, Charles E.] Univ Washington, Sch Med, Dept Pathol, UW Med Diabet Inst, Seattle, WA 98195 USA; [Choi, Jinkuk; Tontonoz, Peter] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA; [Choi, Jinkuk; Tontonoz, Peter] Univ Calif Los Angeles, Dept Lab Med, Los Angeles, CA USA; [Choi, Jinkuk; Tontonoz, Peter] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90024 USA	Kanter, JE (reprint author), Univ Washington, Sch Med, UW Med Diabet Inst, Seattle, WA 98109 USA.	jenka@uw.edu		Kanter, Jenny/0000-0003-3212-772X	NORC [P30 DK035816]; American Diabetes Association grantAmerican Diabetes Association [1-16-IBS-15]; Diabetes Research Center [P30 DK017047]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL062887, P01HL092969, R01HL126028, R01HL066088, DK08339]; Diabetes Research Center's Vector and Transgenic Mouse core at the University of Washington [P30 DK017047]	Supported by NORC Pilot and Feasibility grant P30 DK035816 (J.E.K.) and in part by American Diabetes Association grant 1-16-IBS-15 (J.E.K.), Diabetes Research Center Pilot and Feasibility grant P30 DK017047 (J.E.K.), NIH grants R01HL062887 (K.E.B.), P01HL092969 (K.E.B.), R01HL126028 (K.E.B.), R01HL066088 (P.T.), and DK08339 (C.E.A. and K.L.H.). The adenoassociated viruses were produced through grant P30 DK017047 by the Diabetes Research Center's Vector and Transgenic Mouse core at the University of Washington.	Afkarian M, 2013, J AM SOC NEPHROL, V24, P302, DOI 10.1681/ASN.2012070718; Alpers CE, 2011, CURR OPIN NEPHROL HY, V20, P278, DOI 10.1097/MNH.0b013e3283451901; Andeen NK, 2015, KIDNEY INT, V88, P1099, DOI 10.1038/ki.2015.273; Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3; Bjorklund MM, 2014, CIRC RES, V114, P1684, DOI 10.1161/CIRCRESAHA.114.302937; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Calkin AC, 2014, CIRC RES, V115, P442, DOI 10.1161/CIRCRESAHA.115.304440; Calkin AC, 2011, P NATL ACAD SCI USA, V108, P20107, DOI 10.1073/pnas.1111589108; Chow F, 2004, KIDNEY INT, V65, P116, DOI 10.1111/j.1523-1755.2004.00367.x; Chow FY, 2006, KIDNEY INT, V69, P73, DOI 10.1038/sj.ki.5000014; Chow FY, 2004, NEPHROL DIAL TRANSPL, V19, P2987, DOI 10.1093/ndt/gfh441; de Boer IH, 2011, JAMA-J AM MED ASSOC, V305, P2532, DOI 10.1001/jama.2011.861; de Zeeuw D, 2015, LANCET DIABETES ENDO, V3, P687, DOI 10.1016/S2213-8587(15)00261-2; Falkevall A, 2017, CELL METAB, V25, P713, DOI 10.1016/j.cmet.2017.01.004; Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140-6736(12)61350-6; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Galkina E, 2006, J AM SOC NEPHROL, V17, P368, DOI 10.1681/ASN.2005080859; Grimm D, 2008, J VIROL, V82, P5887, DOI 10.1128/JVI.00254-08; Haynes R, 2014, J AM SOC NEPHROL, V25, P1825, DOI 10.1681/ASN.2013090965; Herman-Edelstein M, 2014, J LIPID RES, V55, P561, DOI 10.1194/jlr.P040501; Hudkins KL, 2010, J AM SOC NEPHROL, V21, P1533, DOI 10.1681/ASN.2009121290; Ibrahim S, 2016, CARDIOVASC RES, V110, P23, DOI 10.1093/cvr/cvw010; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Kang HM, 2015, NAT MED, V21, P37, DOI 10.1038/nm.3762; Kanter JE, 2012, P NATL ACAD SCI USA, V109, pE715, DOI 10.1073/pnas.1111600109; Lewis KE, 2004, CIRCULATION, V110, P540, DOI 10.1161/01.CIR.0000136819.93989.E1; MOORHEAD JF, 1982, LANCET, V2, P1309; Mozaffarian D, 2016, CIRCULATION, V133, P447, DOI 10.1161/CIR.0000000000000366; Nathan DM, 2013, DIABETES, V62, P3976, DOI 10.2337/db13-1093; Nguyen D, 2006, NEPHROLOGY, V11, P226, DOI 10.1111/j.1440-1797.2006.00576.x; O'Brien PD, 2015, NEUROBIOL DIS, V73, P348, DOI 10.1016/j.nbd.2014.10.015; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; Pichaiwong W, 2013, J AM SOC NEPHROL, V24, P1088, DOI 10.1681/ASN.2012050445; Reidy K, 2014, J CLIN INVEST, V124, P2333, DOI 10.1172/JCI72271; Renard CB, 2004, J CLIN INVEST, V114, P659, DOI 10.1172/JCI200417867; Ritz E, 2006, J AM SOC NEPHROL, V17, pS226, DOI 10.1681/ASN.2006080919; Russo GT, 2016, DIABETES CARE, V39, P2278, DOI 10.2337/dc16-1246; Seok SJ, 2013, NEPHROL DIAL TRANSPL, V28, P1700, DOI 10.1093/ndt/gfs555; Stoehr JP, 2000, DIABETES, V49, P1946, DOI 10.2337/diabetes.49.11.1946; Vallerie SN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158316; Perez-Gomez MV, 2016, EXPERT OPIN INV DRUG, V25, P1045, DOI 10.1080/13543784.2016.1196184; Venkatareddy M, 2014, J AM SOC NEPHROL, V25, P1118, DOI 10.1681/ASN.2013080859; Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974; Zhi ZW, 2014, INVEST OPHTH VIS SCI, V55, P1024, DOI 10.1167/iovs.13-12864	46	2	2	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					343	352		10.1016/j.ajpath.2017.10.012			10	Pathology	Pathology	FT6HY	WOS:000423256300009	29154962	Bronze, Green Published			2019-10-28	
J	Dai, YD; Liu, LL; Zeng, TT; Liang, JZ; Song, Y; Chen, K; Li, Y; Chen, LL; Zhu, YH; Li, JC; Li, Y; Xie, D; Yuan, YF; Guan, XY				Dai, Yongdong; Liu, Lulu; Zeng, Tingting; Liang, Jian-Zhong; Song, Ye; Chen, Kai; Li, Yan; Chen, Leilei; Zhu, Ying-Hui; Li, Jiangchao; Li, Yan; Xie, Dan; Yuan, Yun-Fei; Guan, Xin-Yuan			Overexpression of MUC13, a Poor Prognostic Predictor, Promotes Cell Growth by Activating Wnt Signaling in Hepatocellular Carcinoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BETA-CATENIN; GASTRIC-CANCER; SURFACE MUCIN; COLON-CANCER; EXPRESSION; PHOSPHORYLATION; PATHOGENESIS; PROGRESSION; METASTASIS; SUPPRESSES	Recently RNA sequencing revealed high mucin 13 (MUC13) expression in hepatocellular carcinoma (HCC) tissues. To understand the clinicopathologic significance of MUC13 in HCC, quantitative PCR and immunohistochemistry were used to detect its expression in paired tumor tissues and nontumor tissues. The oncoprotein role of MUC13 was determined by in vitro and in vivo assays. Overexpression of MUC13 was detected in 74 of 168 primary HCC cases (44%) and was significantly associated with tumor size (P = 0.027), stage (P = 0.006), encapsulation (P = 0.044), venous invasion (P = 0.024), and poor outcome (P = 0.004). Functional studies demonstrated MUC13 had strong oncogenic activity by promoting cell growth, colony formation, cell migration, and tumor formation in nude mice. The pro-oncogenic effect of MUC13 were effectively inhibited by RNA interference. MUC13 promoted cellular G(1)/S phase transition by activating Wnt signaling. Mechanistically, MUC13 bound to beta-catenin and increased its phosphorylation at Ser552 and Ser675 sites, which subsequently promoted nuclear translocation of beta-catenin and up-regulation of its downstream target genes Axing2, c-Myc, and CyclinDl. Knockdown of AKT with sh RNA in MUC13-overexpressing cells nullified the elevated phosphorylation of beta-catenin by MUC13. In clinical HCC samples, nuclear translocation of beta-catenin was significantly associated with MUC13 overexpression (P = 0.001). Overexpression of MUC13 plays a critical role in the development and progression of HCC by activating Wnt signaling.	[Dai, Yongdong; Liu, Lulu; Zeng, Tingting; Liang, Jian-Zhong; Song, Ye; Chen, Kai; Zhu, Ying-Hui; Li, Jiangchao; Li, Yan; Xie, Dan; Yuan, Yun-Fei; Guan, Xin-Yuan] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Dai, Yongdong] Sir Run Run Shaw Hosp, Coll Med, Dept Obstet & Gynecol, Assisted Reprod Unit, Zhejiang, Peoples R China; [Dai, Yongdong] Canc Biotherapy Ctr, Zhejiang, Peoples R China; [Liu, Lulu] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Li, Yan] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China; [Chen, Leilei; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Guan, XY (reprint author), Room 728,Second Bldg,651 E Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China.	xyguan@hku.hk	/A-3639-2009	/0000-0003-1874-9805; Chen, Polly Leilei/0000-0002-1987-3878	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402131, 81602128, 81472250, 81672357]; National Basic Research Program of ChinaNational Basic Research Program of China [2012CB967001]; China National Key Sci-Tech Special Project of Infectious Diseases [2013ZX10002-011-005]; Hong Kong Research Grant Council General Research Funds [HKU/7668/11M, 767313]; Hong Kong RGC Collaborative Research [C7038-14G, C7027-14G]; Hong Kong Theme-based Research Scheme fund [T12-403/11]	Supported by National Natural Science Foundation of China grants 81402131 (Y.D.), 81602128 (L.L.), 81472250 (X.-Y.G.), and 81672357 [Y.L. (from Sun Yat-sen University Cancer Center)]; National Basic Research Program of China grant 2012CB967001 (X.-Y.G.); China National Key Sci-Tech Special Project of Infectious Diseases grant 2013ZX10002-011-005 (X.-Y.G.); Hong Kong Research Grant Council General Research Funds grants HKU/7668/11M and 767313 (X.-Y.G.); Hong Kong RGC Collaborative Research grants C7038-14G and C7027-14G (X.-Y.G.); and Hong Kong Theme-based Research Scheme fund grant T12-403/11 (X.-Y.G.).	Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Chen LL, 2009, HEPATOLOGY, V50, P122, DOI 10.1002/hep.22933; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gupta BK, 2014, J GASTROENTEROL, V49, P1378, DOI 10.1007/s00535-013-0885-z; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; He L, 2017, MOL MED REP, V15, P3055, DOI 10.3892/mmr.2017.6347; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Khan S, 2017, ONCOGENE, V36, P491, DOI 10.1038/onc.2016.218; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee HJ, 2010, GASTROENTEROLOGY, V139, P213, DOI 10.1053/j.gastro.2010.04.008; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mantelli F, 2008, CURR OPIN ALLERGY CL, V8, P477, DOI 10.1097/ACI.0b013e32830e6b04; Nishii Y, 2015, INT J ONCOL, V46, P1781, DOI 10.3892/ijo.2015.2880; Packer LM, 2004, INT J ONCOL, V25, P1119; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Sheng YH, 2017, ONCOGENE, V36, P700, DOI 10.1038/onc.2016.241; Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x; Song YY, 2015, GASTROENTEROLOGY, V149, P1068, DOI 10.1053/j.gastro.2015.06.010; Suh YS, 2012, ANN SURG ONCOL, V19, P1240, DOI 10.1245/s10434-011-2125-1; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Wang H, 2015, J CANCER RES THER, V11, pC74, DOI 10.4103/0973-1482.163846; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Xu ZY, 2017, ONCOTARGET, V8, P7548, DOI 10.18632/oncotarget.13692; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020	34	3	3	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					378	391		10.1016/j.ajpath.2017.10.016			14	Pathology	Pathology	FT6HY	WOS:000423256300012	29174628	Other Gold			2019-10-28	
J	Li, CS; Zheng, Z; Jiang, J; Jiang, WL; Lee, K; Berthiaume, EA; Chen, EC; Culiat, CT; Zhou, YH; Zhang, XL; Ting, K; Soo, C				Li, Chenshuang; Zheng, Zhong; Jiang, Jie; Jiang, Wenlu; Lee, Kevin; Berthiaume, Emily A.; Chen, Eric C.; Culiat, Cymbeline T.; Zhou, Yan-Heng; Zhang, Xinli; Ting, Kang; Soo, Chia			Neural EGFL-Like 1 Regulates Cartilage Maturation through Runt-Related Transcription Factor 3-Mediated Indian Hedgehog Signaling	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CRANIOSYNOSTOSIS-ASSOCIATED GENE; PERIVASCULAR STEM-CELLS; CHONDROCYTE DIFFERENTIATION; SPINAL-FUSION; GROWTH-PLATE; CHONDROGENIC DIFFERENTIATION; NELL-1; PROLIFERATION; SOX9; OSTEOGENESIS	The pro-chondrogenic function of runt-related transcription factor 2 (Runx2) was previously considered to be dependent on direct binding with the promoter of Indian hedgehog (Ihh)-the major regulator of chondrocyte differentiation, proliferation, and maturation. The authors' previous studies identified neural EGFL like 1 (Nell-1) as a Runx2-responsive growth factor for chondrogenic differentiation and maturation. In this study, it was further revealed that the pro-chondrogenic activities of Nell-1 also rely on Ihh signaling, by showing: i) Nell-1 significantly elevated Ihh signal transduction; ii) Nell-1 deficiency markedly reduced Ihh activation in chondrocytes; and iii) Nell-1-stimulated chondrogenesis was significantly reduced by the specific hedgehog inhibitor cyclopamine. Importantly, the authors demonstrated that Nell-1-responsive Ihh signaling and chondrogenic differentiation extended to Runx2(-/-) models in vitro and in vivo. In Runx2(-/-) chondrocytes, Nell-1 stimulated the expression and signaltransduction of Runx3, another transcription factor required for complete chondrogenic differentiation and maturation. Furthermore, knocking down Runx3 in Runx2(-/-) chondrocytes abolished Nell-1's stimulation of Ihh-associated molecule expression, which validates Runx3 as a major mediator of Nell-1-stimulated Ihh activation. For the first time, the Runx2 -> Nell-1 -> Runx -> Ihh signaling cascade during chondrogenic differentiation and maturation has been identified as an alternative, but critical, pathway for Runx2 to function as a pro-chondrogenic molecule via Nell-1.	[Li, Chenshuang; Zheng, Zhong; Jiang, Wenlu; Lee, Kevin; Chen, Eric C.; Zhang, Xinli; Ting, Kang] UCLA, Sch Dent, Div Plast & Reconstruct Surg, Div Growth & Dev,Sect Orthodont, Los Angeles, CA USA; [Jiang, Jie; Ting, Kang; Soo, Chia] UCLA, Orthopaed Hosp, Res Ctr, Dept Orthopaed Surg, Los Angeles, CA USA; [Jiang, Jie; Ting, Kang; Soo, Chia] UCLA, David Geffen Sch Med, Los Angeles, CA USA; [Berthiaume, Emily A.] Univ Calif Los Angeles, Los Angeles, CA USA; [Li, Chenshuang; Zhou, Yan-Heng] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing, Peoples R China; [Jiang, Wenlu] Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Culiat, Cymbeline T.] Oak Ridge Natl Lab, Oak Ridge, TN USA	Ting, K (reprint author), UCLA, Sch Dent, CHS 30-177,10833 Conte Ave,Box 951668, Los Angeles, CA 90095 USA.; Soo, C (reprint author), 2641A,675 Charles E Young Dr,South, Los Angeles, CA 90095 USA.	kting@dentistry.ucla.edu; bsoo@ucla.edu	Li, Chenshuang/Q-2389-2019	Li, Chenshuang/0000-0001-6331-6983	NIH-National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR066782, R01AR068835, R01AR061399]; UCLA/NIH Clinical and Translational Science Institute [UL1TR000124]; National Aeronautical and Space AdministrationNational Aeronautics & Space Administration (NASA) [GA-2014-154]; International S&T Cooperation Program of China [2013DFB30360]	Supported by NIH-National Institute of Arthritis and Musculoskeletal and Skin Diseases grants R01AR066782 (K.T.), R01AR068835 (C.S.), and R01AR061399 (C.S.), UCLA/NIH Clinical and Translational Science Institute grant UL1TR000124, National Aeronautical and Space Administration grant GA-2014-154 (C.S.), and International S&T Cooperation Program of China grant 2013DFB30360 (Y.-H.Z.).	Aghaloo T, 2010, J ORAL MAXIL SURG, V68, P300, DOI 10.1016/j.joms.2009.03.066; AYDELOTTE MB, 1972, DEV BIOL, V28, P191, DOI 10.1016/0012-1606(72)90137-6; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bokui N, 2008, FEBS LETT, V582, P365, DOI 10.1016/j.febslet.2007.12.006; Bradley EW, 2010, MOL ENDOCRINOL, V24, P1581, DOI 10.1210/me.2010-0037; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Chen F, 2012, INT ORTHOP, V36, P2181, DOI 10.1007/s00264-012-1590-x; Chen HY, 2014, J BONE MINER RES, V29, P2653, DOI 10.1002/jbmr.2287; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Cowan CM, 2007, J BONE MINER RES, V22, P918, DOI 10.1359/JBMR.070312; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656; Goldring MB, 2012, THER ADV MUSCULOSKEL, V4, P269, DOI 10.1177/1759720X12448454; Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95; Gupta RK, 2010, NATURE, V464, P619, DOI 10.1038/nature08816; Huang WD, 2001, P NATL ACAD SCI USA, V98, P160, DOI 10.1073/pnas.011393998; James A, 2013, J BONE MINER RES, V28; James AW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8362; Kim EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055296; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753; Kwak J, 2013, TISSUE ENG PT A, V19, P426, DOI [10.1089/ten.tea.2012.0042, 10.1089/ten.TEA.2012.0042]; Lee JJ, 2016, P NATL ACAD SCI USA, V113, pE7545, DOI 10.1073/pnas.1616447113; Lee M, 2010, TISSUE ENG PT A, V16, P1791, DOI [10.1089/ten.tea.2009.0384, 10.1089/ten.TEA.2009.0384]; Lee S, 2015, STEM CELLS, V33, P3158, DOI 10.1002/stem.2103; Li CS, 2016, TISSUE ENG PT A, V22, P272, DOI [10.1089/ten.tea.2015.0250, 10.1089/ten.TEA.2015.0250]; Li CS, 2017, AM J PATHOL, V187, P963, DOI 10.1016/j.ajpath.2016.12.026; Li WM, 2010, TISSUE ENG PT A, V16, P2861, DOI 10.1089/ten.tea.2009.0550; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020; Machado MV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127991; Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044; Matsumoto T, 2010, J EXP MED, V207, P2207, DOI 10.1084/jem.20100321; Meng QX, 2013, EXP THER MED, V5, P1631, DOI 10.3892/etm.2013.1045; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Minina E, 2001, DEVELOPMENT, V128, P4523; Muto A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004671; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ochiai T, 2010, J DENT RES, V89, P349, DOI 10.1177/0022034510363078; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rinchik EM, 2002, P NATL ACAD SCI USA, V99, P844, DOI 10.1073/pnas.022628199; Sahar DE, 2005, DEV BIOL, V280, P344, DOI 10.1016/j.ydbio.2005.01.022; Shen J, 2016, AM J PATHOL, V186, P419, DOI 10.1016/j.ajpath.2015.10.011; Siu RK, 2012, TISSUE ENG PT A, V18, P252, DOI [10.1089/ten.tea.2011.0142, 10.1089/ten.TEA.2011.0142]; Soung DY, 2007, J BONE MINER RES, V22, P1260, DOI 10.1359/JBMR.070502; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Sugita D, 2013, SPINE, V38, pE1388, DOI 10.1097/BRS.0b013e3182a40489; Takarada T, 2013, J BONE MINER RES, V28, P2064, DOI 10.1002/jbmr.1945; Tan YY, 2013, DIGEST SURG, V30, P466, DOI 10.1159/000357823; Tavella S, 2004, J BONE MINER RES, V19, P1678, DOI 10.1359/JBMR.040706; Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80; Truong T, 2007, J BONE MINER RES, V22, P7, DOI 10.1359/JBMR.061012; Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Wigner NA, 2013, J CELL PHYSIOL, V228, P2232, DOI 10.1002/jcp.24396; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Xu C, 1996, ENDOCRINOLOGY, V137, P3557, DOI 10.1210/en.137.8.3557; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang X, 2010, J DENT RES, V89, P865, DOI 10.1177/0022034510376401; Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; Zhang XL, 2003, J BONE MINER RES, V18, P2126, DOI 10.1359/jbmr.2003.18.12.2126; Zhu S, 2011, OSTEOARTHR CARTILAGE, V19, P743, DOI 10.1016/j.joca.2011.02.015	68	2	3	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					392	403		10.1016/j.ajpath.2017.09.020			12	Pathology	Pathology	FT6HY	WOS:000423256300013	29137952	Bronze, Green Published			2019-10-28	
J	Bugueno, IM; Batool, F; Korah, L; Benkirane-Jessel, N; Huck, O				Bugueno, Isaac M.; Batool, Fareeha; Korah, Linda; Benkirane-Jessel, Nadia; Huck, Olivier			Porphyromonas gingivalis Differentially Modulates Apoptosome Apoptotic Peptidase Activating Factor 1 in Epithelial Cells and Fibroblasts	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEALTHY-SUBJECTS; RECEPTOR 4; IN-VITRO; PERIODONTITIS; INFLAMMATION; EXPRESSION; INFECTION; CYCLE; DEATH; INHIBITION	Porphyromonas gingivalis is able to invade and modulate host-immune response to promote its survival. This bacterium modulates the cell cycle and programed cell death, contributing to periodontal lesion worsening. Several molecular pathways have been identified as key triggers of apoptosis, including apoptosome apoptotic peptidase activating factor 1 (APAF-1). Apaf-1 and X-linked inhibitor of apoptosis protein (Xiap) mRNA were differentially expressed between gingival samples harvested from human healthy and chronic periodontitis tissues (Apaf-1, 19.2-fold; caspase-9, 14.5-fold; caspase-3, 6.8-fold; Xiap: 2.5-fold in chronic periodontitis) (P < 0.05), highlighting their potential role in periodontitis. An increased proteic expression of APAF-1 was also observed in a murine experimental periodontitis model induced by P. gingivalis-soaked ligatures. In vitro, it was observed that P. gingivalis targets APAF-1, XIAP, caspase-3, and caspase-9, to inhibit epithelial cell death at both mRNA and protein levels. Opposite effect was observed in fibroblasts in which P. gingivalis increased cell death and apoptosis. To assess if the observed effects were associated to APAF-1, epithelial cells and fibroblasts were transfected with siRNA targeting Apaf-1. Herein, we confirmed that APAF-1 is targeted by P. gingivalis in both cell types. This study identified APAF-1 apoptosome and XIAP as intracellular targets of P. gingivalis, contributing to the deterioration of periodontal lesion through an increased persistence of the bacteria within tissues and the subversion of host-immune response.	[Bugueno, Isaac M.; Batool, Fareeha; Korah, Linda; Benkirane-Jessel, Nadia; Huck, Olivier] Federat Med Translationnelle Strasbourg FMTS, INSERM Regenerat Nanomed 1260, Strasbourg, France; [Huck, Olivier] Univ Strasbourg, Fac Dent Surg Periodontol, Strasbourg, France	Huck, O (reprint author), Fac Dent, Periodontol, 8 Rue Sainte Elisabeth, F-67000 Strasbourg, France.	o.huck@unistra.fr		huck, olivier/0000-0002-7988-2290; Benkirane-Jessel, Nadia/0000-0003-3059-3559	INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); Faculty de Chirurgie Dentaire, Universite de Strasbourg	Supported by INSERM and Faculty de Chirurgie Dentaire, Universite de Strasbourg.	Al-Taweel FB, 2016, INFECT IMMUN, V84, P1966, DOI 10.1128/IAI.00111-16; Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1; Brozovic S, 2006, MICROBIOL-SGM, V152, P797, DOI 10.1099/mic.0.28472-0; Bugueno IM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154590; Cain K, 2003, DRUG METAB REV, V35, P337, DOI 10.1081/DMR-120026497; Chang MC, 2013, J PERIODONTAL RES, V48, P66, DOI 10.1111/j.1600-0765.2012.01504.x; Chowdhury I, 2006, CELL MOL BIOL LETT, V11, P506, DOI 10.2478/s11658-006-0041-3; Costalonga M, 2014, IMMUNOL LETT, V162, P22, DOI 10.1016/j.imlet.2014.08.017; Desta T, 2007, CELL MICROBIOL, V9, P2667, DOI 10.1111/j.1462-5822.2007.00987.x; Ebersole JL, 2016, MOL ORAL MICROBIOL, V31, P18, DOI 10.1111/omi.12121; Elkaim R, 2008, J DENT RES, V87, P932, DOI 10.1177/154405910808701010; Furuta N, 2009, INFECT IMMUN, V77, P4761, DOI 10.1128/IAI.00841-09; Graves DT, 2012, FRONT ORAL BIOL, V15, P117, DOI 10.1159/000329675; Greenberg DE, 2015, INFECT IMMUN, V83, P4277, DOI 10.1128/IAI.00778-15; Haider UC, 2011, CELL DEATH DIS, V2, pe197; Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785; Hajishengallis G, 2014, EUR J IMMUNOL, V44, P328, DOI 10.1002/eji.201344202; Hasegawa J, 1996, CANCER RES, V56, P1713; Ho AT, 2007, MOL CELL BIOL, V27, P5673, DOI 10.1128/MCB.00188-07; Huck O, 2015, INNATE IMMUN-LONDON, V21, P65, DOI 10.1177/1753425914523459; Ke XJ, 2016, MOL IMMUNOL, V77, P8, DOI 10.1016/j.molimm.2016.07.010; Kocgozlu L, 2009, J DENT RES, V88, P741, DOI 10.1177/0022034509341166; Kuboniwa M, 2008, MICROBES INFECT, V10, P122, DOI 10.1016/j.micinf.2007.10.011; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878; Ledgerwood EC, 2009, CLIN CANCER RES, V15, P420, DOI 10.1158/1078-0432.CCR-08-1172; Lee KI, 2016, APOPTOSIS, V21, P459, DOI 10.1007/s10495-016-1220-y; Lin WC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.81; Liu JR, 2014, ARCH ORAL BIOL, V59, P193, DOI 10.1016/j.archoralbio.2013.11.007; Liu JC, 2015, ARCH ORAL BIOL, V60, P1153, DOI 10.1016/j.archoralbio.2015.05.004; Mao S, 2007, CELL MICROBIOL, V9, P1997, DOI 10.1111/j.1462-5822.2007.00931.x; Murray DA, 2003, INFECT IMMUN, V71, P7232, DOI 10.1128/IAI.71.12.7232-7235.2003; Nakhjiri SF, 2001, FEMS MICROBIOL LETT, V200, P145, DOI 10.1016/S0378-1097(01)00213-0; Olsen I, 2016, J ORAL MICROBIOL, V8, DOI 10.3402/jom.v8.30385; Ong JDH, 2017, J LEUKOCYTE BIOL, V101, P863, DOI 10.1189/jlb.4MR0616-288R; Pan C, 2014, ORAL DIS, V20, P100, DOI 10.1111/odi.12081; Petersen PE, 2012, PERIODONTOL 2000, V60, P7, DOI 10.1111/j.1600-0757.2012.00452.x; Rahman MA, 2015, APOPTOSIS, V20, P1271, DOI 10.1007/s10495-015-1161-x; Ramage G, 2017, J PERIODONTAL RES, V52, P325, DOI 10.1111/jre.12395; Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rosado JA, 2006, J CELL PHYSIOL, V209, P142, DOI 10.1002/jcp.20715; Saadi-Thiers K, 2013, J PERIODONTOL, V84, P396, DOI 10.1902/jop.2012.110540; Sakanaka A, 2016, MICROB PATHOGENESIS, V94, P42, DOI 10.1016/j.micpath.2015.10.003; Sawa T, 1999, INFECT IMMUN, V67, P1450; Shaik-Dasthagirisaheb YB, 2015, J PERIODONTAL RES, V50, P89, DOI 10.1111/jre.12185; Shi CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167636; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Song B, 2017, ORAL DIS, V23, P609, DOI 10.1111/odi.12574; Soto C, 2016, J PERIODONTAL RES, V51, P518, DOI 10.1111/jre.12331; Stathopoulou PG, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-107; Takeuchi H, 2011, CELL MICROBIOL, V13, P677, DOI 10.1111/j.1462-5822.2010.01564.x; Tiwari B, 2015, CELL MICROBIOL, V17, P1653, DOI 10.1111/cmi.12462; Tucka J, 2014, ARTERIOSCL THROM VAS, V34, P2421, DOI 10.1161/ATVBAHA.114.304284; Vasilikos L, 2017, IMMUNOL CELL BIOL, V95, P160, DOI 10.1038/icb.2016.118; Wu Y, 2016, J DENT RES, V95, P460, DOI 10.1177/0022034515625962; Yamada S, 2017, HISTOL HISTOPATHOL, V32, P433, DOI 10.14670/HH-11-840; Yang X, 2014, J PERIODONTOL, V85, P1620, DOI 10.1902/jop.2014.140087; Yilmaz O, 2004, INFECT IMMUN, V72, P3743, DOI 10.1128/IAI.72.7.3743-3751.2004; Yilmaz Ozlem, 2008, Microbiology, V154, P2897, DOI 10.1099/mic.0.2008/021220-0; Yuan SJ, 2013, STRUCTURE, V21, P501, DOI 10.1016/j.str.2013.02.024; Zamaraev AV, 2015, CELL MOL LIFE SCI, V72, P505, DOI 10.1007/s00018-014-1757-2; Zhao PY, 2014, ACTA HISTOCHEM, V116, P1119, DOI 10.1016/j.acthis.2014.05.008	63	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					404	416		10.1016/j.ajpath.2017.10.014			13	Pathology	Pathology	FT6HY	WOS:000423256300014	29154960	Bronze			2019-10-28	
J	Murasawa, Y; Nakamura, H; Watanabe, K; Kanoh, H; Koyama, E; Fujii, S; Kimata, K; Zako, M; Yoneda, M; Isogai, Z				Murasawa, Yusuke; Nakamura, Hiroyuki; Watanabe, Ken; Kanoh, Hiroyuki; Koyama, Emiko; Fujii, Satoshi; Kimata, Koji; Zako, Masahiro; Yoneda, Masahiko; Isogai, Zenzo			The Versican G1 Fragment and Serum-Derived Hyaluronan-Associated Proteins Interact and Form a Complex in Granulation Tissue of Pressure Ulcers	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ALPHA-TRYPSIN INHIBITOR; HEAVY-CHAIN TRANSFER; ADAMTS METALLOPROTEASES; RHEUMATOID-ARTHRITIS; SHAP; BINDING; PROTEOGLYCANS; INFLAMMATION; PROTEOLYSIS; MATRIX	The hyaluronan (HA)-rich extracellular matrix plays dynamic roles during tissue remodeling. Versican and serum-derived HA-associated protein (SHAP), corresponding to the heavy chains of inter-a-trypsin inhibitor, are major HA-binding molecules in remodeling processes, such as wound healing. Versican G1 domain fragment (VG1F) is generated by proteolysis and is present in either remodeling tissues or the mature dermis. However, the macrocomplex formation of VG1F has not been clarified. Therefore, we examined the VG1F-containing macrocomplex in pressure ulcers characterized by chronic refractory wounds. VG1F colocalized with SHAP-HA in specific regions of the granulation tissue but not with fibrillin-1. A unique VG1F-SHAP-HA complex was isolated from granulation tissues using gel filtration chromatography and subsequent cesium chloride-gradient ultracentrifugation under dissociating conditions. Consistent with this molecular composition, recombinant versican G1, but not versican G3, interacted with the two heavy chains of inter-alpha-trypsin inhibitor. The addition of recombinant VG1 in fibroblast cultures enhanced VG1F-SHAP-HA complex deposition in the pericellular extracellular matrix. Comparison with other VG1F-containing macrocomplexes, including dermal VG1F aggregates, versican-bound microfibrils, and intact versican, highlighted the tissue-specific organization of HA-rich extracellular matrix formation containing versican and SHAP. The VG1F-SHAP-HA complex was specifically detected in the edematous granulation tissues of human pressure ulcers and in inflamed stages in a mouse model of moist would healing, suggesting that the complex provides an HA-rich matrix suitable for inflammatory reactions.	[Murasawa, Yusuke; Isogai, Zenzo] Natl Ctr Geriatr & Gerontol, Ctr Adv Med Dent & Oral Dis, Dept Adv Med, Obu, Japan; [Watanabe, Ken] Natl Ctr Geriatr & Gerontol, Ctr Adv Med Dent & Oral Dis, Dept Bone & Joint Dis, Obu, Japan; [Nakamura, Hiroyuki] Natl Ctr Geriatr & Gerontol, Ctr Adv Med Dent & Oral Dis, Dept Dent Regenerat Med, Obu, Japan; [Kanoh, Hiroyuki] Toki Municipal Hosp, Dept Dermatol, Toki, Gifu, Japan; [Koyama, Emiko] Kurashiki Heisei Hosp, Dept Nursing, Kurashiki, Okayama, Japan; [Fujii, Satoshi] Asahikawa Med Univ, Dept Lab Med, Asahikawa, Hokkaido, Japan; [Kimata, Koji] Aichi Med Univ, Res Creat Support Ctr, Nagakute, Aichi, Japan; [Zako, Masahiro; Yoneda, Masahiko; Isogai, Zenzo] Aichi Prefectural Univ, Sch Nursing & Hlth, Nagoya, Aichi, Japan	Isogai, Z (reprint author), Natl Ctr Geriatr & Gerontol, 7-430 Morioka Cho, Obu, Aichi 4748511, Japan.	zenzo@ncgg.go.jp	Watanabe, Ken/I-3960-2013; nakamura, hiroyuki/A-2953-2013	Watanabe, Ken/0000-0003-0664-3915; nakamura, hiroyuki/0000-0002-2524-3063	Ministry of Health, Labor, and Welfare of JapanMinistry of Health, Labour and Welfare, Japan [H19 Chojyu-012]; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25460217]; Mizutani Foundation; National Center for Geriatrics and Gerontology, Japan [23-15]	Supported by the Ministry of Health, Labor, and Welfare of Japan grants-in-aid H19 Chojyu-012 (Z.I., M.Y., and K.W.); the Japan Society for the Promotion of Science grant-in-aid for scientific research 25460217 (S.F. and Z.I.); the Mizutani Foundation, 2007, grant (Z.I.); and the National Center for Geriatrics and Gerontology, Japan, Research Funding for Longevity Sciences 23-15 (Z.I. and M.Y.).	Apte SS, 2009, J BIOL CHEM, V284, P31493, DOI 10.1074/jbc.R109.052340; Baranova NS, 2013, J BIOL CHEM, V288, P29642, DOI 10.1074/jbc.M113.477422; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Briggs DC, 2015, J BIOL CHEM, V290, P28708, DOI 10.1074/jbc.M115.669838; Carrino DA, 2011, GLYCOBIOLOGY, V21, P257, DOI 10.1093/glycob/cwq162; Chang MY, 2014, MATRIX BIOL, V35, P162, DOI 10.1016/j.matbio.2014.04.003; DAY AJ, 2002, J BIOL CHEM, V277, P4575; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; Dechert TA, 2006, WOUND REPAIR REGEN, V14, P252, DOI 10.1111/j.1743-6109.2006.00119.x; Eba H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052523; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337; Enomoto H, 2010, DEVELOPMENT, V137, P4029, DOI 10.1242/dev.050591; Evanko SP, 2012, MATRIX BIOL, V31, P90, DOI 10.1016/j.matbio.2011.10.004; Frenkel JS, 2014, INT WOUND J, V11, P159, DOI 10.1111/j.1742-481X.2012.01057.x; Frey H, 2013, FEBS J, V280, P2165, DOI 10.1111/febs.12145; Hasegawa K, 2007, J INVEST DERMATOL, V127, P1657, DOI 10.1038/sj.jid.5700754; Hatano S, 2012, GLYCOBIOLOGY, V22, P1268, DOI 10.1093/glycob/cws095; He H, 2013, J BIOL CHEM, V288, P25792, DOI 10.1074/jbc.M113.479584; HUANG L, 1993, J BIOL CHEM, V268, P26725; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 1996, CANCER RES, V56, P3902; Jiang DH, 2011, PHYSIOL REV, V91, P221, DOI 10.1152/physrev.00052.2009; Kern CB, 2007, DEV DYNAM, V236, P671, DOI 10.1002/dvdy.21059; Kern CB, 2006, DEV DYNAM, V235, P2238, DOI 10.1002/dvdy.20838; Kern CB, 2010, MATRIX BIOL, V29, P304, DOI 10.1016/j.matbio.2010.01.005; Kida D, 1999, J RHEUMATOL, V26, P1230; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kobayashi N, 2010, CANCER RES, V70, P7073, DOI 10.1158/0008-5472.CAN-09-4687; Korting HC, 2011, J EUR ACAD DERMATOL, V25, P130, DOI 10.1111/j.1468-3083.2010.03775.x; Koyama H, 2007, AM J PATHOL, V170, P1086, DOI 10.2353/ajpath.2007.060793; Lauer ME, 2013, J BIOL CHEM, V288, P205, DOI 10.1074/jbc.M112.403998; Lazaro JL, 2016, J WOUND CARE, V25, P277, DOI 10.12968/jowc.2016.25.5.277; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Matsumoto K, 2006, J BIOL CHEM, V281, P18257, DOI 10.1074/jbc.M510330200; McCulloch DR, 2009, DEV CELL, V17, P687, DOI 10.1016/j.devcel.2009.09.008; Merrilees MJ, 2016, J HISTOCHEM CYTOCHEM, V64, P353, DOI 10.1369/0022155416643913; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Moali C, 2009, EUR J DERMATOL, V19, P552, DOI 10.1684/ejd.2009.0770; Murasawa Y, 2013, J BIOL CHEM, V288, P29170, DOI 10.1074/jbc.M113.456947; Ohno-Jinno A, 2008, INVEST OPHTH VIS SCI, V49, P2870, DOI 10.1167/iovs.07-1488; OKSALA O, 1995, J HISTOCHEM CYTOCHEM, V43, P125, DOI 10.1177/43.2.7529785; Petrey AC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00101; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760; Sorrell JM, 1999, ANAT EMBRYOL, V199, P45, DOI 10.1007/s004290050208; Takahashi Y, 2012, BREAST CANCER-TOKYO, V19, P46, DOI 10.1007/s12282-011-0264-7; VANDEBERG JS, 1995, HUM PATHOL, V26, P195, DOI 10.1016/0046-8177(95)90037-3; Yager DR, 1999, WOUND REPAIR REGEN, V7, P433, DOI 10.1046/j.1524-475X.1999.00433.x; YEO TK, 1991, AM J PATHOL, V138, P1437; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoneda M, 2001, NEW FRONTIERS MED SC, P21; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2006, J BIOL CHEM, V281, P20303, DOI 10.1074/jbc.M506703200; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	59	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					432	449		10.1016/j.ajpath.2017.10.015			18	Pathology	Pathology	FT6HY	WOS:000423256300016	29169988	Bronze			2019-10-28	
J	Rudzitis-Auth, J; Nickels, RM; Menger, MD; Laschke, MW				Rudzitis-Auth, Jeannette; Nickels, Ruth M.; Menger, Michael D.; Laschke, Matthias W.			Inhibition of Cyclooxygenase-2 Suppresses the Recruitment of Endothelial Progenitor Cells in the Microvasculature of Endometriotic Lesions	AMERICAN JOURNAL OF PATHOLOGY			English	Article							IN-VIVO ANALYSIS; MOUSE MODEL; COX-2; ANGIOGENESIS; EXPRESSION; GROWTH; VASCULARIZATION; CELECOXIB; PATHWAY; SDF-1	The incorporation of endothelial progenitor cells (EPCs) into newly developing blood vessels contributes to the vascularization of endometriotic lesions. We analyzed whether cyclooxygenase (COX)-2 signaling regulates this vasculogenic process. Endometriotic lesions were surgically induced in irradiated FVB/N mice, which were reconstituted with bone marrow from FVB/N-TgN [Tie2/green fluorescent protein (GFP)] 287 Sato mice. The animals received beta-estradiol 17-valerate once a week and were treated daily with the selective COX-2 inhibitor parecoxib (25 mg/kg) or vehicle (control) for 7 and 28 days. Analyses involved the determination of lesion growth, cyst formation, homing of GFP(+)/Tie2(+) EPCs, numbers of circulating EPCs, vascularization, cell proliferation, apoptosis, and immune cell infiltration by means of high resolution ultrasonography, caliper measurements, flow cytometry, histologic analysis, and immunohistochemical analysis. In parecoxib-treated mice, blood circulating EPCs were higher, but numbers of recruited EPCs in endometriotic lesions were significantly lower when compared with controls. This finding was associated with an impaired early vascularization and stomal tissue growth as well as reduced glandular secretory activity of the lesions. Parecoxib-treated lesions further contained less proliferating and more apoptotic cells and exhibited Lower numbers of infiltrating macrophages and neutrophilic granulocytes. These findings demonstrate that the inhibition of COX-2 suppresses vasculogenesis in endometriotic lesions, which may contribute to an impaired lesion vascularization and growth.	[Rudzitis-Auth, Jeannette; Nickels, Ruth M.; Menger, Michael D.; Laschke, Matthias W.] Saarland Univ, Inst Clin & Expt Surg, D-66421 Homburg, Germany	Rudzitis-Auth, J (reprint author), Saarland Univ, Inst Clin & Expt Surg, D-66421 Homburg, Germany.	jeannette.rudzitis-auth@uks.eu			Deutsche Forschungsgemeinschaft (German Research Foundation)German Research Foundation (DFG) [LA 2682/3-1]	Supported by Deutsche Forschungsgemeinschaft (German Research Foundation) grant LA 2682/3-1 (M.W.L.).	Vertiz-Hernandez AA, 2015, REV INVEST CLIN, V67, P250; Becker CM, 2008, AM J PATHOL, V172, P534, DOI 10.2353/ajpath.2008.061244; Becker CM, 2011, AM J PATHOL, V178, P1782, DOI 10.1016/j.ajpath.2010.12.037; Chishima F, 2002, AM J REPROD IMMUNOL, V48, P50, DOI 10.1034/j.1600-0897.2002.01101.x; Churchman A, 2007, EUR J PHARMACOL, V573, P176, DOI 10.1016/j.ejphar.2007.06.057; Cobellis L, 2004, EUR J OBSTET GYN R B, V116, P100, DOI 10.1016/j.ejogrb.2004.02.007; Colleselli D, 2006, EXP CELL RES, V312, P2933, DOI 10.1016/j.yexcr.2006.05.021; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; Djokovic D, 2014, ACTA MEDICA PORT, V27, P489, DOI 10.20344/amp.5244; Fan LW, 2013, NEUROSCIENCE, V240, P27, DOI 10.1016/j.neuroscience.2013.02.041; Filippi I, 2016, REPROD SCI, V23, P492, DOI 10.1177/1933719115607978; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; Groothuis P. G., 2005, Angiogenesis, V8, P147, DOI 10.1007/s10456-005-9005-x; Hey-Cunningham Alison J, 2013, Front Biosci (Elite Ed), V5, P1033; Huang FY, 2013, INT J CLIN EXP PATHO, V6, P2129; Iezzi A, 2007, CURR PHARM DESIGN, V13, P1715, DOI 10.2174/138161207780831293; Jana S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163540; Kim YS, 2006, J ORTHOP RES, V24, P1756, DOI 10.1002/jor.20197; Laschke MW, 2012, HUM REPROD UPDATE, V18, P682, DOI 10.1093/humupd/dms026; Laschke MW, 2011, HUM REPROD UPDATE, V17, P628, DOI 10.1093/humupd/dmr023; Laschke MW, 2007, FERTIL STERIL, V87, P163, DOI 10.1016/j.fertnstert.2006.05.068; Laschke MW, 2007, HUM REPROD UPDATE, V13, P331, DOI 10.1093/humupd/dmm006; Laschke MW, 2011, AM J PATHOL, V178, P442, DOI 10.1016/j.ajpath.2010.11.037; Laschke MW, 2010, AM J PATHOL, V176, P585, DOI 10.2353/ajpath.2010.090617; Laschke MW, 2005, FERTIL STERIL, V84, P1199, DOI 10.1016/j.fertnstert.2005.05.010; Long QQ, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.055; Machado DE, 2010, FERTIL STERIL, V93, P2674, DOI 10.1016/j.fertnstert.2009.11.037; Matsuzaki S, 2001, FERTIL STERIL, V76, P712, DOI 10.1016/S0015-0282(01)02003-9; May K, 2008, Minerva Ginecol, V60, P245; McKinnon BD, 2015, TRENDS ENDOCRIN MET, V26, P1, DOI 10.1016/j.tem.2014.10.003; Mohn CE, 2005, P NATL ACAD SCI USA, V102, P6213, DOI 10.1073/pnas.0502136102; Muro S, 2000, ENDOCR J, V47, P429, DOI 10.1507/endocrj.47.429; Nasir L, 2004, J AM BOARD FAM PRACT, V17, pS43, DOI 10.3122/jabfm.17.suppl_1.S43; National Research Council, 2011, GUIDE CARE USE LAB A; Nenicu A, 2014, HUM REPROD, V29, P1011, DOI 10.1093/humrep/deu035; Nenicu A, 2017, BRIT J PHARMACOL, V174, P2623, DOI 10.1111/bph.13874; NISOLLE M, 1993, FERTIL STERIL, V59, P681; Olivares C, 2011, FERTIL STERIL, V96, P428, DOI 10.1016/j.fertnstert.2011.05.063; Olivares CN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152302; OOSTERLYNCK DJ, 1993, ARCH GYNECOL OBSTET, V253, P197, DOI 10.1007/BF02766646; Ota H, 2001, HUM REPROD, V16, P561, DOI 10.1093/humrep/16.3.561; Ozawa Y, 2006, FERTIL STERIL, V86, P1146, DOI 10.1016/j.fertnstert.2006.01.057; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rocha ALL, 2013, OBSTET GYNECOL INT, DOI 10.1155/2013/859619; Rudzitis-Auth J, 2013, HUM REPROD, V28, P1339, DOI 10.1093/humrep/det031; Rudzitis-Auth J, 2012, HUM REPROD, V27, P1735, DOI 10.1093/humrep/des095; Rudzitis-Auth J, 2016, AM J PATHOL, V186, P2129, DOI 10.1016/j.ajpath.2016.04.004; Sato A, 2017, J NEURO-ONCOL, V132, P231, DOI 10.1007/s11060-017-2380-5; Sauer JR, 2000, J INSECT PHYSIOL, V46, P1069, DOI 10.1016/S0022-1910(99)00210-3; Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00; Sui WW, 2014, ONCOL REP, V31, P2252, DOI 10.3892/or.2014.3093; Virani S, 2013, AM J REPROD IMMUNOL, V70, P386, DOI 10.1111/aji.12134; Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4; Wang LR, 2016, INT IMMUNOPHARMACOL, V31, P116, DOI 10.1016/j.intimp.2015.12.019; Yang RQ, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027826; Youn J, 2005, IMMUNOL LETT, V96, P219, DOI 10.1016/j.imlet.2004.08.010; Yu TT, 2016, MINI-REV MED CHEM, V16, P1230, DOI 10.2174/1389557516666160505115743	57	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					450	460		10.1016/j.ajpath.2017.10.013			11	Pathology	Pathology	FT6HY	WOS:000423256300017	29154961	Bronze			2019-10-28	
J	Zhu, R; Cheng, MT; Lu, TT; Yang, N; Ye, S; Pan, YH; Hong, T; Dang, SY; Zhang, W				Zhu, Rui; Cheng, Mengting; Lu, Tiantian; Yang, Ning; Ye, Shuai; Pan, Yi-Hsuan; Hong, Tao; Dang, Suying; Zhang, Wei			A Disintegrin and Metalloproteinase with Thrombospondin Motifs 18 Deficiency Leads to Visceral, Adiposity and Associated Metabolic Syndrome in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							I N-PROTEINASE; EXTRACELLULAR-MATRIX; BINDING-SITES; ADAMTS FAMILY; TISSUE; ADIPOGENESIS; CLONING; OBESITY; CELLS; DIFFERENTIATION	Visceral adiposity is of greater risk than obesity in s.c. adipose tissue for diabetes and cardiovascular disease. Its pathogenesis remains unclear, but it is associated with extracellular matrix (ECM) remodeling. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) are a family of secreted zinc dependent metalloproteinases that play crucial roles in development and various diseases because of their ECM remodeling activity. ADAMTS18 is an orphan ADAMTS whose function and substrate remain unclear. Herein, we showed that Adamts18 mRNA was abundantly expressed in visceral (gonadal) white adipose tissue (vWAT) during the early stage of development after birth. Adamts18 knockout (KO) mice showed increased body fat percentage and larger adipocyte size in vWAT relative to wild-type littermates. These findings may be partly attributed to ECM remodeling, especially increased expression of laminin 1 and adipokine thrombospondin 1 in vWAT. Attenuated extracellular signal regulated kinase 1 and 2 activity, along with increased expression of adipocyte-specific transcription factors peroxisome proliferator-activated receptor-gamma, CCAAT/enhancer binding protein 13, and marker gene Fabp4, was detected in vWAT of Adamts18 KO mice. Furthermore, Adamts18 KO mice showed early metabolic syndrome, including hyperlipidemia, blood glucose metabolic disorder, and hypertension. ADAMTS18 deficiency promotes atherosclerosis in apolipoprotein E-deficient mice. These results indicate a novel function of ADAMTS18 in vWAT development and associated metabolic disorders.	[Zhu, Rui; Cheng, Mengting; Lu, Tiantian; Yang, Ning; Ye, Shuai; Pan, Yi-Hsuan; Hong, Tao; Zhang, Wei] East China Normal Univ, Sch Life Sci, Key Lab Brain Funct Gen, Shanghai Key Lab Brain Funct Gen,Minist Educ, Shanghai, Peoples R China; [Dang, Suying] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai, Peoples R China; [Dang, Suying] Shanghai Res Ctr Model Organisms, Shanghai, Peoples R China	Zhang, W (reprint author), East China Normal Univ, 3663 N Zhongshan Rd, Shanghai 200062, Peoples R China.; Dang, SY (reprint author), Shanghai Jiao Tong Univ, Sch Med, 227 S Chongqing Rd, Shanghai 200025, Peoples R China.	suyingdang@shsmu.edu.cn; wzhang@sat.ecnu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570389, 81170481, 81200352]; Shanghai Municipal Natural Science Foundation [16ZR1423700]	Supported by the National Natural Science Foundation of China grants 81570389 and 81170481 (W.Z.) and 81200352 (S.D.) and the Shanghai Municipal Natural Science Foundation grant 16ZR1423700 (S.D.).	Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Aird AL, 2015, EXP GERONTOL, V63, P18, DOI 10.1016/j.exger.2015.01.044; Aldahmesh MA, 2013, HUM MUTAT, V34, P1195, DOI 10.1002/humu.22374; Aldahmesh MA, 2011, J MED GENET, V48, P597, DOI 10.1136/jmedgenet-2011-100306; Apte SS, 2009, J BIOL CHEM, V284, P31493, DOI 10.1074/jbc.R109.052340; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Ataca D, 2016, BIOL OPEN, V5, P1585, DOI 10.1242/bio.019711; Bauters D, 2017, MOL METAB, V6, P715, DOI 10.1016/j.molmet.2017.05.004; Bauters D, 2016, THROMB HAEMOSTASIS, V116, P694, DOI 10.1160/TH16-01-0015; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018; Brunet FG, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0281-9; Buyse J, 2015, STURKIE'S AVIAN PHYSIOLOGY, 6TH EDITION, P443; Chen J, 2013, J THROMB HAEMOST, V11, P1769, DOI 10.1111/jth.12299; Chen SZ, 2016, CELL DEATH DIFFER, V23, P1778, DOI 10.1038/cdd.2016.66; Choi CHJ, 2017, EXP CELL RES, V360, P6, DOI 10.1016/j.yexcr.2017.04.022; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; de Vries PS, 2017, DIABETOLOGIA, V60, P280, DOI 10.1007/s00125-016-4139-5; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hausman GJ, 1996, J ANIM SCI, V74, P2117; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559; Joe B, 2009, HUM MOL GENET, V18, P2825, DOI 10.1093/hmg/ddp218; Kelwick R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0676-3; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kloting N, 2014, REV ENDOCR METAB DIS, V15, P277, DOI 10.1007/s11154-014-9301-0; Kong P, 2013, AM J PHYSIOL-ENDOC M, V305, pE439, DOI 10.1152/ajpendo.00006.2013; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Leung YM, 2008, CHINESE J PHYSIOL, V51, P1; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Li Z, 2009, BLOOD, V113, P6051, DOI 10.1182/blood-2008-07-170571; Lijnen HR, 2008, CARDIOVASC RES, V78, P286, DOI 10.1093/cvr/cvm007; Lopez LM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.02.003; Lu TT, 2017, ONCOTARGET, V8, P18979, DOI 10.18632/oncotarget.14866; Luan Y, 2008, OSTEOARTHR CARTILAGE, V16, P1413, DOI 10.1016/j.joca.2008.03.017; Mariman ECM, 2010, CELL MOL LIFE SCI, V67, P1277, DOI 10.1007/s00018-010-0263-4; Nakajima I, 1998, DIFFERENTIATION, V63, P193, DOI 10.1046/j.1432-0436.1998.6340193.x; Nicholson AC, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-11; Peluso I, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-16; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Quilliot D, 2008, METABOLISM, V57, P555, DOI 10.1016/j.metabol.2007.11.020; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; ROSS R, 1976, SCIENCE, V193, P1094, DOI 10.1126/science.822515; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840; Volloch V, 2013, MATRIX BIOL, V32, P365, DOI 10.1016/j.matbio.2013.06.001; Xiong DH, 2009, AM J HUM GENET, V84, P388, DOI 10.1016/j.ajhg.2009.01.025; Xu SW, 2010, CYTOTECHNOLOGY, V62, P473, DOI 10.1007/s10616-010-9290-0; Zeidan A, 2005, J PHARMACOL EXP THER, V315, P1075, DOI 10.1124/jpet.105.091561	57	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					461	473		10.1016/j.ajpath.2017.10.020			13	Pathology	Pathology	FT6HY	WOS:000423256300018	29169989	Bronze			2019-10-28	
J	Kozakowska, M; Pietraszek-Gremplewicz, K; Ciesla, M; Seczynska, M; Bronisz-Budzynska, I; Podkalicka, P; Bukowska-Strakova, K; Loboda, A; Jozkowicz, A; Dulak, J				Kozakowska, Magdalena; Pietraszek-Gremplewicz, Katarzyna; Ciesla, Maciej; Seczynska, Marta; Bronisz-Budzynska, Iwona; Podkalicka, PauLina; Bukowska-Strakova, Karolina; Loboda, Agnieszka; Jozkowicz, Alicja; Dulak, Jozef			Lack of Heme Oxygenase-1 Induces Inflammatory Reaction and Proliferation of Muscle Satellite Cells after Cardiotoxin-Induced Skeletal Muscle Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							STEM-CELLS; MUSCULAR-DYSTROPHY; MOLECULAR-MECHANISMS; CROSS-TALK; REGENERATION; ADULT; MICE; MACROPHAGES; EXPRESSION; REPAIR	Heme oxygenase-1 (H0-1, Hmox1) regulates viability, proliferation, and differentiation of many cell types; hence, it may affect regeneration of injured skeletal muscle. Here, we injected cardiotoxin into gastrocnemius muscle of Hmox1(+)/(+) and Hmox1(-/-) animals and analyzed cellular response after muscle injury, focusing on muscle satellite cells (SCs), inflammatory reaction, fibrosis, and formation of new blood vessels. H0-1 is strongly induced after muscle injury, being expressed mostly in the infiltrating leukocytes (CD45(+) cells), including macrophages (F4/80(+) cells). Lack of H0-1 augments skeletal muscle injury, evidenced by increased creatinine kinase and lactate dehydrogenase, as well as expression of monocyte chemoattractant protein-1, IL-6, IL-10, and insulin-like growth factor-1. This, together with disturbed proportion of M1/M2 macrophages, accompanied by enhanced formation of arterioles, may be responsible for shift of Hmox1(-/-) myofiber size distribution toward larger one. Importantly, H0-1 deficient SCs are prone to activation and have higher proliferation on injury. This effect can be partially mimicked by stimulation of Hmox1(+/+) SCs with monocyte chemoattractant protein-1, IL-6, IL-1 beta, and is associated with increased MyoD expression, suggesting that Hmox1(-/-) SCs are shifted toward more differentiated myogenic population. However, multiple rounds of degeneration/regeneration in conditions of H0-1 deficiency may lead to exhaustion of SC pool, and the number of SCs is decreased in old Hmox1(-/-) mice. In summary, H0-1 modulates muscle repair mechanisms preventing its uncontrolled acceleration.	[Kozakowska, Magdalena; Pietraszek-Gremplewicz, Katarzyna; Ciesla, Maciej; Seczynska, Marta; Bronisz-Budzynska, Iwona; Podkalicka, PauLina; Bukowska-Strakova, Karolina; Loboda, Agnieszka; Jozkowicz, Alicja; Dulak, Jozef] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Gronostajowa 7, PL-30387 Krakow, Poland; [Bukowska-Strakova, Karolina] Jagiellonian Univ, Med Coll, Fac Med, Inst Pediat,Dept Clin Immunol, Krakow, Poland	Dulak, J (reprint author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Gronostajowa 7, PL-30387 Krakow, Poland.	jozef.dulak@uj.edu.pl		Pietraszek-Gremplewicz, Katarzyna/0000-0002-4081-5314; Ciesla, Maciej/0000-0002-8460-1991	National Science Center MAESTRO grant [2012/06/A/NZ1/00004]; Polish Ministry of Science and Higher Education Iuventus Plus [IP2012 025572]; Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland	Supported by National Science Center MAESTRO grant 2012/06/A/NZ1/00004 (J.D.) and Polish Ministry of Science and Higher Education Iuventus Plus grant IP2012 025572 (M.K.). Faculty of Biochemistry, Biophysics and Biotechnology of Jagiellonian University is a partner of the Leading National Research Center (KNOW) supported by the Ministry of Science and Higher Education.	Alfaro LAS, 2011, STEM CELLS, V29, P2030, DOI 10.1002/stem.759; Almada AE, 2016, NAT REV MOL CELL BIO, V17, P267, DOI 10.1038/nrm.2016.7; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bentzinger CF, 2013, EMBO REP, V14, P1062, DOI 10.1038/embor.2013.182; Blau HM, 2015, NAT MED, V21, P854, DOI 10.1038/nm.3918; Bosurgi L, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00062; Braun MC, 2001, MICROBES INFECT, V3, P99, DOI 10.1016/S1286-4579(00)01357-5; Brzoska E, 2011, VITAM HORM, V87, P239, DOI 10.1016/B978-0-12-386015-6.00031-7; Chazaud B, 2009, EXERC SPORT SCI REV, V37, P18, DOI 10.1097/JES.0b013e318190ebdb; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Ciesla M, 2016, CANCER RES, V76, P5707, DOI 10.1158/0008-5472.CAN-15-1883; Day K, 2010, DEV BIOL, V340, P330, DOI 10.1016/j.ydbio.2010.01.006; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dumon NA, 2015, DEVELOPMENT, V142, P1572, DOI 10.1242/dev.114223; Essig DA, 1997, AM J PHYSIOL-CELL PH, V272, pC59; Fry CS, 2015, NAT MED, V21, P76, DOI 10.1038/nm.3710; Georgantas RW, 2014, ARTHRITIS RHEUMATOL, V66, P1022, DOI 10.1002/art.38292; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Grochot-Przeczek A, 2012, CLIN SCI, V122, P93, DOI 10.1042/CS20110147; Gunther S, 2013, CELL STEM CELL, V13, P590, DOI 10.1016/j.stem.2013.07.016; Hnia K, 2007, AM J PATHOL, V170, P633, DOI 10.2353/ajpath.2007.060344; Ieronimakis N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010920; Jazwa A, 2013, CARDIOVASC RES, V97, P115, DOI 10.1093/cvr/cvs284; Jiang CH, 2014, DIS MODEL MECH, V7, P997, DOI 10.1242/dmm.015917; Kadi F, 2004, MUSCLE NERVE, V29, P120, DOI 10.1002/mus.10510; Karalaki M, 2009, IN VIVO, V23, P779; Ke BB, 2010, MOL THER, V18, P1019, DOI 10.1038/mt.2009.285; Keefe AC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8087; Kharraz Y, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/491497; Kozakowska M, 2015, J MUSCLE RES CELL M, V36, P377, DOI 10.1007/s10974-015-9438-9; Kozakowska M, 2014, ANTIOXID REDOX SIGN, V20, P1827, DOI 10.1089/ars.2013.5341; Kozakowska M, 2012, ANTIOXID REDOX SIGN, V16, P113, DOI 10.1089/ars.2011.3964; Lepper C, 2011, DEVELOPMENT, V138, P3639, DOI 10.1242/dev.067595; Liu N, 2012, J CLIN INVEST, V122, P2054, DOI 10.1172/JCI62656; Loboda A, 2008, ANTIOXID REDOX SIGN, V10, P1767, DOI 10.1089/ars.2008.2043; Loboda A, 2017, INT J BIOCHEM CELL B, V84, P46, DOI 10.1016/j.biocel.2017.01.003; Lu HY, 2011, FASEB J, V25, P3344, DOI 10.1096/fj.10-178939; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; Munoz-Canoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338; Murphy MM, 2011, DEVELOPMENT, V138, P3625, DOI 10.1242/dev.064162; Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Olguin HC, 2012, J CELL MOL MED, V16, P1013, DOI 10.1111/j.1582-4934.2011.01348.x; Orozco LD, 2007, CIRC RES, V100, P1703, DOI 10.1161/CIRCRESAHA.107.151720; Otis JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092363; Peake JM, 2015, EXERC IMMUNOL REV, V21, P8; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Pillon NJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE453, DOI 10.1152/ajpendo.00553.2012; Pittock ST, 2005, KIDNEY INT, V68, P611, DOI 10.1111/j.1523-1755.2005.00439.x; Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088; Ryter SW, 2016, TRANSL RES, V167, P7, DOI 10.1016/j.trsl.2015.06.011; Saclier M, 2013, FEBS J, V280, P4118, DOI 10.1111/febs.12166; Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587; Saxena S, 2010, ACTA PHYSIOL, V200, P249, DOI 10.1111/j.1748-1716.2010.02136.x; Sciorati C, 2016, CELL DEATH DIFFER, V23, P927, DOI 10.1038/cdd.2015.171; Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011; Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406; Shireman PK, 2007, J VASC SURG, V45, p48A, DOI 10.1016/j.jvs.2007.02.030; Shirernan PK, 2007, J LEUKOCYTE BIOL, V81, P775, DOI 10.1189/jlb.0506356; Snodgrass RG, 2013, J IMMUNOL, V191, P4337, DOI 10.4049/jimmunol.1300298; Soleimani VD, 2012, DEV CELL, V22, P1208, DOI 10.1016/j.devcel.2012.03.014; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Szade A, 2015, IUBMB LIFE, V67, P145, DOI 10.1002/iub.1358; Tidball JG, 2011, COMPR PHYSIOL, V1, P2029, DOI 10.1002/cphy.c100092; Vesely MJJ, 1999, FEBS LETT, V458, P257, DOI 10.1016/S0014-5793(99)01129-1; von Maltzahn J, 2013, P NATL ACAD SCI USA, V110, P16474, DOI 10.1073/pnas.1307680110; Winbanks CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073589; Yahiaoui L, 2008, J PHYSIOL-LONDON, V586, P3991, DOI 10.1113/jphysiol.2008.152090; Yin H, 2013, PHYSIOL REV, V93, P23, DOI 10.1152/physrev.00043.2011; Yuasa K, 2008, CELL STRUCT FUNCT, V33, P163, DOI 10.1247/csf.08022; Zarjou A, 2012, SEMIN NEPHROL, V32, P277, DOI 10.1016/j.semnephrol.2012.04.007; Zhang CC, 2013, J BIOL CHEM, V288, P1489, DOI 10.1074/jbc.M112.419788	72	7	7	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					491	506		10.1016/j.ajpath.2017.10.017			16	Pathology	Pathology	FT6HY	WOS:000423256300020	29169990	Bronze			2019-10-28	
J	Tada, M; Doi, H; Koyano, S; Kubota, S; Fukai, R; Hashiguchi, S; Hayashi, N; Kawamoto, Y; Kunii, M; Tanaka, K; Takahashi, K; Ogawa, Y; Iwata, R; Yamanaka, S; Takeuchi, H; Tanaka, F				Tada, Mikiko; Doi, Hiroshi; Koyano, Shigeru; Kubota, Shun; Fukai, Ryoko; Hashiguchi, Shunta; Hayashi, Noriko; Kawamoto, Yuko; Kunii, Misako; Tanaka, Kenichi; Takahashi, Keita; Ogawa, Yuki; Iwata, Ryo; Yamanaka, Shoji; Takeuchi, Hideyuki; Tanaka, Fumiaki			Matrin 3 Is a Component of Neuronal Cytoplasmic Inclusions of Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; DISTAL MYOPATHY; MUTATIONS; PROTEIN; TDP-43; ALS; REPEAT; PATHOLOGY; FUS	Mutations in the MATR3 gene have been identified as a cause of familial amyotrophic lateral sclerosis, but involvement of the matrin 3 (MATR3) protein in sporadic amyotrophic lateral sclerosis (SALS) pathology has not been fully assessed. We immunohistochemically analyzed MATR3 pathology in the spinal cords of SALS and control autopsy specimens. MATR3 immunostaining of the motor neuron nuclei revealed two distinct patterns: mild and strong staining. There were no differences in the ratio of mild versus strong nuclear staining between the SALS and control cases. MATR3-containing neuronal cytoplasmic inclusions (NCIs) were observed in 60%. of SALS cases. Most motor neurons with MATR3-positive NCIs exhibited a mild nuclear staining pattern. Although 16.8% of NCIs positive for transactivating response region DNA-binding protein 43 (TDP-43) were estimated as double-Labeled by MATR3, no MATR3-positive or TDP-43-negative NCIs were observed. Although a previous study found that MATR3-positive NCIs are present only in cases with C9orf72 hexanucleotide repeat expansion, ubiquitin-positive granular NCIs were not observed in the cerebellum, which have been reported as specific to C9orf72-related ALS. Six ALS cases were confirmed to be negative for the GGGGCC hexanucleotide. Our results reveal that MATR3 is a component of TDP-43-positive NCIs in motor neurons, even in SALS, and indicate the broader involvement of MATR3 in ALS pathology and the heterogeneity of TDP-43-positive NCIs.	[Tada, Mikiko; Doi, Hiroshi; Koyano, Shigeru; Kubota, Shun; Fukai, Ryoko; Hashiguchi, Shunta; Hayashi, Noriko; Kawamoto, Yuko; Kunii, Misako; Tanaka, Kenichi; Takahashi, Keita; Ogawa, Yuki; Iwata, Ryo; Takeuchi, Hideyuki; Tanaka, Fumiaki] Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Yokohama, Kanagawa, Japan; [Yamanaka, Shoji] Yokohama City Univ, Grad Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan	Tanaka, F (reprint author), Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	ftanaka@yokohama-cu.ac.jp			Japan Society for Promotion of the Sciences [15K18367]	Supported by Grant-in-Aid for Young Scientists (B) 15K18367 from the Japan Society for Promotion of the Sciences (M.T.).	Al-Sarraj S, 2011, ACTA NEUROPATHOL, V122, P691, DOI 10.1007/s00401-011-0911-2; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; Brettschneider J, 2013, ANN NEUROL, V74, P20, DOI 10.1002/ana.23937; Coelho MB, 2015, EMBO J, V34, P653, DOI 10.15252/embj.201489852; Da Cruz S, 2017, ACTA NEUROPATHOL, V134, P97, DOI 10.1007/s00401-017-1688-8; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Deng HX, 2011, NATURE, V477, P211, DOI 10.1038/nature10353; Deng HX, 2010, ANN NEUROL, V67, P739, DOI 10.1002/ana.22051; Gallego-Iradi MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142144; Hisada-Ishii S, 2007, BIOCHEM BIOPH RES CO, V354, P72, DOI 10.1016/j.bbrc.2006.12.191; Johnson JO, 2014, NAT NEUROSCI, V17, P664, DOI 10.1038/nn.3688; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Lin KP, 2015, NEUROBIOL AGING, V36, P2005, DOI 10.1016/j.neurobiolaging.2015.02.008; Ling SC, 2010, P NATL ACAD SCI USA, V107, P13318, DOI 10.1073/pnas.1008227107; Mackenzie IR, 2013, ACTA NEUROPATHOL, V126, P859, DOI 10.1007/s00401-013-1181-y; Marangi G, 2017, NEUROBIOL AGING, V49, DOI 10.1016/j.neurobiolaging.2016.09.023; Mori K, 2013, SCIENCE, V339, P1335, DOI 10.1126/science.1232927; Muller TJ, 2014, ANN NEUROL, V76, P669, DOI 10.1002/ana.24255; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Ogaki K, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.05.011; Rayaprolu S, 2016, J COMP NEUROL, V524, P2740, DOI 10.1002/cne.23986; Salton M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023882; Salton M, 2010, CELL CYCLE, V9, P1568, DOI 10.4161/cc.9.8.11298; Senderek J, 2009, AM J HUM GENET, V84, P511, DOI 10.1016/j.ajhg.2009.03.006; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Strong MJ, 2010, J NEUROL SCI, V288, P1, DOI 10.1016/j.jns.2009.09.029; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Zeitz MJ, 2009, J CELL BIOCHEM, V108, P125, DOI 10.1002/jcb.22234	30	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					507	514		10.1016/j.ajpath.2017.10.007			8	Pathology	Pathology	FT6HY	WOS:000423256300021	29128563				2019-10-28	
J	Peretti, AS; Dominguez, D; Grimes, MM; Hathaway, HJ; Prossnitz, ER; Rivera, MR; Wandinger-Ness, A; Kusewitt, DF; Hudson, LG				Peretti, Amanda S.; Dominguez, Dayna; Grimes, Martha M.; Hathaway, Helen J.; Prossnitz, Eric R.; Rivera, Melanie R.; Wandinger-Ness, Angela; Kusewitt, Donna F.; Hudson, Laurie G.			The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BREAST-CANCER CELLS; RHO-GTPASES; TAMOXIFEN SENSITIVITY; RAC1; INHIBITION; TUMORIGENESIS; METASTASIS; EXPRESSION; INVASION; PROMOTES	EpidemioLogic studies report improved breast cancer survival in women who receive ketorolac (Toradol) for postoperative pain relief compared with other analgesic agents. Ketorolac is a racemic drug. The S-enantiomer inhibits cyclooxygenases; R-ketorolac is a selective inhibitor of the small GTPases Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42), which are signaling molecules up-regulated during breast cancer progression and metastasis. The goal of this study was to determine whether R-ketorolac altered breast cancer development in the mouse mammary tumor virus-polyoma middle T-antigen model. Mice were administered ketorolac orally at 1 mg/kg twice daily to approximate the typical human dose. Mammary glands were analyzed for tumor number and immunohistochemical markers of proliferation and differentiation. R-ketorolac treatment significantly reduced mammary epithelial proliferation, based on Ki67 staining, and suppressed tumor development. Proliferative mammary epithelium from R-ketorolac treated mice displayed greater differentiation, based on significantly higher total E-cadherin and decreased keratin 5 staining than epithelium of placebo-treated mice. No differences were detected in estrogen receptor, progesterone receptor, beta-catenin, or vimentin expression between placebo and R-ketorolac treatment groups. These findings indicate that R-ketorolac treatment slows tumor progression in an aggressive model of breast cancer. R-ketorolac may thus represent a novel therapeutic approach for breast cancer prevention or treatment based on its pharmacologic activity as a Rac1 and Cdc42 inhibitor.	[Peretti, Amanda S.; Dominguez, Dayna; Grimes, Martha M.; Hudson, Laurie G.] Univ New Mexico, Coll Pharm, Dept Pharmaceut Sci, Albuquerque, NM 87131 USA; [Hathaway, Helen J.] Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; [Rivera, Melanie R.; Wandinger-Ness, Angela; Kusewitt, Donna F.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; [Prossnitz, Eric R.] Univ New Mexico, Sch Med, Dept Internal Med, Div Mol Med, Albuquerque, NM 87131 USA	Hudson, LG (reprint author), 1 Univ New Mexico, Dept Pharmaceut Sci, MSCO9 5360, Albuquerque, NM 87131 USA.	lhudson@salud.unm.edu	Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 CA170375, 1R21CA170375-01S]; University of New Mexico Comprehensive Cancer Center Animal Models and Human Tissue Repository Shared Resources - National Cancer Institute [2P30 CA118100];  [P50 GM085273]	Supported by NIH grants R21 CA170375 and 1R21CA170375-01S (L.G.H. and A.W.-N.) and Administrative Diversity Supplement to P50 GM085273 (M.R.R.). Additional support was provided by the University of New Mexico Comprehensive Cancer Center Animal Models and Human Tissue Repository Shared Resources funded by National Cancer Institute 2P30 CA118100 (principal investigator: C. Willman).	Alan Jamie K, 2013, Small GTPases, V4, P159, DOI 10.4161/sgtp.26530; Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003; Alshareeda AT, 2013, BREAST CANCER RES TR, V139, P23, DOI 10.1007/s10549-013-2518-x; Arias-Romero LE, 2013, EXPERT OPIN THER TAR, V17, P1263, DOI 10.1517/14728222.2013.828037; Carabaza A, 1996, J CLIN PHARMACOL, V36, P505, DOI 10.1002/j.1552-4604.1996.tb05040.x; Cardama GA, 2014, ANTI-CANCER AGENT ME, V14, P840, DOI 10.2174/18715206113136660334; Castillo-Pichardo L, 2014, TRANSL ONCOL, V7, P546, DOI 10.1016/j.tranon.2014.07.004; Chen HY, 2013, EMBO MOL MED, V5, P723, DOI 10.1002/emmm.201202140; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Flowers M, 2010, CARCINOGENESIS, V31, P1642, DOI 10.1093/carcin/bgq148; Forget P, 2014, BRIT J ANAESTH, V113, P82, DOI 10.1093/bja/aet464; Forget P, 2014, J CANCER RES CLIN, V140, P353, DOI 10.1007/s00432-013-1522-1; Forget P, 2010, ANESTH ANALG, V110, P1630, DOI 10.1213/ANE.0b013e3181d2ad07; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Gonzalez N, 2017, CELL SIGNAL, V30, P154, DOI 10.1016/j.cellsig.2016.12.002; Guo YN, 2015, CLIN CANCER RES, V21, P5064, DOI 10.1158/1078-0432.CCR-15-0461; Guo YN, 2015, MOL CANCER THER, V14, P2215, DOI 10.1158/1535-7163.MCT-15-0419; Hein AL, 2016, ONCOGENE, V35, P6319, DOI 10.1038/onc.2016.163; Hein SM, 2016, ONCOGENE, V35, P1461, DOI 10.1038/onc.2015.206; Inoue T, 2010, ONCOL REP, V24, P1487, DOI 10.3892/or_00001009; Jett MF, 1999, J PHARMACOL EXP THER, V288, P1288; Johansson J, 2013, ONCOGENE, V32, P5614, DOI 10.1038/onc.2013.322; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; KEAN WF, 1991, LANCET, V338, P1565, DOI 10.1016/0140-6736(91)92382-C; Kikuchi K, 2011, FEBS LETT, V585, P286, DOI 10.1016/j.febslet.2010.12.010; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Lam B Daniel, 2013, Small GTPases, V4, P78, DOI 10.4161/sgtp.23310; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Marjon NA, 2014, MOL CANCER RES, V12, P1644, DOI 10.1158/1541-7786.MCR-14-0128-T; Martin T. A., 2013, METASTATIC CANC CLIN, P135; Montalvo-Ortiz BL, 2012, J BIOL CHEM, V287, P13228, DOI 10.1074/jbc.M111.334524; Mroszczak E, 1996, J CLIN PHARMACOL, V36, P521, DOI 10.1002/j.1552-4604.1996.tb05042.x; National Research Council, 2011, GUIDE CARE USE LAB A; Oprea TI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142182; Orgaz Jose L, 2014, Small GTPases, V5, pe29019, DOI 10.4161/sgtp.29019; Pajic Marina, 2015, Small GTPases, V6, P123, DOI 10.4161/21541248.2014.973749; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Retsky M, 2013, CURR MED CHEM, V20, P4163; Retsky M, 2012, BREAST CANCER RES TR, V134, P881, DOI 10.1007/s10549-012-2094-5; Riching KM, 2015, INT J BIOCHEM CELL B, V59, P111, DOI [10.1016/j.bioce1.2014.11.007, 10.1016/j.biocel.2014.11.007]; Ridley AJ, 2015, CURR OPIN CELL BIOL, V36, P103, DOI 10.1016/j.ceb.2015.08.005; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shahi P, 2015, J BIOL CHEM, V290, P3803, DOI 10.1074/jbc.M114.611202; Smithers C, 2016, CELLS, V5, pE26; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Walker MK, 2012, TOXICOL APPL PHARM, V260, P65, DOI 10.1016/j.taap.2012.01.025; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Yan Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3164; Yasui H, 2005, BLOOD, V106, P706, DOI 10.1182/blood-2005-02-0838; Yoshida T, 2010, MOL CANCER THER, V9, P1657, DOI 10.1158/1535-7163.MCT-09-0906; Zakharchenko O, 2011, BREAST CANCER-BASIC, V5, P37, DOI 10.4137/BCBCR.S6263; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zuo Y, 2016, MOL ENDOCRINOL, V30, P278, DOI 10.1210/me.2015-1294	60	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					515	524		10.1016/j.ajpath.2017.10.018			10	Pathology	Pathology	FT6HY	WOS:000423256300022	29169987	Green Published			2019-10-28	
J	Pinol-Jurado, P; Gallardo, E; de Luna, N; Suarez-Calvet, X; Sanchez-Riera, C; Fernandez-Simon, E; Gomis, C; Illa, I; Diaz-Manera, J				Pinol-Jurado, Patricia; Gallardo, Eduard; de Luna, Noemi; Suarez-Calvet, Xavier; Sanchez-Riera, Carles; Fernandez-Simon, Esther; Gomis, Clara; Illa, Isabel; Diaz-Manera, Jordi			Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy (vol 187, pg 1814, 2017)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction														Fundacion Isabel Gemio; Mutua Madrilena de Seguros; Duchenne Parent Project Spain; Myositis Association of the United States fellowship; Fundacion Universia; Fundacio Caixa Enginyers;  [FEDER-ISCII PI15/01822];  [PI12/02291]	Supported by the Fundacion Isabel Gemio, Mutua Madrilena de Seguros, Duchenne Parent Project Spain, grants from Fondos FEDER-ISCII PI15/01822 (J.D.-M.) and PI12/02291 (E.G.), and a Myositis Association of the United States fellowship grant (X.S.-C.), Fundacion Universia (C.S.-R.), and Fundacio Caixa Enginyers (C.S.-R.).	Pinol-Jurado P, 2017, AM J PATHOL, V187, P1814, DOI 10.1016/j.ajpath.2017.04.011	1	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	FEB	2018	188	2					539	539		10.1016/j.ajpath.2017.11.002			1	Pathology	Pathology	FT6HY	WOS:000423256300024					2019-10-28	
J	Aldera, AP; Govender, D				Aldera, Alessandro Pietro; Govender, Dhirendra			Gene of the month: SDH	JOURNAL OF CLINICAL PATHOLOGY			English	Article							GASTROINTESTINAL STROMAL TUMORS; SUCCINATE-DEHYDROGENASE SUBUNIT; COMPLEX-II; GERMLINE MUTATIONS; FAMILIAL PHEOCHROMOCYTOMA; DEFICIENT GISTS; PARAGANGLIOMA; IGF1R	Succinate dehydrogenase (SDH) is a heterotetrameric nuclear encoded mitochondrial protein complex which plays a role in the citric acid cycle and the electron transfer chain. Germline mutations in SDHA are associated with Leigh syndrome. Mutations in SDHB, SDHC and SDHD are found in an increasing number of neoplasms, most notably paragangliomas and wild-type gastrointestinal stromal tumours. SDH deficiency in these tumours has important prognostic implications, and also provides a novel target for molecular therapy. In this article, we outline the structure and function of SDH and provide a summary of its role in various diseases.	[Govender, Dhirendra] Univ Cape Town, Div Anat Pathol, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Natl Hlth Lab Serv, Cape Town, South Africa	Govender, D (reprint author), Univ Cape Town, Div Anat Pathol, Fac Hlth Sci, ZA-7925 Cape Town, South Africa.	dhiren.govender@uct.ac.za					Agaimy A, 2009, LANGENBECK ARCH SURG, V394, P375, DOI 10.1007/s00423-008-0449-5; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Benn DE, 2006, J CLIN ENDOCR METAB, V91, P827, DOI 10.1210/jc.2005-1862; Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A; Brouwers FM, 2006, J CLIN ENDOCR METAB, V91, P4505, DOI 10.1210/jc.2006-0423; Chou A, 2012, MODERN PATHOL, V25, P1307, DOI 10.1038/modpathol.2012.77; Elbehti-Green A, 1998, GENE, V213, P133, DOI 10.1016/S0378-1119(98)00186-3; Favier J, 2015, NAT REV ENDOCRINOL, V11, P101, DOI 10.1038/nrendo.2014.188; Ghezzi D, 2009, NAT GENET, V41, P654, DOI 10.1038/ng.378; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Haller F, 2014, ENDOCR-RELAT CANCER, V21, P567, DOI 10.1530/ERC-14-0254; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Henderson A, 2009, FAM CANCER, V8, P257, DOI 10.1007/s10689-009-9234-z; Her YF, 2015, INT J ENDOCRINOL, V2015, P1; Hoekstra AS, 2013, BBA-BIOENERGETICS, V1827, P543, DOI 10.1016/j.bbabio.2012.11.005; Kang G, 2013, APMIS, V121, P938, DOI 10.1111/apm.12085; Lasota J, 2013, AM J SURG PATHOL, V37, P114, DOI 10.1097/PAS.0b013e3182613c86; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Levitas A, 2010, EUR J HUM GENET, V18, P1160, DOI 10.1038/ejhg.2010.83; Martin TPC, 2007, CLIN OTOLARYNGOL, V32, P7; McWhinney SR, 2007, NEW ENGL J MED, V357, P1054, DOI 10.1056/NEJMc071191; Miettinen M, 2013, AM J SURG PATHOL, V37, P234, DOI 10.1097/PAS.0b013e3182671178; Miettinen M, 2011, AM J SURG PATHOL, V35, P1712, DOI 10.1097/PAS.0b013e3182260752; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Ni Y, 2008, AM J HUM GENET, V83, P261, DOI 10.1016/j.ajhg.2008.07.011; Niemann S, 2000, NAT GENET, V26, P268; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Pasini B, 2008, EUR J HUM GENET, V16, P79, DOI 10.1038/sj.ejhg.5201904; Pawlu C, 2005, FAM CANCER, V4, P49, DOI 10.1007/s10689-004-4227-4; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Ricketts CJ, 2010, HUM MUTAT, V31, P41, DOI 10.1002/humu.21136; Rutter J, 2010, MITOCHONDRION, V10, P393, DOI 10.1016/j.mito.2010.03.001; Schiavi F, 2005, JAMA-J AM MED ASSOC, V294, P2057, DOI 10.1001/jama.294.16.2057; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sitkin Y, 2007, BBA-BIOENERGETICS, V1767, P143, DOI 10.1016/j.bbabio.2006.11.017; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Timmers HJLM, 2009, ENDOCR-RELAT CANCER, V16, P391, DOI 10.1677/ERC-08-0284; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Van Vranken JG, 2015, CRIT REV BIOCHEM MOL, V50, P168, DOI 10.3109/10409238.2014.990556; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Wang YM, 2015, WORLD J GASTROENTERO, V21, P2303, DOI 10.3748/wjg.v21.i8.2303; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Young AL, 2002, J CLIN ENDOCR METAB, V87, P4101, DOI 10.1210/jc.2002-020312	48	3	3	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					95	97		10.1136/jdinpath-2017-204677			3	Pathology	Pathology	FT1RA	WOS:000422912700001	29070651				2019-10-28	
J	Kuhn, E; Ayhan, A				Kuhn, Elisabetta; Ayhan, Ayse			Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TUBAL INTRAEPITHELIAL CARCINOMA; ENDOMETRIAL STROMAL SARCOMA; CLEAR-CELL CARCINOMA; SMOOTH-MUSCLE TUMORS; GRADE SEROUS CARCINOMA; OVARIAN MUCINOUS TUMORS; FEMALE GENITAL-TRACT; FACTOR-I EXPRESSION; DIFFERENTIAL-DIAGNOSIS; ENDOCERVICAL ADENOCARCINOMAS	Immunohistochemistry is a valuable adjunct in routine gynaecological pathology. The molecular revolution has redesigned knowledge of gynaecological cancers and refined histological classification. The direct consequence has been the progressive introduction of new immunostainings for diagnostic and classification purposes. Hence, we review the routine diagnostic use of immunohistochemistry in the field of gynaecological neoplasia. We reviewed the immunomarkers useful in gynaecological pathology according to literature revision, our personal experience and research findings. We discuss the application of immunohistochemistry to reach the most accurate diagnosis in morphologically equivocal cases of gynaecological pathology and present the appropriate panel of immunomarkers in the most common scenarios of gynaecological pathology. This short review provides an updated overview of the essential immunohistochemical markers currently used in the diagnostics of gynaecological malignancies along with their molecular rationale.	[Kuhn, Elisabetta] Arcispedale Santa Maria Nuova IRCCS, Pathol Unit, Reggio Emilia, Italy; [Kuhn, Elisabetta] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy; [Kuhn, Elisabetta] Univ Ferrara, Lab Technol Adv Therapies LTTA, Ferrara, Italy; [Ayhan, Ayse] Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka, Japan; [Ayhan, Ayse] Hiroshima Univ, Sch Med, Seirei Mikatahara Hosp, Hamamatsu, Shizuoka, Japan; [Ayhan, Ayse] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Kuhn, E (reprint author), Univ Ferrara, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy.; Kuhn, E (reprint author), Univ Ferrara, Lab Technol Adv Therapies Ctr, I-44121 Ferrara, Italy.; Ayhan, A (reprint author), Hamamatsu Univ Sch Med, Dept Pathol, Sch Med, Handayama 1-20-1, Hamamatsu, Shizuoka 4313192, Japan.	elisabettakuhn@hotmail.it; ayseayhanjp@gmail.com	AYHAN, Ayse/H-3331-2012	AYHAN, Ayse/0000-0003-0136-4271			Aggarwal N, 2012, INT J GYNECOL PATHOL, V31, P447, DOI 10.1097/PGP.0b013e318249285b; Ali RH, 2015, J CLIN PATHOL, V68, P325, DOI 10.1136/jclinpath-2014-202829; Allison KH, 2012, INT J GYNECOL PATHOL, V31, P159, DOI 10.1097/PGP.0b013e318226b376; Ayhan A, 2017, MODERN PATHOL, V30, P297, DOI 10.1038/modpathol.2016.160; Ayhan A, 2015, J PATHOL CLIN RES, V1, P186, DOI 10.1002/cjp2.22; Ayhan A, 2012, INT J GYNECOL CANCER, V22, P1310, DOI 10.1097/IGC.0b013e31826b5dcc; Bagby C, 2013, INT J GYNECOL PATHOL, V32, P433, DOI 10.1097/PGP.0b013e31826a6446; Broaddus RR, 2006, CANCER, V106, P87, DOI 10.1002/cncr.21560; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Cao DF, 2009, AM J SURG PATHOL, V33, P894, DOI 10.1097/PAS.0b013e318198177d; Carcangiu ML, 2010, INT J SURG PATHOL, V18, P21, DOI 10.1177/1066896909332117; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Chang A, 2012, AM J SURG PATHOL, V36, P1472, DOI 10.1097/PAS.0b013e318260cde7; Chang MC, 2009, INT J GYNECOL PATHOL, V28, P347, DOI 10.1097/PGP.0b013e318195da86; Chapel DB, 2017, AM J SURG PATHOL, V41, P1675, DOI 10.1097/PAS.0000000000000935; Chen LW, 2008, INT J GYNECOL PATHOL, V27, P326, DOI 10.1097/PGP.0b013e31815ea7f5; Chesnais AL, 2011, ANN PATHOL, V31, P152, DOI 10.1016/j.annpat.2011.02.008; Chiang S, 2014, SEMIN DIAGN PATHOL, V31, P205, DOI 10.1053/j.semdp.2014.03.002; Chu AY, 2005, MODERN PATHOL, V18, P105, DOI 10.1038/modpathol.3800259; Clark BZ, 2014, AM J CLIN PATHOL, V142, P64, DOI 10.1309/AJCP8H2VBDSCIOBF; Comin CE, 2007, AM J SURG PATHOL, V31, P1139, DOI 10.1097/PAS.0b013e318033e7a8; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; De Lott LB, 2005, ARCH PATHOL LAB MED, V129, P1100; Endris V, 2016, VIRCHOWS ARCH, V468, P697, DOI 10.1007/s00428-016-1919-8; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Ervine A, 2014, HISTOPATHOLOGY, V64, P840, DOI 10.1111/his.12332; Esheha GE, 2009, AM J SURG PATHOL, V33, P347, DOI 10.1097/PAS.0b013e3181908e24; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fadare O, 2015, PATHOLOGY, V47, P105, DOI 10.1097/PAT.0000000000000223; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fraggetta F, 2003, VIRCHOWS ARCH, V443, P782, DOI 10.1007/s00428-003-0910-3; Garg K, 2009, AM J SURG PATHOL, V33, P925, DOI 10.1097/PAS.0b013e318197a046; Graham AD, 2006, HISTOPATHOLOGY, V48, P764, DOI 10.1111/j.1365-2559.2006.02365.x; Groisman GM, 2004, INT J GYNECOL PATHOL, V23, P52, DOI 10.1097/01.pgp.0000101141.31270.a0; Guedes AC, 2007, INT J GYNECOL CANCER, V17, P1099, DOI 10.1111/j.1525-1438.2007.00899.x; Halbwedl I, 2005, GYNECOL ONCOL, V97, P582, DOI 10.1016/j.ygyno.2005.01.002; Herfs M, 2013, AM J SURG PATHOL, V37, P1311, DOI 10.1097/PAS.0b013e3182989ee2; Hirschowitz L, 2009, HISTOPATHOLOGY, V55, P478, DOI 10.1111/j.1365-2559.2009.03390.x; Houghton O, 2008, HISTOPATHOLOGY, V53, P156, DOI 10.1111/j.1365-2559.2008.03083.x; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Hu A, 2015, J CLIN PATHOL, V68, P522, DOI 10.1136/jclinpath-2015-202951; Huang EC, 2016, MODERN PATHOL, V29, P1501, DOI 10.1038/modpathol.2016.141; Hussein YR, 2016, AM J SURG PATHOL, V40, P404, DOI 10.1097/PAS.0000000000000556; Hwang HC, 2016, AM J SURG PATHOL, V40, P714, DOI 10.1097/PAS.0000000000000616; Hwang HC, 2016, AM J SURG PATHOL, V40, P120, DOI 10.1097/PAS.0000000000000529; Ito T, 2015, AM J CLIN PATHOL, V143, P830, DOI 10.1309/AJCPOATJ9L4GCGDA; Iwamoto M, 2015, HUM PATHOL, V46, P957, DOI 10.1016/j.humpath.2015.03.008; Joiner AK, 2015, INT J GYNECOL PATHOL, V34, P40, DOI 10.1097/PGP.0000000000000185; Karnezis AN, 2016, J PATHOL, V238, P389, DOI 10.1002/path.4633; Kawai T, 2016, J CLIN PATHOL, V69, P706, DOI 10.1136/jclinpath-2015-203211; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Konecny GE, 2017, J CLIN ONCOL, V35, P1151, DOI 10.1200/JCO.2016.72.0052; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kubba LA, 2008, MODERN PATHOL, V21, P485, DOI 10.1038/modpathol.2008.4; Kuhn E, 2016, MODERN PATHOL, V29, P1254, DOI 10.1038/modpathol.2016.101; Kuhn E, 2014, AM J SURG PATHOL, V38, P660, DOI 10.1097/PAS.0000000000000166; Kuhn E, 2013, EUR J CANCER, V49, P3839, DOI 10.1016/j.ejca.2013.08.011; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Kuhn E, 2012, INT J GYNECOL PATHOL, V31, P416, DOI 10.1097/PGP.0b013e31824cbeb4; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Kurman RJ, 2014, WHO CLASSIFICATION T; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee CH, 2014, MODERN PATHOL, V27, P751, DOI 10.1038/modpathol.2013.199; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Loureiro J, 2014, ARCH PATHOL LAB MED, V138, P453, DOI 10.5858/arpa.2012-0493-RA; Lu KH, 2007, J CLIN ONCOL, V25, P5158, DOI 10.1200/JCO.2007.10.8597; Maniar KP, 2015, AM J SURG PATHOL, V39, P1708, DOI 10.1097/PAS.0000000000000494; Mao TL, 2015, HISTOPATHOLOGY, V67, P474, DOI 10.1111/his.12664; Martins FC, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0526-8; McCluggage WG, 2013, HISTOPATHOLOGY, V62, P138, DOI 10.1111/his.12012; McCluggage WG, 2012, J CLIN PATHOL, V65, P596, DOI 10.1136/jcp.2010.085688; McCluggage WG, 2002, INT J GYNECOL PATHOL, V21, P11, DOI 10.1097/00004347-200201000-00003; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; McConechy MK, 2014, MODERN PATHOL, V27, P128, DOI 10.1038/modpathol.2013.107; Meisel JL, 2014, ANN ONCOL, V25, P2372, DOI 10.1093/annonc/mdu461; Mills AM, 2017, AM J SURG PATHOL, V41, P143, DOI 10.1097/PAS.0000000000000747; Miralpeix E, 2017, MODERN PATHOL, V30, P304, DOI 10.1038/modpathol.2016.168; Mittal K, 2001, HUM PATHOL, V32, P984, DOI 10.1053/hupa.2001.27113; Moh M, 2016, AM J SURG PATHOL, V40, P419, DOI 10.1097/PAS.0000000000000553; Monte NM, 2010, CANCER RES, V70, P6225, DOI 10.1158/0008-5472.CAN-10-0149; Mutter GL, 2014, CANCER RES, V74, P2796, DOI 10.1158/0008-5472.CAN-14-0108; Norimatsu Y, 2007, ANN DIAGN PATHOL, V11, P103, DOI 10.1016/j.anndiagpath.2006.06.009; O'Neill CJ, 2007, HISTOPATHOLOGY, V50, P851, DOI 10.1111/j.1365-2559.2007.02699.x; Oe S, 2010, INT J GYNECOL PATHOL, V29, P405, DOI 10.1097/PGP.0b013e3181d3261e; Oliva E, 2002, AM J SURG PATHOL, V26, P403, DOI 10.1097/00000478-200204000-00001; Oliva E, 2014, INT J GYNECOL PATHOL, V33, P374, DOI 10.1097/PGP.0000000000000141; Ordonez NG, 2013, MODERN PATHOL, V26, P553, DOI 10.1038/modpathol.2012.200; Ordonez NG, 2006, MODERN PATHOL, V19, P34, DOI 10.1038/modpathol.3800471; Paquette C, 2016, AM J SURG PATHOL, V40, P236, DOI 10.1097/PAS.0000000000000548; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Montiel DP, 2015, ANN DIAGN PATHOL, V19, P249, DOI 10.1016/j.anndiagpath.2015.05.004; Quick CM, 2012, AM J CLIN PATHOL, V138, P678, DOI 10.1309/AJCP8OMLT7KDWLMF; Ramalingam P, 2004, AM J SURG PATHOL, V28, P1499, DOI 10.1097/01.pas.0000138179.87957.32; Ramalingam P, 2017, HISTOPATHOLOGY, V70, P359, DOI 10.1111/his.13091; Ravishankar S, 2017, AM J SURG PATHOL, V41, P1, DOI 10.1097/PAS.0000000000000722; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Ryan P, 2012, CANCER-AM CANCER SOC, V118, P681, DOI 10.1002/cncr.26323; Saad RS, 2009, AM J CLIN PATHOL, V132, P531, DOI 10.1309/AJCP7E5ASGOENPFP; Segev Y, 2013, GYNECOL ONCOL, V130, P127, DOI 10.1016/j.ygyno.2013.03.027; Sehdev AS, 2010, MODERN PATHOL, V23, P844, DOI 10.1038/modpathol.2010.60; Shah VI, 2016, HISTOPATHOLOGY, V69, P894, DOI 10.1111/his.13019; Siami K, 2007, AM J SURG PATHOL, V31, P1759, DOI 10.1097/PAS.0b013e3181131e21; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Strickland S, 2016, INT J GYNECOL PATHOL, V35, P191, DOI 10.1097/PGP.0000000000000238; Suzuki S, 2014, PATHOL RES PRACT, V210, P130, DOI 10.1016/j.prp.2013.09.009; Tabrizi AD, 2010, INT J GYNECOL PATHOL, V29, P99, DOI 10.1097/PGP.0b013e3181bbbcc1; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Tipps AMP, 2011, ANN DIAGN PATHOL, V15, P376, DOI 10.1016/j.anndiagpath.2010.06.004; Tornillo L, 2004, J CLIN PATHOL, V57, P641, DOI 10.1136/jcp.2003.013615; TORNOS C, 1995, AM J SURG PATHOL, V19, P1343, DOI 10.1097/00000478-199512000-00001; Usubutun A, 2012, MODERN PATHOL, V25, P877, DOI 10.1038/modpathol.2011.220; Vang R, 2006, MODERN PATHOL, V19, P97, DOI 10.1038/modpathol.3800510; Vang R, 2006, MODERN PATHOL, V19, P1421, DOI 10.1038/modpathol.3800698; Vang R, 2006, AM J SURG PATHOL, V30, P1130; Vang R, 2012, INT J GYNECOL PATHOL, V31, P243, DOI 10.1097/PGP.0b013e31823b8831; Wang Y, 2017, J MOL DIAGN, V19, P57, DOI 10.1016/j.jmoldx.2016.07.008; Wani Y, 2008, HUM PATHOL, V39, P1072, DOI 10.1016/j.humpath.2007.07.019; Wu D, 2013, AM J CLIN PATHOL, V139, P39, DOI 10.1309/AJCPT94JVWIHBKRD; Yang EJ, 2015, MODERN PATHOL, V28, P994, DOI 10.1038/modpathol.2015.54; Young RH, 2002, HISTOPATHOLOGY, V41, P185, DOI 10.1046/j.1365-2559.2002.01462.x; Zhang LY, 2008, J MOL DIAGN, V10, P301, DOI 10.2353/jmoldx.2008.080062; Zhang PJ, 2009, INT J GYNECOL PATHOL, V28, P10, DOI 10.1097/PGP.0b013e3181804bc6; Zhu XQ, 2004, GYNECOL ONCOL, V92, P71, DOI 10.1016/j.ygyno.2003.08.038	130	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					98	109		10.1136/jclinpath-2017-204787			12	Pathology	Pathology	FT1RA	WOS:000422912700002	29183921	Bronze			2019-10-28	
J	Munro, MJ; Wickremesekera, SK; Peng, LF; Tan, ST; Itinteang, T				Munro, Matthew J.; Wickremesekera, Susrutha K.; Peng, Lifeng; Tan, Swee T.; Itinteang, Tinte			Cancer stem cells in colorectal cancer: a review	JOURNAL OF CLINICAL PATHOLOGY			English	Review							COLON-CANCER; ADENOMATOUS POLYPS; ADHESION MOLECULE; EXPRESSION; STAT3; CD44; SURVIVAL; MARKER; ABCG2; NANOG	Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men. Adenocarcinoma accounts for 90% of CRC cases. There has been accumulating evidence in support of the cancer stem cell (CSC) concept of cancer which proposes that CSCs are central in the initiation of cancer. CSCs have been the focus of study in a range of cancers, including CRC. This has led to the identification and understanding of genes involved in the induction and maintenance of pluripotency of stem cells, and markers for CSCs, including those investigated specifically in CRC. Knowledge of the expression pattern of CSCs in CRC has been increasing in recent years, revealing a heterogeneous population of cells within CRC ranging from pluripotent to differentiated cells, with overlapping and sometimes unique combinations of markers. This review summarises current literature on the understanding of CSCs in CRC, including evidence of the presence of CSC subpopulations, and the stem cell markers currently used to identify and localise these CSC subpopulations. Future research into this field may lead to improved methods for early detection of CRC, novel therapy and monitoring of treatment for CRC and other cancer types.	[Munro, Matthew J.; Wickremesekera, Susrutha K.; Tan, Swee T.; Itinteang, Tinte] Gillies McIndoe Res Inst, Wellington 6242, New Zealand; [Munro, Matthew J.; Peng, Lifeng] Victoria Univ Wellington, Sch Biol Sci, Wellington, New Zealand; [Munro, Matthew J.; Peng, Lifeng] Victoria Univ Wellington, Ctr Biodiscovery, Wellington, New Zealand; [Wickremesekera, Susrutha K.] Wellington Reg Hosp, Dept Gen Surg, Upper Gastrointestinal Hepatobiliary & Pancreat S, Wellington, New Zealand; [Tan, Swee T.] Hutt Hosp, Wellington Reg Plast Maxillofacial & Burns Unit, Wellington, New Zealand	Tan, ST (reprint author), Gillies McIndoe Res Inst, Wellington 6242, New Zealand.	swee.tan@gmri.org.nz		Munro, Matthew/0000-0003-1596-1667			Amini S, 2014, ANAT CELL BIOL, V47, P1, DOI 10.5115/acb.2014.47.1.1; Avery S, 2006, STEM CELLS DEV, V15, P729, DOI 10.1089/scd.2006.15.729; Baillie R, 2016, J CLIN PATHOL, V69, P742, DOI 10.1136/jclinpath-2015-203599; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Basakran NS, 2015, SAUDI MED J, V36, P273, DOI 10.15537/smj.2015.3.9622; Bradshaw A, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00021; COLE JW, 1963, CANCER, V16, P998, DOI 10.1002/1097-0142(196308)16:8<998::AID-CNCR2820160806>3.0.CO;2-C; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Forghanifard MM, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-6; Ghoncheh M, 2016, ANN GLOB HEALTH, V82, P726, DOI 10.1016/j.aogh.2016.10.004; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hadjimichael C, 2015, WORLD J STEM CELLS, V7, P1150, DOI 10.4252/wjsc.v7.i9.1150; Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458; Hao LL, 2016, J MOL HISTOL, V47, P117, DOI 10.1007/s10735-016-9656-5; Tuy HD, 2016, ONCOL LETT, V12, P2752, DOI 10.3892/ol.2016.4937; Hu J, 2017, ONCOTARGET, V8, P28463, DOI 10.18632/oncotarget.15307; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Khales SA, 2015, J CANCER RES CLIN, V141, P229, DOI 10.1007/s00432-014-1808-y; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; LANE N, 1963, CANCER, V16, P751, DOI 10.1002/1097-0142(196306)16:6<751::AID-CNCR2820160610>3.0.CO;2-0; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; Leng ZW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056082; Li Z, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-17; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X; Liu HG, 2010, ASIAN PAC J CANCER P, V11, P845; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; MASKENS AP, 1979, GASTROENTEROLOGY, V77, P1245; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Morath I, 2016, INT J BIOCHEM CELL B, V81, P166, DOI 10.1016/j.biocel.2016.09.009; Munro MJ, 2017, INTEGR CANC SCI THER, V4, P1, DOI [10.15761/ICST.1000231, DOI 10.15761/ICST.1000231]; Neo JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-134; Neumann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-518; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125; Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002; Ram R, 2017, FRONT SURG, V4, DOI 10.3389/fsurg.2017.00012; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schmohl JU, 2016, TOXINS, V8, DOI 10.3390/toxins8060165; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siegel RL, 2017, CA CANC J CLIN; Spitzner M, 2014, INT J CANCER, V134, P997, DOI 10.1002/ijc.28429; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talebi Ardeshir, 2015, Adv Biomed Res, V4, P234, DOI 10.4103/2277-9175.167958; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187; van der Wath RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073204; Wang XY, 2013, CANCER BIOMARK, V13, P81, DOI 10.3233/CBM-130344; Wen KM, 2013, CANCER LETT, V333, P56, DOI 10.1016/j.canlet.2013.01.009; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Xu X, 2015, CANCER LETT, V369, P50, DOI 10.1016/j.canlet.2015.08.018; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Yu HH, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00046; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yu XZ, 2011, CURR COLORECT CANC R, V7, P253, DOI 10.1007/s11888-011-0106-1; Zhang Shuchen, 2014, World J Stem Cells, V6, P305, DOI 10.4252/wjsc.v6.i3.305; Zheng SH, 2013, CYTOTECHNOLOGY, V65, P505, DOI 10.1007/s10616-012-9517-3	81	18	18	5	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					110	116		10.1136/jclinpath-2017-204739			7	Pathology	Pathology	FT1RA	WOS:000422912700003	28942428				2019-10-28	
J	Misyura, M; Sukhai, MA; Kulasignam, V; Zhang, T; Kamel-Reid, S; Stockley, TL				Misyura, Maksym; Sukhai, Mahadeo A.; Kulasignam, Vathany; Zhang, Tong; Kamel-Reid, Suzanne; Stockley, Tracy L.			Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ACUTE MYELOID-LEUKEMIA; DIGITAL PCR; MUTATIONS; AGREEMENT; SAMPLES; DNA	Aims A standard approach in test evaluation is to compare results of the assay in validation to results from previously validated methods. For quantitative molecular diagnostic assays, comparison of test values is often performed using simple linear regression and the coefficient of determination (R-2), using R-2 as the primary metric of assay agreement. However, the use of R-2 alone does not adequately quantify constant or proportional errors required for optimal test evaluation. More extensive statistical approaches, such as Bland-Altman and expanded interpretation of linear regression methods, can be used to more thoroughly compare data from quantitative molecular assays. Methods We present the application of Bland-Altman and linear regression statistical methods to evaluate quantitative outputs from next-generation sequencing assays (NGS). NGS-derived data sets from assay validation experiments were used to demonstrate the utility of the statistical methods. Results Both Bland-Altman and linear regression were able to detect the presence and magnitude of constant and proportional error in quantitative values of NGS data. Deming linear regression was used in the context of assay comparison studies, while simple linear regression was used to analyse serial dilution data. Bland-Altman statistical approach was also adapted to quantify assay accuracy, including constant and proportional errors, and precision where theoretical and empirical values were known. Conclusions The complementary application of the statistical methods described in this manuscript enables more extensive evaluation of performance characteristics of quantitative molecular assays, prior to implementation in the clinical molecular laboratory.	[Misyura, Maksym; Sukhai, Mahadeo A.; Zhang, Tong; Kamel-Reid, Suzanne; Stockley, Tracy L.] Univ Hlth Network, Adv Mol Diagnost Lab, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Kulasignam, Vathany] Univ Hlth Network, Dept Clin Biochem, Lab Med Program, Toronto, ON, Canada; [Kulasignam, Vathany; Kamel-Reid, Suzanne; Stockley, Tracy L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kamel-Reid, Suzanne] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Kamel-Reid, Suzanne; Stockley, Tracy L.] Univ Hlth Network, Dept Clin Lab Genet, Lab Med Program, Toronto, ON, Canada	Stockley, TL (reprint author), Univ Hlth Network, Dept Clin Lab Genet, Toronto Gen Hosp, 11-454 Eaton Wing, Toronto, ON, Canada.	Tracy.stockley@uhn.ca		Kamel-Reid, Suzanne/0000-0002-4386-0292; Stockley, Tracy/0000-0002-4476-9722	Princess Margaret Cancer FoundationUniversity of Toronto; Genome Canada (Genomic Applications Partnership Program)	The Princess Margaret Cancer Foundation and Genome Canada (Genomic Applications Partnership Program).	[Anonymous], 2006, 353412006 ISO; Batterham AM, 2004, SPORTSCIENCE, V8, P47; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; BLAND JM, 1986, LANCET, V1, P307; Borsu L, 2016, J MOL DIAGN, V18, P903, DOI 10.1016/j.jmoldx.2016.07.004; Budd JR, 2013, EP09A3 CLSI; Chen SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092192; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Dewitte K, 2002, CLIN CHEM, V48, P799; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Drandi D, 2015, J MOL DIAGN, V17, P652, DOI 10.1016/j.jmoldx.2015.05.007; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gale RE, 2008, BLOOD, V111, P2776, DOI 10.1182/blood-2007-08-109090; Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015; Hollis S, 1996, ANN CLIN BIOCHEM, V33, P1; Hopkins W. G., 2004, SPORTSCIENCE, V8; International Organization for Standardization, 151892003 ISO; Kluk MJ, 2016, J MOL DIAGN, V18, P507, DOI 10.1016/j.jmoldx.2016.02.003; Lamy PJ, 2015, J MOL DIAGN, V17, P366, DOI 10.1016/j.jmoldx.2015.02.004; Lewandowska MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117983; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lu MJ, 2016, INT J BIOSTAT, V12, DOI 10.1515/ijb-2015-0039; Ludbrook J, 2002, CLIN EXP PHARMACOL P, V29, P527, DOI 10.1046/j.1440-1681.2002.03686.x; Ludbrook J, 1997, CLIN EXP PHARMACOL P, V24, P193, DOI 10.1111/j.1440-1681.1997.tb01807.x; Ludbrook J, 2010, CLIN EXP PHARMACOL P, V37, P143, DOI 10.1111/j.1440-1681.2009.05288.x; Millson A, 2003, J MOL DIAGN, V5, P184, DOI 10.1016/S1525-1578(10)60471-0; Misyura M, 2016, J MOL DIAGN, V18, P842, DOI 10.1016/j.jmoldx.2016.06.004; O'Leary TJ, 2014, J MOL DIAGN, V16, P1, DOI 10.1016/j.jmoldx.2013.11.002; Simen BB, 2015, ARCH PATHOL LAB MED, V139, P508, DOI 10.5858/arpa.2013-0710-OA; Tsongalis GJ, 2006, CLIN CHIM ACTA, V369, P188, DOI 10.1016/j.cca.2006.02.044; WESTGARD JO, 1973, CLIN CHEM, V19, P49	32	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					117	124		10.1136/jclinpath-2017-204520			8	Pathology	Pathology	FT1RA	WOS:000422912700004	28747393	Green Published, Other Gold			2019-10-28	
J	Chng, TW; Gudi, M; Lim, SH; Li, HH; Tan, PH				Chng, Tze Wei; Gudi, Mihir; Lim, Swee Ho; Li, HuiHua; Tan, Puay Hoon			Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CYSTOSARCOMA-PHYLLODES; LOCAL RECURRENCE; FEATURES; DIFFERENTIATION; FIBROADENOMAS	Aims To validate the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large cohort of Singaporean patients, as previous validation studies were conducted on small numbers of patients. We also investigate the association of fibroadenomas and phyllodes tumours within a subset of our cohort. Methods Histological parameters, surgical margin status and clinical follow-up data of 259 women diagnosed with phyllodes tumours were analysed. Patients with concurrent malignant or premalignant disease were excluded from the validation to minimise confounding influences. Biostatistics modelling was performed, and the concordance between predicted and observed survivals was calculated. The association between fibroadenomas and phyllodes tumours was quantified in a subset of the women. Results Phyllodes tumours with higher number of mitoses, stromal overgrowth and positive surgical margins were found to be associated with greater risk of clinical recurrence. Patients with a higher nomogram score had a significantly higher risk of developing relapse. Forty out of 78 (51.3%) of the subset of phyllodes cases reviewed showed either fibroadenomalike areas within the phyllodes tumours or concurrent fibroadenomas in the ipsilateral or contralateral breast. Conclusions The Singapore nomogram is useful in predicting outcome in breast phyllodes tumours when applied to a large cohort of Singaporean women.	[Chng, Tze Wei] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore; [Gudi, Mihir] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Lim, Swee Ho] KK Womens & Childrens Hosp, Dept Breast Surg, Singapore, Singapore; [Li, HuiHua] Singapore Gen Hosp, Div Med, Singapore, Singapore; [Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, Acad 169856, Singapore, Singapore	Tan, PH (reprint author), Singapore Gen Hosp, Div Pathol, Acad 169856, Singapore, Singapore.	tan.puay.hoon@singhealth.com.sg					Barrio AV, 2007, ANN SURG ONCOL, V14, P2961, DOI 10.1245/s10434-007-9439-z; Ben hassouna J, 2006, AM J SURG, V192, P141, DOI 10.1016/j.amjsurg.2006.04.007; BERNSTEIN L, 1993, CANCER-AM CANCER SOC, V71, P3020, DOI 10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G; Chng TW, 2016, J CLIN PATHOL, V69, P1124, DOI 10.1136/jclinpath-2016-203951; Cristando C, 2017, PT USCAP ANN M 2017; Duman L, 2016, BREAST CARE, V11, P123, DOI 10.1159/000444377; FIKS A, 1981, VIRCHOWS ARCH A, V392, P1, DOI 10.1007/BF00430543; GRIMES MM, 1992, MODERN PATHOL, V5, P232; Hoda SA, 2014, ROSENS BREAST PATHOL; Jara-Lazaro AR, 2010, HISTOPATHOLOGY, V57, P220, DOI 10.1111/j.1365-2559.2010.03607.x; Lee AHS, 2007, HISTOPATHOLOGY, V51, P336, DOI 10.1111/j.1365-2559.2007.02786.x; McCarthy E, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140239; Mishra SP, 2013, INT J INFLAM, V2013, P1; Nishimura R, 2014, J CLIN PATHOL, V67, P748, DOI 10.1136/jclinpath-2014-202215; Pimiento JM, 2011, J AM COLL SURGEONS, V213, P537, DOI 10.1016/j.jamcollsurg.2011.07.012; Schnitt SJ, 2012, WHO CLASSIFICATION T; SMITH C Jr, 1951, Calif Med, V75, P101; Tan HN, 2012, EUR J RADIOL, V81, pE62, DOI 10.1016/j.ejrad.2011.01.085; Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; Tan PH, 2012, J CLIN PATHOL, V65, P69, DOI 10.1136/jclinpath-2011-200368; Tan WJ, 2016, J CLIN PATHOL, V69, P858, DOI 10.1136/jclinpath-2015-203590; Teo JY, 2012, ANZ J SURG, V82, P325, DOI 10.1111/j.1445-2197.2012.06045.x; Wei J, 2014, CHIN J CANCER, V33, P492, DOI 10.5732/cjc.014.10048; Yilmaz E, 2002, ACTA RADIOL, V43, P34, DOI 10.1080/028418502127347619	25	2	2	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					125	128		10.1136/jclinpath-2017-204568			4	Pathology	Pathology	FT1RA	WOS:000422912700005	28751520				2019-10-28	
J	Zombori, T; Furak, J; Nyari, T; Cserni, G; Tiszlavicz, L				Zombori, Tamas; Furak, Jozsef; Nyari, Tibor; Cserni, Gabor; Tiszlavicz, Laszlo			Evaluation of grading systems in stage I lung adenocarcinomas: a retrospective cohort study	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IASLC/ATS/ERS CLASSIFICATION; PULMONARY ADENOCARCINOMAS; INTERNATIONAL ASSOCIATION; INTEROBSERVER VARIABILITY; PROGNOSTIC-SIGNIFICANCE; INDEPENDENT PREDICTOR; HISTOLOGIC SUBTYPE; LIMITED RESECTION; IMPACT; FEATURES	Aims There is no internationally accepted grading system for lung adenocarcinoma despite the new WHO classification. The architectural grade, the Kadota grade and the Sica score were evaluated and compared with overall (OS) and disease-free survival (DFS). Methods Comprehensive histological subtyping was used in a series of resected stage I lung adenocarcinoma to identify subtypes of adenocarcinomas, the architectural grade, the Kadota grade, the Sica grade, the mitotic count, nuclear atypia, the presence of lymphovascular, vascular and airway propagation, necrosis, and micropapillary or solid growth pattern in any percentage. Statistical models fitted included Kaplan-Meier estimates and Cox proportional hazard regression models. Results 261 stage I adenocarcinomas were included. The 5-year survivals of different subtypes were as follows: lepidic (n=40, OS: 92.5%; DFS 91.6%), acinar (n=54, OS: 81.8%; DFS: 68.6%), papillary (n=49, OS: 73,6%; DFS: 61.0%), solid (n=95, OS: 64.7%; DFS: 57.8%) and micropapillary (n=23, OS: 34.8%; DFS: 33.5%). Concerning the architectural grade, there were significant differences between OS and DFS of low and intermediate (pOS=0.005, pDFS<0.001), low and high (pOS<0.001, pDFS<0.001) and intermediate and high grades (pOS=0.002, pDFS<0.001). Low-grade and intermediate grade tumours did not differ in survival according to Kadota grade and Sica grade. In the multivariable model, architectural grade was found to be an independent prognostic marker. In another model, architectural pattern proved to be superior to architectural grade. Conclusions Of the three grading systems compared, the architectural grade makes the best distinction between the outcome of low-grade, intermediate-grade and high-grade stage I adenocarcinomas.	[Zombori, Tamas; Cserni, Gabor; Tiszlavicz, Laszlo] Univ Szeged, Dept Pathol, Szeged, Hungary; [Furak, Jozsef] Univ Szeged, Dept Surg, Szeged, Hungary; [Nyari, Tibor] Univ Szeged, Dept Med Phys & Informat, Szeged, Hungary; [Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Szeged, Hungary	Zombori, T (reprint author), Univ Szeged, Dept Pathol, Fac Med, Allomas U 1, H-6725 Szeged, Hungary.	zomtam@gmail.com		Zombori, Tamas/0000-0002-0654-563X; Cserni, Gabor/0000-0003-1344-7744	National Research, Development and Innovation Office [GINOP-2.3.2-15-2016-00020]	The study was funded by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.	Ambrosini-Spaltro A, 2014, PATHOL RES PRACT, V210, P40, DOI 10.1016/j.prp.2013.09.016; Barletta JA, 2010, CANCER-AM CANCER SOC, V116, P659, DOI 10.1002/cncr.24831; Borezuk AC, 2009, AM J SURG PATHOL, V33, P462, DOI 10.1097/PAS.0b013e318190157c; Duhig EE, 2015, J THORAC ONCOL, V10, P673, DOI 10.1097/JTO.0000000000000446; Gu J, 2013, J SURG ONCOL, V107, P474, DOI 10.1002/jso.23259; Henwood A, 2003, BIOTECH HISTOCHEM, V78, P303, DOI 10.1080/10520290410001671335; Hirano H, 2014, ONCOL LETT, V8, P1107, DOI 10.3892/ol.2014.2284; Kadota K, 2012, MODERN PATHOL, V25, P1117, DOI 10.1038/modpathol.2012.58; Koike T, 2009, ANN THORAC SURG, V88, P1106, DOI 10.1016/j.athoracsur.2009.06.051; Lee HY, 2009, LUNG CANCER, V66, P379, DOI 10.1016/j.lungcan.2009.02.011; Lee MC, 2014, LUNG CANCER MANAG, V3, P245, DOI 10.2217/LMT.14.15; Lin DM, 2006, HISTOL HISTOPATHOL, V21, P627, DOI 10.14670/HH-21.627; Maeshima AM, 2010, J THORAC ONCOL, V5, P333, DOI 10.1097/JTO.0b013e3181c8cb95; Nakazato Y, 2013, J THORAC ONCOL, V8, P736, DOI 10.1097/JTO.0b013e318288dbd8; National Comprehensive Cancer Network, 2017, NCCN CLIN PRACT GUID, pv1; Nitadori J, 2013, JNCI-J NATL CANCER I, V105, P1212, DOI 10.1093/jnci/djt166; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Ozkan TA, 2016, SCAND J UROL, V50, P420, DOI 10.1080/21681805.2016.1206619; Sakurai H, 2004, AM J SURG PATHOL, V28, P198, DOI 10.1097/00000478-200402000-00007; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Sloane JP, 1999, VIRCHOWS ARCH, V434, P3; Travis WD, 2015, WHO CLASSIFICATION T, V7, P26; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsuta K, 2013, LUNG CANCER, V81, P371, DOI 10.1016/j.lungcan.2013.06.012; Ujiie H, 2015, J CLIN ONCOL, V33, P2877, DOI 10.1200/JCO.2015.60.9818; Vazquez M, 2009, LUNG CANCER, V64, P148, DOI 10.1016/j.lungcan.2008.08.009; Warth A, 2012, EUR RESPIR J, V40, P1221, DOI 10.1183/09031936.00219211; Yim J, 2007, MODERN PATHOL, V20, P233, DOI 10.1038/modpathol.3800734; Yokose T, 2000, LUNG CANCER, V29, P179, DOI 10.1016/S0169-5002(00)00103-3; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zhao Y, 2016, ANN SURG ONCOL, V23, P2099, DOI 10.1245/s10434-015-5043-9; Zhao ZR, 2015, LUNG CANCER, V90, P604, DOI 10.1016/j.lungcan.2015.10.026	33	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					135	140		10.1136/jclinpath-2016-204302			6	Pathology	Pathology	FT1RA	WOS:000422912700007	28747392	Green Accepted			2019-10-28	
J	Tsakanova, G; Stepanyan, A; Nahapetyan, K; Sim, RB; Arakelyan, A; Boyajyan, A				Tsakanova, Gohar; Stepanyan, Ani; Nahapetyan, Karen; Sim, Robert B.; Arakelyan, Arsen; Boyajyan, Anna			Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MANNAN-BINDING-LECTIN; PATTERN-RECOGNITION MOLECULES; MBL-ASSOCIATED PROTEIN; MASP2 HAPLOTYPES; ACTIVATION; INJURY; DISEASE; SYSTEM; SERUM; TRIAL	Aims The aim of the current study was to assess the proteolytic activities of collectin-bound MASP-1 and MASP-2 in the blood of patients with ischaemic stroke, as well as the association of their six genetic polymorphisms (rs3203210, rs28945070, rs28945073 in MASP1 gene and rs2273343, rs12711521, rs147270785 in MASP2 gene) with this pathology. Methods In total, 250 patients and 300 healthy subjects were involved in this study. MBL-associated serine protease (MASP)-1 and MASP-2 activities were measured using in-house developed immunofluorescent and enzyme-linked immunosorbent assays, respectively. Sequence specific primer PCR was used to study the association of MASP1 and MASP2 genetic polymorphisms with ischaemic stroke. Results The results obtained demonstrate that the activities of collectin-bound MASP-1 and MASP-2 in patients with ischaemic stroke are significantly higher than those in healthy subjects (p<0.001). According to the data obtained for genotyping, the rs3203210 polymorphism in the MASP1 gene and the rs147270785 polymorphism in the MASP2 gene are associated with ischaemic stroke (p<0.0001). Conclusions In conclusion we suggest that the complement lectin pathway serine proteases, MASP-1 and MASP-2, can be associated with ischaemic stroke development risk and may participate in pathological events leading to post-ischaemic brain damage. Moreover rs3203210 and rs147270785 single nucleotide polymorphisms in the MASP1 and MASP2 genes, respectively, are strongly associated with ischaemic stroke, and the minor rs3203210*C and rs147270785*A alleles of these polymorphisms may be considered as protective factors for ischameic stroke, at least in the Armenian population.	[Tsakanova, Gohar; Stepanyan, Ani; Arakelyan, Arsen; Boyajyan, Anna] Inst Mol Biol NAS RA, Yerevan, Armenia; [Nahapetyan, Karen] Armenia Republican Med Ctr, Dept Neurosurg, Yerevan, Armenia; [Sim, Robert B.] Univ Oxford, Dept Pharmacol, Oxford, England; [Sim, Robert B.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England	Tsakanova, G (reprint author), Inst Mol Biol NAS RA, Lab Human Genom & Immun, 7 Hasratyan St, Yerevan 0014, Armenia.	g_tsakanova@mb.sci.am	Sim, Bob/A-1354-2008	Sim, Bob/0000-0002-2855-7455	State Committee of Science MES RA [13YR-1F0028, 14AR-1f09, 16YR-1F011]	This work was supported by the State Committee of Science MES RA in the frames of 13YR-1F0028, 14AR-1f09 and 16YR-1F011 research projects.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; Ammitzboll CG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073317; Asgari E, 2014, FASEB J, V28, P3996, DOI 10.1096/fj.13-246306; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Boldt ABW, 2011, HUM IMMUNOL, V72, P753, DOI 10.1016/j.humimm.2011.05.015; Boldt ABW, 2011, CLIN IMMUNOL, V140, P63, DOI 10.1016/j.clim.2011.03.008; Boldt ABW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069054; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; de Rooij BJF, 2010, HEPATOLOGY, V52, P1100, DOI 10.1002/hep.23782; Degn SE, 2012, J IMMUNOL, V189, P3957, DOI 10.4049/jimmunol.1201736; Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; Elvington A, 2012, J IMMUNOL, V189, P4640, DOI 10.4049/jimmunol.1201904; Farrar CA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00341; Frauenknecht V, 2013, CLIN EXP IMMUNOL, V173, P112, DOI 10.1111/cei.12093; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Goeldner I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090979; Gorsuch WB, 2012, IMMUNOBIOLOGY, V217, P1026, DOI 10.1016/j.imbio.2012.07.024; Gregory LA, 2004, J BIOL CHEM, V279, P29391, DOI 10.1074/jbc.M402687200; Gulla KC, 2010, IMMUNOLOGY, V129, P482, DOI 10.1111/j.1365-2567.2009.03200.x; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; Hess K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035690; Hinkle Janice L, 2007, J Neurosci Nurs, V39, P285; Holmberg V, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-61; Horstman LL, 2011, FRONT BIOSCI-LANDMRK, V16, P2921, DOI 10.2741/3890; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Kamel H, 2012, ARCH NEUROL-CHICAGO, V69, P576, DOI 10.1001/archneurol.2011.3590; Krarup A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000623; Krarup A, 2008, BBA-PROTEINS PROTEOM, V1784, P1294, DOI 10.1016/j.bbapap.2008.03.020; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lalouel LM, 2002, AM J HYPERTENS, V15, P201, DOI 10.1016/S0895-7061(01)02285-3; Mayilyan KR, 2006, MOL IMMUNOL, V43, P1286, DOI 10.1016/j.molimm.2005.07.011; Mellbin LG, 2012, DIABETES CARE, V35, P911, DOI 10.2337/dc11-1642; Morgan B. Paul, 2000, Immunology Today, V21, P603; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Sambrook J, 2001, MOL CLONING LAB MANU; Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108; Selman L, 2012, IMMUNOBIOLOGY, V217, P851, DOI 10.1016/j.imbio.2011.12.008; Sirmaci A, 2010, AM J HUM GENET, V87, P679, DOI 10.1016/j.ajhg.2010.09.018; Sorensen R, 2005, SPRINGER SEMIN IMMUN, V27, P299, DOI 10.1007/s00281-005-0006-z; Stepanyan AS, 2014, BIOL J ARMENIA, V66, P66; Thiel S, 2000, J IMMUNOL, V165, P878, DOI 10.4049/jimmunol.165.2.878; Thiel S, 2007, GENES IMMUN, V8, P154, DOI 10.1038/sj.gene.6364373; Thiel S, 2012, CLIN EXP IMMUNOL, V169, P38, DOI 10.1111/j.1365-2249.2012.04584.x; Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005; Thiel S, 2009, J IMMUNOL, V182, P2939, DOI 10.4049/jimmunol.0802053; Tulio S, 2011, HUM IMMUNOL, V72, P912, DOI 10.1016/j.humimm.2011.06.016; Zhang M, 2013, INT J CARDIOL, V166, P499, DOI 10.1016/j.ijcard.2011.11.032	50	3	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					141	147		10.1136/jdinpath-2017-204403			7	Pathology	Pathology	FT1RA	WOS:000422912700008	28720568				2019-10-28	
J	Bao, JR; Clark, RB; Master, RN; Shier, KL; Eklund, LL				Bao, Jian R.; Clark, Richard B.; Master, Ronald N.; Shier, Kileen L.; Eklund, Lynn L.			Acid-fast bacterium detection and identification from paraffin-embedded tissues using a PCR-pyrosequencing method	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MYCOBACTERIUM-TUBERCULOSIS COMPLEX; REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; NUCLEIC-ACIDS; DIAGNOSIS; INFECTION; AMPLIFICATION; SMEAR; DNA	Aims Acid-fast bacterium (AFB) identification from formalin-fixed paraffin-embedded (FFPE) tissues is challenging and may not be readily available to the clinical laboratory. A method to detect and identify AFB from FFPE tissues using PCR and pyrosequencing (PCR-Seq) was developed and evaluated. Methods The method was validated using spiked cell-clotted paraffin blocks before use with patients' specimens. DNA was extracted from tissue sections, and a 16S rRNA gene fragment was amplified and a signature sequence was produced on a PyroMark ID system. Sequences were aligned to established databases for AFB identification. Additional tissue sections were stained and examined for AFB. Results Both sensitivity and specificity were 100% on spiked cell-clotted blocks without cross-reactivity with non-AFB. Of 302 FFPE tissues from patients, 116 (38%) were AFB-stain positive; 83 (72%) of these had AFB identified. The 21 AFB identified included Mycobacterium tuberculosis complex (14 cases), Mycobacterium leprae (3), Mycobacterium genavense (2), Mycobacterium marinum-ulcerans group (3) and 17 other AFB (61). Thirteen cases were AFB-stain indeterminate and 4 were positive by the PCR-Seq method. Of the AFB stainnegative cases, 167 were negative and 6 were positive by PCR-Seq. Conclusions The PCR-Seq method provided specific identification of various AFB species or complexes from FFPE tissues.	[Bao, Jian R.; Clark, Richard B.; Master, Ronald N.; Shier, Kileen L.; Eklund, Lynn L.] Quest Diagnost Nichols Inst Chantilly, Dept Microbiol, Chantilly, VA 20151 USA	Clark, RB (reprint author), Quest Diagnost Nichols Inst Chantilly, Dept Microbiol, Chantilly, VA 20151 USA.	richard.b.clark@questdiagnostics.com					Abu Al-Soud W, 2000, J CLIN MICROBIOL, V38, P345; AKANE A, 1994, J FORENSIC SCI, V39, P362; Atlas RM, 2011, MANUAL CLIN MICROBIO; Baba K, 2008, DIAGN MOL PATHOL, V17, P112, DOI 10.1097/PDM.0b013e31814ceac3; Bao JR, 2014, DIAGN MICR INFEC DIS, V79, P228, DOI 10.1016/j.diagmicrobio.2014.03.003; Bao JR, 2010, DIAGN MICR INFEC DIS, V67, P234, DOI 10.1016/j.diagmicrobio.2010.02.022; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; Billinger ME, 2009, EMERG INFECT DIS, V15, P1562, DOI 10.3201/eid1510.090196; Bonin S, 2010, VIRCHOWS ARCH, V457, P309, DOI 10.1007/s00428-010-0917-5; Chakravorty S, 2005, J CLIN MICROBIOL, V43, P4357, DOI 10.1128/JCM.43.9.4357-4362.2005; D'Andrea A, 2012, MEM I OSWALDO CRUZ, V107, P85, DOI 10.1590/S0074-02762012000100012; Dai JL, 2011, J CLIN MICROBIOL, V49, P2296, DOI 10.1128/JCM.02602-10; Field SK, 2004, CHEST, V126, P566, DOI 10.1378/chest.126.2.566; Fukunaga H, 2002, AM J RESP CRIT CARE, V166, P994, DOI 10.1164/rccm.2111028; Hillemann D, 2006, INT J TUBERC LUNG D, V10, P340; Johansen IS, 2006, DAN MED BULL, V53, P28; Kim YN, 2015, J MOL DIAGN, V17, P597, DOI 10.1016/j.jmoldx.2015.04.005; Lee HS, 2011, J MOL DIAGN, V13, P390, DOI 10.1016/j.jmoldx.2011.02.004; Lucas SB, 2013, CLIN TUBERCULOSIS; Luo RF, 2010, J CLIN MICROBIOL, V48, P2569, DOI 10.1128/JCM.02449-09; Martinez RM, 2014, CLIN MICROBIOLOGY NE, V36, P139; Patzina RA, 2002, LAB INVEST, V82, P1095, DOI 10.1097/01.LAB.0000024364.02049.B7; Seo AN, 2014, AM J CLIN PATHOL, V142, P384, DOI 10.1309/AJCP2QZRH4ZNPRDD; Smith MB, 2003, ARCH PATHOL LAB MED, V127, P554; Surat G, 2014, J CLIN PATHOL, V67, P1084, DOI 10.1136/jclinpath-2014-202307; White DA, 1999, AM J RESP CRIT CARE, V160, P1366, DOI 10.1164/ajrccm.160.4.9904003	26	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					148	153		10.1136/jdinpath-2016-204128			6	Pathology	Pathology	FT1RA	WOS:000422912700009	28735303				2019-10-28	
J	Hodgson, A; Xu, B; Satkunasivam, R; Downes, MR				Hodgson, Anjelica; Xu, Bin; Satkunasivam, Raj; Downes, Michelle R.			Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder	JOURNAL OF CLINICAL PATHOLOGY			English	Article							TRANSITIONAL-CELL-CARCINOMA; BACILLUS CALMETTE-GUERIN; UPPER URINARY-TRACT; RADICAL CYSTECTOMY; COLORECTAL-CANCER; NEOADJUVANT CHEMOTHERAPY; RECURRENCE; INDICATOR; SURVIVAL; INFILTRATION	Aims Inflammation and necrosis have been associated with prognosis in multiple epithelial malignancies. Our objective was to evaluate inflammation and necrosis in a cohort of patients with high-grade urothelial carcinomas of the bladder to determine their association with pathological parameters and their prognostic effect on relapse-free and disease-specific survival. Methods A retrospective cohort that underwent radical cystectomy for urothelial carcinomas (n=235) was evaluated for invasive front and central inflammation using the Klintrup-Makinen assessment method. Necrosis was scored using a four-point scale. The relationship of inflammation and necrosis with stage, nodal status, carcinoma in situ, tumour size, margin status and vascular space invasion and the impact on relapse-free and disease-specific survival were calculated using appropriate statistical tests. Results On multivariate analysis, invasive front inflammation (p=0.003) and necrosis (p=0.000) were independent predictors of relapse-free survival. Both invasive front inflammation (p=0.009) and necrosis (p=0.002) again were independent predictors of disease-specific survival. For pathological features, low invasive front inflammation was associated with lymphovascular space invasion (p=0.008), a positive soft tissue margin (p=0.028) and carcinoma in situ (p=0.042). Necrosis was statistically associated with tumours >3 (a) over cap (sic parts per thousand cm in size (p=0.013) and carcinoma in situ (p<0.001). Conclusions Necrosis and invasive front inflammation are additional histological variables with independent prognostic relevance in high-grade urothelial carcinoma of the bladder.	[Hodgson, Anjelica; Xu, Bin; Downes, Michelle R.] Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON, Canada; [Hodgson, Anjelica; Xu, Bin; Downes, Michelle R.] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; [Satkunasivam, Raj] Sunnybrook Hlth Sci Ctr, Div Urol, Dept Surg, Toronto, ON, Canada	Downes, MR (reprint author), Sunnybrook Hlth Sci Ctr, Anat Pathol, E417,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	michelle.downes@sunnybrook.ca		Xu, Bin/0000-0003-4638-9835			Alfred Witjes J, 2016, EUR UROL; American Cancer Society, KEY STAT BLADD CANC; Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; Bochner BH, 2006, J CLIN ONCOL, V24, P3967, DOI 10.1200/JCO.2005.05.3884; Cai T, 2006, ONCOL REP, V16, P329; Canadian Cancer Society, BLADD CANC STAT; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eustace A, 2013, RADIOTHER ONCOL, V108, P40, DOI 10.1016/j.radonc.2013.05.017; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FLAMM J, 1986, UROL INT, V41, P187, DOI 10.1159/000281194; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hiltzik D, 2006, CANCER-AM CANCER SOC, V106, P1286, DOI 10.1002/cncr.21739; Jallad S, 2014, BJU INT, V113, pE22, DOI 10.1111/bju.12334; JASS JR, 1987, LANCET, V1, P1303; KELLEY DR, 1986, J UROLOGY, V135, P268, DOI 10.1016/S0022-5347(17)45605-9; Khor LY, 2016, AM J SURG PATHOL, V40, P1224, DOI 10.1097/PAS.0000000000000690; Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062; Klintrup K, 2005, EUR J CANCER, V41, P2645, DOI 10.1016/j.ejca.2005.07.017; Lam JS, 2005, CANCER-AM CANCER SOC, V103, P2517, DOI 10.1002/cncr.21127; Langner C, 2006, J UROLOGY, V176, P910, DOI 10.1016/j.juro.2006.04.019; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; Madersbacher S, 2003, J CLIN ONCOL, V21, P690, DOI 10.1200/JCO.2003.05.101; MIHATSCH MJ, 1979, UROL RES, V7, P97; Offersen BV, 2002, BRIT J CANCER, V87, P1422, DOI 10.1038/sj.bjc.6600615; Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438; Ord JJ, 2007, J UROLOGY, V178, P677, DOI 10.1016/j.juro.2007.03.112; Pollheimer MJ, 2010, HUM PATHOL, V41, P1749, DOI 10.1016/j.humpath.2010.04.018; Quigley DA, 2015, MOL ONCOL, V9, P2054, DOI 10.1016/j.molonc.2015.10.003; Rink M, 2013, BJU INT, V111, pE30, DOI 10.1111/j.1464-410X.2012.11433.x; Roxburgh CSD, 2012, CANCER TREAT REV, V38, P451, DOI 10.1016/j.ctrv.2011.09.001; Roxburgh CSD, 2009, EUR J CANCER, V45, P2138, DOI 10.1016/j.ejca.2009.04.011; SCHELLHAMMER PF, 1986, J UROLOGY, V135, P261, DOI 10.1016/S0022-5347(17)45603-5; Sengupta S, 2005, CANCER-AM CANCER SOC, V104, P511, DOI 10.1002/cncr.21206; Shariat SF, 2008, EUR UROL, V54, P41, DOI 10.1016/j.eururo.2008.01.004; Shariat SF, 2006, CLIN CANCER RES, V12, P6663, DOI 10.1158/1078-0432.CCR-06-0372; Shariat SF, 2006, J UROLOGY, V176, P2414, DOI 10.1016/j.juro.2006.08.004; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Soave A, 2015, UROLOGY, V86, P92, DOI 10.1016/j.urology.2015.03.036; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Sternberg CN, 2007, UROLOGY, V69, P62, DOI 10.1016/j.urology.2006.10.041; Swinson DEB, 2002, LUNG CANCER, V37, P235, DOI 10.1016/S0169-5002(02)00172-1; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Vanselow B, 2000, OTOLARYNG HEAD NECK, V122, P856, DOI 10.1016/S0194-5998(00)70014-3; Virchow R., 1863, CELLULAR PATHOLOGY B; Wang HJ, 2016, HUM PATHOL, V53, P35, DOI 10.1016/j.humpath.2016.02.011; Zigeuner R, 2010, EUR UROL, V57, P575, DOI 10.1016/j.eururo.2009.11.035	48	4	4	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					154	160		10.1136/jclinpath-2017-204562			7	Pathology	Pathology	FT1RA	WOS:000422912700010	28768702				2019-10-28	
J	Yeong, J; Thike, AA; Ikeda, M; Lim, JCT; Lee, B; Nakamura, S; Iqbal, J; Tan, PH				Yeong, Joe; Thike, Aye Aye; Ikeda, Murasaki; Lim, Jeffrey Chun Tatt; Lee, Bernett; Nakamura, Seigo; Iqbal, Jabed; Tan, Puay Hoon			Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women	JOURNAL OF CLINICAL PATHOLOGY			English	Article							BASAL-LIKE; STROMAL FIBROBLASTS; DUCTAL CARCINOMA; GROWTH; OVEREXPRESSION; RECURRENCE	Background Triple-negative breast cancers (TNBCs) are defined by their lack of oestrogen receptor, progesterone receptor and epidermal growth factor receptor 2. Although heterogeneous, the majority are aggressive and treatment options are limited. Caveolin acts as tumour suppressor or promoter depending on the cancer type. Aim In this study, we aimed to determine if the expression levels of the candidate biomarker caveolin-1 on stromal or tumour cells were associated with clinicopathological parameters and disease outcomes in TNBCs from an ethnically diverse cohort of Asian women. Methods Tumour specimens from 699 women with TNBC were subjected to immunohistochemical analysis of the frequency and intensity of caveolin-1 expression in tumour and stromal cells. A subset of 141 tumour samples also underwent Nanostring measurement of CAV1 mRNA. Results were correlated with clinicopathological parameters and disease outcomes. Results Expression of caveolin-1 in stromal cells was observed in 14.4% of TNBC cases. TNBCs of the basal-like phenotype (85% of samples) were significantly more likely to exhibit stromal cell caveolin-1 expression (p=0.028), as were those with a trabecular growth pattern (p=0.007). Lack of stromal caveolin-1 expression in both TNBCs and those with the basal-like phenotype was significantly associated with worse overall survival (p=0.009 and p=0.026, respectively): accordingly, increasing mRNA levels of CAV1 in TNBC samples predicted better overall survival. Caveolin-1 expression on TNBC tumour cells was not associated with clinical outcome. Conclusion Stromal, but not tumoural, caveolin-1 expression is significantly associated with survival in Asian women with TNBC.	[Yeong, Joe; Thike, Aye Aye; Lim, Jeffrey Chun Tatt; Iqbal, Jabed; Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Level 7,Diagnost Tower, Singapore 169856, Singapore; [Yeong, Joe; Lee, Bernett] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Ikeda, Murasaki; Nakamura, Seigo] Showa Univ, Sch Med, Div Breast Surg Oncol, Tokyo, Japan	Tan, PH (reprint author), Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Level 7,Diagnost Tower, Singapore 169856, Singapore.	tan.puay.hoon@singhealth.com.sg		Yeong, Joe/0000-0002-6674-7153	A*STAR Biomedical Research CouncilAgency for Science Technology & Research (ASTAR); National Medical Research Council Stratified Medicine Programme Office [SMPO201302]; Singapore National Medical Research CouncilNational Medical Research Council, Singapore [NMRC/TA/0041/2015]	This article was funded by the A*STAR Biomedical Research Council, National Medical Research Council Stratified Medicine Programme Office (SMPO201302) awarded to Dr PH Tan. Dr J Iqbal is a recipient of the Transition Award from the Singapore National Medical Research Council (NMRC/TA/0041/2015).	Allred DC, 1998, MODERN PATHOL, V11, P155; Ayala G, 2013, J PATHOL, V231, P77, DOI 10.1002/path.4217; Bhoo-Pathy N, 2013, EUR J CANCER, V49, P703, DOI 10.1016/j.ejca.2012.09.014; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Casey TM, 2008, BREAST CANCER RES TR, V110, P39, DOI 10.1007/s10549-007-9684-7; Chen DL, 2014, FAM CANCER, V13, P449, DOI 10.1007/s10689-014-9707-6; Chen T, 2013, ASIAN PAC J CANCER P, V14, P4501, DOI 10.7314/APJCP.2013.14.8.4501; Cheng CL, 2015, BREAST CANCER RES TR, V151, P99, DOI 10.1007/s10549-015-3371-x; Cheung SY, 2015, BREAST CANCER RES TR, V152, P489, DOI 10.1007/s10549-015-3485-1; de Bruin MA, 2012, FAM CANCER, V11, P429, DOI 10.1007/s10689-012-9531-9; El-Gendi SM, 2012, PATHOL ONCOL RES, V18, P459, DOI 10.1007/s12253-011-9469-5; Elsheikh SE, 2008, BRIT J CANCER, V99, P327, DOI 10.1038/sj.bjc.6604463; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Felsenstein KM, 2016, ACS CHEM BIOL, V11, P139, DOI 10.1021/acschembio.5b00577; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freeman MR, 2012, ADV EXP MED BIOL, V729, P95, DOI 10.1007/978-1-4614-1222-9_7; Fu P, 2017, ONCOTARGETS THER, V10, P819, DOI 10.2147/OTT.S123912; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Hammond ME, 2010, ARCH PATHOL LAB MED, V134, P1543; Kim H, 2013, J BREAST CANCER, V16, P357, DOI 10.4048/jbc.2013.16.4.357; Koo JS, 2011, TUMOR BIOL, V32, P787, DOI 10.1007/s13277-011-0181-6; Leong SPL, 2010, WORLD J SURG, V34, P2308, DOI 10.1007/s00268-010-0683-1; Li X., 2017, WIEN KLIN WOCHENSCHR, P1; Li XA, 2005, TRENDS CARDIOVAS MED, V15, P92, DOI 10.1016/j.tcm.2005.04.001; Martinez-Outschoorn UE, 2015, NAT REV CANCER, V15, P225, DOI 10.1038/nrc3915; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048; Matsumoto H, 2015, J CLIN PATHOL, V68, P506, DOI 10.1136/jclinpath-2015-202944; Mercier I, 2008, CANCER BIOL THER, V7, P1212, DOI 10.4161/cbt.7.8.6220; Mohammed DA, 2017, J EGYPT NATL CANC I, V29; Moon H, 2014, ONCOGENE, V33, P3561, DOI 10.1038/onc.2013.315; Nwosu ZC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0558-7; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Panic A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41138; Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x; Popovska SL, 2014, J BIOMED CLIN RES, V7, P8, DOI DOI 10.1515/JBCR-2015-0118; Ren MJ, 2014, VIRCHOWS ARCH, V465, P291, DOI 10.1007/s00428-014-1614-6; RonnovJessen L, 1996, PHYSIOL REV, V76, P69; Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371; Shen XJ, 2015, INT J BIOL SCI, V11, P370, DOI 10.7150/ijbs.10666; Simpkins SA, 2012, J PATHOL, V227, P490, DOI 10.1002/path.4034; Sloan EK, 2009, AM J PATHOL, V174, P2035, DOI 10.2353/ajpath.2009.080924; Stahlhut M, 2000, EXP CELL RES, V261, P111, DOI 10.1006/excr.2000.4960; Sung HN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv107; Thike AA, 2014, MODERN PATHOL, V27, P352, DOI 10.1038/modpathol.2013.145; Thike AA, 2013, J CLIN PATHOL, V66, P665, DOI 10.1136/jclinpath-2012-201428; Thike AA, 2010, AM J SURG PATHOL, V34, P956, DOI 10.1097/PAS.0b013e3181e02f45; Thike AA, 2010, MODERN PATHOL, V23, P123, DOI 10.1038/modpathol.2009.145; Van den Eynden GG, 2006, BREAST CANCER RES TR, V95, P219, DOI 10.1007/s10549-005-9002-1; Vered M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1030-6; Wang SW, 2012, BREAST CARE, V7, P477, DOI 10.1159/000345464; Witkiewicz AK, 2010, CANCER BIOL THER, V10, P135, DOI 10.4161/cbt.10.2.11983; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wong ESY, 2016, NPJ GENOM MED, V1, DOI 10.1038/npjgenmed.2015.3; Ye Y, 2014, ASIAN PAC J CANCER P, V15, P8367, DOI 10.7314/APJCP.2014.15.19.8367; Zhao Z, 2015, WORLD J GASTROENTERO, V21, P1140, DOI 10.3748/wjg.v21.i4.1140	56	3	3	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					161	167		10.1136/jclinpath-2017-204495			7	Pathology	Pathology	FT1RA	WOS:000422912700011	28735300				2019-10-28	
J	La Gioia, A; Fumi, M; Pezzati, P; Balboni, F; Pancione, Y; Rocco, L; Sale, S; Bombara, M; Fiorini, M; Fiorini, F; Rocco, V				La Gioia, Antonio; Fumi, Maurizio; Pezzati, Paola; Balboni, Fiamma; Pancione, Ylenia; Rocco, Lucia; Sale, Silvia; Bombara, Maria; Fiorini, Marcello; Fiorini, Fabiana; Rocco, Vincenzo			Automatic wedge smears preparation may cause traumatic morphological changes in peripheral blood cells	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MYELODYSPLASTIC SYNDROMES; SURVIVAL; LEUKEMIA	In recent years, several automated analysers that prepare and stain blood smears have been introduced in clinical laboratories. Despite the use of instrumental settings based on physical characteristic of individual samples, traumatic injuries of neutrophil and lymphocytes can be observed. Some samples present a very high percentage of damaged cells, allowing the speculation that a cellular susceptibility may enhance mechanical traumatism. These artefacts can puzzle morphological evaluation in both traditional and digitised microscopy; in addition, unskilled operators can be misled.	[La Gioia, Antonio] Docemus Onlus Theoret & Pract Training Sch Improvi, Torrevecchia Teatina, Italy; [Fumi, Maurizio; Pancione, Ylenia; Rocco, Lucia; Sale, Silvia; Rocco, Vincenzo] UO Patol Clin AORN G Rummo, Benevento, Italy; [Pezzati, Paola] Ctr Reg Controllo Qualita AOU Careggi, Florence, Italy; [Balboni, Fiamma] Ist Fiorentino Cura & Assistenza, Lab Anal IFCA, Florence, Italy; [Bombara, Maria; Fiorini, Marcello] UOC Med Lab Livorno Azienda USL Toscana Nord Ovest, Carrara, MS, Italy; [Bombara, Maria; Fiorini, Marcello] UOC Med Lab Pontede Azienda USL Toscana Nord Ovest, Carrara, MS, Italy	La Gioia, A (reprint author), Via Ripoli 127, I-56035 Casciana Terme Lari, Italy.	ant.lagioia@gmail.com		ROCCO, Lucia/0000-0001-6250-4798			Bain BJ, 2015, Blood Cells: A Practical Guide, 5th Edition, P1; Bain BJ, 2010, AM J HEMATOL, V85, P354, DOI 10.1002/ajh.21659; Bron JW, 2000, SYSMEX J INT, V10, P71; Brunning RD, 2008, WHO CLASSIFICATION T, V4, P88; Chen S, 2012, COMPUT MATH METHOD M, V2012, P1, DOI DOI 10.1016/J.CARBP0L.2012.01.055; D'Onofrio G, 2013, MORFOLOGIA MALATTIE; Goasguen JE, 2014, LEUKEMIA RES, V38, P447, DOI 10.1016/j.leukres.2013.12.020; Nowakowski GS, 2009, J CLIN ONCOL, V27, P1844, DOI 10.1200/JCO.2008.17.0795; Palmer L, 2015, INT J LAB HEMATOL, V37, P287, DOI 10.1111/ijlh.12327; Rizzo D, 2013, AM J HEMATOL, V88, P747, DOI 10.1002/ajh.23494; Rodak BF, 2012, EMATOLOGY CLIN PRINC; Simson E, 2010, INT J LAB HEMATOL, V32, pE64, DOI 10.1111/j.1751-553X.2009.01141.x; Valent P, 2010, ONCOTARGET, V1, P483	13	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					168	171		10.1136/jclinpath-2017-204580			4	Pathology	Pathology	FT1RA	WOS:000422912700012	28775173				2019-10-28	
J	Reed, L; Attarian, S; Pendurti, G; Singh, AP; Budhathoki, A; Abi-Aad, S; Shah, UA; Kim, S; Bachiashvili, K; Moon, JY; Kim, M; Elrafei, T; Alexis, K; Strakhan, M; Li, WJ; Friedman, E				Reed, Louis; Attarian, Shirin; Pendurti, Gopichand; Singh, Aditi P.; Budhathoki, Anjali; Abi-Aad, Simon; Shah, Urvi A.; Kim, Salem; Bachiashvili, Kimo; Moon, Jee Young; Kim, Mimi; Elrafei, Tarek; Alexis, Karenza; Strakhan, Marianna; Li, Weijuan; Friedman, Ellen			Targeting the anterior superior iliac spine yields significantly longer bone marrow cores	JOURNAL OF CLINICAL PATHOLOGY			English	Article								Pathologists and haematologists generally agree that the length of the biopsy core is a good surrogate for the diagnostic quality of the bone marrow. Previous studies suggested that the angulation of the biopsy needle from the posterior superior iliac spine (PSIS) could influence the length of the biopsy cores, targeting the anterior superior iliac spine (ASIS) from the PSIS would yield longer specimens than the traditional angulation technique (TAT), where the biopsy needle is directed straight in, perpendicular to the plane of the back. Twenty five adult haematology patients were prospectively recruited by haematologists-in-training (HITs), who were trained to target the ASIS using a lateral angulationtechnique (LAT), The mean length of biopsy cores was 16 mm and that was significantly longer (p=0.003) than a comparable group of bone marrow biopsies previously obtained by HITs using the TAT approach. These results support the LAT as a new standard of haematology practice.	[Reed, Louis; Attarian, Shirin; Pendurti, Gopichand; Singh, Aditi P.; Budhathoki, Anjali; Abi-Aad, Simon; Shah, Urvi A.; Kim, Salem; Bachiashvili, Kimo; Elrafei, Tarek; Alexis, Karenza; Strakhan, Marianna; Li, Weijuan] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Bronx, NY 10467 USA; [Attarian, Shirin; Singh, Aditi P.; Budhathoki, Anjali; Abi-Aad, Simon; Shah, Urvi A.; Kim, Salem; Bachiashvili, Kimo; Friedman, Ellen] Montefiore Med Ctr, Dept Hematol & Oncol, 111 East 210th St,Hotheimer Bldg,2nd Floor, Bronx, NY 10461 USA; [Moon, Jee Young; Kim, Mimi] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA	Attarian, S (reprint author), Montefiore Med Ctr, Dept Hematol & Oncol, 111 East 210th St,Hotheimer Bldg,2nd Floor, Bronx, NY 10461 USA.	sattaria@montefiore.org		Shah, Urvi/0000-0001-8419-1091			Campbell JK, 2003, ANN ONCOL, V14, P273, DOI 10.1093/annonc/mdg055; Islam A., 2013, MANUAL BONE MARROW E; Konda B, 2014, AM J HEMATOL, V89, P943, DOI 10.1002/ajh.23790; Malempati Suman, 2009, N Engl J Med, V361, pe28, DOI 10.1056/NEJMvcm0804634; Natkunam F, 2004, MODERN PATHOL, V17, p248a; Reed LJ, 2011, HEMATOL REP, V3, P60, DOI 10.4081/hr.2011.e21; Zehnder J, 2017, BONE MARROW ASPIRATI, P1	7	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					172	173		10.1136/jclinpath-2017-204686			2	Pathology	Pathology	FT1RA	WOS:000422912700013	28844037				2019-10-28	
J	Scott, GD; Atwater, SK; Gratzinger, DA				Scott, Gregory David; Atwater, Susan K.; Gratzinger, Dita A.			Normative data for flow cytometry immunophenotyping of benign lymph nodes sampled by surgical biopsy	JOURNAL OF CLINICAL PATHOLOGY			English	Article							B-CELL POPULATIONS; DIAGNOSIS; PROLIFERATIONS; HYPERPLASIA; EXPRESSION; PHENOTYPE; NEOPLASMS; FEATURES	Aims To create clinically relevant normative flow cytometry data for understudied benign lymph nodes and characterise outliers. Methods Clinical, histological and flow cytometry data were collected and distributions summarised for 380 benign lymph node excisional biopsies. Outliers for kappa:lambda light chain ratio, CD10:CD19 coexpression, CD5:CD19 coexpression, CD4:CD8 ratios and CD7 loss were summarised for histological pattern, concomitant diseases and follow-up course. Results We generated the largest data set of benign lymph node immunophenotypes by an order of magnitude. B and T cell antigen outliers often had background immunosuppression or inflammatory disease but did not subsequently develop lymphoma. Conclusions Diagnostic immunophenotyping data from benign lymph nodes provide normative ranges for clinical use. Outliers raising suspicion for B or T cell lymphoma are not infrequent (26% of benign lymph nodes). Caution is indicated when interpreting outliers in the absence of excisional biopsy or clinical history, particularly in patients with concomitant immunosuppression or inflammatory disease.	[Scott, Gregory David; Atwater, Susan K.; Gratzinger, Dita A.] Stanford Hosp & Clin, Dept Pathol, Stanford, CA USA	Gratzinger, DA (reprint author), Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.	ditag@stanford.edu		Gratzinger, Dita/0000-0002-9182-8123			Almasri NM, 1998, ARCH PATHOL LAB MED, V122, P539; Backteman K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032691; Battaglia A, 2003, IMMUNOLOGY, V110, P304, DOI 10.1046/j.1365-2567.2003.01742.x; BRYAN CF, 1993, ANN NY ACAD SCI, V677, P404, DOI 10.1111/j.1749-6632.1993.tb38799.x; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Craig FE, 2008, BLOOD, V111, P3941, DOI 10.1182/blood-2007-11-120535; Flammiger A, 2015, LEUKEMIA LYMPHOMA, V56, P639, DOI 10.3109/10428194.2014.926347; Gibson SE, 2011, HUM PATHOL, V42, P679, DOI 10.1016/j.humpath.2010.07.023; Gorczyca W, 2002, CYTOMETRY, V50, P177, DOI 10.1002/cyto.10003; Gunduz E, 2013, J BUON, V18, P739; Hudnall SD, 2008, CYTOM PART B-CLIN CY, V74B, P1, DOI 10.1002/cyto.b.20376; Jamal S, 2001, AM J CLIN PATHOL, V116, P512; KELLYWILLIAMS S, 1989, LAB MED, V20, P487, DOI 10.1093/labmed/20.7.487; Kussick SJ, 2004, AM J CLIN PATHOL, V121, P464, DOI 10.1309/4EJ8T3R2ERKQ61WH; MAIESE RL, 1995, MODERN PATHOL, V8, P536; Sorigue M, 2016, LEUKEMIA LYMPHOMA, V57, P244, DOI 10.3109/10428194.2015.1046865; Storek J, 1998, CYTOMETRY, V33, P76, DOI 10.1002/(SICI)1097-0320(19980901)33:1<76::AID-CYTO9>3.0.CO;2-9; Szczepanski T, 2006, CLIN CHEM LAB MED, V44, P775, DOI 10.1515/CCLM.2006.146; WESTERMANN CD, 1990, MODERN PATHOL, V3, P54; Youinou P, 1999, IMMUNOL TODAY, V20, P312, DOI 10.1016/S0167-5699(99)01476-0	20	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					174	179		10.1136/jclinpath-2017-204687			6	Pathology	Pathology	FT1RA	WOS:000422912700014	28916595	Other Gold, Green Published			2019-10-28	
J	Pita, ASA; Azevedo, APD; Reichert, A; da Silva, CJP; Henriques, V; Mendes, DS; Reis, AMB; Cerqueira, R; Torres, F; Viana, JF				Andrade Pita, Amelia Soraia; da Silva Azevedo, Ana Paula; Reichert, Alice; Pimenta da Silva, Candido Jose; Henriques, Vanessa; Mendes, Diana Sousa; Batalha Reis, Ana Maria; Cerqueira, Rita; Torres, Fatima; Viana, Joao Faro			Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G > T (p.Met535Ile)	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MYELOPROLIFERATIVE NEOPLASMS; JAK2 EXON-12; ESSENTIAL THROMBOCYTHEMIA; CLONAL HEMATOPOIESIS; V617F; DIAGNOSIS; POPULATION; GUIDELINES; DISORDERS; FREQUENCY	One of the major genetic insights into the pathogenesis of polycythaemia vera included the identification of the somatic point gain-of-function mutations in Janus kinase 2 gene-first JAK2V617F on exon 14, present in 95%-97% of the cases, and later on exon 12. In the literature, we can find some reported studies where different exon 12 mutations are identified. Unlike patients with JAK2V617F mutation in exon 14, the mutation at exon 12 is not usually associated with an increase in the three haematopoietic series (erythrocytosis, leucocytosis and thrombocytosis). It appears to be associated with a distinct syndrome, mostly characterised by isolated and more marked erythrocytosis, independently of the mutational variant. We report here the case of a patient who is JAK2exon 12 positive, presenting a novel mutation-c.1605G>T (p.Met535Ile)-associated with c.1612C>T (p.His538Tyr) mutation previously described, evidencing an atypical clinical phenotype.	[Andrade Pita, Amelia Soraia; Mendes, Diana Sousa] Ctr Hosp Lisboa Ocidental, Dept Transfus Med, Estr Forte do Alto Duque, P-1449005 Lisbon, Portugal; [da Silva Azevedo, Ana Paula; Pimenta da Silva, Candido Jose; Batalha Reis, Ana Maria; Viana, Joao Faro] Ctr Hosp Lisboa Ocidental, Dept Clin Pathol, Lisbon, Portugal; [da Silva Azevedo, Ana Paula] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Ctr Toxicogen & Human Hlth Genet,Oncol & Human Tox, Lisbon, Portugal; [da Silva Azevedo, Ana Paula] Inst Super Ciencias Saude Egas Moniz, Monte De Caparica, Portugal; [Reichert, Alice] Ctr Hosp Lisboa Ocidental, Dept Haematol, Lisbon, Portugal; [Henriques, Vanessa] Ctr Hosp Lisboa Ocidental, Dept Pathol, Lisbon, Portugal; [Cerqueira, Rita; Torres, Fatima] CGC Genet, Porto, Portugal	Pita, ASA (reprint author), Ctr Hosp Lisboa Ocidental, Dept Transfus Med, Estr Forte do Alto Duque, P-1449005 Lisbon, Portugal.	amelia.andrade.pita@hotmail.com		S. Azevedo, Ana Paula/0000-0002-7457-3245			Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Azevedo AP, 2017, ONCOL LETT, V13, P4641, DOI 10.3892/ol.2017.6065; Bench AJ, 2013, BRIT J HAEMATOL, V160, P25, DOI 10.1111/bjh.12075; Berndt SI, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10933; Butcher CM, 2008, LEUKEMIA, V22, P870, DOI 10.1038/sj.leu.2404971; Godfrey AL, 2016, HAEMATOLOGICA, V101, pE15, DOI 10.3324/haematol.2015.128546; Hinds DA, 2016, BLOOD, V128, P1121, DOI 10.1182/blood-2015-06-652941; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; KIM Y, 2016, EXP MOL MED, V48; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Langabeer SE, 2015, EUR J HAEMATOL, V95, P270, DOI 10.1111/ejh.12578; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Li J, 2014, BLOOD, V123, P3139, DOI 10.1182/blood-2013-06-510222; Li M Y, 2017, Zhonghua Xue Ye Xue Za Zhi, V38, P295, DOI 10.3760/cma.j.issn.0253-2727.2017.04.007; McMullin MF, 2005, BRIT J HAEMATOL, V130, P174, DOI 10.1111/j.1365-2141.05535.x; Nielsen C, 2013, BRIT J HAEMATOL, V160, P70, DOI 10.1111/bjh.12099; Nussenzveig RH, 2016, LEUKEMIA LYMPHOMA, V57, P1429, DOI 10.3109/10428194.2015.1091932; Pardanani A, 2007, LEUKEMIA, V21, P1960, DOI 10.1038/sj.leu.2404810; Park CH, 2016, J CLIN PATHOL, V69, P737, DOI 10.1136/jclinpath-2016-203649; Passamonti F, 2010, LEUKEMIA, V24, P1574, DOI 10.1038/leu.2010.148; Passamonti F, 2011, BLOOD, V117, P2813, DOI 10.1182/blood-2010-11-316810; Pietra D, 2008, BLOOD, V111, P1686, DOI 10.1182/blood-2007-07-101576; Rumi E, 2017, BLOOD, V129, P680, DOI 10.1182/blood-2016-10-695957; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Scott LM, 2007, BRIT J HAEMATOL, V139, P511, DOI 10.1111/j.1365-2141.2007.06806.x; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Scott LM, 2011, AM J HEMATOL, V86, P668, DOI 10.1002/ajh.22063; Siemiatkowska A, 2010, LEUKEMIA RES, V34, P387, DOI 10.1016/j.leukres.2009.06.017; Tefferi A, 2015, JAMA ONCOL, V1, P97, DOI 10.1001/jamaoncol.2015.89; Tunde K, 2014, ORVOSI HETILAP, V155, P2074, DOI 10.1556/OH.2014.30051; Williams DM, 2007, EXP HEMATOL, V35, P1641, DOI 10.1016/j.exphem.2007.08.010; Wu ZY, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0048-6	33	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					180	184		10.1136/jclinpath-2017-204556			5	Pathology	Pathology	FT1RA	WOS:000422912700015	29021147				2019-10-28	
J	Gupta, A; Sundram, U				Gupta, Alia; Sundram, Uma			Cutaneous lymphoma	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							T-CELL LYMPHOMA; CLASSIFICATION		[Gupta, Alia; Sundram, Uma] Oakland Univ, William Beaumont Sch Med, Pathol, Royal Oak, MI USA	Sundram, U (reprint author), Oakland Univ, Dept Anat Pathol, William Beaumont Sch Med, William Beaumont Hosp, 3601 West Thirteen Mile Rd, Royal Oak, MI 48073 USA.	usundram@gmail.com					Jaffe ES, 2008, WHO CLASSIFICATION T, P294; Jaffe ES, 2006, WHO CLASSIFICATION S, P182; Kong YY, 2008, AM J SURG PATHOL, V32, P1495, DOI 10.1097/PAS.0b013e31817a9081; Kumar S, 1998, HUM PATHOL, V29, P397, DOI 10.1016/S0046-8177(98)90122-8; Nair RA, 2015, INDIAN J CANCER, V52, P675, DOI 10.4103/0019-509X.178416; Willemze R, 2008, BLOOD, V111, P838, DOI 10.1182/blood-2007-04-087288	6	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					185	+		10.1136/jclinpath-2016-204009			2	Pathology	Pathology	FT1RA	WOS:000422912700016	29146886				2019-10-28	
